PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Canaan, S; Zadori, Z; Ghomashchi, F; Bollinger, J; Sadilek, M; Moreau, ME; Tijssen, P; Gelb, MH				Canaan, S; Zadori, Z; Ghomashchi, F; Bollinger, J; Sadilek, M; Moreau, ME; Tijssen, P; Gelb, MH			Interfacial enzymology of parvovirus phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PORCINE PARVOVIRUS; CAPSID PROTEIN; VIRUS TYPE-2; GROUP-II; GROUP-V; GROUP-X; BINDING; INFECTIVITY; VESICLES	The capsid of parvoviruses proteins were recently shown to contain secreted phospholipase A(2) (sPLA(2))-like activity that is required during host cell entry. Parvoviral PLA(2) domains have little sequence identity with sPLA(2)s and lack disulfide bonds. In the present study, after bacterial expression and purification, the biochemical characterizations of these first PLA(2)s identified in viruses have been investigated, and a comparison has been made with other known PLA(2)s. The specific activities of three viral PLA(2)s differed by 3 orders of magnitude, with porcine parvovirus PLA(2) displaying a specific activity similar to that of the most active sPLA(2)s (e.g. human group IIA) and the human AAV2 and B19 parvoviral enzymes displaying approximately 10(3) lower specific activities (similar to human sPLA(2) groups IIE and XIIA). These differences were not caused by weaker Ca2+ or interfacial binding. The specific activities of the viral PLA(2)s on zwitterionic or anionic phospholipid vesicles were comparable. The viral PLA(2)s did not display a preference for unsaturated versus saturated sn-2 fatty acyl chains and hydrolyzed all major classes of glycero-phospholipids except phosphatidylinositol. Incubation of mammalian cells with porcine parvovirus PLA(2) led to the release of arachidonic acid into the culture medium. Interestingly, among nine previously known sPLA(2) inhibitors, only a subset showed inhibition of the viral PLA(2)s and with weak potency, indicating that the active sites of these new enzymes are structurally distinct from those of sPLA(2)s. Based on these distinct enzymatic and structural properties, we propose to classify the parvovirus PLA(2)s within the PLA(2) superfamily as group XIII enzymes.	Univ Washington, Dept Chem & Biochem, Seattle, WA 98195 USA; CNRS, UMR Architecture & Fonct Macromol Biol 6098, Dept Chem & Biochem, F-13402 Marseille 20, France; Univ Quebec, Inst Armand Frappier, INRS, Dept Chem & Biochem, Laval, PQ H7V 1B7, Canada	University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Quebec; Institut national de la recherche scientifique (INRS)	Tijssen, P (corresponding author), Univ Washington, Dept Chem & Biochem, Box 351700, Seattle, WA 98195 USA.	peter.tijssen@inrs-iaf.uquebec.ca; gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R37HL036235, R23HL036235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Bergeron J, 1996, J VIROL, V70, P2508, DOI 10.1128/JVI.70.4.2508-2515.1996; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; BROWN KE, 1989, BRIT J OBSTET GYNAEC, V96, P764, DOI 10.1111/j.1471-0528.1989.tb03313.x; Canaan S, 2002, J BIOL CHEM, V277, P30984, DOI 10.1074/jbc.M203649200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Girod A, 2002, J GEN VIROL, V83, P973, DOI 10.1099/0022-1317-83-5-973; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; KAWASE M, 1995, VIROLOGY, V211, P359, DOI 10.1006/viro.1995.1418; Kinkaid Adrian R., 1997, Biochemical Society Transactions, V25, p497S; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koprivnjak T, 2002, J BIOL CHEM, V277, P47636, DOI 10.1074/jbc.M205104200; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Rouault M, 2003, BIOCHEMISTRY-US, V42, P11494, DOI 10.1021/bi0349930; Simpson AA, 2002, J MOL BIOL, V315, P1189, DOI 10.1006/jmbi.2001.5319; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; TELERMAN A, 1993, P NATL ACAD SCI USA, V90, P8702, DOI 10.1073/pnas.90.18.8702; TSAO FHC, 1991, BIOCHIM BIOPHYS ACTA, V1081, P141, DOI 10.1016/0005-2760(91)90019-E; TULLIS GE, 1993, J VIROL, V67, P131, DOI 10.1128/JVI.67.1.131-141.1993; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; Zadori Z, 2001, DEV CELL, V1, P291, DOI 10.1016/S1534-5807(01)00031-4	29	93	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14502	14508		10.1074/jbc.M312630200	http://dx.doi.org/10.1074/jbc.M312630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726513	hybrid			2022-12-27	WOS:000220594700007
J	Hagner-McWhirter, A; Li, JP; Oscarson, S; Lindahl, U				Hagner-McWhirter, A; Li, JP; Oscarson, S; Lindahl, U			Irreversible glucuronyl C5-epimerization in the biosynthesis of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN/HEPARAN SULFATE; SUBSTRATE-SPECIFICITY; C-5 EPIMERASE; ACID; PROTEOGLYCANS; DOMAIN; UNITS	Glucuronyl C5-epimerase catalyzes the conversion of D-glucuronic acid to L-iduronic acid units in heparan sulfate biosynthesis. Substrate recognition depends on the N-substituent pattern of the heparan sulfate precursor polysaccharide and requires the adjacent glucosamine residue toward the non-reducing end to be N-sulfated. Epimerization of an appropriately N-sulfated substrate is freely reversible in a soluble system, with equilibrium favoring retention of D-gluco configuration (Hagner-McWhirter, Angstrom., Lindahl, U., and Li, J.- P. ( 2000) Biochem. J. 347, 69 - 75). We studied the reversibility of the epimerase reaction in a cellular system, by incubating human embryonic kidney 293 cells with D-[5-H-3] galactose. The label was incorporated with glucuronic acid units into the heparan sulfate precursor polysaccharide and was lost upon subsequent C5-epimerization to iduronic acid. However, analysis of oligosaccharides obtained by deaminative cleavage of the mature heparan sulfate chains indicated that all glucuronic acid units retained their C5-H-3 label, irrespective of whether they had occurred in sequences susceptible or resistant to the epimerase. All H-3-labels of the final products resisted incubation with epimerase in a soluble system, apparently due to blocking O-sulfate groups. These results indicate that glucuronic acid C5-epimerization is effectively irreversible in vivo and argue for a stringent organization of the biosynthetic machinery.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Biochem, S-75123 Uppsala, Sweden; Stockholm Univ, Arrhenius Lab, Dept Organ Chem, S-10691 Stockholm, Sweden	Uppsala University; Stockholm University	Li, JP (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Biochem, Box 582, S-75123 Uppsala, Sweden.	jin-ping.li@imbim.uu.se		Oscarson, Stefan/0000-0002-8273-4918				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; CONRAD HE, 1998, HEPARIN BINDING PROT, P22; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; ISUDA Y, 1989, CHEM PHARM BULL, V37, P2344; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MALMSTROM A, 1981, BIOCHEM J, V198, P669, DOI 10.1042/bj1980669; MORGENLIE S, 1973, ACTA CHEM SCAND, V27, P3609, DOI 10.3891/acta.chem.scand.27-3609; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; SMITS NC, 2003, AM J RESP CELL MOL B; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303	32	31	33	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14631	14638		10.1074/jbc.M313760200	http://dx.doi.org/10.1074/jbc.M313760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14718527	hybrid			2022-12-27	WOS:000220594700021
J	Misevic, GN; Guerardel, Y; Sumanovski, LT; Slomianny, MC; Demarty, M; Ripoll, C; Karamanos, Y; Maes, E; Popescu, O; Strecker, G				Misevic, GN; Guerardel, Y; Sumanovski, LT; Slomianny, MC; Demarty, M; Ripoll, C; Karamanos, Y; Maes, E; Popescu, O; Strecker, G			Molecular recognition between glyconectins as an adhesion self-assembly pathway to multicellularity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE MICROCIONA-PROLIFERA; GAS-LIQUID-CHROMATOGRAPHY; AGGREGATION FACTOR; CELL-ADHESION; MASS SPECTROMETRY; METHYL-GLYCOSIDES; PROTEOGLYCANS; PROTEIN; BINDING; AFFINITY	The appearance of multicellular forms of life has been tightly coupled to the ability of an organism to retain its own anatomical integrity and to distinguish self from non-self. Large glycoconjugates, which make up the outermost cell surface layer of all Metazoans, are the primary candidates for the primordial adhesion and recognition functions in biological self-assembly systems. Atomic force microscopy experiments demonstrated that the binding strength between a single pair of Porifera cell surface glyconectin 1 glycoconjugates from Microciona prolifera can hold the weight of 1600 cells, proving their adhesion functions. Here, measurement of molecular self-recognition of glyconectins (GNs) purified from three Porifera species was used as an experimental model for primordial xenogeneic self/non-self discrimination. Physicochemical and biochemical characterization of the three glyconectins, their glycans, and peptides using gel electrophoresis, ultracentrifugation, NMR, mass spectrometry, glycosaminoglycan-degrading enzyme treatment, amino acid and carbohydrate analyses, and peptide mapping showed that GNs define a new family of proteoglycan-like molecules exhibiting species-specific structures with complex and repetitive acidic carbohydrate motives different from the classical proteoglycans and mucins. In functional self-assembly color-coded bead, cell, and blotting assays, glyconectins displayed species-specific recognition and adhesion. Affinity-purified monospecific polyclonal antibodies prepared against GN1, -2, and -3 glycans selectively inhibited cell adhesion of the respective sponge species. These results together with species-specific coaggregation of GN carbohydrate-coated beads with cells showed that GN glycans are functional in cell recognition and adhesion. The specificity of carbohydrate-mediated homophilic GN interactions in Porifera approaches the binding selectivity of the evolutionarily advanced immunoglobulin superfamily. Xenoselectivity of primordial glyconectin to glyconectin recognition may be a new paradigm in the self-assembly and non-self discrimination pathway of cellular adhesion leading to multicellularity.	Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France; Univ Sci & Technol Lille, CNRS, UMR 8576, Unite Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France; Univ Basel Hosp, Dept Res, CH-4058 Basel, Switzerland; Univ Artois, Fac J Perrin, Lab Biochim Mol & Cellulaire, F-62307 Lens, France; Univ Babes Bolyai, Ctr Mol Biol, Cluj Napoca 400006, Romania; Univ Babes Bolyai, Inst Interdisciplinary Expt Res, Cluj Napoca 400006, Romania	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; University of Basel; Universite d'Artois; Babes Bolyai University from Cluj; Babes Bolyai University from Cluj	Misevic, GN (corresponding author), Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France.	gradimir@gradimir.com	Karamanos, Yannis/AAE-9379-2020; Popescu, Octavian/E-4942-2010; Popescu, Octavian/O-2134-2019; Misevic, Gradimir/D-8294-2016; Popescu, Octavian/C-4027-2011	Karamanos, Yannis/0000-0002-2411-6636; Popescu, Octavian/0000-0002-2597-7155; Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Guerardel, Yann/0000-0003-4967-9512				BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; CAULDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051, DOI 10.1021/bi00740a017; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CURTIS ASG, 1962, NATURE, V196, P245, DOI 10.1038/196245a0; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DUDMAN WF, 1986, CARBOHYD RES, V145, P175, DOI 10.1016/S0008-6215(00)90428-2; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; FernandezBusquets X, 1996, J BIOL CHEM, V271, P23558, DOI 10.1074/jbc.271.38.23558; GALLAGHER JT, 1995, ADV EXP MED BIOL, V376, P125; GALSTOFF PS, 1925, J EXP ZOOL, V42, P183; Guerardel Y, 2004, J BIOL CHEM, V279, P15591, DOI 10.1074/jbc.M308928200; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; Haseley SR, 2001, P NATL ACAD SCI USA, V98, P9419, DOI 10.1073/pnas.151111298; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Jarchow J, 2000, J STRUCT BIOL, V132, P95, DOI 10.1006/jsbi.2000.4309; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; Maes E, 1999, ANAL BIOCHEM, V267, P300, DOI 10.1006/abio.1998.2967; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1995, J MOL RECOGNIT, V8, P100, DOI 10.1002/jmr.300080118; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MISEVIC GN, 1989, METHOD ENZYMOL, V179, P95; MISEVIC GN, 1991, TRENDS GLYCOSCI GLYC, V3, P400; MOSCONA AA, 1968, DEV BIOL, V18, P250, DOI 10.1016/0012-1606(68)90035-3; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; Popescu O, 1997, NATURE, V386, P231, DOI 10.1038/386231b0; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wilson H.V., 1910, B BUR FISH, V30, P1; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255	40	23	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15579	15590		10.1074/jbc.M308927200	http://dx.doi.org/10.1074/jbc.M308927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14701844	hybrid			2022-12-27	WOS:000220594700130
J	Asano, S; Yoshida, A; Yashiro, H; Kobayashi, Y; Morisato, A; Ogawa, H; Takeguchi, N; Morii, M				Asano, S; Yoshida, A; Yashiro, H; Kobayashi, Y; Morisato, A; Ogawa, H; Takeguchi, N; Morii, M			The cavity structure for docking the K+-competitive inhibitors in the gastric proton pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MUTATIONAL ANALYSIS; BINDING-SITES; TRANSMEMBRANE SEGMENT; FUNCTIONAL EXPRESSION; CALCIUM-PUMP; H+,K+-ATPASE; H,K-ATPASE; SUBUNIT; OMEPRAZOLE	2-Methyl-8-(phenylmethoxy) imidazo[1,2-a] pyridine-3-acetonitrile (SCH 28080) is a reversible inhibitor specific for the gastric proton pump. The inhibition pattern is competitive with K+. Here we studied the binding sites of this inhibitor on the putative three-dimensional structure of the gastric proton pump alpha-subunit that was constructed by homology modeling based on the structure of sarcoplasmic reticulum Ca2+ pump. Alanine and serine mutants of Tyr(801) located in the fifth transmembrane segment of the gastric proton pump alpha-subunit retained the Rb-86 transport and K+-dependent ATPase (K+-ATPase) activities. These mutants showed 60 - 80-times lower sensitivity to SCH 28080 than the wild type in the 86Rb transport activity. The K+-ATPase activities of these mutants were not completely inhibited by SCH 28080. The sensitivity to SCH 28080 was dependent on the bulkiness of the side chain at this position. Therefore, the side chain of Tyr(801) is important for the interaction with this inhibitor. In the three-dimensional structure of the E-2 form (conformation with high affinity for K+) of the gastric proton pump, Tyr(801) faces a cavity surrounded by the first, fourth, fifth, sixth, and eighth transmembrane segments and fifth/sixth, seventh/ eighth, and ninth/tenth loops. SCH 28080 can dock in this cavity. However, SCH 28080 cannot dock in the same location in the E-1 form ( conformation with high affinity for proton) of the gastric proton pump due to the drastic rearrangement of the transmembrane helices between the E-1 and E-2 forms. These results support the idea that this cavity is the binding pocket of SCH 28080.	Toyama Med & Pharmaceut Univ, Life Sci Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bukyo Ku, Tokyo 1130032, Japan	University of Toyama; University of Toyama; University of Tokyo	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Life Sci Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.	shinji@ms.toyama-mpu.ac.jp		Asano, Shinji/0000-0003-1443-8970				Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Asano S, 2001, J BIOL CHEM, V276, P31265, DOI 10.1074/jbc.M103698200; Asano S, 1999, J BIOL CHEM, V274, P6848, DOI 10.1074/jbc.274.11.6848; BEIL W, 1986, BRIT J PHARMACOL, V88, P19, DOI 10.1111/j.1476-5381.1986.tb09466.x; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; Farley RA, 2001, J BIOL CHEM, V276, P2608, DOI 10.1074/jbc.M008784200; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; Grishin AV, 1996, AM J PHYSIOL-RENAL, V271, pF539, DOI 10.1152/ajprenal.1996.271.3.F539; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; HERSEY SJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P49, DOI 10.1016/0167-4838(88)90296-8; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; Kimura T, 2002, J BIOL CHEM, V277, P20671, DOI 10.1074/jbc.M200523200; Kimura T, 2002, J BIOCHEM, V131, P923, DOI 10.1093/oxfordjournals.jbchem.a003183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MORII M, 1993, J BIOL CHEM, V268, P21553; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Munson KB, 2000, BIOCHEMISTRY-US, V39, P2997, DOI 10.1021/bi991837d; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rulli SJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P27, DOI 10.1006/abbi.2000.2243; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanner M F, 1999, Pac Symp Biocomput, P401; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsukimi Y, 2000, JPN J PHARMACOL, V82, P21, DOI 10.1254/jjp.82.21; Ushiro T, 1997, JPN J PHARMACOL, V75, P303; Vagin O, 2002, BIOCHEMISTRY-US, V41, P12755, DOI 10.1021/bi025921w; Vagin O, 2001, BIOCHEMISTRY-US, V40, P7480, DOI 10.1021/bi0105328; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	46	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13968	13975		10.1074/jbc.M308934200	http://dx.doi.org/10.1074/jbc.M308934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699149	hybrid			2022-12-27	WOS:000220478500084
J	Sheader, K; Vruchte, DT; Rudenko, G				Sheader, K; Vruchte, DT; Rudenko, G			Bloodstream form-specific up-regulation of silent VSG expression sites and procyclin in Trypanosoma brucei after inhibition of DNA synthesis or DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RNA-POLYMERASE-I; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; STRAND BREAKS; SIR PROTEINS; HUMAN NUCLEI; HUMAN SERUM	The African trypanosome Trypanosoma brucei transcribes the active variant surface glycoprotein (VSG) gene from one of about 20 VSG expression sites (ESs). In order to study ES control, we made reporter lines with a green fluorescent protein gene inserted behind the promoter of different ESs. We attempted to disrupt the silencing machinery, and we used fluorescence-activated cell sorter analysis for the rapid and sensitive detection of ES up-regulation. We find that a range of treatments that either block nuclear DNA synthesis, like aphidicolin, or modify DNA-like cisplatin and 1-methyl-3-nitro-1-nitrosoguanidine results in up-regulation of silent ESs. Aphidicolin treatment was the most effective, with almost 80% of the cells expressing green fluorescent protein from a silent ES. All of these treatments blocked the cells in S phase. In contrast, a range of toxic chemicals had little or no effect on expression. These included berenil and pentamidine, which selectively cleave the mitochondrial kinetoplast DNA, the metabolic inhibitors suramin and difluoromethylornithine, and the mitotic inhibitor rhizoxin. Up-regulation also affected other RNA polymerase I (pol I) transcription units, as procyclin genes were also up-regulated after cells were treated with either aphidicolin or DNA-modifying agents. Strikingly, this up-regulation of silent pol I transcription units was bloodstream form-specific and was not observed in insect form T. brucei. We postulate that the redistribution of a limiting bloodstream form-specific factor involved in both silencing and DNA repair results in the derepression of normally silenced pol I transcription units after DNA damage.	Univ Oxford, Oxford OX1 3SY, England	University of Oxford	Rudenko, G (corresponding author), Univ Oxford, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.	gloria.rudenko@medawar.ox.ac.uk		Rudenko, Gloria/0000-0003-1884-4933	Wellcome Trust [095161] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALBER AE, 1985, EXP PARASITOL, V59, P74, DOI 10.1016/0014-4894(85)90059-1; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; Berriman M, 2002, MOL BIOCHEM PARASIT, V122, P131, DOI 10.1016/S0166-6851(02)00092-0; Biebinger S, 1996, NUCLEIC ACIDS RES, V24, P1202, DOI 10.1093/nar/24.7.1202; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Boibessot I, 2002, ACTA TROP, V84, P219, DOI 10.1016/S0001-706X(02)00188-2; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; Breidbach T, 2002, EXP PARASITOL, V101, P223, DOI 10.1016/S0014-4894(02)00133-9; BRUN R, 1979, ACTA TROP, V36, P289; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; Conway C, 2002, J BIOL CHEM, V277, P21269, DOI 10.1074/jbc.M200550200; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; FAIRLAMB AH, 1980, MOL BIOCHEM PARASIT, V1, P315, DOI 10.1016/0166-6851(80)90050-X; Feuerbach F, 2002, NAT CELL BIOL, V4, P214, DOI 10.1038/ncb756; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Garcia-Salcedo JA, 2003, EMBO J, V22, P5851, DOI 10.1093/emboj/cdg553; Gerrits H, 2002, MOL BIOCHEM PARASIT, V119, P237, DOI 10.1016/S0166-6851(01)00417-0; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hediger F, 2002, CURR BIOL, V12, P2076, DOI 10.1016/S0960-9822(02)01338-6; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hoogstraten D, 2002, MOL CELL, V10, P1163, DOI 10.1016/S1097-2765(02)00709-8; Horn D, 1997, EMBO J, V16, P7422, DOI 10.1093/emboj/16.24.7422; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; Isobe T, 2003, J MOL EVOL, V56, P377, DOI 10.1007/s00239-002-2408-z; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lau A, 2002, GENE DEV, V16, P2935, DOI 10.1101/gad.764102; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Mutomba MC, 1996, MOL BIOCHEM PARASIT, V80, P89, DOI 10.1016/0166-6851(96)02675-8; Navarro M, 1996, MOL CELL BIOL, V16, P3615; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Navarro M, 1998, MOL BIOCHEM PARASIT, V94, P53, DOI 10.1016/S0166-6851(98)00049-8; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; PEDRALINOY G, 1980, J VIROL, V36, P457, DOI 10.1128/JVI.36.2.457-464.1980; Perez-Morga D, 2001, J EUKARYOT MICROBIOL, V48, P221, DOI 10.1111/j.1550-7408.2001.tb00306.x; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; Ploubidou A, 1999, J CELL SCI, V112, P4641; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Rudenko G, 1998, MOL BIOCHEM PARASIT, V95, P97, DOI 10.1016/S0166-6851(98)00099-1; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Sambrook J., 2001, MOL CLONING LAB MANU; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; Sheader K, 2003, MOL BIOCHEM PARASIT, V128, P147, DOI 10.1016/S0166-6851(03)00056-2; SHEAFF R, 1991, BIOCHEMISTRY-US, V30, P8590, DOI 10.1021/bi00099a014; Shore D, 2001, CURR BIOL, V11, pR816, DOI 10.1016/S0960-9822(01)00493-6; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Ulbert S, 2002, MOL BIOCHEM PARASIT, V120, P225, DOI 10.1016/S0166-6851(02)00003-8; van de Vaart PJM, 2000, INT J CANCER, V89, P160, DOI 10.1002/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J; van Leeuwen F, 1998, MOL CELL BIOL, V18, P5643, DOI 10.1128/MCB.18.10.5643; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanhamme L, 2001, INT J PARASITOL, V31, P523, DOI 10.1016/S0020-7519(01)00143-6; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Vassella E, 1997, J CELL SCI, V110, P2661; Vruchte DT, 2003, MOL BIOCHEM PARASIT, V128, P123, DOI 10.1016/S0166-6851(03)00053-7; WOODWARD R, 1990, J CELL SCI, V95, P49; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005; ZWEYGARTH E, 1991, ACTA TROP, V48, P223, DOI 10.1016/0001-706X(91)90050-T	81	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13363	13374		10.1074/jbc.M312307200	http://dx.doi.org/10.1074/jbc.M312307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726511	hybrid			2022-12-27	WOS:000220478500013
J	Gamero, AM; Sakamoto, S; Montenegro, J; Larner, AC				Gamero, AM; Sakamoto, S; Montenegro, J; Larner, AC			Identification of a novel conserved motif in the STAT family that is required for tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INTERFERON; GENE-EXPRESSION; V-ABL; ACTIVATION; PROTEINS; PATHWAY; MUTATIONS; CELLS; DNA; PROLIFERATION	The rapid transcriptional activation of cellular genes by either type 1 interferons (IFNalpha/beta) or type 2 interferon (IFNgamma) is responsible for many of the pleiotropic effects of these cytokines, including their antiviral, antigrowth, and immunomodulatory activities. Interferon-stimulated gene expression is mediated by transcription factors termed Stats, which upon being tyrosine-phosphorylated, translocate to the nucleus and bind enhancers of interferon-activated genes. We have recently characterized a new Jurkat cell variant, named H123, where IFNalpha stimulates programmed cell death. H123 clones that are resistant to the apoptotic actions of IFNalpha have been selected. One of these clones (Clone 8) is defective in its responses to IFNalpha with regard to activation of genes that require tyrosine phosphorylation of Stat2. Stimulation of Clone 8 cells with IFNalpha induces normal tyrosine phosphorylation of Stat1 and Stat3. Sequencing of Stat2 RNA reveals a substitution of proline 630 located within the Src homology 2 domain of Stat2 to leucine (P630L). Pro-630 and its adjacent amino acids are conserved in all Stat family members but are absent in other proteins that contain Src homology 2 domains. Expression of Stat2 P630L in cells inhibits IFNalpha-stimulated gene expression. These results not only define a critical motif in Stat2 required for its transcriptional activity, but they also provide evidence that resistance to type one IFNs can be mediated by mutations in Stat2 as well as those previously described for Stat1.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Larner, AC (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB-3-30,9500 Euclid Ave, Cleveland, OH 44195 USA.	larnera@ccf.org			NCI NIH HHS [CA 77366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAI H, 1989, J BIOL CHEM, V264, P3252; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Lau JF, 2003, MOL CELL BIOL, V23, P620, DOI 10.1128/MCB.23.2.620-628.2003; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	23	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12379	12385		10.1074/jbc.M310787200	http://dx.doi.org/10.1074/jbc.M310787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722125	hybrid			2022-12-27	WOS:000220334900046
J	Pauwels, F; Vergauwen, B; Van Beeumen, JJ				Pauwels, F; Vergauwen, B; Van Beeumen, JJ			Physiological characterization of Haemophilus influenzae Rd deficient in its glutathione-dependent peroxidase PGdx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; OXIDATIVE STRESS DEFENSE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; CATALASE; GENE; SURVIVAL; MUTANTS; OPERON; DNA	The chimeric peroxidase PGdx of Haemophilus influenzae Rd belongs to a recently identified family of thiol peroxidases capable of reducing hydrogen peroxide as well as alkylhydroperoxides by means of glutathione redox cycling. In the present study, we constructed a H. influenzae Rd strain, deficient in its PGdx encoding gene ( open reading frame HI0572). The mutant was shown by disk inhibition and liquid culture growth assays to exhibit increased susceptibility to organic hydroperoxides. The hampered growth was restored by complementing the interrupted gene on the genome with a replicating plasmid bearing an intact copy of the gene, hereby rejecting the possible influences of polar effects. Elevated levels of hydrogen peroxide scavenging activity, due to the catalase HktE, were measured in the absence of a functional pgdx gene rendering the mutant more resilient against hydrogen peroxide. On the other hand, after initiation of the stationary phase, aerobic cultures of the pgdx mutant were practically devoid of living cells, whereas wild-type counterparts retained viability. This observed feature was alleviated by complementation with the functional gene or with the addition of catalase.	Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 95, B-9000 Ghent, Belgium.	Jozef.vanbeeumen@UGent.be						Bandyopadhyay P, 1998, J BACTERIOL, V180, P5369, DOI 10.1128/JB.180.20.5369-5374.1998; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHAI WR, 1994, INFECT IMMUN, V62, P4855, DOI 10.1128/IAI.62.11.4855-4860.1994; BISHAI WR, 1994, J BACTERIOL, V176, P2914, DOI 10.1128/JB.176.10.2914-2921.1994; Bsat N, 1996, J BACTERIOL, V178, P6579, DOI 10.1128/jb.178.22.6579-6586.1996; Craig JE, 2001, FEMS MICROBIOL LETT, V203, P55, DOI 10.1016/S0378-1097(01)00328-7; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; GonzalezFlecha B, 1997, J BACTERIOL, V179, P382, DOI 10.1128/jb.179.2.382-388.1997; Herbert M, 2003, INT J MED MICROBIOL, V293, P145, DOI 10.1078/1438-4221-00261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; Mongkolsuk S, 2000, J BACTERIOL, V182, P6845, DOI 10.1128/JB.182.23.6845-6849.2000; Ochsner UA, 2000, J BACTERIOL, V182, P4533, DOI 10.1128/JB.182.16.4533-4544.2000; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Pericone CD, 2000, INFECT IMMUN, V68, P3990, DOI 10.1128/IAI.68.7.3990-3997.2000; Rocha ER, 1999, J BACTERIOL, V181, P5701, DOI 10.1128/JB.181.18.5701-5710.1999; Rouhier N, 2003, FEBS LETT, V554, P149, DOI 10.1016/S0014-5793(03)01156-6; SAMBROOK J, 1989, MOL CLONING, V2, P9; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Steinman HM, 1997, J BACTERIOL, V179, P6831, DOI 10.1128/jb.179.21.6831-6836.1997; Vergauwen B, 2003, J BACTERIOL, V185, P5555, DOI 10.1128/JB.185.18.5555-5562.2003; Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; [No title captured]	24	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12163	12170		10.1074/jbc.M312037200	http://dx.doi.org/10.1074/jbc.M312037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701867	hybrid			2022-12-27	WOS:000220334900022
J	Romsicki, Y; Reece, M; Gauthier, JY; Asante-Appiah, E; Kennedy, BP				Romsicki, Y; Reece, M; Gauthier, JY; Asante-Appiah, E; Kennedy, BP			Protein tyrosine phosphatase-1B dephosphorylation of the insulin receptor occurs in a perinuclear endosome compartment in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; QUANTITATIVE-ANALYSIS; INTERNALIZATION; IDENTIFICATION; SENSITIVITY; ENDOCYTOSIS; BINDING; PTP-1B; GRB2	Protein tyrosine phosphatase-1B (PTP-1B) is a negative regulator of insulin signaling. It is thought to carry out this role by interacting with and dephosphorylating the activated insulin receptor (IR). However, little is known regarding the nature of the cellular interaction between these proteins, especially because the IR is localized to the plasma membrane and PTP-1B to the endoplasmic reticulum. Using confocal microscopy and fluorescence resonance energy transfer (FRET), the interaction between PTP-1B and the IR was examined in co-transfected human embryonic kidney 293 cells. Biological activities were not significantly affected for either PTP-1B or the IR with the fusion of W1B-green fluorescent protein (GFP) to the N terminus of PTP-1B (W1B-PTP-1B) or the fusion of Topaz-GFP to the C terminus of the IR (Topaz-IR). FRET between W1B and Topaz was monitored in cells transfected with either wild type PTP-1B (W1B-PTP-1B) or the substrate-trapping form PTP-1B(D181A) (W1B-PTP-1B(D181A)) and Topaz-IR. Co-expression of W1B-PTP-1B with Topaz-IR resulted in distribution of Topaz-IR to the plasma membrane, but no FRET was obtained upon insulin treatment. In contrast, co-expression of W1B-PTP-1B(D181A) with Topaz-IR caused an increase in cytosolic Topaz-IR fluorescence and, in some cells, a significant basal FRET signal, suggesting that PTP-1B is interacting with the IR during its synthesis. Stimulation of these cells with insulin resulted in a rapid induction of FRET that increased over time and was localized to a perinuclear spot. Co-expression of Topaz-IR with a GFP-labeled RhoB endosomal marker and treatment of the cells with insulin identified a perinuclear endosome compartment as the site of localization. Furthermore, the insulin-induced FRET could be prevented by the treatment of the cells with a specific PTP-1B inhibitor. These results suggest that PTP-1B appears not only to interact with and dephosphorylate the insulin-stimulated IR in a perinuclear endosome compartment but is also involved in maintaining the IR in a dephosphorylated state during its biosynthesis.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Chem, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company; Merck & Company	Kennedy, BP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	Brian_Kennedy@merck.com						ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Bevan AP, 2000, MOL CELL ENDOCRINOL, V164, P145, DOI 10.1016/S0303-7207(00)00224-0; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; Conway RR, 2001, J CELL PHYSIOL, V189, P341, DOI 10.1002/jcp.10028; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAURE R, 1992, J BIOL CHEM, V267, P11215; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Ghosh RN, 2000, BIOTECHNIQUES, V29, P170, DOI 10.2144/00291pf01; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; OLSON TS, 1988, J BIOL CHEM, V263, P7342; Romsicki Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P40, DOI 10.1016/S0003-9861(03)00178-4; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SING LC, 2001, Patent No. 200170753; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tawa P, 2001, CELL DEATH DIFFER, V8, P30, DOI 10.1038/sj.cdd.4400769; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1	30	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12868	12875		10.1074/jbc.M309600200	http://dx.doi.org/10.1074/jbc.M309600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722096	hybrid			2022-12-27	WOS:000220334900103
J	Yadava, N; Houchens, T; Potluri, P; Scheffler, IE				Yadava, N; Houchens, T; Potluri, P; Scheffler, IE			Development and characterization of a conditional mitochondrial complex I assembly system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; HAMSTER CELL MUTANTS; 3-DIMENSIONAL STRUCTURE; QUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; KDA SUBUNIT; PROTEIN; DEFICIENT; GENE; IDENTIFICATION	We developed a conditional complex I assembly system in a Chinese hamster fibroblast mutant line, CCL16-B2, that does not express the NDUFA1 gene (encoding the MWFE protein). In this mutant, a hemagglutinin (HA) epitope-tagged MWFE protein was expressed from a doxycycline-inducible promoter. The expression of the protein was absolutely dependent on the presence of doxycycline, and the gene could be turned off completely by removal of doxycycline. These experiments demonstrated a key role of MWFE in the pathway of complex I assembly. Upon induction the MWFE.HA protein reached steady-state levels within 24 h, but the appearance of fully active complex I was delayed by another similar to24 h. The MWFE appeared in a precomplex that probably includes one or more subunits encoded by mtDNA. The fate of MWFE and the stability of complex I were themselves very tightly linked to the activity of mitochondrial protein synthesis and to the assembly of subunits encoded by mtDNA (ND1-6 and ND4L). This novel conditional system can shed light not only on the mechanism of complex I assembly but emphasizes the role of subunits previously thought of as "accessory." It promises to have broader applications in the study of cellular energy metabolism and production of reactive oxygen species and related processes.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Scheffler, IE (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA.	ischeffler@ucsd.edu						Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354; Au HC, 1997, SOMAT CELL MOLEC GEN, V23, P27, DOI 10.1007/BF02679953; BAI Y, 2001, EMBO J, V17, P4848; BREEN GAM, 1979, SOMAT CELL GENET, V5, P441, DOI 10.1007/BF01538879; BURNETT KG, 1981, J CELL BIOL, V90, P108, DOI 10.1083/jcb.90.1.108; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; DITTA G, 1977, NATURE, V268, P64, DOI 10.1038/268064a0; Ferreirinha F, 1999, BIOCHEM J, V342, P551, DOI 10.1042/0264-6021:3420551; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Green-Willms NS, 2001, J BIOL CHEM, V276, P6392, DOI 10.1074/jbc.M009856200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; HALL RE, 1990, J BIOL CHEM, V265, P16484; HARE JF, 1982, J BIOL CHEM, V257, P3575; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Kuffner R, 1998, J MOL BIOL, V283, P409, DOI 10.1006/jmbi.1998.2114; Marques I, 2003, J MOL BIOL, V329, P283, DOI 10.1016/S0022-2836(03)00443-1; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Nargang FE, 2002, J BIOL CHEM, V277, P12846, DOI 10.1074/jbc.M112099200; NEHLS U, 1992, J MOL BIOL, V227, P1032, DOI 10.1016/0022-2836(92)90519-P; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Papa S, 2001, FEBS LETT, V489, P259, DOI 10.1016/S0014-5793(00)02334-6; Petruzzella V, 2002, GENE, V286, P149, DOI 10.1016/S0378-1119(01)00810-1; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Scheffler IE, 2001, J BIOENERG BIOMEMBR, V33, P243, DOI 10.1023/A:1010739120891; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; SODERBERG K, 1979, SOMAT CELL GENET, V5, P225, DOI 10.1007/BF01539163; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Videira A, 2001, J BIOENERG BIOMEMBR, V33, P197, DOI 10.1023/A:1010778802236; Yadava N, 2002, J BIOL CHEM, V277, P21221, DOI 10.1074/jbc.M202016200	43	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12406	12413		10.1074/jbc.M313588200	http://dx.doi.org/10.1074/jbc.M313588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722084	hybrid			2022-12-27	WOS:000220334900049
J	Zhao, M; Qiao, M; Harris, SE; Oyajobi, BO; Mundy, GR; Chen, D				Zhao, M; Qiao, M; Harris, SE; Oyajobi, BO; Mundy, GR; Chen, D			Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; RECEPTOR; DEGRADATION; EXPRESSION; TARGETS; SMAD7; SCLEROSTIN; NOGGIN; ROLES; CELLS	Bone morphogenetic proteins (BMPs) are required for normal postnatal bone formation and osteoblast differentiation. There is evidence from recent studies that BMP signaling in osteoblasts is controlled by an ubiquitin-proteasome regulatory mechanism involving a cascade of enzymatic reactions. The specificity of protein ubiquitination is determined by E3 ubiquitin ligases, which play a crucial role in defining substrate specificity and subsequent protein degradation by 26S proteasomes. We have examined the role of the E3 ubiquitin ligase (Sm) under bar ad (u) under bar biquitin (r) under bar egulatory factor 1 (Smurf1), a member of the Hect domain family of E3 ubiquitin ligases in osteoblast function. Smurf1 has been found to interact with BMP-activated Smad1 and -5 and to mediate degradation of these Smad proteins. Recently we have found that Smurf1 mediates the protein degradation of the osteoblast-specific transcription factor Runx2/Cbfa1. To determine the role of Smurf1 in osteoblast differentiation, in the present studies we transfected a Smurf1 expression plasmid into 2T3 osteoblast precursor cells and found that Smurf1 overexpression inhibits BMP signaling and osteoblast differentiation. To further investigate the role of Smurf1 in bone formation in vivo, we generated transgenic mice in which expression of the epitope-tagged Smurf1 transgene was targeted to osteoblasts using the murine 2.3-kb osteoblast-specific type I collagen promoter. In these transgenic mice, bone formation was significantly reduced during postnatal life. Our results demonstrate for the first time that Smurf1 plays a specific role in osteoblast differentiation and bone formation in vivo.	Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Missouri, Dept Oral Biol, Kansas City, MO 64108 USA	University of Rochester; University of Texas System; University of Texas Health San Antonio; University of Missouri System; University of Missouri Kansas City	Chen, D (corresponding author), Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, 601 Elmwood Ave, Rochester, NY 14642 USA.	di_chen@urmc.rochester.edu		Oyajobi, Babatunde/0000-0002-1064-3072	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051189, R03AR048920] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR048920, R01 AR051189-01, AR 051189, R03 AR048920-04, AR 048920, R01 AR051189, R03 AR048920-03] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	28	168	183	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12854	12859		10.1074/jbc.M313294200	http://dx.doi.org/10.1074/jbc.M313294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701828	Green Accepted, hybrid			2022-12-27	WOS:000220334900101
J	Wolfger, H; Mamnun, YM; Kuchler, K				Wolfger, H; Mamnun, YM; Kuchler, K			The yeast Pdr15p ATP-binding cassette (ABC) protein is a general stress response factor implicated in cellular detoxification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; OSMOTIC REGULATION; PLASMA-MEMBRANE; BUDDING YEAST; ELEMENT STRE; IN-VIVO; PDR3	ATP-binding cassette (ABC) transporters play important roles in drug efflux, but some may also function in cellular detoxification. The Pdr15p ABC protein is the closest homologue of the multidrug efflux transporter Pdr5p, which mediates pleiotropic drug resistance to hundreds of unrelated compounds. In this study, we show that the plasma membrane protein Pdr15p displays limited drug transport capacity, mediating chloramphenicol and detergent tolerance. Interestingly, Pdr15p becomes most abundant when cells exit the exponential growth phase, whereas its closest homologue, Pdr5p, disappears after exponential growth. Furthermore, in contrast to Pdr5p, Pdr15p is strongly induced by various stress conditions including heat shock, low pH, weak acids, or high osmolarity. PDR15 induction bypasses the Pdr1p/Pdr3p regulators but requires the general stress regulator Msn2p, which directly decorates the stress response elements in the PDR15 promoter. Remarkably, however, Pdr15p induction bypasses upstream components of the high osmolarity glycerol (HOG) pathway including the Hog1p and Pbs2p kinases as well as the dedicated HOG cell surface sensors. Our data provide evidence for a novel upstream branch of the general stress response pathway activating Msn2p. In addition, the results demonstrate a crosstalk between stress response and the pleiotropic drug resistance network.	Med Univ Vienna, Max F Perutz Labs, Div Mol Genet, Dept Biochem Med, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Vienna Biocenter (VBC)	Kuchler, K (corresponding author), Med Univ Vienna, Max F Perutz Labs, Div Mol Genet, Dept Biochem Med, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	karl.kuchler@univie.ac.at	kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Kaiser C., 1994, METHODS YEAST GENETI; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Kontoyiannis DP, 2000, J ANTIMICROB CHEMOTH, V46, P199, DOI 10.1093/jac/46.2.199; Kren A, 2003, MOL CELL BIOL, V23, P1775, DOI 10.1128/MCB.23.5.1775-1785.2003; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MOL CELL BIOL, V19, P5474; Rep M, 2001, MOL MICROBIOL, V40, P1067, DOI 10.1046/j.1365-2958.2001.02384.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SIKORSKI RS, 1989, GENETICS, V122, P19; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8	48	45	48	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11593	11599		10.1074/jbc.M311282200	http://dx.doi.org/10.1074/jbc.M311282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699125	hybrid			2022-12-27	WOS:000220157600092
J	Bondar, T; Ponomarev, A; Raychaudhuri, P				Bondar, T; Ponomarev, A; Raychaudhuri, P			Ddb1 is required for the proteolysis of the Schizosaccharomyces pombe replication inhibitor Spd1 during S phase and after DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COP9 SIGNALOSOME; FISSION YEAST; CULLIN 4A; PROTEIN; DEGRADATION; SCF; COP9/SIGNALOSOME; EXPRESSION; PATHWAY; COMPLEX	Recently we showed that the Schizosaccharomyces pombe ddb1 gene plays a role in S phase progression. A mutant S. pombe strain lacking expression of the ddb1 gene exhibited slow replication through both early and late regions causing a slow S phase phenotype. We attributed the phenotypes in the ddb1 strain to an increased activity of the replication checkpoint kinase Cds1. However, the basis for a high basal Cds1 activity in the ddb1 strain was not clear. It was shown that Ddb1 associates with the Cop9/signalosome. Moreover, the phenotypes of the Deltaddb1 strain are remarkably similar to the Deltacsn1 (or Deltacsn2) strain that lacks expression of the Csn1 (or Csn2) subunit of the Cop9/signalosome. Cop9/signalosome cooperates with Pcu4 to induce proteolysis of Spd1, which inhibits DNA replication by inhibiting ribonucleotide reductase. Therefore, we investigated whether Ddb1 is required for the proteolysis of Spd1. Here we show that a S. pombe strain lacking expression of Ddb1 fails to induce proteolysis of Spd1 in S phase and after DNA damage. Moreover, deletion of the spd1 gene attenuates the Cds1 kinase activity in cells lacking the expression of ddb1, suggesting that an accumulation of Spd1 results in the increase of Cds1 activity in the Deltaddb1 strain. In addition, the double mutant lacking spd1 and ddb1 no longer exhibits the growth defects and DNA damage sensitivity observed in the Deltaddb1 strain. Our results establish an essential role of Ddb1 in the proteolysis of Spd1. In addition, the observation provides evidence for a functional link between Ddb1 and the Cop9/signalosome.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 696, Chicago, IL 60607 USA.	Pradip@uic.edu	Bondar, Tanya/T-5576-2017	Bondar, Tanya/0000-0003-4765-8910	NCI NIH HHS [CA88863] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Bondar T, 2003, J BIOL CHEM, V278, P37006, DOI 10.1074/jbc.M303003200; Borgne A, 2000, J CELL SCI, V113, P4341; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chaboute ME, 2002, J BIOL CHEM, V277, P17845, DOI 10.1074/jbc.M200959200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Schroeder DF, 2002, CURR BIOL, V12, P1462, DOI 10.1016/S0960-9822(02)01106-5; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Woollard A, 1996, EMBO J, V15, P4603, DOI 10.1002/j.1460-2075.1996.tb00838.x; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7; Zolezzi F, 2002, J BIOL CHEM, V277, P41183, DOI 10.1074/jbc.M207890200	31	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9937	9943		10.1074/jbc.M312570200	http://dx.doi.org/10.1074/jbc.M312570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701809	hybrid			2022-12-27	WOS:000220050400035
J	Del Carpio, RV; Gonzalez-Nilo, FD; Jayaram, H; Spencer, E; Prasad, BVV; Patton, JT; Taraporewala, ZF				Del Carpio, RV; Gonzalez-Nilo, FD; Jayaram, H; Spencer, E; Prasad, BVV; Patton, JT; Taraporewala, ZF			Role of the histidine triad-like motif in nucleotide hydrolysis by the rotavirus RNA-packaging protein NSP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; VIRUS NONSTRUCTURAL PROTEIN; CASEIN KINASE-II; SIMIAN ROTAVIRUS-SA11; BINDING ACTIVITY; IN-VITRO; PHOSPHORYLATION; LOCALIZATION; MULTIMERS; RESIDUES	Octamers formed by the nonstructural protein NSP2 of rotavirus are proposed to function as molecular motors in the packaging of the segmented double-stranded RNA genome. The octamers have RNA binding, helix unwinding, and Mg2+-dependent NTPase activities and play a crucial role in assembly of viral replication factories (viroplasms). Comparison of x-ray structures has revealed significant structural homology between NSP2 and the histidine triad ( HIT) family of nucleotidyl hydrolases, which in turn has suggested the location of the active site for NTP hydrolysis in NSP2. Consistent with the structural predictions, we show here using site-specific mutagenesis and ATP docking simulations that the active site for NTP hydrolysis is localized to residues within a 25-Angstrom-deep cleft between the C- and N-terminal domains of the NSP2 monomer. Although lacking the precise signature HIT motif (HOHOHOO where O is a hydrophobic residue), our analyses demonstrate that histidines (His(221) and His(225)) represent critical residues of the active site. Similar to events occurring during nucleotide hydrolysis by HIT proteins, NTP hydrolysis by NSP2 was found to produce a short lived phosphorylated intermediate. Evaluation of the biological importance of the NTPase activity of NSP2 by transient expression in mammalian cells showed that such activity has no impact on the ability of NSP2 to induce the hyperphosphorylation of NSP5 or to interact with NSP5 to form viroplasm-like structures. Hence the NTPase activity of NSP2 probably has a role subsequent to the formation of viroplasms, consistent with its suspected involvement in RNA packaging and/or replication.	NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Santiago Chile, Fac Quim & Biol, Dept Ciencias Quim, Santiago, Chile; Univ Santiago Chile, Virol Lab, Santiago, Chile	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine; Universidad de Santiago de Chile; Universidad de Santiago de Chile	Taraporewala, ZF (corresponding author), NIAID, Infect Dis Lab, NIH, 50 South Dr,MSC 8026,Rm 6314, Bethesda, MD 20892 USA.	ztarapore@niaid.nih.gov	González-Nilo, Fernando/M-5671-2016; Patton, John T/P-1390-2014; González Nilo, Fernando Danilo/M-5368-2017; Patton, John/V-7651-2018	González-Nilo, Fernando/0000-0001-6857-3575; González Nilo, Fernando Danilo/0000-0001-6857-3575; Prasad, B.V.Venkataram/0000-0002-1172-2071; Patton, John/0000-0003-1572-0732; Spencer, Eugenio/0000-0001-6109-140X	NCRR NIH HHS [P41 RR002250, P41 RR007707] Funding Source: Medline; NIAID NIH HHS [P01 AI057788, AI36040, R37 AI036040, R01 AI036040] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR007707, P41RR002250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036040, R01AI036040, Z01AI000754, P01AI057788] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACCELRYS, 1997, INSIGHT 2 DELPHI USE; Afrikanova I, 1998, J GEN VIROL, V79, P2679, DOI 10.1099/0022-1317-79-11-2679; Afrikanova I, 1996, J GEN VIROL, V77, P2059, DOI 10.1099/0022-1317-77-9-2059; Blackhall J, 1997, J VIROL, V71, P138, DOI 10.1128/JVI.71.1.138-144.1997; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHEN DY, 1990, VIROLOGY, V178, P143, DOI 10.1016/0042-6822(90)90387-7; Eichwald C, 2002, J VIROL, V76, P3461, DOI 10.1128/JVI.76.7.3461-3470.2002; Fabbretti E, 1999, J GEN VIROL, V80, P333, DOI 10.1099/0022-1317-80-2-333; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLEGOS CO, 1989, VIROLOGY, V172, P616, DOI 10.1016/0042-6822(89)90204-3; Gonzalez RA, 1998, ARCH VIROL, V143, P981, DOI 10.1007/s007050050347; GONZALEZ SA, 1991, VIROLOGY, V182, P8, DOI 10.1016/0042-6822(91)90642-O; HELMBERGERJONES M, 1986, VIROLOGY, V155, P655, DOI 10.1016/0042-6822(86)90225-4; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HINRICHS MV, 1993, BIOCHEMISTRY-US, V32, P7310, DOI 10.1021/bi00079a030; Horscroft NJ, 2000, J GEN VIROL, V81, P1961, DOI 10.1099/0022-1317-81-8-1961; Jayaram H, 2002, NATURE, V417, P311, DOI 10.1038/417311a; Kapikian A. Z., 2001, FIELDS VIROLOGY, V2, P1787; KATTOURA MD, 1992, VIROLOGY, V191, P698, DOI 10.1016/0042-6822(92)90245-K; KATTOURA MD, 1994, VIROLOGY, V202, P803, DOI 10.1006/viro.1994.1402; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; McIntosh DB, 2003, ANN NY ACAD SCI, V986, P101, DOI 10.1111/j.1749-6632.2003.tb07145.x; MITCHELL DB, 1988, NUCLEIC ACIDS RES, V16, P6244, DOI 10.1093/nar/16.13.6244; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; PETRIE BL, 1982, J GEN VIROL, V63, P457, DOI 10.1099/0022-1317-63-2-457; PETRIE BL, 1984, VIRUS RES, V1, P133, DOI 10.1016/0168-1702(84)90069-8; Poncet D, 1997, J VIROL, V71, P34, DOI 10.1128/JVI.71.1.34-41.1997; RAMIG RF, 1984, J VIROL, V49, P665, DOI 10.1128/JVI.49.3.665-673.1984; Schuck P, 2001, J BIOL CHEM, V276, P9679, DOI 10.1074/jbc.M009398200; Taraporewala Z, 1999, J VIROL, V73, P9934, DOI 10.1128/JVI.73.12.9934-9943.1999; Taraporewala ZF, 2001, VIROLOGY, V280, P221, DOI 10.1006/viro.2000.0764; Taraporewala ZF, 2001, J VIROL, V75, P4519, DOI 10.1128/JVI.75.10.4519-4527.2001; Vende P, 2002, J VIROL, V76, P5291, DOI 10.1128/JVI.76.10.5291-5299.2002	38	31	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10624	10633		10.1074/jbc.M311563200	http://dx.doi.org/10.1074/jbc.M311563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699117	hybrid			2022-12-27	WOS:000220050400116
J	Kouchi, Z; Fukami, K; Shikano, T; Oda, S; Nakamura, Y; Takenawa, T; Miyazaki, S				Kouchi, Z; Fukami, K; Shikano, T; Oda, S; Nakamura, Y; Takenawa, T; Miyazaki, S			Recombinant phospholipase C zeta has high Ca2+ sensitivity and induces Ca2+ oscillations in mouse eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SPATIOTEMPORAL DYNAMICS; FERTILIZATION; ACTIVATION; RECEPTOR; OOCYTES; EMBRYO; DOMAIN; CELL; INVOLVEMENT	Sperm-specific phospholipase Czeta (PLCzeta) is known to induce intracellular Ca2+ oscillations and subsequent early embryonic development when expressed in mouse eggs by injection of RNA encoding PLCzeta (Saunders, C. M., Larman, M. G., Parrington, J., Cox, L. J., Royse, J., Blayney, L. M., Swann, K., and Lai, F. A. (2002) Development 129, 3533-3544). The present study addressed characteristics of purified mouse PLCzeta protein that was synthesized using the baculovirus/ Sf9 cell expression system. Microinjection of recombinant PLCzeta protein into mouse eggs induced serial Ca2+ spikes quite similar to those produced by the injection of sperm extract, probably because of repetitive Ca2+ release from the endoplasmic reticulum caused by continuously produced inositol 1,4,5-trisphosphate. Recombinant PLCzeta1 also induced Ca2+ oscillations, but a 20-fold higher concentration was required compared with PLCzeta. In the enzymatic assay of phosphatidylinositol 4,5-bisphosphate hydrolyzing activity in vitro at various calcium ion concentrations ([Ca2+]), PLCzeta exhibited a significant activity at [Ca2+] as low as 10 nM and had 70% maximal activity at 100 nM [Ca2+] that is usually the basal intracellular calcium ion concentration level of cells. On the other hand, the activity of PLCdelta1 increased at a [Ca2+] between 1 and 30 muM. EC50 was 52 nM for PLCzeta and 5.7 muM for PLCdelta1. Thus, PLCzeta has an similar to100-fold higher Ca2+ sensitivity than PLCdelta1. The ability of purified PLCzeta protein to induce Ca2+ oscillations qualifies PLCzeta as a proper candidate of the mammalian egg-activating sperm factor. Furthermore, such a high Ca2+ sensitivity of PLC activity as PLCzeta that can be active in cells at the resting state is thought to be an appropriate characteristic of the sperm factor, which is introduced into the ooplasm upon sperm-egg fusion, triggers Ca2+ release first, and maintains Ca2+ oscillations.	Tokyo Womens Med Univ, Dept Physiol, Sch Med, Shinjuku Ku, Tokyo 1628666, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, Tokyo 1920392, Japan	Tokyo Women's Medical University; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Kouchi, Z (corresponding author), Tokyo Womens Med Univ, Dept Physiol, Sch Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	zkouchi@research.twmu.ac.jp		Nakamura, Yoshikazu/0000-0001-8355-1091				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Deguchi R, 2000, DEV BIOL, V218, P299, DOI 10.1006/dbio.1999.9573; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Dupont G, 1996, BIOCHEM J, V316, P583, DOI 10.1042/bj3160583; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; Jones KT, 2000, BIOCHEM J, V346, P743, DOI 10.1042/0264-6021:3460743; Jones KT, 1998, INT J DEV BIOL, V42, P1; Jones KT, 2000, DEV BIOL, V225, P1, DOI 10.1006/dbio.2000.9826; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kumakiri J, 2003, DEV BIOL, V260, P522, DOI 10.1016/S0012-1606(03)00273-2; Lee WK, 1999, BIOCHEM BIOPH RES CO, V261, P393, DOI 10.1006/bbrc.1999.1035; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; Mehlmann LM, 1998, DEV BIOL, V203, P221, DOI 10.1006/dbio.1998.9051; MIYAZAKI S, 1993, JPN J PHYSIOL, V43, P409, DOI 10.2170/jjphysiol.43.409; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Nakano Y, 1997, MOL HUM REPROD, V3, P1087, DOI 10.1093/molehr/3.12.1087; Oda S, 1999, DEV BIOL, V209, P172, DOI 10.1006/dbio.1999.9233; Pawelczyk T, 1998, EUR J BIOCHEM, V257, P169, DOI 10.1046/j.1432-1327.1998.2570169.x; Rice A, 2000, DEV BIOL, V228, P125, DOI 10.1006/dbio.2000.9929; Sato Y, 1998, BIOL REPROD, V58, P867, DOI 10.1095/biolreprod58.3.867; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033	27	183	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10408	10412		10.1074/jbc.M313801200	http://dx.doi.org/10.1074/jbc.M313801200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701816	hybrid			2022-12-27	WOS:000220050400091
J	Pagans, S; Pineyro, D; Kosoy, A; Bernues, J; Azorin, F				Pagans, S; Pineyro, D; Kosoy, A; Bernues, J; Azorin, F			Repression by TTK69 of GAGA-mediated activation occurs in the absence of TTK69 binding to DNA and solely requires the contribution of the POZ/BTB domain of TTK69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; POZ DOMAIN; ECTOPIC EXPRESSION; BTB/POZ DOMAIN; DROSOPHILA EYE; FUSHI-TARAZU; CELL FATE	tramtrack 69 (TTK69) is known to repress GAGA-mediated activation of the eve promoter in S2 cells. Here, we show that repression by TTK69 occurs in the absence of bona fide TTK69-binding sites on the template, indicating that it does not require the binding of TTK69 to DNA. Consistent with this interpretation, the POZ/BTB domain of TTK69, which does not bind DNA, is sufficient for repression. Moreover, a fusion protein in which the POZ/BTB domain of GAGA is replaced by that of TTK69 is not capable of activating the eve promoter but efficiently represses GAGA-dependent activation. Repression involves GAGA-TTK69 interaction because TTK69 is not capable of repressing basal transcription. Most probably, GAGA-TTK69 interaction occurs at the promoter because GAGA . TTK69 complexes are fully competent in binding DNA in vitro. Our results also show that repression by TTK69 of GAGA-dependent activation of the eve promoter is not mediated by any of the co-repressors known to interact with TTK69 (dMi2 or C-terminal binding protein) or by trichostatin A-sensitive histone deacetylases. Altogether, these observations strongly suggest that the binding of TTK69 prevents the interaction of GAGA with the transcription machinery and, therefore, compromises its activation potential.	Consejo Super Invest Cient, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Barcelona 08034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Azorin, F (corresponding author), Consejo Super Invest Cient, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Jordi Girona Salgado 18-26, Barcelona 08034, Spain.	fambmc@cid.csic.es	Pagans, Sara/G-3407-2015; Azorin, Fernando/N-4388-2014; Bernues, Jordi/ABE-8360-2021	Pagans, Sara/0000-0003-0772-6982; Azorin, Fernando/0000-0002-8426-7858; Bernues, Jordi/0000-0001-6218-8254; Pineyro, David/0000-0001-5633-3339				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN JL, 1993, DEVELOPMENT, V117, P45; Courey AJ, 2001, GENE DEV, V15, P2786; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Giesen K, 1997, DEVELOPMENT, V124, P2307; Greenberg AJ, 2001, MOL CELL BIOL, V21, P8565, DOI 10.1128/MCB.21.24.8565-8574.2001; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kosoy A, 2002, J BIOL CHEM, V277, P42280, DOI 10.1074/jbc.M207505200; Lai ZC, 1999, GENETICS, V152, P299; Li XM, 1999, CANCER RES, V59, P5275; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Pagans S, 2002, NUCLEIC ACIDS RES, V30, P4406, DOI 10.1093/nar/gkf570; Pointud JC, 2001, DEV BIOL, V237, P368, DOI 10.1006/dbio.2001.0358; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Ryu JR, 2001, P NATL ACAD SCI USA, V98, P12960, DOI 10.1073/pnas.231394998; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Vaquero A, 2000, J BIOL CHEM, V275, P19461, DOI 10.1074/jbc.M000967200; Wen Y, 2000, GENETICS, V156, P195; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085	36	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9725	9732		10.1074/jbc.M313200200	http://dx.doi.org/10.1074/jbc.M313200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701830	hybrid			2022-12-27	WOS:000220050400010
J	Wang, HB; Ma, WG; Tejada, L; Zhang, H; Morrow, JD; Das, SK; Dey, SK				Wang, HB; Ma, WG; Tejada, L; Zhang, H; Morrow, JD; Das, SK; Dey, SK			Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MOUSE UTERUS; EMBRYO IMPLANTATION; EGF-RECEPTOR; IN-VITRO; MICE; DISRUPTION; OVULATION; PROSTAGLANDINS; INFLAMMATION	Cyclooxygenase-2 (COX-2), an inducible rate-limiting enzyme in prostaglandin biosynthesis, is implicated in various physiological and pathological processes including female fertility, renal function, angiogenesis, inflammation, and tumorigenesis. We showed previously that targeted deletion of Ptgs2 encoding COX-2, but not Ptgs1 encoding COX-1, in C57BL/6J/129 mice produces complete female infertility resulting from multiple reproductive failures spanning ovulation, fertilization, and implantation. Here we show that Ptgs2 null mice on a CD1 background have dramatically improved female fertility including ovulation, fertilization, and implantation, giving rise to live births. We provide evidence that this improved fertility in CD1 Ptgs2 null mice is the result of a compensatory up-regulation of Ptgs1 which does not occur in C57BL/6J/129 mice missing Ptgs2. These results clearly demonstrate for the first time that COX-1 can replace specific functions of COX-2 in vivo in the context of genetic disparity. In light of this finding, the therapeutic use and efficacy of COX-2-specific inhibitors among human populations without regard for genetic and ethnic diversities should be revisited.	Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Dev & Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dey, SK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, MCN-D4100, Nashville, TN 37232 USA.	sk.dey@vanderbilt.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R01HD037830, R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA006668, R01DA006668] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839] Funding Source: Medline; NICHD NIH HHS [HD37830, HD33994, HD12304] Funding Source: Medline; NIDA NIH HHS [DA06668] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [ES07814] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonyadi M, 1997, NAT GENET, V15, P207, DOI 10.1038/ng0297-207; Cambria-Kiely JA, 2002, J THROMB THROMBOLYS, V14, P51, DOI 10.1023/A:1022066305399; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; DAS SK, 1994, DEVELOPMENT, V120, P1071; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Ewart-Toland A, 1999, ENDOCRINOLOGY, V140, P732, DOI 10.1210/en.140.2.732; Flower RJ, 2003, NAT REV DRUG DISCOV, V2, P179, DOI 10.1038/nrd1034; Fowler KJ, 2000, GENOME RES, V10, P30; Gupta RA, 2003, CANCER RES, V63, P906; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Li DK, 2003, BRIT MED J, V327, P368, DOI 10.1136/bmj.327.7411.368; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Ma WG, 2003, P NATL ACAD SCI USA, V100, P2963, DOI 10.1073/pnas.0530162100; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; Nielsen GL, 2001, BRIT MED J, V322, P266, DOI 10.1136/bmj.322.7281.266; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Reese J, 2000, P NATL ACAD SCI USA, V97, P9759, DOI 10.1073/pnas.97.17.9759; SIROIS J, 1992, J BIOL CHEM, V267, P11586; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song H, 2002, DEVELOPMENT, V129, P2879; Spearow JL, 1999, BIOL REPROD, V61, P851, DOI 10.1095/biolreprod61.4.851; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; VIGGIANO JM, 1995, PROSTAG LEUKOTR ESS, V53, P261, DOI 10.1016/0952-3278(95)90125-6; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304	33	89	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10649	10658		10.1074/jbc.M312203200	http://dx.doi.org/10.1074/jbc.M312203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701858	hybrid			2022-12-27	WOS:000220050400119
J	Cheng, BK; Feng, JY; Gadgil, S; Tse-Dinh, YC				Cheng, BK; Feng, JY; Gadgil, S; Tse-Dinh, YC			Flexibility at Gly-194 is required for DNA cleavage and relaxation activity of Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; MECHANISM; MUTATIONS; RESIDUES; PROTEIN; REGION	The proposed mechanism of type IA DNA topoisomerase I includes conformational changes by the single enzyme polypeptide to allow binding of the G strand of the DNA substrate at the active site, and the opening or closing of the "gate" created on the G strand of DNA to the passing single or double DNA strand(s) through the cleaved G strand DNA. The shifting of an alpha helix upon G strand DNA binding has been observed from the comparison of the type IA DNA topoisomerase crystal structures (Changela, A., DiGate, R. J., and Mondragon, A. ( 2001) Nature 411, 1077 - 1081). Site-directed mutagenesis of the strictly conserved Gly-194 at the N terminus of this alpha helix in Escherichia coli DNA topoisomerase I showed that flexibility around this glycine residue is required for DNA cleavage and relaxation activity and supports a functional role for this hinge region in the enzyme conformational change.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Tse-Dinh, YC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	yuk-ching_tse-dinh@nymc.edu			NIGMS NIH HHS [R01 GM054226, GM54226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-13; Caron PR, 1999, METH MOL B, V94, P279; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2002, TRENDS PHARMACOL SCI, V23, P199, DOI 10.1016/S0165-6147(02)01997-1; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Keck JL, 1999, NAT STRUCT BIOL, V6, P900; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; McCormack EA, 2001, J STRUCT BIOL, V135, P198, DOI 10.1006/jsbi.2001.4385; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; Perry K, 2002, J BIOL CHEM, V277, P13237, DOI 10.1074/jbc.M112019200; Rafferty JA, 1997, BBA-PROTEIN STRUCT M, V1342, P90, DOI 10.1016/S0167-4838(97)00095-2; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; TSE YC, 1980, J BIOL CHEM, V255, P5560; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; Zhu CX, 1999, METH MOL B, V94, P145; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783	25	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8648	8654		10.1074/jbc.M312095200	http://dx.doi.org/10.1074/jbc.M312095200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14711811	hybrid			2022-12-27	WOS:000189265900017
J	Korn, ED				Korn, ED			The discovery of unconventional myosins: Serendipity or luck?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACTIVATED LIPOPROTEIN LIPASE; ACTIN-BASED MOTILITY; ACANTHAMOEBA MYOSIN; PHOSPHORYLATION SITES; MG2&-ATPASE ACTIVITY; COFACTOR PROTEIN; CLEARING FACTOR; TAIL DOMAINS; LATEX BEADS		NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Korn, ED (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	edk@nih.gov		Korn, Edward/0000-0003-3867-6295	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000506, Z01HL000506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN MR, 1969, BIOCHEMISTRY-US, V8, P4976, DOI 10.1021/bi00840a047; ADELSTEI.RS, 1972, P NATL ACAD SCI USA, V69, P3693, DOI 10.1073/pnas.69.12.3693; ADELSTEIN RS, 1971, P NATL ACAD SCI USA, V68, P2703, DOI 10.1073/pnas.68.11.2703; ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; ANDERSON NG, 1950, P SOC EXP BIOL MED, V74, P768; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BOWERS B, 1968, J CELL BIOL, V39, P95, DOI 10.1083/jcb.39.1.95; BROWN RK, 1953, J BIOL CHEM, V204, P423; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1988, J BIOL CHEM, V263, P427; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CHANTLER PD, 1981, NATURE, V292, P581, DOI 10.1038/292581a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; DAVIDOFF F, 1963, J BIOL CHEM, V238, P3199; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GADASI H, 1979, J BIOL CHEM, V254, P8095; GADASI H, 1979, J BIOL CHEM, V254, P3631; GADASI H, 1980, NATURE, V286, P452, DOI 10.1038/286452a0; GALL JG, 2001, LANDMARKS PAPERS CEL, P455; GOFMAN JW, 1950, SCIENCE, V111, P166, DOI 10.1126/science.111.2877.166; GORDON DJ, 1977, J BIOL CHEM, V252, P8300; Hahn PF, 1943, SCIENCE, V98, P19, DOI 10.1126/science.98.2531.19; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HAMMER JA, 1986, P NATL ACAD SCI USA, V83, P4655, DOI 10.1073/pnas.83.13.4655; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P490, DOI 10.1073/pnas.79.2.490; Hirokawa N, 2003, TRENDS BIOCHEM SCI, V28, P558, DOI 10.1016/j.tibs.2003.08.006; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KORN E D, 1974, Journal of Supramolecular Structure, V2, P517, DOI 10.1002/jss.400020502; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; Korn ED, 2000, P NATL ACAD SCI USA, V97, P12559, DOI 10.1073/pnas.230441597; KORN ED, 1954, SCIENCE, V120, P399, DOI 10.1126/science.120.3114.399-a; KORN ED, 1963, J BIOL CHEM, V238, P3584; KORN ED, 1967, J CELL BIOL, V34, P219, DOI 10.1083/jcb.34.1.219; KORN ED, 1955, J BIOL CHEM, V215, P1; KORN ED, 1955, J BIOL CHEM, V215, P15; Kornberg A, 2003, TRENDS BIOCHEM SCI, V28, P515, DOI 10.1016/j.tibs.2003.08.007; Liu X, 2000, J BIOL CHEM, V275, P24886, DOI 10.1074/jbc.M004287200; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MARUTA H, 1977, J BIOL CHEM, V252, P399; MARUTA H, 1977, J BIOL CHEM, V252, P6501; MCBRIDE OW, 1964, J LIPID RES, V5, P459; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NEFF RJ, 1957, J PROTOZOOL, V4, P176, DOI 10.1111/j.1550-7408.1957.tb02505.x; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1978, J BIOL CHEM, V253, P4798; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Redowicz MJ, 2002, ACTA BIOCHIM POL, V49, P789; STRAUB FB, 1943, STUD I MED CHEM U SZ, V2, P3; Taylor EW, 2001, MOL BIOL CELL, V12, P251, DOI 10.1091/mbc.12.2.251; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; VANDEKERCKHOVE J, 1984, J MOL BIOL, V172, P141, DOI 10.1016/0022-2836(84)90418-2; WAGNER P, 1978, NATURE, V274, P846, DOI 10.1038/274846a0; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEIHING RR, 1969, BIOCHEM BIOPH RES CO, V35, P906, DOI 10.1016/0006-291X(69)90710-4; WEISMAN RA, 1967, BIOCHEMISTRY-US, V6, P485, DOI 10.1021/bi00854a017	70	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8517	8525		10.1074/jbc.X300010200	http://dx.doi.org/10.1074/jbc.X300010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14724268	hybrid			2022-12-27	WOS:000189265900001
J	Kwon, G; Pappan, KL; Marshall, CA; Schaffer, JE; McDaniel, ML				Kwon, G; Pappan, KL; Marshall, CA; Schaffer, JE; McDaniel, ML			cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; INDEPENDENT SIGNALING PATHWAY; CYCLIC-AMP; GENE-TRANSCRIPTION; EPAC; RAP1; POLYPEPTIDE; ACTIVATION; RELEASE; OBESITY	Lipid accumulation in pancreatic beta-cells is thought to cause its dysfunction and/or destruction via apoptosis. Our studies show that incubation of the beta-cell line RINm5F with the saturated free fatty acids (FFA) palmitate caused apoptosis based on increases in caspase 3 activity, Annexin V staining, and cell death. Furthermore, exposure of RINm5F cells to cAMP-increasing agents, 3-isobutyl-1-methylxanthine (IBMX), and forskolin completely abolished palmitate-mediated caspase 3 activity and significantly inhibited Annexin V staining and cell death. The cyclic AMP analogs cpt-cAMP and dibutyryl-cAMP mimicked the protective effects of IBMX and forskolin, suggesting that cAMP is the mediator of the anti-apoptotic effects. The protective action of IBMX and forskolin was rapid and did not appear to require gene transcription or new protein synthesis. However, these protective effects were clearly independent of protein kinase A (PKA) because of the lack of inhibition by the PKA inhibitors H-89 and KT5720. In attempts to identify this PKA-independent mechanism, we found that the newly developed cAMP analog 8CPT-2Me-cAMP, which selectively activates the cAMP-dependent guanine nucleotide exchange factor (cAMP-GEF) pathway, mimicked the protective effects of IBMX and forskolin, suggesting that the cAMP-GEF pathway is involved. In addition, both glucagon-like peptide (GLP-1) and its receptor agonist, Exenatide, inhibited palmitate-mediated caspase 3 activation in a dose-dependent manner. Unexpectedly, H-89 partially reversed the protective effects of GLP-1 and Exenatide, suggesting that PKA may play a role in the protective effects of these incretins. To explain these seemingly conflicting results, we demonstrated that low concentrations of cAMP produced by GLP-1 and Exenatide preferentially activate the PKA pathway, whereas higher cAMP concentrations produced by IBMX and forskolin activate the more dominant cAMP-GEF pathway. Taken together, these results indicate that intracellular concentrations of cAMP may play a key role in determining divergent signaling pathways that lead to antiapoptotic responses.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	mcdaniel@pathology.wustl.edu	Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK006181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-06181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Bok J, 2003, J NEUROSCI, V23, P777; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Ding WQ, 2003, CELL SIGNAL, V15, P27, DOI 10.1016/S0898-6568(02)00051-7; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Farilla L, 2002, ENDOCRINOLOGY, V143, P4397, DOI 10.1210/en.2002-220405; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; Gasperini S, 2002, EUR CYTOKINE NETW, V13, P47; Grbovic O, 2002, CANCER INVEST, V20, P972, DOI 10.1081/CNV-120005913; Hamelink C, 2002, J NEUROSCI, V22, P5310; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hecquet C, 2002, ONCOGENE, V21, P6101, DOI 10.1038/sj.onc.1205765; Holst JJ, 2002, DIABETES-METAB RES, V18, P430, DOI 10.1002/dmrr.328; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; Kang G., 2002, J PHYSL, V546, P175; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Leech CA, 2000, BIOCHEM BIOPH RES CO, V278, P44; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; Sakamoto C, 2003, INT J HEMATOL, V77, P60, DOI 10.1007/BF02982604; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Webster CRL, 2002, AM J PHYSIOL-GASTR L, V283, pG727, DOI 10.1152/ajpgi.00410.2001; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338	29	100	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8938	8945		10.1074/jbc.M310330200	http://dx.doi.org/10.1074/jbc.M310330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688288	hybrid			2022-12-27	WOS:000189265900052
J	Hinton, PR; Johlfs, MG; Xiong, JM; Hanestad, K; Ong, KC; Bullock, C; Keller, S; Tang, MT; Tso, JY; V squez, M; Tsurushita, N				Hinton, PR; Johlfs, MG; Xiong, JM; Hanestad, K; Ong, KC; Bullock, C; Keller, S; Tang, MT; Tso, JY; V squez, M; Tsurushita, N			Engineered human IgG antibodies with longer serum half-lives in primates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEONATAL FC RECEPTOR; AMINO-ACID-RESIDUES; I-RELATED RECEPTOR; CRYSTAL-STRUCTURE; CONSTANT REGION; BINDING; COMPLEX; MOUSE; ANTIGEN; SITE	The neonatal Fe receptor (FcRn) plays an important role in regulating the serum half-lives of IgG antibodies. A correlation has been established between the pH-dependent binding affinity of IgG antibodies to FcRn and their serum half-lives in mice. In this study, molecular modeling was used to identify Fe positions near the FcRn binding site in a human IgG antibody that, when mutated, might alter the binding affinity of IgG to FcRn. Following mutagenesis, several IgG, mutants with increased binding affinity to human FcRn at pH 6.0 were identified at Fc positions 250 and 428. These mutants do not bind to human FcRn at pH 7.5. A pharmacokinetics study of two mutant IgG(2) antibodies with increased FcRn binding affinity indicated that they had serum half-lives in rhesus monkeys similar to2-fold longer than the wild-type antibody.	Prot Design Labs Inc, Fremont, CA 94555 USA		Hinton, PR (corresponding author), Prot Design Labs Inc, Fremont, CA 94555 USA.	phinton@pdl.com						BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CO MS, 1992, J IMMUNOL, V148, P1149; Cole MS, 1997, J IMMUNOL, V159, P3613; Dall'Acqua WF, 2002, J IMMUNOL, V169, P5171, DOI 10.4049/jimmunol.169.9.5171; EHRLICH P H, 1992, Human Antibodies and Hybridomas, V3, P2; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kabat EA, 1991, SEQUENCES PROTEINS I; Kim JK, 1999, EUR J IMMUNOL, V29, P2819, DOI 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Medesan C, 1997, J IMMUNOL, V158, P2211; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Simmons LC, 2002, J IMMUNOL METHODS, V263, P133, DOI 10.1016/S0022-1759(02)00036-4; TAO MH, 1989, J IMMUNOL, V143, P2595; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Weng ZP, 1998, J MOL BIOL, V282, P217, DOI 10.1006/jmbi.1998.2020; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	203	530	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6213	6216		10.1074/jbc.C300470200	http://dx.doi.org/10.1074/jbc.C300470200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14699147	hybrid			2022-12-27	WOS:000188969200003
J	Santos, AD; McIntosh, JM; Hillyard, DR; Cruz, LJ; Olivera, BM				Santos, AD; McIntosh, JM; Hillyard, DR; Cruz, LJ; Olivera, BM			The A-superfamily of conotoxins - Structural and functional divergence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONUS-VENOM PEPTIDES; ALPHA-CONOTOXIN; RECEPTOR; TARGETS; SNAILS; LYASE	The generation of functional novelty in proteins encoded by a gene superfamily is seldom well documented. In this report, we define the A-conotoxin superfamily, which is widely expressed in venoms of the predatory cone snails (Conus), and show how gene products that diverge considerably in structure and function have arisen within the same superfamily. A cDNA clone encoding alpha-conotoxin GI, the first conotoxin characterized, provided initial data that identified the A-superfamily. Conotoxin precursors in the A-superfamily were identified from six Conus species: most (11/16) encoded alpha-conotoxins, but some (5/16) belong to a family of excitatory peptides, the kappaA-conotoxins that target voltage-gated ion channels. alpha-Conotoxins are two-disulfide-bridged nicotinic antagonists, 13-19 amino acids in length; kappaA-conotoxins are larger (31-36 amino acids) with three disulfide bridges. Purification and biochemical characterization of one peptide, kappaA-conotoxin MIVA is reported; five of the other predicted conotoxins were previously venom-purified. A comparative analysis of conotoxins purified from venom, and their precursors reveal novel post-translational processing, as well as mutational events leading to polymorphism. Patterns of sequence divergence and Cys codon usage define the major superfamily branches and suggest how these separate branches arose.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Philippines, Inst Mol Biol & Biotechnol, Quezon City 1101, Philippines; Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman; University of the Philippines System; University of the Philippines Diliman	Olivera, BM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	olivera@biology.utah.edu			NIGMS NIH HHS [GM-48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Conticello SG, 2001, MOL BIOL EVOL, V18, P120, DOI 10.1093/oxfordjournals.molbev.a003786; Craig AG, 1998, BIOCHEMISTRY-US, V37, P16019, DOI 10.1021/bi981690a; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; GRAY WR, 1981, J BIOL CHEM, V256, P4734; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KAHN AJ, 1994, LIFE HIST BIOGEOGRAP; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; Lu BS, 1999, PEPTIDES, V20, P1139; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Miles LA, 2002, J BIOL CHEM, V277, P43033, DOI 10.1074/jbc.M206690200; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; Olivera BM, 2002, ANNU REV ECOL SYST, V33, P25, DOI 10.1146/annurev.ecolsys.33.010802.150424; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; OLIVERA BM, 1996, Patent No. 5589340; PING DS, 1995, J BIOL CHEM, V270, P29250, DOI 10.1074/jbc.270.49.29250; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS AD, 1993, THESIS U PHILIPPINES; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; Shon KJ, 1998, J NEUROSCI, V18, P4473; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065; Zoli M, 2002, J NEUROSCI, V22, P8785	32	108	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17596	17606		10.1074/jbc.M309654200	http://dx.doi.org/10.1074/jbc.M309654200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14701840	hybrid			2022-12-27	WOS:000220870400088
J	Huang, MD; Furie, BC; Furie, B				Huang, MD; Furie, BC; Furie, B			Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING SITE; CARBOXYGLUTAMIC ACID DOMAIN; ELECTRON-DENSITY MAPS; K-DEPENDENT PROTEINS; BLOOD-COAGULATION; MEMBRANE-BINDING; HEMOPHILIA-B; PROTHROMBIN FRAGMENT-1; BOVINE PROTHROMBIN; POINT MUTATIONS	The binding of Factor IX to membranes during blood coagulation is mediated by the N-terminal gamma-carboxyglutamic acid-rich (Gla) domain, a membrane-anchoring domain found on vitamin K-dependent blood coagulation and regulatory proteins. Conformation-specific anti-Factor IX antibodies are directed at the calcium-stabilized Gla domain and interfere with Factor IX-membrane interaction. One such antibody, 10C12, recognizes the calcium-stabilized form of the Gla domain of Factor IX. We prepared the fully carboxylated Gla domain of Factor IX by solid phase peptide synthesis and crystallized Factor IX-(1- 47) in complex with Fab fragments of the 10C12 antibody. The overall structure of the Gla domain in the Factor IX-(1 - 47)-antibody complex at 2.2 Angstrom is similar to the structure of the Factor IX Gla domain in the presence of calcium ions as determined by NMR spectroscopy (Freedman, S. J., Furie, B. C., Furie, B., and Baleja, J. D. (1995) Biochemistry 34, 12126 - 12137) and by x-ray crystallography (Shikamoto, Y., Morita, T., Fujimoto, Z., and Mizuno, H. (2003) J. Biol. Chem. 278, 24090 - 24094). The complex structure shows that the complementarity determining region loops of the 10C12 antibody form a hydrophobic pocket to accommodate the hydrophobic patch of the Gla domain consisting of Leu-6, Phe-9, and Val-10. Polar interactions also play an important role in the antibody-antigen recognition. Furthermore, the calcium coordination network of the Factor IX Gla domain is different than in Gla domain structures of other vitamin K-dependent proteins. We conclude that this antibody is directed at the membrane binding site in the omega loop of Factor IX and blocks Factor IX function by inhibiting its interaction with membranes.	Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Furie, B (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, 330 Brookline Ave, Boston, MA 02215 USA.		Huang, Mingdong/J-4278-2017	Huang, Mingdong/0000-0003-0085-9141				Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FREEDMAN SJ, 1995, J BIOL CHEM, V270, P7980, DOI 10.1074/jbc.270.14.7980; FURIE B, 1979, J BIOL CHEM, V254, P9766; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Gillis S, 1997, PROTEIN SCI, V6, P185; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gui T, 2002, BLOOD, V100, P153, DOI 10.1182/blood.V100.1.153; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; Huang MD, 2003, NAT STRUCT BIOL, V10, P751, DOI 10.1038/nsb971; Jalbert LR, 1996, BIOCHEMISTRY-US, V35, P7093, DOI 10.1021/bi960290p; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS RM, 1983, BIOCHEMISTRY-US, V22, P948, DOI 10.1021/bi00273a037; Li LP, 1997, BIOCHEMISTRY-US, V36, P2132, DOI 10.1021/bi962250r; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LIEBMAN HA, 1985, P NATL ACAD SCI USA, V82, P3879, DOI 10.1073/pnas.82.11.3879; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; MERRITT EA, 1997, METHOD ENZYMOL, V277, P502; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Refino CJ, 2002, ARTERIOSCL THROM VAS, V22, P517, DOI 10.1161/hq0302.105375; Refino CJ, 1999, THROMB HAEMOSTASIS, V82, P1188; Rowley G, 1995, GENOMICS, V30, P574, DOI 10.1006/geno.1995.1279; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Suggett S, 2000, BLOOD COAGUL FIBRIN, V11, P27, DOI 10.1097/00001721-200011010-00004; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; TAI MM, 1980, J BIOL CHEM, V255, P2790; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Wojcik EGC, 1998, BBA-PROTEIN STRUCT M, V1382, P91, DOI 10.1016/S0167-4838(97)00149-0; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	48	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14338	14346		10.1074/jbc.M314011200	http://dx.doi.org/10.1074/jbc.M314011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722079	hybrid, Green Published			2022-12-27	WOS:000220478500129
J	Jeanneau, C; Chazalet, V; Auge, C; Soumpasis, DM; Harduin-Lepers, A; Delannoy, P; Imberty, A; Breton, C				Jeanneau, C; Chazalet, V; Auge, C; Soumpasis, DM; Harduin-Lepers, A; Delannoy, P; Imberty, A; Breton, C			Structure-function analysis of the human sialyltransferase ST3Gal I - Role of N-glycosylation and a novel conserved sialylmotif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND; LOCALIZATION; RECOGNITION; MECHANISM; RESIDUES; HOMOLOGY; MOUSE; DONOR; DIMER	All eukaryotic sialyltransferases have in common the presence in their catalytic domain of several conserved peptide regions (sialylmotifs L, S, and VS). Functional analysis of sialylmotifs L and S previously demonstrated their involvement in the binding of donor and acceptor substrates. The region comprised between the sialylmotifs S and VS contains a stretch of four highly conserved residues, with the following consensus sequence (H/ y) Y(Y/F/W/h)(E/D/q/g). (Capital letters and lowercase letters indicate a strong or low occurrence of the amino acid, respectively.) The functional importance of these residues and of the conserved residues of motif VS (HX4E) was assessed using as a template the human ST3Gal I. Mutational analysis showed that residues His(299) and Tyr(300) of the new motif, and His(316) of the VS motif, are essential for activity since their substitution by alanine yielded inactive enzymes. Our results suggest that the invariant Tyr residue (Tyr(300)) plays an important conformational role mainly attributable to the aromatic ring. In contrast, the mutants W301F, E302Q, and E321Q retained significant enzyme activity (25 - 80% of the wild type). Kinetic analyses and CDP binding assays showed that none of the mutants tested had any significant effect in nucleotide donor binding. Instead the mutant proteins were affected in their binding to the acceptor and/or demonstrated lower catalytic efficiency. Although the human ST3Gal I has four N-glycan attachment sites in its catalytic domain that are potentially glycosylated, none of them was shown to be necessary for enzyme activity. However, N-glycosylation appears to contribute to the proper folding and trafficking of the enzyme.	Univ Grenoble 1, Ctr Rech Macromol Vegetales, CNRS, GDR 2590, F-38041 Grenoble, France; Univ Paris 11, CNRS, UMR 8614, F-91405 Orsay, France; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; USTL, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Technical University of Denmark; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Breton, C (corresponding author), CNRS, CERMAV, BP 53, F-38041 Grenoble 9, France.	Christelle.Breton@cermav.cnrs.fr	Anne, Harduin-Lepers/O-7503-2017; Imberty, Anne/P-6451-2018	Anne, Harduin-Lepers/0000-0002-1233-3799; Imberty, Anne/0000-0001-6825-9527; Delannoy, Philippe/0000-0001-6467-7553				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Breton C, 2002, BIOCHEM SOC SYMP, V69, P23; Breton C, 1998, J BIOCHEM, V123, P1000; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 2001, J BIOL CHEM, V276, P15200, DOI 10.1074/jbc.M010542200; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; Donadio S, 2003, BIOCHIMIE, V85, P311, DOI 10.1016/S0300-9084(03)00080-4; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Kapitonov D, 1999, GLYCOCONJUGATE J, V16, P337, DOI 10.1023/A:1007091926413; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; Laroy W, 2001, GLYCOBIOLOGY, V11, P175, DOI 10.1093/glycob/11.3.175; Legaigneur P, 2001, J BIOL CHEM, V276, P21608, DOI 10.1074/jbc.M100860200; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Qian R, 2001, J BIOL CHEM, V276, P28641, DOI 10.1074/jbc.M103664200; Sarkar M, 1998, GLYCOCONJUGATE J, V15, P193, DOI 10.1023/A:1006928624913; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Vallejo-Ruiz V, 2001, BBA-PROTEIN STRUCT M, V1549, P161, DOI 10.1016/S0167-4838(01)00257-6; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151	32	95	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13461	13468		10.1074/jbc.M311764200	http://dx.doi.org/10.1074/jbc.M311764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722111	hybrid			2022-12-27	WOS:000220478500024
J	Goumon, Y; Angelone, T; Schoentgen, FO; Chasserot-Golaz, S; Almas, B; Fukami, MM; Langley, K; Welters, ID; Tota, B; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Angelone, T; Schoentgen, FO; Chasserot-Golaz, S; Almas, B; Fukami, MM; Langley, K; Welters, ID; Tota, B; Aunis, D; Metz-Boutigue, MH			The hippocampal cholinergic neurostimulating peptide, the N-terminal fragment of the secreted phosphatidylethanolamine-binding protein, possesses a new biological activity on cardiac physiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; DOPAMINE-BETA-HYDROXYLASE; CHROMOGRANIN-A; CHROMAFFIN GRANULES; ENDOCARDIAL ENDOTHELIUM; CARBOXYPEPTIDASE-Y; PROCESSING ENZYME; CRYSTAL-STRUCTURE; PROENKEPHALIN-A; CELLS	Phosphatidylethanolamine- binding protein ( PEBP), alternatively named Raf- 1 kinase inhibitor protein, is the precursor of the hippocampal cholinergic neurostimulating peptide ( HCNP) corresponding to its natural N- terminal fragment, previously described to be released by hippocampal neurons. PEBP is a soluble cytoplasmic protein, also associated with plasma and reticulum membranes of numerous cell types. In the present report, using biochemistry and cell biology techniques, we report for the first time the presence of PEBP in bovine chromaffin cell, a well described secretion model. We have examined its presence at the subcellular level and characterized this protein on both secretory granule membranes and intragranular matrix. In addition, its presence in bovine chromaffin cell and platelet exocytotic medium, as well as in serum, was reported showing that it is secreted. Like many other proteins that lack signal sequence, PEBP may be secreted through non- classic signal secretory mechanisms, which could be due to interactions with granule membrane lipids and lipid rafts. By two- dimensional liquid chromatography- tandem mass spectrometry, HCNP was detected among the intragranular matrix components. The observation that PEBP and HCNP were secreted with catecholamines into the circulation prompted us to investigate endocrine effects of this peptide on cardiovascular system. By using as bioassay an isolated and perfused frog ( Rana esculenta) heart preparation, we show here that HCNP acts on the cardiac mechanical performance exerting a negative inotropism and counteracting the adrenergic stimulation of isoproterenol. All together, these data suggest that PEBP and HCNP might be considered as new endocrine factors involved in cardiac physiology.	INSERM, U575, F-67084 Strasbourg, France; Univ Calabria, Dept Cell Biol, Lab Cardiovasc Physiol, I-87030 Arcavacata Di Rende, Italy; CNRS, UPR 4301, Ctr Biophys Mol, F-45071 Orleans, France; CNRS, UPR 2356, F-67084 Strasbourg, France; Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Giessen, Dept Anaesthesiol Intens Care & Pain Med, D-35385 Giessen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Calabria; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Justus Liebig University Giessen	Metz-Boutigue, MH (corresponding author), INSERM, U575, IFR 37, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Angelone, Tommaso/AAM-1230-2020; Langley, Keith/M-7516-2014; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017	Angelone, Tommaso/0000-0001-7797-7862; Welters, Ingeborg/0000-0002-3408-8798; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Goumon, Yannick/0000-0003-4336-3437				Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; Bond J. S., 1989, PROTEOLYTIC ENZYMES, P240; Bruun AW, 1998, BIOCHEMISTRY-US, V37, P3351, DOI 10.1021/bi971286w; Carvalho AL, 2002, J MOL BIOL, V322, P325, DOI 10.1016/S0022-2836(02)00705-2; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; Dahl A, 2003, RAPID COMMUN MASS SP, V17, P2195, DOI 10.1002/rcm.1183; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; DREYFUS H, 1977, BIOCHIM BIOPHYS ACTA, V489, P89, DOI 10.1016/0005-2760(77)90235-1; EIDEN LE, 1987, J NEUROCHEM, V49, P65, DOI 10.1111/j.1471-4159.1987.tb03395.x; EVANGELISTA R, 1982, BIOCHEM BIOPH RES CO, V106, P895, DOI 10.1016/0006-291X(82)91795-8; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; FUKAMI MH, 2001, HEMOSTASIS THROMBOSI, P561; FURIE B, 1992, NEW ENGL J MED, V326, P800; Gattuso A, 1999, AM J PHYSIOL-HEART C, V276, pH633, DOI 10.1152/ajpheart.1999.276.2.H633; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HELLE KB, 1971, BIOCHIM BIOPHYS ACTA, V245, P94, DOI 10.1016/0005-2728(71)90011-9; HELLE KB, 1969, PHARMACOL RES COMMUN, V1, P25; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Hook VYH, 1996, ANN NY ACAD SCI, V780, P121, DOI 10.1111/j.1749-6632.1996.tb15116.x; HORTNAGL H, 1974, J NEUROCHEM, V22, P197, DOI 10.1111/j.1471-4159.1974.tb12201.x; Hwang SR, 1999, J BIOL CHEM, V274, P34164, DOI 10.1074/jbc.274.48.34164; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Katada E, 2000, J NEUROCYTOL, V29, P199, DOI 10.1023/A:1026555107647; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; KUHN DM, 1990, J BIOL CHEM, V265, P5780; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leone Marc, 2002, Curr Opin Crit Care, V8, P395, DOI 10.1097/00075198-200210000-00005; LINDBERG I, 1982, LIFE SCI, V31, P1713, DOI 10.1016/0024-3205(82)90192-8; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Mima J, 2003, J BIOL CHEM, V278, P29792, DOI 10.1074/jbc.M301859200; MIZUNO K, 1985, BIOCHEM BIOPH RES CO, V128, P884, DOI 10.1016/0006-291X(85)90129-9; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; Otsuka Y, 1996, NEUROCHEM RES, V21, P369, DOI 10.1007/BF02531654; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; ROUSSEL G, 1988, DEV NEUROSCI-BASEL, V10, P65, DOI 10.1159/000111957; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; RUSH RA, 1980, CRC CR REV CL LAB SC, V12, P241, DOI 10.3109/10408368009108731; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SAUNDERS PTK, 1995, MOL CELL ENDOCRINOL, V107, P221, DOI 10.1016/0303-7207(94)03447-2; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SIMON JP, 1989, BIOCHEM J, V262, P1; Slimane TA, 2002, FEBS LETT, V529, P54, DOI 10.1016/S0014-5793(02)03183-6; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; SUZUKI H, 1995, EXP MOL PATHOL, V62, P63, DOI 10.1006/exmp.1995.1007; Sys SU, 1997, J EXP BIOL, V200, P3109; TERLAND O, 1980, BIOCHIM BIOPHYS ACTA, V597, P318, DOI 10.1016/0005-2736(80)90109-1; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Thiriet N, 2001, EUR J NEUROSCI, V14, P1702, DOI 10.1046/j.0953-816x.2001.01791.x; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Tota B, 2003, REGUL PEPTIDES, V114, P123, DOI 10.1016/S0167-0115(03)00112-5; Towbin H, 1992, Biotechnology, V24, P145; Tsugu Y, 1998, EUR J NEUROL, V5, P561, DOI 10.1046/j.1468-1331.1998.560561.x; Turner KJ, 1996, J ANDROL, V17, P127; Vallee BS, 2001, EUR J BIOCHEM, V268, P5831, DOI 10.1046/j.0014-2956.2001.02528.x; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Wortsman J, 2002, ENDOCRIN METAB CLIN, V31, P79, DOI 10.1016/S0889-8529(01)00024-X; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; YOO SH, 1994, J BIOL CHEM, V269, P12001; Zhang CF, 2003, BIOCHEM J, V369, P453, DOI 10.1042/BJ20020827	68	46	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13054	13064		10.1074/jbc.M308533200	http://dx.doi.org/10.1074/jbc.M308533200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724289	Green Published, hybrid			2022-12-27	WOS:000220334900126
J	Kim, MH; Hersh, LB				Kim, MH; Hersh, LB			The vesicular acetylcholine transporter interacts with clathrin-associated adaptor complexes AP-1 and AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; SYNAPTIC VESICLE ENDOCYTOSIS; TAIL SORTING SIGNALS; TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; PROTEIN COMPLEX; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; RAPID INTERNALIZATION; INVARIANT CHAIN	In neuronal cells the neurotransmitter acetylcholine is transferred from the cytoplasm into synaptic vesicles by the vesicular acetylcholine transporter ( VAChT). The cytoplasmic tail of VAChT has been shown to contain signals that direct its sorting and trafficking. The role of clathrin-associated protein complexes in VAChT sorting to synaptic vesicles has been examined. A fusion protein between the VAChT cytoplasmic tail and glutathione S-transferase was used to identify VAChT-clathrin-associated protein adaptor protein 1, adaptor protein 2 and adaptor protein 180 complexes from a rat brain extract. In vivo coimmunoprecipitation confirmed adaptin alpha and adaptin gamma complexes, but adaptor protein 180 complexes were not detected by this technique. Deletion and site directed mutagenesis show that the VAChT cytoplasmic tail contains multiple trafficking signals. These include a non-classical tyrosine motif that serves as the signal for adaptin alpha and a dileucine motif that serves as the signal for adaptin gamma. A classical tyrosine motif is also involved in VAChT trafficking, but does not interact with any known adaptor proteins. There appear to be two endocytosis motifs, one involving the adaptor protein 1 binding site and the other involving the adaptor protein 2 binding site. These results suggest a complex trafficking pathway for VAChT.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Hersh, LB (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 800 Rose St,MS607, Lexington, KY 40536 USA.	lhersh@uky.edu			NIA NIH HHS [AG 05893] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG005893, R55AG005893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barbosa J, 2002, J NEUROCHEM, V82, P1221, DOI 10.1046/j.1471-4159.2002.01068.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Eiden LE, 1998, J NEUROCHEM, V70, P2227; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JADOT M, 1992, J BIOL CHEM, V267, P11069; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLY RB, 1993, ANNU REV NEUROSCI, V16, P95, DOI 10.1146/annurev.ne.16.030193.000523; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kongsvik TL, 2002, J BIOL CHEM, V277, P16484, DOI 10.1074/jbc.M201583200; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Lee WS, 2002, J BIOL CHEM, V277, P3544, DOI 10.1074/jbc.M108531200; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morgan JR, 1999, J NEUROSCI, V19, P10201; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V123, P1093; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHULDINER S, 1994, ANN NY ACAD SCI, V733, P174, DOI 10.1111/j.1749-6632.1994.tb17267.x; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SONG JK, 1999, J BIOL CHEM, V274, P3141; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkina T, 1999, J CELL SCI, V112, P317; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Tao-Cheng J H, 1998, Adv Pharmacol, V42, P250; Teuchert M, 1999, J BIOL CHEM, V274, P8199, DOI 10.1074/jbc.274.12.8199; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	58	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12580	12587		10.1074/jbc.M310681200	http://dx.doi.org/10.1074/jbc.M310681200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724281	hybrid			2022-12-27	WOS:000220334900071
J	Subbaramaiah, K; Yoshimatsu, K; Scherl, E; Das, KM; Glazier, KD; Golijanin, D; Soslow, RA; Tanabe, T; Naraba, H; Dannenberg, AJ				Subbaramaiah, K; Yoshimatsu, K; Scherl, E; Das, KM; Glazier, KD; Golijanin, D; Soslow, RA; Tanabe, T; Naraba, H; Dannenberg, AJ			RETRACTED: Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease - Evidence for involvement of the transcription factor Egr-1 (Retracted article. See vol. 295, pg. 292, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NITRIC-OXIDE; EPITHELIAL-CELLS; GENE-EXPRESSION; ULCERATIVE-COLITIS; PHORBOL ESTER; UP-REGULATION; E-2 SYNTHASE	Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the conversion of cyclooxygenase-derived prostaglandin (PG) H-2 to PGE(2). Increased amounts of mPGES-1 were detected in inflamed intestinal mucosa from patients with inflammatory bowel disease (IBD). Treatment with tumor necrosis factor (TNF)-alpha stimulated mPGES-1 transcription in human colonocytes, resulting in increased amounts of mPGES-1 mRNA and protein. The inductive effect of TNF-alpha localized to the GC box region of the mPGES-1 promoter. Binding of Egr-1 to the GC box region of the mPGES-1 promoter was enhanced by treatment with TNF-alpha. Notably, increased Egr-1 expression and binding activity were also detected in inflamed mucosa from IBD patients. Treatment with TNF-alpha induced the activities of phosphatidylcholine-phospholipase C (PC-PLC) and protein kinase (PK) C and enhanced NO production. A pharmacological approach was used to implicate PC-PLC --> PKC --> NO signaling as being important for the induction of mPGES-1 by TNF-alpha. TNF-alpha also enhanced guanylate cyclase activity and inhibitors of guanylate cyclase activity blocked the induction of mPGES-1 by TNF-alpha. YC-1, an activator of guanylate cyclase, induced mPGES-1. Overexpressing a dominant negative form of PKG blocked TNF-alpha-mediated stimulation of the mPGES-1 promoter. Taken together, these results suggest that overexpression of mPGES-1 in IBD is the result of Egr-1-mediated activation of transcription. Moreover, TNF-alpha induced mPGES-1 by stimulating PC-PLC 3 PKC --> NO --> cGMP --> PKG signal transduction pathway.	Cornell Univ, Weill Med Coll, New Presbyterian Hosp, Dept Med, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA; Tokyo Womens Med Univ, Daini Hosp, Dept Surg, Tokyo 1168567, Japan; UMDNJ Robert Wood Johnson Med Sch, Crohns & Colitis Ctr New Jersey, Div Gastroenterol & Hepatol, New Brunswick, NJ 08093 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Osaka 5658565, Japan	Cornell University; NewYork-Presbyterian Hospital; Tokyo Women's Medical University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Cerebral & Cardiovascular Center - Japan	Subbaramaiah, K (corresponding author), Cornell Univ, Weill Med Coll, 1300 York Ave,Rm F-203A, New York, NY 10021 USA.	ksubba@med.cornell.edu		Soslow, Robert/0000-0002-7269-5898				BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Carty E, 2000, GUT, V46, P487, DOI 10.1136/gut.46.4.487; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Cohen EG, 2003, CLIN CANCER RES, V9, P3425; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cross RK, 2003, INFLAMM BOWEL DIS, V9, P179, DOI 10.1097/00054725-200305000-00006; Della Ragione F, 2003, J BIOL CHEM, V278, P23360, DOI 10.1074/jbc.M300771200; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413, DOI 10.1165/ajrcmb.20.3.3393; FREEMAN B, 1994, CHEST, V105, pS79, DOI 10.1378/chest.105.3_Supplement.79S; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; KAUFMANN HJ, 1987, ANN INTERN MED, V107, P513, DOI 10.7326/0003-4819-107-4-513; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; Logan RFA, 1998, GUT, V42, P309, DOI 10.1136/gut.42.3.309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; MARSH KA, 1993, J PATHOL, V170, P441, DOI 10.1002/path.1711700407; MCCALL RD, 1994, GASTROENTEROLOGY, V106, P960, DOI 10.1016/0016-5085(94)90755-2; Mestre JR, 1997, CANCER RES, V57, P2890; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Mutoh M, 2002, CANCER RES, V62, P28; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Robbins RA, 1997, AM J RESP CRIT CARE, V155, P268, DOI 10.1164/ajrccm.155.1.9001323; SANDS WA, 1994, BIOCHEM BIOPH RES CO, V199, P461, DOI 10.1006/bbrc.1994.1251; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHARON P, 1978, GASTROENTEROLOGY, V75, P638; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Sweeney FJ, 2003, MOL CELL ENDOCRINOL, V205, P151, DOI 10.1016/S0303-7207(03)00091-1; Szabo IL, 2001, J PHYSIOL-PARIS, V95, P379, DOI 10.1016/S0928-4257(01)00051-1; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; van Rees BP, 2003, INT J CANCER, V107, P551, DOI 10.1002/ijc.11422; Wiercinska-Drapalo A, 1999, PROSTAG OTH LIPID M, V58, P159, DOI 10.1016/S0090-6980(99)00032-5; Yang SZ, 2003, J BIOL CHEM, V278, P39906, DOI 10.1074/jbc.M307250200; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669	67	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12647	12658		10.1074/jbc.M312972200	http://dx.doi.org/10.1074/jbc.M312972200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722058	hybrid			2022-12-27	WOS:000220334900078
J	Yang, SC; Cho, YS; Chennathukuzhi, VM; Underkoffler, LA; Loomes, K; Hecht, NB				Yang, SC; Cho, YS; Chennathukuzhi, VM; Underkoffler, LA; Loomes, K; Hecht, NB			Translin-associated factor X is post-transcriptionally regulated by its partner protein TB-RBP, and both are essential for normal cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; MALE GERM-CELLS; TESTIS-BRAIN; MESSENGER-RNAS; CHROMOSOMAL TRANSLOCATIONS; ENDOPLASMIC-RETICULUM; GENOMIC STRUCTURE; DNA-BINDING; TRAX; GENE	To determine the functions of the DNA/RNA-binding protein TB-RBP in somatic cells, we examined cultured primary mouse embryonic fibroblasts (MEFs) derived from TB-RBP-deficient mice. The TB-RBP-deficient MEFs exhibit a reduced growth rate compared with MEFs from littermates. Reintroduction of TB-RBP remedies this defect. A partner protein of TB-RBP, Translin-associated factor X ( TRAX), was absent in TB-RBP-deficient MEFs, despite normal TRAX mRNA levels. TRAX is dependent upon the presence of TB-RBP and is removed from null MEFs following ubiquitination. Re-introduction of TB-RBP, but not TB-RBP lacking an oligomerization domain, into null MEFs stabilized TRAX protein without changing TRAX mRNA levels. The coordinated expression of TB-RBP and TRAX is also seen in synchronized cells, where the amount of TRAX protein but not TRAX RNA closely parallels TB-RBP levels throughout the cell cycle. In transgenic mice overexpressing TRAX in testis, total TB-RBP and TRAX levels are constant with reductions of endogenous TRAX compensating for exogenous TRAX. Using RNA interference, reductions of either TB-RBP or TRAX ( without affecting TB-RBP) slow cell growth rates. We conclude that TRAX is posttranscriptionally stabilized by TB-RBP and both proteins are needed for normal cell proliferation.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Hecht, NB (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, 1310 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	nhecht@mail.med.upenn.edu			NICHD NIH HHS [HD 28832] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028832] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Aoki K, 1997, GENOMICS, V43, P237, DOI 10.1006/geno.1997.4796; Bray JD, 2002, GENOMICS, V79, P799, DOI 10.1006/geno.2002.6779; Chennathukuzhi V, 2003, P NATL ACAD SCI USA, V100, P15566, DOI 10.1073/pnas.2536695100; Chennathukuzhi V, 2003, MOL CELL BIOL, V23, P6419, DOI 10.1128/MCB.23.18.6419-6434.2003; Chennathukuzhi VM, 2001, J BIOL CHEM, V276, P13256, DOI 10.1074/jbc.M009707200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erdemir T, 2002, J CELL SCI, V115, P207; Finkenstadt PM, 2000, J NEUROCHEM, V75, P1754, DOI 10.1046/j.1471-4159.2000.0751754.x; Gu W, 1998, MOL REPROD DEV, V49, P219, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;219::AID-MRD1&gt;3.0.CO;2-R; HAN JR, 1995, BIOL REPROD, V53, P707, DOI 10.1095/biolreprod53.3.707; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Ishida R, 2002, FEBS LETT, V525, P105, DOI 10.1016/S0014-5793(02)03095-8; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kasai M, 1997, J BIOL CHEM, V272, P11402; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; MCCARREY JR, 1987, GENE, V61, P291, DOI 10.1016/0378-1119(87)90192-2; Millar JK, 2000, GENOMICS, V67, P69, DOI 10.1006/geno.2000.6239; Morales CR, 2002, DEV BIOL, V246, P480, DOI 10.1006/dbio.2002.0679; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Pascal JM, 2002, J MOL BIOL, V319, P1049, DOI 10.1016/S0022-2836(02)00364-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; VanLoock MS, 2001, J STRUCT BIOL, V135, P58, DOI 10.1006/jsbi.2001.4383; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wu XQ, 1999, BIOCHEMISTRY-US, V38, P11261, DOI 10.1021/bi990573s; Wu XQ, 2000, BIOL REPROD, V62, P720, DOI 10.1095/biolreprod62.3.720; Wu XQ, 1998, NUCLEIC ACIDS RES, V26, P1675, DOI 10.1093/nar/26.7.1675; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Yang JX, 2003, BIOL REPROD, V68, P853, DOI 10.1095/biolreprod.102.008631; Yang SC, 2001, MOL CELL BIOL, V21, P7807, DOI 10.1128/MCB.21.22.7807-7816.2001; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200; [No title captured]	36	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12605	12614		10.1074/jbc.M313133200	http://dx.doi.org/10.1074/jbc.M313133200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711818	hybrid			2022-12-27	WOS:000220334900074
J	Das, R; Mahabeleshwar, GH; Kundu, GC				Das, R; Mahabeleshwar, GH; Kundu, GC			Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; B-MEDIATED SECRETION; SIGNAL-TRANSDUCTION PATHWAYS; FOCAL ADHESION KINASE; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROMATRIX METALLOPROTEINASE-2; MATRIX-METALLOPROTEINASE; CYCLE PROGRESSION; MELANOMA-CELLS	We have recently reported that osteopontin (OPN) stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase-type plasminogen activator (uPA) through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells (Das, R., Mahabeleshwar, G. H., and Kundu, G. C. ( 2003) J. Biol. Chem. 278, 28593 28606). However, the role(s) of OPN on AP-1-mediated uPA secretion and cell motility and the involvement of c-Src/epidermal growth factor receptor ( EGFR) in these processes in breast cancer cells are not well defined. In this study we report that OPN induces alpha(v)beta(3) integrin-mediated c-Src kinase activity in both highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. Ligation of OPN with alpha(v)beta(3) integrin induces kinase activity and tyrosine phosphorylation of EGFR in MDA-MB-231 and wild type EGFR-transfected MCF-7 cells, and this was inhibited by the dominant negative form of c-Src (dn c-Src) indicating that c-Src kinase plays a crucial role in this process. OPN induces association between alpha(v)beta(3) integrin and EGFR on the cell membrane in a macromolecular form with c-Src. Furthermore, OPN induces alpha(v)beta(3) integrin/ EGFR-mediated ERK1/2 phosphorylation and AP-1 activation. Moreover, dn c-Src also suppressed the OPN-induced phosphatidylinositol ( PI) 3-kinase activity in these cells indicating that c-Src acts as master switch in regulating MEK/ERK1/2 and phosphatidylinositol 3-kinase/ Akt signaling pathways. OPN-induced ERK phosphorylation, AP-1 activation, uPA secretion, and cell motility were suppressed when cells were transfected with dn c-Src or pretreated with alpha(v)beta(3) integrin antibody, c-Src kinase inhibitor (pp2), EGFR tyrosine kinase inhibitor (PD153035), and MEK-1 inhibitor (PD98059). To our knowledge, this is the first report that OPN induces alpha(v)beta(3) integrin-mediated AP-1 activity and uPA secretion by activating c-Src/EGFR/ERK signaling pathways and further demonstrates a functional molecular link between OPN-induced integrin/ c-Src-dependent EGFR phosphorylation and ERK/AP-1-mediated uPA secretion, and all of these ultimately control the motility of breast cancer cells.	NCCS, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), NCCS, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BROWN LF, 1994, AM J PATHOL, V145, P610; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DECESARE D, 1995, ONCOGENE, V11, P365; DEFILIPPI P, 1997, MOL B INT U, P1; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lui VWY, 2002, ANTICANCER RES, V22, P1; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Price JT, 1999, CANCER RES, V59, P5475; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; RADINSKY R, 1995, CLIN CANCER RES, V216, P261; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Shih WL, 2003, J BIOL CHEM, V278, P31807, DOI 10.1074/jbc.M302580200; Teti A, 1998, INT J CANCER, V77, P82; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	58	97	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11051	11064		10.1074/jbc.M310256200	http://dx.doi.org/10.1074/jbc.M310256200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704150	hybrid			2022-12-27	WOS:000220157600028
J	Izard, T; Sygusch, J				Izard, T; Sygusch, J			Induced fit movements and metal cofactor selectivity of class II aldolases - Structure of thermus aquaticus fructose-1,6-bisphosphate aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; MUSCLE ALDOLASE; MECHANISM; MOLSCRIPT; COMPLEX; RESIDUE	Fructose-1,6-bisphosphate (FBP) aldolase is an essential glycolytic enzyme that reversibly cleaves its ketohexose substrate into triose phosphates. Here we report the crystal structure of a metallo-dependent or class II FBP aldolase from an extreme thermophile, Thermus aquaticus (Taq). The quaternary structure reveals a tetramer composed of two dimers related by a 2-fold axis. Taq FBP aldolase subunits exhibit two distinct conformational states corresponding to loop regions that are in either open or closed position with respect to the active site. Loop closure remodels the disposition of chelating active site histidine residues. In subunits corresponding to the open conformation, the metal cofactor, Co2+, is sequestered in the active site, whereas for subunits in the closed conformation, the metal cation exchanges between two mutually exclusive binding loci, corresponding to a site at the active site surface and an interior site vicinal to the metal-binding site in the open conformation. Cofactor site exchange is mediated by rotations of the chelating histidine side chains that are coupled to the prior conformational change of loop closure. Sulfate anions are consistent with the location of the phosphate-binding sites of the FBP substrate and determine not only the previously unknown second phosphate-binding site but also provide a mechanism that regulates loop closure during catalysis. Modeling of FBP substrate into the active site is consistent with binding by the acyclic keto form, a minor solution species, and with the metal cofactor mediating keto bond polarization. The Taq FBP aldolase structure suggests a structural basis for different metal cofactor specificity than in Escherichia coli FBP aldolase structures, and we discuss its potential role during catalysis. Comparison with the E. coli structure also indicates a structural basis for thermostability by Taq FBP aldolase.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38111 USA	Universite de Montreal; St Jude Children's Research Hospital	Sygusch, J (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Succ Centreville, Montreal, PQ H3C 3J7, Canada.	jurgen.sygusch@umontreal.ca		Sygusch, Jurgen/0000-0002-6629-2128	NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANAI M, 1973, ARCH BIOCHEM BIOPHYS, V156, P712, DOI 10.1016/0003-9861(73)90324-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 1997, J MOL MED-JMM, V75, P312; Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BERTHIAUME L, 1993, J BIOL CHEM, V268, P10826; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; Blom NS, 1996, NAT STRUCT BIOL, V3, P856, DOI 10.1038/nsb1096-856; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Chudzik DM, 2000, J MOL BIOL, V300, P697, DOI 10.1006/jmbi.2000.3910; Cooper SJ, 1996, STRUCTURE, V4, P1303, DOI 10.1016/S0969-2126(96)00138-4; Dalby AR, 2001, ACTA CRYSTALLOGR D, V57, P1526, DOI 10.1107/S0907444901012719; DeMontigny C, 1996, EUR J BIOCHEM, V241, P243; DOBELI H, 1991, ACT LEIDENS, V60, P135; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FREEZE H, 1970, J BACTERIOL, V101, P541, DOI 10.1128/JB.101.2.541-550.1970; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; Hall DR, 1999, J MOL BIOL, V287, P383, DOI 10.1006/jmbi.1999.2609; Hall DR, 2002, J BIOL CHEM, V277, P22018, DOI 10.1074/jbc.M202464200; HANNAPPEL E, 1982, ARCH BIOCHEM BIOPHYS, V214, P293, DOI 10.1016/0003-9861(82)90033-9; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; IZARD T, 1994, STRUCTURE, V2, P361, DOI 10.1016/S0969-2126(00)00038-1; Izard T, 2000, EMBO J, V19, P3849, DOI 10.1093/emboj/19.15.3849; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karshikoff A, 2001, TRENDS BIOCHEM SCI, V26, P550, DOI 10.1016/S0968-0004(01)01918-1; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1995, MECH PROTEIN CHEM, P353; LAI CY, 1965, J BIOL CHEM, V240, P1347; Maurady A, 2002, J BIOL CHEM, V277, P9474, DOI 10.1074/jbc.M107600200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Plater AR, 1999, J MOL BIOL, V285, P843, DOI 10.1006/jmbi.1998.2376; Qamar S, 1996, PROTEIN SCI, V5, P154; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; Sauve V, 2001, PROTEIN EXPRES PURIF, V21, P293, DOI 10.1006/prep.2000.1380; Sauve V, 2001, ACTA CRYSTALLOGR D, V57, P310, DOI 10.1107/S0907444900019727; Schoevaart R, 2001, J ORG CHEM, V66, P4559, DOI 10.1021/jo001766k; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Takayama S, 1997, ANNU REV MICROBIOL, V51, P285, DOI 10.1146/annurev.micro.51.1.285; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P743, DOI 10.1107/S0907444996001473; VONDEROSTEN CH, 1989, J AM CHEM SOC, V111, P3924, DOI 10.1021/ja00193a025; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; Wong C. -H., 1994, ENZYMES SYNTHETIC OR, V1st	46	32	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11825	11833		10.1074/jbc.M311375200	http://dx.doi.org/10.1074/jbc.M311375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699122	hybrid			2022-12-27	WOS:000220157600119
J	Li, SY; Gomelsky, M; Duan, JH; Zhang, ZJ; Gomelsky, L; Zhang, XC; Epstein, PN; Ren, J				Li, SY; Gomelsky, M; Duan, JH; Zhang, ZJ; Gomelsky, L; Zhang, XC; Epstein, PN; Ren, J			Overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene prevents acetaldehyde-induced cell injury in human umbilical vein endothelial cells - Role of ERK and p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; LIPID-PEROXIDATION; XANTHINE-OXIDASE; GENE-EXPRESSION; ETHANOL; ALCOHOL; METABOLISM; EXPOSURE; COLLAGEN; BLOOD	Acetaldehyde, the major ethanol metabolite that is far more toxic and reactive than ethanol, has been postulated to be responsible for alcohol-induced tissue and cell injury. This study was to examine whether facilitated acetaldehyde metabolism affects acetaldehyde-induced oxidative stress and apoptosis. Transgene-encoding human aldehyde dehydrogenase-2 (ALDH2), which converts acetaldehyde into acetate, was constructed under chicken beta-actin promoter and transfected into human umbilical vein endothelial cells (HUVECs). Efficacy of ALDH2 transfection was verified using green fluorescent protein and ALDH2 enzymatic assay. Generation of reactive oxygen species (ROS) was measured using chloromethyl-2 ', 7'-dichlorodihydrofluorescein diacetate. Apoptosis was evaluated by 4', 6'-diamidino-2'-phenylindoladihydrochloride fluorescence microscopy, quantitative DNA fragmentation, and caspase-3 assay. Acetaldehyde (0 - 200 muM) elicited ROS generation and apoptosis in HUVECs in a time- and concentration-dependent manner, associated with activation of the stress signal molecules ERK1/2 and p38 mitogen-activated protein ( MAP) kinase. A close liner correlation was observed between the acetaldehyde-induced ROS generation and apoptosis. Interestingly, the acetaldehyde-induced ROS generation, apoptosis, activation of ERK1/2, and p38 MAP kinase were prevented by the ALDH2 transgene or antioxidant alpha-tocopherol. The involvement of ERK1/2 and p38 MAP kinase in acetaldehyde-induced apoptosis was confirmed by selective kinase inhibitors U0126, SB203580, and SB202190. Collectively, our data revealed that facilitation of acetaldehyde metabolism by ALDH2 transgene overexpression may prevent acetaldehyde-induced cell injury and activation of stress signals. These results indicated therapeutic potential of ALDH2 enzyme in the prevention and detoxification of acetaldehyde or alcohol-induced cell injury.	Univ Wyoming, Coll Hlth Sci, Div Pharmaceut Sci, Laramie, WY 82071 USA; Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Univ Wyoming, Microscop Facil, Laramie, WY 82071 USA; Univ Louisville, Dept Pediat, Louisville, KY 40202 USA	University of Wyoming; University of Wyoming; University of Wyoming; University of Louisville	Ren, J (corresponding author), Univ Wyoming, Coll Hlth Sci, Div Pharmaceut Sci, Laramie, WY 82071 USA.	jren@uwyo.edu	Ren, Jun/ACG-5366-2022; gomelsky, mark/F-6209-2010	Ren, Jun/0000-0002-0275-0783; Epstein, Paul/0000-0002-7006-8954; Gomelsky, Mark/0000-0003-4077-3932	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R15AA013575] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15640] Funding Source: Medline; NIAAA NIH HHS [1R15AA/HL13575-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aberle NS, 2003, ALCOHOL CLIN EXP RES, V27, P577, DOI 10.1097/01.ALC.0000060522.40447.8E; AGARWAL DP, 1990, PHARMACOL THERAPEUT, V45, P69, DOI 10.1016/0163-7258(90)90008-P; Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGUNDER JM, 1988, EUR J CLIN INVEST, V18, P420, DOI 10.1111/j.1365-2362.1988.tb01034.x; Cao Q, 2002, BIOCHEM BIOPH RES CO, V299, P459, DOI 10.1016/S0006-291X(02)02672-4; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; Duan JH, 2002, AM J PHYSIOL-HEART C, V282, pH1216, DOI 10.1152/ajpheart.00780.2001; ESPINET C, 1984, IRCS MED SCI-BIOCHEM, V12, P830; FERNANDEZSOLA J, 1994, ANN INTERN MED, V120, P529, DOI 10.7326/0003-4819-120-7-199404010-00001; GUERRI C, 1994, ADV EXP MED BIOL, V366, P291; Hill GE, 1998, ATHEROSCLEROSIS, V141, P107, DOI 10.1016/S0021-9150(98)00153-1; Hintz KK, 2003, ALCOHOL CLIN EXP RES, V27, P1090, DOI 10.1097/01.ALC.0000075823.73536.DD; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; Lee YJ, 2002, J PHARMACOL EXP THER, V301, P908, DOI 10.1124/jpet.301.3.908; Liang QR, 1999, J PHARMACOL EXP THER, V291, P766; Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P991, DOI 10.1111/j.1530-0277.1999.tb04217.x; LIEBER CS, 1988, BIOCHEM SOC T, V16, P241, DOI 10.1042/bst0160241; Masamune A, 2002, J PHARMACOL EXP THER, V302, P36, DOI 10.1124/jpet.302.1.36; McDonough Kathleen H., 1999, Frontiers in Bioscience, V4, pd601, DOI 10.2741/mcdonoug; OEI HHH, 1986, RES COMMUN CHEM PATH, V51, P195; PREEDY VR, 1999, FRONT BIOSCI, V4, P58; Ren J, 2003, CARDIOVASC RES, V57, P738, DOI 10.1016/S0008-6363(02)00788-5; Ren J, 1997, CELL MOL BIOL, V43, P825; Ren J, 2002, ALCOHOL ALCOHOLISM, V37, P30, DOI 10.1093/alcalc/37.1.30; Ren T, 2000, ALCOHOL ALCOHOLISM, V35, P554, DOI 10.1093/alcalc/35.6.554; SHAW S, 1990, BIOCHEM J, V268, P579, DOI 10.1042/bj2680579; SIDDIQ T, 1993, CELL BIOCHEM FUNCT, V11, P45, DOI 10.1002/cbf.290110106; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; TSUKAMOTO S, 1989, ALCOHOL ALCOHOLISM, V24, P101, DOI 10.1093/oxfordjournals.alcalc.a044872; VINA J, 1980, BIOCHEM J, V188, P549, DOI 10.1042/bj1880549; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Weng YI, 2000, EUR J PHARMACOL, V398, P323, DOI 10.1016/S0014-2999(00)00313-7; Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777; YOSHIDA A, 1992, PHARMACOGENETICS, V2, P139, DOI 10.1097/00008571-199208000-00001; Yuan Q, 2002, AM J PHYSIOL-CELL PH, V282, pC1290, DOI 10.1152/ajpcell.00351.2001; Zima T, 2001, J BIOMED SCI, V8, P59, DOI 10.1159/000054014	39	99	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11244	11252		10.1074/jbc.M308011200	http://dx.doi.org/10.1074/jbc.M308011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722101	hybrid			2022-12-27	WOS:000220157600051
J	Tchurikov, NA; Kretova, OV; Chernov, BK; Golova, YB; Zhimulev, IF; Zykov, IA				Tchurikov, NA; Kretova, OV; Chernov, BK; Golova, YB; Zhimulev, IF; Zykov, IA			SuUR protein binds to the boundary regions separating forum domains in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITHORAX GROUP PROTEINS; CHROMATIN-STRUCTURE; BITHORAX COMPLEX; RESPONSE ELEMENT; POLYCOMB; GENE; HETEROCHROMATIN; UNDERREPLICATION; SUPPRESSOR; INTERACTS	Forum domains are 50-150 kb DNA fragments that are released during spontaneous fragmentation of chromosomes. They are separated by islands of putative heterochromatin boundary regions. The SuUR protein, which is involved in the control of chromosome organization, is localized exclusively in heterochromatin and often co-localizes on chromosomes with Polycomb group proteins. To test whether the SuUR protein is associated with boundary regions, we used gel retardation assays and found that the SuUR protein binds specifically to boundary regions and that boundary regions are under-replicated. These results suggest that the regular distribution of boundary regions in chromosomes may represent the dispersion of sites designed for chromosomal silencing.	Russian Acad Sci, VA Engelhardt Mol Biol Inst, Dept Genome Org, Moscow 119991, Russia; Russian Acad Sci, Inst Cytol & Genet, Siberian Div, Dept Mol Cytogenet, Novosibirsk 630090, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Tchurikov, NA (corresponding author), Russian Acad Sci, VA Engelhardt Mol Biol Inst, Dept Genome Org, Vavilov St 32, Moscow 119991, Russia.	tchurikov@eimb.ru	Tchurikov, Nickolai A./R-4850-2016; Zhimulev, Igor F/N-7978-2015; Zykov, Ivan/N-7973-2015	Zhimulev, Igor/0000-0002-6220-3028				ANANEV EV, 1985, ELEKTRONNOMIKROSKOPI, P1; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hodgson JW, 2001, MOL CELL BIOL, V21, P4528, DOI 10.1128/MCB.21.14.4528-4543.2001; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Makunin IV, 2002, GENETICS, V160, P1023; Moshkin YM, 2002, CHROMOSOMA, V111, P114, DOI 10.1007/s00412-002-0190-8; Moshkin YM, 2001, P NATL ACAD SCI USA, V98, P570, DOI 10.1073/pnas.021353598; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Pagans S, 2002, NUCLEIC ACIDS RES, V30, P4406, DOI 10.1093/nar/gkf570; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TCHURIKOV NA, 1992, P NATL ACAD SCI USA, V89, P6751, DOI 10.1073/pnas.89.15.6751; Tchurikov NA, 1998, NUCLEIC ACIDS RES, V26, P3221, DOI 10.1093/nar/26.13.3221; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vazquez M, 1999, DEVELOPMENT, V126, P733; Zhimulev IF, 2003, CHROMOSOMA, V111, P377, DOI 10.1007/s00412-002-0218-0; ZHIMULEV IF, 1998, ADV GENET, V37, P11	29	20	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11705	11710		10.1074/jbc.M306191200	http://dx.doi.org/10.1074/jbc.M306191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702350	hybrid			2022-12-27	WOS:000220157600106
J	Yan, FF; Lin, CW; Weisiger, E; Cartier, EA; Taschenberger, G; Shyng, SL				Yan, FF; Lin, CW; Weisiger, E; Cartier, EA; Taschenberger, G; Shyng, SL			Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; NEPHROGENIC DIABETES-INSIPIDUS; LONG QT SYNDROME; INSULIN-SECRETION; K+ CHANNEL; CHEMICAL CHAPERONES; CYSTIC-FIBROSIS; PHARMACOLOGICAL CHAPERONES; FAMILIAL HYPERINSULINISM; INTRACELLULAR-TRANSPORT	The pancreatic ATP-sensitive potassium (K-ATP) channel, a complex of four sulfonylurea receptor 1 (SUR1) and four potassium channel Kir6.2 subunits, regulates insulin secretion by linking metabolic changes to beta-cell membrane potential. Sulfonylureas inhibit K-ATP channel activities by binding to SUR1 and are widely used to treat type II diabetes. We report here that sulfonylureas also function as chemical chaperones to rescue K-ATP channel trafficking defects caused by two SUR1 mutations, A116P and V187D, identified in patients with congenital hyperinsulinism. Sulfonylureas markedly increased cell surface expression of the A116P and V187D mutants by stabilizing the mutant SUR1 proteins and promoting their maturation. By contrast, diazoxide, a potassium channel opener that also binds SUR1, had no effect on surface expression of either mutant. Importantly, both mutant channels rescued to the cell surface have normal ATP, MgADP, and diazoxide sensitivities, demonstrating that SUR1 harboring either the A116P or the V187D mutation is capable of associating with Kir6.2 to form functional K-ATP channels. Thus, sulfonylureas may be used to treat congenital hyperinsulinism caused by certain K-ATP channel trafficking mutations.	Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA	Oregon Health & Science University	Shyng, SL (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam JAckson Pk Rd, Portland, OR 97239 USA.	shyngs@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057699, DK57699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Cartier EA, 2003, J BIOL CHEM, V278, P7081, DOI 10.1074/jbc.M211395200; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Doyle ME, 2003, PHARMACOL REV, V55, P105, DOI 10.1124/pr.55.1.7; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; Mikhailov MV, 2002, BIOCHEM SOC T, V30, P323, DOI 10.1042/BST0300323; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Perlmutter DH, 2002, PEDIATR RES, V52, P832, DOI 10.1203/01.PDR.0000036878.28942.14; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Reimann F, 2003, DIABETOLOGIA, V46, P241, DOI 10.1007/s00125-002-1014-3; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Stanley CA, 2002, J CLIN ENDOCR METAB, V87, P4857, DOI 10.1210/jc.2002-021403; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	56	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11096	11105		10.1074/jbc.M312810200	http://dx.doi.org/10.1074/jbc.M312810200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707124	hybrid			2022-12-27	WOS:000220157600033
J	Sun, XX; Hodge, JJL; Zhou, Y; Nguyen, M; Griffith, LC				Sun, XX; Hodge, JJL; Zhou, Y; Nguyen, M; Griffith, LC			The eag potassium channel binds and locally activates calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CURRENTS; CAM KINASE; DROSOPHILA; CALMODULIN; MODULATION; PLASTICITY; DENDRITES; SUBUNIT; AUTOPHOSPHORYLATION; AUTOREGULATION	Ca2+/calmodulin-dependent protein kinase II ( CaMKII) has been implicated in the regulation of neuronal excitability in many systems. Recent studies suggest that local regulation of membrane potential can have important computational consequences for neuronal function. In Drosophila, CaMKII regulates the eag potassium channel, but if and how this regulation was spatially restricted was unknown. Using coimmunoprecipitation from head extracts and in vitro binding assays, we show that CaMKII and Eag form a stable complex and that association with Eag activates CaMKII independently of CaM and autophosphorylation. Ca2+/CaM is necessary to initiate binding of CaMKII to Eag but not to sustain association because binding persists when CaM is removed. The Eag CaMKII-binding domain has homology to the CaMKII autoregulatory region, and the constitutively active CaMKII mutant, T287D, binds Eag Ca2+-independently in vitro and in vivo. These results favor a model in which the CaMKII-binding domain of Eag displaces the CaMKII autoinhibitory region. Displacement results in autophosphorylation-independent activation of CaMKII which persists even when Ca2+ levels have gone down. Activity-dependent binding to this potassium channel substrate allows CaMKII to remain locally active even when Ca2+ levels have dropped, providing a novel mechanism by which CaMKII can regulate excitability locally over long time scales.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02454 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	Brandeis University; Brandeis University; University of Pennsylvania	Griffith, LC (corresponding author), Brandeis Univ, Dept Biol, Ms008,415 South St, Waltham, MA 02454 USA.	griffith@brandeis.edu		Griffith, Leslie/0000-0003-3164-9876; Hodge, James/0000-0003-4741-2363	NCRR NIH HHS [S10 RR16780] Funding Source: Medline; NIGMS NIH HHS [R01 GM54408, R01 GM054408, R01 GM054408-08] Funding Source: Medline; NINDS NIH HHS [R01 NS17910] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017910] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Cook EP, 1999, J NEUROPHYSIOL, V81, P535, DOI 10.1152/jn.1999.81.2.535; DRYSDALE R, 1991, GENETICS, V127, P497; Estes PS, 2000, J NEUROGENET, V13, P233, DOI 10.3109/01677060009084496; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; Hansel C, 2001, NAT NEUROSCI, V4, P467, DOI 10.1038/87419; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Hudmon A, 2003, BIOPHYS J, V84, p329A; Jin R, 1998, J NEUROSCI, V18, P8955; Johnston D, 2003, PHILOS T ROY SOC B, V358, P667, DOI 10.1098/rstb.2002.1248; KAPLAN WD, 1969, GENETICS, V61, P399; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Long XM, 2000, J BIOL CHEM, V275, P40765, DOI 10.1074/jbc.M003949200; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Park D, 2002, J NEUROBIOL, V52, P24, DOI 10.1002/neu.10066; Pedarzani P, 1996, PFLUG ARCH EUR J PHY, V431, P723, DOI 10.1007/s004240050057; Peretz A, 1998, J NEUROSCI, V18, P9153; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Reiner DJ, 1999, NATURE, V402, P199, DOI 10.1038/46072; Roeper J, 1997, J NEUROSCI, V17, P3379; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Smith MR, 2002, J NEUROPHYSIOL, V87, P2031, DOI 10.1152/jn.00821.2001; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; Sola C, 1999, PROG NEUROBIOL, V58, P207, DOI 10.1016/S0301-0082(98)00082-3; Takamatsu Y, 2003, BRAIN RES, V974, P99, DOI 10.1016/S0006-8993(03)02562-9; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Varga AW, 2000, LEARN MEMORY, V7, P321, DOI 10.1101/lm.35300; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang Z, 1998, J NEUROCHEM, V71, P378; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Yao WD, 1999, ANN NY ACAD SCI, V868, P450, DOI 10.1111/j.1749-6632.1999.tb11312.x; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002	43	77	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10206	10214		10.1074/jbc.M310728200	http://dx.doi.org/10.1074/jbc.M310728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699099	hybrid			2022-12-27	WOS:000220050400067
J	James, MJ; Zomerdijk, JCBM				James, MJ; Zomerdijk, JCBM			Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL GENE-TRANSCRIPTION; GROWTH-FACTOR STIMULATION; SACCHAROMYCES-CEREVISIAE; RDNA TRANSCRIPTION; CELL-GROWTH; AMINO-ACID; FACTOR UBF; DEPENDENT PHOSPHORYLATION; MAMMALIAN TARGET; FACTOR SL1	Regulation of ribosomal RNA gene transcription by RNA polymerase I (Pol I) is fundamental to ribosome biogenesis and therefore protein translation capacity and cell growth, yet little is known of the key signaling cascades involved. We show here that insulin-like growth factor-1 (IGF-1)-induced Pol I transcription in HEK293 cells is entirely dependent on phosphatidylinositol 3-kinase (PI3K) activity and, additionally, is modulated by the mammalian target of rapamycin ( mTOR), which coordinates Pol I transcription with the availability of amino acids. The mitogen-activated protein kinase ( MAPK) pathway is weakly stimulated by IGF-1 in these cells and partly contributes to Pol I transcription regulation. Activation of Pol I transcription by IGF-1 results from enhancement of the activity of the Pol I transcription machinery and increased occupancy by SL1 of the endogenous tandemly repeated ribosomal promoters in vivo. The inputs from PI3K, mTOR, and MAPK pathways converge to direct appropriate rRNA gene expression by Pol I in the nucleolus of mammalian cells in response to environmental cues, such as growth factors and nutrients.	Univ Dundee, Fac Life Sci, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Zomerdijk, JCBM (corresponding author), Univ Dundee, Fac Life Sci, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland.	j.zomerdijk@dundee.ac.uk	Zomerdijk, Joost/A-5142-2008	James, Martyn John/0000-0001-5094-0314; Zomerdijk, Joost/0000-0003-1865-729X				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GLIBETIC M, 1993, MOL CELL ENDOCRINOL, V94, P243, DOI 10.1016/0303-7207(93)90173-H; GRUMMT I, 1976, CELL, V7, P439, DOI 10.1016/0092-8674(76)90174-4; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Jordan P, 1996, J CELL BIOL, V133, P225, DOI 10.1083/jcb.133.2.225; Kabler RL, 1996, J STEROID BIOCHEM, V59, P431, DOI 10.1016/S0960-0760(96)00126-4; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KERMEKCHIEV M, 1993, NUCLEIC ACIDS RES, V21, P447, DOI 10.1093/nar/21.3.447; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; LEARNED R M, 1982, Journal of Molecular and Applied Genetics, V1, P575; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; Leicht M, 1996, CELL GROWTH DIFFER, V7, P1199; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; OCHS RL, 1989, EXP CELL RES, V184, P552, DOI 10.1016/0014-4827(89)90354-6; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Panov KI, 2001, MOL CELL BIOL, V21, P2641, DOI 10.1128/MCB.21.8.2641-2649.2001; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Reeder R. H., 1995, NUCL ACIDS MOL BIOL, V9, P251; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Roussel P, 1996, J CELL BIOL, V133, P235, DOI 10.1083/jcb.133.2.235; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tsang CK, 2003, EMBO J, V22, P6045, DOI 10.1093/emboj/cdg578; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZATSEPINA OV, 1993, CHROMOSOMA, V102, P599, DOI 10.1007/BF00352307; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4; ZOMERDIJK JCB, 1998, TRANSCRIPTION EUKARY, V1, P67; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	76	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8911	8918		10.1074/jbc.M307735200	http://dx.doi.org/10.1074/jbc.M307735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688273	hybrid			2022-12-27	WOS:000189265900049
J	Papanikolopoulou, K; Forge, V; Goeltz, P; Mitraki, A				Papanikolopoulou, K; Forge, V; Goeltz, P; Mitraki, A			Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage T4 fibritin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 FIBER; CRYSTAL-STRUCTURE; SEROTYPE-2 FIBER; TERMINAL DOMAIN; BINDING DOMAIN; COILED-COIL; BETA-HELIX; PROTEIN; REVEALS; RESOLUTION	The folding of beta-structured, fibrous proteins is a largely unexplored area. A class of such proteins is used by viruses as adhesins, and recent studies revealed novel beta-structured motifs for them. We have been studying the folding and assembly of adenovirus fibers that consist of a globular C-terminal domain, a central fibrous shaft, and an N-terminal part that attaches to the viral capsid. The globular C-terminal, or "head" domain, has been postulated to be necessary for the trimerization of the fiber and might act as a registration signal that directs its correct folding and assembly. In this work, we replaced the head of the fiber by the trimerization domain of the bacteriophage T4 fibritin, termed "foldon." Two chimeric proteins, comprising the foldon domain connected at the C-terminal end of four fiber shaft repeats with or without the use of a natural linker sequence, fold into highly stable, SDS-resistant trimers. The structural signatures of the chimeric proteins as seen by CD and infrared spectroscopy are reported. The results suggest that the foldon domain can successfully replace the fiber head domain in ensuring correct trimerization of the shaft sequences. Biological implications and implications for engineering highly stable, beta-structured nanorods are discussed.	Inst Biol Struct, F-38027 Grenoble, France; CEA Grenoble, Dept Reponse & Dynam Cellulaires, Unite Mixte Rech 5090, Lab Biophys Mol & Cellulaire, F-38054 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Mitraki, A (corresponding author), Inst Biol Struct, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	mitraki@ibs.fr	MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939				Ambriovic-Ristov A, 2003, VIROLOGY, V312, P425, DOI 10.1016/S0042-6822(03)00238-1; Barnett BG, 2002, BBA-GENE STRUCT EXPR, V1575, P1, DOI 10.1016/S0167-4781(02)00249-X; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; Hyman P, 2002, P NATL ACAD SCI USA, V99, P8488, DOI 10.1073/pnas.132544299; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Khurana R, 2000, BIOPHYS J, V78, P994, DOI 10.1016/S0006-3495(00)76657-4; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Letarov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P817; Lortat-Jacob H, 2001, J BIOL CHEM, V276, P9009, DOI 10.1074/jbc.M009304200; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Luckey M, 2000, FEBS LETT, V468, P23, DOI 10.1016/S0014-5793(00)01184-4; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329; Mitraki A, 2002, J STRUCT BIOL, V137, P236, DOI 10.1006/jsbi.2002.4447; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; NOVELLI A, 1991, VIROLOGY, V185, P365, DOI 10.1016/0042-6822(91)90784-9; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Scheibel T, 2003, P NATL ACAD SCI USA, V100, P4527, DOI 10.1073/pnas.0431081100; Seki T, 2002, J VIROL, V76, P1100, DOI 10.1128/JVI.76.3.1100-1108.2002; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Smith TAG, 2003, HUM GENE THER, V14, P777, DOI 10.1089/104303403765255165; Stehle T, 2003, REV MED VIROL, V13, P123, DOI 10.1002/rmv.379; TABOR S, 1990, CURRENT PROTOCOLS MO; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; Weigele PR, 2003, J BACTERIOL, V185, P4022, DOI 10.1128/JB.185.14.4022-4030.2003; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Zhang SG, 2002, CURR OPIN CHEM BIOL, V6, P865, DOI 10.1016/S1367-5931(02)00391-5	41	43	61	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8991	8998		10.1074/jbc.M311791200	http://dx.doi.org/10.1074/jbc.M311791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699113	hybrid			2022-12-27	WOS:000189265900058
J	Harada, K; Potter, JD				Harada, K; Potter, JD			Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; PROTEIN-C GENE; ALTERED REGULATION; ALPHA-TROPOMYOSIN; SUDDEN-DEATH; SKELETAL; BINDING; IDENTIFICATION; DISEASE; DOMAIN	To understand the molecular function of troponin T (TnT) in the Ca2+ regulation of muscle contraction as well as the molecular pathogenesis of familial hypertrophic cardiomyopathy (FHC), eight FHC-linked TnT mutations, which are located in different functional regions of human cardiac TnT (HCTnT), were produced, and their structural and functional properties were examined. Circular dichroism spectroscopy demonstrated different secondary structures of these TnT mutants. Each of the recombinant HCTnTs was incorporated into porcine skinned fibers along with human cardiac troponin I (HCTnI) and troponin C (HCTnC), and the Ca2+ dependent isometric force development of these troponin-replaced fibers was determined at pH 7.0 and 6.5. All eight mutants altered the contractile properties of skinned cardiac fibers. E244D potentiated the maximum force development without changing Ca2+ sensitivity. In contrast, the other seven mutants increased the Ca2+ sensitivity of force development but not the maximal force. R92L, R92W, and R94L also decreased the change in Ca2+ sensitivity of force development observed on lowering the pH from 7 to 6.5, when compared with wild type TnT. The examination of additional mutants, H91Q and a double mutant H91Q/R92W, suggests that mutations in a region including residues 91-94 in HCTnT can perturb the proper response of cardiac contraction to changes in pH. These results suggest that different regions of TnT may contribute to the pathogenesis of TnT-linked FHC through different mechanisms.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA	University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu			NHLBI NIH HHS [HL-674154, HL-42325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL042325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; DONALDSON SKB, 1978, PFLUG ARCH EUR J PHY, V376, P55; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Forissier JF, 1996, CIRCULATION, V94, P3069, DOI 10.1161/01.CIR.94.12.3069; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GOMES AV, 2004, IN PRESS MOL CELL BI; Harada K, 2002, BIOPHYS J, V82, p391A; Harada K, 2000, J BIOCHEM-TOKYO, V127, P263, DOI 10.1093/oxfordjournals.jbchem.a022603; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hinkle A, 2003, J BIOL CHEM, V278, P506, DOI 10.1074/jbc.M209194200; Ho CY, 2000, CIRCULATION, V102, P1950, DOI 10.1161/01.CIR.102.16.1950; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Knollmann BC, 2001, J BIOL CHEM, V276, P10039, DOI 10.1074/jbc.M006745200; KOGA Y, 1996, J CARD FAIL, V2, P97; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Lin TL, 2000, CARDIOLOGY, V93, P155, DOI 10.1159/000007020; LYNCH GS, 1994, EXP PHYSIOL, V79, P47, DOI 10.1113/expphysiol.1994.sp003741; Marian A J, 2001, Minerva Med, V92, P435; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; Moolman-Smook JC, 1999, AM J HUM GENET, V65, P1308, DOI 10.1086/302623; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; Morimoto S, 1999, J BIOCHEM-TOKYO, V126, P121, DOI 10.1093/oxfordjournals.jbchem.a022412; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; Nakaura H, 1999, J BIOCHEM-TOKYO, V126, P457, DOI 10.1093/oxfordjournals.jbchem.a022473; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Richard P, 1999, J MED GENET, V36, P542; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; Sola Francesco, 1997, Angiogenesis, V1, P102, DOI 10.1023/A:1018309200629; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Varnava A, 1999, HEART, V82, P621, DOI 10.1136/hrt.82.5.621; Varnava AM, 2001, CIRCULATION, V104, P1380, DOI 10.1161/hc3701.095952; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	51	71	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14488	14495		10.1074/jbc.M309355200	http://dx.doi.org/10.1074/jbc.M309355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722098	hybrid			2022-12-27	WOS:000220594700005
J	Ahuatzi, D; Herrero, P; de la Cera, T; Moreno, F				Ahuatzi, D; Herrero, P; de la Cera, T; Moreno, F			The glucose-regulated nuclear localization of hexokinase 2 in Saccharomyces cerevisiae is Mig1-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; CARBON CATABOLITE REPRESSION; ATOMIC-FORCE MICROSCOPY; HXK2 GENES; YEAST HEXOKINASE; MIG1 REPRESSOR; PHOSPHORYLATION; PII; EXPRESSION; SUC2	Two major mediators of glucose repression in Saccharomyces cerevisiae are the proteins Mig1 and Hxk2. The mechanism of Hxk2-dependent glucose repression pathway is not well understood, but the Mig1-dependent part of the pathway has been elucidated in great detail. Here we report that Hxk2 has a glucose-regulated nuclear localization and that Mig1, a transcriptional repressor responsible for glucose repression of many genes, is required to sequester Hxk2 into the nucleus. Mig1 and Hxk2 interacted in vivo in a yeast two-hybrid assay and in vitro in immunoprecipitation and glutathione S-transferase pull-down experiments. We found that the Lys(6)-Met(15) decapeptide of Hxk2, which is necessary for nuclear localization of the protein, is also essential for interaction with the Mig1 protein. Our results also show that the Hxk2-Mig1 interaction is of physiological significance because both proteins have been found interacting together in a cluster with DNA fragments containing the MIG1 site of SUC2 promoter. We conclude that Hxk2 operates by interacting with Mig1 to generate a repressor complex located in the nucleus of S. cerevisiae during growth in glucose medium.	Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo	Moreno, F (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Campus Cristo,Edificio Santiago Gascon, E-33006 Oviedo, Spain.	fmoreno@correo.uniovi.es		de la Cera, Tamara/0000-0002-0124-5718				Alms GR, 1999, EMBO J, V18, P4157, DOI 10.1093/emboj/18.15.4157; Ashrafi K, 2000, GENE DEV, V14, P1872; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chaves RS, 1999, BIOCHEM BIOPH RES CO, V254, P345, DOI 10.1006/bbrc.1998.9954; de la Cera T, 2002, J MOL BIOL, V319, P703, DOI 10.1016/S0022-2836(02)00377-7; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; ENTIAN KD, 1977, MOL GEN GENET, V156, P99, DOI 10.1007/BF00272258; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GASCON S, 1968, J BIOL CHEM, V243, P1567; GUELMAN R, 2002, BONE, V30, P23; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MA H, 1989, MOL CELL BIOL, V9, P5643, DOI 10.1128/MCB.9.12.5643; MA H, 1986, MOL CELL BIOL, V6, P4046, DOI 10.1128/MCB.6.11.4046; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; Menezes RA, 2003, J MOL BIOL, V333, P479, DOI 10.1016/j.jmb.2003.08.034; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; Moreno-Herrero F, 2001, BIOCHEM BIOPH RES CO, V280, P151, DOI 10.1006/bbrc.2000.4074; Moreno-Herrero F, 1999, FEBS LETT, V459, P427, DOI 10.1016/S0014-5793(99)01289-2; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Ostling J, 1998, EUR J BIOCHEM, V252, P162, DOI 10.1046/j.1432-1327.1998.2520162.x; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanz P, 1996, J BACTERIOL, V178, P4721, DOI 10.1128/jb.178.15.4721-4723.1996; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; Tomas-Cobos L, 2002, BIOCHEM J, V368, P657, DOI 10.1042/BJ20020984; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; VALLIER LG, 1994, GENETICS, V137, P49; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Wray LV, 2001, CELL, V107, P427, DOI 10.1016/S0092-8674(01)00572-4; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	44	98	100	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14440	14446		10.1074/jbc.M313431200	http://dx.doi.org/10.1074/jbc.M313431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715653	hybrid			2022-12-27	WOS:000220478500140
J	Burrows, JF; McGrattan, MJ; Rascle, A; Humbert, M; Baek, KH; Johnston, JA				Burrows, JF; McGrattan, MJ; Rascle, A; Humbert, M; Baek, KH; Johnston, JA			DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-SPECIFIC PROTEASE; T-CELL LEUKEMIA; CANCER-CELLS; INTERLEUKIN-4; PATHWAY; GROWTH; APOPTOSIS; PROTEINS; DEGRADATION; INTERACTS	Previous studies have identified the DUB family of cytokine-regulated murine deubiquitinating enzymes, which play a role in the control of cell proliferation and survival. Through data base analyses and cloning, we have identified a human cDNA (DUB-3) that shows significant homology to the known murine DUB family members. Northern blotting has shown expression of this gene in a number of tissues including brain, liver, and muscle, with two transcripts being apparent (1.6 and 1.7 kb). In addition, expression was observed in cell lines including those derived from a number of hematopoietic tumors such as the Burkitt's lymphoma cell line RAJI. We have also demonstrated that DUB-3, which was shown to be an active deubiquitinating enzyme, is induced in response to interleukin-4 and interleukin-6 stimulation. Finally, we have demonstrated that constitutive expression of DUB-3 blocks proliferation and can initiate apoptosis in both IL-3-dependent Ba/F3 cells and NIH3T3 fibroblasts. These findings suggest that human DUB-3, like the murine DUB family members, is transiently induced in response to cytokines and can, when constitutively expressed, block growth factor-dependent proliferation.	Queens Univ Belfast, Dept Microbiol & Immunol, Belfast BT9 7BL, Antrim, North Ireland; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Pochon CHA Univ, Coll Med, Cell & Gene Therapy Res Inst, Seoul, South Korea	Queens University Belfast; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Pochon Cha University	Johnston, JA (corresponding author), Queens Univ Belfast, Dept Microbiol & Immunol, Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	jim.johnston@qub.ac.uk	Rascle, Anne/AAC-1904-2019	Rascle, Anne/0000-0001-7464-8545; Baek, Kwang-Hyun/0000-0001-7662-7190				Baek KH, 2003, EXP MOL MED, V35, P1; Baek KH, 2001, BLOOD, V98, P636, DOI 10.1182/blood.V98.3.636; Blanchette P, 2001, ONCOGENE, V20, P5533, DOI 10.1038/sj.onc.1204823; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cai SY, 1999, P NATL ACAD SCI USA, V96, P2828, DOI 10.1073/pnas.96.6.2828; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gewies A, 2003, CANCER RES, V63, P682; Gondo Y, 1998, GENOMICS, V54, P39, DOI 10.1006/geno.1998.5545; Gooch JL, 1998, CANCER RES, V58, P4199; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1994, ONCOGENE, V9, P1729; Henchoz S, 1996, MOL CELL BIOL, V16, P5717; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hirano T, 1998, Int Rev Immunol, V16, P249; HOWARD M, 1982, P NATL ACAD SCI USA, V85, P6107; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KAWANO F, 1992, LEUKEMIA, V6, P66; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Migone TS, 2001, BLOOD, V98, P1935, DOI 10.1182/blood.V98.6.1935; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; NAKAMURA T, 1992, ONCOGENE, V7, P733; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; Pantaleon M, 2001, MECH DEVELOP, V109, P151, DOI 10.1016/S0925-4773(01)00551-2; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; TOI M, 1992, CANCER RES, V52, P275; TOPP MS, 1995, CANCER RES, V55, P2173; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Vugmeyster Y, 2002, MOL IMMUNOL, V39, P431, DOI 10.1016/S0161-5890(02)00123-2; Ward AC, 2000, BLOOD, V95, P19; Watanabe T, 1997, INT J HEMATOL, V66, P257; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu Y, 1996, MOL CELL BIOL, V16, P4808; Zhu YA, 1997, J BIOL CHEM, V272, P51	54	72	77	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13993	14000		10.1074/jbc.M311291200	http://dx.doi.org/10.1074/jbc.M311291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699124	hybrid			2022-12-27	WOS:000220478500087
J	Sato, M; Gettys, TW; Lanier, SM				Sato, M; Gettys, TW; Lanier, SM			AGS3 and signal integration by G alpha(s)- and G alpha(i)-coupled receptors - AGS3 blocks the sensitization of adenylyl cyclase following prolonged stimulation of a G alpha(i)-coupled receptor by influencing processing of G alpha(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; HETEROTRIMERIC G-PROTEINS; REGULATORY MOTIF; ACTIVATION; IDENTIFICATION; EXPRESSION; BINDING; PHOSPHORYLATION; DISSOCIATION; POLARITY	AGS3-LONG and AGS3-SHORT contain G-protein regulatory motifs that interact with and stabilize the GDP-bound conformation of Galpha(i) > Galpha(o). AGS3 and related proteins may influence signal strength or duration as well as the adaptation of the signaling system associated with sustained stimulation. To address these issues, we determined the effect of AGS3 on the integration of stimulatory (Galpha(s)-mediated vasoactive intestinal peptide receptor) and inhibitory (Galpha(i)-mediated alpha(2)-adrenergic receptor (alpha(2)-AR)) signals to adenylyl cyclase in Chinese hamster ovary cells. AGS3-SHORT and AGS3-LONG did not alter the VIP-induced increase in cAMP or the inhibitory effect of alpha(2)-AR activation. System adaptation was addressed by determining the influence of AGS3 on the sensitization of adenylyl cyclase that occurs following prolonged activation of a Galpha(i)-coupled receptor. Incubation of cells with the alpha(2)-AR agonist UK14304 ( 1 muM) for 18 h resulted in a similar to 1.8-fold increase in the vasoactive intestinal peptide-induced activation of adenylyl cyclase, and this was associated with a decrease in membrane-associated Galpha(i3). Both effects were blocked by AGS3-SHORT. AGS3-SHORT also decreased the rate of Galpha(i3) decay. A mutant AGS3-SHORT incapable of binding G-protein was inactive. These data suggest that AGS3 and perhaps other G-protein regulatory motif-containing proteins increase the stability of Galpha(i) in the membrane, which influences the adaptation of the cell to prolonged activation of Galpha(i)-coupled receptors.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Lanier, Stephen/0000-0002-2740-7607	NIMH NIH HHS [MH55391] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adhikari A, 2003, J BIOL CHEM, V278, P51825, DOI 10.1074/jbc.M306300200; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Bayewitch ML, 2000, MOL PHARMACOL, V57, P820, DOI 10.1124/mol.57.4.820; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339; Ma HZ, 2003, BIOCHEMISTRY-US, V42, P8085, DOI 10.1021/bi034561p; Makhlouf M, 1996, BBA-MOL CELL RES, V1312, P163, DOI 10.1016/0167-4889(96)00019-5; Marty C, 2003, MOL CELL BIOL, V23, P3847, DOI 10.1128/MCB.23.11.3847-3858.2003; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Pattingre S, 2003, J BIOL CHEM, V278, P20995, DOI 10.1074/jbc.M300917200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Watts VJ, 2002, J PHARMACOL EXP THER, V302, P1, DOI 10.1124/jpet.302.1.1; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	38	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13375	13382		10.1074/jbc.M312660200	http://dx.doi.org/10.1074/jbc.M312660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726514	hybrid			2022-12-27	WOS:000220478500014
J	Wallis, R; Shaw, JM; Uitdehaag, J; Chen, CB; Torgersen, D; Drickamer, K				Wallis, R; Shaw, JM; Uitdehaag, J; Chen, CB; Torgersen, D; Drickamer, K			Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein - Indirect effects of naturally occurring mutations on protease binding and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ACTIVATION; CRYSTAL-STRUCTURE; TRIPLE-HELIX; I COLLAGEN; LECTIN; PATHWAY; ASSOCIATION; ASYMMETRY; COMPLEXES; SEQUENCE	Mutations in the collagen-like domain of serum mannose-binding protein (MBP) interfere with the ability of the protein to initiate complement fixation through the MBP-associated serine proteases (MASPs). The resulting deficiency in the innate immune response leads to susceptibility to infections. Studies have been undertaken to define the region of MBP that interacts with MASPs and to determine how the naturally occurring mutations affect this interaction. Truncated and modified MBPs and synthetic peptides that represent segments of the collagen-like domain of MBP have been used to demonstrate that MASPs bind on the C-terminal side of the hinge region formed by an interruption in the Gly-X-Y repeat pattern of the collagen-like domain. The binding sites for MASP-2 and for MASP-1 and - 3 overlap but are not identical. The two most common naturally occurring mutations in MBP result in substitution of acidic amino acids for glycine residues in Gly-X-Y triplets on the N-terminal side of the hinge. Circular dichroism analysis and differential scanning calorimetry demonstrate that the triple helical structure of the collagen-like domain is largely intact in the mutant proteins, but it is more easily unfolded than in wild-type MBP. Thus, the effect of the mutations is to destabilize the collagen-like domain, indirectly disrupting the binding sites for MASPs. In addition, at least one of the mutations has a further effect on the ability of MBP to activate MASPs.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	kd@glycob.ox.ac.uk		Wallis, Russell/0000-0002-8705-5295				Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DRICKAMER K, 1986, J BIOL CHEM, V261, P1034; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Gadjeva M, 2001, CURR OPIN IMMUNOL, V13, P74, DOI 10.1016/S0952-7915(00)00185-0; Heise CT, 2000, J IMMUNOL, V165, P1403, DOI 10.4049/jimmunol.165.3.1403; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; LU J, 1990, J IMMUNOL, V144, P2287; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; Mogues T, 1996, GLYCOBIOLOGY, V6, P543, DOI 10.1093/glycob/6.5.543; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SASTRY K, 1991, J IMMUNOL, V147, P692; SCHUMAKER VN, 1981, J MOL BIOL, V148, P191, DOI 10.1016/0022-2836(81)90511-8; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; Slatter DA, 2003, J MOL BIOL, V329, P175, DOI 10.1016/S0022-2836(03)00380-2; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Tiktopulo EI, 1998, BIOCHEMISTRY-US, V37, P8147, DOI 10.1021/bi980360n; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2002, IMMUNOBIOLOGY, V205, P433, DOI 10.1078/0171-2985-00144; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	40	67	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14065	14073		10.1074/jbc.M400171200	http://dx.doi.org/10.1074/jbc.M400171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724269	hybrid			2022-12-27	WOS:000220478500096
J	Kawasaki, J; Davis, GE; Davis, MJ				Kawasaki, J; Davis, GE; Davis, MJ			Regulation of Ca2+-dependent K+ current by alpha(v)beta(3) integrin engagement in vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURRENT I-CRAC; TYROSINE KINASE; CALCIUM CURRENT; CA2+ ENTRY; CHANNEL ACTIVATION; CEREBRAL-ARTERIES; SMOOTH-MUSCLE; SHEAR-STRESS; CELLS; ADHESION	Interactions between endothelial cells and extracellular matrix proteins are important determinants of endothelial cell signaling. Endothelial adhesion to fibronectin through alpha(v)beta(3) integrins or the engagement and aggregation of luminal alpha(v)beta(3) receptors by vitronectin triggers Ca2+ influx. However, the underlying signaling mechanisms are unknown. The electrophysiological basis of alpha(v)beta(3) integrin- mediated changes in endothelial cell Ca2+ signaling was studied using whole cell patch clamp and microfluorimetry. The resting membrane potential of bovine pulmonary artery endothelial cells averaged - 60 +/- 3 mV. In the absence of intracellular Ca2+ buffering, the application of soluble vitronectin ( 200 mug/ml) resulted in activation of an outwardly rectifying K+ current at holding potentials from - 50 to + 50 mV. Neither a significant shift in reversal potential ( in voltage clamp mode) nor a change in membrane potential ( in current clamp mode) occurred in response to vitronectin. Vitronectin- activated current was significantly inhibited by pretreatment with the alpha(v)beta(3) integrin antibody LM609 by exchanging extracellular K+ with Cs+ or by the application of iberiotoxin, a selective inhibitor of large- conductance, Ca2+- activated K+ channels. With intracellular Ca2+ buffered by EGTA in the recording pipette, vitronectin- activated K+ current was abolished. Fura- 2 microfluorimetry revealed that vitronectin induced a significant and sustained increase in intracellular Ca2+ concentration, although vitronectin- induced Ca2+ current could not be detected. This is the first report to show that an endothelial cell ion channel is regulated by integrin activation, and this K+ current likely plays a crucial role in maintaining membrane potential and a Ca2+ driving force during engagement and activation of endothelial cell alpha(v)beta(3) integrin.	Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Dept Med Physiol, College Stn, TX 77845 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Dept Pathol & Lab Med, College Stn, TX 77845 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Davis, MJ (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Dept Med Physiol, Rm 346,Reynolds Med Bldg, College Stn, TX 77845 USA.	mjd@tamu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060180, R01HL059971] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59971, HL 60180] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCANGELI A, 1991, BIOCHEM BIOPH RES CO, V177, P1266, DOI 10.1016/0006-291X(91)90678-Z; Battistella-Patterson AS, 1997, CAN J PHYSIOL PHARM, V75, P1287, DOI 10.1139/cjpp-75-12-1287; BECCHETTI A, 1992, P ROY SOC B-BIOL SCI, V248, P235, DOI 10.1098/rspb.1992.0067; Bhattacharya S, 2000, CIRC RES, V86, P456, DOI 10.1161/01.RES.86.4.456; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Bryan RM, 2001, AM J PHYSIOL-HEART C, V280, pH2011, DOI 10.1152/ajpheart.2001.280.5.H2011; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Clemetson KJ, 1998, CELL MOL LIFE SCI, V54, P499, DOI 10.1007/s000180050178; CONFORTI G, 1992, BLOOD, V80, P437; DAUT J, 1988, J PHYSIOL-LONDON, V402, P237, DOI 10.1113/jphysiol.1988.sp017202; DESMET P, 1994, PFLUG ARCH EUR J PHY, V428, P94, DOI 10.1007/BF00374757; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; FUJIMOTO T, 1991, J BIOL CHEM, V266, P16370; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIMMEL HM, 1994, AM J PHYSIOL-CELL PH, V267, pC1338; HIMMEL HM, 1993, HYPERTENSION, V21, P112, DOI 10.1161/01.HYP.21.1.112; Hofmann G, 2001, J BIOL CHEM, V276, P4923, DOI 10.1074/jbc.M005682200; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Intengan HD, 2000, HYPERTENSION, V36, P312, DOI 10.1161/01.HYP.36.3.312; Kawasaki J, 1999, EUR J PHARMACOL, V373, P111, DOI 10.1016/S0014-2999(99)00257-5; Kelly JJ, 1998, AM J PHYSIOL-LUNG C, V274, pL810, DOI 10.1152/ajplung.1998.274.5.L810; Kramar EA, 2003, J BIOL CHEM, V278, P10722, DOI 10.1074/jbc.M210225200; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Lin B, 2003, J NEUROPHYSIOL, V89, P2874, DOI 10.1152/jn.00783.2002; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; Madden JA, 1999, AM J PHYSIOL-HEART C, V277, pH2264, DOI 10.1152/ajpheart.1999.277.6.H2264; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SHARMA NR, 1994, AM J PHYSIOL, V266, pH156, DOI 10.1152/ajpheart.1994.266.1.H156; Sharma NR, 1996, AM J PHYSIOL-HEART C, V270, pH267, DOI 10.1152/ajpheart.1996.270.1.H267; SHARMA NR, 1995, AM J PHYSIOL-HEART C, V268, pH962, DOI 10.1152/ajpheart.1995.268.3.H962; Singh B, 2000, AM J PHYSIOL-LUNG C, V278, pL217, DOI 10.1152/ajplung.2000.278.1.L217; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; Sjaastad MD, 1996, MOL BIOL CELL, V7, P1025, DOI 10.1091/mbc.7.7.1025; Vaca L, 1996, AM J PHYSIOL-CELL PH, V270, pC819, DOI 10.1152/ajpcell.1996.270.3.C819; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; ZAR JH, 1984, BIOSTAT ANAL, P196	54	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12959	12966		10.1074/jbc.M313791200	http://dx.doi.org/10.1074/jbc.M313791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724272	hybrid			2022-12-27	WOS:000220334900114
J	Yerlikaya, A; Stanley, BA				Yerlikaya, A; Stanley, BA			S-Adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; N-END RULE; ORNITHINE-DECARBOXYLASE; ESCHERICHIA-COLI; IN-VIVO; LYMPHOCYTE MITOGENESIS; RAT PROSTATE; TUMOR-CELLS; PROTEIN; MECHANISM	The short-lived enzyme S-adenosylmethionine decarboxylase uses a covalently bound pyruvoyl cofactor to catalyze the formation of decarboxylated S-adenosylmethionine, which then donates an aminopropyl group for polyamine biosynthesis. Here we demonstrate that S-adenosylmethionine decarboxylase is ubiquitinated and degraded by the 26 S proteasome in vivo, a process that is accelerated by inactivation of S-adenosylmethionine decarboxylase by substrate-mediated transamination of its pyruvoyl cofactor. Proteasome inhibition in COS-7 cells prevents the degradation of S-adenosylmethionine decarboxylase antigen; however, even brief inhibition of the 26 S proteasome caused substantial losses of S-adenosylmethionine decarboxylase activity despite accumulation of S-adenosylmethionine decarboxylase antigen. Levels of the enzyme's substrate (S-adenosylmethionine) increased rapidly after 26 S proteasome inhibition, and this increase in substrate level is consistent with the observed loss of activity arising from an increased rate of inactivation by substrate-mediated transamination. Evidence is also presented that this substrate-mediated transamination accelerates normal degradation of S-adenosylmethionine decarboxylase, as the rate of degradation of the enzyme was increased in the presence of AbeAdo (5'-([(Z)-4-amino-2-butenyl] methylamino]-5'-deoxyadenosine) ( a substrate analogue that transaminates the enzyme); conversely, when the intracellular substrate level was reduced by methionine deprivation, the rate of degradation of the enzyme was decreased. Ubiquitination of S-adenosylmethionine decarboxylase is demonstrated by isolation of His-tagged AdoMetDC (S-adenosylmethionine decarboxylase) from COS-7 cells co-transfected with hemagglutinin-tagged ubiquitin and showing bands that were immunoreactive to both anti-AdoMetDC antibody and anti-hemagglutinin antibody. This is the first study to demonstrate that AdoMetDC is ubiquitinated and degraded by the 26 S proteasome, and substrate-mediated acceleration of degradation is a unique finding.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Sect Res Resources, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Stanley, BA (corresponding author), Penn State Coll Med, Sect Res Resources H093, 500 Univ Dr, Hershey, PA 17033 USA.	bstanley@psu.edu	Stanley, Bruce/R-9856-2019; Yerlikaya, Azmi/AAS-9289-2020	Yerlikaya, Azmi/0000-0002-0678-0701; Stanley, Bruce/0000-0003-1338-2928				ANTON DL, 1987, BIOCHEMISTRY-US, V26, P6444, DOI 10.1021/bi00394a022; AUTELLI R, 1991, EUR J BIOCHEM, V196, P551, DOI 10.1111/j.1432-1033.1991.tb15849.x; Benanti JA, 2002, MOL CELL BIOL, V22, P7385, DOI 10.1128/MCB.22.21.7385-7397.2002; Berntsson PSH, 1999, BIOCHEM BIOPH RES CO, V263, P13, DOI 10.1006/bbrc.1999.1293; Bohley P, 1996, BIOL CHEM, V377, P425; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FREDLUND JO, 1995, EXP CELL RES, V216, P86, DOI 10.1006/excr.1995.1011; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLM I, 1989, BIOCHEM J, V261, P205, DOI 10.1042/bj2610205; JANNE J, 1971, J BIOL CHEM, V246, P1725; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KRAMER DL, 1988, BIOCHEM J, V249, P581, DOI 10.1042/bj2490581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YF, 2001, P NATL ACAD SCI USA, V98, P10578, DOI 10.1073/pnas.181341198; MACH M, 1986, J BIOL CHEM, V261, P1697; MADHUBALA R, 1988, BIOCHEM J, V254, P45, DOI 10.1042/bj2540045; MANN K, 1977, J VIROL, V24, P151, DOI 10.1128/JVI.24.1.151-169.1977; Mitchison JM, 2003, INT REV CYTOL, V226, P165, DOI 10.1016/S0074-7696(03)01004-0; MORRIS DR, 1981, MED BIOL, V59, P314; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nasizadeh S, 2003, FEBS LETT, V553, P131, DOI 10.1016/S0014-5793(03)00986-4; PEGG AE, 1973, BIOCHEM BIOPH RES CO, V52, P696, DOI 10.1016/0006-291X(73)90768-7; PEGG AE, 1979, J BIOL CHEM, V254, P3249; PEGG AE, 1988, BIOCHEM BIOPH RES CO, V150, P788, DOI 10.1016/0006-291X(88)90460-3; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; PEGG AE, 1987, BIOCHEM J, V244, P49, DOI 10.1042/bj2440049; PEGG AE, 1982, AM J PHYSIOL, V243, P212; POSO H, 1981, BIOCHEM J, V200, P629; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Saito T, 2002, J BIOL CHEM, V277, P33624, DOI 10.1074/jbc.M201909200; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; SEYFRIED CE, 1982, BIOCHIM BIOPHYS ACTA, V716, P169, DOI 10.1016/0304-4165(82)90265-3; SHANTZ LM, 1992, BIOCHEM J, V288, P511, DOI 10.1042/bj2880511; SHANTZ LM, 1992, BIOCHEMISTRY-US, V31, P6848, DOI 10.1021/bi00144a027; SHIRAHATA A, 1985, BIOCHEMISTRY-US, V24, P4417, DOI 10.1021/bi00337a024; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; STANLEY BA, 1995, POLYAMINES REGULATIO, P27; STJERNBORG L, 1993, BIOCHEM PHARMACOL, V45, P1174, DOI 10.1016/0006-2952(93)90266-Y; Svensson F, 1997, BIOCHEM J, V322, P297, DOI 10.1042/bj3220297; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TISDALE MJ, 1981, BIOCHIM BIOPHYS ACTA, V675, P366, DOI 10.1016/0304-4165(81)90027-1; Tolbert WD, 2001, BIOCHEMISTRY-US, V40, P9484, DOI 10.1021/bi010735w; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Xiong HS, 1999, BIOCHEMISTRY-US, V38, P2462, DOI 10.1021/bi9825201	53	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12469	12478		10.1074/jbc.M312625200	http://dx.doi.org/10.1074/jbc.M312625200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718534	hybrid			2022-12-27	WOS:000220334900057
J	Arimura, Y; Shiroki, F; Kuwahara, S; Kato, H; Dianzani, U; Uchiyama, T; Yagi, J				Arimura, Y; Shiroki, F; Kuwahara, S; Kato, H; Dianzani, U; Uchiyama, T; Yagi, J			Akt is a neutral amplifier for Th cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE GENE-EXPRESSION; TRANSCRIPTION FACTOR; MOLECULE ICOS; PHOSPHATIDYLINOSITOL 3-KINASE; COSTIMULATORY MOLECULE; CD28-DEFICIENT MICE; IL-4 GENE; CYTOPLASMIC DOMAIN; IN-VIVO; ACTIVATION	Both CD28 and its relative, inducible costimulator ( ICOS), have a binding motif for phosphatidylinositol 3-kinase (PI3K) in their cytoplasmic tail, and the binding of PI3K leads to activation of a serine/threonine kinase, Akt. The role of Akt in cytokine production and helper T (Th) cell differentiation remains obscure. In this study, we found that enforced expression of the constitutively active form (E40K) of Akt rendered CD4(+) T cells activated. Wild-type of Akt and E40K promoted Th1 cell differentiation in C57BL/6-derived and Th1-polarized BALB/c-derived CD4(+) T cells, while both promoted Th2 cell differentiation in BALB/c-derived and Th2-polarized C57BL/6 CD4(+) T cells. E40K also facilitated Th1 differentiation in CD4(+) T cells from IL-4-deficient mice with the BALB/c background. E40K up-regulated expression of NF-AT and c-Myb, which may be related to the augmentation of cytokine production by E40K. These findings indicate that the mechanism by which Akt augments cytokine production via CD28 and ICOS is Th cell type-specific and reflects the intracellular status affected by the cytokine milieu. We conclude that Akt is a neutral amplifier of T cell activation and Th differentiation.	Tokyo Womens Med Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1628666, Japan; A Avogadro Univ Eastern Piedmont, IRCAD, I-28100 Novara, Italy; A Avogadro Univ Eastern Piedmont, Dept Med Sci, I-28100 Novara, Italy	Tokyo Women's Medical University; University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro	Arimura, Y (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	arimura@research.twmu.ac.jp	Dianzani, Umberto/K-1952-2016	DIANZANI, Umberto/0000-0001-6723-3931				Arimura Y, 2002, INT IMMUNOL, V14, P555, DOI 10.1093/intimm/dxf022; Arimura Y, 2001, J BIOL CHEM, V276, P8550, DOI 10.1074/jbc.M009242200; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brown DR, 1996, J EXP MED, V184, P803, DOI 10.1084/jem.184.3.803; Buonfiglio D, 2000, EUR J IMMUNOL, V30, P3463, DOI 10.1002/1521-4141(2000012)30:12<3463::AID-IMMU3463>3.0.CO;2-5; Chen LQ, 2002, J IMMUNOL, V168, P3817, DOI 10.4049/jimmunol.168.8.3817; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; El-Deiry WS, 2001, NAT CELL BIOL, V3, pE71, DOI 10.1038/35060148; Filippi C, 2003, J EXP MED, V198, P201, DOI 10.1084/jem.20021893; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GROSS JA, 1992, J IMMUNOL, V149, P380; Harada Y, 2003, J EXP MED, V197, P257, DOI 10.1084/jem.20021305; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Khattri R, 1999, J IMMUNOL, V162, P5784; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; King CL, 1996, EUR J IMMUNOL, V26, P2448, DOI 10.1002/eji.1830261027; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ogawa S, 2001, J IMMUNOL, V167, P5741, DOI 10.4049/jimmunol.167.10.5741; Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Shi J, 1997, J IMMUNOL, V158, P4688; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Tamatani T, 2000, INT IMMUNOL, V12, P51, DOI 10.1093/intimm/12.1.51; TRUITT KE, 1995, J IMMUNOL, V155, P4702; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944; YAGI J, 1994, J IMMUNOL, V152, P3833; Yagi J, 2003, J IMMUNOL, V171, P783, DOI 10.4049/jimmunol.171.2.783; Yagi J, 1999, J IMMUNOL, V163, P3083; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11408	11416		10.1074/jbc.M309063200	http://dx.doi.org/10.1074/jbc.M309063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707136	hybrid			2022-12-27	WOS:000220157600071
J	Matsuura, K; Nagai, T; Nishigaki, N; Oyama, T; Nishi, J; Wada, H; Sano, M; Toko, H; Akazawa, H; Sato, T; Nakaya, H; Kasanuki, H; Komuro, I				Matsuura, K; Nagai, T; Nishigaki, N; Oyama, T; Nishi, J; Wada, H; Sano, M; Toko, H; Akazawa, H; Sato, T; Nakaya, H; Kasanuki, H; Komuro, I			Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; SIDE POPULATION CELLS; BONE-MARROW-CELLS; TRANSCRIPTION FACTOR; OXYTOCIN RECEPTORS; MYOGENIC SPECIFICATION; MYOCYTE PROLIFERATION; PROGENITOR CELLS; IN-VITRO; EXPRESSION	Although somatic stem cells have been reported to exist in various adult organs, there have been few reports concerning stem cells in the heart. We here demonstrate that Sca-1-positive (Sca-1+) cells in adult hearts have some of the features of stem cells. Sca-1+ cells were isolated from adult murine hearts by a magnetic cell sorting system and cultured on gelatin-coated dishes. A fraction of Sca-1+ cells stuck to the culture dish and proliferated slowly. When treated with oxytocin, Sca-1+ cells expressed genes of cardiac transcription factors and contractile proteins and showed sarcomeric structure and spontaneous beating. Isoproterenol treatment increased the beating rate, which was accompanied by the intracellular Ca2+ transients. The cardiac Sca-1+ cells expressed oxytocin receptor mRNA, and the expression was up-regulated after oxytocin treatment. Some of the Sca-1+ cells expressed alkaline phosphatase after osteogenic induction and were stained with Oil-Red O after adipogenic induction. These results suggest that Sca-1+ cells in the adult murine heart have potential as stem cells and may contribute to the regeneration of injured hearts.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Tokyo Womens Med Univ, Heart Inst Japan, Dept Cardiol, Tokyo 1620054, Japan; Takeda Chem Ind Ltd, Osaka 5408645, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba 2608670, Japan	Chiba University; Tokyo Women's Medical University; Takeda Chemical Industries; Chiba University	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Nishigaki, Nobuhiro/AAZ-3584-2021	Nishigaki, Nobuhiro/0000-0002-7524-1429; Akazawa, Hiroshi/0000-0002-3574-9607				Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Asakura A, 2002, EXP HEMATOL, V30, P1339, DOI 10.1016/S0301-472X(02)00954-2; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Brunskill EW, 2001, DEV BIOL, V235, P507, DOI 10.1006/dbio.2001.0313; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; Gojo S, 2003, EXP CELL RES, V288, P51, DOI 10.1016/S0014-4827(03)00132-0; Hakuno D, 2002, CIRCULATION, V105, P380, DOI 10.1161/hc0302.102593; Hierlihy AM, 2002, FEBS LETT, V530, P239, DOI 10.1016/S0014-5793(02)03477-4; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; Leri A, 2001, P NATL ACAD SCI USA, V98, P8626, DOI 10.1073/pnas.151013298; Limana F, 2002, P NATL ACAD SCI USA, V99, P6257, DOI 10.1073/pnas.092672899; Lu S, 2000, J MOL CELL CARDIOL, V32, P143, DOI 10.1006/jmcc.1999.1063; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Mukaddam-Daher S, 2002, J ENDOCRINOL, V175, P211, DOI 10.1677/joe.0.1750211; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; Okumoto K, 2003, BIOCHEM BIOPH RES CO, V304, P691, DOI 10.1016/S0006-291X(03)00637-5; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Strakova Z, 1998, AM J PHYSIOL-ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634; SUGI Y, 1995, DEV BIOL, V168, P567, DOI 10.1006/dbio.1995.1102; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Tahara A, 2000, BRIT J PHARMACOL, V129, P131, DOI 10.1038/sj.bjp.0702996; Tahara M, 2002, ENDOCRINOLOGY, V143, P920, DOI 10.1210/en.143.3.920; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; Wei L, 2001, DEVELOPMENT, V128, P2953; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Yao A, 1998, AM J PHYSIOL-HEART C, V275, pH1441, DOI 10.1152/ajpheart.1998.275.4.H1441; Yao A, 2003, CIRC J, V67, P83, DOI 10.1253/circj.67.83; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	57	483	527	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11384	11391		10.1074/jbc.M310822200	http://dx.doi.org/10.1074/jbc.M310822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702342	hybrid			2022-12-27	WOS:000220157600068
J	Razem, FA; Luo, M; Liu, JH; Abrams, SR; Hill, RD				Razem, FA; Luo, M; Liu, JH; Abrams, SR; Hill, RD			RETRACTED: Purification and characterization of a barley aleurone abscisic acid-binding protein (Retracted Article. See vol 285, pg 4264, 2010)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							ABA SIGNAL-TRANSDUCTION; ARABIDOPSIS-THALIANA; BIOLOGICAL-ACTIVITY; PLASMA-MEMBRANE; GENE-EXPRESSION; PHOSPHATASE 2C; PERCEPTION; IDENTIFICATION; CHANNELS; DOMAINS	A protein designated ABAP1 and encoded by a novel gene (GenBank(TM) accession number AF127388) was purified and shown to specifically bind abscisic acid (ABA). ABAP1 protein is a 472-amino acid polypeptide containing a WW protein interaction domain and is induced by ABA in barley aleurone layers. Polyclonal anti-idiotypic antibodies (AB2) cross-reacted with purified ABAP1 and with a corresponding 52-kDa protein associated with membrane fractions of ABA-treated barley aleurones. ABAP1 genes were detected in diverse monocot and dicot species, including wheat, tobacco, alfalfa, garden pea, and oilseed rape. The recombinant ABAP1 protein optimally bound H-3-(+)-ABA at neutral pH. Denatured ABAP1 protein did not bind H-3-(+)-ABA, nor did bovine serum albumin. The maximum specific binding as shown by Scatchard plot analysis was 0.8 mol of ABA mol(-1) protein with a linear function of r(2) = 0.94, an indication of one ABA-binding site with a dissociation constant (K-d) of 28 x 10(-9) M. ABA binding in aleurone plasma membranes showed a maximum binding capacity of 330 nmol of ABA g(-1) protein with a K-d of 26.5 x 10(-9) M. The similarities in the dissociation constants for ABA binding of the recombinant protein and that of the plasma membranes suggest that the protein within the plasma membrane fraction is the native form of ABAP1. The stereospecificity of ABAP1 was established by the incapability of ABA analogs and metabolites, including (-)-ABA, trans-ABA, phaseic acid, dihydrophaseic acid, and (+)-abscisic acid-glucose ester, to displace H-3-(+)ABA bound to ABAP1. However, two ABA precursors, (+)-ABA aldehyde and (+)-ABA alcohol, were able to displace H-3-(+)-ABA, an indication that the structural requirement of ABAP1 at the C-1 position is not strict. Our data show that ABAP1 exerts high binding affinity for ABA. The interaction is reversible, follows saturation kinetics, and has stereospecificity, thus meeting the criteria for an ABA-binding protein.	Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	University of Manitoba; National Research Council Canada	Hill, RD (corresponding author), Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.	rob_hill@umanitoba.ca						ALDASORO JJ, 1981, PHYSIOL PLANTARUM, V53, P139, DOI 10.1111/j.1399-3054.1981.tb04123.x; ANDERSON BE, 1994, PLANT PHYSIOL, V104, P1177, DOI 10.1104/pp.104.4.1177; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bleecker AB, 1999, TRENDS PLANT SCI, V4, P269, DOI 10.1016/S1360-1385(99)01427-2; Bonetta D, 1998, TRENDS PLANT SCI, V3, P231, DOI 10.1016/S1360-1385(98)01241-2; BOSTOCK RM, 1992, PLANT PHYSIOL, V98, P1356, DOI 10.1104/pp.98.4.1356; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Churchill GC, 1998, PLANT GROWTH REGUL, V25, P35, DOI 10.1023/A:1005982216957; EISENBERG AJ, 1985, PLANTA, V166, P505, DOI 10.1007/BF00391275; FARID NR, 1989, METHOD ENZYMOL, V178, P191; Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441; FINKELSTEIN RR, 1994, PLANT J, V5, P765, DOI 10.1046/j.1365-313X.1994.5060765.x; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; Ghelis T, 2000, FEBS LETT, V474, P43, DOI 10.1016/S0014-5793(00)01574-X; Gilroy S, 1996, PLANT CELL, V8, P2193, DOI 10.1105/tpc.8.12.2193; GILROY S, 1994, PLANT PHYSIOL, V104, P1185, DOI 10.1104/pp.104.4.1185; GUSTA LV, 1992, CAN J BOT, V70, P1550, DOI 10.1139/b92-195; HARTUNG W, 1983, PLANT CELL ENVIRON, V6, P427, DOI 10.1111/j.1365-3040.1983.tb01276.x; Hays DB, 1996, J PLANT GROWTH REGUL, V15, P5, DOI 10.1007/BF00213128; Heyl A, 2003, CURR OPIN PLANT BIOL, V6, P480, DOI 10.1016/S1369-5266(03)00087-6; HIGGINS T J V, 1982, Plant Molecular Biology, V1, P191, DOI 10.1007/BF00021032; Hill R. D., 1992, Seed Science Research, V2, P207, DOI 10.1017/S0960258500001392; HILL RD, 1995, PLANT PHYSIOL, V108, P573, DOI 10.1104/pp.108.2.573; HOCKING TJ, 1978, PLANTA, V138, P303, DOI 10.1007/BF00386826; Hodges T K, 1974, Methods Enzymol, V32, P392; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; Jaradat ZW, 2001, FOOD AGR IMMUNOL, V13, P241, DOI 10.1080/09540100120094500; Jeannette E, 1999, PLANT J, V18, P13, DOI 10.1046/j.1365-313X.1999.00423.x; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Liu JH, 1999, J EXP BOT, V50, P727, DOI 10.1093/jexbot/50.334.727; Lovegrove A, 2000, TRENDS PLANT SCI, V5, P102, DOI 10.1016/S1360-1385(00)01571-5; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUO M, 1992, J BIOL CHEM, V267, P15367; LUO M, 1992, PLANT RESPONSES ENV, P147; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; Meinhard M, 2001, FEBS LETT, V508, P443, DOI 10.1016/S0014-5793(01)03106-4; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MOHAPATRA SS, 1987, PLANT PHYSIOL, V84, P1172, DOI 10.1104/pp.84.4.1172; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; PATERSON NW, 1988, PLANT CELL ENVIRON, V11, P83, DOI 10.1111/j.1365-3040.1988.tb01122.x; Pedron J, 1998, EUR J BIOCHEM, V252, P385, DOI 10.1046/j.1432-1327.1998.2520385.x; Razem FA, 2003, J EXP BOT, V54, P935, DOI 10.1093/jxb/erg094; Razem FA, 2002, ENVIRON EXP BOT, V48, P247, DOI 10.1016/S0098-8472(02)00039-4; Ritchie SM, 2002, PHYSIOL PLANTARUM, V115, P342, DOI 10.1034/j.1399-3054.2002.1150303.x; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandelius A. S., 1990, The plant plasma membrane., P44; Sauter A, 2002, PLANT CELL ENVIRON, V25, P223, DOI 10.1046/j.1365-3040.2002.00747.x; Sauter A, 2002, J PLANT GROWTH REGUL, V21, P50, DOI 10.1007/s003440010040; Schultz TF, 1997, PLANT SCI, V130, P63, DOI 10.1016/S0168-9452(97)00204-5; SCHWARTZ A, 1994, P NATL ACAD SCI USA, V91, P4019, DOI 10.1073/pnas.91.9.4019; SLOVIK S, 1992, PLANTA, V187, P37, DOI [10.1007/BF00201619, 10.1007/BF00201621]; SUDOL M, 1994, ONCOGENE, V9, P2145; Villaverde A, 2003, BIOTECHNOL LETT, V25, P1385, DOI 10.1023/A:1025024104862; Von Jagow G., 1994, PRACTICAL GUIDE MEMB, P3; WALKERSIMMONS M, 1987, PLANT PHYSIOL, V84, P61, DOI 10.1104/pp.84.1.61; WALKERSIMMONS MK, 1991, PLANT PHYSIOL, V95, P46, DOI 10.1104/pp.95.1.46; Wu Y, 2003, PLANT J, V34, P307, DOI 10.1046/j.1365-313X.2003.01721.x; Yamazaki D, 2003, PLANT J, V35, P129, DOI 10.1046/j.1365-313X.2003.01782.x; Zhang DP, 2002, PLANT PHYSIOL, V128, P714, DOI 10.1104/pp.010531; Zhang DP, 2001, J EXP BOT, V52, P2097, DOI 10.1093/jexbot/52.364.2097	69	50	60	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9922	9929		10.1074/jbc.M311064200	http://dx.doi.org/10.1074/jbc.M311064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699092	hybrid			2022-12-27	WOS:000220050400033
J	Zhou, WB; Freed, CR				Zhou, WB; Freed, CR			Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; OXIDATIVE STRESS; PRECURSOR PROTEIN; WILD-TYPE; MUTANT; SUSCEPTIBILITY; EXPRESSION; MUTATIONS; OVEREXPRESSION	The deposition of alpha-synuclein and other cellular proteins in Lewy bodies in midbrain dopamine neurons is a pathological hallmark of Parkinson's disease. Nitrative and oxidative stress can induce alpha-synuclein protein aggregation, possibly initiated by the formation of stable cross-linking dimers. To determine whether enhanced dimer formation can accelerate protein aggregation and increase cellular toxicity, we have substituted cysteine for tyrosine at positions 39, 125, 133, and 136 in human wild-type (WT) alpha-synuclein, and in A53T and A30P mutant alpha-synuclein. To reduce the likelihood of cross-linking, phenylalanine was substituted for tyrosine at the same sites. We have found that overexpression of Y39C or Y125C mutant proteins leads to increased intracellular inclusions and apoptosis in a rat dopaminergic cell line (N27 cells) and in human embryonic kidney 293 cells. Expression of Y133C, Y136C, and all four Tyr-to-Phe mutations were not more cytotoxic than WT control. Exposure to oxidative stress increased Y39C and Y125C alpha-synuclein aggregation and toxicity. Dimers and oligomers were found in Triton X-100-soluble fractions from adenovirus-mediated overexpression of Y39C and Y125C in N27 cells. In contrast, WT beta-synuclein and all four Tyr-to-Cys mutant beta-synucleins did not cause protein aggregation and cell death. We conclude that cysteine substitution at critical positions in the alpha-synuclein molecule can increase dimer formation and accelerate protein aggregation and cellular toxicity of alpha-synuclein.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Freed, CR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Campus Box C-237,4200 E 9th Ave, Denver, CO 80262 USA.	curt.freed@uchsc.edu						Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Clarkson ED, 1998, P NATL ACAD SCI USA, V95, P1265, DOI 10.1073/pnas.95.3.1265; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kessler JC, 2003, BIOCHEMISTRY-US, V42, P672, DOI 10.1021/bi020429y; Ko LW, 2000, J NEUROCHEM, V75, P2546, DOI 10.1046/j.1471-4159.2000.0752546.x; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lewy F., 1914, DEUT Z NERVENHEILKD, V50, P50; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; OLANOW CW, 1990, NEUROLOGY, V40, P32; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; PICARD V, 1996, METHOD MOL BIOL, V67, P81; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	48	64	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10128	10135		10.1074/jbc.M307563200	http://dx.doi.org/10.1074/jbc.M307563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699135	hybrid			2022-12-27	WOS:000220050400058
J	Meredith, D				Meredith, D			Site-directed mutation of arginine 282 to glutamate uncouples the movement of peptides and protons by the rabbit proton-peptide cotransporter PepT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDE TRANSPORTER; LACTOSE PERMEASE; STOICHIOMETRY; DEPENDENCE; MECHANISM; HPEPT1	A conserved positive residue in the seventh transmembrane domain of the mammalian proton-coupled di- and tripeptide transporter PepT1 has been shown by site-directed mutagenesis to be a key residue for protein function. Substitution of arginine 282 with a glutamate residue (R282E-PepT1) gave a protein at the plasma membrane of Xenopus laevis oocytes that was able to transport the non-hydrolyzable dipeptide [H-3]D-Phe-LGln, although unlike the wild type, the rate of transport by R282E-PepT1 was independent of the extracellular pH level, and the substrate could not be accumulated above equilibrium. The binding affinity of the mutant transport protein was unchanged from the wild type. Thus, R282E-Pept1 appears to have been changed from a proton-driven to a facilitated transporter for peptides. In addition, peptide transport by R282E-PepT1 still induced depolarization as measured by microelectrode recordings of membrane potential. A more detailed study by two-electrode voltage clamping revealed that R282E-PepT1 behaved as a peptide-gated non-selective cation channel with the ion selectivity series lithium > sodium > N-methyl-D-glucamine at pH 7.4. There was also a proton conductance (comparing pH 7.4 and 8.4), and at pH 5.5 the predominant conductance was for potassium ions. Therefore, it can be concluded that changing arginine 282 to a glutamate not only uncouples the cotransport of protons and peptides of the wild-type PepT1 but also creates a peptide-gated cation channel in the protein.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England	University of Oxford	Meredith, D (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.	david.meredith@anat.ox.ac.uk	Meredith, David/F-3664-2010					Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bailey PD, 2000, ANGEW CHEM INT EDIT, V39, P506; BEATTIE LA, 2001, THESIS U OXFORD; Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Covitz KMY, 1998, BIOCHEMISTRY-US, V37, P15214, DOI 10.1021/bi981128k; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Kulkarni AA, 2003, BIOCHEM BIOPH RES CO, V306, P177, DOI 10.1016/S0006-291X(03)00926-4; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Meredith D, 1998, J PHYSIOL-LONDON, V512, P629, DOI 10.1111/j.1469-7793.1998.629bd.x; Meredith D, 2000, CELL MOL LIFE SCI, V57, P754, DOI 10.1007/s000180050040; MEREDITH D, 2003, J PHYSIOL-LONDON, V552, P130; MEREDITH D, 1996, J PHYSIOL-LONDON, V493, P65; Sahin-Toth M, 2001, P NATL ACAD SCI USA, V98, P6068, DOI 10.1073/pnas.111139698; Steel A, 1997, J PHYSIOL-LONDON, V498, P563, DOI 10.1113/jphysiol.1997.sp021883; TEMPLE CS, 1995, PFLUG ARCH EUR J PHY, V430, P825, DOI 10.1007/BF00386182	17	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15795	15798		10.1074/jbc.M313922200	http://dx.doi.org/10.1074/jbc.M313922200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14715671	hybrid			2022-12-27	WOS:000220747900014
J	Blayney, LM; Zissimopoulos, S; Ralph, E; Abbot, E; Matthews, L; Lai, FA				Blayney, LM; Zissimopoulos, S; Ralph, E; Abbot, E; Matthews, L; Lai, FA			Ryanodine receptor oligomeric interaction - Identification of a putative binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA2+ RELEASE; CRYOELECTRON MICROSCOPY; CARDIAC-MUSCLE; COILED COILS; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; MOLECULAR-CLONING	Specific interactions between adjacent ryanodine receptor (RyR) molecules to form ordered two-dimensional arrays in the membrane have been demonstrated using electron microscopy both in situ, in tissues and cells, and in vitro, with the purified protein. RyR interoligomeric association has also been inferred from observations of simultaneous channel gating during multiRyR channel recordings in lipid bilayers. In this study, we report experiments designed to identify the region(s) of the RyR molecule, participating in this reciprocal interaction. Using epitope-specific antibodies, we identified a RyR tryptic fragment that specifically bound the intact immobilized RyR. Three overlapping RyR fragments encompassing this epitope, expressed using an in vitro mammalian expression system, were immunoprecipitated by RyR. To refine the binding regions, smaller RyR fragments were expressed as glutathione S-transferase (GST) fusion proteins, and their binding to RyR was monitored using a "sandwich" enzyme-linked immunosorbent assay. Three GST-RyR fusion proteins demonstrated specific binding, dependent upon ionic strength. Binding was greatest at 50 - 150 mM NaCl for two GST-RyR constructs, and a third GST-RyR construct demonstrated maximum binding between 150 and 450 mM NaCl. The binding at high NaCl concentration suggested involvement of a hydrophobic interaction. In silico analysis of secondary structure showed evidence of coil regions in two of these RyR fragment sequences, which might explain these data. In GST pull-down assays, these same three fragments captured RyR2, and two of them retained RyR1. These results identify a region at the center of the linear RyR ( residues 2540 - 3207 of human RyR2) which is able to bind to the RyR oligomer. This region may constitute a specific subdomain participating in RyR-RyR interaction.	Univ Wales Coll Med, Dept Cardiol, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Blayney, LM (corresponding author), Univ Wales Coll Med, Dept Cardiol, Wales Heart Res Inst, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	blayney@cf.ac.uk	Zissimopoulos, Spyros/GSD-9824-2022	Lai, Tony/0000-0003-2852-8547; Zissimopoulos, Spyros/0000-0001-5196-9450				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; Cannell MB, 1998, TRENDS PHARMACOL SCI, V19, P16, DOI 10.1016/S0165-6147(97)01149-8; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dargan SL, 2002, BIOCHEM J, V361, P401, DOI 10.1042/0264-6021:3610401; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Harlow E., 1999, USING ANTIBODIES LAB; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16776; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARKS AR, 1990, J BIOL CHEM, V265, P13143; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MITCHELL RD, 1983, J CELL BIOL, V96, P1017, DOI 10.1083/jcb.96.4.1017; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Oakley MG, 2001, CURR OPIN STRUC BIOL, V11, P450, DOI 10.1016/S0959-440X(00)00232-3; OTSU K, 1990, J BIOL CHEM, V265, P13472; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Rice JJ, 1999, BIOPHYS J, V77, P1871, DOI 10.1016/S0006-3495(99)77030-X; Rios E, 1999, J GEN PHYSIOL, V114, P31, DOI 10.1085/jgp.114.1.31; Rios E, 1997, ANNU REV BIOPH BIOM, V26, P47, DOI 10.1146/annurev.biophys.26.1.47; Samso M, 1998, J STRUCT BIOL, V121, P172, DOI 10.1006/jsbi.1997.3955; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; Stern MD, 1999, J GEN PHYSIOL, V113, P469, DOI 10.1085/jgp.113.3.469; Stern MD, 1997, J GEN PHYSIOL, V110, P415, DOI 10.1085/jgp.110.4.415; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; WAGENKNECHT T, 1995, FEBS LETT, V369, P43, DOI 10.1016/0014-5793(95)00581-S; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Willis L, 1997, CHEMTECH, V27, P35; Yin CC, 2000, NAT CELL BIOL, V2, P669, DOI 10.1038/35023625; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	55	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14639	14648		10.1074/jbc.M308014200	http://dx.doi.org/10.1074/jbc.M308014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722100	hybrid			2022-12-27	WOS:000220594700022
J	Matsuda, S; Harries, JC; Viskaduraki, M; Troke, PJF; Kindle, KB; Ryan, C; Heery, DM				Matsuda, S; Harries, JC; Viskaduraki, M; Troke, PJF; Kindle, KB; Ryan, C; Heery, DM			A conserved alpha-helical motif mediates the binding of diverse nuclear proteins to the SRC1 interaction domain of CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; STRUCTURAL BASIS; HISTONE ACETYLTRANSFERASE; HORMONE RECEPTORS; POINTED DOMAIN; RETINOIC ACID; CANCER CELLS; CBP/P300	CREB-binding protein (CBP) and p300 contain modular domains that mediate protein-protein interactions with a wide variety of nuclear factors. A C-terminal domain of CBP ( referred to as the SID) is responsible for interaction with the alpha-helical AD1 domain of p160 coactivators such as the steroid receptor coactivator (SRC1), and also other transcriptional regulators such as E1A, Ets-2, IRF3, and p53. Here we show that the pointed (PNT) domain of Ets-2 mediates its interaction with the CBP SID, and describe the effects of mutations in the SID on binding of Ets-2, E1A, and SRC1. In vitro binding studies indicate that SRC1, Ets-2 and E1A display mutually exclusive binding to the CBP SID. Consistent with this, we observed negative cross-talk between ERalpha/ SRC1, Ets-2, and E1A proteins in reporter assays in transiently transfected cells. Transcriptional inhibition of Ets-2 or GAL4-AD1 activity by E1A was rescued by cotransfection with a CBP expression plasmid, consistent with the hypothesis that the observed inhibition was due to competition for CBP in vivo. Sequence comparisons revealed that SID-binding proteins contain a leucine-rich motif similar to the alpha-helix Aalpha1 of the SRC1 AD1 domain. Deletion mutants of E1A and Ets-2 lacking the conserved motif were unable to bind the CBP SID. Moreover, a peptide corresponding to this sequence competed the binding of full-length SRC1, Ets-2, and E1A proteins to the CBP SID. Thus, a leucine-rich amphipathic alpha-helix mediates mutually exclusive interactions of functionally diverse nuclear proteins with CBP.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Heery, DM (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	dh37@le.ac.uk		Heery, David/0000-0002-5035-2392; Garrie, Karin/0000-0003-2204-9975				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Benbow U, 1999, BRIT J CANCER, V79, P221, DOI 10.1038/sj.bjc.6690037; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kitamura S, 1999, BIOCHEM BIOPH RES CO, V265, P453, DOI 10.1006/bbrc.1999.1715; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Le Douarin B, 2001, METH MOL B, V176, P227; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; O'Connor MJ, 1999, J VIROL, V73, P3574; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Yang BS, 1996, MOL CELL BIOL, V16, P538	43	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14055	14064		10.1074/jbc.M310188200	http://dx.doi.org/10.1074/jbc.M310188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722092	hybrid			2022-12-27	WOS:000220478500095
J	Namekata, K; Enokido, Y; Iwasawa, K; Kimura, H				Namekata, K; Enokido, Y; Iwasawa, K; Kimura, H			MOCA induces membrane spreading by activating Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENILIN-BINDING-PROTEIN; SIGNALING PATHWAY; SMALL GTPASES; SH3 DOMAIN; RHO; CELLS; COMPLEX; GROWTH; KINASE; RAS	The modifier of cell adhesion protein ( MOCA), or Dock3, initially identified as presenilin-binding protein (PBP), belongs to the Dock180 family of proteins and is localized specifically in neurons. Here we demonstrate that MOCA binds to Rac1 and enhances its activity, which leads to the activation of c-Jun NH2-terminal kinase (JNK) and causes changes in cell morphology. Farnesylated MOCA, which is localized in the plasma membrane, enhances the activation of Rac1 and JNK more markedly than wild-type MOCA, and cells expressing farnesylated MOCA show flattened morphology similar to those expressing a constitutive active mutant of Rac1, Rac1Q61L. On poly-D-lysine-coated dishes, endogenous MOCA is concentrated on the leading edge of broad membrane protrusions (lamellipodia) where actin filaments are co-localized. MOCA is also concentrated with actin on the growth cone in primary cultures of cortical neurons. These observations suggest that MOCA may induce cytoskeletal reorganization and changes in cell adhesion by regulating the activity of Rac1.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878551, Japan	National Center for Neurology & Psychiatry - Japan	Kimura, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878551, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; Enokido, Yasushi/0000-0003-3252-504X				ABE K, 1990, JPN J PHARMACOL, V54, P45, DOI 10.1254/jjp.54.45; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Chen Q, 2001, AM J PATHOL, V159, P1597, DOI 10.1016/S0002-9440(10)63005-2; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kashiwa A, 2000, J NEUROCHEM, V75, P109, DOI 10.1046/j.1471-4159.2000.0750109.x; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MEIRI H, 1987, P NATL ACAD SCI USA, V84, P5058, DOI 10.1073/pnas.84.14.5058; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Namekata K, 2002, J NEUROCHEM, V82, P819, DOI 10.1046/j.1471-4159.2002.01039.x; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nishihara H, 2002, BLOOD, V100, P3968, DOI 10.1182/blood-2001-11-0032; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Yamaguchi Y, 2000, J NEUROCHEM, V75, P708, DOI 10.1046/j.1471-4159.2000.0750708.x	37	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14331	14337		10.1074/jbc.M311275200	http://dx.doi.org/10.1074/jbc.M311275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718541	hybrid			2022-12-27	WOS:000220478500128
J	Petrolonis, AJ; Yang, Q; Tummino, PJ; Fish, SM; Prack, AE; Jain, S; Parsons, TF; Li, P; Dales, NA; Ge, L; Langston, SP; Schuller, AGP; An, WF; Tartaglia, LA; Chen, H; Hong, SB				Petrolonis, AJ; Yang, Q; Tummino, PJ; Fish, SM; Prack, AE; Jain, S; Parsons, TF; Li, P; Dales, NA; Ge, L; Langston, SP; Schuller, AGP; An, WF; Tartaglia, LA; Chen, H; Hong, SB			Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; INSULIN-SECRETION; IDENTIFICATION; PHOSPHATASES; METABOLISM; INHIBITORS; ACID; GENE	Glucose is the main physiological stimulus for insulin biosynthesis and secretion by pancreatic beta-cells. Glucose-6-phosphatase (G-6-Pase) catalyzes the dephosphorylation of glucose-6-phosphate to glucose, an opposite process to glucose utilization. G-6-Pase activity in pancreatic islets could therefore be an important factor in the control of glucose metabolism and, consequently, of glucose-dependent insulin secretion. While G-6-Pase activity has been shown to be present in pancreatic islets, the gene responsible for this activity has not been conclusively identified. A homolog of liver glucose-6-phosphatase (LG-6-Pase) specifically expressed in islets was described earlier; however, the authors could not demonstrate enzymatic activity for this protein. Here we present evidence that the previously identified islet-specific glucose-6-phosphatase-related protein ( IGRP) is indeed the major islet glucose-6-phosphatase. IGRP overexpressed in insect cells possesses enzymatic activity comparable to the previously described G-6-Pase activity in islets. The K-m and V-max values determined using glucose-6-phosphate as the substrate were 0.45 mM and 32 nmol/mg/min by malachite green assay, and 0.29 mM and 77 nmol/mg/min by glucose oxidase/peroxidase coupling assay, respectively. High-throughput screening of a small molecule library led to the identification of an active compound that specifically inhibits IGRP enzymatic activity. Interestingly, this inhibitor did not affect LG-6-Pase activity, while conversely LG-6-Pase inhibitors did not affect IGRP activity. These data demonstrate that IGRP is likely the authentic islet-specific glucose-6-phosphatase catalytic subunit, and selective inhibitors to this molecule can be obtained. IGRP inhibitors may be an attractive new approach for the treatment of insulin secretion defects in type 2 diabetes.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Hong, SB (corresponding author), Wyeth Res, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	shong@wyeth.com						Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; ASHCROFT SJ, 1968, NATURE, V219, P857, DOI 10.1038/219857a0; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BURCHELL A, 1982, BIOCHEM J, V205, P567, DOI 10.1042/bj2050567; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; Foster JD, 1998, ARCH BIOCHEM BIOPHYS, V354, P125, DOI 10.1006/abbi.1998.0695; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; Iizuka K, 2000, J ENDOCRINOL, V164, P307, DOI 10.1677/joe.0.1640307; KHAN A, 1990, ENDOCRINOLOGY, V126, P2413, DOI 10.1210/endo-126-5-2413; KHAN A, 1989, J BIOL CHEM, V264, P9732; KHAN A, 1990, DIABETES, V39, P456, DOI 10.2337/diabetes.39.4.456; Khan A, 1998, EUR J PHARMACOL, V349, P325, DOI 10.1016/S0014-2999(98)00188-5; KHAN A, 1994, DIABETOLOGIA, V37, pA135; KHAN A, 1995, ENDOCRINOLOGY, V136, P1934, DOI 10.1210/en.136.5.1934; Laybutt DR, 2002, J BIOL CHEM, V277, P10912, DOI 10.1074/jbc.M111751200; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Madsen P, 2000, BIOORGAN MED CHEM, V8, P2277, DOI 10.1016/S0968-0896(00)00153-X; Mao HB, 2002, ANAL CHEM, V74, P379, DOI 10.1021/ac010822u; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OSTENSON CG, 1993, DIABETOLOGIA, V36, P3, DOI 10.1007/BF00399086; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; PERALES MA, 1991, MOL CELL BIOCHEM, V101, P67; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; SPETH M, 1986, FEBS LETT, V202, P32, DOI 10.1016/0014-5793(86)80643-3; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Stukey J, 1997, PROTEIN SCI, V6, P469; WADDELL ID, 1988, BIOCHEM J, V255, P471, DOI 10.1042/bj2550471; Westergaard N, 2002, DIABETES OBES METAB, V4, P96, DOI 10.1046/j.1463-1326.2002.00179.x	38	38	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13976	13983		10.1074/jbc.M307756200	http://dx.doi.org/10.1074/jbc.M307756200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722102	hybrid			2022-12-27	WOS:000220478500085
J	Wu, L; Nicholson, W; Knobel, SM; Steffner, RJ; May, JM; Piston, DW; Powers, AC				Wu, L; Nicholson, W; Knobel, SM; Steffner, RJ; May, JM; Piston, DW; Powers, AC			Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE GENE; BETA-CELL; SUPEROXIDE-DISMUTASE; GLUCOKINASE ACTIVITY; CATALYTIC-ACTIVITY; RATS; DNA; OVEREXPRESSION; GLUTATHIONE; EXPRESSION	Pancreatic beta cells secrete insulin in response to changes in the extracellular glucose. However, prolonged exposure to elevated glucose exerts toxic effects on beta cells and results in beta cell dysfunction and ultimately beta cell death (glucose toxicity). To investigate the mechanism of how increased extracellular glucose is toxic to beta cells, we used two model systems where glucose metabolism was increased in beta cell lines by enhancing glucokinase (GK) activity and exposing cells to physiologically relevant increases in extracellular glucose (3.3 - 20 mM). Exposure of cells with enhanced GK activity to 20 mM glucose accelerated glycolysis, but reduced cellular NAD(P) H and ATP, caused accumulation of intracellular reactive oxygen species (ROS) and oxidative damage to mitochondria and DNA, and promoted apoptotic cell death. These changes required both enhanced GK activity and exposure to elevated extracellular glucose. A ROS scavenger partially prevented the toxic effects of increased glucose metabolism. These results indicate that increased glucose metabolism in beta cells generates oxidative stress and impairs cell function and survival; this may be a mechanism of glucose toxicity in beta cells. The level of beta cell GK may also be critical in this process.	Vanderbilt Univ, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Powers, AC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, 715 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	al.powers@vanderbilt.edu			NIDDK NIH HHS [DK 50435, DK 64339, DK 55233, DK 20593] Funding Source: Medline; NIEHS NIH HHS [P30 ES 00267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK055233, R01DK050435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bennett BD, 1996, J BIOL CHEM, V271, P3647; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cardinal JW, 2001, MOL CELL BIOL, V21, P5605, DOI 10.1128/MCB.21.16.5605-5613.2001; CHEN C, 1994, DIABETES, V43, P684, DOI 10.2337/diabetes.43.5.684; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; DeFronzo RA, 1997, DIABETES REV, V5, P177; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Kooptiwut S, 2002, ENDOCRINOLOGY, V143, P2085, DOI 10.1210/en.143.6.2085; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Levy H R, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P97; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LIANG Y, 1994, J CLIN INVEST, V93, P2473, DOI 10.1172/JCI117256; Liu YQ, 2000, AM J PHYSIOL-ENDOC M, V279, pE68, DOI 10.1152/ajpendo.2000.279.1.E68; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; May JM, 2001, BIOCHEM PHARMACOL, V62, P873, DOI 10.1016/S0006-2952(01)00736-5; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; Rosen P, 2001, DIABETES-METAB RES, V17, P189, DOI 10.1002/dmrr.196; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; SESTILI P, 1990, J CANCER RES CLIN, V116, P615, DOI 10.1007/BF01637083; Sreenan SK, 1998, DIABETES, V47, P1881, DOI 10.2337/diabetes.47.12.1881; Such L, 1999, CYTOMETRY, V37, P140, DOI 10.1002/(SICI)1097-0320(19991001)37:2<140::AID-CYTO7>3.0.CO;2-7; TAKASU N, 1991, J BIOL CHEM, V266, P2112; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; VANGINKEL G, 1994, METHOD ENZYMOL, V233, P273; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; WEST DC, 1985, ANAL BIOCHEM, V147, P289, DOI 10.1016/0003-2697(85)90274-X; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Wu L, 1998, ENDOCRINOLOGY, V139, P4205, DOI 10.1210/en.139.10.4205; YIN L, 1992, DIABETES, V41, P792; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	53	87	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12126	12134		10.1074/jbc.M307097200	http://dx.doi.org/10.1074/jbc.M307097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14688272	hybrid			2022-12-27	WOS:000220334900018
J	Wujek, P; Kida, E; Walus, M; Wisniewski, KE; Golabek, AA				Wujek, P; Kida, E; Walus, M; Wisniewski, KE; Golabek, AA			N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PEPSTATIN-INSENSITIVE PROTEINASE; MANNOSE 6-PHOSPHATE RECEPTOR; SITE-DIRECTED MUTAGENESIS; ER QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYME; CATHEPSIN-L; MISFOLDED GLYCOPROTEINS; HYDROPHOBIC PROTEIN	Tripeptidyl-peptidase I (TPP I) is a lysosomal serine-carboxyl peptidase that sequentially removes tripeptides from polypeptides. Naturally occurring mutations in TPP I are associated with the classic late infantile neuronal ceroid lipofuscinosis. Human TPP I has five potential N-glycosylation sites at Asn residues 210, 222, 286, 313, and 443. To analyze the role of N-glycosylation in the function of the enzyme, we obliterated each N-glycosylation consensus sequence by substituting Gln for Asn, either individually or in combinations, and expressed mutated cDNAs in Chinese hamster ovary and human embryonic kidney 293 cells. Here, we demonstrate that human TPP I in vivo utilizes all five N-glycosylation sites. Elimination of one of these sites, at Asn-286, dramatically affected the folding of the enzyme. However, in contrast to other misfolded proteins that are retained in the endoplasmic reticulum, only a fraction of misfolded TPP I mutant expressed in Chinese hamster ovary cells, but not in human embryonic kidney 293 cells, was arrested in the ER, whereas its major portion was secreted. Secreted proenzyme formed non-native, interchain disulfide bridges and displayed only residual TPP I activity upon acidification. A small portion of TPP I missing Asn-286-linked glycan reached the lysosome and was processed to an active species; however, it showed low thermal and pH stability. N-Glycans at Asn-210, Asn-222, Asn-313, and Asn-443 contributed slightly to the specific activity of the enzyme and its resistance to alkaline pH-induced inactivation. Phospholabeling experiments revealed that N-glycans at Asn-210 and Asn-286 of TPP I preferentially accept a phosphomannose marker. Thus, a dual role of oligosaccharide at Asn-286 in folding and lysosomal targeting could contribute to the unusual, but cell type-dependent, fate of misfolded TPP I conformer and represent the molecular basis of the disease process in subjects with naturally occurring missense mutation at Asn-286.	New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Golabek, AA (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	a.golabek@att.net			NINDS NIH HHS [NS 047335] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047335] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; Bernardini F, 2001, Eur J Paediatr Neurol, V5 Suppl A, P69, DOI 10.1053/ejpn.2000.0438; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Comellas-Bigler M, 2002, STRUCTURE, V10, P865, DOI 10.1016/S0969-2126(02)00772-4; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; Du PG, 2001, BIOL CHEM, V382, P1715, DOI 10.1515/BC.2001.207; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Ezaki J, 1999, J NEUROCHEM, V72, P2573, DOI 10.1046/j.1471-4159.1999.0722573.x; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; HERMANS MMP, 1993, BIOCHEM J, V289, P681, DOI 10.1042/bj2890681; Herscovics A, 2002, GLYCOBIOLOGY, V12, p14G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horwich A, 2002, J CLIN INVEST, V110, P1221, DOI 10.1172/JCI200216781; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Ioannou YA, 1998, BIOCHEM J, V332, P789, DOI 10.1042/bj3320789; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Junaid MA, 1999, CLIN CHIM ACTA, V281, P169, DOI 10.1016/S0301-2115(98)00333-9; KANE SE, 1993, J BIOL CHEM, V268, P11456; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kida E, 2001, ADV GENET, V45, P35, DOI 10.1016/S0065-2660(01)45003-6; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; Liu CG, 1998, GENOMICS, V50, P206, DOI 10.1006/geno.1998.5328; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MCDONALD JK, 1985, BIOCHEM BIOPH RES CO, V126, P63, DOI 10.1016/0006-291X(85)90571-6; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; Steinfeld R, 2002, AM J MED GENET, V112, P347, DOI 10.1002/ajmg.10660; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; Warner JB, 2002, J BIOL CHEM, V277, P41897, DOI 10.1074/jbc.M203097200; WEITZ G, 1992, J BIOL CHEM, V267, P10039; Wisniewski KE, 2001, ADV GENET, V45, P1, DOI 10.1016/S0065-2660(01)45002-4; WISNIEWSKI KE, 2001, EUR J PAED NEUROL SA, V5, P61; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610	70	84	85	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12827	12839		10.1074/jbc.M313173200	http://dx.doi.org/10.1074/jbc.M313173200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702339	hybrid			2022-12-27	WOS:000220334900098
J	Yue, YZ; Lypowy, J; Hedhli, N; Abdellatif, M				Yue, YZ; Lypowy, J; Hedhli, N; Abdellatif, M			Ras GTPase-activating protein binds to Akt and is required for its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SH3 DOMAIN; GENE-EXPRESSION; KINASE-ACTIVITY; PHOSPHORYLATION; HYPERTROPHY; GROWTH; CELLS; GAP; APOPTOSIS	RasGAP ( Ras GTPase- activating protein) is a negative regulator as well as a downstream effector of Ras. To identify partners of RasGAP we used it as the bait in a yeast two- hybrid screen. This resulted in discovering its interaction with Akt. Overexpression of RasGAP or a mutant lacking the GTPase- activating domain ( nGAP) enhanced phosphorylation and activity of Akt, which was dependent on the upstream integrin- linked kinase. Also, nGAP protected the cells against staurosporin- induced apoptosis through an Akt- dependent pathway. To determine the role of RasGAP in receptor- mediated activation of Akt, we used short hairpin RNA interference to knock out endogenous RasGAP expression. Although this procedure resulted in enhanced Ras activity, it inhibited Akt phosphorylation. Thus, we propose that RasGAP interacts with Akt and is necessary for its activation, possibly via integrin- linked kinase- mediated phosphorylation of Ser- 473. The data suggest that this effect is independent of Ras activity.	Univ Med & Dent New Jersey, Inst Cardiovasc Res, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Abdellatif, M (corresponding author), Univ Med & Dent New Jersey, Inst Cardiovasc Res, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA.	abdellma@umdnj.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057970] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL 57970] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdellatif M, 1997, J BIOL CHEM, V272, P525; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; GRAHAM FL, 1991, METHODS MOL BIOL, V7; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MATSUI T, 2002, J BIOL CHEM, V9, P9; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	31	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12883	12889		10.1074/jbc.M312308200	http://dx.doi.org/10.1074/jbc.M312308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707121	hybrid			2022-12-27	WOS:000220334900105
J	Gouffi, K; Gerard, F; Santini, CL; Wu, LF				Gouffi, K; Gerard, F; Santini, CL; Wu, LF			Dual topology of the Escherichia coli TatA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC-INDEPENDENT PROTEIN; TWIN-ARGININE TRANSLOCASE; SIGNAL PEPTIDE; MEMBRANE PROTEINS; TRANSPORT SYSTEM; EXPORT PATHWAY; COMPONENTS; BINDING; GENES; IDENTIFICATION	The Escherichia coli Tat system has unusual capacity of translocating folded proteins across the cytoplasmic membrane. The TatA protein is the most abundant known Tat component and consists of a transmembrane segment followed by an amphipathic helix and a hydrophilic C terminus. To study the operation mechanism of the Tat apparatus, we analyzed the topology of TatA. Intriguingly, alkaline phosphatase (PhoA)-positive fusions were obtained at positions Gly-38, Lys-40, Asp-51, and Thr-53, which are all located at the cytoplasmic C terminus of the TatA protein. Interestingly, replacing phoA with uidAat Thr-53 led to positive beta-glucuronidase fusion, implying cytoplasmic location of the TatA C terminus. To further determine cellular localization of the TatA C terminus, we deleted the phoA gene and left 46 exogenous residues, including the tobacco etch virus (Tev) protease cleavage site (Tcs) after Thr-53, yielding TatA(T53)::Tcs. Unlike the PhoA and UidA fusions, which abolished the TatA function, the TatA(T53)::Tcs construct was able to restore the growth of tatA mutants on the minimal trimethlyamine N-oxide media. In vitro and in vivo proteolysis assay showed that the Tcs site of TatA(T53):: Tcs was accessible from both the periplasm and cytoplasm, indicating a dual topology of the TatA C terminus. Importantly, growth conditions seemed to influence the protein level of TatA and the cytoplasmic accessibility of the Tcs site of TatA(T53):: Tcs. A function-linked change of the TatA topology is suggested, and its implication in protein transport is discussed.	Inst Biol Struct & Microbiol, CNRS, UPR 9043, Chim Bacterienne Lab, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Wu, LF (corresponding author), Inst Biol Struct & Microbiol, CNRS, UPR 9043, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	wu@ibsm.cnrs-mrs.fr						Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Allen SCH, 2002, J BIOL CHEM, V277, P10362, DOI 10.1074/jbc.M109135200; Barrett CML, 2003, FEBS LETT, V537, P42, DOI 10.1016/S0014-5793(03)00068-1; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bordi C, 2003, MOL MICROBIOL, V48, P211, DOI 10.1046/j.1365-2958.2003.03428.x; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Gouffi K, 2002, FEBS LETT, V525, P65, DOI 10.1016/S0014-5793(02)03069-7; Hicks MG, 2003, FEBS LETT, V539, P61, DOI 10.1016/S0014-5793(03)00198-4; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Lee PA, 2002, J BACTERIOL, V184, P5871, DOI 10.1128/JB.184.21.5871-5879.2002; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SIMON G, 1995, MOL MICROBIOL, V17, P971, DOI 10.1111/j.1365-2958.1995.mmi_17050971.x; Slatin SL, 2002, P NATL ACAD SCI USA, V99, P1286, DOI 10.1073/pnas.022480199; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; Tian HP, 2002, J BACTERIOL, V184, P111, DOI 10.1128/JB.184.1.111-118.2002; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	48	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11608	11615		10.1074/jbc.M313187200	http://dx.doi.org/10.1074/jbc.M313187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701831	hybrid			2022-12-27	WOS:000220157600094
J	Hattori, M; Suzuki, AZ; Higo, T; Miyauchi, H; Michikawa, T; Nakamura, T; Inoue, T; Mikoshiba, K				Hattori, M; Suzuki, AZ; Higo, T; Miyauchi, H; Michikawa, T; Nakamura, T; Inoue, T; Mikoshiba, K			Distinct roles of inositol 1,4,5-trisphosphate receptor types 1 and 3 in Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III INSP(3) RECEPTOR; SMOOTH-MUSCLE-CELLS; TRISPHOSPHATE RECEPTORS; GENE-EXPRESSION; IP3 RECEPTOR; FUNCTIONAL-PROPERTIES; INTERFERING RNAS; CHANNEL FUNCTION; CYTOSOLIC CA2+; CALCIUM PUFFS	Three subtypes of inositol 1,4,5-trisphosphate receptor (IP(3)R1, IP(3)R2, and IP(3)R3) Ca2+ release channel share basic properties but differ in terms of regulation. To what extent they contribute to complex Ca2+ signaling, such as Ca2+ oscillations, remains largely unknown. Here we show that HeLa cells express comparable amounts of IP(3)R1 and IP(3)R3, but knockdown by RNA interference of each subtype results in dramatically distinct Ca2+ signaling patterns. Knockdown of IP(3)R1 significantly decreases total Ca2+ signals and terminates Ca2+ oscillations. Conversely, knockdown of IP(3)R3 leads to more robust and long lasting Ca2+ oscillations than in controls. Effects of IP(3)R3 knockdown are surprisingly similar in COS-7 cells that predominantly (> 90% of total IP3R) express IP(3)R3, suggesting that IP(3)R3 functions as an anti-Ca2+-oscillatory unit without contributing to peak amplitude of Ca2+ signals, irrespective of its relative expression level. Therefore, differential expression of the IP3R subtype is critical for various forms of Ca2+ signaling, and, particularly, IP(3)R1 and IP(3)R3 have opposite roles in generating Ca2+ oscillations.	Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Tokyo 1088639, Japan; JST, ICORP, Calcium Oscillat Project, Tokyo, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); RIKEN	Hattori, M (corresponding author), Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, 4-1-8 Honmachi, Kawaguchi, Saitama 3320012, Japan.	mhattori@ims.u-tokyo.ac.jp	Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Hattori, Mitsuharu/F-3859-2010	Inoue, Takafumi/0000-0002-2728-0060; Hattori, Mitsuharu/0000-0002-0503-4969				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Davis RJ, 1999, BIOCHEM J, V341, P813, DOI 10.1042/0264-6021:3410813; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hagar RE, 2000, BIOPHYS J, V79, P271, DOI 10.1016/S0006-3495(00)76289-8; Hirota J, 1998, BIOCHEM J, V333, P615, DOI 10.1042/bj3330615; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Mathias RS, 1998, AM J PHYSIOL-CELL PH, V274, pC1456, DOI 10.1152/ajpcell.1998.274.6.C1456; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Shuai JW, 2003, P NATL ACAD SCI USA, V100, P506, DOI 10.1073/pnas.0236032100; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sorrentino V, 2000, CURR OPIN GENET DEV, V10, P662, DOI 10.1016/S0959-437X(00)00139-8; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Tomida T, 2003, EMBO J, V22, P3825, DOI 10.1093/emboj/cdg381; Tovey SC, 2001, J CELL SCI, V114, P3979; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Van Acker K, 2002, CELL CALCIUM, V32, P71, DOI 10.1016/S0143-4160(02)00092-1; Vermassen E, 2003, J CELL SCI, V116, P1269, DOI 10.1242/jcs.00354; Wang YP, 2001, CIRC RES, V88, P202; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	43	104	105	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11967	11975		10.1074/jbc.M311456200	http://dx.doi.org/10.1074/jbc.M311456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707143	hybrid			2022-12-27	WOS:000220157600134
J	He, G; George, A				He, G; George, A			Dentin matrix protein 1 immobilized on type I collagen fibrils facilitates apatite deposition in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; BONE SIALOPROTEIN; HYDROXYAPATITE FORMATION; BINDING-PROPERTIES; X-RAY; PHOSPHOPHORYN; EXPRESSION; INVITRO; FIBRILLOGENESIS; MINERALIZATION	During bone and dentin mineralization, the crystal nucleation and growth processes are considered to be matrix regulated. Osteoblasts and odontoblasts synthesize a polymeric collagenous matrix, which forms a template for apatite initiation and elongation. Coordinated and controlled reaction between type I collagen and bone/dentin-specific noncollagenous proteins are necessary for well defined biogenic crystal formation. However, the process by which collagen surfaces become mineralized is not understood. Dentin matrix protein 1 (DMP1) is an acidic noncollagenous protein expressed during the initial stages of mineralized matrix formation in bone and dentin. Here we show that DMP1 bound specifically to type I collagen, with the binding region located at the N-telopeptide region of type I collagen. Peptide mapping identified two acidic clusters in DMP1 responsible for interacting with type I collagen. The collagen binding property of these domains was further confirmed by site-directed mutagenesis. Transmission electron microscopy analyses have localized DMP1 in the gap region of the collagen fibrils. Fibrillogenesis assays further demonstrated that DMP1 accelerated the assembly of the collagen fibrils in vitro and also increased the diameter of the reconstituted collagen fibrils. In vitro mineralization studies in the presence of calcium and phosphate ions demonstrated apatite deposition only at the collagen-bound DMP1 sites. Thus specific binding of DMP1 and possibly other noncollagenous proteins on the collagen fibril might be a key step in collagen matrix organization and mineralization.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, M-C 690, Chicago, IL 60612 USA.	anneg@uic.edu		GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE13836, DE 11657] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agarwal G, 2002, BIOCHEMISTRY-US, V41, P11091, DOI 10.1021/bi020087w; BERTHETCOLOMINAS C, 1979, J MOL BIOL, V134, P431, DOI 10.1016/0022-2836(79)90362-0; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; Bradt JH, 1999, CHEM MATER, V11, P2694, DOI 10.1021/cm991002p; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; Camacho NP, 1999, BONE, V25, P287, DOI 10.1016/S8756-3282(99)00165-9; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CLARKSON BH, 1993, ARCH ORAL BIOL, V38, P737, DOI 10.1016/0003-9969(93)90068-W; COCKINGJOHNSON D, 1983, BIOCHIM BIOPHYS ACTA, V742, P49, DOI 10.1016/0167-4838(83)90357-6; Dahl T, 1998, J STRUCT BIOL, V123, P162, DOI 10.1006/jsbi.1998.4025; Dahl T, 2003, CONNECT TISSUE RES, V44, P206, DOI 10.1080/03008200390181672; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; GEHRONROBEY P, 1996, PRINCIPLES BONE BIOL, P155; George A, 1999, P INDIAN AS-CHEM SCI, V111, P121; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GEORGE A, 1991, BIOCHEMISTRY-US, V30, P2372, DOI 10.1021/bi00223a011; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; He G, 2003, CONNECT TISSUE RES, V44, P240, DOI 10.1080/03008200390181726; Hoshi K, 2001, J ELECTRON MICROSC, V50, P33, DOI 10.1093/jmicro/50.1.33; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Hunter GK, 2001, J BIOMED MATER RES, V55, P496, DOI 10.1002/1097-4636(20010615)55:4<496::AID-JBM1042>3.0.CO;2-2; Jager I, 2000, BIOPHYS J, V79, P1737, DOI 10.1016/S0006-3495(00)76426-5; Kamiya N, 2001, HISTOCHEM J, V33, P545, DOI 10.1023/A:1014955925339; MACBEATH JRE, 1993, J BIOL CHEM, V268, P19826; Mizuno M, 2001, J BIOCHEM-TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824; NA GC, 1986, J BIOL CHEM, V261, P2290; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; Orgel JPRO, 2001, STRUCTURE, V9, P1061, DOI 10.1016/S0969-2126(01)00669-4; Paige MF, 1998, BIOPHYS J, V74, P3211, DOI 10.1016/S0006-3495(98)78027-0; PAYNE KJ, 1986, BIOPOLYMERS, V25, P1185, DOI 10.1002/bip.360250703; PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Saito T, 1997, BONE, V21, P305, DOI 10.1016/S8756-3282(97)00149-X; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; TRAUB W, 1992, MATRIX, V12, P251, DOI 10.1016/S0934-8832(11)80076-4; TRAUB W, 1992, MATRIX, V12, P197, DOI 10.1016/S0934-8832(11)80062-4; TRAUB W, 1989, P NATL ACAD SCI USA, V86, P9822, DOI 10.1073/pnas.86.24.9822; Veis A., 1994, EXTRACELLULAR MATRIX, P15, DOI DOI 10.1016/B978-0-12-775170-2.50007-X; Wallwork ML, 2002, CALCIFIED TISSUE INT, V71, P249, DOI 10.1007/s00223-001-1011-4; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; WHITE SW, 1977, NATURE, V266, P421, DOI 10.1038/266421a0; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848	51	170	185	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11649	11656		10.1074/jbc.M309296200	http://dx.doi.org/10.1074/jbc.M309296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699165	hybrid			2022-12-27	WOS:000220157600099
J	Karalis, KP; Venihaki, M; Zhao, J; van Vlerken, LE; Chandras, C				Karalis, KP; Venihaki, M; Zhao, J; van Vlerken, LE; Chandras, C			NF-kappa B participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPAIRED STRESS-RESPONSE; GLUCOCORTICOID REPRESSION; OXIDATIVE STRESS; TRANSCRIPTION; EXPRESSION; ACTIVATION; MECHANISM; RECEPTOR; DEFICIENCY; ANTAGONISM	Corticotropin-releasing hormone is a main regulator of mammalian stress response by stimulating pituitary proopiomelanocortin (POMC) gene expression, and thus adrenocorticotropic hormone (ACTH) secretion, which then causes glucocorticoid release from the adrenal. In a recent study in the pituitary corticotroph cell line AtT20, oxidative stress stimulated the activity of nuclear transcription factor B (NF-kappaB), whereas corticotropin-releasing hormone (CRH) inhibited both the constitutive and the oxidative stress-induced NF-kappaB DNA-binding activity. To further investigate the role of NF-kappaB on the CRH-induced pituitary POMC gene activation, AtT20 cells were transiently transfected with a POMC-luciferase construct mutated at an NF-kappaB binding site. After treatment with CRH, intracellular POMC-luciferase activity was significantly higher from the stimulation observed with transfection of the parental POMC-luciferase construct. In agreement with a previous report, CRH inhibited the constitutive NF-kappaB DNA-binding activity in AtT20 cells, as shown by electrophoretic mobility-shift assay, as soon as within 15 min of treatment. These effects of CRH were blocked by the CRH-R1 antagonist CP154,256. Our findings provide evidence that the regulation of corticotroph NF-kappaB activity by CRH is related to the activation of the pituitary POMC gene and, thus, may play an important role in stress response.	Harvard Univ, Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Karalis, KP (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Endocrinol, 416 Enders,300 Longwood Ave, Boston, MA 02115 USA.	katia.karalis@tch.harvard.edu			NIDDK NIH HHS [R01 DK04777] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Autelitano DJ, 1998, BRAIN RES BULL, V45, P75, DOI 10.1016/S0361-9230(97)00303-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; Bousquet C, 1999, J BIOL CHEM, V274, P10723, DOI 10.1074/jbc.274.16.10723; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; Bozinovski S, 2002, J BIOL CHEM, V277, P42808, DOI 10.1074/jbc.M207840200; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; DROUIN J, 1989, J STEROID BIOCHEM, V34, P63, DOI 10.1016/0022-4731(89)90066-6; Drouin J, 1998, J STEROID BIOCHEM, V65, P59, DOI 10.1016/S0960-0760(97)00180-5; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; Ray DW, 1998, ANN NY ACAD SCI, V840, P162, DOI 10.1111/j.1749-6632.1998.tb09560.x; REISINE T, 1987, MOL PHARMACOL, V32, P488; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; TACCHINI L, 1995, BIOCHEM J, V309, P453, DOI 10.1042/bj3090453; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; Weninger SC, 2000, ENDOCRINOLOGY, V141, P256, DOI 10.1210/en.141.1.256; Zhao J, 2002, MOL ENDOCRINOL, V16, P2561, DOI 10.1210/me.2001-0334	26	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10837	10840		10.1074/jbc.M313063200	http://dx.doi.org/10.1074/jbc.M313063200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711817	hybrid			2022-12-27	WOS:000220157600003
J	Parkin, ET; Watt, NT; Turner, AJ; Hooper, NM				Parkin, ET; Watt, NT; Turner, AJ; Hooper, NM			Dual mechanisms for shedding of the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; ANGIOTENSIN-CONVERTING ENZYME; CULTURED-CELLS; CAVEOLAE-LIKE; SCRAPIE; MEMBRANE; ENDOCYTOSIS; INSERTION; DOMAINS; DISEASE	The cellular prion protein ( PrPC) is essential for the pathogenesis and transmission of prion diseases. Whereas the majority of PrPC is bound to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, a secreted form of the protein has been identified. Here we show that PrPC can be shed into the medium of human neuroblastoma SH-SY5Y cells by both protease- and phospholipase-mediated mechanisms. The constitutive shedding of PrPC was inhibited by a range of hydroxamate-based zinc metalloprotease inhibitors in a manner identical to the alpha-secretase-mediated shedding of the amyloid precursor protein, indicating a proteolytic shedding mechanism. Like amyloid precursor protein, this zinc metalloprotease-mediated shedding of PrPC could be stimulated by phorbol myristate acetate and by copper ions. The lipid raft-disrupting agents filipin and methyl-beta-cyclodextrin promoted the shedding of PrPC via a distinct mechanism that was not inhibited by hydroxamate-based inhibitors. Filipin-mediated shedding of PrPC is likely to occur via phospholipase cleavage of the GPI anchor, since a transmembrane polypeptide-anchored PrP construct was not shed in response to filipin treatment. Collectively, our data indicate that shedding of PrPC can occur via both secretase-like proteolytic cleavage of the protein and phospholipase cleavage of the GPI anchor moiety.	Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hooper, NM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.	n.m.hooper@leeds.ac.uk		Parkin, Edward/0000-0003-3270-3184; Hooper, Nigel/0000-0002-5811-3484				Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Canet-Aviles RM, 2002, MOL BRAIN RES, V102, P62, DOI 10.1016/S0169-328X(02)00184-5; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, BRIT MED BULL, V49, P860, DOI 10.1093/oxfordjournals.bmb.a072651; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; DUCHEN LW, 1993, BRAIN, V116, P555, DOI 10.1093/brain/116.3.555; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Kahl S, 2000, J IMMUNOL, V165, P4463, DOI 10.4049/jimmunol.165.8.4463; KRASEMANN S, 1995, MOL BRAIN RES, V34, P173, DOI 10.1016/0169-328X(95)00175-R; Kretzschmar HA, 1997, J NEURAL TRANSM-SUPP, P191; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Lehmann S, 1999, BIOMED PHARMACOTHER, V53, P39, DOI 10.1016/S0753-3322(99)80059-6; Li RL, 2003, BIOCHEM BIOPH RES CO, V303, P446, DOI 10.1016/S0006-291X(03)00354-1; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OWEN F, 1992, MOL BRAIN RES, V13, P155, DOI 10.1016/0169-328X(92)90056-H; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Parkin ET, 2003, J CELL SCI, V116, P3079, DOI 10.1242/jcs.00626; Parkin ET, 2002, BIOCHEMISTRY-US, V41, P4972, DOI 10.1021/bi015936e; Parkin ET, 1997, J NEUROCHEM, V69, P2179; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; Yang XY, 1996, J BIOL CHEM, V271, P11493, DOI 10.1074/jbc.271.19.11493; Zeng FN, 2003, J NEUROCHEM, V84, P480, DOI 10.1046/j.1471-4159.2003.01529.x	48	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11170	11178		10.1074/jbc.M312105200	http://dx.doi.org/10.1074/jbc.M312105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711812	hybrid			2022-12-27	WOS:000220157600042
J	Lee, HK; Dunzendorfer, S; Tobias, PS				Lee, HK; Dunzendorfer, S; Tobias, PS			Cytoplasmic domain-mediated dimerizations of toll-like receptor 4 observed by beta-lactamase enzyme fragment complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; TOLL-LIKE RECEPTOR-4; ADAPTER PROTEIN; CUTTING EDGE; RECOGNITION; ACTIVATION; DECTIN-1; FAMILY; MYD88; TLR1	Toll-like receptors (TLRs) detect the presence of microbial challenge and initiate innate immune defensive responses. In this work we have explored the mechanism and role of TLR dimerization in signal transduction using the newly developed technique of beta-lactamase protein fragment complementation, among others. We observed that TLR4 interactions with itself, with MyD88, or with TLR2 were accurately reported by the enzyme complementation technique. That technique, as well as co-immunoprecipitation, transfection-initiated cell activation, and site-directed mutagenesis all suggest an important role for TLR intracellular domains in receptor dimerization. These findings broaden our understanding of TLR self-interactions as well as heterodimer formation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Tobias, PS (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,IMM-12, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DUNNE A, 2003, SCI STKE; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Michnick SW, 2000, METHOD ENZYMOL, V328, P208, DOI 10.1016/S0076-6879(00)28399-7; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Tapping RI, 2003, J ENDOTOXIN RES, V9, P264, DOI 10.1179/096805103225001477; Wehrman T, 2002, P NATL ACAD SCI USA, V99, P3469, DOI 10.1073/pnas.062043699; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	22	49	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10564	10574		10.1074/jbc.M311564200	http://dx.doi.org/10.1074/jbc.M311564200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699116	hybrid			2022-12-27	WOS:000220050400110
J	Schneider, S; Campodonico, E; Schwer, B				Schneider, S; Campodonico, E; Schwer, B			Motifs IV and V in the DEAH box splicing factor Prp22 are important for RNA unwinding, and helicase-defective Prp22 mutants are suppressed by Prp8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DOMINANT-NEGATIVE MUTANTS; SMALL NUCLEAR-RNA; DEPENDENT ATPASE; SACCHAROMYCES-CEREVISIAE; U5 SNRNA; MUTATIONAL ANALYSIS; PREMESSENGER RNA; IN-VITRO; NUCLEOSIDE TRIPHOSPHATASE	The yeast pre-mRNA splicing factor Prp22 is a member of the DEAH box family of nucleic acid-stimulated ATPases and RNA helicases. Here we report a mutational analysis of 16 conserved residues in motifs Ia ((534)TQPRRVAA(541)), IV ((695)LVFLTG(700)), and V ((TNI)-T-757-AETSIT(765)). Mutants T757A, I764A, and T765A were lethal, and F697A cells did not grow at less than or equal to30 degreesC. The mutant proteins failed to catalyze mRNA release from the spliceosome in vitro, and they were deficient for RNA unwinding. The F697A, I764A, and T765A proteins were active for ATP hydrolysis in the presence of RNA cofactor. The T757A mutant retained basal ATPase activity but was not stimulated by RNA, whereas ATP hydrolysis by T765A was strictly dependent on the RNA cofactor. Thus Thr-757 and Thr-765 in motif V link ATP hydrolysis to the RNA cofactor. To illuminate the mechanism of Prp22-catalyzed mRNA release, we performed a genetic screen to identify extragenic suppressors of the cold-sensitive growth defect of a helicase/release-defective Prp22 mutant. We identified one of the suppressors as a missense mutation of PRP8 (R1753K), a protein component of the U5 small nuclear ribonucleoprotein. We show that PRP8-R1753K suppressed multiple helicase-deficient prp22 mutations, including the lethal I764A mutation. Replacing Arg-1753 of Prp8 by either Lys, Ala, Gln, or Glu resulted in suppression of helicase-defective Prp22 mutants. Prp8-Arg1753 mutations by themselves caused temperature-sensitive growth defects in a PRP22 strain. These findings suggest a model whereby Prp22 disrupts an RNA/protein or RNA/RNA interaction in the spliceosome that is normally stabilized by Prp8.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	bschwer@med.cornell.edu			NIGMS NIH HHS [GM50288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Burge CB, 1999, RNA WORLD, P525; Campodonico E, 2002, GENETICS, V160, P407; Chang TH, 1997, NUCLEIC ACIDS RES, V25, P5033, DOI 10.1093/nar/25.24.5033; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Edwalds-Gilbert G, 2000, RNA, V6, P1106, DOI 10.1017/S1355838200992483; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HODGES PE, 1995, YEAST, V11, P337; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Kim DH, 1999, RNA, V5, P959, DOI 10.1017/S135583829999012X; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIM SH, 1993, P NATL ACAD SCI USA, V90, P888, DOI 10.1073/pnas.90.3.888; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Kuhn AN, 2002, P NATL ACAD SCI USA, V99, P9145, DOI 10.1073/pnas.102304299; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Martin A, 2002, J BIOL CHEM, V277, P17743, DOI 10.1074/jbc.M200762200; McConnell TS, 2001, EMBO J, V20, P3577, DOI 10.1093/emboj/20.13.3577; McPheeters DS, 2000, NUCLEIC ACIDS RES, V28, P1313, DOI 10.1093/nar/28.6.1313; McPheeters DS, 2003, MOL CELL BIOL, V23, P4174, DOI 10.1128/MCB.23.12.4174-4186.2003; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; Newman AJ, 1995, RNA, V1, P968; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; Reyes JL, 1999, RNA, V5, P167, DOI 10.1017/S1355838299981785; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; Schneider S, 2002, J BIOL CHEM, V277, P15452, DOI 10.1074/jbc.M112473200; Schneider S, 2001, J BIOL CHEM, V276, P21184, DOI 10.1074/jbc.M101964200; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; STRAUSS EJ, 1994, NUCLEIC ACIDS RES, V22, P3187, DOI 10.1093/nar/22.15.3187; Svitkin YV, 2001, RNA, V7, P1743; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, RNA, V1, P584; van Nues RW, 2001, GENETICS, V157, P1451; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WHITTAKER E, 1991, NUCLEIC ACIDS RES, V19, P5483, DOI 10.1093/nar/19.20.5483; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; Xu DM, 1996, NATURE, V381, P709, DOI 10.1038/381709a0; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701	74	49	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8617	8626		10.1074/jbc.M312715200	http://dx.doi.org/10.1074/jbc.M312715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688266	hybrid			2022-12-27	WOS:000189265900013
J	Couve, A; Restituito, S; Brandon, JM; Charles, KJ; Bawagan, H; Freeman, KB; Pangalos, MN; Calver, AR; Moss, SJ				Couve, A; Restituito, S; Brandon, JM; Charles, KJ; Bawagan, H; Freeman, KB; Pangalos, MN; Calver, AR; Moss, SJ			Marlin-1, a novel RNA-binding protein associates with GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INTRACELLULAR-LOCALIZATION; HIPPOCAMPAL-NEURONS; MAMMALIAN STAUFEN; SYNAPTIC SITES; GENE; DENDRITES; COMPLEXES; TRANSPORT; REPRESSOR	GABA(B) receptors are heterodimeric G protein-coupled receptors that mediate slow synaptic inhibition in the central nervous system. Whereas heterodimerization between GABA(B) receptor GABA(B)R1 and GABA(B)R2 subunits is essential for functional expression, how neurons coordinate the assembly of these critical receptors remains to be established. Here we have identified Marlin-1, a novel GABA(B) receptor-binding protein that associates specifically with the GABABR1 subunit in yeast, tissue culture cells, and neurons. Marlin-1 is expressed in the brain and exhibits a granular distribution in cultured hippocampal neurons. Marlin-1 binds different RNA species including the 3'-untranslated regions of both the GABA(B)R1 and GABA(B)R2 mRNAs in vitro and also associates with RNA in cultured neurons. Inhibition of Marlin-1 expression via small RNA interference technology results in enhanced intracellular levels of the GABA(B)R2 receptor subunit without affecting the level of GABA(B)R1. Together our results suggest that Marlin-1 functions to regulate the cellular levels of GABA(B) R2 subunits, which may have significant effects on the production of functional GABA(B) receptor heterodimers. Therefore, our observations provide an added level of regulation for the control of GABA(B) receptor expression and for the efficacy of inhibitory synaptic transmission.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; GlaxoSmithKline, Neurol & Gl Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Genet Res, Dept Comparat Genet, King Of Prussia, PA 19406 USA	University of Pennsylvania; University of London; University College London; University of London; University College London; GlaxoSmithKline; GlaxoSmithKline	Moss, SJ (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu	couve, andres/I-2249-2013	couve, andres/0000-0003-4216-8672				Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Aoki K, 1999, FEBS LETT, V443, P363, DOI 10.1016/S0014-5793(99)00010-1; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Charles KJ, 2003, MOL CELL NEUROSCI, V24, P214, DOI 10.1016/S1044-7431(03)00162-3; Cheng CK, 2002, ENDOCRINOLOGY, V143, P4693, DOI 10.1210/en.2002-220576; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Couve A, 2002, NAT NEUROSCI, V5, P415, DOI 10.1038/nn833; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; El Far O, 2002, BIOCHEM J, V365, P329, DOI 10.1042/BJ20020481; Filippov AK, 2000, J NEUROSCI, V20, P2867; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; Grant SGN, 2001, TRENDS BIOTECHNOL, V19, pS49, DOI 10.1016/S0167-7799(01)01799-1; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kittler JT, 2000, J NEUROSCI, V20, P7972; Knowles RB, 1996, J NEUROSCI, V16, P7812; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lee YC, 2003, MOL BRAIN RES, V111, P61, DOI 10.1016/S0169-328X(02)00670-8; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; MOTT DD, 1994, INT REV NEUROBIOL, V36, P97, DOI 10.1016/S0074-7742(08)60304-9; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Ou XM, 2003, J NEUROSCI, V23, P7415; Palacios IM, 2001, ANNU REV CELL DEV BI, V17, P569, DOI 10.1146/annurev.cellbio.17.1.569; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Prosser HM, 2001, MOL CELL NEUROSCI, V17, P1059, DOI 10.1006/mcne.2001.0995; Roberts DCS, 1997, PSYCHOPHARMACOLOGY, V131, P271, DOI 10.1007/s002130050293; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Sapru MK, 1996, J BIOL CHEM, V271, P7203, DOI 10.1074/jbc.271.12.7203; Schuler V, 2001, NEURON, V31, P47, DOI 10.1016/S0896-6273(01)00345-2; Shahied-Milam L, 1998, J BIOL CHEM, V273, P21359, DOI 10.1074/jbc.273.33.21359; Steward O, 2001, P NATL ACAD SCI USA, V98, P7062, DOI 10.1073/pnas.131146398; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Zhang HL, 1999, J CELL BIOL, V147, P59, DOI 10.1083/jcb.147.1.59	51	45	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13934	13943		10.1074/jbc.M311737200	http://dx.doi.org/10.1074/jbc.M311737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718537	hybrid			2022-12-27	WOS:000220478500080
J	Park, IY; Cho, JH; Kim, KS; Kim, YB; Kim, MS; Kim, SC				Park, IY; Cho, JH; Kim, KS; Kim, YB; Kim, MS; Kim, SC			Helix stability confers salt resistance upon helical antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BUFORIN II; MECHANISM; MEMBRANE; MODEL; ANTIBIOTICS	Salt sensitivity of antimicrobial peptides poses a major obstacle in their development as novel antibiotics. Here we report the use of helix-capping motifs to confer salt resistance upon helical antimicrobial peptides. The helical content of the template peptide [RLLR](5) was almost completely destroyed at salt concentrations over 200 mM NaCl, leading to a 8-32-fold decrease in antimicrobial activity. However, the introduction of helix-capping motifs at the helix termini resulted in a structurally stable peptide, which retained membrane-permeabilizing and antimicrobial activities upon exposure to salt. Furthermore, the peptide with helix-capping motifs directly inhibited the in vivo growth of Streptococcus pyogenes, which causes localized fasciitis in mice, and prevented the necrosis of the epidermis, dermis, and subcutaneous muscle layers. Results indicate that the adoption of helix-capping motifs into salt-sensitive antimicrobial peptides provides the necessary structural stability for the peptides to permeabilize cell membranes and cause cell death at physiological salt concentrations.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 130650, South Korea; Chungbuk Natl Univ, Dept Toxicol, Cheongju 361763, South Korea; Korea Inst Energy Res, Biomass Team, Taejon 305343, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Institute of Science & Technology (KIST); Chungbuk National University; Korea Institute of Energy Research (KIER)	Kim, SC (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Yusong Gu Kusong Dong, Taejon 305701, South Korea.	sunkim@kaist.ac.kr	Kim, Sun Chang/C-2026-2011; Kim, Sun/GSN-4867-2022					Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Kuo CF, 1998, INFECT IMMUN, V66, P3931, DOI 10.1128/IAI.66.8.3931-3935.1998; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MOR A, 1994, J BIOL CHEM, V269, P1934; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; PAULING L, 1951, P NATL ACAD SCI USA, V37, P241, DOI 10.1073/pnas.37.5.241; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Steinberg D A, 1997, Methods Mol Biol, V78, P169; Tam JP, 2000, BIOCHEMISTRY-US, V39, P7159, DOI 10.1021/bi0003487; Tossi A, 2000, BIOPOLYMERS, V55, P4; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299	25	97	104	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13896	13901		10.1074/jbc.M311418200	http://dx.doi.org/10.1074/jbc.M311418200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718539	hybrid			2022-12-27	WOS:000220478500076
J	Szczesna-Skorupa, E; Chen, CD; Liu, H; Kemper, B				Szczesna-Skorupa, E; Chen, CD; Liu, H; Kemper, B			Gene expression changes associated with the endoplasmic reticulum stress response induced by microsomal cytochrome P450 overproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN-RESPONSE; NF-KAPPA-B; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CELL-DEATH; PROLIFERATION; TRANSMEMBRANE; RETENTION; IRE1; ACTIVATION	Induction of drug-metabolizing microsomal cytochromes P450 (P450s) results in a striking proliferation of the smooth endoplasmic reticulum (ER). Overexpression of P450s in yeast and cultured cells produces a similar response. The signals mediating this process are not known but probably involve signal transduction pathways involved in the unfolded protein response (UPR) or the ER overload response (EOR). We have examined the temporal response of specific genes in these pathways and genes globally to overexpression of P450 in cultured cells. Activity of NFkappaB, an EOR component, was substantially increased by overexpression of full-length P450 2C2 or a chimera with the 28-amino acid signal anchor sequence of P450 2C2 in HepG2 cells, and the activation correlated temporally with the accumulation of P450 in the cells. In the UPR pathway, activation of the transcription factor XBP1 by IRE1 also correlated with the accumulation of P450 in the cells, and in contrast, maximum activation of the BiP/grp78 promoter preceded the accumulation. Differential effects of expression of P450 on apoptosis were observed in nonhepatic COS1 and hepatic HepG2 cells. In COS1 cells, apoptosis was induced, and this correlated with sustained activation of the pro-apoptotic JNK pathway, induction of CHOP, and an absence of the increased NFkappaB activity. In HepG2 cells, JNK was only transiently activated, and CHOP expression was not induced. As assessed by DNA microarray analysis, up-regulation of signaling genes was predominant including those involved in anti-apoptosis and ER stress. These results suggest that both the EOR and UPR pathways are involved in the cellular response to induction of P450 expression and that in hepatic cells genes are also induced to block apoptosis, which may be a physiologically relevant response to prevent cell death during xenobiotic induced expression of P450 in the liver.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; Aventis Pharmaceut Inc, Bridgewater, NJ 08807 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Minnesota System; University of Minnesota Twin Cities; Sanofi-Aventis	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave, Urbana, IL 61801 USA.	byronkem@life.uiuc.edu	Longo, Kenneth A/A-5631-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35897] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Cudna RE, 2003, BIOTECHNOL BIOENG, V81, P56, DOI 10.1002/bit.10445; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fu LW, 2003, J CELL BIOL, V160, P157, DOI 10.1083/jcb.200210086; Higashio H, 2002, BIOCHEM BIOPH RES CO, V296, P568, DOI 10.1016/S0006-291X(02)00923-3; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JONES AL, 1966, J HISTOCHEM CYTOCHEM, V14, P215, DOI 10.1177/14.3.215; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Larson LL, 2002, YEAST, V19, P373, DOI 10.1002/yea.839; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leonardi A, 2002, ENDOCRINOLOGY, V143, P2169, DOI 10.1210/en.143.6.2169; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Menzel R, 1996, ARCH BIOCHEM BIOPHYS, V330, P97, DOI 10.1006/abbi.1996.0230; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Szczesna-Skorupa E, 2001, J BIOL CHEM, V276, P45009, DOI 10.1074/jbc.M104676200; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; Takewaka T, 1999, J BIOCHEM-TOKYO, V125, P507, DOI 10.1093/oxfordjournals.jbchem.a022314; Theilhaber J, 2001, J COMPUT BIOL, V8, P585, DOI 10.1089/106652701753307502; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, J CELL SCI, V113, P3697; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; VERGERES G, 1993, J CELL SCI, V106, P249; Yamamoto A, 1996, J CELL SCI, V109, P1727; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang C, 2001, BIOCHEM BIOPH RES CO, V289, P718, DOI 10.1006/bbrc.2001.6044	48	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13953	13961		10.1074/jbc.M312170200	http://dx.doi.org/10.1074/jbc.M312170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718536	hybrid			2022-12-27	WOS:000220478500082
J	Bruce, JIE; Giovannucci, DR; Blinder, G; Shuttleworth, TJ; Yule, DI				Bruce, JIE; Giovannucci, DR; Blinder, G; Shuttleworth, TJ; Yule, DI			Modulation of [Ca2+](i) signaling dynamics and metabolism by perinuclear mitochondria in mouse parotid acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA2+ SIGNALS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ATOMIC-FORCE MICROSCOPY; NUCLEAR-PORE COMPLEX; ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; RUTHENIUM RED; ATP; TRANSPORT; ENVELOPE	Parotid acinar cells exhibit rapid cytosolic calcium signals ([Ca2+](i)) that initiate in the apical region but rapidly become global in nature. These characteristic [Ca2+](i) signals are important for effective fluid secretion, which critically depends on a synchronized activation of spatially separated ion fluxes. Apically restricted [Ca2+](i) signals were never observed in parotid acinar cells. This is in marked contrast to the related pancreatic acinar cells, where the distribution of mitochondria has been suggested to contribute to restricting [Ca2+](i) signals to the apical region. Therefore, the aim of this study was to determine the mitochondrial distribution and the role of mitochondrial Ca2+ uptake in shaping the spatial and temporal properties of [Ca2+](i) signaling in parotid acinar cells. Confocal imaging of cells stained with MitoTracker dyes ( MitoTracker Green FM or MitoTracker CMXRos) and SYTO dyes ( SYTO- 16 and SYTO-61) revealed that a majority of mitochondria is localized around the nucleus. Carbachol ( CCh) and caged inositol 1,4,5- trisphosphate- evoked [Ca2+](i) signals were delayed as they propagated through the nucleus. This delay in the CCh- evoked nuclear [Ca2+](i) signal was abolished by inhibition of mitochondrial Ca2+ uptake with ruthenium red and Ru360. Likewise, simultaneous measurement of [Ca2+](i) with mitochondrial [Ca2+] ([Ca2+](m)), using fura- 2 and rhod- FF, respectively, revealed that mitochondrial Ca2+ uptake was also inhibited by ruthenium red and Ru360. Finally, at concentrations of agonist that evoke [Ca2+](i) oscillations, mitochondrial Ca2+ uptake, and a nuclear [Ca2+] delay, CCh also evoked a substantial increase in NADH autofluorescence. This autofluorescence exhibited a predominant perinuclear localization that was also sensitive to mitochondrial inhibitors. These data provide evidence that perinuclear mitochondria and mitochondrial Ca2+ uptake may differentially shape nuclear [Ca2+] signals but more importantly drive mitochondrial metabolism to generate ATP close to the nucleus. These effects may profoundly affect a variety of nuclear processes in parotid acinar cells while facilitating efficient fluid secretion.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Bruce, JIE (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	jason_bruce@urmc.rochester.edu	Giovannucci, David R/A-5657-2018		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE014756, P01DE013539] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 14756, DE 013539] Funding Source: Medline; NIGMS NIH HHS [GM 40457] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; Atkinson L, 2002, NATURE, V420, P42, DOI 10.1038/420042a; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; Badminton MN, 1998, CELL CALCIUM, V23, P79, DOI 10.1016/S0143-4160(98)90105-1; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Billups B, 2002, J NEUROSCI, V22, P5840; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Bustamante JO, 2000, PFLUG ARCH EUR J PHY, V439, P433, DOI 10.1007/s004240050960; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chamero P, 2002, J BIOL CHEM, V277, P50226, DOI 10.1074/jbc.C200522200; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; Garner MH, 2002, J MEMBRANE BIOL, V187, P97, DOI 10.1007/s00232-001-0155-5; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hebbar PB, 2003, CHROMOSOMA, V111, P495, DOI 10.1007/s00412-003-0232-x; Heist EK, 1998, CELL CALCIUM, V23, P103; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; Johnson PR, 2002, CELL CALCIUM, V32, P59, DOI 10.1016/S0143-4160(02)00091-X; Kargacin GJ, 1998, PFLUG ARCH EUR J PHY, V436, P338, DOI 10.1007/s004240050641; LANINI L, 1992, J BIOL CHEM, V267, P11548; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; Maechler P, 2002, CELL MOL LIFE SCI, V59, P1803, DOI 10.1007/PL00012507; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; Mazzanti M, 2001, PHYSIOL REV, V81, P1, DOI 10.1152/physrev.2001.81.1.1; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; Oberleithner H, 1996, PFLUG ARCH EUR J PHY, V432, P839, DOI 10.1007/s004240050206; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; PETERSEN OH, 1995, CIBA F SYMP, V188, P85; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rizzuto Rosario, 2002, Trends in Pharmacological Sciences, V23, P348, DOI 10.1016/S0165-6147(02)02063-1; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Stoffler D, 1999, J MOL BIOL, V287, P741, DOI 10.1006/jmbi.1999.2637; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; YING WL, 1991, BIOCHEMISTRY-US, V30, P4949, DOI 10.1021/bi00234a016; Zhou Z, 2002, PFLUG ARCH EUR J PHY, V445, P132, DOI 10.1007/s00424-002-0909-7	59	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12909	12917		10.1074/jbc.M309070200	http://dx.doi.org/10.1074/jbc.M309070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699167	hybrid			2022-12-27	WOS:000220334900108
J	Davis, CA; Hearn, AS; Fletcher, B; Bickford, J; Garcia, JE; Leveque, V; Melendez, JA; Silverman, DN; Zucali, J; Agarwal, A; Nick, HS				Davis, CA; Hearn, AS; Fletcher, B; Bickford, J; Garcia, JE; Leveque, V; Melendez, JA; Silverman, DN; Zucali, J; Agarwal, A; Nick, HS			Potent anti-tumor effects of an active site mutant of human manganese-superoxide dismutase - Evolutionary conservation of product inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MATRIX-METALLOPROTEINASE EXPRESSION; HYDROGEN-PEROXIDE; MALIGNANT PHENOTYPE; CELL-GROWTH; MITOCHONDRIAL; OVEREXPRESSION; PROLIFERATION; INVOLVEMENT; SUPPRESSION	Mn-SOD serves as the primary cellular defense against oxidative damage by converting superoxide radicals (O-2(radical anion)) to O-2 and H2O2. A unique characteristic of this mitochondrial anti-oxidant enzyme is the conservation from bacteria to man of a rapidly formed product inhibited state. Using site-directed mutagenesis, we have generated an active site mutant (H30N) of human Mn-SOD, which exhibits significantly reduced product inhibition and increased enzymatic efficiency. Overexpression of the H30N enzyme causes anti-proliferative effects in vitro and anti-tumor effects in vivo. Our results provide a teleological basis for the phylogenetically invariant nature of position His-30 and the evolutionary conservation of product inhibition. These data also provide more direct intracellular evidence for the signaling role associated with H2O2.	Univ Florida, Shands Canc Ctr, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Albany Medical College	Nick, HS (corresponding author), Univ Florida, J Hillis Miller Hlth Ctr, Dept Neurosci, Box 100244,1600 SW Archer Rd, Gainesville, FL 32610 USA.	hnick@ufl.edu		Melendez, Juan/0000-0001-8021-3097				Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; Cabelli DE, 1999, BIOCHEMISTRY-US, V38, P11686, DOI 10.1021/bi9909142; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Davis CA, 2001, J AM SOC NEPHROL, V12, P2683, DOI 10.1681/ASN.V12122683; Fletcher BS, 2002, LEUKEMIA, V16, P1507, DOI 10.1038/sj.leu.2402557; Fridovich I, 1998, J EXP BIOL, V201, P1203; Hearn AS, 2001, BIOCHEMISTRY-US, V40, P12051, DOI 10.1021/bi011047f; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Leveque VJP, 2001, BIOCHEMISTRY-US, V40, P10586, DOI 10.1021/bi010792p; Li SJ, 2000, CANCER RES, V60, P3927; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MITCHELL P, 1965, NATURE, V18, P1205; Nelson KK, 2003, CLIN CANCER RES, V9, P424; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Ramilo CA, 1999, J BIOL CHEM, V274, P27711, DOI 10.1074/jbc.274.39.27711; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SERREZE DV, 1995, DIABETES, V44, P1392, DOI 10.2337/diabetes.44.12.1392; Silverman DN, 2002, METHOD ENZYMOL, V349, P61, DOI 10.1016/S0076-6879(02)49321-4; SUN Y, 1989, INT J CANCER, V44, P1028, DOI 10.1002/ijc.2910440615; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VISNER GA, 1991, AM J PHYSIOL, V260, pL444, DOI 10.1152/ajplung.1991.260.6.L444; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	32	38	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12769	12776		10.1074/jbc.M310623200	http://dx.doi.org/10.1074/jbc.M310623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14688256	hybrid			2022-12-27	WOS:000220334900091
J	Hoppins, SC; Nargang, FE				Hoppins, SC; Nargang, FE			The Tim8-Tim13 complex of Neurospora crassa functions in the assembly of proteins into both mitochondrial membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; DEAFNESS DYSTONIA SYNDROME; PERIPLASMIC CHAPERONE SKP; INNER MEMBRANE; OUTER-MEMBRANE; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; ADP/ATP CARRIER; TOM COMPLEX; MEDIATES INSERTION	The Tim8 and Tim13 proteins in yeast are known to exist in the mitochondrial intermembrane space and to form a hetero-oligomeric complex involved in the import of the mitochondrial inner membrane protein Tim23, the central component of the TIM23 translocase. Here, we have isolated tim8 and tim13 mutants in Neurospora crassa and have shown that mitochondria lacking the Tim8-Tim13 complex were deficient in the import of the outer membrane beta-barrel proteins Tom40 and porin. Cross-linking studies showed that the Tom40 precursor contacts the Tim8-Tim13 complex. The complex is involved at an early point in the Tom40 assembly pathway because cross-links can only be detected during the initial stages of Tom40 import. In mitochondria lacking the Tim8-Tim13 complex, the Tom40 precursor appears in a previously characterized early intermediate of Tom40 assembly more slowly than in wild type mitochondria. Thus, our data suggest a model in which one of the first steps in Tom40 assembly may be interaction with the Tim8-Tim13 complex. As in yeast, the N. crassa Tim23 precursor was imported inefficiently into mitochondria lacking the Tim8-Tim13 complex when the membrane potential was reduced. Tim23 import intermediates could also be cross-linked to the complex, suggesting a dual role for the Tim8-Tim13 intermembrane space complex in the import of proteins found in both the outer and inner mitochondrial membranes.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Nargang, FE (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	frank.nargang@ualberta.ca	Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; de Cock H, 1999, EUR J BIOCHEM, V259, P96, DOI 10.1046/j.1432-1327.1999.00010.x; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Harms N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/jbc.M011194200; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; Rizzitello AE, 2001, J BACTERIOL, V183, P6794, DOI 10.1128/JB.183.23.6794-6800.2001; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Schafer U, 1999, J BIOL CHEM, V274, P24567, DOI 10.1074/jbc.274.35.24567; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; VASILJEV A, 2003, MOL BIOL CELL    DEC; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; Wendland J., 1996, FUNGAL GENETICS REPO, V43, P54; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951	54	137	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12396	12405		10.1074/jbc.M313037200	http://dx.doi.org/10.1074/jbc.M313037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722057	hybrid			2022-12-27	WOS:000220334900048
J	Glowacki, R; Jakubowski, H				Glowacki, R; Jakubowski, H			Cross-talk between Cys(34) and lysine residues in human serum albumin revealed by N-homocysteinylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN HOMOCYSTEINYLATION; PATHOLOGICAL CONSEQUENCES; PLASMA HOMOCYSTEINE; POSSIBLE MECHANISM; ENDOTHELIAL-CELLS; HEART-DISEASE; THIOLACTONE; RISK; METABOLISM; ATHEROSCLEROSIS	Protein N-homocysteinylation involves a post-translational modification by homocysteine (Hcy)-thiolactone. In humans, about 70% of circulating Hcy is N-linked to blood proteins, mostly to hemoglobin and albumin. It was unclear what protein site(s) were prone to Hcy attachment and how N-linked Hcy affected protein function. Here we show that Lys(525) is a predominant site of N-homocysteinylation in human serum albumin in vitro and in vivo. We also show that the reactivity of albumin lysine residues, including Lys525, is affected by the status of Cys(34). The disulfide forms of circulating albumin, albumin-Cys(34)-S-S-Cys and albumin-Cys(34)-S-S-Hcy, are N-homocysteinylated faster than albumin-Cys(34)-SH. Although N-homocysteinylations of albumin-Cys(34)-SH and albumin-Cys(34)-S-S-Cys yield different primary products, subsequent thiol-disulfide exchange reactions result in the formation of a single product, N-(Hcy-S-S-Cys)-albumin-Cys(34)-SH. We also show that N-homocysteinylation affects the susceptibility of albumin to oxidation and proteolysis. The data suggest that a disulfide at Cys(34) of albumin promotes conversion of N-(Hcy-SH)-albumin-Cys(34)-SH to a proteolytically sensitive form N-(HcyS-S-Cys)-albumin-Cys(34)-SH, which would facilitate clearance of the N-homocysteinylated form of mercaptoalbumin.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07103 USA; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07103 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 				Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; Chambers JC, 2001, CIRC RES, V89, P187, DOI 10.1161/hh1401.093459; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; CHRISTODOULOU J, 1994, EUR J BIOCHEM, V225, P363, DOI 10.1111/j.1432-1033.1994.00363.x; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Daneshvar P, 2003, RAPID COMMUN MASS SP, V17, P358, DOI 10.1002/rcm.915; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 2003, CLIN CHEM LAB MED, V41, P1462, DOI 10.1515/CCLM.2003.224; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P21; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 1997, DEV CARDIOVASC MED, P157; Jakubowski H, 2000, J BIOL CHEM, V275, P21813, DOI 10.1074/jbc.C000280200; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2004, IN PRESS CELL MOL LI, V60; JAKUBOWSKI H, 2004, IN PRESS AMINOACYL T; JAKUBOWSKI H, 2001, ENCY LIFE SCI, V18, P441; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Mercie P, 2000, APOPTOSIS, V5, P403, DOI 10.1023/A:1009652011466; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; ROSENBLATT D, 2001, METABOLIC MOL BASES, V2, P3897; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Uji Y, 2002, CLIN CHEM, V48, P941; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zunszain Patricia A, 2003, BMC Struct Biol, V3, P6, DOI 10.1186/1472-6807-3-6	38	107	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10864	10871		10.1074/jbc.M313268200	http://dx.doi.org/10.1074/jbc.M313268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701829	hybrid			2022-12-27	WOS:000220157600007
J	Hormaeche, I; Iloro, I; Arrondo, JLR; Goni, FM; de la Cruz, F; Alkorta, I				Hormaeche, I; Iloro, I; Arrondo, JLR; Goni, FM; de la Cruz, F; Alkorta, I			Role of the transmembrane domain in the stability of TrwB, an integral protein involved in bacterial conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; IV SECRETION SYSTEM; TRAG-LIKE PROTEINS; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; COUPLING PROTEIN; PLASMID R388; DNA; BINDING; ORGANIZATION	TrwB is an integral membrane protein encoded by the conjugative plasmid R388. TrwB binds ATP and is essential for R388-directed bacterial conjugation. The protein consists of a cytosolic domain, which contains an ATP-binding site, and a transmembrane domain. The complete protein has been purified in the presence of detergents, and in addition, the cytosolic domain has also been isolated in the form of a soluble truncated protein, TrwBDeltaN70. The availability of intact and truncated forms of the protein provides a convenient system to study the role of the transmembrane domain in the stability of TrwB. Protein denaturation was achieved by heat, in the presence of guanidinium HCl, or under low salt conditions. In all three cases TrwB was significantly more stable than TrwBDeltaN70 with other conditions being the same. IR spectroscopy of the native and truncated forms revealed significant differences between them. In addition, it was found that TrwBDeltaN70 was stabilized in dispersions of non-ionic detergent, suggesting the presence of hydrophobic patches on the surface of the truncated protein. IR spectroscopy also confirmed the conformational stability provided by the detergent. These results suggest that in integral membrane proteins consisting of a transmembrane and a cytosolic domain, the transmembrane portion may have a role beyond the mere anchoring of the protein to the cell membrane. In addition, this study indicates that the truncated soluble parts of two-domain membrane proteins may not reflect the physiological conformation of their native counterparts.	Univ Basque Country, CSIC, Ctr Mixto, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Univ Cantabria, Dept Biol Mol, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Universidad de Cantabria	Goni, FM (corresponding author), Univ Basque Country, CSIC, Ctr Mixto, Unidad Biofis, Apto 644, E-48080 Bilbao, Spain.	gbpgourf@lg.ehu.es	Goni, Felix M/M-5425-2015; Iloro, Ibon/L-6022-2014; Alkorta, Itziar/N-4374-2014; Alkorta, Itziar/Y-6267-2019; de la Cruz, Fernando/L-2812-2014	Goni, Felix M/0000-0001-6270-9216; Iloro, Ibon/0000-0002-9537-1714; Alkorta, Itziar/0000-0002-1976-8904; de la Cruz, Fernando/0000-0003-4758-6857; ALCORTA CALVO, MIREN ITZIAR/0000-0001-6978-389X				Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; Aussel L, 2002, CELL, V108, P195, DOI 10.1016/S0092-8674(02)00624-4; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; Bowie JU, 2001, CURR OPIN STRUC BIOL, V11, P397, DOI 10.1016/S0959-440X(00)00223-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; DELACRUZ F, 1982, J BACTERIOL, V151, P222, DOI 10.1128/JB.151.1.222-228.1982; Echabe I, 1998, PROTEIN SCI, V7, P1172, DOI 10.1002/pro.5560070511; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P7556, DOI 10.1074/jbc.M110462200; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; Goni F. M., 2000, BIOCHIM BIOPHYS ACTA, V1508, P1; Goni FM, 2002, MOL MEMBR BIOL, V19, P237, DOI 10.1080/0968768021000035078; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; Hormaeche I, 2002, J BIOL CHEM, V277, P46456, DOI 10.1074/jbc.M207250200; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; Llosa M, 2002, MOL MICROBIOL, V45, P1, DOI 10.1046/j.1365-2958.2002.03014.x; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Moncalian G, 1999, J BIOL CHEM, V274, P36117, DOI 10.1074/jbc.274.51.36117; MORO F, 1996, THESIS U BASQUE COUN; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; RACKER E, 1985, RECONSTITUTIONS TRAN; SANDLER JR, 1980, GENE, V8, P279; Schroder G, 2003, J BACTERIOL, V185, P4371, DOI 10.1128/JB.185.15.4371-4381.2003; Schroder G, 2002, J BACTERIOL, V184, P2767, DOI 10.1128/JB.184.10.2767-2779.2002; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	34	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10955	10961		10.1074/jbc.M310422200	http://dx.doi.org/10.1074/jbc.M310422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699106	hybrid			2022-12-27	WOS:000220157600017
J	Mueller, TD; Kamionka, M; Feigon, J				Mueller, TD; Kamionka, M; Feigon, J			Specificity of the interaction between ubiquitin-associated domains and ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN HHR23A; DNA-REPAIR; SUBUNIT S5A; CUE DOMAIN; POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; 20S PROTEASOME; 26S PROTEASOME; UBA DOMAINS; HIV-1 VPR	Ubiquitin-associated (UBA) domains are found in a large number of proteins with diverse functions involved in ubiquitination, DNA repair, and signaling pathways. Recent studies have shown that several UBA domain proteins interact with ubiquitin (Ub), specifically p62, the phosphotyrosine-independent ligand of the SH2 domain of p56(lck); HHR23A, a human nucleotide excision repair protein; and DDI1, another damage-inducible protein. NMR chemical shift mapping reveals that Ub binds specifically but weakly to a conserved hydrophobic epitope on HHR23A UBA( 1) and UBA( 2) and that the UBA domains bind on the hydrophobic patch on the surface of the five-stranded beta-sheet of Ub. Models of the UBA( 1)-Ub and UBA(2)-Ub complexes obtained from de novo docking reveal different orientations of the UBA domains on the Ub surface compared with those obtained by homology modeling with the related CUE domains, which also bind Ub. Our results suggest that UBA domains may interact with Ub as well as other proteins in more than one way while utilizing the same binding surface.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Feigon, J (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave,POB 951569, Los Angeles, CA 90095 USA.	feigon@mbi.ucla.edu		Mueller, Thomas/0000-0003-1862-7357	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043190] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43190] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; CHEN L, 2001, EMBO REP, V24, P24; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Medek A, 2000, J AM CHEM SOC, V122, P1241, DOI 10.1021/ja993921m; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Phillips CL, 2001, ACTA CRYSTALLOGR D, V57, P341, DOI 10.1107/S090744490001800X; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VONARNIM AG, 2001, SCI STKE, pE2; Walters KJ, 2003, P NATL ACAD SCI USA, V100, P12694, DOI 10.1073/pnas.1634989100; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Zhu QZ, 2001, CANCER RES, V61, P64	60	89	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11926	11936		10.1074/jbc.M312865200	http://dx.doi.org/10.1074/jbc.M312865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707125	hybrid			2022-12-27	WOS:000220157600130
J	Verhamme, IM; Bock, PE; Jackson, CM				Verhamme, IM; Bock, PE; Jackson, CM			The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE AFFINITY-CHROMATOGRAPHY; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; FIBRIN-BOUND THROMBIN; AMINO-ACID-RESIDUES; ANTITHROMBIN-III; DERMATAN SULFATE; ALPHA-THROMBIN; EXOSITE-I; PROTHROMBIN FRAGMENT-2	Thrombin ( T) inactivation by the serpin, heparin cofactor II (HCII), is accelerated by the glycosaminoglycans (GAGs) dermatan sulfate (DS) and heparin ( H). Equilibrium binding and thrombin inactivation kinetics at pH 7.8 and ionic strength ( I) 0.125 M demonstrated that DS and heparin bound much tighter to thrombin (K-T(DS) 1 - 5.8 muM; K-T(H) 0.02 - 0.2 muM) than to HCII (K-HCII(DS) 236 - 291 muM; K-HCII(H) 25 - 35 muM), favoring formation of T . GAG over HCII . GAG complexes as intermediates for T GAG . HCII complex assembly. At [GAG] << KHCII( GAG) the GAG and HCII concentration dependences of the first-order inactivation rate constants (k(app)) were hyperbolic, reflecting saturation of T . GAG complex and formation of the T . GAG . HCII complex from T . GAG and free HCII, respectively. At [GAG] >> K-HCII(GAG), HCII . GAG complex formation caused a decrease in k(app). The bell-shaped logarithmic GAG dependences fit an obligatory template mechanism in which free HCII binds GAG in the T . GAG complex. DS and heparin bound fluorescently labeled meizothrombin(des-fragment 1) (MzT(- F1)) with KMzT(-F1)(GAG) 10 and 20 muM, respectively, demonstrating a binding site outside of exosite II. Exosite II ligands did not attenuate the DS-accelerated thrombin inactivation markedly, but DS displaced thrombin from heparin-Sepharose, suggesting that DS and heparin share a restricted binding site in or nearby exosite II, in addition to binding outside exosite II. Both T . DS and MzT(- F1) . DS interactions were saturable at DS concentrations substantially below K-HCII( DS), consistent with DS bridging T . DS and free HCII. The results suggest that GAG template action facilitates ternary complex formation and accommodates HCII binding to GAG and thrombin exosite I in the ternary complex.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Hemosaga Diagnost Corp, San Diego, CA 92121 USA	Vanderbilt University	Verhamme, IM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	Ingrid.Verhamme@vanderbilt.edu	Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420	NHLBI NIH HHS [HL-38779, HL-32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032373, R29HL038779, R01HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; Bauman SJ, 1999, J BIOL CHEM, V274, P34556, DOI 10.1074/jbc.274.49.34556; Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CHURCH FC, 1987, BIOCHEM BIOPH RES CO, V148, P362, DOI 10.1016/0006-291X(87)91119-3; CHURCH FC, 1987, ARCH BIOCHEM BIOPHYS, V259, P331, DOI 10.1016/0003-9861(87)90499-1; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; Colwell NS, 1999, BBA-PROTEIN STRUCT M, V1431, P148, DOI 10.1016/S0167-4838(99)00051-5; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Colwell NS, 1997, BRIT J HAEMATOL, V97, P219, DOI 10.1046/j.1365-2141.1997.d01-2145.x; Cooper ST, 2002, THROMB RES, V107, P67, DOI 10.1016/S0049-3848(02)00180-9; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, V481, P297, DOI 10.1016/0005-2744(77)90264-9; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; Fredenburgh JC, 2001, J BIOL CHEM, V276, P44828, DOI 10.1074/jbc.M108710200; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; Han JH, 1997, J BIOL CHEM, V272, P28660, DOI 10.1074/jbc.272.45.28660; HAYAKAWA Y, 1995, BLOOD COAGUL FIBRIN, V6, P643, DOI 10.1097/00001721-199510000-00004; Hayakawa Y, 2000, J BIOL CHEM, V275, P11379, DOI 10.1074/jbc.275.15.11379; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P70, DOI 10.1016/0003-9861(85)90009-8; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; Maaroufi RM, 1997, BIOMATERIALS, V18, P359, DOI 10.1016/0142-9612(95)00355-X; MACHOVICH R, 1975, BIOCHIM BIOPHYS ACTA, V379, P193, DOI 10.1016/0005-2795(75)90022-7; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; Mitchell JW, 2002, J BIOL CHEM, V277, P19823, DOI 10.1074/jbc.M200630200; Munro PD, 2000, J THEOR BIOL, V203, P407, DOI 10.1006/jtbi.2000.1099; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; NICHOL LW, 1981, BIOCHEMISTRY-US, V20, P4856, DOI 10.1021/bi00520a008; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1988, J BIOL CHEM, V263, P1698; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; Segel I. H, 1975, ENZYME KINETICS, P178; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Shi F, 1998, BIOPHYS CHEM, V75, P187, DOI 10.1016/S0301-4622(98)00205-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VERHAMME IMA, 1989, ARCH INT PHYSL BIOCH, V97, pB117; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P62	71	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9785	9795		10.1074/jbc.M313962200	http://dx.doi.org/10.1074/jbc.M313962200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701814	hybrid			2022-12-27	WOS:000220050400017
J	Schneiders, T; Barbosa, TM; McMurry, LM; Levy, SB				Schneiders, T; Barbosa, TM; McMurry, LM; Levy, SB			The Escherichia coli transcriptional regulator MarA directly represses transcription of purA and hdeA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; NUCLEOID-ASSOCIATED PROTEIN; RNA-POLYMERASE; DNA-BINDING; COMPLEX-FORMATION; ACID-RESISTANCE; ACTIVATION; EXPRESSION; GENES; SUPEROXIDE	The Escherichia coli MarA protein mediates a response to multiple environmental stresses through the activation or repression in vivo of a large number of chromosomal genes. Transcriptional activation for a number of these genes has been shown to occur via direct interaction of MarA with a 20-bp degenerate asymmetric "marbox" sequence. It was not known whether repression by MarA was also direct. We found that purified MarA was sufficient in vitro to repress transcription of both purA and hdeA. Transcription and electrophoretic mobility shift experiments in vitro using mutant promoters suggested that the marbox involved in the repression overlapped the -35 promoter motif and was in the "backward" orientation. This organization contrasts with that of the class II promoters activated by MarA, in which the marbox also overlaps the -35 motif but is in the "forward" orientation. We conclude that MarA, a member of the AraC/XylS family, can act directly as a repressor or an activator, depending on the position and orientation of the marbox within a promoter.	Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, 136 Harrison Ave, Boston, MA 02111 USA.	stuart.levy@tufts.edu		Barbosa, Teresa M./0000-0001-7151-3418; Schneiders, Thamarai/0000-0002-7758-7925	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51661/AI56021] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; ANSARI AZ, 1995, NATURE, V374, P371; ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; ARNQVIST A, 1994, MOL MICROBIOL, V13, P1021, DOI 10.1111/j.1365-2958.1994.tb00493.x; Barbosa TM, 2002, MOL MICROBIOL, V45, P191, DOI 10.1046/j.1365-2958.2002.03006.x; Barbosa TM, 2000, J BACTERIOL, V182, P3467, DOI 10.1128/JB.182.12.3467-3474.2000; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; Caslake LF, 1997, J BACTERIOL, V179, P1787, DOI 10.1128/jb.179.5.1787-1795.1997; CHOY H, 1996, ESCHERICHIA COLI SAL, P1287; COHEN SP, 1988, J BACTERIOL, V170, P5416, DOI 10.1128/jb.170.12.5416-5422.1988; Dangi B, 2001, J MOL BIOL, V314, P113, DOI 10.1006/jmbi.2001.5106; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; Dunstan SJ, 1998, INFECT IMMUN, V66, P732, DOI 10.1128/IAI.66.2.732-740.1998; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Gajiwala KS, 2000, J MOL BIOL, V295, P605, DOI 10.1006/jmbi.1999.3347; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; GEORGE AM, 1983, J BACTERIOL, V155, P531, DOI 10.1128/JB.155.2.531-540.1983; Gralla JD, 1996, ESCHERICHIA COLI SAL, P1232; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; Griffith KL, 2001, MOL MICROBIOL, V40, P1141, DOI 10.1046/j.1365-2958.2001.02456.x; HE B, 1994, J BACTERIOL, V176, P1009, DOI 10.1128/JB.176.4.1009-1013.1994; Hoffman JA, 2001, MICROB PATHOGENESIS, V31, P69, DOI 10.1006/mpat.2001.0451; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JAIR KW, 1995, J BACTERIOL, V177, P7100, DOI 10.1128/jb.177.24.7100-7104.1995; Jair KW, 1996, MOL MICROBIOL, V19, P307, DOI 10.1046/j.1365-2958.1996.368893.x; Jair KW, 1996, J BACTERIOL, V178, P2507, DOI 10.1128/jb.178.9.2507-2513.1996; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Martin RG, 2000, MOL MICROBIOL, V35, P623, DOI 10.1046/j.1365-2958.2000.01732.x; Martin RG, 1999, MOL MICROBIOL, V34, P431, DOI 10.1046/j.1365-2958.1999.01599.x; Martin RG, 2002, MOL MICROBIOL, V43, P355, DOI 10.1046/j.1365-2958.2002.02748.x; Martin RG, 2002, MOL MICROBIOL, V44, P1611, DOI 10.1046/j.1365-2958.2002.02985.x; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; Sambrook J., 2001, MOL CLONING LAB MANU; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; Tucker DL, 2003, J BACTERIOL, V185, P3190, DOI 10.1128/JB.185.10.3190-3201.2003; Van Dyk TK, 1998, J BACTERIOL, V180, P785, DOI 10.1128/JB.180.4.785-792.1998; Waterman SR, 1996, MOL MICROBIOL, V21, P925, DOI 10.1046/j.1365-2958.1996.00058.x; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	43	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9037	9042		10.1074/jbc.M313602200	http://dx.doi.org/10.1074/jbc.M313602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701822	hybrid			2022-12-27	WOS:000189265900064
J	Vulsteke, V; Beullens, M; Boudrez, A; Keppens, S; Van Eynde, A; Rider, MH; Stalmans, W; Bollen, M				Vulsteke, V; Beullens, M; Boudrez, A; Keppens, S; Van Eynde, A; Rider, MH; Stalmans, W; Bollen, M			Inhibition of spliceosome assembly by the cell cycle-regulated protein kinase MELK and involvement of splicing factor NIPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR INHIBITOR; PHOSPHATASE-1; PHOSPHORYLATION; POLYPEPTIDES; PEG3	NIPP1 is a ubiquitous nuclear protein that is required for spliceosome assembly. We report here that the phosphothreonine-binding Forkhead-associated domain of NIPP1 interacts with the cell cycle-regulated protein Ser/Thr kinase MELK ( maternal embryonic leucine zipper kinase). The NIPP1-MELK interaction was critically dependent on the phosphorylaton of Thr-478 of MELK and was increased in lysates from mitotically arrested cells. Recombinant MELK was a potent inhibitor of an early step of spliceosome assembly in nuclear extracts. This splicing defect was also seen with a kinase-dead mutant but was absent after mutation (T478A) of the NIPP1 binding site of MELK, indicating a mediatory role for NIPP1. Our data suggest that MELK has a role in the cell cycle-regulated control of pre-mRNA splicing.	Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium; Univ Louvain, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Bollen, M (corresponding author), Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.ac.be						BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Blot J, 2002, DEV BIOL, V241, P327, DOI 10.1006/dbio.2001.0525; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heyer BS, 1999, DEV DYNAM, V215, P344; Jagiello I, 2000, J CELL SCI, V113, P3761; Jin QM, 2003, J BIOL CHEM, V278, P30677, DOI 10.1074/jbc.M302273200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972	27	68	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8642	8647		10.1074/jbc.M311466200	http://dx.doi.org/10.1074/jbc.M311466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699119	hybrid			2022-12-27	WOS:000189265900016
J	Itano, N; Sawai, T; Atsumi, F; Miyaishi, O; Taniguchi, S; Kannagi, R; Hamaguchi, M; Kimata, K				Itano, N; Sawai, T; Atsumi, F; Miyaishi, O; Taniguchi, S; Kannagi, R; Hamaguchi, M; Kimata, K			Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; RAT 3Y1 FIBROBLASTS; GROWTH-FACTOR; ENDOTHELIAL-CELLS; MESSENGER-RNA; CARCINOMA; INVASION; CANCER; MATRIX; ACID	Malignant transformation of fibroblasts and epithelial cells is often accompanied by increased hyaluronan production and accumulation. Despite recent progress in the study of hyaluronan biosynthesis, the mechanisms underlying the transformation-induced overproduction of hyaluronan have not been elucidated. Here we report that activity and transcriptional levels of hyaluronan synthase ( HAS) significantly increased after oncogenic malignant transformation of a rat 3Y1 fibroblast cell line. Of three HAS isoforms (HAS1, HAS2, and HAS3), only HAS2 gene expression was increased in the v-Ha-ras transformed 3Y1 cells, which show less malignancy. In contrast, both HAS1 and HAS2 expressions were elevated in the highly malignant cells transformed with v-src and/or v-fos. To assess the contribution of HAS expression to the oncogenic malignant transformation, we established stable cell transfectants expressing sense and antisense HAS genes. Antisense suppression of the HAS2 expression significantly decreased hyaluronan production in the cells transformed by the oncogenic v-Ha-ras and eventually led to a reduction in tumorigenicity in the rat peritoneum. The introduction of the HAS1 and HAS2 genes promoted the growth of subcutaneous tumors in a manner dependent on the levels of hyaluronan synthesis. Significant growth promotion was observed within a wide range of HAS1 expression. In contrast, the growth stimulation was only seen within a narrow range of HAS2 expression, and high levels of HAS2 expression even inhibited tumor growth. These results suggest that proper regulation of the expression of each HAS isoform is required for optimal malignant transformation and tumor growth.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Aichi 4801195, Japan; Aichi Med Univ, Lab Anim Res Ctr, Aichi 4801195, Japan; Aichi Med Univ, Dept Pathol 2, Aichi 4801195, Japan; Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol,Angioaging Div, Nagano 3908621, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Nagoya, Aichi 466, Japan	Aichi Medical University; Japan Science & Technology Agency (JST); Aichi Medical University; Aichi Medical University; Shinshu University; Aichi Cancer Center; Nagoya University	Itano, N (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	itano@amugw.aichi-med-u.ac.jp	Kannagi, Reiji/Q-6459-2018	Kannagi, Reiji/0000-0003-4202-2921				Ashley DM, 1998, CANCER RES, V58, P302; Csoka TB, 1997, INVAS METAST, V17, P297; DICK SJ, 1983, SCIENCE, V220, P739, DOI 10.1126/science.6220469; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; HAMERMAN D, 1965, BIOCHIM BIOPHYS ACTA, V101, P343, DOI 10.1016/0926-6534(65)90013-8; HOPWOOD JJ, 1977, J BIOL CHEM, V252, P4777; ISHIMOTO N, 1966, J BIOL CHEM, V241, P2052; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1998, TRENDS GLYCOSCI GLYC, V10, P23, DOI 10.4052/tigg.10.23; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; KIMATA K, 1983, CANCER RES, V43, P1347; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Knudson W, 1996, AM J PATHOL, V148, P1721; Kosaki R, 1999, CANCER RES, V59, P1141; Kuroda K, 2001, J DERMATOL SCI, V26, P156, DOI 10.1016/S0923-1811(00)00155-9; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LEONARD JG, 1978, CANCER RES, V38, P185; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Liu NF, 2001, CANCER RES, V61, P5207; Ohkawa T, 1999, BBA-MOL CELL RES, V1448, P416, DOI 10.1016/S0167-4889(98)00155-4; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Recklies AD, 2001, BIOCHEM J, V354, P17, DOI 10.1042/0264-6021:3540017; Ropponen K, 1998, CANCER RES, V58, P342; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; SHIMURA H, 1988, CANCER RES, V48, P578; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; Spicer AP, 1999, BIOCHEM SOC T, V27, P109, DOI 10.1042/bst0270109; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Sugiyama Y, 1998, J INVEST DERMATOL, V110, P116, DOI 10.1046/j.1523-1747.1998.00093.x; TANAKA H, 1988, J CELL PHYSIOL, V136, P421, DOI 10.1002/jcp.1041360305; TANIGUCHI S, 1989, CANCER RES, V49, P6738; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1985, CANCER RES, V45, P5098; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Wang XD, 1998, INT J ONCOL, V12, P1097; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yamada Y, 1998, BIOCHEM J, V330, P1223, DOI 10.1042/bj3301223; YAMADA Y, 2004, IN PRESS CLIN EXP ME; ZAITSU H, 1984, J CELL PHYSIOL, V119, P82, DOI 10.1002/jcp.1041190114; ZHANG LR, 1995, CANCER RES, V55, P428	51	122	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18679	18687		10.1074/jbc.M313178200	http://dx.doi.org/10.1074/jbc.M313178200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14724275	hybrid			2022-12-27	WOS:000221041500073
J	Castell, L; Vance, C; Abbott, R; Marquez, J; Eggleton, P				Castell, L; Vance, C; Abbott, R; Marquez, J; Eggleton, P			Granule localization of glutaminase in human neutrophils and the consequence of glutamine utilization for neutrophil activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IN-VITRO; POSTOPERATIVE-PATIENTS; EXHAUSTIVE EXERCISE; CYTOKINE PRODUCTION; RAT NEUTROPHILS; IMMUNE-RESPONSE; EXPRESSION; GLUCOSE; PHAGOCYTOSIS	The provision of glutamine in vivo has been observed to reduce to normal levels the neutrophilia observed after exhaustive exercise and to decrease the neutrophil chemoattractant, interleukin-8. Thus, the role for glutamine in the regulation of inflammatory mediators of human neutrophil activation was investigated. The study sought to establish whether glutamine supplementation in vitro affects neutrophil function at rest and whether glutaminase, the major enzyme that metabolizes glutamine, is present in human polymorphonuclear neutrophils (PMN). During in vitro studies, the addition of 2 mM glutamine increased the respiratory burst of human PMN stimulated with both phorbol myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine. These observations were made using a highly sensitive, real time chemiluminescent probe, Pholasin(R). Glutamine alone did not stimulate the release of reactive oxygen species. In a novel finding using glutaminase-specific antibodies in combination with flow cytometry and confocal microscopy, glutaminase was shown to be present on the surface of human PMN. Subcellular fractionation revealed that the enzyme was enriched in the secondary granules and could be released into cell culture medium upon stimulation with PMA. In conclusion, human PMN appeared to utilize glutamine and possess the appropriate glutaminase enzyme for metabolizing glutamine. This may depress some pro-inflammatory factors that occur during prolonged, exhaustive exercise.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX1 2LU, Devon, England; Univ Malaga, Dept Mol Biol & Biochem, E-29071 Malaga, Spain	University of Oxford; University of Oxford; University of Exeter; Universidad de Malaga	Castell, L (corresponding author), Univ Oxford, Radcliffe Infirm, Nuffield Dept Anaesthet, Oxford OX2 6HE, England.	lindy.castell@nda.ox.ac.uk	marquez, javier/K-3289-2012; Vance, Caroline/Q-2633-2019; Vance, Caroline/C-3047-2012	marquez, javier/0000-0003-3317-3963; Vance, Caroline/0000-0001-5780-6951; Vance, Caroline/0000-0001-5780-6951; Eggleton, Paul/0000-0001-8244-2125; Abbott, Rachel/0000-0003-1902-1429				ARDAWI MSM, 1985, ESSAYS BIOCHEM, V21, P1; Blannin AK, 1998, J PHYSIOL-LONDON, V506P, p121P; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Castell LM, 2003, SPORTS MED, V33, P323, DOI 10.2165/00007256-200333050-00001; Castell LM, 1996, EUR J APPL PHYSIOL O, V73, P488, DOI 10.1007/BF00334429; Castell LM, 1998, CAN J PHYSIOL PHARM, V76, P524, DOI 10.1139/cjpp-76-5-524; CASTELL LM, 1996, THESIS U OXFORD OXFO; Coeffier M, 2003, CLIN NUTR, V22, P407, DOI 10.1016/S0261-5614(03)00040-2; Curi TCP, 1997, AM J PHYSIOL-CELL PH, V273, pC1124, DOI 10.1152/ajpcell.1997.273.4.C1124; de Beaux AC, 1998, NUTRITION, V14, P261, DOI 10.1016/S0899-9007(97)00477-2; DUFAUX B, 1989, INT J SPORTS MED, V10, P434, DOI 10.1055/s-2007-1024939; EGGLETON P, 1995, ANN RHEUM DIS, V54, P916, DOI 10.1136/ard.54.11.916; Eggleton P, 1999, ANTICANCER RES, V19, P3711; Furukawa S, 2000, NUTRITION, V16, P323, DOI 10.1016/S0899-9007(00)00228-8; Furukawa S, 1997, NUTRITION, V13, P863, DOI 10.1016/S0899-9007(97)00271-2; Gomez-Fabre PM, 2000, BIOCHEM J, V345, P365, DOI 10.1042/0264-6021:3450365; HANSEN JB, 1991, EUR J APPL PHYSIOL O, V62, P157, DOI 10.1007/BF00643735; Healy DA, 2002, CLIN SCI, V103, P179, DOI 10.1042/cs1030179; Huang Y, 2003, CYTOKINE, V22, P77, DOI 10.1016/S1043-4666(03)00115-7; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; KNOX WE, 1967, CANCER RES, V27, P1456; LARRABEE RC, 1902, J MED RES, V2, P76; Lin MT, 2001, JPEN-PARENTER ENTER, V25, P346, DOI 10.1177/0148607101025006346; MCCARTHY DA, 1988, SPORTS MED, V6, P333, DOI 10.2165/00007256-198806060-00002; NEWSHOLME P, 1989, BIOCHEM J, V261, P211, DOI 10.1042/bj2610211; Nieman DC, 2001, J APPL PHYSIOL, V91, P109, DOI 10.1152/jappl.2001.91.1.109; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OGLE CK, 1994, JPEN-PARENTER ENTER, V18, P128, DOI 10.1177/0148607194018002128; Olalla L, 2002, J BIOL CHEM, V277, P38939, DOI 10.1074/jbc.C200373200; ORIORDAIN MG, 1996, NUTRITION, V12, P82; Pithon-Curi TC, 2002, CELL BIOCHEM FUNCT, V20, P81, DOI 10.1002/cbf.954; Pithon-Curi TC, 2002, CLIN SCI, V103, P403, DOI 10.1042/cs1030403; POWELL H, 1994, CLIN PHYSIOL, V14, P569, DOI 10.1111/j.1475-097X.1994.tb00415.x; Searl TJ, 1998, J PHARMACOL EXP THER, V285, P247; SEGURA JA, 1995, PROTEIN EXPRES PURIF, V6, P343, DOI 10.1006/prep.1995.1045; Suzuki K, 2000, EUR J APPL PHYSIOL, V81, P281, DOI 10.1007/s004210050044; Suzuki K, 1996, J APPL PHYSIOL, V81, P1213, DOI 10.1152/jappl.1996.81.3.1213; Turner A, 2003, BIOCHEM J, V370, P403, DOI 10.1042/BJ20021360; VOETMAN AA, 1980, BLOOD, V55, P741; Wirthmueller U, 1997, J IMMUNOL, V158, P4444; Wood-Harper AT, 1999, AUST COMPUT J, V31, P66	43	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13305	13310		10.1074/jbc.M309520200	http://dx.doi.org/10.1074/jbc.M309520200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722097	hybrid			2022-12-27	WOS:000220478500006
J	Taneja, SS; Ha, S; Swenson, NK; Torra, IP; Rome, S; Walden, PD; Huang, HY; Shapiro, E; Garabedian, MJ; Logan, SK				Taneja, SS; Ha, S; Swenson, NK; Torra, IP; Rome, S; Walden, PD; Huang, HY; Shapiro, E; Garabedian, MJ; Logan, SK			ART-27, an androgen receptor coactivator regulated in prostate development and cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIF; CREB-BINDING-PROTEIN; RAT VENTRAL PROSTATE; GLUCOCORTICOID-RECEPTOR; TERMINAL DOMAIN; GENE-EXPRESSION; MOLECULAR-BASIS; ACTIVATION; CELLS; IDENTIFICATION	Androgen receptor trapped clone-27 (ART-27) is a newly described transcriptional coactivator that binds to the N terminus of the androgen receptor (AR). Given the vital importance of AR signaling in prostate growth and differentiation, we investigated the role of ART-27 in these processes. Immunohistochemical studies indicate that ART-27 protein is expressed in differentiated epithelial cells of adult human prostate and breast tissue. In prostate, ART-27 is abundant in AR-positive prostate luminal epithelial cells, in contrast to the stroma, where cells express AR but not ART-27. The use of a rat model of androgen depletion/ reconstitution indicates that ART-27 expression is associated with the elaboration of differentiated prostate epithelial cells. Interestingly, regulated expression of ART-27 in the androgen-sensitive LNCaP prostate cancer cell line inhibits androgen-mediated cellular proliferation and enhances androgen-mediated transcription of the prostate-specific antigen (PSA) gene. Consistent with a growth suppressive function, we show that ART-27 expression levels are negligible in human prostate cancer. Importantly, examination of ART-27 protein expression in early fetal prostate development demonstrates that ART-27 is detected only when the developing prostate gland has proceeded from a solid mass of undifferentiated cells to a stage in which differentiated luminal epithelial cells are evident. Thus, ART-27 is an AR cofactor shown to be subject to both cell type and developmental regulation in humans. Overall, the results suggest that decreased levels of ART-27 protein in prostate cancer tissue may occur as a result of de-differentiation, and indicate that ART-27 is likely to regulate a subset of AR-responsive genes important to prostate growth suppression and differentiation.	NYU, Sch Med, Dept Urol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Logan, SK (corresponding author), NYU, VAMC, 423 E 23rd St,Room 18064 S, New York, NY 10010 USA.	logans02@med.nyu.edu		Logan, Susan/0000-0002-7904-5927; Pineda Torra, Ines/0000-0002-7349-2208	NIDDK NIH HHS [K08 DK02577-01, DK58024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058024, K08DK002577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Astancolle S, 2000, J ENDOCRINOL, V167, P197, DOI 10.1677/joe.0.1670197; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Cinar B, 2001, CANCER RES, V61, P7310; Cleutjens CBJM, 1997, ENDOCRINOLOGY, V138, P5293, DOI 10.1210/en.138.12.5293; COLOMBEL MC, 1995, METHOD CELL BIOL, V46, P369; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gregory CW, 2001, CANCER RES, V61, P4315; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; LANGELER EG, 1993, PROSTATE, V23, P213, DOI 10.1002/pros.2990230304; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Park JJ, 2000, CANCER RES, V60, P5946; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Schroer A, 1999, GENOMICS, V56, P340, DOI 10.1006/geno.1998.5712; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; Takahashi T, 1999, INT J UROL, V6, P526, DOI 10.1046/j.1442-2042.1999.00104.x; Walden PD, 1998, PROSTATE, V34, P241, DOI 10.1002/(SICI)1097-0045(19980301)34:4<241::AID-PROS1>3.0.CO;2-K; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	46	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13944	13952		10.1074/jbc.M306576200	http://dx.doi.org/10.1074/jbc.M306576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14711828	hybrid			2022-12-27	WOS:000220478500081
J	Appenzeller-Herzog, C; Roche, AC; Nufer, O; Hauri, HP				Appenzeller-Herzog, C; Roche, AC; Nufer, O; Hauri, HP			pH-induced conversion of the transport lectin ERGIC-53 triggers glycoprotein release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; CARBOHYDRATE-RECOGNITION DOMAIN; RECEPTOR-ASSOCIATED PROTEIN; VACUOLAR H+-ATPASE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; ASIALOGLYCOPROTEIN RECEPTOR; LEGUMINOUS LECTINS; RECYCLING PATHWAY; CRYSTAL-STRUCTURE	The recycling mannose lectin ERGIC- 53 operates as a transport receptor by mediating efficient endoplasmic reticulum ( ER) export of some secretory glycoproteins. Binding of cargo to ERGIC- 53 in the ER requires Ca2+. Cargo release occurs in the ERGIC, but the molecular mechanism is unknown. Here we report efficient binding of purified ERGIC- 53 to immobilized mannose at pH 7.4, the pH of the ER, but not at slightly lower pH. pH sensitivity of the lectin was more prominent when Ca2+ concentrations were low. A conserved histidine in the center of the carbohydrate recognition domain was required for lectin activity suggesting it may serve as a molecular pH/Ca2+ sensor. Acidification of cells inhibited the association of ERGIC- 53 with the known cargo cathepsin Z- related protein and dissociation of this glycoprotein in the ERGIC was impaired by organelle neutralization that did not impair the transport of a control protein. The results elucidate the molecular mechanism underlying reversible lectin/ cargo interaction and establish the ERGIC as the earliest low pH site of the secretory pathway.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; CNRS, Ctr Biophys Mol, F-45071 Orleans, France	University of Basel; Centre National de la Recherche Scientifique (CNRS)	Hauri, HP (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Hans-Peter.Hauri@unibas.ch	Appenzeller-Herzog, Christian/A-2894-2014	Appenzeller-Herzog, Christian/0000-0001-7430-294X				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ANTUSCH D, 1990, J IMMUNOL, V145, P885; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Feinberg H, 2000, J BIOL CHEM, V275, P35176, DOI 10.1074/jbc.M005557200; Fiedler K, 1996, J CELL SCI, V109, P271; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hauri HP, 2000, J CELL SCI, V113, P587; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nufer O, 2003, J BIOL CHEM, V278, P15886, DOI 10.1074/jbc.M211199200; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; Pezzati R, 1997, MOL BIOL CELL, V8, P1501, DOI 10.1091/mbc.8.8.1501; PIMPANEAU V, 1991, CARBOHYD RES, V213, P95, DOI 10.1016/S0008-6215(00)90601-3; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Scheel AA, 1996, BIOCHEMISTRY-US, V35, P10203, DOI 10.1021/bi960807x; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Solovyova N, 2002, J NEUROSCI METH, V122, P1, DOI 10.1016/S0165-0270(02)00300-X; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Weisz OA, 2003, INT REV CYTOL, V226, P259, DOI 10.1016/S0074-7696(03)01005-2; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Wu MM, 2000, METHOD ENZYMOL, V327, P546, DOI 10.1016/S0076-6879(00)27301-1; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Ying M, 2000, J CELL SCI, V113, P3623; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	45	84	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12943	12950		10.1074/jbc.M313245200	http://dx.doi.org/10.1074/jbc.M313245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718532	hybrid			2022-12-27	WOS:000220334900112
J	Ashikari-Hada, S; Habuchi, H; Kariya, Y; Itoh, N; Reddi, AH; Kimata, K				Ashikari-Hada, S; Habuchi, H; Kariya, Y; Itoh, N; Reddi, AH; Kimata, K			Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HEPARAN-SULFATE; MOLECULAR-CLONING; CRYSTAL-STRUCTURES; COMPLEXES REVEAL; CDNA CLONING; EXPRESSION; PROTEOGLYCANS; FGF	Heparan sulfate (HS) chains interact with various growth and differentiation factors and morphogens, and the most interactions occur on the specific regions of the chains with certain monosaccharide sequences and sulfation patterns. Here we generated a library of octasaccharides by semienzymatic methods by using recombinant HS 2-O-sulfotransferase and HS 6-O-sulfotransferase, and we have made a systematic investigation of the specific binding structures for various heparin-binding growth factors. An octasaccharide (Octa-I, DeltaHexA-GlcNSO(3)-(HexA-GlcNSO(3))(3)) was prepared by partial heparitinase digestion from completely desulfated N-resulfated heparin. 2-O- and 6-O-sulfated Octa-I were prepared by enzymatically transferring one to three 2-O- sulfate groups and one to three 6-O-sulfate groups per molecule, respectively, to Octa-I. Another octasaccharide containing 3 units of HexA(2SO(4))-GlcNSO(3)(6SO(4)) was prepared also from heparin. This octasaccharide library was subjected to affinity chromatography for interactions with fibroblast growth factor (FGF)-2, -4, -7, -8, -10, and -18, hepatocyte growth factor, bone morphogenetic protein 6, and vascular endothelial growth factor, respectively. Based upon differences in the affinity to those octasaccharides, the growth factors could be classified roughly into five groups: group 1 needed 2-O-sulfate but not 6-O-sulfate (FGF-2); group 2 needed 6-O-sulfate but not 2-O-sulfate (FGF-10); group 3 had the affinity to both 2-O-sulfate and 6-O-sulfate but preferred 2-O-sulfate (FGF-18, hepatocyte growth factor); group 4 required both 2-O-sulfate and 6-O-sulfate (FGF-4, FGF-7); and group 5 hardly bound to any octasaccharides (FGF-8, bone morphogenetic protein 6, and vascular endothelial growth factor). The approach using the oligosaccharide library may be useful to define specific structures required for binding to various heparin-binding proteins. Octasaccharides with the high affinity to FGF-2 and FGF-10 had the activity to release them, respectively, from their complexes with HS. Thus, the library may provide new reagents to specifically regulate bindings of the growth factors to HS.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genet Biochem, Kyoto 6068501, Japan; Univ Calif Davis, Sch Med, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA	Aichi Medical University; Seikagaku Corporation; Kyoto University; University of California System; University of California Davis	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp						Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Deakin JA, 1999, J CELL SCI, V112, P1999; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Fujise M, 2001, DEV BIOL, V235, P433, DOI 10.1006/dbio.2001.0290; Fujise M, 2003, DEVELOPMENT, V130, P1515, DOI 10.1242/dev.00379; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; LYON M, 1994, J BIOL CHEM, V269, P11216; Ohkawara B, 2002, CURR BIOL, V12, P205, DOI 10.1016/S0960-9822(01)00684-4; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Raman R, 2003, P NATL ACAD SCI USA, V100, P2357, DOI 10.1073/pnas.0437842100; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	49	239	249	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12346	12354		10.1074/jbc.M313523200	http://dx.doi.org/10.1074/jbc.M313523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707131	hybrid			2022-12-27	WOS:000220334900042
J	Canto, C; Suarez, E; Lizcano, JM; Grino, E; Shepherd, PR; Fryer, LGD; Carling, D; Bertran, J; Palacin, M; Zorzano, A; Guma, A				Canto, C; Suarez, E; Lizcano, JM; Grino, E; Shepherd, PR; Fryer, LGD; Carling, D; Bertran, J; Palacin, M; Zorzano, A; Guma, A			Neuregulin signaling on glucose transport in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR GENE-EXPRESSION; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MAP KINASE; NEUROMUSCULAR-JUNCTION; GLUT4 TRANSLOCATION; INSULIN STIMULATION; GROWTH-FACTORS	Neuregulin-1, a growth factor that potentiates myogenesis induces glucose transport through translocation of glucose transporters, in an additive manner to insulin, in muscle cells. In this study, we examined the signaling pathway required for a recombinant active neuregulin-1 isoform (rhHeregulin-beta(1), 177-244, HRG) to stimulate glucose uptake in L6E9 myotubes. The stimulatory effect of HRG required binding to ErbB3 in L6E9 myotubes. PI3K activity is required for HRG action in both muscle cells and tissue. In L6E9 myotubes, HRG stimulated PKBalpha, PKBgamma, and PKCzeta activities. TPCK, an inhibitor of PDK1, abolished both HRG- and insulin-induced glucose transport. To assess whether PKB was necessary for the effects of HRG on glucose uptake, cells were infected with adenoviruses encoding dominant negative mutants of PKBalpha. Dominant negative PKB reduced PKB activity and insulin-stimulated glucose transport but not HRG- induced glucose transport. In contrast, transduction of L6E9 myotubes with adenoviruses encoding a dominant negative kinase-inactive PKCzeta abolished both HRG- and insulin-stimulated glucose uptake. In soleus muscle, HRG induced PKCzeta, but not PKB phosphorylation. HRG also stimulated the activity of p70S6K, p38MAPK, and p42/p44MAPK and inhibition of p42/p44MAPK partially repressed HRG action on glucose uptake. HRG did not affect AMPKalpha(1) or AMPKalpha(2) activities. In all, HRG stimulated glucose transport in muscle cells by activation of a pathway that requires PI3K, PDK1, and PKCzeta, but not PKB, and that shows cross-talk with the MAPK pathway. The PI3K, PDK1, and PKCzeta pathway can be considered as an alternative mechanism, independent of insulin, to induce glucose uptake.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Parc Cient Barcelona, E-08028 Barcelona, Spain; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; UCL, Dept Biochem, London WC1E 6BT, England; Hammersmith Hosp, Imperial Coll Med, Sch Med, MRC,Clin Sci Ctr,Cellular Stress Grp, London W12 0NN, England	University of Barcelona; University of Barcelona; University of Dundee; University of London; University College London; Imperial College London	Zorzano, A (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	azorzano@bio.ub.es	Lizcano, Jose M/E-6080-2010; Zorzano, Antonio/R-5479-2018; Gumà, Anna/C-5165-2017; lizcano, jose m/AAK-3577-2020; Bertran, Joan/AAT-3145-2021; Palacín, Manuel/G-9786-2015; Carling, David/F-1943-2014	Lizcano, Jose M/0000-0002-3154-5383; Gumà, Anna/0000-0001-9390-5252; lizcano, jose m/0000-0002-3154-5383; Bertran, Joan/0000-0002-4276-336X; Carling, David/0000-0002-2316-1830; Canto, Carles/0000-0002-5167-7922; Palacin, Manuel/0000-0002-8670-293X	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Bandyopadhyay G, 2002, J CLIN ENDOCR METAB, V87, P716, DOI 10.1210/jc.87.2.716; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Baynes KCR, 2000, DIABETOLOGIA, V43, P321, DOI 10.1007/s001250050050; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; HAN AH, 2002, DIABETOLOGIA, V45, P1475; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lebrasseur NK, 2003, AM J PHYSIOL-CELL PH, V284, pC1149, DOI 10.1152/ajpcell.00487.2002; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Suarez E, 2001, J BIOL CHEM, V276, P18257, DOI 10.1074/jbc.M008100200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Talukder AH, 2000, CANCER RES, V60, P474; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Trinidad JC, 2000, J NEUROSCI, V20, P8762; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wojtaszewski JFP, 1999, AM J PHYSIOL-ENDOC M, V277, pE724, DOI 10.1152/ajpendo.1999.277.4.E724; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x; Zorzano A, 2003, CELL SIGNAL, V15, P141, DOI 10.1016/S0898-6568(02)00081-5	62	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12260	12268		10.1074/jbc.M308554200	http://dx.doi.org/10.1074/jbc.M308554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711829	hybrid			2022-12-27	WOS:000220334900032
J	Wakabayashi, H; Freas, J; Zhou, Q; Fay, PJ				Wakabayashi, H; Freas, J; Zhou, Q; Fay, PJ			Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIII; A2 SUBUNIT; CALCIUM-BINDING; COPPER IONS; LIGHT-CHAIN; FACTOR IXA; FACTOR VA; IDENTIFICATION; CLEAVAGE; RECONSTITUTION	Generation of factor VIII cofactor activity requires divalent metal ions such as Ca2+ or Mn2+. Evaluation of cofactor reconstitution from isolated factor VIIIa subunits revealed the presence of a functional Ca2+ binding site within the A1 subunit. Isothermal titration calorimetry demonstrated at least two Ca2+ binding sites of similar affinity (K-d=0.74 muM) within the A1 subunit. Mutagenesis of an acidic residue-rich region in the A1 domain (residues 110-126) homologous to a putative Ca2+ binding site in factor V (Zeibdawi, A. R., and Pryzdial, E. L. (2001) J. Biol. Chem. 276, 19929-19936) and expression of B-domainless factor VIII molecules yielded reagents to probe Ca2+ and Mn2+ binding in a functional assay. Basal activity observed for wild type factor VIII in a metal ion-free buffer was enhanced similar to2-fold with saturating Ca2+ or Mn2+ and yielded functional K-d values of 1.2 and 1.40 muM, respectively. Ca2+ binding affinity was greatly reduced (or lost) in several mutants including E110A, E110D, D116A, E122A, D125A, and D126A. Alternatively, E113A, D115A, and E124A showed wild type-like activity with little or no reduction in Ca2+ affinity. However, Mn2+ affinity was minimally altered except for mutant D125A (and D116A). These results are consistent with region 110-126 serving a critical role for Ca2+ coordination with selected residues capable of contributing to a partially overlapping site for Mn2+, and that occupancy of either site is required for maximal cofactor activity.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	philip_fay@urmc.rochester.edu			NHLBI NIH HHS [HL 30616, HL 38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ababou A, 2001, BIOCHEMISTRY-US, V40, P12719, DOI 10.1021/bi010405b; Anderson PJ, 1997, BIOCHEMISTRY-US, V36, P11648, DOI 10.1021/bi9709598; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; Bertini I., 2001, HDB METALLOPROTEINS; BIHOREAU N, 1994, EUR J BIOCHEM, V222, P41, DOI 10.1111/j.1432-1033.1994.tb18839.x; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DAVIS J, 1995, COURTS COMMUNITIES C, V1, P6; ESMON CT, 1979, J BIOL CHEM, V254, P964; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; Lollar P, 1995, ADV EXP MED BIOL, V386, P3; MEANS AR, 1995, ADV 2 MESSENGER PHOS, V30, P89; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; Sudhakar K, 1998, BIOCHEMISTRY-US, V37, P6874, DOI 10.1021/bi980084c; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRIGOGONZALEZ G, 1993, BIOCHEMISTRY-US, V32, P9826, DOI 10.1021/bi00088a038; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wakabayashi H, 2001, BIOCHEMISTRY-US, V40, P10293, DOI 10.1021/bi010353q; Wakabayashi H, 2003, BIOCHEMISTRY-US, V42, P145, DOI 10.1021/bi026430e; Wakabayashi H, 2002, BIOCHEMISTRY-US, V41, P8485, DOI 10.1021/bi025589o; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Zeibdawi AR, 2004, BIOCHEM J, V377, P141, DOI 10.1042/BJ20031205; Zeibdawi AR, 2001, J BIOL CHEM, V276, P19929, DOI 10.1074/jbc.M004711200	41	44	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12677	12684		10.1074/jbc.M311042200	http://dx.doi.org/10.1074/jbc.M311042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722121	hybrid			2022-12-27	WOS:000220334900081
J	Brautigam, CA; Chelliah, Y; Deisenhofer, J				Brautigam, CA; Chelliah, Y; Deisenhofer, J			Tetramerization and ATP binding by a protein comprising the A, B, and C domains of rat synapsin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; GLUTATHIONE SYNTHETASE; NEUROTRANSMITTER RELEASE; CRYSTAL-STRUCTURES; FLEXIBLE LOOP; KINASE; LIGASE; COEFFICIENT; CALCIUM; ENZYMES	Synapsins are multidomain proteins that are critical for regulating neurotransmitter release in vertebrates. In the present study, two crystal structures of the C domain of rat synapsin I (rSynI-C) in complex with Ca2+ and ATP reveal that this protein can form a tetramer and that a flexible loop ( the "multifunctional loop") contacts bound ATP. Further experiments were carried out on a protein comprising the A, B, and C domains of rat synapsin I (rSynI-ABC). An ATP-stabilized tetramer of rSynI-ABC is observed during velocity sedimentation and size-exclusion chromatographic experiments. These hydrodynamic results also indicate that the A and B domains exist in an extended conformation. Calorimetric measurements of ATP binding to wild-type and mutant rSynI-ABC demonstrate that the multifunctional loop and a cross-tetramer contact are important for ATP binding. The evidence supports a view of synapsin I as an ATP-utilizing, tetrameric protein made up of monomers that have a flexible, extended N terminus.	Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.	Johann.Deisenhofer@UTSouthwestern.edu		Brautigam, Chad/0000-0001-6563-1338				Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; Feng J, 2002, J NEUROSCI, V22, P4372, DOI 10.1523/JNEUROSCI.22-11-04372.2002; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gushima H, 1983, J Appl Biochem, V5, P210; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; Harrington W F, 1973, Methods Enzymol, V27, P306; Hibi T, 1996, NAT STRUCT BIOL, V3, P16, DOI 10.1038/nsb0196-16; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Hosaka M, 1998, J BIOL CHEM, V273, P13371, DOI 10.1074/jbc.273.22.13371; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; Tanaka T, 1997, ARCH BIOCHEM BIOPHYS, V339, P151, DOI 10.1006/abbi.1996.9821; Thoden JB, 2002, J BIOL CHEM, V277, P23898, DOI 10.1074/jbc.M202251200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSIEN RY, 1988, TRENDS NEUROSCI, V11, P419, DOI 10.1016/0166-2236(88)90192-0; VENDER AJ, 1990, HUMAN PHYSL, P108; Wang CR, 1997, PROTEIN SCI, V6, P2264	46	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11948	11956		10.1074/jbc.M312015200	http://dx.doi.org/10.1074/jbc.M312015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688264	hybrid			2022-12-27	WOS:000220157600132
J	Caviglia, JM; Li, LO; Wang, SL; DiRusso, CC; Coleman, RA; Lewin, TM				Caviglia, JM; Li, LO; Wang, SL; DiRusso, CC; Coleman, RA; Lewin, TM			Rat long chain acyl-CoA synthetase 5, but not 1, 2, 3, or 4, complements Escherichia coli fadD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSPORT; PROTEIN N-MYRISTOYLATION; COENZYME-A SYNTHETASE; SACCHAROMYCES-CEREVISIAE; SIGNATURE MOTIF; PLASMA-MEMBRANE; TRIACSIN-C; EXPRESSION; GENE; METABOLISM	Long chain fatty acids are converted to acyl-CoAs by acyl-CoA synthetase ( fatty acid CoA ligase: AMP forming, E. C. 6.2.1.3; ACS). Escherichia coli has a single ACS, FadD, that is essential for growth when fatty acids are the sole carbon and energy source. Rodents have five ACS isoforms that differ in substrate specificity, tissue expression, and subcellular localization and are believed to channel fatty acids toward distinct metabolic pathways. We expressed rat ACS isoforms 1 - 5 in an E. coli strain that lacked FadD. All rat ACS isoforms were expressed in E. coli fadD or fadDfadR and had ACS specific activities that were 1.6-20-fold higher than the wild type control strain expressing FadD. In the fadD background, the rat ACS isoforms 1, 2, 3, 4 and 5 oxidized [C-14] oleate at 5 to 25% of the wild type levels, but only ACS5 restored growth on oleate as the sole carbon source. To ensure that enzymes of beta-oxidation were not limiting, assays of ACS activity, beta-oxidation, fatty acid transport, and phospholipid synthesis were also examined in a fadD fadR strain, thereby eliminating FadR repression of the transporter FadL and the enzymes of beta-oxidation. In this strain, fatty acid transport levels were low but detectable for ACS1, 2, 3, and 4 and were nearly 50% of wild type levels for ACS5. Despite increases in beta-oxidation, only ACS5 transformants were able to grow on oleate. These studies show that although ACS isoforms 1 - 4 variably supported moderate transport activity, beta-oxidation, and phospholipid synthesis and although their in vitro specific activities were greater than that of chromosomally encoded FadD, they were unable to substitute functionally for FadD regarding growth. Thus, membrane composition and protein-protein interactions may be critical in reconstituting bacterial ACS function.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Ordway Res Inst Inc, Albany, NY 12208 USA	University of North Carolina; University of North Carolina Chapel Hill; Ordway Research Institute	Lewin, TM (corresponding author), Univ N Carolina, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	tal_lewin@unc.edu	DiRusso, Concetta C/M-1884-2014; Li, Lei/B-5164-2010	DiRusso, Concetta/0000-0001-7388-9152	NIDDK NIH HHS [DK59935, DK59931] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059931, R01DK059935] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cho YY, 2000, BIOCHEM BIOPH RES CO, V274, P741, DOI 10.1006/bbrc.2000.3207; Cho YY, 2001, BIOCHEM BIOPH RES CO, V284, P993, DOI 10.1006/bbrc.2001.5065; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; COLEMAN RA, 1983, ENZYMES, V16, P605; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Gargiulo CE, 1999, J LIPID RES, V40, P881; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kansara MS, 1996, AM J PHYSIOL-ENDOC M, V270, pE873, DOI 10.1152/ajpendo.1996.270.5.E873; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; Lewin TM, 2002, ARCH BIOCHEM BIOPHYS, V404, P263, DOI 10.1016/S0003-9861(02)00247-3; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Longo I, 2003, J MED GENET, V40, P11, DOI 10.1136/jmg.40.1.11; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Meloni I, 2002, NAT GENET, V30, P436, DOI 10.1038/ng857; Miller J. H., 1972, EXPT MOL GENETICS, P431; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; OVERATH P, 1967, BIOCHEM BIOPH RES CO, V29, P28, DOI 10.1016/0006-291X(67)90535-9; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; ROCK CO, 1985, J BIOL CHEM, V260, P2720; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; WU XJ, 1994, J BIOL CHEM, V269, P12375	46	22	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11163	11169		10.1074/jbc.M311392200	http://dx.doi.org/10.1074/jbc.M311392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711823	Green Published, hybrid			2022-12-27	WOS:000220157600041
J	Hazra, S; Xiong, SG; Wang, JH; Rippe, RA; Chatterjee, VKK; Tsukamoto, H				Hazra, S; Xiong, SG; Wang, JH; Rippe, RA; Chatterjee, VKK; Tsukamoto, H			Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SMOOTH-MUSCLE CELLS; NF-KAPPA-B; PPAR-GAMMA; RAT-LIVER; DNA-BINDING; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; TISSUE INHIBITOR; EXPRESSION	Depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) accompanies myofibroblastic transdifferentiation of hepatic stellate cells (HSC), the primary cellular event underlying liver fibrogenesis. The treatment of activated HSC in vitro or in vivo with synthetic PPARgamma ligands suppresses the fibrogenic activity of HSC. However, it is uncertain whether PPARgamma is indeed a molecular target of this effect, because the ligands are also known to have receptor-independent actions. To test this question, the present study examined the effects of forced expression of PPARgamma via an adenoviral vector on morphologic and biochemical features of culture-activated HSC. The vector-mediated expression of PPARgamma itself is sufficient to reverse the morphology of activated HSC to the quiescent phenotype with retracted cytoplasm, prominent dendritic processes, reduced stress fibers, and accumulation of retinyl palmitate. These effects are abrogated by concomitant expression of a dominant negative mutant of PPARgamma that prevents transactivation of but not binding to the PPAR response element. PPARgamma expression also inhibits the activation markers such as the expression of alpha-smooth muscle actin, type I collagen, and transforming growth factor beta1; DNA synthesis; and JunD binding to the activator protein-1 (AP-1) site and AP-1 promoter activity. Inhibited JunD activity by PPARgamma is not due to reduced JunD expression or JNK activity or to a competition for p300. But it is due to a JunD-PPARgamma interaction as demonstrated by co-immunoprecipitation and glutathione S-transferase pull-down analysis. Further, the use of deletion constructs reveals that the DNA binding region of PPARgamma is the JunD interaction domain. In summary, our results demonstrate that the restoration of PPARgamma reverses the activated HSC to the quiescent phenotype and suppresses AP-1 activity via a physical interaction between PPARgamma and JunD.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA 90073 USA	University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, 1333 San Pablo St,MMR-402, Los Angeles, CA 90089 USA.	htsukamo@usc.edu		Chatterjee, Vengalil Krishna/0000-0002-2654-8854	NIAAA NIH HHS [R37AA06603, R24AA12885, P50AA11999] Funding Source: Medline; NIDDK NIH HHS [P30DK48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R24AA012885, P50AA011999, R37AA006603] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BHAT PV, 1983, J CHROMATOGR, V272, P269, DOI 10.1016/S0378-4347(00)86129-0; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Buck M, 2000, AM J PHYSIOL-GASTR L, V278, pG321, DOI 10.1152/ajpgi.2000.278.2.G321; Cassiman D, 1999, AM J PATHOL, V155, P1831, DOI 10.1016/S0002-9440(10)65501-0; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, pG947, DOI 10.1152/ajpgi.1993.264.5.G947; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; Gressner AM, 1996, KIDNEY INT, V49, pS39; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Knittel T, 1999, AM J PATHOL, V154, P153, DOI 10.1016/S0002-9440(10)65262-5; Kojima S, 2000, BLOOD, V95, P1309; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; Mann DA, 2002, GUT, V50, P891, DOI 10.1136/gut.50.6.891; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Neubauer K, 1996, J HEPATOL, V24, P719, DOI 10.1016/S0168-8278(96)80269-8; Niki T, 1999, HEPATOLOGY, V29, P520, DOI 10.1002/hep.510290232; Ohata M, 1997, AM J PHYSIOL-GASTR L, V272, pG589, DOI 10.1152/ajpgi.1997.272.3.G589; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sugawara A, 2002, J BIOL CHEM, V277, P9676, DOI 10.1074/jbc.M104560200; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Vincent KJ, 2001, GUT, V49, P713, DOI 10.1136/gut.49.5.713; Xiong SG, 2001, HEPATOLOGY, V34, p520A; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609	44	251	265	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11392	11401		10.1074/jbc.M310284200	http://dx.doi.org/10.1074/jbc.M310284200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702344	Green Published, hybrid			2022-12-27	WOS:000220157600069
J	Mylonis, I; Drosou, V; Brancorsini, S; Nikolakaki, E; Sassone-Corsi, P; Giannakouros, T				Mylonis, I; Drosou, V; Brancorsini, S; Nikolakaki, E; Sassone-Corsi, P; Giannakouros, T			Temporal association of protamine 1 with the inner nuclear membrane protein lamin B receptor during spermiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE METHOD; RNA-BINDING; KINASE; PHOSPHORYLATION; RAT; IDENTIFICATION; LOCALIZATION; QUANTITATION; EXPRESSION; CHROMATIN	During mammalian spermiogenesis, histones are replaced by transition proteins, which are in turn replaced by protamines P1 and P2. P1 protamine contains a short arginine/serine-rich (RS) domain that is highly phosphorylated before being deposited into sperm chromatin and almost completely dephosphorylated during sperm maturation. We now demonstrate that, in elongating spermatids, this phosphorylation is required for the temporal association of P1 protamine with lamin B receptor (LBR), an inner nuclear membrane protein that also possesses a stretch of RS dipeptides at its nucleoplasmic NH2-terminal domain. Previous studies have shown that the cellular protein p32 also binds tightly to the unmodified RS domain of LBR. Extending those findings, we now present evidence that p32 prevents phosphorylation of LBR and furthermore that dissociation of this protein precedes P1 protamine association. Our data suggest that docking of protamine 1 to the nuclear envelope is an important intermediate step in spermiogenesis and reveal a novel role for SR protein kinases and p32.	Aristotle Univ Thessaloniki, Dept Chem, Biochem Lab, Thessaloniki 54124, Greece; Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Aristotle University of Thessaloniki; Institut National de la Sante et de la Recherche Medicale (Inserm)	Giannakouros, T (corresponding author), Aristotle Univ Thessaloniki, Dept Chem, Biochem Lab, GR-54006 Thessaloniki, Greece.	giannako@chem.auth.gr	Sassone-Corsi, Paolo/H-6182-2011; Brancorsini, Stefano/L-8770-2015; GIANNAKOUROS, THOMAS/R-3204-2019	Brancorsini, Stefano/0000-0002-8410-7248; Mylonis, Ilias/0000-0002-0893-6618				Alsheimer M, 1998, J CELL SCI, V111, P2227; BIGGIOGERA M, 1992, MICROSC RES TECHNIQ, V20, P259, DOI 10.1002/jemt.1070200305; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; CHIRAT F, 1993, BIOCHIM BIOPHYS ACTA, V1203, P109, DOI 10.1016/0167-4838(93)90043-Q; Erez O, 2001, MOL CELL BIOL, V21, P175, DOI 10.1128/MCB.21.1.175-184.2001; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Kuroyanagi H, 2000, MECH DEVELOP, V99, P51, DOI 10.1016/S0925-4773(00)00477-9; Lewis JD, 2003, CHROMOSOMA, V111, P473, DOI 10.1007/s00412-002-0226-0; MARUSHIGE Y, 1978, BIOCHIM BIOPHYS ACTA, V518, P440, DOI 10.1016/0005-2787(78)90162-4; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Nikolakaki E, 2001, J BIOL CHEM, V276, P40175, DOI 10.1074/jbc.M104755200; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; Papoutsopoulou S, 1999, NUCLEIC ACIDS RES, V27, P2972, DOI 10.1093/nar/27.14.2972; Papoutsopoulou S, 1999, BIOCHEM BIOPH RES CO, V255, P602, DOI 10.1006/bbrc.1999.0249; PARVINEN M, 1972, ANAT REC, V174, P435, DOI 10.1002/ar.1091740404; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Raukas E, 1999, BIOESSAYS, V21, P440, DOI 10.1002/(SICI)1521-1878(199905)21:5<440::AID-BIES11>3.0.CO;2-V; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	32	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11626	11631		10.1074/jbc.M311949200	http://dx.doi.org/10.1074/jbc.M311949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701833	hybrid			2022-12-27	WOS:000220157600096
J	Robu, ME; Inman, RB; Cox, MM				Robu, ME; Inman, RB; Cox, MM			Situational repair of replication forks - Roles of RecG and RecA proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECG; DOUBLE-STRAND BREAKS; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; PARTIAL DENATURATION; NUCLEOTIDE-SEQUENCE; ADAPTIVE MUTATION; ATP HYDROLYSIS; DNA-REPAIR; RECOMBINATION	Replication forks often stall or collapse when they encounter a DNA lesion. Fork regression is part of several major paths to the repair of stalled forks, allowing nonmutagenic bypass of the lesion. We have shown previously that Escherichia coli RecA protein can promote extensive regression of a forked DNA substrate that mimics a possible structure of a replication fork stalled at a leading strand lesion. Using electron microscopy and gel electrophoresis, we demonstrate that another protein, E. coli RecG helicase, promotes extensive fork regression in the same system. The RecG-catalyzed fork regression is very efficient and faster than the RecA-promoted reaction (up to 240 bp s(-1)), despite very limited processivity of the RecG protein. The reaction is dependent upon ATP hydrolysis and is stimulated by single-stranded binding protein. The RecA- and RecG-promoted reactions are not synergistic. In fact, RecG functions poorly under the conditions optimal for the RecA reaction, and vice versa. When both RecA and RecG proteins are incubated with the DNA substrate, high RecG concentrations inhibit the RecA protein-promoted fork regression. The very different reaction profiles may reflect a situational application of these proteins to the rescue of stalled replication forks in vivo.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; Bolt EL, 2002, MOL CELL, V10, P187, DOI 10.1016/S1097-2765(02)00560-9; Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; EDLHOCH H, 1948, BIOCHEMISTRY-US, V6, P1948; Foster PL, 1996, GENETICS, V142, P25; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Harris RS, 1996, GENETICS, V142, P681; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; HONG XK, 1995, EMBO J, V14, P2385, DOI 10.1002/j.1460-2075.1995.tb07233.x; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; Jaktaji RP, 2003, MOL MICROBIOL, V47, P1091, DOI 10.1046/j.1365-2958.2003.03357.x; KALMAN M, 1992, GENE, V110, P95, DOI 10.1016/0378-1119(92)90449-Y; Layton JC, 2003, MOL MICROBIOL, V50, P549, DOI 10.1046/j.1365-2958.2003.03704.x; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Mahdi AA, 2003, EMBO J, V22, P724, DOI 10.1093/emboj/cdg043; Maisnier-Patin S, 2001, MOL MICROBIOL, V42, P1371, DOI 10.1046/j.1365-2958.2001.02718.x; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; McGlynn P, 2001, J BIOL CHEM, V276, P41938, DOI 10.1074/jbc.M107945200; McKenzie GJ, 2000, P NATL ACAD SCI USA, V97, P6646, DOI 10.1073/pnas.120161797; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; PHILLIPS RC, 1966, J AM CHEM SOC, V88, P2631, DOI 10.1021/ja00964a002; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Seigneur M, 2000, MOL MICROBIOL, V38, P565, DOI 10.1046/j.1365-2958.2000.02152.x; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; SMITH KC, 1989, BIOESSAYS, V10, P12, DOI 10.1002/bies.950100104; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; XIAO H, 1991, J BIOL CHEM, V266, P5980	63	49	51	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10973	10981		10.1074/jbc.M312184200	http://dx.doi.org/10.1074/jbc.M312184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701860	hybrid			2022-12-27	WOS:000220157600019
J	Shiflett, SL; Ward, DM; Huynh, D; Vaughn, MB; Simmons, JC; Kaplan, J				Shiflett, SL; Ward, DM; Huynh, D; Vaughn, MB; Simmons, JC; Kaplan, J			Characterization of Vta1p, a class E Vps protein in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIVESICULAR-BODY; YEAST; COMPLEX; ENDOSOME; UBIQUITIN; PATHWAY; TRANSPORT; MEMBRANE; CHITIN; ENDOCYTOSIS	We identified VTA1 in a screen for mutations that result in altered vacuole morphology. Deletion of VTA1 resulted in delayed trafficking of the lipophilic dye FM4-64 to the vacuole and altered vacuolar morphology when cells were exposed to the dye 5-(and 6)-carboxy-2',7'-dichlorofluorescein diacetate (CDCFDA). Deletion of class E vacuolar protein sorting (VPS) genes, which encode proteins that affect multivesicular body formation, also showed altered vacuolar morphology upon exposure to high concentrations of CDCFDA. These results suggest a VPS defect for Deltavta1 cells. Deletion of VTA1 did not affect growth on raffinose and only mildly affected carboxypeptidase S sorting. Turnover of the surface protein Ste3p, the a-factor receptor, was affected in Deltavta1 cells with the protein accumulating on the vacuolar membrane. Likewise the alpha-factor receptor Ste2p accumulated on the vacuolar membrane in Deltavta1 cells. We demonstrated that many class E VPS deletion strains are hyper-resistant to the cell wall disruption agent calcofluor white. Deletion of VTA1 or VPS60, another putative class E gene, resulted in calcofluor white hypersensitivity. A Vta1p-green fluorescent protein fusion protein transiently associated with a Pep12p-positive compartment. This localization was altered by deletion of many of the class E VPS genes, indicating that Vta1p binds to endosomes in a manner dependent on the assembly of the endosomal sorting complexes required for transport. Membrane-associated Vta1p co-purified with Vps60p, suggesting that Vta1p is a class E Vps protein that interacts with Vps60p on a prevacuolar compartment.	Univ Utah, Hlth Sci Ctr, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29622] Funding Source: Medline; NIGMS NIH HHS [5T32GM07464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Brachmann CB, 1998, YEAST, V14, P115; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kranz A, 2001, MOL BIOL CELL, V12, P711, DOI 10.1091/mbc.12.3.711; Lussier M, 1997, GENETICS, V147, P435; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Valdivia RH, 2003, P NATL ACAD SCI USA, V100, P10287, DOI 10.1073/pnas.1834246100; Valdivieso MH, 2000, J BACTERIOL, V182, P4752, DOI 10.1128/JB.182.17.4752-4757.2000; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751	27	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10982	10990		10.1074/jbc.M312669200	http://dx.doi.org/10.1074/jbc.M312669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701806	hybrid			2022-12-27	WOS:000220157600020
J	Yung, TMC; Parent, M; Ho, ELY; Satoh, MS				Yung, TMC; Parent, M; Ho, ELY; Satoh, MS			Camptothecin-sensitive relaxation of supercoiled DNA by the topoisomerase I-like activity associated with poly(ADP-ribose) polymerase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGASE-III; AUTOMODIFICATION DOMAIN; APOPTOTIC FRAGMENT; CELLULAR-RESPONSES; EXCISION-REPAIR; ADP-RIBOSE; TRANSCRIPTION; DAMAGE; CELLS; IDENTIFICATION	Poly( ADP-ribose) polymerase-1 is a highly abundant nuclear enzyme implicated in transcription, DNA replication, and DNA repair through binding of nascent RNA and interactions with various factors. We found that purified fractions of recombinant human poly(ADP-ribose) polymerase-1 expressed in Escherichia coli possess yet another activity, a Mg2+-dependent DNA super-coil relaxation activity. Cleavage of recombinant poly(ADP-ribose) polymerase-1 by caspase-3, an apoptotic protease, reduced this activity, as did the removal of either of the two zinc finger motifs located in the N-terminal DNA-binding domain of poly( ADP-ribose) polymerase-1. In addition, this activity was separated from E. coli topoisomerase I by gel-filtration column chromatography, suggesting that this activity is specifically associated with poly( ADP-ribose) polymerase-1. Because this relaxation activity did not require ATP and was resistant to VP16, a topoisomerase II inhibitor, this activity is closer to that of topoisomerase I. However, the supercoiled DNA relaxation activity associated with poly( ADP-ribose) polymerase-1 is distinct from that of human or E. coli topoisomerase I, as this activity could not completely remove superhelical tensions from plasmid DNA. Thus, we referred to this activity as topoisomerase I-like activity. This Mg2+-dependent DNA supercoil relaxation activity was found to be sensitive to camptothecin, a mammalian topoisomerase I inhibitor.	Univ Laval, Fac Med, Ctr Hosp Univ Quebec,Laval Unv Med Ctr, DNA Repair Grp,Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada	Laval University	Satoh, MS (corresponding author), Univ Laval, Fac Med, Ctr Hosp Univ Quebec,Laval Unv Med Ctr, DNA Repair Grp,Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada.	Masahiko.sato@crchul.ulaval.ca						Affar EB, 1999, MOL CELL BIOCHEM, V193, P127, DOI 10.1023/A:1006984715891; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; ATTARDI DG, 1981, J BIOL CHEM, V256, P3654; Bauer PI, 2000, INT J MOL MED, V5, P533; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; DARPA P, 1990, CANCER RES, V50, P6919; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JONGSTRABILEN J, 1983, EUR J BIOCHEM, V136, P391, DOI 10.1111/j.1432-1033.1983.tb07754.x; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; YOSHIDA S, 1994, MOL CELL BIOCHEM, V138, P39, DOI 10.1007/BF00928441; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200	42	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11992	11999		10.1074/jbc.M312459200	http://dx.doi.org/10.1074/jbc.M312459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715657	hybrid			2022-12-27	WOS:000220157600137
J	Ahn, S; Wei, HJ; Garrison, TR; Lefkowitz, RJ				Ahn, S; Wei, HJ; Garrison, TR; Lefkowitz, RJ			Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; CLATHRIN ADAPTER; ENDOCYTOSIS; INTERNALIZATION; SCAFFOLD; TYROSINE; 1A	beta-Arrestin2 not only plays essential roles in seven membrane-spanning receptor desensitization and internalization but also functions as a signal transducer in mitogen-activated protein kinase cascades. Here we show that the angiotensin II type 1A receptor-mediated activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HEK-293 cells is increased when the cellular level of beta-arrestin1 is down-regulated by RNA interference but is decreased or eliminated when the cellular level of beta-arrestin2 is diminished. Such reciprocal effects of down-regulated levels of beta-arrestins 1 and 2 are primarily due to differences in the ability of the two forms of beta-arrestins to directly mediate ERK activation. These results are the first to demonstrate reciprocal activity of beta-arrestin isoforms on a signaling pathway and suggest that physiological levels of beta-arrestin1 may act as "dominant-negative" inhibitors of beta-arrestin2-mediated ERK activation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med & Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [R01 HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goel R, 2002, ANN NY ACAD SCI, V973, P138, DOI 10.1111/j.1749-6632.2002.tb04622.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	30	141	148	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7807	7811		10.1074/jbc.C300443200	http://dx.doi.org/10.1074/jbc.C300443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14711824	hybrid			2022-12-27	WOS:000189103300055
J	Novitskiy, G; Potter, JJ; Rennie-Tankersley, L; Mezey, E				Novitskiy, G; Potter, JJ; Rennie-Tankersley, L; Mezey, E			Identification of a novel NF-kappa B-binding site with regulation of the murine alpha(2)(I) collagen promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE GENE; ALPHA-1(I) COLLAGEN GENE; HEPATIC STELLATE CELLS; GROWTH-FACTOR-BETA; NUCLEAR FACTOR-I; KUPFFER CELLS; ACETALDEHYDE; ACTIVATION; TRANSCRIPTION; EXPRESSION	Hepatic fibrosis is due to the increased synthesis and deposition of type I collagen. Acetaldehyde activates type I collagen promoters. Nuclear factor kappaB (NF-kappaB) was previously shown to inhibit expression of murine alpha(1)(I) and human alpha(2)(I) collagen promoters. The present study identifies binding of NF-kappaB, present in nuclear extracts of stellate cells, to a region between -553 and -537 of the murine alpha(2)(I) collagen promoter. The NF-kappaB (p65) expression vector inhibited promoter activity. Mutation of the promoter at the NF-kappaB-binding site increased basal promoter activity and abrogated the activating and inhibitory effects of transforming growth factor beta and tumor necrosis factor alpha, respectively, on promoter activity. Acetaldehyde increased IkappaB-alpha kinase activity and phosphorylated IkappaB-alpha, NF-kappaB nuclear protein, and its binding to the promoter. However, the activating effect of acetaldehyde was not affected by the mutation of the promoter. In conclusion, although acetaldehyde increases the binding of NF-kappaB to the murine alpha(2)(I) collagen promoter, this binding does not mediate the activating effect of acetaldehyde on promoter activity. The effects of acetaldehyde in increasing the translocation of NF-kappaB to the nucleus with increased DNA binding activity may be important in mediating the effects of acetaldehyde on other genes.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Mezey, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 921 Ross Res Bldg, Baltimore, MD 21205 USA.	emezey@jhmi.edu			NIAAA NIH HHS [AA00626] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA000626] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; Anania FA, 1996, ARCH BIOCHEM BIOPHYS, V331, P187, DOI 10.1006/abbi.1996.0297; Attard FA, 2001, DNA CELL BIOL, V20, P455, DOI 10.1089/104454901316976082; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRENNER DA, 1993, HEPATOLOGY, V17, P287, DOI 10.1016/0270-9139(93)90090-A; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; Chen A, 2002, BIOCHEM J, V368, P683, DOI 10.1042/BJ20020949; Cheon H, 2002, CLIN EXP IMMUNOL, V127, P547, DOI 10.1046/j.1365-2249.2002.01785.x; DECROMBRUGGHE B, 1990, ANN NY ACAD SCI, V580, P88, DOI 10.1111/j.1749-6632.1990.tb17921.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN SL, 1990, SEMIN LIVER DIS, V10, P20, DOI 10.1055/s-2008-1040454; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLT K, 1984, HEPATOLOGY, V4, P843, DOI 10.1002/hep.1840040508; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; Jokelainen K, 1998, BIOCHEM BIOPH RES CO, V253, P834, DOI 10.1006/bbrc.1998.9863; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kouba DJ, 1999, J IMMUNOL, V162, P4226; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miao K, 1999, ARCH BIOCHEM BIOPHYS, V361, P7, DOI 10.1006/abbi.1998.0977; Miao K, 1997, ARCH BIOCHEM BIOPHYS, V341, P140, DOI 10.1006/abbi.1997.9948; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Potter JJ, 2001, ARCH BIOCHEM BIOPHYS, V391, P41, DOI 10.1006/abbi.2001.2393; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P246, DOI 10.1016/0003-9861(91)90356-N; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	35	30	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15639	15644		10.1074/jbc.M311499200	http://dx.doi.org/10.1074/jbc.M311499200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722113	hybrid			2022-12-27	WOS:000220594700136
J	Kawamoto, Y; Takeda, K; Okuno, Y; Yamakawa, Y; Ito, Y; Taguchi, R; Kato, M; Suzuki, H; Takahashi, M; Nakashima, I				Kawamoto, Y; Takeda, K; Okuno, Y; Yamakawa, Y; Ito, Y; Taguchi, R; Kato, M; Suzuki, H; Takahashi, M; Nakashima, I			Identification of RET autophosphorylation sites by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; INSULIN-RECEPTOR; SRC KINASE; NEUROTROPHIC FACTOR; PROTEIN-KINASE; DOCKING SITE; SIGNAL-TRANSDUCTION; NEURONAL SURVIVAL; CRYSTAL-STRUCTURE; IN-VIVO	The catalytic and signaling activities of RET, a receptor-type tyrosine kinase, are regulated by the autophosphorylation of several tyrosine residues in the cytoplasmic region of RET. Some studies have revealed a few possible autophosphorylation sites of RET by [P-32] phosphopeptide mapping or by using specific anti-phosphotyrosine antibodies. To ultimately identify these and other autophosphorylation sites of RET, we performed mass spectrometry analysis of an originally prepared RET recombinant protein. Both the autophosphorylation and kinase activity of myelin basic protein as an external substrate of the recombinant RET protein were substantially elevated in the presence of ATP without stimulation by a glial cell line-derived neurotrophic factor, a natural ligand for RET. Mass spectrometric analysis revealed that RET Tyr(806), Tyr(809), Tyr(900), Tyr(905), Tyr(981), Tyr(1062), Tyr(1090), and Tyr(1096) were autophosphorylation sites. Levels of autophosphorylation and kinase activity of RET-MEN2A ( multiple endocrine neoplasia 2A), a constitutively active form of RET with substitution of Tyr900 by phenylalanine (Y900F), were comparable with those of original RET-MEN2A, whereas those of the mutant Y905F were greatly decreased. Interestingly, those of a double mutant, Y900F/Y905F, were completely abolished. Both the kinase activity and transforming activity were impaired in the mutants Y806F and Y809F. These results provide convincing evidence for both previously suggested and new tyrosine autophosphorylation sites of RET as well as for novel functions of Tyr(806), Tyr(809), and Tyr(900) phosphorylation in both catalytic kinase activities and cell growth. The significance of the identified autophosphorylation sites in various protein-tyrosine kinases registered in a data base is discussed in this paper.	Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Equipment Ctr Res & Educ, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Grad Sch Med, Dept Metabolme, Bunkyo Ku, Tokyo, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Environm & Prevent Med, Kanazawa, Ishikawa 920, Japan	Nagoya University; Nagoya University; Nagoya University; University of Tokyo; Kanazawa University	Nakashima, I (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	inakashi@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; Okuno, Yusuke/C-9082-2009; 善之, 川本/GPT-3802-2022; TAKAHASHI, Masahide/I-7244-2014; KATO, Masashi/I-7250-2014	Takahashi, Masahide/0000-0002-2803-2683; Okuno, Yusuke/0000-0003-3139-9272; 				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, BIOCHEM BIOPH RES CO, V281, P682, DOI 10.1006/bbrc.2001.4338; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Kato M, 2002, CANCER RES, V62, P2414; Kato M, 1999, ONCOGENE, V18, P837, DOI 10.1038/sj.onc.1202329; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kato M, 2001, ONCOGENE, V20, P7536, DOI 10.1038/sj.onc.1204918; Kato M, 2000, ANTIOXID REDOX SIGN, V2, P841, DOI 10.1089/ars.2000.2.4-841; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Nakashima I, 2002, XI BIENNIAL MEETING OF THE SOCIETY FOR FREE RADICAL RESEARCH INTERNATIONAL, P229; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pu MY, 1996, J CELL BIOCHEM, V63, P104; Pu MY, 1996, ONCOGENE, V13, P2615; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Takeda K, 2001, ANTIOXID REDOX SIGN, V3, P473, DOI 10.1089/15230860152409103; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	65	62	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14213	14224		10.1074/jbc.M312600200	http://dx.doi.org/10.1074/jbc.M312600200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14711813	hybrid			2022-12-27	WOS:000220478500114
J	Choi, J; Levey, AI; Weintraub, ST; Rees, HD; Gearing, M; Chin, LS; Li, L				Choi, J; Levey, AI; Weintraub, ST; Rees, HD; Gearing, M; Chin, LS; Li, L			Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SULFOXIDE REDUCTASE; NEURODEGENERATIVE DISEASES; MODIFIED PROTEINS; IDENTIFICATION; STRESS; DEGENERATION; DEGRADATION; CATALYSIS; RESIDUES; NEURON	Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that occur either in relatively rare, familial forms or in common, sporadic forms. The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear. To gain insights into the pathogenic mechanisms involved in AD and PD, we used a proteomic approach to identify proteins with altered expression levels and/or oxidative modifications in idiopathic AD and PD brains. Here, we report that the protein level of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), a neuronal de-ubiquitinating enzyme whose mutation has been linked to an early-onset familial PD, is down-regulated in idiopathic PD as well as AD brains. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified three human brain UCH-L1 isoforms, a full-length form and two amino-terminally truncated forms. Our proteomic analyses reveal that the full-length UCH-L1 is a major target of oxidative damage in AD and PD brains, which is extensively modified by carbonyl formation, methionine oxidation, and cysteine oxidation. Furthermore, immunohistochemical studies show that prominent UCH-L1 immunostaining is associated with neurofibrillary tangles and that the level of soluble UCH-L1 protein is inversely proportional to the number of tangles in AD brains. Together, these results provide evidence supporting a direct link between oxidative damage to the neuronal ubiquitination/de-ubiquitination machinery and the pathogenesis of sporadic AD and PD.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Disorders, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Emory University; Emory University; Emory University; University of Texas System; University of Texas Health San Antonio	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Chin, Lih-Shen/0000-0002-0817-0368; Li, Lian/0000-0003-4700-1134	NCI NIH HHS [CA 54174] Funding Source: Medline; NIA NIH HHS [AG 10130, AG 021489] Funding Source: Medline; NIEHS NIH HHS [ES 12068] Funding Source: Medline; NINDS NIH HHS [NS 047199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG010130, R01AG021489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Choi JG, 2002, BIOCHEM BIOPH RES CO, V293, P1566, DOI 10.1016/S0006-291X(02)00420-5; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Conrad CC, 2001, PROTEOMICS, V1, P829, DOI 10.1002/1615-9861(200107)1:7<829::AID-PROT829>3.0.CO;2-R; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; GEARING M, 1995, NEUROLOGY, V45, P1985, DOI 10.1212/WNL.45.11.1985; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Layfield R, 2003, AGEING RES REV, V2, P343, DOI 10.1016/S1568-1637(03)00025-4; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; van Leeuwen FW, 2002, INT J BIOCHEM CELL B, V34, P1502, DOI 10.1016/S1357-2725(02)00043-2; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WU J, 1996, ALZHEIMERS RES, V2, P163	39	461	492	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13256	13264		10.1074/jbc.M314124200	http://dx.doi.org/10.1074/jbc.M314124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722078	hybrid			2022-12-27	WOS:000220334900148
J	Day, JM; Olin, AI; Murdoch, AD; Canfield, A; Sasaki, T; Timpl, R; Hardingham, TE; Aspberg, A				Day, JM; Olin, AI; Murdoch, AD; Canfield, A; Sasaki, T; Timpl, R; Hardingham, TE; Aspberg, A			Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CARTILAGE PROTEOGLYCANS; LECTIN DOMAINS; CORE PROTEIN; VERSICAN; IDENTIFICATION; EXPRESSION; FAMILY; PROLIFERATION; HYALURONATE	The proteoglycans aggrecan, versican, neurocan, and brevican bind hyaluronan through their N-terminal G1 domains, and other extracellular matrix proteins through the C-type lectin repeat in their C-terminal G3 domains. Here we identify tenascin-C as a ligand for the lectins of all these proteoglycans and map the binding site on the tenascin molecule to fibronectin type III repeats, which corresponds to the proteoglycan lectin-binding site on tenascin-R. In the G3 domain, the C-type lectin is flanked by epidermal growth factor (EGF) repeats and a complement regulatory protein-like motif. In aggrecan, these are subject to alternative splicing. To investigate if these flanking modules affect the C-type lectin ligand interactions, we produced recombinant proteins corresponding to aggrecan G3 splice variants. The G3 variant proteins containing the C-type lectin showed different affinities for various ligands, including tenascin-C, tenascin-R, fibulin-1, and fibulin-2. The presence of an EGF motif enhanced the affinity of interaction, and in particular the splice variant containing both EGF motifs had significantly higher affinity for ligands, such as tenascin-R and fibulin-2. The mRNA for this splice variant was shown by reverse transcriptase-PCR to be expressed in human chondrocytes. Our findings suggest that alternative splicing in the aggrecan G3 domain may be a mechanism for modulating interactions and extracellular matrix assembly.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, DE-82152 Martinsried, Germany	University of Manchester; Max Planck Society	Aspberg, A (corresponding author), Lund Univ, BMC-C12, SE-22184 Lund, Sweden.	anders.aspberg@medkem.lu.se		Hardingham, Timothy/0000-0001-8271-6763; Aspberg, Anders/0000-0002-6588-6944; Canfield, Ann/0000-0002-8983-5674				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; Brissett NC, 1998, BIOCHEM J, V329, P415; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; Fulop C, 1996, BIOCHEM J, V319, P935; FULOP C, 1993, J BIOL CHEM, V268, P17377; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 1996, CANCER RES, V56, P3902; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lee V, 2002, J BIOL CHEM, V277, P22279, DOI 10.1074/jbc.M110227200; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	47	94	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12511	12518		10.1074/jbc.M400242200	http://dx.doi.org/10.1074/jbc.M400242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722076	hybrid			2022-12-27	WOS:000220334900062
J	Hebeisen, S; Biela, A; Giese, B; Muller-Newen, G; Hidalgo, P; Fahlke, C				Hebeisen, S; Biela, A; Giese, B; Muller-Newen, G; Hidalgo, P; Fahlke, C			The role of the carboxyl terminus in ClC chloride channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; MYOTONIA-CONGENITA; MUTATIONS; DOMAINS; DOMINANT; COMMON; LEADS; GENE	The human muscle chloride channel ClC-1 has a 398-mino acid carboxyl-terminal domain that resides in the cytoplasm and contains two CBS (cystathionine-beta-synthase) domains. To examine the role of this region, we studied various carboxyl-terminal truncations by heterologous expression in mammalian cells, whole-cell patch clamp recording, and confocal imaging. Channel constructs lacking parts of the distal CBS domain, CBS2, did not produce functional channels, whereas deletion of CBS1 was tolerated. ClC channels are dimeric proteins with two ion conduction pathways (protopores). In heterodimeric channels consisting of one wild type subunit and one subunit in which the carboxyl terminus was completely deleted, only the wild type protopore was functional, indicating that the carboxyl terminus supports the function of the protopore. All carboxyl-terminal-truncated mutant channels fused to yellow fluorescent protein were translated and the majority inserted into the plasma membrane as revealed by confocal microscopy. Fusion proteins of cyan fluorescent protein linked to various fragments of the carboxyl terminus formed soluble proteins that could be redistributed to the surface membrane through binding to certain truncated channel subunits. Stable binding only occurs between carboxyl-terminal fragments of a single subunit, not between carboxyl termini of different subunits and not between carboxyl-terminal and transmembrane domains. However, an interaction with transmembrane domains can modify the binding properties of particular carboxyl-terminal proteins. Our results demonstrate that the carboxyl terminus of ClC-1 is not necessary for intracellular trafficking but is critical for channel function. Carboxyl termini fold independently and modify individual protopores of the double-barreled channel.	Rhein Westfal TH Aachen, Inst Physiol, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Ctr Estudios Cient, Valdivia, Chile	RWTH Aachen University; RWTH Aachen University	Fahlke, C (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52057 Aachen, Germany.	chfahlke@physiology.rwthaachen.de	Hidalgo, Patricia/I-7506-2013; Fahlke, Christoph/G-3635-2013	Hidalgo, Patricia/0000-0002-4162-6590; Fahlke, Christoph/0000-0001-8602-9952				Accardi A, 2000, J GEN PHYSIOL, V116, P433, DOI 10.1085/jgp.116.3.433; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Beck CL, 1996, P NATL ACAD SCI USA, V93, P11248, DOI 10.1073/pnas.93.20.11248; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P361; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Estevez R, 2003, NEURON, V38, P47, DOI 10.1016/S0896-6273(03)00168-5; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; Fong PY, 1998, AM J PHYSIOL-CELL PH, V274, pC966, DOI 10.1152/ajpcell.1998.274.4.C966; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hebeisen S, 2003, BIOPHYS J, V84, P2306, DOI 10.1016/S0006-3495(03)75036-X; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; Hryciw DH, 1998, J BIOL CHEM, V273, P4304, DOI 10.1074/jbc.273.8.4304; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Maduke M, 1998, BIOCHEMISTRY-US, V37, P1315, DOI 10.1021/bi972418o; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; MO L, 2003, AM J PHYSIOL, V286, pC79; Ponting CP, 1997, J MOL MED-JMM, V75, P160; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Warnstedt M, 2002, J NEUROSCI, V22, P7462; Wu FF, 2002, BRAIN, V125, P2392, DOI 10.1093/brain/awf246	32	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13140	13147		10.1074/jbc.M312649200	http://dx.doi.org/10.1074/jbc.M312649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718533	hybrid			2022-12-27	WOS:000220334900135
J	Koike, K; Conseil, GL; Leslie, EM; Deeley, RG; Cole, SPC				Koike, K; Conseil, GL; Leslie, EM; Deeley, RG; Cole, SPC			Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; LEUKOTRIENE C-4; CYSTIC-FIBROSIS; BINDING DOMAINS; ATP HYDROLYSIS; MRP1 ABCC1; GLUTATHIONE; MUTATION; GENE; CONJUGATE	Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-binding cassette transporter that confers resistance to drugs and mediates the transport of organic anions. MRP1 has a core structure of two membrane spanning domains (MSDs) each followed by a nucleotide binding domain. This core structure is preceded by a third MSD with five transmembrane (TM) helices, whereas MSD2 and MSD3 each contain six TM helices. We investigated the consequences of Ala substitution of 18 Pro residues in both the non-membrane and TM regions of MSD2 and MSD3 on MRP1 expression and organic anion transport function. All MRP1-Pro mutants except P1113A were expressed in human embryonic kidney cells at levels comparable with wild-type MRP1. In addition, five mutants containing substitutions of Pro residues in or proximal to the TM helices of MSD2 (TM6-Pro(343), TM8-Pro(448), TM10-Pro(557), and TM11-Pro(595)) and MSD3 (TM14-Pro(1088)) exhibited significantly reduced transport of five organic anion substrates. In contrast, mutation of Pro(1150) in the cytoplasmic loop (CL7) linking TM15 to TM16 caused a substantial increase in 17beta-estradiol-17-beta-(D-glucuronide) and methotrexate transport, whereas transport of other organic anions was reduced or unchanged. Significant substrate-specific changes in the ATP dependence of transport and binding by the P1150A mutant were also observed. Our findings demonstrate the importance of TM6, TM8, TM10, TM11, and TM14 in MRP1 transport function and suggest that CL7 may play a differential role in coupling the activity of the nucleotide binding domains to the translocation of different substrates across the membrane.	Queens Univ, Canc Res Lab, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Lab, Botterell Hall, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Leslie, Elaine/0000-0003-1825-348X				Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Campbell JD, 2004, J BIOL CHEM, V279, P463, DOI 10.1074/jbc.M310711200; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Deeley RG, 2003, ABC PROTEINS BACTERI, P393; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; HAIMEUR A, 2003, P AM ASSOC CANC RES, V44, P3688; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hooijberg JH, 1999, CANCER RES, V59, P2532; Ito K, 2003, BBA-BIOMEMBRANES, V1615, P103, DOI 10.1016/S0005-2736(03)00228-1; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; KONIG J, 2003, ABC PROTEINS BACTERI, P423; Kulczycki LL, 2003, AM J MED GENET A, V116A, P262, DOI 10.1002/ajmg.a.10886; Lee SH, 2003, BIOCHEM J, V370, P357, DOI 10.1042/BJ20021452; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1993, J BIOL CHEM, V268, P3143; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nilsson I, 1998, J MOL BIOL, V284, P1185, DOI 10.1006/jmbi.1998.2219; Ostedgaard LS, 1999, J CELL SCI, V112, P2091; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ren XQ, 2003, BRIT J PHARMACOL, V138, P1553, DOI 10.1038/sj.bjp.0705197; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Ri Y, 1999, BIOPHYS J, V76, P2887, DOI 10.1016/S0006-3495(99)77444-8; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Sheppard DN, 1996, J BIOL CHEM, V271, P14995, DOI 10.1074/jbc.271.25.14995; Tieleman DP, 2001, PROTEINS, V44, P63, DOI 10.1002/prot.1073; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2003, BIOCHEMISTRY-US, V42, P6784, DOI 10.1021/bi0273415; WEBB DC, 1992, J BIOL CHEM, V267, P24661; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	60	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12325	12336		10.1074/jbc.M311435200	http://dx.doi.org/10.1074/jbc.M311435200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722114	hybrid			2022-12-27	WOS:000220334900040
J	Lu, JY; Schneider, RJ				Lu, JY; Schneider, RJ			Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-UNTRANSLATED REGION; STABILITY FACTOR; ELAV PROTEIN; HEAT-SHOCK; FACTOR HUR; IN-VITRO; DEGRADATION; EXPRESSION; TRISTETRAPROLIN; ELEMENTS	Short lived cytokine and proto- oncogene mRNAs are destabilized by an A + U- rich element ( ARE) in the 3 '-untranslated region. Several regulatory proteins bind to AREs in cytokine and proto- oncogene mRNAs, participate in inhibiting or promoting their rapid degradation of ARE mRNAs, and influence cytokine expression and cellular transformation in experimental models. The tissue distribution and cellular localization of the different AU- rich binding proteins ( AUBPs), however, have not been uniformly characterized in the mouse, a model for ARE mRNA decay. We therefore carried out immunoblot and immunohistochemical analyses of the different AUBPs using the same mouse tissues. We show that HuR protein, a major AUBP that stabilizes the ARE mRNAs, is most strongly expressed in the thymus, spleen ( predominantly in lymphocytic cells), intestine, and testes. AUF1 protein, a negative regulator of ARE mRNA stability, displayed strong expression in thymus and spleen cells within lymphocytic cells, moderate expression in the epithelial linings of lungs, gonadal tissues, and nuclei of most neurons in the brain, and little expression in the other tissues. Tristetraprolin, a negative regulator of ARE mRNA stability, displayed a largely non- overlapping tissue distribution with AUF1 and was predominantly expressed in the liver and testis. KH- type splicing regulatory protein, a presumptive negative regulator of ARE mRNA stability, was distributed widely in murine organs. These results indicate that HuR and AUF1, which functionally oppose each other, have generally similar distributions, suggesting that the balance between HuR and AUF1 is likely important in control of short lived mRNA degradation, lymphocyte development, and/ or cytokine production, and possibly in certain aspects of neurological function.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Schneider, RJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	schner01@popmail.med.nyu.edu			NIGMS NIH HHS [GM 60428] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atasoy U, 1998, J CELL SCI, V111, P3145; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Gouble A, 2000, ONCOGENE, V19, P5377, DOI 10.1038/sj.onc.1203910; Gouble A, 2002, CANCER RES, V62, P1489; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KING PH, 1994, J NEUROSCI, V14, P1943; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; Nabors LB, 2001, CANCER RES, V61, P2154; Okano HJ, 1997, J NEUROSCI, V17, P3024; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	52	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12974	12979		10.1074/jbc.M310433200	http://dx.doi.org/10.1074/jbc.M310433200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711832	hybrid			2022-12-27	WOS:000220334900116
J	Mohler, PJ; Davis, JQ; Davis, LH; Hoffman, JA; Michaely, P; Bennett, V				Mohler, PJ; Davis, JQ; Davis, LH; Hoffman, JA; Michaely, P; Bennett, V			Inositol 1,4,5-trisphosphate receptor localization and stability in neonatal cardiomyocytes requires interaction with ankyrin-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CA2+ RELEASE; T-LYMPHOMA CELLS; TRISPHOSPHATE RECEPTOR; INSP(3) RECEPTORS; ANION-EXCHANGER; PURKINJE-CELLS; BINDING-SITES; RAT-BRAIN; CALCIUM; PROTEIN	The molecular mechanisms required for inositol 1,4,5-trisphosphate receptor ( InsP(3)R) targeting to specialized endoplasmic reticulum membrane domains are unknown. We report here a direct, high affinity interaction between InsP(3)R and ankyrin- B and demonstrate that this association is critical for InsP(3)R post- translational stability and localization in cultures of neonatal cardiomyocytes. Recombinant ankyrin- B membrane- binding domain directly interacts with purified cerebellar InsP(3)R ( K-d = 2 nM). 220- kDa ankyrin- B co- immunoprecipitates with InsP(3)R in tissue extracts from brain, heart, and lung. Alanine- scanning mutagenesis of the ankyrin- B ANK ( ankyrin repeat) repeat beta- hairpin loop tips revealed that consecutive ANK repeat beta- hairpin loop tips ( repeats 22 - 24) are required for InsP(3)R interaction, thus providing the first detailed evidence of how ankyrin polypeptides associate with membrane proteins. Pulse- chase biosynthesis experiments demonstrate that reduction or loss of ankyrin- B in ankyrin- B (+/-) or ankyrin- B (-/-) neonatal cardiomyocytes leads to similar to 3- fold reduction in half- life of newly synthesized InsP3R. Furthermore, interactions with ankyrin- B are required for InsP(3)R stability as abnormal InsP(3)R phenotypes, including mis- localization, and reduced half-life in ankyrin- B (+/-) cardiomyocytes can be rescued by green fluorescent protein ( GFP)- 220- kDa ankyrin- B but not by GFP- 220- kDa ankyrin- B mutants, which do not associate with InsP(3)R. These new results provide the first physiological evidence of a molecular partner required for early post- translational stability of InsP(3)R.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mohler, PJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3892, Durham, NC 27710 USA.	p.mohler@cellbio.duke.edu						Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; DAVIS JQ, 1991, J CELL BIOL, V115, P43; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Miyata M, 1999, ACTA NEUROPATHOL, V98, P226, DOI 10.1007/s004010051073; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Salanova M, 2002, CELL CALCIUM, V32, P193, DOI 10.1016/S0143416002001549; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	35	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12980	12987		10.1074/jbc.M313979200	http://dx.doi.org/10.1074/jbc.M313979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722080	hybrid			2022-12-27	WOS:000220334900117
J	Sulzenbacher, G; Bignon, C; Nishimura, T; Tarling, CA; Withers, SG; Henrissat, B; Bourne, Y				Sulzenbacher, G; Bignon, C; Nishimura, T; Tarling, CA; Withers, SG; Henrissat, B; Bourne, Y			Crystal structure of Thermotoga maritima alpha-L-fucosidase - Insights into the catalytic mechanism and the molecular basis for fucosidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSYL-TRANSFERASE; GLYCOSYLATION; IDENTIFICATION; ENDOGLUCANASE; BIOSYNTHESIS; NUCLEOPHILE; REFINEMENT; EXPRESSION; SPECTRUM; GLYCANS	Fucosylated glycoconjugates are involved in numerous biological events, and alpha-L-fucosidases, the enzymes responsible for their processing, are therefore of crucial importance. Deficiency in alpha-L-fucosidase activity is associated with fucosidosis, a lysosomal storage disorder characterized by rapid neurodegeneration, resulting in severe mental and motor deterioration. To gain insight into alpha-L-fucosidase function at the molecular level, we have determined the crystal structure of Thermotoga maritima alpha-L-fucosidase. This enzyme assembles as a hexamer and displays a two-domain fold, composed of a catalytic (beta/alpha)(8)-like domain and a C-terminal beta-sandwich domain. The structures of an enzyme-product complex and of a covalent glycosyl-enzyme intermediate, coupled with kinetic and mutagenesis studies, allowed us to identify the catalytic nucleophile, Asp(244), and the Bronsted acid/base, Glu(266). Because T. maritima alpha-L-fucosidase occupies a unique evolutionary position, being far more closely related to the mammalian enzymes than to any other prokaryotic homolog, a structural model of the human enzyme was built to document the structural consequences of the genetic mutations associated with fucosidosis.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of British Columbia	Henrissat, B (corresponding author), CNRS, UMR 6098, 31 Chemin J Aiguier, F-13402 Marseille 20, France.	bernie@afmb.cnrs-mrs.fr; yves@afmb.cnrs-mrs.fr	Henrissat, Bernard/J-2475-2012; Bourne, Yves/AAC-4635-2022; Sulzenbacher, Gerlind/A-6801-2018	Henrissat, Bernard/0000-0002-3434-8588; Bourne, Yves/0000-0003-3850-0548; Sulzenbacher, Gerlind/0000-0003-4844-2820				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Berteau O, 2002, GLYCOBIOLOGY, V12, P273, DOI 10.1093/glycob/12.4.273; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cobucci-Ponzano B, 2003, BIOCHEMISTRY-US, V42, P9525, DOI 10.1021/bi035036t; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Delves PJ, 1998, AUTOIMMUNITY, V27, P239, DOI 10.3109/08916939808993836; Eneyskaya EV, 2001, GLYCOCONJUGATE J, V18, P827, DOI 10.1023/A:1021163720282; Fox JD, 2003, FEBS LETT, V537, P53, DOI 10.1016/S0014-5793(03)00070-X; Fujimoto Z, 2003, J BIOL CHEM, V278, P20313, DOI 10.1074/jbc.M302292200; Garman SC, 2002, STRUCTURE, V10, P425, DOI 10.1016/S0969-2126(02)00726-8; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIRAISHI K, 1993, GLYCOBIOLOGY, V3, P381, DOI 10.1093/glycob/3.4.381; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; HUTCHINSON WL, 1991, CLIN SCI, V81, P177, DOI 10.1042/cs0810177; JOHNSON SW, 1991, COMP BIOCHEM PHYS B, V99, P479, DOI 10.1016/0305-0491(91)90327-A; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nerinckx W, 2003, FEBS LETT, V538, P1, DOI 10.1016/S0014-5793(03)00148-0; Numao S, 2003, J BIOL CHEM, V278, P48074, DOI 10.1074/jbc.M309249200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490; SANO M, 1992, J BIOL CHEM, V267, P1522; Sinowatz F, 1998, ACTA ANAT, V161, P196; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; Tarling CA, 2003, J BIOL CHEM, V278, P47394, DOI 10.1074/jbc.M306610200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tyagarajan K, 1996, GLYCOBIOLOGY, V6, P83, DOI 10.1093/glycob/6.1.83; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Varrot A, 2000, J MOL BIOL, V297, P819, DOI 10.1006/jmbi.2000.3567; Varrot A, 1999, BIOCHEMISTRY-US, V38, P8884, DOI 10.1021/bi9903998; WHITE WJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P132, DOI 10.1016/0167-4838(87)90256-1; Wiese TJ, 1997, BBA-GEN SUBJECTS, V1335, P61, DOI 10.1016/S0304-4165(96)00123-7; WILLEMS PJ, 1991, AM J MED GENET, V38, P111, DOI 10.1002/ajmg.1320380125; Willems PJ, 1999, EUR J HUM GENET, V7, P60, DOI 10.1038/sj.ejhg.5200272; XIANG JM, 1992, BIOCHEM BIOPH RES CO, V189, P27, DOI 10.1016/0006-291X(92)91520-Z	54	131	132	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13119	13128		10.1074/jbc.M313783200	http://dx.doi.org/10.1074/jbc.M313783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715651	Green Published, hybrid			2022-12-27	WOS:000220334900133
J	Suzuki, S; Ferjani, A; Suzuki, I; Murata, N				Suzuki, S; Ferjani, A; Suzuki, I; Murata, N			The SphS-SphR two component system is the exclusive sensor for the induction of gene expression in response to phosphate limitation in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; SIGNAL-TRANSDUCTION; PHO REGULON; SP PCC-6803; STARVATION; PROMOTER; TRANSCRIPTION; METABOLISM; MUTANTS; OPERON	Living organisms respond to phosphate limitation by expressing various genes whose products maintain an appropriate range of phosphate concentrations within each cell. We identified previously a two component system, which consists of histidine kinase SphS and its cognate response regulator SphR, which regulates the expression of the phoA gene for alkaline phosphatase under phosphate-limiting conditions in the cyanobacterium Synechocystis sp. PCC 6803. In the present study, we used DNA microarrays to investigate the role of SphS and SphR in the regulation of the genome-wide expression of genes in response to phosphate limitation. In wild-type cells, phosphate limitation strongly induced the expression of 12 genes with induction factors greater than 7. These genes were included in three clusters of genes, namely, the pst1 and pst2 clusters that encode phosphate transporters; the phoA gene and the nucH gene for the extracellular nuclease. Phosphate limitation strongly repressed the expression of only the urtA gene with induction factors below 0.2. Inactivation of either of SphS or SphR completely eliminated the phosphate limitation-inducible expression of the 12 genes and the phosphate limitation-repressible expression of the urtA gene. These results suggest that the SphS-SphR two component system in Synechocystis sp. PCC 6803 is the dominant sensory system that controls gene expression in response to phosphate limitation.	Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Murata, N (corresponding author), Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	Suzuki, Shingo/O-3651-2014; Murata, Norio/E-6569-2010; Murata, Norio/O-7945-2019	Suzuki, Shingo/0000-0003-1332-3194; Murata, Norio/0000-0002-6605-5800				AIBA H, 1994, MOL MICROBIOL, V13, P25, DOI 10.1111/j.1365-2958.1994.tb00399.x; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hammond JP, 2003, PLANT PHYSIOL, V132, P578, DOI 10.1104/pp.103.020941; Hirani TA, 2001, PLANT MOL BIOL, V45, P133, DOI 10.1023/A:1006425214168; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Hulett F. M, 2002, BACILLUS SUBTILIS IT, P193, DOI [10.1128/9781555817992.ch15, DOI 10.1128/9781555817992.CH15]; Kaneko T, 1996, DNA Res, V3, P109; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu W, 1997, J BACTERIOL, V179, P6302, DOI 10.1128/jb.179.20.6302-6310.1997; Liu W, 1998, MOL MICROBIOL, V28, P119, DOI 10.1046/j.1365-2958.1998.00779.x; MAKINO K, 1994, PHOSPHATE IN MICROORGANISMS, P5; MANN N, 1974, J GEN MICROBIOL, V83, P399; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Qi Y, 1998, MOL MICROBIOL, V28, P1187, DOI 10.1046/j.1365-2958.1998.00882.x; Qi Y, 1997, J BACTERIOL, V179, P2534, DOI 10.1128/jb.179.8.2534-2539.1997; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Taylor BL, 1998, MOL MICROBIOL, V28, P683, DOI 10.1046/j.1365-2958.1998.00835.x; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Wu P, 2003, PLANT PHYSIOL, V132, P1260, DOI 10.1104/pp.103.021022; Yamaguchi K, 2002, PLANT CELL, V14, P2901, DOI 10.1105/tpc.006262; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zinchenko VV, 1999, RUSS J GENET+, V35, P228	27	128	132	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13234	13240		10.1074/jbc.M313358200	http://dx.doi.org/10.1074/jbc.M313358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707128	hybrid			2022-12-27	WOS:000220334900145
J	Zhang, Q; Pangrsic, T; Kreft, M; Krzan, M; Li, NZ; Sul, JY; Halassa, M; Van Bockstaele, E; Zorec, R; Haydon, PG				Zhang, Q; Pangrsic, T; Kreft, M; Krzan, M; Li, NZ; Sul, JY; Halassa, M; Van Bockstaele, E; Zorec, R; Haydon, PG			Fusion-related release of glutamate from astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; MEMBRANE-FUSION; SYNAPTIC-TRANSMISSION; CAPACITANCE STEPS; GLIAL-CELLS; TRANSPORTER; EXOCYTOSIS; SNAP-23; PROTEIN; SINGLE	Although cell culture studies have implicated the presence of vesicle proteins in mediating the release of glutamate from astrocytes, definitive proof requires the identification of the glutamate release mechanism and the localization of this mechanism in astrocytes at synaptic locales. In cultured murine astrocytes we show an array of vesicle proteins, including SNARE proteins, and vesicular glutamate transporters that are required to fill vesicles with glutamate. Using immunocytochemistry and single-cell multiplex reverse transcription-PCR we demonstrate the presence of these proteins and their transcripts within astrocytes freshly isolated from the hippocampus. Moreover, immunoelectron microscopy demonstrates the presence of VGLUT1 in processes of astrocytes of the hippocampus. To determine whether calcium-dependent glutamate release is mediated by exocytosis, we expressed the SNARE motif of synaptobrevin II to prevent the formation of SNARE complexes, which reduces glutamate release from astrocytes. To further determine whether vesicular exocytosis mediates calcium-dependent glutamate release from astrocytes, we performed whole cell capacitance measurements from individual astrocytes and demonstrate an increase in whole cell capacitance, coincident with glutamate release. Together, these data allow us to conclude that astrocytes in situ express vesicle proteins necessary for filling vesicles with the chemical transmitter glutamate and that astrocytes release glutamate through a vesicle- or fusion-related mechanism.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia; Celica Biomed Sci Ctr, Ljubljana 1000, Slovenia; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Thomas Jefferson Univ, Farber Inst Neurosci, Dept Neurosurg, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Ljubljana; University of Washington; University of Washington Seattle; Jefferson University	Haydon, PG (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Rm 215,Stemmler Hall, Philadelphia, PA 19104 USA.	pghaydon@mail.med.upenn.edu		Zorec, Robert/0000-0002-7478-3875	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043142, R37NS037585] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 43142, R37 NS 37585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; ATTWELL D, 1994, NATURE, V369, P707, DOI 10.1038/369707a0; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Blank U, 2002, MOL IMMUNOL, V38, P1341, DOI 10.1016/S0161-5890(02)00085-8; Boudin H, 2000, J NEUROSCI, V20, P5932, DOI 10.1523/JNEUROSCI.20-16-05932.2000; BRAMHAM CR, 1990, NEUROSCIENCE, V39, P405, DOI 10.1016/0306-4522(90)90277-B; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Castle JD, 2002, MOL IMMUNOL, V38, P1337, DOI 10.1016/S0161-5890(02)00084-6; CHAN J, 1990, J NEUROSCI METH, V33, P113, DOI 10.1016/0165-0270(90)90015-8; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fremeau RT, 2002, P NATL ACAD SCI USA, V99, P14488, DOI 10.1073/pnas.222546799; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hepp R, 1999, GLIA, V27, P181, DOI 10.1002/(SICI)1098-1136(199908)27:2<181::AID-GLIA8>3.0.CO;2-9; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Innocenti B, 2000, J NEUROSCI, V20, P1800; Ishikawa T, 2002, NEURON, V34, P613, DOI 10.1016/S0896-6273(02)00692-X; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jeftinija SD, 1997, BRAIN RES, V750, P41, DOI 10.1016/S0006-8993(96)00610-5; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kimelberg HK, 2000, J NEUROSCI RES, V61, P577, DOI 10.1002/1097-4547(20000915)61:6<577::AID-JNR1>3.0.CO;2-T; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Kreft M, 1997, PFLUG ARCH EUR J PHY, V434, P212, DOI 10.1007/s004240050387; KREFT M, 2004, IN PRESS GLIA; Lai KC, 2003, J CELL PHYSIOL, V194, P206, DOI 10.1002/jcp.10222; Maienschein V, 1999, GLIA, V26, P233, DOI 10.1002/(SICI)1098-1136(199905)26:3<233::AID-GLIA5>3.0.CO;2-2; Marty A., 1983, SINGLE CHANNEL RECOR, P107; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; NUSSER Z, 1995, J NEUROSCI, V15, P2948; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Polgar J, 2003, J BIOL CHEM, V278, P44369, DOI 10.1074/jbc.M307864200; Robitaille R, 1998, NEURON, V21, P847, DOI 10.1016/S0896-6273(00)80600-5; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; SCHAFER MK, 2002, J BIOL CHEM; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; STORMMATHISEN J, 1992, PROG BRAIN RES, V94, P225; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Wang CT, 2003, NATURE, V424, P943, DOI 10.1038/nature01857; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408; Zhou M, 2001, J NEUROSCI, V21, P7901, DOI 10.1523/JNEUROSCI.21-20-07901.2001; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473	56	191	200	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12724	12733		10.1074/jbc.M312845200	http://dx.doi.org/10.1074/jbc.M312845200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722063	hybrid			2022-12-27	WOS:000220334900086
J	Zharova, TV; Vinogradov, AD				Zharova, TV; Vinogradov, AD			Energy-dependent transformation of F-0 center dot F-1-ATPase in Paracoccus denitrificans plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; STEADY-STATE KINETICS; APPARENT NEGATIVE COOPERATIVITY; PROTON MOTIVE FORCE; ATP-SYNTHASE; CATALYTIC SITE; OXIDATIVE-PHOSPHORYLATION; EPSILON-SUBUNIT; ESCHERICHIA-COLI	F-0.F-1-ATP synthase in tightly coupled inside-out vesicles derived from Paracoccus denitrificans catalyzes rapid respiration-supported ATP synthesis, whereas their ATPase activity is very low. In the present study, the conditions required to reveal the Deltamu(H+)-generating ATP hydrolase activity of the bacterial enzyme have been elucidated. Energization of the membranes by respiration results in strong activation of the venturicidin-sensitive ATP hydrolysis, which is coupled with generation of Delta(mu) over tilde (H+). Partial uncoupling stimulates the proton-translocating ATP hydrolysis, whereas complete uncoupling results in inhibition of the ATPase activity. The presence of inorganic phosphate is indispensable for the steady-state turnover of the Delta(mu) over tilde (H+)-activated ATPase. The collapse of Delta(mu) over tilde (H+) brings about rapid deactivation of the enzyme, which has been subjected to pre-energization. The rate and extent of the deactivation depend on protein concentration, i.e. the more vesicles are present in the assay mixture, the higher the rate and extent of the deactivation is seen. Sulfite and the ADP-trapping system protect ATPase against the Delta(mu) over tilde (H+) collapse-induced deactivation, whereas phosphate delays the rate of deactivation. A low concentration of ADP (<1 mu M) increases the rate of deactivation. Taken together, the results suggest that latent proton-translocating ATPase in P. denitrificans is kinetically equivalent to the previously characterized ADP(Mg2+)-inhibited, azide-trapped bovine heart mitochondrial F-0 center dot F-1-ATPase (Galkin, M. A., and Vinogradov, A. D. (1999) FEBS Lett. 448, 123-126). A Delta<(mu)over tilde>(H+)-sensitive mechanism operates in P. denitrificans that prevents physiologically wasteful consumption of ATP by F-0.F-1-ATPase (synthase) complex when the latter is unable to maintain certain value of Delta(mu) over tilde (H+).	Moscow MV Lomonosov State Univ, Sch Biol, Dept Biochem, Moscow 119992, Russia	Lomonosov Moscow State University	Vinogradov, AD (corresponding author), Moscow MV Lomonosov State Univ, Sch Biol, Dept Biochem, Moscow 119992, Russia.	adv@biochem.bio.msu.su	Zharova, Tatiana/AAO-4438-2021					Allison WS, 1996, J BIOENERG BIOMEMBR, V28, P433, DOI 10.1007/BF02113985; ASAMI K, 1970, BIOCHIM BIOPHYS ACTA, V205, P307, DOI 10.1016/0005-2728(70)90261-6; Bakels RHA, 1996, ARCH BIOCHEM BIOPHYS, V332, P170, DOI 10.1006/abbi.1996.0329; BAKELS RHA, 1991, BIOCHIM BIOPHYS ACTA, V1058, P225, DOI 10.1016/S0005-2728(05)80241-5; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; Bald D, 1999, EUR J BIOCHEM, V262, P563, DOI 10.1046/j.1432-1327.1999.00410.x; Beharry S, 2001, J BIOENERG BIOMEMBR, V33, P35, DOI 10.1023/A:1005620606871; Bottcher B, 2000, BBA-BIOENERGETICS, V1458, P404, DOI 10.1016/S0005-2728(00)00090-6; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; Boyer PD, 1998, BIOSCIENCE REP, V18, P97, DOI 10.1023/A:1020188311092; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; BULYGIN VV, 1988, FEBS LETT, V236, P497, DOI 10.1016/0014-5793(88)80085-1; Capaldi RA, 2000, J EXP BIOL, V203, P29; Cappellini P, 1997, EUR J BIOCHEM, V248, P496, DOI 10.1111/j.1432-1033.1997.00496.x; Chance B., 1967, METHODS ENZYMOL, V10, P641; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; EBEL RE, 1975, J BIOL CHEM, V250, P191; FERGUSON SJ, 1977, BIOCHEM SOC T, V5, P1525, DOI 10.1042/bst0051525; FERGUSON SJ, 1976, FEBS LETT, V62, P272, DOI 10.1016/0014-5793(76)80073-7; Fischer S, 2000, J BIOL CHEM, V275, P30157, DOI 10.1074/jbc.275.39.30157; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; Galkin MA, 1999, FEBS LETT, V448, P123, DOI 10.1016/S0014-5793(99)00347-6; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HARRIS DA, 1991, BIOCHEM J, V280, P561, DOI 10.1042/bj2800561; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V459, P546, DOI 10.1016/0005-2728(77)90053-6; Heytler P G, 1979, Methods Enzymol, V55, P462; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JOHN P, 1970, FEBS LETT, V10, P246, DOI 10.1016/0014-5793(70)80639-1; JOHN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P342, DOI 10.1016/0005-2728(70)90225-2; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kato-Yamada Y, 2003, J BIOL CHEM, V278, P36013, DOI 10.1074/jbc.M306140200; Lodeyro AF, 2001, BBA-BIOENERGETICS, V1506, P236, DOI 10.1016/S0005-2728(01)00221-3; Lu YM, 2001, J BIOCHEM-TOKYO, V130, P873, DOI 10.1093/oxfordjournals.jbchem.a003060; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MINKOV IB, 1980, BIOCHEM INT, V1, P478; Mitome N, 2002, EUR J BIOCHEM, V269, P53, DOI 10.1046/j.0014-2956.2002.02623.x; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; Muneyuki E, 2000, BBA-BIOENERGETICS, V1458, P467, DOI 10.1016/S0005-2728(00)00095-5; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; Pacheco-Moises F, 2000, EUR J BIOCHEM, V267, P993, DOI 10.1046/j.1432-1327.2000.01088.x; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10518, DOI 10.1021/bi00498a014; RECKTENWALD D, 1979, FEBS LETT, V108, P257, DOI 10.1016/0014-5793(79)81223-5; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; VASIL'EVA E A, 1989, Biokhimiya, V54, P1490; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VASILYEVA EA, 1980, BIOCHEM J, V188, P807, DOI 10.1042/bj1880807; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Waggoner A S, 1979, Methods Enzymol, V55, P689; YALAMOVA MV, 1982, BIOCHEM INT, V4, P337; Zharova TV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1101, DOI 10.1023/A:1026306611821	59	46	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12319	12324		10.1074/jbc.M311397200	http://dx.doi.org/10.1074/jbc.M311397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722115	hybrid			2022-12-27	WOS:000220334900039
J	Lemrow, SM; Anderson, KA; Joseph, JD; Ribar, TJ; Noeldner, PK; Means, AR				Lemrow, SM; Anderson, KA; Joseph, JD; Ribar, TJ; Noeldner, PK; Means, AR			Catalytic activity is required for calcium/calmodulin-dependent protein kinase IV to enter the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; AMINO-ACID-SEQUENCE; IMMUNOHISTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; BRAIN CALMODULIN; RAT-BRAIN; KAPPA-B; PHOSPHORYLATION; ACTIVATION; TRANSPORT	Calcium/calmodulin-dependent protein kinase IV (CaMKIV) is a nuclear protein kinase that responds to acute rises in intracellular calcium by phosphorylating and activating proteins involved in transcription. Consistent with these roles, CaMKIV is found predominantly in the nucleus of cells in which it is expressed. Here we evaluate nuclear entry of CaMKIV and demonstrate that the protein kinase homology domain is both necessary and sufficient for nuclear localization. Unexpectedly, although catalytic activity is required for nuclear translocation, it is not required for CaMKIV to interact with the nuclear adaptor protein, importin-alpha. Because the catalytically inactive molecules remain in the cytoplasm, these data suggest that this interaction is not sufficient for nuclear entry. We evaluated a role for other proteins known to interact with CaMKIV in regulation of its nuclear entry. Although our data do not support a role for calmodulin or protein phosphatase 2A, the catalytically inactive CaMKIV proteins interact more avidly with CaM-dependent protein kinase kinase (CaMKK), which is restricted to the cytoplasm. We find that the catalytically inactive proteins do not inhibit nuclear entry of wild-type CaMKIV but do inhibit the ability of the wild-type protein kinase to stimulate cyclic AMP response element-binding protein-mediated transcription. Because activation loop phosphorylation is required for the transcriptional roles of CaMKIV, these data suggest that CaMKK phosphorylation of CaMKIV may occur in the cytoplasm. We propose that sequestration of CaMKK may be the molecular mechanism by which catalytically inactive mutants of CaMKIV exert their "dominant-negative" functions within the cell.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; FELDHERR CM, 1991, J CELL BIOL, V115, P933, DOI 10.1083/jcb.115.4.933; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1986, ENZYMES, P17; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Ji RR, 1996, BRAIN RES, V721, P167, DOI 10.1016/0006-8993(95)01316-4; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MIYANO O, 1992, J BIOL CHEM, V267, P1198; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; Nakamura Y, 2001, NEUROSCI RES, V39, P175, DOI 10.1016/S0168-0102(00)00209-1; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Sakagami H, 1996, BRAIN RES, V719, P154, DOI 10.1016/0006-8993(96)00088-1; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sorg G, 1999, BIOTECHNIQUES, V26, P858, DOI 10.2144/99265bm12; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	42	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11664	11671		10.1074/jbc.M312613200	http://dx.doi.org/10.1074/jbc.M312613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701808	hybrid			2022-12-27	WOS:000220157600101
J	Young, AP; Longmore, GD				Young, AP; Longmore, GD			Ras protects Rb family null fibroblasts from cell death - A role for AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; C-JUN; RETINOBLASTOMA PROTEIN; ONCOGENIC RAS; G(1) CONTROL; DNA-BINDING; IN-VITRO; APOPTOSIS; KINASE; GENE	The retinoblastoma protein (Rb) controls cell proliferation, differentiation, and senescence and provides an essential tumor suppressive function that cells must eliminate to attain unlimited proliferative potential. Elimination of the Rb pathway also results in apoptosis, however, thereby providing an efficient surveillance mechanism to sense the loss of Rb. To become tumorigenic cells must thus overcome not only Rb function but also the apoptotic response caused by the loss of Rb function. We show that oncogenic Ras (RasV12) potently blocks cell death in Rb family member knockout mouse embryo fibroblasts (TKO cells). Activation of phosphatidylinositol 3-kinase and Raf by oncogenic Ras mediated this protection, implying that multiple Ras effector pathways are required, in concert, for this pro-survival signal. Although activation of Raf by selective Ras mutants protected TKO cells from cell death, pharmacologic inhibition of MEK had little effect on RasV12 protection, suggesting that a Raf-dependent, MEK-independent pathway was important for this effect. We show that this Raf-dependent protection occurred through activation of c-Jun and thus AP-1 activation. These observations could account for the dependence of Ras transformation on c-Jun activity and for the roles of AP-1 in oncogenesis. Our results support the concept of two oncogenic events cooperating to achieve a balance between immortalization and survival.	Washington Univ, Sch Med, Div Hematol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	glongmor@im.wustl.edu			NCI NIH HHS [CA 85839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chresta C M, 1996, Behring Inst Mitt, P232; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hilgers W, 2002, HEMATOL ONCOL CLIN N, V16, P17, DOI 10.1016/S0889-8588(01)00005-3; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; LAMB JA, 2003, GENE DEV, V11, P1479; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Ma PH, 2002, MOL CELL BIOL, V22, P2928, DOI 10.1128/MCB.22.9.2928-2938.2002; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Orecchia R, 2000, J PATHOL, V190, P423; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Reed SI, 1997, CANCER SURV, V29, P7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Webb CP, 2001, METHOD ENZYMOL, V333, P318; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	55	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10931	10938		10.1074/jbc.M311814200	http://dx.doi.org/10.1074/jbc.M311814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688262	hybrid			2022-12-27	WOS:000220157600014
J	Gaudreau, R; Beaulieu, ME; Chen, ZG; Le Gouill, C; Lavigne, P; Stankova, J; Rola-Pleszczynski, M				Gaudreau, R; Beaulieu, ME; Chen, ZG; Le Gouill, C; Lavigne, P; Stankova, J; Rola-Pleszczynski, M			Structural determinants regulating expression of the high affinity leukotriene B-4 receptor - Involvement of dileucine motifs and alpha-helix VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DI-LEUCINE MOTIF; CYTOPLASMIC TAIL; SORTING SIGNALS; MDCK CELLS; BETA(2)-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; PLASMA-MEMBRANE; DOWN-REGULATION; HUMAN MONOCYTES	Mutational analysis of determinants located in the C-terminal (C) tail of the high affinity leukotriene (LT) B-4 receptor, BLT1, was performed to assess their significance in BLT1 trafficking. When expressed in COS-7 cells, a BLT1 deletion mutant lacking the C-tail (G291stop) displayed higher numbers of binding sites and increased signal transduction compared with wildtype (WT) BLT1. Addition of the C-tail from either the platelet-activating factor receptor or the LTD4 receptor, CysLT1, did not restore WT phenotype. Moreover, the number of LTB4 binding sites was higher in the chimeras than in the WT BLT1, suggesting the requirement for specific structural determinants within the BLT1 C-tail. Elimination of a distal C-tail dileucine motif (Leu(304)-Leu(305)), but not the proximal (Leu(292)-Leu(293)) motif, altered BLT1 pharmacological characteristics and caused a moderate constitutive receptor activation. Surprisingly, all mutant receptors were efficiently delivered to the plasma membrane, but not to a greater extent than WT BLT1, as assessed by flow cytometry. Furthermore, substitution of Leu(304)-Leu(305) prevented LTB4-induced BLT1 internalization. Molecular modeling of BLT1 on the bovine rhodopsin receptor scaffold strongly suggested the involvement of the distal dileucine motif (Leu(304)-Leu(305)) in a hydrophobic core, including intrahelical interactions within alpha-helix VIII and interhelical interactions with residues of helix I. Disruption of this hydrophobic core is proposed to increase the population of receptors in the active form, to restrain their trafficking and to facilitate the activation of BLT1 as indicated by the increased maximal level of binding of the ligand and constitutive activation of the receptor.	Univ Sherbrooke, Div Immunol, Dept Pediat, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Pharmacol, Fac Med, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Div Immunol, Dept Pediat, Fac Med, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	marek.rola-pleszczynski@usherbrooke.ca	Chen, Zhangguo/AAW-2032-2021	Chen, Zhangguo/0000-0002-2741-0080				Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Claeysen S, 1999, MOL PHARMACOL, V55, P910; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Deraet M, 2002, CAN J PHYSIOL PHARM, V80, P418, DOI 10.1139/Y02-060; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hall DA, 2000, MOL PHARMACOL, V58, P1412, DOI 10.1124/mol.58.6.1412; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Martens AS, 2000, J CELL SCI, V113, P3593; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OKUNO T, 2003, J BIOL CHEM; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; ROLAPLESZCZYNSKI M, 1985, IMMUNOL TODAY, V6, P302, DOI 10.1016/0167-5699(85)90181-1; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; STANKOVA J, 1992, BIOCHEM J, V282, P625; STANKOVA J, 1992, IMMUNOLOGY, V76, P258; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492	53	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10338	10345		10.1074/jbc.M309207200	http://dx.doi.org/10.1074/jbc.M309207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688279	hybrid			2022-12-27	WOS:000220050400083
J	London, M; London, E				London, M; London, E			Ceramide selectively displaces cholesterol from ordered lipid domains (rafts) - Implications for lipid raft structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PENETRATION DEPTH; GPI-ANCHORED PROTEINS; MODEL MEMBRANES; BIOLOGICAL-MEMBRANES; SIGNAL-TRANSDUCTION; HUMAN FIBROBLASTS; CELL-SURFACE; SPHINGOMYELINASE; BILAYERS; RESISTANCE	Ceramide is a membrane lipid involved in a number of crucial biological processes. Recent evidence suggests that ceramide is likely to reside and function within lipid rafts; ordered sphingolipid and cholesterol-rich lipid domains believed to exist within many eukaryotic cell membranes. Using lipid vesicles containing co-existing raft domains and disordered fluid domains, we find that natural and saturated synthetic ceramides displace sterols from rafts. Other raft lipids remain raft-associated in the presence of ceramide, showing displacement is relatively specific for sterols. Like cholesterol-containing rafts, ceramide-rich "rafts" remain in a highly ordered state. Comparison of the sterol-displacing abilities of natural ceramides with those of saturated diglycerides and an unsaturated ceramide demonstrates that tight lipid packing is critical for sterol displacement by ceramide. Based on these results, and the fact that cholesterol and ceramides both have small polar headgroups, we propose that ceramides and cholesterol compete for association with rafts because of a limited capacity of raft lipids with large headgroups to accommodate small headgroup lipids in a manner that prevents unfavorable contact between the hydrocarbon groups of the small headgroup lipids and the surrounding aqueous environment. Minimizing the exposure of cholesterol and ceramide to water may be a strong driving force for the association of other molecules with rafts. Furthermore, displacement of sterol from rafts by ceramide is very likely to have marked effects upon raft structure and function, altering liquid ordered properties as well as molecular composition. In this regard, certain previously observed physiological processes may be a result of displacement. In particular, a direct connection to the previously observed sphingomyelinase-induced displacement of cholesterol from plasma membranes in cells is proposed.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Erwin.London@stonybrook.edu			NIGMS NIH HHS [GM48596] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Al-Makdissy N, 2003, CELL SIGNAL, V15, P1019, DOI 10.1016/S0898-6568(03)00070-6; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; BECK A, 1993, CHEM PHYS LIPIDS, V66, P135, DOI 10.1016/0009-3084(93)90038-5; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Fastenberg ME, 2003, BIOCHEMISTRY-US, V42, P12376, DOI 10.1021/bi034718d; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; HALE JE, 1982, EUR J BIOCHEM, V122, P649; Heerklotz H, 2003, J MOL BIOL, V329, P793, DOI 10.1016/S0022-2836(03)00504-7; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Ito J, 2000, J LIPID RES, V41, P894; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Khan TK, 2003, BIOCHEMISTRY-US, V42, P4780, DOI 10.1021/bi0265877; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lange Y, 1999, J LIPID RES, V40, P2264; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; Loidl A, 2003, J BIOL CHEM, V278, P32921, DOI 10.1074/jbc.M306088200; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Michael JM, 1997, CANCER RES, V57, P3600; Niu SL, 2002, BIOPHYS J, V83, P3408, DOI 10.1016/S0006-3495(02)75340-X; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Radhakrishnan A, 2000, BIOCHEMISTRY-US, V39, P8119, DOI 10.1021/bi0005097; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; Subbaiah PV, 2003, J LIPID RES, V44, P1574, DOI 10.1194/jlr.M300103-JLR200; tenGrotenhuis E, 1996, BIOPHYS J, V71, P1389, DOI 10.1016/S0006-3495(96)79341-4; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; Wang TY, 2003, BIOPHYS J, V84, P367, DOI 10.1016/S0006-3495(03)74857-7; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Zitzer A, 2001, J BIOL CHEM, V276, P14628, DOI 10.1074/jbc.M100241200	46	303	310	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9997	10004		10.1074/jbc.M309992200	http://dx.doi.org/10.1074/jbc.M309992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699154	hybrid			2022-12-27	WOS:000220050400043
J	Xu, J; Lai, YJ; Lin, WC; Lin, FT				Xu, J; Lai, YJ; Lin, WC; Lin, FT			TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FOCAL ADHESION KINASE; LIM DOMAIN; GROWTH-FACTOR; CANCER CELLS; ZYXIN; IDENTIFICATION; EXPRESSION; PAXILLIN; NUCLEAR	Lysophosphatidic acid (LPA) induces actin rearrangement, focal adhesion assembly, and cell migration through the activation of small G protein Rho and its downstream effectors. These diverse cellular responses are mediated by its associated G protein-coupled receptors. However, the mechanisms and specificity by which these LPA receptors mediate LPA actions are still poorly understood. Here we show that LPA stimulation promotes the interaction of the LPA(2) receptor with a focal adhesion molecule, TRIP6 (thyroid receptor interacting protein 6)/ZRP-1 (zyxin-related protein 1). TRIP6 directly binds to the carboxyl-terminal tail of the LPA(2) receptor through its LIM domains. LPA-dependent recruitment of TRIP6 to the plasma membrane promotes its targeting to focal adhesions and co-localization with actin stress fibers. In addition, TRIP6 associates with the components of focal complexes including paxillin, focal adhesion kinase, c-Src, and p130(cas) in an agonist-dependent manner. Overexpression of TRIP6 augments LPA-induced cell migration; in contrast, suppression of endogenous TRIP6 expression by a TRIP6-specific small interfering RNA reduces it in SKOV3 ovarian cancer cells. Strikingly, the association with TRIP6 is specific to the LPA(2) receptor but not LPA(1) or LPA(3) receptor, indicating a specific role for TRIP6 in regulating LPA(2) receptor-mediated signaling. Taken together, our results suggest that TRIP6 functions at a point of convergence between the activated LPA(2) receptor and downstream signals involved in cell adhesion and migration.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lin, FT (corresponding author), MCLM 360A,1918 Univ Blvd, Birmingham, AL 35294 USA.	flin@uab.edu			NATIONAL CANCER INSTITUTE [R01CA100848, R01CA100857] Funding Source: NIH RePORTER; NCI NIH HHS [CA100848, R01 CA100857, R01 CA100848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, GENOMICS, V64, P155, DOI 10.1006/geno.2000.6122; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Gorenne I, 2003, AM J PHYSIOL-CELL PH, V285, pC674, DOI 10.1152/ajpcell.00608.2002; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Panetti TS, 2001, PROSTAG OTH LIPID M, V64, P93, DOI 10.1016/S0090-6980(01)00102-2; Petit MMR, 2003, J BIOL CHEM, V278, P2157, DOI 10.1074/jbc.M206106200; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200	34	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10459	10468		10.1074/jbc.M311891200	http://dx.doi.org/10.1074/jbc.M311891200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688263	Green Accepted, hybrid			2022-12-27	WOS:000220050400097
J	Kovari, J; Barabas, O; Takacs, E; Bekesi, A; Dubrovay, F; Pongracz, V; Zagyva, I; Imre, T; Szabo, P; Vertessy, BG				Kovari, J; Barabas, O; Takacs, E; Bekesi, A; Dubrovay, F; Pongracz, V; Zagyva, I; Imre, T; Szabo, P; Vertessy, BG			Altered active site flexibility and a structural metal-binding site in eukaryotic dUTPase - Kinetic characterization, folding, and crystallographic studies of the homotrimeric Drosophila enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; ESCHERICHIA-COLI DUTPASE; CRYSTAL-STRUCTURE; DEOXYURIDINE TRIPHOSPHATASE; URACIL INCORPORATION; C-TERMINUS; EXPRESSION; PYROPHOSPHATASE; PROTEINS; IDENTIFICATION	dUTPase is responsible for preventive DNA repair via exclusion of uracil. Developmental regulation of the Drosophila enzyme is suggested to be involved in thymine-less apoptosis. Here we show that in addition to conserved dUTPase sequence motifs, the gene of Drosophila enzyme codes for a unique Ala-Pro-rich segment. Kinetic and structural analyses of the recombinant protein and a truncation mutant show that the Ala-Pro segment is flexible and has no regulatory role in vitro. The homotrimer enzyme unfolds reversibly as a trimeric entity with a melting temperature of 54degreesC, 23degreesC lower than Escherichia coli dUTPase. In contrast to the bacterial enzyme, Mg2+ binding modulates conformation of fly dUTPase, as identified by spectroscopy and by increment in melting temperature. A single well folded, but inactive, homotrimeric core domain is generated through three distinct steps of limited trypsinolysis. In fly, but not in bacterial dUTPase, binding of the product dUMP induces protection against proteolysis at the tryptic site reflecting formation of the catalytically competent closed conformer. Crystallographic analysis argues for the presence of a stable monomer of Drosophila dUTPase in crystal phase. The significant differences between prototypes of eukaryotic and prokaryotic dUTPases with respect to conformational flexibility of the active site, substrate specificity, metal ion binding, and oligomerization in the crystal phase are consistent with alteration of the catalytic mechanism and hydropathy of subunit interfaces.	Hungarian Acad Sci, BRC, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1518 Budapest, Hungary; Hungarian Acad Sci, Chem Res Ctr, Dept Mass Spectrometry, H-1525 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences	Vertessy, BG (corresponding author), Hungarian Acad Sci, BRC, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Vertessy, Beata G/H-6202-2012; Barabas, Orsolya/F-3961-2012	Barabas, Orsolya/0000-0002-2873-5872; Vertessy, Beata G./0000-0002-1288-2982; Szabo, Pal/0000-0003-2260-4641				Aherne G.W., 1999, ANTICANCER DRUG DEV, P409; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Babu KR, 2000, BIOCHEMISTRY-US, V39, P14702, DOI 10.1021/bi001265t; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barabas O, 2003, J BIOL CHEM, V278, P38803, DOI 10.1074/jbc.M306967200; Begun DJ, 2000, GENETICS, V156, P1879; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; Bergman AC, 1998, FEBS LETT, V441, P327, DOI 10.1016/S0014-5793(98)01575-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; CANMAN CE, 1994, CANCER RES, V54, P2296; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Chu RY, 1996, J BIOL CHEM, V271, P27670, DOI 10.1074/jbc.271.44.27670; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; Evans W, 1997, CHEM BRIT, V33, P22; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gigliotti S, 1998, J CELL BIOL, V142, P1195, DOI 10.1083/jcb.142.5.1195; GIROIR IE, 1987, J BIOL CHEM, V262, P130; Gonzalez A, 2001, ACTA CRYSTALLOGR D, V57, P767, DOI 10.1107/S0907444901004255; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; Kornberg A., 1991, DNA REPLICATION; Ladner RD, 1996, J BIOL CHEM, V271, P7752, DOI 10.1074/jbc.271.13.7752; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; Ladner RD, 2000, CANCER RES, V60, P3493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LESLIE AG, 1999, MOSFLM 6 01; Leyden Webb J, 1963, ENZYME METABOLIC INH; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MORRISON ID, 1985, LANGMUIR, V1, P496, DOI 10.1021/la00064a016; Munoz-Pinedo C, 2001, BIOCHEM J, V353, P101, DOI 10.1042/bj3530101; Mustafi D, 2003, P NATL ACAD SCI USA, V100, P5670, DOI 10.1073/pnas.1031504100; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nord J, 1997, FEBS LETT, V414, P271, DOI 10.1016/S0014-5793(97)00935-6; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; Persson R, 2002, PREP BIOCHEM BIOTECH, V32, P157, DOI 10.1081/PB-120004128; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; Privalov P L, 1986, Methods Enzymol, V131, P4; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Theopold U, 1999, BIOCHEM BIOPH RES CO, V261, P923, DOI 10.1006/bbrc.1999.1121; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; Tinkelenberg BA, 2003, EXP CELL RES, V287, P39, DOI 10.1016/S0014-4827(03)00048-X; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; Vertessy BG, 1996, BIOCHEM BIOPH RES CO, V219, P294, DOI 10.1006/bbrc.1996.0226; VERTESSY BG, 1994, BBA-PROTEIN STRUCT M, V1205, P146, DOI 10.1016/0167-4838(94)90103-1; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vertessy BG, 1998, FEBS LETT, V421, P83, DOI 10.1016/S0014-5793(97)01545-7; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	68	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17932	17944		10.1074/jbc.M313643200	http://dx.doi.org/10.1074/jbc.M313643200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14724274	hybrid			2022-12-27	WOS:000220870400127
J	Guerardel, Y; Czeszak, X; Sumanovski, LT; Karamanos, Y; Popescu, O; Strecker, G; Misevic, GN				Guerardel, Y; Czeszak, X; Sumanovski, LT; Karamanos, Y; Popescu, O; Strecker, G; Misevic, GN			Molecular fingerprinting of carbohydrate structure phenotypes of three Porifera proteoglycan-like glyconectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE MICROCIONA-PROLIFERA; MAGNETIC-RESONANCE SPECTROSCOPY; GAS-LIQUID-CHROMATOGRAPHY; CELL-ADHESION; AGGREGATION FACTOR; METHYL-GLYCOSIDES; MELANOMA-CELLS; RECOGNITION; GLYCOPROTEINS; GLYCAN	Glyconectins (GNs) represent a new class of proteoglycan-like cell adhesion and recognition molecules found in several Porifera species. Physico-chemical properties of GN carbohydrate moieties, such as size, composition, and resistance to most glycosaminoglycan-degrading enzymes, distinguish them from any other type of known glycoproteins. The molecular mechanism of GN-mediated self/non-self discrimination function is based on highly species-specific and Ca2+-dependent GN to GN associations that approach the selectivity of the evolutionarily advanced immunoglobulin superfamily. Carbohydrates of glyconectins 1, 2, and 3 are essential for species-specific auto-aggregation properties in three respective Porifera species. To obtain a structural insight into the molecular mechanisms, we performed carbohydrate structural analyses of glyconectins isolated from the three sponge model systems, Microciona prolifera (GN1), Halichondria panicea (GN2), and Cliona celata (GN3). The glycan content of all three GNs ranged between 40 and 60% of their total mass. Our approach using sequential and selective chemical degradation of GN glycans and subsequent mass spectrometric and NMR analyses revealed that each glyconectin presents novel and highly species-specific carbohydrate sequences. All three GNs include distinct acid-resistant and acid-labile carbohydrate domains, the latter composed of novel repetitive units. We have sequenced four short sulfated and one pyruvilated unit in GN1, eight larger and branched pyruvilated oligosaccharides in GN2, which represent a heterogeneous but related family of structures, and four sulfated units in GN3.	Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France; Univ Sci & Technol Lille, CNRS, UMR 8576, Unite Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France; Univ Basel Hosp, Dept Res, CH-4058 Basel, Switzerland; Univ Artois, Fac J Perrin, Lab Biochim Mol & Cellulaire, F-62307 Lens, France; Univ Babes Bolyai, Ctr Mol Biol, Cluj Napoca 400006, Romania; Univ Babes Bolyai, Inst Interdisciplinary Expt Res, Cluj Napoca 400006, Romania	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; University of Basel; Universite d'Artois; Babes Bolyai University from Cluj; Babes Bolyai University from Cluj	Misevic, GN (corresponding author), Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France.	gradimir@gradimir.com	Popescu, Octavian/O-2134-2019; Karamanos, Yannis/AAE-9379-2020; Popescu, Octavian/E-4942-2010; Popescu, Octavian/C-4027-2011; Misevic, Gradimir/D-8294-2016	Popescu, Octavian/0000-0002-2597-7155; Karamanos, Yannis/0000-0002-2411-6636; Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Guerardel, Yann/0000-0003-4967-9512				BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; Cerantola S, 1996, CARBOHYD RES, V285, P59, DOI 10.1016/0008-6215(96)00014-6; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FONTAINE T, 1991, EUR J BIOCHEM, V196, P105, DOI 10.1111/j.1432-1033.1991.tb15792.x; Haseley SR, 2001, P NATL ACAD SCI USA, V98, P9419, DOI 10.1073/pnas.151111298; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; Misevic GN, 2004, J BIOL CHEM, V279, P15579, DOI 10.1074/jbc.M308927200; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; Van Calsteren MR, 2002, BIOCHEM J, V363, P7, DOI 10.1042/0264-6021:3630007; Yang BY, 2001, CARBOHYD RES, V331, P59, DOI 10.1016/S0008-6215(01)00004-0; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255	22	27	29	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15591	15603		10.1074/jbc.M308928200	http://dx.doi.org/10.1074/jbc.M308928200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14701843	hybrid			2022-12-27	WOS:000220594700131
J	Holthauzen, LMF; Correa, F; Farah, CS				Holthauzen, LMF; Correa, F; Farah, CS			Ca2+-induced rolling of tropomyosin in muscle thin filaments - The alpha- and beta-band hypothesis revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE SKELETAL-MUSCLE; MYOSIN-ACTIN INTERACTIONS; CRYSTAL-STRUCTURE; TROPONIN-I; 3-DIMENSIONAL RECONSTRUCTION; COOPERATIVE REGULATION; REGULATORY PROPERTIES; ESCHERICHIA-COLI; STRIATED-MUSCLE; MODEL	Tropomyosin is a filamentous coiled-coil protein directly involved in the regulation of the actomyosin interaction responsible for muscle contraction: it transmits the local calcium-induced conformational change in troponin to the helical array of myosin-binding sites on the surface of the actin filament. McLachlan and Stewart (McLachlan, A. D., and Stewart, M. (1976) J. Mol. Biol. 103, 271-298) proposed that the tropomyosin coiled-coil structure can be divided into 14 alternating 19- to 20-residue "alpha- and beta-bands," which could act as alternate 7-fold sets of sites for specific binding to actin in the different conformational states of the regulated thin filament. Here we present the first direct experimental evidence in support of the alpha- and beta-band hypothesis: we analyze the acrylamide quenching of the fluorescence of mutant tropomyosins containing 5-hydroxytryptophan residues at different positions along the coiled-coil structure under a variety of conditions (alone, complexed with actin, and complexed with actin and troponin with or without Ca2+). We show that fluorescent probes placed in the alpha-bands become less solvent-exposed in the absence of calcium, whereas those in the beta-bands become less solvent-exposed in the presence of calcium. A model in which the tropomyosin coiled-coil rolls across the actin surface in response to Ca2+-binding to troponin most easily explains these observations.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo	Farah, CS (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Av Prof Lineu Prestes 748, BR-05508900 Sao Paulo, Brazil.	chsfarah@iq.usp.br	Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302; Correa, Fernando/0000-0001-5349-1104				Bacchiocchi C, 2002, BIOPHYS J, V82, P1524, DOI 10.1016/S0006-3495(02)75505-7; COHEN CAROLYN, 1963, JOUR MOLECULAR BIOL, V6, P423; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Das K, 1999, PHOTOCHEM PHOTOBIOL, V70, P719; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; Eftink MR, 1991, TOPICS FLUORESCENCE, V2, P53; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; ISHII Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P193, DOI 10.1006/abbi.1993.1410; JOHNSON P, 1975, BIOCHEM BIOPH RES CO, V64, P1316, DOI 10.1016/0006-291X(75)90836-0; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer S S, 1978, Methods Enzymol, V49, P222; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Palm T, 2003, BIOPHYS J, V84, P3181, DOI 10.1016/S0006-3495(03)70042-3; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PARRY DAD, 1974, BIOCHEM BIOPH RES CO, V57, P216, DOI 10.1016/S0006-291X(74)80379-7; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; Paulucci AA, 2002, J BIOL CHEM, V277, P39574, DOI 10.1074/jbc.M204749200; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; Smith DA, 2003, BIOPHYS J, V84, P3168, DOI 10.1016/S0006-3495(03)70041-1; Sousa AD, 2002, J BIOL CHEM, V277, P2081, DOI 10.1074/jbc.M109568200; SOUSA AD, 2002, THESIS U SAO PAULO B; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STEWART M, 1975, NATURE, V257, P331, DOI 10.1038/257331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WAHL P, 1978, EUR J BIOCHEM, V88, P421, DOI 10.1111/j.1432-1033.1978.tb12464.x; Whitby FG, 2000, PROTEINS, V38, P49; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	58	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15204	15213		10.1074/jbc.M308904200	http://dx.doi.org/10.1074/jbc.M308904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724287	hybrid			2022-12-27	WOS:000220594700087
J	Rousset, M; Cens, T; Gouin-Charnet, A; Scamps, F; Charnet, P				Rousset, M; Cens, T; Gouin-Charnet, A; Scamps, F; Charnet, P			Ca2+ and phosphatidylinositol 4,5-bisphosphate stabilize a G beta gamma-sensitive state of Ca(V)2 Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN INHIBITION; VOLTAGE-DEPENDENT FACILITATION; RECTIFYING K+ CHANNELS; CALCIUM-CHANNELS; CA2+-DEPENDENT INACTIVATION; KINASE-C; N-TYPE; DIFFERENTIAL MODULATION; BINDING; ACTIVATION	Direct interactions between G-protein betagamma subunits and N- or P/Q-type Ca2+ channels mediate the inhibitory action of several neurotransmitters in the brain. Membrane potential, channel phosphorylation, or auxiliary subunit association tightly regulate these interactions and the consequent inhibition of Ca2+ current. We now provide evidence that intracellular Ca2+ concentration and phosphoinositides play a stabilizing role in this direct voltage-dependent inhibition. Lowering resting cytosolic Ca2+ concentration in Xenopus oocytes expressing Ca(V)2 Ca2+ channels strongly decreased basal as well as phasic, agonist-dependent inhibition of Ca2+ channels by G-proteins. Decreasing phosphoinositide levels also suppressed G-protein inhibition and completely occluded the effects of a subsequent injection of Ca2+ chelator. Similar regulations are observed in mouse dorsal root ganglia neurons. Alteration of G-protein block by these agents is independent of protein phosphorylation, cytoskeleton dynamics, and GTPase or GDP/GTP exchange activity, suggesting a direct action at the level of the Ca2+ channel/Gbetagamma-protein interaction. Moreover, affinity binding experiments of intracellular loops of the Ca(V)2.1 Ca2+ channels to different phospholipids revealed specific interactions between the C-terminal tail of the channel and phosphoinositides. Taken together these data indicate that a Ca2+-sensitive interaction of the C-terminal tail of P/Q channels with the plasma membrane is important for G-protein regulation.	CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier, France; CNRS, INSERM, U469, F-34094 Montpellier, France; INSERM, U583, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Charnet, P (corresponding author), CNRS, Ctr Rech Biochim Macromol, FRE 2593,1919 Route Mende, F-34293 Montpellier, France.	charnet@crbm.cnrs-mop.fr	Scamps, Frédérique/M-5268-2018; Cens, Thierry/M-3337-2017	Scamps, Frédérique/0000-0001-9545-407X; Cens, Thierry/0000-0002-4109-2779; Charnet, Pierre/0000-0003-4692-528X; Rousset, Matthieu/0000-0003-2064-2791				Andre S, 2003, NEUROREPORT, V14, P147, DOI 10.1097/01.wnr.0000051545.96524.bb; BEECH DJ, 1991, P NATL ACAD SCI USA, V88, P652, DOI 10.1073/pnas.88.2.652; Bodding M, 1999, PFLUG ARCH EUR J PHY, V439, P27, DOI 10.1007/s004240051124; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; Burrone J, 2002, NEURON, V33, P101, DOI 10.1016/S0896-6273(01)00565-7; Canti C, 2000, J PHYSIOL-LONDON, V527, P419, DOI 10.1111/j.1469-7793.2000.t01-1-00419.x; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Herlitze S, 2001, P NATL ACAD SCI USA, V98, P4699, DOI 10.1073/pnas.051628998; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; JACQUES JP, 1999, J GEN PHYSIOL, V114, P673; Kinoshita M, 2001, J BIOL CHEM, V276, P28731, DOI 10.1074/jbc.M104806200; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; LORENZEN A, 1993, MOL PHARMACOL, V44, P115; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; MOGUL DJ, 1993, NEURON, V10, P327, DOI 10.1016/0896-6273(93)90322-I; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Page KM, 1998, J NEUROSCI, V18, P4815; Page KM, 1997, J NEUROSCI, V17, P1330; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; ROCHE JP, 1995, FEBS LETT, V371, P43, DOI 10.1016/0014-5793(95)00860-C; Roche JP, 1998, J NEUROSCI, V18, P4883; Roche JP, 1998, J NEUROSCI, V18, P878; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x; You YD, 1997, BIOPHYS J, V72, P175, DOI 10.1016/S0006-3495(97)78656-9; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	59	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14619	14630		10.1074/jbc.M313284200	http://dx.doi.org/10.1074/jbc.M313284200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722074	hybrid			2022-12-27	WOS:000220594700020
J	Hekman, M; Wiese, S; Metz, R; Albert, S; Troppmair, J; Nickel, J; Sendtner, M; Rapp, UR				Hekman, M; Wiese, S; Metz, R; Albert, S; Troppmair, J; Nickel, J; Sendtner, M; Rapp, UR			Dynamic changes in C-raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation - Differential roles of 14-3-3 protein binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-RAF; MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; SIGNALING PROTEINS; PHOSPHATIDIC-ACID; ACTIVATES RAF-1; LIPID RAFTS; V-RAF; A-RAF; KINASE	Phosphorylation events play a crucial role in Raf activation. Phosphorylation of serines 259 and 621 in C-Raf and serines 364 and 728 in B-Raf has been suggested to be critical for association with 14-3-3 proteins. To study the functional consequences of Raf phosphorylations at these positions, we developed and characterized phosphospecific antibodies directed against 14-3-3 binding epitopes: a monoclonal phosphospecific antibody (6B4) directed against pS621 and a polyclonal antibody specific for B-Raf-pS364 epitope. Although 6B4 detected both C- and B-Raf in Western blots, it specifically recognizes the native form of C- Raf but not B-Raf. Contrary to B-Raf, a kinase-dead mutant of C- Raf was found to be only poorly phosphorylated in the Ser-621 position. Moreover, serine 259 to alanine mutation prevented the Ser-621 phosphorylation suggesting an interdependence between these two 14-3-3 binding domains. Direct C- Raf . 14-3-3 binding studies with purified proteins combined with competition assays revealed that the 14-3-3 binding domain surrounding pS621 represents the high affinity binding site, whereas the pS259 epitope mediates lower affinity binding. Raf isozymes differ in their 14-3-3 association rates. The time course of endogenous C- Raf activation in mammalian cells by nerve growth factor (NGF) has been examined using both phosphospecific antibodies directed against 14-3-3 binding sites (6B4 and anti-pS259) as well as phosphospecific antibodies directed against the activation domain (anti-pS338 and anti-pY340/pY341). Time course of Ser-621 phosphorylation, in contrast to Ser-259 phosphorylation, exhibited unexpected pattern reaching maximal phosphorylation within 30 s of NGF stimulation. Phosphorylation of tyrosine 340/341 reached maximal levels subsequent to Ser-621 phosphorylation and was coincident with emergence of kinase activity. Taken together, we found substantial differences between C- Raf . 14-3-3 binding epitopes pS259 and pS621 and visualized for the first time the sequence of the essential C- Raf phosphorylation events in mammalian cells in response to growth factor stimulation.	Univ Wurzburg, Inst Med Radiat & Cell Res, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Clin Neurobiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Radiat & Cell Res, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de	Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Troppmair, Jakob/0000-0002-0611-3837				Afanassiev V, 1998, HYBRIDOMA, V17, P383, DOI 10.1089/hyb.1998.17.383; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Papin C, 1996, ONCOGENE, V12, P2213; Raabe T, 2003, CURR BIOL, V13, pR635, DOI 10.1016/S0960-9822(03)00568-2; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SCHULTZ AM, 1988, ONCOGENE, V2, P187; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; SUEN KL, 1995, ONCOGENE, V11, P825; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Weber CK, 2001, CANCER RES, V61, P3595; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	47	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14074	14086		10.1074/jbc.M309620200	http://dx.doi.org/10.1074/jbc.M309620200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14688280	hybrid			2022-12-27	WOS:000220478500097
J	Hu, MC; Wasserman, D; Hartwig, S; Rosenblum, ND				Hu, MC; Wasserman, D; Hartwig, S; Rosenblum, ND			p38(MAPK) acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; RENAL BRANCHING MORPHOGENESIS; SIGNALING PATHWAYS; TGF-BETA; I RECEPTORS; EXPRESSION; COMPLEXES; ACTIVIN	Bone morphogenetic protein (BMP)-7 exerts dose-dependent stimulatory and inhibitory effects during renal branching morphogenesis. Previously, we identified an inhibitory role for activin-like kinase receptors and Smad1 in BMP-dependent inhibition (Piscione, T. D., Phan, T., and Rosenblum, N. D. (2001) Am. J. Physiol. 280, F19-F33). Here we demonstrate a novel role for p38 mitogen-activated kinase (p38(MAPK)) in BMP7-dependent stimulatory signaling. Stimulatory doses (0.25 nM) of BMP7 increased p38(MAPK) activity and stimulated phosphorylation of endogenous activating transcription factor 2 (ATF2) in a p38(MAPK)-dependent manner in murine inner medullary collecting duct (mIMCD-3) cells. In contrast, high doses ( 10 nM) of BMP7 inhibited p38(MAPK) activity and phosphorylation of endogenous ATF2. Treatment with BMP7 exerted no significant effect on the levels of the phosphorylated forms of endogenous SAPK/JNK or p44 and p42 (ERK1 and ERK2) protein kinases. To investigate the functional importance of p38(MAPK) signaling, we showed that SB203580, a p38(MAPK) inhibitor, blocked the stimulatory effect of BMP7 on mIMCD-3 cell morphogenesis but had no effect on BMP7-dependent inhibition in a three-dimensional culture model. To identify mechanisms by which BMP7-dependent inhibitory signaling suppresses p38(MAPK) activity, we measured p38(MAPK) activity in ligand independent mIMCD-3 models of enhanced and suppressed Smad signaling. Basal activity of p38(MAPK) was decreased in mIMCD-3 cells and in embryonic kidney tissue expressing a constitutively active activin-like kinase receptor, but was increased in mIMCD-3 cells stably expressing a dominant negative form of Smad1. We conclude that BMP7 stimulates renal epithelial cell morphogenesis via p38(MAPK) and that p38(MAPK) activity is negatively regulated by Smad1.	Univ Toronto, Hosp Sick Children, Div Nephrol, Program Dev Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rosenblum, ND (corresponding author), Univ Toronto, Hosp Sick Children, Div Nephrol, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	norman.rosenblum@sickkids.ca	Rosenblum, Norman D/H-4737-2015	Rosenblum, Norman D/0000-0003-1767-6464				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1997, DEV DYNAM, V208, P349; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Gupta IR, 1999, J BIOL CHEM, V274, P26305, DOI 10.1074/jbc.274.37.26305; Gupta IR, 2000, J CELL SCI, V113, P269; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Hida M, 2002, KIDNEY INT, V61, P1252, DOI 10.1046/j.1523-1755.2002.00273.x; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hu MC, 2003, DEVELOPMENT, V130, P2753, DOI 10.1242/dev.00478; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Piscione TD, 1997, AM J PHYSIOL-RENAL, V273, pF961, DOI 10.1152/ajprenal.1997.273.6.F961; Piscione TD, 2001, AM J PHYSIOL-RENAL, V280, pF19, DOI 10.1152/ajprenal.2001.280.1.F19; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Yamanaka Y, 2001, BIOCHEM BIOPH RES CO, V281, P373, DOI 10.1006/bbrc.2001.4385; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	37	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12051	12059		10.1074/jbc.M310526200	http://dx.doi.org/10.1074/jbc.M310526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718543	hybrid			2022-12-27	WOS:000220334900008
J	Keyel, PA; Watkins, SC; Traub, LM				Keyel, PA; Watkins, SC; Traub, LM			Endocytic adaptor molecules reveal an endosomal population of clathrin by total internal reflection fluorescence microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEMBRANE-ASSOCIATED CLATHRIN; TRANS-GOLGI NETWORK; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; LIVING CELLS; FACTOR RECEPTOR; AP-1 COMPLEX; COATED PITS; PROTEIN	Most eukaryotes utilize a single pool of clathrin to assemble clathrin-coated transport vesicles at different intracellular locations. Coat assembly is a cyclical process. Soluble clathrin triskelia are recruited to the membrane surface by compartment-specific adaptor and/or accessory proteins. Adjacent triskelia then pack together to assemble a polyhedral lattice that progressively invaginates, budding off the membrane surface encasing a nascent transport vesicle that is quickly uncoated. Using total internal reflection fluorescence microscopy to follow clathrin dynamics close to the cell surface, we find that the majority of labeled clathrin structures are relatively static, moving vertically in and out of the evanescent field but with little lateral motion. A small minority shows rapid lateral and directed movement over micrometer distances. Adaptor proteins, including the alpha subunit of AP-2, ARH, and Dab2 are also relatively static and exhibit virtually no lateral movement. A fluorescently labeled AP-2 beta2 subunit, incorporated into both AP-2 and AP-1 adaptor complexes, exhibits both types of behavior. This suggests that the highly motile clathrin puncta may be distinct from plasma membrane-associated clathrin structures. When endocytosed cargo molecules, such as transferrin or low density lipoprotein, are followed into cells, they exhibit even more lateral motion than clathrin, and gradually concentrate in the perinuclear region, consistent with classical endosomal trafficking. Importantly, clathrin partially colocalizes with internalized transferrin, but diverges as the structures move longitudinally. Thus, highly motile clathrin structures are apparently distinct from the plasma membrane, accompany transferrin, and contain AP-1, revealing an endosomal population of clathrin structures.	Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Traub, LM (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, S325 BSTWR, Pittsburgh, PA 15261 USA.	traub@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249, T32DK061296] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK 061296-02, R01 DK 53249] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Bennett EM, 2001, MOL BIOL CELL, V12, P2790, DOI 10.1091/mbc.12.9.2790; Blanpied TA, 2003, NEUROBIOL AGING, V24, P1095, DOI 10.1016/j.neurobiolaging.2003.04.004; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang FT, 2001, TRAFFIC, V2, P345, DOI 10.1034/j.1600-0854.2001.25020506.x; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; Santini F, 2002, NAT CELL BIOL, V4, pE230, DOI 10.1038/ncb1002-e230; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Wu XF, 2003, MOL BIOL CELL, V14, P516, DOI 10.1091/mbc.E02-06-0353; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085	55	72	73	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13190	13204		10.1074/jbc.M312717200	http://dx.doi.org/10.1074/jbc.M312717200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722064	hybrid			2022-12-27	WOS:000220334900141
J	Takano, M; Koyama, Y; Ito, H; Hoshino, S; Onogi, H; Hagiwara, M; Furukawa, K; Horigome, T				Takano, M; Koyama, Y; Ito, H; Hoshino, S; Onogi, H; Hagiwara, M; Furukawa, K; Horigome, T			Regulation of binding of lamin B receptor to chromatin by SR protein kinase and cdc2 kinase in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; SPLICING FACTORS; MEMBRANE; LOCALIZATION; LBR; PHOSPHORYLATION; EMERIN; SRPK2	Participation of multiple kinases in regulation of the binding of lamin B receptor (LBR) to chromatin was suggested previously (Takano, M., Takeuchi, M., Ito, H., Furukawa, K., Sugimoto, K., Omata, S., and Horigome, T. (2002) Eur. J. Biochem. 269, 943 - 953). To identify these kinases, regulation of the binding of the nucleoplasmic region (NK, amino acid residues 1 - 211) of LBR to sperm chromatin was studied using a cell cycle-dependent Xenopus egg extract in vitro. The binding was stimulated on specific phosphorylation of the NK fragment by an S-phase egg extract. Protein depletion with beads bearing SF2/ASF, which binds SR protein kinases, abolished this stimulation, suggesting that an SR protein kinase(s) is responsible for the activation of LBR. This was confirmed by direct phosphorylation and activation with recombinant SR protein-specific kinase 1. The binding of the NK fragment to chromatin pretreated with an S-phase extract was suppressed by incubation with an M-phase extract. Enzyme inhibitor experiments revealed that multiple kinases participate in the suppression. One of these kinases was shown to be cdc2 kinase using a specific inhibitor, roscovitine, and protein depletion with beads bearing p13, which specifically binds cdc2 kinase. Experiments involving a mutant NK fragment showed that the phosphorylation of serine 71 by cdc2 kinase is responsible for the suppression.	Niigata Univ, Fac Sci, Dept Chem, Niigata 9502181, Japan; Niigata Univ, Grad Sch Sci & Technol, Course Biosphere Sci, Niigata 9502181, Japan; Niigata Univ, Grad Sch Sci & Technol, Course Funct Biol, Niigata 9502181, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Bunkyo Ku, Tokyo 1130034, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata 9502181, Japan	Niigata University; Niigata University; Niigata University; Tokyo Medical & Dental University (TMDU); Niigata University	Horigome, T (corresponding author), Niigata Univ, Fac Sci, Dept Chem, Igarashi 2, Niigata 9502181, Japan.	thori@chem.sc.niigata-u.ac.jp						Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; Dreger M, 1999, BIOCHEMISTRY-US, V38, P9426, DOI 10.1021/bi990645f; Duband-Goulet I, 2000, BIOCHEMISTRY-US, V39, P6483, DOI 10.1021/bi992908b; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Haraguchi T, 2000, J CELL SCI, V113, P779; Hoffmann K, 2002, NAT GENET, V31, P410, DOI 10.1038/ng925; Kawahire S, 1996, EXP CELL RES, V222, P385, DOI 10.1006/excr.1996.0048; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Papoutsopoulou S, 1999, BIOCHEM BIOPH RES CO, V255, P602, DOI 10.1006/bbrc.1999.0249; PFALLER R, 1995, J BIOL CHEM, V270, P19066, DOI 10.1074/jbc.270.32.19066; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Takano M, 2002, EUR J BIOCHEM, V269, P943, DOI 10.1046/j.0014-2956.2001.02730.x; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737	23	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13265	13271		10.1074/jbc.M308854200	http://dx.doi.org/10.1074/jbc.M308854200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718546	hybrid			2022-12-27	WOS:000220334900149
J	Wong, GT; Manfra, D; Poulet, FM; Zhang, Q; Josien, H; Bara, T; Engstrom, L; Pinzon-Ortiz, M; Fine, JS; Lee, HJJ; Zhang, LL; Higgins, GA; Parker, EM				Wong, GT; Manfra, D; Poulet, FM; Zhang, Q; Josien, H; Bara, T; Engstrom, L; Pinzon-Ortiz, M; Fine, JS; Lee, HJJ; Zhang, LL; Higgins, GA; Parker, EM			Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; E-CADHERIN; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; FATE; CLEAVAGE; NOTCH1; NEUROPATHOLOGY; RELEASE; APP	Inhibition of gamma-secretase, one of the enzymes responsible for the cleavage of the amyloid precursor protein (APP) to produce the pathogenic beta-amyloid (Abeta) peptides, is an attractive approach to the treatment of Alzheimer disease. In addition to APP, however, several other gamma-secretase substrates have been identified (e.g. Notch), and altered processing of these substrates by gamma-secretase inhibitors could lead to unintended biological consequences. To study the in vivo consequences of gamma-secretase inhibition, the gamma-secretase inhibitor LY-411,575 was administered to C57BL/6 and TgCRND8 APP transgenic mice for 15 days. Although most tissues were unaffected, doses of LY-411,575 that inhibited Abeta production had marked effects on lymphocyte development and on the intestine. LY-411,575 decreased overall thymic cellularity and impaired intrathymic differentiation at the CD4(-)CD8(-)CD44(+)CD25(+) precursor stage. No effects on peripheral T cell populations were noted following LY-411,575 treatment, but evidence for the altered maturation of peripheral B cells was observed. In the intestine, LY-411,575 treatment increased goblet cell number and drastically altered tissue morphology. These effects of LY-411,575 were not seen in mice that were administered LY-D, a diastereoisomer of LY-411,575, which is a very weak gamma-secretase inhibitor. These studies show that inhibition of gamma-secretase has the expected benefit of reducing Abeta in a murine model of Alzheimer disease but has potentially undesirable biological effects as well, most likely because of the inhibition of Notch processing.	Schering Plough Res Inst, Dept CNS Res, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Immunol, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Chem Res, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Drug Safety, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Parker, EM (corresponding author), Schering Plough Res Inst, Dept CNS Res, Mail Stop K-15-2-2760,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	eric.parker@spcorp.com						Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berzins SP, 2002, TRENDS MOL MED, V8, P469, DOI 10.1016/S1471-4914(02)02415-2; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ewbank DC, 1999, AM J PUBLIC HEALTH, V89, P90, DOI 10.2105/AJPH.89.1.90; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Garcia-Peydro M, 2003, BLOOD, V102, P2444, DOI 10.1182/blood-2002-10-3261; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Josien H, 2002, CURR OPIN DRUG DI DE, V5, P513; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Kutlesa S, 2002, J CELL SCI, V115, P4505, DOI 10.1242/jcs.00142; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MAY PC, 2001, SOC NEUR 31 ANN M SA, P681; Muller KM, 1997, IMMUNITY, V6, P257, DOI 10.1016/S1074-7613(00)80328-3; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Stoop R, 2002, EUR J IMMUNOL, V32, P2532, DOI 10.1002/1521-4141(200209)32:9<2532::AID-IMMU2532>3.0.CO;2-A; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WU J, 1998, Patent No. [09828268, 9828268]; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	46	600	647	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12876	12882		10.1074/jbc.M311652200	http://dx.doi.org/10.1074/jbc.M311652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709552	hybrid			2022-12-27	WOS:000220334900104
J	Zaballos, A; Villares, R; Albar, JP; Martinez, C; Marquez, G				Zaballos, A; Villares, R; Albar, JP; Martinez, C; Marquez, G			Identification on mouse chromosome 8 of new beta-defensin genes with regionally specific expression in the male reproductive organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL ACTIVITY; CHEMOKINE RECEPTOR; DENDRITIC CELLS; IMMUNITY; PURIFICATION; EPIDIDYMIS; MULTIPLE; PEPTIDE; CCR6; MICE	Defensins are important elements in innate immunity that can also trigger adaptive immune responses. The defensins form a family of small cationic antimicrobial peptides with six characteristic cysteine residues, whose pairing pattern in forming three intramolecular disulfide bonds defines the alpha- and beta-defensin subfamilies. In a search for new beta-defensin genes, we performed computational analysis using the Celera mouse genome data base and found exons encoding 23 different beta-defensins, including the eight previously characterized members of this family. Among the new beta-defensins, nine of them form two groups of phylogenetically related sequences that were characterized in greater detail. Northern blot, reverse transcription PCR, and in situ hybridization analysis showed that expression of these genes is restricted to the epididymis, with a specific regional expression pattern. One of the new beta-defensins (Defb38) was chemically synthesized; in in vitro assays on Gram-positive and -negative bacterial strains, Defb38 showed the characteristic salt-dependent antimicrobial activity of beta-defensins. The results demonstrate the existence of a relatively large number of beta-defensins with specific expression in distinct regions of the murine epididymis and suggest complex roles for these proteins in host defense and other physiological processes of the male reproductive tract.	Univ Autonoma Madrid, Dept Inmunol & Oncol, Ctr Nacl Biotecnol, Consejo Super Invest Cient, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Marquez, G (corresponding author), Univ Autonoma Madrid, Dept Inmunol & Oncol, Ctr Nacl Biotecnol, Consejo Super Invest Cient, E-28049 Madrid, Spain.	gmarquez@cnb.uam.es	Villares, Ricardo/AAN-3755-2021; Villares, Ricardo/AAA-7236-2020; Zaballos, Ángel/O-2853-2015	Villares, Ricardo/0000-0001-7562-6700; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Carramolino L, 2001, BLOOD, V97, P850, DOI 10.1182/blood.V97.4.850; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Latifi A, 1996, MOL MICROBIOL, V21, P1137, DOI 10.1046/j.1365-2958.1996.00063.x; Li P, 2001, SCIENCE, V291, P1783, DOI 10.1126/science.1056545; Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200; Rodriguez-Jimenez FJ, 2003, GENOMICS, V81, P175, DOI 10.1016/S0888-7543(02)00034-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Yamaguchi Y, 2002, J IMMUNOL, V169, P2516, DOI 10.4049/jimmunol.169.5.2516; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	22	29	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12421	12426		10.1074/jbc.M307697200	http://dx.doi.org/10.1074/jbc.M307697200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718547	hybrid			2022-12-27	WOS:000220334900051
J	Flandez, M; Cosano, IC; Nombela, C; Martin, H; Molina, M				Flandez, M; Cosano, IC; Nombela, C; Martin, H; Molina, M			Reciprocal regulation between Slt2 MAPK and isoforms of Msg5 dual-specificity protein phosphatase modulates the yeast cell integrity pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHATASES; KINASE PATHWAY; BUDDING YEAST; MESSENGER-RNA; DIFFERENTIAL REGULATION; ESCHERICHIA-COLI; SHUTTLE VECTORS; FUSION PROTEINS	Dual-specificity protein phosphatases (DSPs) are involved in the negative regulation of mitogen-activated protein kinases (MAPKs) by dephosphorylating both threonine- and tyrosine-conserved residues located at the activation loop. Here we show that Msg5 DSP activity is essential for maintaining a low level of signaling through the cell integrity pathway in Saccharomyces cerevisiae. Consistent with a role of this phosphatase on cell wall physiology, cells lacking Msg5 displayed an increased sensitivity to the cell wall-interfering compound Congo Red. We have observed that the N-terminal non-catalytic region of this phosphatase was responsible for binding to the kinase domain of Slt2, the MAPK that operates in this pathway. In vivo and in vitro experiments revealed that both proteins act on each other. Msg5 bound and dephosphorylated activated Slt2. Reciprocally, Slt2 phosphorylated Msg5 as a consequence of the activation of the cell integrity pathway. In addition, alternative use of translation initiation sites at MSG5 resulted in two protein forms that are functional on Slt2 and became equally phosphorylated following activation of this MAPK. Under activating conditions, a decrease in the affinity between Msg5 and Slt2 was observed, leading us to suggest that the mechanism by which Slt2 controls the action of Msg5 was via the modulation of protein-protein interactions. Our results indicate the existence of posttranscriptional mechanisms of regulation of DSPs in yeast and provide new insights into the negative control of the cell integrity pathway.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Molina, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Pza Ramon & Cajal S-N, E-28040 Madrid, Spain.	molmifa@farm.ucm.es	Brieva, Humberto Martin/E-9254-2016; Canet, Marta Flández/E-2681-2019; Molina, Maria/ABE-7186-2021; Martín, Humberto/Z-3423-2019; Nombela Cano, César/H-2565-2015	Brieva, Humberto Martin/0000-0002-6736-3602; Canet, Marta Flández/0000-0002-9096-2267; Molina, Maria/0000-0003-0074-3309; Martín, Humberto/0000-0002-6736-3602; Nombela Cano, César/0000-0003-0757-4034				Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Collister M, 2002, FEBS LETT, V527, P186, DOI 10.1016/S0014-5793(02)03220-9; Davenport KD, 1999, GENETICS, V153, P1091; de Groot PWJ, 2001, COMP FUNCT GENOM, V2, P124, DOI 10.1002/cfg.85; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HUANG KN, 1995, GENETICS, V141, P1275; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Logette E, 2003, ONCOGENE, V22, P935, DOI 10.1038/sj.onc.1206172; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; RONCERO C, 1985, J BACTERIOL, V163, P1180, DOI 10.1128/JB.163.3.1180-1185.1985; SAMROOK J, 1989, MOL CLONING LAB MANU; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; SOLER M, 1995, MOL MICROBIOL, V17, P833, DOI 10.1111/j.1365-2958.1995.mmi_17050833.x; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; Vink E, 2002, MICROBIOL-SGM, V148, P4035, DOI 10.1099/00221287-148-12-4035; Vivier MA, 1999, MOL GEN GENET, V261, P11, DOI 10.1007/s004380050936; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811; Zhang ZY, 2002, PHARMACOL THERAPEUT, V93, P307, DOI 10.1016/S0163-7258(02)00199-7; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	51	61	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11027	11034		10.1074/jbc.M306412200	http://dx.doi.org/10.1074/jbc.M306412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14703512	hybrid			2022-12-27	WOS:000220157600025
J	Koonpaew, S; Janssen, E; Zhu, MH; Zhang, WG				Koonpaew, S; Janssen, E; Zhu, MH; Zhang, WG			The importance of three membrane-distal tyrosines in the adaptor protein NTAL/LAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; MOLECULAR-CLONING; ANTIGEN RECEPTOR; MEDIATED ACTIVATION; SIGNALING PATHWAYS; LINKER PROTEIN; LAT; SLP-76; REQUIREMENT	NTAL (non-T cell activation linker)/LAB ( linker for activation of B cells) is a LAT ( linker for activation of T cells)-like molecule that is expressed in B cells, mast cells, natural killer cells, and monocytes. Upon engagement of the B cell receptor or Fc receptors, it is phosphorylated and interacts with Grb2. LAB is capable of rescuing thymocyte development in LAT(-/-) mice. In this study, we utilized various LAB Tyr to Phe mutants to map the phosphorylation and Grb2-binding sites of LAB. We also examined the function of these mutants by investigating their ability to rescue signaling defects in LAT-deficient Jurkat cells and thymocyte development in LAT(-/-) mice. Our results indicated that human LAB was primarily phosphorylated on three membrane-distal tyrosines, Tyr(136), Tyr(193), and Tyr(233). Mutation of these three tyrosines abolished Grb2 binding and LAB function. Our data suggested that these tyrosines are the most important tyrosines for LAB function.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Zhang, WG (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Jones Bldg Rm 112,Box 3010, Durham, NC 27710 USA.	zhang033@mc.duke.edu	Koonpaew, Surapong/C-8295-2011	Janssen, Erin/0000-0002-0687-2550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056156, R01AI048674, R56AI056156] Funding Source: NIH RePORTER; NIAID NIH HHS [AI056156, 1 R01 AI048674, R01 AI056156] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguado E, 2002, SCIENCE, V296, P2036, DOI 10.1126/science.1069057; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Sommers CL, 2001, J EXP MED, V194, P135, DOI 10.1084/jem.194.2.135; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu MH, 2002, J BIOL CHEM, V277, P46151, DOI 10.1074/jbc.M208946200; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	34	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11229	11235		10.1074/jbc.M311394200	http://dx.doi.org/10.1074/jbc.M311394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722116	hybrid			2022-12-27	WOS:000220157600049
J	Stoorvogel, W; Kerstens, S; Fritzsche, I; den Hartigh, JC; Oud, R; van der Heyden, MAG; Voortman, J; Henegouwen, PMPVE				Stoorvogel, W; Kerstens, S; Fritzsche, I; den Hartigh, JC; Oud, R; van der Heyden, MAG; Voortman, J; Henegouwen, PMPVE			Sorting of ligand-activated epidermal growth factor receptor to lysosomes requires its actin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; EGF-RECEPTOR; DOWN-REGULATION; POSTENDOCYTIC TRAFFICKING; COATED PITS; ENDOCYTOSIS; INTERNALIZATION; PROTEIN; GRB2; DEGRADATION	Ligand-induced down-regulation of the epidermal growth factor receptor (EGFR) comprises activation of two sequential transport steps. The first involves endocytic uptake by clathrin-coated vesicles, the second transfer of endocytosed EGFR from endosomes to lysosomes. Here we demonstrate that the second transport step requires a domain of the EGFR that encompasses residues 985-996 and was previously found to interact with actin. Deletion of domain 989-994 (Delta989-994 EGFR) did not interfere with EGFR uptake but completely abrogated its degradation. In contrast, both uptake and degradation were affected for K721A EGFR, a kinase-deficient EGFR mutant. To measure intracellular EGFR sorting, we developed a novel cell fractionation assay toward which cells were co-transfected for chicken hepatic lectin, a receptor for agialoglycoproteins. These cells were incubated with agialofetuin-coupled colloidal gold, which was targeted to lysosomes after receptor-mediated endocytosis. Compartments within the lysosomal pathway gained buoyant density because of the presence of colloidal gold and could be isolated from cell homogenates by ultracentrifugation through a high-density sucrose cushion. In contrast to endocytosed wild type EGFR, both Delta989-994 EGFR and K721A EGFR were largely not retrieved in gold-containing endocytic compartments. These results are supported with morphological data. We conclude that sorting of endocytosed EGFR into the degradation pathway requires both its kinase activity and actin-binding domain.	Univ Med Ctr, Dept Cell Biol, NL-3585 CX Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3585 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, Dept Mol Cell Biol, NL-3585 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University	Stoorvogel, W (corresponding author), Univ Utrecht, Dept Biochem & Cell Biol, Yalelaan 2,POB 80-176, NL-3508 TD Utrecht, Netherlands.	W.Stoorvogel@vet.uu.nl	van Bergen en Henegouwen, Paul/B-8870-2011	van Bergen en Henegouwen, Paul/0000-0001-6050-9042; van der Heyden, Marcel/0000-0002-4225-7942				Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; ENHENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Holbrook MR, 1999, BIOCHEMISTRY-US, V38, P9348, DOI 10.1021/bi990195r; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HORWICH AL, 1985, J CELL BIOL, V100, P1515, DOI 10.1083/jcb.100.5.1515; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUND KA, 1990, J BIOL CHEM, V265, P15713; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; Mosesson Y., 2003, J BIOL CHEM; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SORKIN A, 1992, J BIOL CHEM, V267, P8672; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; SPIRO RG, 1964, J BIOL CHEM, V239, P567; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; vanderHeyden MAG, 1997, EXP CELL RES, V234, P521, DOI 10.1006/excr.1997.3661; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; WUBBOLTS RW, 2003, J BIOL CHEM	43	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11562	11569		10.1074/jbc.M308449200	http://dx.doi.org/10.1074/jbc.M308449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702346	hybrid			2022-12-27	WOS:000220157600089
J	Haidar, B; Denis, M; Marcil, M; Krimbou, L; Genest, J				Haidar, B; Denis, M; Marcil, M; Krimbou, L; Genest, J			Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; FAMILIAL HDL DEFICIENCY; PROTEIN-KINASE-A; TANGIER-DISEASE; APOA-I; DEPENDENT PATHWAY; PHOSPHOLIPASE-C; CYCLIC-AMP; EFFLUX	It has been suggested that the signal transduction pathway initiated by apoA-I activates key proteins involved in cellular lipid efflux. We investigated apoA-I-mediated cAMP signaling in cultured human fibroblasts induced with (22R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Treatment of stimulated fibroblasts with apoA-I for short periods of time (<45 min) increased ATP binding cassette A1 (ABCA1) phosphorylation in a concentration-dependent manner. Concomitantly, apoA-I increased the intracellular level of cAMP in a concentration- and time-dependent manner. The maximal cAMP level was reached within 10 min at 10 mu g/ml apoA-I representing a 1-fold increase. The ability of apoA-I to mediate cAMP production was only observed in stimulated fibroblasts. Furthermore, overexpression of ABCA1 in Chinese hamster ovary cells resulted in a 1.5-fold increase in apoA-I-mediated cAMP accumulation as compared with untransfected cells. In contrast, forskolin increased cAMP production significantly in unstimulated fibroblasts as well as in untransfected Chinese hamster ovary cells. Pharmacological inhibition of protein kinase A (H89) completely blocked apoA-I-mediated ABCA1 phosphorylation. Naturally occurring mutations of ABCA1 associated with Tangier disease (C1477R, 2203X, and 2145X) severely reduced apoA-I-mediated cAMP production, ABCA1 phosphorylation, I-125-apoA-I binding, and lipid efflux, without affecting forskolin-mediated cAMP elevation. In contrast, the protein kinase A catalytic subunit was able to phosphorylate ABCA1 similarly from mutant and normal cell lines in vitro. Together, our results indicate that apoA-I activates ABCA1 phosphorylation through the cAMP/protein kinase A-dependent pathway, apoA-I-mediated cAMP production required high level expression of functional ABCA1, and Tangier disease mutants have defective apoA-I-mediated cAMP signaling. These findings suggest that apoA-I may activate cAMP signaling through G protein-coupled ABCA1 transporter.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Genest, J (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	jacques.genest@muhc.mcgill.ca						Allouche S, 1996, J NEUROCHEM, V67, P2461; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, J BIOL CHEM, V277, P41307, DOI 10.1074/jbc.C200436200; Cockerill GW, 1999, INT REV CYTOL, V188, P257; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Haidar B, 2002, CIRCULATION, V106, P219; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haidar B, 2001, J LIPID RES, V42, P249; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Krimbou L, 2003, J LIPID RES, V44, P884, DOI 10.1194/jlr.M200273-JLR200; Krimbou L, 2001, J BIOL CHEM, V276, P33241, DOI 10.1074/jbc.M100326200; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; Nofer JR, 2003, J BIOL CHEM, V278, P53055, DOI 10.1074/jbc.M305673200; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TALL AR, 1993, J LIPID RES, V34, P1255; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; Utech M, 2001, BIOCHEM BIOPH RES CO, V280, P229, DOI 10.1006/bbrc.2000.4061; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Wu V, 1997, J BIOL CHEM, V272, P9037; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	44	77	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9963	9969		10.1074/jbc.M313487200	http://dx.doi.org/10.1074/jbc.M313487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701824	hybrid			2022-12-27	WOS:000220050400039
J	Laprise, P; Viel, A; Rivard, N				Laprise, P; Viel, A; Rivard, N			Human homolog of disc-large is required for adherens junction assembly and differentiation of human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR BINDS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; ADHESION; ACTIVATION; CADHERINS; DOMAINS; SAP97; HDLG	We and others have shown that phosphatidylinositol 3-kinase (PI3K) is recruited to and activated by E-cadherin engagement. This PI3K activation is essential for adherens junction integrity and intestinal epithelial cell differentiation. Here we provide evidence that hDlg, the homolog of disc-large tumor suppressor, is another key regulator of adherens junction integrity and differentiation in mammalian epithelial cells. We report the following. 1) hDlg co-localizes with E-cadherin, but not with ZO-1, at the sites of cell-cell contact in intestinal epithelial cells. 2) Reduction of hDlg expression levels by RNA(i) in intestinal cells not only severely alters adherens junction integrity but also prevents the recruitment of p85/PI3K to E-cadherin-mediated cell-cell contact and inhibits sucrase-isomaltase gene expression. 3) PI3K and hDlg are associated with E-cadherin in a common macromolecular complex in living differentiating intestinal cells. 4) This interaction requires the association of hDlg with E-cadherin and with Src homology domain 2 domains of the p85/PI3K subunit. 5) Phosphorylation of hDlg on serine and threonine residues prevents its interaction with the p85 Src homology domain 2 in subconfluent cells, whereas phosphorylation of hDlg on tyrosine residues is essential. We conclude that hDlg may be a determinant in E-cadherin-mediated adhesion and signaling in mammalian epithelial cells.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University of Sherbrooke; Harvard University	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Rivard@USherbrooke.ca						Calzado MA, 2000, CLIN EXP IMMUNOL, V120, P317, DOI 10.1046/j.1365-2249.2000.01203.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Caruana G, 2002, INT J DEV BIOL, V46, P511; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Reuver SM, 1998, J CELL SCI, V111, P1071; Somasiri A, 2000, DIFFERENTIATION, V66, P116, DOI 10.1046/j.1432-0436.2000.660206.x; Tepass U, 2002, BIOESSAYS, V24, P690, DOI 10.1002/bies.10129; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	25	101	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10157	10166		10.1074/jbc.M309843200	http://dx.doi.org/10.1074/jbc.M309843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699157	hybrid			2022-12-27	WOS:000220050400062
J	Lin, Y; Choksi, S; Shen, HM; Yang, QF; Hur, GM; Kim, YS; Tran, JH; Nedospasov, SA; Liu, ZG				Lin, Y; Choksi, S; Shen, HM; Yang, QF; Hur, GM; Kim, YS; Tran, JH; Nedospasov, SA; Liu, ZG			Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN KINASE RIP; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; TERMINAL KINASE; JNK ACTIVATION; TNF; PATHWAY; TRAF2; CYTOTOXICITY	The mechanism of tumor necrosis factor (TNF)-induced nonapoptotic cell death is largely unknown, although the mechanism of TNF-induced apoptosis has been studied extensively. In wild-type mouse embryonic fibroblast cells under a caspase-inhibited condition, TNF effectively induced cell death that morphologically resembled necrosis. In this study, we utilized gene knockout mouse embryonic fibroblasts cells and found that tumor necrosis factor receptor ( TNFR) I mediates TNF-induced necrotic cell death, and that RIP, FADD, and TRAF2 are critical components of the signaling cascade of this TNF-induced necrotic cell death. Inhibitors of NF-kappaB facilitated TNF-induced necrotic cell death, suggesting that NF-kappaB suppresses the necrotic cell death pathway. JNK, p38, and ERK activation seem not to be required for this type of cell death because mitogen-activated protein kinase inhibitors did not significantly affect TNF-induced necrotic cell death. In agreement with the previous reports that the reactive oxygen species (ROS) may play an important role in this type of cell death, the ROS scavenger butylated hydroxyanisole efficiently blocked TNF-induced necrotic cell death. Interestingly, during TNF-induced necrotic cell death, the cellular ROS level was significantly elevated in wild type, but not in RIP-/-, TRAF2(-/-), and FADD(-/-) cells. These results suggest that RIP, TRAF2, and FADD are crucial in mediating ROS accumulation in TNF-induced necrotic cell death.	NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Program, Sci Applicat Int Corp, LMI,CCR,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Lin, Y (corresponding author), NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Bldg 10,Rm 6N105,9000 Rockville Pike, Bethesda, MD 20892 USA.	linyo@mail.nih.gov	Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Hur, Gang-min/ABF-9263-2021; SHEN, Han-Ming/B-5942-2011; Nedospasov, Sergei/Q-7319-2016	Hur, Gang-min/0000-0003-4870-6574; SHEN, Han-Ming/0000-0001-7369-5227; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC010601] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC010376, Z01SC010376] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Izban KF, 2000, HUM PATHOL, V31, P1482, DOI 10.1053/hupa.2000.20370; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JJ, 1997, CANCER RES, V57, P1991; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lin Y, 2003, MOL CELL BIOL, V23, P5849, DOI 10.1128/MCB.23.16.5849-5856.2003; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	333	345	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10822	10828		10.1074/jbc.M313141200	http://dx.doi.org/10.1074/jbc.M313141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701813	hybrid			2022-12-27	WOS:000220050400138
J	Wittamer, V; Gregoire, F; Robberecht, P; Vassart, G; Communi, D; Parmentier, M				Wittamer, V; Gregoire, F; Robberecht, P; Vassart, G; Communi, D; Parmentier, M			The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AGONIST; ANAPHYLATOXIN; PEPTIDE; BINDING; IDENTIFICATION; NEUROPEPTIDE; CHEMOTAXIS; RESIDUES; ANALOGS	Chemerin is a novel protein identified as the natural ligand of ChemR23 (chemerinR), a previously orphan G protein-coupled receptor expressed in immature dendritic cells and macrophages. Chemerin is synthesized as a secreted precursor, prochemerin, which is poorly active, but converted into a full agonist of chemerinR by proteolytic removal of the last six amino acids. In the present work, we have synthesized a number of peptides derived from the C-terminal domain of human prochemerin and have investigated their functional properties as agonists or antagonists of human chemerinR. We found that the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR. Extension of this peptide at its N terminus did not increase the activity, whereas further truncations rapidly resulted in inactive compounds. The C-terminal end of the peptide appeared crucial for its activity, as addition of a single amino acid or removal of two amino acids modified the potency by four orders of magnitude. Alanine- scanning mutagenesis identified residues Tyr(149), Phe(150), Gly(152), Phe(154), and Phe(156) as the key positions for chemerinR activation. A modified peptide (YHSFFFPGQFAFS) was synthesized and iodinated, and a radioligand binding assay was established. It was found that the ability of the various peptides to activate the chemerin receptor was strictly correlated with their affinity in the binding assay. These results confirm that a precise C-terminal processing is required for the generation of a chemerinR agonist. The possibility to restrict a medium sized protein to a nonapeptide, while keeping a low nanomolar affinity for its receptor is unusual among G protein-coupled receptors ligands. The identification of these short bioactive peptides will considerably accelerate the pharmacological analysis of chemerin-chemerinR interactions.	Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Mol, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Chim Biol & Nutr, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Mol, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.	mparment@ulb.ac.be		Wittamer, Valerie/0000-0003-0003-2646; Parmentier, Marc/0000-0001-8081-4685; Gregoire, Francoise/0000-0003-0452-8868				CAPORALE LH, 1980, J BIOL CHEM, V255, P758; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; EMBER JA, 1992, J IMMUNOL, V148, P3165; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Katugampola S, 2003, TRENDS PHARMACOL SCI, V24, P30, DOI 10.1016/S0165-6147(02)00007-X; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Methner A, 1997, BIOCHEM BIOPH RES CO, V233, P336, DOI 10.1006/bbrc.1997.6455; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOSER B, 1993, J BIOL CHEM, V268, P7125; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; WILLIAMSON MP, 1990, BIOCHEMISTRY-US, V29, P2895, DOI 10.1021/bi00464a002; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	33	147	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9956	9962		10.1074/jbc.M313016200	http://dx.doi.org/10.1074/jbc.M313016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701797	hybrid			2022-12-27	WOS:000220050400038
J	Liu, XF; Bagchi, MK				Liu, XF; Bagchi, MK			Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; DNA METHYLATION; BREAST-CANCER; N-COR; MOLECULAR DETERMINANTS; COACTIVATOR COMPLEXES; COREPRESSOR COMPLEX; NUCLEAR RECEPTORS; LIVING CELLS	Tamoxifen, a breast cancer therapeutic, is a tissue-selective estrogen receptor modulator ( SERM), which acts as an antiestrogen in the mammary tissue and displays estrogenic activity in other tissues such as bone and uterus. In order to understand the mechanisms underlying the antiestrogenic effect of this prototype SERM, we performed an analysis of the cofactors that interact with ER complexed with 4-hydroxytamoxifen (OHT) at natural target genes in a human breast tumor cell line MCF-7. Employing chromatin immunoprecipitation (ChIP), we observed that treatment with OHT rapidly induces the binding of ERalpha to the E-responsive promoter regions of pS2 and c-myc genes. Promoter-bound OHT-complexed ERa coordinately recruited the components of a multiprotein complex containing the corepressor NCoR, histone deacetylase 3 (HDAC3), and a WD40-repeat protein TBL1. Surprisingly, the OHT-complexed ERalpha also recruited a chromatin-remodeling NuRD complex in which histone deacetylase 1 (HDAC1) is associated with several polypeptides including metastasis-associated protein 1/2 (MTA1/ 2), and SWI2/SNF2-related ATPase Mi2. Kinetic studies revealed that following OHT addition the recruitment of these HDAC complexes to pS2 or the c-myc promoter occurs in a sequential manner; the NCoR-HDAC3 complex is recruited earlier than the NuRD complex. Serial ChIP experiments indicated that the ER-NCoR- HDAC3 and ER-NuRD complexes are distinct, and they do not occupy the target gene promoter simultaneously. We also established a close temporal link between the appearance of the HDAC complexes at the E-responsive regions of pS2 and c-myc promoters, local hypoacetylation of specific lysine residues in N-terminal tails of histones H3 and H4, and disappearance of RNA polymerase II from the target gene loci. Collectively, our studies indicated that transcriptional repression by tamoxifen-bound ER at E-regulated gene promoters involves a dynamic interplay of multiple distinct chromatin-modifying/remodeling complexes.	Univ Illinois, Dept Mol & Integrat Physiol, Sch Mol & Cellular Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Bagchi, MK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Sch Mol & Cellular Biol, 534 Burrill Hall,MC-114,407 S Goodwin Ave, Urbana, IL 61801 USA.	mbagchi@life.uiuc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 50257-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; CLARK GM, 1988, SEMIN ONCOL, V15, P20; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DUBIK D, 1992, ONCOGENE, V7, P1587; Feng Q, 2001, GENE DEV, V15, P827; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2000, GENE DEV, V14, P1048; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jordan VC, 1999, TRENDS ENDOCRIN MET, V10, P312, DOI 10.1016/S1043-2760(99)00181-2; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Kraus WL, 2002, EUR J BIOCHEM, V269, P2275, DOI 10.1046/j.1432-1033.2002.02889.x; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	51	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15050	15058		10.1074/jbc.M311932200	http://dx.doi.org/10.1074/jbc.M311932200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722073	hybrid			2022-12-27	WOS:000220594700069
J	Hiruma, T; Togayachi, A; Okamura, K; Sato, T; Kikuchi, N; Kwon, YD; Nakamura, A; Fujimura, K; Gotoh, M; Tachibana, K; Ishizuka, Y; Noce, T; Nakanishi, H; Narimatsu, H				Hiruma, T; Togayachi, A; Okamura, K; Sato, T; Kikuchi, N; Kwon, YD; Nakamura, A; Fujimura, K; Gotoh, M; Tachibana, K; Ishizuka, Y; Noce, T; Nakanishi, H; Narimatsu, H			A novel human beta 1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc beta 1-3GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN GLYCAN STRUCTURES; CURATED RELATIONAL DATABASE; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; MOLECULAR-CLONING; UDP-GALACTOSE; EXPRESSION CLONING; BIOLOGICAL SOURCES; N-GLYCOSYLATION; TYPE-1 CHAIN; O-GLYCANS	We found, using a BLAST search, a novel human gene (GenBank(TM) accession number BC029564) that possesses beta3-glycosyltransferase motifs. The full-length open reading frame consists of 500 amino acids and encodes a typical type II membrane protein. This enzyme has a domain containing beta1,3-glycosyltransferase motifs, which are widely conserved in the beta1,3-galactosyltransferase and beta1,3-N-acetylglucosaminyltransferase families. The putative catalytic domain was expressed in human embryonic kidney 293T cells as a soluble protein. Its N-acetylgalactosaminyltransferase activity was observed when N-acetylglucosamine (GlcNAc) beta1-O-benzyl was used as an acceptor substrate. The enzyme product was determined to have a beta1,3-linkage by NMR spectroscopic analysis, and was therefore named beta1,3-N-acetylgalactosaminyltransferase-II (beta3GalNAc-T2). The acceptor substrate specificity of beta3GalNAc-T2 was examined using various oligosaccharide substrates. Galbeta-1-3(GlcNAc beta1-6) GalNAcalpha1-O-para-nitrophenyl (core 2-pNP) was the best acceptor substrate for beta3GalNAc-T2, followed by GlcNAcbeta1 - 4GlcNAcbeta1-O-benzyl, and GlcN-Ac beta1-6GalNAcalpha1-O-para-nitrophenyl (core 6-pNP), among the tested oligosaccharide substrates. Quantitative real time PCR analysis revealed that the beta3GalNAc-T2 transcripts was restricted in its distribution mainly to the testis, adipose tissue, skeletal muscle, and ovary. Its putative orthologous gene, mbeta3GalNAc-T2, was also found in a data base of mouse expressed sequence tags. In situ hybridization analysis with mouse testis showed that the transcripts are expressed in germ line cells. beta3GalNAc-T2 efficiently transferred GalNAc to N-glycans of fetal calf fetuin, which was treated with neuraminidase and beta-galactosidase. However, it showed no activity toward any glycolipid examined. Although the GalNAcbeta1 3GlcNAcbeta1-R structure has not been reported in humans or other mammals, we have discovered a novel human glycosyltransferase producing this structure on N- and O-glycans.	Natl Inst Adv Ind Sci & Technol, Open Space Lab Cent 2, RCG, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan; Fujirebio Inc, Fundamental Res Dept, Frontier Res Div, Tokyo 1920031, Japan; JGS Japan Genome Solut Inc, Tokyo 1920031, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; Mitsubishi Kagaku Inst Life Sci, Reprod Biol Lab, Machida, Tokyo 1948511, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; AIST, Biol Informat Res Ctr, Mol Recognit Team, Tsukuba, Ibaraki 3058568, Japan	National Institute of Advanced Industrial Science & Technology (AIST); H.U. Group Holdings Inc; Mitsubishi Kagaku Institute of Life Sciences (MITILS); National Institute of Advanced Industrial Science & Technology (AIST)	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Open Space Lab Cent 2, RCG, Glycogene Funct Team, 1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.	h.narimatsu@aist.go.jp	Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; noce, toshiaki/L-1739-2013; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X				Akama TO, 2002, SCIENCE, V295, P124, DOI 10.1126/science.1065570; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Cooper CA, 2003, NUCLEIC ACIDS RES, V31, P511, DOI 10.1093/nar/gkg099; Cooper CA, 2001, NUCLEIC ACIDS RES, V29, P332, DOI 10.1093/nar/29.1.332; Dorscheid DR, 2001, AM J PHYSIOL-LUNG C, V281, pL982, DOI 10.1152/ajplung.2001.281.4.L982; FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; HOSOMI O, 1989, JPN J MED SCI BIOL, V42, P77, DOI 10.7883/yoken1952.42.77; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; ISSHIKI S, 2003, J BIOL CHEM; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; JONES CJP, 1992, HISTOCHEM J, V24, P327, DOI 10.1007/BF01046164; Karlsson NG, 2002, ANAL BIOCHEM, V305, P173, DOI 10.1006/abio.2002.5657; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; Kudo K, 1998, EUR J BIOCHEM, V252, P492, DOI 10.1046/j.1432-1327.1998.2520492.x; Ludwig A, 2000, J IMMUNOL, V165, P1044, DOI 10.4049/jimmunol.165.2.1044; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; RECNY MA, 1992, J BIOL CHEM, V267, P22428; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x	29	40	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14087	14095		10.1074/jbc.M310614200	http://dx.doi.org/10.1074/jbc.M310614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724282	hybrid			2022-12-27	WOS:000220478500098
J	Tepper, AWJW; Bubacco, L; Canters, GW				Tepper, AWJW; Bubacco, L; Canters, GW			Stopped-flow fluorescence studies of inhibitor binding to tyrosinase from Streptomyces antibioticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL OXIDASE; ACTIVE-SITE; SPECTROSCOPIC PROPERTIES; MUSHROOM TYROSINASE; CRYSTAL-STRUCTURE; FUNCTIONAL UNIT; EPIDERMIS TYROSINASE; MAGNETIC-PROPERTIES; NATIVE HEMOCYANIN; STRUCTURAL BASIS	Tyrosinase (Ty) is a type 3 copper protein involved in the rate-limiting step of melanin synthesis. It is shown that the endogenous Trp fluorescence of tyrosinase from Streptomyces antibioticus is remarkably sensitive to the redox state. The fluorescence emission intensity of the [(Cu(I) Cu(I)] reduced species is more than twice that of the oxygen-bound [Cu(II)-O-2(2-)- Cu(II)] form. The emission intensity of the oxidized [Cu(II)-OH--Cu(II)] protein (Ty(met)) appears to be dependent on an acid-base equilibrium with a pK(a) value of 4.5 +/- 0.1. The binding of fluoride was studied under pseudo first-order conditions using stopped-flow fluorescence spectroscopy. The kinetic parameters k(on), K-d, and the fraction of fluorescence emission quenched upon fluoride binding show a similar pH dependence as above with an average pKa value of 4.62 +/- 0.05. Both observations are related to the dissociation of Cu-2-bridging hydroxide at low pH. It is further shown that Ty is rapidly inactivated at low pH and that halide protects the enzyme from this inactivation. All results support the hypothesis that halide displaces hydroxide as the Cu-2-bridging ligand in Ty(met). The relevance of the experimental findings for the catalytic cycle is discussed. The data are consistent with the data obtained from other techniques, validating the use of fluorescence quenching as a sensitive and effective tool in studying ligand binding and substrate conversion.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2333 CC Leiden, Netherlands; Univ Padua, Dept Biol, I-30121 Padua, Italy	Leiden University; Leiden University - Excl LUMC; University of Padua	Canters, GW (corresponding author), Leiden Univ, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	canters@chem.leidenuniv.nl	Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208				Ali SA, 1999, COMP BIOCHEM PHYS A, V122, P65; Amudha P, 1999, POLYHEDRON, V18, P1355, DOI 10.1016/S0277-5387(98)00401-X; Belle C, 2002, INORG CHEM, V41, P479, DOI 10.1021/ic010534g; BELTRAMINI M, 1982, BIOCHEM J, V205, P173, DOI 10.1042/bj2050173; Bubacco L, 1999, FEBS LETT, V442, P215, DOI 10.1016/S0014-5793(98)01662-7; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; Bubacco L, 2003, J BIOL CHEM, V278, P7381, DOI 10.1074/jbc.M206394200; CABANES J, 1984, BIOCHIM BIOPHYS ACTA, V790, P101, DOI 10.1016/0167-4838(84)90212-7; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Dean J. A., 1999, LANGES HDB CHEM; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; Dolashka P, 1996, BIOCHEM J, V315, P139, DOI 10.1042/bj3150139; Dolashka-Angelova P, 1999, SPECTROCHIM ACTA A, V55, P2927, DOI 10.1016/S1386-1425(99)00172-9; Dolashka-Angelova P, 2000, INT J BIOCHEM CELL B, V32, P529, DOI 10.1016/S1357-2725(99)00151-X; Dolashka-Angelova P, 2000, SPECTROCHIM ACTA A, V56, P1985, DOI 10.1016/S1386-1425(99)00273-5; Eicken C, 1998, FEBS LETT, V436, P293, DOI 10.1016/S0014-5793(98)01113-2; Eicken C, 1999, CURR OPIN STRUC BIOL, V9, P677, DOI 10.1016/S0959-440X(99)00029-9; Espin JC, 1999, J AGR FOOD CHEM, V47, P2638, DOI 10.1021/jf981055b; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; HASHIGUCHI H, 1977, MOL PHARMACOL, V13, P362; HAZES B, 1993, PROTEIN SCI, V2, P597; HEALEY DF, 1981, ARCH BIOCHEM BIOPHYS, V211, P86, DOI 10.1016/0003-9861(81)90432-X; Hristova R, 1997, SPECTROCHIM ACTA A, V53, P471, DOI 10.1016/S1386-1425(96)01837-9; Hristova R, 2000, OXID COMMUN, V23, P145; Idakieva K, 1995, COMP BIOCHEM PHYS B, V112, P599, DOI 10.1016/0305-0491(95)00102-6; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; Jimenez M, 2001, J AGR FOOD CHEM, V49, P4060, DOI 10.1021/jf010194h; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Kubo I, 1999, J AGR FOOD CHEM, V47, P4121, DOI 10.1021/jf990201q; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P242; LEBODIA L, 1993, PROTEIN-STRUCT FUNCT, V16, P219; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; Lippitz M, 2002, P NATL ACAD SCI USA, V99, P2772, DOI 10.1073/pnas.052662999; MADDALUNO JF, 1988, EXPERIENTIA, V44, P885, DOI 10.1007/BF01941189; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MARTINEZ JH, 1985, BIOCHEM INT, V11, P729; MARTINEZ JH, 1986, COMP BIOCHEM PHYS B, V83, P633, DOI 10.1016/0305-0491(86)90309-3; Meier B, 1998, BIOCHEM J, V331, P403, DOI 10.1042/bj3310403; MENON S, 1990, ARCH BIOCHEM BIOPHYS, V280, P27, DOI 10.1016/0003-9861(90)90513-X; Monzani E, 1998, INORG CHEM, V37, P553, DOI 10.1021/ic970996n; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; Neri F, 1997, BIOCHEMISTRY-US, V36, P8947, DOI 10.1021/bi970248+; No JK, 1999, LIFE SCI, V65, pPL241, DOI 10.1016/S0024-3205(99)00492-0; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; OETTING WS, 1994, J INVEST DERMATOL, V103, pS131, DOI 10.1111/1523-1747.ep12399447; PENAFIEL R, 1984, BIOCHIM BIOPHYS ACTA, V788, P327, DOI 10.1016/0167-4838(84)90045-1; Pervanova K, 2000, SPECTROCHIM ACTA A, V56, P615, DOI 10.1016/S1386-1425(99)00261-9; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P10497, DOI 10.1021/bi000539+; Salvato B, 1998, BIOCHEMISTRY-US, V37, P14065, DOI 10.1021/bi980879j; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; Schutz J, 2001, BBA-PROTEIN STRUCT M, V1546, P325, DOI 10.1016/S0167-4838(01)00152-2; Seo SY, 2003, J AGR FOOD CHEM, V51, P2837, DOI 10.1021/jf020826f; SHAKLAI N, 1978, BIOCHEMISTRY-US, V17, P4438, DOI 10.1021/bi00614a013; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stoeva S, 1995, SPECTROCHIM ACTA A, V51, P1965, DOI 10.1016/0584-8539(95)01538-6; Tepper AWJW, 2002, J BIOL CHEM, V277, P30436, DOI 10.1074/jbc.M202461200; Todd MJ, 2000, BIOCHEMISTRY-US, V39, P5389, DOI 10.1021/bi992287m; Torelli S, 2000, INORG CHEM, V39, P3526, DOI 10.1021/ic991450z; van Gastel M, 2000, FEBS LETT, V474, P228, DOI 10.1016/S0014-5793(00)01609-4; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; Xu F, 1997, J BIOL CHEM, V272, P924, DOI 10.1074/jbc.272.2.924	66	23	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13425	13434		10.1074/jbc.M309367200	http://dx.doi.org/10.1074/jbc.M309367200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699163	hybrid			2022-12-27	WOS:000220478500020
J	Chakrabarty, P; Sethi, DK; Padhan, N; Kaur, KJ; Salunke, DM; Bhattacharya, S; Bhattacharya, A				Chakrabarty, P; Sethi, DK; Padhan, N; Kaur, KJ; Salunke, DM; Bhattacharya, S; Bhattacharya, A			Identification and characterization of EhCaBP2 - A second member of the calcium-binding protein family of the protozoan parasite Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC ACTIVITY; CALMODULIN GENES; CENTRAL HELIX; EXPRESSION; DENATURATION; ACTIVATION; SECRETION; GRANULES; ENZYMES; GROWTH	Entamoeba histolytica, an early branching eukaryote, is the etiologic agent of amebiasis. Calcium plays a pivotal role in the pathogenesis of amebiasis by modulating the cytopathic properties of the parasite. However, the mechanistic role of Ca2+ and calcium- binding proteins in the pathogenesis of E. histolytica remains poorly understood. We had previously characterized a novel calcium- binding protein ( EhCaBP1) from E. histolytica. Here, we report the identification and partial characterization of an isoform of this protein, EhCaBP2. Both EhCaBPs have four canonical EF- hand Ca2+ binding domains. The two isoforms are encoded by genes of the same size ( 402 bp). Comparison between the two genes showed an overall identity of 79% at the nucleotide sequence level. This identity dropped to 40% in the 75- nucleotide central linker region between the second and third Ca2+ binding domains. Both of these genes are single copy, as revealed by Southern hybridization. Analysis of the available E. histolytica genome sequence data suggested that the two genes are non- allelic. Homology- based structural modeling showed that the major differences between the two EhCaBPs lie in the central linker region, normally involved in binding target molecules. A number of studies indicated that EhCaBP1 and EhCaBP2 are functionally different. They bind different sets of E. histolytica proteins in a Ca2+- dependent manner. Activation of endogenous kinase was also found to be unique for the two proteins and the Ca2+ concentration required for their optimal functionality was also different. In addition, a 12- mer peptide was identified from a random peptide library that could differentially bind the two proteins. Our data suggest that EhCaBP2 is a new member of a class of E. histolytica calcium- binding proteins involved in a novel calcium signal transduction pathway.	Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India; Jawaharlal Nehru Univ, Sch Environm Sci, New Delhi 110067, India; Natl Inst Immunol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Jawaharlal Nehru University, New Delhi; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Bhattacharya, A (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, New Mehrauli Rd, New Delhi 110067, India.	alok0200@mail.jnu.ac.in	Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				Atreya HS, 2001, BIOCHEMISTRY-US, V40, P14392, DOI 10.1021/bi0114978; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Bernal RM, 1998, PARASITOL RES, V84, P687, DOI 10.1007/s004360050471; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; CHANDOK MR, 1992, PHYTOCHEMISTRY, V31, P2255, DOI 10.1016/0031-9422(92)83259-2; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; EDMAN CF, 1994, EUR J BIOCHEM, V226, P725, DOI 10.1111/j.1432-1033.1994.tb20101.x; Ganguly A, 2001, MOL BIOCHEM PARASIT, V112, P277, DOI 10.1016/S0166-6851(00)00376-5; Gilchrist CA, 2003, J BIOL CHEM, V278, P4646, DOI 10.1074/jbc.M211271200; Gilchrist CA, 2001, J BIOL CHEM, V276, P11838, DOI 10.1074/jbc.M007375200; Gopal B, 1997, BIOCHEMISTRY-US, V36, P10910, DOI 10.1021/bi9702546; Gopal B, 1998, ACTA CRYSTALLOGR D, V54, P1442, DOI 10.1107/S0907444998001759; JOHNSON JG, 1981, J PROTOZOOL, V28, P160, DOI 10.1111/j.1550-7408.1981.tb02825.x; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Makioka A, 2001, PARASITOL RES, V87, P833, DOI 10.1007/s004360100453; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; MATSUMOTO Y, 1987, EUR J CELL BIOL, V45, P36; Meza I, 2000, PARASITOL TODAY, V16, P23, DOI 10.1016/S0169-4758(99)01586-0; Modha J, 1999, PARASITOLOGY, V118, P509, DOI 10.1017/S0031182099004266; MOORTHY AL, 2001, THESIS INDIAN I SCI; MUNOZ MD, 1991, MOL MICROBIOL, V5, P1707, DOI 10.1111/j.1365-2958.1991.tb01919.x; MUNOZ MD, 1992, COMP BIOCHEM PHYS B, V103, P517, DOI 10.1016/0305-0491(92)90363-V; Nickel R, 2000, FEBS LETT, V486, P112, DOI 10.1016/S0014-5793(00)02245-6; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; Pereira C, 1997, J EUKARYOT MICROBIOL, V44, P155, DOI 10.1111/j.1550-7408.1997.tb05952.x; PRASAD J, 1993, CELL MOL BIOL RES, V39, P167; PRASAD J, 1992, MOL BIOCHEM PARASIT, V52, P137, DOI 10.1016/0166-6851(92)90044-K; Protasevich I, 1997, BIOCHEMISTRY-US, V36, P2017, DOI 10.1021/bi962538g; RAVDIN JI, 1988, INFECT IMMUN, V56, P1505, DOI 10.1128/IAI.56.6.1505-1512.1988; Sahoo N, 2003, MOL BIOCHEM PARASIT, V126, P281, DOI 10.1016/S0166-6851(02)00284-0; Sahoo N, 2000, ARCH MED RES, V31, pS57, DOI 10.1016/S0188-4409(00)00212-5; Sahu SC, 1999, FEBS LETT, V459, P51, DOI 10.1016/S0014-5793(99)01204-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHEIBEL LW, 1992, INT REV CYTOL, V134, P165, DOI 10.1016/S0074-7696(08)62029-X; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN JP, 1983, P NATL ACAD SCI-BIOL, V80, P6485, DOI 10.1073/pnas.80.21.6485; Tabernero L, 1997, STRUCTURE, V5, P613, DOI 10.1016/S0969-2126(97)00217-7; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V236, P611, DOI 10.1006/bbrc.1997.7019; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VanderSpoel D, 1996, PROTEIN SCI, V5, P2044; WEIKEL CS, 1988, INFECT IMMUN, V56, P1485, DOI 10.1128/IAI.56.6.1485-1491.1988; Yadava N, 1997, MOL BIOCHEM PARASIT, V84, P69, DOI 10.1016/S0166-6851(96)02782-X; YAKUBU MA, 1994, MOL BIOCHEM PARASIT, V66, P119, DOI 10.1016/0166-6851(94)90042-6	53	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12898	12908		10.1074/jbc.M304716200	http://dx.doi.org/10.1074/jbc.M304716200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711825	hybrid			2022-12-27	WOS:000220334900107
J	Fischer, R; Kohler, K; Fotin-Mleczek, M; Brock, R				Fischer, R; Kohler, K; Fotin-Mleczek, M; Brock, R			A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PEPTIDES; PROTEIN TRANSDUCTION; ANTENNAPEDIA HOMEODOMAIN; PLASMA-MEMBRANE; GENE-TRANSFER; BASIC DOMAIN; 3RD HELIX; TAT; DELIVERY; BINDING	The role of endosomal acidification and retrograde transport for the uptake of the highly basic cell-penetrating peptides penetratin, Tat, and oligoarginine was investigated. The effect of a panel of drugs that interfere with discrete steps of endocytosis or Golgi-mediated transport on uptake and cellular distribution of fluorescein-labeled peptide analogues was probed by confocal microscopy, flow cytometry, and fluorescence spectroscopy of whole cell lysates. The analyses were carried out in MC57 fibrosarcoma cells and in HeLa cells. While MC57 fibrosarcoma cells showed some vesicular fluorescence and a pronounced cytoplasmic fluorescence, in HeLa cells little cytoplasmic fluorescence was observed. In MC57 cells the inhibitors of endosomal acidification chloroquine and bafilomycin A1 abolished the release of the peptides into the cytoplasm. Release into the cytosol preserved endosomal integrity. In addition, cellular uptake of the peptides was inhibited by brefeldin A, a compound interfering with trafficking in the trans-Golgi network. In contrast, nordihydroguaiaretic acid, a drug that stimulates the rapid retrograde movement of both Golgi stacks and trans-Golgi network to the endoplasmic reticulum, promoted a cytoplasmic localization of Tat peptides in peptide-pulsed HeLa cells. The effects of these drugs on trafficking shared characteristics with those reported for the trafficking of plant and bacterial toxins, such as cholera toxin, which reach the cytoplasm by means of retrograde transport. A sequence comparison revealed a common stretch of 8 - 10 amino acids with high sequence homology to the Tat peptide. The structural and functional data therefore strongly suggest a common mechanism of import for cationic cell-penetrating peptides and the toxins.	Univ Tubingen, Inst Cell Biol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Brock, R (corresponding author), Univ Tubingen, Inst Cell Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	roland.brock@uni-tuebingen.de	Brock, Roland/O-9411-2019; Brock, Roland/K-2590-2012	Brock, Roland/0000-0003-1395-6127				Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHEN RF, 1988, ANAL BIOCHEM, V172, P61, DOI 10.1016/0003-2697(88)90412-5; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drecktrah D, 1998, J CELL SCI, V111, P951; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044; Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115; Fischer R, 2003, BIOCONJUGATE CHEM, V14, P653, DOI 10.1021/bc025658b; Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; GARRED O, 1995, J BIOL CHEM, V270, P10817; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; HOSAKA Y, 1986, J VIROL, V57, P1113, DOI 10.1128/JVI.57.3.1113-1118.1986; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; Kozak SL, 1999, J BIOL CHEM, V274, P23499, DOI 10.1074/jbc.274.33.23499; Langel U., 2002, CELL PENETRATING PEP, V1st ed; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; Lord JM, 1998, J CELL BIOL, V140, P733; Lu J, 2001, J IMMUNOL, V166, P7063, DOI 10.4049/jimmunol.166.12.7063; Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200; Merdan T, 2002, PHARMACEUT RES, V19, P140, DOI 10.1023/A:1014212630566; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Persson D, 2003, BIOCHEMISTRY-US, V42, P421, DOI 10.1021/bi026453t; Pietersz GA, 2001, VACCINE, V19, P1397, DOI 10.1016/S0264-410X(00)00373-X; PLANK C, 1994, J BIOL CHEM, V269, P12918; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; SANDOVAL RM, 2004, IN PRESS AM J PHYSL; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Sandvig K, 2002, FEBS LETT, V529, P49, DOI 10.1016/S0014-5793(02)03182-4; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x; SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Singh D, 1999, BIOCONJUGATE CHEM, V10, P745, DOI 10.1021/bc980131d; Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; THEODORE L, 1995, J NEUROSCI, V15, P7158; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang RF, 2002, NAT BIOTECHNOL, V20, P149, DOI 10.1038/nbt0202-149	59	254	263	1	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12625	12635		10.1074/jbc.M311461200	http://dx.doi.org/10.1074/jbc.M311461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707144	hybrid			2022-12-27	WOS:000220334900076
J	Fukuda, M; Kanno, E; Yamamoto, A				Fukuda, M; Kanno, E; Yamamoto, A			Rabphilin and Noc2 are recruited to dense-core vesicles through specific interaction with Rab27A in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CALCIUM-DEPENDENT OLIGOMERIZATION; SLP HOMOLOGY DOMAIN; TANDEM C2 DOMAINS; MYOSIN-VA; GRISCELLI-SYNDROME; SYNAPTOTAGMIN FAMILY; MELANOSOME TRANSPORT; REGULATED SECRETION; CA2+-DEPENDENT EXOCYTOSIS	Rabphilin and Noc2 were originally described as Rab3A effector proteins involved in the regulation of secretory vesicle exocytosis, however, recently both proteins have been shown to bind Rab27A in vitro in preference to Rab3A ( Fukuda, M. ( 2003) J. Biol. Chem. 278, 15373 - 15380), suggesting that Rab3A is not their major ligand in vivo. In the present study we showed by means of deletion and mutation analyses that rabphilin and Noc2 are recruited to dense- core vesicles through specific interaction with Rab27A, not with Rab3A, in PC12 cells. Rab3A bindingdefective mutants of rabphilin( E50A) and Noc2( E51A) were still localized in the distal portion of the neurites ( where dense- core vesicles had accumulated) in nerve growth factor- differentiated PC12 cells, the same as the wild- type proteins, whereas Rab27A binding- defective mutants of rabphilin( E50A/ I54A) and Noc2( E51A/ I55A) were present throughout the cytosol. We further showed that expression of the wild- type or the E50A mutant of rabphilin- RBD, but not the E50A/ I54A mutant of rabphilinRBD, significantly inhibited high KCl- dependent neuropeptide Y secretion by PC12 cells. We also found that rabphilin and its binding partner, Rab27 have been highly conserved during evolution ( from nematoda to humans) and that Caenorhabditis elegans and Drosophila rabphilin ( ce/ dm- rabphilin) specifically interact with ce/ dm- Rab27, but not with ce/ dm- Rab3 or ce/ dm- Rab8, suggesting that rabphilin functions as a Rab27 effector across phylogeny. Based on these findings, we propose that the N- terminal Rab binding domain of rabphilin and Noc2 be referred to as " RBD27 ( Rab binding domain for Rab27)", the same as the synaptotagmin- like protein homology domain ( SHD) of Slac2- a/ melanophilin.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Nagahama Inst Biosci & Technol, Nagahama 5260829, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Adolfsen B, 2001, CELL MOL LIFE SCI, V58, P393, DOI 10.1007/PL00000865; Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Barral DC, 2002, J CLIN INVEST, V110, P247, DOI 10.1172/JCI200215058; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Chen YR, 2003, P NATL ACAD SCI USA, V100, P14012, DOI 10.1073/pnas.2436350100; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2003, J BIOCHEM, V133, P641, DOI 10.1093/jb/mvg082; Fukuda M, 2003, J BIOL CHEM, V278, P3220, DOI 10.1074/jbc.M208323200; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2003, J BIOL CHEM, V278, P15390, DOI 10.1074/jbc.M213090200; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; IMAI A, 2003, IN PRESS J CELL SCI; Joberty G, 1999, J CELL SCI, V112, P3579; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; Masumoto N, 1996, J CELL BIOL, V135, P1741, DOI 10.1083/jcb.135.6.1741; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; NAGATA K, 1989, J BIOL CHEM, V264, P17000; Novak EK, 2002, BLOOD, V100, P128, DOI 10.1182/blood.V100.1.128; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Sasaki T, 1997, ADV SEC MESS PHOSPH, V31, P279; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Serano J, 2003, P NATL ACAD SCI USA, V100, P13368, DOI 10.1073/pnas.1835727100; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Tiwari S, 2003, BLOOD, V102, P3970, DOI 10.1182/blood-2003-03-0977; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	83	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13065	13075		10.1074/jbc.M306812200	http://dx.doi.org/10.1074/jbc.M306812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722103	hybrid			2022-12-27	WOS:000220334900127
J	Gillam, MP; Sidhaye, AR; Lee, EJ; Rutishauser, J; Stephan, CW; Kopp, P				Gillam, MP; Sidhaye, AR; Lee, EJ; Rutishauser, J; Stephan, CW; Kopp, P			Functional characterization of pendrin in a polarized cell system - Evidence for pendrin-mediated apical iodide efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENLARGED VESTIBULAR AQUEDUCT; SULFATE-TRANSPORTER; SYNDROME GENE; ENDOPLASMIC-RETICULUM; MOLECULAR ANALYSIS; NADPH OXIDASE; INNER-EAR; PDS GENE; MUTATIONS; PROTEIN	Pendred's syndrome is an autosomal recessive disorder characterized by sensorineural deafness, goiter, and impaired iodide organification. It is caused by mutations in the PDS/ SLC26A4 gene that encodes pendrin. Functionally, pendrin is a transporter of chloride and iodide in Xenopus oocytes and heterologous mammalian cells and a chloride/ base exchanger in beta- intercalated cells of the renal cortical collecting duct. The partially impaired thyroidal iodide organification in Pendred's syndrome suggests a possible role of pendrin in iodide transport at the apical membrane of thyroid follicular cells, but experimental evidence for this concept is lacking. The iodide transport properties of pendrin were determined in polarized Madin- Darby canine kidney cells expressing the sodium iodide symporter ( NIS), pendrin, or NIS and pendrin using a bicameral system- permitting measurement of iodide content in the basal, intracellular, and apical compartments. Moreover, we determined the functional consequences of two naturally occurring mutations ( L676Q and FS306> 309X). In polarized Madin- Darby canine kidney cells, NIS mediates uptake at the basolateral membrane. Only minimal amounts of iodide reach the apical compartment in the absence of pendrin. In cells expressing NIS and pendrin, pendrin mediates transport of iodide into the apical chamber. Wild type pendrin also mediates iodide efflux in transiently transfected cells. In contrast, both pendrin mutants lose the ability to promote iodide efflux. These results provide evidence that pendrin mediates apical iodide efflux from polarized mammalian cells loaded with iodide. Consistent with the partial organification defect observed in patients with Pendred's syndrome, naturally occurring mutations of pendrin lead to impaired transport of iodide.	Northwestern Univ, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; Endocrine Practice, CH-1700 Fribourg, Switzerland	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Kopp, P (corresponding author), Northwestern Univ, Div Endocrinol Metab & Mol Med, Tarry 15,303 Chicago Ave, Chicago, IL 60611 USA.	p-kopp@northwestern.edu		Kopp, Peter A/0000-0001-5980-0529	NIDDK NIH HHS [2T32 DK 07169-22, 1R01 DK 63024-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169, R01DK063024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Bidart JM, 2000, J CLIN ENDOCR METAB, V85, P2028, DOI 10.1210/jc.85.5.2028; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Everett LA, 2001, HUM MOL GENET, V10, P153, DOI 10.1093/hmg/10.2.153; Everett LA, 1999, HUM MOL GENET, V8, P1883, DOI 10.1093/hmg/8.10.1883; Fugazzola L, 2000, J CLIN ENDOCR METAB, V85, P2469, DOI 10.1210/jc.85.7.2469; GOLSTEIN P, 1992, AM J PHYSIOL, V263, pC590, DOI 10.1152/ajpcell.1992.263.3.C590; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kopp P, 2000, Rev Endocr Metab Disord, V1, P109, DOI 10.1023/A:1010024722595; Kopp P., 1999, CURR OPIN ENDOCRINOL, V6, P261; Kraiem Z, 1999, J CLIN ENDOCR METAB, V84, P2574, DOI 10.1210/jc.84.7.2574; Lee EJ, 1999, J CLIN ENDOCR METAB, V84, P786, DOI 10.1210/jc.84.2.786; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; NILSSON M, 1992, ACTA ENDOCRINOL-COP, V126, P67, DOI 10.1530/acta.0.1260067; NILSSON M, 1990, EUR J CELL BIOL, V52, P270; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Park HJ, 2003, J MED GENET, V40, P242, DOI 10.1136/jmg.40.4.242; Pendred V, 1896, LANCET, V148, P532, DOI [DOI 10.1016/S0140-6736(01)74403-0, 10.1016/S0140-6736(01)74403-0]; Reardon W, 2000, QJM-INT J MED, V93, P99, DOI 10.1093/qjmed/93.2.99; Rodriguez AM, 2002, J CLIN ENDOCR METAB, V87, P3500, DOI 10.1210/jc.87.7.3500; Rotman-Pikielny P, 2002, HUM MOL GENET, V11, P2625, DOI 10.1093/hmg/11.21.2625; Royaux IE, 2000, ENDOCRINOLOGY, V141, P839, DOI 10.1210/en.141.2.839; Royaux IE, 2001, P NATL ACAD SCI USA, V98, P4221, DOI 10.1073/pnas.071516798; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Scott DA, 2000, AM J PHYSIOL-CELL PH, V278, pC207, DOI 10.1152/ajpcell.2000.278.1.C207; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Taylor JP, 2002, J CLIN ENDOCR METAB, V87, P1778, DOI 10.1210/jc.87.4.1778; Trevino OG, 2001, EUR J ENDOCRINOL, V144, P585, DOI 10.1530/eje.0.1440585; Tsukamoto K, 2003, EUR J HUM GENET, V11, P916, DOI 10.1038/sj.ejhg.5201073; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Usami S, 1999, HUM GENET, V104, P188, DOI 10.1007/s004390050933; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; WOLFF J, 1964, PHYSIOL REV, V44, P45, DOI 10.1152/physrev.1964.44.1.45; Yoshida A, 2002, J CLIN ENDOCR METAB, V87, P3356, DOI 10.1210/jc.87.7.3356; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	47	122	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13004	13010		10.1074/jbc.M313648200	http://dx.doi.org/10.1074/jbc.M313648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715652	hybrid			2022-12-27	WOS:000220334900120
J	Singh, SK; Yang, K; Karthikeyan, S; Huynh, T; Zhang, XJ; Phillips, MA; Zhang, H				Singh, SK; Yang, K; Karthikeyan, S; Huynh, T; Zhang, XJ; Phillips, MA; Zhang, H			The thrH gene product of Pseudomonas aeruginosa is a dual activity enzyme with a novel phosphoserine : homoserine phosphotransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PHOSPHATASE; KINASE; DEHALOGENASE; ORGANIZATION; ASPARTATE; CATALYSIS; PROTEINS; ANALOG	The thrH gene product of Pseudomonas aeruginosa has been shown to complement both homoserine kinase ( thrB gene product) and phosphoserine phosphatase (serB gene product) activities in vivo. Sequence comparison has revealed that ThrH is related to phosphoserine phosphatases (PSP, EC 3.1.3.3) and belongs to the L-2-haloacid dehalogenase-like protein superfamily. We have solved the crystal structures of ThrH in the apoform and in complex with a bound product phosphate. The structure confirms an overall fold similar to that of PSP. Most of the catalytic residues of PSP are also conserved in ThrH, suggesting that similar catalytic mechanisms are used by both enzymes. Spectrophotometry-based in vitro assays show that ThrH is indeed a phosphoserine phosphatase with a K-m of 0.207 mM and k(cat) of 13.4 min(-1), comparable with those of other PSPs. More interestingly, using high pressure liquid chromatography-based assays, we have demonstrated that ThrH is able to further transfer the phosphoryl group to homoserine using phosphoserine as the phosphoryl group donor, indicating that ThrH has a novel phosphoserine: homoserine phosphotransferase activity.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zhang, H (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	zhang@chop.swmed.edu	Karthikeyan, Subramanian/F-8808-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 63689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; CLEPET C, 1992, MOL MICROBIOL, V6, P3109, DOI 10.1111/j.1365-2958.1992.tb01768.x; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Daugherty M, 2001, J BACTERIOL, V183, P292, DOI 10.1128/JB.183.1.292-300.2001; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Huo XW, 1996, ARCH BIOCHEM BIOPHYS, V330, P373, DOI 10.1006/abbi.1996.0264; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HY, 2002, J BIOL CHEM, V277, P46651, DOI 10.1074/jbc.M204866200; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Marchenko GN, 1999, MICROBIOL-UK, V145, P3273, DOI 10.1099/00221287-145-11-3273; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; Patte J. C., 1996, ESCHERICHIA COLI SAL, V1, P528; Patte JC, 1999, MICROBIOL-SGM, V145, P845, DOI 10.1099/13500872-145-4-845; Peeraer Y, 2003, ACTA CRYSTALLOGR D, V59, P971, DOI 10.1107/S0907444903005407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; ROBICHON-SZULMAJSTER H., 1966, GENETICS, V53, P609; STAUFFER GV, 1996, ESCHERICHIA COLI SAL, V1, P509; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	37	16	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13166	13173		10.1074/jbc.M311393200	http://dx.doi.org/10.1074/jbc.M311393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699121	hybrid			2022-12-27	WOS:000220334900138
J	Arndt, PG; Suzuki, N; Avdi, NJ; Malcolm, KC; Worthen, GS				Arndt, PG; Suzuki, N; Avdi, NJ; Malcolm, KC; Worthen, GS			Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils - Role of phosphatidylinositol 3-kinase and Syk-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; KAPPA-B ACTIVATION; TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; GROWTH-FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; SELECTIVE ACTIVATION; SIGNAL-TRANSDUCTION; ADAPTER MOLECULE; FACTOR-RECEPTOR	Polymorphonuclear leukocytes (neutrophils) respond to lipopolysaccharide (LPS) through the up-regulation of several pro-inflammatory mediators. We have recently shown that LPS-stimulated neutrophils express monocyte chemoattractant protein 1 (MCP-1), an AP-1-dependent gene, suggesting that LPS activates the c-Jun N-terminal kinase (JNK) pathway in neutrophils. Previously, we have shown the activation of p38 MAPK, but not JNK, in suspended neutrophils stimulated with LPS but have recently shown activation of JNK by TNF-alpha in an adherent neutrophil system. We show here that exposure to LPS activates JNK in non-suspended neutrophils and that LPS-induced MCP-1 expression, but not tumor necrosis factor-alpha (TNF-alpha) or interleukin-8 (IL-8), is dependent on JNK activation. In addition, LPS stimulation of non-suspended neutrophils activates Syk and phosphatidylinositol 3-kinase (PI3K). Inhibition of Syk with piceatannol or PI3K with wortmannin inhibited LPS-induced JNK activation and decreased MCP-1 expression after exposure to LPS, suggesting that both Syk and PI3K reside in a signaling pathway leading to LPS-induced JNK activation in neutrophils. This Syk- and PI3K-dependent pathway leading to JNK activation after LPS exposure in non-suspended neutrophils is specific for JNK, because inhibition of neither Syk nor PI3K decreased p38 activation after LPS stimulation. Furthermore we show that PI3K inhibition decreased LPS-induced Syk activation suggesting that PI3K resides upstream of Syk in this pathway. Finally, we show that Syk associates with Toll-like receptor 4 (TLR4) upon LPS stimulation further implicating Syk in the LPS-induced signaling pathway in neutrophils. Overall our data suggests that LPS induces JNK activation only in non-suspended neutrophils, which proceeds through Syk- and PI3K-dependent pathways, and that JNK activation is important for LPS-induced MCP-1 expression but not for TNF-alpha or IL-8 expression.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Cell Biol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Div Pulm & Crit Care Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Arndt, PG (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,D403, Denver, CO 80206 USA.	Patrick.Arndt@UCHSC.edu						Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Assefa Z, 1999, BIOCHEM BIOPH RES CO, V261, P641, DOI 10.1006/bbrc.1999.1090; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bisotto S, 2001, BIOCHEM J, V360, P77, DOI 10.1042/0264-6021:3600077; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Cesaris P. D., 1999, J BIOL CHEM, V274, P28978; Chae P, 2002, INFECT IMMUN, V70, P3164, DOI 10.1128/IAI.70.6.3164-3169.2002; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; DJEU JY, 1990, BLOOD, V76, P1405; Fernandez R, 1998, J IMMUNOL, V160, P5154; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GANZ T, 1987, INFECT IMMUN, V55, P568, DOI 10.1128/IAI.55.3.568-571.1987; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Inanami O, 1999, ANTIOXID REDOX SIGN, V1, P113, DOI 10.1089/ars.1999.1.1-113; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kang JL, 2001, AM J RESP CRIT CARE, V164, P2206, DOI 10.1164/ajrccm.164.12.2104017; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Klein JB, 2001, CELL SIGNAL, V13, P335, DOI 10.1016/S0898-6568(01)00151-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; LEVY O, 1995, J IMMUNOL, V154, P5403; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Naccache PH, 2000, J BIOL CHEM, V275, P23636, DOI 10.1074/jbc.M001780200; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Procyk KJ, 2000, BLOOD, V96, P2592; Raeder EMB, 1999, J IMMUNOL, V163, P6785; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STRIETER RM, 1992, AM J PATHOL, V141, P397; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yoshimura A, 1999, J IMMUNOL, V163, P1; Yoshizumi M, 2001, MOL PHARMACOL, V60, P656; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	79	119	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10883	10891		10.1074/jbc.M309901200	http://dx.doi.org/10.1074/jbc.M309901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699155	hybrid			2022-12-27	WOS:000220157600009
J	Dulhunty, AF; Curtis, SM; Watson, S; Cengia, L; Casarotto, MG				Dulhunty, AF; Curtis, SM; Watson, S; Cengia, L; Casarotto, MG			Multiple actions of imperatoxin a on ryanodine receptors - Interactions with the II-III loop "A" fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL-MUSCLE; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; SUBCONDUCTANCE STATES; CYTOPLASMIC LOOP; SCORPION TOXIN; CARDIAC-MUSCLE; ACTIVATION	Imperatoxin A is a high affinity activator of ryanodine receptors. The toxin contains a positively charged surface structure similar to that of the A fragment of skeletal dihydropyridine receptors ( peptide A), suggesting that the toxin and peptide could bind to a common site on the ryanodine receptor. However, the question of a common binding site has not been resolved, and the concentration dependence of the actions of the toxin has not been fully explored. We characterize two novel high affinity actions of the toxin on the transient gating of cardiac and skeletal channels, in addition to the well documented lower affinity induction of prolonged substates. Transient activity was ( a) enhanced with 0.2 - 10 nM toxin and ( b) depressed by > 50 nM toxin. The toxin at greater than or equal to1 nM enhanced Ca2+ release from SR in a manner consistent with two independent activation processes. The effects of the toxin on transient activity, as well as the toxin-induced substate, were independent of cytoplasmic Ca2+ or Mg2+ concentrations or the presence of adenine nucleotide and were seen in diisothiocyanostilbene-2', 2'-disulfonic acid-modified channels. Peptide A activated skeletal and cardiac channels with 100 nM cytoplasmic Ca2+ and competed with Imperatoxin A in the high affinity enhancement of transient channel activity and Ca2+ release from SR. In contrast to transient activity, prolonged substate openings induced by the toxin were not altered in the presence of peptide A. The results suggest that Imperatoxin A has three independent actions on ryanodine receptor channels and competes with peptide A for at least one action.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT, Australia; Australian Natl Univ, Biotron Ltd, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Australian National University	Dulhunty, AF (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia.	angela.dulhunty@anu.edu.au	Casarotto, Marco/D-8704-2011; Dulhunty, Angela/AAO-5421-2020	Dulhunty, Angela/0000-0001-9493-4944; Casarotto, Marco/0000-0002-0571-7671				Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Casarotto MG, 2001, BIOPHYS J, V80, P2715, DOI 10.1016/S0006-3495(01)76240-6; Chen L, 2003, J BIOL CHEM, V278, P16095, DOI 10.1074/jbc.M209501200; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; Gallant EM, 2001, BIOPHYS J, V80, P1769, DOI 10.1016/S0006-3495(01)76147-4; Green D, 2003, BIOCHEM J, V370, P517, DOI 10.1042/BJ20021488; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; Haarmann CS, 2003, BIOCHEM J, V372, P305, DOI 10.1042/BJ20021763; Hill AP, 2002, BIOPHYS J, V82, P3037, DOI 10.1016/S0006-3495(02)75644-0; Hirata Y, 1999, BBA-MOL CELL RES, V1451, P132, DOI 10.1016/S0167-4889(99)00082-8; Klinger M, 2001, BIOCHEM J, V355, P827, DOI 10.1042/bj3550827; Lamb GD, 2000, AM J PHYSIOL-CELL PH, V279, pC891, DOI 10.1152/ajpcell.2000.279.4.C891; LAVER DR, 1995, J MEMBRANE BIOL, V147, P7; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Li YX, 2001, J PHYSIOL-LONDON, V537, P17, DOI 10.1111/j.1469-7793.2001.0017k.x; LU XY, 1994, J BIOL CHEM, V269, P6511; MINUM EW, 1993, STAT REASONING PSYCH, P475; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; O'Neill ER, 2003, BIOPHYS J, V84, P1674, DOI 10.1016/S0006-3495(03)74976-5; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Oba T, 1996, AM J PHYSIOL-CELL PH, V271, pC819, DOI 10.1152/ajpcell.1996.271.3.C819; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	37	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11853	11862		10.1074/jbc.M310466200	http://dx.doi.org/10.1074/jbc.M310466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699105	hybrid			2022-12-27	WOS:000220157600122
J	Khan, MM; Nomura, T; Chiba, T; Tanaka, K; Yoshida, H; Mori, K; Ishii, S				Khan, MM; Nomura, T; Chiba, T; Tanaka, K; Yoshida, H; Mori, K; Ishii, S			The fusion oncoprotein PML-RAR alpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR RECEPTOR COREPRESSOR; RING-FINGER DOMAIN; RETINOIC ACID; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR; QUALITY-CONTROL; PROTEIN; UBIQUITIN; TARGET	PML-RARalpha, a fusion protein of promyelocytic leukemia (PML) and the retinoic acid receptor-alpha (RARalpha), causes acute promyelocytic leukemias (APL). Although the role of nuclear PML-RARalpha has been extensively studied, a significant amount of PML-RARalpha is in the cytoplasm. The role cytoplasmic PML-RARalpha plays in leukemogenesis is unknown. Here we report that PML-RARalpha induces the N-CoR accumulation in the endoplasmic reticulum ( ER), leading to the induction of ER stress and the processing of activating transcription factor 6 (ATF6), the unfolded protein response. PML-RARalpha stimulates the ubiquitylation of N-CoR via Ubc6 that is involved in the protein quality control. This ER-associated degradation (ERAD) of N-CoR reduces the soluble NCoR protein levels in the nucleus. The two N-CoR-interacting sites in PML-RARalpha are required for the ERAD of N-CoR, suggesting the aberrant binding of PML-RARalpha to N-CoR may induce the ERAD of N-CoR. Overexpression of N-CoR induces the differentiation of APL-derived NB4 cells, suggesting that the low levels of N-CoR in the nucleus may contribute at least partly to PML-RARalpha mediated leukemogenesis.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan	RIKEN; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016; Mori, Kazutoshi/K-6106-2015	Ishii, Shunsuke/0000-0002-6530-2478; Yoshida, Hiderou/0000-0002-5773-1408				Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bussolino DF, 2001, FASEB J, V15, P556; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lenk U, 2002, J CELL SCI, V115, P3007; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shiraki K, 2002, J BIOCHEM, V132, P591, DOI 10.1093/oxfordjournals.jbchem.a003261; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	49	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11814	11824		10.1074/jbc.M312121200	http://dx.doi.org/10.1074/jbc.M312121200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701861	hybrid			2022-12-27	WOS:000220157600118
J	Kim, E; Muga, SJ; Fischer, SM				Kim, E; Muga, SJ; Fischer, SM			Identification and characterization of a phorbol ester-responsive element in the murine 8S-lipoxygenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ORNITHINE DECARBOXYLASE ACTIVITY; ARACHIDONIC-ACID METABOLISM; HUMAN 5-LIPOXYGENASE GENE; MOUSE EPIDERMAL-CELLS; LONG TERMINAL REPEAT; SKIN TUMOR PROMOTION; TRANSCRIPTIONAL ACTIVATION; LIPOXYGENASE INHIBITORS; 12-LIPOXYGENASE GENE	Murine 8S-lipoxygenase (8S-LOX) is a 12-O-tetradecanoylphorbol-13-acetate (TPA)-inducible lipoxygenase. That is, it is not detected in normal mouse skin, however, a significant increase in expression is detected in the skin of TPA promotion-sensitive strains of mice after TPA treatment. In this study, we found TPA-induced 8S-LOX mRNA expression is a result of increased transcription in SSIN primary keratinocytes and further investigated transcriptional regulation of 8S-LOX expression by cloning its promoter. The cloned 8S-LOX promoter (similar to2 kb) in which a transcription initiation site was mapped at -27 from the ATG has neither a TATA box nor a CCAAT box. However, the promoter was highly responsive to TPA in TPA promotion-sensitive SSIN but not in TPA promotion-resistant C57BL/6J primary keratinocytes. We then identified a Sp1 binding site located -77 to -68 from the ATG that is a TPA-responsive element (TRE) of the promoter and that Sp1, Sp2, and Sp3 proteins bind to the TRE. We also found that the binding of these proteins to the TRE was significantly increased by TPA treatment and inhibition of the binding by mithramycin A decreased TPA-induced promoter activity as well as 8S-LOX mRNA expression. These data suggest that increased binding of Sp1, Sp2, and Sp3 to the TRE of the 8S-LOX promoter is a mechanism by which TPA induces 8S-LOX expression in keratinocytes.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Univ S Carolina, Sch Med, S Carolina Canc Ctr, Columbia, SC 29203 USA	University of Texas System; UTMD Anderson Cancer Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, POB 389, Smithville, TX 78957 USA.	sa83161@odin.mdacc.tmc.edu			NCI NIH HHS [CA34443, CA83794] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083794, R01CA034443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Burger F, 1999, MOL CARCINOGEN, V24, P108, DOI 10.1002/(SICI)1098-2744(199902)24:2<108::AID-MC5>3.0.CO;2-R; CAREY M, 2000, TRANSCRIPTIONAL REGU, P249; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1982, CARCINOGENESIS, V3, P1243, DOI 10.1093/carcin/3.11.1243; FISCHER SM, 1987, CANCER RES, V47, P3174; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOLDBERG IH, 1971, ANNU REV BIOCHEM, V40, P775, DOI 10.1146/annurev.bi.40.070171.004015; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; Heidt M, 2000, LIPIDS, V35, P701, DOI 10.1007/s11745-000-0576-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kinzig A, 1997, FEBS LETT, V402, P162, DOI 10.1016/S0014-5793(96)01517-7; KRIEG P, 1995, MOL CARCINOGEN, V14, P118, DOI 10.1002/mc.2940140208; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Mar PK, 1995, MOL CARCINOGEN, V14, P240, DOI 10.1002/mc.2940140404; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; NAKADATE T, 1982, CARCINOGENESIS, V3, P1411, DOI 10.1093/carcin/3.12.1411; Noe V, 2001, EUR J BIOCHEM, V268, P3163, DOI 10.1046/j.1432-1327.2001.02198.x; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RISTOW HJ, 1982, J INVEST DERMATOL, V79, P408, DOI 10.1111/1523-1747.ep12530331; Silverman ES, 2000, AM J RESP CRIT CARE, V161, pS77, DOI 10.1164/ajrccm.161.supplement_1.ltta-16; Silverman ES, 2002, AM J RESP CELL MOL, V26, P475, DOI 10.1165/ajrcmb.26.4.4747; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P1; Steele VE, 1999, CANCER EPIDEM BIOMAR, V8, P467; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 1999, VIROLOGY, V254, P279, DOI 10.1006/viro.1998.9556; VERMA AK, 1980, CANCER RES, V40, P308; Wang Jun, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P497; YOSHIMOTO T, 1992, J BIOL CHEM, V267, P24805; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	42	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11188	11197		10.1074/jbc.M313291200	http://dx.doi.org/10.1074/jbc.M313291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711820	hybrid			2022-12-27	WOS:000220157600044
J	Laudes, M; Christodoulides, C; Sewter, C; Rochford, JJ; Considine, RV; Sethi, JK; Vidal-Puig, A; O'Rahilly, S				Laudes, M; Christodoulides, C; Sewter, C; Rochford, JJ; Considine, RV; Sethi, JK; Vidal-Puig, A; O'Rahilly, S			Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; MITOTIC CLONAL EXPANSION; ADIPOCYTE DIFFERENTIATION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; DOMAIN PROTEIN; GAMMA AGONISTS; PPAR-GAMMA; CELLS; BINDING	Poxvirus zinc finger (POZ) zinc finger domain transcription factors have been shown to play a role in the control of growth arrest and differentiation in several types of mesenchymal cells but not, as yet, adipocytes. We found that a POZ domain protein, factor that binds to inducer of short transcripts-1 (FBI-1), was induced during both murine and human preadipocyte differentiation with maximal expression levels seen at days 2-4. FBI-1 mRNA was expressed in human adipose tissue with the highest levels found in samples from morbidly obese subjects. Murine cell lines constitutively expressing FBI-1 showed evidence for accelerated adipogenesis with earlier induction of markers of differentiation and enhanced lipid accumulation, suggesting that FBI-1 may be an active participant in the differentiation process. Consistent with the properties of this family of proteins in other cell systems, 3T3L1 cells stably overexpressing FBI-1 showed reduced DNA synthesis and reduced expression of cyclin A, cyclin-dependent kinase 2, and p107, proteins known to be involved in the regulation of mitotic clonal expansion. In addition, FBI-1 reduced the transcriptional activity of the cyclin A promoter. Thus, FBI-1, a POZ zinc finger transcription factor, is induced during the early phases of human and murine preadipocyte differentiation where it may contribute to adipogenesis through influencing the switch from cellular proliferation to terminal differentiation.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Indiana Univ, Sch Med, Div Endocrinol & Metab, Indianapolis, IN 46202 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Indiana University System; Indiana University-Purdue University Indianapolis	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd,Box 232, Cambridge CB2 2QR, England.	sorahill@hgmp.mrc.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Laudes, Matthias/C-8885-2011; Sethi, Jaswinder K./B-1413-2008	O'Rahilly, Stephen/0000-0003-2199-4449; Sethi, Jaswinder K./0000-0003-4157-0475; Rochford, Justin/0000-0002-5020-4939; Vidal-Puig, Antonio/0000-0003-4220-9577	Biotechnology and Biological Sciences Research Council [JF16994] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Entenmann G, 1996, AM J PHYSIOL-CELL PH, V270, pC1011, DOI 10.1152/ajpcell.1996.270.4.C1011; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Hajra AK, 2000, J BIOL CHEM, V275, P9441, DOI 10.1074/jbc.275.13.9441; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Landsberg RL, 2003, P NATL ACAD SCI USA, V100, P2456, DOI 10.1073/pnas.0138064100; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nugent C, 2001, MOL ENDOCRINOL, V15, P1729, DOI 10.1210/me.15.10.1729; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Pessler F, 2003, J BIOL CHEM, V278, P29327, DOI 10.1074/jbc.M302980200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Sewter CP, 2002, DIABETES, V51, P718, DOI 10.2337/diabetes.51.3.718; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tu AY, 2001, DIABETES, V50, P1851, DOI 10.2337/diabetes.50.8.1851; Xu HY, 1999, J BIOL CHEM, V274, P26287, DOI 10.1074/jbc.274.37.26287; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	38	44	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11711	11718		10.1074/jbc.M310240200	http://dx.doi.org/10.1074/jbc.M310240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701838	Green Accepted, hybrid			2022-12-27	WOS:000220157600107
J	Murai-Takebe, R; Noguchi, T; Ogura, T; Mikami, T; Yanagi, K; Inagaki, K; Ohnishi, H; Matozaki, T; Kasuga, M				Murai-Takebe, R; Noguchi, T; Ogura, T; Mikami, T; Yanagi, K; Inagaki, K; Ohnishi, H; Matozaki, T; Kasuga, M			Ubiquitination-mediated regulation of biosynthesis of the adhesion receptor SHPS-1 in response to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ER-ASSOCIATED DEGRADATION; F-BOX; TRANSMEMBRANE GLYCOPROTEIN; QUALITY-CONTROL; SIRP-ALPHA; GROWTH; LIGAND; CELLS; CD47	Misfolding of proteins during endoplasmic reticulum (ER) stress results in the formation of cytotoxic aggregates. The ER-associated degradation pathway counteracts such aggregation through the elimination of misfolded proteins by the ubiquitin-proteasome system. We now show that SHP substrate-1 (SHPS-1), a transmembrane glycoprotein that regulates cytoskeletal reorganization and cell-cell communication, is a physiological substrate for the Skp1-Cullin1-NFB42-Rbx1 (SCFNFB42) E3 ubiquitin ligase, a proposed mediator of ER-associated degradation. SCFNFB42 mediated the polyubiquitination of immature SHPS-1 and its degradation by the proteasome. Ectopic expression of NFB42 both suppressed the formation of aggresome-like structures and the phosphorylation of the translational regulator eIF2alpha induced by overproduction of SHPS-1 as well as increased the amount of mature SHPS-1 at the cell surface. An NFB42 mutant lacking the F box domain had no such effects. Our results suggest that SCFNFB42 regulates SHPS-1 biosynthesis in response to ER stress.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Takarazuka, Hyogo 6658555, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Sumitomo Chem Co Ltd; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	noguchi@med.kobe-u.ac.jp						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cant CA, 2001, CELL MOL LIFE SCI, V58, P117, DOI 10.1007/PL00000771; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Comu S, 1997, J NEUROSCI, V17, P8702; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Graves TK, 2001, J CELL SCI, V114, P3685; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Machida K, 2000, ONCOGENE, V19, P1710, DOI 10.1038/sj.onc.1203497; Mi ZP, 2000, J COMP NEUROL, V416, P335; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van den Nieuwenhof IM, 2001, J CELL SCI, V114, P1321; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890	44	14	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11616	11625		10.1074/jbc.M311463200	http://dx.doi.org/10.1074/jbc.M311463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701835	hybrid			2022-12-27	WOS:000220157600095
J	Araki, R; Takahashi, H; Fukumura, R; Sun, FY; Umeda, N; Sujino, M; Inouye, SIT; Saito, T; Abe, M				Araki, R; Takahashi, H; Fukumura, R; Sun, FY; Umeda, N; Sujino, M; Inouye, SIT; Saito, T; Abe, M			Restricted expression and photic induction of a novel mouse regulatory factor X4 transcript in the suprachiasmatic nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II DEFICIENCY; PROMOTER BINDING-PROTEIN; DNA-BINDING; CIRCADIAN CLOCK; GENE-EXPRESSION; MESSENGER-RNAS; RFX FAMILY; LIGHT; DROSOPHILA; SYSTEM	The regulatory factor X (RFX) family of transcription factors is characterized by a unique and highly conserved 76-amino acid residue DNA-binding domain. Mammals have five RFX genes, but the physiological functions of their products are unknown, with the exception of RFX5. Here a mouse RFX4 transcript was identified that encodes a peptide of 735 amino acids, including the DNA-binding domain. Its expression was localized in the suprachiasmatic nucleus, the central pacemaker site of the circadian clock. Also, light exposure was found to induce its gene expression in a subjective night-specific manner. Polyclonal antibodies were prepared, and an 80-kDa band was detected in the suprachiasmatic nucleus by Western hybridization. A histochemical study showed a localization of the products in the nucleus. This is the first report on mouse RFX4, which contains the RFX DNA-binding motif. Our investigation may provide clues to the physiological function of RFX4.	Natl Inst Radiol Sci, Transcriptome Res Ctr, Inage Ku, Chiba 2638555, Japan; Japan Soc Promot Sci, Kawaguchi, Saitama 3320012, Japan; Yamaguchi Univ, Dept Phys Informat & Biol, Yamaguchi 7538512, Japan	National Institutes for Quantum Science & Technology; Japan Society for the Promotion of Science; Yamaguchi University	Abe, M (corresponding author), Natl Inst Radiol Sci, Transcriptome Res Ctr, Inage Ku, Anagawa 4-9-1, Chiba 2638555, Japan.	abemasum@nirs.go.jp		Abe, Masumi/0000-0003-1550-2006; Takahashi, Hirokazu/0000-0002-9425-6546				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; Blackshear PJ, 2003, DEVELOPMENT, V130, P4539, DOI 10.1242/dev.00661; Cermakian N, 2002, CURR OPIN NEUROBIOL, V12, P359, DOI 10.1016/S0959-4388(02)00347-1; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; Doyle J, 1996, GENOMICS, V35, P227, DOI 10.1006/geno.1996.0343; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Durand B, 2000, GENE, V246, P285, DOI 10.1016/S0378-1119(00)00093-7; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FLOREZ JC, 1995, ANN MED, V27, P481, DOI 10.3109/07853899709002457; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gau D, 2002, NEURON, V34, P245, DOI 10.1016/S0896-6273(02)00656-6; Gillette MU, 1997, CURR OPIN NEUROBIOL, V7, P797, DOI 10.1016/S0959-4388(97)80138-9; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Guido ME, 1996, BRAIN RES, V739, P132, DOI 10.1016/S0006-8993(96)00816-5; Honrado GI, 1996, J COMP PHYSIOL A, V178, P563; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; Karsai A, 2002, BIOTECHNIQUES, V32, P790, DOI 10.2144/02324st05; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kilduff TS, 1998, J BIOL RHYTHM, V13, P347, DOI 10.1177/074873098129000174; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Kornhauser JM, 1996, BEHAV GENET, V26, P221, DOI 10.1007/BF02359382; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Romijn HJ, 1996, J COMP NEUROL, V372, P1; RUSAK B, 1992, MOL BRAIN RES, V14, P124, DOI 10.1016/0169-328X(92)90019-8; Schmitt EK, 2000, J BIOL CHEM, V275, P9348, DOI 10.1074/jbc.275.13.9348; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Stehle JH, 1996, NEUROSCI LETT, V217, P169, DOI 10.1016/0304-3940(96)13103-7; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Vandaele C, 2001, MECH DEVELOP, V103, P159, DOI 10.1016/S0925-4773(01)00340-9; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wiechmann AF, 2002, J PINEAL RES, V33, P178, DOI 10.1034/j.1600-079X.2002.02935.x; Wisor JP, 1997, J COMP NEUROL, V378, P229; WU SY, 1995, MOL CELL BIOL, V15, P1479; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	49	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10237	10242		10.1074/jbc.M312761200	http://dx.doi.org/10.1074/jbc.M312761200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701801	hybrid			2022-12-27	WOS:000220050400071
J	Debril, MB; Gelman, L; Fayard, E; Annicotte, JS; Rocchi, S; Auwerx, J				Debril, MB; Gelman, L; Fayard, E; Annicotte, JS; Rocchi, S; Auwerx, J			Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; RETINOIC ACID RECEPTOR; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID-RECEPTOR; PPAR-GAMMA; HISTONE ACETYLTRANSFERASES; ESTROGEN-RECEPTOR; HORMONE RECEPTORS; GENE ACTIVATION; HUMAN HOMOLOGS	Transcriptional activity relies on coregulators that modify chromatin structure or serve as bridging factors between transcription factors and the basal transcription machinery. We identified a new coregulator of peroxisome proliferator-activated receptor gamma, BRG1/Brm-associated factor of 60 kDa, subunit c2 (BAF60c2), in a yeast two-hybrid screen of a human adipose tissue cDNA library. BAF60c2 represents a new isoform of BAF60c, a component of the SWI/SNF (mating type switching/sucrose non-fermenting) chromatin remodeling complex. This new isoform as well as the previously identified protein, renamed BAF60c1, is localized primarily in the cell nucleus and is expressed in a wide variety of tissues. Both BAF60c isoforms bind to several nuclear receptors and transcription factors of various families. BAF60c proteins interact in a ligand-independent manner with peroxisome proliferator-activated receptor gamma and enhance its transcriptional activity. Both isoforms are enriched in the central nervous system and also modulate the transcriptional activity of retinoic acid-related orphan receptor alpha1. In conclusion, BAF60c represents a new coregulator that constitutes an important anchoring point by which the SWI/SNF complex is recruited to nuclear receptors and other transcription factors.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP10142, F-67404 Illkirch Graffenstaden, France.	auwerx@igbmc.u-strasbg.fr	Auwerx, Johan/ABE-9307-2021; Annicotte, Jean-Sébastien/H-4641-2018; Rocchi, Stephane/O-4152-2016	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Rocchi, Stephane/0000-0002-0943-1304; Auwerx, Johan/0000-0002-5065-5393; Gelman, Laurent/0000-0003-3277-3115				Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Brendel C, 2002, MOL ENDOCRINOL, V16, P1367, DOI 10.1210/me.16.6.1367; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fayard E, 2003, J BIOL CHEM, V278, P35725, DOI 10.1074/jbc.M302370200; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Remboutsika E, 1999, J CELL SCI, V112, P1671; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	55	101	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16677	16686		10.1074/jbc.M312288200	http://dx.doi.org/10.1074/jbc.M312288200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14701856	hybrid			2022-12-27	WOS:000220747900120
J	Hayashi, H; Campenot, RB; Vance, DE; Vance, JE				Hayashi, H; Campenot, RB; Vance, DE; Vance, JE			Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; APOLIPOPROTEIN-E RECEPTORS; PICK C1-DEFICIENT NEURONS; HUMAN CEREBROSPINAL-FLUID; NEURITE OUTGROWTH; CHOLESTEROL TRANSPORT; HUMAN BRAIN; SYMPATHETIC NEURONS; ALZHEIMERS-DISEASE; SYNAPSE FORMATION	The role of lipoproteins secreted by cortical glial cells in axon growth of central nervous system (CNS) neurons was investigated. We first established compartmented cultures of CNS neurons ( retinal ganglion cells). Addition of glial cell-conditioned medium (GCM) to distal axons increased the rate of axon extension by similar to 50%. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase in glial cells diminished the secretion of cholesterol and apolipoprotein E, and prevented the growth stimulatory effect of GCM. When glia-derived lipoproteins containing apolipoprotein E were provided to distal axons, axon extension was stimulated to the same extent as by GCM. In contrast, addition of lipoproteins to cell bodies failed to enhance growth. The growth stimulatory effect of glial lipoproteins was abrogated in the presence of receptor-associated protein, RAP, indicating involvement of receptor(s) of the low density lipoprotein receptor family in stimulation of axonal extension. These observations suggest that glial cells stimulate axon growth of CNS neurons by providing lipoproteins containing cholesterol and apolipoprotein E to distal axons.	Univ Alberta, Dept Med, Grp Mol & Cell Biol Lipids, HMRC 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Dept Med, Grp Mol & Cell Biol Lipids, HMRC 328, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca						Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; Barres BA, 2000, CURR OPIN NEUROBIOL, V10, P642, DOI 10.1016/S0959-4388(00)00134-3; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; Beisiegel U, 2001, CURR OPIN LIPIDOL, V12, P243, DOI 10.1097/00041433-200106000-00001; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Brown MD, 1997, BRAIN RES, V747, P313, DOI 10.1016/S0006-8993(96)01321-2; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; CAMPENOT RB, 1979, METHOD ENZYMOL, V28, P302; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; CAMPENOT RB, 2001, PROTOCOLS NEURAL CEL, P49; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; de Chaves EIP, 2000, J BIOL CHEM, V275, P19883, DOI 10.1074/jbc.275.26.19883; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; DeMattos RB, 2001, J LIPID RES, V42, P976; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; Hering H, 2003, J NEUROSCI, V23, P3262; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Ivins KJ, 1998, NEUROBIOL DIS, V5, P365, DOI 10.1006/nbdi.1998.0228; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; KARTEN B, 2002, APOPTOSIS METHODS TE, V37, P163; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koch S, 2001, J LIPID RES, V42, P1143; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; MacInnis BL, 2002, SCIENCE, V295, P1536, DOI 10.1126/science.1064913; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Motoi Y, 1999, BRAIN RES, V833, P209, DOI 10.1016/S0006-8993(99)01542-5; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nimpf J, 2000, BBA-MOL CELL BIOL L, V1529, P287, DOI 10.1016/S1388-1981(00)00155-4; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Petegnief V, 2001, NEUROSCIENCE, V104, P223, DOI 10.1016/S0306-4522(01)00046-X; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; PFRIEGER FW, 2003, BIOESSAYS, V25, P486; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TOOYAMA I, 1995, BRAIN RES, V691, P235, DOI 10.1016/0006-8993(95)00735-9; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1994, J NEUROCHEM, V62, P329; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WOLF BB, 1992, AM J PATHOL, V141, P37; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; YOSHINO G, 1988, ATHEROSCLEROSIS, V71, P95, DOI 10.1016/0021-9150(88)90133-5	71	138	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14009	14015		10.1074/jbc.M313828200	http://dx.doi.org/10.1074/jbc.M313828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14709547	hybrid			2022-12-27	WOS:000220478500089
J	Lewin, TM; Schwerbrock, NMJ; Lee, DP; Coleman, RA				Lewin, TM; Schwerbrock, NMJ; Lee, DP; Coleman, RA			Identification of a new glycerol-3-phosphate acyltransferase isoenzyme, mtGPAT2, in mitochondria*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; RAT-LIVER MITOCHONDRIA; MICROSOMAL GLYCEROPHOSPHATE ACYLTRANSFERASE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; TRIACYLGLYCEROL-SYNTHESIS; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; MONOACYLGLYCEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE; FUNCTIONAL EXPRESSION	Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the initial and rate-limiting step of glycerolipid synthesis. Two distinct GPAT isoenzymes had been identified in mammalian tissues, an N-ethylmaleimide (NEM)-sensitive isoform in the endoplasmic reticulum membrane ( microsomal GPAT) and an NEM-resistant form in the outer mitochondrial membrane (mtGPAT). Although only mtGPAT has been cloned, the microsomal and mitochondrial GPAT isoforms can be distinguished, because they differ in acyl-CoA substrate preference, sensitivity to inhibition by dihydroxyacetone phosphate and polymixin B, temperature sensitivity, and ability to be activated by acetone. The preponderance of evidence supports a role for mtGPAT in synthesizing the precursors for triacylglycerol synthesis. In mtGPAT(-/-) mice, PCR genotyping and Northern analysis showed successful knockout of mtGPAT; however, we detected a novel NEM-sensitive GPAT activity in mitochondrial fractions and an anti-mtGPAT immunoreactive protein in liver mitochondria, but not in microsomes. Rigorous analysis using two-dimensional gel electrophoresis revealed that the anti-mtGPAT immunoreactive proteins in wild type and mtGPAT(-/-) liver mitochondria have different isoelectric points. These results suggested the presence of a second GPAT in liver mitochondria from mtGPAT(-/-) mice. Characterization of this GPAT activity in liver from mtGPAT null mice showed that, unlike the mtGPAT activity in wild type samples, activity in mtGPAT knockout mitochondria did not prefer palmitoyl-CoA, was sensitive to inactivation by NEM, was inhibited by dihydroxyacetone phosphate and polymixin B, was temperature-sensitive, and was not activated by acetone. We conclude that a novel GPAT (mtGPAT2) with antigenic epitopes similar to those of mtGPAT is detectable in mitochondria from the livers of mtGPAT(-/-) mice.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059935, K01DK059931, R01DK056598] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59931, DK56598, DK59935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BREMER J, 1976, MOL CELL BIOCHEM, V12, P113, DOI 10.1007/BF01731557; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P17, DOI 10.1016/0003-9861(82)90003-0; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG YY, 1967, J LIPID RES, V8, P447; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; COLEMAN RA, 1988, BIOCHIM BIOPHYS ACTA, V963, P367, DOI 10.1016/0005-2760(88)90303-7; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DAS SK, 1987, LIPIDS, V22, P757, DOI 10.1007/BF02533977; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; HALDAR D, 1979, J BIOL CHEM, V254, P4502; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; MITCHELL JRD, 1994, INT J BIOCHEM, V26, P181, DOI 10.1016/0020-711X(94)90143-0; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; SCHLOSSMAN DM, 1977, ARCH BIOCHEM BIOPHYS, V182, P732, DOI 10.1016/0003-9861(77)90555-0; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SHIN DH, 1991, J BIOL CHEM, V266, P23834; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	45	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13488	13495		10.1074/jbc.M314032200	http://dx.doi.org/10.1074/jbc.M314032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724270	hybrid, Green Published			2022-12-27	WOS:000220478500027
J	Davis, AJ; Perugini, MA; Smith, BJ; Stewart, JD; Ilg, T; Hodder, AN; Handman, E				Davis, AJ; Perugini, MA; Smith, BJ; Stewart, JD; Ilg, T; Hodder, AN; Handman, E			Properties of GDP-mannose pyrophosphorylase, a critical enzyme and drug target in Leishmania mexicana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE; PHENOTYPES; PROTEINS	Leishmania parasites synthesize a range of mannose-containing glycoconjugates thought to be essential for virulence in the mammalian host and sandfly vector. A prerequisite for the synthesis of these molecules is the availability of the activated mannose donor, GDP-Man, the product of the catalysis of mannose-1-phosphate and GTP by GDP-mannose pyrophosphorylase (GDP-MP). In contrast to the lethal phenotype in fungi, the deletion of the gene in Leishmania mexicana did not affect parasite viability but led to a total loss of virulence, making GDP-MP an ideal target for anti-Leishmania drug development. We show by immunofluorescence and subcellular fractionation that GDP-MP is a cytoplasmic protein, and we describe a colorimetric activity assay suitable for the high throughput screening of small molecule inhibitors. We expressed recombinant GDP-MP as a fusion with maltose-binding protein and separated the enzyme from maltose-binding protein by thrombin cleavage, ion-exchange, and size exclusion chromatography. Size exclusion chromatography and analytical ultracentrifugation studies demonstrate that GDP-MP self-associates to form an enzymatically active and stable hexamer. However, sedimentation studies show that the GDP-MP hexamer dissociates to trimers and monomers in a time-dependent manner, at low protein concentrations, at low ionic strength, and at alkaline pH. Circular dichroism spectroscopy reveals that GDP-MP is comprised of mixed alpha/beta structure, similar to its closest related homologue, N-acetyl-glucoseamine-1-phosphate uridyltransferase (Glmu) from Streptococcus pneumoniae. Our studies provide insight into the structure of a novel target for the development of anti-Leishmania drugs.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Intervet Innovat GmbH, D-55270 Schwabenheim, Germany	Walter & Eliza Hall Institute; University of Melbourne; Merck & Company; Intervet International B.V.	Handman, E (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	handman@wehi.edu.Au	Smith, Brian J/F-8282-2011	Smith, Brian J/0000-0003-0498-1910; Perugini, Matthew/0000-0001-8052-5584; Stewart, James/0000-0002-1774-8619				BORDIER C, 1981, J BIOL CHEM, V256, P1604; Croft SL, 1999, MEM I OSWALDO CRUZ, V94, P215, DOI 10.1590/S0074-02761999000200017; Davis AJ, 2004, TRENDS PARASITOL, V20, P73, DOI 10.1016/j.pt.2003.11.006; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; HANDMAN E, 1992, ADV MOL CELL BIOL, V5, P133; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 1999, TRENDS GLYCOSCI GLYC, V11, P53, DOI 10.4052/tigg.11.53; Ilgoutz SC, 2001, INT J PARASITOL, V31, P899, DOI 10.1016/S0020-7519(01)00197-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MCCONVILLE MJ, 1991, LEISHMANIA PARASITES, P38; Ohta A, 2000, BBA-GEN SUBJECTS, V1475, P265, DOI 10.1016/S0304-4165(00)00075-1; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Ralton JE, 2003, J BIOL CHEM, V278, P40757, DOI 10.1074/jbc.M307660200; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARKI A, 1999, ESSENTIALS GLYCOBIOL, P57; Warit S, 2000, MOL MICROBIOL, V36, P1156, DOI 10.1046/j.1365-2958.2000.01944.x; World Health Organization (WHO), 1998, LEISHM CONTR BURD TR, P1; Yardley V, 2000, INT J ANTIMICROB AG, V13, P243, DOI 10.1016/S0924-8579(99)00133-8	28	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12462	12468		10.1074/jbc.M312365200	http://dx.doi.org/10.1074/jbc.M312365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718535	hybrid			2022-12-27	WOS:000220334900056
J	Ghosh, A; Shieh, JJ; Pan, CJ; Chou, JY				Ghosh, A; Shieh, JJ; Pan, CJ; Chou, JY			Histidine 167 is the phosphate acceptor in glucose-6-phosphatase-beta forming a phosphohistidine enzyme intermediate during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; SUBUNIT-RELATED PROTEIN; ACTIVE-SITE; MICROSOMAL GLUCOSE-6-PHOSPHATASE; MURINE GLUCOSE-6-PHOSPHATASE; TRANSMEMBRANE TOPOLOGY; GLUCOSE 6-PHOSPHATASE; CURVULARIA-INAEQUALIS; IDENTIFICATION; GENE	The glucose-6-phosphatase (Glc-6-Pase) family comprises two active endoplasmic reticulum (ER)-associated isozymes: the liver/kidney/intestine Glc-6-Pase-alpha and the ubiquitous Glc-6-Pase-beta. Both share similar kinetic properties. Sequence alignments predict the two proteins are structurally similar. During glucose 6-phosphate (Glc-6-P) hydrolysis, Glc-6-Pase-beta, a nine-transmembrane domain protein, forms a covalently bound phosphoryl enzyme intermediate through His(176), which lies on the lumenal side of the ER membrane. We showed that Glc-6-Pase-beta is also a nine-transmembrane domain protein that forms a covalently bound phosphoryl enzyme intermediate during Glc-6-P hydrolysis. However, the intermediate was not detectable in Glc-6-Pase-alpha active site mutants R79A, H114A, and H167A. Using [P-32] Glc-6-P coupled with cyanogen bromide mapping, we demonstrated that the phosphate acceptor in Glc-6-Pase-beta is His(167) and that it lies inside the ER lumen with the active site residues, Arg(79) and His(114). Therefore Glc-6-Pase-alpha and Glc-6-Pase-beta share a similar active site structure, topology, and mechanism of action.	NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	chouja@mail.nih.gov	Shieh, Jeng-Jer/AAX-6903-2020	Shieh, Jeng-Jer/0000-0001-8412-3603	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Chou Janice Yang, 2001, Current Molecular Medicine (Hilversum), V1, P25; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Coligan JE, 1996, CURRENT PROTOCOLS PR; Cordoba OL, 1997, J BIOCHEM BIOPH METH, V35, P1, DOI 10.1016/S0165-022X(97)00018-3; FELDMAN F, 1972, BIOCHIM BIOPHYS ACTA, V268, P698, DOI 10.1016/0005-2744(72)90274-4; FELDMAN F, 1969, BIOCHEM BIOPH RES CO, V36, P119, DOI 10.1016/0006-291X(69)90657-3; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hemrika W, 1999, J BIOL CHEM, V274, P23820, DOI 10.1074/jbc.274.34.23820; Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; NORDLIE RC, 1966, J BIOL CHEM, V241, P3136; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P21658, DOI 10.1074/jbc.273.34.21658; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; PARVIN R, 1969, BIOCHEMISTRY-US, V8, P1748, DOI 10.1021/bi00832a058; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2002, J BIOL CHEM, V277, P5047, DOI 10.1074/jbc.M110486200; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Stukey J, 1997, PROTEIN SCI, V6, P469; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	32	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12479	12483		10.1074/jbc.M313271200	http://dx.doi.org/10.1074/jbc.M313271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718531	hybrid			2022-12-27	WOS:000220334900058
J	Nie, YZ; Zhao, QC; Su, YJ; Yang, JH				Nie, YZ; Zhao, QC; Su, YJ; Yang, JH			Subcellular distribution of ADAR1 isoforms is synergistically determined by three nuclear discrimination signals and a regulatory motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-EDITING ENZYME; SEMLIKI-FOREST VIRUS; ADENOSINE-DEAMINASE; BINDING DOMAINS; MESSENGER-RNA; EXPORT SIGNAL; UNWINDING ACTIVITY; IN-VIVO; PROTEIN; RECEPTOR	ADAR1 is an RNA-specific adenosine deaminase that edits RNA sequences. We have demonstrated previously that different ADAR1 isoforms are induced during acute inflammation. Here we show that the mouse ADAR1 isoforms are differentially localized in cellular compartments and that their localization is controlled by several independent signals. Nuclear import of the full-length ADAR1 is predominantly regulated by a nuclear localization signal at the C terminus (NLS-c), which consists of a bipartite basic amino acid motif plus the last 39 residues of ADAR1. Deletion of the NLS-c causes the truncated ADAR1 protein to be retained in the cytoplasm. The addition of this sequence to pyruvate kinase causes the cytoplasmic protein to be localized within the nucleus. The localization of nuclear ADAR1 is determined by a dynamic balance between the nucleolar binding activity of the nucleolar localization signal (NoLS) in the middle of the protein and the exporting activity of the nuclear exporter signal (NES) near the N terminus. The NoLS consists of a typical monopartite cluster of basic residues followed by the third double-stranded RNA-binding domain. These signals act independently; however, NES function can be completely silenced by the NLS-c when a regulatory motif within the catalytic domain and the NoLS are deleted. Thus, the intracellular distribution of the various ADAR1 isoforms is determined by NLS-c, NES, NoLS, and a regulatory motif.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University	Yang, JH (corresponding author), Yale Univ, Sch Med, Dept Surg, 333 Cedar St, New Haven, CT 06520 USA.	jinghua.yang@yale.edu			NIGMS NIH HHS [GM 60426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doyle M, 2003, J CELL BIOL, V161, P309, DOI 10.1083/jcb.200301034; Eckmann CR, 1999, J CELL BIOL, V144, P603, DOI 10.1083/jcb.144.4.603; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Herbert A, 2002, MOL CELL, V10, P1235, DOI 10.1016/S1097-2765(02)00737-2; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; JAKOB R, 1993, VIRUS RES, V30, P145, DOI 10.1016/0168-1702(93)90003-6; Kawakubo K, 2000, GENE, V258, P165, DOI 10.1016/S0378-1119(00)00368-1; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOUIS BG, 1988, MOL BIOL REP, V13, P103, DOI 10.1007/BF00539058; Maas S, 1999, P NATL ACAD SCI USA, V96, P8895, DOI 10.1073/pnas.96.16.8895; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MICHEL MR, 1990, J VIROL, V64, P5123, DOI 10.1128/JVI.64.10.5123-5131.1990; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; Rabinovici R, 2001, CIRC RES, V88, P1066, DOI 10.1161/hh1001.090877; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; Slavov D, 2000, GENE, V250, P41, DOI 10.1016/S0378-1119(00)00174-8; Strehblow A, 2002, MOL BIOL CELL, V13, P3822, DOI 10.1091/mbc.E02-03-0161; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wong SK, 2003, RNA, V9, P586, DOI 10.1261/rna.5160403; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 2003, J BIOL CHEM, V278, P45833, DOI 10.1074/jbc.M308612200; Yang JH, 2003, IMMUNOLOGY, V109, P15, DOI 10.1046/j.1365-2567.2003.01598.x; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354	46	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13249	13255		10.1074/jbc.M312753200	http://dx.doi.org/10.1074/jbc.M312753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711814	hybrid			2022-12-27	WOS:000220334900147
J	Peterson, FC; Elgin, ES; Nelson, TJ; Zhang, FM; Hoeger, TJ; Linhardt, RJ; Volkman, BF				Peterson, FC; Elgin, ES; Nelson, TJ; Zhang, FM; Hoeger, TJ; Linhardt, RJ; Volkman, BF			Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SURFACE; HEPARIN-BINDING; SITE; OLIGOMERIZATION; INHIBITION; MIP-1-BETA; EXPRESSION; STRATEGIES; PROTEIN-1; CYTOKINE	Chemokine-mediated recruitment of leukocytes in vivo depends on interactions with cell surface glycosaminoglycans. Lymphotactin, the unique member of the "C" chemokine subclass, is a highly basic protein that binds heparin, a glycosaminoglycan, with high affinity ( similar to 10 nM). We detected lymphotactin-heparin binding by NMR and mapped this interaction to a narrow surface that wraps around the protein. Substitutions in and around this binding site and surface plasmon resonance analysis of heparin binding affinity identified two arginine residues of lymphotactin as critical for glycosaminoglycan binding. Both arginine mutant proteins and the combined double mutant had dramatically diminished in vivo activity in a leukocyte recruitment assay, suggesting that the lymphotactin-glycosaminoglycan interactions detected in vitro are important for the function of this chemokine. Our results demonstrate that like other chemokines, lymphotactin utilizes highly specific glycosaminoglycan-binding sites that represent potential targets for drug development.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Mugla Univ, Kimya Bolumu, TR-48000 Mugla, Turkey; Rensselaer Polytech Inst, Dept Chem, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol & Chem Engn, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA	Medical College of Wisconsin; Mugla Sitki Kocman University; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	Volkman, BF (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	bvolkman@mcw.edu	Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; Nelson, Timothy/0000-0002-3862-7023	NIAID NIH HHS [R01 AI045843, R01 AI045843-04, R01 AI045843-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045843] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Blaschke S, 2003, ARTHRITIS RHEUM, V48, P1858, DOI 10.1002/art.11171; Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hedrick JA, 1997, J IMMUNOL, V158, P1533; Hedrick JA, 1998, CLIN IMMUNOL IMMUNOP, V87, P218, DOI 10.1006/clin.1998.4546; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuloglu ES, 2002, J BIOL CHEM, V277, P17863, DOI 10.1074/jbc.M200402200; Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; McFadden G, 1997, BIOCHEM PHARMACOL, V54, P1271, DOI 10.1016/S0006-2952(97)00182-2; Middel P, 2001, AM J PATHOL, V159, P1751, DOI 10.1016/S0002-9440(10)63022-2; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Proudfoot AEI, 1998, EUR J DERMATOL, V8, P147; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2003, SEMIN IMMUNOL, V15, P57, DOI 10.1016/S1044-5323(02)00128-8; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rousseau RF, 2003, BLOOD, V101, P1718, DOI 10.1182/blood-2002-08-2493; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Wang JD, 1998, IMMUNOLOGY, V95, P56; Yu GL, 2000, THROMB RES, V100, P549, DOI 10.1016/S0049-3848(00)00368-6; Zhang FM, 2002, ANAL BIOCHEM, V304, P271, DOI 10.1006/abio.2002.5617; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	46	69	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12598	12604		10.1074/jbc.M311633200	http://dx.doi.org/10.1074/jbc.M311633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707146	hybrid			2022-12-27	WOS:000220334900073
J	Yu, XR; Rajala, RVS; McGinnis, JF; Li, F; Anderson, RE; Yan, XR; Li, S; Elias, RV; Knapp, RR; Zhou, XH; Cao, W				Yu, XR; Rajala, RVS; McGinnis, JF; Li, F; Anderson, RE; Yan, XR; Li, S; Elias, RV; Knapp, RR; Zhou, XH; Cao, W			Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17 beta-estradiol-mediated neuroprotection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; APOPTOTIC CELL-DEATH; HYDROGEN-PEROXIDE; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; RETINAL NEURONS; LIGHT DAMAGE; IN-VITRO; ACTIVATION	In the present study, we tested the hypothesis that 17beta-estradiol (betaE2) is a neuroprotectant in the retina, using two experimental approaches: 1) hydrogen peroxide (H2O2)-induced retinal neuron degeneration in vitro, and 2) light-induced photoreceptor degeneration in vivo. We demonstrated that both betaE2 and 17alpha-estradiol (alphaE2) significantly protected against H2O2-induced retinal neuron degeneration; however, progesterone had no effect. betaE2 transiently increased the phosphoinositide 3-kinase (PI3K) activity, when phosphoinositide 4,5-bisphosphate and [(32)gammaATP] were used as substrate. Phospho-Akt levels were also transiently increased by betaE2 treatment. Addition of the estrogen receptor antagonist tamoxifen did not reverse the protective effect of betaE2, whereas the PI3K inhibitor LY294002 inhibited the protective effect of betaE2, suggesting that betaE2 mediates its effect through some PI3K-dependent pathway, independent of the estrogen receptor. Pull-down experiments with glutathione S-transferase fused to the N-Src homology 2 domain of p85, the regulatory subunit of PI3K, indicated that betaE2 and alphaE2, but not progesterone, identified phosphorylated insulin receptor beta-subunit (IRbeta) as a binding partner. Pretreatment with insulin receptor inhibitor, HNMPA, inhibited IRbeta activation of PI3K. Systemic administration of betaE2 significantly protected the structure and function of rat retinas against light-induced photoreceptor cell degeneration and inhibited photoreceptor apoptosis. In addition, systemic administration of betaE2 activated retinal IRbeta, but not the insulin-like growth factor receptor-1, and produced a transient increase in PI3K activity and phosphorylation of Akt in rat retinas. The results show that estrogen has retinal neuroprotective properties in vivo and in vitro and suggest that the insulin receptor/PI3K/Akt signaling pathway is involved in estrogen-mediated retinal neuroprotection.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Xi An Jiao Tong Univ, Sch Med, Dept Biochem & Mol Biol, Xian 710061, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Xi'an Jiaotong University	Cao, W (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, 608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	wei-cao@ouhsc.edu			NCRR NIH HHS [P20 RR 17703] Funding Source: Medline; NEI NIH HHS [EY 13050, EY 12190, EY 00871, EY 06973, EY 014427, EY 04149] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013050, R01EY000871, R03EY014427, R01EY004149, P30EY012190] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Banerjee S, 2003, BIOCHEM BIOPH RES CO, V300, P209, DOI 10.1016/S0006-291X(02)02830-9; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Bennett J, 2000, CURR OPIN MOL THER, V2, P420; Berglin L, 1997, GRAEF ARCH CLIN EXP, V235, P306, DOI 10.1007/BF01739640; Berson EL, 2000, INT OPHTHALMOL CLIN, V40, P93, DOI 10.1097/00004397-200010000-00008; BLANKS JC, 1992, INVEST OPHTH VIS SCI, V33, P2814; Cambiasso MJ, 2001, J NEUROSCI RES, V66, P475, DOI 10.1002/jnr.1238; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao W, 2003, ADV EXP MED BIOL, V533, P395; Cao W, 2000, J NEUROSCI RES, V60, P195, DOI 10.1002/(SICI)1097-4547(20000415)60:2<195::AID-JNR8>3.0.CO;2-7; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Carrer HF, 2002, CELL MOL NEUROBIOL, V22, P479, DOI 10.1023/A:1021825317546; Chen WH, 2001, J NEUROSCI RES, V63, P116, DOI 10.1002/1097-4547(20010115)63:2<116::AID-JNR1003>3.0.CO;2-G; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Diaz B, 1999, EUR J NEUROSCI, V11, P1624, DOI 10.1046/j.1460-9568.1999.00577.x; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fitzpatrick JL, 2002, J NEUROCHEM, V82, P674, DOI 10.1046/j.1471-4159.2002.01000.x; Gallaher BW, 2001, HORM METAB RES, V33, P511, DOI 10.1055/s-2001-17213; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gosbell AD, 2000, CLIN EXP OPHTHALMOL, V28, P212, DOI 10.1046/j.1442-9071.2000.00305.x; Guo XX, 1997, INVEST OPHTH VIS SCI, V38, P1873; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hivert B, 1998, NEUROREPORT, V9, P1835, DOI 10.1097/00001756-199806010-00031; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; Lawlor MA, 2001, J CELL SCI, V114, P2903; LORENZO A, 1992, J NEUROSCI RES, V33, P418, DOI 10.1002/jnr.490330308; Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Moosmann B, 2002, EXPERT OPIN INV DRUG, V11, P1407, DOI 10.1517/13543784.11.10.1407; Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200; Organisciak DT, 2003, INVEST OPHTH VIS SCI, V44, P486, DOI 10.1167/iovs.02-0708; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Rajala RVS, 2002, J BIOL CHEM, V277, P43319, DOI 10.1074/jbc.M206355200; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Rosenbaum DM, 1997, VISION RES, V37, P3445, DOI 10.1016/S0042-6989(96)00328-8; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Sherwin BB, 1999, J PSYCHIATR NEUROSCI, V24, P315; Simoncini T, 2002, STEROIDS, V67, P935, DOI 10.1016/S0039-128X(02)00040-5; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x; STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513; Taguchi H, 1996, INVEST OPHTH VIS SCI, V37, P1444; Toth G, 2002, J NEUROSCI RES, V69, P622, DOI 10.1002/jnr.10358; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Tsai EM, 2001, CANCER RES, V61, P8390; Vaughan DK, 2003, INVEST OPHTH VIS SCI, V44, P848, DOI 10.1167/iovs.02-0709; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wong JK, 2003, J NEUROSCI, V23, P4984; YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012; YU KT, 1985, J BIOL CHEM, V260, P5838	61	139	147	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13086	13094		10.1074/jbc.M313283200	http://dx.doi.org/10.1074/jbc.M313283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711819	hybrid			2022-12-27	WOS:000220334900129
J	Jimenez-Vidal, M; Gasol, E; Zorzano, A; Nunes, V; Palacin, M; Chillaron, J				Jimenez-Vidal, M; Gasol, E; Zorzano, A; Nunes, V; Palacin, M; Chillaron, J			Thiol modification of cysteine 327 in the eighth transmembrane domain of the light subunit xCT of the heteromeric cystine/glutamate antiporter suggests close proximity to the substrate binding site/permeation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; CONSENSUS AMPHIPATHIC REGION; ESCHERICHIA-COLI; EXCHANGE TRANSPORTER; 4-AMINOBUTYRATE TRANSPORTER; FUNCTIONAL-ANALYSIS; MEMBRANE TOPOLOGY; HEAVY-CHAIN; GXXXG MOTIF; HELIX 8	We measured sensitivity to thiol modification of the heteromeric glutamate/cystine transporter 4F2hc-xCT expressed in Xenopus oocytes. p-Chloromercuribenzoate (pCMB) and p-chloromercuribenzenesulfonate (pCMBS) rapidly blocked transport activity. Cys(327), located in the middle of the eighth transmembrane domain of the light subunit (xCT), was found to be the main target of inactivation. Cysteine, an impermeant reducing reagent, reversed pCMB and pCMBS effects only when applied from the extracellular medium. L-Glutamate and L-cystine, but not L-arginine, protected from the inactivation with an IC50 similar to the K-m. Protection was not temperature-dependent, suggesting that it did not depend on large substrate-induced conformational changes. Mutation of Cys(327) to Ala and Ser slightly modified the K-m and a C327L mutant abolished transport function without compromising transporter expression at the plasma membrane. The results indicate that Cys(327) is a functionally important residue accessible to the aqueous extracellular environment and is structurally linked to the permeation pathway and/or the substrate binding site.	Univ Barcelona, Barcelona Sci Pk, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Inst Recerca Oncol, Med & Mol Genet Ctr, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona	Chillaron, J (corresponding author), Univ Barcelona, Barcelona Sci Pk, Josep Samitier 1-5, E-08028 Barcelona, Spain.	chillaro@worldonline.es	Chillaron, Josep/ABF-7663-2021; Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Nunes, Virginia/AAD-1014-2019	Chillaron, Josep/0000-0003-3068-7598; Nunes, Virginia/0000-0002-5747-9310; Palacin, Manuel/0000-0002-8670-293X				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BANNAI S, 1989, J BIOL CHEM, V264, P18480; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Boado RJ, 2003, J NEUROCHEM, V84, P1322, DOI 10.1046/j.1471-4159.2003.01622.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; Dodd JR, 2001, J BIOL CHEM, V276, P46983, DOI 10.1074/jbc.M107137200; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Habermeier A, 2003, J BIOL CHEM, V278, P19492, DOI 10.1074/jbc.M210254200; Hu LA, 1998, J BIOL CHEM, V273, P20162, DOI 10.1074/jbc.273.32.20162; Hu LA, 1998, BIOCHEM J, V336, P69, DOI 10.1042/bj3360069; Hu LYA, 1998, BIOCHEM J, V330, P771; Hu LYA, 1999, BIOCHEM J, V339, P649, DOI 10.1042/0264-6021:3390649; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12160, DOI 10.1021/bi00206a019; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; Mykkanen J, 2000, HUM MOL GENET, V9, P431, DOI 10.1093/hmg/9.3.431; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001	39	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11214	11221		10.1074/jbc.M309866200	http://dx.doi.org/10.1074/jbc.M309866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722095	hybrid, Green Published			2022-12-27	WOS:000220157600047
J	Mukhopadhyay, D; Asari, A; Rugg, MS; Day, AJ; Fulop, C				Mukhopadhyay, D; Asari, A; Rugg, MS; Day, AJ; Fulop, C			Specificity of the tumor necrosis factor-induced protein 6-mediated heavy chain transfer from inter-alpha-trypsin inhibitor to hyaluronan - Implications for the assembly of the cumulus extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; FACTOR-STIMULATED GENE-6; CELL-OOCYTE COMPLEX; HUMAN FOLLICULAR-FLUID; CHROMOSOMAL LOCALIZATION; RHEUMATOID-ARTHRITIS; MAMMALIAN OVARY; CODING SEQUENCE; ACID SYNTHESIS; MOUSE OOCYTES	The formation of the hyaluronan-rich cumulus extracellular matrix is crucial for female fertility and accompanied by a transesterification reaction in which the heavy chains (HCs) of inter-alpha-trypsin inhibitor (IalphaI)-related proteins are covalently transferred to hyaluronan. Tumor necrosis factor-induced protein-6 (TNFIP6) is essential for this transfer reaction. Female mice deficient in TNFIP6 are infertile due to the lack of a correctly formed cumulus matrix. In this report, we characterize the specificity of TNFIP6-mediated HC transfer from IalphaI to hyaluronan. Hyaluronan oligosaccharides with eight or more monosaccharide units are potent acceptors in the HC transfer, with longer oligosaccharides being somewhat more efficient. Epimerization of the N-acetylglucosamine residues to N-acetyl-galactosamines (i.e. in chondroitin) still allows the HC transfer although at a significantly lower efficiency. Sulfation of the N-acetylgalactosamines in dermatan-4-sulfate or chondroitin-6- sulfate prevents the HC transfer. Hyaluronan oligosaccharides disperse cumulus cells from expanding cumulus cell-oocyte complexes with the same size specificity as their HC acceptor specificity. This process is accompanied by the loss of hyaluronan-linked HCs from the cumulus matrix and the appearance of oligosaccharide-linked HCs in the culture medium. Chondroitin interferes with the expansion of cumulus cell-oocyte complexes only when added with exogenous TNFIP6 before endogenous hyaluronan synthesis starts, supporting that chondroitin is a weaker HC acceptor than hyaluronan. Our data indicate that TNFIP6-mediated HC transfer to hyaluronan is a prerequisite for the correct cumulus matrix assembly and hyaluronan oligosaccharides and chondroitin interfere with this assembly by capturing the HCs of the IalphaI-related proteins.	Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan	Cleveland Clinic Foundation; University of Oxford; Seikagaku Corporation	Fulop, C (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	fulop@bme.ri.ccf.org	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134				BEDFORD JM, 1993, J EXP ZOOL, V265, P321, DOI 10.1002/jez.1402650314; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Camaioni A, 1996, ARCH BIOCHEM BIOPHYS, V325, P190, DOI 10.1006/abbi.1996.0024; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DEFELICI M, 1982, GAMETE RES, V6, P107, DOI 10.1002/mrd.1120060203; DEKEL N, 1978, ENDOCRINOLOGY, V102, P1797, DOI 10.1210/endo-102-6-1797; DOWNS SM, 1989, BIOL REPROD, V41, P371, DOI 10.1095/biolreprod41.2.371; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; EPPIG JJ, 1981, BIOL REPROD, V25, P191, DOI 10.1095/biolreprod25.1.191; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Hess KA, 1999, BIOL REPROD, V61, P436, DOI 10.1095/biolreprod61.2.436; HUANG L, 1993, J BIOL CHEM, V268, P26725; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; Kida D, 1999, J RHEUMATOL, V26, P1230; Lam X, 2000, BIOL REPROD, V62, P579, DOI 10.1095/biolreprod62.3.579; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; POWERS RW, 1995, AM J PHYSIOL-ENDOC M, V269, pE290, DOI 10.1152/ajpendo.1995.269.2.E290; Protin U, 1999, J IMMUNOL, V163, P4917; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; Salustri A, 1999, HUM REPROD UPDATE, V5, P293, DOI 10.1093/humupd/5.4.293; Salustri A, 2000, SERONO SYMP, P67; SALUSTRI A, 1993, OVARY, P209; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; UNDERHILL CB, 1979, J CELL BIOL, V82, P475, DOI 10.1083/jcb.82.2.475; UNDERHILL CB, 1985, J BIOL CHEM, V260, P8128; VANDERHYDEN BC, 1989, BIOL REPROD, V40, P720, DOI 10.1095/biolreprod40.4.720; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	50	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11119	11128		10.1074/jbc.M313471200	http://dx.doi.org/10.1074/jbc.M313471200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707130	hybrid			2022-12-27	WOS:000220157600036
J	Sugimoto, Y; Nakato, T; Kita, A; Takahashi, Y; Hatae, N; Tabata, H; Tanaka, S; Ichikawa, A				Sugimoto, Y; Nakato, T; Kita, A; Takahashi, Y; Hatae, N; Tabata, H; Tanaka, S; Ichikawa, A			A cluster of aromatic amino acids in the i2 loop plays a key role for G(s) coupling in prostaglandin EP2 and EP3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING PROPERTIES; G-BETA-GAMMA; CARBOXYLIC-ACID; ARGININE RESIDUE; 2 ISOFORMS; FUNCTIONAL INTERACTION; MOLECULAR-MECHANISMS; DOMAINS DETERMINE; TERMINAL DOMAINS; G-PROTEINS	To assess the structural requirements for G(s) coupling by prostaglandin E receptors (EPs), the G(s)-coupled EP2 and G(i)-coupled EP3beta receptors were used to generate hybrid receptors. Interchanging of the whole i2 loop and its N-terminal half (i2N) had no effect on the binding of both receptors expressed in HEK293 cells. Agonist-induced cAMP formation was observed in wild type EP2 but not in the i2 loop- or i2N-substituted EP2. Wild type EP3beta left cAMP levels unaffected, whereas i2 loop- and i2N-substituted EP3 gained agonist-induced adenylyl cyclase stimulation. In EP2, the ability to stimulate cAMP formation was lost by mutation of Tyr(143) into Ala but retained by mutations into Phe, Trp, and Leu. Consistent with this observation, substitution of the equivalent His(140) enabled EP3beta to stimulate cAMP formation with the rank order of Phe > Tyr > Trp > Leu. The point mutation of His140 into Phe was effective in another EP3 variant in which its C-terminal tail is different or lacking. Simultaneous mutation of the adjacent Trp(141) to Ala but not at the following Tyr(142) weakened the acquired ability to stimulate cAMP levels in the EP3 mutant. Mutation of EP2 at adjacent Phe(144) to Ala but not at Tyr(145) reduced the efficiency of agonist-induced cAMP formation. In Chinese hamster ovary cells stably expressing G(s)-acquired EP3 mutant, an agonist-dependent cAMP formation was observed, and pertussis toxin markedly augmented cAMP formation. These results suggest that a cluster of hydrophobic aromatic amino acids in the i2 loop plays a key role for G(s) coupling.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Ichikawa, A (corresponding author), Mukogawa Womens Univ, Sch Pharmaceut Sci, 11-68 Kyuban Chou, Nishinomiya, Hyogo 6638179, Japan.	aichikaw@mwu.mukogawa-u.ac.jp	Tanaka, Satoshi/H-6800-2019; Sugimoto, Yukihiko/AAV-6470-2021; TANAKA, Satoshi/B-1624-2011	Tanaka, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; TANAKA, Satoshi/0000-0002-3468-7694				ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Chang CS, 1997, PROSTAGLANDINS, V54, P437, DOI 10.1016/S0090-6980(97)00064-6; Chang CS, 1997, BIOCHEM J, V322, P597, DOI 10.1042/bj3220597; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; Hatae N, 2002, BIOCHEM BIOPH RES CO, V290, P162, DOI 10.1006/bbrc.2001.6169; Hizaki H, 1997, FEBS LETT, V414, P323, DOI 10.1016/S0014-5793(97)01020-X; Ichikawa A, 1997, ADV EXP MED BIOL, V433, P239; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; MILLIGAN G, 1994, METHOD ENZYMOL, V237, P268; MORO O, 1993, J BIOL CHEM, V268, P22273; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Negishi M, 1996, FEBS LETT, V386, P165, DOI 10.1016/0014-5793(96)00354-7; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P379, DOI 10.1016/0929-7855(95)00024-K; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NEGISHI M, 1995, BIOCHEM BIOPH RES CO, V212, P279, DOI 10.1006/bbrc.1995.1967; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Satoh S, 1999, BIOCHEM BIOPH RES CO, V255, P164, DOI 10.1006/bbrc.1998.0161; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	39	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11016	11026		10.1074/jbc.M307404200	http://dx.doi.org/10.1074/jbc.M307404200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699136	hybrid			2022-12-27	WOS:000220157600024
J	Baba, SW; Belogrudov, GI; Lee, JC; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF				Baba, SW; Belogrudov, GI; Lee, JC; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF			Yeast Coq5 C-methyltransferase is required for stability of other polypeptides involved in coenzyme Q biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; GENE ENCODES; PROTEIN; STEPS; IDENTIFICATION; MITOCHONDRIA; MEMBRANE; STRAINS; DISEASE	Coenzyme Q (Q) functions in the electron transport chain of both prokaryotes and eukaryotes. The biosynthesis of Q requires a number of steps involving at least eight Coq polypeptides. Coq5p is required for the C-methyltransferase step in Q biosynthesis. In this study we demonstrate that Coq5p is peripherally associated with the inner mitochondrial membrane on the matrix side. Phenotypic characterization of a collection of coq5 mutant yeast strains indicates that while each of the coq5 mutant strains are rescued by the Saccharomyces cerevisiae COQ5 gene, only the coq5-2 and coq5-5 mutants are rescued by expression of Escherichia coli ubiE, a homolog of COQ5. The coq5-2 and coq5-5 mutants contain mutations within or adjacent to conserved methyltransferase motifs that would be expected to disrupt the catalysis of C-methylation. The steady state levels of the Coq5-2 and Coq5-5 mutant polypeptides are not decreased relative to wild type Coq5p. Two other polypeptides required for Q biosynthesis, Coq3p and Coq4p, are detected in the wild type parent and in the coq5-2 and coq5-5 mutants, but are not detected in the coq5-null mutant, or in the coq5-4 or coq5-3 mutants. The effect of the coq5-4 mutation is similar to a null, since it results in a stop codon at position 93. However, the coq5-3 mutation (G304D) is located just four amino acids away from the C terminus. While C-methyltransferase activity is detectable in mitochondria isolated from this mutant, the steady state level of Coq5p is dramatically decreased. These studies show that at least two functions can be attributed to Coq5p; first, it is required to catalyze the C-methyltransferase step in Q biosynthesis and second, it is involved in stabilizing the Coq3 and Coq4 polypeptides required for Q biosynthesis.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Gonzaga Univ, Dept Chem, Spokane, WA 99258 USA	University of California System; University of California Los Angeles; Gonzaga University	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@mbi.ucla.edu		Lee, Justine C./0000-0002-8943-0837	NIGMS NIH HHS [GM45952] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Burke D., 2000, METHODS YEAST GENETI, P171; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063; Culbertson MR, 2003, CURR OPIN GENET DEV, V13, P207, DOI 10.1016/S0959-437X(03)00014-5; Dibrov E, 1997, J BIOL CHEM, V272, P9175; Dutton P.L., 2001, COENZYME Q OXIDATION, P65; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hagerman RA, 2002, BBA-GENE STRUCT EXPR, V1578, P51, DOI 10.1016/S0167-4781(02)00496-7; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; JONASSEN T, 2001, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Katz JE, 2003, MOL CELL PROTEOMICS, V2, P525, DOI 10.1074/mcp.M300037-MCP200; Koch M, 2003, EUR J BIOCHEM, V270, P84, DOI 10.1046/j.1432-1033.2003.03364.x; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; PAYNE GS, 1987, MOL CELL BIOL, V7, P3888, DOI 10.1128/MCB.7.11.3888; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YOUNG IG, 1971, J BACTERIOL, V105, P769, DOI 10.1128/JB.105.3.769-778.1971	37	51	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10052	10059		10.1074/jbc.M313712200	http://dx.doi.org/10.1074/jbc.M313712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701817	hybrid			2022-12-27	WOS:000220050400049
J	Chen, CH; Paing, MM; Trejo, J				Chen, CH; Paing, MM; Trejo, J			Termination of protease-activated receptor-1 signaling by beta-arrestins is independent of receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; THROMBIN-RECEPTOR; COUPLED RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; PLATELET ACTIVATION; INTERNALIZATION; TRAFFICKING; DESENSITIZATION; ENDOCYTOSIS	Protease-activated receptor 1 (PAR1), a G protein-coupled receptor (GPCR) for thrombin, is the prototypic member of a family of protease-activated receptors. PAR1 is irreversibly proteolytically activated; thus, the magnitude and duration of thrombin cellular responses are determined primarily by mechanisms responsible for termination of receptor signaling. Both phosphorylation and beta-arrestins contribute to rapid desensitization of PAR1 signaling. However, the relative contribution of each of these pathways to the termination of PAR1 signaling is not known. Co-expression of PAR1 with beta-arrestin 1 (betaarr1) in COS-7 cells resulted in a marked inhibition of PAR1 signaling, whereas beta-arrestin 2 (betaarr2) was essentially inactive. Strikingly, signaling by a PAR1 cytoplasmic tail mutant defective in agonist-induced phosphorylation was also attenuated more effectively by betaarr1 compared with betaarr2. In contrast, both beta-arrestin isoforms were equally effective at desensitizing the substance P receptor, a classic reversibly activated GPCR. PAR1 coimmunoprecipitated betaarr1 in an agonist-dependent manner, whereas betaarr2 association was virtually undetectable. Remarkably, betaarr1 also interacted with phosphorylation defective PAR1 mutant, whereas betaarr2 did not. Moreover, constitutively active beta-arrestin mutants, betaarr1 R169E and betaarr2 R170E, that bind to activated receptor independent of phosphorylation failed to enhance either wild type or mutant PAR1 desensitization compared with normal versions of these proteins. In contrast, beta-arrestin mutants displayed enhanced activity at desensitizing the serotonin 5-hydroxytryptamine(2A) receptor. Taken together, these results suggest that, in addition to PAR1 cytoplasmic tail phosphorylation itself, beta-arrestin binding independent of phosphorylation promotes desensitization of PAR1 signaling. These findings reveal a new level of complexity in the regulation of protease-activated GPCR signaling.	Univ N Carolina, Sch Med, Dept Pharmacol, Cardiovasc Biol Ctr,Lineberger Comprehens Canc Ct, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Trejo, J (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Cardiovasc Biol Ctr,Lineberger Comprehens Canc Ct, 1106 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	joann_trejo@med.unc.edu		TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073328, K01HL067697] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67697, HL073328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; CHEN J, 1994, J BIOL CHEM, V269, P16041; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gray JA, 2003, MOL PHARMACOL, V63, P961, DOI 10.1124/mol.63.5.961; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	34	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10020	10031		10.1074/jbc.M310590200	http://dx.doi.org/10.1074/jbc.M310590200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699102	Green Published, hybrid			2022-12-27	WOS:000220050400046
J	Goldman, EH; Chen, L; Fu, H				Goldman, EH; Chen, L; Fu, H			Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; PROTEIN-KINASE; MOLECULAR-CLONING; OXIDATIVE STRESS; ASK1; PHOSPHORYLATION; SURVIVAL; BAD; PHOSPHATASE; THIOREDOXIN	Oxidative stress has been indicated in a variety of pathological processes such as atherosclerosis, diabetes, and neurodegenerative diseases. Understanding how intracellular signaling pathways respond to oxidative insults such as hydrogen peroxide (H2O2) would have significant therapeutic implications. Recent genetic studies have placed apoptosis signal-regulating kinase 1 (ASK1) in a pivotal position in transmitting H2O2-initiated signals. How ASK1 is activated by H2O2, though, remains a subject of intense investigation. Here we report a mechanism by which H2O2 induces ASK1 activation through dynamic control of its phosphorylation at serine 967. We found that treatment of COS7 cells with H2O2 triggers dephosphorylation of Ser-967 through an okadaic acid-sensitive phosphatase, resulting in dissociation of the ASK1.14-3-3 complex with concomitant increase of ASK1 catalytic activity and ASK1-mediated activation of JNK and p38 pathways.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; Cell Signaling Technol, Beverly, MA 01915 USA	Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165, R01GM060033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53165, GM60033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	41	173	188	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10442	10449		10.1074/jbc.M311129200	http://dx.doi.org/10.1074/jbc.M311129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688258	hybrid			2022-12-27	WOS:000220050400095
J	Testa, A; Lotti, F; Cairns, L; Grande, A; Ottolenghi, S; Ferrari, G; Ronchi, A				Testa, A; Lotti, F; Cairns, L; Grande, A; Ottolenghi, S; Ferrari, G; Ronchi, A			Deletion of a negatively acting sequence in a chimeric GATA-1 enhancer-long terminal repeat greatly increases retrovirally mediated erythroid expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; HEMATOPOIETIC STEM-CELLS; GLOBIN MESSENGER-RNA; GENE-TRANSFER; VECTORS; PROMOTER; UPSTREAM; METHYLATION; ELEMENT; MICE	The locus control region of the beta-globin gene cluster has been used previously to direct erythroid expression of globin genes from retroviral vectors for the purpose of gene therapy. Short erythroid regulatory elements represent a potentially valuable alternative to the locus control region. Among them, the GATA-1 enhancer HS2 was used to replace the retroviral enhancer within the 3'-long terminal repeat (LTR) of the retroviral vector SFCM, converting it into an erythroid-specific regulatory element. In this work, we have functionally studied an additional GATA-1 enhancer, HS1. HS1 participates in the transcriptional autoregulation of GATA-1 through an essential GATA-binding site that is footprinted in vivo. In this work we identified within HS1 a new in vivo footprinted region, and we showed that this sequence indeed binds a nuclear protein in vitro. Addition of HS1 to HS2 within the LTR of SFCM significantly improves the expression of a reporter gene. The deletion of the newly identified footprinted sequence in the retroviral construct further increases expression up to a level almost equal to that of the wild type retroviral LTR, without loss of erythroid specificity, suggesting that this sequence may act as a negative regulatory element. An improved vector backbone, MDeltaN, allows even better expression from the new GATA cassette. These results suggest that substantial improvement of overall expression can be achieved by the combination of multiple changes in both regulatory elements and vectors.	Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, I-41100 Modena, Italy; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy	University of Milano-Bicocca; Universita di Modena e Reggio Emilia; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ronchi, A (corresponding author), Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	antonella.ronchi@unimib.it	Grande, Alexis/D-5816-2015; Ferrari, Giuliana/AAB-5546-2019; Lotti, Francesco/AAC-3186-2019	Grande, Alexis/0000-0003-3319-1707; Ferrari, Giuliana/0000-0003-0790-3133; RONCHI, ANTONELLA ELLENA/0000-0002-3905-1038	Telethon [TGT06S01, TGT03E01] Funding Source: Medline	Telethon(Fondazione Telethon)		BECKER PB, 1993, METHOD ENZYMOL, V218, P568; Cairns L, 2003, J CELL PHYSIOL, V195, P38, DOI 10.1002/jcp.10241; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Grande A, 1999, BLOOD, V93, P3276, DOI 10.1182/blood.V93.10.3276.410k08_3276_3285; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Krall WJ, 1996, GENE THER, V3, P37; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Lotti F, 2002, J VIROL, V76, P3996, DOI 10.1128/JVI.76.8.3996-4007.2002; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Moreau-Gaudry F, 2001, BLOOD, V98, P2664, DOI 10.1182/blood.V98.9.2664; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; PEVNY L, 1995, DEVELOPMENT, V121, P163; Phillips K, 1996, NAT MED, V2, P1154, DOI 10.1038/nm1096-1154; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; Ronchi Antonella, 1997, Genes and Function, V1, P245; Russell D, 2001, BLOOD, V98, P2595, DOI 10.1182/blood.V98.9.2595a; Sabatino DE, 2000, P NATL ACAD SCI USA, V97, P13294, DOI 10.1073/pnas.230453097; Sanyal A, 1999, HUM GENE THER, V10, P2859, DOI 10.1089/10430349950016582; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Verzeletti S, 1998, HUM GENE THER, V9, P2243, DOI 10.1089/hum.1998.9.15-2243; Vyas P, 1999, DEVELOPMENT, V126, P2799; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Yamamoto M, 1997, GENES CELLS, V2, P107, DOI 10.1046/j.1365-2443.1997.1080305.x	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10523	10531		10.1074/jbc.M313638200	http://dx.doi.org/10.1074/jbc.M313638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701820	hybrid			2022-12-27	WOS:000220050400105
J	Liu, WL; Tang, L; Zhang, G; Wei, HD; Cui, YF; Guo, LH; Gou, ZK; Chen, XX; Jiang, DF; Zhu, YP; Kang, GF; He, FC				Liu, WL; Tang, L; Zhang, G; Wei, HD; Cui, YF; Guo, LH; Gou, ZK; Chen, XX; Jiang, DF; Zhu, YP; Kang, GF; He, FC			Characterization of a novel C-type lectin-like gene, LSECtin - Demonstration of carbohydrate node	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; DC-SIGN; DENDRITIC CELL; MANNOSE RECEPTOR; ENDOTHELIAL-CELLS; TISSUE EXPRESSION; RAT-LIVER; BINDING; CD23; RECOGNITION	A new C-type lectin-like gene encodes 293 amino acids and maps to chromosome 19p13.3 adjacent to the previously described C-type lectin genes, CD23, dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), and DC-SIGN-related protein (DC-SIGNR). The four genes form a tight cluster in an insert size of 105 kb and have analogous genomic structures. The new C-type lectin-like molecule, designated liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin), is a type II integral membrane protein of similar to 40 kDa in size with a single C-type lectin-like domain at the COOH terminus, closest in homology to DC-SIGNR, DC-SIGN, and CD23. LSECtin mRNA was only expressed in liver and lymph node among 15 human tissues tested, intriguingly neither expressed on hematopoietic cell lines nor on monocyte-derived dendritic cells (DCs). Moreover, LSECtin is expressed predominantly by sinusoidal endothelial cells of human liver and lymph node and co-expressed with DC-SIGNR. LSECtin binds to mannose, GlcNAc, and fucose in a Ca2+-dependent manner but not to galactose. Our results indicate that LSECtin is a novel member of a family of proteins comprising CD23, DC-SIGN, and DC-SIGNR and might function in vivo as a lectin receptor.	Beijing Inst Radiat Med, Chinese Human Genome Ctr Beijing, Dept Gen & Prote, Beijing 100850, Peoples R China; Chongqing Univ Med Sci, Fac Med Lab Sci, Chongqing, Peoples R China; Sun Yat Sen Univ, Mol Med Lab, Guangzhou, Peoples R China; Tsinghua Univ, Sch Life Sci & Technol, Beijing 100084, Peoples R China	Academy of Military Medical Sciences - China; Chongqing Medical University; Sun Yat Sen University; Tsinghua University	He, FC (corresponding author), Beijing Inst Radiat Med, Chinese Human Genome Ctr Beijing, Dept Gen & Prote, 27 Taiping Rd, Beijing 100850, Peoples R China.	hefc@nic.bmi.ac.cn		Liu, Wanli/0000-0003-0395-2800				Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; AUBRY JP, 1994, J IMMUNOL, V152, P5806; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Bonnefoy J Y, 1997, Int Rev Immunol, V16, P113, DOI 10.3109/08830189709045705; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; East L, 2002, J BIOL CHEM, V277, P50469, DOI 10.1074/jbc.M208985200; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; FARR AG, 1980, AM J ANAT, V157, P265, DOI 10.1002/aja.1001570304; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Fernandes MJ, 1999, CANCER RES, V59, P2709; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; GOERDT S, 1992, CLIN INVESTIGATOR, V70, P89; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; HARLOW E, 1998, ANTIBODIES LAB MANUA, P72; Irjala H, 2001, J EXP MED, V194, P1033, DOI 10.1084/jem.194.8.1033; Kawai Y, 1998, CELL TISSUE RES, V292, P395, DOI 10.1007/s004410051069; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Kijimoto-Ochiai S, 2002, CELL MOL LIFE SCI, V59, P648, DOI 10.1007/s00018-002-8455-1; Knolle PA, 2000, IMMUNOL REV, V174, P21, DOI 10.1034/j.1600-0528.2002.017408.x; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Qu XH, 2002, J BIOL CHEM, V277, P35574, DOI 10.1074/jbc.M206451200; Qu XH, 2001, GENE, V264, P37, DOI 10.1016/S0378-1119(01)00324-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SAMBROOK J, 1989, MOL CLONING LAB MANU, P852; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Soilleux EJ, 2003, CLIN SCI, V104, P437, DOI 10.1042/CS20020092; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; van Kooyk Y, 2002, IMMUNOL REV, V186, P47, DOI 10.1034/j.1600-065X.2002.18605.x; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Yu YT, 2001, GENOME RES, V11, P1392, DOI 10.1101/gr.175501; YUKAWA K, 1987, J IMMUNOL, V138, P2576; Zhang CG, 2000, GENOMICS, V63, P400, DOI 10.1006/geno.1999.6095	59	116	130	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18748	18758		10.1074/jbc.M311227200	http://dx.doi.org/10.1074/jbc.M311227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14711836	hybrid			2022-12-27	WOS:000221041500082
J	Tashima, Y; Oe, R; Lee, S; Sugihara, G; Chambers, EJ; Takahashi, M; Yamada, T				Tashima, Y; Oe, R; Lee, S; Sugihara, G; Chambers, EJ; Takahashi, M; Yamada, T			The effect of cholesterol and monosialoganglioside (GM1) on the release and aggregation of amyloid beta-peptide from liposomes prepared from brain membrane-like lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; ULTRASTRUCTURAL EVIDENCE; PLASMALOGEN DEFICIENCY; PROTEIN; FIBRILLOGENESIS; GANGLIOSIDE; ASSOCIATION; DOMAIN	In order to investigate the influence of cholesterol (Ch) and monosialoganglioside (GM1) on the release and subsequent deposition/aggregation of amyloid beta peptide (Abeta)-(1-40) and Abeta-(1-42), we have examined Abeta peptide model membrane interactions by circular dichroism, turbidity measurements, and transmission electron microscopy (TEM). Model liposomes containing Abeta peptide and a lipid mixture composition similar to that found in the cerebral cortex membranes (CCM-lipid) have been prepared. In all, four Abeta-containing liposomes were investigated: CCM-lipid; liposomes with no GM1 (GM1-free lipid); those with no cholesterol (Ch-free lipid); liposomes with neither cholesterol nor GM1 (Ch-GM1-free lipid). In CCM liposomes, Abeta was rapidly released from membranes to form a well defined fibril structure. However, for the GM1-free lipid, Abeta was first released to yield a fibril structure about the membrane surface, then the membrane became disrupted resulting in the formation of small vesicles. In Ch-free lipid, a fibril structure with a phospholipid membrane-like shadow formed, but this differed from the well defined fibril structure seen for CCM-lipid. In Ch-GM1-free lipid, no fibril structure formed, possibly because of membrane solubilization by Abeta. The absence of fibril structure was noted at physiological extracellular pH (7.4) and also at liposomal/endosomal pH (5.5). Our results suggest a possible role for both Ch and GM1 in the membrane release of Abeta from brain lipid bilayers.	Fukuoka Univ, Fac Sci, Dept Chem, Fukuoka 8140180, Japan; Fukuoka Univ, Fac Pharmaceut Sci, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Fukuoka 8140180, Japan; Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA	Fukuoka University; Fukuoka University; Fukuoka University; University of Southern California	Lee, S (corresponding author), Fukuoka Univ, Fac Sci, Dept Chem, Fukuoka 8140180, Japan.	leesan@cis.fukuoka-u.ac.jp	Chambers, Eric J/B-7537-2012; Taylor, Graham/A-4027-2012					BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; De Strooper B, 2000, J CELL SCI, V113, P1857; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Ferraretto A, 1997, BIOCHEMISTRY-US, V36, P9232, DOI 10.1021/bi970428j; Furuya T, 2003, BIOPHYS J, V84, P1950, DOI 10.1016/S0006-3495(03)75003-6; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Han XL, 2001, J NEUROCHEM, V77, P1168, DOI 10.1046/j.1471-4159.2001.00332.x; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; Kitamura A, 1999, BIOPHYS J, V76, P1457, DOI 10.1016/S0006-3495(99)77306-6; Lee S, 2001, J BIOL CHEM, V276, P41224, DOI 10.1074/jbc.M104705200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Li YH, 1999, J NEUROCHEM, V73, P1477; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; MORIYAMA Y, 1992, FEBS LETT, V302, P18, DOI 10.1016/0014-5793(92)80274-K; Natte R, 1999, ACTA NEUROPATHOL, V98, P577, DOI 10.1007/s004010051121; ROSSITER RJ, 1962, NEUROCHEMISTRY; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; Shigematsu D, 2002, BBA-BIOMEMBRANES, V1564, P271, DOI 10.1016/S0005-2736(02)00462-5; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Torp R, 2000, NEUROSCIENCE, V96, P495, DOI 10.1016/S0306-4522(99)00568-0; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Waschuk SA, 2001, J BIOL CHEM, V276, P33561, DOI 10.1074/jbc.M103598200; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7	43	46	48	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17587	17595		10.1074/jbc.M308622200	http://dx.doi.org/10.1074/jbc.M308622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14709559	hybrid			2022-12-27	WOS:000220870400087
J	Plakoutsi, G; Taddei, N; Stefani, M; Chiti, F				Plakoutsi, G; Taddei, N; Stefani, M; Chiti, F			Aggregation of the acylphosphatase from Sulfolobus solfataricus - The folded and partially unfolded states can both be precursors for amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; 3-DIMENSIONAL STRUCTURE; PROTEIN AGGREGATION; CRYSTAL-STRUCTURE; ALPHA-SYNUCLEIN; BETA-PEPTIDE; TRANSTHYRETIN; INTERMEDIATE; STABILITY; TOXICITY	Protein aggregation is associated with a number of human pathologies including Alzheimer's and Creutzfeldt-Jakob diseases and the systemic amyloidoses. In this study, we used the acylphosphatase from the hyperthermophilic Archaea Sulfolobus solfataricus (Sso AcP) to investigate the mechanism of aggregation under conditions in which the protein maintains a folded structure. In the presence of 15 - 25% (v/v) trifluoroethanol, Sso AcP was found to form aggregates able to bind specific dyes such as thioflavine T, Congo red, and 1-anilino-8-naphthalenesulfonic acid. The presence of aggregates was confirmed by circular dichroism and dynamic light scattering. Electron microscopy revealed the presence of small aggregates generally referred to as amyloid protofibrils. The monomeric form adopted by Sso AcP prior to aggregation under these conditions retained enzymatic activity; in addition, folding was remarkably faster than unfolding. These observations indicate that Sso AcP adopts a folded, although possibly distorted, conformation prior to aggregation. Most important, aggregation appeared to be 100-fold faster than unfolding under these conditions. Although aggregation of Sso AcP was faster at higher trifluoroethanol concentrations, in which the protein adopted a partially unfolded conformation, these findings suggest that the early events of amyloid fibril formation may involve an aggregation process consisting of the assembly of protein molecules in their folded state. This conclusion has a biological relevance as globular proteins normally spend most of their lifetime in folded structures.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Chiti, F (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	fchiti@scibio.unifi.it		STEFANI, MASSIMO/0000-0002-4490-1922; Taddei, Niccolo/0000-0003-2513-1018				BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAMICI G, 1976, EXPERIENTIA, V32, P535, DOI 10.1007/BF01920843; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, NAT STRUCT BIOL, V6, P380; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Fernandez A, 2003, P NATL ACAD SCI USA, V100, P6446, DOI 10.1073/pnas.0731893100; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Funahashi J, 1996, J BIOCHEM, V120, P1216; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hamada D, 2000, NAT STRUCT BIOL, V7, P58; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kremer JJ, 2000, BIOCHEMISTRY-US, V39, P10309, DOI 10.1021/bi0001980; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Laurine E, 2003, J BIOL CHEM, V278, P51770, DOI 10.1074/jbc.M306767200; LeVine H, 1999, METHOD ENZYMOL, V309, P274; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Quintas A, 2001, J BIOL CHEM, V276, P27207, DOI 10.1074/jbc.M101024200; Raffen R, 1999, PROTEIN SCI, V8, P509; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Rosano C, 2002, J MOL BIOL, V321, P785, DOI 10.1016/S0022-2836(02)00713-1; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Sousa MM, 2001, AM J PATHOL, V159, P1993; Srisailam S, 2003, J BIOL CHEM, V278, P17701, DOI 10.1074/jbc.M300336200; Staniforth RA, 2001, EMBO J, V20, P4774, DOI 10.1093/emboj/20.17.4774; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stefani M, 1997, CELL MOL LIFE SCI, V53, P141, DOI 10.1007/PL00000585; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 1996, BIOCHEMISTRY-US, V35, P7077, DOI 10.1021/bi952900b; Taddei N, 1996, FEBS LETT, V384, P172, DOI 10.1016/0014-5793(96)00292-X; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Thunnissen MMGM, 1997, STRUCTURE, V5, P69, DOI 10.1016/S0969-2126(97)00167-6; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; VANDEHULST HC, 1957, LIGHT SCATTERING SMA, P1; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	56	91	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14111	14119		10.1074/jbc.M312961200	http://dx.doi.org/10.1074/jbc.M312961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724277	hybrid			2022-12-27	WOS:000220478500101
J	Belli, G; Molina, MM; Garcia-Martinez, J; Perez-Ortin, JE; Herrero, E				Belli, G; Molina, MM; Garcia-Martinez, J; Perez-Ortin, JE; Herrero, E			Saccharomyces cerevisiae glutaredoxin 5-deficient cells subjected to continuous oxidizing conditions are affected in the expression of specific sets of genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; YEAST FRATAXIN; IRON; PROTEIN; CLUSTER; IDENTIFICATION; MITOCHONDRIA; FAMILIES	The Saccharomyces cerevisiae GRX5 gene codes for a mitochondrial glutaredoxin involved in the synthesis of iron/sulfur clusters. Its absence prevents respiratory growth and causes the accumulation of iron inside cells and constitutive oxidation of proteins. Null Deltagrx5 mutants were used as an example of continuously oxidized cells, as opposed to situations in which oxidative stress is instantaneously caused by addition of external oxidants. Whole transcriptome analysis was carried out in the mutant cells. The set of genes whose expression was affected by the absence of Grx5 does not significantly overlap with the set of genes affected in respiratory petite mutants. Many Aft1-dependent genes involved in iron utilization that are up-regulated in a frataxin mutant were also up-regulated in the absence of Grx5. BIO5 is another Aft1-dependent gene induced both upon iron deprivation and in Deltagrx5 cells; this links iron and biotin metabolism. Other genes are specifically affected under the oxidative conditions generated by the grx5 mutation. One of these is MLP1, which codes for a homologue of the Slt2 kinase. Cells lacking MLP1 and GRX5 are hypersensitive to oxidative stress caused by external agents and exhibit increased protein oxidation in relation to single mutants. This in turn points to a role for Mlp1 in protection against oxidative stress. The genes of the Hap4 regulon, which are involved in respiratory metabolism, are down-regulated in Deltagrx5 cells. This effect is suppressed by HAP4 overexpression. Inhibition of respiratory metabolism during continuous moderately oxidative conditions could be a protective response by the cell.	Univ Lleida, Fac Med, Dept Ciencias Med Basiques, Lleida 25198, Spain; Univ Valencia, Fac Ciencias Biol, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Univ Valencia, DNA SCSIE, Serv Chips, E-46100 Valencia, Spain	Universitat de Lleida; University of Valencia; University of Valencia	Herrero, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencias Med Basiques, Rovira Roure 44, Lleida 25198, Spain.	enric.herrero@cmb.udl.es	Garcia-Martinez, Jose/F-6790-2016; belli, gemma/A-7424-2011; Herrero, Enrique/B-5592-2009; Bellí, Gemma/AAD-5325-2019; Garcia-Martinez, Jose/X-4995-2019; Pérez-Ortín, José E./K-8582-2014	Garcia-Martinez, Jose/0000-0001-5866-5994; belli, gemma/0000-0002-4161-3204; Herrero, Enrique/0000-0002-6763-111X; Bellí, Gemma/0000-0002-4161-3204; Garcia-Martinez, Jose/0000-0001-5866-5994; Pérez-Ortín, José E./0000-0002-1992-513X; , Micaela/0000-0002-2103-0351				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Charizanis C, 1999, MOL GEN GENET, V261, P740, DOI 10.1007/s004380050017; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Hasan R, 2002, MOL MICROBIOL, V45, P233, DOI 10.1046/j.1365-2958.2002.03011.x; Joseph-Horne T, 2001, BBA-BIOENERGETICS, V1504, P179, DOI 10.1016/S0005-2728(00)00251-6; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lascaris R, 2003, GENOME BIOL, V4; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Phalip V, 1999, GENE, V232, P43, DOI 10.1016/S0378-1119(99)00117-1; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Toledano MB, 2003, TOP CURR GENET, V1, P241; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200	61	53	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12386	12395		10.1074/jbc.M311879200	http://dx.doi.org/10.1074/jbc.M311879200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722110	hybrid, Green Published			2022-12-27	WOS:000220334900047
J	Guo, Q; Detweiler, CD; Mason, RP				Guo, Q; Detweiler, CD; Mason, RP			Protein radical formation during lactoperoxidase-mediated oxidation of the suicide substrate glutathione - Immunochemical detection of a lactoperoxidase radical-derived 5,5-dimethyl-1-pyrroline N-oxide nitrone adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; IRREVERSIBLE ENZYME INACTIVATION; RHO-SIGMA CORRELATION; CYTOCHROME-C-OXIDASE; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; THYROID PEROXIDASE; THIYL RADICALS; COMPOUND-II; ONE-ELECTRON	A novel anti-5,5-dimethyl-1-pyrroline N-oxide ( DMPO) polyclonal antiserum that specifically recognizes protein radical-derived DMPO nitrone adducts has been developed. In this study, we employed this new approach, which combines the specificity of spin trapping and the sensitivity of antigen-antibody interactions, to investigate protein radical formation from lactoperoxidase (LPO). When LPO reacted with GSH in the presence of DMPO, we detected an LPO radical-derived DMPO nitrone adduct using enzyme-linked immunosorbent assay and Western blotting. The formation of this nitrone adduct depended on the concentrations of GSH, LPO, and DMPO as well as pH values, and GSH could not be replaced by H2O2. The level of this nitrone adduct was decreased significantly by azide, catalase, ascorbate, iodide, thiocyanate, phenol, or nitrite. However, its formation was unaffected by chemical modification of free cysteine, tyrosine, and tryptophan residues on LPO. ESR spectra showed that a glutathiyl radical was formed from the LPO/GSH/DMPO system, but no protein radical adduct could be detected by ESR. Its formation was decreased by azide, catalase, ascorbate, iodide, or thiocyanate, whereas phenol or nitrite increased it. GSH caused marked changes in the spectrum of compound II of LPO, indicating that GSH binds to the heme of compound II, whereas phenol or nitrite prevented these changes and reduced compound II back to the native enzyme. GSH also dose-dependently inhibited the peroxidase activity of LPO as determined by measuring 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) oxidation. Taken together, these results demonstrate that the GSH-dependent LPO radical formation is mediated by the glutathiyl radical, possibly via the reaction of the glutathiyl radical with the heme of compound II to form a heme-centered radical trapped by DMPO.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Guo, Q (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	guo1@niehs.nih.gov	Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050139, Z01ES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BANDYOPADHYAY U, 1995, BIOCHEM J, V306, P751, DOI 10.1042/bj3060751; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; Bruck TB, 2001, EUR J BIOCHEM, V268, P3214, DOI 10.1046/j.1432-1327.2001.02213.x; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burner U, 1997, FEBS LETT, V411, P269, DOI 10.1016/S0014-5793(97)00713-8; Burner U, 1999, FEBS LETT, V443, P290, DOI 10.1016/S0014-5793(98)01727-X; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2000, BIOCHEMISTRY-US, V39, P4415, DOI 10.1021/bi992652+; CLARKE AJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P424, DOI 10.1016/0167-4838(87)90048-3; DAS D, 1995, BIOCHEM J, V305, P59, DOI 10.1042/bj3050059; DAVIDSON B, 1978, BIOCHIM BIOPHYS ACTA, V522, P318, DOI 10.1016/0005-2744(78)90066-9; Dayan FE, 1998, ARCH BIOCHEM BIOPHYS, V351, P27, DOI 10.1006/abbi.1997.0533; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; DROGE W, 1993, PHARMACOLOGY, V46, P61, DOI 10.1159/000139029; DUNFORD HB, 1986, ARCH BIOCHEM BIOPHYS, V251, P536, DOI 10.1016/0003-9861(86)90361-9; DUNFORD HB, 1995, XENOBIOTICA, V25, P725, DOI 10.3109/00498259509061888; EASTMOND DA, 1986, MOL PHARMACOL, V30, P674; EDELHOCH H, 1979, J BIOL CHEM, V254, P1822; Ferrari RP, 1997, J INORG BIOCHEM, V68, P17, DOI 10.1016/S0162-0134(97)00003-2; FERRARI RP, 1995, J INORG BIOCHEM, V58, P109, DOI 10.1016/0162-0134(94)00041-8; Furtmuller PG, 2002, BIOCHEMISTRY-US, V41, P11895, DOI 10.1021/bi026326x; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HEWSON WD, 1976, J BIOL CHEM, V251, P6043; HUWILER M, 1986, EUR J BIOCHEM, V158, P609, DOI 10.1111/j.1432-1033.1986.tb09798.x; ILLY C, 1991, BIOCHEMISTRY-US, V30, P7135, DOI 10.1021/bi00243a014; JENZER H, 1986, BIOCHEM BIOPH RES CO, V139, P327, DOI 10.1016/S0006-291X(86)80117-6; JENZER H, 1986, J BIOL CHEM, V261, P5550; Jones CM, 2002, FREE RADICAL BIO MED, V32, P982, DOI 10.1016/S0891-5849(02)00791-8; JOYCE DA, 1989, PHARMACOL THERAPEUT, V42, P405, DOI 10.1016/0163-7258(89)90033-8; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KOHLER H, 1988, ARCH BIOCHEM BIOPHYS, V264, P438, DOI 10.1016/0003-9861(88)90309-8; Kolberg M, 2002, ARCH BIOCHEM BIOPHYS, V403, P141, DOI 10.1016/S0003-9861(02)00264-3; Kolberg M, 2002, ARCH BIOCHEM BIOPHYS, V397, P57, DOI 10.1006/abbi.2001.2658; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; LOVAAS E, 1992, FREE RADICAL BIO MED, V13, P187, DOI 10.1016/0891-5849(92)90014-8; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; METODIEWA D, 1989, BIOCHEM BIOPH RES CO, V160, P1183, DOI 10.1016/S0006-291X(89)80128-7; METODIEWA D, 1989, ARCH BIOCHEM BIOPHYS, V274, P601, DOI 10.1016/0003-9861(89)90475-X; MICHOT JL, 1979, J BIOL CHEM, V254, P2205; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; Mottley C, 2001, J BIOL CHEM, V276, P42677, DOI 10.1074/jbc.M104889200; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; NAKAMURA M, 1986, J BIOL CHEM, V261, P13923; NAKAMURA S, 1984, J BIOL CHEM, V259, P7080; OHLSSON PI, 1983, ACTA CHEM SCAND B, V37, P917, DOI 10.3891/acta.chem.scand.37b-0917; OLSEN J, 1976, BIOCHIM BIOPHYS ACTA, V445, P324, DOI 10.1016/0005-2744(76)90086-3; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; RAO DNR, 1990, J BIOL CHEM, V265, P844; Reszka KJ, 1999, FREE RADICAL BIO MED, V26, P669, DOI 10.1016/S0891-5849(98)00244-5; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; SERBINOVA E, 1992, FREE RADICAL RES COM, V17, P49, DOI 10.3109/10715769209061088; SHAN XQ, 1990, PHARMACOL THERAPEUT, V47, P61, DOI 10.1016/0163-7258(90)90045-4; STOCK BH, 1986, J BIOL CHEM, V261, P5959; STOCK BH, 1986, J BIOL CHEM, V261, P5915; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V317, P315, DOI 10.1006/abbi.1995.1169; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; SVENSSON BE, 1993, FREE RADICAL BIO MED, V14, P167, DOI 10.1016/0891-5849(93)90007-H; SVENSSON BE, 1988, BIOCHEM J, V256, P757, DOI 10.1042/bj2560757; SVENSSON BE, 1988, BIOCHEM J, V253, P441, DOI 10.1042/bj2530441; SVENSSON BE, 1988, BIOCHEM J, V256, P751, DOI 10.1042/bj2560751; TAUROG A, 1994, ARCH BIOCHEM BIOPHYS, V315, P82, DOI 10.1006/abbi.1994.1474; TAUROG A, 1991, ARCH BIOCHEM BIOPHYS, V287, P288, DOI 10.1016/0003-9861(91)90481-W; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WEFERS H, 1985, Journal of Free Radicals in Biology and Medicine, V1, P311, DOI 10.1016/0748-5514(85)90137-0; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; YAMAZAKI I, 1973, MOL CELL BIOCHEM, V2, P39, DOI 10.1007/BF01738677; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; ZHANG HC, 1993, CAN J CHEM, V71, P1990, DOI 10.1139/v93-248	85	25	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13272	13283		10.1074/jbc.M310034200	http://dx.doi.org/10.1074/jbc.M310034200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724284	hybrid			2022-12-27	WOS:000220334900150
J	Kwon, C; Chung, IK				Kwon, C; Chung, IK			Interaction of an Arabidopsis RNA-binding protein with plant single-stranded telomeric DNA modulates telomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; HNRNP A1; END; LENGTH; YEAST; REPLICATION; DOMAIN; EST1; ASSOCIATION; INHIBITION	Telomeres are the specialized structures at the end of linear chromosomes and terminate with a single-stranded 3' overhang of the G-rich strand. The primary role of telomeres is to protect chromosome ends from recombination and fusion and from being recognized as broken DNA ends. This protective function can be achieved through association with specific telomere-binding proteins. Although proteins that bind single-stranded G-rich overhang regulate telomere length and telomerase activity in mammals and lower eukaryotes, equivalent factors have yet to be identified in plants. Here we have identified proteins capable of interacting with the G-rich single-stranded telomeric repeat from the Arabidopsis extracts by affinity chromatography. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis indicates that the isolated protein is a chloroplast RNA-binding protein (and a truncated derivative). The truncated derivative, which we refer to as STEP1 (single-stranded telomere-binding protein 1), binds specifically the single-stranded G-rich plant telomeric DNA sequences but not double-stranded telomeric DNA. Unlike the chloroplast-localized full-length RNA-binding protein, STEP1 localizes exclusively to the nucleus, suggesting that it plays a role in plant telomere biogenesis. We also demonstrated that the specific binding of STEP1 to single-stranded telomeric DNA inhibits telomerase-mediated telomere extension. The evidence presented here suggests that STEP1 is a telomere-end binding protein that may contribute to telomere length regulation by capping the ends of chromosomes and thereby repressing telomerase activity in plants.	Yonsei Univ, Coll Sci, Dept Biol, Mol Aging Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Mol Aging Res Ctr, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr						Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Cesare AJ, 2003, PLANT J, V36, P271, DOI 10.1046/j.1365-313X.2003.01882.x; CHENG SH, 1994, PLANT PHYSIOL, V106, P303, DOI 10.1104/pp.106.1.303; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fitzgerald MS, 1996, P NATL ACAD SCI USA, V93, P14422, DOI 10.1073/pnas.93.25.14422; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Fulneckova J, 2000, FEBS LETT, V467, P305, DOI 10.1016/S0014-5793(00)01178-9; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greider CW, 1999, CELL, V97, P419, DOI 10.1016/S0092-8674(00)80750-3; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hwang MG, 2001, FEBS LETT, V503, P35, DOI 10.1016/S0014-5793(01)02685-0; Kamma H, 2001, BIOCHEM BIOPH RES CO, V280, P625, DOI 10.1006/bbrc.2000.4173; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; Kim JH, 2003, MOL PHARMACOL, V63, P1117, DOI 10.1124/mol.63.5.1117; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OHTA M, 1995, PLANT MOL BIOL, V27, P529, DOI 10.1007/BF00019319; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Riha K, 1998, PLANT CELL, V10, P1691, DOI 10.1105/tpc.10.10.1691; Riha K, 2000, PLANT J, V23, P633, DOI 10.1046/j.1365-313x.2000.00831.x; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SHENG H, 1995, MOL CELL BIOL, V15, P1144; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	53	45	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12812	12818		10.1074/jbc.M312011200	http://dx.doi.org/10.1074/jbc.M312011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14703514	hybrid			2022-12-27	WOS:000220334900096
J	McLeod, SJ; Shum, AJ; Lee, RL; Takei, F; Gold, MR				McLeod, SJ; Shum, AJ; Lee, RL; Takei, F; Gold, MR			The Rap GTPases regulate integrin-mediated adhesion, cell spreading, actin polymerization, and Pyk2 tyrosine phosphorylation in B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR; T-CELL; RAP1-INDUCED ADHESION; ACTIVATION; KINASE; CHEMOKINE; LFA-1; MORPHOLOGY; EXPRESSION; MIGRATION	Integrin-mediated adhesion plays an important role in B cell development and activation. Signaling initiated by antigens, chemokines, or phorbol esters can rapidly convert integrins to an activated adhesion-competent state. The binding of integrins to their ligands can then induce actin-dependent cell spreading, which can facilitate cell-cell adhesion or cell migration on extracellular matrices. The signaling pathways involved in integrin activation and post-adhesion events in B cells are not completely understood. We have previously shown that anti-Ig antibodies, the chemokine stromal cell-derived factor-1 (SDF-1; CXCL12), and phorbol esters activate the Rap1 and Rap2 GTPases in B cells and that Rap activation is essential for SDF-1-induced B cell migration (McLeod, S. J., Li, A. H. Y., Lee, R. L., Burgess, A. E., and Gold, M. R. ( 2002) J. Immunol. 169, 1365 - 1371; Christian, S. L., Lee, R. L., McLeod, S. J., Burgess, A. E., Li, A. H. Y., Dang-Lawson, M., Lin, K. B. L., and Gold, M. R. (2003) J. Biol. Chem. 278, 41756 - 41767). We show here that preventing Rap activation by expressing Rap-specific GTPase-activating protein II (RapGAPII) significantly decreased lymphocyte function-associated antigen-1- and alpha(4) integrin-dependent binding of murine B cell lines to purified adhesion molecules and to other cells. Conversely, augmenting Rap activation by expressing a constitutively active form of Rap2 enhanced B cell adhesion, showing for the first time that Rap2 can promote integrin activation. We also show that blocking Rap activation inhibited anti-Ig-induced cell spreading and phorbol ester-induced actin polymerization as well as anti-Ig- and SDF-1-induced phosphorylation of Pyk2, a tyrosine kinase involved in morphological changes and chemokine-induced B cell migration. Thus, the Rap GTPases regulate integrin-mediated B cell adhesion as well as processes that control B cell morphology and migration.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; British Columbia Cancer Agency	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mgold@interchange.ubc.ca	Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191; Takei, Fumio/0000-0002-3620-5046				Abraham RT, 2002, NAT IMMUNOL, V3, P212, DOI 10.1038/ni0302-212; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; CORRADI MP, 1987, J IMMUNOL, V138, P2075; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; DANG LH, 1991, J IMMUNOL, V146, P3273; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gismondi A, 2003, J IMMUNOL, V170, P3065, DOI 10.4049/jimmunol.170.6.3065; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Heo WD, 2003, CELL, V113, P315; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katagiri T, 2000, J BIOL CHEM, V275, P19645, DOI 10.1074/jbc.M909828199; Kellermann SA, 2002, IMMUNOL REV, V186, P172, DOI 10.1034/j.1600-065X.2002.18615.x; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEMOINE FM, 1990, BLOOD, V76, P2311; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Leuker CE, 2001, J EXP MED, V193, P755, DOI 10.1084/jem.193.6.755; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Lo CG, 2003, J EXP MED, V197, P353, DOI 10.1084/jem.20021569; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; MELAMED I, 1991, J IMMUNOL, V147, P1139; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Montoya MC, 2002, IMMUNOL REV, V186, P68, DOI 10.1034/j.1600-065X.2002.18607.x; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Oostendorp RAJ, 1997, LEUKEMIA LYMPHOMA, V24, P423, DOI 10.3109/10428199709055581; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PATARROYO M, 1983, CELL IMMUNOL, V81, P373, DOI 10.1016/0008-8749(83)90244-7; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POSTIGO AA, 1991, EUR J IMMUNOL, V21, P2437, DOI 10.1002/eji.1830211021; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x; Rott LS, 2000, J LEUKOCYTE BIOL, V68, P807; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; WELDER CA, 1993, J IMMUNOL, V150, P2203	70	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12009	12019		10.1074/jbc.M313098200	http://dx.doi.org/10.1074/jbc.M313098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701796	hybrid			2022-12-27	WOS:000220334900003
J	Tikhomirov, O; Carpenter, G				Tikhomirov, O; Carpenter, G			Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN-BREAST-CANCER; EGF RECEPTOR; QUANTITATIVE-ANALYSIS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; DOWN-REGULATION; FACTOR-ALPHA; HEAT-SHOCK; C-NEU	Increased expression of the epidermal growth factor ( EGF) receptor ( EGFR) and ErbB- 2 is implicated into the development and progression of breast cancer. Constant ligand- induced activation of EGFR and ErbB- 2 receptor-tyrosine kinases is thought to be involved in the transformation of fibroblasts and mammary epithelial cells. Data herein show that ligand stimulation of cells that express both the EGFR and the ErbB- 2 may result either in cell proliferation or apoptosis depending on the expression levels of EGFR and ErbB- 2. Mammary tumor cells that express low levels of both receptors or high levels of ErbB- 2 and low levels of EGFR survive and proliferate in the presence of EGF. In contrast, fibroblastic cells or mammary tumor cells, which co- express high levels of EGFR and ErbB- 2 invariably undergo apoptosis in response to EGF. In these cells persistent activation of p38 MAPK is an essential element of the apoptotic mechanism. Also, the data implicate a p38- dependent change in mitochondrial membrane permeability as a downstream effector of apoptosis. Ligand- dependent apoptosis in cells co- expressing high levels of EGFR and ErbB- 2 could be a natural mechanism that protects tissues from unrestricted proliferation in response to the sustained activation of receptor- tyrosine kinases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	Graham.Carpenter@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, R01CA097456] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 68485, CA 97456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baulida J, 1996, J BIOL CHEM, V271, P5251; Bera TK, 1999, CANCER RES, V59, P4018; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Christensen JG, 2001, CLIN CANCER RES, V7, P4230; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Darcy KM, 1999, EUR J CELL BIOL, V78, P511, DOI 10.1016/S0171-9335(99)80077-6; Darcy KM, 2000, J HISTOCHEM CYTOCHEM, V48, P63, DOI 10.1177/002215540004800107; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; DiAugustine RP, 1997, J MAMMARY GLAND BIOL, V2, P109, DOI 10.1023/A:1026395513038; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Garcia I, 2003, ANN SURG ONCOL, V10, P234, DOI 10.1245/ASO.2003.05.010; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HARRIS RA, 1995, BRIT J CANCER, V72, P386, DOI 10.1038/bjc.1995.343; Hendriks BS, 2003, CANCER RES, V63, P1130; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Klapper LN, 2000, ADV CANCER RES, V77, P25; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; SORKIN A, 1993, ONCOGENE, V8, P3021; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Suzuki Y, 1997, BIOCHEM BIOPH RES CO, V240, P856, DOI 10.1006/bbrc.1997.7758; Takada E, 2002, IMMUNOL LETT, V81, P93, DOI 10.1016/S0165-2478(02)00002-0; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Troyer KL, 2001, J MAMMARY GLAND BIOL, V6, P7, DOI 10.1023/A:1009560330359; Tsutsui S, 2003, SURGERY, V133, P219, DOI 10.1067/msy.2003.32; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	61	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12988	12996		10.1074/jbc.M311655200	http://dx.doi.org/10.1074/jbc.M311655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711810	hybrid			2022-12-27	WOS:000220334900118
J	Usui, S; Sugimoto, N; Takuwa, N; Sakagami, S; Takata, S; Kaneko, S; Takuwa, Y				Usui, S; Sugimoto, N; Takuwa, N; Sakagami, S; Takata, S; Kaneko, S; Takuwa, Y			Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P(1)-G(i)-Ras-MAPK-dependent induction of Kruppel-like factor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; ANGIOTENSIN-II; TRANSCRIPTION FACTOR; GENE-EXPRESSION; RECEPTOR EDG-1; PDGF-B; SPHINGOSINE-1-PHOSPHATE; MIGRATION; PATHWAYS	Platelet-derived growth factors (PDGFs), potent mitogens and chemoattractants for mesenchymal cell types, play essential roles in development of several organs including blood vessels, kidney, and lung, and are also implicated in the pathogenesis of atherosclerosis and malignancies. Blood lipid mediator sphingosine 1-phosphate (S1P) regulates migration, proliferation, and apoptosis in a variety of cell types through multiple G protein-coupled receptors of the Edg family, and is necessary for vascular formation at the developmental stage. We found in the present study that S1P induced severalfold increases in the mRNA and protein levels of PDGF-A and -B chains in vascular smooth muscle cells and neointimal cells. S1P stimulation of PDGF mRNA and protein expression was abolished by the small interfering RNA duplexes targeting S1P(1)/Edg1 receptor subtype. S1P stimulated the small GTPase Ras in a G(i)-dependent manner, and activated ERK and p38 MAPK in G(i)- and Ras-dependent manners. Pertussis toxin pretreatment, adenovirus-mediated Asn(17)Ras expression, the MEK inhibitor PD98059, or the p38 MAPK inhibitor SB203580 markedly suppressed PDGF mRNA and protein up-regulation, indicating the involvement of Gi- Ras-ERK/p38 MAPK in S1P stimulation of PDGF expression. S1P stimulated expression of the transcription factor KLF5 in manners dependent on G(i), Ras, and ERK/p38 MAPK. Down-regulation of KLF5 by small interfering RNA duplexes abolished S1P-induced PDGF-A and -B chain expression. On the other hand, overexpression of KLF5 stimulated basal and S1P-induced PDGF expression. Either S1P stimulation or KLF5 overexpression increased the PDGF-B promoter activity in a cis-element-dependent manner. These results reveal the S1P(1)-triggered, G(i)-Ras-ERK/p38 MAPK-KLF5-dependent, stimulatory regulation of PDGF gene transcription in vascular smooth muscle cells.	Kanazawa Univ, Grad Sch Med, Dept Cellular & Mol Physiol, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med, Dept Internal Med, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med, Dept Hlth Sci, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University; Kanazawa University	Takuwa, Y (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Physiol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	ytakuwa@med.kanazawa-u.ac.jp	Sugimoto, Naotoshi/C-4739-2015; USUI, Soichiro/GQH-4849-2022	Sugimoto, Naotoshi/0000-0003-1995-5002; TAKUWA, Noriko/0000-0002-4278-2704; Usui, Soichiro/0000-0003-1752-8082				Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bischoff A, 2000, BRIT J PHARMACOL, V130, P1871, DOI 10.1038/sj.bjp.0703515; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Deguchi J, 1999, CIRC RES, V85, P565, DOI 10.1161/01.RES.85.7.565; FUKUSHIMA N, 2001, ANNU REV PHARMACOL, V131, P767; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; KATAYOSE D, 1993, AM J PHYSIOL, V264, pL100, DOI 10.1152/ajplung.1993.264.2.L100; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MITUI H, 1997, J BIOL CHEM, V272, P4904; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; NODA M, 1994, J BIOL CHEM, V269, P17911; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sachinidis A, 1999, ARTERIOSCL THROM VAS, V19, P2412, DOI 10.1161/01.ATV.19.10.2412; Sakurada S, 2001, AM J PHYSIOL-CELL PH, V281, pC571, DOI 10.1152/ajpcell.2001.281.2.C571; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; TAMAMA K, 2001, BIOCHEM J, V352, P809; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yatomi Y, 1997, J BIOCHEM, V121, P969	42	83	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12300	12311		10.1074/jbc.M305025200	http://dx.doi.org/10.1074/jbc.M305025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711826	hybrid, Green Submitted			2022-12-27	WOS:000220334900037
J	Chang, JD; Field, SJ; Rameh, LE; Carpenter, CL; Cantley, LC				Chang, JD; Field, SJ; Rameh, LE; Carpenter, CL; Cantley, LC			Identification and characterization of a phosphoinositide phosphate kinase homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASES; PROTEIN; FAMILY; MYOTUBULARIN; VESICLES; ALPHA; 3-PHOSPHATASE; REGULATORS; MOVEMENT; PATHWAY	Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) plays a central role in regulating the actin cytoskeleton as a substrate for phosphoinositide 3-kinase and phospholipase C as well as by binding directly to proteins that control the processes of actin monomer sequestration, filament severing, capping, nucleation, cross-linking, and bundling (Ma, L., Cantley, L. C., Janmey, P. A., and Kirschner, M. W. (1998) J. Cell Biol. 140, 1125 1136; Hinchliffe, K. (2000) Curr. Biol. 10, R104-R1051). Three related phosphatidylinositol 4-phosphate 5-kinases (PI(4)P 5-kinases) have been identified in mammalian cells (types Ialpha, Ibeta, and Igamma) and appear to play distinct roles in actin remodeling. Here we have identified a fourth member of this family by searching the human genome and EST data bases. This new protein, which we have designated phosphatidylinositol phosphate kinase homolog (PIPKH), is expressed at relatively high levels in brain and testis. Immunoprecipitates of PIPKH expressed in mammalian cells contain PI(4)P 5-kinase activity, but this activity is not affected by mutations in residues that inactivate other type I PI(4)P 5-kinases. We show that the PI(4)P 5-kinase activity in PIPKH immunoprecipitates can be explained by the ability of PIPKH to heterodimerize with other type I PI(4)P 5-kinases. Transfection of 293t cells with PIPKH resulted in >8-fold increase in total phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) without a significant net increase in total PI(4,5)P-2. When coexpressed with PIPKH, green fluorescent protein (GFP) fusion construct of the pleckstrin homology domain from Bruton's tyrosine kinase (GFP-BTK-PH) localized in intracellular vesicular structures, suggesting an unusual intracellular site of PI(3,4,5)P-3 production. Finally, expression of PIPKH induced the reorganization of actin from predominantly stress fibers to predominantly foci and comets similar to those observed previously in cells infected with the intracellular pathogen Listeria or transfected with recombinant PIPKIalpha. These results suggest that PIPKH acts as a scaffold to localize and regulate type I PI(4)P 5-kinases and the synthesis of PI(3,4,5)P-3.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Chang, JD (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.	jchang@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Field, Seth/0000-0002-8893-4806	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03313] Funding Source: Medline; NIGMS NIH HHS [GM36624, GM54389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Guo J, 2003, P NATL ACAD SCI USA, V100, P3995, DOI 10.1073/pnas.0230488100; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hinchliffe K, 2000, CURR BIOL, V10, pR104, DOI 10.1016/S0960-9822(00)00303-1; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ma L, 1998, J CELL BIOL, V140, P1125; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Nandurkar HH, 2003, P NATL ACAD SCI USA, V100, P8660, DOI 10.1073/pnas.1033097100; Nandurkar HH, 2002, IUBMB LIFE, V53, P37, DOI 10.1080/15216540210812; Nandurkar HH, 2001, P NATL ACAD SCI USA, V98, P9499, DOI 10.1073/pnas.171306098; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Tolias K, 2000, METHOD ENZYMOL, V325, P190; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1	31	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11672	11679		10.1074/jbc.M309721200	http://dx.doi.org/10.1074/jbc.M309721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701839	hybrid			2022-12-27	WOS:000220157600102
J	Gao, CJ; Guo, HT; Wei, JP; Mi, ZY; Wai, P; Kuo, PC				Gao, CJ; Guo, HT; Wei, JP; Mi, ZY; Wai, P; Kuo, PC			S-nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ELEMENT-BINDING PROTEIN; DNA-BINDING; EXPRESSION; CLONING; CELLS; GENE; INHIBITION; IDENTIFICATION; ENHANCER	Osteopontin (OPN) is a highly hydrophilic and negatively charged sialoprotein of similar to 298 amino acids that contains a Gly-Arg-Gly-Asp-Ser sequence. It is a secreted protein with diverse regulatory functions, including cell adhesion and migration, tumor growth and metastasis, atherosclerosis, aortic valve calcification, and repair of myocardial injury. Despite the many recognized functions of OPN, very little is known of the transcriptional regulation of OPN. In this regard, we have previously demonstrated that OPN transcription and promoter activity are significantly up-regulated in response to NO in a system of endotoxin-stimulated murine macrophages. However, the specific cis- and trans-regulatory elements that determine the extent of endotoxin- and NO-mediated induction of OPN synthesis are unknown. In this follow-up study, we demonstrate that: 1) OPN gene transcription is regulated by a constitutive transcriptional repressor protein, heterogeneous nuclear ribonucleoprotein A/B ( hnRNP A/B); 2) inhibition of in vivo hnRNP DNA binding activity is accompanied by increased S-nitrosylation of hnRNP A/B in the setting of lipopolysaccharide (LPS)-mediated NO synthesis; 3) inhibition of LPS mediated NO synthesis restores hnRNP DNA binding and decreases the extent of S-nitrosylation; and 4) S-nitrosylation of hnRNP at cysteine 104 inhibits in vitro DNA binding activity, which is reversed by dithiothreitol. Our findings suggest that LPS induced S-nitrosylation of hnRNP inhibits its activity as a constitutive repressor of the OPN promoter and results in enhanced OPN expression.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University	Kuo, PC (corresponding author), 110 Bell Bldg,Box 3522,DUMC, Durham, NC 27710 USA.	kuo00004@mc.duke.edu		Gao, Chengjiang/0000-0002-9365-4497	NIAID NIH HHS [R01 AI44629] Funding Source: Medline; NIGMS NIH HHS [R01 GM65113] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065113] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Attur MG, 2001, ARTHRITIS RHEUM-US, V44, P578, DOI 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.3.CO;2-Z; Calmels S, 1997, CANCER RES, V57, P3365; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; delaTorre A, 1999, J IMMUNOL, V162, P4101; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; Guo HT, 2002, J BIOL CHEM, V277, P5054, DOI 10.1074/jbc.M109017200; Guo HT, 2001, J IMMUNOL, V166, P1079, DOI 10.4049/jimmunol.166.2.1079; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; HWANG S, 1994, J BIOL CHEM, V269, P711; HWANG SM, 1994, J CELL PHYSIOL, V160, P61, DOI 10.1002/jcp.1041600108; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Rollo EE, 1996, J LEUKOCYTE BIOL, V60, P397, DOI 10.1002/jlb.60.3.397; Saitoh Y, 2002, NUCLEIC ACIDS RES, V30, P5205, DOI 10.1093/nar/gkf642; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; SINGH K, 1995, J BIOL CHEM, V270, P28471; Singh K, 1999, HYPERTENSION, V33, P663, DOI 10.1161/01.HYP.33.2.663; SMIDT MP, 1995, NUCLEIC ACIDS RES, V23, P2389, DOI 10.1093/nar/23.13.2389; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TAY N, 1992, J VIROL, V66, P6841, DOI 10.1128/JVI.66.12.6841-6848.1992; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Vossen Christine, 2002, Med Sci Monit, V8, pRA217; Wang D, 1999, J VIROL, V73, P7761, DOI 10.1128/JVI.73.9.7761-7768.1999; WILSON AB, 1988, CELL IMMUNOL, V113, P130, DOI 10.1016/0008-8749(88)90012-3; Yabuki T, 2001, GENE, V264, P123, DOI 10.1016/S0378-1119(00)00592-8	41	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11236	11243		10.1074/jbc.M313385200	http://dx.doi.org/10.1074/jbc.M313385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722087	hybrid			2022-12-27	WOS:000220157600050
J	Hong, M; Luo, SZ; Baumeister, P; Huang, JM; Gogia, RK; Li, MQ; Lee, AS				Hong, M; Luo, SZ; Baumeister, P; Huang, JM; Gogia, RK; Li, MQ; Lee, AS			Underglycosylation of ATF6 as a novel sensing mechanism for activation of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM STRESS-RESPONSE; CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; ER STRESS; TRANSCRIPTION FACTOR-6; NF-Y; ELEMENT; GLYCOSYLATION; PROMOTER; KINASE	ATF6 is a key transcriptional activator of the unfolded protein response (UPR), which allows mammalian cells to maintain cellular homeostasis when they are subjected to a variety of environmental and physiological stresses that target the endoplasmic reticulum (ER). ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain. Although it is well established that p90ATF6 activation requires transit from the ER to the Golgi, where it is cleaved by the S1P/S2P protease system to generate a nuclear form p60ATF6 that acts as a transcriptional activator, the functional significance of p90ATF6 N-linked glycosylation is unknown. Here we show that ER Ca2+ depletion stress, a triggering mechanism for the UPR, induces the formation of ATF6(f), which represents de novo partial glycosylation of newly synthesized p90ATF6. By mutating a single amino acid within the N-linked glycosylation site closest to the carboxyl terminus of p90ATF6, we recreated ATF6(f). This mutation sharply reduces p90ATF6 association with calreticulin, a major Ca2+-binding chaperone for N-glycoprotein. We further determined that ATF6(f) exhibits a faster rate of constitutive transport to the Golgi, resulting in a higher level of p60ATF6 in the nucleus and stronger transactivating activity in the absence of ER stress. Additional analysis of p90ATF6 mutants targeting single or multiple N-glycosylation sites also showed higher constitutive transactivating activity than wild type ATF6. Because accumulation of underglycosylated proteins in the ER is a potent inducer for the UPR, these studies uncover a novel mechanism whereby the glycosylation status of p90ATF6 can serve as a sensor for ER homeostasis, resulting in ATF6 activation to trigger the UPR.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FEIGE JJ, 1987, J CELL PHYSIOL, V133, P461, DOI 10.1002/jcp.1041330306; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Harris MR, 1998, J IMMUNOL, V160, P5404; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reddy RK, 2002, CANCER RES, V62, P7207; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thuerauf DJ, 2001, J BIOL CHEM, V276, P48309, DOI 10.1074/jbc.M107146200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wormald MR, 1999, STRUCTURE, V7, pR155, DOI 10.1016/S0969-2126(99)80095-1; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	40	121	124	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11354	11363		10.1074/jbc.M309804200	http://dx.doi.org/10.1074/jbc.M309804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699159	hybrid			2022-12-27	WOS:000220157600064
J	Iwase, A; Shen, RQ; Navarro, D; Nanus, DM				Iwase, A; Shen, RQ; Navarro, D; Nanus, DM			Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID-BINDING; PROSTATE-CANCER CELLS; SCHIZOSACCHAROMYCES-POMBE; CYTOPLASMIC DOMAIN; GLYCOPROTEIN CD44; FAMILY MEMBERS; ACTIN-BINDING; IN-VIVO; EXPRESSION; ADHESION	Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by numerous tissues including prostatic epithelial cells. We reported that NEP inhibits prostate cancer cell proliferation and cell migration by enzymatic inactivation of neuropeptide substrates and through protein-protein interaction independent of catalytic function. The cytoplasmic domain of NEP contains a positively charged amino acid cluster, previously identified as a binding site for ezrin/radixin/moesin (ERM) proteins. We report here that NEP co-immunoprecipitates with ERM proteins in NEP-expressing LNCaP prostate cancer cells and MeWo melanoma cells. Co-immunoprecipitation showed that ERM proteins associate with wild-type NEP protein but not NEP protein containing a truncated cytoplasmic domain or point mutations replacing the positively charged amino acid cluster. In vitro binding assays showed that NEP binds directly to recombinant N terminus fragments of ERM proteins at the positively charged amino acid cluster within the NEP cytoplasmic domain. Binding of ERM proteins to NEP results in decreased binding of ERM proteins to the hyaluronan receptor CD44, a main binding partner of ERM proteins. Moreover, cells expressing wild-type NEP demonstrate decreased adhesion to hyaluronic acid and cell migration. These data suggest that NEP can affect cell adhesion and migration through direct binding to ERM proteins.	Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10021 USA	Cornell University; Cornell University	Nanus, DM (corresponding author), Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, 525 E 68th St, New York, NY 10021 USA.	dnanus@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA080240] Funding Source: NIH RePORTER; NCI NIH HHS [CA80240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; CHECLER F, 1984, J NEUROCHEM, V43, P1295, DOI 10.1111/j.1471-4159.1984.tb05386.x; Cichy J, 2000, J BIOL CHEM, V275, P18061, DOI 10.1074/jbc.M907962199; Dai J, 2001, CLIN CANCER RES, V7, P1370; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Dhir R, 1997, MOL DIAGN, V2, P197, DOI 10.1016/S1084-8592(97)80029-X; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Fukui M, 2000, CLIN IMMUNOL, V94, P173, DOI 10.1006/clim.1999.4830; Girardi ACC, 2001, J BIOL CHEM, V276, P46671, DOI 10.1074/jbc.M106897200; Goi T, 2002, INT SURG, V87, P130; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Granes F, 2000, J CELL SCI, V113, P1267; Gschwend JE, 1997, PROSTATE, V33, P166; Harrison GM, 2002, INT J ONCOL, V21, P935; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hiscox S, 1999, J CELL SCI, V112, P3081; HOOSEIN NM, 1991, CANCER COMMUN, V3, P255, DOI 10.3727/095535491820873146; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Huhn J, 2000, IMMUNOL LETT, V72, P127, DOI 10.1016/S0165-2478(00)00170-X; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; JOENSUU H, 1993, AM J PATHOL, V143, P867; KENNY J, 1993, BIOCHEM SOC T, V21, P663, DOI 10.1042/bst0210663; Kim HS, 2002, CLIN ORTHOP RELAT R, P184; Knupfer MM, 1999, CLIN EXP METASTAS, V17, P71; Lang SH, 2002, PROSTATE, V52, P253, DOI 10.1002/pros.10088; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LOKESHWAR BL, 1995, ANTICANCER RES, V15, P1191; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lu Q, 1997, GENE, V200, P135, DOI 10.1016/S0378-1119(97)00393-4; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; NANUS DM, 1997, CELL SURFACE PEPTIDA; Noordzij MA, 1999, INT J CANCER, V84, P478, DOI 10.1002/(SICI)1097-0215(19991022)84:5<478::AID-IJC5>3.0.CO;2-N; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shen RQ, 2002, ANTICANCER RES, V22, P2533; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2001, CANCER RES, V61, P3294; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	54	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11898	11905		10.1074/jbc.M212737200	http://dx.doi.org/10.1074/jbc.M212737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704146	hybrid			2022-12-27	WOS:000220157600127
J	Sawamura, N; Ko, MH; Yu, WX; Zou, K; Hanada, K; Suzuki, T; Gong, JS; Yanagisawa, K; Michikawa, M				Sawamura, N; Ko, MH; Yu, WX; Zou, K; Hanada, K; Suzuki, T; Gong, JS; Yanagisawa, K; Michikawa, M			Modulation of amyloid precursor protein cleavage by cellular sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; BETA-PROTEIN; KINASE-C; LIPID RAFTS; SERINE PALMITOYLTRANSFERASE; CHOLESTEROL DEPLETION; PRION PROTEIN; SIGNAL-TRANSDUCTION; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE	Lipid rafts and their component, cholesterol, modulate the processing of beta-amyloid precursor protein (APP). However, the role of sphingolipids, another major component of lipid rafts, in APP processing remains undetermined. Here we report the effect of sphingolipid deficiency on APP processing in Chinese hamster ovary cells treated with a specific inhibitor of serine palmitoyltransferase, which catalyzes the first step of sphingolipid biosynthesis, and in a mutant LY-B strain defective in the LCB1 subunit of serine palmitoyltransferase. We found that in sphingolipid-deficient cells, the secretion of soluble APPalpha (sAPPalpha) and the generation of C-terminal fragment cleaved at alpha-site dramatically increased, whereas epsilon-cleavage activity remained unchanged, and the epsilon-cleavage activity decreased without alteration of the total APP level. The secretion of amyloid beta-protein 42 increased in sphingolipid-deficient cells, whereas that of amyloid beta-protein 40 did not. All of these alterations were restored in sphingolipid-deficient cells by adding exogenous sphingosine and in LY-B cells by transfection with cLCB1. Sphingolipid deficiency increased MAPK/ERK activity and a specific inhibitor of MAPK kinase, PD98059, restored sAPPalpha level, indicating that sphingolipid deficiency enhances sAPPalpha secretion via activation of MAPK/ERK pathway. These results suggest that not only the cellular level of cholesterol but also that of sphingolipids may be involved in the pathological process of Alzheimer's disease by modulating APP cleavage.	Natl Inst Longev Sci, Dept Dementia Res, Aichi 4748522, Japan; Japan Soc Promot Sci, Tokyo 1028471, Japan; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido 0600812, Japan; Org Pharmaceut Safety & Res Japan, Tokyo 1000013, Japan	Japan Society for the Promotion of Science; National Institute of Infectious Diseases (NIID); Hokkaido University	Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Aichi 4748522, Japan.	michi@nils.go.jp	Suzuki, Toshiharu/B-5342-2013; Sawamura, Naoya/K-1663-2018	Sawamura, Naoya/0000-0003-4753-1119; Hanada, Kentaro/0000-0003-1383-2781				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 2000, J CELL SCI, V113, P1857; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HANADA K, 1993, J BIOL CHEM, V268, P13820; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Harter D, 2001, BEHAV BRAIN SCI, V24, P45, DOI 10.1017/S0140525X01303916; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; KOO EH, 1994, J BIOL CHEM, V269, P17386; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Mills J, 1997, J NEUROSCI, V17, P9415; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; Sawamura N, 2003, J NEUROCHEM, V84, P1086, DOI 10.1046/j.1471-4159.2003.01596.x; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o	62	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11984	11991		10.1074/jbc.M309832200	http://dx.doi.org/10.1074/jbc.M309832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715666	hybrid			2022-12-27	WOS:000220157600136
J	Bao, XF; Nishimura, S; Mikami, T; Yamada, S; Itoh, N; Sugahara, K				Bao, XF; Nishimura, S; Mikami, T; Yamada, S; Itoh, N; Sugahara, K			Chondroitin sulfate/dermatan sulfate hybrid chains from embryonic pig brain, which contain a higher proportion of L-iduronic acid than those from adult pig brain, exhibit neuritogenic and growth factor binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; DERMATAN SULFATE; NEURITE OUTGROWTH; ZETA/RPTP-BETA; HEPARAN-SULFATE; FACTOR MIDKINE; HIGH-AFFINITY; RAT-BRAIN; PROTEOGLYCANS; SPECIFICITIES	We have shown that over-sulfated chondroitin sulfate/ dermatan sulfate (CS/DS) chains from various marine organisms exhibit growth factor binding activities and neurite outgrowth-promoting activities in embryonic mouse hippocampal neurons in vitro. In this study we demonstrated that CS/DS hybrid chains purified from embryonic pig brain displayed marked neuritogenic activity and growth factor binding activities toward fibroblast growth factor 2 (FGF2), FGF10, FGF18, pleiotrophin, and midkine, all of which exhibit neuroregulatory activities in the brain. In contrast, the CS/DS preparation from adult pig brain showed considerably less activity to bind these growth factors and no neuritogenic activity. Structural analysis indicated that the average size of the CS/DS chains was similar ( 40 kDa) between these two preparations, but the disaccharide compositions differed considerably, with a significant proportion of L-iduronic acid (IdoUA)-containing disaccharides ( 8 similar to 9%) in the CS/DS chains from embryos but not in those from adults (< 1%). Interestingly, both neurite out-growth-promoting activity and growth factor binding activities of the CS/DS chains from embryos were abolished by digestion not only with chondroitinase ABC but also with chondroitinase B, suggesting that the IdoUA-containing motifs are essential for these activities. These findings imply that the temporal expression of CS/DS hybrid structures containing both GlcUA and IdoUA and binding activities toward various growth factors play important roles in neurogenesis in the early stages of the development of the brain.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Kobe Pharmaceutical University; Kyoto University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BAO X, 2003, SEIKAGAKU, V75, P908; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P747; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; ICHIJO H, 2003, CONNECT TISSUE, V35, P11; Kappler J, 1998, BRAIN RES, V793, P328, DOI 10.1016/S0006-8993(98)00260-1; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; Mikami T, 2003, J BIOL CHEM, V278, P36115, DOI 10.1074/jbc.M306044200; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; SAITO H, 1968, J BIOL CHEM, V243, P1536; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Snow DM, 2003, EXP NEUROL, V182, P310, DOI 10.1016/S0014-4886(03)00034-7; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUGAHARA K, 2002, ANAL TECHNIQUES EVAL, P79; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Tiedemann K, 2001, ARCH BIOCHEM BIOPHYS, V391, P65, DOI 10.1006/abbi.2001.2376; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yoshida K., 1993, DERMATAN SULFATE PRO, P55; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	58	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9765	9776		10.1074/jbc.M310877200	http://dx.doi.org/10.1074/jbc.M310877200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699094	hybrid			2022-12-27	WOS:000220050400015
J	Chabes, AL; Bjorklund, S; Thelander, L				Chabes, AL; Bjorklund, S; Thelander, L			S phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-CYCLE; DNA-DAMAGE; SUBUNIT GENE; IN-VITRO; R1 GENE; NF-Y; PROTEIN; E2F; EXPRESSION	Ribonucleotide reductase is essential for supplying a balanced pool of the four deoxyribonucleotides required for DNA synthesis and repair. The active enzyme consists of two non-identical subunits called proteins R1 and R2. There are multiple levels of regulation of ribonucleotide reductase activity, which is highest during the S and G(2) phases of an unperturbed cell cycle in mammalian cells. Previous reports in the literature have indicated that the S phase-specific transcription of the mammalian R2 gene is regulated by a transcriptional block, is dependent on the transcription factor E2F1, or is simply regulated by proteins that bind to promoter CCAAT boxes plus the TATA box. Here, we demonstrate that the S phase-specific transcription of the mouse R2 gene is dependent on an upstream promoter activating region (located at nucleotides (nt) - 672 to - 527 from the transcription start site) and one proximal promoter repressive element ( located at nt - 112 to - 107) that binds E2F4. Binding to the E2F site is modulated by binding of nuclear factor-Y to an adjacent CCAAT element ( nt - 79 to - 75). The upstream activating region is crucial for overall R2 promoter activity. Mutation of the E2F-binding site leads to premature promoter activation in G(1) and increases overall promoter activity but only when the upstream activating region is present and intact. Therefore, E2F-dependent repression is essential for cell cycle-specific R2 transcription.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Thelander, L (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	Lars.Thelander@medchem.umu.se	Bjørklund, Geir/B-7319-2014	Bjørklund, Geir/0000-0003-2632-3935				BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BRISSENDEN JE, 1988, EXP CELL RES, V174, P302, DOI 10.1016/0014-4827(88)90165-6; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Kotova I, 2003, EUR J BIOCHEM, V270, P1791, DOI 10.1046/j.1432-1033.2003.03541.x; Kotova I, 2001, EUR J BIOCHEM, V268, P4527, DOI 10.1046/j.1432-1327.2001.02378.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Park JB, 2000, BIOCHEM BIOPH RES CO, V267, P651, DOI 10.1006/bbrc.1999.1980; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PAVLOFF N, 1992, J DNA SEQUENCING MAP, V2, P227; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; YANG-FENG T L, 1987, Genomics, V1, P77, DOI 10.1016/0888-7543(87)90108-X; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhou B, 2001, CYTOGENET CELL GENET, V95, P52, DOI 10.1159/000057017	36	73	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10796	10807		10.1074/jbc.M312482200	http://dx.doi.org/10.1074/jbc.M312482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688249	hybrid			2022-12-27	WOS:000220050400135
J	Rezk, BM; Haenen, GRMM; van der Vijgh, WJF; Bast, A				Rezk, BM; Haenen, GRMM; van der Vijgh, WJF; Bast, A			Lipoic acid protects efficiently only against a specific form of peroxynitrite-induced damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOCHLOROUS ACID; GLUTATHIONE DISULFIDE; TYROSINE NITRATION; POTENT INHIBITOR; NITRIC-OXIDE; OXIDATION; INACTIVATION; ALPHA(1)-ANTIPROTEINASE; DERIVATIVES; SUPEROXIDE	The ability of the sulfur-containing compounds glutathione (GSH), glutathione disulphide (GSSG), S-methylglutathione ( GSMe), lipoic acid ( LA), and dihydrolipoic acid ( DHLA) to protect against hypochlorous acid (HOCl)-mediated damage and peroxynitrite (ONOOH)induced damage has been compared. Protective activity was assessed in competition assays by monitoring several detectors, i.e. dihydrorhodamine-123 (DHR-123) oxidation, alpha(1)-antiproteinase (alpha(1)-AP) inactivation, and glutathione S-transferase P1-1 (GST-P1-1) inactivation. In addition, nitration of tyrosine was measured to assess protection of the sulfur-containing compounds against ONOOH. For protection against HOCl, the efficacy of the antioxidant was controlled by the ratio of the reaction rates of the antioxidant and the detector molecule with the oxidant. The rank order of the activity of the antioxidants (GSH > DHLA approximate to LA approximate to GSMe > GSSG) appeared to be independent of the detector used. However, the rank order of the antioxidants against ONOOH-induced damage is strongly dependent on the detector. LA was 40 times less active than GSH in the inhibition of ONOOH-induced DHR-123 oxidation, whereas LA was 20 times more active than GSH in preventing the inhibition of GST-P1-1 by ONOOH. This points to different molecular mechanisms of ONOOH damage to DHR-123 compared with ONOOH damage to GST-P1-1. LA is a poor antioxidant in protecting against the form of ONOOH damage involved in DHR-123 oxidation. In the form of ONOOH toxicity involved in GST-P1-1 inhibition, LA is the most potent sulfur-containing antioxidant in our series. It is proposed that an intermediate product in which both sulfur atoms of LA have reacted is involved in the reaction of ONOOH with LA. The high potency of LA to protect GST-P1-1 against ONOOH might be of therapeutic interest.	Univ Maastricht, Fac Med, Dept Pharmacol & Toxicol, NL-6200 MD Maastricht, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Maastricht University; Vrije Universiteit Amsterdam	Bast, A (corresponding author), Univ Maastricht, Fac Med, Dept Pharmacol & Toxicol, POB 616, NL-6200 MD Maastricht, Netherlands.	a.bast@farmaco.unimaas.nl	Bast, Aalt/I-7809-2013; Haenen, Guido/H-9209-2013	Haenen, Guido/0000-0001-6986-290X; Bast, Aalt/0000-0002-5383-2789				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BIEWENGA GP, 1994, ARCH BIOCHEM BIOPHYS, V312, P114, DOI 10.1006/abbi.1994.1288; Chen HJC, 2003, ARCH BIOCHEM BIOPHYS, V415, P109, DOI 10.1016/S0003-9861(03)00220-0; den Hartog GJM, 2002, TOXICOL APPL PHARM, V181, P228, DOI 10.1006/taap.2002.9419; den Hartog GJM, 2002, BIOL CHEM, V383, P709; EVANS MD, 1994, AM J PHYSIOL, V266, P593; HAENEN GRMM, 1991, BIOCHEM PHARMACOL, V42, P2244, DOI 10.1016/0006-2952(91)90363-A; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Jenner AM, 2002, ARTERIOSCL THROM VAS, V22, P574, DOI 10.1161/01.ATV.0000013785.03265.5C; Kirsch M, 2001, CHEM-EUR J, V7, P3313, DOI 10.1002/1521-3765(20010803)7:15<3313::AID-CHEM3313>3.0.CO;2-7; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Mannervik B, 1981, Methods Enzymol, V77, P231; Nakagawa H, 2000, CHEM PHARM BULL, V48, P261; Priyadarsini KI, 2001, CHEM RES TOXICOL, V14, P567, DOI 10.1021/tx000239t; RADI R, 1991, J BIOL CHEM, V266, P4244; Terentis AC, 2002, CIRC RES, V90, P333, DOI 10.1161/hh0302.104454; Trujillo M, 2002, ARCH BIOCHEM BIOPHYS, V397, P91, DOI 10.1006/abbi.2001.2619; van Haaften RIM, 2001, CHEM-BIOL INTERACT, V138, P77, DOI 10.1016/S0009-2797(01)00262-9; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Whiteman M, 1997, FEBS LETT, V414, P497, DOI 10.1016/S0014-5793(97)01058-2; Whiteman M, 1996, FEBS LETT, V379, P74, DOI 10.1016/0014-5793(95)01489-6; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532	23	31	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9693	9697		10.1074/jbc.M312289200	http://dx.doi.org/10.1074/jbc.M312289200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701855	hybrid			2022-12-27	WOS:000220050400006
J	Ruchira; Hink, MA; Bosgraaf, L; van Haastert, PJM; Visser, AJWG				Ruchira; Hink, MA; Bosgraaf, L; van Haastert, PJM; Visser, AJWG			Pleckstrin homology domain diffusion in Dictyostelium cytoplasm studied using fluorescence correlation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS; FUSION PROTEINS; BINDING; CELLS; LEVEL	The translocation of pleckstrin homology (PH) domain-containing proteins from the cytoplasm to the plasma membrane plays an important role in the chemotaxis mechanism of Dictyostelium cells. The diffusion of three PH domain-green fluorescent protein (GFP) fusions (PH2-GFP, PH10-GFP, and PH-CRAC (cytosolic regulator of adenylyl cyclase)-GFP) in the cytoplasm of vegetative and chemotaxing Dictyostelium cells has been studied using fluorescence correlation spectroscopy to gain a better understanding of the functioning of the domains and to assess the effect of initiation of chemotaxis on these domains in the cell. PH2-GFP was homogeneously distributed in vegetative as well as chemotaxing cells, whereas PH10-GFP and PH-CRAC-GFP showed translocation to the leading edge of the chemotaxing cell. The diffusion characteristics of PH2-GFP and PH-CRAC-GFP were very similar; however, PH10-GFP exhibited slower diffusion. Photon counting histogram statistics show that this slow diffusion was not due to aggregation. Diffusion of the three PH domains was affected to similar extents by intracellular heterogeneities in vegetative as well as chemotaxing cells. From the diffusion of free cytoplasmic GFP, it was calculated that the viscosity in chemotaxing cells was 1.7 times lower than in vegetative cells. In chemotaxing cells, PH2-GFP showed increased mobility, whereas the mobilities of PH10-GFP and PH-CRAC-GFP remained unchanged.	Univ Wageningen & Res Ctr, Biochem Lab, Microspect Ctr, NL-6703 HA Wageningen, Netherlands; Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	Wageningen University & Research; University of Groningen	Ruchira (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Microspect Ctr, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	ru.ruchira@wur.nl	Engel, Ruchira/A-5394-2010	Engel, Ruchira/0000-0002-0630-5767				Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Brock R, 2001, SPRINGER SERIES CHEM, V65, P132; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Dittrich P, 2001, BIOL CHEM, V382, P491, DOI 10.1515/BC.2001.061; Eid JS, 2000, REV SCI INSTRUM, V71, P361, DOI 10.1063/1.1150208; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hink MA, 2003, METHOD ENZYMOL, V361, P93; Hink MA, 1999, LANGMUIR, V15, P992, DOI 10.1021/la980949n; Hirata M, 1998, JPN J PHARMACOL, V76, P255, DOI 10.1254/jjp.76.255; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LUBYPHELPS K, 1986, J CELL BIOL, V102, P2015, DOI 10.1083/jcb.102.6.2015; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Muller JD, 2000, BIOPHYS J, V78, P474, DOI 10.1016/S0006-3495(00)76610-0; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Potma EO, 2001, BIOPHYS J, V81, P2010, DOI 10.1016/S0006-3495(01)75851-1; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692	22	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10013	10019		10.1074/jbc.M310039200	http://dx.doi.org/10.1074/jbc.M310039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699152	hybrid, Green Published			2022-12-27	WOS:000220050400045
J	Sunters, A; Thomas, DP; Yeudall, WA; Grigoriadis, AE				Sunters, A; Thomas, DP; Yeudall, WA; Grigoriadis, AE			Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene - Induction of cyclin A and enhanced CDK2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-2; INDUCED OSTEOSARCOMA FORMATION; S-PHASE; NEGATIVE REGULATORS; PROTEIN EXPRESSION; TRANSGENIC MICE; GENE-EXPRESSION; BONE-FORMATION; UP-REGULATION; JUN	Transgenic mice overexpressing the c-Fos oncoprotein develop osteosarcomas that are associated with deregulated expression of cell cycle genes. Here we have generated osteoblast cell lines expressing c-fos under the control of a tetracycline-regulatable promoter to investigate the role of c-Fos in osteoblast cell cycle control in vitro. Three stable subclones, AT9.2, AT9.3, and AT9.7, derived from MC3T3-E1 mouse osteoblasts, expressed high levels of exogenous c-fos mRNA and protein in the absence of tetracycline. Functional contribution of ectopic c-Fos to AP-1 complexes was confirmed by electromobility shift assays and transactivation of AP-1 reporter constructs. Induction of exogenous c-Fos in quiescent AT9.2 cells caused accelerated S-phase entry following serum stimulation, resulting in enhanced growth rate. Ectopic c-Fos resulted in increased expression of cyclins A and E protein levels, and premature activation of cyclin A-, cyclin E-, and cyclin-dependent kinase (CDK) 2-associated kinase activities, although cyclin D levels and CDK4 activity were not affected significantly in these cell lines. The enhanced CDK2 kinase activity was associated with a rapid, concomitant dissociation of p27 from CDK2-containing complexes. Deregulated cyclin A expression and CDK2 activity was also observed in primary mouse osteoblasts overexpressing c-Fos, but not in fibroblasts, and c-Fos transgenic tumor-derived osteosarcoma cells constitutively expressed high levels of cyclin A protein. These data suggest that overexpression of c-Fos in osteoblasts results in accelerated S phase entry as a result of deregulated cyclin A/E-CDK2 activity. This represents a novel role for c-Fos in osteoblast growth control and may provide c-Fos-overexpressing osteoblasts with a growth advantage during tumorigenesis.	Univ London Kings Coll, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England; Univ London Kings Coll, Guys Hosp, Dept Orthodont, London SE1 9RT, England; Virginia Commonwealth Univ, Philips Inst Oral & Craniofacial Mol Biol, Richmond, VA 23298 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Virginia Commonwealth University	Grigoriadis, AE (corresponding author), Univ London Kings Coll, Guys Hosp, Dept Craniofacial Dev, Guys Tower,Floor 28,London Bridge, London SE1 9RT, England.	agrigori@hgmp.mrc.ac.uk						ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BALSALOBRE A, 1995, ONCOGENE, V11, P455; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Bellows CG, 1998, BONE, V23, P119, DOI 10.1016/S8756-3282(98)00084-2; Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Crowe David L., 2000, Molecular Cell Biology Research Communications, V3, P243, DOI 10.1006/mcbr.2000.0221; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Drissi H, 1999, CANCER RES, V59, P3705; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kobayashi K, 1997, J IMMUNOL, V158, P2050; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Longhi A, 2001, ONCOL REP, V8, P131; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nielsen GP, 1998, AM J PATHOL, V153, P159, DOI 10.1016/S0002-9440(10)65556-3; OCONNOR PM, 1991, CANCER RES, V51, P6550; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; SMITH E, 1995, CANCER RES, V55, P5019; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Thomas DP, 2000, J CELL SCI, V113, P439; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; WIMMEL A, 1994, ONCOGENE, V9, P995; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	72	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9882	9891		10.1074/jbc.M310184200	http://dx.doi.org/10.1074/jbc.M310184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699150	hybrid			2022-12-27	WOS:000220050400028
J	Zsembery, A; Fortenberry, JA; Liang, LH; Bebok, Z; Tucker, TA; Boyce, AT; Braunstein, GM; Welty, E; Bell, PD; Sorscher, EJ; Clancy, JP; Schwiebert, EM				Zsembery, A; Fortenberry, JA; Liang, LH; Bebok, Z; Tucker, TA; Boyce, AT; Braunstein, GM; Welty, E; Bell, PD; Sorscher, EJ; Clancy, JP; Schwiebert, EM			Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CHANNELS; CYTOSOLIC CA2+; SURFACE LIQUID; COMMON COLD; RELEASE; TRANSPORT; MEMBRANE; CONDUCTANCE; VOLUME; DESENSITIZATION	Cystic fibrosis (CF) is caused by defective cyclic AMP-dependent cystic fibrosis transmembrane conductance regulator Cl- channels. Thus, CF epithelia fail to transport Cl- and water. A postulated therapeutic avenue in CF is activation of alternative Ca2+- dependent Cl- channels. We hypothesized that stimulation of Ca2+ entry from the extracellular space could trigger a sustained Ca2+ signal to activate Ca2+-dependent Cl- channels. Cytosolic [Ca2+](i) was measured in non-polarized human CF (IB3-1) and non-CF (16HBE14o(-)) airway epithelial cells. Primary human CF and non-CF airway epithelial monolayers as well as Calu-3 monolayers were used to assess anion secretion. In vivo nasal potential difference measurements were performed in non-CF and two different CF mouse (DeltaF508 homozygous and bitransgenic gut-corrected but lung-null) models. Zinc and ATP induced a sustained, reversible, and reproducible increase in cytosolic Ca2+ in CF and non-CF cells with chemistry and pharmacology most consistent with activation of P2X purinergic receptor channels. P2X purinergic receptor channel-mediated Ca2+ entry stimulated sustained Cl- and HCO3- secretion in CF and non-CF epithelial monolayers. In non-CF mice, zinc and ATP induced a significant Cl- secretory response similar to the effects of agonists that increase intracellular cAMP levels. More importantly, in both CF mouse models, Cl- permeability of nasal epithelia was restored in a sustained manner by zinc and ATP. These effects were reversible and reacquirable upon removal and readdition of agonists. Our data suggest that activation of P2X calcium entry channels may have profound therapeutic benefit for CF that is independent of cystic fibrosis transmembrane conductance regulator genotype.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Hungarian Acad Sci, H-1089 Budapest, Hungary; Semmelweis Univ, Nephrol Res Grp, H-1089 Budapest, Hungary	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Hungarian Academy of Sciences; Semmelweis University	Zsembery, A (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 740,1918 Univ Blvd, Birmingham, AL 35294 USA.	zsembery@physiology.uab.edu; eschwiebert@physiology.uab.edu		Tucker, Torry/0000-0002-0823-3234; Sorscher, Eric J./0000-0001-9341-3354	NHLBI NIH HHS [R01 HL63934] Funding Source: Medline; NIDDK NIH HHS [DK 54367, DK62397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnon A, 2000, AM J PHYSIOL-CELL PH, V278, pC163, DOI 10.1152/ajpcell.2000.278.1.C163; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Brady KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1173, DOI 10.1152/ajplung.2001.281.5.L1173; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Brewer GJ, 1999, J LAB CLIN MED, V134, P322, DOI 10.1016/S0022-2143(99)90213-5; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; Colvin RA, 1998, NEUROREPORT, V9, P3091, DOI 10.1097/00001756-199809140-00032; Cuthbert AW, 2003, J PHYSIOL-LONDON, V551, P79, DOI 10.1113/jphysiol.2003.046482; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; ESCHENBACHER WL, 1991, AM REV RESPIR DIS, V143, P341, DOI 10.1164/ajrccm/143.2.341; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; Fuller CM, 2000, NEWS PHYSIOL SCI, V15, P165; Gabriel SE, 2000, J BIOL CHEM, V275, P35028, DOI 10.1074/jbc.M004953200; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; Haidl P, 2000, EUR RESPIR J, V16, P1102, DOI 10.1034/j.1399-3003.2000.16f14.x; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Hogstrand C, 1999, TOXICOLOGY, V133, P139, DOI 10.1016/S0300-483X(99)00020-7; Jan CR, 1999, N-S ARCH PHARMACOL, V360, P249, DOI 10.1007/s002109900055; Kellerman D, 2002, ADV DRUG DELIVER REV, V54, P1463, DOI 10.1016/S0169-409X(02)00154-0; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Krebs NF, 2000, PEDIATR RES, V48, P256, DOI 10.1203/00006450-200008000-00022; Kunzelmann K, 2001, CLIN EXP PHARMACOL P, V28, P857, DOI 10.1046/j.1440-1681.2001.03541.x; Lansley AB, 1999, BIOPHYS J, V77, P629, DOI 10.1016/S0006-3495(99)76919-5; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; McNulty TJ, 1999, BIOCHEM J, V339, P555, DOI 10.1042/0264-6021:3390555; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; Mossad SB, 2003, QJM-INT J MED, V96, P35, DOI 10.1093/qjmed/hcg004; Negulyaev YA, 2000, NEUROSCI LETT, V279, P165, DOI 10.1016/S0304-3940(99)00976-3; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Novick SG, 1997, MED HYPOTHESES, V49, P347, DOI 10.1016/S0306-9877(97)90201-2; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; Rychkov G, 2001, HEPATOLOGY, V33, P938, DOI 10.1053/jhep.2001.23051; Tarran R, 2002, J GEN PHYSIOL, V120, P407, DOI 10.1085/jgp.20028599; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Truong-Tran AQ, 2001, IMMUNOL CELL BIOL, V79, P170, DOI 10.1046/j.1440-1711.2001.00986.x; Tucker TA, 2003, AM J PHYSIOL-CELL PH, V284, pC791, DOI 10.1152/ajpcell.00435.2002; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; Vennekens R, 2001, PFLUG ARCH EUR J PHY, V442, P237, DOI 10.1007/s004240100517; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Widdicombe JH, 2002, AM J RESP CRIT CARE, V165, P1566, DOI 10.1164/ajrccm.165.11.165111; WILEY JS, 1989, BLOOD, V73, P1316; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zsembery A, 2003, J BIOL CHEM, V278, P13398, DOI 10.1074/jbc.M212277200	58	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10720	10729		10.1074/jbc.M313391200	http://dx.doi.org/10.1074/jbc.M313391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701827	hybrid			2022-12-27	WOS:000220050400127
J	Pan, F; Ye, ZH; Cheng, LZ; Liu, JO				Pan, F; Ye, ZH; Cheng, LZ; Liu, JO			Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes - A calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT).	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; HISTONE DEACETYLASES; LENTIVIRAL VECTORS; CYCLOSPORINE-A; FACTOR MEF2; EXPRESSION; APOPTOSIS; CYCLOPHILIN; DIFFERENTIATION; ASSOCIATION	The second messenger calcium plays an essential role in the T cell receptor-mediated signal transduction pathways leading to transcription of the interleukin-2 gene. A key mechanism of calcium signaling has been shown to be mediated by calcineurin and NFAT. We report herein that the transcription factor myocyte enhancer factor (MEF)-2 is another calcium signal transducer involved in the regulation of the interleukin (IL)-2 promoter. A MEF2-binding site was identified in proximity to the TATA box of the IL-2 promoter. This site was shown to be bound by MEF2 in both resting and activated T cells. Overexpression of MEF2 enhanced, while overexpression of a dominant negative form of MEF2 or the MEF2-specific transcriptional corepressors Cabin1 and histone deacetylase 4 inhibited, the T cell receptor-dependent activation of an IL-2 reporter gene. Down-regulation of MEF2 by RNA interference in primary human T cells led to the inhibition of endogenous IL-2 transcription. These results suggest that MEF2 is required for the transcriptional activation of IL-2 and likely other cytokine genes in response to calcium signaling and may serve as a novel target for development of immunosuppressants.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Div Immunol & Hematopoiesis, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Liu, JO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Hunterian Bldg,Rm 516,725 N Wolfe St, Baltimore, MD 21205 USA.	joliu@jhu.edu		Ye, Zhaohui/0000-0001-5272-9168	NIGMS NIH HHS [GM55783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cavalieri S, 2003, BLOOD, V102, P497, DOI 10.1182/blood-2003-01-0297; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cui Y, 2002, BLOOD, V99, P399, DOI 10.1182/blood.V99.2.399; Esau C, 2001, J EXP MED, V194, P1449, DOI 10.1084/jem.194.10.1449; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhou XZ, 2003, HUM GENE THER, V14, P1089, DOI 10.1089/104303403322124800	34	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14477	14480		10.1074/jbc.C300487200	http://dx.doi.org/10.1074/jbc.C300487200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722108	hybrid			2022-12-27	WOS:000220594700002
J	Tsujita, K; Itoh, T; Ijuin, T; Yamamoto, A; Shisheva, A; Laporte, J; Takenawa, T				Tsujita, K; Itoh, T; Ijuin, T; Yamamoto, A; Shisheva, A; Laporte, J; Takenawa, T			Myotubularin regulates the function of the late endosome through the GRAM domain-phosphatidylinositol 3,5-bisphosphate interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; HIGH-AFFINITY BINDING; INOSITOL PHOSPHATES; PROTEIN-KINASE; MUTATIONS; GENE; MYOPATHY; PHOSPHOINOSITIDES; PTDINS(3,5)P-2; 3-PHOSPHATE	Myotubularin and related proteins constitute a large and highly conserved family possessing phosphoinositide 3-phosphatase activity, although not all members possess this activity. This family contains a conserved region called the GRAM domain that is found in a variety of proteins associated with membrane-coupled processes and signal transduction. Mutations of myotubularin are found in X-linked myotubular myopathy, a severe muscle disease. Mutations in the GRAM domain are responsible for this condition, suggesting crucial roles for this region. Here, we show that the GRAM domain of myotubularin binds to phosphoinositide with the highest affinity to phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5) P-2). In patients with myotubular myopathy, mutations in the myotubularin GRAM domain eliminate this binding, indicating that the PtdIns(3,5) P-2 binding ability of the GRAM (glucosyltransferases, Rab-like GTPase activators and myotubularin) domain is crucial for the functions of myotubularin in vivo. Stimulation of epidermal growth factor recruits myotubularin to the late endosomal compartment in a manner dependent on the phosphoinositide binding. Overexpression of myotubularin inhibits epidermal growth factor receptor trafficking from late endosome to lysosome and induces the large endosomal vacuoles. Thus, our data suggest that myotubularin phosphatase physiologically functions in late endosomal trafficking and vacuolar morphology through interaction with PtdIns(3,5) P-2.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; JST, Minato Ku, Tokyo 1088639, Japan; Nagahama Inst Biosci & Technol, Dept Biosci, Tamura, Nagahama 5260829, Japan; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Inst Genet & Biol Mol & Cellulaire, Equipe Genet Humaine, F-67404 Illkirch Graffenstaden, France	University of Tokyo; Japan Science & Technology Agency (JST); Wayne State University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Laporte, Jocelyn/H-6801-2016; Ijuin, Takeshi/H-7016-2017; laporte, jocelyn/J-7008-2012; laporte, jocelyn/O-4888-2019	Ijuin, Takeshi/0000-0002-0618-1776; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-58058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; deGouyon BM, 1997, HUM MOL GENET, V6, P1499, DOI 10.1093/hmg/6.9.1499; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Friant S, 2003, DEV CELL, V5, P499, DOI 10.1016/S1534-5807(03)00238-7; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Herman GE, 2002, HUM MUTAT, V19, P114, DOI 10.1002/humu.10033; Ikonomov OC, 2002, J BIOL CHEM, V277, P46785, DOI 10.1074/jbc.M208068200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Laporte J, 1997, HUM MOL GENET, V6, P1505, DOI 10.1093/hmg/6.9.1505; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Laporte J, 2001, TRENDS GENET, V17, P221, DOI 10.1016/S0168-9525(01)02245-4; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stenmark H, 2001, SEMIN CELL DEV BIOL, V12, P193, DOI 10.1006/scdb.2000.0236; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	34	118	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13817	13824		10.1074/jbc.M312294200	http://dx.doi.org/10.1074/jbc.M312294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722070	hybrid			2022-12-27	WOS:000220478500067
J	Charles, N; Monteiro, RC; Benhamou, M				Charles, N; Monteiro, RC; Benhamou, M			p28, a novel IgE receptor-associated protein, is a sensor of receptor occupation by its ligand in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID SCRAMBLASE; IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; UP-REGULATION; GAMMA-CHAIN; BINDING	Mast cells express the high affinity receptor for IgE (FcepsilonRI). Aggregation of this receptor by IgE and antigen leads to a signaling cascade resulting in the secretion of histamine, in the synthesis of other pro-inflammatory mediators such as leukotrienes and prostaglandins, and in the production of various cytokines, all of which participate in the development of the allergic reaction. In the last years, growing evidence accumulated that binding of IgEs to FcepsilonRI in itself induces active signals leading to mast cell survival, increased expression of FcepsilonRI, transient induction of histidine decarboxylase synthesis, and increased cell adhesion. The mechanisms underlying monomeric IgE signaling in the absence of receptor aggregation are still poorly understood. Here, we show that a protein of 28 kDa (p28) is physically and constitutively associated with FcepsilonRI in mast cells. Coimmunoprecipitation studies from I-125 surface-labeled cells demonstrated that this association involves at least 50% of membrane-expressed FcepsilonRI. After the addition of monomeric IgE to the cells, the p28.FcepsilonRI complex dissociates almost completely in less than 2 min. This dissociation is temperature-sensitive and is not due to the recruitment of additional proteins to the complex. Stripping bound IgE from the cells by acidic treatment promotes a rapid reassociation between p28 and FcepsilonRI. Altogether, these data are consistent with a conformational regulation of the complex. Thus, p28 is a sensor for FcepsilonRI occupation by IgE on mast cells, and its dissociation from the receptor could represent an early step of monomeric IgE signaling.	Fac Xavier Bichat, INSERM, EMI0225, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benhamou, M (corresponding author), Fac Xavier Bichat, INSERM, EMI0225, 16 Rue Henri Huchard, F-75870 Paris 18, France.	benhamou@bichat.inserm.fr	Monteiro, Renato C/U-8633-2017; CHARLES, Nicolas/P-5430-2014; CHARLES, Nicolas/S-2214-2019	Monteiro, Renato C/0000-0001-5202-5646; CHARLES, Nicolas/0000-0002-5416-5834; CHARLES, Nicolas/0000-0002-5416-5834; Benhamou, Marc/0000-0001-7763-3795				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; EISEMAN E, 1992, NATURE, V355, P78; FRANDJI P, 1995, CELL IMMUNOL, V163, P37, DOI 10.1006/cimm.1995.1096; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Garman SC, 2001, J MOL BIOL, V311, P1049, DOI 10.1006/jmbi.2001.4929; GERMANO P, 1994, J BIOL CHEM, V269, P23102; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISERSKY C, 1979, J IMMUNOL, V122, P1926; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1997, J IMMUNOL, V159, P4426; Kubo S, 2001, J IMMUNOL, V167, P3427, DOI 10.4049/jimmunol.167.6.3427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam V, 2003, BLOOD, V102, P1405, DOI 10.1182/blood-2002-10-3176; LIU FT, 1980, J IMMUNOL, V124, P2728; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Mecheri S, 1997, IMMUNOL TODAY, V18, P212; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Nadler M J, 2000, Adv Immunol, V76, P325; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pastorelli C, 2002, MOL IMMUNOL, V38, P1235, DOI 10.1016/S0161-5890(02)00069-X; Pastorelli C, 2001, J BIOL CHEM, V276, P20407, DOI 10.1074/jbc.M100790200; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Tkaczyk C, 2000, J ALLERGY CLIN IMMUN, V105, P134, DOI 10.1016/S0091-6749(00)90188-X; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yano K, 1997, LAB INVEST, V77, P185	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12312	12318		10.1074/jbc.M309456200	http://dx.doi.org/10.1074/jbc.M309456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715661	hybrid			2022-12-27	WOS:000220334900038
J	Forouhar, F; Lee, I; Benach, J; Kulkarni, K; Xiao, R; Acton, TB; Montelione, GT; Tong, L				Forouhar, F; Lee, I; Benach, J; Kulkarni, K; Xiao, R; Acton, TB; Montelione, GT; Tong, L			A novel NAD-binding protein revealed by the crystal structure of 2,3-diketo-L-gulonate reductase (YiaK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CARBOHYDRATE UTILIZATION; PROGRAM; DIFFRACTION; METABOLISM; EXPRESSION; SEQUENCE; OPERON; ACID; SITE	Escherichia coli YiaK catalyzes the reduction of 2,3-diketo-L-gulonate in the presence of NADH. It belongs to a large family of oxidoreductases that is conserved in archaea, bacteria, and eukaryotes but shows no sequence homology to other proteins. We report here the crystal structures at up to 2.0-Angstrom resolution of YiaK alone and in complex with NAD-tartrate. YiaK has a new polypeptide backbone fold and a novel mode of recognizing the NAD cofactor. In addition, NAD is bound in an unusual conformation, at the interface of a dimer of the enzyme. The crystallographic analysis unexpectedly revealed the binding of tartrate in the active site. Enzyme kinetics studies confirm that tartrate and the related D-malate are inhibitors of YiaK. In contrast to most other enzymes where substrate binding produces a more closed conformation, the binding of NAD-tartrate to YiaK produces a more open active site. The free enzyme conformation is incompatible with NAD binding. His(44) is likely the catalytic residue of the enzyme.	Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, NE Struct Genom Consortium, Piscataway, NJ 08854 USA	Columbia University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA.	tong@como.bio.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059; Tong, Liang/0000-0002-0563-6468	NIGMS NIH HHS [P50 GM 62413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badia J, 1998, J BIOL CHEM, V273, P8376, DOI 10.1074/jbc.273.14.8376; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ibanez E, 2000, J BACTERIOL, V182, P4617, DOI 10.1128/JB.182.16.4617-4624.2000; Ibanez E, 2000, J BACTERIOL, V182, P4625, DOI 10.1128/JB.182.16.4625-4627.2000; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Saridakis V, 2003, J BIOL CHEM, V278, P34356, DOI 10.1074/jbc.M205369200; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLK WA, 1962, J BIOL CHEM, V237, P2454; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Yew WS, 2002, J BACTERIOL, V184, P302, DOI 10.1128/JB.184.1.302-306.2002	25	9	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13148	13155		10.1074/jbc.M313580200	http://dx.doi.org/10.1074/jbc.M313580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718529	hybrid			2022-12-27	WOS:000220334900136
J	Gaertner, TR; Kolodziej, SJ; Wang, D; Kobayashi, R; Koomen, JM; Stoops, JK; Waxham, MN				Gaertner, TR; Kolodziej, SJ; Wang, D; Kobayashi, R; Koomen, JM; Stoops, JK; Waxham, MN			Comparative analyses of the three-dimensional structures and enzymatic properties of alpha, beta, gamma, and delta Isoforms of Ca2+-calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; ELECTRON-MICROSCOPY; CA2+ OSCILLATIONS; RAT-BRAIN; CALMODULIN; EXPRESSION; IDENTIFICATION; SUBUNIT; FREQUENCY; DOMAINS	Ca2+-calmodulin-dependent protein kinase II (CaM-kinase II) is a ubiquitous Ser/Thr-directed protein kinase that is expressed from a family of four genes (alpha, beta, gamma, and delta) in mammalian cells. We have documented the three-dimensional structures and the biophysical and enzymatic properties of the four gene products. Biophysical analyses showed that each isoform assembles into oligomeric forms and their three-dimensional structures at 21 - 25 Angstrom revealed that all four isoforms were dodecamers with similar but highly unusual architecture. A gear-shaped core comprising the association domain has the catalytic domains tethered on appendages, six of which extend from both ends of the core. At this level of resolution, we can discern no isoform-dependent differences in ultrastructure of the holoenzymes. Enzymatic analyses showed that the isoforms were similar in their K-m for ATP and the peptide substrate syntide, but showed significant differences in their interactions with Ca2+-calmodulin as assessed by binding, substrate phosphorylation, and autophosphorylation. Interestingly, the rank order of CaM binding affinity (gamma > beta > delta > alpha) does not directly correlate with the rank order of their CaM dependence for autophosphorylation (beta > gamma > delta > alpha). Simulations utilizing this data revealed that the measured differences in CaM binding affinities play a minor role in the autophosphorylation of the enzyme, which is largely dictated by the rate of autophosphorylation for each isoform.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System; UTMD Anderson Cancer Center	Waxham, MN (corresponding author), 6431 Fannin St, Houston, TX 77030 USA.	m.n.waxham@uth.tmc.edu	Koomen, John/D-1844-2013	Waxham, M. Neal/0000-0003-4801-1190	NINDS NIH HHS [NS 26086] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS026086, R01NS026086] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayer KU, 1999, MOL BRAIN RES, V70, P147, DOI 10.1016/S0169-328X(99)00131-X; Bayer KU, 2002, EMBO J, V21, P3590, DOI 10.1093/emboj/cdf360; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; Bradshaw JM, 2002, J BIOL CHEM, V277, P20991, DOI 10.1074/jbc.M202154200; Brocke L, 1999, J BIOL CHEM, V274, P22713, DOI 10.1074/jbc.274.32.22713; Caran N, 2001, J BIOL CHEM, V276, P42514, DOI 10.1074/jbc.M103013200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Dosemeci A, 1999, BIOCHEM BIOPH RES CO, V263, P657, DOI 10.1006/bbrc.1999.1433; Dupont G, 2003, CELL CALCIUM, V34, P485, DOI 10.1016/S0143-4160(03)00152-0; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; Hoelz A, 2003, MOL CELL, V11, P1241, DOI 10.1016/S1097-2765(03)00171-0; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; Kolodziej SJ, 2000, J BIOL CHEM, V275, P14354, DOI 10.1074/jbc.275.19.14354; Kwiatkowski AP, 2000, ARCH BIOCHEM BIOPHYS, V378, P377, DOI 10.1006/abbi.2000.1846; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; Morris EP, 2001, J MOL BIOL, V308, P1, DOI 10.1006/jmbi.2001.4584; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Singer HA, 1997, J BIOL CHEM, V272, P9393; TAKAISHI T, 1992, J NEUROCHEM, V58, P1971, DOI 10.1111/j.1471-4159.1992.tb10079.x; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x; Wu XL, 2001, J BIOL CHEM, V276, P1735, DOI 10.1074/jbc.M006727200; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951; ZHOU ZHL, 1994, BIOCHEM J, V299, P489, DOI 10.1042/bj2990489; ZHOU ZHL, 1995, BIOCHEM J, V310, P517, DOI 10.1042/bj3100517	43	136	141	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12484	12494		10.1074/jbc.M313597200	http://dx.doi.org/10.1074/jbc.M313597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722083	hybrid			2022-12-27	WOS:000220334900059
J	Wernimont, AK; Yatsunyk, LA; Rosenzweig, AC				Wernimont, AK; Yatsunyk, LA; Rosenzweig, AC			Binding of copper(I) by the Wilson disease protein and its copper chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; TRANSPORTING ATPASE ATP7B; P-TYPE ATPASES; MENKES-DISEASE; SACCHAROMYCES-CEREVISIAE; ATX1 METALLOCHAPERONE; FUNCTIONAL EXPRESSION; SUPEROXIDE-DISMUTASE; CATALYTIC-ACTIVITY; GENE	The Wilson disease protein (WND) is a transport ATPase involved in copper delivery to the secretory pathway. Mutations in WND and its homolog, the Menkes protein, lead to genetic disorders of copper metabolism. The WND and Menkes proteins are distinguished from other P-type ATPases by the presence of six soluble N-terminal metal-binding domains containing a conserved CXXC metal-binding motif. The exact roles of these domains are not well established, but possible functions include exchanging copper with the metallochaperone Atox1 and mediating copper-responsive cellular relocalization. Although all six domains can bind copper, genetic and biochemical studies indicate that the domains are not functionally equivalent. One way the domains could be tuned to perform different functions is by having different affinities for Cu(I). We have used isothermal titration calorimetry to measure the association constant (K-a) and stoichiometry (n) values of Cu(I) binding to the WND metal-binding domains and to their metallochaperone Atox1. The association constants for both the chaperone and target domains are similar to10(5) to 10(6) M-1, suggesting that the handling of copper by Atox1 and copper transfer between Atox1 and WND are under kinetic rather than thermodynamic control. Although some differences in both n and K-a values are observed for variant proteins containing less than the full complement of six metal-binding domains, the data for domains 1-6 were best fitted with a single site model. Thus, the individual functions of the six WND metal-binding domains are not conferred by different Cu(I) affinities but instead by fold and electrostatic surface properties.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu			NIGMS NIH HHS [GM 008061, GM 58518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; DASILVA JJR, 2001, BIOL CHEM ELEMENTS, P431; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Elam JS, 2002, ADV PROTEIN CHEM, V60, P151; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HIROSE J, 1982, ARCH BIOCHEM BIOPHYS, V218, P179, DOI 10.1016/0003-9861(82)90334-4; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Jensen PY, 1999, BBA-PROTEIN STRUCT M, V1434, P103, DOI 10.1016/S0167-4838(99)00161-2; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; OBRIEN R, 2001, PROTEIN LIGAND INTER, P263; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ralle M, 2003, J BIOL CHEM, V278, P23163, DOI 10.1074/jbc.M303474200; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; SYVERTSEN C, 1986, J INORG BIOCHEM, V26, P63, DOI 10.1016/0162-0134(86)80037-X; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	48	70	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12269	12276		10.1074/jbc.M311213200	http://dx.doi.org/10.1074/jbc.M311213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709553	hybrid			2022-12-27	WOS:000220334900033
J	Davidson, L; Pawson, AJ; de Maturana, RL; Freestone, SH; Barran, P; Millar, RP; Maudsley, S				Davidson, L; Pawson, AJ; de Maturana, RL; Freestone, SH; Barran, P; Millar, RP; Maudsley, S			Gonadotropin-releasing hormone-induced activation of diacylglycerol kinase-zeta and its association with active c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHOLIPASE-C; PHORBOL ESTER; SH3 DOMAIN; CELLS; ACID; BINDING; TRANSLOCATION; INHIBITION; MECHANISM	Gonadotropin-releasing hormone (GnRH)-induced receptor activation has been demonstrated to entrain a wide variety of signaling modalities. Most signaling pathways are concerned with the control of serine, threonine, or tyrosine-protein kinases, however, in the current article we demonstrate that in both a model cell line and in gonadotropes, GnRH additionally mediates the activation of lipid-directed kinases. We have shown that there is a functional connection between protein-tyrosine kinase modulation and lipid kinase activation. In HEK293 cells stably expressing the Type I mammalian GnRH receptor, we employed a proteomic approach to identify novel protein binding partners for GnRH-activated c-Src. Using matrix-assisted laser desorption ionization time-of-flight mass spectrometry we identified a GnRH-induced association between c-Src and the lipid kinase, diacylglycerol kinase-zeta (DGK-zeta). Using reciprocal co-immunoprecipitation we show that there is a significant elevation of the association between catalytically active c-Src with DGK-zeta in both HEK293 cells and murine gonadotrope LbetaT2 cells. Employing lipid kinase assays we have shown that the catalytic activity of DGK-zeta is significantly heightened in both HEK293 and LbetaT2 cells by GnRH. In addition, we demonstrate that the activation of DGK-zeta exerts a functional role in the murine gonadotrope LbetaT2 cell line. Elevated expression of DGK-zeta resulted in a shortening of the time scale of ERK activation in these cells suggesting a potential role of endogenous DGK-zeta in controlling the induction of LHbeta transcription by ERK1/2.	Univ Edinburgh, Royal Infirm Edinburgh, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Ardana Biosci, Edinburgh EH2 3NS, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Maudsley, S (corresponding author), Univ Edinburgh, Royal Infirm Edinburgh, MRC, Human Reprod Sci Unit, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	s.maudsley@hrsu.mrc.ac.uk	Millar, Robert P/A-4853-2012; Maudsley, Stuart/Q-4782-2019; Barran, Perdita/AAY-6303-2021; Pawson, Adam J/Q-5678-2016; Maudsley, Stuart/AAV-9929-2021	Pawson, Adam J/0000-0003-2280-845X; Maudsley, Stuart/0000-0002-1868-184X; Millar, Robert P/0000-0003-3606-2708	Medical Research Council [U.1276.00.005.00002.01 (85842), MC_U127685842] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON L, 1995, ENDOCRINOLOGY, V136, P5228, DOI 10.1210/en.136.11.5228; ARNOLD S, 1998, BIOCHEMISTRY-US, V37, P14683; Badola P, 1997, J BIOL CHEM, V272, P24176, DOI 10.1074/jbc.272.39.24176; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; CHOI KY, 1994, CELL, V78, P499; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; Ebinu JO, 2000, BLOOD, V95, P3199; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fukami Y, 2002, PHARMACOL THERAPEUT, V93, P263, DOI 10.1016/S0163-7258(02)00195-X; HARDEN N, 1993, BIOCHEM J, V289, P439, DOI 10.1042/bj2890439; Harris BZ, 2001, J CELL SCI, V114, P3219; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee S, 2003, MOL CELLS, V15, P313; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; OHANIAN J, 1994, BIOCHEM J, V300, P51, DOI 10.1042/bj3000051; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; Schnapp BJ, 2003, J CELL SCI, V116, P2125, DOI 10.1242/jcs.00488; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; SUDOL M, 1993, ONCOGENE, V8, P823; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tsuganezawa H, 2002, KIDNEY INT, V62, P41, DOI 10.1046/j.1523-1755.2002.00418.x; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200	41	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11906	11916		10.1074/jbc.M310784200	http://dx.doi.org/10.1074/jbc.M310784200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707140	hybrid			2022-12-27	WOS:000220157600128
J	Hambrock, HO; Kaufmann, B; Muller, S; Hanisch, FG; Nose, K; Paulsson, M; Maurer, P; Hartmann, U				Hambrock, HO; Kaufmann, B; Muller, S; Hanisch, FG; Nose, K; Paulsson, M; Maurer, P; Hartmann, U			Structural characterization of TSC-36/Flik - Analysis of two charge isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLISTATIN-RELATED PROTEIN; CALCIUM-BINDING PROTEIN; MOLECULAR-CLONING; COLLAGEN-IV; BM-40 SPARC; GENE; EXPRESSION; OSTEONECTIN; TRANSCRIPTION; RECOMBINANT	Recombinant forms of the glycoprotein TSC-36/Flik were expressed in human cells and used to compare their structural and functional properties with those described for other members of the BM-40/SPARC/osteonectin protein family. TSC-36 was found to occur in two charge isoforms that differ in the extent of sialylation of otherwise identical N-linked, complex type oligosaccharides. Conformational analysis with both circular dichroism and intrinsic fluorescence spectroscopy showed a lack of significant structural changes upon calcium addition or depletion. This finding is in contrast to results obtained for several other BM-40 family members and indicates that the extracellular calcium-binding domain in TSC-36 is non-functional. The lack of conservation of important functional features common to several other members of the BM-40 family indicates that TSC-36, despite its sequence homology to BM-40, has evolved clearly distinct properties.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Tokyo 1428555, Japan	University of Cologne; University of Cologne; Showa University	Hartmann, U (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	ursula.hartmann@uni-koeln.de						ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; Amthor H, 1996, DEV BIOL, V178, P343, DOI 10.1006/dbio.1996.0223; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Hambrock HO, 2003, J BIOL CHEM, V278, P11351, DOI 10.1074/jbc.M212291200; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; Maurer P, 1997, CELL MOL LIFE SCI, V53, P478, DOI 10.1007/s000180050059; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; Nakada M, 2001, CANCER RES, V61, P8896; Okabayashi K, 1999, BIOCHEM BIOPH RES CO, V254, P42, DOI 10.1006/bbrc.1998.9892; Patel K, 1996, DEV BIOL, V178, P327, DOI 10.1006/dbio.1996.0222; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Tochitani S, 2001, EUR J NEUROSCI, V13, P297, DOI 10.1046/j.0953-816X.2000.01390.x; Towers P, 1999, DEV BIOL, V214, P298, DOI 10.1006/dbio.1999.9421; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Vannahme C, 2002, J BIOL CHEM, V277, P37977, DOI 10.1074/jbc.M203830200; Vannahme C, 1999, J NEUROCHEM, V73, P12, DOI 10.1046/j.1471-4159.1999.0730012.x; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	32	63	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11727	11735		10.1074/jbc.M309318200	http://dx.doi.org/10.1074/jbc.M309318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701841	hybrid			2022-12-27	WOS:000220157600109
J	Chu, X; Tong, Q; Cheung, JY; Wozney, J; Conrad, K; Mazack, V; Zhang, WY; Stahl, R; Barber, DL; Miller, BA				Chu, X; Tong, Q; Cheung, JY; Wozney, J; Conrad, K; Mazack, V; Zhang, WY; Stahl, R; Barber, DL; Miller, BA			Interaction of TRPC2 and TRPC6 in erythropoietin modulation of calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-FREE CALCIUM; CAPACITATIVE CA2+ ENTRY; PHENYLHYDRAZINE-TREATED MICE; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN ERYTHROID PRECURSORS; CENTRAL-NERVOUS-SYSTEM; HUMAN ERYTHROBLASTS; CATION CHANNEL; RECEPTOR; DIFFERENTIATION	Erythropoietin (Epo) modulates calcium influx through voltage-independent calcium-permeable channel(s). Here, we characterized the expression of transient receptor potential channels (TRPCs) in primary erythroid cells and examined their regulation. Erythroblasts were isolated from the spleens of phenylhydrazine-treated mice, and Epo stimulation resulted in a significant and dose-dependent increase in [Ca](i). Among the classical TRPC channels, expression of three N-terminal splice variants of TRPC2 (clones 14, 17, and alpha) and of TRPC6 were demonstrated in these erythroblasts by both reverse transcriptase-PCR and Western blotting. Confocal microscopy confirmed localization to the plasma membrane. To determine the function of individual TRPC channels in erythropoietin modulation of calcium influx, digital video imaging was used to measure calcium influx through these TRPCs in a Chinese hamster ovary (CHO) cell model. Single CHO-S cells, expressing transfected Epo-R, were identified by detection of green fluorescent protein. Cells that express transfected TRPCs were identified by detection of blue fluorescent protein. [Ca](i) was monitored with Fura Red. Epo stimulation of CHO-S cells transfected with single TRPC2 isoforms (clone 14, 17, or alpha) and Epo-R resulted in a significant increase in [ Ca] i. This was not observed in cells transfected with Epo-R and TRPC6. In addition, coexpression of TRPC6 with TRPC2 and Epo-R inhibited the increase in [Ca](i) observed after Epo stimulation. Immunoprecipitation experiments demonstrated that TRPC2 associates with TRPC6, indicating that these TRPCs can form multimeric channels. These data demonstrate that specific TRPCs are expressed in primary erythroid cells and that two of these channels, TRPC2 and TRPC6, can interact to modulate calcium influx stimulated by erythropoietin.	Geisinger Med Clin, Henry Hood Res Program, Sigfried & Janet Weis Ctr Res, Danville, PA 17822 USA; Geisinger Med Clin, Dept Med, Danville, PA 17822 USA; Geisinger Med Clin, Dept Pediat, Danville, PA 17822 USA; Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5S 2M9, Canada	Geisinger Medical Center; Geisinger Medical Center; Geisinger Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Miller, BA (corresponding author), Geisinger Med Clin, Henry Hood Res Program, Sigfried & Janet Weis Ctr Res, 100 N Acad Dr, Danville, PA 17822 USA.	bamiller1@geisinger.edu		Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58672] Funding Source: Medline; NIDDK NIH HHS [DK 46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto T, 2001, NEPHROL DIAL TRANSPL, V16, P491, DOI 10.1093/ndt/16.3.491; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Buess M, 1999, ONCOGENE, V18, P1487, DOI 10.1038/sj.onc.1202445; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Dame C, 2001, BIOL NEONATE, V79, P228; Duncan LM, 1998, CANCER RES, V58, P1515; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLO B, 1993, BLOOD, V81, P783; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; HENSOLD JO, 1991, BLOOD, V77, P1362; Hodges VM, 1999, BRIT J HAEMATOL, V106, P325, DOI 10.1046/j.1365-2141.1999.01535.x; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; Miller CP, 2002, BLOOD, V99, P898, DOI 10.1182/blood.V99.3.898; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Ni ZM, 1998, HYPERTENSION, V32, P724, DOI 10.1161/01.HYP.32.4.724; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wu YM, 1997, AM J PHYSIOL-HEART C, V273, pH2161, DOI 10.1152/ajpheart.1997.273.5.H2161; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Yildirim E, 2003, P NATL ACAD SCI USA, V100, P2220, DOI 10.1073/pnas.0438036100; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	57	55	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10514	10522		10.1074/jbc.M308478200	http://dx.doi.org/10.1074/jbc.M308478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699131	hybrid			2022-12-27	WOS:000220050400104
J	Mahabeleshwar, GH; Das, R; Kundu, GC				Mahabeleshwar, GH; Das, R; Kundu, GC			Tyrosine kinase, p56(lck)-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-MEDIATED SECRETION; BREAST-CANCER CELLS; KAPPA-B; PROTEIN-KINASE; PROMATRIX METALLOPROTEINASE-2; MATRIX-METALLOPROTEINASE; DEPENDENT MECHANISM; T-CELLS; PHOSPHORYLATION; MIGRATION	We have recently reported that tyrosine kinase, p56(lck) regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase-type plasminogen activator (uPA) through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation (Mahabeleshwar, G. H., and Kundu, G. C. ( 2003) J. Biol. Chem. 278, 52598 - 52612). However, the role of hypoxia/reoxygenation (H/R) on ERK1/2-mediated uPA secretion and cell motility and the involvement of p56(lck) and EGF receptor in these processes in breast cancer cells is not well defined. We provide here evidence that H/R induces Lck kinase activity and Lck-dependent tyrosine phosphorylation of EGF receptor in highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. H/R also stimulates MEK-1 and ERK1/2 phosphorylations, and H/R-induced phosphorylations were suppressed by the dominant negative form of Lck (DN Lck, K273R) as well as pharmacological inhibitors of EGF receptor and Lck indicating that EGF receptors and Lck are involved in these processes. Transfection of these cells with wild type Lck or Lck F505 (Y505F) but not with Lck F394 (Y394F) induced phosphorylations of EGF receptor followed by MEK-1 and ERK1/2, suggesting that Lck is upstream of EGF receptor and Tyr-394 of Lck is crucial for these processes. H/R also induced uPA secretion and cell motility in these cells. DN Lck and inhibitors of Lck, EGF receptor, and MEK-1 suppressed H/R-induced uPA secretion and cell motility. To our knowledge, this is the first report that p56lck in presence of H/R regulates MEK-1-dependent ERK1/2 phosphorylation and uPA secretion through tyrosine phosphorylation of EGF receptor, and it further demonstrates that all of these signaling molecules ultimately control the motility of breast cancer cells.	NCCS, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), NCCS, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bevan P, 2001, J CELL SCI, V114, P1429; BOULET I, 1987, BIOCHEM BIOPH RES CO, V149, P56, DOI 10.1016/0006-291X(87)91604-4; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DECESARE D, 1995, ONCOGENE, V11, P365; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hashimoto Y, 2000, J BIOL CHEM, V275, P34541, DOI 10.1074/jbc.M005332200; Hensley K, 2002, ARCH BIOCHEM BIOPHYS, V397, P377, DOI 10.1006/abbi.2001.2630; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KOSTER A, 1991, ANTICANCER RES, V11, P193; LAURA M, 2002, J BIOL CHEM, V277, P9405; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; Price JT, 1999, CANCER RES, V59, P5475; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; Yousefi S, 2003, CLIN EXP IMMUNOL, V133, P78, DOI 10.1046/j.1365-2249.2003.02187.x	31	24	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9733	9742		10.1074/jbc.M311400200	http://dx.doi.org/10.1074/jbc.M311400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699120	hybrid			2022-12-27	WOS:000220050400011
J	Mansy, SS; Wu, SP; Cowan, JA				Mansy, SS; Wu, SP; Cowan, JA			Iron-sulfur cluster biosynthesis - Biochemical characterization of the conformational dynamics of Thermotoga maritima IscU and the relevance for cellular cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN-GLOBULE STATE; ESCHERICHIA-COLI; ALPHA-LACTALBUMIN; STRUCTURAL-CHARACTERIZATION; 2FE-2S CLUSTER; SERUM-ALBUMIN; BINDING SITE; PROTEIN; STABILITY; INTERMEDIATE	Important for the understanding of the functional properties of the iron-sulfur scaffold IscU is knowledge of the structure and dynamics of this protein class. Structural characterization of Thermotoga maritima IscU by CD (Mansy, S. S., Wu, G., Surerus, K. K., and Cowan, J. A. (2002) J. Biol. Chem. 277, 21397-21404) and high resolution NMR (Bertini, I., Cowan, J. A., Del Bianco, C., Luchinat, C., and Mansy, S. S. (2003) J. Mol. Biol. 331, 907-924) yielded data indicating a high degree of secondary structure. However, the latter also revealed IscU to exist in a dynamic equilibrium between two or more distinct conformations, possibly existing in a molten globule state. Herein, we further characterize the molten globule characteristics of T. maritima IscU by near-ultraviolet circular dichroism, 1-anilino-8-naphthalenesulfonic acid binding, free energy of unfolding, hydrodynamic radius measurements, and limited tryptic digestion. The data suggest unusual dynamic behavior that is not fully consistent with typical protein states such as fully folded, fully unfolded, or molten globule. For instance, the existence of a stable tertiary fold is supported by near-UV CD spectra and hydrodynamic radius measurements, whereas other data are less clearly interpretable and may be viewed as consistent with either a molten globule or fully folded state. However, all of the data are consistent with our previous hypothesis of a protein sampling multiple discrete tertiary conformations in which these structural transitions occur on a "slow" time scale. To describe such proteins, we introduce the term multiple discrete conformers.	Ohio State Univ, Evans Lab Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Cowan, JA (corresponding author), Ohio State Univ, Evans Lab Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	cowan@chemistry.ohio-state.edu	Mansy, Sheref/E-6266-2010	Mansy, Sheref/0000-0003-2382-198X				Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; AHMAD F, 1992, BIOCHEM J, V287, P481, DOI 10.1042/bj2870481; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BUROVA TV, 1995, PROTEIN SCI, V4, P909; Cavagnero S, 2001, BIOCHEMISTRY-US, V40, P14459, DOI 10.1021/bi011500n; CHAFFOTTE A, 1991, BIOCHEMISTRY-US, V30, P8067, DOI 10.1021/bi00246a027; Dams T, 1999, BIOCHEMISTRY-US, V38, P9169, DOI 10.1021/bi990635e; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; de Laureto PP, 2002, PROTEIN SCI, V11, P2932, DOI 10.1110/ps.0205802; Del Vecchio P, 2002, BIOCHEMISTRY-US, V41, P1364, DOI 10.1021/bi011146t; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; EISENBERG D, 1979, PHYSICAL CHEM, P718; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; Felitsky DJ, 2003, BIOCHEMISTRY-US, V42, P2202, DOI 10.1021/bi0270992; Fernandez-Recio J, 1999, J MOL BIOL, V290, P319, DOI 10.1006/jmbi.1999.2863; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; HURLEY JK, 1995, PROTEIN SCI, V4, P58; Hwang DM, 1996, J MOL EVOL, V43, P536, DOI 10.1007/PL00006114; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Kusmierczyk AR, 2000, J BIOL CHEM, V275, P33504, DOI 10.1074/jbc.M006256200; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; MARMORINO JL, 1995, BIOCHEMISTRY-US, V34, P3140, DOI 10.1021/bi00010a002; Matthews JM, 2000, BIOCHEMISTRY-US, V39, P1942, DOI 10.1021/bi991973i; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; McElroy C, 2002, J MOL BIOL, V323, P463, DOI 10.1016/S0022-2836(02)00940-3; MONTONO C, 1999, BIOCHEMISTRY-US, V38, P1332; Muzammil S, 2000, PROTEINS, V40, P29, DOI 10.1002/(SICI)1097-0134(20000701)40:1<29::AID-PROT50>3.0.CO;2-P; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; PACE CN, 1988, J BIOL CHEM, V263, P11820; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; SCHECHTER AN, 1968, J MOL BIOL, V35, P567, DOI 10.1016/S0022-2836(68)80015-4; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SIRANGELO I, 1994, FEBS LETT, V338, P11, DOI 10.1016/0014-5793(94)80107-X; SPUERGIN P, 1995, EUR J BIOCHEM, V231, P405, DOI 10.1111/j.1432-1033.1995.tb20713.x; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TAKASE K, 1974, BIOCHIM BIOPHYS ACTA, V371, P352, DOI 10.1016/0005-2795(74)90031-2; TANFORD C, 1964, J AM CHEM SOC, V86, P2050, DOI 10.1021/ja01064a028; TANFORD C, 1967, J AM CHEM SOC, V89, P729, DOI 10.1021/ja00980a001; Tchorzewski M, 2003, BIOCHEMISTRY-US, V42, P3399, DOI 10.1021/bi0206006; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; Wang CQ, 1998, BIOCHEMISTRY-US, V37, P8457, DOI 10.1021/bi9723010; WEBER G, 1964, J BIOL CHEM, V239, P1415; Wittung-Stafshede P, 1998, BBA-PROTEIN STRUCT M, V1382, P324, DOI 10.1016/S0167-4838(97)00176-3; Wittung-Stafshede P, 2000, J INORG BIOCHEM, V78, P35, DOI 10.1016/S0162-0134(99)00202-0; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2002, BIOCHEMISTRY-US, V41, P8876, DOI 10.1021/bi0256781; XIE D, 1991, BIOCHEMISTRY-US, V30, P10673, DOI 10.1021/bi00108a010; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	73	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10469	10475		10.1074/jbc.M312051200	http://dx.doi.org/10.1074/jbc.M312051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688265	hybrid			2022-12-27	WOS:000220050400098
J	Sheng, SH; Bruns, JB; Kleyman, TR				Sheng, SH; Bruns, JB; Kleyman, TR			Extracellular histidine residues crucial for Na+ self-inhibition of epithelial Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMILORIDE BINDING DOMAIN; SIDE-CHAIN INTERACTIONS; XENOPUS-LAEVIS OOCYTES; SODIUM-CHANNEL; ALPHA-SUBUNIT; ION CHANNELS; FROG-SKIN; CONCENTRATION-DEPENDENCE; GAMMA-SUBUNIT; CYTOSOLIC NA+	Epithelial Na+ channels ( ENaC) participate in the regulation of extracellular fluid volume homeostasis and blood pressure. Channel activity is regulated by both extracellular and intracellular Na+. The down- regulation of ENaC activity by external Na+ is referred to as Na+ self-inhibition. We investigated the structural determinants of Na+ self-inhibition by expressing wildtype or mutant ENaCs in Xenopus oocytes and analyzing changes in whole-cell Na+ currents following a rapid increase of bath Na+ concentration. Our results indicated that wild-type mouse alphabetagammaENaC has intrinsic Na+ self-inhibition similar to that reported for human, rat, and Xenopus ENaCs. Mutations at His(239) (gammaH239R, gammaH239D, and gammaH239C) in the extracellular loop of the gammaENaC subunit prevented Na+ self- inhibition whereas mutations of the corresponding His(282) in alphaENaC (alphaH282D, alphaH282R, alphaH282W, and alphaH282C) significantly enhanced Na+ self-inhibition. These results suggest that these two histidine residues within the extracellular loops are crucial structural determinants for Na+ self-inhibition.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J PHYSIOL-LONDON, V516, P31, DOI 10.1111/j.1469-7793.1999.031aa.x; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Askwith CC, 2001, P NATL ACAD SCI USA, V98, P6459, DOI 10.1073/pnas.111155398; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Bhattacharyya R, 2003, J PROTEOME RES, V2, P255, DOI 10.1021/pr025584d; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P14; Cucu D, 2003, J MEMBRANE BIOL, V194, P33, DOI 10.1007/s00232-003-2023-y; Firsov D, 1999, J BIOL CHEM, V274, P2743, DOI 10.1074/jbc.274.5.2743; FUCHS W, 1977, J PHYSIOL-LONDON, V267, P137, DOI 10.1113/jphysiol.1977.sp011805; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gilbertson TA, 1998, J GEN PHYSIOL, V111, P667, DOI 10.1085/jgp.111.5.667; GORDON SE, 1995, NEURON, V14, P177; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hummler E, 2003, CURR HYPERTENS REP, V5, P11, DOI 10.1007/s11906-003-0005-1; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kelly O, 2003, AM J PHYSIOL-RENAL, V285, pF1279, DOI 10.1152/ajprenal.00094.2003; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Komwatana P, 1998, J MEMBRANE BIOL, V162, P225, DOI 10.1007/s002329900360; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; KOSSIAKOFF AA, 1980, NATURE, V288, P414, DOI 10.1038/288414a0; LI JHY, 1983, J MEMBRANE BIOL, V75, P179, DOI 10.1007/BF01871949; Meurisse R, 2003, BBA-PROTEINS PROTEOM, V1649, P85, DOI 10.1016/S1570-9639(03)00161-4; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Palmer LG, 1998, J PHYSIOL-LONDON, V509, P151, DOI 10.1111/j.1469-7793.1998.151bo.x; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; Schafer JA, 2002, AM J PHYSIOL-RENAL, V283, pF221, DOI 10.1152/ajprenal.00068.2002; SCHULZ AR, 1984, ENZYME KINETICS DIS, P38; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Sherwood AL, 2002, GLYCOBIOLOGY, V12, P599, DOI 10.1093/glycob/cwf075; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Thomas A, 2002, PROTEINS, V48, P628, DOI 10.1002/prot.10190; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; VANDRIESSCHE W, 1985, PHYSIOL REV, V65, P833, DOI 10.1152/physrev.1985.65.4.833; VANDRIESSCHE W, 1979, NATURE, V282, P519, DOI 10.1038/282519a0	43	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9743	9749		10.1074/jbc.M311952200	http://dx.doi.org/10.1074/jbc.M311952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701851	hybrid			2022-12-27	WOS:000220050400012
J	Crane, A; Aguilar-Bryan, L				Crane, A; Aguilar-Bryan, L			Assembly, maturation, and turnover of K-ATP channel subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; AFFINITY SULFONYLUREA RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNEL; INSULIN-SECRETION; CONGENITAL HYPERINSULINISM; FAMILIAL HYPERINSULINISM; SURFACE EXPRESSION; CYSTIC-FIBROSIS	ATP-sensitive K+, or K-ATP, channels are comprised of K(IR)6.x and sulfonylurea receptor (SUR) subunits that assemble as octamers, (K-IR/SUR)(4). The assembly pathway is unknown. Pulse-labeling studies show that when K(IR)6.2 is expressed individually, its turnover is biphasic; similar to60% is lost with t(1/2) similar to 36 min. The remainder converts to a long-lived species (t(1/2) similar to 26 h) with an estimated half-time of 1.2 h. Expressed alone, SUR1 has a long half-life, similar to25.5 h. When K(IR)6.2 and SUR1 are co-expressed, they associate rapidly and the fast degradation of KIR6.2 is eliminated. Based on changes in the glycosylation state of SUR1, the half-time for the maturation of K-ATP channels, including completion of assembly, transit to the Golgi, and glycosylation, is similar to 2.2 h. Estimation of the turnover rates of mature, fully glycosylated SUR1 associated with K(IR)6.2 and of K(IR)6.2 associated with Myc-tagged SUR1 gave similar values for the half-life of K-ATP channels, a mean value of similar to 7.3 h. K-ATP channel subunits in INS-1 beta-cells displayed qualitatively similar kinetics. The results imply the octameric channels are stable. Two mutations, K(IR)6.2 W91R and SUR1 DeltaF1388, identified in patients with the severe form of familial hyperinsulinism, profoundly alter the rate of KIR6.2 and SUR1 turnover, respectively. Both mutant subunits associate with their respective partners but dissociate freely and degrade rapidly. The data support models of channel formation in which K(IR)6.2-SUR1 heteromers assemble functional channels and are inconsistent with models where SUR1 can only assemble with K(IR)6.2 tetramers.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Aguilar-Bryan, L (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	lbryan@bcm.tmc.edu			NIDDK NIH HHS [DK57671] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057671] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; BRYAN J, 2000, DIABETES MELLITUS, P61; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Fournet JC, 2003, HORM RES, V59, P30, DOI 10.1159/000067842; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Glaser B, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P299, DOI 10.1016/B978-044450489-0/50014-8; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; Huopio H, 2003, LANCET, V361, P301, DOI 10.1016/S0140-6736(03)12325-2; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nufer O, 2003, CURR BIOL, V13, pR391, DOI 10.1016/S0960-9822(03)00318-X; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Reimann F, 2003, DIABETOLOGIA, V46, P241, DOI 10.1007/s00125-002-1014-3; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; SCHWANSTECHER M, 1994, J BIOL CHEM, V269, P17768; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Thornton PS, 2003, DIABETES, V52, P2403, DOI 10.2337/diabetes.52.9.2403; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; WARD CL, 1994, J BIOL CHEM, V269, P25710; YOSHIMURA A, 1989, BIOCHIM BIOPHYS ACTA, V992, P307, DOI 10.1016/0304-4165(89)90089-5; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	51	58	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9080	9090		10.1074/jbc.M311079200	http://dx.doi.org/10.1074/jbc.M311079200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699091	hybrid			2022-12-27	WOS:000189265900069
J	Eyers, PA; Maller, JL				Eyers, PA; Maller, JL			Regulation of Xenopus aurora A activation by TPX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIPOLAR MITOTIC SPINDLE; CENTROSOME AMPLIFICATION; SIGNALING PATHWAY; KINASE-ACTIVITY; IMPORTIN-ALPHA; CELL-DIVISION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; MICROTUBULES	The oncogenic protein kinase Aurora A is a critical regulator of meiotic and mitotic cell cycles in eukaryotic cells. Aurora A autoactivation by autophosphorylation is promoted by specific non-catalytic binding proteins. One such protein is TPX2, a required spindle assembly factor in higher eukaryotes whose ability to activate Aurora A by direct binding to the kinase catalytic domain has been established by biochemical and structural analysis. In this report we clarify the autoactivation mechanism of Aurora A by demonstrating that of seven amino acids which become autophosphorylated by Aurora A, only Thr-295 is required for activity. Association of Aurora A with TPX2 leads to activation of the kinase, in parallel with phosphorylation of TPX2. We identify the sites as three Ser residues in the N terminus of TPX2; however, mutation of these residues does not affect Aurora A activation by TPX2. In contrast, the mutation of a putative Aurora A-binding motif in TPX2 abolishes both phosphorylation of TPX2 and activation of Aurora A. We have also investigated the interaction between Xenopus p53 and Xenopus Aurora A. p53 blocks the activity of either full-length Aurora A or the isolated catalytic domain. Interestingly, inhibition is blocked by TPX2, suggesting that the ability of Aurora A to transform cells could be regulated by p53, TPX2, or other binding proteins.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	jim.maller@uchsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28353-21] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CHAN CSM, 1993, GENETICS, V135, P677; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Giet R, 2001, J CELL SCI, V114, P2095; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hamada M, 2003, BRIT J HAEMATOL, V121, P439, DOI 10.1046/j.1365-2141.2003.04311.x; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Li DH, 2003, CLIN CANCER RES, V9, P991; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Roghi C, 1998, J CELL SCI, V111, P557; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Terada Y, 2003, J CELL BIOL, V162, P757, DOI 10.1083/jcb.200305048; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	38	108	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9008	9015		10.1074/jbc.M312424200	http://dx.doi.org/10.1074/jbc.M312424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701852	hybrid			2022-12-27	WOS:000189265900060
J	Grant, GA; Xu, XL; Hu, ZQ				Grant, GA; Xu, XL; Hu, ZQ			Quantitative relationships of site to site interaction in Escherichia coli D-3-phosphoglycerate dehydrogenase revealed by asymmetric hybrid tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED ALLOSTERIC REGULATION; END PRODUCT INHIBITION; EFFECTOR-BINDING; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE BIOSYNTHESIS; DOMAIN INTERFACE; SERA GENE; MECHANISM; PHOSPHOFRUCTOKINASE; COOPERATIVITY	A set of asymmetric hybrid tetramers of Escherichia coli D-3-phosphoglycerate dehydrogenase ( PGDH) have been made by gene co-expression and KSCN-induced dimer exchange. These tetramers contain varied numbers of active sites and effector binding sites arranged in different orientations within the tetramer. They reveal that PGDH displays half-of-the-sites activity with respect to its active sites and that the two sites that are active at any particular time lie in subunits on either side of the nucleotide binding domain interface. Half-of-the-sites functionality is also observed for the effector even though all four sites eventually bind effector. That is, only two effector sites need to be occupied for maximum inhibition. Binding of the last two effector molecules does not contribute functionally to inhibition of activity. Furthermore, positive cooperativity of inhibition of activity by the effector is completely dependent on the positive cooperativity of binding of the effector. Binding of the first effector molecule produces a conformational change that essentially completely inhibits the active site within the subunit to which it binds and produces an approximate 33% inhibition of the active site in the subunit to which it is not bound. Binding of the second effector at the opposite regulatory domain interface completes the inhibition of activity. This simple relationship defines the positional and quantitative influence of effector ligand binding on activity and can be used to predict the maximum level of inhibition of individual hybrid tetramers. In addition, the site-specific quantitative relationship of effector binding to individual active sites can be used to model the inhibition profile with relatively good agreement. These simple rules for the site to site interaction in PGDH provide significant new insight into the mechanism of allostery of this enzyme.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	ggrant@molecool.wustl.edu			NIGMS NIH HHS [GM 56676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BELL JE, 1988, PROTEINS ENZYMES, P465; DEVILLEBONNE D, 1989, BIOCHEMISTRY-US, V28, P1917, DOI 10.1021/bi00430a073; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 2003, J BIOL CHEM, V278, P18170, DOI 10.1074/jbc.M213050200; Grant GA, 2002, J BIOL CHEM, V277, P39548, DOI 10.1074/jbc.M208019200; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; GRANT GA, BIOCHEMISTRY, V38, P16548; Kimmel JL, 2001, BIOCHEMISTRY-US, V40, P11623, DOI 10.1021/bi010844a; LAZDUNSKI M, 1972, CURRENT TOPICS CELLU, V6, P267; Neet K E, 1980, Methods Enzymol, V64, P139; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	21	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13452	13460		10.1074/jbc.M313593200	http://dx.doi.org/10.1074/jbc.M313593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718528	hybrid			2022-12-27	WOS:000220478500023
J	Muhlenbein, N; Hofmann, S; Rothbauer, U; Bauer, MF				Muhlenbein, N; Hofmann, S; Rothbauer, U; Bauer, MF			Organization and function of the small Tim complexes acting along the import pathway of metabolite carriers into mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAFNESS DYSTONIA SYNDROME; ADP ATP CARRIER; INNER MEMBRANE; PROTEIN IMPORT; INTERMEMBRANE SPACE; PREPROTEIN TRANSLOCASE; ADP/ATP CARRIER; MEDIATES INSERTION; PEPTIDE-1 DDP1; COMPONENT	Tim9, Tim10a, and Tim10b are members of the family of small Tim proteins located in the intermembrane space of mammalian mitochondria. In yeast, members of this family act along the TIM22 import pathway during import of metabolite carriers and other integral inner membrane proteins. Here, we show that the human small proteins form two distinct hetero-oligomeric complexes. A 70-kDa complex that contains Tim9 and Tim10a and a Tim9-10a-10b that is part of a higher molecular weight assembly of 450 kDa. This distribution among two complexes suggests Tim10b to be the functional homologue of yeast Tim12. Both human complexes are tightly associated with the inner membrane and, compared with yeast, soluble 70-kDa complexes appear to be completely absent in the intermembrane space. Thus, the function of soluble 70-kDa complexes as trans-site receptors for incoming carrier proteins is not conserved from lower to higher eukaryotes. During import, the small Tim complexes directly interact with human adenine nucleotide translocator (ANT) in transit in a metal-dependent manner. For insertion of carrier preproteins into the inner membrane, the human small Tim proteins directly interact with human Tim22, the putative insertion pore of the TIM22 translocase. However, in contrast to yeast, only a small fraction of Tim9-Tim10a-Tim10b complex is in a stable association with Tim22. We conclude that different mechanisms and specific requirements for import and insertion of mammalian carrier preproteins have evolved in higher eukaryotes.	Akad Krankenhaus Munchen Schwabing, Inst Diabet Forsch, D-80804 Munich, Germany; Akad Krankenhaus Munchen Schwabing, Inst Klin Chem Mol Biol Diagnost & Mitochondriale, D-80804 Munich, Germany		Bauer, MF (corresponding author), KH Munchen Schwabing, Inst Klin Chem Mol Biol Diagnost & Mitochondriale, Kolner Pl 1, D-80804 Munich, Germany.	bauer@bio.med.uni-muenchen.de	Rothbauer, Ulrich/C-7712-2018	Rothbauer, Ulrich/0000-0001-5923-8986				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2002, INT REV NEUROBIOL, V53, P57; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dyall SD, 2003, J BIOL CHEM, V278, P26757, DOI 10.1074/jbc.M302700200; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Jin H, 1999, GENOMICS, V61, P259, DOI 10.1006/geno.1999.5966; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Murphy MP, 2001, MOL CELL BIOL, V21, P6132, DOI 10.1128/MCB.21.18.6132-6138.2001; Okamoto K, 2002, EMBO J, V21, P3659, DOI 10.1093/emboj/cdf358; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	42	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13540	13546		10.1074/jbc.M312485200	http://dx.doi.org/10.1074/jbc.M312485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726512	hybrid			2022-12-27	WOS:000220478500033
J	Pichiule, P; Chavez, JC; LaManna, JC				Pichiule, P; Chavez, JC; LaManna, JC			Hypoxic regulation of angiopoietin-2 expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; GROWTH-FACTOR; GENE-EXPRESSION; TIE2 RECEPTOR; UP-REGULATION; SIGNAL-TRANSDUCTION; MESSENGER-RNA; BINDING-SITE; RAT-BRAIN; ANGIOGENESIS	Exposure of endothelial cells to hypoxia-induced angiopoietin-2 (Ang2) expression. The increase in Ang2 mRNA levels occurred by transcriptional regulation and by post-transcriptional increase in mRNA stability. Induction of Ang2 mRNA resulted in an increase of intracellular and secreted Ang2 protein levels. Since the transcriptional regulation of several genes involved in angiogenesis during hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1), it was conceivable that Ang2 expression might be regulated by the same oxygen-dependent mechanism. However, our data showed that pharmacological HIF inducers, CoCl2 and DFO, did not affect Ang2 expression. Moreover, HIF-1-deficient hepatoma cell ( Hepa1 c4) and its wild-type counterpart (Hepa1 c1c4) up-regulates Ang2 during hypoxia. These results indicated that hypoxia-driven Ang2 expression may be independent of the HIF pathway. Using neutralizing VEGF antibody or pharmacological inhibitors of VEGF receptors, we showed that hypoxia-induced VEGF participates but could not account completely for Ang2 expression during hypoxia. In addition, hypoxia elicited an increase of cyclooxygenase-2 (COX-2) expression and a parallel increase in prostanglandin E-2 (PGE(2)) and prostacyclin (PGI(2)) production. COX-2 inhibitors decreased the hypoxic induction of Ang2 and the hypoxic induction of PGE(2) and PGI(2) in a dose-dependent manner. Similarly, COX-2 but not COX-1 antisense treatment decreased hypoxic induction of Ang2 expression, and this effect was reversed by exogenous PGE(2). Finally, exogenous PGE(2) and PGI(2) were able to stimulate Ang2 under normoxic conditions. These findings suggest that COX-2-dependent prostanoids may play an important role in the regulation of hypoxia-induced Ang2 expression.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University	LaManna, JC (corresponding author), Cornell Univ, Coll Med, Burke Med Res Inst, White Plains, NY 10605 USA.	JCL4@po.cwru.edu	LaManna, Joseph C/C-3347-2012; LaManna, Joseph/D-3860-2013	LaManna, Joseph C/0000-0002-0159-4512; LaManna, Joseph/0000-0002-0159-4512	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038632, R01NS037111] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 37111, NS 38632] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Bruick RK, 2001, GENE DEV, V15, P2497, DOI 10.1101/gad.931601; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Goede V, 1998, LAB INVEST, V78, P1385; GREENBERG ME, 1994, CURRENT PROTOCOLS 4, V26; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hofer T, 2003, BLOOD, V101, P348, DOI 10.1182/blood-2002-03-0773; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang YQ, 2002, BLOOD, V99, P1646, DOI 10.1182/blood.V99.5.1646; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Jones MK, 1999, NAT MED, V5, P1418; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; Koh GY, 2002, EXP MOL MED, V34, P1; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 2000, AM J PATHOL, V156, P2077, DOI 10.1016/S0002-9440(10)65079-1; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Masferrer JL, 2000, CANCER RES, V60, P1306; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Mezquita J, 2000, BIOCHEM BIOPH RES CO, V275, P643, DOI 10.1006/bbrc.2000.3345; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; Mochizuki Y, 2002, J CELL SCI, V115, P175; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026-2862(02)00035-3; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; WANG GL, 1993, BLOOD, V82, P3610; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; XU XP, 1995, CARDIOVASC RES, V30, P345, DOI 10.1016/S0008-6363(95)00037-2; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	63	144	155	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12171	12180		10.1074/jbc.M305146200	http://dx.doi.org/10.1074/jbc.M305146200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702352	hybrid			2022-12-27	WOS:000220334900023
J	Pili-Floury, S; Leulier, F; Takahashi, K; Saigo, K; Samain, E; Ueda, R; Lemaitre, B				Pili-Floury, S; Leulier, F; Takahashi, K; Saigo, K; Samain, E; Ueda, R; Lemaitre, B			In vivo RNA interference analysis reveals an unexpected role for GNBP1 in the Defense against Gram-positive bacterial infection in Drosophila adults	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN-RECOGNITION PROTEIN; ANTIMICROBIAL PEPTIDE GENES; INNATE IMMUNE-RESPONSES; NEGATIVE BACTERIA; BOMBYX-MORI; BINDING PROTEIN; HOST-DEFENSE; CDNA CLONING; TOLL; MELANOGASTER	The Drosophila immune system discriminates between different classes of infectious microbes and responds with pathogen-specific defense reactions via the selective activation of the Toll and the immune deficiency (Imd) signaling pathways. The Toll pathway mediates most defenses against Gram-positive bacteria and fungi, whereas the Imd pathway is required to resist Gram-negative bacterial infection. Microbial recognition is achieved through peptidoglycan recognition proteins (PGRPs); Gram-positive bacteria activate the Toll pathway through a circulating PGRP (PGRP-SA), and Gram-negative bacteria activate the Imd pathway via PGRP-LC, a putative transmembrane receptor, and PGRP-LE. Gram-negative binding proteins (GNBPs) were originally identified in Bombyx mori for their capacity to bind various microbial compounds. Three GNBPs and two related proteins are encoded in the Drosophila genome, but their function is not known. Using inducible expression of GNBP1 double-stranded RNA, we now demonstrate that GNBP1 is required for Toll activation in response to Gram-positive bacterial infection; GNBP1 double-stranded RNA expression renders flies susceptible to Gram-positive bacterial infection and reduces the induction of the antifungal peptide encoding gene Drosomycin after infection by Gram-positive bacteria but not after fungal infection. This phenotype induced by GNBP1 inactivation is identical to a loss-of-function mutation in PGRP-SA, and our genetic studies suggest that GNBP1 acts upstream of the Toll ligand Spatzle. Altogether, our results demonstrate that the detection of Gram-positive bacteria in Drosophila requires two putative pattern recognition receptors, PGRP-SA and GNBP1.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Natl Inst Genet, Genet Strains Res Ctr, Shizuoka 4118540, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Univ Franche Comte, Ctr Hosp Univ, F-25030 Besancon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Tokyo; Universite de Franche-Comte; CHU Besancon	Lemaitre, B (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.	lemaitre@cgm.cnrs-gif.fr	Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Girardin SE, 2003, EMBO REP, V4, P932, DOI 10.1038/sj.embor.embor940; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Kurata S, 2004, DEV COMP IMMUNOL, V28, P89, DOI 10.1016/S0145-305X(03)00121-6; Lee MH, 2003, J BIOL CHEM; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Reichhart JM, 2002, GENESIS, V34, P160, DOI 10.1002/gene.10122; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Tzou P, 2002, METHOD MICROBIOL, V31, P507, DOI 10.1016/S0580-9517(02)31028-6; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	38	129	142	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12848	12853		10.1074/jbc.M313324200	http://dx.doi.org/10.1074/jbc.M313324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722090	Green Submitted, hybrid			2022-12-27	WOS:000220334900100
J	Guizouarn, H; Gabillat, N; Borgese, F				Guizouarn, H; Gabillat, N; Borgese, F			Evidence for up-regulation of the endogenous Na-K-2Cl co-transporter by molecular interactions with the anion exchanger tAE1 expressed in Xenopus oocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL-VOLUME REGULATION; RED-CELL; TROUT ERYTHROCYTES; CHLORIDE CHANNELS; NA+/H+ EXCHANGE; TRANSPORT; CFTR; BAND-3; INHIBITION	Expression of trout anion exchanger 1 (tAE1) in Xenopus oocyte led to the stimulation of a Na+- and Cl--dependent Rb influx. Functional features and pharmacological data strongly suggest that this Rb influx is mediated by the endogenous Na-K-2Cl (NKCC) co-transporter. The functional relationship between expression of tAE1 and activation of the NKCC co-transporter was investigated. Indeed, it was shown previously that tAE1 expressed in Xenopus oocyte induces a strong anion conductance which is correlated with an increased taurine permeability. Measurements of intracellular ion contents ruled out the involvement of any modification of known electrochemical parameters in NKCC co-transporter activation by tAE1. Furthermore, using chimera of tAE1 made with AE1 from other species unable to exhibit anion conductance led to the conclusion that there was no correlation between tAE1 anion conductance and NKCC co-transporter stimulation. Therefore, a possible molecular interaction between tAE1 and the NKCC co-transporter was investigated. Our results clearly show that NKCC activation is dependent upon the C-terminal part of tAE1. Chimeric constructions where tAE1 C-terminal part was substituted by the corresponding part of mouse AE1 abolished co-transporter activation. Moreover, steric encumbrance on the C-terminal end of tAE1 with a specific antibody or with a protein fusion also prevented the co-transporter activation. These data suggest a new role for some anion exchangers in controlling other transporter activity by molecular interactions.	Univ Nice Sophia Antipolis, CNRS, UMR 6078, Lab Physiol Membranes Cellulaires, F-06230 Villefranche Sur Mer, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Guizouarn, H (corresponding author), Univ Nice Sophia Antipolis, CNRS, UMR 6078, Lab Physiol Membranes Cellulaires, Chemin Lazaret, F-06230 Villefranche Sur Mer, France.	guizouarn@obs-vlfr.fr		BORGESE, Franck/0000-0001-7718-2111; Guizouarn, Helene/0000-0002-8757-6672				Alper SL, 2002, J NEPHROL, V15, pS41; BORGESE F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P252, DOI 10.1016/0005-2736(91)90194-D; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Casey JR, 1998, BIOCHEM CELL BIOL, V76, P709, DOI 10.1139/bcb-76-5-709; CHETRITE G, 1985, J MOL BIOL, V185, P639, DOI 10.1016/0022-2836(85)90076-2; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Fievet B, 1998, P NATL ACAD SCI USA, V95, P10996, DOI 10.1073/pnas.95.18.10996; Fujinaga J, 1999, J BIOL CHEM, V274, P6626, DOI 10.1074/jbc.274.10.6626; GARCIAROMEU F, 1991, J PHYSIOL-LONDON, V440, P547, DOI 10.1113/jphysiol.1991.sp018724; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Guizouarn H, 1999, AM J PHYSIOL-CELL PH, V276, pC210, DOI 10.1152/ajpcell.1999.276.1.C210; Guizouarn H, 2003, J MEMBRANE BIOL, V193, P109, DOI 10.1007/s00232-002-2012-6; Guizouarn H, 2001, J PHYSIOL-LONDON, V535, P497, DOI 10.1111/j.1469-7793.2001.t01-1-00497.x; Guizouarn H, 2000, J PHYSIOL-LONDON, V523, P147, DOI 10.1111/j.1469-7793.2000.t01-1-00147.x; Jay DG, 1996, CELL, V86, P853, DOI 10.1016/S0092-8674(00)80160-9; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Lamprecht G, 2002, BIOCHEMISTRY-US, V41, P12336, DOI 10.1021/bi0259103; Lee M G, 2001, JOP, V2, P203; Liedtke CM, 2002, AM J PHYSIOL-LUNG C, V282, pL1151, DOI 10.1152/ajplung.00143.2001; LOW PS, 1993, J BIOL CHEM, V268, P14627; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; MOTAIS R, 1987, J GEN PHYSIOL, V90, P197, DOI 10.1085/jgp.90.2.197; Palfrey HC, 1994, CELLULAR MOL PHYSL C, P201; RABE A, 1995, PFLUG ARCH EUR J PHY, V429, P659, DOI 10.1007/BF00373986; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schreiber R, 2000, FEBS LETT, V475, P291, DOI 10.1016/S0014-5793(00)01689-6; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHETLAR RE, 1990, BIOCHIM BIOPHYS ACTA, V1023, P184, DOI 10.1016/0005-2736(90)90412-H; SHIGERU BHK, 2002, EMBO J, V21, P5662; Shumaker H, 1999, AM J PHYSIOL-CELL PH, V277, pC1100, DOI 10.1152/ajpcell.1999.277.6.C1100; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; SUVITAYAVAT W, 1994, AM J PHYSIOL, V266, pC284, DOI 10.1152/ajpcell.1994.266.1.C284; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020	40	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11513	11520		10.1074/jbc.M311920200	http://dx.doi.org/10.1074/jbc.M311920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699110	hybrid			2022-12-27	WOS:000220157600083
J	Herr, AJ; Wills, NM; Nelson, CC; Gesteland, RF; Atkins, JF				Herr, AJ; Wills, NM; Nelson, CC; Gesteland, RF; Atkins, JF			Factors that influence selection of coding resumption sites in translational bypassing - Minimal conventional peptidyl-tRNA : mRNA pairing can suffice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN L9; OPEN READING FRAMES; ESCHERICHIA-COLI; NASCENT PEPTIDE; BACTERIOPHAGE-T4; SEQUENCE; GENE-60; ELONGATION; EXPRESSION; SIGNALS	This study investigates bypassing initiated from codons immediately 5' of a stop codon. The mRNA slips and is scanned by the peptidyl-tRNA for a suitable landing site, and standard decoding resumes at the next 3' codon. This work shows that landing sites with potentially strong base pairing between the peptidyl-tRNA anticodon and mRNA are preferred, but sites with little or no potential for Watson-Crick or wobble base pairing can also be utilized. These results have implications for re-pairing in ribosomal frameshifting. Shine-Dalgarno sequences in the mRNA can alter the distribution of landing sites observed. The bacteriophage T4 gene 60 nascent peptide, known to influence take-off in its native context, imposes stringent P-site pairing requirements, thereby limiting the number of suitable landing sites.	Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Atkins, JF (corresponding author), Univ Utah, Dept Human Genet, 15 N 2030 E, Salt Lake City, UT 84112 USA.	john.atkins@genetics.utah.edu		Atkins, John/0000-0001-7933-0165; Herr, Alan/0000-0002-9498-0972	NIGMS NIH HHS [GM48152, 5T32GM07464-024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152, T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkins JF, 2001, COLD SPRING HARB SYM, V66, P217, DOI 10.1101/sqb.2001.66.217; Baranov PV, 2002, EMBO REP, V3, P373, DOI 10.1093/embo-reports/kvf065; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CONDRON BG, 1991, NUCLEIC ACIDS RES, V19, P5607, DOI 10.1093/nar/19.20.5607; Gallant J, 2003, P NATL ACAD SCI USA, V100, P13430, DOI 10.1073/pnas.2233745100; Gallant JA, 1998, P NATL ACAD SCI USA, V95, P13771, DOI 10.1073/pnas.95.23.13771; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; HERBST KL, 1994, P NATL ACAD SCI USA, V91, P12525, DOI 10.1073/pnas.91.26.12525; Herr AJ, 2000, ANNU REV BIOCHEM, V69, P343, DOI 10.1146/annurev.biochem.69.1.343; Herr AJ, 1999, EMBO J, V18, P2886, DOI 10.1093/emboj/18.10.2886; Herr AJ, 2000, EMBO J, V19, P2671, DOI 10.1093/emboj/19.11.2671; Herr AJ, 2001, J MOL BIOL, V311, P445, DOI 10.1006/jmbi.2001.4899; Herr AJ, 2001, J MOL BIOL, V309, P1029, DOI 10.1006/jmbi.2001.4717; Hoffman DW, 1996, J MOL BIOL, V264, P1058, DOI 10.1006/jmbi.1996.0696; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Larsen B, 1995, BIOCHEM CELL BIOL, V73, P1123, DOI 10.1139/o95-121; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; Licznar P, 2003, EMBO J, V22, P4770, DOI 10.1093/emboj/cdg465; Lieberman KR, 2000, J MOL BIOL, V297, P1129, DOI 10.1006/jmbi.2000.3621; Lindsley D, 2003, MOL MICROBIOL, V48, P1267, DOI 10.1046/j.1365-2958.2003.03514.x; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Mejlhede N, 1999, J BACTERIOL, V181, P2930, DOI 10.1128/JB.181.9.2930-2937.1999; Miller JH., 1992, SHORT COURSE BACTERI, P72; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; OMAHONY DJ, 1989, P NATL ACAD SCI USA, V86, P7979, DOI 10.1073/pnas.86.20.7979; OPPENHEIM DS, 1980, GENETICS, V95, P785; PAGEL FT, 1992, J BACTERIOL, V174, P4179, DOI 10.1128/jb.174.12.4179-4182.1992; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; Yu JS, 2001, MOL MICROBIOL, V42, P821, DOI 10.1046/j.1365-2958.2001.02681.x; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; YUSUPOVA GZ, 1986, FEBS LETT, V206, P142, DOI 10.1016/0014-5793(86)81356-4; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	42	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11081	11087		10.1074/jbc.M311491200	http://dx.doi.org/10.1074/jbc.M311491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707145	hybrid			2022-12-27	WOS:000220157600031
J	Morante, S; Gonzalez-Iglesias, R; Potrich, C; Meneghini, C; Meyer-Klaucke, W; Menestrina, G; Gasset, M				Morante, S; Gonzalez-Iglesias, R; Potrich, C; Meneghini, C; Meyer-Klaucke, W; Menestrina, G; Gasset, M			Inter- and intra-octarepeat Cu(II) site geometries in the prion protein - Implications in Cu(II) binding cooperativity and Cu(II)-mediated assemblies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; BODY DISTRIBUTION-FUNCTIONS; COPPER-BINDING; QUERCETIN 2,3-DIOXYGENASE; CONDENSED MATTER; TERMINAL DOMAIN; SPECTROSCOPY; CU2+; IDENTIFICATION; TRAFFICKING	Cu(II) binding to the alpha prion protein (alphaPrP) can be both intramolecular and intermolecular. X-ray absorption spectroscopy at the copper K-edge has been used to explore the site geometry under each binding mode using both insoluble polymeric Cu(II).alphaBoPrP-(24-242) (bovine PrP) complexes and soluble Cu(II) complexes of peptides containing one, two, and four copies of the octarepeat. Analysis of the extended region of the spectra using a multiple scattering approach revealed two types of sites differing in the number of His residues in the first coordination shell of Cu(II). Peptides containing one and two-octarepeat copies in sub-stoichiometric Cu(II) complexes showed the direct binding of a single His in accord with crystallographic intra-repeat geometry. Alternatively, the polymeric Cu(II).alphaBoPrP-(24-242) complex and Cu(II) in its soluble complex with a four-octarepeat peptide at half-site-occupancy showed Cu(II) directly bound to two His residues, consistent with an inter-repeat binding mode. Increasing the Cu(II) site occupancy from 0.5 to 0.75 in the peptide containing four octarepeats resulted in spectral features that are intermediate to those of the inter-and intra-repeat modes. The transition from His-Cu-His (inter-repeat) to Cu-His (intra-repeat) on increasing Cu(II) saturation offers a structural basis for the positive cooperativity of the cation binding process and explains the capacity of alphaPrP to participate in Cu(II)-mediated intermolecular interactions.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy; Ist Nazl Fis Mat, I-00133 Rome, Italy; CNR, Inst Trentino Cultura, Ist Biofis, Sez Trento, I-38050 Trent, Italy; Dept Phys E Amaldi, I-00146 Rome, Italy; European Synchrotron Radiat Facil, GILDA, Operat Grp Grenoble, F-38043 Grenoble, France; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Gasset, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	mgasset@iqfr.csic.es	Gasset, Maria/K-4339-2012; meneghini, carlo/F-7761-2013; Gasset, Maria/I-2050-2014; Meyer-Klaucke, Wolfram/G-1148-2010; Potrich, Cristina/AAR-7812-2020	Gasset, Maria/0000-0001-6436-4055; meneghini, carlo/0000-0003-4846-8422; Gasset, Maria/0000-0001-6436-4055; Potrich, Cristina/0000-0002-0793-7547; Morante, Silvia/0000-0002-3913-5733				Arnesano F, 2003, P NATL ACAD SCI USA, V100, P3814, DOI 10.1073/pnas.0636904100; Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; BENFATTO M, 1986, PHYS REV B, V34, P5774, DOI 10.1103/PhysRevB.34.5774; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Filipponi A, 1995, PHYS REV B, V52, P15135, DOI 10.1103/PhysRevB.52.15135; Filipponi A, 1995, PHYS REV B, V52, P15122, DOI 10.1103/PhysRevB.52.15122; Filipponi A., 2000, TASK Quarterly, V4, P575; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Gonzalez-Iglesias R, 2004, FEBS LETT, V556, P161, DOI 10.1016/S0014-5793(03)01397-8; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; Meneghini C, 1998, BIOPHYS J, V75, P1953, DOI 10.1016/S0006-3495(98)77636-2; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Rachidi W, 2003, J BIOL CHEM, V278, P14595, DOI 10.1074/jbc.C300092200; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; Steiner RA, 2002, BIOCHEMISTRY-US, V41, P7963, DOI 10.1021/bi015974y; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SULKOWSKI E, 1992, FEBS LETT, V307, P129, DOI 10.1016/0014-5793(92)80750-B; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55	39	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11753	11759		10.1074/jbc.M312860200	http://dx.doi.org/10.1074/jbc.M312860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14703517	hybrid			2022-12-27	WOS:000220157600112
J	Sharma, S; Sommers, JA; Wu, L; Bohr, VA; Hickson, ID; Brosh, RM				Sharma, S; Sommers, JA; Wu, L; Bohr, VA; Hickson, ID; Brosh, RM			Stimulation of flap endonuclease-1 by the Bloom's syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; OKAZAKI FRAGMENT MATURATION; WERNERS-SYNDROME GENES; DNA-REPLICATION; BIOCHEMICAL-CHARACTERIZATION; MUTATION AVOIDANCE; MISMATCH REPAIR; RECQ HELICASES; BLM HELICASE; IN-VIVO	Bloom's syndrome (BS) is a rare autosomal recessive genetic disorder associated with genomic instability and an elevated risk of cancer. Cellular features of BS include an accumulation of abnormal replication intermediates and increased sister chromatid exchange. Although it has been suggested that the underlying defect responsible for hyper-recombination in BS cells is a temporal delay in the maturation of DNA replication intermediates, the precise role of the BS gene product, BLM, in DNA metabolism remains elusive. We report here a novel interaction of the BLM protein with the human 5'-flap endonuclease/5'-3' exonuclease (FEN-1), a genome stability factor involved in Okazaki fragment processing and DNA repair. BLM protein stimulates both the endonucleolytic and exonucleolytic cleavage activity of FEN-1 and this functional interaction is independent of BLM catalytic activity. BLM and FEN-1 are associated with each other in human nuclei as shown by their reciprocal co-immunoprecipitation from HeLa nuclear extracts. The BLM-FEN-1 physical interaction is mediated through a region of the BLM C-terminal domain that shares homology with the FEN-1 interaction domain of the Werner syndrome protein, a RecQ helicase family member homologous to BLM. This study provides the first evidence for a direct interaction of BLM with a human nucleolytic enzyme. We suggest that functional interactions between RecQ helicases and Rad2 family nucleases serve to process DNA substrates that are intermediates in DNA replication and repair.	NIA, Lab Mol Gerontol, NIH, DHHS, Baltimore, MD 21224 USA; Univ Oxford, Weatherall Inst Mol Med, Canc Res UK Labs, John Radcliffe Hosp, Oxford OX3 9DS, England; Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford; University of Hyderabad	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, DHHS, Baltimore, MD 21224 USA.	BroshR@grc.nia.gov	Sharma, Sudha/AAV-6152-2021; Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Sharma, Sudha/0000-0003-2765-2482; Hickson, Ian/0000-0002-0583-566X	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000741, ZIAAG000726, Z01AG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2002, BIOCHEMISTRY-US, V41, P12204, DOI 10.1021/bi026031j; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 2000, MOL METABOLIC BASIS, P733; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; GRODEN J, 1992, HUM GENET, V90, P360; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Johnson FB, 2000, CANCER RES, V60, P1162; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; LONN U, 1990, CANCER RES, V50, P3141; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Qiu JZ, 1999, J BIOL CHEM, V274, P17893, DOI 10.1074/jbc.274.25.17893; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun XM, 2003, DNA REPAIR, V2, P925, DOI 10.1016/S1568-7864(03)00093-4; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yankiwski V, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-11; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	66	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9847	9856		10.1074/jbc.M309898200	http://dx.doi.org/10.1074/jbc.M309898200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688284	hybrid			2022-12-27	WOS:000220050400024
J	Fraser, CS; Lee, JY; Mayeur, GL; Bushell, M; Doudna, JA; Hershey, JWB				Fraser, CS; Lee, JY; Mayeur, GL; Bushell, M; Doudna, JA; Hershey, JWB			The j-subunit of human translation initiation factor eIF3 is required for the stable binding of eIF3 and its subcomplexes to 40 S ribosomal subunits in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; MESSENGER-RNA; FACTOR 4G; COMPLEX; YEAST; INTERACTS; PURIFICATION; PRT1; HOMOLOG; ASSOCIATION	Eukaryotic initiation factor 3 (eIF3) is a 12-subunit protein complex that plays a central role in binding of initiator methionyl-tRNA and mRNA to the 40 S ribosomal subunit to form the 40 S initiation complex. The molecular mechanisms by which eIF3 exerts these functions are poorly understood. To learn more about the structure and function of eIF3 we have expressed and purified individual human eIF3 subunits or complexes of eIF3 subunits using baculovirus-infected Sf9 cells. The results indicate that the subunits of human eIF3 that have homologs in Saccharomyces cerevisiae form subcomplexes that reflect the subunit interactions seen in the yeast eIF3 core complex. In addition, we have used an in vitro 40 S ribosomal subunit binding assay to investigate subunit requirements for efficient association of the eIF3 subcomplexes to the 40 S ribosomal subunit. eIF3j alone binds to the 40 S ribosomal subunit, and its presence is required for stable 40 S binding of an eIF3bgi subcomplex. Furthermore, purified eIF3 lacking eIF3j binds 40 S ribosomal subunits weakly, but binds tightly when eIF3j is added. Cleavage of a 16-residue C-terminal peptide from eIF3j by caspase-3 significantly reduces the affinity of eIF3j for the 40 S ribosomal subunit, and the cleaved form provides substantially less stabilization of purified eIF3-40S complexes. These results indicate that eIF3j, and especially its C terminus, play an important role in the recruitment of eIF3 to the 40 S ribosomal subunit.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.	jwhershey@ucdavis.edu	Fraser, Christopher/H-9186-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lin L, 2001, J CELL BIOCHEM, V80, P483, DOI 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Morris-Desbois C, 2001, J BIOL CHEM, V276, P45988, DOI 10.1074/jbc.M104966200; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Palecek J, 2001, BIOCHEM BIOPH RES CO, V282, P1244, DOI 10.1006/bbrc.2001.4721; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Pincheira R, 2001, EUR J CELL BIOL, V80, P410, DOI 10.1078/0171-9335-00176; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Valasek L, 2001, J BIOL CHEM, V276, P43351, DOI 10.1074/jbc.M106887200; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Valasek L, 1999, J BIOL CHEM, V274, P27567, DOI 10.1074/jbc.274.39.27567	40	97	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8946	8956		10.1074/jbc.M312745200	http://dx.doi.org/10.1074/jbc.M312745200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688252	hybrid			2022-12-27	WOS:000189265900053
J	Lee, YI; Hwang, JM; Im, JH; Lee, YI; Kim, NS; Kim, DG; Yu, DY; Moon, HB; Park, SK				Lee, YI; Hwang, JM; Im, JH; Lee, YI; Kim, NS; Kim, DG; Yu, DY; Moon, HB; Park, SK			Human hepatitis B virus-X protein alters mitochondrial function and physiology in human liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HBX PROTEIN; NUCLEAR-FACTOR; CYTOCHROME-C; T-CELLS; KAPPA-B; TRANSITION; GENERATION; EXPRESSION; REDUCTION; APOPTOSIS	The hepatitis B virus-X protein (HBx) regulates fundamental aspects of mitochondrial physiology. We show that HBx down-regulates mitochondrial enzymes involved in electron transport in oxidative phosphorylation ( complexes I, III, IV, and V) and sensitizes the mitochondrial membrane potential in a hepatoma cell line. HBx also increases the level of mitochondrial reactive oxygen species and lipid peroxide production. HBx does not activate apoptotic signaling, although it sensitizes hepatoma cells to apoptotic signaling, which is dependent on reactive oxygen species. Increased intrahepatic lipid peroxidation in HBx transgenic mice demonstrated that oxidative injury occurs as a direct result of HBx expression. Therefore, we conclude that mitochondrial dysfunction is a crucial pathophysiological factor in HBx-expressing hepatoma cells and provides an experimental rationale in the investigation of mitochondrial function in rapidly renewed tissues, as in hepatocellular carcinomas.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Lab, Taejon 305600, South Korea; Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Dev & Differentiat Lab, Taejon 305600, South Korea; Wonkwang Univ, Wonkwang Med Sch, Dept Pathol, Iksan 570749, Chonbook, South Korea; Conbook Natl Univ, Div Gastroenterol & Hepatol, Chonju 561756, Chonbook, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Wonkwang University; Jeonbuk National University	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Lab, POB 115, Taejon 305600, South Korea.	yilee@mail.kribb.re.kr			NIGMS NIH HHS [0GM0100311] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Das AM, 2003, MOL GENET METAB, V79, P71, DOI 10.1016/S1096-7192(03)00069-6; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Kageyama F, 2000, AM J GASTROENTEROL, V95, P1041, DOI 10.1111/j.1572-0241.2000.01979.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P70; KITA K, 1989, J BIOL CHEM, V264, P2672; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Montine TJ, 1996, AM J PATHOL, V148, P89; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Munger J, 2001, P NATL ACAD SCI USA, V98, P10410, DOI 10.1073/pnas.181344498; Oh SW, 1998, MOL CELLS, V8, P212; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4; SHEFFLER IE, 1999, MITOCHONDRIA; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VIZI V, 2003, J NEUROCHEM, V85, P3; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	48	129	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15460	15471		10.1074/jbc.M309280200	http://dx.doi.org/10.1074/jbc.M309280200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724286	hybrid			2022-12-27	WOS:000220594700117
J	Sinha, SC; Chaudhuri, BN; Burgner, JW; Yakovleva, G; Davisson, VJ; Smith, JL				Sinha, SC; Chaudhuri, BN; Burgner, JW; Yakovleva, G; Davisson, VJ; Smith, JL			Crystal structure of imidazole glycerol-phosphate dehydratase - Duplication of an unusual fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; GHMP KINASE SUPERFAMILY; IMIDAZOLEGLYCEROLPHOSPHATE DEHYDRATASE; SALMONELLA-TYPHIMURIUM; ANALYTICAL ULTRACENTRIFUGATION; SACCHAROMYCES-CEREVISIAE; BIFUNCTIONAL ENZYME; PROTEIN STRUCTURES; ESCHERICHIA-COLI; HISB GENE	Imidazole glycerol-phosphate dehydratase (IGPD) catalyzes the sixth step of histidine biosynthesis. The enzyme is of fundamental biochemical interest, because it catalyzes removal of a non-acidic hydrogen atom in the dehydration reaction. It is also a potential target for development of herbicides. IGPD is a metalloenzyme in which transition metals induce aggregation and are required for catalysis. Addition of 1 equivalent of Mn2+/ subunit is shown by analytical ultracentrifugation to induce the formation of 24-mers from trimeric IGPD. Two histidine-rich motifs may participate in metal binding and aggregation. The 2.3-Angstrom crystal structure of metal-free trimeric IGPD from the fungus Filobasidiella neoformans reveals a novel fold containing an internal repeat, apparently the result of gene duplication. The 95-residue alpha/beta half-domain occurs in a few other proteins, including the GHMP kinase superfamily (galactohomoserine-mevalonate-phosphomevalonate), but duplication to form a compact domain has not been seen elsewhere. Conserved residues cluster at two types of sites in the trimer, each site containing a conserved histidine-rich motif. A model is proposed for the intact, active 24-mer in which all highly conserved residues, including the histidine-rich motifs in both the N- and C-terminal halves of the polypeptide, cluster at a common site between trimers. This site is a candidate for the active site and also for metal binding leading to aggregation of trimers. The structure provides a basis for further studies of enzyme function and mechanism and for development of more potent and specific herbicides.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Med Chem & Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Smith, JL (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	smithj@purdue.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK042303, DK-42303] Funding Source: Medline; NIGMS NIH HHS [GM-45756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMES BN, 1957, J BIOL CHEM, V228, P131; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; BRADY DR, 1973, J BIOL CHEM, V248, P2588; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIARIOTTI L, 1986, MOL GEN GENET, V202, P42, DOI 10.1007/BF00330514; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GLASER RD, 1974, BIOCHEMISTRY-US, V13, P5145, DOI 10.1021/bi00722a015; HAWKES TR, 1995, BIOCHEM J, V306, P385, DOI 10.1042/bj3060385; HAWKES TR, 1993, PROC BRIGHTON CROP, P739; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOUSTON LL, 1973, J BIOL CHEM, V248, P4144; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; LOPER JC, 1961, P NATL ACAD SCI USA, V47, P1440, DOI 10.1073/pnas.47.9.1440; MANO J, 1993, PLANT PHYSIOL, V103, P733, DOI 10.1104/pp.103.3.733; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORI I, 1995, J AM CHEM SOC, V117, P4411, DOI 10.1021/ja00120a029; MORI I, 1995, PLANT PHYSIOL, V107, P719, DOI 10.1104/pp.107.3.719; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKER A, 1995, MED CHEM MOL PHARMAC, P218; PARKER AR, 1994, GENE, V145, P135, DOI 10.1016/0378-1119(94)90336-0; Petersen J, 2000, J INORG BIOCHEM, V80, P161, DOI 10.1016/S0162-0134(00)00025-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stams T, 1998, SCIENCE, V280, P752, DOI 10.1126/science.280.5364.752; STAPLES MA, 1979, J BIOL CHEM, V254, P1395; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; TADA S, 1995, PLANT PHYSIOL, V109, P153, DOI 10.1104/pp.109.1.153; TADA S, 1994, PLANT PHYSIOL, V105, P579, DOI 10.1104/pp.105.2.579; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VASINGTON FD, 1967, BIOCHEM BIOPH RES CO, V26, P153, DOI 10.1016/0006-291X(67)90227-6; Wallace AC, 1997, PROTEIN SCI, V6, P2308; WILKINSON KW, 1995, ACTA CRYSTALLOGR D, V51, P845, DOI 10.1107/S0907444995001569; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	47	23	24	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15491	15498		10.1074/jbc.M312733200	http://dx.doi.org/10.1074/jbc.M312733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724278	hybrid			2022-12-27	WOS:000220594700120
J	Takada, Y; Singh, S; Aggarwal, BB				Takada, Y; Singh, S; Aggarwal, BB			Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappa B-mediated gene expression and up-regulation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NUCLEAR-LOCALIZATION SEQUENCE; CASEIN KINASE-II; FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVITY; TRANSACTIVATION DOMAIN; PROTEIN TRANSDUCTION; SIGNAL-TRANSDUCTION; PERMEABLE PEPTIDES; CYCLIN D1	Because of the critical role of the nuclear transcription factor NF-kappaB in inflammation, viral replication, carcinogenesis, antiapoptosis, invasion, and metastasis, specific inhibitors of this nuclear factor are being sought and tested as treatments. NF-kappaB activation is known to require p65 phosphorylation at serine residues 276, 529, and 536 before it undergoes nuclear translocation. Small protein domains, termed protein transduction domains (PTDs), which are able to penetrate cell membranes can be used to transport other proteins across the cell membrane. We have identified two peptides from the p65 subunit of NF-kappaB (P1 and P6 were from amino acid residues 271 - 282 and 525 - 537, respectively) that, when linked with a PTD derived from the third helix sequence of antenna-pedia, inhibited tumor necrosis factor (TNF)-induced NF-kappaB activation in vivo. Linkage to the PTD was not, however, required to suppress the binding of the p50-p65-heterodimer to the DNA in vitro. PTD-p65-P1 had no effect on TNF-induced AP-1 activation. PTD-p65-P1 suppressed NF-kappaB activation induced by lipopolysaccharide, interleukin-1, okadaic acid, phorbol 12-myristate 13-acetate, H2O2, and cigarette smoke condensate as well as that induced by TNF. PTD-p65-P1 had no effect on TNF-induced inhibitory subunit of NF-kappaB (IkappaBalpha) phosphorylation, IkappaBalpha degradation, or IkappaBalpha kinase activation, but it blocked TNF-induced p65 phosphorylation and nuclear translocation. NF-kappaB-regulated reporter gene expression induced by TNF, TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kinase, IkappaBalpha kinase, and p65 was also suppressed by these peptides. Suppression of NF-kappaB by PTD-p65-P1 enhanced the apoptosis induced by TNF and chemotherapeutic agents. Overall, our results demonstrate the identification of a p65 peptide that can selectively inhibit NF-kappaB activation induced by various inflammatory stimuli, down-regulate NF-kappaB-mediated gene expression, and up-regulate apoptosis.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Bioimmunotherapy,Unit 143, Houston, TX 77030 USA; Imgenex, San Diego, CA 92121 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Bioimmunotherapy,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		DIVISION OF BASIC SCIENCES - NCI [Z01BC010610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [CA 91844, BC 010610] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cao GD, 2002, J NEUROSCI, V22, P5423; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fujihara SM, 2000, J IMMUNOL, V165, P1004, DOI 10.4049/jimmunol.165.2.1004; Futaki S, 2003, CURR PROTEIN PEPT SC, V4, P87, DOI 10.2174/1389203033487261; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu XY, 2000, J BIOL CHEM, V275, P16774; Mai JC, 2001, CANCER RES, V61, P7709; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Roshak AK, 2002, CURR OPIN PHARMACOL, V2, P316, DOI 10.1016/S1471-4892(02)00165-0; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	60	158	166	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15096	15104		10.1074/jbc.M311192200	http://dx.doi.org/10.1074/jbc.M311192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14711835	hybrid			2022-12-27	WOS:000220594700075
J	Bharadwaj, R; Qi, W; Yu, HT				Bharadwaj, R; Qi, W; Yu, HT			Identification of two novel components of the human NDC80 kinetochore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SPINDLE CHECKPOINT; CHROMOSOME SEGREGATION; MICROTUBULE ATTACHMENT; MAMMALIAN-CELLS; BUDDING YEAST; MAD2; MITOSIS; CENTROMERE; TENSION	Proper kinetochore function is essential for the accurate segregation of chromosomes during mitosis. Kinetochores provide the attachment sites for spindle microtubules and are required for the alignment of chromosomes at the metaphase plate ( chromosome congression). Components of the conserved NDC80 complex are required for chromosome congression, and their disruption results in mitotic arrest accompanied by multiple spindle aberrations. To better understand the function of the NDC80 complex, we have identified two novel subunits of the human NDC80 complex, termed human SPC25 ( hSPC25) and human SPC24 ( hSPC24), using an immunoaffinity approach. hSPC25 interacted with HEC1 ( human homolog of yeast Ndc80) throughout the cell cycle and localized to kinetochores during mitosis. RNA interference- mediated depletion of hSPC25 in HeLa cells caused aberrant mitosis, followed by cell death, a phenotype similar to that of cells depleted of HEC1. Loss of hSPC25 also caused multiple spindle aberrations, including elongated, multipolar, and fractured spindles. In the absence of hSPC25, MAD1 and HEC1 failed to localize to kinetochores during mitosis, whereas the kinetochore localization of BUB1 and BUBR1 was largely unaffected. Interestingly, the kinetochore localization of MAD1 in cells with a compromised NDC80 function was restored upon microtubule depolymerization. Thus, hSPC25 is an essential kinetochore component that plays a significant role in proper execution of mitotic events.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hongtao.yu@utsouthwestern.edu		Qi, Wei/0000-0003-0813-5316; Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Campbell MS, 2001, J CELL SCI, V114, P953; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; DeLuca JG, 2003, CURR BIOL, V13, P2103, DOI 10.1016/j.cub.2003.10.056; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Taylor SS, 2001, J CELL SCI, V114, P4385; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200	39	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13076	13085		10.1074/jbc.M310224200	http://dx.doi.org/10.1074/jbc.M310224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699129	hybrid			2022-12-27	WOS:000220334900128
J	Fairfax, BP; Pitcher, JA; Scott, MGH; Calver, AR; Pangalos, MN; Moss, SJ; Couve, A'S				Fairfax, BP; Pitcher, JA; Scott, MGH; Calver, AR; Pangalos, MN; Moss, SJ; Couve, A'S			Phosphorylation and chronic agonist treatment atypically modulate GABA(B) receptor cell surface stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOWN-REGULATION; POSTSYNAPTIC GABA(B); INTRATHECAL BACLOFEN; HIPPOCAMPAL-NEURONS; SUBUNIT EXPRESSION; ENDOCYTOSIS; DESENSITIZATION; LOCALIZATION; ASSOCIATION	GABA(B) receptors are heterodimeric G protein-coupled receptors that mediate slow synaptic inhibition in the central nervous system. The dynamic control of the cell surface stability of GABA(B) receptors is likely to be of fundamental importance in the modulation of receptor signaling. Presently, however, this process is poorly understood. Here we demonstrate that GABA(B) receptors are remarkably stable at the plasma membrane showing little basal endocytosis in cultured cortical and hippocampal neurons. In addition, we show that exposure to baclofen, a well characterized GABA(B) receptor agonist, fails to enhance GABA(B) receptor endocytosis. Lack of receptor internalization in neurons correlates with an absence of agonist-induced phosphorylation and lack of arrestin recruitment in heterologous systems. We also demonstrate that chronic exposure to baclofen selectively promotes endocytosis-independent GABA(B) receptor degradation. The effect of baclofen can be attenuated by activation of cAMP-dependent protein kinase or co-stimulation of beta-adrenergic receptors. Furthermore, we show that increased degradation rates are correlated with reduced receptor phosphorylation at serine 892 in GABA(B)R2. Our results support a model in which GABA(B)R2 phosphorylation specifically stabilizes surface GABA(B) receptors in neurons. We propose that signaling pathways that regulate cAMP levels in neurons may have profound effects on the tonic synaptic inhibition by modulating the availability of GABA(B) receptors.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; GlaxoSmithKline Inc, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Pennsylvania; University of London; University College London; University of London; University College London; GlaxoSmithKline	Moss, SJ (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu	Pitcher, Julie/ABH-2078-2020; couve, andres/I-2249-2013; Scott, Mark/R-3521-2019	couve, andres/0000-0003-4216-8672; Fairfax, Benjamin/0000-0001-7413-5002; Scott, Mark G.H./0000-0002-1557-1856				Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Calver AR, 2000, NEUROSCIENCE, V100, P155, DOI 10.1016/S0306-4522(00)00262-1; Calver AR, 2001, J NEUROSCI, V21, P1203; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Couve A, 2002, NAT NEUROSCI, V5, P415, DOI 10.1038/nn833; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; El Far O, 2002, BIOCHEM J, V365, P329, DOI 10.1042/BJ20020481; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Filippov AK, 2000, J NEUROSCI, V20, P2867; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; Kittler JT, 2000, J NEUROSCI, V20, P7972; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Kulik A, 2002, EUR J NEUROSCI, V15, P291, DOI 10.1046/j.0953-816x.2001.01855.x; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lehmann A, 2003, NEUROCHEM RES, V28, P387, DOI 10.1023/A:1022353923578; Luttrell LM, 2002, J CELL SCI, V115, P455; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 1999, SPINAL DRUG DELIVERY, P513; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; MOTT DD, 1994, INT REV NEUROBIOL, V36, P97, DOI 10.1016/S0074-7742(08)60304-9; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prosser HM, 2001, MOL CELL NEUROSCI, V17, P1059, DOI 10.1006/mcne.2001.0995; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Roberts DCS, 1997, PSYCHOPHARMACOLOGY, V131, P271, DOI 10.1007/s002130050293; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com; Sands SA, 2003, J PHARMACOL EXP THER, V305, P191, DOI 10.1124/jpet.102.046342; Scanziani M, 2000, NEURON, V25, P673, DOI 10.1016/S0896-6273(00)81069-7; Schuler V, 2001, NEURON, V31, P47, DOI 10.1016/S0896-6273(01)00345-2; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; Wetherington JP, 2002, J PHYSIOL-LONDON, V544, P459, DOI 10.1113/jphysiol.2002.023093; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Xi ZX, 2003, J NEUROSCI, V23, P3498	50	85	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12565	12573		10.1074/jbc.M311389200	http://dx.doi.org/10.1074/jbc.M311389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707142	hybrid			2022-12-27	WOS:000220334900069
J	Fujimura, T; Esteban, R				Fujimura, T; Esteban, R			Bipartite 3 '-cis-acting signal for replication in yeast 23 S RNA virus and its repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CCA-ADDING ENZYME; 23 S RNA; SACCHAROMYCES-CEREVISIAE; 20S RNA; 20-S RNA; POLYMERASE; FORM; IDENTIFICATION; POLYMERIZATION	23 S RNA narnavirus is a persistent positive strand RNA virus found in Saccharomyces cerevisiae. The viral genome is small (2.9 kb) and only encodes its RNA-dependent RNA polymerase. Recently, we have succeeded in generating 23 S RNA virus from an expression vector containing the entire viral cDNA sequence. Using this in vivo launching system, we analyzed the 3'-cis-acting signals for replication. The 3'-non-coding region of 23 S RNA contains two cis-elements. One is a stretch of 4 Cs at the 3' end, and the other is a mismatched pair in a stem-loop structure that partially overlaps the terminal 4 Cs. In the latter element, the loop or stem sequence is not important but the stem structure with the mismatch pair is essential. The mismatched bases should be purines. Any combination of purines at the mismatch pair bestowed capability of replication on the RNA, whereas converting it to a single bulge at either side of the stem abolished the activity. The terminal and penultimate Cs at the 3' end could be eliminated or modified to other nucleotides in the launching plasmid without affecting virus generation. However, the viruses generated regained or restored these Cs at the 3' terminus. Considering the importance of the viral 3' ends in RNA replication, these results suggest that this 3' end repair may contribute to the persistence of 23 S RNA virus in yeast by maintaining the genomic RNA termini intact. We discuss possible mechanisms for this 3' end repair in vivo.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain.	tfujimura@usal.es	Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769				Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chapman MR, 1999, J MOL BIOL, V286, P709, DOI 10.1006/jmbi.1998.2503; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN LM, 1993, THESIS U SALAMANCA S; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; Esteban R, 2003, P NATL ACAD SCI USA, V100, P2568, DOI 10.1073/pnas.0530167100; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; Guan HC, 2000, P NATL ACAD SCI USA, V97, P12451, DOI 10.1073/pnas.97.23.12451; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Maniatis T., 1982, MOL CLONING LAB MANU; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Nagy PD, 1997, P NATL ACAD SCI USA, V94, P1113, DOI 10.1073/pnas.94.4.1113; NEUFELD KL, 1994, J VIROL, V68, P5811, DOI 10.1128/JVI.68.9.5811-5818.1994; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Siegel RW, 1999, J VIROL, V73, P6424, DOI 10.1128/JVI.73.8.6424-6429.1999; Solorzano A, 2000, J BIOL CHEM, V275, P26428, DOI 10.1074/jbc.M002281200; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1980, CELL, V21, P217, DOI 10.1016/0092-8674(80)90129-4; WICKNER RB, 2000, VIRUS TAXONOMY, P651; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905	39	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13215	13223		10.1074/jbc.M313797200	http://dx.doi.org/10.1074/jbc.M313797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722081	hybrid			2022-12-27	WOS:000220334900143
J	Huang, CC; You, JL; Wu, MY; Hsu, KS				Huang, CC; You, JL; Wu, MY; Hsu, KS			Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI center dot Rab5 complex - Potential role in (S)-3,5-dihydroxyphenylglycine-induced long term depression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DHPG-INDUCED LTD; METABOTROPIC GLUTAMATE RECEPTORS; HIPPOCAMPAL CA1 REGION; G-BETA-GAMMA; MAP KINASE; SYNAPTIC PLASTICITY; COUPLED RECEPTORS; FREQUENCY STIMULATION; RAT HIPPOCAMPUS; AREA CA1	Recent evidence has emphasized the importance of p38 mitogen-activated protein kinase (MAPK) in the induction of metabotropic glutamate receptor (mGluR)-dependent long term depression (LTD) at hippocampal CA3-CA1 synapses. However, the cascade responsible of mGluR to activate p38 MAPK and the signaling pathway immediately downstream from it to induce synaptic depression is poorly understood. Here, we show that transient activation of group I mGluR with the selective agonist (S)-3,5-dihydroxyphenylglycine (DHPG) activates p38 MAPK through G protein betagamma-subunit, small GTPase Rap1, and MAPK kinase 3/6 (MKK3/6), thus resulting in mGluR5-dependent LTD. Furthermore, our data clearly show that an accelerating AMPA receptor endocytosis by stimulating the formation of guanyl nucleotide dissociation inhibitor-Rab5 complex is a potential downstream processing of p38 MAPK activation to mediate DHPG-LTD. These results suggest an important role for Rap1-MKK3/6-p38 MAPK pathway in the induction of mGluR-dependent LTD by directly coupling to receptor trafficking machineries to facilitate the loss of synaptic AMPA receptors.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan	National Cheng Kung University	Hsu, KS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, No 1 Univ Rd, Tainan 701, Taiwan.	richard@mail.ncku.edu.tw	Hsu, Kuei-Sen/AAV-8386-2021	Yu, Chia-Ling/0000-0003-4471-8711				Bashir ZI, 2003, NEUROSCI RES, V45, P363, DOI 10.1016/S0168-0102(03)00002-6; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Clark BP, 1997, BIOORG MED CHEM LETT, V7, P2777, DOI 10.1016/S0960-894X(97)10071-3; Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Faas GC, 2002, J NEUROSCI, V22, P6885; Fitzjohn SM, 1999, NEUROPHARMACOLOGY, V38, P1577, DOI 10.1016/S0028-3908(99)00123-9; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CC, 1999, J NEUROSCI, V19, P9728; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kemp N, 1999, NEUROPHARMACOLOGY, V38, P495, DOI 10.1016/S0028-3908(98)00222-6; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Kleppisch T, 2001, J NEUROSCI, V21, P4943, DOI 10.1523/JNEUROSCI.21-14-04943.2001; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; Moult PR, 2002, NEUROPHARMACOLOGY, V43, P175, DOI 10.1016/S0028-3908(02)00110-7; Palmer MJ, 1997, NEUROPHARMACOLOGY, V36, P1517, DOI 10.1016/S0028-3908(97)00181-0; Rammes G, 2003, J PHYSIOL-LONDON, V546, P455, DOI 10.1113/jphysiol.2002.033514; Rush AM, 2002, J NEUROSCI, V22, P6121; Sawada Y, 2001, J CELL SCI, V114, P1221; Schnabel R, 1999, NEUROPHARMACOLOGY, V38, P1585, DOI 10.1016/S0028-3908(99)00062-3; Schnabel R, 1999, NEUROPHARMACOLOGY, V38, P605, DOI 10.1016/S0028-3908(98)00229-9; Schnabel R, 2001, BRIT J PHARMACOL, V132, P1095, DOI 10.1038/sj.bjp.0703905; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Watabe AM, 2002, J NEUROPHYSIOL, V87, P1395, DOI 10.1152/jn.00723.2001; Xiao MY, 2001, NEUROPHARMACOLOGY, V41, P664, DOI 10.1016/S0028-3908(01)00134-4; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zho WM, 2002, J NEUROSCI, V22, P8838; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	50	148	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12286	12292		10.1074/jbc.M312868200	http://dx.doi.org/10.1074/jbc.M312868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709549	hybrid			2022-12-27	WOS:000220334900035
J	Ogushi, K; Wada, A; Niidome, T; Okuda, T; Llanes, R; Nakayama, M; Nishi, Y; Kurazono, H; Smith, KD; Aderem, A; Moss, J; Hirayama, T				Ogushi, K; Wada, A; Niidome, T; Okuda, T; Llanes, R; Nakayama, M; Nishi, Y; Kurazono, H; Smith, KD; Aderem, A; Moss, J; Hirayama, T			Gangliosides act as co-receptors for Salmonella enteritidis FliC and promote FliC induction of human beta-defensin-2 expression in Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAYS; TOLL-LIKE RECEPTORS; EPITHELIAL-CELLS; BETA-DEFENSINS; HELICOBACTER-PYLORI; BACTERIAL FLAGELLIN; DENDRITIC CELLS; INNATE IMMUNITY; INFLUENZA-VIRUS; LINKING INNATE	Antimicrobial peptides such as defensins are crucial for host defense at mucosal surfaces. We reported previously that Salmonella enteritidis flagellin (FliC) induced human beta-defensin-2 (hBD-2) mRNA expression in Caco-2 cells via NF-kappaB activation (Ogushi, K., Wada, A., Niidome, T., Mori, N., Oishi, K., Nagatake, T., Takahashi, A., Asakura, H., Makino, S., Hojo, H., Nakahara, Y., Ohsaki, M., Hatakeyama, T., Aoyagi, H., Kurazono, H., Moss, J., and Hirayama, T. (2001) J. Biol. Chem. 276, 30521-30526). In this study, we examined the role of ganglioside as co-receptors with Toll-like receptor 5 (TLR5) on FliC induction of hBD-2 expression in Caco-2 cells. Exogenous gangliosides suppressed FliC induction of hBD-2 promoter activity and binding of FliC to Caco-2 cells. Incorporation of exogenous ganglioside GD1a into Caco-2 cell membranes increased the effect of FliC on hBD-2 promoter activity. In support of a role for endogenous gangliosides, incubation of Caco-2 cells with DL-threo-2-hexadecanoylamino-3-morpholino-1-phenylpropanol, a glucosylceramide synthase inhibitor, reduced FliC induction of hBD-2 promoter activity. GD1a-loaded CHO-K1-expressing TLR5 cells had a higher potential for hBD-2 induction following FliC stimulation than GD1a-loaded CHO-K1 cells not expressing TLR5. FliC increased phosphorylation of mitogen-activated protein kinase, p38, and ERK1/2. Exogenous gangliosides GD1a, GD1b, and GT1b each suppressed FliC induction of p38 and ERK1/2 phosphorylation. Furthermore, FliC did not enhance luciferase activity in Caco-2 cells transfected with a plasmid containing a mutated activator protein 1-binding site. These results suggest that gangliosides act as co-receptors with TLR5 for FliC and promote hBD-2 expression via mitogen-activated protein kinase.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Okayama 7008558, Japan; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Inst Syst Biol, Seattle, WA 98103 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Nagasaki University; Okayama University; University of Washington; University of Washington Seattle; Institute for Systems Biology (ISB); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; BENSCH KW, 1995, FEBS LETT, V368, P311; BERGELSON LD, 1982, EUR J BIOCHEM, V128, P467; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; FISHMAN PH, 1982, J MEMBRANE BIOL, V69, P85, DOI 10.1007/BF01872268; Frendeus B, 2001, MOL MICROBIOL, V40, P37, DOI 10.1046/j.1365-2958.2001.02361.x; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; GOUY H, 1994, J IMMUNOL, V152, P3271; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Jia HP, 2001, GENE, V263, P211; JONES DE, 1992, J BIOL CHEM, V267, P23216; JONES DE, 1993, FEBS LETT, V315, P182; Krisanaprakornkit S, 2002, J IMMUNOL, V168, P316, DOI 10.4049/jimmunol.168.1.316; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Moon SK, 2002, BBA-MOL CELL RES, V1590, P41, DOI 10.1016/S0167-4889(02)00196-9; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Ohsaki M, 2002, BIOCONJUGATE CHEM, V13, P510, DOI 10.1021/bc015525a; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; Rusnati M, 2002, P NATL ACAD SCI USA, V99, P4367, DOI 10.1073/pnas.072651899; SUZUKI Y, 1985, J BIOL CHEM, V260, P1362; Svanborg C, 2001, J INFECT DIS, V183, pS61, DOI 10.1086/318858; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200; YAMADA KM, 1983, EXP CELL RES, V143, P295, DOI 10.1016/0014-4827(83)90054-X; Yamaguchi Y, 2002, J IMMUNOL, V169, P2516, DOI 10.4049/jimmunol.169.5.2516; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yowler BC, 2002, J BIOL CHEM, V277, P32815, DOI 10.1074/jbc.M205258200; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	51	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12213	12219		10.1074/jbc.M307944200	http://dx.doi.org/10.1074/jbc.M307944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707135	hybrid			2022-12-27	WOS:000220334900027
J	Pajvani, UB; Hawkins, M; Combs, TP; Rajala, MW; Doebber, T; Berger, JP; Wagner, JA; Wu, M; Knopps, A; Xiang, AH; Utzschneider, KM; Kahn, SE; Olefsky, JM; Buchanan, TA; Scherer, PE				Pajvani, UB; Hawkins, M; Combs, TP; Rajala, MW; Doebber, T; Berger, JP; Wagner, JA; Wu, M; Knopps, A; Xiang, AH; Utzschneider, KM; Kahn, SE; Olefsky, JM; Buchanan, TA; Scherer, PE			Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GLUCOSE-PRODUCTION; DIABETES-MELLITUS; PROTEIN ACRP30; RESISTANCE; AGONISTS; OBESITY; TROGLITAZONE; ASSOCIATION; INDUCTION	Adiponectin is an adipocyte-specific secretory protein that circulates in serum as a hexamer of relatively low molecular weight (LMW) and a larger multimeric structure of high molecular weight (HMW). Serum levels of the protein correlate with systemic insulin sensitivity. The full-length protein affects hepatic gluconeogenesis through improved insulin sensitivity, and a proteolytic fragment of adiponectin stimulates beta oxidation in muscle. Here, we show that the ratio, and not the absolute amounts, between these two oligomeric forms ( HMW to LMW) is critical in determining insulin sensitivity. We define a new index, SA, that can be calculated as the ratio of HMW/(HMW + LMW). db/db mice, despite similar total adiponectin levels, display decreased SA values compared with wild type littermates, as do type II diabetic patients compared with insulin-sensitive individuals. Furthermore, SA improves with peroxisome proliferator-activated receptor-gamma agonist treatment ( thiazolidinedione; TZD) in mice and humans. We demonstrate that changes in SA in a number of type 2 diabetic cohorts serve as a quantitative indicator of improvements in insulin sensitivity obtained during TZD treatment, whereas changes in total serum adiponectin levels do not correlate well at the individual level. Acute alterations in S-A (DeltaS(A)) are strongly correlated with improvements in hepatic insulin sensitivity and are less relevant as an indicator of improved muscle insulin sensitivity in response to TZD treatment, further underscoring the conclusions from previous clamp studies that suggested that the liver is the primary site of action for the full-length protein. These observations suggest that the HMW adiponectin complex is the active form of this protein, which we directly demonstrate in vivo by its ability to depress serum glucose levels in a dose-dependent manner.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Merck Res Labs, Rahway, NJ 07065 USA; SGS Biopharma, B-12060 Antwerp, Belgium; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA; Univ Washington, Seattle, WA 98108 USA; Univ Calif San Diego, Dept Endocrinol & Metab, La Jolla, CA 92093 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Merck & Company; University of Southern California; University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of California System; University of California San Diego	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Utzschneider, Kristina/0000-0002-4924-196X; Kahn, Steven/0000-0001-7307-9002	NIDDK NIH HHS [2R01 DK 46374, DK 02654, DK 17047] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002654, R01DK046374, P30DK017047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AD, 2003, BIOORG MED CHEM LETT, V13, P3185, DOI 10.1016/S0960-894X(03)00702-9; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Azen SP, 1998, CONTROL CLIN TRIALS, V19, P217, DOI 10.1016/S0197-2456(97)00151-7; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Prigeon RL, 1998, J CLIN ENDOCR METAB, V83, P819, DOI 10.1210/jc.83.3.819; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; VAAG A, 1995, DIABETOLOGIA, V38, P326, DOI 10.1007/s001250050289; VASSEUR F, 2002, CURR DIAB REP, V3, P151; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	939	981	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12152	12162		10.1074/jbc.M311113200	http://dx.doi.org/10.1074/jbc.M311113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699128	hybrid			2022-12-27	WOS:000220334900021
J	Weiss, S; Doan, T; Bernstein, KE; Dascal, N				Weiss, S; Doan, T; Bernstein, KE; Dascal, N			Modulation of cardiac Ca2+ channel by G(q)-activating neurotransmitters reconstituted in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VASCULAR SMOOTH-MUSCLE; SENSITIVE CALCIUM-CHANNEL; PHORBOL ESTER INCREASES; ANGIOTENSIN-II; ALPHA(1C) SUBUNIT; RENAL VASOCONSTRICTION; FUNCTIONAL EXPRESSION; TYROSINE KINASE; N-TERMINUS	L-type dihydropyridine-sensitive voltage dependent Ca2+ channels (L-VDCCs; alpha(1C)) are crucial in cardiovascular physiology. Currents via L-VDCCs are enhanced by hormones and transmitters operating via G(q), such as angiotensin II (AngII) and acetylcholine (ACh). It has been proposed that these modulations are mediated by protein kinase C (PKC). However, reports on effects of PKC activators on L-type channels are contradictory; inhibitory and/or enhancing effects have been observed. Attempts to reproduce the enhancing effect of AngII in heterologous expression systems failed. We previously found that PKC modulation of the channel depends on alpha(1C) isoform used; only a long N-terminal (NT) isoform was up-regulated. Here we report the reconstitution of the AngII- and ACh-induced enhancement of the long-NT isoform of L-VDCC expressed in Xenopus oocytes. The current initially increased over several minutes but later declined to below baseline levels. Using different NT deletion mutants and human short- and long-NT isoforms of the channel, we found the initial segment of the NT to be crucial for the enhancing, but not for the inhibitory, effect. Using blockers of PKC and of phospholipase C ( PLC) and a mutated AngII receptor lacking Gq coupling, we demonstrate that the signaling pathway of the enhancing effect includes the activation of Gq, PLC, and PKC. The inhibitory modulation, present in both alpha(1C) isoforms, was G(q)- and PLC-independent and Ca2+-dependent, but not Ca2+-mediated, as only basal levels of Ca2+ were essential. Reconstitution of AngII and ACh effects in Xenopus oocytes will advance the study of molecular mechanisms of these physiologically important modulations.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Tel Aviv University; Sackler Faculty of Medicine; Emory University	Weiss, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146; Bernstein, Kenneth/0000-0001-8097-3272; Weiss, Sharon/0000-0002-0981-6917	NIDDK NIH HHS [DK 39777, DK 44280] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R37DK039777, R01DK039777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauer J, 1999, AM J PHYSIOL-HEART C, V277, pH1, DOI 10.1152/ajpheart.1999.277.1.H1; Beech DJ, 1997, PHARMACOL THERAPEUT, V73, P91, DOI 10.1016/S0163-7258(97)87271-3; BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Blumenstein Y, 2002, J BIOL CHEM, V277, P3419, DOI 10.1074/jbc.C100642200; Boixel C, 2000, AM J PHYSIOL-HEART C, V278, pH670, DOI 10.1152/ajpheart.2000.278.2.H670; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; Dai BS, 2002, BIOCHEM BIOPH RES CO, V296, P429, DOI 10.1016/S0006-291X(02)00894-X; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Doan TN, 2001, J BIOL CHEM, V276, P20954, DOI 10.1074/jbc.C100199200; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; EGLEN RM, 1994, TRENDS PHARMACOL SCI, V15, P114, DOI 10.1016/0165-6147(94)90047-7; Fan QI, 2002, BBA-GENE STRUCT EXPR, V1577, P401, DOI 10.1016/S0167-4781(02)00441-4; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hughes AD, 1995, J VASC RES, V32, P353, DOI 10.1159/000159111; JACKSON EK, 1996, GOODMAN GILMANS PHAR, P733; Kanki H, 2001, MOL PHARMACOL, V60, P989, DOI 10.1124/mol.60.5.989; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LAMBERT C, 1995, BRIT J PHARMACOL, V115, P795, DOI 10.1111/j.1476-5381.1995.tb15003.x; LIU QY, 1993, BIOCHEM BIOPH RES CO, V191, P796, DOI 10.1006/bbrc.1993.1287; Liu XR, 2001, GASTROENTEROLOGY, V120, P480, DOI 10.1053/gast.2001.21167; Love JA, 1998, AM J PHYSIOL-GASTR L, V274, pG397, DOI 10.1152/ajpgi.1998.274.2.G397; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nagahama T, 2000, KIDNEY INT, V57, P215, DOI 10.1046/j.1523-1755.2000.00822.x; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Oz M, 1998, MOL PHARMACOL, V54, P1106, DOI 10.1124/mol.54.6.1106; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; PURDY RE, 1988, CIRC RES, V63, P748, DOI 10.1161/01.RES.63.4.748; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; SCHOLZ H, 1990, AM J PHYSIOL, V259, pC421, DOI 10.1152/ajpcell.1990.259.3.C421; SCHUHMANN K, 1994, FEBS LETT, V341, P208, DOI 10.1016/0014-5793(94)80458-3; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SHI SZ, 2000, AM J PHYSIOL-GASTR L, V278, pG234; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; TAKENAKA T, 1993, CIRC RES, V73, P743, DOI 10.1161/01.RES.73.4.743; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; Watts SW, 1998, J PHARMACOL EXP THER, V286, P1431; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	63	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12503	12510		10.1074/jbc.M310196200	http://dx.doi.org/10.1074/jbc.M310196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722109	hybrid			2022-12-27	WOS:000220334900061
J	Bayless, KJ; Davis, GE				Bayless, KJ; Davis, GE			Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL MORPHOGENESIS; CASPASE-MEDIATED ACTIVATION; FOCAL ADHESIONS; LUMEN FORMATION; STRESS FIBERS; APOPTOSIS; INHIBITION; MEMBRANE; PROTEINS; PHOSPHORYLATION	Maintenance of endothelial cell tube integrity is dependent on an intact cytoskeleton. We present data indicating that rapid collapse of endothelial tubular networks in vitro occurs in a dose-dependent manner after administration of microtubule-depolymerizing reagents but not after actin depolymerization. Pretreatment of endothelial cell networks with C3 exoenzyme or recombinant adenoviruses expressing dominant negative RhoA resulted in complete blockade of tube collapse, indicating a role for RhoA in these events. Microtubule depolymerization also resulted in activation of RhoA, whereas increased expression of constitutively active RhoA induced cell rounding and apoptosis of endothelial cells. Furthermore, following treatment with the chemotherapeutic agent vinblastine, rapid capillary tube network collapse occurred followed by endothelial cell apoptosis. Vinblastine, but not control agents, induced cleavage of procaspase-3, procaspase-9, and procaspase-8, along with the known caspase targets p21-activated kinase-2 and gelsolin, indicating that tube collapse caused a defined apoptotic response. Using a model of vascular endothelial growth factor-stimulated angiogenesis in vivo, vinblastine treatment also resulted in collapse and apoptosis of angiogenic blood vessels. Apoptotic endothelial cells stained strongly for cleaved caspase-3, and terminal dUTP nick-end labeling staining revealed fragmented nuclei in vinblastine-treated but not control angiogenic areas. Together, these findings indicate that microtubule-depolymerizing agents directly induce endothelial network collapse in vitro and in vivo leading to endothelial cell apoptosis in a manner dependent on the small GTPase, RhoA. In addition, these findings reveal a novel function for microtubule disrupting chemotherapeutic agents, namely their ability to rapidly collapse newly formed angiogenic vessels, which may contribute to their effectiveness in limiting angiogenesis and tumor growth.	Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Davis, GE (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, 255 Reynolds Med Bldg, College Stn, TX 77843 USA.	gedavis@tamu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL069603, R01HL059373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59373, F32 HL69603] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bell SE, 2001, J CELL SCI, V114, P2755; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BORNSTEIN MB, 1958, LAB INVEST, V7, P134; Browder T, 2000, CANCER RES, V60, P1878; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Davis GE, 2000, IN VITRO CELL DEV-AN, V36, P513; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Davis GE, 2002, ANAT RECORD, V268, P252, DOI 10.1002/ar.10159; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Eikesdal HP, 2001, INT J RADIAT ONCOL, V51, P535, DOI 10.1016/S0360-3016(01)01693-5; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hippenstiel S, 2002, AM J PHYSIOL-LUNG C, V283, pL830, DOI 10.1152/ajplung.00467.2001; Hotchkiss KA, 2002, MOL CANCER THER, V1, P1191; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; OCONNOLLY JO, 2002, MOL BIOL CELL, V13, P2474; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Platts SH, 2002, J VASC RES, V39, P173, DOI 10.1159/000057765; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ribatti D, 1999, HISTOCHEM CELL BIOL, V112, P447, DOI 10.1007/s004180050427; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salazar R, 1999, EXP CELL RES, V249, P22, DOI 10.1006/excr.1999.4460; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Senger DR, 1996, AM J PATHOL, V149, P1; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	46	95	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11686	11695		10.1074/jbc.M308373200	http://dx.doi.org/10.1074/jbc.M308373200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699132	hybrid			2022-12-27	WOS:000220157600104
J	Kimbell, LM; Ohno, K; Engel, AG; Rotundo, RL				Kimbell, LM; Ohno, K; Engel, AG; Rotundo, RL			C-terminal and heparin-binding domains of collagenic tail subunit are both essential for anchoring acetylcholinesterase at the synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MYASTHENIC SYNDROME; EXONIC SPLICING ENHANCERS; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE; ASYMMETRIC FORMS; SKELETAL-MUSCLE; BASAL LAMINA; DEFICIENCY	The collagen-tailed form of acetylcholinesterase (A(12)-AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan. The heparan sulfate binding domains (HSBD) of ColQ are thought to be involved in anchoring ColQ to the synaptic basal lamina. The C-terminal domain (CTD) of ColQ is also likely involved, but there has been no direct evidence. Mutations in COLQ cause endplate AChE deficiency in humans. Nine previously reported and three novel mutations are in CTD of ColQ, and most CTD mutations do not abrogate formation of A(12)-AChE in transfected COS cells. Patient endplates, however, are devoid of AChE, suggesting that CTD mutations affect anchoring of ColQ to the synaptic basal lamina. Based on our observations that purified AChE can be transplanted to the heterologous frog neuromuscular junction, we tested insertion competence of nine naturally occurring CTD mutants and two artificial HSBD mutants. Wild-type human A(12)-AChE inserted into the frog neuromuscular junction, whereas six CTD mutants and two HSBD mutants did not. Our studies establish that the CTD mutations indeed compromise anchoring of ColQ and that both HSBD and CTD are essential for anchoring ColQ to the synaptic basal lamina.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33136 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Neuromuscular Res Lab, Rochester, MN 55905 USA	University of Miami; University of Miami; Mayo Clinic; Mayo Clinic	Rotundo, RL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, 1600 NW 10th Ave, Miami, FL 33136 USA.	rrotundo@med.miami.edu	Ohno, Kinji/H-4020-2012; Ohno, Kinji/ABD-5787-2020	Ohno, Kinji/0000-0002-1529-2750; Ohno, Kinji/0000-0002-1529-2750	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS006277] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG005917, AG05917] Funding Source: Medline; NINDS NIH HHS [NS6277] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; Anglister L, 1998, J NEUROSCI METH, V81, P63, DOI 10.1016/S0165-0270(98)00015-6; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; Bon S, 2003, NEUROCHEM RES, V28, P523, DOI 10.1023/A:1022821306722; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BRANDAN E, 1984, BIOCHEM J, V221, P415, DOI 10.1042/bj2210415; CAMP S, 1995, J CLIN INVEST, V95, P333, DOI 10.1172/JCI117661; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Donger C, 1998, AM J HUM GENET, V63, P967, DOI 10.1086/302059; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; FAMBROUGH DM, 1982, P NATL ACAD SCI-BIOL, V79, P1078, DOI 10.1073/pnas.79.4.1078; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Gorlov IP, 2003, AM J HUM GENET, V73, P1157, DOI 10.1086/378819; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HUTCHINSON DO, 1993, BRAIN, V116, P633, DOI 10.1093/brain/116.3.633; INESTROSA NC, 1989, TRENDS PHARMACOL SCI, V10, P325, DOI 10.1016/0165-6147(89)90067-9; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; Legay C, 2000, MICROSC RES TECHNIQ, V49, P56, DOI 10.1002/(SICI)1097-0029(20000401)49:1<56::AID-JEMT7>3.0.CO;2-R; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; Ohno K, 2000, ANN NEUROL, V47, P162, DOI 10.1002/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; Rotundo RL, 1997, J CELL BIOL, V136, P367, DOI 10.1083/jcb.136.2.367; Rotundo RL, 1994, MYOLOGY, P607; SALPETER MM, 1987, VERTEBRATE NEUROMUSC, P247; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VIGNY M, 1983, J BIOL CHEM, V258, P8794	41	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10997	11005		10.1074/jbc.M305462200	http://dx.doi.org/10.1074/jbc.M305462200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702351	hybrid			2022-12-27	WOS:000220157600022
J	Rishi, V; Gal, J; Krylov, D; Fridriksson, J; Boysen, MS; Mandrup, S; Vinson, C				Rishi, V; Gal, J; Krylov, D; Fridriksson, J; Boysen, MS; Mandrup, S; Vinson, C			SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains - Use of a dominant negative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL SYSTEM; DNA-BINDING; GENE-EXPRESSION; AMINO-ACID; TRANSCRIPTION FACTOR; B/HLH/Z DOMAIN; PROTEINS; CHOLESTEROL; STABILITY; RECOGNITION	The mammalian SREBP family contains two genes that code for B-HLH-ZIP proteins that bind sequence-specific DNA to regulate the expression of genes involved in lipid metabolism. We have designed a dominant negative (DN), termed A-SREBP-1, that inhibits the DNA binding of either SREBP protein. A-SREBP-1 consists of the dimerization domain of B-SREBP-1 and a polyglutamic acid sequence that replaces the basic region. A-SREBP-1 heterodimerizes with either B-SREBP-1 or B-SREBP-2, and both heterodimers are more stable than B-SREBP-1 bound to DNA. Circular dichroism thermal denaturation studies show that the B-SREBP-1 . A-SREBP-1 heterodimer is - 9.8 kcal mol(-1) dimer(-1) more stable than the B-SREBP-1 homodimer. EMSA assays demonstrate that A-SREBP-1 can inhibit the DNA binding of either B-SREBP-1 or B-SREBP-2 in an equimolar competition but does not inhibit the DNA binding of the three B-HLH-ZIP proteins MAX, USF, or MITF, even at 100 molar eq. Chimeric proteins containing the HLH domain of SREBP-1 and the leucine zipper from either MAX, USF, or MITF indicate that both the HLH and leucine zipper regions of SREBP-1 contribute to its dimerization specificity. Transient co-transfection studies demonstrate that A-SREBP-1 can inhibit the transactivation of SREBP-1 and SREBP-2 but not USF. A-SREBP-1 may be useful in metabolic diseases where SREBP family members are overexpressed.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Gene Log Inc, Gaithersburg, MD 20878 USA; Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern Denmark	Vinson, C (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 3128C, Bethesda, MD 20892 USA.	Vinsonc@dc37a.nci.nih.gov	Mandrup, Susanne/B-6693-2008	Gal, Jozsef/0000-0002-5865-6534; Mandrup, Susanne/0000-0002-0961-5787	NATIONAL CANCER INSTITUTE [ZIABC005271, Z01BC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya A, 2002, BIOCHEMISTRY-US, V41, P14122, DOI 10.1021/bi020486r; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Dragan AI, 2002, J MOL BIOL, V321, P891, DOI 10.1016/S0022-2836(02)00699-X; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LEDENT V, 2002, GENOME BIOL; Litowski JR, 2002, J BIOL CHEM, V277, P37272, DOI 10.1074/jbc.M204257200; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; Moll JR, 2002, NUCLEIC ACIDS RES, V30, P1240, DOI 10.1093/nar/30.5.1240; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1992, NEW BIOL, V4, P396; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zitzewitz JA, 2000, J MOL BIOL, V296, P1105, DOI 10.1006/jmbi.2000.3507	35	29	29	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11863	11874		10.1074/jbc.M308000200	http://dx.doi.org/10.1074/jbc.M308000200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702347	hybrid			2022-12-27	WOS:000220157600123
J	Tanabe, H; Qu, XQ; Weeks, CS; Cummings, JE; Kolusheva, S; Walsh, KB; Jelinek, R; Vanderlick, TK; Selsted, ME; Ouellette, AJ				Tanabe, H; Qu, XQ; Weeks, CS; Cummings, JE; Kolusheva, S; Walsh, KB; Jelinek, R; Vanderlick, TK; Selsted, ME; Ouellette, AJ			Structure-activity determinants in Paneth cell alpha-defensins - Loss-of-function in mouse cryptdin-4 by charge-reversal at arginine residue positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT NEUTROPHIL DEFENSINS; INTESTINAL HOST-DEFENSE; ANTIMICROBIAL PEPTIDES; MEMBRANE PERMEABILIZATION; MICROBICIDAL PROTEINS; ESCHERICHIA-COLI; INNATE IMMUNITY; HUMAN HNP-1; GERM-FREE; MECHANISM	Paneth cells secrete microbicidal enteric alpha-defensins into the small intestinal lumen, and cryptdin-4 (Crp4) is the most bactericidal of the mouse alpha-defensin peptides in vitro. Here, site-directed Arg to Asp mutations in Crp4 have been shown to attenuate or eliminate microbicidal activity against all of the bacterial species tested regardless of the Arg residue position. R31D/R32D charge-reversal mutagenesis at the C terminus and mutations at R16D/R18D, R16D/R24D, and R18D/R24D in the Crp4 polypeptide chain eliminated in vitro bactericidal activity, blocked peptide-membrane interactions, as well as Crp4-mediated membrane vesicle disruption. Lys for Arg charge-neutral substitutions in (R16K/R18K)-Crp4 did not alter the bactericidal activity relative to Crp4, showing that bactericidal activity appears not to require the guanidinium side chain of Arg at those two positions. Partial restoration of (R31D/R32D)-Crp4 bactericidal activity occurred when an electropositive Arg for Gly substitution was introduced at the peptide N terminus and the (G1R/R31D/R32D)-Crp4 peptide exhibited intermediate membrane binding capability. Also, the loss of peptide bactericidal activity in (G1D/R31D/ R32D)-Crp4 and (R16D/R24D)-Crp4 mutants corresponded with diminished phospholipid vesicle disruptive activity. Fluorophore leakage from anionic phospholipid vesicles induced by the charge-reversal variants was negligible relative to Crp4 and lower than that induced by pro-Crp4, the inactive Crp4 precursor. Thus, Arg residues function as determinants of Crp4 bactericidal activity by facilitating or enabling target cell membrane disruption. The role of the Arg residues, however, was surprisingly independent of their position in the polypeptide chain.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Princeton University; Ben Gurion University	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Med Sci I D-440, Irvine, CA 92697 USA.	aouellet@uci.edu	Van Damme, Els J/B-4410-2015; JELINEK, RAZ/F-2023-2012	Kolusheva, Sofiya/0000-0002-4406-2241; jelinek, raz/0000-0002-0336-1384	NIAID NIH HHS [AI22931] Funding Source: Medline; NIDDK NIH HHS [DK44632] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; CROSS M, 1990, EMBO J, V9, P1283, DOI 10.1002/j.1460-2075.1990.tb08237.x; Cummings JE, 2003, AUST J CHEM, V56, P1031, DOI 10.1071/CH03110; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GEYER G, 1973, ACTA HISTOCHEM, V45, P126; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; HUANG HW, 1999, NOVARTIS FD S, V225, P186; Kolusheva S, 2000, NAT BIOTECHNOL, V18, P225, DOI 10.1038/72697; Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b; Kolusheva S, 2001, J AM CHEM SOC, V123, P417, DOI 10.1021/ja0034139; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; Nyman KM, 2000, J HISTOCHEM CYTOCHEM, V48, P1469, DOI 10.1177/002215540004801104; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Ouellette AJ, 2001, INFLAMM BOWEL DIS, V7, P43, DOI 10.1097/00054725-200102000-00007; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; SMOLARSKY M, 1977, J IMMUNOL METHODS, V15, P255, DOI 10.1016/0022-1759(77)90063-1; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Zanetti M, 1997, ANN NY ACAD SCI, V832, P147, DOI 10.1111/j.1749-6632.1997.tb46244.x; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZHANG XL, 1992, BIOCHEMISTRY-US, V31, P11348, DOI 10.1021/bi00161a012	50	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11976	11983		10.1074/jbc.M310251200	http://dx.doi.org/10.1074/jbc.M310251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702345	hybrid			2022-12-27	WOS:000220157600135
J	Tang, W; Hemler, ME				Tang, W; Hemler, ME			Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGENASE-STIMULATORY FACTOR; IMMUNOGLOBULIN SUPERFAMILY; EXPRESSION; INTEGRIN; CD147; TUMOR; BASIGIN; INDUCER; EMMPRIN; MEMBER	CD147, a regulator of matrix metalloproteinase (MMP) production, showed highly specific association with caveolin-1 on the surface of multiple cell types. CD147-caveolin-1 complex formation was temperature and cholesterol dependent, reminiscent of associations seen within caveolae/lipid rafts. However, the subset of caveolin-1 associated with CD147 appeared exclusively within intermediate density sucrose gradient fractions, rather than in the low density fractions containing the bulk of caveolin-1. Mutagenesis experiments revealed that CD147 Ig domain 2 was required for caveolin-1 association. In contrast to CD147-caveolin-1 complexes, CD147-alpha(3) integrin association was not disrupted upon cholesterol depletion, occurred in high density sucrose fractions, and did not involve CD147 Ig domain 2. Overexpression of caveolin-1 caused a specific decrease in clustering of cell surface CD147, as detected by "cluster specific" mAb M6/13. Conversely, a mutant CD147 deficient in caveolin-1 association showed enhanced spontaneous cell surface clustering ( detected by mAb M6/13), and did not show decreased clustering in response to caveolin-1 overexpression. Furthermore, the same CD147 mutant yielded an elevated induction of MMP-1. In conclusion, caveolin-1 associates with CD147, in a complex distinct from CD147-alpha(3) integrin complexes, thereby diminishing both CD147 clustering and CD147-dependent MMP-1-inducing activity.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Rm D-1430,44 Binney St, Boston, MA 02115 USA.	Martin_Hemler@dfci.harvard.edu			NCI NIH HHS [CA86712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Coste I, 2001, BLOOD, V97, P3984, DOI 10.1182/blood.V97.12.3984; Deeg HJ, 2001, BLOOD, V98, P2052, DOI 10.1182/blood.V98.7.2052; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elliott MH, 2003, BIOCHEMISTRY-US, V42, P7892, DOI 10.1021/bi027162n; ELLIS SM, 1989, CANCER RES, V49, P3385; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Guo HM, 1997, J BIOL CHEM, V272, P24; Hori K, 2000, INVEST OPHTH VIS SCI, V41, P3128; Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; KASINRERK W, 1992, J IMMUNOL, V149, P847; KATAOKA H, 1993, CANCER RES, V53, P3154; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Kuno N, 1998, FEBS LETT, V425, P191, DOI 10.1016/S0014-5793(98)00213-0; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; MURAOKA K, 1993, INT J CANCER, V55, P19, DOI 10.1002/ijc.2910550105; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1305, DOI 10.1167/iovs.02-0552; Polette M, 1997, J HISTOCHEM CYTOCHEM, V45, P703, DOI 10.1177/002215549704500508; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Renno T, 2002, J IMMUNOL, V168, P4946, DOI 10.4049/jimmunol.168.10.4946; Sameshima T, 2000, INT J CANCER, V88, P21, DOI 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Sun JX, 2001, CANCER RES, V61, P2276; Taylor PM, 2002, ONCOGENE, V21, P5765, DOI 10.1038/sj.onc.1205702; Tomita T, 2002, ARTHRITIS RHEUM, V46, P373, DOI 10.1002/art.10050; vandenOord JJ, 1997, AM J PATHOL, V151, P665; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yang HL, 2001, J BIOL CHEM, V276, P18775, DOI 10.1074/jbc.M009852200; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	51	129	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11112	11118		10.1074/jbc.M312947200	http://dx.doi.org/10.1074/jbc.M312947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707126	hybrid			2022-12-27	WOS:000220157600035
J	Tsitsigiannis, DI; Zarnowski, R; Keller, NP				Tsitsigiannis, DI; Zarnowski, R; Keller, NP			The lipid body protein, PpoA, coordinates sexual and asexual sporulation in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS GAEUMANNOMYCES-GRAMINIS; LINOLEATE DIOL SYNTHASE; FATTY-ACID-COMPOSITION; ESSENTIAL REGULATOR; COP9 SIGNALOSOME; GENE; BODIES; IDENTIFICATION; EXPRESSION; DIOXYGENASE	The coexistence of sexual and asexual reproductive cycles within the same individual is a striking phenomenon in numerous fungi. In the fungus Aspergillus nidulans (teleomorph: Emericella nidulans) endogenous oxylipins, called psi factor, serve as hormone-like signals that modulate the timing and balance between sexual and asexual spore development. Here, we report the identification of A. nidulans ppoA, encoding a putative fatty acid dioxygenase, involved in the biosynthesis of the linoleic acid derived oxylipin psiBalpha. PpoA is required for balancing anamorph and teleomorph development. Deletion of ppoA significantly reduced the level of psiBalpha and increased the ratio of asexual to sexual spore numbers 4-fold. In contrast, forced expression of ppoA resulted in elevated levels of psiBalpha and decreased the ratio of asexual to sexual spore numbers 6-fold. ppoA expression is mediated by two developmental regulators, VeA and the COP9 signalosome, such that ppoA transcript levels are correlated with the initiation of asexual and sexual fruiting body formation. PpoA localizes in lipid bodies in these tissues. These data support an important role for oxylipins in integrating mitotic and meiotic spore development.	Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Keller, NP (corresponding author), Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA.	npk@plantpath.wisc.edu	Tsitsigiannis, Dimitrios/F-1009-2017; Zarnowski, Robert/A-2786-2009; Keller, Nancy P./ABC-5911-2021	Tsitsigiannis, Dimitrios/0000-0003-2006-6106; Zarnowski, Robert/0000-0001-6343-1500; 				Abell BM, 1997, PLANT CELL, V9, P1481, DOI 10.1105/tpc.9.8.1481; Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BENNETT JW, 1992, ASPERGILLUS BIOL IND, V23, P35; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; Braus GH, 2002, MYCOLOGY S, V15, P215; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Busch S, 2003, MOL MICROBIOL, V49, P717, DOI 10.1046/j.1365-2958.2003.03612.x; BUTNICK NZ, 1984, J BACTERIOL, V160, P533, DOI 10.1128/JB.160.2.533-540.1984; Calvo AM, 2002, MICROBIOL MOL BIOL R, V66, P447, DOI 10.1128/MMBR.66.3.447-459.2002; Calvo AM, 2001, J BIOL CHEM, V276, P25766, DOI 10.1074/jbc.M100732200; Calvo AM, 1999, APPL ENVIRON MICROB, V65, P3668; Carvalho MDF, 2002, GENET MOL BIOL, V25, P485, DOI 10.1590/S1415-47572002000400019; Champe S, 1981, FUNGAL SPORE MORPHOG, P255; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMPE SP, 1987, J GEN MICROBIOL, V133, P1383; Chen JCF, 2001, PLANT CELL PHYSIOL, V42, P1245, DOI 10.1093/pcp/pce160; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; EVANS JL, 1986, CAN J MICROBIOL, V32, P179, DOI 10.1139/m86-035; Fox SR, 2000, LIPIDS, V35, P23, DOI 10.1007/s11745-000-0490-5; Ghanevati M, 2002, EUR J BIOCHEM, V269, P3531, DOI 10.1046/j.1432-1033.2002.03039.x; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; Han KH, 2001, MOL MICROBIOL, V41, P299, DOI 10.1046/j.1365-2958.2001.02472.x; Hause B, 2000, PLANTA, V210, P708, DOI 10.1007/s004250050671; Herman R.P., 1999, EICOSANOIDS RELATED, DOI [10.1515/9781400873111-008, DOI 10.1515/9781400873111-008]; Hornsten L, 1999, J BIOL CHEM, V274, P28219, DOI 10.1074/jbc.274.40.28219; Huber SMFE, 2002, MOL GENET GENOMICS, V267, P757, DOI 10.1007/s00438-002-0717-y; Kamisaka Y, 1999, BBA-MOL CELL BIOL L, V1438, P185, DOI 10.1016/S1388-1981(99)00050-5; Kim HS, 2002, FUNGAL GENET BIOL, V37, P72, DOI 10.1016/S1087-1845(02)00029-4; Lee SB, 1990, PCR PROTOCOLS GUIDE, P282, DOI DOI 10.1016/B978-0-12-372180-8.50038-X; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; MAZUR P, 1991, J CHEM SOC CHEM COMM, P1486, DOI 10.1039/c39910001486; MILLER BL, 1985, MOL CELL BIOL, V5, P1714, DOI 10.1128/MCB.5.7.1714; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PUNT PJ, 1991, J BIOTECHNOL, V17, P19, DOI 10.1016/0168-1656(91)90024-P; SAMBROOK J, 2001, MOL CLON LAB MANUAL; Sienko M, 1999, CURR GENET, V35, P638, DOI 10.1007/s002940050463; Su C, 1998, J BIOL CHEM, V273, P20744, DOI 10.1074/jbc.273.33.20744; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; Ting JTL, 1997, J BIOL CHEM, V272, P3699, DOI 10.1074/jbc.272.6.3699; Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161; YAGER LN, 1992, ASPERGILLUS BIOL IND, P19; Yu JH, 1996, CURR GENET, V29, P549, DOI 10.1007/s002940050084; Zarnowski R, 2000, PHYTOCHEMISTRY, V55, P975, DOI 10.1016/S0031-9422(00)00219-3; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	48	144	157	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11344	11353		10.1074/jbc.M310840200	http://dx.doi.org/10.1074/jbc.M310840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699095	hybrid			2022-12-27	WOS:000220157600063
J	Abbas, T; White, D; Hui, L; Yoshida, K; Foster, DA; Bargonetti, J				Abbas, T; White, D; Hui, L; Yoshida, K; Foster, DA; Bargonetti, J			Inhibition of human p53 basal transcription by down-regulation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TUMOR PROMOTION; PHORBOL ESTER; CELLS; EXPRESSION; ACTIVATION; GENE; APOPTOSIS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; PHOSPHORYLATION	In response to DNA damage, signal transduction pathways are activated that result in the increase of p53 protein levels, leading to either growth arrest or apoptosis. Protein kinase C (PKC) delta has been implicated as a tumor suppressor that is down-regulated by tumor-promoting phorbol esters in both mouse skin and cell culture models. We report here that the tumor-promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate prevents DNA damage-induced up-regulation of p53 by down-regulating PKC delta. Regulation of p53 in response to stress most commonly occurs by preventing ubiquitination and degradation of the p53 protein. Surprisingly, suppression of p53 expression by inhibition of PKC delta was caused by the inhibition of p53 synthesis, not increased degradation of p53 protein. Inhibiting PKC delta blocked both basal transcription of the human p53 gene and initiation of transcription from the human p53 promoter. Therefore, the tumor-suppressing effects of PKC delta are mediated at least in part through activating p53 transcription.	CUNY Hunter Coll, Inst Biomolec Struct & Funct, New York, NY 10021 USA; CUNY Hunter Coll, Dept Biol Sci, Grad Sch, New York, NY 10021 USA; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Tokyo 1138510, Japan	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Tokyo Medical & Dental University (TMDU)	Bargonetti, J (corresponding author), CUNY Hunter Coll, Inst Biomolec Struct & Funct, 695 Pk Ave, New York, NY 10021 USA.	bargonetti@genectr.hunter.cuny.edu		Bargonetti, Jill/0000-0003-2692-0991	NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas T, 2002, J BIOL CHEM, V277, P40513, DOI 10.1074/jbc.M205495200; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durland-Busbice S, 2002, LEUKEMIA, V16, P2165, DOI 10.1038/sj.leu.2402647; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; Ghosh JC, 1999, J RADIAT RES, V40, P23, DOI 10.1269/jrr.40.23; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HANSEN LA, 1990, CANCER RES, V50, P5740; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; Hornia A, 1999, MOL CELL BIOL, V19, P7672; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MAGNELLI L, 1995, BIOCHEM BIOPH RES CO, V215, P641, DOI 10.1006/bbrc.1995.2512; Magnelli L, 1998, BIOCHEM BIOPH RES CO, V249, P222, DOI 10.1006/bbrc.1998.9039; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Reddig PJ, 1999, CANCER RES, V59, P5710; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; ROCKWELL S, 1995, ONCOL RES, V7, P39; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKOUV J, 1994, CELL GROWTH DIFFER, V5, P329; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	45	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9970	9977		10.1074/jbc.M306979200	http://dx.doi.org/10.1074/jbc.M306979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699137	hybrid			2022-12-27	WOS:000220050400040
J	Jindou, S; Soda, A; Karita, S; Kajino, T; Beguin, P; Wu, JHD; Inagaki, M; Kimura, T; Sakka, K; Ohmiya, K				Jindou, S; Soda, A; Karita, S; Kajino, T; Beguin, P; Wu, JHD; Inagaki, M; Kimura, T; Sakka, K; Ohmiya, K			Cohesin-dockerin Interactions within and between Clostridium josui and Clostridium thermocellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATING PROTEIN CIPA; SCAFFOLDING PROTEIN; NUCLEOTIDE-SEQUENCES; CELLULOSOME; CELLULOLYTICUM; ENDOGLUCANASE; COMPONENT; DOMAINS; PURIFICATION; EXPRESSION	The cellulosome components are assembled into the cellulosome complex by the interaction between one of the repeated cohesin domains of a scaffolding protein and the dockerin domain of an enzyme component. We prepared five recombinant cohesin polypeptides of the Clostridium thermocellum scaffolding protein CipA, two dockerin polypeptides of C. thermocellum Xyn11A and Xyn10C, four cohesin polypeptides of Clostridium josui CipA, and two dockerin polypeptides of C. josui Aga27A and Cel8A, and qualitatively and quantitatively examined the cohesin-dockerin interactions within C. thermocellum and C. josui, respectively, and the species specificity of the cohesin-dockerin interactions between these two bacteria. Surface plasmon resonance (SPR) analysis indicated that there was a certain selectivity, with a maximal 34-fold difference in the K-D values, in the cohesin-dockerin interactions within a combination of C. josui, although this was not detected by qualitative analysis. Affinity blotting analysis suggested that there was at least one exception to the species specificity in the cohesin-dockerin interactions, although species specificity was generally conserved among the cohesin and dockerin polypeptides from C. thermocellum and C. josui, i.e. the dockerin polypeptides of C. thermocellum Xyn11A exceptionally bound to the cohesin polypeptides from C. josui CipA. SPR analysis confirmed this exceptional binding. We discuss the relationship between the species specificity of the cohesin-dockerin binding and the conserved amino acid residues in the dockerin domains.	Mie Univ, Fac Bioresources, Tsu, Mie 5148507, Japan; Toyota Cent Res & Dev Labs Inc, Special Res Lab 2, Aichi 4801192, Japan; Inst Pasteur, Dept Biotechnol, F-75724 Paris 15, France; Univ Rochester, Dept Chem Engn, Rochester, NY 14627 USA	Mie University; Toyota Central R&D Labs Inc; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Rochester	Sakka, K (corresponding author), Mie Univ, Fac Bioresources, 1515 Kamihamacho, Tsu, Mie 5148507, Japan.	sakka@bio.mie-u.ac.jp		Beguin, Pierre/0000-0002-5372-6281				Ahsan MM, 1996, J BACTERIOL, V178, P5732, DOI 10.1128/jb.178.19.5732-5740.1996; Beguin P, 1996, PROTEIN SCI, V5, P1192; Ciruela A, 1998, FEBS LETT, V422, P221, DOI 10.1016/S0014-5793(97)01590-1; DOI RH, 1994, CRIT REV MICROBIOL, V20, P87, DOI 10.3109/10408419409113548; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; FUJINO T, 1993, J FERMENT BIOENG, V76, P243, DOI 10.1016/0922-338X(93)90188-E; GarciaCampayo V, 1997, J BIOTECHNOL, V57, P39, DOI 10.1016/S0168-1656(97)00086-2; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; Hayashi H, 1997, J BACTERIOL, V179, P4246, DOI 10.1128/jb.179.13.4246-4253.1997; Hayashi H, 1999, APPL MICROBIOL BIOT, V51, P348, DOI 10.1007/s002530051401; Jindou S, 2002, J BACTERIOL, V184, P600, DOI 10.1128/JB.184.2.600-604.2002; Kakiuchi M, 1998, J BACTERIOL, V180, P4303, DOI 10.1128/JB.180.16.4303-4308.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamed R, 1983, BIOTECHNOL BIOENG S, V13, P163; Lytle B, 1996, J BACTERIOL, V178, P1200, DOI 10.1128/jb.178.4.1200-1203.1996; Mechaly A, 2000, PROTEINS, V39, P170, DOI 10.1002/(SICI)1097-0134(20000501)39:2<170::AID-PROT7>3.0.CO;2-H; MORAG E, 1992, Enzyme and Microbial Technology, V14, P289, DOI 10.1016/0141-0229(92)90153-F; Ohara H, 2000, BIOSCI BIOTECH BIOCH, V64, P254, DOI 10.1271/bbb.64.254; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Pages S, 1996, J BACTERIOL, V178, P2279, DOI 10.1128/jb.178.8.2279-2286.1996; SAKKA K, 1994, GENETICS BIOCH ECOLO, P32; SHOSEYOV O, 1992, P NATL ACAD SCI USA, V89, P3483, DOI 10.1073/pnas.89.8.3483; Steenbakkers PJM, 2001, J BACTERIOL, V183, P5325, DOI 10.1128/JB.183.18.5325-5333.2001; SUKHUMAVASI J, 1988, INT J SYST BACTERIOL, V38, P179, DOI 10.1099/00207713-38-2-179; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	26	48	52	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9867	9874		10.1074/jbc.M308673200	http://dx.doi.org/10.1074/jbc.M308673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688277	hybrid			2022-12-27	WOS:000220050400026
J	Bisognano, C; Kelley, WL; Estoppey, T; Francois, P; Schrenzel, J; Li, DM; Lew, DP; Hooper, DC; Cheung, AL; Vaudaux, P				Bisognano, C; Kelley, WL; Estoppey, T; Francois, P; Schrenzel, J; Li, DM; Lew, DP; Hooper, DC; Cheung, AL; Vaudaux, P			A RecA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBINHIBITORY CONCENTRATIONS; ESCHERICHIA-COLI; DNA-DAMAGE; INCREASED EXPRESSION; BACILLUS-SUBTILIS; EPITHELIAL-CELLS; VIRULENCE GENES; SOS RESPONSE; MURINE MODEL; PROTEINS	Subinhibitory concentrations of ciprofloxacin (CPX) raise the fibronectin-mediated attachment of fluoroquinolone-resistant Staphylococcus aureus by selectively inducing fnbB coding for one of two fibronectin-binding proteins: FnBPB. To identify candidate regulatory pathway(s) linking drug exposure to up-regulation of fnbB, we disrupted the global response regulators agr, sarA, and recA in the highly quinolone-resistant strain RA1. Whereas agr and sarA mutants of RA1 exposed to CPX still displayed increased adhesion to fibronectin, the CPX-triggered response was abolished in the uvs-568 recA mutant, but was restored following complementation with wild type recA. Steady-state levels of recA and fnbB, but not fnbA, mRNA were co-coordinately increased >3-fold in CPX-exposed strain RA1. Electrophoretic mobility shift assays revealed specific binding of purified S. aureus SOS-repressor LexA to recA and fnbB, but not to fnbA or rpoB promoters. DNase I footprint analysis showed LexA binding overlapping the core promoter elements in fnbB. We conclude that activation of recA and derepression of lexA-regulated genes by CPX may represent a response to drug-induced damage that results in a novel induction of a virulence factor leading to increased bacterial tissue adherence.	Univ Hosp, Div Infect Dis, CH-1211 Geneva 14, Switzerland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Dartmouth Coll, Sch Med, Dept Microbiol, Hanover, NH 03755 USA	University of Geneva; Harvard University; Harvard Medical School; Massachusetts General Hospital; Dartmouth College	Kelley, WL (corresponding author), Univ Hosp, Div Infect Dis, CH-1211 Geneva 14, Switzerland.	william.kelley@hcuge.ch	Schrenzel, Jacques/AAC-5685-2021; francois, patrice/AAL-5583-2020; Schrenzel, Jacques/P-8525-2017	Schrenzel, Jacques/0000-0001-5464-7764; Schrenzel, Jacques/0000-0001-5464-7764; francois, patrice/0000-0002-0540-750X	NIAID NIH HHS [AI47441, AI23988] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047441, R37AI023988, R01AI023988] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson DG, 1998, CELL, V95, P975, DOI 10.1016/S0092-8674(00)81721-3; BAYLES KW, 1994, GENE, V147, P13, DOI 10.1016/0378-1119(94)90033-7; Bischoff M, 2001, J BACTERIOL, V183, P5171, DOI 10.1128/JB.183.17.5171-5179.2001; Bisognano C, 1997, ANTIMICROB AGENTS CH, V41, P906, DOI 10.1128/AAC.41.5.906; Bisognano C, 2000, ANTIMICROB AGENTS CH, V44, P1428, DOI 10.1128/AAC.44.6.1428-1437.2000; BLEDOV I, 2003, SCIENCE, V300, P1404; BUTCHER WG, 1994, CHEMOTHERAPY, V40, P114, DOI 10.1159/000239182; CHEUNG AL, 1994, ANAL BIOCHEM, V222, P511, DOI 10.1006/abio.1994.1528; Courcelle J, 2001, GENETICS, V158, P41; Dziewanowska K, 2000, INFECT IMMUN, V68, P6321, DOI 10.1128/IAI.68.11.6321-6328.2000; Dziewanowska K, 1999, INFECT IMMUN, V67, P4673, DOI 10.1128/IAI.67.9.4673-4678.1999; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Fournier B, 2000, ANTIMICROB AGENTS CH, V44, P2160, DOI 10.1128/AAC.44.8.2160-2165.2000; Gertz S, 2000, J BACTERIOL, V182, P6983, DOI 10.1128/JB.182.24.6983-6991.2000; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; Hooper DC, 2002, LANCET INFECT DIS, V2, P530, DOI 10.1016/S1473-3099(02)00369-9; HOWARD BMA, 1993, J PHARM PHARMACOL, V45, P658, DOI 10.1111/j.2042-7158.1993.tb05673.x; Karlsson A, 2001, INFECT IMMUN, V69, P4742, DOI 10.1128/IAI.69.8.4742-4748.2001; KERNODLE DS, 1995, J INFECT DIS, V172, P410, DOI 10.1093/infdis/172.2.410; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kullik I, 1998, J BACTERIOL, V180, P4814, DOI 10.1128/JB.180.18.4814-4820.1998; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; LEE CY, 1991, GENE, V103, P101, DOI 10.1016/0378-1119(91)90399-V; LEE JC, 1995, METHOD MOL BIOL, V47, P209, DOI DOI 10.1385/0-89603-310-4:209; LI D, 2003, CLIN MICRO INF S1, V9, P89; LITTLE JW, 1994, METHOD ENZYMOL, V244, P273; LOVETT CM, 1988, J BACTERIOL, V170, P1467, DOI 10.1128/jb.170.4.1467-1474.1988; Manna AC, 1998, J BACTERIOL, V180, P3828, DOI 10.1128/JB.180.15.3828-3836.1998; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Menzies BE, 2003, CURR OPIN INFECT DIS, V16, P225, DOI 10.1097/00001432-200306000-00007; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Ohlsen K, 1998, ANTIMICROB AGENTS CH, V42, P2817, DOI 10.1128/AAC.42.11.2817; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PHILLIPS I, 1987, J ANTIMICROB CHEMOTH, V20, P631, DOI 10.1093/jac/20.5.631; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; POWER EGM, 1992, J MED MICROBIOL, V36, P78, DOI 10.1099/00222615-36-2-78; PROCTOR RA, 1983, J ANTIMICROB CHEMOTH, V12, P85, DOI 10.1093/jac/12.suppl_C.85; PROCTOR RA, 1983, ANTIMICROB AGENTS CH, V24, P823, DOI 10.1128/AAC.24.5.823; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; STAHL ML, 1983, J BACTERIOL, V154, P406, DOI 10.1128/JB.154.1.406-412.1983; Sutton MD, 2000, ANNU REV GENET, V34, P479, DOI 10.1146/annurev.genet.34.1.479; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; Vaudaux P, 2002, INFECT IMMUN, V70, P5428, DOI 10.1128/IAI.70.10.5428-5437.2002; Vaudaux P., 2000, INFECT ASS INDWELLIN, P1; Vaudaux PE, 1998, ANTIMICROB AGENTS CH, V42, P564, DOI 10.1128/AAC.42.3.564; WALKER GC, 1987, ESCHERICHIA COLI SAL, V2, P1346; Winterling KW, 1998, J BACTERIOL, V180, P2201, DOI 10.1128/JB.180.8.2201-2211.1998; Wolz C, 2000, MOL MICROBIOL, V36, P230, DOI 10.1046/j.1365-2958.2000.01853.x; Yeiser B, 2002, P NATL ACAD SCI USA, V99, P8737, DOI 10.1073/pnas.092269199	50	64	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9064	9071		10.1074/jbc.M309836200	http://dx.doi.org/10.1074/jbc.M309836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699158	hybrid			2022-12-27	WOS:000189265900067
J	Hankamer, BD; Elderkin, SL; Buck, M; Nield, J				Hankamer, BD; Elderkin, SL; Buck, M; Nield, J			Organization of the AAA(+) adaptor protein PspA is an oligomeric ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHAGE-SHOCK; CRYOELECTRON MICROSCOPY; YERSINIA-ENTEROCOLITICA; TRANSCRIPTION; GENE; RECONSTRUCTION; EXPRESSION; BIOGENESIS; SYSTEM	The 25.3 kDa "adaptor" protein, PspA (dphage shock protein A), is found in the cytoplasm and in association with the inner membrane of certain bacteria. PspA plays critical roles in negatively regulating the phage shock response and maintaining membrane integrity, especially during the export of proteins such as virulence factors. Homologues of PspA function exist for thylakoid biogenesis. Here we report the first three-dimensional reconstruction of a PspA assembly from Escherichia coli, visualized by electron microscopy and single particle analysis to a resolution of 30 Angstrom. The assembly forms a 9-fold rotationally symmetric ring with an outer diameter of 200 Angstrom, an inner diameter of 95 Angstrom, and a height of similar to85 Angstrom. The molecular mass of the complex was calculated to be 1023 kDa by size exclusion chromatography, suggesting that each of the nine domains is likely to be composed of four PspA subunits. The functional implications of this PspA structure are discussed in terms of its interaction with the protein export machinery of the bacterial cell and its AAA(+) protein partner, PspF.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	Imperial College London; University of Queensland	Nield, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England.	j.nield@imperial.ac.uk	Nield, Jon/C-5892-2013; Hankamer, Ben D/C-9688-2015	Nield, Jon/0000-0001-9983-0239; Hankamer, Ben D/0000-0001-9284-4929				Adams H, 2003, J BACTERIOL, V185, P1174, DOI 10.1128/JB.185.4.1174-1180.2003; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; Darwin AJ, 2001, MOL MICROBIOL, V39, P429, DOI 10.1046/j.1365-2958.2001.02235.x; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; Jones SE, 2003, J BACTERIOL, V185, P6707, DOI 10.1128/JB.185.22.6707-6711.2003; JONES TA, 1993, O VERSION 5 9 MANUAL; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; KLEEREBEZEM M, 1993, MOL MICROBIOL, V7, P947, DOI 10.1111/j.1365-2958.1993.tb01186.x; Kleerebezem M, 1996, EMBO J, V15, P162, DOI 10.1002/j.1460-2075.1996.tb00344.x; Koster M, 2000, INT J MED MICROBIOL, V290, P325; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; Model P, 1997, MOL MICROBIOL, V24, P255, DOI 10.1046/j.1365-2958.1997.3481712.x; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; Ruprecht J, 2001, PROG BIOPHYS MOL BIO, V75, P121, DOI 10.1016/S0079-6107(01)00004-9; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	27	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8862	8866		10.1074/jbc.M307889200	http://dx.doi.org/10.1074/jbc.M307889200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688274	hybrid			2022-12-27	WOS:000189265900042
J	Martin, D; Rojo, AI; Salinas, M; Diaz, R; Gallardo, G; Alam, J; de Galarreta, CMR; Cuadrado, A				Martin, D; Rojo, AI; Salinas, M; Diaz, R; Gallardo, G; Alam, J; de Galarreta, CMR; Cuadrado, A			Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OXIDATIVE STRESS; GENE-EXPRESSION; NF-E2-RELATED FACTOR-2; EPITHELIAL-CELLS; PRIMARY CULTURES; SODIUM ARSENITE; DNA-DAMAGE; INDUCTION; ACTIVATION	The phosphatidylinositol 3-kinase (PI3K)/Akt pathway elicits a survival signal against multiple apoptotic insults. In addition, phase II enzymes such as heme oxygenase-1 (HO-1) protect cells against diverse toxins and oxidative stress. In this work, we describe a link between these defense systems at the level of transcriptional regulation of the antioxidant enzyme HO-1. The herb-derived phenol carnosol induced HO-1 expression at both mRNA and protein levels. Luciferase reporter assays indicated that carnosol targeted the mouse ho1 promoter at two enhancer regions comprising the antioxidant response elements (AREs). Moreover, carnosol increased the nuclear levels of Nrf2, a transcription factor governing AREs. Electrophoretic mobility shift assays and luciferase reporter assays with a dominant-negative Nrf2 mutant indicated that carnosol increased the binding of Nrf2 to ARE and induced Nrf2-dependent activation of the ho1 promoter. While investigating the signaling pathways responsible for HO-1 induction, we observed that carnosol activated the ERK, p38, and JNK pathways as well as the survival pathway driven by PI3K. Inhibition of PI3K reduced the increase in Nrf2 protein levels and activation of the ho1 promoter. Expression of active PI3K-CAAX ( where A is aliphatic amino acid) was sufficient to activate AREs. The use of dominant-negative mutants of protein kinase Czeta and Akt1, two kinases downstream from PI3K, demonstrated a requirement for active Akt1, but not protein kinase Czeta. Moreover, the long-term antioxidant effect of carnosol was partially blocked by PI3K or HO-1 inhibitors, further demonstrating that carnosol attenuates oxidative stress through a pathway that involves PI3K and HO-1.	Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Inst Invest Biomed, E-28029 Madrid, Spain; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Univ Palmas Gran Canaria, Fac Med, Dept Bioquim, Gran Canaria 35016, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Universidad de Las Palmas de Gran Canaria	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	antonio.cuadrado@uam.es	campos, german gallardo/Z-5267-2019; Alam, Jawed/F-2596-2010; Rojo, Ana I/AAA-5203-2019	campos, german gallardo/0000-0002-1516-1750; Alam, Jawed/0000-0001-6520-482X; Rojo, Ana I/0000-0002-0312-5867; Martin Izquierdo, Daniel/0000-0002-8880-9087; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Bauer M, 2002, ANTIOXID REDOX SIGN, V4, P749, DOI 10.1089/152308602760598891; Chen J, 2003, J NEUROCHEM, V85, P1247, DOI 10.1046/j.1471-4159.2003.01776.x; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Dinkova-Kostova AT, 2002, MINI-REV MED CHEM, V2, P595, DOI 10.2174/1389557023405558; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hill-Kapturczak N, 2001, AM J PHYSIOL-RENAL, V281, pF851, DOI 10.1152/ajprenal.0140.2001; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Iqbal M, 2003, PHARMACOL TOXICOL, V92, P33, DOI 10.1034/j.1600-0773.2003.920106.x; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Liu HL, 2003, J NEUROCHEM, V86, P1553, DOI 10.1046/j.1471-4159.2003.01978.x; Lo AH, 2002, CARCINOGENESIS, V23, P983, DOI 10.1093/carcin/23.6.983; Maeshima H, 1996, NUCLEIC ACIDS RES, V24, P2959, DOI 10.1093/nar/24.15.2959; Maines MD, 2003, TOXICOL SCI, V71, P9, DOI 10.1093/toxsci/71.1.9; Maines MD, 2000, CELL MOL BIOL, V46, P573; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mazza F, 2003, EXP BIOL MED, V228, P576, DOI 10.1177/15353702-0322805-31; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Oguro T, 1998, J PHARMACOL EXP THER, V287, P773; Ohlmann A, 2003, EXP BIOL MED, V228, P584, DOI 10.1177/15353702-0322805-51; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P625, DOI 10.1089/15230860260220120; Saikawa Y, 2000, Hum Mutat, V16, P178, DOI 10.1002/1098-1004(200008)16:2<178::AID-HUMU16>3.0.CO;2-X; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; Zeng HH, 2001, ACTA PHARMACOL SIN, V22, P1094	54	592	607	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8919	8929		10.1074/jbc.M309660200	http://dx.doi.org/10.1074/jbc.M309660200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688281	hybrid			2022-12-27	WOS:000189265900050
J	Watanabe, I; Zhu, J; Recio-Pinto, E; Thornhill, WB				Watanabe, I; Zhu, J; Recio-Pinto, E; Thornhill, WB			Glycosylation affects the protein stability and cell surface expression of Kv1.4 but not Kv1.1 potassium channels - A pore region determinant dictates the effect of glycosylation on trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNELS; DIVERSITY	Kv1.1 and Kv1.4 potassium channels are plasma membrane glycoproteins involved in action potential repolarization. We have shown previously that glycosylation affects the gating function of Kv1.1 (Watanabe, I., Wang, H. G., Sutachan, J. J., Zhu, J., Recio-Pinto, E. & Thornhill, W. B. (2003) J. Physiol. (Lond.) 550, 51-66) and that a pore region determinant of Kv1.1 and Kv1.4 affects their cell surface trafficking negatively or positively, respectively (Zhu, J., Watanabe, I., Gomez, B. & Thornhill, W. B. (2001) J. Biol. Chem. 276, 39419-39427). Here we investigated the role of N-glycosylation of Kv1.1 and Kv1.4 on their protein stability, cellular localization pattern, and trafficking to the cell surface. We found that preventing N-glycosylation of Kv1.4 decreased its protein stability, induced its high partial intracellular retention, and decreased its cell surface protein levels, whereas it had little or no effect on these parameters for Kv1.1. Exchanging a trafficking pore region determinant between Kv1.1 and Kv1.4 reversed these effects of glycosylation on these chimeric channels. Thus it appeared that the Kv1.4 pore region determinant and the sugar tree attached to the S1-S2 linker showed some type of dependence in promoting proper trafficking of the protein to the cell surface, and this dependence can be transferred to chimeric Kv1.1 proteins that contain the Kv1.4 pore. Understanding the different trafficking programs of Kv1 channels, and whether they are altered by glycosylation, will highlight the different posttranslational mechanisms available to cells to modify their cell surface ion channel levels and possibly their signaling characteristics.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA; NYU, Sch Med, Dept Anesthesiol, New York, NY 10016 USA	Fordham University; New York University	Thornhill, WB (corresponding author), Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA.	thornhill@fordham.edu			NINDS NIH HHS [NS29633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Carchon H, 1999, BBA-MOL BASIS DIS, V1455, P155, DOI 10.1016/S0925-4439(99)00073-3; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Hille B., 2001, IONIC CHANNELS EXCIT, P814; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jaeken J, 1991, Acta Paediatr Scand Suppl, V375, P1; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; LENNARZ W, 1983, METHOD ENZYMOL, V98, P91; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Watanabe I, 2003, J PHYSIOL-LONDON, V550, P51, DOI 10.1113/jphysiol.2003.040337; Zhu J, 2003, BIOCHEM J, V375, P761, DOI 10.1042/BJ20030885; Zhu J, 2003, J BIOL CHEM, V278, P25558, DOI 10.1074/jbc.M207984200; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	17	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8879	8885		10.1074/jbc.M309802200	http://dx.doi.org/10.1074/jbc.M309802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688283	hybrid			2022-12-27	WOS:000189265900045
J	Edelman, GM				Edelman, GM			Biochemistry and the sciences of recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							CELL-ADHESION MOLECULE; MYELOMA GLOBULINS; NEURAL CELLS; CHICK-EMBRYO; SEQUENCE; ANTIBODIES; SELECTION; PROTEINS; BINDING		Inst Neurosci, San Diego, CA 92121 USA; Scripps Res Inst, San Diego, CA 92121 USA	Scripps Research Institute	Edelman, GM (corresponding author), Inst Neurosci, San Diego, CA 92121 USA.	edelman@nsi.edu						BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; CURTIS ASG, 1967, CELL SURFACE ITS MOL; Edelman G. M., 1988, TOPOBIOLOGY INTRO MO; Edelman G.M., 1992, BRIGHT AIR BRILLIANT; EDELMAN GM, 1973, SCIENCE, V180, P830, DOI 10.1126/science.180.4088.830; EDELMAN GM, 1987, IMMUNOL REV, V100, P11, DOI 10.1111/j.1600-065X.1987.tb00526.x; EDELMAN GM, 1994, GENETICS, V138, P975; EDELMAN GM, 1962, P NATL ACAD SCI USA, V48, P1035, DOI 10.1073/pnas.48.6.1035; EDELMAN GM, 1992, DEV DYNAM, V193, P2, DOI 10.1002/aja.1001930103; Edelman GM, 2003, P NATL ACAD SCI USA, V100, P5520, DOI 10.1073/pnas.0931349100; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EDELMAN GM, 1959, J AM CHEM SOC, V81, P3155, DOI 10.1021/ja01521a071; EDELMAN GM, 1983, SCIENCE, V219, P450, DOI 10.1126/science.6823544; Edelman GM, 2001, P NATL ACAD SCI USA, V98, P13763, DOI 10.1073/pnas.231499798; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; EDELMAN GM, 1962, J EXP MED, V116, P207; Edelman GM, 1987, NEURAL DARWINISM THE; Edelman GM., 1978, MINDFUL BRAIN CORTIC; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; HILSCHMANN N, 1965, P NATL ACAD SCI USA, V53, P1403, DOI 10.1073/pnas.53.6.1403; HIRS CHW, 1960, J BIOL CHEM, V235, P633; HIS W, 1874, OUR BODY SHAPE PHYSL; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOLLINGSWORTH R, 2000, PRACTISING INTERDISC, P215; Holtreter J, 1939, ARCH EXP ZELLFORSCH, V23, P169; JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849; Krichmar JL, 2002, CEREB CORTEX, V12, P818, DOI 10.1093/cercor/12.8.818; Krushel LA, 1999, J BIOL CHEM, V274, P2432, DOI 10.1074/jbc.274.4.2432; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Mayr E., 1982, GROWTH BIOL THOUGHT; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pauling L, 1940, J AM CHEM SOC, V62, P2643, DOI 10.1021/ja01867a018; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; POULIK MD, 1961, NATURE, V191, P1274, DOI 10.1038/1911274a0; ROUX W, 1986, DEFINING BIOL LECT 1, P107; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; Smart FM, 2003, P NATL ACAD SCI USA, V100, P14403, DOI 10.1073/pnas.2436349100; Spemann H., 1938, EMBRYONIC DEV INDUCT; Srinivasan R, 1999, J NEUROSCI, V19, P5435; Stretton AOW, 2002, GENETICS, V162, P527; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THIERY JP, 1977, J BIOL CHEM, V252, P6841; Tiselius A, 1939, J EXP MED, V69, P119, DOI 10.1084/jem.69.1.119; TONEGAWA S, 1993, SCAND J IMMUNOL, V38, P305, DOI 10.1111/j.1365-3083.1993.tb01731.x; 1993, NEURON, V10, P1	48	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7361	7369		10.1074/jbc.X400001200	http://dx.doi.org/10.1074/jbc.X400001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14718522	hybrid			2022-12-27	WOS:000189103300001
J	Cho, WK; Siegrist, VJ; Zinzow, W				Cho, WK; Siegrist, VJ; Zinzow, W			Impaired regulatory volume decrease in freshly isolated cholangiocytes from cystic fibrosis mice - Implications for cystic fibrosis transmembrane conductance regulator effect on potassium conductance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	52nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases/International-Liver-Transplantation-Society	NOV 09-13, 2001	DALLAS, TX	Amer Assoc Study Liver Dis, Int Liver Transplant Soc			INTRACELLULAR PH REGULATION; BILE-DUCT UNITS; CELL-VOLUME; ATP RELEASE; PRIMARY CULTURES; HYPOTONIC SHOCK; ANION CHANNELS; CL-CHANNELS; K+ CHANNELS; RAT	Various K+ and Cl- channels are important in cell volume regulation and biliary secretion, but the specific role of cystic fibrosis transmembrane conductance regulator in cholangiocyte cell volume regulation is not known. The goal of this research was to study regulatory volume decrease (RVD) in bile duct cell clusters (BD-CCs) from normal and cystic fibrosis (CF) mouse livers. Mouse BDCCs without an enclosed lumen were prepared as described (Cho, W. K. (2002) Am. J. Physiol. 283, G1320 - G1327). The isotonic solution consisted of HEPES buffer with 40% of the NaCl replaced with isomolar amounts of sucrose, whereas hypotonic solution was the same as isotonic solution without sucrose. The cell volume changes were indirectly assessed by measuring cross-sectional area (CSA) changes of the BDCCs using quantitative videomicroscopy. Exposure to hypotonic solutions increased relative CSAs of normal BDCCs to 1.20 +/- 0.01 (mean +/- S. E., n = 50) in 10 min, followed by RVD to 1.07 +/- 0.01 by 40 min. Hypotonic challenge in CF mouse BDCCs also increased relative CSA to 1.20 +/- 0.01 ( n = 53) in 10 min but without significant recovery. Coadministration of the K+-selective ionophore valinomycin restored RVD in CF mouse BDCCs, suggesting that the impaired RVD was likely from a defect in K+ conductance. Moreover, this valinomycin-induced RVD in CF mice was inhibited by 5-nitro-2'-(3-phenylpropylamino)benzoate, indicating that it is not from nonspecific effects. Neither cAMP nor calcium agonists could reverse the impaired RVD seen in CF cholangiocytes. Our conclusion is that CF mouse cholangiocytes have defective RVD from an impaired K+ efflux pathway, which could not be reversed by cAMP nor calcium agonists.	Indiana Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; University of North Carolina; University of North Carolina Chapel Hill	Cho, WK (corresponding author), Indiana Univ, Sch Med, Roudebush VA Med Ctr, Div GI Hepatol 111G, 1481 W 10th St, Indianapolis, IN 46202 USA.	wkcho@iupui.edu		Zinzow-Kramer, Wendy/0000-0003-1469-5803	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002613, R03DK061409] Funding Source: NIH RePORTER; NIDDK NIH HHS [R03 DK61409, K08 DK02613] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARO D, 1993, J CLIN INVEST, V92, P1314, DOI 10.1172/JCI116705; Ando-Akatsuka Y, 2002, PFLUG ARCH EUR J PHY, V445, P177, DOI 10.1007/s00424-002-0920-z; Arreola J, 2003, J PHYSIOL-LONDON, V547, P197, DOI 10.1113/jphysiol.2002.028373; BANDERALI U, 1992, J MEMBRANE BIOL, V126, P219; Barriere H, 2003, AM J PHYSIOL-RENAL, V284, pF796, DOI 10.1152/ajprenal.00237.2002; Belfodil R, 2003, AM J PHYSIOL-RENAL, V284, pF812, DOI 10.1152/ajprenal.00238.2002; BENEDETTI A, 1993, HEPATOLOGY, V18, P422, DOI 10.1016/0270-9139(93)90028-L; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; Cho WK, 2002, AM J PHYSIOL-GASTR L, V283, pG1320, DOI 10.1152/ajpgi.00256.2002; Cho WK, 1998, HEPATOLOGY, V28, p534A; Cho WK, 2001, AM J PHYSIOL-GASTR L, V280, pG241, DOI 10.1152/ajpgi.2001.280.2.G241; CHO WK, 2000, GASTR HEPAT, V7, P99; CIVAN MM, 1992, EXP EYE RES, V54, P181, DOI 10.1016/S0014-4835(05)80207-6; CIVAN MM, 1994, INVEST OPHTH VIS SCI, V35, P2876; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COHN JA, 1993, GASTROENTEROLOGY, V105, P1857, DOI 10.1016/0016-5085(93)91085-V; Feranchak AP, 2002, SEMIN LIVER DIS, V22, P251, DOI 10.1055/s-2002-34503; Fischbarg J, 1997, BRIT J OPHTHALMOL, V81, P85, DOI 10.1136/bjo.81.1.85; FITZ JG, 1993, J CLIN INVEST, V91, P319, DOI 10.1172/JCI116188; FOSKETT JK, 1994, J EXP ZOOL, V268, P104, DOI 10.1002/jez.1402680206; Graf J, 1996, J HEPATOL, V24, P53; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; HALL SK, 1995, J PHYSIOL-LONDON, V488, P359, DOI 10.1113/jphysiol.1995.sp020972; Haussinger D, 1996, Prog Liver Dis, V14, P29; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; LIRA M, 1992, GASTROENTEROLOGY, V102, P563, DOI 10.1016/0016-5085(92)90104-7; LOHR JW, 1994, BRAIN RES, V667, P263, DOI 10.1016/0006-8993(94)91504-0; MCCARTY NA, 1991, J MEMBRANE BIOL, V123, P149, DOI 10.1007/BF01998085; MCGILL JM, 1992, AM J PHYSIOL, V262, pG703, DOI 10.1152/ajpgi.1992.262.4.G703; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; MENNONE A, 1995, P NATL ACAD SCI USA, V92, P6527, DOI 10.1073/pnas.92.14.6527; Mignen O, 1999, J PHYSIOL-LONDON, V515, P501, DOI 10.1111/j.1469-7793.1999.501ac.x; MONTROSERAFIZADEH C, 1991, AM J PHYSIOL, V260, pF402, DOI 10.1152/ajprenal.1991.260.3.F402; Morales-Mulia S, 1998, J NEUROCHEM, V71, P2330; Moran J, 1997, J NEUROSCI RES, V47, P144, DOI 10.1002/(SICI)1097-4547(19970115)47:2<144::AID-JNR3>3.0.CO;2-F; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; Roman R, 2002, AM J PHYSIOL-GASTR L, V282, pG116, DOI 10.1152/ajpgi.2002.282.1.G116; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SIRICA AE, 1985, AM J PATHOL, V120, P67; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRAZZABOSCO M, 1991, J CLIN INVEST, V87, P1503, DOI 10.1172/JCI115160; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; THOMASYOUNG RJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P81, DOI 10.1016/0005-2736(93)90341-V; Tinel H, 2000, CELL PHYSIOL BIOCHEM, V10, P297, DOI 10.1159/000016375; VALVERDE MA, 1995, P NATL ACAD SCI USA, V92, P9038, DOI 10.1073/pnas.92.20.9038; Vennekens R, 1999, J PHYSIOL-LONDON, V515, P75, DOI 10.1111/j.1469-7793.1999.075ad.x; Walker VE, 1999, AM J PHYSIOL-CELL PH, V276, pC1432, DOI 10.1152/ajpcell.1999.276.6.C1432; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wang ZR, 1997, J GEN PHYSIOL, V110, P73, DOI 10.1085/jgp.110.1.73; Weskamp M, 2000, J MEMBRANE BIOL, V178, P11, DOI 10.1007/s002320010010	55	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14610	14618		10.1074/jbc.M310855200	http://dx.doi.org/10.1074/jbc.M310855200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	808UT	14722124	hybrid			2022-12-27	WOS:000220594700019
J	Daroui, P; Desai, SD; Li, TK; Liu, AA; Liu, LF				Daroui, P; Desai, SD; Li, TK; Liu, AA; Liu, LF			Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT COMPLEXES; YEAST-CELLS; IONIZING-RADIATION; RADICAL GENERATION; INDUCED APOPTOSIS; OXIDATIVE STRESS; FENTON REACTION; CAMPTOTHECIN; REPAIR; SACCHAROMYCES	Reactive oxygen species modify DNA, generating various DNA lesions including modified bases such as 8-oxoguanine (8-oxoG). These base-modified DNA lesions have been shown to trap DNA topoisomerase I (TOP1) into covalent cleavage complexes. In this study, we have investigated the role of TOP1 in hydrogen peroxide toxicity. We showed that ectopic expression of TOP1 in Saccharomyces cerevisiae conferred sensitivity to hydrogen peroxide, and this sensitivity was dependent on RAD9 checkpoint function. Moreover, in the mammalian cell culture system, hydrogen peroxide-induced growth inhibition and apoptosis were shown to be partly TOP1-dependent as evidenced by a specific increase in resistance to hydrogen peroxide in TOP1-deficient P388/ CPT45 murine leukemia cells as compared with their TOP1-proficient parental cell line P388. In addition, hydrogen peroxide was shown to induce TOP1-DNA cross-links. These results support a model in which hydrogen peroxide promotes the trapping of TOP1 on oxidative DNA lesions to form TOP1-DNA cleavage complexes that contribute to hydrogen peroxide toxicity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		LI, TSAI-KUN/0000-0003-0393-2340; Daroui, Parima/0000-0002-9669-9383; Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA077433, CA39662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662, R01CA077433] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORNSTI MA, 1989, CANCER RES, V49, P6318; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Buda F, 2003, CHEM-EUR J, V9, P3436, DOI 10.1002/chem.200204444; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CARMICHAEL J, 1987, CANCER RES, V47, P936; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chatgilialoglu C, 2001, EXP GERONTOL, V36, P1459, DOI 10.1016/S0531-5565(01)00132-2; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; ENG WK, 1990, MOL PHARMACOL, V38, P471; Epe B, 2002, BIOL CHEM, V383, P467, DOI 10.1515/BC.2002.049; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; Khelifa T, 1999, BIOCHEM PHARMACOL, V58, P1247, DOI 10.1016/S0006-2952(99)00213-0; KNAB AM, 1993, J BIOL CHEM, V268, P22322; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Li TK, 2003, CANCER RES, V63, P8400; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; MATTERN MR, 1993, ONCOL RES, V5, P467; MATTERN MR, 1991, CANCER RES, V51, P5813; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Nitiss JL, 2001, J BIOL CHEM, V276, P26708, DOI 10.1074/jbc.M102674200; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Ren JG, 2001, FEBS LETT, V488, P123, DOI 10.1016/S0014-5793(00)02377-2; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sekiguchi M, 2002, ONCOGENE, V21, P8895, DOI 10.1038/sj.onc.1206023; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Toh GWL, 2003, BIOCHEM SOC T, V31, P242, DOI 10.1042/bst0310242; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WOESSNER RD, 1992, ONCOL RES, V4, P481; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023	56	108	113	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14587	14594		10.1074/jbc.M311370200	http://dx.doi.org/10.1074/jbc.M311370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14688260	hybrid			2022-12-27	WOS:000220594700016
J	Brame, CJ; Boutaud, O; Davies, SS; Yang, T; Oates, JA; Roden, D; Roberts, LJ				Brame, CJ; Boutaud, O; Davies, SS; Yang, T; Oates, JA; Roden, D; Roberts, LJ			Modification of proteins by isoketal-containing oxidized phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; VENTRICULAR MYOCYTES; ALDEHYDIC PRODUCT; FREE-RADICALS; PROSTANOIDS F2-ISOPROSTANES; 4-HYDROXYNONENAL TRIGGERS; CA2+ INFLUX; PATHWAY; INHIBITION; CURRENTS	Oxidative stress frequently leads to altered function of membrane proteins. Isoketals are highly reactive products of the isoprostane pathway of free radical-induced lipid peroxidation that rapidly form covalent protein adducts and exhibit a remarkable proclivity to form protein cross links in vitro. Examination of isoketal adducts from an animal model of oxidative injury revealed that initial adducts were formed by isoketals esterified in phospholipids, representing a novel oxidative injury-associated modification of proteins by phospholipids. Maturation of adducts involved cleavage from phospholipids and conversion of adducts to a more stable chemical form that can be detected for extended periods. Because initial adducts were formed by phospholipid-esterified isoketals, the functional consequence of isoketal adduction was examined using a model membrane protein ( a cardiac K+ channel). These studies revealed that isoketal adduction profoundly altered protein function, inhibiting potassium current in a dose-dependent manner. These findings indicate that phospholipid-esterified isoketals rapidly adduct membrane proteins and that such modification can alter protein function, suggesting a generalized cellular mechanism for alteration of membrane function as a consequence of oxidative stress.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; Vanderbilt Univ, Dept Med, Nashville, TN USA	Vanderbilt University; Vanderbilt University	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA.	jack.roberts@vanderbilt.edu	Roden, Dan/ABD-5412-2021	Davies, Sean/0000-0001-9879-8062	NHLBI NIH HHS [HL46881] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, P50GM015431, R01GM042056, P01GM015431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoine S, 1998, J MOL CELL CARDIOL, V30, P2623, DOI 10.1006/jmcc.1998.0818; Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; BHATNAGAR A, 1995, CIRC RES, V76, P293, DOI 10.1161/01.RES.76.2.293; Blanc EM, 1997, J NEUROCHEM, V69, P570; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; Carini R, 1996, BIOCHEM BIOPH RES CO, V218, P772, DOI 10.1006/bbrc.1996.0137; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GILL JS, 1995, EUR J PHARM-ENVIRON, V292, P337, DOI 10.1016/0926-6917(95)90042-X; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Kagan V. E, 1988, LIPID PEROXIDATION B; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Liu W, 1999, J CELL SCI, V112, P2409; Mark RJ, 1997, J NEUROCHEM, V68, P255; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; SATOH N, 1995, EUR J PHARM-ENVIRON, V292, P233, DOI 10.1016/0926-6917(95)90027-6; SHATTOCK MJ, 1993, CIRC RES, V72, P91, DOI 10.1161/01.RES.72.1.91; Tokube K, 1996, AM J PHYSIOL-HEART C, V271, pH478, DOI 10.1152/ajpheart.1996.271.2.H478; Ueda K, 1997, J NEUROCHEM, V68, P265; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870	27	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13447	13451		10.1074/jbc.M313349200	http://dx.doi.org/10.1074/jbc.M313349200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715668	hybrid			2022-12-27	WOS:000220478500022
J	Planque, S; Bangale, Y; Song, XT; Karle, S; Taguchi, H; Poindexter, B; Bick, R; Edmundson, A; Nishiyama, Y; Paul, S				Planque, S; Bangale, Y; Song, XT; Karle, S; Taguchi, H; Poindexter, B; Bick, R; Edmundson, A; Nishiyama, Y; Paul, S			Ontogeny of proteolytic immunity - IgM serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODIES; MONOCLONAL-ANTIBODIES; MURINE IGM; B-CELLS; BINDING; INHIBITORS; PEPTIDE; HYDROLYSIS; EXPRESSION; REACTIVITY	We report the chemical activity of immunoglobulin mu and kappa/lambda subunits expressed on the surface of B cells and in secreted IgM antibodies (Abs) found in the preimmune repertoire. Most of the nucleophilic reactivity of B cells measured by formation of covalent adducts of a hapten amidino phosphonate diester was attributed to mu and kappa/lambda subunits of the B cell receptor. Secreted IgM Abs displayed superior nucleophilic reactivity than IgG Abs. IgM Abs catalyzed the cleavage of model peptide substrates at rates up to 344-fold greater than IgG Abs. Catalytic activities were observed in polyclonal IgM Abs from immunologically naive mice and humans without immunological disease, as well as monoclonal IgM Abs to unrelated antigens. Comparison of several IgM Abs indicated divergent activity levels and substrate preferences, with the common requirement of a basic residue flanking the cleavage site. Fab fragments of a monoclonal IgM Ab expressed catalytic activity, confirming the V domain location of the catalytic site. The catalytic reaction was inhibited by the covalently reactive hapten probe and diisopropylfluorophosphate, suggesting a serine protease-like mechanism. These observations indicate the existence of serine protease-like BCRs and secreted IgM Abs as innate immunity components with potential roles in B cell development and Ab effector functions.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Oklahoma Med Res Fdn, Crystallog Program, Oklahoma City, OK 73104 USA	University of Texas System; Oklahoma Medical Research Foundation	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, 6431 Fannin, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268] Funding Source: NIH RePORTER; NCI NIH HHS [CA80312] Funding Source: Medline; NIAID NIH HHS [AI31268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1983, P NATL ACAD SCI-BIOL, V80, P5071, DOI 10.1073/pnas.80.16.5071; Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; BIRO A, 1992, EUR J IMMUNOL, V22, P2547, DOI 10.1002/eji.1830221013; CHAVIN SI, 1969, J BIOL CHEM, V244, P1345; CHEN TY, 1993, AM J HEMATOL, V44, P276, DOI 10.1002/ajh.2830440411; CORNISHBOWDEN AJ, 1969, BIOCHEM J, V113, P353, DOI 10.1042/bj1130353; Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102; Dunn-Walters DK, 2000, J IMMUNOL, V164, P1595, DOI 10.4049/jimmunol.164.3.1595; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Hatiuchi K, 2003, IMMUNOL LETT, V86, P249, DOI 10.1016/S0165-2478(03)00030-0; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; Jeannin P, 1998, EUR J IMMUNOL, V28, P1815, DOI 10.1002/(SICI)1521-4141(199806)28:06<1815::AID-IMMU1815>3.0.CO;2-5; KALAGA R, 1995, J IMMUNOL, V155, P2695; KOHEN F, 1980, FEBS LETT, V111, P427, DOI 10.1016/0014-5793(80)80842-8; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; KU GSB, 1983, J IMMUNOL, V131, P2494; KU GSB, 1981, J IMMUNOL, V126, P2209; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Li L, 1996, MOL IMMUNOL, V33, P593, DOI 10.1016/0161-5890(96)00021-1; LI L, 1995, J IMMUNOL, V154, P3328; MACKENZIE MR, 1978, SCAND J IMMUNOL, V7, P367, DOI 10.1111/j.1365-3083.1978.tb00466.x; Malynn BA, 2002, MOL IMMUNOL, V38, P547, DOI 10.1016/S0161-5890(01)00085-2; Marangoni AG, 2002, ENZYME KINETICS, P70; MARKS R, 1985, J EXP MED, V162, P1862, DOI 10.1084/jem.162.6.1862; Matsuura K, 1998, IMMUNOLOGY, V95, P26; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; MIZUGUCHI J, 1989, BIOCHEM J, V263, P641, DOI 10.1042/bj2630641; MORELOCK MM, 1994, J BIOL CHEM, V269, P13048; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Planque S, 2003, J BIOL CHEM, V278, P20436, DOI 10.1074/jbc.M301468200; Poindexter BJ, 2002, MICROSC ANAL, V89, P21; PRAK EL, 1995, J EXP MED, V182, P541, DOI 10.1084/jem.182.2.541; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020; ROHEN PW, 1995, J IMMUNOL, V154, P6437; Roux KH, 1998, J IMMUNOL, V161, P4083; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; Sato S, 1996, J IMMUNOL, V157, P4371; Saveliev AN, 2003, IMMUNOL LETT, V86, P291, DOI 10.1016/S0165-2478(03)00042-7; Shaw DC, 2002, J MOL RECOGNIT, V15, P341, DOI 10.1002/jmr.596; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; VANERP R, 1991, J IMMUNOL METHODS, V140, P235, DOI 10.1016/0022-1759(91)90376-Q; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	54	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14024	14032		10.1074/jbc.M312152200	http://dx.doi.org/10.1074/jbc.M312152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726510	hybrid			2022-12-27	WOS:000220478500091
J	Denti, S; Sirri, A; Cheli, A; Rogge, L; Innamorati, G; Putignano, S; Fabbri, M; Pardi, R; Bianchi, E				Denti, S; Sirri, A; Cheli, A; Rogge, L; Innamorati, G; Putignano, S; Fabbri, M; Pardi, R; Bianchi, E			RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MAP KINASE; SIGNAL-TRANSDUCTION; NUCLEAR-PROTEIN; BINDING-PROTEIN; CELL-MIGRATION; ACTIVATION; PHOSPHORYLATION; ADHESION; IDENTIFICATION	Integrin adhesion receptors can act as signaling receptors that transmit information from the extracellular environment to the interior of the cell, affecting many fundamental cellular processes, such as cell motility, proliferation, differentiation, and survival. Integrin signaling depends on the formation of organized sub- membrane complexes that comprise cytoskeletal, adapter, and signaling molecules. The identification of molecules that interact with the cytoplasmic domain of integrins has been the focus of research aimed to elucidating the mechanistic basis of integrin signal transduction. We have identified RanBPM as a novel interactor of the beta(2) integrin LFA- 1 in a yeast- two- hybrid screen. In the same assay, RanBPM also interacted with the beta(1) integrin cytoplasmic domain. We demonstrate that RanBPM is a peripheral membrane protein and that integrins and RanBPM interact in vitro and in vivo and co- localize at the cell membrane. We find that RanBPM is phosphorylated on serine residues; phosphorylation of RanBPM is increased by stress stimuli and decreased by treatment with the p38 kinase inhibitor SB203580. Transfection of RanBPM synergizes with LFA- 1- mediated adhesion in the transcriptional activation of an AP- 1- dependent promoter, indicating that the two proteins interact functionally as well. We suggest that RanBPM may constitute a molecular scaffold that contributes to coupling LFA- 1 and other integrins with intracellular signaling pathways.	Inst Pasteur, Dept Immunol, Immunoregulat Lab, F-75724 Paris, France; DIBIT, Lab Leukocyte Biol, I-20132 Milan, Italy; Univ Vita San Raffaele, I-20132 Milan, Italy	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bianchi, E (corresponding author), Inst Pasteur, Dept Immunol, Immunoregulat Lab, 25 Rue Dr Roux, F-75724 Paris, France.	ebianchi@pasteur.fr	Rogge, Lars/GYJ-6142-2022; Innamorati, Giulio/AAR-6314-2020; Innamorati, Giulio/GVU-1941-2022	Innamorati, Giulio/0000-0003-0123-8777; Rogge, Lars/0000-0003-1262-9204	Telethon [E.1300] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bai D, 2003, BIOCHEM BIOPH RES CO, V309, P552, DOI 10.1016/j.bbrc.2003.08.033; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bokel C, 2002, DEV CELL, V3, P311, DOI 10.1016/S1534-5807(02)00265-4; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COPPOLINO M, 1995, BIOCHEM J, V306, P129, DOI 10.1042/bj3060129; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Geginat J, 1999, J IMMUNOL, V162, P5085; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hogg N, 2000, MATRIX BIOL, V19, P211, DOI 10.1016/S0945-053X(00)00066-4; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Juliano RL, 2001, METHOD ENZYMOL, V333, P151; Liu SC, 2000, J CELL SCI, V113, P3563; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nebe B, 1998, EXP CELL RES, V243, P263, DOI 10.1006/excr.1998.4143; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Smith J.A., 2000, CURRENT PROTOCOLS MO; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Xie B, 2001, J BIOL CHEM, V276, P19512, DOI 10.1074/jbc.M009063200; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	47	83	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13027	13034		10.1074/jbc.M313515200	http://dx.doi.org/10.1074/jbc.M313515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722085	hybrid			2022-12-27	WOS:000220334900123
J	Nakai, Y; Umeda, N; Suzuki, T; Nakai, M; Hayashi, H; Watanabe, K; Kagamiyama, H				Nakai, Y; Umeda, N; Suzuki, T; Nakai, M; Hayashi, H; Watanabe, K; Kagamiyama, H			Yeast Nfs1p is involved in thio-modification of both mitochondrial and cytoplasmic tRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; ENTERICA SEROVAR TYPHIMURIUM; ANTICODON WOBBLE NUCLEOTIDE; IN-VITRO BIOSYNTHESIS; COLI TRANSFER-RNA; FE-S CLUSTER; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; SACCHAROMYCES-CEREVISIAE; AZOTOBACTER-VINELANDII	The IscS protein is a pyridoxal phosphate-containing cysteine desulfurase involved in iron-sulfur cluster biogenesis. In prokaryotes, IscS is also involved in various metabolic functions, including thio-modification of tRNA. By contrast, the eukaryotic ortholog of IscS (Nfs1) has thus far been shown to be functional only in mitochondrial iron-sulfur cluster biogenesis. We demonstrate here that yeast Nfs1p is also required for the post-transcriptional thio-modification of both mitochondrial (mt) and cytoplasmic (cy) tRNAs in vivo. Depletion of Nfs1p resulted in an immediate impairment of the 2-thio-modification of 5-carboxymethylaminomethyl-2-thiouridine at the wobble positions of mt-tRNA(UUU)(Lys) and mt-tRNA(UUG)(Gln). In addition, we observed a severe reduction in the 2-thiomodification of 5-methoxycarbonylmethyl-2-thiouridine (mcm(5)s(2)U) of cy-tRNA(UUU)(Lys2) and cy-tRNA(UUC)(Glu3), although the effect was somewhat delayed compared with that seen in mt-tRNAs. Mass spectrometry analysis revealed an increase in 5-methoxycarbonylmethyluridine concomitant with a decrease in mcm(5)s(2)U in cy-tRNAs that were prepared from Nfs1p-depleted cells. These results suggest that Nfs1p is involved in the 2-thio-modification of both 5-carboxymethylaminomethyl-2-thiouridine in mt-tRNAs and mcm(5)s(2)U in cy-tRNAs.	Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Chiba 2778562, Japan; Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Osaka Medical College; University of Tokyo; Osaka University	Nakai, Y (corresponding author), Osaka Med Coll, Dept Biochem, 2-7 Daigaku Machi, Osaka 5698686, Japan.	med004@art.osaka-med.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731				Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Bjork GR, 1995, TRNA STRUCTURE BIOSY; Chheda GB, 1999, NUCLEOS NUCLEOT, V18, P2155, DOI 10.1080/07328319908044873; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Frazzon J, 2002, BIOCHEM SOC T, V30, P680, DOI 10.1042/BST0300680; GROSSENBACHER AM, 1986, J BIOL CHEM, V261, P6351; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; ISEL C, 1993, J BIOL CHEM, V268, P25269; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LATEN HM, 1983, BIOCHIM BIOPHYS ACTA, V741, P1, DOI 10.1016/0167-4781(83)90002-7; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Mihara H, 2002, P NATL ACAD SCI USA, V99, P6679, DOI 10.1073/pnas.102176099; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; PATWARDHAN S, 1985, J BACTERIOL, V62, P55; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	47	98	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12363	12368		10.1074/jbc.M312448200	http://dx.doi.org/10.1074/jbc.M312448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722066	hybrid			2022-12-27	WOS:000220334900044
J	van Slegtenhorst, M; Carr, E; Stoyanova, R; Kruger, WD; Henske, EP				van Slegtenhorst, M; Carr, E; Stoyanova, R; Kruger, WD; Henske, EP			Tsc1(+) and tsc2(+) regulate arginine uptake and metabolism in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEINS; TUBEROUS SCLEROSIS GENE; CELL-GROWTH; FISSION YEAST; CANAVANINE RESISTANCE; POLYAMINE METABOLISM; 3-KINASE/AKT PATHWAY; DIRECT TARGET; RHEB GTPASE; COMPLEX	Mutations in either TSC1 or TSC2 cause tuberous sclerosis complex, an autosomal dominant disorder characterized by seizures, mental retardation, and benign tumors of the skin, brain, heart, and kidneys. Homologs for the TSC1 and TSC2 genes have been identified in mouse, rat, Fugu, Drosophila, and in the yeast Schizosaccharomyces pombe. Here we show that S. pombe lacking tsc1(+) or tsc2(+) have similar phenotypes including decreased arginine uptake, decreased expression of three amino acid permeases, and low intracellular levels of four members of the arginine biosynthesis pathway. Recently, the small GTPase Rheb was identified as a target of the GTPase-activating domain of tuberin in mammalian cells and in Drosophila. We show that the defect in arginine uptake in cells lacking tsc2(+) is rescued by the expression of a dominant negative form of rhb1(+), the Rheb homolog in S. pombe, but not by expressing wildtype rhb1(+). Expression of the tsc2(+) gene with a patient-derived mutation within the GAP domain did not rescue the arginine uptake defect in tsc2(+) mutant yeast. Taken together, these findings support a model in which arginine uptake is regulated through tsc1(+), tsc2(+), and rhb1(+) in S. pombe and also suggest a role for the Tsc1 and Tsc2 proteins in amino acid biosynthesis and sensing.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	van Slegtenhorst, M (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Marjon.van.Slegtenhorst@fccc.edu; Elizabeth.Henske@fccc.edu	Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695				ASTRINIDIS A, 2003, J BIOL CHEM; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bansal V, 2003, CURR OPIN CLIN NUTR, V6, P223, DOI 10.1097/00075197-200303000-00012; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chattopadhyay MK, 2002, P NATL ACAD SCI USA, V99, P10330, DOI 10.1073/pnas.162362899; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GRIMM C, 1988, MOL GEN GENET, V215, P87, DOI 10.1007/BF00331308; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Mach KE, 2000, GENETICS, V155, P611; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Matsumoto S, 2002, GENETICS, V161, P1053; NELLIST M, 1993, CELL, V75, P1305; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wong M, 2003, ANN NEUROL, V54, P251, DOI 10.1002/ana.10648; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yang WL, 2000, J BIOL CHEM, V275, P429, DOI 10.1074/jbc.275.1.429; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	40	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12706	12713		10.1074/jbc.M313874200	http://dx.doi.org/10.1074/jbc.M313874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718525	hybrid			2022-12-27	WOS:000220334900084
J	Yamamoto, T; Shimano, H; Nakagawa, Y; Ide, T; Yahagi, N; Matsuzaka, T; Nakakuki, M; Takahashi, A; Suzuki, H; Sone, H; Toyoshima, H; Sato, R; Yamada, N				Yamamoto, T; Shimano, H; Nakagawa, Y; Ide, T; Yahagi, N; Matsuzaka, T; Nakakuki, M; Takahashi, A; Suzuki, H; Sone, H; Toyoshima, H; Sato, R; Yamada, N			SREBP-1 interacts with hepatocyte nuclear factor-4 alpha and interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; TRANSCRIPTION FACTOR; MISSENSE MUTATION; PROMOTER ACTIVITY; TRANSGENIC MICE; FACTOR 4-ALPHA; X-RECEPTOR; CHOLESTEROL; EXPRESSION; INSULIN	The hepatocyte nuclear factor-4alpha (HNF-4alpha)/PGC-1 pathway plays a crucial role in the transcriptional regulation of hepatic gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and Glc-6-Pase, genes that are activated at fasting and suppressed in a fed state. SREBP-1c dominates the nutritional regulation of lipogenic genes inverse to gluconeogenesis. Here we show the mechanism by which SREBP-1 suppresses expression of gluconeogenic genes. A series of luciferase reporter assays demonstrated that SREBP-1a and - 1c effectively inhibited the PEPCK promoter activity that was induced by HNF-4alpha. The HNF-4alpha-binding site in the glucocorticoid-response unit was responsible for the SREBP-1 inhibition, although SREBP-1 did not bind to the PEPCK promoter as demonstrated by electrophoretic mobility shift assays. The inhibitory effect was more potent in the isoform of SREBP-1a than SREBP-1c and was eliminated by deletion of the amino-terminal transactivation domain of SREBP-1. Coimmunoprecipitation experiments demonstrated that these two transcription factors directly interact through the transactivation domain of SREBP-1 and the ligand binding/ AF2 domains of HNF-4alpha. Estimation of coactivator recruitment using HNF-4alpha-Gal4DBD fusion assay showed that SREBP-1 competitively inhibited PGC-1 recruitment, a requirement for HNF-4alpha activation. Consistent with these results, hepatic PEPCK and Glc-6-Pase mRNA levels are suppressed by overexpression of SREBP-1a and - 1c in the transgenic mice. Our data indicate that SREBP-1 has a novel role as negative regulator of gluconeogenic genes through a cross-talk with HNF-4alpha interference with PGC-1 recruitment.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	University of Tsukuba; University of Tokyo; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/AAI-5648-2020; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019	Sone, Hirohito/0000-0003-1263-2817; Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572				Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Drewes T, 1996, MOL CELL BIOL, V16, P925; Furuta H, 1997, DIABETES, V46, P1652, DOI 10.2337/diabetes.46.10.1652; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2002, VITAM HORM, V65, P167, DOI 10.1016/S0083-6729(02)65064-2; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 2000, TRENDS CARDIOVAS MED, V10, P275, DOI 10.1016/S1050-1738(00)00079-7; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshikawa T, 2003, MOL ENDOCRINOL, V17, P1240, DOI 10.1210/me.2002-0190; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	33	121	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12027	12035		10.1074/jbc.M310333200	http://dx.doi.org/10.1074/jbc.M310333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722127	hybrid			2022-12-27	WOS:000220334900005
J	Gardner, AF; Joyce, CM; Jack, WE				Gardner, AF; Joyce, CM; Jack, WE			Comparative kinetics of nucleotide analog incorporation by vent DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SUGAR RECOGNITION; ARCHAEON; ALPHA; IDENTIFICATION; REPLICATION; MECHANISM; FAMILY	Comparative kinetic and structural analyses of a variety of polymerases have revealed both common and divergent elements of nucleotide discrimination. Although the parameters for dNTP incorporation by the hyperthermophilic archaeal Family B Vent DNA polymerase are similar to those previously derived for Family A and B DNA polymerases, parameters for analog incorporation reveal alternative strategies for discrimination by this enzyme. Discrimination against ribonucleotides was characterized by a decrease in the affinity of NTP binding and a lower rate of phosphoryl transfer, whereas discrimination against ddNTPs was almost exclusively due to a slower rate of phosphodiester bond formation. Unlike Family A DNA polymerases, incorporation of 9-[(2-hydroxyethoxy) methyl] X triphosphates (where X is adenine, cytosine, guanine, or thymine; acyNTPs) by Vent DNA polymerase was enhanced over ddNTPs via a 50-fold increase in phosphoryl transfer rate. Furthermore, a mutant with increased propensity for nucleotide analog incorporation (Vent(A488L) DNA polymerase) had unaltered dNTP incorporation while displaying enhanced nucleotide analog binding affinity and rates of phosphoryl transfer. Based on kinetic data and available structural information from other DNA polymerases, we propose active site models for dNTP, ddNTP, and acyNTP selection by hyperthermophilic archaeal DNA polymerases to rationalize structural and functional differences between polymerases.	New England Biolabs Inc, Beverly, MA 01915 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Jack, WE (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	jack@neb.com			NIGMS NIH HHS [GM-28550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arezi B, 2002, J MOL BIOL, V322, P719, DOI 10.1016/S0022-2836(02)00843-4; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bankier A T, 1993, Methods Mol Biol, V23, P83; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Brandis JW, 1999, NUCLEIC ACIDS RES, V27, P1912, DOI 10.1093/nar/27.8.1912; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Chen XN, 1999, GENOME RES, V9, P492; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONG Q, 1993, J BIOL CHEM, V268, P24163; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Evans SJ, 2000, NUCLEIC ACIDS RES, V28, P1059, DOI 10.1093/nar/28.5.1059; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Filee J, 2002, J MOL EVOL, V54, P763, DOI 10.1007/s00239-001-0078-x; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Freeman S, 1996, MOL BIOTECHNOL, V5, P125, DOI 10.1007/BF02789061; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Gardner AF, 1999, NUCLEIC ACIDS RES, V27, P2545, DOI 10.1093/nar/27.12.2545; Gardner AF, 2002, NUCLEIC ACIDS RES, V30, P605, DOI 10.1093/nar/30.2.605; GILLIN FD, 1975, BIOCHEM BIOPH RES CO, V64, P457, DOI 10.1016/0006-291X(75)90343-5; Hashimoto H, 2001, J MOL BIOL, V306, P469, DOI 10.1006/jmbi.2000.4403; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; ILSLEY DD, 1999, FASEB J, V13, pA144; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KONG HM, 1993, J BIOL CHEM, V268, P1965; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; PETERSON MG, 1988, NUCLEIC ACIDS RES, V16, P10915, DOI 10.1093/nar/16.22.10915; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; REID R, 1988, J BIOL CHEM, V263, P3898; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TRAINOR GL, 1996, Patent No. 5558991; Truniger V, 1999, J MOL BIOL, V286, P57, DOI 10.1006/jmbi.1998.2477; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171; Yang GW, 2002, BIOCHEMISTRY-US, V41, P2526, DOI 10.1021/bi0119924; Zhao YX, 1999, STRUCTURE, V7, P1189, DOI 10.1016/S0969-2126(00)80053-2; [No title captured]	50	30	60	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11834	11842		10.1074/jbc.M308286200	http://dx.doi.org/10.1074/jbc.M308286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699133	hybrid			2022-12-27	WOS:000220157600120
J	Weber, J; Wilke-Mounts, S; Nadanaciva, S; Senior, AE				Weber, J; Wilke-Mounts, S; Nadanaciva, S; Senior, AE			Quantitative determination of direct binding of b subunit to F-1 in Escherichia coli F1F0-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; DELTA-SUBUNIT; ELECTRON-MICROSCOPY; CATALYTIC SITES; CROSS-LINKING; ALPHA-SUBUNIT; 2ND STALK; F-1-ATPASE; F1-ATPASE; STATOR	The stator in F1F0-ATP synthase resists strain generated by rotor torque. In Escherichia coli, the b(2)delta subunit complex comprises the stator, bound to subunit a in F-0 and to the alpha(3)beta(3) hexagon of F-1. To quantitatively characterize binding of b subunit to the F-1 alpha(3)beta(3) hexagon, we developed fluorimetric assays in which wild-type F-1, or F-1 enzymes containing introduced Trp residues, were titrated with a soluble portion of the b subunit (b(ST34-156)). With five different F-1 enzymes, K-d(b(ST34-156)) ranged from 91 to 157 nM. Binding was strongly Mg2+-dependent; in EDTA buffer, K-d(b(ST34-156)) was increased to 1.25 muM. The addition of the cytoplasmic portion of the b subunit increases the affinity of binding of delta subunit to delta-depleted F-1. The apparent K-d(b(ST34-156)) for this effect was increased from 150 nM in Mg2+ buffer to 1.36 muM in EDTA buffer. This work demonstrates quantitatively how binding of the cytoplasmic portion of the b subunit directly to F-1 contributes to stator resistance and emphasizes the importance of Mg2+ in stator interactions.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2000, J EXP BIOL, V203, P29; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; Grabar TB, 2003, J BIOL CHEM, V278, P34751, DOI 10.1074/jbc.M303361200; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; HAZARD AL, 1994, J BIOL CHEM, V269, P418; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; RAO R, 1988, J BIOL CHEM, V263, P5569; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WEBER J, 1994, J BIOL CHEM, V269, P20462; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Weber J, 2000, BIOCHEMISTRY-US, V39, P5287, DOI 10.1021/bi992730t; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	44	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11253	11258		10.1074/jbc.M312576200	http://dx.doi.org/10.1074/jbc.M312576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722065	hybrid			2022-12-27	WOS:000220157600052
J	Bosc, LVG; Wilkerson, MK; Bradley, KN; Eckman, DM; Hill-Eubanks, DC; Nelson, MT				Bosc, LVG; Wilkerson, MK; Bradley, KN; Eckman, DM; Hill-Eubanks, DC; Nelson, MT			Intraluminal pressure is a stimulus for NFATc3 nuclear accumulation - Role of calcium, endothelium-derived nitric oxide, and cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ACTIVATED T-CELLS; CEREBRAL-ARTERIES; TRANSCRIPTIONAL PATHWAY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CALCINEURIN; CA2+; HYPERTROPHY; CHANNELS	The transcription factor NFAT ( nuclear factor of activated T-cells) is implicated in cardiac hypertrophy and vasculogenesis. NFAT activation, reflecting dephosphorylation by the calcium-dependent phosphatase, calcineurin, and subsequent nuclear localization, is generally thought to require a sustained increase in intracellular calcium. However, in smooth muscle we have found that elevation of calcium by membrane depolarization fails to induce an increase in nuclear localization of the NFATc3 isoform. Here, we demonstrate that physiological intravascular pressure ( 100 mm Hg) induces an increase in NFATc3 nuclear localization in mouse cerebral arteries. Pressure-induced NFATc3 nuclear accumulation is abrogated by endothelial denudation and by nitric-oxide synthase, cGMP-dependent kinase (PKG), and voltage-dependent calcium channels inhibition. We further show that exogenous nitric oxide, in combination with an elevation in calcium, is an effective stimulus for NFATc3 nuclear accumulation. c-Jun terminal kinase 2 (JNK) activity, which has been shown to regulate NFATc3 nuclear export, is also reduced by pressure, an effect that is prevented by pretreatment with a PKG inhibitor. Consistent with this, pressure-induced NFATc3 nuclear accumulation is independent of PKG in arteries from JNK2(-/-) mice. Collectively, our results indicate that both activation of the NO/PKG pathway and elevation of smooth muscle calcium are required for NFATc3 nuclear accumulation and that PKG inhibits JNK2 to decrease NFAT nuclear export. Our findings suggest that at physiological intravascular pressures NFATc3 is localized to the nucleus in smooth muscle cells of intact arteries and indicate a novel and unexpected role for nitric oxide/PKG in NFAT activation.	Univ Vermont, Dept Pharmacol, Coll Med, Burlington, VT 05405 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Vermont; University of Glasgow	Nelson, MT (corresponding author), Univ Vermont, Dept Pharmacol, Coll Med, 89 Beaumont Ave, Burlington, VT 05405 USA.	mark.nelson@uvm.edu		Nelson, Mark/0000-0002-6608-8784; Gonzalez Bosc, Laura/0000-0001-7505-4909	NHLBI NIH HHS [HL63722, HL07647-12, HL44455, HL07944] Funding Source: Medline; NIDDK NIH HHS [DDK53832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007944, R01HL044455, R01HL063722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053832, R01DK053832] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bang L, 1999, SCAND CARDIOVASC J, V33, P71; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Bolz SS, 2003, CIRCULATION, V107, P3081, DOI 10.1161/01.CIR.0000074202.19612.8C; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Doughty JM, 1998, PFLUG ARCH EUR J PHY, V436, P220, DOI 10.1007/s004240050625; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; HO AM, 1994, J BIOL CHEM, V269, P28181; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hofmann F, 2000, J CELL SCI, V113, P1671; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jacob A, 2002, AM J PHYSIOL-CELL PH, V283, pC704, DOI 10.1152/ajpcell.00110.2002; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Koller A, 2003, BIOCHEM BIOPH RES CO, V300, P155, DOI 10.1016/S0006-291X(02)02799-7; Lehen'kyi V V, 2002, Cardiovasc Toxicol, V2, P151, DOI 10.1385/CT:2:2:151; Lincoln TM, 1998, ACTA PHYSIOL SCAND, V164, P507, DOI 10.1111/j.1365-201X.1998.tb10700.x; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Ohkawa Y, 2003, BIOCHEM BIOPH RES CO, V301, P78, DOI 10.1016/S0006-291X(02)02965-0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Rubart M, 1996, J GEN PHYSIOL, V107, P459, DOI 10.1085/jgp.107.4.459; Ruiz-Velasco V, 1998, CIRC RES, V82, P557, DOI 10.1161/01.RES.82.5.557; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Sharma GD, 2002, MOL CELL BIOCHEM, V233, P165, DOI 10.1023/A:1015882302796; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Sun D, 2001, AM J PHYSIOL-HEART C, V280, pH714, DOI 10.1152/ajpheart.2001.280.2.H714; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yamahara K, 2003, P NATL ACAD SCI USA, V100, P3404, DOI 10.1073/pnas.0538059100; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8	62	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10702	10709		10.1074/jbc.M312920200	http://dx.doi.org/10.1074/jbc.M312920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688253	hybrid			2022-12-27	WOS:000220050400125
J	Schnepp, RW; Mao, H; Sykes, SM; Zong, WX; Silva, A; La, P; Hua, XX				Schnepp, RW; Mao, H; Sykes, SM; Zong, WX; Silva, A; La, P; Hua, XX			Menin induces apoptosis in murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; TYPE-1 GENE-PRODUCT; CHROMOSOME-ABNORMALITIES; CHILDHOOD NEUROBLASTOMAS; EXPRESSION; GROWTH; PROTEINS; CASPASE-8; ORTHOLOG; BAX	Multiple endocrine neoplasia type I (MEN1) is a hereditary tumor syndrome characterized by multiple endocrine and occasionally non-endocrine tumors. The tumor suppressor gene Men1, which is frequently mutated in MEN1 patients, encodes the nuclear protein menin. Although many tumor suppressor genes are involved in the regulation of apoptosis, it is unclear whether menin facilitates apoptosis. Here we show that ectopic overexpression of menin via adenoviruses induces apoptosis in murine embryonic fibroblasts. The induction of apoptosis depends on Bax and Bak, two proapoptotic proteins. Moreover, loss of menin expression compromises apoptosis induced by UV irradiation and tumor necrosis factor-alpha (TNF-alpha), whereas complementation of meninnull cells with menin restores sensitivity to UV- and TNF-alpha-induced apoptosis. Interestingly, loss of menin reduces the expression of procaspase 8, a critical protease that is essential for apoptosis induced by death-related receptors, whereas complementation of the meninnull cells up-regulates the expression of procaspase 8. Furthermore, complementation of menin-null cells with menin increases the activation of caspase 8 in response to TNF-alpha treatment. These results suggest a proapoptotic function for menin that may be important in suppressing the development of MEN1.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, XX (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu			NCI NIH HHS [K01 CA078592-06, K01CA78592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA078592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guru SC, 2001, GENE, V263, P31, DOI 10.1016/S0378-1119(00)00562-X; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; Itakura Y, 2000, BIOMED PHARMACOTHER, V54, p187S, DOI 10.1016/S0753-3322(00)80041-4; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Khodaei S, 1999, BIOCHEM BIOPH RES CO, V264, P404, DOI 10.1006/bbrc.1999.1529; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Namihira H, 2002, J MOL ENDOCRINOL, V29, P297, DOI 10.1677/jme.0.0290297; Nord B, 2000, INT J CANCER, V87, P463, DOI 10.1002/1097-0215(20000815)87:4<463::AID-IJC1>3.0.CO;2-8; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Saito Y, 2003, GENE THER, V10, P1961, DOI 10.1038/sj.gt.3302100; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; SCAPPATICCI S, 1992, CANCER GENET CYTOGEN, V63, P17, DOI 10.1016/0165-4608(92)90057-F; SCAPPATICCI S, 1991, CANCER GENET CYTOGEN, V52, P85, DOI 10.1016/0165-4608(91)90057-2; Schussheim DH, 2001, TRENDS ENDOCRIN MET, V12, P173, DOI 10.1016/S1043-2760(00)00372-6; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thakker RV, 2000, ENDOCRIN METAB CLIN, V29, P541, DOI 10.1016/S0889-8529(05)70150-X; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	51	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10685	10691		10.1074/jbc.M308073200	http://dx.doi.org/10.1074/jbc.M308073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688275	Green Accepted, hybrid			2022-12-27	WOS:000220050400123
J	Walczak, R; Joseph, SB; Laffitte, BA; Castrillo, A; Pei, LM; Tontonoz, P				Walczak, R; Joseph, SB; Laffitte, BA; Castrillo, A; Pei, LM; Tontonoz, P			Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; SMOOTH-MUSCLE-CELLS; FACTOR EXPRESSION; ACTIVATED RECEPTOR; LXR-ALPHA; MURINE MACROPHAGES; LIPID-METABOLISM; ANGIOGENESIS; ATHEROSCLEROSIS; MICE	Macrophages are an important source of angiogenic activity in wound healing, cancer, and chronic inflammation. Vascular endothelial growth factor ( VEGF), a cytokine produced by macrophages, is a primary inducer of angiogenesis and neovascularization in these contexts. VEGF expression by macrophages is known to be stimulated by low oxygen tension as well as by inflammatory signals. In this study, we provide evidence that Vegfa gene expression is also regulated by activation of liver X receptors (LXRs). VEGF mRNA was induced in response to synthetic LXR agonists in murine and human primary macrophages as well as in murine adipose tissue in vivo. The effects of LXR ligands on VEGF expression were independent of hypoxia-inducible factor HIF-1alpha activation and did not require the previously characterized hypoxia response element in the VEGF promoter. Rather, LXR/retinoid X receptor heterodimers bound directly to a conserved hormone response element (LXRE) in the promoter of the murine and human Vegfa genes. Both LXRalpha and LXRbeta transactivated the VEGF promoter in transient transfection assays. Finally, we show that induction of VEGF expression by inflammatory stimuli was independent of LXRs, because these effects were preserved in LXR null macrophages. These observations identify VEGF as an LXR target gene and point to a previously unrecognized role for LXRs in vascular biology.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Box 951662, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu		Joseph, Sean/0000-0002-2602-8517	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bamba H, 2000, BIOCHEM BIOPH RES CO, V273, P485, DOI 10.1006/bbrc.2000.2969; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Fehrenbach H, 1999, ANAT REC, V254, P61; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; Itaya H, 2001, THROMB HAEMOSTASIS, V85, P171, DOI 10.1055/s-0037-1612921; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Jozkowicz A, 2000, ACTA BIOCHIM POL, V47, P1147, DOI 10.18388/abp.2000_3967; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kiriakidis S, 2003, J CELL SCI, V116, P665, DOI 10.1242/jcs.00286; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Phillips G D, 1994, In Vivo, V8, P961; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5	49	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9905	9911		10.1074/jbc.M310587200	http://dx.doi.org/10.1074/jbc.M310587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699103	hybrid			2022-12-27	WOS:000220050400031
J	Schaaf, G; Ludewig, U; Erenoglu, BE; Mori, S; Kitahara, T; von Wiren, N				Schaaf, G; Ludewig, U; Erenoglu, BE; Mori, S; Kitahara, T; von Wiren, N			ZmYS1 functions as a proton-coupled symporter for phytosiderophore- and nicotianamine-chelated metals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPEPTIDE TRANSPORTER; IRON-PHYTOSIDEROPHORES; CALCAREOUS SOIL; H+-COTRANSPORTS; MUGINEIC ACID; PLANT; MAIZE; AFFINITY; ENCODES; ROOTS	Among higher plants graminaceous species have the unique ability to efficiently acquire iron from alkaline soils with low iron solubility by secreting phytosiderophores, which are hexadentate metal chelators with high affinity for Fe(III). Iron(III)-phytosiderophores are subsequently taken up by roots via YS1 transporters, that belong to the OPT oligopeptide transporter family. Despite its physiological importance at alkaline pH, uptake of Fe-phytosiderophores into roots of wild-type maize plants was greater at acidic pH and sensitive to the proton uncoupler CCCP. To access the mechanism of Fe-phytosiderophore acquisition, ZmYS1 was expressed in an iron uptake-defective yeast mutant and in Xenopus oocytes, where ZmYS1-dependent Fe-phytosiderophore transport was stimulated at acidic pH and sensitive to CCCP. Electrophysiological analysis in oocytes demonstrated that Fe-phytosiderophore transport depends on proton cotransport and on the membrane potential, which allows ZmYS1-mediated transport even at alkaline pH. We further investigated substrate specificity and observed that ZmYS1 complemented the growth defect of the zinc uptake-defective yeast mutant zap1 and transported various phytosiderophore-bound metals into oocytes, including zinc, copper, nickel, and, at a lower rate, also manganese and cadmium. Unexpectedly, ZmYS1 also transported Ni(II), Fe( II), and Fe( III) complexes with nicotianamine, a structural analog of phytosiderophores, which has been shown to act as an intracellular metal chelator in all higher plants. Our results show that ZmYS1 encodes a proton-coupled broad-range metal-phytosiderophore transporter that additionally transports Fe- and Ni-nicotianamine. These biochemical properties indicate a novel role of YS1 transporters for heavy metal homeostasis in plants.	Univ Hohenheim, Inst Pflanzenernahrung, D-70593 Stuttgart, Germany; Univ Tubingen, ZMBP Pflanzenphysiol, D-72076 Tubingen, Germany; Univ Tokyo, Lab Plant Mol Physiol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Organ Chem Lab, Bunkyo Ku, Tokyo 1138657, Japan	University Hohenheim; Eberhard Karls University of Tubingen; University of Tokyo; University of Tokyo	von Wiren, N (corresponding author), Univ Hohenheim, Inst Pflanzenernahrung, D-70593 Stuttgart, Germany.	vonwiren@uni-hohenheim.de	Schaaf, Gabriel/F-1956-2014	Schaaf, Gabriel/0000-0001-9022-4515; von Wiren, Nicolaus/0000-0002-4966-425X				Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Chrispeels MJ, 1999, PLANT CELL, V11, P661, DOI 10.1105/tpc.11.4.661; Connolly EL, 2002, PLANT CELL, V14, P1347, DOI 10.1105/tpc.001263; Curie C, 2001, NATURE, V409, P346, DOI 10.1038/35053080; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hauser M, 2000, J BIOL CHEM, V275, P3037, DOI 10.1074/jbc.275.5.3037; Ling HQ, 1999, P NATL ACAD SCI USA, V96, P7098, DOI 10.1073/pnas.96.12.7098; Liu LH, 2003, PLANT CELL, V15, P790, DOI 10.1105/tpc.007120; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; MA JF, 1993, PHYTOCHEMISTRY, V34, P599, DOI 10.1016/0031-9422(93)85323-J; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; Miyakoshi K, 2001, TETRAHEDRON, V57, P3355, DOI 10.1016/S0040-4020(01)00215-0; Mizuno D, 2003, PLANT PHYSIOL, V132, P1989, DOI 10.1104/pp.102.019869; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Pich A, 2001, PLANTA, V213, P967, DOI 10.1007/s004250100573; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; ROMHELD V, 1986, PLANT PHYSIOL, V80, P175, DOI 10.1104/pp.80.1.175; Romheld V, 2000, J PLANT NUTR, V23, P1857, DOI 10.1080/01904160009382148; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt W, 2003, TRENDS PLANT SCI, V8, P188, DOI 10.1016/S1360-1385(03)00048-7; SHI WM, 1988, SOIL SCI PLANT NUTR, V34, P585, DOI 10.1080/00380768.1988.10416473; SHOJIMA S, 1990, PLANT PHYSIOL, V93, P1497, DOI 10.1104/pp.93.4.1497; Spizzo T, 1997, MOL GEN GENET, V256, P547; SUGIURA Y, 1984, STRUCT BOND, V58, P107, DOI 10.1007/BFb0111313; Takahashi M, 2003, PLANT CELL, V15, P1263, DOI 10.1105/tpc.010256; Takahashi M, 2001, NAT BIOTECHNOL, V19, P466, DOI 10.1038/88143; THIBAUD JB, 1988, PLANT PHYSIOL, V88, P1469, DOI 10.1104/pp.88.4.1469; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; Tolay I, 2001, J EXP BOT, V52, P1093, DOI 10.1093/jexbot/52.358.1093; TOULON V, 1989, PLANTA, V179, P235, DOI 10.1007/BF00393694; TREEBY M, 1989, PLANT SOIL, V114, P217, DOI 10.1007/BF02220801; Vacchina V, 2003, ANAL CHEM, V75, P2740, DOI 10.1021/ac020704m; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; von Wiren N, 2000, PLANT PHYSIOL, V124, P1149, DOI 10.1104/pp.124.3.1149; von Wiren N, 1999, PLANT PHYSIOL, V119, P1107, DOI 10.1104/pp.119.3.1107; VONWIREN N, 1994, PLANT PHYSIOL, V106, P71, DOI 10.1104/pp.106.1.71; VONWIREN N, 1995, PHYSIOL PLANTARUM, V93, P611, DOI 10.1111/j.1399-3054.1995.tb05107.x; vonWiren N, 1996, PLANT PHYSIOL, V111, P1119, DOI 10.1104/pp.111.4.1119; WALTER A, 1995, J PLANT NUTR, V18, P1577, DOI 10.1080/01904169509365005; Yen MR, 2001, MICROBIOL-SGM, V147, P2881, DOI 10.1099/00221287-147-11-2881; ZHANG FS, 1991, SOIL SCI PLANT NUTR, V37, P671, DOI 10.1080/00380768.1991.10416935; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	47	260	286	3	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9091	9096		10.1074/jbc.M311799200	http://dx.doi.org/10.1074/jbc.M311799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699112	hybrid			2022-12-27	WOS:000189265900070
J	Tortorella, MD; Arner, EC; Hills, R; Easton, A; Korte-Sarfaty, J; Fok, K; Wittwer, AJ; Liu, RQ; Malfait, AM				Tortorella, MD; Arner, EC; Hills, R; Easton, A; Korte-Sarfaty, J; Fok, K; Wittwer, AJ; Liu, RQ; Malfait, AM			alpha(2)-Macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOSAMINOGLYCANS; ALPHA-MACROGLOBULIN; AGGRECANASE SITE; SYNOVIAL-FLUID; CLEAVAGE SITES; BAIT REGION; CARTILAGE; ALPHA-2-MACROGLOBULIN; METALLOPROTEINASES; DEGRADATION	Osteoarthritis is characterized by the loss of aggrecan and collagen from the cartilage extracellular matrix. The proteinases responsible for the breakdown of cartilage aggrecan include ADAMTS-4 (aggrecanase 1) and ADAMTS-5 (aggrecanase 2). Post-translational inhibition of ADAMTS-4/-5 activity may be important for maintaining normal homeostasis of aggrecan metabolism, and thus, any disruption to this inhibition could lead to accelerated aggrecan breakdown. To date TIMP-3 (tissue inhibitor of matrix metalloproteinases-3) is the only endogenous inhibitor of ADAMTS-4/-5 that has been identified. In the present studies we identify alpha(2)-macroglobulin (alpha(2)M) as an additional endogenous inhibitor of ADAMTS-4 and ADAMTS-5. alpha(2)M inhibited the activity of both ADAMTS-4 and ADAMTS-5 in a concentration-dependent manner, demonstrating 1:1 stoichiometry with second-order rate constants on the order of 10(6) and 10(5) M-1 s(-1), respectively. Inhibition of the aggrecanases was mediated by proteolysis of the bait region within alpha(2)M, resulting in physical entrapment of these proteinases. Both ADAMTS-4 and ADAMTS-5 cleaved alpha(2)M at Met(690)/Gly(691), representing a novel proteinase cleavage site within alpha(2)M and a novel site of cleavage for ADAMTS-4 and ADAMTS-5. Finally, the use of the anti-neoepitope antibodies to detect aggrecanase-generated alpha(2)M-fragments in synovial fluid was investigated and found to be uninformative.	Pfizer Global Res & Dev, Chesterfield, MO 63017 USA; Bristol Myers Squibb Co, Wilmington, DE 19880 USA	Pfizer; Bristol-Myers Squibb	Tortorella, MD (corresponding author), Pfizer Global Res & Dev, 700 Chesterfield Pkwy, Chesterfield, MO 63017 USA.	micky.d.tortorella@pfizer.com		Malfait, Anne-Marie/0000-0003-1428-0384				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Andersen OM, 2000, BIOCHEMISTRY-US, V39, P10627, DOI 10.1021/bi000498h; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; CHU CT, 1994, ANN NY ACAD SCI, V737, P291, DOI 10.1111/j.1749-6632.1994.tb44319.x; Curtis CL, 2002, ARTHRITIS RHEUM, V46, P1544, DOI 10.1002/art.10305; DeGroot J, 2002, CURR OPIN RHEUMATOL, V14, P585, DOI 10.1097/00002281-200209000-00019; DOWNING MR, 1978, BIOCHEMISTRY-US, V17, P2649, DOI 10.1021/bi00606a030; ELLIS V, 1982, BIOCHIM BIOPHYS ACTA, V701, P24; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; GEORGIADIS KE, 2002, 48 ANN M ORTH RES SO; HADLER NM, 1981, ANN RHEUM DIS, V40, P55, DOI 10.1136/ard.40.1.55; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; MORT JS, 2003, 49 ANN M ORTH RES SO; MORTENSEN SB, 1981, FEBS LETT, V135, P295, DOI 10.1016/0014-5793(81)80804-6; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P127, DOI 10.1016/0014-5793(81)81097-6; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Su S, 1999, RHEUMATOL INT, V18, P183, DOI 10.1007/s002960050083; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; VANLEUVEN F, 1982, BIOCHEM J, V201, P119, DOI 10.1042/bj2010119; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	50	97	109	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17554	17561		10.1074/jbc.M313041200	http://dx.doi.org/10.1074/jbc.M313041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14715656	hybrid			2022-12-27	WOS:000220870400083
J	Bergman, A; Hansson, EM; Pursglove, SE; Farmery, MR; Lannfelt, L; Lendahl, U; Lundkvist, J; Naslund, J				Bergman, A; Hansson, EM; Pursglove, SE; Farmery, MR; Lannfelt, L; Lendahl, U; Lundkvist, J; Naslund, J			Pen-2 is sequestered in the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE CLEAVAGE; AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE PRODUCTION; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; SIGNAL-TRANSDUCTION; NOTCH; NICASTRIN; APH-1; PATHWAY	The gamma-secretase complex catalyzes intramembrane proteolysis of a number of transmembrane proteins, including amyloid precursor protein, Notch, ErbB4, and E-cadherin. gamma-Secretase is known to contain four major protein constituents: presenilin (PS), nicastrin, Aph-1, and Pen-2, all of which are integral membrane proteins. There is increasing evidence that the formation of the complex and the stability of the individual components are tightly controlled in the cell, assuring correct composition of functional complexes. In this report, we investigate the topology, localization, and mechanism for destabilization of Pen-2 in relation to PS function. We show that PS1 regulates the subcellular localization of Pen-2: in the absence of PS, Pen-2 is sequestered in the endoplasmic reticulum ( ER) and not transported to post-ER compartments, where the mature gamma-secretase complexes reside. PS deficiency also leads to destabilization of Pen-2, which is alleviated by proteasome inhibitors. In keeping with this, we show that Pen-2, which adopts a hairpin structure with the N and C termini facing the luminal space, is ubiquitylated prior to degradation and presumably retrotranslocated from the ER to the cytoplasm. Collectively, our data suggest that failure to become incorporated into the gamma-secretase complex leads to degradation of Pen-2 through the ER-associated degradation-proteasome pathway.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurotec, Sect Expt Geriatr, Novum, SE-14186 Huddinge, Sweden; Univ Uppsala Hosp, Dept Geriatr Med, SE-75125 Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Uppsala University; Uppsala University Hospital	Lundkvist, J (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.	johan.lundkvist@cmb.ki.se		Lendahl, Urban/0000-0001-9543-8141				Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	32	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16744	16753		10.1074/jbc.M313999200	http://dx.doi.org/10.1074/jbc.M313999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14724271	hybrid			2022-12-27	WOS:000220747900127
J	Zhou, JL; Hoggatt, AM; Herring, BP				Zhou, JL; Hoggatt, AM; Herring, BP			Activation of the smooth muscle-specific telokin gene by thyrotroph embryonic factor (TEF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; LEUCINE-ZIPPER PROTEINS; DNA-BINDING SPECIFICITY; LIGHT-CHAIN KINASE; TRANSCRIPTION FACTOR; EXPRESSION; PROMOTER; MYOSIN; PAR; DOMAIN	Transcription of the telokin gene is restricted to smooth muscle cells throughout development, making this gene an excellent model for unraveling the mechanisms that regulate gene expression in smooth muscle tissues. To identify proteins that bind to the telokin promoter, the AT-rich/CArG core of the promoter was used as a probe to perform a Southwestern screen of a mouse bladder cDNA library. Four clones corresponding to two distinct isoforms of mouse thyrotroph embryonic factor (TEFalpha and TEFbeta) were identified from this screen. The two TEF isoforms differ from each other at their amino termini and result from alternative promoter usage. An RNase protection assay showed that both TEF isoforms are expressed at high levels in mouse lung, bladder, kidney, gut, and brain. Gel mobility shift assays demonstrated that purified TEF protein can specifically bind to an AT-rich region within the core of the telokin promoter. Furthermore, when overexpressed in 10T1/2 cells, TEF significantly increased the activity of a telokin promoter-reporter gene; this activation was further augmented by elevated intracellular calcium levels. In contrast, overexpression of TEF had no effect on reporter genes driven by SM22alpha, smooth muscle alpha-actin, or smooth muscle myosin heavy chain promoters. Consistent with these results, overexpression of TEFalpha and TEFbeta in A10 cells, using adenoviral vectors, increased expression of endogenous telokin without altering expression of myosin light chain 20, SM22alpha, smooth muscle alpha-actin, or calponin. These findings suggest that TEF factors contribute to the activation of the telokin promoter in smooth muscle cells in a calcium-dependent manner. These data also suggest that distinct transcription factors are required to control the expression of different smooth muscle genes in a single tissue.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pherring@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL058571] Funding Source: Medline; NIDDK NIH HHS [DK61130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BURCH JBE, 1994, NUCLEIC ACIDS RES, V22, P4733, DOI 10.1093/nar/22.22.4733; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Falvey E, 1996, BIOL CHEM, V377, P797; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Herring BP, 2001, AM J PHYSIOL-CELL PH, V280, pC12, DOI 10.1152/ajpcell.2001.280.1.C12; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Hoggatt AM, 2002, CIRC RES, V91, P1151, DOI 10.1161/01.RES.0000047508.30800.4F; Hoggatt AM, 2000, J BIOL CHEM, V275, P31162, DOI 10.1074/jbc.M005595200; Hunger SP, 1996, BLOOD, V87, P4607, DOI 10.1182/blood.V87.11.4607.bloodjournal87114607; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Krueger DA, 2000, J BIOL CHEM, V275, P14524, DOI 10.1074/jbc.275.19.14524; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Ossipow V, 1999, MOL CELL BIOL, V19, P1242; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; Watanabe M, 2002, CIRC RES, V91, P382, DOI 10.1161/01.RES.0000033593.05545.7B; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; WUARIN J, 1992, J CELL SCI, P123; Zeidan A, 2003, AM J PHYSIOL-CELL PH, V284, pC1387, DOI 10.1152/ajpcell.00508.2002	33	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15929	15937		10.1074/jbc.M313822200	http://dx.doi.org/10.1074/jbc.M313822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14702338	hybrid			2022-12-27	WOS:000220747900029
J	Ling, X; Bernacki, RJ; Brattain, MG; Li, FZ				Ling, X; Bernacki, RJ; Brattain, MG; Li, FZ			Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G(2)/M arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OVARIAN-CANCER; INDUCED APOPTOSIS; PROTEIN SURVIVIN; CELL-CYCLE; CASPASE ACTIVITY; BREAST-CANCER; GENE; PATHWAY; TUBULIN; PHOSPHORYLATION	Survivin is a novel anti-apoptotic protein that is highly expressed in cancer but is undetectable in most normal adult tissues. It was reported that taxol-mediated mitotic arrest of cancer cells is associated with survivin induction, which preserves a survival pathway and results in resistance to taxol. In this study, we provide new evidence that induction of survivin by taxol is an early event and is independent of taxol-mediated G(2)/M arrest. Taxol treatment of MCF-7 cells rapidly up-regulated survivin expression (3.5-15-fold) within 4 h without G(2)/M arrest. Lengthening the treatment of cells (48 h) with taxol resulted in decreased survivin expression in comparison with early times following taxol treatment, although G(2)/M cells were significantly increased at later times. Interestingly, 3 nM taxol induces survivin as effectively as 300 nM and more effectively than 3000 nM. As a result, 3 nM taxol is ineffective at inducing cell death. However, inhibition of taxol-mediated survivin induction by small interfering RNA significantly increased taxol-mediated cell death. Taxol rapidly activated the phosphatidylinositol 3-kinase/Akt and MAPK pathways. Inhibition of these pathways diminished survivin induction and sensitized cells to taxol-mediated cell death. A cis-acting DNA element upstream of -1430 in the survivin pLuc-2840 construct is at least partially responsible for taxol-mediated survivin induction. Together, these data show, for the first time, that taxol-mediated induction of survivin is an early event and independent of taxol-mediated G(2)/M arrest. This appears to be a new mechanism for cancer cells to evade taxol-induced apoptosis. Targeting this survival pathway may result in novel approaches for cancer therapeutics.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Li, Fengzhi/GXF-0115-2022		NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109481, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; BHALLA K, 1994, LEUKEMIA, V8, P465; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Casazza A M, 1996, Cancer Treat Res, V87, P149; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Eisenhauer EA, 1998, DRUGS, V55, P5, DOI 10.2165/00003495-199855010-00002; Fan WM, 1999, BIOCHEM PHARMACOL, V57, P1215; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Grossman D, 1999, LAB INVEST, V79, P1121; IRELAND CM, 1995, BIOCHEM PHARMACOL, V49, P1491, DOI 10.1016/0006-2952(95)00030-4; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; KUMAR N, 1981, J BIOL CHEM, V256, P435; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; LING X, 2004, IN PRESS BIOTECHNIQU; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SCHIBLER MJ, 1986, J CELL BIOL, V102, P1522, DOI 10.1083/jcb.102.4.1522; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Stadheim TA, 2001, CANCER RES, V61, P1533; Tamm I, 1998, CANCER RES, V58, P5315; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wall NR, 2003, CANCER RES, V63, P230; Wiseman LR, 1998, DRUG AGING, V12, P305, DOI 10.2165/00002512-199812040-00005; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	45	157	169	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15196	15203		10.1074/jbc.M310947200	http://dx.doi.org/10.1074/jbc.M310947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722122	hybrid			2022-12-27	WOS:000220594700086
J	Singer, AL; Bunnell, SC; Obstfeld, AE; Jordan, MS; Wu, JN; Myung, PS; Samelson, LE; Koretzky, GA				Singer, AL; Bunnell, SC; Obstfeld, AE; Jordan, MS; Wu, JN; Myung, PS; Samelson, LE; Koretzky, GA			Roles of the proline-rich domain in SLP-76 subcellular localization and T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SLP-76; ANTIGEN RECEPTOR; DIFFERENTIAL REQUIREMENT; TYROSINE PHOSPHORYLATION; INTERLEUKIN-2 PRODUCTION; MEDIATED ACTIVATION; MOLECULAR-CLONING; LINKER PROTEIN; LIVING CELLS; LAT	The adaptor protein Src homology (SH) 2 domain-containing and leukocyte-specific phosphoprotein of 76 kDa (SLP-76) is critical for signal transduction in multiple hematopoietic lineages. It links proximal and distal T cell receptor signaling events through its function as a molecular scaffold in the assembly of multimolecular signaling complexes. Here we studied the functional roles of sub-domains within the SLP-76 proline-rich region, specifically the Gads binding domain and the recently defined P1 domain. To gain a further understanding of the functions mediated by this region, we used three complementary approaches as follows: reconstitution of SLP-76-deficient cells with functional domain deletion mutants, blocking molecular associations through the expression of a dominant negative protein fragment, and directed localization of SLP-76 to assess the role of the domains in SLP-76 recruitment. We find the Gads binding domain and the P1 domain are both necessary for optimal SLP-76 function, and in the absence of these two regions, SLP-76 is functionally inert. Furthermore, we provide direct evidence that SLP-76 localization and, in turn, function are dependent upon association with Gads.	Univ Penn, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Koretzky, GA (corresponding author), 421 Curie Blvd,415 BRB 2-3, Philadelphia, PA 19104 USA.	koretzky@mail.med.upenn.edu	Koretzky, Gary/AAU-5381-2021	Bunnell, Stephen/0000-0001-6887-0828	NCI NIH HHS [P01-CA93615] Funding Source: Medline; NIAMS NIH HHS [T32-AR07442] Funding Source: Medline; NIDDK NIH HHS [F32-DK09969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA093615, Z01BC010304, ZIABC010304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; BUNNELL SC, 2003, SCIENCES; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Peterson EJ, 1999, EUR J IMMUNOL, V29, P2223, DOI 10.1002/(SICI)1521-4141(199907)29:07<2223::AID-IMMU2223>3.0.CO;2-6; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Weijer CJ, 2003, SCIENCE, V300, P96, DOI 10.1126/science.1082830; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamasaki S, 2003, MOL CELL BIOL, V23, P2515, DOI 10.1128/MCB.23.7.2515-2529.2003; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	52	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15481	15490		10.1074/jbc.M313339200	http://dx.doi.org/10.1074/jbc.M313339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722089	hybrid			2022-12-27	WOS:000220594700119
J	Luo, SH; Rohloff, P; Cox, J; Uyemura, SA; Docampo, R				Luo, SH; Rohloff, P; Cox, J; Uyemura, SA; Docampo, R			Trypanosoma brucei plasma membrane-type Ca2+-ATPase 1 (TbPMC1) and 2 (TbPMC2) genes encode functional Ca2+-ATPases localized to the acidocalcisomes and plasma membrane, and essential for Ca2+ homeostasis and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; P-TYPE ATPASE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; H+-PYROPHOSPHATASE; CALCIUM-PUMP; EXPRESSION; FORMS; INTERFERENCE; INHIBITION	Trypanosoma brucei adaptation and survival in its host involve integrated regulation of Ca2+ pumps (Ca2+-ATPases), which are essential in calcium ion homeostasis. Here we report the cloning and sequencing of two genes (TbPMC1 and TbPMC2) encoding plasma membrane-type Ca2+-ATPases (PMCAs) of T. brucei, an agent of African trypanosomiasis. Indirect immunofluorescence analysis using antibodies against the proteins and against epitope tags introduced into each protein showed that TbPMC1 co-localized with the vacuolar H+-pyrophosphatase to the acidocalcisomes while TbPMC2 localized to the plasma membrane. Northern and Western blot analyses revealed that TbPMC1 and TbPMC2 are up-regulated during blood stages. TbPMC1 and TbPMC2 suppressed the Ca2+ hypersensitivity of a mutant of S. cerevisiae that has a defect in vacuolar Ca2+ accumulation. T. brucei Ca2+-ATPase genes were functionally characterized by using double-stranded RNA interference (RNAi) methodology to produce inducible Ca2+-ATPase-deficient procyclic forms. Similar results were obtained with bloodstream form trypomastigotes, except that the RNAi system was leaky and mRNA and protein levels recovered with time. The induction of dsRNA ( RNAi) caused gross morphological alterations, and growth inhibition of procyclic forms. Induction of RNAi against TbPMC1 but not against TbPMC2 caused elevated levels of cytosolic Ca2+ and decreased mobilization of Ca2+ from intracellular stores following ionophore addition. These results establish that T. brucei PMCA-Ca2+-ATPases are essential for parasite viability and validate them as targets for drug development.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Uyemura, Sergio/B-4656-2011; Rohloff, Peter/P-8722-2017	Uyemura, Sergio/0000-0001-5505-9817; Rohloff, Peter/0000-0001-7274-8315				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BABABUNMI E, 1982, ANN NY ACAD SCI, V402, P349; BABABUNMI E A, 1987, Microbios Letters, V36, P71; BASSILIAN R, 1981, ANNU REV BIOCHEM, V50, P349; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; BENAIM G, 1993, BIOCHEM J, V296, P759, DOI 10.1042/bj2960759; BRUN R, 1979, ACTA TROP, V36, P289; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Docampo R, 2003, PARASITOL RES, V90, pS10, DOI 10.1007/s00436-002-0752-y; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Ghosh SK, 2000, MOL BIOCHEM PARASIT, V108, P125, DOI 10.1016/S0166-6851(00)00196-1; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MONIAKIS J, 1995, J BIOL CHEM, V270, P28276; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; SVERDLOV ED, 1987, FEBS LETT, V221, P129, DOI 10.1016/0014-5793(87)80366-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Wang CC, 1997, PARASITOLOGY, V114, pS31; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	49	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14427	14439		10.1074/jbc.M309978200	http://dx.doi.org/10.1074/jbc.M309978200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724285	hybrid			2022-12-27	WOS:000220478500139
J	Cahoon, EB; Kinney, AJ				Cahoon, EB; Kinney, AJ			Dimorphecolic acid is synthesized by the coordinate activities of two divergent Delta(12)-oleic acid desaturases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; OLEATE 12-HYDROXYLASE; CALENDULA-OFFICINALIS; BIOSYNTHETIC ORIGIN; SOYBEAN EMBRYOS; IDENTIFICATION; BONDS; OILS; EXPRESSION; COMPONENTS	Dimorphecolic acid (9-OH-18:2Delta(10trans,12trans)) is the major fatty acid of seeds of Dimorphotheca species. This fatty acid contains structural features that are not typically found in plant fatty acids, including a C-9 hydroxyl group, Delta(10),Delta(12)-conjugated double bonds, and trans-Delta(12) unsaturation. Expressed sequence tag analysis was conducted to determine the biosynthetic origin of dimorphecolic acid. cDNAs for two divergent forms of Delta(12)-oleic acid desaturase, designated DsFAD2-1 and Ds-FAD2-2, were identified among expressed sequence tags generated from developing Dimorphotheca sinuata seeds. Expression of DsFAD2-1 in Saccharomyces cerevisiae and soybean somatic embryos resulted in the accumulation of the trans-Delta(12) isomer of linoleic acid (18: 2Delta(9cis,12trans)) rather than the more typical cis-Delta(12) isomer. When co-expressed with DsFAD2-1 in soybean embryos or yeast, DsFAD2-2 converted 18:2Delta(9cis,12trans) into dimorphecolic acid. When DsFAD2-2 was expressed alone in soybean embryos or together with a typical cis-Delta(12)-oleic acid desaturase in yeast, trace amounts of the cis-Delta(12) isomer of dimorphecolic acid (9-OH-18:2Delta(9cis,12cis)) were formed from DsFAD2-2 activity with cis-Delta(12)-linoleic acid. These results indicate that DsFAD2-2 catalyzes the conversion of the Delta(9) double bond of linoleic acid into a C-9 hydroxyl group and Delta(10trans) double bond and displays a substrate preference for the trans-Delta(12), rather than the cis-Delta(12), isomer of linoleic acid. Overall these data are consistent with a biosynthetic pathway of dimorphecolic acid involving the concerted activities of DsFAD2-1 and DsFAD2-2. The evolution of two divergent Delta(12)-oleic acid desaturases for the biosynthesis of an unusual fatty acid is unprecedented in plants.	ARS, USDA, Plant Genet Res Unit, Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; DuPont Co Inc, Expt Stn, Pioneer Hi Bred Int Inc, Crop Genet Res, Wilmington, DE 19880 USA	Donald Danforth Plant Science Center; United States Department of Agriculture (USDA); DuPont	Cahoon, EB (corresponding author), ARS, USDA, Plant Genet Res Unit, Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	ecahoon@danforthcenter.org						*AG TECHN, 2002, CHROM SUPPL REF GUID, P391; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Behrouzian B, 2002, CURR OPIN CHEM BIOL, V6, P577, DOI 10.1016/S1367-5931(02)00365-4; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Cahoon EB, 2000, PLANT PHYSIOL, V124, P243, DOI 10.1104/pp.124.1.243; Cahoon EB, 1999, P NATL ACAD SCI USA, V96, P12935, DOI 10.1073/pnas.96.22.12935; Cahoon EB, 2002, PLANT PHYSIOL, V128, P615, DOI 10.1104/pp.010768; Cahoon EB, 2001, J BIOL CHEM, V276, P2637, DOI 10.1074/jbc.M009188200; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; Dyer JM, 2002, PLANT PHYSIOL, V130, P2027, DOI 10.1104/pp.102.010835; Finer JJ., 1991, IN VITRO CELL DEV-PL, V27, P175, DOI [10.1007/bf02632213, DOI 10.1007/BF02632213, 10.2307/4292952]; GEITZ RD, 1994, MOL GENETICS YEAST P, P121; Hitz WD, 1998, U.S. Patent, Patent No. [5,846,784, 5846784]; Hof L., 1996, Progress in new crops: Proceedings of the Third National Symposium Indianapolis, Indiana, 22-25 October, 1996., P372; Hornung E, 2002, EUR J BIOCHEM, V269, P4852, DOI 10.1046/j.1432-1033.2002.03184.x; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; Kinney AJ, 1996, J FOOD LIPIDS, V3, P273, DOI 10.1111/j.1745-4522.1996.tb00074.x; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; MCCLEAN J, 1956, J CHEM SOC, P777; MORRIS F M, 1960, Am J Optom Arch Am Acad Optom, V37, P327; MORRIS LJ, 1966, CHEM IND-LONDON, P1493; Muuse B. G., 1992, Industrial Crops and Products, V1, P57, DOI 10.1016/0926-6690(92)90046-X; NILSSON R, 1991, PHYTOCHEM ANALYSIS, V2, P253, DOI 10.1002/pca.2800020604; Qiu X, 2001, PLANT PHYSIOL, V125, P847, DOI 10.1104/pp.125.2.847; Reed DW, 2002, EUR J BIOCHEM, V269, P5024, DOI 10.1046/j.1432-1033.2002.03209.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SMITH CR, 1960, J AM CHEM SOC, V82, P1417, DOI 10.1021/ja01491a034; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Sperling P., 2002, PROSTAGLANDINS LEUKO, V68, P73; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743	32	42	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12495	12502		10.1074/jbc.M314329200	http://dx.doi.org/10.1074/jbc.M314329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718523	hybrid			2022-12-27	WOS:000220334900060
J	Chiba, H; Michibata, H; Wakimoto, K; Seishima, M; Kawasaki, S; Okubo, K; Mitsui, H; Torii, H; Imai, Y				Chiba, H; Michibata, H; Wakimoto, K; Seishima, M; Kawasaki, S; Okubo, K; Mitsui, H; Torii, H; Imai, Y			Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A(2), cPLA(2)delta, induced in psoriatic skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MOLECULAR-CLONING; MESSENGER-RNA; EXPRESSION; A(2); PROTEIN; HOMOLOGY; CONTAINS; MOUSE; GAP	Psoriasis is a common skin disease characterized by hyperplastic regenerative epidermal growth and infiltration of immunocytes. The etiology of psoriasis is unknown, although several genetic and cellular factors have been elucidated. To find new psoriasis- related genes, we have cloned cDNAs that are differentially expressed between normal and psoriatic skins. Among these clones, we have identified a new gene that codes for a new member of the type IV cytosolic phospholipase A(2) ( cPLA(2)) family. We refer to this gene as cPLA(2)delta. It encodes a polypeptide of 818 amino acids that has significant homology with known cPLA(2) proteins in the C2 and catalytic domains. The cPLA(2)delta gene was mapped to the 15q13 - 14 chromosomal locus, near to the locus of the cPLA(2)beta gene, from which it is separated by a physical distance of about 220 kb. To identify the phospholipase A(2) activity of cPLA(2)delta, we transfected COS- 7 cells with His- tagged cPLA(2)delta. The cell lysate from these cells had calcium- dependent phospholipase A(2) activity. Northern blot analysis revealed that a cPLA(2)delta transcript of about 4 kb is expressed in stratified squamous epithelia, such as those in skin and cervix, but not in other tissues. In situ hybridization and immunohistochemistry revealed that cPLA(2)delta is expressed strongly in the upper spinous layer of the psoriatic epidermis, expressed weakly and discontinuously in atopic dermatitis and mycosis fungoides, and not detected in the epidermis of normal skin; cPLA(2)alpha is not detected in either normal or psoriatic skin. These results suggest that cPLA(2)delta exhibits a unique distribution pattern compared with that of known cPLA(2) subtypes, and it may play a critical role in inflammation in psoriatic lesions.	Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, Toda, Saitama 3358305, Japan; Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, Yodogawa Ku, Osaka 5328505, Japan; Ogaki Municipal Hosp, Dept Dermatol, Ogaki 5038502, Japan; Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6028566, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan; Social Hlth Insurance Med Ctr, Dept Dermatol, Shinjyuku Ku, Tokyo 1690073, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Ogaki Municipal Hospital; Kyoto Prefectural University of Medicine; Kyushu University; University of Tokyo	Imai, Y (corresponding author), Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358305, Japan.	y-imai@tanabe.co.jp		Torii, Hideshi/0000-0003-2123-3033				ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; BAER AN, 1990, J LIPID RES, V31, P125; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOHERTY NS, 1988, J INVEST DERMATOL, V91, P298, DOI 10.1111/1523-1747.ep12475630; FARBER EM, 1974, DERMATOLOGICA, V148, P1, DOI 10.1159/000251595; FOGH K, 1989, J INVEST DERMATOL, V92, P837, DOI 10.1111/1523-1747.ep12696858; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; IMAI Y, 1994, MOL BRAIN RES, V24, P313, DOI 10.1016/0169-328X(94)90144-9; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P407; Kawamoto S, 1999, GENOME RES, V9, P1305, DOI 10.1101/gr.9.12.1305; KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Nickoloff BJ, 1999, J CLIN INVEST, V104, P1161, DOI 10.1172/JCI8633; Nyman KM, 2000, J HISTOCHEM CYTOCHEM, V48, P1469, DOI 10.1177/002215540004801104; Okubo K, 1991, DNA Seq, V2, P137, DOI 10.3109/10425179109039684; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; ZHANG YY, 1991, METHOD ENZYMOL, V197, P456	26	59	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12890	12897		10.1074/jbc.M305801200	http://dx.doi.org/10.1074/jbc.M305801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709560	hybrid			2022-12-27	WOS:000220334900106
J	Hausmann, S; Erdjument-Bromage, H; Shuman, S				Hausmann, S; Erdjument-Bromage, H; Shuman, S			Schizosaccharomyces pombe carboxyl-terminal domain (CTD) phosphatase Fcp1 - Distributive mechanism, minimal CTD substrate, and active site mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; T4 POLYNUCLEOTIDE KINASE; PHOSPHOSERINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; TRANSCRIPTION ELONGATION; MUTATIONAL ANALYSIS; CAPPING ENZYME; REPAIR ENZYME; PHOSPHORYLATION	Schizosaccharomyces pombe Fcp1 is an essential protein serine phosphatase that preferentially dephosphorylates Ser(2) of the RNA polymerase II C-terminal domain (CTD) heptad repeat (YSPTSPS7)-S-1-P-2-T-3-S-4-P-5-S-6. Here we show that: (i) Fcp1 acts distributively during the hydrolysis of substrates containing tandem Ser(2)-PO4 heptads; (ii) the minimal optimal CTD substrate for Fcp1 is a single heptad of phasing (SPSYSPT4)-P-5-S-6-Y-7-S-1-P-2-T-3; and (iii) single alanine mutations of flanking residues Tyr(1) or Pro(3) result in 6-fold decrements in CTD phosphatase activity. Fcp1 belongs to the DXDX(T/V) family of phosphotransferases that act via an acyl-phosphoenzyme intermediate. An alanine scan of 11 conserved positions of S. pombe Fcp1 identifies Thr(174), Tyr(237), Thr(243), and Tyr(249) as important for phosphatase activity. Structure-activity relationships at these positions were determined by introducing conservative substitutions. Our results, together with previous mutational studies, highlight a constellation of 11 amino acids that are conserved in all Fcp1 orthologs and likely comprise the active site.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Friedl EM, 2003, P NATL ACAD SCI USA, V100, P2328, DOI 10.1073/pnas.2628049100; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hausmann S, 2003, J BIOL CHEM, V278, P13627, DOI 10.1074/jbc.M213191200; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Karagiannis J, 2001, J CELL SCI, V114, P2929; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Koiwa H, 2002, P NATL ACAD SCI USA, V99, P10893, DOI 10.1073/pnas.112276199; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Palancade B, 2002, J BIOL CHEM, V277, P36061, DOI 10.1074/jbc.M205192200; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Takagi T, 2002, EUKARYOT CELL, V1, P448, DOI 10.1128/EC.1.3.448-457.2002; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Varon R, 2003, NAT GENET, V35, P185, DOI 10.1038/ng1243; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	46	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10892	10900		10.1074/jbc.M312513200	http://dx.doi.org/10.1074/jbc.M312513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701811	hybrid			2022-12-27	WOS:000220157600010
J	Gao, G; Plaas, A; Thompson, VP; Jin, S; Zuo, FR; Sandy, JD				Gao, G; Plaas, A; Thompson, VP; Jin, S; Zuo, FR; Sandy, JD			ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN DEGRADATION; HUMAN SYNOVIAL-FLUID; MATRIX-METALLOPROTEINASE; INTERGLOBULAR DOMAIN; ARTICULAR-CARTILAGE; STRUCTURAL CHARACTERIZATION; MEDIATED CATABOLISM; PHYSICAL-PROPERTIES; EPITHELIAL-CELLS; EXPLANT CULTURES	C-terminal truncation of ADAMTS-4 from the p68 form to the p53 form is required for activation of its capacity to cleave the Glu(373)-Ala(374) interglobular domain bond of aggrecan. In transfected human chondrosarcoma cells, this process is not autoproteolytic because the same products form with an inactive mutant of ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin-like motif 4) and truncation is completely blocked by tissue inhibitor of metalloproteinase-1. Instead, activation can be mediated by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase (MT4-MMP, MMP-17) because co-transfection with the active form of MT4-MMP markedly enhanced activation, whereas an inactive mutant of MT4-MMP was ineffective. Treatment of co-transfected cells with phosphatidylinositol-specific phospholipase C liberated the complex of MT4-MMP and p68 ADAMTS4 from the cell membrane, but the p53 ADAMTS4 remained associated. Specific glycosaminoglycan lyase digestions, followed by product analyses using fluorescence-assisted carbohydrate electrophoresis and immunoprecipitation experiments, showed that the p53 form is associated with syndecan-1 through both chondroitin sulfate and heparan sulfate. We conclude that ADAMTS-4 activation in this cell system involves the coordinated activity of both glycosylphosphatidyl inositol-anchored MT4-MMP and the proteoglycan form of syndecan-1 on the cell surface.	Shriners Hosp Children, Ctr Res Skeletal Dev & Paediat Orthopaed, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33620 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33620 USA; Roche Biosci, Arthrit Dept, Palo Alto, CA 94304 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Roche Holding	Sandy, JD (corresponding author), Shriners Hosp Children, Ctr Res Skeletal Dev & Paediat Orthopaed, 12502 N Pine Dr, Tampa, FL 33612 USA.	jsandy@shctampa.usf.edu						Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Bonassar LJ, 1997, ARCH BIOCHEM BIOPHYS, V344, P404, DOI 10.1006/abbi.1997.0205; Bryson H, 1998, ARCH BIOCHEM BIOPHYS, V355, P15, DOI 10.1006/abbi.1998.0696; BUTTLE DJ, 1992, BIOCHEM J, V281, P175, DOI 10.1042/bj2810175; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Chevrier A, 2001, ARCH BIOCHEM BIOPHYS, V396, P178, DOI 10.1006/abbi.2001.2608; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; FLANNERY CR, 2003, ORTHOP RES SOC, V28, P157; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; Ilic MZ, 2003, OSTEOARTHR CARTILAGE, V11, P613, DOI 10.1016/S1063-4584(03)00092-X; KASHIWAGI M, 2003, J BIOL CHEM; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Munteanu SE, 2002, MATRIX BIOL, V21, P429, DOI 10.1016/S0945-053X(02)00034-3; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; Plaas AHK, 2001, GLYCOBIOLOGY, V11, P779, DOI 10.1093/glycob/11.10.779; PLAAS AHK, 1993, MATRIX, V13, P135, DOI 10.1016/S0934-8832(11)80072-7; Plaimauer B, 2002, BLOOD, V100, P3626, DOI 10.1182/blood-2002-05-1397; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Puente XS, 1996, CANCER RES, V56, P944; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; Sandy JD, 1999, ARCH BIOCHEM BIOPHYS, V367, P258, DOI 10.1006/abbi.1999.1234; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schwartz AJ, 2002, AM J VET RES, V63, P1564, DOI 10.2460/ajvr.2002.63.1564; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sztrolovics R, 2002, BIOCHEM J, V362, P465, DOI 10.1042/0264-6021:3620465; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Westling J, 2004, BIOCHEM J, V377, P787, DOI 10.1042/bj20030896; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0	64	155	163	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10042	10051		10.1074/jbc.M312100200	http://dx.doi.org/10.1074/jbc.M312100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701864	hybrid			2022-12-27	WOS:000220050400048
J	Koivunen, P; Hirsila, M; Gunzler, V; Kivirikko, KI; Myllyharju, J				Koivunen, P; Hirsila, M; Gunzler, V; Kivirikko, KI; Myllyharju, J			Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; DISULFIDE-ISOMERASE SUBUNIT; VON-HIPPEL-LINDAU; HIF-ALPHA; COLLAGEN; PROTEIN; FAMILY; BIOSYNTHESIS; HIF-1-ALPHA; DESTRUCTION	The activity of hypoxia-inducible transcription factor HIF, an alphabeta heterodimer that has an essential role in adaptation to low oxygen availability, is regulated by two oxygen-dependent hydroxylation events. Hydroxylation of specific proline residues by HIF prolyl 4-hydroxylases targets the HIF-alpha subunit for proteasomal destruction, whereas hydroxylation of an asparagine in the C-terminal transactivation domain prevents its interaction with the transcriptional coactivator p300. The HIF asparaginyl hydroxylase is identical to a previously known factor inhibiting HIF (FIH). We report here that recombinant FIH has unique catalytic and inhibitory properties when compared with those of the HIF prolyl 4-hydroxylases. FIH was found to require particularly long peptide substrates so that omission of only a few residues from the N or C terminus of a 35-residue HIF-1alpha sequence markedly reduced its substrate activity. Hydroxylation of two HIF-2alpha peptides was far less efficient than that of the corresponding HIF-1alpha peptides. The K-m of FIH for O-2 was about 40% of its atmospheric concentration, being about one-third of those of the HIF prolyl 4-hydroxylases but 2.5 times that of the type I collagen prolyl 4-hydroxylase. Several 2-oxoglutarate analogs were found to inhibit FIH but with distinctly different potencies from the HIF prolyl 4-hydroxylases. For example, the two most potent HIF prolyl 4-hydroxylase inhibitors among the compounds studied were the least effective ones for FIH. It should therefore be possible to develop specific small molecule inhibitors for the two enzyme classes involved in the hypoxia response.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						ACKER H, 2003, OXYGEN SENSING RESPO, P507; BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	31	317	327	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9899	9904		10.1074/jbc.M312254200	http://dx.doi.org/10.1074/jbc.M312254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701857	hybrid			2022-12-27	WOS:000220050400030
J	Li, QM; Sudhof, TC				Li, QM; Sudhof, TC			Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; CELL-SURFACE PROTEINS; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; TERMINAL FRAGMENT; ASPARTYL PROTEASE; FE65 PROTEIN; APP GENE; FAMILY	Site-specific proteolysis of the amyloid-beta precursor protein (APP) by BACE 1 and gamma-secretase, a central event in Alzheimer disease, releases a large secreted extracellular fragment ( called APPS), peptides of 40 - 43 residues derived from extracellular and transmembrane sequences (Abeta), and a short intracellular fragment ( APP intracellular domain) that may function as a transcriptional activator in a complex with the adaptor protein Fe65 and the nuclear protein Tip60. APP is closely related to APP-like protein (APLP) 1 and APLP2, but only APP is known to be cleaved by BACE 1 and to be involved in Alzheimer disease. We now demonstrate that similar to APP, APLP1 and APLP2 are also cleaved by BACE 1 but not by ADAM 9, another APP protease, and also transactivate nuclear Tip60 in a complex with Fe65. Paradoxically, although BACE 1 cleavage appears to be specific for APP and APLPs, their cleavage sequences exhibit no homology, and a short sequence ( 7 amino acids) from APP that when placed close to the membrane converts a membrane protein that is normally not cleaved by BACE 1 into a BACE 1 substrate. Our data demonstrate that APLPs and APP are processed similarly to act via the same nuclear target, suggesting that BACE 1 cleavage regulates a common function of APP and APLPs in neurons.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069585] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH69585-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Biederer T, 2002, J NEUROSCI, V22, P7340; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fortini ME, 2001, CURR OPIN CELL BIOL, V13, P627, DOI 10.1016/S0955-0674(00)00261-1; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Heber S, 2000, J NEUROSCI, V20, P7951; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; McLoughlin DM, 1996, FEBS LETT, V397, P197; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAEGGER H, 1978, ANAL BIOCHEM, V166, P368; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scholefield Z, 2003, J CELL BIOL, V163, P97, DOI 10.1083/jcb.200303059; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 1996, ANN NY ACAD SCI, V777, P77, DOI 10.1111/j.1749-6632.1996.tb34404.x; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Steiner H, 2001, J MOL NEUROSCI, V17, P193, DOI 10.1385/JMN:17:2:193; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	58	190	191	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10542	10550		10.1074/jbc.M310001200	http://dx.doi.org/10.1074/jbc.M310001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699153	hybrid			2022-12-27	WOS:000220050400107
J	Gillian, AL; Svaren, J				Gillian, AL; Svaren, J			The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GROWTH-RESPONSE-2 GENE; TOOTH-DISEASE TYPE-1; NGFI-A EGR-1; DEVELOPING HINDBRAIN; INHERITED NEUROPATHIES; SEGMENTAL EXPRESSION; MISSENSE MUTATION; NAB PROTEINS; RNA HELICASE; KROX-20	The early growth response 2 (Egr2/Krox- 20) transcription factor is essential for myelination of the peripheral nervous system and segmentation of the vertebrate hindbrain. To probe the mechanism by which Egr2 is regulated, we used a yeast two-hybrid assay and identified an RNA helicase, Ddx20 (DP103/Gemin3), as an Egr2-interacting protein. Mammalian two-hybrid assays indicated that Ddx20 can interact with Egr1, Egr3, and Egr4, in addition to Egr2, making it the only known cofactor that interacts with all four Egr family members. Using several Egr2 target promoters, we found that Ddx20 repressed Egr2-mediated transcriptional activation with significant promoter specificity. In addition, Ddx20 repressed Egr2-mediated activation of the endogenous insulin-like growth factor 2 (IGF2) gene. Interestingly, the C-terminal segment of Ddx20, which lacks the DEAD box helicase domain, was sufficient for its robust and specific repression. We also examined possible interactions between Ddx20 and Nab proteins, the only other known corepressors of the Egr family, and found that these two corepressors act independently. Finally, transcriptional repression assays performed in the presence of a histone deacetylase inhibitor ( trichostatin A) indicate that although repression of certain promoters by Ddx20 requires histone deacetylase activity, another repression mechanism must also be involved. Because Egr2 is critical for hindbrain development and peripheral nerve myelination, modulation of Egr2 by Ddx20 may play an important role in maintaining the correct expression level of Egr2 target genes.	Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Svaren, J (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007654] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL007654] Funding Source: Medline; NICHD NIH HHS [HD41590] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bae SK, 1999, CANCER RES, V59, P5989; Bellone E, 1999, Hum Mutat, V14, P353, DOI 10.1002/(SICI)1098-1004(199910)14:4<353::AID-HUMU17>3.3.CO;2-W; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Boerkoel CF, 2001, NEUROGENETICS, V3, P153, DOI 10.1007/s100480100107; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V20; Giudicelli F, 2001, GENE DEV, V15, P567, DOI 10.1101/gad.189801; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; James P, 1996, GENETICS, V144, P1425; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Levi G, 1996, DEVELOPMENT, V122, P113; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mechta-Grigoriou F, 2000, DEVELOPMENT, V127, P119; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Nonchev S, 1996, DEVELOPMENT, V122, P543; Numakura C, 2003, J NEUROL SCI, V210, P61, DOI 10.1016/S0022-510X(03)00028-5; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Pareyson D, 2000, NEUROLOGY, V54, P1696, DOI 10.1212/WNL.54.8.1696; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Schenone A, 1999, CURR OPIN NEUROL, V12, P603, DOI 10.1097/00019052-199910000-00015; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Seitanidou T, 1997, MECH DEVELOP, V65, P31, DOI 10.1016/S0925-4773(97)00051-8; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Theil T, 1998, DEVELOPMENT, V125, P443; Timmerman V, 1999, NEUROLOGY, V52, P1827, DOI 10.1212/WNL.52.9.1827; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Warner LE, 1999, ANNU REV MED, V50, P263, DOI 10.1146/annurev.med.50.1.263; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; WILSON TE, 1992, J BIOL CHEM, V267, P3718; Yan XM, 2003, MOL CELL BIOL, V23, P414, DOI 10.1128/MCB.23.1.414-423.2003; Yoshihara T, 2001, J NEUROL SCI, V184, P149, DOI 10.1016/S0022-510X(00)00504-9	50	48	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9056	9063		10.1074/jbc.M309308200	http://dx.doi.org/10.1074/jbc.M309308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699164	hybrid			2022-12-27	WOS:000189265900066
J	Kahlig, KM; Javitch, JA; Galli, A				Kahlig, KM; Javitch, JA; Galli, A			Amphetamine regulation of dopamine transport - Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PARKINSONISM-INDUCING NEUROTOXIN; GREEN FLUORESCENT PROTEIN; XENOPUS-LAEVIS OOCYTES; PLASMA-MEMBRANE; MEDIATED INTERNALIZATION; SURFACE EXPRESSION; MICE LACKING; CELL-LINES; COCAINE	Dopaminergic neurotransmission is fine-tuned by the rate of removal of dopamine (DA) from the extracellular space via the Na+/ Cl--dependent DA transporter (DAT). DAT is a target of psychostimulants such as amphetamine ( AMPH) and cocaine. Previously, we reported that AMPH redistributes the human DAT away from the cell surface. This process was associated with a reduction in transport capacity. This loss of transport capacity may result either from a modification of the function of DAT that is independent of its cell surface redistribution and/or from a reduction in the number of active transporters at the plasma membrane that results from DAT trafficking. To discriminate between these possibilities, we stably transfected HEK-293 cells with a yellow fluorescent protein (YFP)tagged human DAT (hDAT cells). In hDAT cells, acute exposure to AMPH induced a time-dependent loss of hDAT activity. By coupling confocal imaging with patch-clamp whole-cell recordings, we have demonstrated for the first time that the loss of AMPH-induced hDAT activity temporally parallels the accumulation of intracellular hDAT. In addition, presteady-state current analysis revealed a cocaine-sensitive, voltage-dependent capacitance current that correlated with the level of transporter membrane expression and in turn served to monitor the AMPH-induced trafficking of hDAT. We found that the decrease in hDAT cell surface expression induced by AMPH was not paralleled by changes in the ability of the single transporter to carry charges. Quasi-stationary noise analysis of the AMPH-induced hDAT currents revealed that the unitary transporter current remained unaltered during the loss of hDAT membrane expression. Taken together, these data strongly suggest that the AMPH-induced reduction of hDAT transport capacity results from the removal of active hDAT from the plasma membrane.	Vanderbilt Univ, Ctr Mol Neurosci, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, Dept Pharmacol, New York, NY 10032 USA	Vanderbilt University; Columbia University; Columbia University	Galli, A (corresponding author), Vanderbilt Univ, Ctr Mol Neurosci, Dept Physiol & Mol Biophys, 465 21st Ave S, Nashville, TN 37232 USA.	Aurelio.Galli@vanderbilt.edu		Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014684, R01DA013975, R01DA011495] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11495, DA14684, DA13975] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Derbez AE, 2002, J PHARMACOL EXP THER, V301, P306, DOI 10.1124/jpet.301.1.306; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GALLI A, 1995, J EXP BIOL, V198, P2197; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Gulley JM, 2002, J NEUROCHEM, V83, P400, DOI 10.1046/j.1471-4159.2002.01133.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Howell LL, 2001, J PHARMACOL EXP THER, V298, P1; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jones SR, 1998, J NEUROSCI, V18, P1979; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lippincott-Schwartz J, 1999, METHOD CELL BIOL, V58, P261; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Mager S, 1998, METHOD ENZYMOL, V296, P551; Mayfield RD, 2001, MOL PHARMACOL, V59, P113, DOI 10.1124/mol.59.1.113; Melikian HE, 1999, J NEUROSCI, V19, P7699; Page G, 2001, J NEUROCHEM, V76, P1282, DOI 10.1046/j.1471-4159.2001.00179.x; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; Piston DW, 1999, METHOD CELL BIOL, V58, P31; Rees S, 1996, BIOTECHNIQUES, V20, P102; Robbins AK, 1998, BIOTECHNIQUES, V25, P240, DOI 10.2144/98252st04; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Sonders MS, 1997, J NEUROSCI, V17, P960; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; SULZER D, 1993, J NEUROCHEM, V60, P527, DOI 10.1111/j.1471-4159.1993.tb03181.x; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	52	76	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8966	8975		10.1074/jbc.M303976200	http://dx.doi.org/10.1074/jbc.M303976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699142	hybrid			2022-12-27	WOS:000189265900055
J	Galkin, A; Kulakova, L; Sarikaya, E; Lim, K; Howard, A; Herzberg, O				Galkin, A; Kulakova, L; Sarikaya, E; Lim, K; Howard, A; Herzberg, O			Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; AMIDINOTRANSFERASE; PROTEIN; ENZYME; IDENTIFICATION; BIOSYNTHESIS; EXPRESSION; SOFTWARE; CLONING	L-Arginine deiminase (ADI) catalyzes the irreversible hydrolysis of arginine to citrulline and ammonia. ADI is involved in the first step of the most widespread anaerobic route of arginine degradation. ADI, missing in high eukaryotes, is a potential antimicrobial and antiparasitic drug target. We have determined the crystal structure of ADI from Pseudomonas aeruginosa by the multi-wavelength anomalous diffraction method at 2.45 Angstrom resolution. The structure exhibits similarity to other arginine-modifying or substituted arginine-modifying enzymes such as dimethylarginine dimethylaminohydrolase (DDAH), arginine: glycine amidinotransferase, and arginine: inosamine-phosphate amidinotransferase, despite the lack of significant amino acid sequence homology to these enzymes. The similarity spans a core domain comprising five betabetaalphabeta motifs arranged in a circle around a 5-fold pseudosymmetry axis. ADI contains an additional alpha-helical domain of novel topology inserted between the first and the second betabetaalphabeta modules. A catalytic triad, Cys-His-Glu/Asp ( arranged in a different manner from that of the thiol proteases), seen in the other arginine-modifying enzymes is also conserved in ADI, as well as many other residues involved in substrate binding. Based on this conservation pattern and the assumption that the substrate binding mode is similar to that of DDAH, an ADI catalytic mechanism is proposed. The main players are Cys-406, which mounts the nucleophilic attack on the carbon atom of the guanidinium group of arginine, and His-278, which serves as a general base.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; IIT, Chicago, IL 60616 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Energy (DOE); Argonne National Laboratory; Illinois Institute of Technology	Herzberg, O (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	osnat@carb.umbi.umd.edu	ID, IMCACAT/D-5867-2014	Herzberg, Osnat/0000-0003-2823-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057890] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM57890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; Beloussow K, 2002, CANCER LETT, V183, P155, DOI 10.1016/S0304-3835(01)00793-5; Biagini GA, 2003, MOL BIOCHEM PARASIT, V128, P11, DOI 10.1016/S0166-6851(03)00025-2; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano WL, 2002, PYMOL USERS MANUAL; Eckmann L, 2000, J IMMUNOL, V164, P1478, DOI 10.4049/jimmunol.164.3.1478; Fritsche E, 1998, BIOCHEMISTRY-US, V37, P17664, DOI 10.1021/bi981949p; Fritsche E, 1999, J BIOL CHEM, V274, P3026, DOI 10.1074/jbc.274.5.3026; GAMPER M, 1991, J BACTERIOL, V173, P4742, DOI 10.1128/jb.173.15.4742-4750.1991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; Krissinel E., 2003, P 5 INT C MOL STRUCT, P88; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Lu CD, 1999, J BACTERIOL, V181, P2459, DOI 10.1128/JB.181.8.2459-2464.1999; LUTHI E, 1986, J GEN MICROBIOL, V132, P2667; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oudjama Y, 2002, ACTA CRYSTALLOGR D, V58, P2150, DOI 10.1107/S0907444902015743; Palm JED, 2003, J INFECT DIS, V187, P1849, DOI 10.1086/375356; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; Smith RS, 2003, CURR OPIN MICROBIOL, V6, P56, DOI 10.1016/S1369-5274(03)00008-0; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Ye S, 2001, CURR OPIN STRUC BIOL, V11, P740, DOI 10.1016/S0959-440X(01)00275-5; Zuniga M, 2002, MOL PHYLOGENET EVOL, V25, P429, DOI 10.1016/S1055-7903(02)00277-4	30	67	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14001	14008		10.1074/jbc.M313410200	http://dx.doi.org/10.1074/jbc.M313410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14701825	hybrid			2022-12-27	WOS:000220478500088
J	Eichler, R; Lenz, O; Strecker, T; Eickmann, M; Klenk, HD; Garten, W				Eichler, R; Lenz, O; Strecker, T; Eickmann, M; Klenk, HD; Garten, W			Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; POSITIVELY CHARGED RESIDUES; SUBTILASE SKI-1/S1P; ANCHOR PROTEINS; ER MEMBRANE; GP-C; ORIENTATION; IDENTIFICATION; SEQUENCE; DOMAIN	Lassa virus glycoprotein C (GP-C) is translated as a precursor (preGP-C) into the lumen of the endoplasmic reticulum (ER) and cotranslationally cleaved into the signal peptide and immature GP-C before GP-C is proteolytically processed into its subunits, GP-1 and GP-2, which form the mature virion spikes. The signal peptide of preGP-C comprises 58 amino acids and contains two distinct hydrophobic domains. Here, we show that each hydrophobic domain alone can insert preGP-C into the ER membrane. Furthermore, we demonstrate that the native signal peptide only uses the N-terminal hydrophobic domain for membrane insertion, exhibiting a novel type of a topology for signal peptides with an extended ER luminal part, which is essential for proteolytic processing of GP-C into GP-1 and GP-2.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Garten, W (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	garten@mailer.uni-marburg.de	Strecker, Thomas/AAR-8442-2020	Strecker, Thomas/0000-0002-7857-937X				ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; Beyer WR, 2003, J VIROL, V77, P2866, DOI 10.1128/JVI.77.5.2866-2872.2003; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Eichler R, 2003, EMBO REP, V4, P1084, DOI 10.1038/sj.embor.7400002; Eichler R, 2003, FEBS LETT, V538, P203, DOI 10.1016/S0014-5793(03)00160-1; Froeschke M, 2003, J BIOL CHEM, V278, P41914, DOI 10.1074/jbc.M302343200; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laemmli U. K., 1970, NATURE, V227, P860; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; Lenz O, 2000, J VIROL, V74, P11418, DOI 10.1128/JVI.74.23.11418-11421.2000; Lindemann D, 2001, J VIROL, V75, P5762, DOI 10.1128/JVI.75.13.5762-5771.2001; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Sanz MA, 2003, J BIOL CHEM, V278, P2051, DOI 10.1074/jbc.M206611200; Sato M, 1998, J BIOL CHEM, V273, P25203, DOI 10.1074/jbc.273.39.25203; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; von Heijne G, 1994, Subcell Biochem, V22, P1; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555	34	31	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12293	12299		10.1074/jbc.M312975200	http://dx.doi.org/10.1074/jbc.M312975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709548	hybrid			2022-12-27	WOS:000220334900036
J	Yasui, Y; Urano, T; Kawajiri, A; Nagata, K; Tatsuka, M; Saya, H; Furukawa, K; Takahashi, T; Izawa, I; Inagaki, M				Yasui, Y; Urano, T; Kawajiri, A; Nagata, K; Tatsuka, M; Saya, H; Furukawa, K; Takahashi, T; Izawa, I; Inagaki, M			Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 PHOSPHORYLATION; CHROMOSOME SEGREGATION; CLEAVAGE FURROW; CENTRAL SPINDLE; KINASE; FILAMENTS; INCENP; CONDENSATION; PHOSPHATASE; REGULATORS	Mitotic kinases regulate cell division and its checkpoints, errors of which can lead to aneuploidy or genetic instability. One of these is Aurora- B, a key kinase that is required for chromosome alignment at the metaphase plate and for cytokinesis in mammalian cells. We report here that human Aurora- B is phosphorylated at Thr- 232 through interaction with the inner centromere protein ( INCENP) in vivo. The phosphorylation of Thr- 232 occurs by means of an autophosphorylation mechanism, which is indispensable for the Aurora- B kinase activity. The activation of Aurora- B spatio- temporally correlated with the site- specific phosphorylation of its physiological substrates, histone H3 and vimentin. Overexpression of the TA mutant of Aurora- B, in which Thr- 232 was changed into alanine, frequently induced multinuclearity in cells. These results indicate that the phosphorylation of Thr- 232 is an essential regulatory mechanism for Aurora- B activation.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Kumamoto Univ, Dept Tumor Genet & Biol, Sch Med, Kumamoto 8600811, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Hiroshima University; Kumamoto University	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Aichi 4648681, Japan.	minagaki@aichi-cc.jp	Saya, Hideyuki/J-4325-2013; Inagaki, Masaki/B-9920-2016	Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; YASNI Y, 1998, J CELL BIOL, V143, P1249; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yasui Y, 2001, ONCOGENE, V20, P2868, DOI 10.1038/sj.onc.1204407; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	26	182	186	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12997	13003		10.1074/jbc.M311128200	http://dx.doi.org/10.1074/jbc.M311128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722118	hybrid			2022-12-27	WOS:000220334900119
J	Chrestensen, CA; Schroeder, MJ; Shabanowitz, J; Hunt, DF; Pelo, JW; Worthington, MT; Sturgill, TW				Chrestensen, CA; Schroeder, MJ; Shabanowitz, J; Hunt, DF; Pelo, JW; Worthington, MT; Sturgill, TW			MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser(178), a site required for 14-3-3 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILITY; ZINC-FINGER PROTEINS; AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE-2; TNF-ALPHA; NUCLEAR EXPORT; P38; IDENTIFICATION; SUBSTRATE	MAPKAP kinase 2 (MK2) is required for tumor necrosis factor synthesis. Tristetraprolin (TTP) binds to the 3'-untranslated region of tumor necrosis factor mRNA and regulates its fate. We identified in vitro and in vivo phosphorylation sites in TTP using nanoflow high pressure liquid chromatography microelectrospray ionization tandem mass spectrometry and novel methods for direct digestion of TTP bound to affinity matrices (GSH-beads or anti-Myc linked to magnetic beads). MK2Delta3B, activated in Escherichia coli by p38alpha, phosphorylates TTP in vitro at major sites Ser(52) and Ser(178) (> 10-fold in abundance) as well as at several minor sites that were detected after enriching for phosphopeptides with immobilized metal affinity chromatography. MK2 phosphorylation of TTP creates a functional 14-3-3 binding site. In cells, TTP was phosphorylated at Ser(52), Ser(178), Thr(250), and Ser(316) and at SP sites in a cluster (Ser(80)/ Ser(82)/Ser(85)). Anisomycin treatment of NIH 3T3 cells increased phosphorylation of Ser(52) and Ser(178). Overexpression of MK2 sufficed to increase phosphorylation of Ser(52) and Ser(178) but not Ser(80)/Ser(82)/ Ser(85) or Thr(250). Thus, Ser(52) and Ser(178) are putative MK2 sites in vivo. Identified phosphosite(s) may be biologic switches controlling mRNA stability and translation.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Sturgill, TW (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 800735, Charlottesville, VA 22908 USA.	tws7w@virginia.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060720, T32DK007320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537, R01GM062890] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK07320, DK60720] Funding Source: Medline; NIGMS NIH HHS [GM37537, GM62890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann BT, 2003, BIOCHEMISTRY-US, V42, P217, DOI 10.1021/bi026988m; Baseggio L, 2002, EUR CYTOKINE NETW, V13, P92; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; BOSWORTH HB, 2002, J PALLIATIVE MED, V5, P829; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Cano E, 1996, ONCOGENE, V12, P805; Cao HP, 2003, ARCH BIOCHEM BIOPHYS, V412, P106, DOI 10.1016/S0003-9861(03)00012-2; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Cheng TJ, 2003, J CELL BIOCHEM, V89, P589, DOI 10.1002/jcb.10511; Chrestensen CA, 2002, J BIOL CHEM, V277, P27733, DOI 10.1074/jbc.M202663200; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Fairhurst AM, 2003, ARTHRITIS RES THER, V5, pR214, DOI 10.1186/ar778; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, BIOCHEM SOC T, V30, P959, DOI 10.1042/BST0300959; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; Murata T, 2000, BIOCHEM BIOPH RES CO, V274, P526, DOI 10.1006/bbrc.2000.3182; Murata T, 2002, BIOCHEM BIOPH RES CO, V293, P1242, DOI 10.1016/S0006-291X(02)00363-7; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	54	219	231	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10176	10184		10.1074/jbc.M310486200	http://dx.doi.org/10.1074/jbc.M310486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688255	hybrid			2022-12-27	WOS:000220050400064
J	Condliffe, SB; Zhang, H; Frizzell, RA				Condliffe, SB; Zhang, H; Frizzell, RA			Syntaxin 1A regulates ENaC channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; CFTR CHLORIDE CHANNELS; NA+ CHANNEL; TRAFFICKING; SPECIFICITY; INSERTION; SNARES; KV2.1; CAMP	Na+ entry across the apical membranes of many absorptive epithelia is determined by the number (N) and open probability (P-o) of epithelial sodium channels (ENaC). Previous results showed that the H3 domain of syntaxin-1A (S1A) binds to ENaC to reduce N, supporting a role for S1A in the regulation of ENaC trafficking. The aim of this study was to determine whether S1A-induced reductions in ENaC current also result from interactions between cell surface ENaC and S1A that alter ENaC P-o. Injection of a glutathione S-transferase (GST)-H3 S1A fusion protein into ENaC-expressing Xenopus oocytes inhibited whole cell Na+ current (I-Na) by 33% within 5 min. This effect was dose-dependent, with a K-i of 7 ng/mul (similar to200 nM). In contrast, injection of GST alone or a H3 domain-deleted GST-S1A fusion protein had no effect on I-Na. In cell-attached patch clamp experiments, GST-H3 acutely decreased ENaC P-o by 30%, whereas GST-S1ADeltaH3 was without effect. Further analysis revealed that ENaC mean closed time was significantly prolonged by S1A. Interestingly, GST-H3 had no effect on channel activity of an ENaC pore mutant that constitutively gates open (P-o congruent to 1.0), supporting the idea that S1A alters the closed state of ENaC and indicating that the actions of S1A on ENaC trafficking and gating can be separated experimentally. This study indicates that, in addition to a primary effect on ENaC trafficking, S1A interacts with cell surface ENaC to rapidly decrease channel gating. This rapid effect of S1A may modulate Na+ entry rate during rapid increases in ENaC N.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu			NIDDK NIH HHS [DK54814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; Butterworth MB, 2003, FASEB J, V17, pA914; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Ganeshan R, 2003, J BIOL CHEM, V278, P2876, DOI 10.1074/jbc.M211790200; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; Li GM, 2003, J BIOL CHEM, V278, P19791, DOI 10.1074/jbc.M212250200; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; Michaelevski I, 2003, J BIOL CHEM, V278, P34320, DOI 10.1074/jbc.M304943200; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Sterling H, 2003, AM J PHYSIOL-RENAL, V284, pF510, DOI 10.1152/ajprenal.00309.2002; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659	31	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10085	10092		10.1074/jbc.M313592200	http://dx.doi.org/10.1074/jbc.M313592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14703519	hybrid			2022-12-27	WOS:000220050400053
J	Lee, JH; Jeong, SM; Lee, BH; Noh, HS; Kim, BK; Kim, JI; Rhim, H; Kim, HC; Kim, KM; Nah, SY				Lee, JH; Jeong, SM; Lee, BH; Noh, HS; Kim, BK; Kim, JI; Rhim, H; Kim, HC; Kim, KM; Nah, SY			Prevention of ginsenoside-induced desensitization of Ca2+-activated Cl- current by microinjection of inositol hexakisphosphate in Xenopus laevis oocytes - Involvement of GRK2 AND beta-arrestin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; PROTEIN-KINASE-C; NEUROTRANSMITTER RESPONSES; PHOSPHOLIPASE-C; PHORBOL ESTER; CHANNEL; ROLES; PENTAKISPHOSPHATE; PHOSPHORYLATION; INHIBITION	We demonstrated that ginsenosides, the active ingredient of Panax ginseng, enhance endogenous Ca2+-activated Cl- currents via Galpha(q/11)-phospholipase C-beta3 pathway in Xenopus laevis oocytes. Moreover, prolonged treatment of ginsenosides induced Cl- channel desensitization. However, the molecular mechanisms involved in ginsenoside-induced Cl- channel desensitization have not yet been determined precisely. To provide answers to these questions, we investigated the changes in ginsenoside-induced Cl- channel desensitization after intraoocyte injection of inositol hexakisphosphate (InsP(6)), which is known to bind beta-arrestins and interfere with beta-arrestin- induced receptor down-regulation, and cRNAs coding beta-arrestin I/II and G-protein receptor kinase 2 (GRK2), which is known to phosphorylate G protein-coupled receptors and attenuate agonist stimulations. When control oocytes were stimulated with ginsenosides, the second, third, and fourth responses to ginsenosides were 69.6 +/- 4.1, 9.2 +/- 2.3, and 2.6 +/- 2.2% of the first responses, respectively. Preintraoocyte injection of InsP(6) before ginsenoside treatment restored ginsenoside effect to initial response levels in a concentration, time-, and structurally specific manner, in that inositol hexasulfate had no effect. The EC50 was 13.9 +/- 8.7 muM. Injection of cRNA coding beta-arrestin I but not beta-arrestin II blocked InsP(6) effect on prevention of ginsenoside-induced Cl- channel desensitization. Injection of cRNA coding GRK2 abolished ginsenoside effect enhancing Cl- current. However, the GRK2-caused loss of ginsenoside effect on Cl- current was prevented by coinjection of GRK2 with GRK2-K220R, a dominant-negative mutant of GRK. These results indicate that ginsenoside-induced Cl- channel desensitization is mediated via activation of GRK2 and beta-arrestin I.	Konkuk Univ, Coll Vet Med, Res Lab Study Ginseng Signal Transduct, Seoul 143701, South Korea; Konkuk Univ, Coll Med, Seoul 143701, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Korean Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea; Kangwon Natl Univ, Coll Pharm, Chunchon 200701, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea	Konkuk University; Konkuk University; Konkuk University Medical Center; Gwangju Institute of Science & Technology (GIST); Korea Institute of Science & Technology (KIST); Kangwon National University; Chonnam National University	Nah, SY (corresponding author), Konkuk Univ, Coll Vet Med, Res Lab Study Ginseng Signal Transduct, Seoul 143701, South Korea.	synah@konkuk.ac.kr		Lee, Junho/0000-0003-0913-8578				Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Choi S, 2003, EUR J PHARMACOL, V468, P83, DOI 10.1016/S0014-2999(03)01666-2; Choi S, 2001, J BIOL CHEM, V276, P48797, DOI 10.1074/jbc.M104346200; Choi S, 2001, BRIT J PHARMACOL, V132, P641, DOI 10.1038/sj.bjp.0703856; CYR CR, 1993, J BIOL CHEM, V268, P26071; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Hanley NRS, 2002, J PHARMACOL EXP THER, V300, P468, DOI 10.1124/jpet.300.2.468; HESLOP JP, 1985, J EXP BIOL, V119, P395; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; ITO I, 1988, J CELL PHYSIOL, V134, P155, DOI 10.1002/jcp.1041340120; KATO K, 1988, J NEUROCHEM, V50, P766, DOI 10.1111/j.1471-4159.1988.tb02980.x; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LUPUMEIRI M, 1989, PFLUG ARCH EUR J PHY, V413, P498, DOI 10.1007/BF00594180; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; MORAN O, 1989, MOL BRAIN RES, V5, P193, DOI 10.1016/0169-328X(89)90035-1; NAH SY, 1994, J ETHNOPHARMACOL, V42, P45, DOI 10.1016/0378-8741(94)90022-1; NAH SY, 1995, P NATL ACAD SCI USA, V92, P8739, DOI 10.1073/pnas.92.19.8739; Nah SY, 1997, KOREAN J GINSENG SCI, V21, P1; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SINGER D, 1990, PFLUG ARCH EUR J PHY, V416, P7, DOI 10.1007/BF00370215; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Tyler Varro E., 1995, Journal of Pharmacy Technology, V11, P214	32	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9912	9921		10.1074/jbc.M310824200	http://dx.doi.org/10.1074/jbc.M310824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699097	hybrid			2022-12-27	WOS:000220050400032
J	Medeiros, LA; Khan, T; El Khoury, JB; Pham, CLL; Hatters, DM; Howlett, GJ; Lopez, R; O'Brien, KD; Moore, KJ				Medeiros, LA; Khan, T; El Khoury, JB; Pham, CLL; Hatters, DM; Howlett, GJ; Lopez, R; O'Brien, KD; Moore, KJ			Fibrillar amyloid protein present in atheroma activates CD36 signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR CD36; APOLIPOPROTEIN-C-II; ALZHEIMERS-DISEASE; ATHEROSCLEROTIC PLAQUES; A-I; DENSITY; MACROPHAGES; MECHANISMS; DEPOSITS	The self-association of proteins to form amyloid fibrils has been implicated in the pathogenesis of a number of diseases including Alzheimer's, Parkinson's, and Creutzfeldt-Jakob diseases. We recently reported that the myeloid scavenger receptor CD36 initiates a signaling cascade upon binding to fibrillar beta-amyloid that stimulates recruitment of microglia in the brain and production of inflammatory mediators. This receptor plays a key role in the pathogenesis of atherosclerosis, prompting us to evaluate whether fibrillar proteins were present in atherosclerotic lesions that could initiate signaling via CD36. We show that apolipoprotein C-II, a component of very low and high density lipoproteins, readily forms amyloid fibrils that initiate macrophage inflammatory responses including reactive oxygen production and tumor necrosis factor alpha expression. Using macrophages derived from wild type and Cd36(-/-) mice to distinguish CD36-specific events, we show that fibrillar apolipoprotein C-II activates a signaling cascade downstream of this receptor that includes Lyn and p44/42 MAPKs. Interruption of this signaling pathway through targeted deletion of Cd36 or blocking of p44/42 MAPK activation inhibits macrophage tumor necrosis factor alpha gene expression. Finally, we demonstrate that apolipoprotein C-II in human atheroma co-localizes to regions positive for markers of amyloid and macrophage accumulation. Together, these data characterize a CD36-dependent signaling cascade initiated by fibrillar amyloid species that may promote atherogenesis.	Harvard Univ, Sch Med, Lipid Metab Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Washington, Div Cardiol, Seattle, WA 98195 USA; Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Melbourne, Vic 3010, Australia	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Washington; University of Washington Seattle; University of Melbourne	Moore, KJ (corresponding author), Harvard Univ, Sch Med, Lipid Metab Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA.	kmoore@molbio.mgh.harvard.edu	O'Brien, Kevin Douglas/HDO-1461-2022; O'Brien, Kevin/CAH-4638-2022; Moore, Kathryn/ABE-6416-2020	O'Brien, Kevin Douglas/0000-0002-2293-9196; O'Brien, Kevin/0000-0002-2293-9196; Moore, Kathryn/0000-0003-2505-2547; Hatters, Danny/0000-0002-9965-2847	NIA NIH HHS [R01AG/HL20255] Funding Source: Medline; NINDS NIH HHS [NS41330-3] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020255] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bamberger ME, 2003, J NEUROSCI, V23, P2665; Bergstrom J, 2001, BIOCHEM BIOPH RES CO, V285, P903, DOI 10.1006/bbrc.2001.5260; Clarke R, 2002, CARDIOVASC DRUG THER, V16, P411, DOI 10.1023/A:1022134418372; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; Dichtl Wolfgang, 2000, Molecular Cell Biology Research Communications, V4, P50, DOI 10.1006/mcbr.2000.0256; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; GOWN AM, 1986, AM J PATHOL, V125, P191; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Hatters DM, 2003, BIOPHYS J, V85, P3979, DOI 10.1016/S0006-3495(03)74812-7; Hatters DM, 2000, BIOCHEMISTRY-US, V39, P8276, DOI 10.1021/bi000002w; HAVEL RJ, 1973, BIOCHEMISTRY-US, V12, P1828, DOI 10.1021/bi00733a026; HIGUCHI K, 1991, BIOCHEM J, V279, P427, DOI 10.1042/bj2790427; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; Janciauskiene S, 2001, ATHEROSCLEROSIS, V158, P41, DOI 10.1016/S0021-9150(00)00767-X; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lin CY, 1999, J LIPID RES, V40, P1618; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Marsche G, 2003, J BIOL CHEM, V278, P47562, DOI 10.1074/jbc.M308428200; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Mucchiano GI, 2001, J PATHOL, V193, P270, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH753>3.0.CO;2-S; Mucchiano GI, 2001, AM J CLIN PATHOL, V115, P298; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; PEPYS MB, 1994, P NATL ACAD SCI USA, V91, P5602, DOI 10.1073/pnas.91.12.5602; Pham CLL, 2002, BIOCHEMISTRY-US, V41, P14313, DOI 10.1021/bi026070v; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Tedgui A, 2002, CIRC RES, V90, P1145, DOI 10.1161/01.RES.0000023048.87638.92; Wang CS, 1996, BBA-LIPID LIPID MET, V1302, P224, DOI 10.1016/0005-2760(96)00065-3; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WESTERMARK P, 1995, AM J PATHOL, V147, P1186; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1995, AM J PATHOL, V147, P238	42	118	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10643	10648		10.1074/jbc.M311735200	http://dx.doi.org/10.1074/jbc.M311735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699114	hybrid			2022-12-27	WOS:000220050400118
J	Bandsma, RHJ; van Dijk, TH; ter Harmsel, A; Kok, T; Reijngoud, DJ; Staels, B; Kuipers, F				Bandsma, RHJ; van Dijk, TH; ter Harmsel, A; Kok, T; Reijngoud, DJ; Staels, B; Kuipers, F			Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-4-ALPHA; ISOTOPOMER DISTRIBUTION ANALYSIS; AMINO ACIDS; GLUCONEOGENESIS; FLUX; CHROMATOGRAPHY; INHIBITION; TURNOVER; RATS	Apart from impaired beta-oxidation, Pparalpha-deficient (Pparalpha(-/-)) mice suffer from hypoglycemia during prolonged fasting, suggesting alterations in hepatic glucose metabolism. We compared hepatic glucose metabolism in vivo in wild type (WT) and Pparalpha(-/-) mice after a short term fast, applying novel isotopic methods. After a 9-h fast, mice were infused with [U-C-13] glucose, [2-C-13] glycerol, [1-H-2]galactose, and paracetamol for 6 h, and blood and urine was collected in timed intervals. Plasma glucose concentrations remained constant and were not different between the groups. Hepatic glycogen content was 69 +/- 11 and 90 +/- 31 mumol/g liver after 15 h of fasting in WT and Pparalpha(-/-) mice, respectively. The gluconeogenic flux toward glucose 6-phosphate was not different between the groups (i.e. 157 +/- 9 and 153 +/- 9 mumol/kg/min in WT and Pparalpha(-/-) mice, respectively). The gluconeogenic flux toward plasma glucose, however, was decreased in PPARalpha(-/-) mice (i.e. 142 +/- 9 versus 124 +/- 13 mumol/kg/min) (p < 0.05), accounting for the observed decrease (-15%) in hepatic glucose production in Ppar alpha(-/-) mice. Expression of the gene encoding glucose-6-phosphate hydrolase (G6ph) was lower in the PPAR alpha(-/-) mice compared with WT mice. In conclusion, Ppar alpha(-/-) mice were able to maintain a normal total gluconeogenic flux to glucose 6-phosphate during moderate fasting, despite their inability to up-regulate beta-oxidation. However, this gluconeogenic flux was directed more toward glycogen, leading to a decreased hepatic glucose output. This was associated with a down-regulation of the expression of G6ph in PPAR alpha-deficient mice.	Univ Groningen Hosp, Dept Pediat, Ctr Liver Digest & Metab Dis, NL-9713 G2 Groningen, Netherlands; Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France; Univ Lille, Fac Pharm, F-59019 Lille, France	University of Groningen; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille	Kuipers, F (corresponding author), Acad Hosp Groningen, CMCIV, Dept Pediat, Rm Y2115,Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	f.kuipers@med.rug.nl	Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Kuipers, Folkert/0000-0003-2518-737X; Reijngoud, Dirk-Jan/0000-0003-1157-4491				Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; Hellerstein MK, 1997, METABOLISM, V46, P1390, DOI 10.1016/S0026-0495(97)90137-2; Hellerstein MK, 1997, J CLIN INVEST, V100, P1305, DOI 10.1172/JCI119644; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KUIPERS F, 1985, GASTROENTEROLOGY, V88, P403, DOI 10.1016/0016-5085(85)90499-8; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE S, 1958, ANAL CHEM, V30, P1185, DOI 10.1021/ac60139a005; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; Previs SF, 1999, AM J PHYSIOL-ENDOC M, V277, pE154, DOI 10.1152/ajpendo.1999.277.1.E154; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TUTWILER GF, 1982, EUR J BIOCHEM, V124, P465; van Dijk TH, 2003, ANAL BIOCHEM, V322, P1, DOI 10.1016/j.ab.2003.07.008; van Dijk TH, 2001, J BIOL CHEM, V276, P25727, DOI 10.1074/jbc.M101223200; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200	21	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8930	8937		10.1074/jbc.M310067200	http://dx.doi.org/10.1074/jbc.M310067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688286	hybrid			2022-12-27	WOS:000189265900051
J	He, F; Mao, ML; Wensel, TG				He, F; Mao, ML; Wensel, TG			Enhancement of phototransduction G protein-effector interactions by phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; CGMP PHOSPHODIESTERASE; PHOSPHOLIPASE-C; RETINAL RODS; IN-VIVO; BOVINE; ADAPTATION; PHOTORECEPTOR; MEMBRANES	Light responses in photoreceptor cells are mediated by the action of the G protein transducin (G(t)) on the effector enzyme cGMP phosphodiesterase (PDE6) at the surface of disk membranes. The enzymatic components needed for phosphoinositide-based signaling are known to be present in rod cells, but it has remained uncertain what role phosphoinositides play in vertebrate phototransduction. Reconstitution of PDE6 and activated G(alphat), on the surface of large unilamellar vesicles containing D-myo-phosphatidylinositol-4,5-bisphosphate (PI(4,5) P-2), stimulated PDE activity nearly 4-fold above the level observed with membranes containing no phosphoinositides, whereas G protein-independent activation by trypsin was unaffected by the presence of phosphoinositides. PDE activity was similarly stimulated by D-myo-phosphatidylinositol-3,4-bisphosphate and D-myophosphatidylinositol-4- phosphate ( PI( 4) P), but much less by D-myo-phosphatidylinositol-5-phosphate (PI(5) P-2) or D-myo-phosphatidylinositol-3,5-bisphosphate. Incubation of rod outer segment membranes with phosphoinositide-specific phospholipase C decreased G protein-stimulated activation of endogenous PDE6, but not trypsin-stimulated PDE activity. Binding experiments using phosphoinositide-containing vesicles revealed patterns of PDE6 binding and PDE6-enhanced G(alphat)-GTPgammaS binding, consistent with the activation profile PI(4,5) P-2 > PI(4) P > PI(5) P similar to control vesicles. These results suggest that enhancement of effector-G protein interactions represents a possible mechanism for modulation of phototransduction gain by changes in phosphoinositide levels, perhaps occurring in response to long-term changes in illumination or other environmental cues.	Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	twensel@bcm.tmc.edu		Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07001] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Calvert PD, 2002, J GEN PHYSIOL, V119, P129, DOI 10.1085/jgp.119.2.129; CHOE HG, 1990, EXP EYE RES, V51, P167, DOI 10.1016/0014-4835(90)90069-7; DAS ND, 1986, CELL STRUCT FUNCT, V11, P53, DOI 10.1247/csf.11.53; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; Ghalayini AJ, 1998, J NEUROCHEM, V70, P171; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; GHALAYINI AJ, 1992, J BIOL CHEM, V267, P17977; GHALAYINI AJ, 1995, CURR EYE RES, V14, P1025, DOI 10.3109/02713689508998525; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200; Hessel E, 2003, J BIOL CHEM, V278, P22853, DOI 10.1074/jbc.M302747200; Hurley JB, 2002, J GEN PHYSIOL, V119, P125, DOI 10.1085/jgp.119.2.125; Jindrova H, 1998, PHYSIOL RES, V47, P285; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Nikonov S, 2000, J GEN PHYSIOL, V116, P795, DOI 10.1085/jgp.116.6.795; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; SRIVASTAVA D, 1995, BIOCHEM J, V308, P653, DOI 10.1042/bj3080653; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; Womack KB, 2000, J NEUROSCI, V20, P2792	29	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8986	8990		10.1074/jbc.M311488200	http://dx.doi.org/10.1074/jbc.M311488200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699118	hybrid			2022-12-27	WOS:000189265900057
J	Leach, MR; Williams, DB				Leach, MR; Williams, DB			Lectin-deficient calnexin is capable of binding class I histocompatibility molecules in vivo and preventing their degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MHC ANTIGENS; TCR-ALPHA PROTEINS; MISFOLDED GLYCOPROTEINS; QUALITY-CONTROL; LINKED OLIGOSACCHARIDE; CALRETICULIN FUNCTIONS; MONOCLONAL-ANTIBODIES; CHAPERONE; COMPLEX; ASSOCIATION	Calnexin is a membrane-bound lectin of the endoplasmic reticulum (ER) that binds transiently to newly synthesized glycoproteins. By interacting with oligosaccharides of the form Glc(1)Man(9)GlcNAc(2), calnexin enhances the folding of glycoprotein substrates, retains misfolded variants in the ER, and in some cases participates in their degradation. Calnexin has also been shown to bind polypeptides in vivo that do not possess a glycan of this form and to function in vitro as a molecular chaperone for nonglycosylated proteins. To test the relative importance of the lectin site compared with the polypeptide-binding site, we have generated six calnexin mutants defective in oligosaccharide binding using site-directed mutagenesis. Expressed as glutathione S-transferase fusions, these mutants were still capable of binding ERp57, a thiol oxidoreductase, and preventing the aggregation of a nonglycosylated substrate, citrate synthase. They were, however, unable to bind Glc(1) Man(9)GlcNAc(2) oligosaccharide and were compromised in preventing the aggregation of the monoglucosylated substrate jack bean alpha-mannosidase. Two of these mutants were then engineered into full-length calnexin for heterologous expression in Drosophila cells along with the murine class I histocompatibility molecules K-b and D-b as model glycoproteins. In this system, lectin site-defective calnexin was able to replace wild type calnexin in forming a complex with K-b and D-b heavy chains and preventing their degradation. Thus, at least for class I molecules, the lectin site of calnexin is dispensable for some of its chaperone functions.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.williams@utoronto.ca						Adar R, 1996, EUR J BIOCHEM, V239, P668, DOI 10.1111/j.1432-1033.1996.0668u.x; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Chillaron J, 2000, BIOL CHEM, V381, P1155, DOI 10.1515/BC.2000.143; Christodoulou S, 1997, GENE, V191, P143, DOI 10.1016/S0378-1119(97)00025-5; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAPEL AJ, 1981, CELL, V25, P179, DOI 10.1016/0092-8674(81)90242-7; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; MIRKOV TE, 1993, GLYCOBIOLOGY, V3, P581, DOI 10.1093/glycob/3.6.581; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; Smith M J, 1992, DNA Seq, V3, P247, DOI 10.3109/10425179209034025; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; VANEIJSDEN RR, 1994, GLYCOCONJUGATE J, V11, P375, DOI 10.1007/BF00731212; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Wang J, 2000, BIOCHEMISTRY-US, V39, P8993, DOI 10.1021/bi000027v; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; Zhu KY, 1996, FEBS LETT, V390, P271, DOI 10.1016/0014-5793(96)00671-0	67	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9072	9079		10.1074/jbc.M310788200	http://dx.doi.org/10.1074/jbc.M310788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699098	hybrid			2022-12-27	WOS:000189265900068
J	Li, L; Wang, CC				Li, L; Wang, CC			Capped mRNA with a single nucleotide leader is optimally translated in a primitive eukaryote, Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; SECONDARY STRUCTURE; FIREFLY LUCIFERASE; INITIATOR CODONS; SEQUENCE; GENE; IDENTIFICATION; RECOGNITION; TRANSCRIPT; ELEMENTS	The 5'-untranslated region (5'-UTR) of an mRNA plays an important role in translation initiation in eukaryotes. A minimal length of about 20 nucleotides is required to prevent leaky ribosome scanning. In one of the most primitive eukaryotes, Giardia lamblia, however, the mRNAs have 5'-UTRs mostly in the range of 0 to 14 nucleotides without a conserved sequence, which raises the question on how the ribosome could effectively scan such short 5'-UTRs for an accurate initiation of translation. In the present study, we expressed capped transcripts of luciferase gene in Giardia trophozoites via transfection and observed that when the 5'-UTR of the transcript was lengthened from 9 to 21 nucleotides, there was a corresponding decrease of translation efficiency. Conversely, shortening of the 5'-UTR from nine nucleotides down to a single nucleotide did not result in any reduced translation or leaky scanning. Translation appeared to initiate exclusively from the first initiation codon located downstream from the cap. Experimental evidence indicated also that a stem-loop structure immediately downstream from the initiation codon exerted significant inhibition on translation initiation when the 5'-UTR consisted of less than seven nucleotides. This inhibitory effect was abolished by increasing the distance between the stem-loop and the cap-G structure either upstream or downstream from the start codon, thus suggesting a spatial requirement for effective ribosome recruitment. Overall, our results suggest an absence of ribosome scanning for AUG in initiating translation in Giardia. A capped mRNA with a single nucleotide leader is apparently sufficient for recruiting ribosome and initiating translation.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NIAID NIH HHS [AI-30475] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030475] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; CIGAN AM, 1987, GENE, V59, P1; Davis-Hayman SR, 2000, PARASITOL RES, V86, P608, DOI 10.1007/PL00008538; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Elmendorf HG, 2001, NUCLEIC ACIDS RES, V29, P4674, DOI 10.1093/nar/29.22.4674; Garlapati S, 2002, RNA, V8, P601, DOI 10.1017/S135583820202071X; Garlapati S, 2001, J MOL BIOL, V308, P623, DOI 10.1006/jmbi.2001.4568; Inagaki Y, 2000, MOL BIOL EVOL, V17, P882, DOI 10.1093/oxfordjournals.molbev.a026368; Keeling PJ, 1998, J MOL EVOL, V47, P649, DOI 10.1007/PL00006422; KIRKMASON KE, 1989, MOL BIOCHEM PARASIT, V36, P87, DOI 10.1016/0166-6851(89)90204-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, GENE EXPRESSION, V1, P111; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Li L, 2001, J VIROL, V75, P10612, DOI 10.1128/JVI.75.22.10612-10622.2001; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Moll I, 2002, MOL MICROBIOL, V43, P239, DOI 10.1046/j.1365-2958.2002.02739.x; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; NOHRIA A, 1992, MOL BIOCHEM PARASIT, V56, P27, DOI 10.1016/0166-6851(92)90151-9; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Prevot D, 2003, EMBO J, V22, P1909, DOI 10.1093/emboj/cdg175; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Sachs MS, 2002, METHODS, V26, P105, DOI 10.1016/S1046-2023(02)00013-0; SHINE J, 1975, EUR J BIOCHEM, V57, P221, DOI 10.1111/j.1432-1033.1975.tb02294.x; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; WANG AL, 1986, MOL BIOCHEM PARASIT, V21, P269, DOI 10.1016/0166-6851(86)90132-5; Wang XC, 2002, INT J BIOCHEM CELL B, V34, P983, DOI 10.1016/S1357-2725(02)00019-5; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; YU DC, 1995, MOL CELL BIOL, V15, P4867	39	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14656	14664		10.1074/jbc.M309879200	http://dx.doi.org/10.1074/jbc.M309879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722094	hybrid			2022-12-27	WOS:000220594700024
J	Tropak, MB; Reid, SP; Guiral, M; Withers, SG; Mahuran, D				Tropak, MB; Reid, SP; Guiral, M; Withers, SG; Mahuran, D			Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISORDERS; N-BUTYLDEOXYNOJIRIMYCIN; MOLECULAR-BASIS; HEXA-GENE; DISEASE; SUBUNIT; ENZYME; BIOSYNTHESIS; INHIBITOR; MUTATIONS	Tay-Sachs and Sandhoff diseases are lysosomal storage disorders that result from an inherited deficiency of beta-hexosaminidase A (alphabeta). Whereas the acute forms are associated with a total absence of hexosaminidase A and early death, the chronic adult forms exist with activity and protein levels of similar to5%, and unaffected individuals have been found with only 10% of normal levels. Surprisingly, almost all disease-associated missense mutations do not affect the active site of the enzyme but, rather, inhibit its ability to obtain and/or retain its native fold in the endoplasmic reticulum, resulting in its retention and accelerated degradation. By growing adult TaySachs fibroblasts in culture medium containing known inhibitors of hexosaminidase we have raised the residual protein and activity levels of intralysosomal hexosaminidase A well above the critical 10% of normal levels. A similar effect was observed in fibroblasts from an adult Sandhoff patient. We propose that these hexosaminidase inhibitors function as pharmacological chaperones, enhancing the stability of the native conformation of the enzyme, increasing the amount of hexosaminidase A capable of exiting the endoplasmic reticulum for transport to the lysosome. Therefore, pharmacological chaperones could provide a novel approach to the treatment of adult Tay-Sachs and possibly Sandhoff diseases.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z1, Canada; Univ Toronto, Banting Inst, Dept Lab Med & Pathol, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia; University of Toronto	Mahuran, D (corresponding author), Hosp Sick Children, Res Inst, Rm 9146A,Elm Wing,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.ca			Canadian Institutes of Health Research [82944] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		AKLI S, 1993, HUM MOL GENET, V2, P61, DOI 10.1093/hmg/2.1.61; Andersson U, 2000, BIOCHEM PHARMACOL, V59, P821, DOI 10.1016/S0006-2952(99)00384-6; BIKKER H, 1988, NUCLEIC ACIDS RES, V16, P8198, DOI 10.1093/nar/16.16.8198; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BROWN CA, 1993, AM J HUM GENET, V53, P497; Cao ZM, 1997, J BIOL CHEM, V272, P14975, DOI 10.1074/jbc.272.23.14975; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; DeGasperi R, 1996, NEUROLOGY, V47, P547, DOI 10.1212/WNL.47.2.547; Diettrich O, 1998, FEBS LETT, V441, P369, DOI 10.1016/S0014-5793(98)01578-6; DLOTT B, 1990, J BIOL CHEM, V265, P17921; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Fernandes MJG, 1997, EUR J HUM GENET, V5, P129, DOI 10.1159/000484748; Frustaci A, 2001, NEW ENGL J MED, V345, P25, DOI 10.1056/NEJM200107053450104; Glombitza GJ, 1997, J BIOL CHEM, V272, P5199, DOI 10.1074/jbc.272.8.5199; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HOEKSEMA HL, 1977, AM J HUM GENET, V29, P14; Hou YM, 1998, J BIOL CHEM, V273, P21386, DOI 10.1074/jbc.273.33.21386; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; KAPPES E, 1989, J CARBOHYD CHEM, V8, P371, DOI 10.1080/07328308908048567; KAPUR DK, 1986, BIOCHEM J, V236, P103, DOI 10.1042/bj2360103; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; LIU PS, 1991, TETRAHEDRON LETT, V32, P719, DOI 10.1016/S0040-4039(00)74866-0; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; MAHURAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1096, P87, DOI 10.1016/0925-4439(91)90044-A; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; NAVON R, 1995, NEUROLOGY, V45, P539, DOI 10.1212/WNL.45.3.539; NEOTE K, 1990, J BIOL CHEM, V265, P20799; ODOWD B, 1986, ENZYMES LIPID METABO, V2, P779; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RUBIN M, 1988, J NEUROL SCI, V87, P103, DOI 10.1016/0022-510X(88)90058-5; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Tominaga L, 2001, BRAIN DEV-JPN, V23, P284, DOI 10.1016/S0387-7604(01)00216-9; Zhao KW, 2000, PROTEIN EXPRES PURIF, V19, P202, DOI 10.1006/prep.2000.1230	40	164	180	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13478	13487		10.1074/jbc.M308523200	http://dx.doi.org/10.1074/jbc.M308523200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724290	hybrid, Green Accepted			2022-12-27	WOS:000220478500026
J	Green, JD; Goldsbury, C; Kistler, J; Cooper, GJS; Aebi, U				Green, JD; Goldsbury, C; Kistler, J; Cooper, GJS; Aebi, U			Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; ATOMIC-FORCE MICROSCOPY; BETA-PROTEIN; CONGO-RED; TRANSGENIC MICE; PARKINSONS-DISEASE; DIABETES-MELLITUS; PLAQUE-FORMATION; ALPHA-SYNUCLEIN; IN-VITRO	Human amylin (hA), a 37-amino-acid polypeptide, is one of a number of peptides with the ability to form amyloid fibrils and cause disease. It is the main constituent of the pancreatic amyloid deposits associated with type 2 diabetes. Increasing interest in early assembly intermediates rather than the mature fibrils as the cytotoxic agent has led to this study in which the smallest hA oligomers have been captured by atomic force microscopy. These are 2.3 +/- 1.9 nm in height, 23 +/- 14 nm in length, and consist of an estimated 16 hA molecules. Oligomers first grow to a height of about 6 nm before they begin to significantly elongate into fibrils. Congo red inhibits elongation but not the growth in height of hA oligomers. Two distinct phases have thus been identified in hA fibrillogenesis: lateral growth of oligomers followed by longitudinal growth into mature fibrils. These observations suggest that mature fibrils are assembled directly via longitudinal growth of full-width oligomers, making assembly by lateral association of protofibrils appear less likely.	Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Univ Auckland, Fac Sci, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Sch Med, Dept Med, Auckland, New Zealand	University of Basel; University of Auckland; University of Auckland	Aebi, U (corresponding author), Univ Basel, Biozentrum, ME Muller Inst Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Ueli.Aebi@unibas.ch	Cooper, Garth JS/I-3201-2015	Cooper, Garth JS/0000-0001-5241-3163; Goldsbury, Claire/0000-0003-0647-1789				Aitken JF, 2003, BIOCHEM J, V374, P779, DOI 10.1042/BJ20030422; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BURGEVIN MC, 1994, NEUROREPORT, V5, P2429, DOI 10.1097/00001756-199412000-00006; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Castle AL, 1998, AM J PHYSIOL-ENDOC M, V275, pE531, DOI 10.1152/ajpendo.1998.275.3.E531; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CLARK A, 1987, LANCET, V2, P231; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; Cornish J, 1998, AM J PHYSIOL-ENDOC M, V275, pE694, DOI 10.1152/ajpendo.1998.275.4.E694; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; Harroun TA, 2001, FEBS LETT, V507, P200, DOI 10.1016/S0014-5793(01)02972-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hettiarachchi M, 1997, AM J PHYSIOL-ENDOC M, V273, pE859, DOI 10.1152/ajpendo.1997.273.5.E859; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Rhoades E, 2000, BBA-PROTEIN STRUCT M, V1476, P230, DOI 10.1016/S0167-4838(99)00248-4; Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Yong W, 2002, P NATL ACAD SCI USA, V99, P150, DOI 10.1073/pnas.012584899; YOUNG AA, 1993, AM J PHYSIOL, V264, P943; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	40	134	137	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12206	12212		10.1074/jbc.M312452200	http://dx.doi.org/10.1074/jbc.M312452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14704152	hybrid			2022-12-27	WOS:000220334900026
J	Hamasaki-Katagiri, N; Molchanova, T; Takeda, K; Ames, JB				Hamasaki-Katagiri, N; Molchanova, T; Takeda, K; Ames, JB			Fission yeast homolog of neuronal calcium sensor-1 (Ncs1p) regulates sporulation and confers calcium tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; EF-HAND PROTEINS; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; RHODOPSIN PHOSPHORYLATION; MYRISTOYLATED RECOVERIN; RECOMBINANT RECOVERIN; CA2+-BINDING PROTEINS; CRYSTAL-STRUCTURE; BINDING PROTEIN	The neuronal calcium sensor (NCS) proteins (e.g. recoverin, neurocalcins, and frequenin) are expressed at highest levels in excitable cells, and some of them regulate desensitization of G protein-coupled receptors. Here we present NMR analysis and genetic functional studies of an NCS homolog in fission yeast (Ncs1p). Ncs1p binds three Ca2+ ions at saturation with an apparent affinity of 2 muM and Hill coefficient of 1.9. Analysis of NMR and fluorescence spectra of Ncs1p revealed significant Ca2+-induced protein conformational changes indicative of a Ca2+-myristoyl switch. The amino-terminal myristoyl group is sequestered inside a hydrophobic cavity of the Ca2+-free protein and becomes solvent-exposed in the Ca2+-bound protein. Subcellular fractionation experiments showed that myristoylation and Ca2+ binding by Ncs1p are essential for its translocation from cytoplasm to membranes. The ncs1 deletion mutant (ncs1Delta) showed two distinct phenotypes: nutrition-insensitive sexual development and a growth defect at high levels of extracellular Ca2+ (0.1 M CaCl2). Analysis of Ncs1p mutants lacking myristoylation (Ncs1p(G2A)) or deficient in Ca2+ binding (Ncs1p(E84Q/E120Q/E168Q)) revealed that Ca2+ binding was essential for both phenotypes, while myristoylation was less critical. Exogenous cAMP, a key regulator for sexual development, suppressed conjugation and sporulation of ncs1Delta, suggesting involvement of Ncs1p in the adenylate cyclase pathway turned on by the glucose-sensing G protein-coupled receptor Git3p. Starvation-independent sexual development of ncs1Delta was also complemented by retinal recoverin, which controls Ca2+-regulated desensitization of rhodopsin. In contrast, the Ca2+ intolerance of ncs1Delta was not affected by cAMP or recoverin, suggesting that the two ncs1Delta phenotypes are mechanistically independent. We propose that Schizosaccharomyces pombe Ncs1p negatively regulates sporulation perhaps by controlling Ca2+-dependent desensitization of Git3p.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NHLBI, Pathol Core, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ames, JB (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	james@carb.nist.gov			NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12347] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALFA C, 1993, EXPT FISSION YEAST, P77; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Andoh T, 1998, MOL GEN GENET, V258, P139, DOI 10.1007/s004380050716; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Carnero E, 2000, MOL GEN GENET, V264, P173, DOI 10.1007/s004380000318; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Catty P, 1996, BIOSCIENCE REP, V16, P75, DOI 10.1007/BF01206198; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; D'souza VM, 2001, CELL STRUCT FUNCT, V26, P555, DOI 10.1247/csf.26.555; DAVIS TN, 1995, ADV SEC MESS PHOSPH, V30, P339; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; Facanha ALO, 2002, J CELL BIOL, V157, P1029, DOI 10.1083/jcb.200111012; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GHISLAIN M, 1990, J BIOL CHEM, V265, P18400; HALACHMI D, 1992, EUR J BIOCHEM, V207, P1003, DOI 10.1111/j.1432-1033.1992.tb17136.x; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HIDAKA H, 1993, NEUROSCI RES, V16, P73, DOI 10.1016/0168-0102(93)90074-Z; Hirayama S, 2003, J BIOL CHEM, V278, P18078, DOI 10.1074/jbc.M212900200; Huttner IG, 2003, J BIOL CHEM, V278, P4862, DOI 10.1074/jbc.M207920200; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAWAMUKAI M, 1991, CELL REGUL, V2, P155, DOI 10.1091/mbc.2.2.155; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kitamura K, 1998, GENE, V214, P131, DOI 10.1016/S0378-1119(98)00203-0; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moser MJ, 1997, J CELL SCI, V110, P1805; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Okorokov LA, 2001, FEBS LETT, V505, P321, DOI 10.1016/S0014-5793(01)02852-6; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Panaretou B, 1996, Methods Mol Biol, V53, P117; PAULUS H, 1969, ANAL BIOCHEM, V32, P91, DOI 10.1016/0003-2697(69)90107-9; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Saitoh K, 2003, BIOSCI BIOTECH BIOCH, V67, P651, DOI 10.1271/bbb.67.651; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Slupsky CM, 2001, J BIOL CHEM, V276, P5943, DOI 10.1074/jbc.M008716200; Tanaka T, 1998, J BIOMOL NMR, V11, P135, DOI 10.1023/A:1008212316986; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Tasaka Y, 2000, BIOCHEM BIOPH RES CO, V269, P265, DOI 10.1006/bbrc.2000.2278; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Welton RM, 2000, GENETICS, V156, P513; Wu JQ, 2001, MOL BIOL CELL, V12, P1061, DOI 10.1091/mbc.12.4.1061; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	71	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12744	12754		10.1074/jbc.M311895200	http://dx.doi.org/10.1074/jbc.M311895200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722091	hybrid			2022-12-27	WOS:000220334900088
J	Ochi, S; Oda, M; Matsuda, H; Ikari, S; Sakurai, J				Ochi, S; Oda, M; Matsuda, H; Ikari, S; Sakurai, J			Clostridium perfringens alpha-toxin activates the sphingomyelin metabolism system in sheep erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; SITE-DIRECTED MUTAGENESIS; RAT ISOLATED AORTA; PROTEIN-KINASE; PHOSPHOLIPASE-C; QUANTITATIVE MEASUREMENT; RABBIT ERYTHROCYTES; HL-60 CELLS; CERAMIDE	Clostridium perfringens alpha-toxin induces hemolysis of rabbit erythrocytes through the activation of glycerophospholipid metabolism. Sheep erythrocytes contain large amounts of sphingomyelin (SM) but not phosphatidylcholine. We investigated the relationship between the toxin-induced hemolysis and SM metabolic system in sheep erythrocytes. alpha-Toxin simultaneously induced hemolysis and a reduction in the levels of SM and formation of ceramide and sphingosine 1-phosphate (S1P). N-Oleoylethanolamine, a ceramidase inhibitor, inhibited the toxin-induced hemolysis and caused ceramide to accumulate in the toxin-treated cells. Furthermore, DL-threo-dihydrosphingosine and B-5354c, isolated from a novel marine bacterium, both sphingosine kinase inhibitors, blocked the toxin-induced hemolysis and production of S1P and caused sphingosine to accumulate. These observations suggest that the toxin-induced activation of the SM metabolic system is closely related to hemolysis. S1P potentiated the toxin-induced hemolysis of saponin-permeabilized erythrocytes but had no effect on that of intact cells. Preincubation of lysated sheep erythrocytes with pertussis toxin blocked the alpha-toxin-induced formation of ceramide from SM. In addition, incubation of C. botulinum C3 exoenzyme-treated lysates of sheep erythrocytes with alpha-toxin caused an accumulation of sphingosine and inhibition of the formation of S1P. These observations suggest that the alpha-toxin-induced hemolysis of sheep erythrocytes is dependent on the activation of the SM metabolic system through GTP-binding proteins, especially the formation of S1P.	Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Tokushima 7708514, Japan; Fujita Hlth Univ, Sch Med, Dept Microbiol, Aichi 4701192, Japan	Tokushima Bunri University; Fujita Health University	Sakurai, J (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro Cho, Tokushima 7708514, Japan.	sakurai@ph.bunri-u.ac.jp	Oda, Masataka/ABG-6047-2020					Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DITTMER JC, 1964, J LIPID RES, V5, P126; FUJII Y, 1989, BRIT J PHARMACOL, V97, P119, DOI 10.1111/j.1476-5381.1989.tb11931.x; FUJII Y, 1986, BRIT J PHARMACOL, V88, P531, DOI 10.1111/j.1476-5381.1986.tb10233.x; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Guillouard I, 1996, INFECT IMMUN, V64, P2440, DOI 10.1128/IAI.64.7.2440-2444.1996; Guo C, 1998, EUR J BIOCHEM, V257, P403, DOI 10.1046/j.1432-1327.1998.2570403.x; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; IKEZAWA H, 1982, J TOXICOL-TOXIN REV, V1, P223; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kono K, 2000, J ANTIBIOT, V53, P759, DOI 10.7164/antibiotics.53.759; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; MACFARLANE MG, 1950, BIOCHEM J, V47, P270, DOI 10.1042/bj0470270; McDonel J. L., 1986, Pharmacology of bacterial toxins, P477; NAGAHAMA M, 1995, J BACTERIOL, V177, P1179, DOI 10.1128/jb.177.5.1179-1185.1995; Nagahama M, 2002, MICROBIOL IMMUNOL, V46, P647, DOI 10.1111/j.1348-0421.2002.tb02748.x; Nagahama M, 1996, BBA-BIOMEMBRANES, V1280, P120, DOI 10.1016/0005-2736(95)00288-X; NAKASHIMA S, 1989, BIOCHEM J, V259, P139, DOI 10.1042/bj2590139; NELSON GJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P221, DOI 10.1016/0005-2760(67)90152-X; Niedernberg A, 2003, BRIT J PHARMACOL, V138, P481, DOI 10.1038/sj.bjp.0705055; Ochi S, 2002, MICROBIOL-SGM, V148, P237, DOI 10.1099/00221287-148-1-237; Ochi S, 1996, INFECT IMMUN, V64, P3930, DOI 10.1128/IAI.64.9.3930-3933.1996; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pyne S, 1996, BIOCHEM J, V315, P917, DOI 10.1042/bj3150917; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Rani CSS, 1997, J BIOL CHEM, V272, P10777; SAKURAI J, 1990, TOXICON, V28, P411, DOI 10.1016/0041-0101(90)90079-M; Sakurai J., 1995, Reviews in Medical Microbiology, V6, P175; SAKURAI J, 1993, INFECT IMMUN, V61, P3711, DOI 10.1128/IAI.61.9.3711-3718.1993; SAKURAI J, 1994, INFECT IMMUN, V62, P717, DOI 10.1128/IAI.62.2.717-721.1994; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spinedi A, 1999, BIOCHEM BIOPH RES CO, V255, P456, DOI 10.1006/bbrc.1999.0230; Stevens DL, 2000, INT J MED MICROBIOL, V290, P497; TITBALL RW, 1991, INFECT IMMUN, V59, P1872, DOI 10.1128/IAI.59.5.1872-1874.1991; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; Titball RW, 1997, CLOSTRIDIA MOL BIOL, P223; UI M, 1990, ADP RIBOSYLATING TOX, P45; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; Young KW, 2001, SEMIN CELL DEV BIOL, V12, P19, DOI 10.1006/scdb.2000.0213; Zhang P, 1997, J BIOL CHEM, V272, P9609	57	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12181	12189		10.1074/jbc.M307046200	http://dx.doi.org/10.1074/jbc.M307046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702348	hybrid			2022-12-27	WOS:000220334900024
J	Noguchi, S; Keira, Y; Murayama, K; Ogawa, M; Fujita, M; Kawahara, G; Oya, Y; Imazawa, M; Goto, Y; Hayashi, YK; Nonaka, I; Nishino, I				Noguchi, S; Keira, Y; Murayama, K; Ogawa, M; Fujita, M; Kawahara, G; Oya, Y; Imazawa, M; Goto, Y; Hayashi, YK; Nonaka, I; Nishino, I			Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOPATHY; SIALIC-ACID; BIFUNCTIONAL ENZYME; MUSCULAR-DYSTROPHY; BIOSYNTHESIS; AGGLUTININ; LECTINS; GLCNAC; LOCUS; GENE	Distal myopathy with rimmed vacuoles is an autosomal recessive muscle disease with preferential involvement of the tibialis anterior that spares the quadriceps muscles in young adulthood. In a Japanese patient with distal myopathy with rimmed vacuoles, we identified pathogenic mutations in the gene encoding the bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase, which catalyzes the initial two steps in the biosynthesis of sialic acid. In this study, we demonstrated the relationship between the genetic mutations and enzymatic activities using an in vitro expression assay system. Furthermore, we also showed that the levels of sialic acid in muscle and primary cultured cells from DMRV patients were reduced to 60-75% of control. The reactivities to lectins were also variable in some myofibers, suggesting that hyposialylation and abnormal glycosylation in muscles may contribute to the focal accumulations of autophagic vacuoles, amyloid deposits, or both in patient muscle tissue. The addition of ManNAc and NeuAc to primary cultured cells normalized sialylation levels, thus demonstrating the therapeutic potential of these compounds for this disease.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Radiat Protect, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Ctr Hosp Mental Nervous & Muscular Disorders, Tokyo 1878502, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Japan Science & Technology Agency (JST)	Noguchi, S (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	noguchi@ncnp.go.jp	Nishino, Ichizo/G-2676-2010	Nishino, Ichizo/0000-0001-9452-112X				BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Eisenberg I, 1999, GENOMICS, V55, P43, DOI 10.1006/geno.1998.5630; Eisenberg Iris, 2003, Hum Mutat, V21, P99, DOI 10.1002/humu.9100; GRIGGS RC, 1995, ANN NEUROL, V38, P705, DOI 10.1002/ana.410380504; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Ikeuchi T, 1997, ANN NEUROL, V41, P432, DOI 10.1002/ana.410410405; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Nishino I, 2002, NEUROLOGY, V59, P1689, DOI 10.1212/01.WNL.0000041631.28557.C6; Noguchi S, 2000, EUR J BIOCHEM, V267, P640, DOI 10.1046/j.1432-1327.2000.00998.x; Nonaka I, 1998, NEUROMUSCULAR DISORD, V8, P333, DOI 10.1016/S0960-8966(98)00027-3; NONAKA I, 1981, J NEUROL SCI, V51, P141, DOI 10.1016/0022-510X(81)90067-8; NONAKA I, 1985, ANN NEUROL, V17, P51, DOI 10.1002/ana.410170113; Oetke C, 2001, EUR J BIOCHEM, V268, P4553, DOI 10.1046/j.1432-1327.2001.02379.x; PALJARVI L, 1984, ARCH NEUROL-CHICAGO, V41, P39, DOI 10.1001/archneur.1984.04050130045020; PEREIRA MEA, 1974, CARBOHYD RES, V37, P89, DOI 10.1016/S0008-6215(00)87066-4; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; Yamamoto K, 1997, J BIOCHEM-TOKYO, V121, P756	24	116	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11402	11407		10.1074/jbc.M313171200	http://dx.doi.org/10.1074/jbc.M313171200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707127	hybrid			2022-12-27	WOS:000220157600070
J	Runko, AP; Sagerstrom, CG				Runko, AP; Sagerstrom, CG			Isolation of nlz2 and characterization of essential domains in Nlz family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; ZINC-FINGER PROTEINS; DROSOPHILA GENE PAIR; AUG INITIATOR CODON; DNA-BINDING; ACTIVATION DOMAINS; ZEBRAFISH; RECOGNITION; EXPRESSION; NUCLEOTIDES	In this study, we first cloned nlz2, a second zebrafish member of the nlz-related zinc-finger gene family. nlz2 was expressed together with nlz1 in a broad posterior domain during gastrula stages as well as at the mid-brain-hindbrain boundary and in the hindbrain caudal to rhombomere 4 during segmentation. nlz2 was also expressed in regions distinct from nlz1, notably in the forebrain, midbrain, and trunk. Misexpression of nlz2 in zebrafish embryos disrupted gene expression in the rostral hindbrain, similar to the effect of misexpressing nlz1. We next compared the nlz1 and nlz2 sequences to identify and characterize domains conserved within this family. We found a C-terminal domain required for nuclear localization and two conserved domains ( the Sp motif and a putative C2H2 zinc finger) required for nlz1 function. We also demonstrate that Nlz1 self-associated via its C terminus, interacted with Nlz2, and bound to histone deacetylases. Last, we found two forms of Nlz1 generated from alternative translation initiation sites in vivo. These forms have distinct activities, apparently depending on the function of the N-terminal Sp motif. Our data demonstrate that nlz2 functions similarly to nlz1 and define conserved domains essential for nuclear localization, self-association, and corepressor binding in this novel family of zinc-finger genes.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Sagerstrom, CG (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, LRB 822,364 Plantat St, Worcester, MA 01605 USA.	charles.sagerstrom@umassmed.edu			NICHD NIH HHS [HD39156] Funding Source: Medline; NINDS NIH HHS [NS38183] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038183, R56NS038183] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreazzoli M, 2001, MECH DEVELOP, V104, P117, DOI 10.1016/S0925-4773(01)00359-8; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BERG JM, 1990, J BIOL CHEM, V265, P6513; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; CHEAH PY, 1994, MOL CELL BIOL, V14, P1487, DOI 10.1128/MCB.14.2.1487; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Courey AJ, 2001, GENE DEV, V15, P2786; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Dorfman R, 2002, DEVELOPMENT, V129, P3585; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Harrison SM, 2000, DEV BIOL, V227, P358, DOI 10.1006/dbio.2000.9878; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; Ossipova O, 2002, MECH DEVELOP, V115, P117, DOI 10.1016/S0925-4773(02)00086-2; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Runko AP, 2003, DEV BIOL, V262, P254, DOI 10.1016/S0012-1606(03)00388-9; Sagerstrom CG, 1996, DEVELOPMENT, V122, P1873; Sagerstrom GC, 2001, DEV DYNAM, V220, P402, DOI 10.1002/dvdy.1119; Schock F, 1999, MECH DEVELOP, V89, P125, DOI 10.1016/S0925-4773(99)00215-4; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Tallafuss A, 2001, DEVELOPMENT, V128, P4021; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; Wimmer EA, 1996, MECH DEVELOP, V59, P53, DOI 10.1016/0925-4773(96)00575-8; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wulbeck C, 1997, DEV GENES EVOL, V207, P156, DOI 10.1007/s004270050103; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Zhao XJ, 2002, DEVELOPMENT, V129, P1497	50	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11917	11925		10.1074/jbc.M310076200	http://dx.doi.org/10.1074/jbc.M310076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14709556	hybrid			2022-12-27	WOS:000220157600129
J	Fernandez, D; Ghanta, A; Kauffman, GW; Sanguinetti, MC				Fernandez, D; Ghanta, A; Kauffman, GW; Sanguinetti, MC			Physicochemical features of the hERG channel drug binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QT INTERVAL PROLONGATION; K+ CHANNEL; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; BLOCK; INHIBITION; RECTIFIER; MUTATIONS; AFFINITY; PORE	Blockade of hERG K+ channels in the heart is an unintentional side effect of many drugs and can induce cardiac arrhythmia and sudden death. It has become common practice in the past few years to screen compounds for hERG channel activity early during the drug discovery process. Understanding the molecular basis of drug binding to hERG is crucial for the rational design of medications devoid of this activity. We previously identified 2 aromatic residues, Tyr-652 and Phe-656, located in the S6 domain of hERG, as critical sites of interaction with structurally diverse drugs. Here, Tyr-652 and Phe-656 were systematically mutated to different residues to determine how the physicochemical properties of the amino acid side group affected channel block by cisapride, terfenadine, and MK-499. The potency for block by all three drugs was well correlated with measures of hydrophobicity, especially the two-dimensional approximation of the van der Waals hydrophobic surface area of the side chain of residue 656. For residue 652, an aromatic side group was essential for high affinity block, suggesting the importance of a cation-pi interaction between Tyr-652 and the basic tertiary nitrogen of these drugs. hERG also lacks a Pro-Val-Pro motif common to the S6 domain of most other voltage-gated K+ channels. Introduction of Pro-Val-Pro into hERG reduced sensitivity to drugs but also altered channel gating. Together, these findings assign specific residues to receptor fields predicted by pharmacophore models of hERG channel blockers and provide a refined molecular understanding of the drug binding site.	Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Pfizer Global R&D, Groton, CT 06340 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Pfizer	Sanguinetti, MC (corresponding author), Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, 95 N 2000 E, Salt Lake City, UT 84112 USA.	michael.sanguinetti@hmbg.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL55236] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055236] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cavalli A, 2002, J MED CHEM, V45, P3844, DOI 10.1021/jm0208875; Chen J, 2002, P NATL ACAD SCI USA, V99, P12461, DOI 10.1073/pnas.192367299; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ekins S, 2002, J PHARMACOL EXP THER, V301, P427, DOI 10.1124/jpet.301.2.427; Fermini B, 2003, NAT REV DRUG DISCOV, V2, P439, DOI 10.1038/nrd1108; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; JURS PC, 1979, COMPUTER ASSISTED DR, P103; Kamiya K, 2001, MOL PHARMACOL, V60, P244, DOI 10.1124/mol.60.2.244; Karplus PA, 1997, PROTEIN SCI, V6, P1302; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Milnes JT, 2003, BRIT J PHARMACOL, V139, P887, DOI 10.1038/sj.bjp.0705335; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Mitcheson JS, 2003, BRIT J PHARMACOL, V139, P883, DOI 10.1038/sj.bjp.0705336; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Pearlstein R, 2003, J MED CHEM, V46, P2017, DOI 10.1021/jm0205651; Pearlstein RA, 2003, BIOORG MED CHEM LETT, V13, P1829, DOI 10.1016/S0960-894X(03)00196-3; Potet F, 2001, J PHARMACOL EXP THER, V299, P1007; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008-6363(02)00846-5; Roy ML, 1996, CIRCULATION, V94, P817, DOI 10.1161/01.CIR.94.4.817; Sanchez-Chapula JA, 2003, MOL PHARMACOL, V63, P1051, DOI 10.1124/mol.63.5.1051; Sanchez-Chapula JA, 2002, J BIOL CHEM, V277, P23587, DOI 10.1074/jbc.M200448200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; STUPER AJ, 1976, J CHEM INF COMP SCI, V16, P99, DOI 10.1021/ci60006a014; SUTTER JM, 1995, J CHEM INF COMP SCI, V35, P77, DOI 10.1021/ci00023a011; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l	34	240	249	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10120	10127		10.1074/jbc.M310683200	http://dx.doi.org/10.1074/jbc.M310683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699101	hybrid			2022-12-27	WOS:000220050400057
J	Nyborg, AC; Kornilova, AY; Jansen, K; Ladd, TB; Wolfe, MS; Golde, TE				Nyborg, AC; Kornilova, AY; Jansen, K; Ladd, TB; Wolfe, MS; Golde, TE			Signal peptide peptidase forms a homodimer that is labeled by an active site-directed gamma-secretase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMEMBRANE-CLEAVING PROTEASES; FAMILIAL ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; BETA-APP; IN-VIVO; PRESENILIN; COMPLEX; NICASTRIN; TARGETS; ENDOPROTEOLYSIS	Presenilin (PS) is the presumptive catalytic component of the intramembrane aspartyl protease gamma-secretase complex. Recently a family of presenilin homologs was identified. One member of this family, signal peptide peptidase (SPP), has been shown to be a protease, which supports the hypothesis that PS and presenilin homologs are related intramembrane-cleaving aspartyl proteases. SPP has been reported as a glycoprotein of similar to 45 kDa. Our initial characterization of SPP isolated from human brain and cell lines demonstrated that SPP is primarily present as an SDS-stable similar to 95-kDa protein on Western blots. Upon heating or treatment of this similar to95-kDa SPP band with acid, a similar to45-kDa band could be resolved. Co-purification of two different epitope-tagged forms of SPP from a stably transfected cell line expressing both tagged versions demonstrated that the similar to 95-kDa band is a homodimer of SPP. Pulse-chase metabolic labeling studies demonstrated that the SPP homodimer assembles rapidly and is metabolically stable. In a glycerol velocity gradient, SPP sedimented from similar to 100 - 200 kDa. Significantly the SPP homodimer was specifically labeled by an active site-directed photoaffinity probe (III-63) for PS, indicating that the active sites of SPP and PS/gamma-secretase are similar and providing strong evidence that the homodimer is functionally active. Collectively these data suggest that SPP exists in vivo as a functional dimer.	Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Mayo Clinic; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu			NINDS NIH HHS [NS44734, NS41355, NS39072] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039072, R01NS041355, F32NS044734] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Golde TE, 2001, TRENDS MOL MED, V7, P264, DOI 10.1016/S1471-4914(01)02064-0; GOLDE TE, 2003, SCI STKE; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Hebert SS, 2003, BIOCHEM BIOPH RES CO, V301, P119, DOI 10.1016/S0006-291X(02)02984-4; KARRE K, 1991, IMMUNOL TODAY, V12, P343, DOI 10.1016/0167-5699(91)90062-X; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Urny J, 2003, GENE EXPR PATTERNS, V3, P685, DOI 10.1016/S1567-133X(03)00094-2; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	36	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15153	15160		10.1074/jbc.M309305200	http://dx.doi.org/10.1074/jbc.M309305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14704149	hybrid			2022-12-27	WOS:000220594700081
J	Bharadwaj, S; Hitchcock-DeGregori, S; Thorburn, A; Prasad, GL				Bharadwaj, S; Hitchcock-DeGregori, S; Thorburn, A; Prasad, GL			N terminus is essential for tropomyosin functions - N-terminal modification disrupts stress fiber organization and abolishes anti-oncogenic effects of tropomyosin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-TRANSFORMED FIBROBLASTS; ALTERNATIVELY SPLICED EXONS; SIGNAL-REGULATED KINASE; II TUMOR-SUPPRESSOR; ACTIN CYTOSKELETON; FORCED EXPRESSION; DOWN-REGULATION; LIM-KINASE; NONMUSCLE CALDESMON; MUSCLE TROPOMYOSIN	Down-regulation of several key actin-binding proteins, such as alpha-actinin, vinculin, gelsolin, and tropomyosins (TMs), is considered to contribute to the disorganized cytoskeleton present in many neoplastic cells. TMs stabilize actin filaments against the gel severing actions of proteins such as cofilin. Among multiple TMs expressed in non-muscle cells, tropomyosin-1 (TM1) isoform induces stress fibers and functions as a suppressor of malignant transformation. However, the molecular mechanisms of TM1-mediated cytoskeletal effects and tumor suppression remain poorly understood. We have hypothesized that the ability of TM1 to stabilize microfilaments is crucial for tumor suppression. In this study, by employing a variant TM1, which contains an N-terminal hemagglutinin epitope tag, we demonstrate that the N terminus is a key determinant of tropomyosin-1 function. Unlike the wild type TM1, the modified protein fails to restore stress fibers and inhibit anchorage-independent growth in transformed cells. Furthermore, the N-terminal modification of TM1 disorganizes the cytoskeleton and delays cytokinesis in normal cells, abolishes binding to F-actin, and disrupts the dimeric associations in vivo. The functionally defective TM1 allows the association of cofilin to stress fibers and disorganizes the microfilaments, whereas wild type TM1 appears to restrict the binding of cofilin to stress fibers. TM1-induced cytoskeletal reorganization appears to be mediated through preventing cofilin interaction with microfilaments. Our studies provide in vivo functional evidence that the N terminus is a critical determinant of TM1 functions, which in turn determines the organization of stress fibers.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gprasad@wfubmc.edu			NIGMS NIH HHS [GM 63257] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063257] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; Braverman RH, 1996, ONCOGENE, V13, P537; Bryce NS, 2003, MOL BIOL CELL, V14, P1002, DOI 10.1091/mbc.E02-04-0244; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CHO YJ, 1990, J BIOL CHEM, V265, P538; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; DesMarais V, 2002, J CELL SCI, V115, P4649, DOI 10.1242/jcs.00147; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Glantz SA., 1997, PRIMER BIOSTATISTICS; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Jagatheesan G, 2003, J BIOL CHEM, V278, P23204, DOI 10.1074/jbc.M303073200; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; LEHRER SS, 1987, ARCH BIOCHEM BIOPHYS, V256, P1, DOI 10.1016/0003-9861(87)90419-X; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Moraczewska J, 1999, BIOCHEMISTRY-US, V38, P15885, DOI 10.1021/bi991816j; NicholsonFlynn K, 1996, J NEUROSCI, V16, P6853; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Ono S, 2002, J CELL BIOL, V156, P1065, DOI 10.1083/jcb.200110013; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RANUCCI D, 1993, CELL MOTIL CYTOSKEL, V24, P119, DOI 10.1002/cm.970240205; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; SOBUE K, 1991, J BIOL CHEM, V266, P12115; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; TARDIF M, 1995, J BIOL CHEM, V270, P28075; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yager ML, 2003, BRIT J CANCER, V89, P860, DOI 10.1038/sj.bjc.6601201; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	66	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14039	14048		10.1074/jbc.M310934200	http://dx.doi.org/10.1074/jbc.M310934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722123	hybrid			2022-12-27	WOS:000220478500093
J	Akari, H; Fujita, M; Kao, S; Khan, MA; Shehu-Xhilaga, M; Adachi, A; Strebel, K				Akari, H; Fujita, M; Kao, S; Khan, MA; Shehu-Xhilaga, M; Adachi, A; Strebel, K			High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the gag precursor at the p2/nucleocapsid processing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 VIF; ANTIVIRAL ACTIVITY; CO-ENCAPSIDATION; ENZYME APOBEC3G; PROTEIN BINDS; CELL-LINE; DNA; DEGRADATION; VIRIONS; STABILITY	The human immunodeficiency virus type-1 Vif protein has a crucial role in regulating viral infectivity. However, we found that newly synthesized Vif is rapidly degraded by cellular proteases. We tested the dose dependence of Vif in non-permissive H9 cells and found that Vif, when expressed at low levels, increased virus infectivity in a dose-dependent manner. Surprisingly, however, the range of Vif required for optimal virus infectivity was narrow, and further increases in Vif severely reduced viral infectivity. Inhibition of viral infectivity at higher levels of Vif was cell type-independent and was associated with an accumulation of Gag-processing intermediates. Vif did not act as a general protease inhibitor but selectively inhibited Gag processing at the capsid and nucleocapsid (NC) boundary. Identification of Vif variants that were efficiently packaged but were unable to modulate Gag processing suggests that Vif packaging was necessary but insufficient for the production of 33- and 34-kDa processing intermediates. Interestingly, these processing intermediates, like Vif, associated with viral nucleoprotein complexes more rigidly than mature capsid and NC. We conclude that virus-associated Vif inhibits processing of a subset of Gag precursor molecules at the p2/NC primary cleavage site. Modulation of processing of a small subset of Gag molecules by physiological levels of Vif may be important for virus maturation. However, the accumulation of such processing intermediates at high levels of Vif is inhibitory. Thus, rapid intracellular degradation of Vif may have evolved as a mechanism to prevent such inhibitory effects of Vif.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Infect Dis, Tsukuba Primate Ctr Med Sci, Ibaraki 3050843, Japan; Univ Tokushima, Grad Sch Med, Dept Virol, Tokushima 7708502, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institute of Infectious Diseases (NIID); Tokushima University	Strebel, K (corresponding author), NIAID, Mol Microbiol Lab, NIH, 4-312,4 Ctr Dr,MSC 0460, Bethesda, MD 20892 USA.	kstrebel@nih.gov	botla, Gomathi/A-5724-2008; AKARI, Hirofumi/AGR-4616-2022	Akari, Hirofumi/0000-0003-2166-6015; Fujita, Mikako/0000-0001-6705-4052; Adachi, Akio/0000-0003-1674-332X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000669, ZIAAI000669] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Akari H, 1999, J GEN VIROL, V80, P2945, DOI 10.1099/0022-1317-80-11-2945; Bardy M, 2001, J GEN VIROL, V82, P2719, DOI 10.1099/0022-1317-82-11-2719; Bour S, 1996, J VIROL, V70, P8285, DOI 10.1128/JVI.70.12.8285-8300.1996; Bour S, 2000, Adv Pharmacol, V48, P75; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; HENDERSON LE, 1990, J MED PRIMATOL, V19, P411; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Karczewski MK, 1996, J VIROL, V70, P494, DOI 10.1128/JVI.70.1.494-507.1996; Khan MA, 2002, J VIROL, V76, P9112, DOI 10.1128/JVI.76.18.9112-9123.2002; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; REDDY TR, 1995, J VIROL, V69, P3549, DOI 10.1128/JVI.69.6.3549-3553.1995; Roos JW, 2000, VIROLOGY, V273, P307, DOI 10.1006/viro.2000.0431; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wiegers K, 1998, J VIROL, V72, P2846, DOI 10.1128/JVI.72.4.2846-2854.1998; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	46	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12355	12362		10.1074/jbc.M312426200	http://dx.doi.org/10.1074/jbc.M312426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722068	hybrid			2022-12-27	WOS:000220334900043
J	Browne, GJ; Finn, SG; Proud, CG				Browne, GJ; Finn, SG; Proud, CG			Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, Serine 398	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MR 100,000 SUBSTRATE; FACTOR-II KINASE; FACTOR-2 KINASE; MAMMALIAN-CELLS; EEF2 KINASE; TRANSLATION; IDENTIFICATION; PURIFICATION; INSULIN; SYSTEM	Protein synthesis consumes a high proportion of the metabolic energy of mammalian cells, and most of this is used by peptide chain elongation. An important regulator of energy supply and demand in eukaryotic cells is the AMP-activated protein kinase (AMPK). The rate of peptide chain elongation can be modulated through the phosphorylation of eukaryotic elongation factor (eEF) 2, which inhibits its activity and is catalyzed by a specific calcium/calmodulin-dependent protein kinase termed eEF2 kinase. Here we show that AMPK directly phosphorylates eEF2 kinase, and we identify the major site of phosphorylation as Ser-398 in a regulatory domain of eEF2 kinase. AMPK also phosphorylates two other sites (Ser-78 and Ser-366) in eEF2 kinase in vitro. We develop appropriate phosphospecific antisera and show that phosphorylation of Ser-398 in eEF2 kinase is enhanced in intact cells under a range of conditions that activate AMPK and increase the phosphorylation of eEF2. Ser-78 and Ser-366 do not appear to be phosphorylated by AMPK within cells. Although cardiomyocytes appear to contain a distinct isoform of eEF2 kinase, it also contains a site corresponding to Ser-398 that is phosphorylated by AMPK in vitro. Stimuli that activate AMPK and increase eEF2 phosphorylation within cells increase the activity of eEF2 kinase. Thus, AMPK and eEF2 kinase may provide a key link between cellular energy status and the inhibition of protein synthesis, a major consumer of metabolic energy.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk		Proud, Christopher/0000-0003-0704-6442				Arthur PG, 2000, BBA-GEN SUBJECTS, V1475, P83, DOI 10.1016/S0304-4165(00)00046-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; BROWNE GJ, 2004, IN PRESS MOL CELL BI, V24; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HENIN N, 2003, BIOCHIM BIOPHYS ACTA, V1290, P197; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Kimball SR, 2002, CURR OPIN CLIN NUTR, V5, P63, DOI 10.1097/00075197-200201000-00012; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; McLeod LE, 2001, FEBS LETT, V489, P225, DOI 10.1016/S0014-5793(01)02100-7; MERRICK WC, 2000, TRANSLATIONAL CONTRO, P59; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; REDPATH NT, 1993, EUR J BIOCHEM, V212, P511, DOI 10.1111/j.1432-1033.1993.tb17688.x; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; RYAZANOV AG, 1988, BIOCHIMIE, V70, P619, DOI 10.1016/0300-9084(88)90245-3; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Yan LM, 2003, J BIOL CHEM, V278, P18177, DOI 10.1074/jbc.M301116200	35	250	266	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12220	12231		10.1074/jbc.M309773200	http://dx.doi.org/10.1074/jbc.M309773200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709557	hybrid			2022-12-27	WOS:000220334900028
J	Gautam, R; Chintala, S; Li, W; Zhang, Q; Tan, J; Novak, EK; Di Pietro, SM; Dell'Angelica, EC; Swank, RT				Gautam, R; Chintala, S; Li, W; Zhang, Q; Tan, J; Novak, EK; Di Pietro, SM; Dell'Angelica, EC; Swank, RT			The Hermansky-Pudlak syndrome 3 (cocoa) protein is a component of the biogenesis of lysosome-related organelles complex-2 (BLOC-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; STORAGE-POOL DEFICIENCY; PLATELET-DENSE GRANULES; MOUSE MODELS; RUBY-EYE; GENE; MUTATION; HPS1; MELANOSOMES; PALLIDIN	Hermansky- Pudlak syndrome ( HPS) is a genetically heterogeneous inherited disease affecting vesicle trafficking among lysosome- related organelles. The Hps3, Hps5, and Hps6 genes are mutated in the cocoa, rubyeye-2, and ruby- eye mouse pigment mutants, respectively, and their human orthologs are mutated in HPS3, HPS5, and HPS6 patients. These three genes encode novel proteins of unknown function. The phenotypes of Hps5/ Hps5, Hps6/ Hps6 and Hps3/ Hps3, Hps6/ Hps6 double mutant mice mimic, in coat and eye colors, in melanosome ultrastructure, and in levels of platelet dense granule serotonin, the corresponding phenotypes of single mutants. These facts suggest that the proteins encoded by these genes act within the same pathway or protein complex in vivo to regulate vesicle trafficking. Further, the Hps5 protein is destabilized within tissues of Hps3 and Hps6 mutants, as is the Hps6 protein within tissues of Hps3 and Hps5 mutants. Also, proteins encoded by these genes co- immunoprecipitate and occur in a complex of 350 kDa as determined by sucrose gradient and gel filtration analyses. Together, these results indicate that the Hps3, Hps5, and Hps6 proteins regulate vesicle trafficking to lysosome- related organelles at the physiological level as components of the BLOC- 2 ( biogenesis of lysosome- related organelles complex- 2) protein complex and suggest that the pathogenesis and future therapies of HPS3, HPS5, and HPS6 patients are likely to be similar. Interaction of the Hps5 and Hps6 proteins within BLOC- 2 is abolished by the three- amino acid deletion in the Hps6(ru) mutant allele, indicating that these three amino acids are important for normal BLOC- 2 complex formation.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	Roswell Park Cancer Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Swank, RT (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	Richard.Swank@roswellpark.org	di pietro, santiago/AAR-6899-2020		NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051480, R01HL031698, R01HL068117] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056] Funding Source: Medline; NEI NIH HHS [EY 12104] Funding Source: Medline; NHLBI NIH HHS [HL 31698, HL 51480, HL 68117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Chiang PW, 2003, J BIOL CHEM, V278, P20332, DOI 10.1074/jbc.M300090200; Ciciotte SL, 2003, BLOOD, V101, P4402, DOI 10.1182/blood-2003-01-0020; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Feng LJ, 2002, BLOOD, V99, P1651, DOI 10.1182/blood.V99.5.1651.h8001651_1651_1658; Gwynn B, 2000, BLOOD, V96, P4227; Huizing M, 2002, Curr Mol Med, V2, P451, DOI 10.2174/1566524023362357; Huizing M, 2001, AM J HUM GENET, V69, P1022, DOI 10.1086/324168; Kantheti P, 2003, MAMM GENOME, V14, P157, DOI 10.1007/s00335-002-2238-8; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; Luzio JP, 2003, MOL MEMBR BIOL, V20, P141, DOI 10.1080/0968768031000089546; Martina JA, 2003, J BIOL CHEM, V278, P29376, DOI 10.1074/jbc.M301294200; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nazarian R, 2003, P NATL ACAD SCI USA, V100, P8770, DOI 10.1073/pnas.1532040100; Nguyen T, 2002, J INVEST DERMATOL, V119, P1156, DOI 10.1046/j.1523-1747.2002.19535.x; NOVAK EK, 1988, BRIT J HAEMATOL, V69, P371, DOI 10.1111/j.1365-2141.1988.tb02376.x; NOVAK EK, 1984, BLOOD, V63, P536; NOVAK EK, 1980, BIOCHEM GENET, V18, P549, DOI 10.1007/BF00484401; Oberhauser AF, 1996, P NATL ACAD SCI USA, V93, P14349, DOI 10.1073/pnas.93.25.14349; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; REDDINGTON M, 1987, BLOOD, V69, P1300; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SILVERS WK, 1979, COAT COLORS MICE MOD, P103; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; Sviderskaya EV, 1998, GENETICS, V148, P381; SWANK RT, 1991, BLOOD, V78, P2036, DOI 10.1182/blood.V78.8.2036.bloodjournal7882036; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; SWEET HO, 1985, MOUSE NEWS LETT, V73, P18; Yang W, 2000, J CELL SCI, V113, P4077; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087	38	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12935	12942		10.1074/jbc.M311311200	http://dx.doi.org/10.1074/jbc.M311311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718540	hybrid			2022-12-27	WOS:000220334900111
J	van den Heuvel, RHH; Westphal, AH; Heck, AJR; Walsh, MA; Rovida, S; van Berkel, WJH; Mattevi, A				van den Heuvel, RHH; Westphal, AH; Heck, AJR; Walsh, MA; Rovida, S; van Berkel, WJH; Mattevi, A			Structural studies on flavin reductase PheA2 reveal binding of NAD in an unusual folded conformation and support novel mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-THERMOGLUCOSIDASIUS A7; CRYSTAL-STRUCTURE; NAD(P)H-FLAVIN OXIDOREDUCTASE; BIOLUMINESCENT BACTERIUM; ELECTROSPRAY-IONIZATION; PHENOL HYDROXYLASE; ESCHERICHIA-COLI; FERRIC REDUCTASE; VIBRIO-FISCHERI; DNA PHOTOLYASE	The catabolism of toxic phenols in the thermophilic organism Bacillus thermoglucosidasius A7 is initiated by a two-component enzyme system. The smaller flavin reductase PheA2 component catalyzes the NADH-dependent reduction of free FAD according to a ping-pong bisubstrate-biproduct mechanism. The reduced FAD is then used by the larger oxygenase component PheA1 to hydroxylate phenols to the corresponding catechols. We have determined the x-ray structure of PheA2 containing a bound FAD cofactor (2.2 Angstrom), which is the first structure of a member of this flavin reductase family. We have also determined the x-ray structure of reduced holo-PheA2 in complex with oxidized NAD (2.1 Angstrom). PheA2 is a single domain homodimeric protein with each FAD-containing subunit being organized around a six-stranded beta-sheet and a capping alpha-helix. The tightly bound FAD prosthetic group (K-d=10 nM) binds near the dimer interface, and the re face of the FAD isoalloxazine ring is fully exposed to solvent. The addition of NADH to crystalline PheA2 reduced the flavin cofactor, and the NAD product was bound in a wide solvent-accessible groove adopting an unusual folded conformation with ring stacking. This is the first observation of an enzyme that is very likely to react with a folded compact pyridine nucleotide. The PheA2 crystallographic models strongly suggest that reactive exogenous FAD substrate binds in the NADH cleft after release of NAD product. Nanoflow electrospray mass spectrometry data indeed showed that PheA2 is able to bind one FAD cofactor and one FAD substrate. In conclusion, the structural data provide evidence that PheA2 contains a dual binding cleft for NADH and FAD substrate, which alternate during catalysis.	Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; European Synchrotron Radiat Facil, MRC France, F-38043 Grenoble, France	University of Pavia; Utrecht University; Utrecht University; Wageningen University & Research; European Synchrotron Radiation Facility (ESRF)	van den Heuvel, RHH (corresponding author), Univ Pavia, Dept Genet & Microbiol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	r.h.h.vandenheuvel@chem.uu.nl; mattevi@ipvgen.unipv.it	Mattevi, Andrea/R-4469-2019; mattevi, andrea/K-5464-2012; van Berkel, Willem J.H./O-2431-2014; Heck, Albert/D-7098-2011; Westphal, Adrie Herman/L-3517-2019; Walsh, Martin A/I-1566-2013	Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128; van Berkel, Willem J.H./0000-0002-6551-2782; Heck, Albert/0000-0002-2405-4404; Westphal, Adrie Herman/0000-0003-4264-6267; Walsh, Martin A/0000-0001-5683-1151				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell CE, 1997, PROTEIN SCI, V6, P2084; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHIEN Y, 1973, BIOCHEM BIOPH RES CO, V50, P538, DOI 10.1016/0006-291X(73)90873-5; Chiu HJ, 2001, STRUCTURE, V9, P311, DOI 10.1016/S0969-2126(01)00589-5; Christendat D, 2000, NAT STRUCT BIOL, V7, P903; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Duffner FM, 2000, GENE, V256, P215, DOI 10.1016/S0378-1119(00)00352-8; Duffner FM, 1998, FEMS MICROBIOL LETT, V161, P37, DOI 10.1016/S0378-1097(98)00047-0; Engel MFM, 2002, J BIOL CHEM, V277, P10922, DOI 10.1074/jbc.M106005200; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705; HECK AJR, 2004, IN PRESS MASS SPECTR; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P975, DOI 10.1038/nsb1297-975; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murzin AG, 1998, NAT STRUCT BIOL, V5, P101, DOI 10.1038/nsb0298-101; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schroder I, 2003, FEMS MICROBIOL REV, V27, P427, DOI 10.1016/S0168-6445(03)00043-3; Singh SK, 2002, J BIOL CHEM, V277, P33291, DOI 10.1074/jbc.M204368200; Smith PE, 2000, J MOL RECOGNIT, V13, P27, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<27::AID-JMR483>3.3.CO;2-#; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tahallah N, 2002, J BIOL CHEM, V277, P36425, DOI 10.1074/jbc.M205841200; TAKIZAWA N, 1995, J FERMENT BIOENG, V80, P318, DOI 10.1016/0922-338X(95)94198-Z; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; Vadas A, 1999, J BIOL CHEM, V274, P36715, DOI 10.1074/jbc.274.51.36715; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Witschel M, 1997, J BACTERIOL, V179, P6937, DOI 10.1128/jb.179.22.6937-6943.1997; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	56	66	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12860	12867		10.1074/jbc.M313765200	http://dx.doi.org/10.1074/jbc.M313765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14703520	hybrid			2022-12-27	WOS:000220334900102
J	Yang, Y; Rijnbrand, R; Watowich, S; Lemon, SM				Yang, Y; Rijnbrand, R; Watowich, S; Lemon, SM			Genetic evidence for an interaction between a picornaviral cis-acting RNA replication element and 3CD protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; POLIOVIRUS RNA; VPG URIDYLYLATION; POSITIVE-STRAND; CODING SEQUENCE; VIRAL-RNA; IDENTIFICATION; BINDING; GENOME; CRE	Internally located, cis-acting RNA replication elements, termed cres, are essential for replication of the genomes of picornaviruses such as human rhinovirus 14 (HRV-14) and poliovirus because they template uridylylation of the protein primer, VPg, by the polymerase 3D(pol). These cres form stem-loop structures sharing a common loop motif, and the HRV-14 cre can substitute functionally for the poliovirus cre in both uridylylation in vitro and RNA replication in vivo. We show, however, that the poliovirus cre is unable to support HRV-14 RNA replication. This lack of complementation maps to the stem of the poliovirus cre and was reversed by single nucleotide substitutions in the stem as well as the base of the loop. Replication-competent, revertant viruses rescued from dicistronic HRV-14 RNAs containing the poliovirus cre, or a chimeric cre containing the poliovirus stem, contained adaptive amino acid substitutions. These mapped to the surface of both the polymerase 3D(pol), at the tip of the "thumb" domain, and the protease 3C(pro), on the side opposing the active site and near the end of an extended strand segment implicated previously in RNA binding. These mutations substantially enhanced replication competence when introduced into HRV-14 RNAs containing the poliovirus cre, and they were additive in their effects. The data support a model in which 3CD or its derivatives 3C(pro) and 3D(pol) interact directly with the stem of the cre during uridylylation of VPg.	Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lemon, SM (corresponding author), Univ Texas, Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	smlemon@utmb.ed			NIAID NIH HHS [R01 AI 140282] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; Gamarnik AV, 2000, J VIROL, V74, P2219, DOI 10.1128/JVI.74.5.2219-2226.2000; Gerber K, 2001, J VIROL, V75, P10979, DOI 10.1128/JVI.75.22.10979-10990.2001; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Goodfellow IG, 2003, RNA, V9, P124, DOI 10.1261/rna.2950603; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; Lobert PE, 1999, P NATL ACAD SCI USA, V96, P11560, DOI 10.1073/pnas.96.20.11560; Mason PW, 2002, J VIROL, V76, P9686, DOI 10.1128/JVI.76.19.9686-9694.2002; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; McKnight KL, 1998, RNA, V4, P1569, DOI 10.1017/S1355838298981006; McKnight KL, 1996, J VIROL, V70, P1941, DOI 10.1128/JVI.70.3.1941-1952.1996; Melchers WJG, 1997, J VIROL, V71, P686, DOI 10.1128/JVI.71.1.686-696.1997; Mellits KH, 1998, J GEN VIROL, V79, P1715, DOI 10.1099/0022-1317-79-7-1715; Meredith JM, 1999, J VIROL, V73, P9952, DOI 10.1128/JVI.73.12.9952-9958.1999; Mirmomeni MH, 1997, J VIROL, V71, P2363, DOI 10.1128/JVI.71.3.2363-2370.1997; Morasco BJ, 2003, J VIROL, V77, P5136, DOI 10.1128/JVI.77.9.5136-5144.2003; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pilipenko EV, 1996, EMBO J, V15, P5428, DOI 10.1002/j.1460-2075.1996.tb00926.x; Racaniello V.R., 2001, FIELDS VIROLOGY, P455; REGENMORTEL MHV, 2000, VIRUS TAXONOMY CLASS, P657; ROHLL JB, 1995, J VIROL, V69, P7835, DOI 10.1128/JVI.69.12.7835-7844.1995; Seipelt J, 1999, VIRUS RES, V62, P159, DOI 10.1016/S0168-1702(99)00043-X; Todd S, 1997, J VIROL, V71, P8868, DOI 10.1128/JVI.71.11.8868-8874.1997; TODD S, 1995, J VIROL, V69, P3605, DOI 10.1128/JVI.69.6.3605-3614.1995; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995; Yang Y, 2002, J VIROL, V76, P7485, DOI 10.1128/JVI.76.15.7485-7494.2002; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003	41	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12659	12667		10.1074/jbc.M312992200	http://dx.doi.org/10.1074/jbc.M312992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711816	hybrid			2022-12-27	WOS:000220334900079
J	Zhong, L; Qing, KY; Si, Y; Chen, LY; Tan, MQ; Srivastava, A				Zhong, L; Qing, KY; Si, Y; Chen, LY; Tan, MQ; Srivastava, A			Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-MEDIATED GENE-TRANSFER; GROWTH-FACTOR RECEPTOR; CASEIN KINASE-II; IMPAIRED INTRACELLULAR TRAFFICKING; HEMATOPOIETIC PROGENITOR CELLS; PROTEIN-TYROSINE-PHOSPHATASE; INVERTED TERMINAL REPEATS; MILD LUNG-DISEASE; BETA-GLOBIN GENE; TRANSGENE EXPRESSION	Recombinant adeno-associated virus 2 (AAV) vectors transduction efficiency varies greatly in different cell types. We have described that a cellular protein, FKBP52, in its phosphorylated form interacts with the D-sequence in the viral inverted terminal repeat, inhibits viral second strand DNA synthesis, and limits transgene expression. Here we investigated the role of cellular heat-shock protein 90 (HSP90) in AAV transduction because FKBP52 forms a complex with HSP90, and because heat-shock treatment augments AAV transduction efficiency. Heat-shock treatment of HeLa cells resulted in tyrosine dephosphorylation of FKBP52, led to stabilization of the FKBP52-HSP90 complex, and resulted in similar to6-fold increase in AAV transduction. However, when HeLa cells were pre-treated with tyrphostin 23, a specific inhibitor of cellular epidermal growth factor receptor tyrosine kinase, which phosphorylates FKBP52 at tyrosine residues, heat-shock treatment resulted in a further 18-fold increase in AAV transduction. HSP90 was shown to be a part of the FKBP52-AAV D-sequence complex, but HSP90 by itself did not bind to the D-sequence. Geldanamycin treatment, which disrupts the HSP90-FKBP52 complex, resulted in >22-fold increase in AAV transduction in heat-shock-treated cells compared with heat shock alone. Deliberate overexpression of the human HSP90 gene resulted in a significant decrease in AAV-mediated transduction in tyrphostin 23-treated cells, whereas down-modulation of HSP90 levels led to a decrease in HSP90-FKBP52-AAV D-sequence complex formation, resulting in a significant increase in AAV transduction following pre-treatment with tyrphostin 23. These studies suggest that the observed increase in AAV transduction efficiency following heat-shock treatment is unlikely to be mediated by HSP90 alone and that increased levels of HSP90, in the absence of heat shock, facilitate binding of FKBP52 to the AAV D-sequence, thereby leading to inhibition of AAV-mediated transgene expression. These studies have implications in the optimal use of recombinant AAV vectors in human gene therapy.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr,Walther Canc Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; Eli Lilly & Co, Indianapolis, IN 46229 USA; Cent S Univ, Xiang Ya Sch Med, Changsha 410078, Hunan, Peoples R China	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Central South University	Srivastava, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr,Walther Canc Inst, Med Sci Bldg,Rm 415-A,635 Barnhill Dr, Indianapolis, IN 46202 USA.	asrivast@iupui.edu	Si, Yue/A-1171-2010		NHLBI NIH HHS [HL 65570, R01 HL058881, R01 HL058881-06, R01 HL065570] Funding Source: Medline; NIBIB NIH HHS [R01 EB002073, R01 EB 002073] Funding Source: Medline; NIDDK NIH HHS [P01 DK058327, P50 DK049218-050003, P01 DK058327-060004, P50 DK049218] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065570, R01HL058881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218, P01DK058327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken ML, 2001, HUM GENE THER, V12, P1907, DOI 10.1089/104303401753153956; Ashok A, 2003, J VIROL, V77, P1347, DOI 10.1128/JVI.77.2.1347-1356.2003; Bartlett JS, 2000, J VIROL, V74, P2777, DOI 10.1128/JVI.74.6.2777-2785.2000; Berns KI, 1996, CURR TOP MICROBIOL, V218, P1; Carter BJ, 1996, CURR TOP MICROBIOL, V218, P119; Chatterjee S, 1995, ANN NY ACAD SCI, V770, P79, DOI 10.1111/j.1749-6632.1995.tb31045.x; CYBULSKY AV, 1994, AM J PHYSIOL, V267, pF428, DOI 10.1152/ajprenal.1994.267.3.F428; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; Duan DS, 2000, J CLIN INVEST, V105, P1573, DOI 10.1172/JCI8317; Duan DS, 1999, J VIROL, V73, P10371, DOI 10.1128/JVI.73.12.10371-10376.1999; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Flotte T, 1996, HUM GENE THER, V7, P1145, DOI 10.1089/hum.1996.7.9-1145; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hansen J, 2001, MOL THER, V4, P289, DOI 10.1006/mthe.2001.0457; Hansen J, 2000, J VIROL, V74, P992, DOI 10.1128/JVI.74.2.992-996.2000; Hansen J, 2001, J VIROL, V75, P4080, DOI 10.1128/JVI.75.9.4080-4090.2001; Hung JJ, 2002, J VIROL, V76, P1379, DOI 10.1128/JVI.76.3.1379-1390.2002; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kaplitt MG, 1996, ANN THORAC SURG, V62, P1669, DOI 10.1016/S0003-4975(96)00946-0; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Knossl M, 1999, J VIROL, V73, P1254; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; Kube DM, 1997, J VIROL, V71, P7361, DOI 10.1128/JVI.71.10.7361-7371.1997; Lam MHC, 2001, J BIOL CHEM, V276, P37700, DOI 10.1074/jbc.M105128200; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mah C, 1998, J VIROL, V72, P9835, DOI 10.1128/JVI.72.12.9835-9843.1998; MAH C, 1999, GENE THER MOL BIOL, V3, P57; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; MULLER MT, 1987, J VIROL, V61, P858, DOI 10.1128/JVI.61.3.858-865.1987; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Nathwani AC, 2000, GENE THER, V7, P183, DOI 10.1038/sj.gt.3301068; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pennisi E, 1998, SCIENCE, V282, P1796; Petit C, 2003, J CELL SCI, V116, P3433, DOI 10.1242/jcs.00613; Ping P., 1996, Microcirculation (Philadelphia), V3, P225, DOI 10.3109/10739689609148292; Ponnazhagan S, 1997, GENE, V190, P203, DOI 10.1016/S0378-1119(96)00576-8; Ponnazhagan S, 1997, J VIROL, V71, P3098, DOI 10.1128/JVI.71.4.3098-3104.1997; Ponnazhagan S, 1997, J VIROL, V71, P8262, DOI 10.1128/JVI.71.11.8262-8267.1997; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Qing KY, 2001, J VIROL, V75, P8968, DOI 10.1128/JVI.75.19.8968-8976.2001; Qing KY, 2003, J VIROL, V77, P2741, DOI 10.1128/JVI.77.4.2741-2746.2003; Qing KY, 1997, P NATL ACAD SCI USA, V94, P10879, DOI 10.1073/pnas.94.20.10879; Qing KY, 1998, J VIROL, V72, P1593, DOI 10.1128/JVI.72.2.1593-1599.1998; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; Sanlioglu S, 2000, J VIROL, V74, P9184, DOI 10.1128/JVI.74.19.9184-9196.2000; Schlatter H, 2002, BIOCHEM J, V362, P675, DOI 10.1042/0264-6021:3620675; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Srivastava A, 1996, CURR TOP MICROBIOL, V218, P93; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Tan MQ, 2001, MOL THER, V3, P940, DOI 10.1006/mthe.2001.0346; Wagner JA, 2002, HUM GENE THER, V13, P1349, DOI 10.1089/104303402760128577; WALSH CE, 1993, P SOC EXP BIOL MED, V204, P289, DOI 10.3181/00379727-204-43665; Wang XS, 1997, J VIROL, V71, P3077, DOI 10.1128/JVI.71.4.3077-3082.1997; Wang XS, 1996, J VIROL, V70, P1668, DOI 10.1128/JVI.70.3.1668-1677.1996; WEBER W, 1984, J BIOL CHEM, V259, P4631; Xiao W, 2002, J VIROL, V76, P11505, DOI 10.1128/JVI.76.22.11505-11517.2002; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; YAKINOGLU AO, 1988, CANCER RES, V48, P3123; Yang ZC, 2003, MOL THER, V7, pS14; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200; Zhong L, 2002, ANESTHESIOLOGY, V96, P148, DOI 10.1097/00000542-200201000-00028; Zhou SZ, 1996, GENE THER, V3, P223	86	33	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12714	12723		10.1074/jbc.M310548200	http://dx.doi.org/10.1074/jbc.M310548200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711833	hybrid, Green Accepted			2022-12-27	WOS:000220334900085
J	de Jong, RM; Brugman, W; Poelarends, GJ; Whitman, CP; Dijkstra, BW				de Jong, RM; Brugman, W; Poelarends, GJ; Whitman, CP; Dijkstra, BW			The X-ray structure of trans-3-chloroacrylic acid dehalogenase reveals a novel hydration mechanism in the tautomerase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.8 ANGSTROM RESOLUTION; AMINO-TERMINAL PROLINE; SITE ARGININE RESIDUES; 4-OXALOCROTONATE TAUTOMERASE; CRYSTAL-STRUCTURE; PH-DEPENDENCE; PK(A) VALUES; MUTATIONS; PROGRAM; ENZYME	Isomer-specific 3-chloroacrylic acid dehalogenases function in the bacterial degradation of 1,3-dichloropropene, a compound used in agriculture to kill plant-parasitic nematodes. The crystal structure of the heterohexameric trans-3-chloroacrylic acid dehalogenase (CaaD) from Pseudomonas pavonaceae 170 inactivated by 3-bromopropiolate shows that Glu-52 in the alpha-subunit is positioned to function as the water-activating base for the addition of a hydroxyl group to C-3 of 3-chloroacrylate and 3-bromopropiolate, whereas the nearby Pro-1 in the beta-subunit is positioned to provide a proton to C-2. Two arginine residues, alphaArg-8 and alphaArg-11, interact with the C-1 carboxylate groups, thereby polarizing the alpha,beta-unsaturated acids. The reaction with 3-chloroacrylate results in the production of an unstable halohydrin, 3-chloro-3-hydroxypropanoate, which decomposes into the products malonate semialdehyde and HCl. In the inactivation mechanism, however, malonyl bromide is produced, which irreversibly alkylates the betaPro-1. CaaD is related to 4-oxalocrotonate tautomerase, with which it shares an N-terminal proline. However, in 4-oxalocrotonate tautomerase, Pro-1 functions as a base participating in proton transfer within a hydrophobic active site, whereas in CaaD, the acidic proline is stabilized in a hydrophilic active site. The altered active site environment of CaaD thus facilitates a previously unknown reaction in the tautomerase superfamily, the hydration of the alpha,beta-unsaturated bonds of trans-3-chloroacrylate and 3-bromopropiolate. The mechanism for these hydration reactions represents a novel catalytic strategy that results in carbon-halogen bond cleavage.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA	University of Groningen; University of Texas System; University of Texas Austin	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	B.W.Dijkstra@chem.rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Poelarends, Gerrit/0000-0002-6917-6368	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-65324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2002, BIOCHEMISTRY-US, V41, P12010, DOI 10.1021/bi020271h; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BRUICE PY, 2003, ORGANIC CHEM, P670; CHEN LH, 1992, J BIOL CHEM, V267, P17716; Czerwinski RM, 2001, BIOCHEMISTRY-US, V40, P1984, DOI 10.1021/bi0024714; Czerwinski RM, 1999, BIOCHEMISTRY-US, V38, P12358, DOI 10.1021/bi9911177; Czerwinski RM, 1997, BIOCHEMISTRY-US, V36, P14551, DOI 10.1021/bi971545h; de Jong RM, 2003, EMBO J, V22, P4933, DOI 10.1093/emboj/cdg479; Harris TK, 1999, BIOCHEMISTRY-US, V38, P12343, DOI 10.1021/bi991116e; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1; Janssen DB, 2003, DEHALOGENATION: MICROBIAL PROCESSES AND ENVIRONMENTAL APPLICATIONS, P207; Janssen DB, 2001, CURR OPIN BIOTECH, V12, P254, DOI 10.1016/S0958-1669(00)00208-1; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P116; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1315, DOI 10.1021/bi0117504; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARLETTA MA, 1982, BIOCHEMISTRY-US, V21, P2637, DOI 10.1021/bi00540a010; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Neumann A, 2002, ARCH MICROBIOL, V177, P420, DOI 10.1007/s00203-002-0409-3; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poelarends GJ, 2003, J BIOL CHEM, V278, P48674, DOI 10.1074/jbc.M306706200; Poelarends GJ, 1998, APPL ENVIRON MICROB, V64, P2931; Poelarends GJ, 2001, J BACTERIOL, V183, P4269, DOI 10.1128/JB.183.14.4269-4277.2001; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P814, DOI 10.1021/bi9510789; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P803, DOI 10.1021/bi951077g; Straus F, 1930, BER DTSCH CHEM GES, V63, P1868, DOI 10.1002/cber.19300630739; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Taylor AB, 1998, BIOCHEMISTRY-US, V37, P14692, DOI 10.1021/bi981607j; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; van Hylckama Vlieg J E, 1991, Biodegradation, V2, P139; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; Wang SC, 2003, J AM CHEM SOC, V125, P14282, DOI 10.1021/ja0370948; Wang SC, 2003, BIOCHEMISTRY-US, V42, P8762, DOI 10.1021/bi034598+; Whitman CP, 2002, ARCH BIOCHEM BIOPHYS, V402, P1, DOI 10.1016/S0003-9861(02)00052-8	45	42	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11546	11552		10.1074/jbc.M311966200	http://dx.doi.org/10.1074/jbc.M311966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701869	hybrid, Green Published			2022-12-27	WOS:000220157600087
J	Nakano, N; Higashiyama, S; Ohmoto, H; Ishiguro, H; Taniguchi, N; Wada, Y				Nakano, N; Higashiyama, S; Ohmoto, H; Ishiguro, H; Taniguchi, N; Wada, Y			The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASES; TUMOR-GROWTH; CELL-GROWTH; RECEPTOR; GENE; ACTIVATION; FAMILY; NEUREGULINS; EXPRESSION	NTAK (neural- and thymus-derived activator for ErbB kinases), also known as neuregulin-2, is a member of the epidermal growth factor (EGF) family, which binds directly to ErbB3 and ErbB4 and transactivates ErbB2. Because ErbB signaling has been implicated in various angiogenic mechanisms, the effect of NTAK (which has at least nine isoforms due to alternative splicing) in angiogenesis is explored. One isoform, NTAKgamma, inhibited cell growth in terms of DNA synthesis and cell numbers in vascular endothelial cells specifically, whereas NTAKalpha and beta had no activity. On the other hand, NTAKgamma secreted by transfected MDA-MB-231 cells inhibited endothelial cell growth, and NTAKgamma expressed in endothelial cells by adenovirus infection suppressed cell growth in a dose-dependent manner. The EGF-like domain of NTAKgamma did not have this activity. The NTAKdelta isoform, which had the Ig-like domain but not the EGF-like domain, inhibited proliferation of endothelial cells. NTAKdelta prevented hyper-phosphorylation of the retinoblastoma tumor suppressor protein and caused G(1) arrest in endothelial cells. Both NTAKgamma and delta isoforms displayed anti-angiogenic activity in the chick embryo chorioallantoic membrane in vivo. These results suggest that the active site of NTAK is localized outside of the EGF-like domain but within the N-terminal region, including the Ig-like domain, of NTAK.	Osaka Med Ctr & Res Inst Maternal & Child Hlth, Dept Mol Med, Osaka 5941101, Japan; Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 7910295, Japan; Carna Biosci Inc, Chuo Ku, Kobe, Hyogo 6508543, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Ehime University; Osaka University	Nakano, N (corresponding author), Osaka Med Ctr & Res Inst Maternal & Child Hlth, Dept Mol Med, 840 Murodo Cho, Osaka 5941101, Japan.	nakanon@lab.mch.pref.osaka.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; Hyder SM, 1998, CANCER RES, V58, P392; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuba K, 2000, CANCER RES, V60, P6737; Li QF, 2001, J BIOL CHEM, V276, P38068; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Nakano N, 2000, J BIOCHEM-TOKYO, V127, P925, DOI 10.1093/oxfordjournals.jbchem.a022688; Nakano N, 1999, J BIOCHEM, V125, P368; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; TANAKA NG, 1986, EXP PATHOL-JENA, V30, P143, DOI 10.1016/S0232-1513(86)80087-1; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamada K, 2000, GENE, V255, P15, DOI 10.1016/S0378-1119(00)00309-7; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	29	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11465	11470		10.1074/jbc.M311045200	http://dx.doi.org/10.1074/jbc.M311045200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722120	hybrid			2022-12-27	WOS:000220157600077
J	Sinha, D; Bannergee, S; Schwartz, JH; Lieberthal, W; Levine, JS				Sinha, D; Bannergee, S; Schwartz, JH; Lieberthal, W; Levine, JS			Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; 2 DISTINCT PHASES; LYSOPHOSPHATIDIC ACID; PROTEIN; GROWTH; ACTIVATION; PHOSPHORYLATION; TRANSLOCATION; 3-KINASE; PKB/AKT	Mouse kidney proximal tubular epithelial (MK-PT) cells die by apoptosis over 7-10 days when deprived of all survival factors. We show here that withdrawal of all survival factors from MK-PT cells is associated with a progressive increase in the activity of extracellular signal-regulated kinase-1 and -2 (ERK1/2) and a progressive decrease in phosphorylated Akt, a kinase critical to cell survival. Pharmacological inhibition of MEK1/2, the immediate upstream kinase for ERK1/2, not only prevented the decrease in phosphorylated Akt, but also prolonged MK-PT cell survival. Inhibition of ERK1/2, by itself, in the absence of any other known survival factors, was as potent as epidermal growth factor in maintaining MK-PT cell viability. ERK1/2 co-immunoprecipitated with Akt in a multimolecular assembly of signaling molecules, containing at a minimum ERK1/2, Akt, Rsk, and 3-phosphoinositide dependent kinase 1 (PDK1). We hypothesize that the kinase Rsk, whose activation requires phosphorylation by both ERK1/2 and PDK1, acts as a bridge bringing ERK1/2 into proximity with PDK1-associated Akt. Although a number of interactions between the Raf-MEK-ERK and PI3K-Akt signaling pathways have been described, our results are the first to show modulation of Akt activity by signaling events originating with ERK1/2. Spontaneous activation of ERK1/2 occurs via MEK1/2 and appears to depend on oxidant stress, accompanying induction of the default pathway of apoptosis. Together, these data suggest that the spontaneous activation of ERK1/2, in the absence of known extracellular stimuli, represents a previously unrecognized major regulatory pathway determining the fate of cells destined to die by the default pathway of apoptosis.	Univ Chicago, Nephrol Sect, Chicago, IL 60637 USA; Boston Univ, Sch Med, Boston Med Ctr, Renal Sect, Boston, MA 02118 USA	University of Chicago; Boston Medical Center; Boston University	Levine, JS (corresponding author), Univ Chicago, Nephrol Sect, MC-5100,S-506,5841 S Maryland Ave, Chicago, IL 60637 USA.	jlevine@medicine.bsd.uchicago.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681	NHLBI NIH HHS [HL69722] Funding Source: Medline; NIDDK NIH HHS [DK52898, DK59793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL069722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052898, R01DK059793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DINHA D, 2002, AM J PHYSIOL, V284, pF488; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Igleslas J, 1999, AM J PHYSIOL-RENAL, V277, pF711, DOI 10.1152/ajprenal.1999.277.5.F711; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sinha D, 2003, AM J PHYSIOL-RENAL, V284, pF488, DOI 10.1152/ajprenal.00172.2002; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILSON NJ, 1988, BIOCHEM BIOPH RES CO, V244, P475; Wright BE, 1999, P NATL ACAD SCI USA, V96, P5089, DOI 10.1073/pnas.96.9.5089; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	45	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10962	10972		10.1074/jbc.M312048200	http://dx.doi.org/10.1074/jbc.M312048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701865	hybrid			2022-12-27	WOS:000220157600018
J	Tsai, PL; Chen, CH; Huang, CJ; Chou, CM; Chang, GD				Tsai, PL; Chen, CH; Huang, CJ; Chou, CM; Chang, GD			Purification and cloning of an endogenous protein inhibitor of carp nephrosin, an astacin metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASE; RAY CRYSTAL-STRUCTURE; 2 CONSTITUENT PROTEASES; GEL-ELECTROPHORESIS; ZINC-ENDOPEPTIDASE; MATRIX METALLOPROTEINASES; MOLECULAR-STRUCTURE; POLYACRYLAMIDE-GEL; CATALYTIC DOMAIN; HATCHING ENZYME	Nephrosin is a newly discovered member of the astacin family. It is a secreted proteinase and is present in carp head kidney, kidney, and spleen, all of which are responsible for immune and hematopoietic functions in fish. A complex formed by nephrosin and its inhibitor was purified from carp kidney extract by heparin affinity column chromatography. The presence of the nephrosin-inhibitor complex in different tissues was examined by immunoblotting with polyclonal antisera against the purified nephrosin inhibitor and nephrosin. Both nephrosin and the nephrosin inhibitor were present mainly in gill, head kidney, kidney, and spleen. In addition, we have cloned the cDNA encoding the nephrosin inhibitor. There are two different cDNA clones possibly resulting from two different genes, and the long form contains unique tandem repeat sequences in the 3'-end. The deduced primary structure of nephrosin inhibitor is similar to that of fetuin-A, a mammalian protein present in blood, liver, cerebrospinal fluid, and cerebral cortex during fetal development. Treatment with both N-glycosidase F and O-glycosidase removed the carbohydrate moiety of the nephrosin inhibitor and decreased the apparent molecular mass from 40 to 30 kDa. The nephrosin inhibitor seems to be synthesized in liver and then secreted to the blood as a precursor. When it was distributed into hematopoietic tissues, it was processed from 67 to 40 kDa and acquired inhibitory activity. This processing phenomenon of fetuin has not been reported elsewhere. Importantly, the presence of an endogenous inhibitor of nephrosin is the first report of this kind for astacin enzymes. It is very likely that endogenous tissue inhibitors may also be present for the regulation of other astacin enzymes.	Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Taipei Med Univ, Dept Biochem, Taipei 117, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Taipei Medical University	Chang, GD (corresponding author), Natl Taiwan Univ, Grad Inst Biochem Sci, POB 23-106, Taipei 106, Taiwan.	gdchang@ccms.ntu.edu.tw						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Binkert C, 1999, J BIOL CHEM, V274, P28514, DOI 10.1074/jbc.274.40.28514; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown WM, 1997, PROTEIN SCI, V6, P5; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; Chen HW, 2001, ELECTROPHORESIS, V22, P1894, DOI 10.1002/1522-2683(200106)22:10<1894::AID-ELPS1894>3.0.CO;2-5; Doherty NS, 1998, ELECTROPHORESIS, V19, P355, DOI 10.1002/elps.1150190234; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hung CH, 1997, J BIOL CHEM, V272, P13772, DOI 10.1074/jbc.272.21.13772; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Johnson GD, 1997, J BIOL CHEM, V272, P28126, DOI 10.1074/jbc.272.44.28126; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Perez JC, 1999, TOXICON, V37, P703, DOI 10.1016/S0041-0101(98)00205-0; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOCKER W, 1995, PROTEIN SCI, V4, P823; Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200; Taylor KB, 1996, J BIOL CHEM, V271, P23938, DOI 10.1074/jbc.271.39.23938; Traut R., 1989, PROTEIN FUNCTION PRA, P101; Valente RH, 2001, EUR J BIOCHEM, V268, P3042, DOI 10.1046/j.1432-1327.2001.02199.x; VOGT G, 1989, HISTOCHEMISTRY, V91, P373, DOI 10.1007/BF00493824; Wang HC, 1998, P NATL ACAD SCI USA, V95, P14429, DOI 10.1073/pnas.95.24.14429; YAMAGUCHI T, 1993, BIOCHEMISTRY-US, V113, P299; YAMAKAWA Y, 1992, J BIOCHEM-TOKYO, V112, P583, DOI 10.1093/oxfordjournals.jbchem.a123944; YAN L, 1995, DEVELOPMENT, V121, P1591; YASUMASU S, 1992, DEV BIOL, V149, P349, DOI 10.1016/0012-1606(92)90290-W; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3	52	19	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11146	11155		10.1074/jbc.M310423200	http://dx.doi.org/10.1074/jbc.M310423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14709555	Green Published, hybrid			2022-12-27	WOS:000220157600039
J	Zwartjes, CGM; Jayne, S; van den Berg, DLC; Timmers, HTM				Zwartjes, CGM; Jayne, S; van den Berg, DLC; Timmers, HTM			Repression of promoter activity by CNOT2, a subunit of the transcription regulatory Ccr4-not complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; GENE-EXPRESSION; RETINOIC ACID; CAF1 PROTEINS; YEAST; HISTONE; TBP; COMPONENTS; MEDIATOR; NOT2	The evolutionary conserved Ccr4-Not complex controls mRNA metabolism at multiple levels in eukaryotic cells. Genetic analysis of not mutants in yeast identifies a negative role in transcription, which is dependent on core promoter structure. To obtain direct support for this we targeted individual core subunits of the human Ccr4-Not complex to promoters in transient transfections of human cells. In this experimental setup we found that the CNOT2 and CNOT9(hRcd1/hCaf40) subunits act as repressors of reporter gene activity. Interestingly, recruitment of other Ccr4-Not subunits did not affect the reporter gene. The major repression function of CNOT2 is localized in a specialized protein motif, the Not-Box. This conserved motif is present in all CNOT2 orthologs and surprisingly also in CNOT3 orthologs. Repression by the Not-Box was sensitive to treatment with the histone deacetylase inhibitor trichostatin A. In addition, mutation of a canonical TATA-box enhanced repression. Our experiments show for the first time direct regulation of promoter activity by components of the Ccr4-Not complex.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Timmers, HTM (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Stratenum STR 3-229,Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	h.t.m.timmers@med.uu.nl./		van den Berg, Debbie L.C./0000-0001-6026-8808				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Aoki T, 2002, BIOCHEM BIOPH RES CO, V296, P1097, DOI 10.1016/S0006-291X(02)02031-4; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Badarinarayana V, 2000, GENETICS, V155, P1045; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Bai YL, 1999, MOL CELL BIOL, V19, P6642; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Deluen C, 2002, MOL CELL BIOL, V22, P6735, DOI 10.1128/MCB.22.19.6735-6749.2002; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; DERUWE MJ, 2000, THESIS UTRECHT U UTR, P55; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Hiroi N, 2002, EMBO J, V21, P5235, DOI 10.1093/emboj/cdf521; Johnson KM, 2002, GENE DEV, V16, P1852, DOI 10.1101/gad.995702; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Maillet L, 2000, J MOL BIOL, V303, P131, DOI 10.1006/jmbi.2000.4131; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Morel AP, 2003, J CELL SCI, V116, P2929, DOI 10.1242/jcs.00480; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Russell P, 2002, J MOL BIOL, V322, P27, DOI 10.1016/S0022-2836(02)00707-6; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van der Eb A J, 1980, Methods Enzymol, V65, P826; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300	52	45	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10848	10854		10.1074/jbc.M311747200	http://dx.doi.org/10.1074/jbc.M311747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707134	hybrid			2022-12-27	WOS:000220157600005
J	Holstein, DM; Berg, KA; Leeb-Lundberg, LMF; Olson, MS; Saunders, C				Holstein, DM; Berg, KA; Leeb-Lundberg, LMF; Olson, MS; Saunders, C			Calcium-sensing receptor-mediated ERK1/2 activation requires G alpha(i2) coupling and dynamin-independent receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CALCIUM; PROTEIN-KINASE; CA2+-SENSING RECEPTOR; PROLIFERATION; EXPRESSION; CELLS; CA2+; PHOSPHORYLATION; STIMULATION; ENDOCYTOSIS	The calcium-sensing receptor (CaR) recently has been shown to activate MAP kinase (ERK1/2) in various cell types as well as in heterologous expression systems. In this study we show that the CaR agonist NPS R-467 (1 muM), which does not activate the CaR by itself, robustly activates ERK1/2 in the presence of a low concentration of Ca2+ (0.5 mM CaCl2) in human embryonic kidney (HEK) cells permanently expressing the human CaR (HEK-hCaR). Ca2+ (4 mM) also activates ERK1/2 but with differing kinetics. CaR-dependent ERK1/2 activation begins to desensitize to 4 mM Ca2+ after 10 min, whereas there is no desensitization to NPS R-467/CaCl2 as late as 4 h. Moreover, recovery from desensitization occurs as rapidly as 30 min with 4 mM CaCl2. Pretreatment of HEK-hCaR cells with concanavalin A (250 mug/ml) to block CaR internalization completely eliminated the NPS R-467/CaCl2-mediated ERK1/2 activation but did not block the 2-min time point of 4 mM Ca2+-mediated ERK1/2 activation. Neither dominant-negative dynamin (K44A) nor dominant-negative beta-arrestin inhibited ERK1/2 activation by either CaR agonist treatment, suggesting that CaR- elicited ERK1/2 signaling occurs via a dynamin-independent pathway. Pertussis toxin pretreatment partially attenuated the 4 mM Ca2+-ERK1/2 activation; this attenuated activity was completely restored by co-expression of the Galpha(i2)(C351I) but not Galpha(i1)(C351I) or Galpha(i3)(C351I) G proteins, PTX-insensitive G protein mutants. Taken together, these data suggest that both 4 mM Ca2+ and NPS R-467/CaCl2 activate ERK1/2 via distinguishable pathways in HEK-hCaR cells and may represent a nexus to differentially regulate differentiation versus proliferation via CaR activation.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	Vanderbilt University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Saunders, C (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 417B Preston Res Bldg, Nashville, TN 37232 USA.	christine.saunders@vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879, K01DK002852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02852, DK-43879] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bennett VJ, 2002, J PHARMACOL EXP THER, V303, P1155, DOI 10.1124/jpet.102.040378; Bilderback TR, 2002, AM J PHYSIOL-CELL PH, V283, pC282, DOI 10.1152/ajpcell.00437.2001; Blaukat A, 1999, FEBS LETT, V451, P337, DOI 10.1016/S0014-5793(99)00613-4; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1998, RECENT PROG HORM RES, V53, P257; Brown EM, 1997, HORM RES, V48, P199, DOI 10.1159/000185516; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Chattopadhyay N, 1997, BIOCHEM BIOPH RES CO, V233, P801, DOI 10.1006/bbrc.1997.6553; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Chattopadhyay N, 1999, BRAIN RES, V851, P116, DOI 10.1016/S0006-8993(99)02132-0; Chattopadhyay N, 1996, AM J PHYSIOL-RENAL, V271, pF736, DOI 10.1152/ajprenal.1996.271.3.F736; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; Dutour A, 1996, EUR J ENDOCRINOL, V134, P542, DOI 10.1530/eje.0.1340542; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Handlogten ME, 2000, AM J PHYSIOL-RENAL, V279, pF1083, DOI 10.1152/ajprenal.2000.279.6.F1083; Hinson TK, 1997, GENOMICS, V45, P279, DOI 10.1006/geno.1997.4943; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hobson SA, 2000, EXP CELL RES, V258, P1, DOI 10.1006/excr.2000.4910; Hoff Ana O., 1999, Neoplasia (New York), V1, P485; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Kallay E, 1997, BIOCHEM BIOPH RES CO, V232, P80, DOI 10.1006/bbrc.1997.6225; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacLeod RJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE435, DOI 10.1152/ajpendo.00143.2002; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; ROGERS KV, 1995, J BONE MINER RES, V10, pS483; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Tang H, 2000, J BIOL CHEM, V275, P13420, DOI 10.1074/jbc.275.18.13420; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; Vargas-Poussou R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025781.16723.68; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Ward DT, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015623.73739.B8; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530; Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396	53	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10060	10069		10.1074/jbc.M312039200	http://dx.doi.org/10.1074/jbc.M312039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701866	hybrid			2022-12-27	WOS:000220050400050
J	Robalino, J; Joshi, B; Fahrenkrug, SC; Jagus, R				Robalino, J; Joshi, B; Fahrenkrug, SC; Jagus, R			Two zebrafish eIF4E family members are differentially expressed and functionally divergent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; CAP-BINDING-PROTEIN; FACTOR 4G EIF4G; RNA 5' CAP; FACTOR 4E; CAENORHABDITIS-ELEGANS; DEPENDENT TRANSLATION; FACTOR EIF-4E; PHOSPHORYLATION; YEAST	Eukaryotic translation initiation factor 4E (eIF4E) is an essential component of the translational machinery that binds m(7)GTP and mediates the recruitment of capped mRNAs by the small ribosomal subunit. Recently, a number of proteins with homology to eIF4E have been reported in plants, invertebrates, and mammals. Together with the prototypical translation factor, these constitute a new family of structurally related proteins. To distinguish the prototypical translation factor eIF4E from other family members, it has been termed eIF4E-1 (Keiper, B. D., Lamphear, B. J., Deshpande, A. M., Jankowska-Anyszka, M., Aamodt, E. J., Blumenthal, T., and Rhoads, R. E. ( 2000) J. Biol. Chem. 275, 10590 - 10596). We describe the characterization of two eIF4E family members in the zebrafish Danio rerio. Based on their relative identities with human eIF4E-1, these zebrafish proteins are termed eIF4E-1A (82%) and eIF4E-1B (66%). eIF4E-1B, originally termed eIF4E( L), has been reported previously as the zebrafish eIF4E-1 counterpart (Fahrenkrug, S. C., Dahlquist, M. O., Clark, K., and Hackett, P. B. ( 1999) Differentiation 65, 191 - 201; Fahrenkrug, S. C., Joshi, B., Hackett, P. B., and Jagus, R. ( 2000) Differentiation 66, 15 - 22). Sequence comparisons suggest that the two genes probably evolved from a duplication event that occurred during vertebrate evolution. eIF4E-1A is expressed ubiquitously in zebrafish, whereas expression of eIF4E-1B is restricted to early embryonic development and to gonads and muscle of the tissues investigated. The ability of these two zebrafish proteins to bind m7GTP, eIF4G, and 4E-BP, as well as to complement yeast conditionally deficient in functional eIF4E, show that eIF4E-1A is a functional equivalent of human eIF4E-1. Surprisingly, although eIF4E-1B possesses all known residues thought to be required for interaction with the cap structure, eIF4G, and 4E-BPs, it fails to interact with any of these components, suggesting that this protein serves a role other than that assigned to eIF4E.	Univ Maryland, Ctr Marine Biotechnol, Columbus Ctr, Baltimore, MD 21202 USA; Escuela Super Polit Litoral, Guayaquil, Ecuador; Greenebaum Canc Ctr, Program Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Escuela Superior Politecnica del Litoral; University System of Maryland; University of Maryland Baltimore	Jagus, R (corresponding author), Univ Maryland, Ctr Marine Biotechnol, Columbus Ctr, 701 E Pratt St,Suite 236, Baltimore, MD 21202 USA.	jagus@umbi.umd.edu		Fahrenkrug, Scott/0000-0002-7176-6551				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Fahrenkrug SC, 1999, DIFFERENTIATION, V65, P191, DOI 10.1046/j.1432-0436.1999.6540191.x; Fahrenkrug SC, 2000, DIFFERENTIATION, V66, P15, DOI 10.1046/j.1432-0436.2000.066001015.x; FAHRENKRUG SC, 1997, THESIS U MINNESOTA M; Fletcher CM, 1998, BIOCHEMISTRY-US, V37, P9, DOI 10.1021/bi972494r; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JAGUS R, 1993, DEV GENET, V14, P412, DOI 10.1002/dvg.1020140603; JAGUS R, 1998, CURRENT PROTOCOLS CE; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Joshi B, 2002, BIOTECHNIQUES, V33, P392, DOI 10.2144/02332rr06; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Keiper BD, 2000, J BIOL CHEM, V275, P10590, DOI 10.1074/jbc.275.14.10590; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McKendrick L, 1999, INT J BIOCHEM CELL B, V31, P31, DOI 10.1016/S1357-2725(98)00129-0; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; Miyoshi H, 2002, EMBO J, V21, P4680, DOI 10.1093/emboj/cdf473; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Ptushkina M, 2001, NUCLEIC ACIDS RES, V29, P4561, DOI 10.1093/nar/29.22.4561; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Rudolph R, 1997, PROTEIN FUNCTION PRA, P57; Ruud KA, 1998, J BIOL CHEM, V273, P10325, DOI 10.1074/jbc.273.17.10325; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Stolarski R, 1996, BBA-PROTEIN STRUCT M, V1293, P97, DOI 10.1016/0167-4838(95)00232-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P49; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1075, P181, DOI 10.1016/0304-4165(91)90249-G; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; Wakiyama M, 2001, BIOSCI BIOTECH BIOCH, V65, P232, DOI 10.1271/bbb.65.232; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WESTERFIELD M, 1995, ZEBRAFISH BOOK	65	39	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10532	10541		10.1074/jbc.M313688200	http://dx.doi.org/10.1074/jbc.M313688200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701818				2022-12-27	WOS:000220050400106
J	Gao, YT; Smith, SME; Weinberg, JB; Montgomery, HJ; Newman, E; Guillemette, JG; Ghosh, DK; Roman, LJ; Martasek, P; Salerno, JC				Gao, YT; Smith, SME; Weinberg, JB; Montgomery, HJ; Newman, E; Guillemette, JG; Ghosh, DK; Roman, LJ; Martasek, P; Salerno, JC			Thermodynamics of oxidation-reduction reactions in mammalian nitric-oxide synthase Isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX PROPERTIES; MOLECULAR-CLONING; FLAVIN; EXPRESSION; BRAIN; INDUCTION; SUBSTRATE; RELEASE; P-450; HEME	The three mammalian nitric-oxide synthases produce NO from arginine in a reaction requiring 3 electrons per NO, which are supplied to the catalytic center from NADPH through reductase domains incorporating FAD and FMN cofactors. The isoforms share a common reaction mechanism and requirements for reducing equivalents but differ in regulation; the endothelial and neuronal isoforms are controlled by calcium/calmodulin modulation of the electron transfer system, while the inducible isoform binds calmodulin at all physiological Ca2+ concentrations and is always on. The thermodynamics of electron transfer through the flavin domains in all three isoforms are basically similar. The major flavin states are FMN, FMNH., FMNH2, FAD, FADH(.), and FADH(2). The FMN/FMNH. couple is high potential ( similar to 100 mV) in all three isoforms and is unlikely to be catalytically competent; the other three flavin couples form a nearly isopotential group clustered around - 250 mV. Reduction of the flavins by the pyridine nucleotide couple at - 325 mV is thus moderately thermodynamically favorable. The ferri/ferroheme couple in all three isoforms is similar to - 270 mV in the presence of saturating arginine. Ca2+/calmodulin has no effect on the potentials of any of the couples in endothelial nitric-oxide synthase ( eNOS) or neuronal nitric-oxide synthase ( nNOS). The pH dependence of the flavin couples suggests the presence of ionizable groups coupled to the flavin redox/ protonation states.	Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA; Duke Univ, Dept Med, Durham, NC 27705 USA; Vet Affairs Med Ctr, Durham, NC 27705 USA; Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Texas, SW Hlth Ctr, Dept Biochem, San Antonio, TX 78284 USA	Rensselaer Polytechnic Institute; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Waterloo; University of Texas System	Salerno, JC (corresponding author), Rensselaer Polytech Inst, Dept Biol, 110 8th St, Troy, NY 12180 USA.	salerj@rpi.edu	Martásek, Pavel/G-6622-2017; salerno, john c/A-2595-2014	Martásek, Pavel/0000-0001-6165-4444; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; Dutton P L, 1978, Methods Enzymol, V54, P411; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 2001, P NATL ACAD SCI USA, V98, P10392, DOI 10.1073/pnas.181251298; GUNSALUS IC, 1976, BIOCHIMIE, V58, P143, DOI 10.1016/S0300-9084(76)80364-1; HAUSCHILDT S, 1990, BIOCHEM J, V270, P351, DOI 10.1042/bj2700351; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno J. C., 2002, Nitric Oxide, V6, P458; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SLIGAR SG, 1979, BIOCHEM BIOPH RES CO, V90, P925, DOI 10.1016/0006-291X(79)91916-8; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Stuehr D J, 1995, Adv Pharmacol, V34, P207; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	36	51	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18759	18766		10.1074/jbc.M308936200	http://dx.doi.org/10.1074/jbc.M308936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14715665	hybrid			2022-12-27	WOS:000221041500083
J	Dubrovay, Z; Gaspari, Z; Hunyadi-Gulyes, E; Medzihradszky, KF; Perczel, A; Vertessy, BG				Dubrovay, Z; Gaspari, Z; Hunyadi-Gulyes, E; Medzihradszky, KF; Perczel, A; Vertessy, BG			Multidimensional NMR identifies the conformational shift essential for catalytic competence in the 60-kDa Drosophila melanogaster dUTPase trimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; ESCHERICHIA-COLI; C-TERMINUS; KINETIC CHARACTERIZATION; SUBSTRATE-ANALOG; LIGAND-BINDING; ACTIVE-SITE; PYROPHOSPHATASE; TRIPHOSPHATE; PHOSPHORYLASE	The catalytic mechanism of dUTP pyrophosphatase (dUTPase), responsible for the prevention of uracil incorporation into DNA, involves ordering of the flexible C terminus of the enzyme. This conformational shift is investigated by multidimensional NMR on the Drosophila enzyme. Flexible segments of the homotrimer give rise to sharp resonances in the (1)H-(15)N heteronuclear single-quantum coherence (HSQC) spectra, which are clearly distinguishable from the background resonances of the well folded protein globule. Binding of the product dUMP or the analogues dUDP and alpha,beta-imino-dUTP to the enzyme induces a conformational change reflected in the disappearance of eight sharp resonances. This phenomenon is interpreted as nucleotide binding-induced ordering of some residues upon the folded protein globule. Three-dimensional (15)N-edited (1)H-(15)N HSQC total correlation spectroscopy (TOCSY) and (1)H-(15)N HSQC nuclear Overhauser effect spectroscopy measurements allowed clear assignment of these eight specific resonance peaks. The residues identified correspond to the conserved C-terminal sequence motif, indicating that (i) this conformational shift is amenable to NMR studies in solution even in the large trimeric molecule and (ii) formation of the closed enzyme conformer in the case of the Drosophila enzyme does not require the complete triphosphate chain of the substrate. NMR titration of the enzyme with the nucleotide ligands as well as kinetic data indicated significant deviation from the model of independent active sites within the homotrimer. The results suggest allosterism in the eukaryotic dUTPase.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Organ Chem, H-1518 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Mass Spectrometry Facil, H-6701 Szeged, Hungary; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of California System; University of California San Francisco	Vertessy, BG (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Gáspári, Zoltán/D-9594-2011; Vertessy, Beata G/H-6202-2012	Gáspári, Zoltán/0000-0002-8692-740X; Hunyadi-Gulyas, Eva/0000-0003-2089-1499; Vertessy, Beata G./0000-0002-1288-2982				Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; Kovari J, 2004, J BIOL CHEM, V279, P17932, DOI 10.1074/jbc.M313643200; LARSEN M, 1969, SCIENCE, V166, P1510, DOI 10.1126/science.166.3912.1510; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; Nord J, 2000, FEBS LETT, V472, P312, DOI 10.1016/S0014-5793(00)01453-8; Nyman PO, 2001, CURR PROTEIN PEPT SC, V2, P277, DOI 10.2174/1389203013381071; Persson T, 1996, BIOORGAN MED CHEM, V4, P553, DOI 10.1016/0968-0896(96)00044-2; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Prasad GS, 2001, CURR PROTEIN PEPT SC, V2, P301, DOI 10.2174/1389203013381017; Rath VL, 1996, STRUCTURE, V4, P463, DOI 10.1016/S0969-2126(96)00051-2; Shao H, 1997, BBA-PROTEIN STRUCT M, V1339, P181, DOI 10.1016/S0167-4838(96)00229-4; TRIPOS I, 1998, SYBYL VERSION 6 5; Venters RA, 2002, J MOL STRUCT, V602, P275, DOI 10.1016/S0022-2860(01)00690-1; Vertessy BG, 1996, BIOCHEM BIOPH RES CO, V219, P294, DOI 10.1006/bbrc.1996.0226; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vertessy BG, 1998, FEBS LETT, V421, P83, DOI 10.1016/S0014-5793(97)01545-7; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	22	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17945	17950		10.1074/jbc.M313644200	http://dx.doi.org/10.1074/jbc.M313644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14724273	hybrid			2022-12-27	WOS:000220870400128
J	Sau, AK; Li, ZL; Anderson, KS				Sau, AK; Li, ZL; Anderson, KS			Probing the role of metal ions in the catalysis of Helicobacter pylori 3-deoxy-D-manno-octulosonate-8-phosphate synthase using a transient kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-PHOSPHATE DAHP SYNTHETASE; 8-PHOSPHATE SYNTHASE; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE BIOSYNTHESIS; KDO8P SYNTHASE; MECHANISM; AEOLICUS; ACID; PHOSPHOENOLPYRUVATE; STEREOCHEMISTRY	3-Deoxy-D-manno-2-octulosonate-8-phosphate (KDO8P) synthase catalyzes the net condensation of phosphoenolpyruvate and D-arabinose 5-phosphate to form KDO8P and inorganic phosphate (Pi). Two classes of KDO8P synthases have been identified. The Class I KDO8P synthases (e. g. Escherchia coli KDO8P synthase) catalyze the condensation reaction in a metal-independent fashion, whereas the Class II enzymes (e. g. Aquifex aeolicus) require metal ions for catalysis. Helicobacter pylori (H. pylori) KDO8P synthase, a Zn2+- dependent metalloenzyme, has recently been found to be a Class II enzyme and has a high degree of clinical significance since it is an attractive molecular target for the design of novel antibiotic therapy. Although the presence of a divalent metal ion in Class II KDO8P synthases is essential for catalysis, there is a paucity of mechanistic information on the role of the metal ions and functional differences as compared with Class I enzymes. Using H. pylori KDO8P synthase as a prototypical Class II enzyme, a steady-state and transient kinetic approach was undertaken to understand the role of the metal ion in catalysis and define the kinetic reaction pathway. Metal reconstitution experiments examining the reaction kinetics using Zn2+, Cd2+, Cu2+, Co2+, Mn2+, and Ni2+ yielded surprising results in that the Cd2+ enzyme has the greatest activity. Unlike Class-I KDO8P synthases, the Class II metallo-KDO8P synthases containing Zn2+, Cd2+, Cu2+, and Co2+ show cooperativity. This study presents the first detailed kinetic characterization of a metal-dependent Class II KDO8P synthase and offers mechanistic insight for how the divalent metal ions modulate catalysis through effects on chemistry as well as quaternary protein structure.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu			NIGMS NIH HHS [GM61413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON L, 1983, ACS S SERIES, V231; Baasov T, 2000, DRUG DEVELOP RES, V50, P416; Birck MR, 2001, J MOL EVOL, V52, P205, DOI 10.1007/s002390010149; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; BLASER MJ, 1992, CLIN INFECT DIS, V15, P386, DOI 10.1093/clind/15.3.386; Brabetz W, 2000, PLANTA, V212, P136, DOI 10.1007/s004250000459; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; Duewel HS, 2001, J BIOL CHEM, V276, P8393, DOI 10.1074/jbc.M007884200; Duewel HS, 2000, J BIOL CHEM, V275, P22824, DOI 10.1074/jbc.M000133200; EIDT S, 1995, EUR J GASTROEN HEPAT, V7, P318; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; Hunt RH, 1996, SCAND J GASTROENTERO, V31, P3, DOI 10.3109/00365529609094743; INOUYE M, 1979, BACTERIAL OUTER MEMB; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHEN A, 1992, EUR J BIOCHEM, V208, P443, DOI 10.1111/j.1432-1033.1992.tb17206.x; Krosky DJ, 2002, BBA-PROTEIN STRUCT M, V1594, P297, DOI 10.1016/S0167-4838(01)00319-3; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; Li ZL, 2003, J AM CHEM SOC, V125, P9938, DOI 10.1021/ja0354768; Liang PH, 1997, BIOORG MED CHEM LETT, V7, P2463; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; ONDERKA DK, 1969, BIOCHEM BIOPH RES CO, V35, P801, DOI 10.1016/0006-291X(69)90694-9; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; Perez-Canadillas JM, 1998, BIOCHEMISTRY-US, V37, P15865, DOI 10.1021/bi981672t; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; SHULAMI S, 2003, IN PRESS EXTREMOPHIL; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; Stolte, 1998, Oncologist, V3, P124; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; Walsh AG, 1999, FEMS MICROBIOL LETT, V173, P27, DOI 10.1111/j.1574-6968.1999.tb13480.x; Walsh CT, 1996, CHEM BIOL, V3, P83, DOI 10.1016/S1074-5521(96)90282-3	36	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15787	15794		10.1074/jbc.M308989200	http://dx.doi.org/10.1074/jbc.M308989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14701842	hybrid			2022-12-27	WOS:000220747900013
J	Lee, JL; Lin, CT; Chueh, LL; Chang, CJ				Lee, JL; Lin, CT; Chueh, LL; Chang, CJ			Autocrine/paracrine secreted Frizzled-related protein 2 induces cellular resistance to apoptosis - A possible mechanism of mammary tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; EXTRACELLULAR-MATRIX; INHIBIT MOTILITY; FIBRONECTIN; CANCER; CELLS; RECEPTOR; INTEGRIN; OVARIAN; GROWTH	Abnormal regulation of apoptosis and cell proliferation is thought to be involved in tumor formation. The secreted Frizzled-related protein 2 (SFRP2) was detected in primary culture of canine mammary gland tumors but not in normal mammary tissues. Thus, to elucidate the role of SFRP2 in mammary tumorigenesis, we overexpressed SFRP2 in mammary gland tumor and MCF7 cells. The results indicated that SFRP2 is secreted and incorporated into the extracellular matrix (ECM) of the tumor and normal cells. In an attempt to understand the molecular basis underlying the interaction between SFRP2 and ECM, co-immunoprecipitation and cell adhesion assays were carried out. SFRP2 was found to be associated with the fibronectin-integrin protein complex and could promote cell adhesion. DNA fragmentation and caspase 3 activity analyses showed that the susceptibility of the cells to UV-induced apoptosis decreased in the context of SFRP2 overexpression. Upon disruption of the fibronectin-integrin connection, the antiapoptosis activity of SFRP2 was decreased. Moreover, SFRP2 was found to induce tumorous transformation in normal mammary epithelial cells and to inhibit apoptosis in a modified paracrine model. Collectively, our results emphasize the relevance of SFRP2 and ECM in mammary tumorigenesis and provide further insight into the mechanism of SFRP2 action.	Acad Sinica, Inst Biol Chem, Taipei 106, Taiwan; Natl Taiwan Univ, Coll Bioresources & Agr, Dept & Grad Inst Vet Med, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Chang, CJ (corresponding author), Acad Sinica, Inst Biol Chem, 1,Sect 4,Roosevelt Rd, Taipei 106, Taiwan.	chingjin@gate.sinica.edu.tw	Chang, Ching-Jin/G-4511-2019	Lee, Jia-Lin/0000-0002-6984-1313; Chang, Ching-Jin/0000-0001-7129-8092				Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Cosgrove RH, 2002, SEMIN THROMB HEMOST, V28, P79, DOI 10.1055/s-2002-20566; Dale TC, 1996, CANCER RES, V56, P4320; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; HUGUET EL, 1994, CANCER RES, V54, P2615; Jones SE, 2000, INVEST OPHTH VIS SCI, V41, P1297; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kakkar AK, 1999, BMJ-BRIT MED J, V318, P1571, DOI 10.1136/bmj.318.7198.1571; Kim AS, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-05-j0002.2001; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Lee JL, 2003, IN VITRO CELL DEV-AN, V39, P221; LEE JL, 2004, IN PRESS BREAST CANC; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin CT, 1997, NUCLEIC ACIDS RES, V25, P4427, DOI 10.1093/nar/25.21.4427; Lin CT, 2001, BIOCHEM BIOPH RES CO, V282, P394, DOI 10.1006/bbrc.2001.4587; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PRICE JE, 1990, CANCER RES, V50, P717; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; Schleger C, 1997, EXP CELL RES, V236, P418, DOI 10.1006/excr.1997.3744; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Woodward TL, 2001, ENDOCRINOLOGY, V142, P3214, DOI 10.1210/en.142.7.3214; Woodward TL, 2000, ENDOCRINOLOGY, V141, P3578, DOI 10.1210/en.141.10.3578; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200	51	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14602	14609		10.1074/jbc.M309008200	http://dx.doi.org/10.1074/jbc.M309008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14709558	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000220594700018
J	Pranada, AL; Metz, S; Herrmann, A; Heinrich, PC; Muller-Newen, G				Pranada, AL; Metz, S; Herrmann, A; Heinrich, PC; Muller-Newen, G			Real time analysis of STAT3 nucleocytoplasmic shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STUDYING PROTEIN DYNAMICS; LIVING CELLS; TARGETED DISRUPTION; SIGNAL TRANSDUCER; NUCLEAR IMPORT; ACTIVATION; PHOSPHORYLATION; RECEPTOR; COMPLEX; BINDING	The transcription factor STAT3 is most important for the signal transduction of interleukin-6 and related cytokines. Upon stimulation cytoplasmic STAT3 is phosphorylated at tyrosine 705, translocates into the nucleus, and induces target genes. Notably, STAT proteins are also detectable in the nuclei of unstimulated cells. In this report we introduce a new method for the real time analysis of STAT3 nucleocytoplasmic shuttling in living cells which is based on the recently established fluorescence localization after photobleaching (FLAP) approach. STAT3 was C-terminally fused with the cyan (CFP) and yellow (YFP) variants of the green fluorescent protein. In the resulting STAT3-CFP-YFP (STAT3-CY) fusion protein the YFP can be selectively bleached using the 514-nm laser of a confocal microscope. This setting allows studies on the dynamics of STAT3 nucleocytoplasmic transport by monitoring the subcellular distribution of fluorescently labeled and selectively bleached STAT3-CY. By this means we demonstrate that STAT3-CY shuttles continuously between the cytosol and the nucleus in unstimulated cells. This constitutive shuttling does not depend on the phosphorylation of tyrosine 705 because a STAT3(Y705F)-CY mutant shuttles to the same extent as STAT3-CY. Experiments with deletion mutants reveal that the N-terminal moiety of STAT3 is essential for shuttling. Further studies suggest that a decrease in STAT3 nuclear export contributes to the nuclear accumulation of STAT3 in response to cytokine stimulation. The new approach presented in this study is generally applicable to any protein of interest for analyzing nucleocytoplasmic transport mechanisms in real time.	Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Muller-Newen, G (corresponding author), Rhein Westfal TH Aachen Klinikum, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.	mueller-newen@rwth-aachen.de						ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dunn GA, 2002, J MICROSC-OXFORD, V205, P109, DOI 10.1046/j.0022-2720.2001.001007.x; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Herrmann A, 2004, J CELL SCI, V117, P339, DOI 10.1242/jcs.00833; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Ma J, 2003, J BIOL CHEM, V278, P29252, DOI 10.1074/jbc.M304196200; MCBRIDE K, 2003, SCI STKE; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Stancato LF, 1996, J BIOL CHEM, V271, P4134; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zeng R, 2002, J IMMUNOL, V168, P4567, DOI 10.4049/jimmunol.168.9.4567; Zhang T, 2002, J BIOL CHEM, V277, P17556, DOI 10.1074/jbc.M105525200; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	38	118	122	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15114	15123		10.1074/jbc.M312530200	http://dx.doi.org/10.1074/jbc.M312530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14701810	hybrid			2022-12-27	WOS:000220594700077
J	Havaux, M; Dall'Osto, L; Cuine, S; Giuliano, G; Bassi, R				Havaux, M; Dall'Osto, L; Cuine, S; Giuliano, G; Bassi, R			The effect of zeaxanthin as the only xanthophyll on the structure and function of the photosynthetic apparatus in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CHLOROPHYLL A/B PROTEIN; ACID-DEFICIENT MUTANTS; PHOTOSYSTEM-II; ANTENNA COMPLEX; VIOLAXANTHIN CYCLE; BINDING-SITES; BETA-CAROTENE; LHC PROTEINS; IN-VITRO	In green plants, the xanthophyll carotenoid zeaxanthin is synthesized transiently under conditions of excess light energy and participates in photoprotection. In the Arabidopsis lut2 npq2 double mutant, all xanthophylls were replaced constitutively by zeaxanthin, the only xanthophyll whose synthesis was not impaired. The relative proportions of the different chlorophyll antenna proteins were strongly affected with respect to the wild-type strain. The major antenna, LHCII, did not form trimers, and its abundance was strongly reduced as was CP26, albeit to a lesser extent. In contrast, CP29, CP24, LHCI proteins, and the PSI and PSII core complexes did not undergo major changes. PSII-LHCII supercomplexes were not detectable while the PSI-LHCI supercomplex remained unaffected. The effect of zeaxanthin accumulation on the stability of the different Lhc proteins was uneven: the LHCII proteins from lut2 npq2 had a lower melting temperature as compared with the wild-type complex while LHCI showed increased resistance to heat denaturation. Consistent with the loss of LHCII, light-state 1 to state 2 transitions were suppressed, the photochemical efficiency in limiting light was reduced and photosynthesis was saturated at higher light intensities in lut2 npq2 leaves, resulting in a photosynthetic phenotype resembling that of high light-acclimated leaves. Zeaxanthin functioned in vivo as a light-harvesting accessory pigment in lut2 npq2 chlorophyll antennae. As a whole, the in vivo data are consistent with the results obtained by using recombinant Lhc proteins reconstituted in vitro with purified zeaxanthin. While PSII photoinhibition was similar in wild type and lut2 npq2 exposed to high light at low temperature, the double mutant was much more resistant to photooxidative stress and lipid peroxidation than the wild type. The latter observation is consistent with an antioxidant and lipid protective role of zeaxanthin in vivo.	Univ Mediterranee, CEA 1000,CNRS,UMR 163, Lab Ecophysiol Photosynth, CEA Cadarache,DSV,DEVM, F-13108 St Paul Les Durance, France; Univ Verona, Dipartimento Sci Tecnol, I-37134 Verona, Italy; ENEA, Casaccia Res Ctr, I-00100 Rome AD, Italy; Univ Meditarranee, CNRS,UMR 163, CEA Cadarache, DSV,DEVM,Lab Genet & Biophys Plantes, F-13288 Marseille 09, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Verona; Italian National Agency New Technical Energy & Sustainable Economics Development; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Havaux, M (corresponding author), Univ Mediterranee, CEA 1000,CNRS,UMR 163, Lab Ecophysiol Photosynth, CEA Cadarache,DSV,DEVM, F-13108 St Paul Les Durance, France.	michel.havaux@cea.fr	Giuliano, Giovanni/A-2701-2012; Dall'Osto, Luca/A-9384-2010	Giuliano, Giovanni/0000-0002-2486-0510; bassi, roberto/0000-0002-4140-8446; Dall'Osto, Luca/0000-0001-9497-5156				ADAMS WW, 1995, AUST J PLANT PHYSIOL, V22, P75, DOI 10.1071/PP9950075; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; Baroli I, 2003, PLANT CELL, V15, P992, DOI 10.1105/tpc.010405; Baroli I, 1998, PLANTA, V205, P288, DOI 10.1007/s004250050323; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V935, P152, DOI 10.1016/0005-2728(88)90212-5; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; BAZDA V, 1996, BIOCHEMISTRY-US, V35, P8981; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; Demmig-Adams B, 2000, NATURE, V403, P371, DOI 10.1038/35000315; DUCKHAM SC, 1991, PLANT CELL ENVIRON, V14, P601, DOI 10.1111/j.1365-3040.1991.tb01531.x; Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; Garab G, 2002, BIOCHEMISTRY-US, V41, P15121, DOI 10.1021/bi026157g; Gastaldelli M, 2003, J BIOL CHEM, V278, P19190, DOI 10.1074/jbc.M212125200; Gotz T, 2002, PLANT MOL BIOL, V50, P129, DOI 10.1023/A:1016072218801; Gussakovsky EE, 1997, PHOTOSYNTH RES, V51, P119, DOI 10.1023/A:1005775720376; HAGER A, 1994, PLANTA, V192, P581, DOI 10.1007/BF00203597; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2003, TRENDS PLANT SCI, V8, P409, DOI 10.1016/S1360-1385(03)00185-7; Havaux M, 2003, PLANT PHYSIOL, V132, P300, DOI 10.1104/pp.102.017178; Havaux M, 1997, PLANT PHYSIOL, V113, P913, DOI 10.1104/pp.113.3.913; Havaux M, 2001, PLANTA, V213, P953, DOI 10.1007/s004250100572; Havaux M, 2000, PLANT PHYSIOL, V124, P273, DOI 10.1104/pp.124.1.273; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; Kulheim C, 2002, SCIENCE, V297, P91, DOI 10.1126/science.1072359; Lee JW, 2002, APPL BIOCHEM BIOTECH, V98, P37, DOI 10.1385/ABAB:98-100:1-9:37; LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178; Lokstein H, 2002, BBA-BIOENERGETICS, V1553, P309, DOI 10.1016/S0005-2728(02)00184-6; MALKIN S, 1981, PLANT PHYSIOL, V67, P570, DOI 10.1104/pp.67.3.570; MALKIN S, 1994, ANNU REV PLANT PHYS, V45, P493, DOI 10.1146/annurev.pp.45.060194.002425; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Morosinotto T, 2003, PHYSIOL PLANTARUM, V119, P347, DOI 10.1034/j.1399-3054.2003.00213.x; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; MULLERMOULE P, 2003, PLANT PHYSIOL, DOI DOI 10.1104/PP103.025320; MURRAY DL, 1991, PLANT MOL BIOL, V16, P71, DOI 10.1007/BF00017918; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P184, DOI 10.1016/0003-9861(92)90658-J; Pesaresi P, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL IV, P95; PETER GF, 1991, J BIOL CHEM, V266, P16745; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058; ROBINSON HH, 1980, BIOCHIM BIOPHYS ACTA, V590, P97, DOI 10.1016/0005-2728(80)90149-8; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Ruban AV, 2003, NATURE, V421, P648, DOI 10.1038/nature01344; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; TYYSTJARVI E, 1994, BBA-BIOENERGETICS, V1186, P177, DOI 10.1016/0005-2728(94)90177-5; TYYSTJARVI E, 1991, PLANT PHYSIOL, V97, P477, DOI 10.1104/pp.97.2.477; Vavilin DV, 1998, PHOTOCHEM PHOTOBIOL, V68, P191, DOI 10.1111/j.1751-1097.1998.tb02488.x; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; WISE RR, 1995, PHOTOSYNTH RES, V45, P79, DOI 10.1007/BF00032579; Yakushevska AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/bi027109z; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639; Yang DH, 2000, FEBS LETT, V466, P385, DOI 10.1016/S0014-5793(00)01107-8; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827	66	133	140	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13878	13888		10.1074/jbc.M311154200	http://dx.doi.org/10.1074/jbc.M311154200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722117	hybrid			2022-12-27	WOS:000220478500074
J	Kallen, J; Schlaeppi, JM; Bitsch, F; Delhon, I; Fournier, B				Kallen, J; Schlaeppi, JM; Bitsch, F; Delhon, I; Fournier, B			Crystal structure of the human ROR alpha ligand binding domain in complex with cholesterol sulfate at 2.2 angstrom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; NUCLEAR; DISRUPTION; METABOLISM	The retinoic acid-related orphan receptor alpha (RORalpha) is an orphan member of the subfamily 1 of nuclear hormone receptors. Our recent structural and functional studies have led to the hypothesis that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. We have now solved the x-ray crystal structure of the ligand binding domain of RORalpha in complex with cholesterol-3-O-sulfate following a ligand exchange experiment. In contrast to the 3-hydroxyl of cholesterol, the 3-O-sulfate group makes additional direct hydrogen bonds with three residues of the RORalpha ligand binding domain, namely NH-Gln(289), NH-Tyr(290), and NH1-Arg(370). When compared with the complex with cholesterol, seven well ordered water molecules have been displaced, and the ligand is slightly shifted toward the hydrophilic part of the ligand binding pocket, which is ideally suited for interactions with a sulfate group. These additional ligand-protein interactions result in an increased affinity of cholesterol sulfate when compared with cholesterol, as shown by mass spectrometry analysis done under native conditions and differential scanning calorimetry. Moreover, mutational studies show that the higher binding affinity of cholesterol sulfate translates into an increased transcriptional activity of RORalpha. Our findings suggest that cholesterol sulfate could play a crucial role in the regulation of RORalpha in vivo.	Novartis Pharma AG, Prot Struct Unit, Discovery Technol, CH-4002 Basel, Switzerland; Novartis Pharma AG, Biomol Prod Unit, Discovery Technol, CH-4002 Basel, Switzerland; Novartis Pharma AG, Bone Metab Unit, Arthrit & Bone Metab, CH-4002 Basel, Switzerland	Novartis; Novartis; Novartis	Kallen, J (corresponding author), Novartis Pharma AG, Prot Struct Unit, Discovery Technol, CH-4002 Basel, Switzerland.	joerg.kallen@pharma.novartis.com; brigitte.fournier@pharma.novartis.com						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bitsch F, 2003, ANAL BIOCHEM, V323, P139, DOI 10.1016/j.ab.2003.08.029; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; EPSTEIN EH, 1981, SCIENCE, V214, P659, DOI 10.1126/science.6945674; Falany JL, 2002, BREAST CANCER RES TR, V74, P167, DOI 10.1023/A:1016147004188; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Hanley K, 2001, J LIPID RES, V42, P390; Jarvis CI, 2002, MOL CELL ENDOCRINOL, V186, P1, DOI 10.1016/S0303-7207(01)00668-2; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kashiwagi M, 2002, J BIOCHEM, V132, P853, DOI 10.1093/oxfordjournals.jbchem.a003297; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN YN, 1980, STEROIDS, V36, P697, DOI 10.1016/0039-128X(80)90052-5; MASON JI, 1982, ENDOCRINOLOGY, V111, P208, DOI 10.1210/endo-111-1-208; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAGAWA M, 1976, J BIOCHEM-TOKYO, V80, P729, DOI 10.1093/oxfordjournals.jbchem.a131333; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Stehlin-Gaon C, 2003, NAT STRUCT BIOL, V10, P820, DOI 10.1038/nsb979; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Strott CA, 2003, J LIPID RES, V44, P1268, DOI 10.1194/jlr.R300005-JLR200; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; Tsutsui K, 2003, J STEROID BIOCHEM, V85, P311, DOI 10.1016/S0960-0760(03)00229-2; WILLIAMS ML, 1981, J CLIN INVEST, V68, P1404, DOI 10.1172/JCI110391; WILLIAMS ML, 1985, BIOCHIM BIOPHYS ACTA, V845, P349, DOI 10.1016/0167-4889(85)90198-3	31	178	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14033	14038		10.1074/jbc.M400302200	http://dx.doi.org/10.1074/jbc.M400302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722075	hybrid, Green Published			2022-12-27	WOS:000220478500092
J	Rameau, GA; Chiu, LY; Ziff, EB				Rameau, GA; Chiu, LY; Ziff, EB			Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; AUTOINHIBITORY CONTROL ELEMENT; ISCHEMIC-STROKE; TERNARY COMPLEX; ACID RECEPTOR; NMDA; GLUTAMATE; CALCINEURIN; INDUCTION	At glutamatergic synapses, the scaffolding protein PSD95 links the neuronal isoform of nitric-oxide synthase (nNOS) to the N-methyl-D-aspartate (NMDA) receptor. Phosphorylation of nNOS at serine 847 (Ser(847)) by the calcium-calmodulin protein kinase II (CaMKII) inhibits nNOS activity, possibly by blocking the binding of Ca2+-CaM. Here we show that the NMDA mediates a novel bidirectional regulation of Ser(847) phosphorylation. nNOS phosphorylated at Ser(847) colocalizes with the NMDA receptor at spines of cultured hippocampal neurons. Treatment of neurons with 5 muM glutamate stimulated CaMKII phosphorylation of nNOS at Ser(847), whereas excitotoxic concentrations of glutamate, 100 and 500 muM, induced Ser(847)-PO4 dephosphorylation by protein phosphatase 1. Strong NMDA receptor stimulation was likely to activate nNOS under these conditions because protein nitration to form nitrotyrosine, a marker of nNOS activity, correlated in individual neurons with Ser(847)-PO4 dephosphorylation. Of particular note, stimulation with low glutamate that increased phosphorylation of nNOS at Ser(847) could be reversed by subsequent high glutamate treatment which induced dephosphorylation. The reversibility of NMDA receptor-induced phosphorylation at Ser(847) by different doses of glutamate suggests two mechanisms with opposite effects: 1) a time-dependent negative feedback induced by physiological concentrations of glutamate that limits nNOS activation and precludes the overproduction of NO; and 2) a pathological stimulation by high concentrations of glutamate that leads to unregulated nNOS activation and production of toxic levels of NO. These mechanisms may share pathways, respectively, with NMDA receptor-induced forms of synaptic plasticity and excitotoxicity.	NYU, Sch Med, Howard Hughes Med Inst, Dept Biochem, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University	Ziff, EB (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.	edward.ziff@med.nyu.edu		Ziff, Edward/0000-0001-7389-8649	NIA NIH HHS [R01 AG13620] Funding Source: Medline; NIEHS NIH HHS [ES00260] Funding Source: Medline; NINDS NIH HHS [NS 07457-04] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013620] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Aronowski J, 2000, J CEREBR BLOOD F MET, V20, P343, DOI 10.1097/00004647-200002000-00016; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Ayata C, 1997, J NEUROSCI, V17, P6908; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Brown GP, 2000, J NEUROSCI, V20, P7880; Burette A, 2002, J NEUROSCI, V22, P8961; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; Cohen PTW, 2002, J CELL SCI, V115, P241; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Dawson T M, 1993, NIDA Res Monogr, V136, P258; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Dawson VL, 1996, J NEUROSCI, V16, P2479; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Franks KM, 2002, BIOESSAYS, V24, P1130, DOI 10.1002/bies.10193; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Hansel C, 1996, J PHYSIOLOGY-PARIS, V90, P317, DOI 10.1016/S0928-4257(97)87906-5; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hasegawa Y, 2003, J CEREBR BLOOD F MET, V23, P1040, DOI 10.1097/01.WCB.0000085160.71791.3F; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Kang-Park MH, 2003, J NEUROPHYSIOL, V89, P684, DOI 10.1152/jn.01041.2001; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; Komeima K, 2000, J BIOL CHEM, V275, P28139; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lane P, 2000, ACTA PHYSIOL SCAND, V168, P53; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; Nishi A, 2002, J NEUROCHEM, V81, P832, DOI 10.1046/j.1471-4159.2002.00876.x; Rameau GA, 2003, NEUROBIOL AGING, V24, P1123, DOI 10.1016/j.neurobiolaging.2003.07.002; Rameau GA, 2000, NEUROPHARMACOLOGY, V39, P2255, DOI 10.1016/S0028-3908(00)00066-6; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Springer JE, 2000, J NEUROSCI, V20, P7246; Zanelli SA, 2002, NEUROSCIENCE, V112, P869, DOI 10.1016/S0306-4522(02)00141-0; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	71	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14307	14314		10.1074/jbc.M311103200	http://dx.doi.org/10.1074/jbc.M311103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722119	hybrid			2022-12-27	WOS:000220478500125
J	Rosini, P; De Chiara, G; Bonini, P; Lucibello, M; Marcocci, ME; Garaci, E; Cozzolino, F; Torcia, M				Rosini, P; De Chiara, G; Bonini, P; Lucibello, M; Marcocci, ME; Garaci, E; Cozzolino, F; Torcia, M			Nerve growth factor-dependent survival of CESS B cell line is mediated by increased expression and decreased degradation of MAPK phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BCL-2 PHOSPHORYLATION; P38 MAPK; TYROSINE-PHOSPHATASE; INDUCED APOPTOSIS; CONDITIONAL EXPRESSION; SYMPATHETIC NEURONS; MKP-1; INHIBITION; STRESS	The sIgG(+) lymphoblastoid B cell line CESS spontaneously produces a high amount of nerve growth factor (NGF) and expresses both high affinity (p140(Trk-A)) and low affinity (p75(NTR)) NGF receptors. Autocrine production of NGF maintains the survival of CESS cells through the continuous deactivation of p38 MAPK, an enzyme able to induce Bcl-2 phosphorylation and subsequent cytochrome c release and caspase activation. In this paper, we show that NGF induces transcriptional activation and synthesis of MAPK phosphatase 1 (MKP-1), a dual specificity phosphatase that dephosphorylates p38 MAPK, thus preventing Bcl-2 phosphorylation. Furthermore, NGF increases MKP-1 protein stability by preventing its degradation through the proteasome pathway. Following NGF stimulation, MKP-1 protein mainly localizes on mitochondria, suggesting an interaction with p38 MAPK in this compartment. Incubation of CESS cells with MKP-1-specific antisense oligonucleotides induces cell death, which was not prevented by exogenous NGF. By contrast, overexpression of native MKP-1, but not of its catalytically impaired form, inhibits apoptosis induced by NGF neutralization in CESS cells. Thus, the molecular mechanisms underlying the survival function of NGF in CESS B cell line predominantly consist in maintaining elevated levels of MKP-1 protein, which controls p38 MAPK activation.	Univ Florence, Dept Clin Physiopathol, I-50139 Florence, Italy; Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy	University of Florence; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Torcia, M (corresponding author), Univ Florence, Dept Clin Physiopathol, Viale Pieraccini 6, I-50139 Florence, Italy.	g.torcia@dfc.unifi.it	Elena, Marcocci Maria/I-9550-2014; Torcia, Maria Gabriella G/K-1840-2018; De Chiara, Giovanna/AAJ-7843-2021; lucibello, maria/AAI-1417-2020; GARACI, ENRICO/AAB-3349-2021	Elena, Marcocci Maria/0000-0003-4751-4263; Torcia, Maria Gabriella G/0000-0003-4740-4646; De Chiara, Giovanna/0000-0002-2219-6097; Cozzolino, Federico/0000-0002-2800-640X				ALESSI DR, 1993, ONCOGENE, V8, P2015; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; FRANKLIN RA, 1995, J IMMUNOL, V154, P4965; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacob A, 2002, AM J PHYSIOL-CELL PH, V283, pC704, DOI 10.1152/ajpcell.00110.2002; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Muda M, 1996, J BIOL CHEM, V271, P4319; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; Peinado-Ramon P, 1998, MOL BRAIN RES, V56, P256, DOI 10.1016/S0169-328X(98)00047-3; Pincelli C, 2000, J DERMATOL SCI, V22, P71, DOI 10.1016/S0923-1811(99)00065-1; Ridderstad A, 1998, J IMMUNOL, V160, P4688; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; WHITMARSH AJ, 1999, SCI STKE; Wiltshire C, 2002, BIOCHEM J, V367, P577, DOI 10.1042/BJ20020553; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	55	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14016	14023		10.1074/jbc.M305356200	http://dx.doi.org/10.1074/jbc.M305356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724291	hybrid, Green Published			2022-12-27	WOS:000220478500090
J	Dale, LB; Seachrist, JL; Babwah, AV; Ferguson, SSG				Dale, LB; Seachrist, JL; Babwah, AV; Ferguson, SSG			Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7, and Rab11 GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; MEDIATED ENDOCYTOSIS; GTP-BINDING; SUBSTANCE-P; TRAFFICKING; INTERNALIZATION; MECHANISMS	Previous studies have demonstrated that the interaction of the angiotensin II type 1A receptor (AT(1A)R) carboxylterminal tail with Rab5a may modulate Rab5a activity, leading to the homotypic fusion of endocytic vesicles. Therefore, we have investigated whether AT(1A)R/Rab5a interactions mediate the retention of AT(1A)R.beta-arrestin complexes in early endosomes and whether the overexpression of Rab7 and Rab11 GTPases influences AT(1A)R lysosomal degradation and plasma membrane recycling. We found that internalized AT(1A)R was retained in Rab5a-positive early endosomes and was neither targeted to lysosomes nor recycled back to the cell surface, whereas a mutant defective in Rab5a binding, AT(1A)R-(1 - 349), was targeted to lysosomes for degradation. However, the loss of Rab5a binding to the AT(1A)R carboxyl-terminal tail did not promote AT(1A)R recycling. Rather, it was the stable binding of beta-arrestin to the AT(1A)R that prevented, at least in part, AT1AR recycling. The overexpression of wild-type Rab7 and Rab7-Q67L resulted in both increased AT(1A)R degradation and AT(1A)R targeting to lysosomes. The Rab7 expression-dependent transition of "putative" AT(1A)R.beta-arrestin complexes to late endosomes was blocked by the expression of dominant-negative Rab5a-S34N. Rab11 overexpression established AT(1A)R recycling and promoted the redistribution of AT(1A)R.beta-arrestin complexes from early to recycling endosomes. Taken together, our data suggest that Rab5, Rab7, and Rab11 work in concert with one another to regulate the intracellular trafficking patterns of the AT(1A)R.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca						Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kreuzer OJ, 2001, J NEUROENDOCRINOL, V13, P279, DOI 10.1046/j.1365-2826.2001.00630.x; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Moore RH, 1999, J CELL SCI, V112, P329; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Paasche JD, 2001, J BIOL CHEM, V276, P34041, DOI 10.1074/jbc.M103243200; Rodman JS, 2000, J CELL SCI, V113, P183; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Touyz RM, 2000, PHARMACOL REV, V52, P639; Trischler M, 1999, J CELL SCI, V112, P4773; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	40	98	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13110	13118		10.1074/jbc.M313333200	http://dx.doi.org/10.1074/jbc.M313333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711821	hybrid			2022-12-27	WOS:000220334900132
J	Lee, YL; Lee, KF; Xu, JS; He, QY; Chiu, JF; Lee, WM; Luk, JM; Yeung, WSB				Lee, YL; Lee, KF; Xu, JS; He, QY; Chiu, JF; Lee, WM; Luk, JM; Yeung, WSB			The embryotrophic activity of oviductal cell-derived complement C3b and iC3b, a novel function of complement protein in reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; DECAY-ACCELERATING FACTOR; HUMAN FALLOPIAN-TUBE; MOUSE EMBRYO; MENSTRUAL-CYCLE; ESTROUS-CYCLE; COMPONENT C3; IN-VITRO; EXPRESSION; ENDOMETRIUM	The oviduct-derived embryotrophic factor, ETF-3, enhances the development of trophectoderm and the hatching process of treated embryos. Monoclonal anti-ETF-3 antibody that abolishes the embryotrophic activity of ETF-3 recognized a 115-kDa protein from the conditioned medium of immortalized human oviductal cells. Mass spectrometry analysis showed that the protein was complement C3. Western blot analysis using an antibody against C3 confirmed the cross-reactivities between anti-C3 antibody with ETF-3 and anti-ETF-3 antibody with C3 and its derivatives, C3b and iC3b. Both derivatives, but not C3, were embryotrophic. iC3b was most efficient in enhancing the development of blastocysts with larger size and higher hatching rate, consistent with the previous reported embryotrophic activity of ETF-3. Embryos treated with iC3b contained iC3b immunoreactivity. The oviductal epithelium produced C3 as evidenced by the presence of C3 immunoreactivity and mRNA in the human oviduct and cultured oviductal cells. Cyclical changes in the expression of C3 immunoreactivity and mRNA were also found in the mouse oviduct with the highest expression at the estrus stage. Molecules involving in the conversion of C3b to iC3b and binding of iC3b were present in the human oviduct (factor I) and mouse preimplantation embryo (Crry and CR3), respectively. In conclusion, the present data showed that the oviduct produced C3/C3b, which was converted to iC3b to stimulate embryo development.	Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Yeung, WSB (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	wsbyeung@hkucc.hku.hk	Lee, Will M/D-2357-2009; Luk, John/A-4085-2008; He, Qing-Yu/H-7078-2014; Lee, Yin Lau/C-4639-2009; Lee, Calvin Kai Fai/C-4328-2009	Luk, John/0000-0002-6323-7940; He, Qing-Yu/0000-0003-0503-9492; Lee, Yin Lau/0000-0003-0559-4381; Lee, Calvin Kai Fai/0000-0001-5957-439X				ANDERSON DJ, 1993, P NATL ACAD SCI USA, V90, P10051, DOI 10.1073/pnas.90.21.10051; Bloor DJ, 2002, MOL HUM REPROD, V8, P237, DOI 10.1093/molehr/8.3.237; BONGSO A, 1989, HUM REPROD, V4, P706, DOI 10.1093/oxfordjournals.humrep.a136971; Buhi WC, 2003, THERIOGENOLOGY, V60, P225, DOI 10.1016/S0093-691X(03)00027-X; BUHI WC, 1992, J EXP ZOOL, V262, P426, DOI 10.1002/jez.1402620409; Buhi WC, 2000, CELLS TISSUES ORGANS, V166, P165, DOI 10.1159/000016731; Caucheteux SM, 2003, IMMUNITY, V18, P169, DOI 10.1016/S1074-7613(03)00028-1; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; HASTY LA, 1994, AM J OBSTET GYNECOL, V170, P168; He QY, 2003, J CELL BIOCHEM, V89, P868, DOI 10.1002/jcb.10576; He QY, 2003, PROTEOMICS, V3, P666, DOI 10.1002/pmic.200300394; Hogan B., 1994, MANIPULATING MOUSE E, P19; JENSEN TS, 1995, AM J REPROD IMMUNOL, V34, P1; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Lee YL, 2003, BIOL REPROD, V68, P375, DOI 10.1095/biolreprod.102.007336; Lee YL, 2001, MOL REPROD DEV, V59, P400, DOI 10.1002/mrd.1046; Li SH, 2002, BIOL REPROD, V66, P322, DOI 10.1095/biolreprod66.2.322; LIU LPS, 1995, HUM REPROD, V10, P2781, DOI 10.1093/oxfordjournals.humrep.a135791; Liu LPS, 1998, HUM REPROD, V13, P1613, DOI 10.1093/humrep/13.6.1613; Llanos RJ, 2000, COMP BIOCHEM PHYS A, V127, P29, DOI 10.1016/S1095-6433(00)00228-2; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; LUK JMC, 1990, J IMMUNOL METHODS, V129, P243, DOI 10.1016/0022-1759(90)90445-2; Molina H, 2002, CELL MOL LIFE SCI, V59, P220, DOI 10.1007/s00018-002-8418-6; MORLEY BJ, 2000, COMPLEMENT FACTSBOOK, P88; PUY LA, 1993, J REPROD FERTIL, V99, P385, DOI 10.1530/jrf.0.0990385; RIOTSONIS K, 1998, J IMMUNOL, V161, P6819; SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397; Schlaf G, 1999, IMMUNOLOGY, V98, P464, DOI 10.1046/j.1365-2567.1999.00886.x; SERVIS C, 1989, J IMMUNOL, V142, P2207; SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sjoblom C, 1999, HUM REPROD, V14, P3069, DOI 10.1093/humrep/14.12.3069; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; Tao XJ, 1997, FERTIL STERIL, V68, P460, DOI 10.1016/S0015-0282(97)00254-9; TAUBER PF, 1985, AM J OBSTET GYNECOL, V151, P1115, DOI 10.1016/0002-9378(85)90394-1; Taylor CT, 1996, MOL HUM REPROD, V2, P52, DOI 10.1093/molehr/2.1.52; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Xu JS, 2001, BIOL REPROD, V65, P1481, DOI 10.1095/biolreprod65.5.1481; Yeung W.S.B., 2002, REPROD MED REV, V10, P21, DOI [10.1017/S0962279902000121, DOI 10.1017/S0962279902000121]; YEUNG WSB, 1992, HUM REPROD, V7, P1144, DOI 10.1093/oxfordjournals.humrep.a137810; ZHAO Y, 1994, J CLIN ENDOCR METAB, V79, P662, DOI 10.1210/jc.79.2.662	44	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12763	12768		10.1074/jbc.M311160200	http://dx.doi.org/10.1074/jbc.M311160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699127	hybrid, Green Submitted			2022-12-27	WOS:000220334900090
J	Abad, MFC; Di Benedetto, G; Magalhaes, PJ; Filippin, L; Pozzan, T				Abad, MFC; Di Benedetto, G; Magalhaes, PJ; Filippin, L; Pozzan, T			Mitochondrial pH monitored by a new engineered green fluorescent protein mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; INTACT-CELLS; CA2+; CALCIUM; VARIANTS; HOMEOSTASIS; APOPTOSIS; SECRETION; TRANSPORT; INDICATOR	We here describe a new molecularly engineered green fluorescent protein chimera that shows a high sensitivity to pH in the alkaline range. This probe was named mtAlpHi, for mitochondrial alkaline pH indicator, and possesses several key properties that render it optimal for studying the dynamics of mitochondrial matrix pH, e. g. it has an apparent pK(a) (pK(a)') around 8.5, it shows reversible and large changes in fluorescence in response to changes in pH (both in vitro and in intact cells), and it is selectively targeted to the mitochondrial matrix. Using mtAlpHi we could monitor pH changes that occur in the mitochondrial matrix in a variety of situations, e. g. treatment with uncouplers or Ca2+ ionophores, addition of drugs that interfere with ATP synthesis or electron flow in the respiratory chain, weak bases or acids, and receptor activation. We observed heterogeneous pH increases in the mitochondrial matrix during Ca2+ accumulation by this organelle. Finally, we demonstrate that Ca2+ mobilization from internal stores induced by ionomycin and A23187 cause a dramatic acidification of the mitochondrial matrix.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; CNR, Inst Neurosci, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); Veneto Institute Molecular Medicine	Pozzan, T (corresponding author), Univ Padua, Dept Biomed Sci, Viale G Colombo 3, I-35121 Padua, Italy.	tullio.pozzan@unipd.it	Di Benedetto, Giulietta/L-9842-2019	Di Benedetto, Giulietta/0000-0002-1489-3896; Cano-Abad, Maria F./0000-0002-2602-6626; Filippin, Luisa/0000-0001-7690-9147	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Burgo A, 2003, J PHYSIOL-LONDON, V549, P537, DOI 10.1113/jphysiol.2003.041871; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hanson GT, 2002, BIOCHEMISTRY-US, V41, P15477, DOI 10.1021/bi026609p; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McAnaney TB, 2002, BIOCHEMISTRY-US, V41, P15489, DOI 10.1021/bi026610o; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; PASTI L, 1995, J BIOL CHEM, V270, P15203, DOI 10.1074/jbc.270.25.15203; Pozzan T, 2003, EUR J BIOCHEM, V270, P2343, DOI 10.1046/j.1432-1033.2003.03615.x; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; Pozzan T, 2000, EUR J BIOCHEM, V267, P5269, DOI 10.1046/j.1432-1327.2000.01567.x; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rudolf R, 2003, NAT REV MOL CELL BIO, V4, P579, DOI 10.1038/nrm1153; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; Takahashi A, 2001, BIOTECHNIQUES, V30, P804, DOI 10.2144/01304rv01; THOMAS PJ, 1991, ARCH BIOCHEM BIOPHYS, V288, P250, DOI 10.1016/0003-9861(91)90192-L; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Weinlich M, 1998, J EXP BIOL, V201, P57; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	32	196	200	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11521	11529		10.1074/jbc.M306766200	http://dx.doi.org/10.1074/jbc.M306766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701849	hybrid			2022-12-27	WOS:000220157600084
J	Jana, NR; Dikshit, P; Goswami, A; Nukina, N				Jana, NR; Dikshit, P; Goswami, A; Nukina, N			Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-MYELOMA CELLS; CYTOCHROME-C RELEASE; AK-5 TUMOR-CELLS; FACTOR-KAPPA-B; COLON CARCINOGENESIS; MEDIATED APOPTOSIS; CASPASE ACTIVATION; SIGNALING PATHWAY; OXIDATIVE STRESS; DOWN-REGULATION	Curcumin is a natural polyphenolic compound having an antiproliferative property, which recent evidence suggests is due to its ability to induce apoptosis. However, the molecular mechanisms through which curcumin induces apoptosis are not fully understood. Here, we report that the curcumin-induced apoptosis is mediated through the impairment of the ubiquitin-proteasome system. Exposure of curcumin to the mouse neuro 2a cells causes a dose-dependent decrease in proteasome activity and an increase in ubiquitinated proteins. Curcumin exposure also decreases the turnover of the destabilized enhanced green fluorescence protein, a model substrate for proteasome and cellular p53 protein. Like other proteasome inhibitors, curcumin targets proliferative cells more efficiently than differentiated cells and induces apoptosis via mitochondrial pathways. Addition of curcumin to neuro 2a cells induces a rapid decrease in mitochondrial membrane potential and the release of cytochrome c into cytosol, followed by activation of caspase-9 and caspase-3.	Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India; RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); RIKEN	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India.	nihar@nbrc.ac.in	Nukina, Nobuyuki/GPP-6265-2022	Jana, Nihar/0000-0002-6549-4211				Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Chaudhury LR, 2003, J CELL BIOCHEM, V89, P1, DOI 10.1002/jcb.10495; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Chuang SE, 2000, CARCINOGENESIS, V21, P331, DOI 10.1093/carcin/21.2.331; DIDIER M, 2001, FEBS LETT, V495, P131; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Huang MT, 1997, CARCINOGENESIS, V18, P83, DOI 10.1093/carcin/18.1.83; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Kato K, 1998, CELL STRESS CHAPERON, V3, P152, DOI 10.1379/1466-1268(1998)003<0152:SOTSIE>2.3.CO;2; Khar A, 1999, FEBS LETT, V445, P165, DOI 10.1016/S0014-5793(99)00114-3; KIEFER J, 1995, J IMMUNOL, V145, P1227; Kim JM, 1998, CARCINOGENESIS, V19, P81, DOI 10.1093/carcin/19.1.81; Li N, 2002, CARCINOGENESIS, V23, P1307, DOI 10.1093/carcin/23.8.1307; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Mullally JE, 2002, MOL PHARMACOL, V62, P351, DOI 10.1124/mol.62.2.351; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; REDDY ACP, 1994, MOL CELL BIOCHEM, V137, P1, DOI 10.1007/BF00926033; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082	43	191	195	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11680	11685		10.1074/jbc.M310369200	http://dx.doi.org/10.1074/jbc.M310369200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701837	hybrid			2022-12-27	WOS:000220157600103
J	Prentice, E; Jerome, WG; Yoshimori, T; Mizushima, N; Denison, MR				Prentice, E; Jerome, WG; Yoshimori, T; Mizushima, N; Denison, MR			Coronavirus replication complex formation utilizes components of cellular autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATITIS-VIRUS; ACUTE RESPIRATORY SYNDROME; 3C-LIKE PROTEINASE ACTIVITY; DOUBLE-MEMBRANE VESICLES; EMBRYONIC STEM-CELLS; MURINE CORONAVIRUS; ENDOPLASMIC-RETICULUM; POLIOVIRUS INFECTION; VIRAL-RNA; IN-VITRO	The coronavirus mouse hepatitis virus (MHV) performs RNA replication on double membrane vesicles (DMVs) in the cytoplasm of the host cell. However, the mechanism by which these DMVs form has not been determined. Using genetic, biochemical, and cell imaging approaches, the role of autophagy in DMV formation and MHV replication was investigated. The results demonstrated that replication complexes co-localize with the autophagy proteins, microtubule-associated protein light-chain 3 and Apg12. MHV infection induces autophagy by a mechanism that is resistant to 3-methyladenine inhibition. MHV replication is impaired in autophagy knockout, APG5-/-, embryonic stem cell lines, but wild-type levels of MHV replication are restored by expression of Apg5 in the APG5-/- cells. In MHV-infected APG5-/- cells, DMVs were not detected; rather, the rough endoplasmic reticulum was dramatically swollen. The results of this study suggest that autophagy is required for formation of double membrane-bound MHV replication complexes and that DMV formation significantly enhances the efficiency of replication. Furthermore, the rough endoplasmic reticulum is implicated as the possible source of membranes for replication complexes.	Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37221 USA; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Unit Proc & Combines Circuit, Kawaguchi 3320012, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol Program, Kawaguchi 3320012, Japan	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Denison, MR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, D6217 MCN, Nashville, TN 37232 USA.	mark.denison@vanderbilt.edu	Denison, Mark R/O-7258-2018; Mizushima, Noboru/C-3635-2009	Denison, Mark R/0000-0003-2655-0900; Mizushima, Noboru/0000-0002-6258-6444	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [5 T32HL07751] Funding Source: Medline; NIAID NIH HHS [AI50083] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226; Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000; Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932; Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999; Denison MR, 2001, ADV EXP MED BIOL, V494, P655; DONG SH, 1994, VIROLOGY, V204, P541, DOI 10.1006/viro.1994.1567; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581; HIRANO N, 1984, JPN J VET SCI, V46, P757; HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Kyuwa S, 1997, EXP ANIM TOKYO, V46, P311, DOI 10.1538/expanim.46.311; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998; Lu XT, 1996, VIROLOGY, V222, P375, DOI 10.1006/viro.1996.0434; Lu YQ, 1997, VIROLOGY, V230, P335, DOI 10.1006/viro.1997.8479; LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Okumura A, 1996, J VIROL, V70, P4146, DOI 10.1128/JVI.70.6.4146-4149.1996; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999; Sims AC, 2000, J VIROL, V74, P5647, DOI 10.1128/JVI.74.12.5647-5654.2000; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299	34	334	359	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10136	10141		10.1074/jbc.M306124200	http://dx.doi.org/10.1074/jbc.M306124200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699140	Green Published, hybrid			2022-12-27	WOS:000220050400059
J	Roll-Mecak, A; Alone, P; Cao, CN; Dever, TE; Burley, SK				Roll-Mecak, A; Alone, P; Cao, CN; Dever, TE; Burley, SK			X-ray structure of translation initiation factor eIF2 gamma - Implications for tRNA and eIF2 alpha binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EF-TU; ANOMALOUS DIFFRACTION; BETA-SUBUNIT; GCN4; COMPLEX; INSIGHTS; REVEALS; GAMMA; YEAST	The x-ray structure of the gamma-subunit of the heterotrimeric translation initiation factor eIF2 has been determined to 2.4-Angstrom resolution. eIF2 is a GTPase that delivers the initiator Met-tRNA to the P site on the small ribosomal subunit during a rate-limiting initiation step in translation. The structure of eIF2gamma closely resembles that of EF1A . GTP, consisting of an N-terminal G domain followed by two beta-barrels arranged in a closed configuration with domain II packed against the G domain in the vicinity of the Switch regions. The G domain of eIF2gamma has an unusual zinc ribbon motif, not previously found in other GTPases. Structure-based site-directed mutagenesis was used to identify two adjacent features on the surface of eIF2gamma that bind the alpha-subunit and Met-tRNA(i)(Met), respectively. These structural, biochemical, and genetic results provide new insights into eIF2 ternary complex assembly.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Burley, SK (corresponding author), Struct GenomiX Inc, 10505 Roselle St, San Diego, CA 92121 USA.	stephen_burley@stromix.com	Dever, Thomas/GSE-0966-2022	Roll-Mecak, Antonina/0000-0003-2621-7307; Burley, Stephen K./0000-0002-2487-9713; Dever, Thomas/0000-0001-7120-9678	NIGMS NIH HHS [GM61262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061262] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, J MOL BIOL, V297, P421, DOI 10.1006/jmbi.2000.3564; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Erickson FL, 1997, MOL GEN GENET, V253, P711; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Erickson FL, 2001, GENETICS, V158, P123; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HARASHIMA S, 1986, MOL CELL BIOL, V6, P3990, DOI 10.1128/MCB.6.11.3990; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P3726, DOI 10.1073/pnas.95.7.3726; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurino JP, 1999, MOL CELL BIOL, V19, P173; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice LM, 2000, ACTA CRYSTALLOGR D, V56, P1413, DOI 10.1107/S0907444900010039; Roll-Mecak A, 2001, TRENDS BIOCHEM SCI, V26, P705, DOI 10.1016/S0968-0004(01)02024-2; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Schmitt E, 2002, EMBO J, V21, P1821, DOI 10.1093/emboj/21.7.1821; Sherman F., 1974, METHODS YEAST GENETI; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	35	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10634	10642		10.1074/jbc.M310418200	http://dx.doi.org/10.1074/jbc.M310418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688270	hybrid			2022-12-27	WOS:000220050400117
J	Soskine, M; Adam, Y; Schuldiner, S				Soskine, M; Adam, Y; Schuldiner, S			Direct evidence for substrate-induced proton release in detergent-solubilized EmrE, a multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BINDING-SITE; ESCHERICHIA-COLI; ANTIPORTER; OLIGOMER; REVEALS; H+	A novel approach to study coupling of substrate and ion fluxes is presented. EmrE is an H+-coupled multidrug transporter from Escherichia coli. Detergent-solubilized EmrE binds substrate with high affinity in a pH-dependent mode. Here we show, for the first time in an ion-coupled transporter, substrate-induced release of protons in a detergent-solubilized preparation. The direct measurements allow for an important quantitation of the phenomenon. Thus, stoichiometry of the release in the wild type and a mutant with a single carboxyl at position 14 is very similar and about 0.8 protons/monomer. The findings demonstrate that the only residue involved in proton release is a highly conserved membrane-embedded glutamate (Glu-14) and that all the Glu-14 residues in the EmrE functional oligomer participate in proton release. Furthermore, from the pH dependence of the release we determined the pK of Glu-14 as 8.5 and for an aspartate replacement at the same position as 6.7. The high pK of the carboxyl at position 14 is essential for coupling of fluxes of protons and substrates.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Adam, Yoav/AAU-4570-2020; Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237; Soskine, Misha/0000-0002-2198-9466	NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; HUMPHREYS CJ, 1991, BIOCHEM SOC T, V19, P95, DOI 10.1042/bst0190095; Koteiche HA, 2003, BIOCHEMISTRY-US, V42, P6099, DOI 10.1021/bi0342867; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	21	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9951	9955		10.1074/jbc.M312853200	http://dx.doi.org/10.1074/jbc.M312853200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701800	hybrid			2022-12-27	WOS:000220050400037
J	Tohyama, O; Imura, A; Iwano, A; Freund, JN; Henrissat, B; Fujimori, T; Nabeshima, Y				Tohyama, O; Imura, A; Iwano, A; Freund, JN; Henrissat, B; Fujimori, T; Nabeshima, Y			Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; GLYCOSYL HYDROLASES; HUMAN LIVER; LACTOSE-INTOLERANCE; GLUCOSIDASE; GENE; EXPRESSION; MECHANISMS; PROTEIN; SIMILARITIES	klotho mutant mice provide a unique model to analyze mechanisms of aging because their phenotypes resemble those of human aging-associated disorders. The klotho gene encodes Klotho, a type I membrane protein that shares sequence similarity with members of the glycosidase family 1. Because Klotho lacks the glutamic acid residues that have been shown to be involved in the catalytic activity of this family of enzymes, the function of this protein was unknown. Here, we have studied the biochemical characteristics of recombinant Klotho. The purified chimeric Klotho-human IgG1 Fc protein (KLFc) was assayed with a series of 4-methylumbelliferyl (4Mu) beta-glycosides as potential substrates. An enzymatic activity of Klotho was observed only with 4-methylumbelliferyl beta-D-glucuronide in contrast to bovine liver beta-glucuronidase, which exhibits a rather wide substrate specificity. Furthermore, the enzymatic activity of KLFc was reduced by the addition of specific inhibitors of beta-glucuronidase. A number of natural beta-glucuronides were screened by competitive inhibition for KLFc beta-glucuronidase. We found that steroid beta-glucuronides such as beta-estradiol 3-beta-D-glucuronide, estrone 3-beta-D-glucuronide, and estriol 3beta-D-glucuronide were hydrolyzed by KLFc. The artificial fluorescent substrate and the steroid conjugates share a common phenolic structure. Collectively, these data suggest that Klotho functions as a novel beta-glucuronidase and that steroid beta-glucuronides are potential candidates for the natural substrate(s) of Klotho.	Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Horizontal Med Res Org, Sakyo Ku, Kyoto 6068501, Japan; Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan; INSERM, U381, F-67200 Strasbourg, France; CNRS, UMR 6098, F-13402 Marseille, France; Univ Aix Marseille 1, F-13402 Marseille, France; Univ Aix Marseille 2, F-13402 Marseille, France	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Nabeshima, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan.	nabemr@lmls.med.kyoto-u.ac.jp	Fujimori, Toshihiko/L-7711-2016; Henrissat, Bernard/J-2475-2012; Freund, Jean-Noel/R-4383-2016	Fujimori, Toshihiko/0000-0001-5200-4634; Henrissat, Bernard/0000-0002-3434-8588; Freund, Jean-Noel/0000-0002-0971-3774				BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; BULLER HA, 1990, ANNU REV MED, V41, P141; Burmeister WP, 2000, J BIOL CHEM, V275, P39385, DOI 10.1074/jbc.M006796200; CHESTER MA, 1976, BIOCHIM BIOPHYS ACTA, V429, P517, DOI 10.1016/0005-2744(76)90299-0; CONTRACTOR SF, 1972, BIOCHEM J, V128, P11, DOI 10.1042/bj1280011; Coutinho PM, 2003, TRENDS PLANT SCI, V8, P563, DOI 10.1016/j.tplants.2003.10.002; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; GOPALAN V, 1992, J BIOL CHEM, V267, P14027; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Higashi T, 1999, STEROIDS, V64, P715, DOI 10.1016/S0039-128X(99)00057-4; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2002, BBA-GENE STRUCT EXPR, V1576, P341, DOI 10.1016/S0167-4781(02)00281-6; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; Lotsch J, 2001, CLIN PHARMACOKINET, V40, P485; Matern H, 1997, J BIOL CHEM, V272, P11261; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; Nabeshima Y, 2002, AGEING RES REV, V1, P627, DOI 10.1016/S1568-1637(02)00027-2; Naim HY, 2001, HISTOL HISTOPATHOL, V16, P553, DOI 10.14670/HH-16.553; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; O'Leary KA, 2001, FEBS LETT, V503, P103, DOI 10.1016/S0014-5793(01)02684-9; Rask L, 2000, PLANT MOL BIOL, V42, P93, DOI 10.1023/A:1006380021658; Raychaudhuri A, 2003, BIOCHEMISTRY-US, V42, P6848, DOI 10.1021/bi034137o; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; Semenza G, 1989, METABOLIC BASIS INHE, V6th, P2975; SINNOTT M, 1990, CHEM REV, V90, P149; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Vishwanath BS, 1996, BIOCHEM J, V320, P93, DOI 10.1042/bj3200093; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wittstock U, 2002, TRENDS PLANT SCI, V7, P263, DOI 10.1016/S1360-1385(02)02273-2; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	42	174	192	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9777	9784		10.1074/jbc.M312392200	http://dx.doi.org/10.1074/jbc.M312392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701853	hybrid, Green Published			2022-12-27	WOS:000220050400016
J	Xing, HY; Mayhew, CN; Cullen, KE; Park-Sarge, OK; Sarge, KD				Xing, HY; Mayhew, CN; Cullen, KE; Park-Sarge, OK; Sarge, KD			HSF1 modulation of hsp70 mRNA polyadenylation via interaction with symplekin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; HEAT-SHOCK PROTEINS; POLYMERASE-II; TERMINAL DOMAIN; TRANSCRIPTION; STRESS; ACTIVATION; GRANULES	Induction of heat shock protein (HSP) gene expression by stress is initiated by binding of HSF1 to HSP gene promoters to increase their transcription. The cytoprotective functions of these HSPs are essential for cell survival, and thus it is critical that inducible HSP gene expression be executed rapidly and efficiently. Here we report an interaction between heat shock factor 1 ( HSF1) and symplekin, a protein known to form a complex with the polyadenylation factors CstF and CPSF. HSF1-symplekin complexes are detected only after stress treatment, and these two proteins co-localize in punctate nuclear structures in stressed cells. HSF1 also complexes in a stress-induced manner with the 3' processing factor CstF-64. Interfering with HSF1-symplekin interaction by overexpressing a non-DNA-binding mutant HSF1 protein significantly decreases Hsp70 mRNA polyadenylation in stressed cells, supporting the functional role for HSF1 in promoting 3' processing of this transcript. Importantly, this was also found to result in a significant loss of Hsp70 protein induction and increased cell death in response to stress exposure. These results indicate that the HSF1-symplekin interaction functions as a mechanism for recruiting polyadenylation factors to HSP genes to enhance the efficiency/ kinetics of production of mature Hsp mRNA transcripts to achieve the critical cellular need for rapid HSP expression after stress. Thus, HSF1 regulates HSP gene expression at not one but two different steps of the expression pathway, functioning both as a transcription factor and a polyadenylation stimulatory factor.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Univ Cincinnati, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	University of Kentucky; University of Kentucky; University System of Ohio; University of Cincinnati	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	kdsarge@uky.edu	Mayhew, Christopher N/AGB-4929-2022					Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Cotto JJ, 1997, J CELL SCI, V110, P2925; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 2000, GENE DEV, V14, P1415; Hofmann I, 2002, MOL BIOL CELL, V13, P1665, DOI 10.1091/mbc.01-12-0567; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaufman Randal J., 1999, Biochimica et Biophysica Acta, V1423, pR13, DOI 10.1016/S0304-419X(98)00029-8; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; Morano KA, 1999, GENE EXPRESSION, V7, P271; Naylor DJ, 2001, BIOCHEM SOC SYMP, V68, P45, DOI 10.1042/bss0680045; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Ryan K, 2002, MOL CELL BIOL, V22, P1684, DOI 10.1128/MCB.22.6.1684-1692.2002; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000	27	49	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10551	10555		10.1074/jbc.M311719200	http://dx.doi.org/10.1074/jbc.M311719200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14707147	hybrid			2022-12-27	WOS:000220050400108
J	Yano, M; Terada, K; Mori, M				Yano, M; Terada, K; Mori, M			Mitochondrial import receptors Tom20 and Tom22 have chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; OUTER-MEMBRANE; TRIGGER FACTOR; FUNCTIONAL-ANALYSIS; TOM70; IDENTIFICATION; RECOGNITION; PRECURSOR; BINDING	Mitochondrial preproteins are synthesized in the cytosol with N-terminal signal sequences (presequences) or internal targeting signals. Generally, preproteins with presequences are initially recognized by Tom20 ( translocase of the outer membrane) and, subsequently, by Tom22, whereas hydrophobic preproteins with internal targeting signals are first recognized by Tom70. Recent studies suggest that Tom70 associates with molecular chaperones, thereby maintaining their substrate preproteins in an import-competent state. However, such a function has not been reported for other Tom component(s). Here, we investigated a role for Tom20 in preventing substrate preproteins from aggregating. In vitro binding assays showed that Tom20 binds to guanidinium chloride unfolded substrate proteins regardless of the presence or absence of presequences. This suggests that Tom20 functions as a receptor not only for presequences but also for mature portions exposed in unfolded preproteins. Aggregation suppression assays on citrate synthase showed that the cytosolic domain of Tom20 has a chaperone-like activity to prevent this protein from aggregating. This activity was inhibited by a presequence peptide, suggesting that the binding site of Tom20 for presequence is identical or close to the active site for the chaperone-like activity. The cytosolic domain of Tom22 also showed a similar activity for citrate synthase, whereas Tom70 did not. These results suggest that the cytosolic domains of Tom20 and Tom22 function to maintain their substrate preproteins unfolded and prevent them from aggregating on the mitochondrial surface.	Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan	Kumamoto University	Yano, M (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Honjo 1-1-1, Kumamoto 8608556, Japan.	myano@gpo.kumamoto-u.ac.jp; masa@gpo.kumamoto-u.ac.jp						Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Alvarez-Dolado M, 1999, J NEUROCHEM, V73, P2240, DOI 10.1046/j.1471-4159.1999.0732240.x; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; GOPING IS, 1995, FEBS LETT, V373, P45; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Obita T, 2003, J MOL BIOL, V328, P495, DOI 10.1016/S0022-2836(03)00288-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; Suzuki H, 2002, J CELL SCI, V115, P1895; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; TERADA K, 1995, MOL CELL BIOL, V15, P3708; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Wright G, 2001, EXP CELL RES, V263, P107, DOI 10.1006/excr.2000.5096; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000; Yano M, 1998, J BIOL CHEM, V273, P26844, DOI 10.1074/jbc.273.41.26844; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	34	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10808	10813		10.1074/jbc.M311710200	http://dx.doi.org/10.1074/jbc.M311710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699115	hybrid			2022-12-27	WOS:000220050400136
J	Larrayoz, IM; Casado, FJ; Pastor-Anglada, M; Lostao, MP				Larrayoz, IM; Casado, FJ; Pastor-Anglada, M; Lostao, MP			Electrophysiological characterization of the human Na+/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; NUCLEOSIDE TRANSPORTER; ELECTROGENIC PROPERTIES; PYRIMIDINE; KINETICS; CURRENTS; PURINE; SGLT1; IDENTIFICATION; SELECTIVITY	We previously reported that the human Na+/nucleoside transporter pyrimidine-preferring 1 (hCNT1) is electrogenic and transports gemcitabine and 5'-deoxy-5- fluorouridine, a precursor of the active drug 5-fluorouracil. Nevertheless, a complete electrophysiological characterization of the basic properties of hCNT1-mediated translocation has not been performed yet, and the exact role of adenosine in hCNT1 function has not been addressed either. In the present work we have used the two-electrode voltage clamp technique to investigate hCNT1 transport mechanism and study the kinetic properties of adenosine as an inhibitor of hCNT1. We show that hCNT1 exhibits presteady-state currents that disappear upon the addition of adenosine or uridine. Adenosine, a purine nucleoside described as a substrate of the pyrimidine-preferring transporters, is not a substrate of hCNT1 but a high affinity blocker able to inhibit uridine-induced inward currents, the Na+-leak currents, and the presteady-state currents, with a K-i of 6.5 muM. The kinetic parameters for uridine, gemcitabine, and 5'-deoxy-5-fluorouridine were studied as a function of membrane potential; at -50 mV, K-0.5 was 37, 18, and 245 muM, respectively, and remained voltage-independent. I-max for gemcitabine was voltage-independent and accounts for similar to40% that for uridine at -50 mV. Maximal current for 5'-DFUR was voltage-dependent and was similar to150% that for uridine at all membrane potentials. K-0.5(Na+) for Na+ was voltage-independent at hyperpolarized membrane potentials (1.2 mM at - 50 mV), whereas I-max(Na+) was voltage-dependent, increasing 2-fold from -50 to -150 mV. Direct measurements of H-3-nucleoside or Na-22 fluxes with the charge-associated revealed a ratio of two positive inward charges per nucleoside and one Na+ per positive inward charge, suggesting a stoichiometry of two Na+/nucleoside.	Univ Navarra, Dept Fisiol & Nutr, E-31080 Pamplona, Spain; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08071 Barcelona, Spain	University of Navarra; University of Barcelona	Lostao, MP (corresponding author), Univ Navarra, Dept Fisiol & Nutr, C Irunlarrea S-N, E-31080 Pamplona, Spain.	plostao@unav.es	Lostao, M. Pilar/AAW-4238-2021; Lostao, M. Pilar/ABH-4714-2020; Larrayoz, Ignacio M/I-5613-2012	Lostao, M. Pilar/0000-0002-7319-3451; Lostao, M. Pilar/0000-0002-7319-3451; Larrayoz, Ignacio M/0000-0003-1629-152X; Casado Merediz, Francisco Javier/0000-0003-0192-841X				Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; Casado FJ, 2002, J PHYSIOL BIOCHEM, V58, P207, DOI 10.1007/BF03179858; Diez-Sampedro A, 2000, J MEMBRANE BIOL, V176, P111, DOI 10.1007/s002320001081; Diez-Sampedro A, 2001, AM J PHYSIOL-RENAL, V280, pF278, DOI 10.1152/ajprenal.2001.280.2.F278; Dresser MJ, 2000, DRUG METAB DISPOS, V28, P1135; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Forlani G, 2001, BBA-MOL CELL RES, V1538, P172, DOI 10.1016/S0167-4889(00)00144-0; Gerstin KM, 2002, AM J PHYSIOL-RENAL, V283, pF344, DOI 10.1152/ajprenal.00274.2001; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; Lostao MP, 2000, FEBS LETT, V481, P137, DOI 10.1016/S0014-5793(00)01983-9; Mackenzie B, 2003, J BIOL CHEM, V278, P23720, DOI 10.1074/jbc.M212718200; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Mata JF, 2001, MOL PHARMACOL, V59, P1542, DOI 10.1124/mol.59.6.1542; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; Yao SYM, 1996, MOL PHARMACOL, V50, P1529	32	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8999	9007		10.1074/jbc.M311940200	http://dx.doi.org/10.1074/jbc.M311940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701834	Green Published, hybrid			2022-12-27	WOS:000189265900059
J	Li, MH; Kwok, F; Chang, WR; Liu, SQ; Lo, SCL; Zhang, JP; Jiang, T; Liang, DC				Li, MH; Kwok, F; Chang, WR; Liu, SQ; Lo, SCL; Zhang, JP; Jiang, T; Liang, DC			Conformational changes in the reaction of pyridoxal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.5 ANGSTROM RESOLUTION; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; ADENOSINE KINASE; BRAIN; RIBOKINASE; PROGRAM; IDENTIFICATION; ENCODES	To understand the processes involved in the catalytic mechanism of pyridoxal kinase (PLK),(1) we determined the crystal structures of PLK.AMP-PCP-pyridoxamine, PLK.ADP.PLP, and PLK.ADP complexes. Comparisons of these structures have revealed that PLK exhibits different conformations during its catalytic process. After the binding of AMP-PCP (an analogue that replaced ATP) and pyridoxamine to PLK, this enzyme retains a conformation similar to that of the PLK.ATP complex. The distance between the reacting groups of the two substrates is 5.8 Angstrom apart, indicating that the position of ATP is not favorable to spontaneous transfer of its phosphate group. However, the structure of PLK.ADP.PLP complex exhibited significant changes in both the conformation of the enzyme and the location of the ligands at the active site. Therefore, it appears that after binding of both substrates, the enzyme-substrate complex requires changes in the protein structure to enable the transfer of the phosphate group from ATP to vitamin B-6. Furthermore, a conformation of the enzyme-substrate complex before the transition state of the enzymatic reaction was also hypothesized.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Dept Appl Biol Chem Technol, Hong Kong, Hong Kong, Peoples R China; Polytech Univ, Hong Kong, Hong Kong, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Jiang, T (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	x-ray@sun5.ibp.ac.cn		Lo, Samuel Chun-lap/0000-0003-1134-7299				BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Cheng G, 2002, STRUCTURE, V10, P225, DOI 10.1016/S0969-2126(02)00708-6; Hanna MC, 1997, J BIOL CHEM, V272, P10756; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KIM YT, 1988, J BIOL CHEM, V263, P13712; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWOK F, 1980, J BIOL CHEM, V255, P882; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MH, 2002, ACTA CRYSTALLOGR D, V58, P1479, DOI 10.1107/S0907444902011034; Li MH, 2002, J BIOL CHEM, V277, P46385, DOI 10.1074/jbc.M208600200; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; MCCORMICK D, 1961, J BIOL CHEM, V236, P2085; MCCORMICK DB, 1959, P NATL ACAD SCI USA, V45, P1371, DOI 10.1073/pnas.45.9.1371; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yang Y, 1996, FEMS MICROBIOL LETT, V141, P89, DOI 10.1016/0378-1097(96)00203-0; Yang Y, 1998, J BACTERIOL, V180, P1814, DOI 10.1128/JB.180.7.1814-1821.1998; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	27	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17459	17465		10.1074/jbc.M312380200	http://dx.doi.org/10.1074/jbc.M312380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14722069	hybrid			2022-12-27	WOS:000220870400072
J	Hirotani, H; Tuohy, NA; Woo, JT; Stern, PH; Clipstone, NA				Hirotani, H; Tuohy, NA; Woo, JT; Stern, PH; Clipstone, NA			The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; NECROSIS-FACTOR-ALPHA; CYCLOSPORINE-A; BONE-RESORPTION; TRANSCRIPTION FACTOR; OSTEOPROTEGERIN LIGAND; GENE-EXPRESSION; NUCLEAR FACTOR; KEY REGULATOR	Although best known for its role in T lymphocyte activation, the calcineurin/nuclear factor of activated T cells ( NFAT) signaling pathway is also known to be involved in a wide range of other biological responses in a variety of different cell types. Here we have investigated the role of the calcineurin/NFAT signaling pathway in the regulation of osteoclast differentiation. Osteoclasts are bone-resorbing multinucleated cells that are derived from the monocyte/macrophage cell lineage after stimulation with a member of the tumor necrosis factor family of ligands known as receptor activator of nuclear factor-kappaB ligand (RANKL). We now report that inhibition of calcineurin with either the immunosuppressant drugs cyclosporin A and FK506, or the retrovirally mediated ectopic expression of a specific calcineurin inhibitory peptide, all potently inhibit the RANKL-induced differentiation of the RAW264.7 monocyte/macrophage cell line into mature multinucleated osteoclasts. In addition, we find that NFAT family members are expressed in RAW264.7 cells and that their expression is up-regulated in response to RANKL stimulation. Most importantly, we find that ectopic expression of a constitutively active, calcineurin-independent NFATc1 mutant in RAW264.7 cells is sufficient to induce these cells to express an osteoclast-specific pattern of gene expression and differentiate into morphologically distinct, multinucleated osteoclasts capable of inducing the resorption of a physiological mineralized matrix substrate. Taken together, these data define calcineurin as an essential downstream effector of the RANKL-induced signal transduction pathway leading toward the induction of osteoclast differentiation and furthermore, indicate that the activation of the NFATc1 transcription factor is sufficient to initiate a genetic program that results in the specification of the mature functional osteoclast cell phenotype.	Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Clipstone, NA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, 303 E Chicago Ave, Chicago, IL 60611 USA.	n-clipstone@northwestern.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60 AR30692] Funding Source: Medline; NIGMS NIH HHS [R29 GM55292] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; Awumey EM, 1999, BIOCHEM BIOPH RES CO, V254, P248, DOI 10.1006/bbrc.1998.9785; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BALDARI CT, 1993, FEBS LETT, V323, P233, DOI 10.1016/0014-5793(93)81346-2; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHOWDHURY MH, 1991, CALCIFIED TISSUE INT, V49, P275, DOI 10.1007/BF02556217; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006-2952(01)00861-9; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; KLAUSHOFER K, 1987, J PHARMACOL EXP THER, V243, P584; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; LEE SK, 1995, ENDOCRINOLOGY, V136, P4572, DOI 10.1210/en.136.10.4572; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Neal JW, 2002, J BIOL CHEM, V277, P49776, DOI 10.1074/jbc.M207913200; ORCEL P, 1991, ENDOCRINOLOGY, V128, P1638, DOI 10.1210/endo-128-3-1638; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; Quinn JMW, 1999, BONE, V25, P1, DOI 10.1016/S8756-3282(99)00094-0; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SKJODT H, 1985, BRIT J RHEUMATOL, V24, P165; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEWART PJ, 1986, J BONE MINER RES, V1, P285; SUDA T, 1995, BONE S2, V17, P87; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; TONG HS, 1994, J BONE MINER RES, V9, P577; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	69	209	216	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13984	13992		10.1074/jbc.M213067200	http://dx.doi.org/10.1074/jbc.M213067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722106	hybrid			2022-12-27	WOS:000220478500086
J	Yoo, B; Iyengar, R; Chen, YB				Yoo, B; Iyengar, R; Chen, YB			Functional analysis of the interface regions involved in interactions between the central cytoplasmic loop and the C-terminal tail of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; INHIBITION; MUTANTS; DOMAINS; GAMMA; SITE	The mammalian adenylyl cyclase is a membrane-bound enzyme that is predicted to have 12 trans-membrane spans. Between membrane spans 6 and 7 there is a large cytoplasmic loop, which, along with the C-terminal tail, makes up the catalytic site of the enzyme. Crystal structures of these soluble cytoplasmic domains have identified the regions that are involved in interactions with each other. The functional consequences of these interactions in the full-length membrane-embedded enzymes have not been established. In this study, we analyzed the role of various interaction regions within the central cytoplasmic loop (C1) and the C-terminal tail (C2) on basal, Galphas-, forskolin-, and Mn2+-stimulated activities of adenylyl cyclases 2 and 6 (AC2 and AC6). We tested synthetic peptides encoding the different interface surfaces of both the C1 and C2 domain on different activities of membrane-bound AC2 and AC6 expressed in insect cells. We found the C1-alpha2-beta2-beta3 and C2-beta2'-beta3' regions to be involved in stimulation by Galphas and forskolin but not in the basal or Mn2+-stimulated activities. Both the C1-beta4-beta5-alpha4 region and the C2-alpha3'-beta4' region play a role in the Galphas- and forskolin-stimulated activities as well as in basal activity, because the peptides encoding these regions inhibit basal activity by 30%. In contrast, the C2-alpha2' region peptide inhibits both basal and Mn2+-stimulated activity by > 50%. These results suggest that the different stimulated activities may involve distinct interface interactions in the intact enzyme and, consequently, the distinct mechanisms by which Mn2+ activates the enzyme as compared with Galphas and forskolin, leading to the possibility that the full-length adenylyl cyclase may have multiple catalytically competent configurations.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.	ravi.iyengar@mssm.edu			NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen YB, 2001, J BIOL CHEM, V276, P45751, DOI 10.1074/jbc.M107191200; Dessauer CW, 2002, J BIOL CHEM, V277, P28823, DOI 10.1074/jbc.M203962200; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DESSAUER CW, 1997, J BIOL CHEM, V272, P27772; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; Hatley ME, 2000, J BIOL CHEM, V275, P38626, DOI 10.1074/jbc.M007148200; HILDEBRANDT JD, 1983, J BIOL CHEM, V258, P3141; Parent CA, 2002, J BIOL CHEM, V277, P1354, DOI 10.1074/jbc.M106430200; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Skiba NP, 1998, NAT STRUCT BIOL, V5, P88, DOI 10.1038/nsb0298-88; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849	20	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13925	13933		10.1074/jbc.M314334200	http://dx.doi.org/10.1074/jbc.M314334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722077	hybrid			2022-12-27	WOS:000220478500079
J	De Cristofaro, R; Akhavan, S; Altomare, C; Carotti, A; Peyvandi, F; Mannucci, PM				De Cristofaro, R; Akhavan, S; Altomare, C; Carotti, A; Peyvandi, F; Mannucci, PM			A natural prothrombin mutant reveals an unexpected influence of A-chain structure on the activity of human alpha-thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; ACTIVATION; MECHANISM; ANTITHROMBIN; DEFICIENCY; FIBRINOGEN; INHIBITORS; MUTATIONS; LETHALITY; GEOMETRY	We have recently identified in two unrelated patients with bleeding tendency a homozygous mutation causing a deletion of one of the two contiguous Lys(9)/Lys(10) residues in the A- chain of alpha-thrombin ( DeltaK9). We used in vitro expression analysis to clarify the role of the deletion of Lys(9) or Lys(10) in the thrombin function. The k(cat)/ K-m value of the hydrolysis by DeltaK9 of the synthetic substrate Phe-Pip- Arg- p- nitroanilide ( where Pip represents L- pipecolyl) and fibrinopeptide A was 18- and 60- fold lower, respectively, compared with wild type ( WT). Interaction with antithrombin was also reduced in the mutant, the association rate being about 20- fold lower than in the WT thrombin. The sensitivity to sodium ion of DeltaK9 was found significantly attenuated compared with the WT form. DeltaK9 has a very weak platelet- activating capacity, attributed to a severely defective PAR1 interaction, whereas the binding to the platelet glycoprotein Ibalpha was unaffected. Likewise, the interaction with protein C was severely impaired, whereas interaction with thrombomodulin had a normal K-d value. At variance with these findings, both low affinity ( basic pancreatic trypsin inhibitor) and high affinity ( N-alpha-[2-naphthylsulfonyl- glycyl]4- amidinophenylalanine- piperidide) thrombin inhibitors displayed a better binding to DeltaK9 than to the WT form, indicating a better accommodation of these inhibitors into the catalytic pocket of DeltaK9. A molecular dynamics simulation of the DeltaK9 thrombin in full explicit water solvent provided support to the role of the A-chain in affecting conformation and catalytic properties of the B- chain, especially in some insertion loops of the enzyme, such as the 60- loop, as well as in the geometry of the catalytic triad residues.	Catholic Univ, Sch Med, Inst Internal Med & Geriatr, Hemostasis Res Ctr, I-00168 Rome, Italy; Univ Milan, IRCCS Maggiore Hosp, Angelo Bianchi Hemophilia & Thrombosis Ctr, I-20121 Milan, Italy; Univ Milan, IRCCS Maggiore Hosp, Fdn Luigi Villa, I-20121 Milan, Italy; Univ Bari, Dept Pharmaceut Chem, I-70125 Bari, Italy; Univ Paris 07, Fac Xavier Bichat, INSERM, E0348, F-75870 Paris, France	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universita degli Studi di Bari Aldo Moro; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	De Cristofaro, R (corresponding author), Catholic Univ, Sch Med, Inst Internal Med, Hemostasis Res Ctr, Largo F Vito 1, I-00168 Rome, Italy.	rdecristofaro@rm.unicatt.it	De Cristofaro, Raimondo/K-3942-2018; Peyvandi, Flora/AAK-7437-2020; Carotti, Andrea/B-4825-2015	De Cristofaro, Raimondo/0000-0002-8066-8849; Peyvandi, Flora/0000-0001-7423-9864; Carotti, Andrea/0000-0001-6097-3996				Akhavan S, 2000, THROMB HAEMOSTASIS, V84, P989; Akhavan S, 2003, BRIT J HAEMATOL, V120, P142, DOI 10.1046/j.1365-2141.2003.03986.x; Akhavan S, 2002, BLOOD, V100, P1347, DOI 10.1182/blood-2002-01-0243; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BODE W, 1992, PROTEIN SCI, V1, P426; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; De Cristofaro R, 1999, EUR J BIOCHEM, V260, P97, DOI 10.1046/j.1432-1327.1999.00118.x; De Filippis V, 2002, BIOCHEMISTRY-US, V41, P13556, DOI 10.1021/bi0203482; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DECRISTOFARO R, 1994, J MOL BIOL, V239, P569, DOI 10.1006/jmbi.1994.1396; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; FERSHT A, 1985, ENZYME STRUCTURE MEC, P405; Fischer BE, 1996, PROTEIN ENG, V9, P921, DOI 10.1093/protein/9.10.921; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; GEPPERT AG, 1992, ARCH BIOCHEM BIOPHYS, V297, P205, DOI 10.1016/0003-9861(92)90663-H; HAGEMAN TC, 1975, ARCH BIOCHEM BIOPHYS, V171, P327, DOI 10.1016/0003-9861(75)90039-9; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HILL TL, 1975, P NATL ACAD SCI USA, V72, P4918, DOI 10.1073/pnas.72.12.4918; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Lefkowitz JB, 2000, BRIT J HAEMATOL, V108, P182, DOI 10.1046/j.1365-2141.2000.01810.x; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; ORTIZ I, 2002, HAEMOPHILIA, V8, P836; Petrovan RJ, 1998, BIOCHEMISTRY-US, V37, P1185, DOI 10.1021/bi971948h; PICOZZI M, 1994, EUR J BIOCHEM, V219, P1013, DOI 10.1111/j.1432-1033.1994.tb18584.x; SEREISKAYA A A, 1989, Biokhimiya, V54, P542; SPEIJER H, 1986, J BIOL CHEM, V261, P3258; STONE SR, 1991, BIOCHEMISTRY-US, V30, P9841, DOI 10.1021/bi00105a005; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; van Gunsteren W. F., 1998, ENCY COMPUTATIONAL C, V2, P1211, DOI DOI 10.1002/0470845015.CGA011; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Xue JC, 1998, P NATL ACAD SCI USA, V95, P7603, DOI 10.1073/pnas.95.13.7603	39	21	23	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13035	13043		10.1074/jbc.M312430200	http://dx.doi.org/10.1074/jbc.M312430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722067	hybrid			2022-12-27	WOS:000220334900124
J	Herr, DR; Fyrst, H; Creason, MB; Phan, VH; Saba, JD; Harris, GL				Herr, DR; Fyrst, H; Creason, MB; Phan, VH; Saba, JD; Harris, GL			Characterization of the Drosophila sphingosine kinases and requirement for Sk2 in normal reproductive function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DIACYLGLYCEROL KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; PROTEIN; GENE; LOCALIZATION; TRANSLOCATION	Sphingosine kinase is a highly conserved enzyme that catalyzes the synthesis of sphingosine 1-phosphate and reduces cellular levels of sphingosine and ceramide. Although ceramide is pro-apoptotic and sphingosine is generally growth-inhibitory, sphingosine 1-phosphate signaling promotes cell proliferation, survival, and migration. Sphingosine kinase is thus in a strategic position to regulate important cell fate decisions which may contribute to normal animal development. To facilitate studies examining the potential role of sphingosine kinase and long chain base metabolism in Drosophila development, we characterized two putative Drosophila sphingosine kinase genes, Sk1 and Sk2. Both genes functionally and biochemically complement a yeast sphingosine kinase mutant, express predominantly cytosolic activities, and are capable of phosphorylating a range of endogenous and non-endogenous sphingoid base substrates. The two genes demonstrate overlapping but distinct temporal and spatial expression patterns in the Drosophila embryo, and timing of expression is consistent with observed changes in long chain base levels throughout development. A null Sk2 transposon insertion mutant demonstrated elevated long chain base levels, impaired flight performance, and diminished ovulation. This is the first reported mutation of a sphingosine kinase in an animal model; the associated phenotypes indicate that Sk1 and Sk2 are not redundant in biological function and that sphingosine kinase is essential for diverse physiological functions in this organism.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; California State University System; San Diego State University; California State University System; San Diego State University	Saba, JD (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org; gharris@sunstroke.sdsu.edu	Herr, Deron/AAB-7380-2020	Herr, Deron/0000-0001-5755-0896	NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066954] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 77528] Funding Source: Medline; NIGMS NIH HHS [1R01 GM 066954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P7276; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Fyrst H, 2004, J LIPID RES, V45, P54, DOI 10.1194/jlr.M300005-JLR200; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kim S, 2000, GENETICS, V156, P1519; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; MISRA S, 2002, GENOME BIOL, V3, P14; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Murate T, 2001, J HISTOCHEM CYTOCHEM, V49, P845, DOI 10.1177/002215540104900705; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qazi MCB, 2003, DEV BIOL, V256, P195, DOI 10.1016/S0012-1606(02)00125-2; Renault Andrew D., 2002, Gene Expression Patterns, V2, P337, DOI 10.1016/S0925-4773(02)00389-1; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; ROSEMAN RR, 1995, GENETICS, V141, P1061; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Stapleton M, 2002, GENOME RES, V12, P1294, DOI 10.1101/gr.269102; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Vann LR, 2002, J BIOL CHEM, V277, P12649, DOI 10.1074/jbc.M109111200; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12685	12694		10.1074/jbc.M310647200	http://dx.doi.org/10.1074/jbc.M310647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722126	hybrid			2022-12-27	WOS:000220334900082
J	Masuyama, H; Hiramatsu, Y				Masuyama, H; Hiramatsu, Y			Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-DEPENDENT DEGRADATION; ENDOCRINE-DISRUPTING CHEMICALS; PREGNANE-X RECEPTOR; HORMONE RECEPTOR; 26S PROTEASOME; AF-2 DOMAIN; TRANSCRIPTION; COACTIVATOR; SUPERFAMILY; ACTIVATION	The proteasome-mediated pathway involves the degradation of several nuclear receptors. Previously we demonstrated that the interaction between the suppressor for Gal 1 (SUG1) and nuclear receptors, the vitamin D receptor, or the pregnane X receptor was involved in proteasome-mediated degradation. In our recent experiments, we examined the potential role of SUG1 in the proteasome-mediated degradation of estrogen receptors (ER)alpha and - beta. Both ERs interacted with SUG1 in a ligand-dependent manner. Functionally, the overexpression of SUG1 inhibited both ERalpha- and ERbeta-mediated transcription in the presence of ligands. Transient expression studies demonstrated that the overexpression of wildtype SUG1 generated proteolytic fragments of both ERs and that these products were blocked by a proteasome inhibitor. The overexpression of SUG1 also enhanced the formation of ubiquitinated proteins of both ERs in the presence of ligand. On the other hand, bisphenol A (BSA), which activated ER-mediated transcription, did not enhance the interaction between ERbeta and SUG1. Furthermore, the degradation of ERbeta was much slower in the presence of BSA than in the presence of estradiol or phthalate, which is another endocrine-disrupting chemical. Also, BSA had no effect on the formation of proteolytic fragments of ERbeta, and neither did it have any effect on the ubiquitination of ERbeta. These findings indicate that the ubiquitin/proteasome-mediated degradation of both ER proteins may involve the interaction of SUG1 with both ERs. Moreover, BSA strongly blocked the ubiquitination and degradation of ERbeta compared with estradiol, suggesting that BSA may affect the ERbeta-mediated transcription of target genes by inhibiting ERbeta degradation.	Okayama Univ, Sch Med, Dept Obstet & Gynecol, Okayama 7008558, Japan	Okayama University	Masuyama, H (corresponding author), Okayama Univ, Sch Med, Dept Obstet & Gynecol, 2-5-1 Shikata, Okayama 7008558, Japan.	masuyama@cc.okayama-u.ac.jp						Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cooper RL, 1997, J ENDOCRINOL, V152, P159, DOI 10.1677/joe.0.1520159; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; Gorbea C, 1999, MOL BIOL REP, V26, P15, DOI 10.1023/A:1006957802028; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Inoshita H, 2003, J MOL ENDOCRINOL, V31, P551, DOI 10.1677/jme.0.0310551; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.1289/ehp.96104s4715; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Masuyama H, 2000, MOL ENDOCRINOL, V14, P421, DOI 10.1210/me.14.3.421; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Masuyama H, 2002, ENDOCRINOLOGY, V143, P55, DOI 10.1210/en.143.1.55; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; ONATE SA, 1995, SCIENCE, V270, P1354; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; Tanahashi N, 1999, MOL BIOL REP, V26, P3, DOI 10.1023/A:1006909522731; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VOM BE, 1996, EMBO J, V15, P110	28	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12020	12026		10.1074/jbc.M312762200	http://dx.doi.org/10.1074/jbc.M312762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702340	hybrid			2022-12-27	WOS:000220334900004
J	Zitt, C; Strauss, B; Schwarz, EC; Spaeth, N; Rast, G; Hatzelmann, A; Hoth, M				Zitt, C; Strauss, B; Schwarz, EC; Spaeth, N; Rast, G; Hatzelmann, A; Hoth, M			Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-AMINOETHOXYDIPHENYL BORATE; MAST-CELLS; STORE DEPLETION; CALCIUM-RELEASE; IL-2 PRODUCTION; CRAC CHANNELS; MIC CHANNELS; INFLUX; ENTRY; 3,5-BIS(TRIFLUOROMETHYL)PYRAZOLES	Ca2+ entry through store-operated Ca2+ release-activated Ca2+ (CRAC) channels is essential for T-cell activation and proliferation. Recently, it has been shown that 3,5-bistrifluoromethyl pyrazole (BTP) derivatives are specific inhibitors of Ca2+-dependent transcriptional activity in T-cells (Trevillyan, J.M., Chiou, X. G., Chen, Y.W., Ballaron, S.J., Sheets, M. P., Smith, M. L., Wiedeman, P. E., Warrior, U., Wilkins, J., Gubbins, E. J., Gagne, G. D., Fagerland, J., Carter, G. W., Luly, J. R., Mollison, K. W., and Djuric, S. W. (2001) J. Biol. Chem. 276, 48118-48126). Whereas inhibition of Ca2+ signals was reported for BTP2 (Ishikawa, J., Ohga, K., Yoshino, T., Takezawa, R., Ichikawa, A., Kubota, H., and Yamada, T. (2003) J. Immunol. 170, 4441-4449), it was not found for BTP3 (Chen, Y., Smith, M. L., Chiou, G. X., Ballaron, S., Sheets, M. P., Gubbins, E., Warrior, U., Wilkins, J., Surowy, C., Nakane, M., Carter, G. W., Trevillyan, J. M., Mollison, K., and Djuric, S. W. ( 2002) Cell. Immunol. 220, 134-142). We show that BTP2 specifically inhibits CRAC channels in T-cells with an IC50 of similar to10 nM. It does not interfere with other mechanisms important for Ca2+ signals in T-cells, including Ca2+ pumps, mitochondrial Ca2+ signaling, endoplasmic reticulum Ca2+ release, and K+ channels. BTP2 inhibits Ca2+ signals in peripheral blood T-lymphocytes (in particular in CD4(+) T-cells) and in human Jurkat T-cells. Inhibition of Ca2+ signals is independent of the stimulation method as Ca2+ entry was blocked following stimulation with anti-CD3, which activates the T-cell receptor, and also following stimulation with thapsigargin or inositol 1,4,5-trisphosphate. BTP2 also inhibited Ca2+-dependent gene expression (interleukins 2 and 5 and interferon gamma) and proliferation of T-lymphocytes with similar IC50 values. BTP2 is the first potent and specific inhibitor of CRAC channels in primary T-lymphocytes. The inhibition of CRAC channels as well as Ca2+-dependent signal transduction with similar IC50 values in T-lymphocytes emphasizes the importance of CRAC channel activity during T-cell activation. Furthermore, BTP2 could prove to be a tool to finally unmask the molecular identity of CRAC channels.	Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; ALTANA Pharma AG, Dept Biochem, RDR B2, D-78467 Constance, Germany	Saarland University; Altana	Hoth, M (corresponding author), Univ Saarland, Dept Physiol, D-66421 Homburg, Germany.	markus.hoth@uniklinik-saarland.de		Hoth, Markus/0000-0001-7080-4643; Schwarz, Eva C./0000-0002-6503-4864				Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Chen YW, 2002, CELL IMMUNOL, V220, P134, DOI 10.1016/S0008-8749(03)00005-4; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Djuric SW, 2000, J MED CHEM, V43, P2975, DOI 10.1021/jm990615a; DONNADIEU E, 1993, PFLUG ARCH EUR J PHY, V424, P448, DOI 10.1007/BF00374907; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishikawa J, 2003, J IMMUNOL, V170, P4441, DOI 10.4049/jimmunol.170.9.4441; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Trevillyan JM, 2001, J BIOL CHEM, V276, P48118, DOI 10.1074/jbc.M107919200; Wu J, 2000, MOL PHARMACOL, V58, P1368, DOI 10.1124/mol.58.6.1368; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	32	226	242	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12427	12437		10.1074/jbc.M309297200	http://dx.doi.org/10.1074/jbc.M309297200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718545	hybrid			2022-12-27	WOS:000220334900052
J	Cha, MK; Hong, SK; Lee, DS; Kim, IH				Cha, MK; Hong, SK; Lee, DS; Kim, IH			Vibrio cholerae thiol peroxidase-glutaredoxin fusion is a 2-Cys TSA/AhpC subfamily acting as a lipid hydroperoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANTIOXIDANT PROTEIN; PEROXIREDOXIN; THIOREDOXIN; FAMILY; PURIFICATION; OXIDATION; POPLAR; ENZYME	Recently, novel hybrid thiol peroxidase (TPx) proteins fused with a glutaredoxin (Grx) were found from some pathogenic bacteria, cyanobacteria, and anaerobic sulfur-oxidizing phototroph. The phylogenic tree analysis that was constructed from the aligned sequences showed two major branches. Haemophilus influenzae TPx.Grx was grouped in one branch as a 1-Cys subfamily of the thiol-specific antioxident protein/AhpC family. Most TPx.Grx proteins, including Vibrio cholerae TPx.Grx, were grouped in the 2-Cys subfamily. To explain the existence of two subgroups in novel hybrid TPx proteins, we have compared the kinetics given by V. cholerae TPx.Grx, H. influenzae TPx.Grx, their separated TPx domains, and a set of mutants devoid of the redox-active cysteines. The kinetic study described here demonstrates clearly that V. cholerae TPx.Grx is a 2-Cys TPx subfamily. For the first time, we also demonstrate the lipid peroxidase activity of V. cholerae TPx.Grx fusion and suggest the in vivo function of 2-Cys TPx.Grx fusion serving as a lipid peroxidase.	Paichai Univ, Dept Biochem, Taejon 302735, South Korea	Pai Chai University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, 439-6 Doma 2 Dong, Taejon 302735, South Korea.	ihkim@mail.paichai.ac.kr	Kim, Il-Han/W-1401-2019					BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Cha MK, 2003, J BIOL CHEM, V278, P24636, DOI 10.1074/jbc.M302628200; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FERRI A, 1995, BIOCHEM MOL BIOL INT, V35, P691; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim SJ, 2003, J BIOL CHEM, V278, P10790, DOI 10.1074/jbc.M209553200; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; LYNCH AS, 1996, E COLI SALMONELLA CE, V6, P1526; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; POOLE LB, 2003, SIGNAL TRANSDUCTION, P80; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Sambrook J., 2001, MOL CLONING LAB MANU; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; SIKORSKI RS, 1989, GENETICS, V122, P19; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	35	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11035	11041		10.1074/jbc.M312657200	http://dx.doi.org/10.1074/jbc.M312657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702341	hybrid			2022-12-27	WOS:000220157600026
J	Dominguez, F; Moreno, J; Cejudo, FJ				Dominguez, F; Moreno, J; Cejudo, FJ			A gibberellin-induced nuclease is localized in the nucleus of wheat aleurone cells undergoing programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY ALEURONE; GENE-EXPRESSION; MAIZE ENDOSPERM; DNA FRAGMENTATION; APOPTOSIS; DEGRADATION; GERMINATION; MECHANISMS; CARBOXYPEPTIDASE; DIFFERENTIATION	The aleurone layer of cereal grains undergoes a gibberellin-regulated process of programmed cell death (PCD) following germination. We have applied a combination of ultrastructural and biochemical approaches to analyze aleurone PCD in intact wheat grains. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay revealed that PCD was initiated in aleurone cells proximal to the embryo and then extended to distal cells. DNA fragmentation and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling analysis revealed PCD of aleurone cells in maize grains, although the process was delayed as compared with wheat. Aleurone cells undergoing PCD showed a rapid vacuolation with high lytic activity in the cytoplasm, whereas the nucleus, which adopted an irregular shape, appeared essentially intact and showed symptoms of degradation at the end of the process. A nuclease activity was identified localized in the nucleus of aleurone cells undergoing PCD, just prior to the appearance of DNA laddering. This nuclease was induced by gibberellic acid treatment and was not detected when gibberellin synthesis was inhibited or in gibberellic acid-insensitive mutants. This nuclease was activated by Ca2+ and Mg2+, strongly inhibited by Zn2+, and showed optimum activity at neutral pH, resembling nucleases involved in apoptosis of animal cells.	Ctr Invest Cient Isla de la Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; Univ Seville, Fac Biol, Dept Biol Celular, E-41012 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-JA-USE - Centro de Investigaciones Cientificas Isla de La Cartuja (CICIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); University of Sevilla	Cejudo, FJ (corresponding author), Ctr Invest Cient Isla de la Cartuja, Inst Bioquim Vegetal & Fotosintesis, Avda Amer Vespucio S-N, Seville 41092, Spain.	fjcejudo@us.es	Cejudo, Francisco Javier/M-2749-2014	Cejudo, Francisco Javier/0000-0002-3936-5491				ALNEMRI ES, 1989, J BIOL CHEM, V264, P4104; Appleford NEJ, 1997, PHYSIOL PLANTARUM, V100, P534, DOI 10.1034/j.1399-3054.1997.1000315.x; BAULCOMBE DC, 1987, J BIOL CHEM, V262, P13726; Becraft PW, 2000, DEVELOPMENT, V127, P4039; Bethke PC, 1996, PLANT PHYSIOL, V110, P521, DOI 10.1104/pp.110.2.521; Bethke PC, 1999, PLANT CELL, V11, P1033, DOI 10.1105/tpc.11.6.1033; Bethke PC, 1997, J EXP BOT, V48, P1337, DOI 10.1093/jxb/48.7.1337; Bethke PC, 1998, ANN BOT-LONDON, V82, P399, DOI 10.1006/anbo.1998.0702; Buckner B, 1998, TRENDS PLANT SCI, V3, P218, DOI 10.1016/S1360-1385(98)01254-0; Buckner B, 2000, PHYSIOL PLANTARUM, V108, P231, DOI 10.1034/j.1399-3054.2000.108003231.x; CEJUDO FJ, 1992, PLANT J, V2, P937; Counis MF, 2000, BIOCHEM CELL BIOL, V78, P405, DOI 10.1139/bcb-78-4-405; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Dominguez F, 2002, PLANTA, V215, P727, DOI 10.1007/s00425-002-0809-2; Dominguez F, 1999, PLANT PHYSIOL, V119, P81, DOI 10.1104/pp.119.1.81; Dominguez F, 1998, PLANT J, V15, P569, DOI 10.1046/j.1365-313X.1998.00233.x; Dominguez F, 2001, PLANTA, V213, P352, DOI 10.1007/s004250000517; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fath A, 1999, PLANT J, V20, P305, DOI 10.1046/j.1365-313X.1999.t01-2-00605.x; Fath A, 2000, PLANT MOL BIOL, V44, P255, DOI 10.1023/A:1026584207243; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; FLINTHAM JE, 1983, THEOR APPL GENET, V66, P249, DOI 10.1007/BF00251155; Gonzalez MC, 1998, PLANT PHYSIOL, V116, P1249, DOI 10.1104/pp.116.4.1249; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ito J, 2002, PLANT CELL, V14, P3201, DOI 10.1105/tpc.006411; Jones AM, 1996, TRENDS PLANT SCI, V1, P114, DOI 10.1016/S1360-1385(96)90005-9; Jones AM, 2001, PLANT PHYSIOL, V125, P94, DOI 10.1104/pp.125.1.94; KALINSKI A, 1986, J BIOL CHEM, V261, P1393; KERR JFR, 1995, METHOD CELL BIOL, V46, P1; Korthout HAAJ, 2000, FEBS LETT, V475, P139, DOI 10.1016/S0014-5793(00)01643-4; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; Kuriyama H, 2002, CURR OPIN PLANT BIOL, V5, P568, DOI 10.1016/S1369-5266(02)00305-9; Lam E, 1999, CURR OPIN PLANT BIOL, V2, P502, DOI 10.1016/S1369-5266(99)00026-6; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Marty F, 1999, PLANT CELL, V11, P587, DOI 10.1105/tpc.11.4.587; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; MORRISON IN, 1978, PLANTA, V140, P19, DOI 10.1007/BF00389375; NORSTOG K, 1974, BOT GAZ, V135, P97, DOI 10.1086/336736; Obara K, 2001, PLANT PHYSIOL, V125, P615, DOI 10.1104/pp.125.2.615; Orzaez D, 1997, PLANT J, V11, P137, DOI 10.1046/j.1365-313X.1997.11010137.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Rademacher W, 2000, ANNU REV PLANT PHYS, V51, P501, DOI 10.1146/annurev.arplant.51.1.501; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Skadsen RW, 1998, PHYSIOL PLANTARUM, V104, P486, DOI 10.1034/j.1399-3054.1998.1040326.x; Sugiyama M, 2000, PLANT MOL BIOL, V44, P387, DOI 10.1023/A:1026504911786; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Swanson SJ, 1998, PLANT CELL, V10, P685, DOI 10.1105/tpc.10.5.685; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WANG HL, 1994, PROTOPLASMA, V182, P39, DOI 10.1007/BF01403687; Wang M, 1998, J EXP BOT, V49, P1293, DOI 10.1093/jexbot/49.325.1293; Wang M, 1996, PLANT MOL BIOL, V32, P1125, DOI 10.1007/BF00041396; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338; Young TE, 1997, PLANT PHYSIOL, V115, P737, DOI 10.1104/pp.115.2.737; Young TE, 2000, PLANT MOL BIOL, V42, P397, DOI 10.1023/A:1006333103342; Young TE, 1999, PLANT MOL BIOL, V39, P915, DOI 10.1023/A:1006134027834; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591	60	62	67	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11530	11536		10.1074/jbc.M308082200	http://dx.doi.org/10.1074/jbc.M308082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699134	Green Published, hybrid			2022-12-27	WOS:000220157600085
J	Kozlov, G; Cheng, J; Ziomek, E; Banville, D; Gehring, K; Ekiel, I				Kozlov, G; Cheng, J; Ziomek, E; Banville, D; Gehring, K; Ekiel, I			Structural insights into molecular function of the metastasis-associated phosphatase PRL-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; REDOX REGULATION; NMR; SPECIFICITY; 1B; INACTIVATION; PRENYLATION	Phosphatases and kinases are the cellular signal transduction enzymes that control protein phosphorylation. PRL phosphatases constitute a novel class of small (20 kDa), prenylated phosphatases with oncogenic activity. In particular, PRL-3 is consistently overexpressed in liver metastasis in colorectal cancer cells and represents a new therapeutic target. Here, we present the solution structure of PRL-3, the first structure of a PRL phosphatase. The structure places PRL phosphatases in the class of dual specificity phosphatases with closest structural homology to the VHR phosphatase. The structure, coupled with kinetic studies of site-directed mutants, identifies functionally important residues and reveals unique features, differentiating PRLs from other phosphatases. These differences include an unusually hydrophobic active site without the catalytically important serine/threonine found in most other phosphatases. The position of the general acid loop indicates the presence of conformational change upon catalysis. The studies also identify a potential regulatory role of Cys(49) that forms an intramolecular disulfide bond with the catalytic Cys(104) even under mildly reducing conditions. Molecular modeling of the highly homologous PRL-1 and PRL-2 phosphatases revealed unique surface elements that are potentially important for specificity.	Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada	National Research Council Canada; McGill University; Concordia University - Canada	Ekiel, I (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	irena.ekiel@nrc.ca	Gehring, Kalle/N-2945-2019; Gehring, Kalle/I-4403-2013	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Billeter M, 1995, J BIOMOL NMR, V5, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Diamond RH, 1996, AM J PHYSIOL-GASTR L, V271, pG121, DOI 10.1152/ajpgi.1996.271.1.G121; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kozlov G, 2002, J BIOMOL NMR, V24, P169, DOI 10.1023/A:1020937316065; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; McCain DF, 2002, J BIOL CHEM, V277, P11190, DOI 10.1074/jbc.M109636200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; Werner SR, 2003, CANCER LETT, V202, P201, DOI 10.1016/S0304-3835(03)00517-2; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	43	87	96	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11882	11889		10.1074/jbc.M312905200	http://dx.doi.org/10.1074/jbc.M312905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704153	hybrid			2022-12-27	WOS:000220157600125
J	Lambert, O; Cavusoglu, N; Gallay, J; Vincent, M; Rigaud, JL; Henry, JP; Ayala-Sanmartin, J				Lambert, O; Cavusoglu, N; Gallay, J; Vincent, M; Rigaud, JL; Henry, JP; Ayala-Sanmartin, J			Novel organization and properties of annexin 2-membrane complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; TRYPTOPHAN RESIDUE TRP-59; SITE-DIRECTED MUTAGENESIS; HEART APOCYTOCHROME-C; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; VESICLE AGGREGATION; CALPACTIN-I; MOLECULAR CHARACTERIZATION	Annexin 2 belongs to the annexin family of proteins that bind to phospholipid membranes in a Ca2+-dependent manner. Here we show that, under mild acidic conditions, annexin 2 binds to and aggregates membranes containing anionic phospholipids, a fact that questions the mechanism of its interaction with membranes via Ca2+ bridges only. The H+ sensitivity of annexin 2-mediated aggregation is modulated by lipid composition (i.e. cholesterol content). Cryo-electron microscopy of aggregated liposomes revealed that both the monomeric and the tetrameric forms of the protein form bridges between the liposomes at acidic pH. Monomeric annexin 2 induced two different organizations of the membrane junctions. The first resembled that obtained at pH 7 in the presence of Ca2+. For the tetramer, the arrangement was different. These bridges seemed more flexible than the Ca2+-mediated junctions allowing the invagination of membranes. Time-resolved fluorescence analysis at mild acidic pH and the measurement of Stokes radius revealed that the protein undergoes conformational changes similar to those induced by Ca2+. Labeling with the lipophilic probe 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine indicated that the protein has access to the hydrophobic part of the membrane at both acidic pH in the absence of Ca2+ and at neutral pH in the presence of Ca2+. Models for the membrane interactions of annexin 2 at neutral pH in the presence of Ca2+ and at acidic pH are discussed.	CHU St Antoine, INSERM, U538, F-75012 Paris, France; CNRS, Inst Biol Physicochim, UPR 1929, Unite Biol Cellulaire & Mol Secret, F-75005 Paris, France; CNRS, Inst Curie, F-75005 Paris, France; Univ Paris 11, CNRS, Lab Utilisat Rayonnement Electromagnet, F-91898 Orsay, France; Hop St Antoine, INSERM, U592, Lab Physiopathol Cellulaire & Mol Retine, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Ayala-Sanmartin, J (corresponding author), CHU St Antoine, INSERM, U538, 27 Rue Chaligny, F-75012 Paris, France.	jayala@chusa.jussieu.fr		Lambert, Olivier/0000-0002-5651-8082; Cavusoglu, Nukhet/0000-0001-9350-5312				Ayala-Sanmartin J, 2001, BIOCHEM BIOPH RES CO, V283, P72, DOI 10.1006/bbrc.2001.4748; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15179, DOI 10.1021/bi000501x; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15190, DOI 10.1021/bi000764r; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Bitto E, 2000, BIOCHEMISTRY-US, V39, P13469, DOI 10.1021/bi001275u; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; Brazill DT, 2000, J BIOL CHEM, V275, P19231, DOI 10.1074/jbc.M000900200; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DELAFUENTE M, 1995, BIOCHEMISTRY-US, V34, P10393, DOI 10.1021/bi00033a010; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERNST JD, 1991, J BIOL CHEM, V266, P6670; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; Faure AV, 2002, EXP CELL RES, V276, P79, DOI 10.1006/excr.2002.5512; GENGE BR, 1991, J BIOL CHEM, V266, P10678; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; Golczak Marcin, 2001, FASEB Journal, V15, P1083; Goldmann WH, 1999, EUR J BIOCHEM, V261, P155, DOI 10.1046/j.1432-1327.1999.00259.x; HOEKSTRA D, 1993, BIOCHEMISTRY-US, V32, P14194, DOI 10.1021/bi00214a019; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JONES PG, 1994, BIOCHEMISTRY-US, V33, P13751, DOI 10.1021/bi00250a028; Jost M, 1997, J CELL SCI, V110, P221; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lee KH, 1999, FEBS LETT, V442, P143, DOI 10.1016/S0014-5793(98)01643-3; Liu L, 1999, CELL SIGNAL, V11, P317, DOI 10.1016/S0898-6568(98)00047-3; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Otto JC, 1996, J BIOL CHEM, V271, P9906, DOI 10.1074/jbc.271.17.9906; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; Ramirez MA, 2000, J MEMBRANE BIOL, V177, P149, DOI 10.1007/s002320001108; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Rosengarth A, 1999, J MOL BIOL, V288, P1013, DOI 10.1006/jmbi.1999.2732; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SOPKOVA J, 1994, BIOCHEMISTRY-US, V33, P4490, DOI 10.1021/bi00181a008; SOPKOVA J, 1993, J MOL BIOL, V234, P816, DOI 10.1006/jmbi.1993.1627; Sopkova J, 1998, BIOCHEMISTRY-US, V37, P11962, DOI 10.1021/bi980773o; Souza MM, 2000, MOL CELL BIOCHEM, V210, P173, DOI 10.1023/A:1007154412805; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; THIEL C, 1991, J BIOL CHEM, V266, P14732; VINCENT M, 1995, J PHYS CHEM-US, V99, P14931, DOI 10.1021/j100041a006; VINCENT M, 1988, BIOCHEMISTRY-US, V27, P8752, DOI 10.1021/bi00424a010; VINCENT M, 1991, EUR BIOPHYS J, V20, P183, DOI 10.1007/BF01561141; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592	63	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10872	10882		10.1074/jbc.M313657200	http://dx.doi.org/10.1074/jbc.M313657200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701819	hybrid			2022-12-27	WOS:000220157600008
J	Stromer, T; Fischer, E; Richter, K; Haslbeck, M; Buchner, J				Stromer, T; Fischer, E; Richter, K; Haslbeck, M; Buchner, J			Analysis of the regulation of the molecular chaperone Hsp26 by temperature-induced dissociation - The N-terminal domain is important for oligomer assembly and the binding of unfolding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-CRYSTALLIN; QUATERNARY STRUCTURE; ESCHERICHIA-COLI; SUBUNIT EXCHANGE; CITRATE SYNTHASE; EXPRESSION; EVOLUTION; FAMILY	Small heat shock proteins (sHsps) are molecular chaperones that efficiently bind non-native proteins. All members of this family investigated so far are oligomeric complexes. For Hsp26, an sHsp from the cytosol of Saccharomyces cerevisiae, it has been shown that at elevated temperatures the 24-subunit complex dissociates into dimers. This dissociation seems to be required for the efficient interaction with unfolding proteins that results in the formation of large, regular complexes comprising Hsp26 and the non-native proteins. To gain insight into the molecular mechanism of this chaperone, we analyzed the dynamics and stability of the two oligomeric forms of Hsp 26 (i.e. the 24-mer and the dimer) in comparison to a construct lacking the N-terminal domain (Hsp26DeltaN). Furthermore, we determined the stabilities of complexes between Hsp26 and non-native proteins. We show that the temperature-induced dissociation of Hsp26 into dimers is a completely reversible process that involves only a small change in energy. The unfolding of the dissociated Hsp26 dimer or Hsp26DeltaN, which is a dimer, requires a much higher energy. Because Hsp26DeltaN was inactive as a chaperone, these results imply that the N-terminal domain is of critical importance for both the association of Hsp26 with non-native proteins and the formation of large oligomeric complexes. Interestingly, complexes of Hsp26 with non-native proteins are significantly stabilized against dissociation compared with Hsp26 complexes. Taken together, our findings suggest that the quaternary structure of Hsp26 is determined by two elements, (i) weak, regulatory interactions required to form the shell of 24 subunits and (ii) a strong and stable dimerization of the C-terminal domain.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010; Haslbeck, Martin/A-4413-2013	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				Arrigo AP, 2000, PATHOL BIOL, V48, P280; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Halevi I, 1998, J PALESTINE STUD, V27, P35, DOI 10.1525/jps.1998.27.3.00p0186t; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Haslbeck M, 2003, J CHROMATOGR B, V786, P127, DOI 10.1016/S1570-0232(02)00716-X; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; Kappe Guido, 2002, Prog Mol Subcell Biol, V28, P1; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kokke BPA, 1998, FEBS LETT, V433, P228, DOI 10.1016/S0014-5793(98)00917-X; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; van de Klundert FAJM, 1998, EUR J BIOCHEM, V258, P1014, DOI 10.1046/j.1432-1327.1998.2581014.x; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VIERLING E, 1989, MOL CELL BIOL, V9, P461, DOI 10.1128/MCB.9.2.461; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Waters ER, 1999, P NATL ACAD SCI USA, V96, P14394, DOI 10.1073/pnas.96.25.14394	33	112	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11222	11228		10.1074/jbc.M310149200	http://dx.doi.org/10.1074/jbc.M310149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722093	hybrid			2022-12-27	WOS:000220157600048
J	Leu, TH; Yeh, HH; Huang, CC; Chuang, YC; Su, SL; Maa, MC				Leu, TH; Yeh, HH; Huang, CC; Chuang, YC; Su, SL; Maa, MC			Participation of p97(Eps8) in Src-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; HISTONE DEACETYLASE INHIBITOR; TYROSINE KINASE SUBSTRATE; TRICHOSTATIN-A; MORPHOLOGICAL REVERSION; WAF1/CIP1 GENE; EPS8; EXPRESSION; CELLS; PHOSPHORYLATION	Histone acetylase and histone deacetylase are two crucial enzymes that determine the structure of chromatin, regulating gene expression. In this study, we observed that trichostatin A (TSA), a specific histone deacetylase inhibitor, could effectively inhibit the growth of v-Src-transformed (IV5) cells and abrogate their ability to form colonies in soft agar. Further analysis demonstrated that, although TSA reduced the expression of Eps8 in a dose- and time-dependent manner, both the protein expression and kinase activity of v-Src remained constant, and the abundance and phosphotyrosine levels of Src substrates, including cortactin, focal adhesion kinase, p130(Cas), paxillin, and Shc, were not altered. Notably, removal of TSA from the medium restored not only the expression of Eps8, but also cellular growth. Northern and reverse transcription-PCR analyses revealed the significant reduction of eps8 transcripts in TSA-treated IV5 cells relative to control cells. When active Src-expressing chicken embryonic cells were forced to overexpress p97(Eps8), they became resistant to TSA-mediated anti-proliferation. Furthermore, using small interference RNA of eps8, we demonstrated the requirement for Eps8 in IV5 cell proliferation. Thus, our results highlight a critical role for p97(Eps8) in TSA-exerted growth inhibition of v-Src-transformed cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung Shan Med Univ, Inst Biochem, Taichung 402, Taiwan	National Cheng Kung University; Chung Shan Medical University	Maa, MC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.	mc1331@csmc.edu.tw	Hsu, Kuei-Sen/AAV-8386-2021					Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; KARLSSON T, 1995, ONCOGENE, V10, P1475; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Mariadason JM, 2000, CANCER RES, V60, P4561; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MIYASHITA T, 1994, FEBS LETT, V353, P225, DOI 10.1016/0014-5793(94)01034-X; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Rombouts K, 2002, J HEPATOL, V37, P788, DOI 10.1016/S0168-8278(02)00275-1; Rombouts K, 2002, EXP CELL RES, V278, P184, DOI 10.1006/excr.2002.5577; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUGITA K, 1992, CANCER RES, V52, P168; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; TSUJI N, 1976, J ANTIBIOT, V29, P1, DOI 10.7164/antibiotics.29.1; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WONG WT, 1994, ONCOGENE, V9, P3057; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	42	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9875	9881		10.1074/jbc.M309884200	http://dx.doi.org/10.1074/jbc.M309884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699156	hybrid			2022-12-27	WOS:000220050400027
J	Perez-Ortiz, JM; Tranque, P; Vaquero, CF; Domingo, B; Molina, F; Calvo, S; Jordan, J; Cena, V; Llopis, J				Perez-Ortiz, JM; Tranque, P; Vaquero, CF; Domingo, B; Molina, F; Calvo, S; Jordan, J; Cena, V; Llopis, J			Glitazones differentially regulate primary astrocyte and glioma cell survival - Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDATIVE STRESS; CYCLE ARREST; METABOLISM; APOPTOSIS; AGONISTS; KINASE; INHIBIT; GROWTH	The glitazones or thiazolidinediones are ligands of the peroxisome proliferator-activated receptor gamma (PPARgamma). The glitazones are used in the treatment of diabetes, regulate adipogenesis, inflammation, cell proliferation, and induce apoptosis in several cancer cell types. High grade astrocytomas are rapidly growing tumors derived from astrocytes, for which new treatments are needed. We determined the effects of two glitazones, ciglitazone and the therapeutic rosiglitazone, on the survival of serum-deprived primary rat astrocytes and glioma cell lines C6 and U251, which were assessed by the methylthiazolyl tetrazolium assay and lactate dehydrogenase release. Rosiglitazone ( 5 - 20 muM) decreased survival of glioma cells without affecting primary astrocytes, whereas ciglitazone at 20 muM was toxic for both cell types. Ciglitazone at 10 muM was cytoprotective for primary astrocytes but toxic to glioma cells. Cell death induced by ciglitazone, but not rosiglitazone, presented apoptotic features ( Hoechst staining and externalization of phosphatidylserine). Two mechanisms to explain cytotoxicity were investigated: activation of PPARgamma and production of reactive oxygen species (ROS). PPARgamma does not seem to be the main mechanism involved, because the order of efficacy for cytotoxicity, ciglitazone > rosiglitazone, was inverse of their reported affinities for activating PPARgamma. In addition, GW9662, an inhibitor of PPARgamma, only slightly attenuated cytotoxicity. However, the rapid increase in ROS production and the marked reduction of cell death with the antioxidants ebselen and N-acetylcysteine, indicate that ROS have a key role in glitazone cytotoxicity. Ciglitazone caused a dose-dependent and rapid loss ( in minutes) of mitochondrial membrane potential in glioma cells. Therefore, mitochondria are a likely source of ROS and early targets of glitazone cytotoxicity. Our results highlight the potential of rosiglitazone and related compounds for the treatment of astrogliomas.	Univ Castilla La Mancha, Fac Med, Physiol Unit, Albacete 02006, Spain; Univ Castilla La Mancha, Ctr Reg Invest Biomed, Albacete 02006, Spain	Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha	Tranque, P (corresponding author), Univ Castilla La Mancha, Fac Med, Physiol Unit, Ave Almansa S-N, Albacete 02006, Spain.	pedro.tranque@uclm.es	Cena, Valentin/L-1751-2017; Llopis, Juan/I-2622-2012; PÉREZ-ORTIZ, JOSÉ M./R-5379-2019	Cena, Valentin/0000-0001-8928-3681; Llopis, Juan/0000-0002-9460-0642; PÉREZ-ORTIZ, JOSÉ M./0000-0002-3588-6273; Tranque Gomez, Pedro Antonio/0000-0003-1072-7337; jordan, joaquin/0000-0002-6809-3384; Fernandez Vaquero, Cecilia/0000-0002-7415-9060; Domingo, Beatriz/0000-0001-9430-4803				ALTMAN FP, 1976, HISTOCHEM J, V8, P471, DOI 10.1007/BF01003837; Bae MA, 2003, TOXICOL LETT, V139, P67, DOI 10.1016/S0378-4274(02)00468-X; BASS DA, 1983, J IMMUNOL, V130, P1910; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Gupta RA, 2003, J BIOL CHEM, V278, P7431, DOI 10.1074/jbc.M208076200; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; INOUE I, 2004, AM J PHYSIOL, V286, pE252; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Mossner R, 2002, J INVEST DERMATOL, V119, P576, DOI 10.1046/j.1523-1747.2002.01861.x; Narayanan PK, 2003, CYTOM PART A, V52A, P28, DOI 10.1002/cyto.a.10011; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wilmer WA, 2001, BIOCHEM BIOPH RES CO, V281, P57, DOI 10.1006/bbrc.2001.4301; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; YOUNG PR, 1994, BBA-GEN SUBJECTS, V1201, P461, DOI 10.1016/0304-4165(94)90077-9; Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471-4159.2002.00899.x	47	113	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8976	8985		10.1074/jbc.M308518200	http://dx.doi.org/10.1074/jbc.M308518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699130	hybrid			2022-12-27	WOS:000189265900056
J	Kimura, A; Kinjyo, I; Matsumura, Y; Mori, H; Mashima, R; Harada, M; Chien, KR; Yasukawa, H; Yoshimura, A				Kimura, A; Kinjyo, I; Matsumura, Y; Mori, H; Mashima, R; Harada, M; Chien, KR; Yasukawa, H; Yoshimura, A			SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-CSF RECEPTOR; NEUTROPHIL CHEMOTAXIS; CYTOKINE SIGNALING-3; STAT3 ACTIVATION; WHOLE-BLOOD; MICE; MACROPHAGES; MUTATION; BINDING; GENE	The suppressor of cytokine signaling-3 (SOCS3/CIS3) has been shown to be an important negative regulator of cytokines, especially cytokines that activate STAT3. To examine the role of SOCS3 in neutrophils and the granulocyte colony-stimulating factor (G-CSF) signaling in vivo, we compared neutrophils from two types of conditional knockout mice, LysM-Cre:SOCS3(fl/fl) mice and Tie2-Cre:SOCS3(fl/fl) mice, in which the Socs3 gene had been deleted in mature neutrophils and hematopoietic stem cells, respectively. The size of the G-CSF-dependent colonies from Tie2-Cre:SOCS3(fl/fl) mouse bone marrow was much larger than that of colonies from control wild-type mice, while the size of interleukin-3-dependent colonies was similar. Moreover, LysM-Cre:SOCS3(fl/fl) mice had more neutrophils than SOCS3(fl/fl) mice, suggesting that SOCS3 is a negative regulator of G-CSF signaling in neutrophils. Consistent with this notion, G-CSF-induced STAT3 as well as mitogen-activated protein kinase activation was much stronger and prolonged in SOCS3-deficient mature neutrophils than in wildtype neutrophils. The preventive effect of G-CSF on apoptosis was more prominent in SOCS3-deficient mature neutrophils than in control neutrophils. These data indicate that SOCS3 negatively regulates granulopoiesis and G-CSF signaling in neutrophils and may contribute to neutrophilia or neutropenia.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med, Dept Internal Med, Higashi Ku, Fukuoka 8128582, Japan; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kurume Univ, Cardiovasc Res Inst, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan	Kyushu University; Kyushu University; University of California System; University of California San Diego; University of California System; University of California San Diego; Kurume University; Kurume University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	MORI, HIROYUKI/D-3343-2013; Yoshimura, Akihiko/K-5515-2013	Kinjyo, Ichiko/0000-0001-7051-3790; Kimura, Akiko/0000-0001-8136-5009				Basu S, 2000, BLOOD, V95, P3725; BELLAVITE P, 1983, EUR J CLIN INVEST, V13, P363; Cassatella MA, 1999, BLOOD, V94, P2880, DOI 10.1182/blood.V94.8.2880.420k31_2880_2889; Cavallaro A, 2003, PHYSIOL RES, V52, P555; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Hermans MHA, 1998, BLOOD, V92, P32, DOI 10.1182/blood.V92.1.32.413k42_32_39; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Ludwig A, 1997, BLOOD, V90, P4588; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; MIER JW, 1990, BLOOD, V76, P1933; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rodriguez ME, 2001, J IMMUNOL METHODS, V252, P33, DOI 10.1016/S0022-1759(01)00329-5; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; Tonko-Geymayer S, 2002, MOL ENDOCRINOL, V16, P1680, DOI 10.1210/me.16.7.1680; Ward AC, 1998, BBA-MOL CELL RES, V1448, P70, DOI 10.1016/S0167-4889(98)00120-7; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	37	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6905	6910		10.1074/jbc.C300496200	http://dx.doi.org/10.1074/jbc.C300496200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14699146	hybrid			2022-12-27	WOS:000188969200085
J	El Hadri, K; Glorian, M; Monsempes, C; Dieudonne, MN; Pecquery, R; Giudicelli, Y; Andreani, M; Dugail, I; Feve, B				El Hadri, K; Glorian, M; Monsempes, C; Dieudonne, MN; Pecquery, R; Giudicelli, Y; Andreani, M; Dugail, I; Feve, B			In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV PROTEASE INHIBITORS; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; ELEMENT-BINDING PROTEIN-1C; FATTY-ACID SYNTHETASE; INSULIN-RESISTANCE; HIV-1-INFECTED PATIENTS; ADIPOSE-TISSUE; GENE-EXPRESSION; DIABETES-MELLITUS	A serious metabolic syndrome combining insulin-resistance, dyslipidemia, central adiposity, and peripheral lipoatrophy has arisen in HIV-infected patients receiving highly active antiretroviral therapy. The aim of this work was to examine the effects of the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz on adipocyte differentiation and metabolism. When induced to differentiate in the presence of efavirenz ( 5 - 50 muM), 3T3-F442A preadipocytes failed to accumulate cytoplasmic triacylglycerol droplets. This phenomenon was rapidly reversible and was also readily detectable in the 3T3-L1 preadipose cell line and in primary cultures of human preadipocytes. When applied to mature 3T3-F442A adipocytes, efavirenz induced a delayed and moderate reduction in cell triglyceride content. Measurement of [H-3] deoxyglucose uptake, basal and agonist-stimulated lipolysis, and cell viability indicated that these pathways are not involved in efavirenz effects on triacylglycerol accumulation. By contrast, we found that the NNRTI induced a dramatic dose- and time-dependent decrease in gene and protein expression of the lipogenic transcription factor sterol regulatory element-binding protein-1c (SREBP-1c). Adipose conversion was only altered at the highest efavirenz concentrations, as suggested by the mild reduction in peroxisome proliferator-activated receptor-gamma and CCAAT/enhancer-binding protein-alpha. CCAAT/enhancer-binding protein-beta remained unchanged. The inhibition of SREBP-1c expression was accompanied by a sharp reduction in the expression of SREBP-1c target genes and in the adipocyte lipogenic activity in efavirenz-treated cells. Finally, the inhibitory effect of efavirenz on cell triglyceride accumulation was prevented by directly providing free fatty acids to the cells and was reversed by overexpression of a dominant positive form of SREBP-1c, reinforcing the implication of this transcription factor in the antilipogenic effect of the drug. When considered together, these results demonstrate for the first time that the NNRTI efavirenz induces a strong inhibition of the SREBP-1c-dependent lipogenic pathway that might contribute to adipose tissue atrophy.	Univ Paris 06, CNRS, UMR 7079, F-75006 Paris, France; Ctr Rech Biomed Cordeliers, INSERM, U465, F-75006 Paris, France; Univ Versailles, Fac Med Paris Ile France Ouest, Ctr Hosp Poissy, Serv Biochim, F-78303 Poissy, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Hospital Chi of Poissy Saint Germain; UDICE-French Research Universities; Universite Paris Saclay	Feve, B (corresponding author), Univ Paris 06, CNRS, UMR 7079, 15 Rue Ecole Med, F-75006 Paris, France.	feve@bhdc.jussieu.fr	Dugail, Isabelle/L-1567-2017	Dugail, Isabelle/0000-0003-3631-2252; GLORIAN, Martine/0000-0002-4502-3543; EL HADRI, KHADIJA/0000-0002-1275-9861; Feve, Bruno/0000-0001-6577-9009				Barreiro P, 2000, AIDS, V14, P807, DOI 10.1097/00002030-200005050-00006; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Beach JW, 1998, CLIN THER, V20, P2; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Boffito M, 2003, AIDS RES HUM RETROV, V19, P825, DOI 10.1089/088922203769232629; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bonnet F, 2002, CLIN INFECT DIS, V35, P776, DOI 10.1086/342326; Caron M, 2003, AIDS, V17, P2437, DOI 10.1097/00002030-200311210-00005; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clumeck N, 2001, AIDS, V15, P1517, DOI 10.1097/00002030-200108170-00009; Dieleman JP, 1999, AIDS, V13, P1423, DOI 10.1097/00002030-199907300-00029; Dieudonne MN, 1998, AM J PHYSIOL-CELL PH, V274, pC1645, DOI 10.1152/ajpcell.1998.274.6.C1645; Diraison F, 2003, J LIPID RES, V44, P846, DOI 10.1194/jlr.M200461-JLR200; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Doser N, 2001, J ACQ IMMUN DEF SYND, V26, P389, DOI 10.1097/00126334-200104010-00018; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Dupin N, 2002, AIDS, V16, P2419, DOI 10.1097/00002030-200212060-00006; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FOLCH J, 1957, J BIOL CHEM, V226, P497; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Gagnon A, 1998, LANCET, V352, P1032, DOI 10.1016/S0140-6736(05)60074-8; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Grinspoon S, 2001, TRENDS ENDOCRIN MET, V12, P413, DOI 10.1016/S1043-2760(01)00472-6; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hirschel B, 2002, AIDS, V16, P381, DOI 10.1097/00002030-200202150-00009; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Hsieh SM, 2000, J ACQ IMMUN DEF SYND, V24, P287; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; Langmann P, 2002, EUR J MED RES, V7, P309; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madge S, 1999, AIDS, V13, P735, DOI 10.1097/00002030-199904160-00020; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miserez AR, 2002, AIDS, V16, P1587, DOI 10.1097/00002030-200208160-00003; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Nerurkar PV, 2001, CLIN BIOCHEM, V34, P519, DOI 10.1016/S0009-9120(01)00239-9; Nguyen AT, 2000, AIDS, V14, P2467, DOI 10.1097/00002030-200011100-00007; Ogedegbe AEO, 2003, LANCET INFECT DIS, V3, P329, DOI 10.1016/S1473-3099(03)00654-6; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rey D, 2001, J ACQ IMMUN DEF SYND, V27, P459, DOI 10.1097/00126334-200108150-00006; Riddle TM, 2001, J BIOL CHEM, V276, P37514, DOI 10.1074/jbc.M104557200; ROLLAND V, 1995, J BIOL CHEM, V270, P1102, DOI 10.1074/jbc.270.3.1102; Rosen ED, 2000, GENE DEV, V14, P1293; Rudich A, 2001, DIABETES, V50, P1425, DOI 10.2337/diabetes.50.6.1425; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Smith PF, 2001, CLIN PHARMACOKINET, V40, P893, DOI 10.2165/00003088-200140120-00002; Stocker DN, 1998, LANCET, V352, P320, DOI 10.1016/S0140-6736(05)60295-4; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Tashima KT, 1999, J INFECT DIS, V180, P862, DOI 10.1086/314945; van der Valk M, 2003, CURR OPIN INFECT DIS, V16, P19, DOI 10.1097/00001432-200302000-00004; Vernochet C, 2003, AIDS, V17, P2177, DOI 10.1097/00002030-200310170-00005; Vigouroux C, 1999, DIABETES METAB, V25, P225; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	76	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15130	15141		10.1074/jbc.M312875200	http://dx.doi.org/10.1074/jbc.M312875200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722061	hybrid			2022-12-27	WOS:000220594700079
J	Mao, HP; Wang, YH; Li, ZJ; Ruchalski, KL; Yu, XQ; Schwartz, JH; Borkan, SC				Mao, HP; Wang, YH; Li, ZJ; Ruchalski, KL; Yu, XQ; Schwartz, JH; Borkan, SC			Hsp72 interacts with paxillin and facilitates the reassembly of focal adhesions during recovery from ATP depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL EPITHELIAL-CELLS; HEAT-SHOCK PROTEINS; NA+-K+-ATPASE; MOLECULAR CHAPERONES; INHIBITS APOPTOSIS; SUBLETHAL INJURY; STRESS FIBER; ACTIN; CYTOSKELETON; REDISTRIBUTION	The cytoprotective effect of heat stress proteins on epithelial cell detachment, an important cause of acute, ischemic renal failure, was examined after ATP depletion by evaluating focal adhesion complex (FAC) integrity. The intracellular distribution of FAC proteins ( paxillin, talin, and vinculin) was assessed by immunohistochemistry before, during, and after exposure of renal epithelial cells to metabolic inhibitors. The resulting ATP depletion caused reversible re-distribution of all three proteins from focal adhesions to the cytosol. Paxillin, a key adaptor protein, was selected as a surrogate marker for FAC integrity in subsequent studies. Prior heat stress increased hsp72, a molecular chaperone, in both the Triton X-100-soluble and - insoluble protein fractions. Compared with ATP depleted control, heat stress significantly decreased paxillin and hsp72 shift from the Triton X-100 soluble to the insoluble protein fraction ( an established marker of denaturation and aggregation); increased paxillin-hsp72 interaction detected by co-immunoprecipitation; enhanced paxillin extractability from Triton X-100-insoluble precipitates, increased the reformation of focal adhesions, and improved cell attachment ( p < 0.05). To determine whether hsp72 mediates protection afforded by heat stress, cells were infected with adenovirus containing human hsp72 or empty vector. Hsp72 overexpression increased its interaction with paxillin and improved focal adhesion reformation during recovery, mimicking the protective effects of heat stress. These data suggest that hsp72 facilitates the reassembly of focal adhesions and improves cell attachment by reducing paxillin denaturation and increasing its re-solubilization after ATP depletion.	Zhongshan Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510080, Peoples R China; Boston Med Ctr, Renal Sect, Evans Biomed Res Ctr, Boston, MA 02118 USA	Sun Yat Sen University; Boston Medical Center	Borkan, SC (corresponding author), Boston Med Ctr, Renal Sect, Evans Biomed Res Ctr, Rm 546,650 Albany St, Boston, MA 02118 USA.	sborkan@bu.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Mao, Haiping/0000-0002-3608-3851; Borkan, Steven/0000-0003-3062-9486	NIDDK NIH HHS [DK-5298, DK-47994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF268, DOI 10.1152/ajprenal.1998.274.2.F268; Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF215, DOI 10.1152/ajprenal.1998.274.1.F215; Aufricht C, 2002, PEDIATR RES, V51, P722, DOI 10.1203/01.PDR.0000015128.65800.28; Beissinger M, 1998, BIOL CHEM, V379, P245; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Bidmon B, 2000, KIDNEY INT, V58, P2400, DOI 10.1046/j.1523-1755.2000.00423.x; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; Borkan SC, 1997, AM J PHYSIOL-RENAL, V272, pF347, DOI 10.1152/ajprenal.1997.272.3.F347; BRADY HR, 2000, KIDNEY, V1, P1201; BRAGA VMM, 1995, CELL ADHES COMMUN, V3, P201, DOI 10.3109/15419069509081287; EMAMI A, 1991, AM J PHYSIOL, V260, pF479, DOI 10.1152/ajprenal.1991.260.4.F479; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FISH EM, 1994, AM J PHYSIOL-RENAL, V267, pF566, DOI 10.1152/ajprenal.1994.267.4.F566; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; GABAI VL, 1992, TISSUE CELL, V24, P171, DOI 10.1016/0040-8166(92)90090-T; GABAI VL, 1993, FEBS LETT, V327, P247, DOI 10.1016/0014-5793(93)80997-9; GAILIT J, 1993, AM J PHYSIOL, V264, pF149, DOI 10.1152/ajprenal.1993.264.1.F149; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; GLASCOTT PA, 1987, CELL MOTIL CYTOSKEL, V8, P118, DOI 10.1002/cm.970080204; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; Herget-Rosenthal S, 2001, AM J PHYSIOL-CELL PH, V281, pC1858, DOI 10.1152/ajpcell.2001.281.6.C1858; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HINSHAW DB, 1988, AM J PATHOL, V132, P479; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KABAKOV AE, 1993, EXPERIENTIA, V49, P706, DOI 10.1007/BF01923956; KABAKOV AE, 2002, AM J PHYSIOL, V283, pL521; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; Lieberthal W, 1998, SEMIN NEPHROL, V18, P505; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Martin JL, 1997, CIRCULATION, V96, P4343; Martin-Bermudo MD, 2000, J CELL SCI, V113, P3715; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MOLITORIS BA, 1992, AM J PHYSIOL, V263, pF488, DOI 10.1152/ajprenal.1992.263.3.F488; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; NOIRI E, 1994, KIDNEY INT, V46, P1050, DOI 10.1038/ki.1994.366; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; RACUSEN LC, 1991, LAB INVEST, V64, P546; Racusen LC, 1998, CLIN EXP PHARMACOL P, V25, P273, DOI 10.1111/j.1440-1681.1998.t01-3-.x; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Shelden EA, 2002, J AM SOC NEPHROL, V13, P2667, DOI 10.1097/01.ASN.0000033353.21502.31; Shelden EA, 2002, J AM SOC NEPHROL, V13, P332, DOI 10.1681/ASN.V132332; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; SIMON EE, 1994, AM J PHYSIOL-RENAL, V267, pF612, DOI 10.1152/ajprenal.1994.267.4.F612; Sogabe K, 1996, AM J PHYSIOL-RENAL, V271, pF292, DOI 10.1152/ajprenal.1996.271.2.F292; Tessier DJ, 2003, J SURG RES, V111, P152, DOI 10.1016/S0022-4804(03)00113-6; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; VANWHY SK, 1994, AM J PHYSIOL, V267, pF75, DOI 10.1152/ajprenal.1994.267.1.F75; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2001, AM J PHYSIOL-CELL PH, V281, pC1667, DOI 10.1152/ajpcell.2001.281.5.C1667	59	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15472	15480		10.1074/jbc.M313484200	http://dx.doi.org/10.1074/jbc.M313484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14718530	hybrid			2022-12-27	WOS:000220594700118
J	Schneider, M; Brufatto, N; Neill, E; Nesheim, M				Schneider, M; Brufatto, N; Neill, E; Nesheim, M			Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCARBOXYPEPTIDASE-B; THERMAL-STABILITY; KINETICS; TAFI; ALPHA(2)-ANTIPLASMIN; ALPHA-2-ANTIPLASMIN; CARBOXYPEPTIDASE; VARIANTS; RESPECT; MODEL	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is a carboxypeptidase B-like plasma enzyme that can slow clot lysis by removing lysine residues exposed on fibrin as it is cleaved by plasmin. Previously, it was shown that fibrin treated with TAFIa is less able to promote plasminogen activation by tissue-type plasminogen activator. In this study, the effect of TAFIa modification of a fibrin surface on the rate of plasmin inhibition by antiplasmin was studied using high molecular weight fibrin degradation products (HMw-FDPs) as a soluble model for intact plasmin-modified fibrin. To quantify the inhibition, a novel end point assay was employed where plasmin, antiplasmin, and cofactors were mixed in the presence of a chromogenic substrate and the end point in the substrate hydrolysis reaction was used to measure the second order rate constant of inhibition. When HMw-FDPs were titrated in the presence of plasmin and antiplasmin, the rate constant for inhibition decreased by 16-fold at saturation (9.6 x 10(6) M-1 s(-1) to 0.59 x 10(6) M-1 s(-1)). When HMw-FDPs were pretreated with TAFIa, nearly two-thirds of the protective effect was lost. When 730 nM HMw-FDPs were treated for 20 min with TAFIa, the rate constant for plasmin inhibition was increased 3-fold from 1.9 x 10(6) M-1 s(-1) to 6.2 x 10(6) M-1 s(-1). Therefore, a novel mechanism was identified whereby TAFIa can modulate plasmin levels by increasing the susceptibility of plasmin to inhibition by antiplasmin.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Rm A212,Botterell Hall, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Brufatto N, 2001, J BIOL CHEM, V276, P17663, DOI 10.1074/jbc.M011586200; Christensen U, 1996, FEBS LETT, V387, P58, DOI 10.1016/0014-5793(96)00429-2; EATON DL, 1991, J BIOL CHEM, V266, P21833; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; KOLEV K, 1994, J BIOL CHEM, V269, P17030; Lee AYY, 2001, THROMB HAEMOSTASIS, V85, P502, DOI 10.1055/s-0037-1615612; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Mutch NJ, 2003, J THROMB HAEMOST, V1, P2000, DOI 10.1046/j.1538-7836.2003.00383.x; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; Wang HY, 2003, EUR J BIOCHEM, V270, P2023, DOI 10.1046/j.1432-1033.2003.03578.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	25	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13340	13345		10.1074/jbc.M313211200	http://dx.doi.org/10.1074/jbc.M313211200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715654	hybrid			2022-12-27	WOS:000220478500010
J	Chao, Y; Fu, D				Chao, Y; Fu, D			Kinetic study of the antiport mechanism of an Escherichia coli zinc transporter, ZitB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSION FACILITATOR FAMILY; CONFERS RESISTANCE; MAMMALIAN ZINC; UPTAKE SYSTEM; ZNTA GENE; MEMBER; ENCODES; CELLS; PH	ZitB is a member of the cation diffusion facilitator (CDF) family that mediates efflux of zinc across the plasma membrane of Escherichia coli. We describe the first kinetic study of the purified and reconstituted ZitB by stopped-flow measurements of transmembrane fluxes of metal ions using a metal-sensitive fluorescent indicator encapsulated in proteoliposomes. Metal ion filling experiments showed that the initial rate of Zn2+ influx was a linear function of the molar ratio of ZitB to lipid and was related to the concentration of Zn2+ or Cd2+ by a hyperbola with a Michaelis-Menten constant (K-m) of 104.9 +/- 5.4 muM and 90.1 +/- 3.7 muM, respectively. Depletion of proton stalled Cd2+ transport down its diffusion gradient, whereas tetraethylammonium ion substitution for K+ did not affect Cd2+ transport, indicating that Cd2+ transport is coupled to H+ rather than to K+. H+ transport was inferred by the H+ dependence of Cd2+ transport, showing a hyperbolic relationship with a K-m of 19.9 nM for H+. Applying H+ diffusion gradients across the membrane caused Cd2+ fluxes both into and out of proteoliposomes against the imposed H+ gradients. Likewise, applying outwardly oriented membrane electrical potential resulted in Cd2+ efflux, demonstrating the electrogenic effect of ZitB transport. Taken together, these results indicate that ZitB is an antiporter catalyzing the obligatory exchange of Zn2+ or Cd2+ for H+. The exchange stoichiometry of metal ion for proton is likely to be 1: 1.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Fu, D (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 65137] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; Beavis RC, 1996, METHOD ENZYMOL, V270, P519; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; Blencowe DK, 2003, FEMS MICROBIOL REV, V27, P291, DOI 10.1016/S0168-6445(03)00041-X; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; DASILVA JJR, 2001, BIOL CHEM ELEMENTS I, P315; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Gee KR, 2002, CELL CALCIUM, V31, P245, DOI 10.1016/S0143-4160(02)00053-2; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; Grass G, 2001, J BACTERIOL, V183, P4664, DOI 10.1128/JB.183.15.4664-4667.2001; Guffanti AA, 2002, MOL MICROBIOL, V45, P145, DOI 10.1046/j.1365-2958.2002.02998.x; Harris ED, 2002, NUTR REV, V60, P121, DOI 10.1301/00296640260085877; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kimura E, 2000, J BIOL INORG CHEM, V5, P139, DOI 10.1007/s007750050359; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Lee SM, 2002, FEMS MICROBIOL LETT, V215, P273, DOI 10.1016/S0378-1097(02)00961-8; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PADAN E, 1987, J MEMBRANE BIOL, V95, P189, DOI 10.1007/BF01869481; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PRESSMAN BC, 1967, P NATL ACAD SCI USA, V58, P1949, DOI 10.1073/pnas.58.5.1949; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W	33	112	121	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12043	12050		10.1074/jbc.M313510200	http://dx.doi.org/10.1074/jbc.M313510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715669	hybrid			2022-12-27	WOS:000220334900007
J	Hanson, GT; Aggeler, R; Oglesbee, D; Cannon, M; Capaldi, RA; Tsien, RY; Remington, SJ				Hanson, GT; Aggeler, R; Oglesbee, D; Cannon, M; Capaldi, RA; Tsien, RY; Remington, SJ			Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; STRUCTURAL BASIS; GLUTATHIONE; VARIANTS; PH; DEPENDENCE; ISOMERASE; PROGRAM; PATHWAY; BINDING	Current methods for determining ambient redox potential in cells are labor- intensive and generally require destruction of tissue. This precludes single cell or real time studies of changes in redox poise that result from metabolic processes or environmental influences. By substitution of surface- exposed residues on the Aequorea victoria green fluorescent protein ( GFP) with cysteines in appropriate positions to form disulfide bonds, reduction- oxidation- sensitive GFPs ( roGFPs) have been created. roGFPs have two fluorescence excitation maxima at about 400 and 490 nm and display rapid and reversible ratiometric changes in fluorescence in response to changes in ambient redox potential in vitro and in vivo. Crystal structure analyses of reduced and oxidized crystals of roGFP2 at 2.0- and 1.9-Angstrom resolution, respectively, reveal in the oxidized state a highly strained disulfide and localized main chain structural changes that presumably account for the state- dependent spectral changes. roGFP1 has been targeted to the mitochondria in HeLa cells. Fluorometric measurements on these cells using a fluorescence microscope or in cell suspension using a fluorometer reveal that the roGFP1 probe is in dynamic equilibrium with the mitochondrial redox status and responds to membrane- permeable reductants and oxidants. The roGFP1 probe reports that the matrix space in HeLa cell mitochondria is highly reducing, with a midpoint potential near - 360 mV ( assuming mitochondrial pH similar to8.0 at 37degreesC). In other work ( C. T. Dooley, T. M. Dore, G. Hanson, W. C. Jackson, S. J. Remington, and R. Y. Tsien, submitted for publication), it is shown that the cytosol of HeLa cells is also unusually reducing but somewhat less so than the mitochondrial matrix.	Univ Oregon, Inst Mol Biol, Dept Phys, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Biol, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of Oregon; University of Oregon; University of Oregon; University of California System; University of California San Diego; University of California System; University of California San Diego	Remington, SJ (corresponding author), Univ Oregon, Inst Mol Biol, Dept Phys, Eugene, OR 97403 USA.	jim@uoxray.uoregon.edu	Oglesbee, Devin/AAU-5420-2021	Oglesbee, Devin/0000-0002-7147-5527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042618, T32GM007759] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07759, GM 42618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; CAPALDI RA, 2002, BIOCHIM BIOPHYS ACTA, V155, P192; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Hanson GT, 2002, BIOCHEMISTRY-US, V41, P15477, DOI 10.1021/bi026609p; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keese MA, 1999, FEBS LETT, V447, P135, DOI 10.1016/S0014-5793(99)00296-3; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ostergaard H, 2001, EMBO J, V20, P5853, DOI 10.1093/emboj/20.21.5853; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Remington SJ, 2000, METHOD ENZYMOL, V305, P196; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Topell S, 1999, FEBS LETT, V457, P283, DOI 10.1016/S0014-5793(99)01044-3; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905; Wachter RM, 1999, CURR BIOL, V9, pR628, DOI 10.1016/S0960-9822(99)80408-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; WHITAKER JE, 1991, ANAL BIOCHEM, V194, P330, DOI 10.1016/0003-2697(91)90237-N; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; ZHANG RM, 1989, J BIOL CHEM, V264, P18472; Zimmer M, 2002, CHEM REV, V102, P759, DOI 10.1021/cr010142r	63	701	725	5	139	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13044	13053		10.1074/jbc.M312846200	http://dx.doi.org/10.1074/jbc.M312846200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722062	hybrid			2022-12-27	WOS:000220334900125
J	Mani, K; Cheng, F; Havsmark, B; David, S; Fransson, LA				Mani, K; Cheng, F; Havsmark, B; David, S; Fransson, LA			Involvement of glycosylphosphatidylinositol-linked ceruloplasmin in the copper/zinc-nitric oxide-dependent degradation of glypican-1 heparan sulfate in rat C6 glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED FORM; PROTEOGLYCANS; AUTOCLEAVAGE; MECHANISM; NEURONS	The core protein of glypican- 1, a glycosylphosphatidylinositol-linked heparan sulfate proteoglycan, can bind Cu( II) or Zn( II) ions and undergo S- nitrosylation in the presence of nitric oxide. Cu( II)- to- Cu( I)- reduction supports extensive and permanent nitrosothiol formation, whereas Zn( II) ions appear to support a more limited, possibly transient one. Ascorbate induces release of nitric oxide, which catalyzes deaminative degradation of the heparan sulfate chains on the same core protein. Although free Zn( II) ions support a more limited degradation, Cu( II) ions support a more extensive self- pruning process. Here, we have investigated processing of glypican- 1 in rat C6 glioma cells and the possible participation of the copper- containing glycosylphosphatidylinositol-linked splice variant of ceruloplasmin in nitrosothiol formation. Confocal microscopy demonstrated colocalization of glypican- 1 and ceruloplasmin in endosomal compartments. Ascorbate induced extensive, Zn( II)- supported heparan sulfate degradation, which could be demonstrated using a specific zinc probe. RNA interference silencing of ceruloplasmin expression reduced the extent of Zn( II)- supported degradation. In cell- free experiments, the presence of free Zn( II) ions prevented free Cu( II) ion from binding to glypican- 1 and precluded extensive heparan sulfate autodegradation. However, in the presence of Cu( II)- loaded ceruloplasmin, heparan sulfate in Zn( II)loaded glypican- 1 underwent extensive, ascorbate- induced degradation. We propose that the Cu( II)- to- Cu( I)- reduction that is required for S- nitrosylation of glypican- 1 can take place on ceruloplasmin and thereby ensure extensive glypican-1 processing in the presence of free Zn( II) ions.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, Biomed Ctr C13, SE-22184 Lund, Sweden; McGill Univ, Montreal Gen Hosp, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	Lund University; McGill University	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, Biomed Ctr C13, SE-22184 Lund, Sweden.	lars-ake.fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634				Bansal R, 1996, MOL CELL NEUROSCI, V7, P276, DOI 10.1006/mcne.1996.0021; Bansal R, 2002, DEV NEUROSCI-BASEL, V24, P35, DOI 10.1159/000064944; Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; Berger UV, 2003, J NEUROCHEM, V86, P896, DOI 10.1046/j.1471-4159.2003.01891.x; Bielli P, 2002, CELL MOL LIFE SCI, V59, P1413, DOI 10.1007/s00018-002-8519-2; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fransson LA, 2003, INT J BIOCHEM CELL B, V35, P125, DOI 10.1016/S1357-2725(02)00095-X; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Lee JY, 2003, J NEUROSCI RES, V73, P156, DOI 10.1002/jnr.10647; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Machonkin TE, 2000, J AM CHEM SOC, V122, P12547, DOI 10.1021/ja002339r; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Ornitz DM, 2001, GENOME BIOL, V2; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Patel BN, 2002, J NEUROSCI, V22, P6578; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Qiao DH, 2003, J BIOL CHEM, V278, P16045, DOI 10.1074/jbc.M211259200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805	26	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12918	12923		10.1074/jbc.M313678200	http://dx.doi.org/10.1074/jbc.M313678200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707133	hybrid			2022-12-27	WOS:000220334900109
J	Mitsui, K; Ochi, F; Nakamura, N; Doi, Y; Inoue, H; Kanazawa, H				Mitsui, K; Ochi, F; Nakamura, N; Doi, Y; Inoue, H; Kanazawa, H			A novel membrane protein capable of binding the Na+/H+ antiporter (Nha1p) enhances the salinity-resistant cell growth of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN HOMOLOGOUS PROTEIN; MOLECULAR-CLONING; ESCHERICHIA-COLI; INTRACELLULAR PH; SALT-TOLERANCE; EXCHANGER ISOFORM-1; BETA-SUBUNIT; YEAST; GENE; H+	The Na+/H+ antiporter Nha1p of Saccharomyces cerevisiae plays an important role in maintaining intracellular pH and Na+ homeostasis. Nha1p has a two-domain structure composed of integral membrane and hydrophilic tail regions. Overexpression of a peptide of similar to40 residues (C1 + C2 domains) that is localized in the juxtamembrane area of its cytoplasmic tail caused cell growth retardation in highly saline conditions, possibly by decreasing Na+/H+ antiporter activity. A multicopy suppressor gene of this growth retardation was identified from a yeast genome library. The clone encodes a novel membrane protein denoted as COS3 in the genome data base. Overexpression or deletion of COS3 increases or decreases salinity-resistant cell growth, respectively. However, in nha1Delta cells, overexpression of COS3 alone did not suppress the growth retardation. Cos3p and a hydrophilic portion of Cos3p interact with the C1 + C2 peptide in vitro, and Cos3p is co-precipitated with Nha1p from yeast cell extracts. Cos3p-GFP mainly resides at the vacuole, but overexpression of Nha1p caused a portion of the Cos3p-GFP proteins to shift to the cytoplasmic membrane. These observations suggest that Cos3p is a novel membrane protein that can enhance salinity-resistant cell growth by interacting with the C1 + C2 domain of Nha1p and thereby possibly activating the antiporter activity of this protein.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toynaka, Osaka 5600043, Japan	Osaka University	Kanazawa, H (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Machikaneyama Cho 1-16, Toynaka, Osaka 5600043, Japan.	kanazawa@bio.sci.osaka-u.ac.jp						ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Blumwald E, 2000, CURR OPIN CELL BIOL, V12, P431, DOI 10.1016/S0955-0674(00)00112-5; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Ekuni A, 1998, FEBS LETT, V427, P64, DOI 10.1016/S0014-5793(98)00395-0; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; HOULE JG, 1983, DEV BIOL, V97, P302, DOI 10.1016/0012-1606(83)90088-X; Inoue H, 2003, BIOL PHARM BULL, V26, P148, DOI 10.1248/bpb.26.148; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kamauchi S, 2002, J BIOCHEM, V131, P821, DOI 10.1093/oxfordjournals.jbchem.a003171; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; Kinclova O, 2001, MOL MICROBIOL, V40, P656, DOI 10.1046/j.1365-2958.2001.02412.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mailander J, 2001, FEBS LETT, V507, P331, DOI 10.1016/S0014-5793(01)02986-6; MANIATAS T, 1982, MOL CLONING LAB MANU; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; MIKI JJ, 1990, J BIOL CHEM, V265, P21567; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUBIN H, 1973, J CELL PHYSIOL, V82, P231, DOI 10.1002/jcp.1040820211; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Soong TW, 2000, MICROBIOL-UK, V146, P1035, DOI 10.1099/00221287-146-5-1035; Spode I, 2002, J MOL BIOL, V319, P407, DOI 10.1016/S0022-2836(02)00322-4; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WATANABE Y, 1995, YEAST, V11, P829, DOI 10.1002/yea.320110905; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Wiederkehr A, 2001, YEAST, V18, P759, DOI 10.1002/yea.726; WINKLER MM, 1978, NATURE, V273, P536, DOI 10.1038/273536a0	61	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12438	12447		10.1074/jbc.M310806200	http://dx.doi.org/10.1074/jbc.M310806200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718542	hybrid			2022-12-27	WOS:000220334900053
J	Whitehurst, AW; Robinson, FL; Moore, MS; Cobb, MH				Whitehurst, AW; Robinson, FL; Moore, MS; Cobb, MH			The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; EXPORT SIGNAL; GROWTH-FACTOR; BETA-CATENIN; CELL-CYCLE; TRANSLOCATION; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; ACTIVATION	ERK2 nuclear-cytoplasmic distribution is regulated in response to hormones and cellular state without the requirement for karyopherin-mediated nuclear import. One proposed mechanism for the movement of ERK2 into the nucleus is through a direct interaction between ERK2 and nucleoporins present in the nuclear pore complex. Previous reports have attributed regulation of ERK2 localization to proteins that activate or deactivate ERK2, such as the mitogen-activated protein (MAP) kinase kinase MEK1 and MAP kinase phosphatases. Recently, a small non-catalytic protein, PEA-15, has also been demonstrated to promote a cytoplasmic ERK2 localization. We found that the MAP kinase insert in ERK2 is required for its interaction with PEA-15. Consistent with its recognition of the MAP kinase insert, PEA-15 blocked activation of ERK2 by MEK1, which also requires the MAP kinase insert to interact productively with ERK2. To determine how PEA-15 influences the localization of ERK2, we used a permeabilized cell system to examine the effect of PEA-15 on the localization of ERK2 and mutants that have lost the ability to bind PEA-15. Wild type ERK2 was unable to enter the nucleus in the presence of an excess of PEA-15; however, ERK2 lacking the MAP kinase insert largely retained the ability to enter the nucleus. Binding assays demonstrated that PEA-15 interfered with the ability of ERK2 to bind to nucleoporins. These results suggest that PEA-15 sequesters ERK2 in the cytoplasm at least in part by interfering with its ability to interact with nucleoporins, presenting a potential paradigm for regulation of ERK2 localization.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNET A, 1996, SCIENCE, V272, P1653; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Robinson MJ, 2002, J BIOL CHEM, V277, P5094, DOI 10.1074/jbc.M110935200; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	51	62	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12840	12847		10.1074/jbc.M310031200	http://dx.doi.org/10.1074/jbc.M310031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707138	hybrid			2022-12-27	WOS:000220334900099
J	Ren, Y; Aguirre, J; Ntamack, AG; Chu, CH; Schulz, H				Ren, Y; Aguirre, J; Ntamack, AG; Chu, CH; Schulz, H			An alternative pathway of oleate beta-oxidation in Escherichia coli involving the hydrolysis of a dead end intermediate by a thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RAT-HEART MITOCHONDRIA; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; MULTIENZYME COMPLEX; MOLECULAR-CLONING; DOUBLE-BONDS; COENZYME-A; OLEIC-ACID; METABOLISM; LIVER	The degradation of 2-trans,5-cis-tetradecadienoyl-CoA, a metabolite of oleic acid, by the purified complex of fatty acid oxidation from Escherichia coli was studied to determine how much of the metabolite is converted to 3,5-cis-tetradecadienoyl-CoA and thereby diverted from the classical, isomerase-dependent pathway of oleate beta-oxidation. Approximately 10% of the 2,5-intermediate was converted to the 3,5-isomer. When the latter compound was allowed to accumulate, it strongly inhibited the flux through the main pathway. Since Delta(3,5), Delta(2,4)-dienoyl-CoA isomerase was not detected in E. coli cells grown on oleate, the 3,5- intermediate cannot be metabolized via the reductase-dependent pathway. However, it was hydrolyzed by a thioesterase, which was most active with 3,5-cis-tetradecadienoyl-CoA as substrate and which was induced by growth of E. coli on oleate. An analysis of fatty acids present in the medium after growth of E. coli on oleate revealed the presence of 3,5-tetradecadienoate, which was not detected after cells were grown on palmitate or glucose. Altogether, these data prompt the conclusion that oleate is mostly degraded via the classical, isomerase-dependent pathway in E. coli but that a small amount of 2-trans, 5-cis-tetradecadienoyl-CoA is diverted from the pathway via conversion to 3,5- cis-tetradecadienoyl-CoA by Delta(3), Delta(2)-enoyl- CoA isomerase. The 3,5- intermediate, which would strongly inhibit beta-oxidation if allowed to accumulate, is hydrolyzed, and the resultant 3,5-tetradecadienoate is excreted into the growth medium. This study provides evidence for the novel function of a thioesterase in beta-oxidation.	CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Sch, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.	hoschu@sci.ccny.cuny.edu			NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES EM, 1970, J BIOL CHEM, V245, P3122; BARNES EM, 1968, J BIOL CHEM, V243, P2955; BINSTOCK JF, 1977, P NATL ACAD SCI USA, V74, P492, DOI 10.1073/pnas.74.2.492; BONNER WM, 1972, J BIOL CHEM, V247, P3123; CHO HS, 1993, J BIOL CHEM, V268, P9238; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; He XY, 1998, BBA-LIPID LIPID MET, V1392, P119, DOI 10.1016/S0005-2760(98)00031-9; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LINESTEAD RP, 1931, J CHEM SOC, P740; LUO MJ, 1994, J BIOL CHEM, V269, P2384; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PAWAR S, 1981, J BIOL CHEM, V256, P3894; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; THORPE C, 1986, ANAL BIOCHEM, V155, P391, DOI 10.1016/0003-2697(86)90452-5; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581; YANG SY, 1995, BIOCHEMISTRY-US, V34, P6441, DOI 10.1021/bi00019a025; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988; Zhang DY, 2002, J BIOL CHEM, V277, P9127, DOI 10.1074/jbc.M112228200; Zhang DY, 2001, J BIOL CHEM, V276, P13622, DOI 10.1074/jbc.M011315200	30	15	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11042	11050		10.1074/jbc.M310032200	http://dx.doi.org/10.1074/jbc.M310032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707139	hybrid			2022-12-27	WOS:000220157600027
J	Tsunoda, SP; Wiesner, B; Lorenz, D; Rosenthal, W; Pohl, P				Tsunoda, SP; Wiesner, B; Lorenz, D; Rosenthal, W; Pohl, P			Aquaporin-1, nothing but a water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; STRUCTURAL DETERMINANTS; CYCLIC-AMP; ION; PERMEATION; PERMEABILITY; DYNAMICS; PROTEIN; CELLS	Aquaporin-1 (AQP1) is a membrane channel that allows rapid water movement driven by a transmembrane osmotic gradient. It was claimed to have a secondary function as a cyclic nucleotide-gated ion channel. However, upon reconstitution into planar bilayers, the ion channel exhibited a 10-fold lower open probability (<10(-6)) of doubtful physiological significance (Saparov, S. M., Kozono, D., Rothe, U., Agre, P., and Pohl, P. (2001) J. Biol. Chem. 276, 31515-31520). Investigating AQP1 expressed in human embryonic kidney cells, we now have shown that the discrepancy is not due to alterations of AQP1 properties upon reconstitution into bilayers but rather to regulatory processes of the oocyte expression system that may have been misinterpreted as AQP1 ion channel activity. As confirmed by laser scanning reflection microscopy, from 0.8 to 1.4 x 10(6) AQP1 copies/cell contributed to osmotic cell swelling. The proper plasma membrane localization was confirmed by observing the fluorescence of the N-terminal yellow fluorescent protein tag. Whole-cell patch clamp experiments of wild type or tagged AQP1-expressing cells revealed that neither cGMP nor cAMP mediated ion channel activity. The lack of significant CNG ion channels in cellular signal transduction.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin	Pohl, P (corresponding author), Forschungsinst Mol Pharmakol, Robert Roessle Str 10, D-13125 Berlin, Germany.	pohl@fmp-berlin.de	Tsunoda, Satoshi/AAN-7023-2021; Pohl, Peter/A-5361-2008	Pohl, Peter/0000-0002-1792-2314; Tsunoda, Satoshi/0000-0003-3636-1521				Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; Boassa D, 2002, TRENDS PHARMACOL SCI, V23, P558, DOI 10.1016/S0165-6147(02)02112-0; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Fotiadis D, 2002, J MOL BIOL, V318, P1381, DOI 10.1016/S0022-2836(02)00143-2; Hatakeyama S, 2001, BIOCHEM BIOPH RES CO, V287, P814, DOI 10.1006/bbrc.2001.5661; Hoque ATMS, 2000, CANCER GENE THER, V7, P476, DOI 10.1038/sj.cgt.7700146; Ikeda M, 2002, J BIOL CHEM, V277, P39873, DOI 10.1074/jbc.M207008200; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Maric K, 2001, BIOPHYS J, V80, P1783, DOI 10.1016/S0006-3495(01)76148-6; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; Pohl P, 2001, P NATL ACAD SCI USA, V98, P9624, DOI 10.1073/pnas.161299398; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; Yool AJ, 2002, NEWS PHYSIOL SCI, V17, P68, DOI 10.1152/nips.01372.2001; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	25	46	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11364	11367		10.1074/jbc.M310881200	http://dx.doi.org/10.1074/jbc.M310881200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701836	hybrid			2022-12-27	WOS:000220157600065
J	Usatyuk, PV; Natarajan, V				Usatyuk, PV; Natarajan, V			Role of mitogen-activated protein kinases in 4-hydroxy-2-nonenal-induced actin remodeling and barrier function in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; P38 MAP KINASE; LIPID-PEROXIDATION PRODUCT; OXIDATIVE STRESS; 4-HYDROXYNONENAL-INDUCED APOPTOSIS; GENE-EXPRESSION; INHIBITION; INVOLVEMENT; ALDEHYDE; CA2+	In vivo and in vitro studies indicate that 4-hydroxy-2-nonenal (4-HNE), generated by cellular lipid peroxidation or after oxidative stress, affects endothelial permeability and vascular tone. However, the mechanism(s) of 4-HNE-induced endothelial barrier function is not well defined. Here we provide evidence for the first time on the involvement of mitogen-activated protein kinases (MAPKs) in 4-HNE-mediated actin stress fiber formation and barrier function in lung endothelial cells. Treatment of bovine lung microvascular endothelial cells with hydrogen peroxide (H2O2), as a model oxidant, resulted in accumulation of 4-HNE as evidenced by the formation of 4-HNE-Michael protein adducts. Exposure of cells to 4-HNE, in a dose- and time-dependent manner, decreased endothelial cell permeability measured as transendothelial electrical resistance. The 4-HNE-induced permeability changes were not because of cytotoxicity or endothelial cell apoptosis, which occurred after prolonged treatment and at higher concentrations of 4-HNE. 4-HNE-induced changes in transendothelial electrical resistance were calcium independent, as 4-HNE did not alter intracellular free calcium levels as compared with H2O2 or diperoxovanadate. Stimulation of quiescent cells with 4-HNE (1-100 muM) resulted in phosphorylation of ERK1/2, JNK, and p38 MAPKs, and actin cytoskeleton remodeling. Furthermore, pretreatment of bovine lung microvascular endothelial cells with PD 98059 (25 muM), an inhibitor of MEK1/2, or SP 600125 (25 muM), an inhibitor of JNK, or SB 202190 (25 muM), an inhibitor of p38 MAPK, partially attenuated 4-HNE-mediated barrier function and cytoskeletal remodeling. These results suggest that the activation of ERK, JNK, and p38 MAP kinases is involved in 4-HNE-mediated actin remodeling and endothelial barrier function.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	Johns Hopkins University	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Mason F Lord Bldg,Ctr Tower,Rm 675,5200 Eastern A, Baltimore, MD 21224 USA.	vnataraj@jhmi.edu			NHLBI NIH HHS [R01 HL 69909] Funding Source: Medline; PHS HHS [P01 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069909] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRERA G, 1994, BIOCHEM BIOPH RES CO, V203, P553, DOI 10.1006/bbrc.1994.2218; Barrera G, 1996, BIOCHEM BIOPH RES CO, V227, P589, DOI 10.1006/bbrc.1996.1550; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Carini R, 1996, BIOCHEM BIOPH RES CO, V218, P772, DOI 10.1006/bbrc.1996.0137; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Compton CN, 1998, J TRAUMA, V44, P783, DOI 10.1097/00005373-199805000-00007; Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fischer TA, 2001, HYPERTENSION, V37, P1222, DOI 10.1161/01.HYP.37.5.1222; Fleuranceau-Morel P, 1999, NEUROSCI LETT, V277, P91, DOI 10.1016/S0304-3940(99)00652-7; Garcia JGN, 2002, FASEB J, V16, P1064, DOI 10.1096/fj.01-0895com; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamilton RF, 1998, AM J PHYSIOL-LUNG C, V274, pL8, DOI 10.1152/ajplung.1998.274.1.L8; Herbst U, 1999, J CELL PHYSIOL, V181, P295, DOI 10.1002/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Koh YH, 2000, FREE RADICAL RES, V33, P739, DOI 10.1080/10715760000301261; Kyaw M, 2001, HYPERTENS RES, V24, P251, DOI 10.1291/hypres.24.251; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Liu RM, 2001, AM J RESP CELL MOL, V24, P499, DOI 10.1165/ajrcmb.24.4.4307; Lu CB, 2002, J BIOL CHEM, V277, P24368, DOI 10.1074/jbc.M201924200; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Mark RJ, 1997, J NEUROCHEM, V68, P255; McConnell EJ, 2002, ENDOTHELIUM-J ENDOTH, V9, P45, DOI 10.1080/10623320210708; Mertsch K, 2001, NEUROSCI LETT, V314, P135, DOI 10.1016/S0304-3940(01)02299-6; Mikalsen SO, 1998, J BIOL CHEM, V273, P10036, DOI 10.1074/jbc.273.16.10036; Minekura H, 2001, BIOCHEM BIOPH RES CO, V282, P557, DOI 10.1006/bbrc.2001.4586; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Natarajan V, 1997, AM J RESP CELL MOL, V17, P251, DOI 10.1165/ajrcmb.17.2.2623; NATARAJAN V, 1993, FREE RADICAL BIO MED, V15, P365, DOI 10.1016/0891-5849(93)90036-T; Natarajan V, 2001, AM J PHYSIOL-LUNG C, V281, pL435, DOI 10.1152/ajplung.2001.281.2.L435; Neely MD, 2002, CHEM RES TOXICOL, V15, P40, DOI 10.1021/tx010115w; Nitti M, 2002, BIOCHEM BIOPH RES CO, V294, P547, DOI 10.1016/S0006-291X(02)00512-0; Ogihara T, 1999, ARCH DIS CHILD-FETAL, V80, pF21, DOI 10.1136/fn.80.1.F21; Parinandi NL, 1999, ANTIOXID REDOX SIGN, V1, P193, DOI 10.1089/ars.1999.1.2-193; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Pross M, 2000, SURG ENDOSC, V14, P1180, DOI 10.1007/s004640000189; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Reagan LP, 2000, BRAIN RES, V862, P292, DOI 10.1016/S0006-8993(00)02212-5; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; SHANKAR HNR, 1993, MOL CELL BIOCHEM, V129, P9, DOI 10.1007/BF00926572; Shi S, 2000, AM J PHYSIOL-LUNG C, V279, pL441, DOI 10.1152/ajplung.2000.279.3.L441; Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; STEVENSON MA, 1994, CANCER RES, V54, P12; Tsukagoshi H, 2002, TOXICOL APPL PHARM, V184, P127, DOI 10.1006/taap.2002.9514; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025; Usatyuk PV, 2003, AM J PHYSIOL-LUNG C, V285, pL1006, DOI 10.1152/ajplung.00408.2002; Vepa S, 1999, AM J PHYSIOL-LUNG C, V277, pL150, DOI 10.1152/ajplung.1999.277.1.L150; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877	62	121	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11789	11797		10.1074/jbc.M311184200	http://dx.doi.org/10.1074/jbc.M311184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699126	hybrid			2022-12-27	WOS:000220157600116
J	Veach, RA; Liu, DY; Yao, S; Chen, YL; Liu, XY; Downs, S; Hawiger, J				Veach, RA; Liu, DY; Yao, S; Chen, YL; Liu, XY; Downs, S; Hawiger, J			Receptor/transporter-independent targeting of functional peptides across the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAINS; NF-KAPPA-B; NUCLEAR-LOCALIZATION SEQUENCE; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCES; MECHANISM; LIPOSOMES; TRANSLOCATION; ENDOCYTOSIS	Targeting of peptides, proteins, and other functional cargo into living cells is contingent upon efficient transport across the plasma membrane barrier. We have harnessed the signal sequence hydrophobic region (SSHR) to deliver functional cargoes to cultured cells and to experimental animals. We now report evidence that two chirally distinct forms of SSHR composed of all L or all D amino acids showed similar membrane-translocating activity as assessed by confocal microscopy, flow cytometry, and direct fluorescence measurement. An attached nuclear localization sequence ferried by the SSHR enantiomers displayed similar intracellular function by inhibiting inducible nuclear import of transcription factor nuclear factor kappa B and suppressing nuclear factor kappa B-dependent gene expression of cytokines. A nuclear localization sequence comprised of a positively charged cluster of amino acids was rapidly translocated by SSHR enantiomers to the interior of unilamellar phospholipid vesicles. These findings indicate that the SSHR translocates functional peptides directly through the plasma membrane phospholipid bilayer without involving chirally specific receptor/transporter mechanisms. This mechanism of SSHR translocation is suitable for facile delivery of biologically active peptides for cell-based and animal-based functional proteomic studies.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, A-5321 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu		Veach, Ruth Ann/0000-0003-0038-8802	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062356, P01HL068744, R43HL069542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054072] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA68485] Funding Source: Medline; NHLBI NIH HHS [HL 69542, HL 62356, HL 68744] Funding Source: Medline; NIDDK NIH HHS [DK 54072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; DEGIER J, 1968, BIOCHIM BIOPHYS ACTA, V150, P666, DOI 10.1016/0005-2736(68)90056-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hawiger J, 1997, CURR OPIN IMMUNOL, V9, P189, DOI 10.1016/S0952-7915(97)80134-3; HAWIGER J, 1969, NATURE, V222, P276, DOI 10.1038/222276a0; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; KAJSTURA J, 1989, FOLIA HISTOCHEM CYTO, V27, P39; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu XY, 2000, J BIOL CHEM, V275, P16774; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Penefsky H S, 1979, Methods Enzymol, V56, P527; Peuvot J, 1999, J THEOR BIOL, V198, P173, DOI 10.1006/jtbi.1999.0908; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; Takiguchi K, 2002, CHEMPHYSCHEM, V3, P571, DOI 10.1002/1439-7641(20020715)3:7<571::AID-CPHC571>3.0.CO;2-A; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Torok Z, 2003, P NATL ACAD SCI USA, V100, P3131, DOI 10.1073/pnas.0438003100; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	43	44	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11425	11431		10.1074/jbc.M311089200	http://dx.doi.org/10.1074/jbc.M311089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699109	hybrid			2022-12-27	WOS:000220157600073
J	Kiessling, S; Muller-Newen, G; Leeb, SN; Hausmann, M; Rath, HC; Strater, J; Spottl, T; Schlottmann, K; Grossmann, J; Montero-Julian, FA; Scholmerich, J; Andus, T; Buschauer, A; Heinrich, PC; Rogler, G				Kiessling, S; Muller-Newen, G; Leeb, SN; Hausmann, M; Rath, HC; Strater, J; Spottl, T; Schlottmann, K; Grossmann, J; Montero-Julian, FA; Scholmerich, J; Andus, T; Buschauer, A; Heinrich, PC; Rogler, G			Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-11; SIGNAL TRANSDUCER GP130; SMALL-INTESTINAL-MUCOSA; ACTIVE CROHNS-DISEASE; FACTOR-KAPPA-B; GROWTH-FACTOR; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC CYTOKINE; ENDOTHELIAL-CELLS	A tissue-protective effect of interleukin-11 (IL-11) for the intestinal mucosa has been postulated from animal models of inflammatory bowel disease (IBD). Despite the fact that the clinical usefulness of the anti-inflammatory effects of this cytokine is presently investigated in patients with IBD, there are no data available regarding the target cells of IL-11 action and the mechanisms of tissue protection within the human colonic mucosa. IL-11 responsiveness is restricted to cells that express the interleukin-11 receptor alpha-chain (IL-11Ralpha) and an additional signal-transducing subunit (gp130). In this study, we identified the target cells for IL-11 within the human colon with a new IL-11Ralpha monoclonal antibody and investigated the functional expression of the receptor and downstream effects of IL-11-induced signaling. Immunohistochemistry revealed expression of the IL-11Ralpha selectively on colonic epithelial cells. HT-29 and colonic epithelial cells (CEC) constitutively expressed IL-11Ralpha mRNA and protein. Co-expression of the signal-transducing subunit gp130 was also demonstrated. IL-11 induced signaling through triggering activation of the Jak-STAT pathway without inducing antiinflammatory or proliferative effects in colonic epithelial cells. However, IL-11 stimulation resulted in a dose-dependent tyrosine phosphorylation of Akt, a decreased activation of caspase-9, and a reduced induction of apoptosis in cultured CEC. In HLA-B27 transgenic rats treated with IL-11, a reduction of apoptotic cell numbers was found. This study demonstrates functional expression of the IL-11Ralpha restricted on CEC within the human colonic mucosa. IL-11 induced signaling through triggering activation of the Jak-STAT pathway, without inducing anti-inflammatory or proliferative effects. The beneficial effects of IL-11 therapy are likely to be mediated by CEC via activation of the Akt-survival pathway, mediating antiapoptotic effects to support mucosal integrity.	Univ Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; Univ Regensburg, Inst Pharmaceut Chem, D-93040 Regensburg, Germany; Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Imunotech, F-13276 Marseille 9, France; Univ Ulm, Inst Pathol, D-89081 Ulm, Germany	University of Regensburg; University of Regensburg; RWTH Aachen University; Ulm University	Rogler, G (corresponding author), Univ Regensburg, Dept Internal Med 1, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	gerhard.rogler@klinik.uni-regensburg.de	Rogler, Gerhard/O-5308-2015; Buschauer, Armin/D-2861-2009	Rogler, Gerhard/0000-0002-1733-9188; 				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Alavi K, 2000, J PEDIATR SURG, V35, P371, DOI 10.1016/S0022-3468(00)90043-5; Barton VA, 2000, J BIOL CHEM, V275, P36197, DOI 10.1074/jbc.M004648200; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Blanc C, 2000, J IMMUNOL METHODS, V241, P43, DOI 10.1016/S0022-1759(00)00194-0; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHEREL M, 1995, BLOOD, V86, P2534; Chung TDK, 2000, PROSTATE, V42, P1; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davidson AJ, 1997, STEM CELLS, V15, P119, DOI 10.1002/stem.150119; Du XX, 1997, AM J PHYSIOL-GASTR L, V272, pG545, DOI 10.1152/ajpgi.1997.272.3.G545; DU XX, 1994, BLOOD, V83, P33; DU XX, 1994, BLOOD, V83, P2023; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Greenwood-Van Meerveld B, 2000, LAB INVEST, V80, P1269, DOI 10.1038/labinvest.3780135; Grosfeld JL, 1999, JPEN-PARENTER ENTER, V23, pS67, DOI 10.1177/014860719902300517; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KEITH JC, 1994, STEM CELLS, V12, P79; KISHIMOTO T, 1994, STEM CELLS, V12, P37; Krajewski S, 1996, CANCER RES, V56, P2849; Kuenzler KA, 2002, J SURG RES, V108, P268, DOI 10.1006/jsre.2002.6542; Lebeau B, 1997, FEBS LETT, V407, P141, DOI 10.1016/S0014-5793(97)00326-8; Leng SX, 1997, J IMMUNOL, V159, P2161; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Nandurkar HH, 1996, ONCOGENE, V12, P585; Opal SM, 2000, J INFECT DIS, V181, P754, DOI 10.1086/315247; Orazi A, 1996, LAB INVEST, V75, P33; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Peterson RL, 1998, LAB INVEST, V78, P1503; Peterson RL, 1996, AM J PATHOL, V149, P895; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; Potten CS, 1996, STEM CELLS, V14, P452, DOI 10.1002/stem.140452; Qiu BS, 1996, DIGEST DIS SCI, V41, P1625, DOI 10.1007/BF02087911; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rogler G, 1998, LAB INVEST, V78, P889; Ropeleski MJ, 2003, GASTROENTEROLOGY, V124, P1358, DOI 10.1016/S0016-5085(03)00282-8; Sands BE, 2002, ALIMENT PHARM THERAP, V16, P399, DOI 10.1046/j.1365-2036.2002.01179.x; Sands BE, 1999, GASTROENTEROLOGY, V117, P58, DOI 10.1016/S0016-5085(99)70550-0; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; SONIS S, 1995, ORAL ONCOL, V31B, P261, DOI 10.1016/0964-1955(95)00015-A; Sonis ST, 1997, CYTOKINE, V9, P605, DOI 10.1006/cyto.1997.0208; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TIDBALL CS, 1971, AM J DIG DIS, V16, P745, DOI 10.1007/BF02239605; Trepicchio WL, 1999, J CLIN INVEST, V104, P1527, DOI 10.1172/JCI6910; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; Trepicchio WL, 1997, J IMMUNOL, V159, P5661; WEINSTEIN WM, 1974, MED CLIN N AM, V58, P1375, DOI 10.1016/S0025-7125(16)32078-8; Yang YC, 1995, ANN NY ACAD SCI, V762, P31; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	64	53	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10304	10315		10.1074/jbc.M312757200	http://dx.doi.org/10.1074/jbc.M312757200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701802	hybrid			2022-12-27	WOS:000220050400079
J	Kim, JE; Tannenbaum, SR				Kim, JE; Tannenbaum, SR			S-nitrosation regulates the activation of endogenous procaspase-9 in HT-29 human colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOCHROME-C RELEASE; CASPASE ACTIVATION; INHIBITS APOPTOSIS; NITROSYLATION; PROTEASE; DEATH; CLEAVAGE; FAS; PROTEINS	Nitric oxide-mediated signals have been suggested to regulate the activity of caspases negatively, yet literature has provided little direct evidence. We show in this paper that cytokines and nitric-oxide synthase ( NOS) inhibitors regulate S-nitrosation of an initiator caspase, procaspase-9, in a human colon adenocarcinoma cell line, HT-29. A NOS inhibitor, N-G-methyl-L-arginine, enhanced the tumor necrosis factor-alpha (TNF-alpha)-induced cleavage of procaspase-9, procaspase-3, and poly-(ADPribose) polymerase, as well as the level of apoptosis. N-G-Methyl-L-arginine, however, did not affect the cleavage of procaspase-8. These results suggest that nitric oxide regulates the cleavage of procaspase-9 and its downstream proteins and, subsequently, apoptosis in HT-29 cells. Labeling S-nitrosated cysteines with a biotin tag enabled us to reveal S-nitrosation of endogenous procaspase-9 that was immunoprecipitated from the HT-29 cell extracts. Furthermore, the treatment with TNF-alpha, as well as NOS inhibitors, decreased interferon-gamma induced S-nitrosation in procaspase-9. Our results show that S-nitrosation of endogenous procaspase-9 occurs in the HT-29 cells under normal conditions and that denitrosation of procaspase-9 enhances its cleavage and consequent apoptosis. We, therefore, suggest that S-nitrosation regulates activation of endogenous procaspase-9 in HT-29 cells.	MIT, Div Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Tannenbaum, SR (corresponding author), MIT, Div Biol Engn, 77 Massachusetts Ave,Rm 56-731, Cambridge, MA 02139 USA.	srt@mit.edu			NIGMS NIH HHS [1-P50-GM68762-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Buendia B, 1999, J CELL SCI, V112, P1743; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KOLIOS G, 1995, BRIT J PHARMACOL, V116, P2866, DOI 10.1111/j.1476-5381.1995.tb15938.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANE P, 2001, SCI STKE, pRE1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; O'Connell J, 2000, J CELL PHYSIOL, V185, P331, DOI 10.1002/1097-4652(200012)185:3<331::AID-JCP3>3.0.CO;2-V; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Rudel T, 1998, J IMMUNOL, V160, P7; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torok NJ, 2002, CANCER RES, V62, P1648; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Xu XL, 1998, CANCER RES, V58, P2832; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zech B, 1999, J BIOL CHEM, V274, P20931, DOI 10.1074/jbc.274.30.20931; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	84	58	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9758	9764		10.1074/jbc.M312722200	http://dx.doi.org/10.1074/jbc.M312722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701803	hybrid			2022-12-27	WOS:000220050400014
J	Ligeti, E; Dagher, MC; Hernandez, SE; Koleske, AJ; Settleman, J				Ligeti, E; Dagher, MC; Hernandez, SE; Koleske, AJ; Settleman, J			Phospholipids can switch the GTPase substrate preference of a GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO; RAS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; INHIBITION; DOMAIN; LIPIDS; FAMILY; ARF	The major cellular inhibitors of the small GTPases of the Ras superfamily are the GTPase-activating proteins ( GAPs), which stimulate the intrinsic GTP hydrolyzing activity of GTPases, thereby inactivating them. The catalytic activity of several GAPs is reportedly inhibited or stimulated by various phospholipids and fatty acids in vitro, indicating a likely physiological role for lipids in regulating small GTPases. We find that the p190 RhoGAP, a potent GAP for the Rho and Rac GTPases, is similarly sensitive to phospholipids. Interestingly, however, several of the tested phospholipids were found to effectively inhibit the RhoGAP activity of p190 but stimulate its RacGAP activity. Thus, phospholipids have the ability to "switch" the GTPase substrate preference of a GAP, thereby providing a novel regulatory mechanism for the small GTPases.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary; CEA Grenoble, Biochim Lab, F-38054 Grenoble, France; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Semmelweis University; CEA; Yale University; Harvard University	Settleman, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.	Settleman@helix.mgh.harvard.edu		DAGHER, Marie-Claire/0000-0001-6878-3169	NINDS NIH HHS [R01 NS039475] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039475] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED S, 1995, METHOD ENZYMOL, V256, P114; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; LIGETI E, 1993, EUR J BIOCHEM, V216, P813, DOI 10.1111/j.1432-1033.1993.tb18202.x; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Nie ZZ, 2002, J BIOL CHEM, V277, P48965, DOI 10.1074/jbc.M202969200; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260	17	52	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5055	5058		10.1074/jbc.C300547200	http://dx.doi.org/10.1074/jbc.C300547200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14699145	hybrid			2022-12-27	WOS:000188776500003
J	Teng, SC; Chen, YY; Su, YN; Chou, PC; Chiang, YC; Tseng, SF; Wu, KJ				Teng, SC; Chen, YY; Su, YN; Chou, PC; Chiang, YC; Tseng, SF; Wu, KJ			Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; INTERACTING PROTEIN; CELL-PROLIFERATION; DNA-BINDING; EXPRESSION; GENE; TARGET; COMPLEX; KINASE; IDENTIFICATION	The c-myc proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and differentiation and implicated in inducing tumorigenesis. Understanding the function of c-Myc and its role in cancer depends upon the identification of c-Myc target genes. Heat shock protein 90 (HSP90) is involved in the folding of proteins such as signal transduction molecules (Src, Raf1, cdk4) and steroid receptors and in enhancing the activity of telomerase and nitric-oxide synthase. Here we show that c-Myc directly activates HSP90A transcription. c-Myc-mediated induction of HSP90A transcription occurs in different tissues, is independent of cell proliferation, and is mediated by a c-Myc binding site in the proximal promoter region of HSP90A gene. Overexpression of HSP90A in Rat1a cells induces transformation. Short interference RNA of HSP90A/Hsp86alpha reduces transformation activity in HeLa and RatMyc cells. These results indicate that by induction of HSP90A c-Myc may control the activity of multiple signal pathways involved in cellular transformation.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan; Natl Taiwan Univ, Dept Med Genet, Taipei 100, Taiwan	National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University	Wu, KJ (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	kjwu2@ym.edu.tw	Wu, Kou-Juey/P-4654-2015; Chiang, Yun/GRJ-5251-2022	TENG, SHU-CHUN/0000-0002-6492-2560	PHS HHS [EX93-9329SI] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Akalin A, 2001, CANCER RES, V61, P4791; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Bonvini P, 2002, CANCER RES, V62, P1559; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cardillo MR, 2000, ANTICANCER RES, V20, P4579; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; Dang CV, 1999, MOL CELL BIOL, V19, P1; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Guo QM, 2000, CANCER RES, V60, P5922; Hermisson M, 2000, NEUROLOGY, V54, P1357, DOI 10.1212/WNL.54.6.1357; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hur E, 2002, MOL PHARMACOL, V62, P975, DOI 10.1124/mol.62.5.975; Imai J, 2000, MOL CELL BIOL, V20, P9262, DOI 10.1128/MCB.20.24.9262-9270.2000; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Ito T, 1998, J ORAL PATHOL MED, V27, P18; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Nanbu K, 1996, CANCER, V77, P330, DOI 10.1002/(SICI)1097-0142(19960115)77:2<330::AID-CNCR16>3.0.CO;2-2; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ogata Masao, 2000, Journal of Nippon Medical School, V67, P177, DOI 10.1272/jnms.67.177; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SASSON S, 1991, PATHOL BIOL, V39, P59; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Schnaider T, 1999, LIFE SCI, V65, P2417, DOI 10.1016/S0024-3205(99)00508-1; Schnaider T, 2000, LIFE SCI, V67, P1455, DOI 10.1016/S0024-3205(00)00735-9; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu WP, 2002, CELL STRESS CHAPERON, V7, P91, DOI 10.1379/1466-1268(2002)007<0091:HNGRTI>2.0.CO;2; Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349-7006.1996.tb02119.x; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Zhang SL, 1999, FEBS LETT, V444, P130, DOI 10.1016/S0014-5793(99)00044-7; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	67	50	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14649	14655		10.1074/jbc.M308842200	http://dx.doi.org/10.1074/jbc.M308842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724288	Green Published, hybrid			2022-12-27	WOS:000220594700023
J	Ramos, PC; Marques, AJ; London, MK; Dohmen, RJ				Ramos, PC; Marques, AJ; London, MK; Dohmen, RJ			Role of C-terminal extensions of Subunits beta 2 and beta 7 in assembly and activity of eukaryotic proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN 20S PROTEASOME; SACCHAROMYCES-CEREVISIAE; SITE FORMATION; YEAST; MATURATION; RESOLUTION; PARTICLE; ACIDOPHILUM; PROPEPTIDES; COMPLETION	A close inspection of the crystal structure of the yeast 20 S proteasome revealed that a prominent connection between the two beta-rings is mediated by the subunit beta7/ Pre4. Its C-terminal extension intercalates between the beta1/Pre3 and beta2/Pup1 subunits on the opposite ring. We show that the interactions promoted by the beta7/Pre4 tail are important to facilitate the formation of 20 S particles from two half-proteasome precursor complexes and/or to stabilize mature 20 S proteasomes. The deletion of 19 residues from the beta7/Pre4 C terminus leads to an accumulation of half-proteasome precursor complexes containing the maturation factor Ump1. The C-terminal extension of beta7/Pre4, which forms several hydrogen bonds with beta1/Pre3, is in addition required for the post-acidic activity mediated by the latter subunit. Deletion of the C-terminal tail of beta7/Pre4 results in an inhibition of beta1/Pre3 propeptide processing and abrogation of post-acidic activity. Our data obtained with yeast strains that expressed the mature form of Pre3 lacking its propeptide suggest that interactions between the Pre4 C terminus and Pre3 stabilize a conformation of its active site, which is essential for post-acidic activity. Deletion of the C-terminal extension of beta2/Pup1, which wraps around beta3/Pup3 within the same beta-ring, is lethal, indicating that this extension serves an essential function in proteasome assembly or stability.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Algarve, Fac Ciencias & Tecnol, Dept Quim & Bioquim, P-8000117 Faro, Portugal	University of Cologne; Universidade do Algarve	Dohmen, RJ (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	j.dohmen@uni-koeln.de	Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780				Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HILT W, 1993, J BIOL CHEM, V268, P3479; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	25	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14323	14330		10.1074/jbc.M308757200	http://dx.doi.org/10.1074/jbc.M308757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722099	Green Published, hybrid			2022-12-27	WOS:000220478500127
J	Dohke, Y; Oh, YS; Ambudkar, IS; Turner, RJ				Dohke, Y; Oh, YS; Ambudkar, IS; Turner, RJ			Biogenesis and topology of the transient receptor potential Ca2+ channel TRPC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; TRANSMEMBRANE SEGMENTS; ANION-EXCHANGER; PREDICTION; INSERTION; IDENTIFICATION; TRANSLOCATION; INTEGRATION; MUTAGENESIS	The TRPC ion channels are candidates for the store-operated Ca2+ entry pathway activated in response to depletion of intracellular Ca2+ stores. Hydropathy analyses indicate that these proteins contain eight hydrophobic regions (HRs) that could potentially form alpha-helical membrane-spanning segments. Based on limited sequence similarities to other ion channels, it has been proposed that only six of the eight HRs actually span the membrane and that the last two membrane-spanning segments (HRs 6 and 8) border the ion-conducting pore of which HR 7 forms a part. Here we study the biogenesis and transmembrane topology of human TRPC1 to test this model. We have employed a truncation mutant approach combined with insertions of glycosylation sites into full-length TRPC1. In our truncation mutants, portions of the TRPC1 sequence containing one or more HRs were fused between the enhanced green fluorescent protein and a C-terminal glycosylation tag. These chimeras were transiently expressed in the human embryonic cell line HEK-293T. Glycosylation of the tag was used to monitor its location relative to the lumen of the endoplasmic reticulum and thereby HR orientation. Our data indicate that HRs 1, 4, and 6 cross the membrane from cytosol to the ER lumen, that HRs 2, 5, and 8 have the opposite orientation, and that HR 3 is left out of the membrane on the cytosolic side. Our results also show that the sequence downstream of HR 8 plays an important role in anchoring its C-terminal end on the cytosolic side of the membrane. This effect appears to prevent HR 7 from spanning the bilayer and to result in its forming a pore-like structure of the type previously envisioned for the TRPC channels. We speculate that a similar mechanism may be responsible for the formation of other ion channel pores.	Natl Inst Dent & Craniofacial Res, Membrane Biol Sect, NIH, DHHS, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Secretory Physiol Sec, Gene Therepy & Therapeut Branch, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Turner, RJ (corresponding author), NIH, Bldg 10,Rm 1A01,10 Ctr Dr,MSC 1190, Bethesda, MD 20892 USA.	rjturner@nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000438, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dohke Y, 2002, J BIOL CHEM, V277, P15215, DOI 10.1074/jbc.C100646200; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Guo DP, 1996, J BIOL CHEM, V271, P30829, DOI 10.1074/jbc.271.48.30829; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; SKACH WR, 1993, J BIOL CHEM, V268, P23552; Tatishchev S, 2003, BIOCHEMISTRY-US, V42, P755, DOI 10.1021/bi026826q; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turner RJ, 2003, J MEMBRANE BIOL, V192, P149, DOI 10.1007/s00232-002-1071-z; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	44	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12242	12248		10.1074/jbc.M312456200	http://dx.doi.org/10.1074/jbc.M312456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707123	hybrid			2022-12-27	WOS:000220334900030
J	Loayza, D; Parsons, H; Donigian, J; Hoke, K; de Lange, T				Loayza, D; Parsons, H; Donigian, J; Hoke, K; de Lange, T			DNA binding features of human POT1 - A nonamer 5 '-TAGGGTTAG-3 ' minimal binding site, sequence specificity, and internal binding to multimeric sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED TELOMERIC DNA; PROTEIN; TRF1; CDC13; END; REPLICATION; RECOGNITION; LENGTH	The human telomeric protein POT1 is known to bind single-stranded telomeric DNA in vitro and to participate in the regulation of telomere maintenance by telomerase in vivo. We examined the in vitro DNA binding features of POT1. We report that deleting the oligosaccharide/ oligonucleotide-binding fold of POT1 abrogates its DNA binding activity. The minimal binding site (MBS) for POT1 was found to be the telomeric nonamer 5'-TAGGGTTAG-3', and the optimal substrate is [TTAGGG](n( n greater than or equal to 2)). POT1 displays exceptional sequence specificity when binding to MBS, tolerating changes only at position 7 (T7A). Whereas POT1 binding to MBS or [TTAGGG](2) was enhanced by the proximity of a 3' end, POT1 was able to bind to a [TTAGGG](5) array when positioned internally. These data indicate that POT1 has a strong sequence preference for the human telomeric repeat tract and predict that POT1 can bind both the 3' telomeric overhang and the displaced TTAGGG repeats at the base of the t-loop.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NCI NIH HHS [CA 076027, T32 CA 09673-26] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076027, T32CA009673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson EM, 2003, BIOCHEMISTRY-US, V42, P3751, DOI 10.1021/bi027047c; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; SMOGORZEWSKA A, 2004, IN PRESS ANN REV BIO; SOUTHERN EM, 1970, NATURE, V227, P794, DOI 10.1038/227794a0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	19	125	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13241	13248		10.1074/jbc.M312309200	http://dx.doi.org/10.1074/jbc.M312309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715659	hybrid			2022-12-27	WOS:000220334900146
J	Matsuo, H; Morita, E; Tatham, AS; Morimoto, K; Horikawa, T; Osuna, H; Ikezawa, Z; Kaneko, S; Kohno, K; Dekio, S				Matsuo, H; Morita, E; Tatham, AS; Morimoto, K; Horikawa, T; Osuna, H; Ikezawa, Z; Kaneko, S; Kohno, K; Dekio, S			Identification of the IgE-binding epitope in omega-5 gliadin, a major allergen in wheat-dependent exercise-induced anaphylaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTEN PROTEINS; GAMMA-GLIADIN; GENE FAMILY; PRESUMPTIVE ALLERGEN; SEQUENCES; SECALINS; CHILDREN	Wheat-dependent exercise-induced anaphylaxis (WDEIA) is a severe IgE-mediated allergic reaction provoked by the combination of wheat-ingestion with intensive physical exercise over the next few hours. Among wheat proteins, omega-5 gliadin, which is one of the components of fast omega-gliadin, has been reported as a major allergen in the anaphylaxis. In this study, we detected IgE-binding epitopes within the primary sequence of omega-5 gliadin using arrays of overlapping peptides synthesized on derivatized cellulose membranes. Sera from four patients with WDEIA having specific IgE to the fast omega-gliadin were used to probe the membrane. Seven epitopes, QQIPQQQ, QQLPQQQ, QQFPQQQ, QQSPEQQ, QQSPQQQ, QQYPQQQ, and PYPP, were detected within the primary sequence of omega-5 gliadin. By using sera of 15 patients, 4 of them, QQIPQQQ, QQFPQQQ, QQSPEQQ, and QQSPQQQ, were found to be dominant epitopes. Mutational analysis of the QQIPQQQ and QQFPQQQ indicated that amino acids at positions Gln(1), Pro(4), Gln(5), Gln(6), and Gln(7) were critical for IgE binding. These results will provide a useful tool for developing safer wheat products in addition to diagnostic and immunotherapy techniques for WDEIA.	Shimane Univ, Sch Med, Dept Dermatol, Izumo, Shimane 6938501, Japan; Dstl, Biomed Sci, Salisbury SP4 0JQ, Wilts, England; Hiroshima Univ, Grad Sch Med, Dept Dermatol, Minami Ku, Hiroshima 7348551, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Dermatol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Shimane University; Defence Science & Technology Laboratory; Hiroshima University; Kobe University; Yokohama City University	Matsuo, H (corresponding author), Shimane Univ, Sch Med, Dept Dermatol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	hmatsuo@med.shimane-u.ac.jp	Matsuo, Hiroaki/B-4290-2008	Matsuo, Hiroaki/0000-0002-8730-5389; Tatham, Arthur/0000-0001-5080-5585				Amano M, 1998, BIOCHEM J, V330, P1229, DOI 10.1042/bj3301229; Anderson OD, 1997, THEOR APPL GENET, V95, P59, DOI 10.1007/s001220050532; Anderson OD, 2001, THEOR APPL GENET, V103, P323, DOI 10.1007/s00122-001-0551-3; Busse PJ, 2002, INT ARCH ALLERGY IMM, V129, P93, DOI 10.1159/000065178; Cassidy BG, 1998, THEOR APPL GENET, V96, P743, DOI 10.1007/s001220050797; Cocco RR, 2003, J ALLERGY CLIN IMMUN, V112, P433, DOI 10.1067/mai.2003.1617; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; DuPont FM, 2000, CEREAL CHEM, V77, P607, DOI 10.1094/CCHEM.2000.77.5.607; Hsia CC, 2001, THEOR APPL GENET, V103, P37, DOI 10.1007/s00122-001-0552-2; KASARDA DD, 1983, BIOCHIM BIOPHYS ACTA, V747, P138, DOI 10.1016/0167-4838(83)90132-2; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Maruyama N, 1998, EUR J BIOCHEM, V255, P739, DOI 10.1046/j.1432-1327.1998.2550739.x; MCNEIL D, 1988, ANN ALLERGY, V61, P440; Mine Y, 2002, BIOCHEM BIOPH RES CO, V292, P1070, DOI 10.1006/bbrc.2002.6725; Morita E, 2000, BRIT J DERMATOL, V143, P1059, DOI 10.1046/j.1365-2133.2000.03844.x; Morita E, 2003, J DERMATOL SCI, V33, P99, DOI 10.1016/S0923-1811(03)00156-7; Morita E, 2001, BRIT J DERMATOL, V145, P182, DOI 10.1046/j.1365-2133.2001.04314.x; MUNOZ FM, 1994, ALLERGY, V49, P314, DOI 10.1111/j.1398-9995.1994.tb02274.x; Noma T, 2001, ASIAN PAC J ALLERGY, V19, P283; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P1672; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Palosuo K, 2001, CLIN EXP ALLERGY, V31, P466, DOI 10.1046/j.1365-2222.2001.01023.x; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Pauls JD, 1998, J ALLERGY CLIN IMMUN, V101, P853, DOI 10.1016/S0091-6749(98)70317-3; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; Seilmeier W, 2001, EUR FOOD RES TECHNOL, V212, P355, DOI 10.1007/s002170000260; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; SILVERSTEIN S R, 1986, Journal of Emergency Medicine, V4, P195, DOI 10.1016/0736-4679(86)90040-5; Tanabe S, 1996, BIOCHEM BIOPH RES CO, V219, P290, DOI 10.1006/bbrc.1996.0225; TATHAM AS, 1985, J CEREAL SCI, V3, P103, DOI 10.1016/S0733-5210(85)80021-7; WATANABE M, 1995, BIOSCI BIOTECH BIOCH, V59, P1596, DOI 10.1271/bbb.59.1596; Wieser H, 2000, EUR FOOD RES TECHNOL, V211, P262, DOI 10.1007/s002170000165; Xiang P, 2002, ARCH BIOCHEM BIOPHYS, V408, P51, DOI 10.1016/S0003-9861(02)00534-9; Yamashita H, 2002, BIOSCI BIOTECH BIOCH, V66, P2487, DOI 10.1271/bbb.66.2487	37	135	144	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12135	12140		10.1074/jbc.M311340200	http://dx.doi.org/10.1074/jbc.M311340200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699123	hybrid			2022-12-27	WOS:000220334900019
J	Rickman, C; Archer, DA; Meunier, FA; Craxton, M; Fukuda, M; Burgoyne, RD; Davletov, B				Rickman, C; Archer, DA; Meunier, FA; Craxton, M; Fukuda, M; Burgoyne, RD; Davletov, B			Synaptotagmin interaction with the syntaxin/SNAP-25 dimer is mediated by an evolutionarily conserved motif and is sensitive to inositol hexakisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-TRANSMISSION; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; CA2+ SENSOR; I FUNCTIONS; TIME-COURSE; C2B DOMAIN; CALCIUM; EXOCYTOSIS; MEMBRANE	Synaptotagmins are membrane proteins that possess tandem C2 domains and play an important role in regulated membrane fusion in metazoan organisms. Here we show that both synaptotagmins I and II, the two major neuronal isoforms, can interact with the syntaxin/ synaptosomal-associated protein of 25 kDa (SNAP-25) dimer, the immediate precursor of the soluble NSF attachment protein receptor ( SNARE) fusion complex. A stretch of basic amino acids highly conserved throughout the animal kingdom is responsible for this calcium-independent interaction. Inositol hexakisphosphate modulates synaptotagmin coupling to the syntaxin/ SNAP-25 dimer, which is mirrored by changes in chromaffin cell exocytosis. Our results shed new light on the functional importance of the conserved polybasic synaptotagmin motif, suggesting that synaptotagmin interacts with the t-SNARE dimer to up-regulate the probability of SNARE-mediated membrane fusion.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	MRC Laboratory Molecular Biology; University of Liverpool; RIKEN	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	baz@mrc-lmb.cam.ac.uk	Burgoyne, Robert/C-6706-2008; Fukuda, MItsunori/I-1511-2015; Meunier, Frederic A/C-8161-2009; Davletov, Bazbek/ABA-8569-2021; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Fukuda, MItsunori/0000-0002-8620-5853; Meunier, Frederic A/0000-0001-6400-1107; Burgoyne, Robert D/0000-0002-9219-0387; Rickman, Colin/0000-0001-8938-524X; Davletov, Bazbek/0000-0003-4658-3275				ANGAUTPETIT D, 1995, BRAIN RES, V681, P213, DOI 10.1016/0006-8993(95)00294-Z; Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAZUKA CD, 1999, FR MOLEC B, V23, P81; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Juzans Pascal, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR283, DOI 10.1007/BF02346379; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Meunier FA, 2002, EMBO J, V21, P6733, DOI 10.1093/emboj/cdf677; Osborne SL, 2001, NEURON, V32, P9, DOI 10.1016/S0896-6273(01)00455-X; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; SUDHOF TC, 2001, SYNAPSES; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6	51	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12574	12579		10.1074/jbc.M310710200	http://dx.doi.org/10.1074/jbc.M310710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709554	hybrid			2022-12-27	WOS:000220334900070
J	Frank, C; Burkhardt, C; Imhof, D; Ringel, J; Zschornig, O; Wieligmann, K; Zacharias, M; Bohmer, FD				Frank, C; Burkhardt, C; Imhof, D; Ringel, J; Zschornig, O; Wieligmann, K; Zacharias, M; Bohmer, FD			Effective dephosphorylation of Src substrates by SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; SH2 DOMAIN; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; CRYSTAL-STRUCTURE; NUCLEAR-LOCALIZATION; MEDIATED ACTIVATION; SYNTHETIC PEPTIDES; HOMOLOGY-2 DOMAINS	The protein-tyrosine phosphatase SHP-1 is a negative regulator of multiple signal transduction pathways. We observed that SHP-1 effectively antagonized Src-dependent phosphorylations in HEK293 cells. This occurred by dephosphorylation of Src substrates, because Src activity was unaffected in the presence of SHP-1. One reason for efficient dephosphorylation was activation of SHP-1 by Src. Recombinant SHP-1 had elevated activity subsequent to phosphorylation by Src in vitro, and SHP-1 variants with mutated phosphorylation sites in the C terminus, SHP-1 Y538F, and SHP-1 Y538F, Y566F were less active toward Src-generated phosphoproteins in intact cells. A second reason for efficient dephosphorylation is the substrate selectivity of SHP-1. Pull-down experiments with different GST-SHP-1 fusion proteins revealed efficient interaction of Src-generated phosphoproteins with the SHP-1 catalytic domain rather than with the SH2 domains. Phosphopeptides that correspond to good Src substrates were efficiently dephosphorylated by SHP-1 in vitro. Phosphorylated "optimal Src substrate" AEEEIpYGEFEA (where pY is phosphotyrosine) and a phosphopeptide corresponding to a recently identified Src phosphorylation site in p120 catenin, DDLDpY(296)GMMSD, were excellent SHP-1 substrates. Docking of these phosphopeptides into the catalytic domain of SHP-1 by molecular modeling was consistent with the biochemical data and explains the efficient interaction. Acidic residues N-terminal of the phosphotyrosine seem to be of major importance for efficient substrate interaction. Residues C-terminal of the phosphotyrosine probably contribute to the substrate selectivity of SHP-1. We propose that activation of SHP-1 by Src and complementary substrate specificities of SHP-1 and Src may lead to very transient Src signals in the presence of SHP-1.	Univ Jena, Fac Med, Inst Mol Cell Biol, D-07747 Jena, Germany; Univ Jena, Fac Biol & Pharm, Inst Biochem & Biophys, D-07747 Jena, Germany; Univ Leipzig, Inst Med Phys & Biophys, D-04103 Leipzig, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Leipzig University	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Inst Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de	Imhof, Diana/AAD-7491-2019	Imhof, Diana/0000-0003-4163-7334				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Barford D, 1999, BIOCHEM SOC T, V27, P751, DOI 10.1042/bst0270751; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P13251, DOI 10.1021/bi0014397; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Jin YJ, 1999, J BIOL CHEM, V274, P28301, DOI 10.1074/jbc.274.40.28301; Johnson TM, 1997, J PEPT RES, V50, P365; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; PINNA LA, 1994, BBA-MOL CELL RES, V1222, P415, DOI 10.1016/0167-4889(94)90050-7; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002-9440(10)65116-4; Wang P, 2002, BIOCHEMISTRY-US, V41, P6202, DOI 10.1021/bi025591f; Wishcamper CA, 2001, J COMP NEUROL, V441, P118; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Yang WT, 1998, BLOOD, V91, P3746; Yang WT, 2002, BLOOD CELL MOL DIS, V28, P63, DOI 10.1006/bcmd.2002.0485; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zhang ZS, 2003, J BIOL CHEM, V278, P4668, DOI 10.1074/jbc.M210028200; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	69	68	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11375	11383		10.1074/jbc.M309096200	http://dx.doi.org/10.1074/jbc.M309096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699166	hybrid			2022-12-27	WOS:000220157600067
J	Gore, A; Moran, A; Hershfinkel, M; Sekler, I				Gore, A; Moran, A; Hershfinkel, M; Sekler, I			Inhibitory mechanism of store-operated Ca2+ channels by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE ZINC; SYNAPTICALLY-RELEASED ZINC; CRAC CHANNELS; BINDING-SITE; PROTEIN-KINASE; CALCIUM-ENTRY; TRP CHANNEL; ZN2+; INFLUX; RECEPTORS	Capacitative calcium influx plays an important role in shaping the Ca2+ response of various tissues and cell types. Inhibition by heavy metals is a hallmark of store-operated calcium channel (SOCC) activity. Paradoxically, although zinc is the only potentially physiological relevant ion, it is the least investigated in terms of inhibitory mechanism. In the present study, we characterize the inhibitory mechanism of the SOCC by Zn2+ in the human salivary cell line, HSY, and rat salivary submandibular ducts and acini by monitoring SOCC activity using fluorescence imaging. Analysis of Zn2+ inhibition indicated that Zn2+ acts as a competitive inhibitor of Ca2+ influx but does not permeate through the SOCC, suggesting that Zn2+ interacts with an extracellular site of SOCC. Application of the reducing agents, dithiothreitol (DTT) and beta-mercaptoethanol, totally eliminated Zn2+ and Cd2+ inhibition of SOCC, suggesting that cysteines are part of the Zn2+ and Cd2+ binding site. Interestingly, reducing conditions failed to eliminate the inhibition of SOCC by La3+ and Gd3+, indicating that the Zn2+ and lanthanides binding sites are distinct. Finally, we show that changes in redox potential and Zn2+ are regulating, via SOCC activity, the agonist-induced Ca2+ response in salivary ducts. The presence of a specific Zn2+ site, responsive to physiological Zn2+ and redox potential, may not only be instrumental for future structural studies of various SOCC candidates but may also reveal novel physiological aspects of the interaction between zinc, redox potential, and cellular Ca2+ homeostasis.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Morphol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Gore, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, POB 653, IL-84105 Beer Sheva, Israel.	arie@bgumail.bgu.ac.il; sekler@bgumail.bgu.ac.il	Hershfinkel, Michal/F-1548-2012; MORAN, ARIE/F-1210-2012	Hershfinkel, Michal/0000-0003-1652-1989; 				ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bakowski D, 2002, CELL CALCIUM, V32, P379, DOI 10.1016/S0143416002001914; Barroso AS, 2003, ARCH ORAL BIOL, V48, P133, DOI 10.1016/S0003-9969(02)00169-3; Canzoniero LMT, 1999, J NEUROSCI, V19; Canzoniero LMT, 1997, NEUROBIOL DIS, V4, P275, DOI 10.1006/nbdi.1997.0160; Carmel Z, 1999, ARCH ORAL BIOL, V44, pS63, DOI 10.1016/S0003-9969(99)00053-9; Chauthaiwale JV, 1998, J MEMBRANE BIOL, V162, P139, DOI 10.1007/s002329900351; Chetham PM, 1999, AM J PHYSIOL-LUNG C, V276, pL41, DOI 10.1152/ajplung.1999.276.1.L41; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; DEHAYE JP, 1995, J TRACE ELEM MED BIO, V9, P94, DOI 10.1016/S0946-672X(11)80017-9; Dehaye JP, 1999, ARCH ORAL BIOL, V44, pS39, DOI 10.1016/S0003-9969(99)00048-5; Ebisawa T, 2000, J ENDOCRINOL, V167, P473, DOI 10.1677/joe.0.1670473; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2003, J NEUROCHEM, V85, P10, DOI 10.1046/j.1471-4159.85.s2.10_1.x; Gee KR, 2002, J AM CHEM SOC, V124, P776, DOI 10.1021/ja011774y; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Hamada T, 1997, APOPTOSIS, V2, P359, DOI 10.1023/A:1026401506914; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063; Kawamura M, 2003, J PHARMACOL SCI, V91, P23, DOI 10.1254/jphs.91.23; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; KNUDSEN E, 1995, J NUTR, V125, P1274; Krishek BJ, 1998, J PHYSIOL-LONDON, V507, P639, DOI 10.1111/j.1469-7793.1998.639bs.x; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Kurz LL, 1999, J BIOL CHEM, V274, P11687, DOI 10.1074/jbc.274.17.11687; Li CY, 1997, J PHYSIOL-LONDON, V505, P641, DOI 10.1111/j.1469-7793.1997.641ba.x; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Minke B, 2001, CELL MOL NEUROBIOL, V21, P629, DOI 10.1023/A:1015191702536; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Molnar P, 2001, BRAIN RES, V910, P205, DOI 10.1016/S0006-8993(01)02720-2; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; Nagler RM, 1997, ARCH OTOLARYNGOL, V123, P989; NEVIN ST, 2003, J BIOL CHEM, V9, P9; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; Olivi L, 2000, CELL CALCIUM, V27, P187, DOI 10.1054/ceca.1999.0115; Paoletti P, 1997, J NEUROSCI, V17, P5711; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; SCHMIDT HW, 1981, EUR J CELL BIOL, V24, P85; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Voets T, 2003, J MEMBRANE BIOL, V192, P1, DOI 10.1007/s00232-002-1059-8; Voets T, 2003, CELL CALCIUM, V33, P299, DOI 10.1016/S0143-4160(03)00044-7; Voss J, 1995, P NATL ACAD SCI USA, V92, P12295, DOI 10.1073/pnas.92.26.12295; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	59	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11106	11111		10.1074/jbc.M400005200	http://dx.doi.org/10.1074/jbc.M400005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715648	hybrid			2022-12-27	WOS:000220157600034
J	Lin, TL; Shun, CT; Chang, KC; Wang, JT				Lin, TL; Shun, CT; Chang, KC; Wang, JT			Isolation and characterization of a HpyC1I restriction-modification system in Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; GASTRIC-CARCINOMA; INFECTION; STRAINS; TRANSFORMATION; INFLAMMATION; RESISTANCE; SEQUENCE; PLASMID; ADHESIN	Using transposon shuttle mutagenesis, we identified six Helicobacter pylori mutants from the NTUH-C1 strain that exhibited decreased adherence and cell elongation. Inverse polymerase chain reaction and DNA sequencing revealed that the same locus was interrupted in these six mutants. Nucleotide and amino acid sequences showed no homologies with H. pylori 26695 and J99 strains. This novel open reading frame contained 1617 base pairs. The amino acid sequence shared 24% identity with a putative nicking enzyme in Bacillus halodurans and 23 and 20% identity with type IIS restriction endonucleases PleI and MlyI, respectively. The purified protein, HpyC1I, showed endonuclease activity with the recognition and cleavage site 5'-CCATC( 4/5)-3'. Two open reading frames were located upstream of the gene encoding HpyC1I. Together, HpyC1I and these two putative methyltransferases (M1.HpyC1I and M2.HpyC1I) function as a restriction-modification (R-M) system. The HpyC1I R-M genes were found in 9 of the 15 H. pylori strains tested. When compared with the full genome, significantly lower G + C content of HpyC1I R-M genes implied that these genes might have been acquired by horizontal gene transfer. Plasmid DNA transformation efficiencies and chromosomal DNA digestion assays demonstrated protection from HpyC1I digestion by the R-M system. In conclusion, we have identified a novel R-M system present in similar to60% of H. pylori strains. Disruption of this R-M system results in cell elongation and susceptibility to HpyC1I digestion.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Forens Med, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Wang, JT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, 1,Sec 1,Jen Ai Rd, Taipei 10016, Taiwan.	wangjt@ccms.ntu.edu.tw	Shun, Chia-Tung/M-1400-2019	SHUN, CHIA-TUNG/0000-0002-0468-4468				Akopyants NS, 1998, P NATL ACAD SCI USA, V95, P13108, DOI 10.1073/pnas.95.22.13108; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Ando T, 2000, MOL MICROBIOL, V37, P1052, DOI 10.1046/j.1365-2958.2000.02049.x; Ang S, 2001, INFECT IMMUN, V69, P1679, DOI 10.1128/IAI.69.3.1679-1686.2001; Aras RA, 2002, NUCLEIC ACIDS RES, V30, P5391, DOI 10.1093/nar/gkf686; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Chang KC, 2001, BIOCHEM BIOPH RES CO, V288, P961, DOI 10.1006/bbrc.2001.5877; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; Hsieh PF, 1998, J FORMOS MED ASSOC, V97, P445; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Jiang SY, 1996, ONCOLOGY-BASEL, V53, P334; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; LIN JT, 1993, SCAND J GASTROENTERO, V28, P1067, DOI 10.3109/00365529309098311; Lin LF, 2001, P NATL ACAD SCI USA, V98, P2740, DOI 10.1073/pnas.051612298; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; MARSHALL BJ, 1984, LANCET, V1, P1311; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P418, DOI 10.1093/nar/gkg069; Skowron PM, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng074; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wang G, 1999, TRENDS MICROBIOL, V7, P488, DOI 10.1016/S0966-842X(99)01632-7; WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	26	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11156	11162		10.1074/jbc.M311639200	http://dx.doi.org/10.1074/jbc.M311639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711809	hybrid			2022-12-27	WOS:000220157600040
J	Lopes, DHJ; Chapeaurouge, A; Manderson, GA; Johansson, JS; Ferreira, ST				Lopes, DHJ; Chapeaurouge, A; Manderson, GA; Johansson, JS; Ferreira, ST			Redesigning the folding energetics of a model three-helix bundle protein by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD DENATURATION; FREE-ENERGY; ACIDIC CONDITIONS; HYDROPHOBIC CORE; MOLTEN GLOBULE; HIGH-PRESSURE; EQUILIBRIUM; PATHWAY; INTERMEDIATE; MUTATIONS	Because of their limited size and complexity, de novo designed proteins are particularly useful for the detailed investigation of folding thermodynamics and mechanisms. Here, we describe how subtle changes in the hydrophobic core of a model three-helix bundle protein (GM-0) alter its folding energetics. To explore the folding tolerance of GM-0 toward amino acid sequence variability, two mutant proteins (GM-1 and GM-2) were generated. In the mutants, cavities were created in the hydrophobic core of the protein by either singly (GM-1; L35A variant) or doubly (GM-2; L35A/I39A variant) replacing large hydrophobic side chains by smaller Ala residues. The folding of GM-0 is characterized by two partially folded intermediate states exhibiting characteristics of molten globules, as evidenced by pressure-unfolding and pressure-assisted cold denaturation experiments. In contrast, the folding energetics of both mutants, GM-1 and GM-2, exhibit only one folding intermediate. Our results support the view that simple but biologically important folding motifs such as the three-helix bundle can reveal complex folding plasticity, and they point to the role of hydrophobic packing as a determinant of the overall stability and folding thermodynamic of the helix bundle.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Fiocruz MS, Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Johnson Res Fdn, Philadelphia, PA 19104 USA	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; University of Pennsylvania; University of Pennsylvania	Chapeaurouge, A (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	henk@ioc.fiocruz.br	Ferreira, Sergio/AAZ-1576-2020	Ferreira, Sergio/0000-0001-7160-9866; , Dahabada/0000-0002-5411-9264	NIGMS NIH HHS [GM65218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Boice JA, 1996, BIOCHEMISTRY-US, V35, P14480, DOI 10.1021/bi961831d; Botelho MM, 2000, EUR J BIOCHEM, V267, P2235, DOI 10.1046/j.1432-1327.2000.01226.x; BRIDGMAN PW, 1931, PHYS HIGH PRESSURE, P233; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; Eastwood MP, 2001, J CHEM PHYS, V114, P4702, DOI 10.1063/1.1315994; Ferreira ST, 2001, FEBS LETT, V498, P129, DOI 10.1016/S0014-5793(01)02491-7; Frye KJ, 1998, PROTEIN SCI, V7, P2217, DOI 10.1002/pro.5560071020; Godbole S, 1997, BIOCHEMISTRY-US, V36, P119, DOI 10.1021/bi961915m; Gorski SA, 2001, J MOL BIOL, V312, P849, DOI 10.1006/jmbi.2001.5001; Gruebele M, 2002, CURR OPIN STRUC BIOL, V12, P161, DOI 10.1016/S0959-440X(02)00304-4; Hobart SA, 2002, BIOCHEMISTRY-US, V41, P13744, DOI 10.1021/bi0265224; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; Johansson JS, 1998, J AM CHEM SOC, V120, P3881, DOI 10.1021/ja973538m; KAUZMANN W, 1959, ADV PROTEIN CHEM, P1; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Lassalle MW, 2003, PROTEIN SCI, V12, P66, DOI 10.1110/ps.0221303; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; Martins SM, 2002, EUR J BIOCHEM, V269, P5484, DOI 10.1046/j.1432-1033.2002.03248.x; MASTERTO.WL, 1968, J PHYS CHEM-US, V72, P4257, DOI 10.1021/j100858a053; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nauli S, 2001, NAT STRUCT BIOL, V8, P602, DOI 10.1038/89638; Nguyen H, 2003, P NATL ACAD SCI USA, V100, P3948, DOI 10.1073/pnas.0538054100; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PTITSYN OB, 1995, TRENDS BIOCHEM SCI, V20, P376, DOI 10.1016/S0968-0004(00)89081-7; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; Sasahara K, 2002, PROTEINS, V49, P472, DOI 10.1002/prot.10215; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; Walsh STR, 2001, J MOL BIOL, V305, P361, DOI 10.1006/jmbi.2000.4184; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; Zhou YQ, 1999, NATURE, V401, P400, DOI 10.1038/43940	35	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10991	10996		10.1074/jbc.M308174200	http://dx.doi.org/10.1074/jbc.M308174200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701847	hybrid			2022-12-27	WOS:000220157600021
J	Tiravanti, E; Samouilov, A; Zweier, JL				Tiravanti, E; Samouilov, A; Zweier, JL			Nitrosyl-heme complexes are formed in the ischemic heart - Evidence of nitrite-derived nitric oxide formation, storage, and signaling in post-ischemic tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; FREE-RADICAL GENERATION; PARAMAGNETIC-RESONANCE; REPERFUSION INJURY; XANTHINE-OXIDASE; BIOLOGICAL-SYSTEMS; REDUCTASE-ACTIVITY; ANOXIC TISSUES; SERUM NITRITE; EPR DETECTION	In addition to the generation from specific nitric-oxide (NO) synthases, NO formation from nitrite occurs in ischemic tissues, such as the heart. Although NO binding to heme-centers is the basis for NO-mediated signaling as occurs through guanylate cyclase, it is not known if this process is triggered with physiologically relevant periods of sublethal ischemia and if nitrite serves as a critical substrate. Therefore electron paramagnetic resonance studies were performed to measure nitrosylheme formation during the time course of myocardial ischemia and reperfusion and the role of nitrite in this process. Rat hearts were either partially nitrite-depleted by nitrite-free buffer perfusion or nitrite-enriched by preinfusion with 50 muM nitrite. Ischemic hearts loaded with nitrite showed prominent spectra of six-coordinate nitrosyl-heme complexes, primarily NO-myoglobin, that increased as a function of ischemic duration, whereas in nonischemic-controls these signals were not seen. Total nitrosyl-heme concentrations within the heart were 6.6 +/- 0.7 muM after 30 min of ischemia. Nitrite-depleted hearts also gave rise to NO-heme signals during ischemia, but levels were 8-fold lower. Nitrite-mediated NO-heme complex formation during ischemia was associated with activation of guanylate cyclase. Upon reperfusion, the levels of NO-heme complexes decreased 3-fold by the first 15 min but remained elevated for over 45 min. The decrease in NO-heme complex levels was paralleled by the formation of nitrate, suggesting the oxidation of heme-bound NO upon reperfusion. Thus, nitrite-mediated NO-heme formation occurs progressively during ischemia, with these complexes serving as a store of NO with concordant activation of NO signaling pathways.	Ohio State Univ, Ctr Biomed EPR Spect & Imaging, Coll Med, Columbus, OH 43210 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Coll Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Cardiovasc Med, Coll Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zweier, JL (corresponding author), 110G Davis Heart & Lung Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.	zweier-1@medctr.osu.edu	Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R01HL063744, R29HL038324, P01HL065608] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; EVANS T, 1994, J INFECT DIS, V169, P343, DOI 10.1093/infdis/169.2.343; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GARSIDE C, 1982, MAR CHEM, V11, P159, DOI 10.1016/0304-4203(82)90039-1; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; HAGLER L, 1979, J BIOL CHEM, V254, P6505; HenryYA, 1997, NITRIC OXIDE RES CHE; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; Kitakaze M, 2001, J MOL CELL CARDIOL, V33, P1727, DOI 10.1006/jmcc.2001.1435; KOMAROV A, 1993, BIOCHEM BIOPH RES CO, V195, P1191, DOI 10.1006/bbrc.1993.2170; KON H, 1968, J BIOL CHEM, V243, P4350; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; KUPPUSAMY P, 1995, J CEREBR BLOOD F MET, V15, P899, DOI 10.1038/jcbfm.1995.114; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Lecour S, 2001, J CARDIOVASC PHARM, V37, P55, DOI 10.1097/00005344-200101000-00007; Lepore DA, 1999, NITRIC OXIDE-BIOL CH, V3, P75, DOI 10.1006/niox.1999.0211; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; McKnight GM, 1999, BRIT J NUTR, V81, P349, DOI 10.1017/S000711459900063X; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; NAVA E, 1992, J CARDIOVASC PHARM, V20, P132; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; Oldreive C, 2001, FREE RADICAL RES, V35, P215, DOI 10.1080/10715760100300761; Payne WJ, 1997, BIOFACTORS, V6, P47, DOI 10.1002/biof.5520060106; RADI R, 1991, J BIOL CHEM, V266, P4244; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sastry KVH, 2002, ANAL BIOCHEM, V306, P79, DOI 10.1006/abio.2002.5676; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Tari A, 2002, DIGEST DIS SCI, V47, P100, DOI 10.1023/A:1013271605493; TOMINAGA T, 1994, J CEREBR BLOOD F MET, V14, P715, DOI 10.1038/jcbfm.1994.92; TOMINAGA T, 1993, BRAIN RES, V614, P342, DOI 10.1016/0006-8993(93)91053-U; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Witting PK, 2001, J BIOL CHEM, V276, P3991, DOI 10.1074/jbc.M005758200; Wunderlich C, 2003, CIRC RES, V92, P1352, DOI 10.1161/01.RES.0000079026.70629.E5; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; Zhao YD, 1998, BIOCHEMISTRY-US, V37, P12458, DOI 10.1021/bi9811563; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1994, J MAGN RESON SER B, V105, P52, DOI 10.1006/jmrb.1994.1099; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	58	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11065	11073		10.1074/jbc.M311908200	http://dx.doi.org/10.1074/jbc.M311908200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704151	hybrid			2022-12-27	WOS:000220157600029
J	Richer, MJ; Juliano, L; Hashimoto, C; Jean, F				Richer, MJ; Juliano, L; Hashimoto, C; Jean, F			Serpin mechanism of hepatitis C virus nonstructural 3 (NS3) protease inhibition - Induced fit as a mechanism for narrow specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; NS3-NS4A SERINE PROTEINASE; ACTIVE-SITE; VIRAL PROTEASES; NS4A COFACTOR; IN-VITRO; ACTIVATION; DOMAIN; FURIN; SUBSTRATE	Hepatitis C virus (HCV) nonstructural 3 (NS3) serine protease disrupts important cellular antiviral signaling pathways and plays a pivotal role in the proteolytic maturation of the HCV polyprotein precursor. This recent discovery has fostered the search for NS3 protease inhibitors. However, the enzyme's unusual induced fit behavior and peculiar molecular architecture have imposed considerable obstacles to the development of small molecule inhibitors. In this article, we demonstrate that such unique induced fit behavior and the chymotrypsin-like catalytic domain can provide the structural plasticity necessary to generate protein-based inhibitors of the NS3 protease. We took advantage of the macromolecular scaffold of a Drosophila serpin, SP6, which intrinsically supports chymotrypsin-like enzyme inhibition, to design a novel class of potent and selective inhibitors. We show that altering the SP6 reactive site loop (RSL) resulted in the development of the first effective (K-i of 34 nM) and selective serpin, SP6(EVC/S), directed at the NS3 protease. SP6(EVC/S) operates as a suicide substrate inhibitor, and its partitioning between the complex-forming and proteolytic pathways for the NS3 protease is HCV NS4A cofactor-dependent and - specific. Once bound to the protease active site, SP6(EVC/S) partitions with equal probability to undergo proteolysis by NS3 at the C-terminal site of the engineered RSL, (P-6) Glu-Ile-( P-4) Val-Met-Thr-(P-1) Cys- down arrow-(P-1') Ser, or to form a covalent acyl-enzyme complex characteristic of cognate protease-serpin pairs. Our results also reveal a novel cofactor-induced serpin mechanism of enzyme inhibition that could be explored for developing effective and selective inhibitors of other important induced fit viral proteases of the Flaviviridae family such as the West Nile virus NS3 endoprotease.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	University of British Columbia; Universidade Federal de Sao Paulo (UNIFESP); Yale University	Jean, F (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	fjean@interchange.ubc.ca	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIGMS NIH HHS [GM49370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049370] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbato G, 2000, EMBO J, V19, P1195, DOI 10.1093/emboj/19.6.1195; Barbato G, 1999, J MOL BIOL, V289, P371, DOI 10.1006/jmbi.1999.2745; Bartenschlager R, 1999, J VIRAL HEPATITIS, V6, P165, DOI 10.1046/j.1365-2893.1999.00152.x; Bianchi E, 1999, BIOCHEMISTRY-US, V38, P13844, DOI 10.1021/bi991220w; Bianchi E, 2002, BIOPOLYMERS, V66, P101, DOI 10.1002/bip.10230; De Francesco R, 2003, ANTIVIR RES, V58, P1, DOI 10.1016/S0166-3542(03)00028-7; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Han JH, 2000, FEBS LETT, V468, P194, DOI 10.1016/S0014-5793(00)01224-2; Ingallinella P, 2000, BIOCHEMISTRY-US, V39, P12898, DOI 10.1021/bi001590g; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; KURZCHALIA TV, 1992, J BIOL CHEM, V267, P18419; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Narjes F, 2003, EXPERT OPIN INV DRUG, V12, P153, DOI 10.1517/eoid.12.2.153.21407; Pimenta DC, 2003, BIOCHEM J, V371, P1021, DOI 10.1042/BJ20021952; PO A, 2001, PEPTIDES WAVE FUTURE, P563; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Ryan MD, 1998, J GEN VIROL, V79, P947, DOI 10.1099/0022-1317-79-5-947; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Tong L, 2002, CHEM REV, V102, P4609, DOI 10.1021/cr010184f; Vishnuvardhan D, 1997, FEBS LETT, V402, P209, DOI 10.1016/S0014-5793(96)01532-3; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	36	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10222	10227		10.1074/jbc.M313852200	http://dx.doi.org/10.1074/jbc.M313852200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701815	hybrid			2022-12-27	WOS:000220050400069
J	Rossignol, P; Ho-Tin-Noe, B; Vranckx, R; Bouton, MC; Meilhac, O; Lijnen, HR; Guillin, MC; Michel, JB; Angles-Cano, E				Rossignol, P; Ho-Tin-Noe, B; Vranckx, R; Bouton, MC; Meilhac, O; Lijnen, HR; Guillin, MC; Michel, JB; Angles-Cano, E			Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GLIA-DERIVED NEXIN; RECOMBINANT HUMAN-PLASMINOGEN; NEURITE-PROMOTING FACTOR; SINGLE-CHAIN UROKINASE; HAMSTER OVARY CELLS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; SERINE PROTEASES; MAMMALIAN-CELLS	Degradation of adhesive glycoproteins by plasmin is implicated in cell migration. In this study, we further explored the role of plasminogen activation in cell adhesion and survival and show that uncontrolled plasminogen activation at the cell surface may induce cell detachment and apoptosis. We hypothesized that this process could be prevented in adherent cells by expression of protease nexin-1, a potent serpin able to inhibit thrombin, plasmin, and plasminogen activators. Using two- and three-dimensional culture systems, we demonstrate that Chinese hamster ovary fibroblasts constitutively express tissue-type plasminogen activator and efficiently activate exogenously added plasminogen in a specific and saturable manner (K-m = 46 nM). The formation of plasmin results in proteolysis of fibronectin and laminin, which is followed by cell detachment and apoptosis. Protease nexin-1 expressed by transfected cells significantly inhibited the activity of plasmin and tissue-type plasminogen activator via the formation of inhibitory complexes and prevented cell detachment and apoptosis. In conclusion, protease nexin-1 may be an important anti-apoptotic factor for adherent cells. This cell model could be a useful tool to evaluate therapeutic agents such as serpins in vascular pathologies involving pericellular protease-protease inhibitor imbalance.	Ctr Hosp Univ Bichat Claude Bernard, INSERM, U460, F-75877 Paris 18, France; Univ Paris 07, INSERM, EMI 348, Unite Format Rech Med, F-75870 Paris 18, France; Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; KU Leuven	Angles-Cano, E (corresponding author), Ctr Hosp Univ Bichat Claude Bernard, INSERM, U460, 46 Rue Henri Huchard, F-75877 Paris 18, France.	angles@infobiogen.fr	Michel, Jean-Baptiste/AAH-9336-2020; ANGLES-CANO, Eduardo/G-2311-2012; Bouton, Marie-Christine/L-1583-2017; Ho-Tin-Noé, Benoit/U-8059-2018; Lijnen, Roger/AAA-4085-2020; ANGLES-CANO, Eduardo/ABA-1739-2020; Meilhac, Olivier/N-4385-2017	ANGLES-CANO, Eduardo/0000-0001-7891-3975; Ho-Tin-Noé, Benoit/0000-0002-7428-1760; ANGLES-CANO, Eduardo/0000-0001-7891-3975; BOUTON, Marie-Christine/0000-0001-5092-7363; Meilhac, Olivier/0000-0002-3740-7539				Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Adderley SR, 2000, J BIOL CHEM, V275, P5760, DOI 10.1074/jbc.275.8.5760; ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Badier-Commander C, 2000, J PATHOL, V192, P105, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH670>3.0.CO;2-1; BAKER JB, 1986, SEMIN THROMB HEMOST, V12, P216, DOI 10.1055/s-2007-1003554; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BERGMAN BL, 1986, P NATL ACAD SCI USA, V83, P996, DOI 10.1073/pnas.83.4.996; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BJORK I, 1972, European Journal of Biochemistry, V29, P579, DOI 10.1111/j.1432-1033.1972.tb02024.x; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Bouton MC, 2003, ARTERIOSCL THROM VAS, V23, P142, DOI 10.1161/01.ATV.0000047867.98019.2D; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHOI BH, 1990, AM J PATHOL, V137, P741; Chung CY, 1997, J CELL SCI, V110, P1413; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; Davis GE, 2001, J CELL SCI, V114, P917; Davis J, 2003, J BIOL CHEM, V278, P19054, DOI 10.1074/jbc.M301398200; DECLERCK PJ, 1990, THROMB RES, P3; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; Edman P, 1975, PROTEIN SEQUENCE DET, P232; FLEURY V, 1993, J BIOL CHEM, V268, P18554; Fontaine V, 2002, AM J PATHOL, V161, P1701, DOI 10.1016/S0002-9440(10)64447-1; Fowler B, 1998, THROMB HAEMOSTASIS, V80, P148, DOI 10.1055/s-0037-1615154; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; GLOOR S, 1986, CELL, V47, P687; Guan HC, 2003, VIROLOGY, V309, P114, DOI 10.1016/S0042-6822(02)00135-6; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; HARPER PA, 1983, J CELL SCI, V63, P287; HERVIO L, 1993, BLOOD, V82, P392; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ikari Y, 2001, J BIOL CHEM, V276, P11798, DOI 10.1074/jbc.M008503200; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee E, 1996, CIRC RES, V78, P44, DOI 10.1161/01.RES.78.1.44; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Meilhac O, 2003, FASEB J, V17, P1301, DOI 10.1096/fj.02-0687fje; Michel JB, 2001, ARTERIOSCL THROM VAS, V21, P1389; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MONARD D, 1992, ANN NY ACAD SCI, V674, P237, DOI 10.1111/j.1749-6632.1992.tb27492.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; Montes R, 1996, BRIT J HAEMATOL, V92, P979, DOI 10.1046/j.1365-2141.1996.416951.x; MOORE A, 1995, CYTOTECHNOLOGY, V17, P1, DOI 10.1007/BF00749215; Mtairag EM, 2002, ARTERIOSCL THROM VAS, V22, P1824, DOI 10.1161/01.ATV.0000037102.31086.F4; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RAJARAMAN R, 1984, CELL BIOL INT REP, V8, P383, DOI 10.1016/0309-1651(84)90141-3; RAO JS, 1989, MUSCLE NERVE, V12, P640, DOI 10.1002/mus.880120805; Reijerkerk A, 2003, MOL CANCER RES, V1, P561; REINARTZ J, 1995, EXP CELL RES, V220, P274, DOI 10.1006/excr.1995.1316; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Scott KK, 2003, DNA CELL BIOL, V22, P95, DOI 10.1089/104454903321515904; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SOMMER J, 1987, BIOCHEMISTRY-US, V26, P6407, DOI 10.1021/bi00394a016; SOMMER J, 1989, GENE, V85, P453, DOI 10.1016/0378-1119(89)90439-3; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720; Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4; WHITE EA, 1993, THROMB HAEMOSTASIS, V69, P119; Zhang X, 2003, MOL VIS, V9, P238; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	78	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10346	10356		10.1074/jbc.M310964200	http://dx.doi.org/10.1074/jbc.M310964200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699093	hybrid			2022-12-27	WOS:000220050400084
J	Weeks, DL; Gushansky, G; Scott, DR; Sachs, G				Weeks, DL; Gushansky, G; Scott, DR; Sachs, G			Mechanism of proton gating of a urea channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI UREASE; ACID RESISTANCE; EXPRESSION; PROTEIN; PH; COLONIZATION; ACTIVATION; GENES; H+	The size and complexity of many pH-gated channels have frustrated the development of specific structural models. The small acid-activated six-membrane segment urea channel of Helicobacter hepaticus (HhUreI), homologous to the essential UreI of the gastric pathogen Helicobacter pylori, enables identification of all the periplasmic sites of proton gating by site-directed mutagenesis. Exposure to external acidity enhances [C-14]urea uptake by Xenopus oocytes expressing HhUreI, with half-maximal activity (pH(0.5)) at pH 6.8. A downward shift of pH(0.5) in single site mutants identified four of six protonatable periplasmic residues (His-50 at the boundary of the second transmembrane segment TM2, Glu-56 in the first periplasmic loop, Asp-59 at the boundary of TM3, and His-170 at the boundary of TM6) that affect proton gating. Asp-59 was the only site at which a protonatable residue appeared to be essential for pH gating. Mutation of Glu-110 or Glu-114 in PL2 did not affect the pH(0.5) of gating. A chimera, where the entire periplasmic domain of HhUreI was fused to the membrane domain of Streptococcus salivarius UreI (SsUreI), retained the pH-independent properties of SsUreI. Hence, proton gating of HhUreI likely depends upon the formation of hydrogen bonds by periplasmic residues that in turn produce conformational changes of the transmembrane domain. Further studies on HhUreI may facilitate understanding of other physiologically important pH-responsive channels.	Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Sachs, G (corresponding author), Wadsworth Vet Affairs Hosp, Bldg 113,Rm 324, Los Angeles, CA 90073 USA.	gsachs@ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058333, R56DK058333] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58333] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auzanneau C, 2003, J BIOL CHEM, V278, P19230, DOI 10.1074/jbc.M301096200; Avdonin V, 2003, BIOPHYS J, V84, P2969, DOI 10.1016/S0006-3495(03)70023-X; Bagnasco SM, 2003, AM J PHYSIOL-RENAL, V284, pF3, DOI 10.1152/ajprenal.00260.2002; Beckwith CS, 2001, INFECT IMMUN, V69, P5914, DOI 10.1128/IAI.69.9.5914-5920.2001; Bury-Mone S, 2001, MOL MICROBIOL, V42, P1021, DOI 10.1046/j.1365-2958.2001.02689.x; Chen YYM, 1998, J BACTERIOL, V180, P5769, DOI 10.1128/JB.180.21.5769-5775.1998; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; DelVecchio VG, 2002, VET MICROBIOL, V90, P587, DOI 10.1016/S0378-1135(02)00238-9; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Low CM, 2003, MOL PHARMACOL, V63, P1212, DOI 10.1124/mol.63.6.1212; McGee DJ, 1999, J BACTERIOL, V181, P2477, DOI 10.1128/JB.181.8.2477-2484.1999; MeyerRosberg K, 1996, GASTROENTEROLOGY, V111, P886, DOI 10.1016/S0016-5085(96)70056-2; MOLLENHAUER M, 2002, THESIS U KONSTANZ KO; Mollenhauer-Rektorschek M, 2002, RES MICROBIOL, V153, P659, DOI 10.1016/S0923-2508(02)01380-3; Rektorschek M, 2000, MOL MICROBIOL, V36, P141, DOI 10.1046/j.1365-2958.2000.01835.x; Scott DR, 2000, INFECT IMMUN, V68, P470, DOI 10.1128/IAI.68.2.470-477.2000; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; Sebbane F, 2002, MOL MICROBIOL, V45, P1165, DOI 10.1046/j.1365-2958.2002.03096.x; Skouloubris S, 1998, INFECT IMMUN, V66, P4517; Spencer RH, 2002, ANNU REV BIOPH BIOM, V31, P207, DOI 10.1146/annurev.biophys.31.082901.134329; Stroffekova K, 1998, AM J PHYSIOL, V275, P1113; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Weeks DL, 2001, MOL MICROBIOL, V40, P1249, DOI 10.1046/j.1365-2958.2001.02466.x; Xu HX, 2001, J BIOL CHEM, V276, P38690, DOI 10.1074/jbc.M106595200; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	28	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9944	9950		10.1074/jbc.M312680200	http://dx.doi.org/10.1074/jbc.M312680200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701805	hybrid			2022-12-27	WOS:000220050400036
J	Lewis, J; Burstein, E; Reffey, SB; Bratton, SB; Roberts, AB; Duckett, CS				Lewis, J; Burstein, E; Reffey, SB; Bratton, SB; Roberts, AB; Duckett, CS			Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SERINE-PROTEASE OMI/HTRA2; STRUCTURAL BASIS; CYTOCHROME-C; BIR DOMAIN; BACULOVIRAL-INHIBITOR; ENDOTHELIAL-CELLS; NMR STRUCTURE; XIAP; IAP	In addition to its well described function as an enzymatic inhibitor of specific caspases, X-linked inhibitor of apoptosis (X-linked IAP or XIAP) can function as a cofactor in Smad, NF-kappaB, and JNK signaling pathways. However, caspases themselves have been shown to regulate the activity of a number of signaling cascades, raising the possibility that the effect of XIAP in these pathways is indirect. Here we examine this question by introducing point mutations in XIAP predicted to disrupt the ability of the molecule to bind to and inhibit caspases. We show that whereas these mutant variants of XIAP lost caspase-inhibitory activity, they maintained their ability to activate Smad, NF-kappaB, and JNK signaling pathways. Indeed, the signaling properties of the molecule were mapped to domains not directly involved in caspase binding and inhibition. The activation of NF-kappaB by XIAP was dependent on the E3 ubiquitin ligase activity of the RING domain. On the other hand, the ability of XIAP to activate Smad-dependent signaling was mapped to the third baculoviral IAP repeat (BIR) and loop regions of the molecule. Thus, the antiapoptotic and signaling properties of XIAP can be uncoupled.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Sci Applicat Int Corp, Conressionally Directed Med Res Program, Biomed Technol Div, MCMRPLF, Ft Detrick, MD 21702 USA; Univ Texas, Coll Pharm, Ctr Mol & Cellular Toxicol, Austin, TX 78718 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Science Applications International Corporation (SAIC); University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duckett, CS (corresponding author), Rm 5315,1301 Catherine, Ann Arbor, MI 48109 USA.	colind@umich.edu	Burstein, Ezra/B-7247-2016	Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263; Bratton, Shawn/0000-0003-2895-5020				Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Li FZ, 2000, J BIOL CHEM, V275, P6707, DOI 10.1074/jbc.275.10.6707; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; SANNA MG, 2002, J BIOL CHEM; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	51	84	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9023	9029		10.1074/jbc.M312891200	http://dx.doi.org/10.1074/jbc.M312891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701799	hybrid			2022-12-27	WOS:000189265900062
J	Basavapathruni, A; Bailey, CM; Anderson, KS				Basavapathruni, A; Bailey, CM; Anderson, KS			Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT PRIMER UNBLOCKING; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; RESISTANCE MUTATIONS; ANTIVIRAL ACTIVITY; INHIBITORS NNRTIS; DNA-POLYMERASE; REPLICATION; DERIVATIVES	Combination therapies treating human immunodeficiency virus type 1 (HIV-1) infection delay the emergence of drug-resistant virus and exhibit synergistic inhibition. This synergy is observed within the two classes of inhibitors that target the essential viral reverse transcriptase (RT): the chain-terminating nucleoside analogs (NRTIs) and the allosteric nonnucleosides (NNR-Tis) that bind in a pocket distinct from the active site. A general mechanism to define the molecular basis for synergy between these two classes remains to be elucidated. Previous mechanistic studies from our laboratory (Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Science 267, 988-993) have shown that the natural deoxynucleoside triphosphate and the NNRTI can simultaneously bind to their respective sites. This work also suggests communication between the two sites, since the inhibition of RT by NNRTIs is manifested through a remote effect on the chemical step. This interplay between the two sites offers a plausible hypothesis for understanding synergy in which binding of NNRTIs modulates the chain termination by NRTIs. The present study supports this hypothesis by illustrating that the clinically approved NNRTIs, nevirapine and efavirenz, inhibit the ATP-mediated removal of AZTMP, d4TMP, ddCMP, (-)3TCMP, (-)FTCMP, and (+)3TCMP, thereby prolonging the effectiveness of chain termination. This inhibition is mediated through an effect on both the rate of the chemical step and binding of ATP, resulting in an overall decrease in efficiency of removal. This work substantiates communication between the two binding pockets, the sustained use of combination therapy to treat HIV infection, and a molecular basis for understanding synergy.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B350B,333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu		Bailey, Chris/0000-0002-5962-9511	NIGMS NIH HHS [GM49551] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Balzarini J, 1996, MOL PHARMACOL, V50, P394; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; Carr A, 1996, AIDS, V10, P635, DOI 10.1097/00002030-199606000-00009; CARROLL SS, 1993, J BIOL CHEM, V268, P276; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; HAMME AT, 1994, CHEMTRACTS ORG CHEM, V7, P24; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; King RW, 2002, ANTIMICROB AGENTS CH, V46, P1640, DOI 10.1128/AAC.46.6.1640-1646.2002; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Merrill DP, 1996, J INFECT DIS, V173, P355, DOI 10.1093/infdis/173.2.355; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200; Odriozola L, 2003, J BIOL CHEM, V278, P42710, DOI 10.1074/jbc.M212673200; PAUWELS R, 1994, ANTIMICROB AGENTS CH, V38, P2863, DOI 10.1128/AAC.38.12.2863; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; Ray AS, 2002, BIOCHEMISTRY-US, V41, P5150, DOI 10.1021/bi0121858; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Zembower DE, 1997, J MED CHEM, V40, P1005, DOI 10.1021/jm960355m; Zhu QY, 1996, AIDS RES HUM RETROV, V12, P507, DOI 10.1089/aid.1996.12.507	33	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6221	6224		10.1074/jbc.C300523200	http://dx.doi.org/10.1074/jbc.C300523200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14722107				2022-12-27	WOS:000188969200005
J	Alvarez, J; Hamplova, J; Hohaus, A; Morano, I; Haase, H; Vassort, G				Alvarez, J; Hamplova, J; Hohaus, A; Morano, I; Haase, H; Vassort, G			Calcium current in rat cardiomyocytes is modulated by the carboxyl-terminal ahnak domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BETA-SUBUNIT; VOLTAGE-DEPENDENT FACILITATION; CA2+ CHANNEL; PROTEIN-KINASE; MOLECULAR DETERMINANTS; DESMOYOKIN/AHNAK PROTEIN; INACTIVATION; IDENTIFICATION; PHOSPHORYLATION; EXPRESSION	Ahnak, a protein of 5643 amino acids, interacts with the regulatory beta-subunit of cardiac calcium channels and with F-actin. Recently, we defined the binding sites among the protein partners in the carboxyl-terminal domain of ahnak. Here we further narrowed down the beta(2)-interaction sites to the carboxyl-terminal 188 amino acids of ahnak by the recombinant ahnak protein fragments P3 ( amino acids 5456 - 5556) and P4 ( amino acids 5556 - 5643). The effects of these P3 and P4 fragments on the calcium current were investigated under whole-cell patch clamp conditions on rat ventricular cardiomyocytes. P4 but not P3 increased significantly the current amplitude by 22.7 +/- 5% without affecting its voltage dependence. The slow component of calcium current inactivation was slowed down by both P3 and P4, whereas only P3 slowed significantly the fast one. The composite recombinant protein fragment P3 - P4 induced similar modifications to the ones induced by each of the ahnak fragments. In the presence of carboxyl-terminal ahnak protein fragments, isoprenaline induced a similar relative increase in current amplitude and shift in current kinetics. The actin-stabilizing agents, phalloidin and jasplakinolide, did not modify the effects of these ahnak protein fragments on calcium current in control conditions nor in the presence of isoprenaline. Hence, our results suggest that the functional effects of P3, P4, and P3 - P4 on calcium current are mediated by targeting the ahnak-beta(2)-subunit interaction rather than by targeting the ahnak-F-actin interaction. More specifically they suggest that binding of the beta(2)-subunit to the endogenous subsarcolemmal giant ahnak protein re-primes the alpha(1C)/beta(2)-subunit interaction and that the ahnak-derived proteins relieve the beta(2)-subunit from this inhibition.	CHU Arnaud de Villeneuve, INSERM, U390, F-34295 Montpellier 5, France; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ Charite, Johannes Muller Inst Physiol, D-10117 Berlin, Germany; Inst Cardiol, Havana, Cuba	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Vassort, G (corresponding author), CHU Arnaud de Villeneuve, INSERM, U390, F-34295 Montpellier 5, France.	vassort@montp.inserm.fr						Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; Cens T, 1999, FEBS LETT, V450, P17, DOI 10.1016/S0014-5793(99)00463-9; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Delgado C, 1999, J MOL CELL CARDIOL, V31, P1783, DOI 10.1006/jmcc.1999.1023; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gerhardstein BL, 1999, BIOCHEMISTRY-US, V38, P10361, DOI 10.1021/bi990896o; Guo J, 2003, J PHYSIOL-LONDON, V547, P797, DOI 10.1113/jphysiol.2002.033340; Haase H, 2000, J CELL BIOCHEM, V76, P695, DOI 10.1002/(SICI)1097-4644(20000315)76:4<695::AID-JCB17>3.0.CO;2-Q; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126, DOI 10.1152/ajpheart.2000.278.1.H126; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; Lader AS, 1999, AM J PHYSIOL-CELL PH, V277, pC1277, DOI 10.1152/ajpcell.1999.277.6.C1277; LEE KS, 1987, P NATL ACAD SCI USA, V84, P3941, DOI 10.1073/pnas.84.11.3941; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; Nakamura M, 2000, AM J PHYSIOL-CELL PH, V279, pC480, DOI 10.1152/ajpcell.2000.279.2.C480; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1996, AM J PHYSIOL-CELL PH, V271, pC1539, DOI 10.1152/ajpcell.1996.271.5.C1539; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982	50	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12456	12461		10.1074/jbc.M312177200	http://dx.doi.org/10.1074/jbc.M312177200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722071	hybrid			2022-12-27	WOS:000220334900055
J	Grossman, CE; Qian, YM; Banki, K; Perl, A				Grossman, CE; Qian, YM; Banki, K; Perl, A			ZNF143 mediates basal and tissue-specific expression of human transaldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER-RNA; PENTOSE-PHOSPHATE PATHWAY; TRANSCRIPTION-ACTIVATING FACTOR; SMALL NUCLEAR-RNA; MOUSE MAMMARY-GLAND; ZINC-FINGER; GENE-TRANSCRIPTION; POLYMERASE-III; GLUTATHIONE LEVELS; INDUCED APOPTOSIS	Transaldolase regulates redox-dependent apoptosis through controlling NADPH and ribose 5-phosphate production via the pentose phosphate pathway. The minimal promoter sufficient to drive chloramphenicol acetyltransferase reporter gene activity was mapped to nucleotides - 49 to - 1 relative to the transcription start site of the human transaldolase gene. DNase I footprinting with nuclear extracts of transaldolase-expressing cell lines unveiled protection of nucleotides - 29 to - 16. Electrophoretic mobility shift assays identified a single dominant DNA-protein complex that was abolished by consensus sequence for transcription factor ZNF143/76 or mutation of the ZNF76/143 motif within the transaldolase promoter. Mutation of an AP-2alpha recognition sequence, partially overlapping the ZNF143 motif, increased TAL-H promoter activity in HeLa cells, without significant impact on HepG2 cells, which do not express AP-2alpha. Cooperativity of ZNF143 with AP-2alpha was supported by supershift analysis of HeLa cells where AP-2 may act as cell type-specific repressor of TAL promoter activity. However, overexpression of full-length ZNF143, ZNF76, or dominant-negative DNA-binding domain of ZNF143 enhanced, maintained, or abolished transaldolase promoter activity, respectively, in HepG2 and HeLa cells, suggesting that ZNF143 initiates transcription from the transaldolase core promoter. ZNF143 overexpression also increased transaldolase enzyme activity. ZNF143 and transaldolase expression correlated in 21 different human tissues and were coordinately upregulated 14- and 34-fold, respectively, in lactating mammary glands compared with nonlactating ones. Chromatin immunoprecipitation studies confirm that ZNF143/73 associates with the transaldolase promoter in vivo. Thus, ZNF143 plays a key role in basal and tissue-specific expression of transaldolase and regulation of the metabolic network controlling cell survival and differentiation.	SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA; SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.	perla@upstate.edu		Qian, Yueming/0000-0001-7340-6421; Perl, Andras/0000-0002-5017-1348	NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; Adachi K, 1999, ENDOCRINOLOGY, V140, P618, DOI 10.1210/en.140.2.618; ASAHINA T, 1995, DIABETES, V44, P520, DOI 10.2337/diabetes.44.5.520; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; BANKI K, 1994, J BIOL CHEM, V269, P2847; Banki K, 1997, GENOMICS, V45, P233, DOI 10.1006/geno.1997.4932; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; Banki K, 1999, J IMMUNOL, V162, P1466; BAQUER NZ, 1977, DEV MED CHILD NEUROL, V19, P81; Baquer NZ, 1975, NORMAL PATHOLOGICAL, P109; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BHATNAGAR A, 1990, CIRC RES, V67, P535, DOI 10.1161/01.RES.67.3.535; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOSS GR, 1984, J BIOL CHEM, V259, P2936; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Cabezas H, 1999, MOL CELL BIOCHEM, V201, P57, DOI 10.1023/A:1007042531454; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Constantini P., 1996, J BIOL CHEM, V271, P6746; Cooper R.A., 1991, HARRISONS PRINCIPLES, P1531; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; Franze A, 1998, FEBS LETT, V437, P313, DOI 10.1016/S0014-5793(98)01259-9; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greene DA, 1999, EUR J PHARMACOL, V375, P217, DOI 10.1016/S0014-2999(99)00356-8; HEINRICH PC, 1976, CANCER RES, V36, P3189; HELD KD, 1993, RADIAT RES, V134, P383, DOI 10.2307/3578201; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Horecker BL, 2002, J BIOL CHEM, V277, P47965, DOI 10.1074/jbc.X200007200; HOTHERSALL JS, 1982, ENZYME, V27, P259, DOI 10.1159/000459058; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; James H M, 1985, Int J Vitam Nutr Res Suppl, V28, P29; Kashiwagi A., 1996, DIABETES, V45, P84; KAUFFMAN FC, 1977, J NEUROCHEM, V28, P745, DOI 10.1111/j.1471-4159.1977.tb10622.x; KELSO TB, 1989, AM J PHYSIOL, V257, pE885, DOI 10.1152/ajpendo.1989.257.6.E885; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; KUHN E, 1972, BIOCHEMISTRY-US, V11, P1767, DOI 10.1021/bi00760a006; Lachaise F, 2002, GENE, V299, P263, DOI 10.1016/S0378-1119(02)01051-X; Lebeda RA, 1999, BBA-GENE STRUCT EXPR, V1445, P314, DOI 10.1016/S0167-4781(99)00064-0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mach CM, 2002, J BIOL CHEM, V277, P4853, DOI 10.1074/jbc.M108308200; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTINS RN, 1985, AUST J BIOL SCI, V38, P295; Mayes P., 1993, HARPERS BIOCH, P201; MCDOUGAL DB, 1961, J GEN PHYSIOL, V44, P487, DOI 10.1085/jgp.44.3.487; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; MYSLINSKI E, 1993, J MOL BIOL, V234, P311, DOI 10.1006/jmbi.1993.1588; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Ni TC, 1996, J BIOL CHEM, V271, P7927, DOI 10.1074/jbc.271.14.7927; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOVELLO F, 1968, BIOCHEM J, V107, P775, DOI 10.1042/bj1070775; Perl A, 2000, J BIOL CHEM, V275, P7261, DOI 10.1074/jbc.275.10.7261; Perl A, 2002, ANTIOXID REDOX SIGN, V4, P427, DOI 10.1089/15230860260196227; PILZ RB, 1984, J BIOL CHEM, V259, P2927; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; ROSA LFBPC, 1993, PHYSIOL BEHAV, V53, P651, DOI 10.1016/0031-9384(93)90169-G; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schaub M, 2000, NUCLEIC ACIDS RES, V28, P2114, DOI 10.1093/nar/28.10.2114; Schaub M, 1999, J BIOL CHEM, V274, P24241, DOI 10.1074/jbc.274.34.24241; Schaub M, 1999, J BIOL CHEM, V274, P25042, DOI 10.1074/jbc.274.35.25042; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Severin S E, 1980, Adv Enzyme Regul, V19, P235; SPOLARICS Z, 1991, BIOCHEM J, V278, P515, DOI 10.1042/bj2780515; STARK KL, 1989, BIOCHEM PHARMACOL, V38, P2685, DOI 10.1016/0006-2952(89)90555-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAN EL, 1969, COMP BIOCHEM PHYSIOL, V31, P635, DOI 10.1016/0010-406X(69)90064-4; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; Thom E, 1998, PLANTA, V204, P226, DOI 10.1007/s004250050251; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; URSINI MV, 1993, VIROLOGY, V196, P338, DOI 10.1006/viro.1993.1485; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOOD T, 1985, PENTOSE PHOSPHATE PA; Wu F, 2002, J CELL BIOCHEM, V84, P699, DOI 10.1002/jcb.10094; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070; YOUNG AJ, 1990, P SOC EXP BIOL MED, V193, P274	99	31	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12190	12205		10.1074/jbc.M307039200	http://dx.doi.org/10.1074/jbc.M307039200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702349	hybrid			2022-12-27	WOS:000220334900025
J	Kajimoto, T; Shirai, Y; Sakai, N; Yamamoto, T; Matsuzaki, H; Kikkawa, U; Saito, N				Kajimoto, T; Shirai, Y; Sakai, N; Yamamoto, T; Matsuzaki, H; Kikkawa, U; Saito, N			Ceramide-induced apoptosis by translocation, phosphorylation, and activation of protein kinase C delta in the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; ABL TYROSINE KINASE; SRC FAMILY KINASES; PKC-DELTA; PROTEOLYTIC ACTIVATION; TRANSDUCTION PATHWAY; CELLULAR-RESPONSES; EPSILON; DOMAIN; IDENTIFICATION	Protein kinase C (PKC), a Ca2+/phospholipid-dependent protein kinase, is known as a key enzyme in various cellular responses, including apoptosis. However, the functional role of PKC in apoptosis has not been clarified. In this study, we focused on the involvement of PKCdelta in ceramide-induced apoptosis in HeLa cells and examined the importance of spatiotemporal activation of the specific PKC subtype in apoptotic events. Ceramide-induced apoptosis was inhibited by the PKCdelta-specific inhibitor rottlerin and also was blocked by knockdown of endogenous PKCdelta expression using small interfering RNA. Ceramide induced the translocation of PKCdelta to the Golgi complex and the concomitant activation of PKCdelta via phosphorylation of Tyr(311) and Tyr(332) in the hinge region of the enzyme. Unphosphorylatable PKCdelta (mutants Y311F and Y332F) could translocate to the Golgi complex in response to ceramide, suggesting that tyrosine phosphorylation is not necessary for translocation. However, ceramide failed to activate PKCdelta lacking the C1B domain, which did not translocate to the Golgi complex, but could be activated by tyrosine phosphorylation. These findings suggest that ceramide translocates PKCdelta to the Golgi complex and that PKCdelta is activated by tyrosine phosphorylation in the compartment. Furthermore, we utilized species-specific knockdown of PKCdelta by small interfering RNA to study the significance of phosphorylation of Tyr(311) and Tyr(332) in PKCdelta for ceramide-induced apoptosis and found that phosphorylation of Tyr(311) and Tyr(332) is indispensable for ceramide-induced apoptosis. We demonstrate here that the targeting mechanism of PKCdelta, dual regulation of both its activation and translocation to the Golgi complex, is critical for the ceramide-induced apoptotic event.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Biosignal Res Ctr, Biochem Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Pharmacol Neurosci, Minami Ku, Hiroshima 7348551, Japan	Kobe University; Kobe University; Hiroshima University	Saito, N (corresponding author), Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.	naosaito@kobe-u.ac.jp	Shirai, Yasuhito/O-3255-2018					Bard F, 2002, EUR J CELL BIOL, V81, P26, DOI 10.1078/0171-9335-00217; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brugg B, 1996, J NEUROCHEM, V66, P733; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hu H, 2001, BIOCHEM BIOPH RES CO, V288, P573, DOI 10.1006/bbrc.2001.5814; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Ibitayo AI, 1999, AM J PHYSIOL-GASTR L, V277, pG445, DOI 10.1152/ajpgi.1999.277.2.G445; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Sawai H, 1997, J BIOL CHEM, V272, P2452; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	57	86	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12668	12676		10.1074/jbc.M312350200	http://dx.doi.org/10.1074/jbc.M312350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715667	hybrid			2022-12-27	WOS:000220334900080
J	Goren, EN; Reeves, DC; Akabas, MH				Goren, EN; Reeves, DC; Akabas, MH			Loose protein packing around the extracellular half of the GABA(A) receptor beta(1) subunit M2 channel-lining segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; GATED ION-CHANNEL; AMINOBUTYRIC ACID(A) RECEPTORS; MEMBRANE-SPANNING SEGMENT; LIGAND-BINDING DOMAIN; ALPHA-SUBUNIT; 5-HT3 RECEPTOR; SCANNING MUTAGENESIS; CHARGE SELECTIVITY; THREONINE RESIDUE	GABA(A) receptors are ligand-gated ion channels formed by the pseudosymmetrical assembly of five homologous subunits around the central channel axis. The five M2 membrane-spanning segments largely line the channel. In the present work we probed the water surface accessibility of the beta(1) subunit M2 segment using the substituted cysteine accessibility method. We assayed the reaction of the negatively charged sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS(-)), by its effect on subsequent currents elicited by EC50 and saturating GABA concentrations. pCMBS(-), applied with GABA, reacted with 14 of the 19 residues tested. At the M2 cytoplasmic end from 2' to 6' only beta(1)A252C (2') and beta(1)T256C (6') were pCMBS(-) -reactive in the presence of GABA. We infer that the M2 segments are tightly packed in this region. Toward the extracellular half of M2 all residues from beta(1)T262C (12') through beta(1)E270C (20') reacted with pCMBS(-) applied with GABA. We infer that this region is highly mobile and loosely packed against the rest of the protein. Based on differences in pCMBS(-) reaction rates two domains can be distinguished on the putative channel-lining side of M2. A faster reacting domain includes the 2', 9', 12', 13', and 16' residues. The slower reacting face contains the 6', 10', and 14' residues. We hypothesize that these may represent the channel-lining faces in the closed and open states and that gating involves an 80-100degrees rotation of the M2 segments. These results are consistent with the loose packing of the M2 segments inferred from the structure of the homologous Torpedo nicotinic acetylcholine receptor.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	makabas@aecom.yu.edu		Akabas, Myles/0000-0001-8781-7846	NIGMS NIH HHS [GM61925] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bianchi MT, 2001, NEUROPHARMACOLOGY, V41, P737, DOI 10.1016/S0028-3908(01)00132-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Burkat PM, 2001, J NEUROSCI, V21, P7026, DOI 10.1523/JNEUROSCI.21-18-07026.2001; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Changeux JP, 2001, CURR OPIN NEUROBIOL, V11, P369, DOI 10.1016/S0959-4388(00)00221-X; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HASINOFF BB, 1971, CAN J BIOCHEM CELL B, V49, P742, DOI 10.1139/o71-105; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Mortensen M, 2003, EUR J PHARMACOL, V476, P17, DOI 10.1016/S0014-2999(03)02125-3; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; Scheller M, 2002, J NEUROSCI, V22, P8411; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Tretter V, 1997, J NEUROSCI, V17, P2728; TWYMAN RE, 1990, J PHYSIOL-LONDON, V423, P193, DOI 10.1113/jphysiol.1990.sp018018; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VANSTEVENINCK J, 1965, J GEN PHYSIOL, V48, P617, DOI 10.1085/jgp.48.4.617; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	62	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11198	11205		10.1074/jbc.M314050200	http://dx.doi.org/10.1074/jbc.M314050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715650	hybrid			2022-12-27	WOS:000220157600045
J	Li, Y; Gazdoiu, S; Pan, ZQ; Fuchs, SY				Li, Y; Gazdoiu, S; Pan, ZQ; Fuchs, SY			Stability of homologue of Slimb F-box protein is regulated by availability of its substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; UBIQUITIN LIGASE COMPLEX; CELL-CYCLE; DEPENDENT DEGRADATION; BETA-TRCP; SCF; NEDD8; HOS; PHOSPHORYLATION; PATHWAY	The homologue of Slimb (HOS) F-box protein is a receptor of the Skp1-Cullin1-F-box protein (SCFHOS) E3 ubiquitin ligase, which mediates ubiquitination and degradation of beta-catenin and the inhibitor of NF-kappaB, IkappaB. We found that HOS itself is an unstable protein that undergoes ubiquitination and degradation in a 26 S proteasome-dependent manner. A HOS mutant lacking the F-box that is deficient in binding to the core SCF components underwent ubiquitination less efficiently and was more stable than the wild type protein. Furthermore, ubiquitination and degradation of HOS was impaired in ts41 cells, in which the activities of Cullin-based ligases were decreased because the NEDD8 pathway was abrogated. Whereas HOS was directly ubiquitinated within the SCFHOS complex in vitro, the addition of phosphorylated IkappaBalpha inhibited this ubiquitination. Increasing cellular levels of HOS substrate ( phosphorylated IkappaBalpha) by activating IkappaB kinase inhibited HOS ubiquitination and led to stabilization of HOS, indicating that interaction between HOS and its substrate might protect HOS from proteolysis. Taken together, our data suggest that proteolysis of HOS depends on its interaction with active components of the SCF complex and that HOS stability is regulated by a bound substrate. These findings may define a mechanism for maintaining activities of specific SCF complexes based on availability of a particular substrate.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Pennsylvania; Icahn School of Medicine at Mount Sinai	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Rm 161E, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061051] Funding Source: NIH RePORTER; NCI NIH HHS [CA92900] Funding Source: Medline; NIGMS NIH HHS [GM61051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bottero V, 2001, CANCER RES, V61, P7785; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; HERTER JR, 2002, MED SCI MONIT, V8, P283; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Smothers DB, 2000, MOL CELL BIOL, V20, P7845, DOI 10.1128/MCB.20.21.7845-7852.2000; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	47	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11074	11080		10.1074/jbc.M312301200	http://dx.doi.org/10.1074/jbc.M312301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707120	hybrid			2022-12-27	WOS:000220157600030
J	Mirshahi, T; Logothetis, DE				Mirshahi, T; Logothetis, DE			Molecular determinants responsible for differential cellular distribution of G protein-gated inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; RECTIFIER; TRAFFICKING; DOMAINS; GIRK1; HETEROMULTIMER; IDENTIFICATION; LOCALIZATION; SUBUNITS; SIGNALS	Activation of the heteromeric G protein-gated inwardly rectifying K+ channel (GIRK) GIRK1 and GIRK4 subunits gives rise to I-KACh, which controls excitability in atrial tissue. Although homomeric GIRK4 channels localize to the plasma membrane and display moderate function, GIRK1 channels fail to localize to the cell surface and do not exhibit significant function as homomers. Using oocytes to express GFP-tagged GIRK1 and GIRK4 and chimeras between these two proteins, we have identified two regions, one in the proximal C terminus and another in the distal N terminus that are critical for their subcellular localization. Replacement of both of these regions in GIRK1 with corresponding regions from GIRK4 was required for efficient expression of GIRK1 on the plasma membrane. Replacement of either region by itself was ineffective. The distal N terminus and proximal C terminus have been previously suggested to play important roles in ER-export and subunit co-assembly respectively in this family of channels. Our data indicate for the first time that both of these regions need to work in concert to mediate efficient targeting of these channels to the plasma membrane.	Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Logothetis, DE (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.	Diomedes.Logothetis@mssm.edu			NHLBI NIH HHS [HL 54185, HL10307] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010307, R01HL054185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jones PA, 2001, FEBS LETT, V508, P85, DOI 10.1016/S0014-5793(01)03023-X; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Konstas AA, 2003, AM J PHYSIOL-CELL PH, V284, pC910, DOI 10.1152/ajpcell.00479.2002; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Mirshahi T, 2001, METHOD PHARMACOL TOX, P215; Mirshahi Tooraj, 2002, Mol Interv, V2, P289, DOI 10.1124/mi.2.5.289; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sui JL, 1999, ADV SEC MESS PHOSPH, V33, P179; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Woodward R, 1997, J BIOL CHEM, V272, P10823; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	27	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11890	11897		10.1074/jbc.M313322200	http://dx.doi.org/10.1074/jbc.M313322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14703518	hybrid			2022-12-27	WOS:000220157600126
J	Chandrasekaran, EV; Lakhaman, SS; Chawda, R; Piskorz, CF; Neelamegham, S; Matta, KL				Chandrasekaran, EV; Lakhaman, SS; Chawda, R; Piskorz, CF; Neelamegham, S; Matta, KL			Identification of physiologically relevant substrates for cloned Gal : 3-O-sulfotransferases (Gal3STs) - Distinct high affinity of Gal3ST-2 and LS180 sulfotransferase for the Globo H backbone, Gal3ST-3 for N-glycan multiterminal Gal beta 1,4GlcNAc beta units and 6-sulfoGal beta 1,4GlcNAc beta, and Gal3ST-4 for the mucin core-2 trisaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP T-HAPTEN; L-SELECTIN; MOLECULAR-CLONING; MASS-SPECTROMETRY; LEWIS-TYPE; O-GLYCANS; ALPHA-2,3-SIALYLTRANSFERASE; OLIGOSACCHARIDES; GLYCOPROTEIN; BIOSYNTHESIS	Sulfated glycoconjugates regulate biological processes such as cell adhesion and cancer metastasis. We examined the acceptor specificities and kinetic properties of three cloned Gal: 3-O-sulfotransferases (Gal3STs) ST-2, ST-3, and ST-4 along with a purified Gal3ST from colon carcinoma LS180 cells. Gal3ST-2 was the dominant Gal3ST in LS180. While the mucin core-2 structure Galbeta1,4GlcNAcbeta1,6(3-O-MeGalbeta1,3)GalNAalpha-O-Bn (where Bn is benzyl) and the disaccharide Galbeta1,4GlcNAc served as high affinity acceptors for Gal3ST-2 and Gal3ST-3, 3-O-MeGalbeta1,4GlcNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn and GalX1,3GalNAcalpha-O-Al (where Al is allyl) were efficient acceptors for Gal3ST-4. The activities of Gal3ST-2 and Gal3ST-3 could be distinguished with the Globo H precursor (Galbeta1,3GalNAcbeta1,3Galalpha-O-Me) and fetuin triantennary asialoglycopeptide. Gal3ST-2 acted efficiently on the former, while Gal3ST-3 showed preference for the latter. Gal3ST-4 also acted on the Globo H precursor but not the glycopeptide. In support of the specificity, Gal3ST-2 activity toward the Galbeta1,4GlcNAcbeta unit on mucin core-2 as well as the Globo H precursor could be inhibited competitively by Galbeta1,4GlcNAcbeta1,6(3-O-sulfoGalbeta1,3)GalNAcalpha-O-Bn but not 3-O-sulfoGalbeta1,-4GlcNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn. Remarkably these sulfotransferases were uniquely specific for sulfated substrates: Gal3ST-3 utilized Galbeta1,4(6-O-sulfo)GlcNAcbeta-O-Al as acceptor, Gal3ST-2 acted efficiently on Galbeta1,3(6-O-sulfo)GlcNAcbeta-O-Al, and Gal3ST-4 acted efficiently on Galbeta1,3(6-O-sulfo)GalNAcbeta-O-Al. Mg2+, Mn2+, and Ca2+ stimulated the activities of Gal3ST-2, whereas only Mg2+ augmented Gal3ST-3 activity. Divalent cations did not stimulate Gal3ST-4, although inhibition was noted at high Mn2+ concentrations. The fine substrate specificities of Gal3STs indicate a distinct physiological role for each enzyme.	Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA; SUNY Buffalo, Dept Biol & Chem Engn, Buffalo, NY 14260 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Matta, KL (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Elm & Carlton Sts, Buffalo, NY 14263 USA.	Khushi.Matta@RoswellPark.org		Neelamegham, Sriram/0000-0002-1371-8500	NATIONAL CANCER INSTITUTE [R01CA035329, P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063014] Funding Source: NIH RePORTER; NCI NIH HHS [CA35329, CA63213, CA16056] Funding Source: Medline; NHLBI NIH HHS [HL63014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adobati E, 1997, GLYCOBIOLOGY, V7, P173, DOI 10.1093/glycob/7.2.173; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Chance DL, 1996, CARBOHYD RES, V295, P157, DOI 10.1016/S0008-6215(96)90136-6; Chandrasekaran EV, 2002, GLYCOBIOLOGY, V12, P153, DOI 10.1093/glycob/12.3.153; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; Chandrasekaran EV, 1999, GLYCOCONJUGATE J, V16, P523, DOI 10.1023/A:1007074005371; CHANDRASEKARAN EV, 1994, BIOCHEM BIOPH RES CO, V201, P78, DOI 10.1006/bbrc.1994.1671; CHANDRASEKARAN EV, 1994, BIOCHEM BIOPH RES CO, V198, P350, DOI 10.1006/bbrc.1994.1049; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P2925, DOI 10.1021/bi00009a024; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P4748, DOI 10.1021/bi00014a032; de Graffenried CL, 2003, J BIOL CHEM, V278, P40282, DOI 10.1074/jbc.M304928200; El-Fasakhany FM, 2001, J BIOL CHEM, V276, P26988, DOI 10.1074/jbc.M100348200; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P293, DOI 10.1016/0304-4165(78)90357-4; Jain RK, 1998, GLYCOBIOLOGY, V8, P707, DOI 10.1093/glycob/8.7.707; Jain RK, 1998, GLYCOCONJUGATE J, V15, P951, DOI 10.1023/A:1006977607394; JAIN RK, 1993, CARBOHYD RES, V243, P385, DOI 10.1016/0008-6215(93)87042-Q; Jain RK, 1996, CARBOHYD RES, V282, P101, DOI 10.1016/0008-6215(95)00376-2; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Miyamoto D, 1995, BIOCHEM BIOPH RES CO, V217, P852, DOI 10.1006/bbrc.1995.2850; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Sandhoff R, 2002, J BIOL CHEM, V277, P20386, DOI 10.1074/jbc.M110641200; Seko A, 2001, J BIOL CHEM, V276, P25697, DOI 10.1074/jbc.M101558200; Slovin SF, 1999, P NATL ACAD SCI USA, V96, P5710, DOI 10.1073/pnas.96.10.5710; Sujino K, 2000, GLYCOBIOLOGY, V10, P313, DOI 10.1093/glycob/10.3.313; TADANOARITOMI K, 1995, CARBOHYD RES, V273, P41, DOI 10.1016/0008-6215(95)00106-4; Veerman ECI, 1997, GLYCOBIOLOGY, V7, P37, DOI 10.1093/glycob/7.1.37; Xia J, 2003, SYNLETT, P1291	35	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10032	10041		10.1074/jbc.M311989200	http://dx.doi.org/10.1074/jbc.M311989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701868	hybrid			2022-12-27	WOS:000220050400047
J	Shirakawa, R; Higashi, T; Tabuchi, A; Yoshioka, A; Nishioka, H; Fukuda, M; Kita, T; Horiuchi, H				Shirakawa, R; Higashi, T; Tabuchi, A; Yoshioka, A; Nishioka, H; Fukuda, M; Kita, T; Horiuchi, H			Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED ALPHA-GRANULE; RAB5 EFFECTOR EEA1; MYOSIN-VA; MOLECULAR-MECHANISMS; GRISCELLI-SYNDROME; MEMBRANE-FUSION; BINDING DOMAIN; BOVINE BRAIN; ASHEN MICE; KINASE-C	Platelets store self-agonists such as ADP and serotonin in dense core granules. Although exocytosis of these granules is crucial for hemostasis and thrombosis, the underlying mechanism is not fully understood. Here, we show that incubation of permeabilized platelets with unprenylated active mutant Rab27A-Q78L, wild type Rab27A, and Rab27B inhibited the secretion, whereas inactive mutant Rab27A-T23N and other GTPases had no effects. Furthermore, we affinity-purified a GTP-Rab27A-binding protein in platelets and identified it as Munc13-4, a homologue of Munc13-1 known as a priming factor for neurotransmitter release. Recombinant Munc13-4 directly bound to GTP-Rab27A and - Rab27B in vitro, but not other GTPases, and enhanced secretion in an in vitro assay. The inhibition of secretion by unprenylated Rab27A was rescued by the addition of Munc13-4, suggesting that Munc13-4 mediates the function of GTP-Rab27. Thus, Rab27 regulates the dense core granule secretion in platelets by employing its binding protein, Munc13-4.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; RIKEN	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp	Higashi, Tomohito/AHE-7942-2022; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Higashi, Tomohito/0000-0001-5616-1477				AKAYAMA M, 1986, CELL STRUCT FUNCT, V11, P259, DOI 10.1247/csf.11.259; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Barral DC, 2002, J CLIN INVEST, V110, P247, DOI 10.1172/JCI200215058; Brass L. F, 2000, HEMATOLOGY BASIC PRI, P1753; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; KNIGHT DE, 1980, THROMB RES, V20, P437, DOI 10.1016/0049-3848(80)90282-0; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Novak EK, 2002, BLOOD, V100, P128, DOI 10.1182/blood.V100.1.128; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Sassa T, 1999, J NEUROSCI, V19, P4772; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yoshioka A, 2001, ANN NY ACAD SCI, V947, P403; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	54	162	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10730	10737		10.1074/jbc.M309426200	http://dx.doi.org/10.1074/jbc.M309426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699162	Green Submitted, hybrid			2022-12-27	WOS:000220050400128
J	Kim, S; Zhang, ZM; Upchurch, S; Isern, N; Chen, Y				Kim, S; Zhang, ZM; Upchurch, S; Isern, N; Chen, Y			Structure and DNA-binding sites of the SWI1 AT-rich interaction domain (ARID) suggest determinants for sequence-specific DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD RINGER GENE; CHEMICAL-SHIFT; NMR; PROTEINS; COMPLEX; DYNAMICS; FAMILY; ASSIGNMENT; MEMBER; C-13	ARID ((A) under barT-(r) under bar ich (i) under bar nteraction (d) under bar omain) is a homologous family of DNA-binding domains that occur in DNA-binding proteins from a wide variety of species, ranging from yeast to nematodes, insects, mammals, and plants. SWI1, a member of the SWI/SNF protein complex that is involved in chromatin remodeling during transcription, contains the ARID motif. The ARID domain of human SWI1 (also known as p270) does not select for a specific DNA sequence from a random sequence pool. The lack of sequence specificity shown by the SWI1 ARID domain stands in contrast to the other characterized ARID domains, which recognize specific AT-rich sequences. We have solved the three-dimensional structure of human SWI1 ARID using solution NMR methods. In addition, we have characterized nonspecific DNA binding by the SWI1 ARID domain. Results from this study indicate that a flexible, long, internal loop in the ARID motif is likely to be important for sequence-specific DNA recognition. The structure of the human SWI1 ARID domain also represents a distinct structural subfamily. Studies of ARID indicate that the boundary of DNA binding structural and functional domains can extend beyond the sequence homologous region in a homologous family of proteins. Structural studies of homologous domains such as the ARID family of DNA-binding domains should provide information to better predict the boundary of structural and functional domains in structural genomic studies.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Grad Sch Biol Sci, Duarte, CA 91010 USA; Pacific NW Natl Lab, William R Wiley Environm Mol Sci Lab, Richland, WA 99352 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.			Isern, Nancy/0000-0001-9571-8864	NIGMS NIH HHS [GM54190] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1994, METHOD ENZYMOL, V239, P79; Burley SK, 2002, ANNU REV GENOM HUM G, V3, P243, DOI 10.1146/annurev.genom.3.022502.103227; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Iwahara J, 1999, EMBO J, V18, P6084, DOI 10.1093/emboj/18.21.6084; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; Kim S, 2003, J BIOMOL NMR, V27, P277, DOI 10.1023/A:1025434004184; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Numata S, 1999, CANCER RES, V59, P3741; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Peterson CL, 2002, CURR BIOL, V12, pR245, DOI 10.1016/S0960-9822(02)00782-0; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Rost B, 1996, METHOD ENZYMOL, V266, P525; Shandala T, 1999, DEVELOPMENT, V126, P4341; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Staunton D, 2003, ACCOUNTS CHEM RES, V36, P207, DOI 10.1021/ar010119s; Warren AJ, 2002, CURR OPIN STRUC BIOL, V12, P107, DOI 10.1016/S0959-440X(02)00296-8; Whitson RH, 2003, BIOCHEM BIOPH RES CO, V312, P997, DOI 10.1016/j.bbrc.2003.11.026; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yuan YC, 1998, NAT STRUCT BIOL, V5, P959, DOI 10.1038/2934; Zhu LY, 2001, BIOCHEMISTRY-US, V40, P9142, DOI 10.1021/bi010476a	31	32	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16670	16676		10.1074/jbc.M312115200	http://dx.doi.org/10.1074/jbc.M312115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14722072	hybrid			2022-12-27	WOS:000220747900119
J	Mahimainathan, L; Choudhury, GG				Mahimainathan, L; Choudhury, GG			Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; MESANGIAL CELL-PROLIFERATION; INDUCED DNA-SYNTHESIS; PDGF-BETA-RECEPTOR; NEGATIVE REGULATION; PROTEIN-KINASE; C-FOS; MICE; AKT; ACTIVATION	PTEN, mutated in a variety of human cancers, is a dual specificity protein phosphatase and also possesses D3-phosphoinositide phosphatase activity on phosphatidylinositol 3,4,5-tris-phosphate (PIP3), a product of phosphatidylinositol 3-kinase. This PIP3 phosphatase activity of PTEN contributes to its tumor suppressor function by inhibition of Akt kinase, a direct target of PIP3. We have recently shown that Akt regulates PDGF-induced DNA synthesis in mesangial cells. In this study, we demonstrate that expression of PTEN in mesangial cells inhibits PDGF-induced Akt activation leading to reduction in PDGF-induced DNA synthesis. As a potential mechanism, we show that PTEN inhibits PDGF-induced protein tyrosine phosphorylation with concomitant dephosphorylation and inactivation of tyrosine phosphorylated and activated PDGF receptor. Recombinant as well as immunopurified PTEN dephosphorylates autophosphorylated PDGF receptor in vitro. Expression of phosphatase deficient mutant of PTEN does not dephosphorylate PDGF-induced tyrosine phosphorylated PDGF receptor. Rather its expression increases tyrosine phosphorylation of PDGF receptor. Furthermore, expression of PTEN attenuated PDGF-induced signal transduction including phosphatidylinositol 3-kinase and Erk1/2 MAPK activities. Our data provide the first evidence that PTEN is physically associated with platelet-derived growth factor (PDGF) receptor and that PDGF causes its dissociation from the receptor. Finally, we show that both the C2 and tail domains of PTEN contribute to binding to the PDGF receptor. These data demonstrate a novel aspect of PTEN function where it acts as an effector for the PDGF receptor function and negatively regulates PDGF receptor activation.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhuryg@uthscsa.edu		/0000-0001-5077-3552	NIDDK NIH HHS [R01 DK 55815, P50 DK 61597] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815, P50DK061597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud Hanna E., 1995, P573; ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; BECKMAN SA, 2001, NAT GENET, V29, P396; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheyney IW, 1999, CANCER RES, V59, P2318; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; Choudhury GG, 2001, BIOCHEM BIOPH RES CO, V286, P1183, DOI 10.1006/bbrc.2001.5483; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FRAKE TF, 1997, SCIENCE, V275, P665; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnari FB, 1998, CANCER RES, V58, P5002; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gottschalk AR, 2001, CANCER RES, V61, P2105; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Huang H, 1999, DEVELOPMENT, V126, P5365; Huang JH, 2002, ARTERIOSCL THROM VAS, V22, P745, DOI 10.1161/01.ATV.0000016358.05294.8D; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Jefferson JA, 1999, J NEPHROL, V12, P297; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; KIYOMOTO H, 1994, FEBS LETT, V353, P217, DOI 10.1016/0014-5793(94)01039-0; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lokker NA, 2002, CANCER RES, V62, P3729; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RON D, 1992, BIOTECHNIQUES, V13, P866; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Weng LP, 1999, CANCER RES, V59, P5808; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	64	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15258	15268		10.1074/jbc.M314328200	http://dx.doi.org/10.1074/jbc.M314328200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14718524	hybrid			2022-12-27	WOS:000220594700093
J	Zhu, WG; Hileman, T; Ke, Y; Wang, PC; Lu, SL; Duan, WR; Dai, ZY; Tong, TJ; Villalona-Calero, MA; Plass, C; Otterson, GA				Zhu, WG; Hileman, T; Ke, Y; Wang, PC; Lu, SL; Duan, WR; Dai, ZY; Tong, TJ; Villalona-Calero, MA; Plass, C; Otterson, GA			5-aza-2 '-deoxycytidine activates the p53/p21(Waf1/Cip1) pathway to inhibit cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASE INHIBITION; LUNG-CANCER CELLS; P21(WAF1/CIP1) EXPRESSION; MYELODYSPLASTIC SYNDROME; MAMMALIAN-CELLS; P53; METHYLATION; DAMAGE; GENE; LEUKEMIA	In addition to its demethylating function, 5-aza-2'-deoxycytidine (5-aza-CdR) also plays an important role in inducing cell cycle arrest, differentiation, and cell death. However, the mechanism by which 5-aza-CdR induces antineoplastic activity is not clear. In this study, we found that 5-aza-CdR at limited concentrations (0.01-5 muM) induces inhibition of cell proliferation as well as increased p53/p21(Waf1/Cip1) expression in A549 cells (wild-type p53) but not in H1299 (p53-null) and H719 cells ( p53 mutant). The p53-dependent p21(Waf1/Cip1) expression induced by 5-aza-CdR was not seen in A549 cells transfected with the wild-type human papilloma virus type-16 E6 gene that induces p53 degradation. Furthermore, deletion analysis and site-directed mutagenesis of the p21 promoter reveals that 5-aza-CdR induces p21(Waf1/Cip1) expression through two p53 binding sites in the p21 promoter. Finally, 5-aza-CdR-induced p21(Waf1)/ (Cip1) expression was dependent on DNA damage but not on DNA demethylation as demonstrated by comet assay and bisulfite sequencing, respectively. Our data provide useful clues for judging the therapeutic efficacy of 5-aza-CdR in the treatment of human cancer cells.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Canc Res Ctr, Beijing 100083, Peoples R China; Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA	Peking University; Peking University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Zhu, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	zhuweiguo@bjmu.edu.cn; otterson-1@medctr.osu.edu	zhu, wei-guo/E-1334-2012; Wang, Pa-Chun/AAD-4094-2019; Plass, Christoph/H-7192-2014	Zhu, Wei-Guo/0000-0001-8385-6581; duan, wenrui/0000-0001-6512-7350	NCI NIH HHS [P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrendt SA, 2003, J NATL CANCER I, V95, P961, DOI 10.1093/jnci/95.13.961; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; COVEY JM, 1986, CANCER RES, V46, P5511; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; DeSimone J, 2002, BLOOD, V99, P3905, DOI 10.1182/blood.V99.11.3905; DINCALCI M, 1985, CANCER RES, V45, P3197; Ding H, 2003, BIOCHEM BIOPH RES CO, V305, P950, DOI 10.1016/S0006-291X(03)00873-8; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fruhwald MC, 2002, MOL GENET METAB, V75, P1, DOI 10.1006/mgme.2001.3265; Fukuoka K, 1997, JPN J CANCER RES, V88, P1009, DOI 10.1111/j.1349-7006.1997.tb00322.x; GLAZER RI, 1984, MOL PHARMACOL, V26, P381; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koshy M, 2000, BLOOD, V96, P2379, DOI 10.1182/blood.V96.7.2379.h8002379_2379_2384; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LI LH, 1970, CANCER RES, V30, P2760; LIN KT, 1981, J PHARM SCI, V70, P1228, DOI 10.1002/jps.2600701112; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Momparler RL, 1997, LEUKEMIA, V11, P175, DOI 10.1038/sj.leu.2400550; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; VESELY J, 1977, CANCER RES, V37, P3684; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; WILSON VL, 1983, CANCER RES, V43, P3493; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zhu WG, 2001, CANCER RES, V61, P1327	58	126	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15161	15166		10.1074/jbc.M311703200	http://dx.doi.org/10.1074/jbc.M311703200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722112	hybrid			2022-12-27	WOS:000220594700082
J	Hesberg, C; Hansch, R; Mendel, RR; Bittner, F				Hesberg, C; Hansch, R; Mendel, RR; Bittner, F			Tandem orientation of duplicated xanthine dehydrogenase genes from Arabidopsis thaliana - Differential gene expression and enzyme activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR SULFURASE; LEAF SENESCENCE; HYPERSENSITIVE RESPONSE; DROSOPHILA-MELANOGASTER; ASPERGILLUS-NIDULANS; PURINE CATABOLISM; MOLECULAR-OXYGEN; CDNA CLONING; WHEAT LEAVES; OXIDASE TYPE	Xanthine dehydrogenase from the plant Arabidopsis thaliana was analyzed on molecular and biochemical levels. Whereas most other organisms appear to own only one gene for xanthine dehydrogenase A. thaliana possesses two genes in tandem orientation spaced by 704 base pairs. The cDNAs as well as the proteins AtXDH1 and AtXDH2 share an overall identity of 93% and show high homologies to xanthine dehydrogenases from other organisms. Whereas AtXDH2 mRNA is expressed constitutively, alterations of AtXDH1 transcript levels were observed at various stresses like drought, salinity, cold, and natural senescence, but also after abscisic acid treatment. Transcript alteration did not mandatorily result in changes of xanthine dehydrogenase activities. Whereas salt treatment had no effect on xanthine dehydrogenase activities, cold stress caused a decrease, but desiccation and senescence caused a strong increase of activities in leaves. Because AtXDH1 presumably is the more important isoenzyme in A. thaliana it was expressed in Pichia pastoris, purified, and used for biochemical studies. AtXDH1 protein is a homodimer of about 300 kDa consisting of identical subunits of 150 kDa. Like xanthine dehydrogenases from other organisms AtXDH1 uses hypoxanthine and xanthine as main substrates and is strongly inhibited by allopurinol. AtXDH1 could be activated by the purified molybdenum cofactor sulfurase ABA3 that converts inactive desulfo-into active sulfoenzymes. Finally it was found that AtXDH1 is a strict dehydrogenase and not an oxidase, but is able to produce superoxide radicals indicating that besides purine catabolism it might also be involved in response to various stresses that require reactive oxygen species.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany	Braunschweig University of Technology	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	R.Mendel@tu-bs.de		Hansch, Robert/0000-0003-1310-8419				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; BALLOU D, 1969, BIOCHEM BIOPH RES CO, V36, P898, DOI 10.1016/0006-291X(69)90288-5; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; BOLAND MJ, 1981, BIOCHEM INT, V2, P567; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUGHLAN MP, 1980, MOLYBDENUM MOLYBDENU, P121; Della Corte E, 1968, FEBS Lett, V2, P83, DOI 10.1016/0014-5793(68)80107-3; Drake R, 1996, PLANT MOL BIOL, V30, P755, DOI 10.1007/BF00019009; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Glatigny A, 1998, J MOL BIOL, V278, P431, DOI 10.1006/jmbi.1998.1707; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; HUNT J, 1992, J BIOL CHEM, V267, P21479; KEITH TP, 1987, GENETICS, V116, P67; Koiwai H, 2000, J BIOCHEM-TOKYO, V127, P659, DOI 10.1093/oxfordjournals.jbchem.a022654; Komoto N, 1999, INSECT MOL BIOL, V8, P73, DOI 10.1046/j.1365-2583.1999.810073.x; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LOHMAN KN, 1994, PHYSIOL PLANTARUM, V92, P322, DOI 10.1111/j.1399-3054.1994.tb05343.x; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEHRA RK, 1984, ARCH BIOCHEM BIOPHYS, V229, P585, DOI 10.1016/0003-9861(84)90191-7; MENDEL RR, 1976, BIOCHEM PHYSIOL PFL, V170, P538; MONTALBINI P, 1995, PHYSIOL MOL PLANT P, V46, P275, DOI 10.1006/pmpp.1995.1022; MONTALBINI P, 1992, PLANT SCI, V87, P225, DOI 10.1016/0168-9452(92)90154-E; MONTALBINI P, 1992, J PHYTOPATHOL, V134, P218, DOI 10.1111/j.1439-0434.1992.tb01230.x; Montalbini P, 1996, PHYSIOL MOL PLANT P, V48, P273, DOI 10.1006/pmpp.1996.0023; Montalbini P, 1998, PLANT SCI, V134, P89, DOI 10.1016/S0168-9452(98)00046-6; Montalbini P, 2000, J PLANT PHYSIOL, V156, P3, DOI 10.1016/S0176-1617(00)80266-7; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1994, J BIOCHEM, V116, P1; Pastori GM, 1997, PLANT PHYSIOL, V113, P411, DOI 10.1104/pp.113.2.411; PEREZVICENTE R, 1992, BIOCHIM BIOPHYS ACTA, V1117, P159, DOI 10.1016/0304-4165(92)90074-5; ROBINS RK, 1985, J HETEROCYCLIC CHEM, V22, P601, DOI 10.1002/jhet.5570220303; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; RYU SB, 1995, PLANT PHYSIOL, V108, P713, DOI 10.1104/pp.108.2.713; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Sauer P, 2002, PLANT PHYSIOL BIOCH, V40, P393, DOI 10.1016/S0981-9428(02)01393-1; Schwartz SH, 1997, PLANT PHYSIOL, V114, P161, DOI 10.1104/pp.114.1.161; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TAYLOR CB, 1993, P NATL ACAD SCI USA, V90, P5118, DOI 10.1073/pnas.90.11.5118; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; WAHL RC, 1982, J BIOL CHEM, V257, P3958; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; Xi HL, 2000, J BACTERIOL, V182, P5332, DOI 10.1128/JB.182.19.5332-5341.2000; Xiong LM, 2001, PLANT CELL, V13, P2063, DOI 10.1105/tpc.13.9.2063	53	109	120	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13547	13554		10.1074/jbc.M312929200	http://dx.doi.org/10.1074/jbc.M312929200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726515	hybrid			2022-12-27	WOS:000220478500034
J	Melton, JA; Parker, MW; Rossjohn, J; Buckley, JT; Tweten, RK				Melton, JA; Parker, MW; Rossjohn, J; Buckley, JT; Tweten, RK			The identification and structure of the membrane-spanning domain of the Clostridium septicum alpha toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING TOXIN; ANTHRAX PROTECTIVE ANTIGEN; PROTEIN MODELS; AEROLYSIN; CHANNEL; TRANSMEMBRANE; PROAEROLYSIN; CYTOLYSIN; ENTEROLOBIN; MUTAGENESIS	Alpha toxin (AT) is a pore-forming toxin produced by Clostridium septicum that belongs to the unique aerolysin-like family of pore-forming toxins. The location and structure of the transmembrane domains of these toxins have remained elusive. Using deletion mutagenesis, cysteine-scanning mutagenesis and multiple spectrofluorimetric methods a membrane-spanning amphipathic beta-hairpin of AT has been identified. Spectrofluorimetric analysis of cysteine-substituted residues modified with an environmentally sensitive fluorescent probe via the cysteine sulfydryl showed that the side chains of residues 203 - 232 alternated between the aqueous milieu and the membrane core when the AT oligomer was inserted into membranes, consistent with the formation of an amphipathic transmembrane beta-hairpin. AT derivatives that contained deletions that removed up to 90% of the beta-hairpin did not form a pore but were similar to native toxin in all other aspects of the mechanism. Furthermore, a mutant of AT that contained an engineered disulfide, predicted to restrict the movement of the beta-hairpin, functioned similarly to native toxin except that it did not form a pore unless the disulfide bond was reduced. Together these studies revealed the location and structure of the membrane-spanning domain of AT.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Prot Crystallog Unit, Melbourne, Vic 3168, Australia; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Oklahoma System; University of Oklahoma Health Sciences Center; St. Vincent's Institute of Medical Research; Monash University; University of Victoria	Tweten, RK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, 940 Stanton L Young Blvd, Oklahoma City, OK 73190 USA.	Rod-Tweten@ouhsc.edu	Rossjohn, Jamie/F-9032-2013; Parker, Michael W/F-9069-2013	Rossjohn, Jamie/0000-0002-2020-7522; Parker, Michael W/0000-0002-3101-1138	NIAID NIH HHS [AI37657, R01 AI032097] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032097, R01AI037657, R37AI037657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; BALLARD J, 1992, INFECT IMMUN, V60, P784, DOI 10.1128/IAI.60.3.784-790.1992; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Barnham M, 1998, EMERG INFECT DIS, V4, P321, DOI 10.3201/eid0402.980224; Barry R, 2001, J BIOL CHEM, V276, P551, DOI 10.1074/jbc.M008097200; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Bittencourt SET, 2003, FEBS LETT, V549, P47, DOI 10.1016/S0014-5793(03)00763-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; de Sousa M V, 1989, An Acad Bras Cienc, V61, P405; Diep DB, 1999, MOL MICROBIOL, V31, P785, DOI 10.1046/j.1365-2958.1999.01217.x; Diep DB, 1998, MOL MICROBIOL, V30, P341, DOI 10.1046/j.1365-2958.1998.01068.x; Fontes W, 1997, ARCH BIOCHEM BIOPHYS, V347, P201, DOI 10.1006/abbi.1997.0358; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; Haugland R., 1996, HDB FLUORESCENT PROB; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Rossjohn J, 1998, BIOCHEMISTRY-US, V37, P741, DOI 10.1021/bi9721039; Sellman BR, 1997, MOL MICROBIOL, V25, P429, DOI 10.1046/j.1365-2958.1997.4541820.x; Sellman BR, 1997, MOL MICROBIOL, V23, P551, DOI 10.1046/j.1365-2958.1997.d01-1876.x; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STEVENS D L, 1990, Reviews of Infectious Diseases, V12, P286; Tsitrin Y, 2002, NAT STRUCT BIOL, V9, P729, DOI 10.1038/nsb839; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Wichroski MJ, 2002, INFECT IMMUN, V70, P4353, DOI 10.1128/IAI.70.8.4353-4361.2002	41	76	80	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14315	14322		10.1074/jbc.M313758200	http://dx.doi.org/10.1074/jbc.M313758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715670	hybrid			2022-12-27	WOS:000220478500126
J	Dinadayala, P; Lemassu, A; Granovski, P; Cerantola, S; Winter, N; Daffe, M				Dinadayala, P; Lemassu, A; Granovski, P; Cerantola, S; Winter, N; Daffe, M			Revisiting the structure of the anti-neoplastic Glucans of Mycobacterium bovis Bacille Calmette-Guerin - Structural analysis of the extracellular and boiling water extract-derived glucans of the vaccine substrains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARATIVE GENOMICS; BLADDER-CANCER; BCG VACCINE; TUBERCULOSIS; POLYSACCHARIDES; SURFACE; IDENTIFICATION; PHTHIOCEROL; LOCATION; POINT	The attenuated strain of Mycobacterium bovis Bacille Calmette-Guerin (BCG), used worldwide to prevent tuberculosis and leprosy, is also clinically used as an immunotherapeutic agent against superficial bladder cancer. An anti-tumor polysaccharide has been isolated from the boiling water extract of the Tice substrain of BCG and tentatively characterized as consisting primarily of repeating units of 6-linked-glucosyl residues. Mycobacterium tuberculosis and other mycobacterial species produce a glycogen-like alpha-glucan composed of repeating units of 4-linked glucosyl residues substituted at some 6 positions by short oligoglucosyl units that also exhibits an anti-tumor activity. Therefore, the impression prevails that mycobacteria synthesize different types of anti-neoplastic glucans or, alternatively, the BCG substrains are singular in producing a unique type of glucan that may confer to them their immunotherapeutic property. The present study addresses this question through the comparative analysis of alpha-glucans purified from the extracellular materials and boiling water extracts of three vaccine substrains. The polysaccharides were purified, and their structural features were established by mono- and two-dimensional NMR spectroscopy and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of the enzymatic and chemical degradation products of the purified compounds. The glucans isolated by the two methods from the three substrains of BCG were shown to exhibit identical structural features shared with the glycogen-like alpha-glucan of M. tuberculosis and other mycobacteria. Incidentally, we observed an occasional release of dextrans from Sephadex columns that may explain the reported occurrence of 6-substituted alpha-glucans in mycobacteria.	CNRS, UMR 5089, Inst Pharmacol & Biol STruct, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse 04, France; Univ Toulouse 3, F-31077 Toulouse 04, France; Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Daffe, M (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol STruct, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse 04, France.	mamadou.daffe@ipbs.fr	Winter, Nathalie/U-2690-2018	Winter, Nathalie/0000-0003-0994-7834; Lemassu, Anne/0000-0002-9323-2497				Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 2000, J BACTERIOL, V182, P3394, DOI 10.1128/JB.182.12.3394-3399.2000; BRADBURY JH, 1984, CARBOHYD RES, V126, P125, DOI 10.1016/0008-6215(84)85131-9; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Cywes C, 1997, INFECT IMMUN, V65, P4258, DOI 10.1128/IAI.65.10.4258-4266.1997; DAFFE M, 1988, BIOCHIM BIOPHYS ACTA, V958, P443, DOI 10.1016/0005-2760(88)90230-5; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DAFFE M, 1983, ANN INST PASTEUR MIC, VB134, P241, DOI 10.1016/S0769-2609(83)80037-4; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dische Z., 1962, METHODS CARBOHYDRATE, V1, P488; Dubnau E, 1998, MOL MICROBIOL, V29, P1526; FINE PEM, 1989, REV INFECT DIS S2, V11, P353; FINNE J, 1980, CARBOHYD RES, V80, P336, DOI 10.1016/S0008-6215(00)84873-9; Garrido JL, 1997, CYTOBIOS, V90, P47; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Jodelet A, 1998, CARBOHYD RES, V312, P139, DOI 10.1016/S0008-6215(98)00241-9; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Lemassu A, 1996, MICROBIOL-UK, V142, P1513, DOI 10.1099/13500872-142-6-1513; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; MISAKI A, 1966, J BIOCHEM-TOKYO, V59, P511, DOI 10.1093/oxfordjournals.jbchem.a128335; Nseyo UO, 1997, SEMIN SURG ONCOL, V13, P342; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; Schwebach JR, 2002, INFECT IMMUN, V70, P2566, DOI 10.1128/IAI.70.5.2566-2575.2002; STEWART TS, 1968, BIOCHEMISTRY-US, V7, P1855, DOI 10.1021/bi00845a033; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; TORREA G, 1995, J CLIN MICROBIOL, V33, P1899, DOI 10.1128/JCM.33.7.1899-1904.1995; WANG RH, 1995, BIOCHEM J, V311, P867, DOI 10.1042/bj3110867; ZANG LH, 1991, CARBOHYD RES, V220, P1, DOI 10.1016/0008-6215(91)80001-4; Zlotta AR, 2000, INT J CANCER, V87, P844, DOI 10.1002/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5	33	55	58	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12369	12378		10.1074/jbc.M308908200	http://dx.doi.org/10.1074/jbc.M308908200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715664	Green Published, hybrid			2022-12-27	WOS:000220334900045
J	Harwell, RM; Mull, BB; Porter, DC; Keyomarsi, K				Harwell, RM; Mull, BB; Porter, DC; Keyomarsi, K			Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-TRANSITION; PROTEIN; PROLIFERATION; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION; P40(MO15); P34(CDC2); P27(KIP1)	Cyclin E, a positive regulator of the cell cycle, controls the transition of cells from G(1) to S phase. Deregulation of the G(1)-S checkpoint contributes to uncontrolled cell division, a hallmark of cancer. We have reported previously that cyclin E is overexpressed in breast cancer and such overexpression is usually accompanied by the appearance of low molecular weight isoforms of cyclin E protein, which are not present in normal cells. Furthermore, we have shown that the expression of cyclin E low molecular weight isoforms can be used as a reliable prognostic marker for breast cancer to predict patient outcome. In this study we examined the role of cyclin E in directly activating cyclin-dependent kinase (CDK) 2. For this purpose, a series of N-terminal deleted forms of cyclin E corresponding to the low molecular weight forms detected only in cancer cells were translated in vitro and mixed with cell extracts. These tumor-specific N-terminal deleted forms of cyclin E are able to activate CDK2. Addition of cyclin E into both normal and tumor cell extracts was shown to increase the levels of CDK2 activity, along with an increase in the amount of phosphorylated CDK2. The increase in CDK2 activity was because of cyclin E binding to endogenous CDK2 in complex with endogenous cyclin E, cyclin A, or unbound CDK2. The increase in CDK2 phosphorylation was through a pathway involving cyclin-activating kinase, but addition of cyclin E to an extract containing unphosphorylated CDK2 can still lead to increase in CDK2 activity. Our data suggest that the ability of high levels of full-length and low molecular weight forms of cyclin E to activate CDK2 may be one mechanism that leads to the constitutive activation of cyclin E.CDK2 complexes leading to G(1)/S deregulation and tumor progression.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; SUNY Albany, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Mull, Benjamin/0000-0001-8379-873X	NCI NIH HHS [R01 CA 87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COULONVAL K, 2003, J BIOL CHEM; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DOU QP, 1993, CANCER RES, V53, P1493; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harwell RM, 2000, CANCER RES, V60, P481; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 2003, NAT MED, V9, P152, DOI 10.1038/nm0203-152; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sclafani RA, 1996, CURR OPIN CELL BIOL, V8, P788, DOI 10.1016/S0955-0674(96)80079-2; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	35	27	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12695	12705		10.1074/jbc.M313407200	http://dx.doi.org/10.1074/jbc.M313407200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701826	hybrid			2022-12-27	WOS:000220334900083
J	Hail, N; Konopleva, M; Sporn, M; Lotan, R; Andreeff, M				Hail, N; Konopleva, M; Sporn, M; Lotan, R; Andreeff, M			Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; CERVICAL-CARCINOMA CELLS; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; ENDOPLASMIC-RETICULUM; LEUKEMIA-CELLS; CANCER CELLS	The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9- dien-28-oic acid ( CDDO) is a novel anticancer agent that induces apoptosis in tumor cells. The cytotoxic stress underpinning CDDO-induced apoptosis has not been established. This study compared and contrasted the effects of CDDO on COLO 16 human skin cancer cells and their respiration-deficient (rho(0)) clones to elucidate the stress signal responsible for initiating apoptosis. CDDO promoted apoptosis in COLO 16 cells in a dose- and time-dependent manner. The rho(0) clones appeared to be more sensitive to CDDO-induced apoptosis implying that the disruption of mitochondrial respiration was not directly associated with triggering cell death. After a 4-h exposure to CDDO, mitochondrial inner transmembrane potential-sensitive dyes revealed mitochondrial hyperpolarization in the COLO 16 cells and mitochondrial depolarization in the rho(0) clones. Electron microscopy illustrated that this exposure also promoted mitochondrial condensation, endoplasmic reticulum dilation, and chromatin condensation in the COLO 16 cells. Endoplasmic reticulum dilation and chromatin condensation were also observed in the rho(0) clones, but the mitochondria in these cells were markedly swollen implying that the disruption of intracellular Ca2+ homeostasis was associated with cell death. A Ca2+-sensitive dye confirmed that CDDO increased cytoplasmic free Ca2+ in the COLO 16 cells, their rho(0) clones, as well as in malignant breast and lung epithelial cells. A cell-permeant Ca2+ chelator reduced the CDDO-induced increase in cytoplasmic free Ca2+, and inhibited caspase activation, the development of apoptotic morphology, and DNA fragmentation in the COLO 16 cells, implying that Ca2+ played a pivotal role in signaling the initiation of apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Dartmouth Coll, Dartmouth Med Sch, Dept Pharmacol, Hanover, NH 03755 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Dartmouth College	Andreeff, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, Box 448,1515 Holcombe Blvd, Houston, TX 77030 USA.	mandreef@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA055164, R01CA089346, P50CA100632, P01CA068233, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA16672, P01 CA55164, 1P50 CA100632-01, P01 CA68233, R01 CA89346, R25 CA57780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gunter TE, 2001, IUBMB LIFE, V52, P197, DOI 10.1080/15216540152846000; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2001, CANCER RES, V61, P6698; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Honda T, 1999, BIOORG MED CHEM LETT, V9, P3429, DOI 10.1016/S0960-894X(99)00623-X; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Joshi B, 1999, CANCER RES, V59, P4343; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Kim KB, 2002, MOL CANCER THER, V1, P177; Kindmark H, 2001, J BIOL CHEM, V276, P34530, DOI 10.1074/jbc.M102492200; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lapillonne H, 2003, CANCER RES, V63, P5926; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729; Muriel MP, 2000, J COMP NEUROL, V426, P297, DOI 10.1002/1096-9861(20001016)426:2<297::AID-CNE10>3.0.CO;2-O; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Pedersen IM, 2002, BLOOD, V100, P2965, DOI 10.1182/blood-2002-04-1174; Poppe M, 2002, J NEUROCHEM, V82, P482, DOI 10.1046/j.1471-4159.2002.01007.x; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sharma RA, 2001, EUR J CANCER, V37, P12, DOI 10.1016/S0959-8049(00)00326-9; SHERER TB, 2003, BIOCHIM BIOPHYS ACTA, V1496, P341; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Stadheim TA, 2002, J BIOL CHEM, V277, P16448, DOI 10.1074/jbc.M108974200; Suh NJ, 1999, CANCER RES, V59, P336; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Swerdlow RH, 1998, EXP NEUROL, V153, P135, DOI 10.1006/exnr.1998.6866; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Vandecasteele G, 2001, IUBMB LIFE, V52, P213, DOI 10.1080/15216540152846028; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Zell R, 1997, MOL CELL BIOCHEM, V177, P61, DOI 10.1023/A:1006896832582; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	58	42	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11179	11187		10.1074/jbc.M312758200	http://dx.doi.org/10.1074/jbc.M312758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711815	hybrid			2022-12-27	WOS:000220157600043
J	Kondapalli, J; Flozak, AS; Albuquerque, MLC				Kondapalli, J; Flozak, AS; Albuquerque, MLC			Laminar shear stress differentially modulates gene expression of p120 catenin, Kaiso transcription factor, and vascular endothelial cadherin in human coronary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOUND CLOSURE; LOCALIZATION; SIGNAL; P120(CTN); PATTERNS; ADHESION; PROTEIN; BINDING; FLOW; RNA	We demonstrated previously that laminar shear stress (LSS) enhances human coronary artery endothelial cell (HCAEC) wound closure via a vascular endothelial cadherin (VE-cadherin)-dependent mechanism. VE-cadherin can interact with p120 catenin (p120(ctn)) to mediate cell locomotion and proliferation. In this study, we hypothesized that p120(ctn) and an interacting protein, Kaiso, a transcriptional factor with which p120(ctn) may interact, would be expressed differentially at the wound border and away from the wound border in HCAEC exposed to LSS. One of the major goals in this study was to assess the differential gene expression of p120(ctn), Kaiso, and VE-cadherin in HCAEC at specific locations along the wound border to further our understanding of the molecular mechanisms involved in wound closure. We combined the technique of laser capture microdissection with quantitative real time PCR to compare p120(ctn), Kaiso, and VE-cadherin mRNA expression in HCAEC at and away from the wound border under LSS. Total RNA was isolated from 200-1,000 laser-captured HCAEC and reverse transcribed into cDNA. Detection of p120(ctn), Kaiso, and VE-cadherin mRNA was carried out using quantitative real time PCR. Normalization of cDNA templates was achieved by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) quantification. Quantitative real time PCR analysis revealed p120(ctn): GAPDH ratios, Kaiso: GAPDH ratios, and VE-cadherin:GAPDH ratios, relative to static control for each set, of 0.99-4.18 ( mean +/- S. E., 1.94 +/- 0.404), 1.0-5.24 ( 2.11 +/- 0.51), and 0.99-1.42 ( 1.09 +/- 0.09) after 3 h of LSS, respectively. With these techniques, we found that p120(ctn) and Kaiso transcripts were increased in laser-captured HCAEC at the wound border compared with HCAEC away from the wound border. In addition, differential expression of p120(ctn) and Kaiso mRNA was observed in HCAEC depending on how LSS was applied in relation to the wounding process. These techniques may have wide applicability for studying wound healing because gene expression of key adhesion molecules in HCAEC may now be determined from select regions of the endothelial wound border.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Childrens Mem Hosp, Div Crit Care Med, Crit Care Lab Vasc Res, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago	Albuquerque, MLC (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, W-140,Ward 12-108,303 E Chicago Ave, Chicago, IL 60611 USA.	malbuquerque@northwestern.edu			NIGMS NIH HHS [R01 GM59931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albuquerque MLC, 2003, J CELL PHYSIOL, V195, P50, DOI 10.1002/jcp.10228; Albuquerque MLC, 2002, EXP BIOL MED, V227, P1006, DOI 10.1177/153537020222701109; Albuquerque MLC, 2001, EXP CELL RES, V270, P223, DOI 10.1006/excr.2001.5351; Albuquerque MLC, 2000, AM J PHYSIOL-HEART C, V279, pH293, DOI 10.1152/ajpheart.2000.279.1.H293; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; BONNER RF, 1997, SCIENCE, V278, P1482; Boylan S, 2001, LAB INVEST, V81, P1167, DOI 10.1038/labinvest.3780329; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Chiu JJ, 2003, BLOOD, V101, P2667, DOI 10.1182/blood-2002-08-2560; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Ferber A, 2002, EXP CELL RES, V274, P35, DOI 10.1006/excr.2001.5436; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Passerini AG, 2003, J VASC SURG, V37, P182, DOI 10.1067/mva.2003.66; Peters DG, 2002, PHYSIOL GENOMICS, V12, P25, DOI 10.1152/physiolgenomics.00016.2002; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Wang WH, 2001, MOL VIS, V7, P89	28	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11417	11424		10.1074/jbc.M306057200	http://dx.doi.org/10.1074/jbc.M306057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699141	hybrid			2022-12-27	WOS:000220157600072
J	Pasqualato, S; Senic-Matuglia, F; Renault, L; Goud, B; Salamero, J; Cherfils, J				Pasqualato, S; Senic-Matuglia, F; Renault, L; Goud, B; Salamero, J; Cherfils, J			The structural GDP/GTP cycle of Rab11 reveals a novel interface involved in the dynamics of recycling endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; TRANS-GOLGI NETWORK; CRYSTAL-STRUCTURE; NUCLEOTIDE EXCHANGE; MEMBRANE-TRANSPORT; EFFECTOR PROTEIN; MYOSIN VB; GTPASES; FAMILY	The small GTP-binding protein Rab11 is an essential regulator of the dynamics of recycling endosomes. Here we report the crystallographic analysis of the GDP/GTP cycle of human Rab11a, and a structure-based mutagenesis study that identifies a novel mutant phenotype. The crystal structures show that the nucleotide-sensitive switch 1 and 2 regions differ from those of other Rab proteins. In Rab11-GDP, they contribute to a close packed symmetrical dimer, which may associate to membranes in the cell and allow Rab11 to undergo GDP/GTP cycles without recycling to the cytosol. The structure of active Rab11 delineates a three-dimensional site that includes switch 1 and is separate from the site defined by the Rab3/Rabphilin interface. It is proposed to form a novel interface for a Rab11 partner compatible with the simultaneous binding of another partner at the Rabphilin interface. Mutation of Ser(29) to Phe in this epitope resulted in morphological modifications of the recycling compartment that are distinct from those induced by the classical dominant-negative and constitutively active Rab11 mutants. Recycling endosomes condensed in the perinuclear region where they retained recycling transferrin, and they clustered Rab11- and EEA1-positive membranes. Altogether, our study suggests that this mutation impairs a specific subset of Rab11 interactions, possibly those involved in cytoskeleton-based movements driving the slow recycling pathway.	Inst Curie Rech, CNRS, UMR 144, Lab Mecanismes Mol Transport Intracellulaire, F-75248 Paris 05, France; CNRS, UPR 9063, Lab Enxymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Salamero, J (corresponding author), Inst Curie Rech, CNRS, UMR 144, Lab Mecanismes Mol Transport Intracellulaire, 12 Rue Lhomond, F-75248 Paris 05, France.	salamero@curie.fr	Senic-Matuglia, Francesca/AAQ-3815-2020; Goud, Bruno/GWC-4807-2022; Pasqualato, Sebastiano/G-1032-2011	Pasqualato, Sebastiano/0000-0002-9038-7768; salamero, jean/0000-0002-2610-5826; RENAULT, Louis/0000-0003-1722-074X				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BERANGER F, 1994, J BIOL CHEM, V269, P13637; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Chattopadhyay D, 2000, ACTA CRYSTALLOGR D, V56, P937, DOI 10.1107/S0907444900007575; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Constantinescu AT, 2002, STRUCTURE, V10, P569, DOI 10.1016/S0969-2126(02)00737-2; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; Esters H, 2000, J MOL BIOL, V298, P111, DOI 10.1006/jmbi.2000.3645; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mohrmann K, 2002, J BIOL CHEM, V277, P32029, DOI 10.1074/jbc.M203064200; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pereira-Leal JB, 2003, BIOCHEM BIOPH RES CO, V301, P92, DOI 10.1016/S0006-291X(02)02963-7; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smythe E, 2002, MOL CELL, V9, P205, DOI 10.1016/S1097-2765(02)00462-8; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wallace DME, 2002, BIOCHEM BIOPH RES CO, V299, P770, DOI 10.1016/S0006-291X(02)02720-1; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu GY, 2003, J BIOL CHEM, V278, P2452, DOI 10.1074/jbc.M211042200; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P15699, DOI 10.1021/bi0116792	58	67	71	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11480	11488		10.1074/jbc.M310558200	http://dx.doi.org/10.1074/jbc.M310558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699104	hybrid			2022-12-27	WOS:000220157600079
J	Soltoff, SP				Soltoff, SP			Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PAROTID ACINAR-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; DELTA TYROSINE PHOSPHORYLATION; RAT SUBMANDIBULAR-GLAND; ION-TRANSPORT; EXTRACELLULAR ATP; SUBSTANCE-P; PKC-DELTA; C-DELTA	Receptor agonists that initiate fluid secretion in salivary gland epithelial cells also increase protein phosphorylation. To assess contributions of tyrosine phosphorylation to secretion, changes in muscarinic receptor-initiated secretion (estimated from sodium pump-dependent increases in oxygen consumption) were measured in parotid acinar cells exposed to tyrosine kinase inhibitors. However, like the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenyl hydrazone, tyrphostins AG10 and AG18 increased the rate of oxygen consumption and reduced cellular ATP by similar to90% in the absence of the muscarinic agonist carbachol, indicating that these tyrphostins uncouple mitochondria. Exposure of isolated mitochondria to five structurally related tyrphostins demonstrated that their relative potencies as uncouplers differed from their in vitro kinase-inhibitory potencies due to different molecular requirements for the two effects. AG10 and AG18 blocked parotid phosphorylation events only at concentrations that reduced ATP content. The tyrosine kinase inhibitor genistein reduced ATP content by 15-20% and weakly uncoupled isolated mitochondria, but its inhibition of carbachol-mediated protein kinase Cdelta tyrosine phosphorylation and ERK1/2 activation appeared attributable to blocking tyrosine kinases directly. Carbachol itself rapidly reduced ATP content by 15-20%. Carbachol, 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (P2X(7) receptor agonist), AG10, AG18, and carbonyl cyanide p-trifluoromethoxyphenyl hydrazone rapidly activated the fuel sensor AMP-activated protein kinase (AMPK); however, only AMPK activation by carbachol and BzATP was due to sodium pump stimulation. AG10 and AG18 also activated AMPK and/or uncoupled mitochondria in PC12, HeLa, and HEK293 cells. These studies demonstrate that some tyrosine kinase inhibitors produce cellular effects that are mechanistically different from their primary in vitro characterizations and, as do salivary secretory stimuli, promote rapid metabolic alterations that initiate secondary signaling events.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Soltoff, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, New Res Bldg,Rm 1030 J,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10877] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arreola J, 2003, J PHYSIOL-LONDON, V547, P197, DOI 10.1113/jphysiol.2002.028373; BALABAN RS, 1980, P NATL ACAD SCI-BIOL, V77, P447, DOI 10.1073/pnas.77.1.447; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Bradford MD, 2002, BIOCHEM J, V366, P745, DOI 10.1042/BJ20020358; Bradford MD, 1998, EUR J MORPHOL, V36, P176; BURGER AM, 1995, CANCER RES, V55, P2794; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; KAPAS S, 1995, BIOCHEM J, V305, P433, DOI 10.1042/bj3050433; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL LJ, 1981, AM J PHYSIOL, V240, pF357, DOI 10.1152/ajprenal.1981.240.5.F357; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; MURAKAMI M, 1990, J PHYSIOL-LONDON, V426, P127, DOI 10.1113/jphysiol.1990.sp018130; Niisato N, 1999, J PHYSIOL-LONDON, V518, P417, DOI 10.1111/j.1469-7793.1999.0417p.x; Niisato N, 2001, BIOCHEM BIOPH RES CO, V285, P880, DOI 10.1006/bbrc.2001.5251; Palumbo GA, 1997, CANCER RES, V57, P2434; PURUSHOTHAM KR, 1995, CRIT REV ORAL BIOL M, V6, P119, DOI 10.1177/10454411950060020201; Sagara Y, 2002, J BIOL CHEM, V277, P36204, DOI 10.1074/jbc.M203895200; SEGER R, 1995, J BIOL CHEM, V270, P28325; SEO Y, 1991, BIOCHIM BIOPHYS ACTA, V971, P289; SMAJE LH, 1986, PFLUGERS ARCH, V406; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; SOLTOFF SP, 1984, J GEN PHYSIOL, V84, P643, DOI 10.1085/jgp.84.4.643; SOLTOFF SP, 1987, SEMIN NEPHROL, V7, P20; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SOLTOFF SP, 1990, ANN NY ACAD SCI, V603, P76; STEWART DJ, 1983, AM J PHYSIOL, V245, pG364, DOI 10.1152/ajpgi.1983.245.3.G364; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; Turner R. J., 1993, BIOL SALIVARY GLANDS, P105; Turner RJ, 2002, ORAL DIS, V8, P3, DOI 10.1034/j.1601-0825.2002.10815.x; Yoon HS, 2000, BIOCHEM BIOPH RES CO, V276, P151, DOI 10.1006/bbrc.2000.3445; YOUNG SW, 1993, FEBS LETT, V316, P278, DOI 10.1016/0014-5793(93)81308-M; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	45	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10910	10918		10.1074/jbc.M305396200	http://dx.doi.org/10.1074/jbc.M305396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688271	hybrid			2022-12-27	WOS:000220157600012
J	Benson, MA; Tinsley, CL; Blake, DJ				Benson, MA; Tinsley, CL; Blake, DJ			Myospryn is a novel binding partner for dysbindin in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LYSOSOME-RELATED ORGANELLES; HERMANSKY-PUDLAK-SYNDROME; SYNDROME GENE-PRODUCT; OPITZ-SYNDROME; REGULATORY SUBUNIT; ALPHA-DYSTROBREVIN; CONTAINING PROTEIN; BETA-DYSTROBREVIN; PHOSPHATASE 2A	Dysbindin is a coiled-coil-containing protein that was initially identified in a screen for dystrobrevin-interacting proteins. Recently, dysbindin has been shown to be involved in the biogenesis of lysosome-related organelles and is also a major schizophrenia susceptibility factor. Although dysbindin has been implicated in a number of different cellular processes, little is known about its function. To determine the function of dysbindin in muscle, we performed a yeast two-hybrid screen to identify potential interacting proteins. Here we show that dysbindin binds to a novel 413-kDa protein, myospryn, which is expressed in cardiac and skeletal muscle. The transcript encoding myospryn encompasses genethonin-3, a transcript that is down-regulated in muscle from Duchenne muscular dystrophy patients and stretch-responsive protein 553, which is up-regulated in experimental muscle hypertrophy. The C terminus of myospryn contains BBC, FN3, and SPRY domains in a configuration reminiscent of the tripartite motif protein family, as well as the dysbindin-binding site and a region mediating self-association. Dysbindin and myospryn co-immunoprecipitate from muscle extracts and are extensively co-localized. These data demonstrate for the first time that there are tissue-specific ligands for dysbindin that may play important roles in the different disease states involving this protein.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Blake, DJ (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	derek.blake@pharm.ox.ac.uk		Benson, Matthew/0000-0003-4459-0439				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, NEUROMUSCULAR DISORD, V12, pS110, DOI 10.1016/S0960-8966(02)00091-3; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bray NJ, 2003, HUM GENET, V113, P149, DOI 10.1007/s00439-003-0956-y; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Buchner G, 1999, HUM MOL GENET, V8, P1397, DOI 10.1093/hmg/8.8.1397; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Carim-Todd L, 2001, BBA-GENE STRUCT EXPR, V1518, P200, DOI 10.1016/S0167-4781(01)00178-6; CHU A, 1988, METHOD ENZYMOL, V157, P36; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Kemp TJ, 2000, GENOMICS, V66, P229, DOI 10.1006/geno.2000.6213; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Perry J, 1999, GENOMICS, V62, P385, DOI 10.1006/geno.1999.6043; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwab SG, 2003, AM J HUM GENET, V72, P185, DOI 10.1086/345463; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; Sillitoe RV, 2003, J NEUROSCI, V23, P6576; Stein PA, 2002, J CELL SCI, V115, P3389; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762	42	54	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10450	10458		10.1074/jbc.M312664200	http://dx.doi.org/10.1074/jbc.M312664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688250	hybrid			2022-12-27	WOS:000220050400096
J	Liu, CH; Chopra, R; Swanberg, S; Olland, S; O'Connell, J; Herrmann, S				Liu, CH; Chopra, R; Swanberg, S; Olland, S; O'Connell, J; Herrmann, S			Elongation of synthetic RNA templates by hepatitis C virus NS5B polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; MECHANISM; IDENTIFICATION; REQUIREMENTS	Here we examine the ability of seven, 3'-related, short synthetic RNAs to serve as templates for the hepatitis C virus (HCV) polymerase, non-structural protein 5B (NS5B). These RNAs, termed HL, range from 8 to 16 nucleotides in length, each with ACC at the 3' terminus. Interestingly HL12 and longer templates have a predicted secondary structure. Those with one or two unpaired adenylates at the 5'-end of a stem were increased in size by one or two nucleotides, respectively, following incubation with NS5B and UTP. Using labeled template RNA and cold UTP, extension in size could be inhibited by addition of non-labeled template of the same size. This template elongation was not inhibited by cold linear HL10 template unless pGpG was added. Fluorescence anisotropy demonstrated HL14, a template with secondary structure, bound with an apparent K-d of 22 nM. A linear template, HL10, plus pGpG primer was bound by NS5B with a Kd of 45 nM, whereas HL10 alone bound with an apparent Kd of 182 nM. The amplitude of the template extension product was increased by a brief preincubation at 4 degreesC followed by incubation at 23 or 30 degreesC. The nucleotide- mediated increase in size occurred for both templates that required a mismatch or bulge at the 3'-end as well as for those without the mismatch. These results suggest an NS5B active site pocket can readily accommodate short templates with four or five base stems and initiate copy-back replication in the presence of a one nucleotide mismatch.	Wyeth Res, Cambridge, MA 02140 USA; Wyeth Res, Pearl River, NY 10965 USA	Pfizer; Pfizer	Herrmann, S (corresponding author), Wyeth Res, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	shermann@wyeth.com						Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; [Anonymous], 1999, J Hepatol, V30, P956; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	28	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10738	10746		10.1074/jbc.M310062200	http://dx.doi.org/10.1074/jbc.M310062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688285	hybrid			2022-12-27	WOS:000220050400129
J	Roccisana, JL; Kawanabe, N; Kajiya, H; Koide, M; Roodman, GD; Reddy, SV				Roccisana, JL; Kawanabe, N; Kajiya, H; Koide, M; Roodman, GD; Reddy, SV			Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; KAPPA-B-LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; NECROSIS-FACTOR-ALPHA; BONE-MARROW CULTURES; RECEPTOR ACTIVATOR; OSTEOBLASTIC CELLS; NUCLEAR-FACTOR; PARATHYROID-HORMONE; PAGETS-DISEASE	RANK Ligand (RANKL) is a critical osteoclastogenic factor that is expressed on stromal cells and osteoblasts. Most resorption stimuli induce osteoclast formation by modulating RANKL gene expression in marrow stromal/osteoblast cells. However, it is unclear how these stimuli modulate RANKL gene expression in the bone microenvironment. To characterize the transcriptional control of human RANKL gene expression in stromal/osteoblast cells, we PCR-amplified and cloned a 2-kb 5'-flanking sequence of the RANKL gene, using normal human osteoblast derived genomic DNA as a template. Sequence analysis identified the presence of several potential Heat Shock Factor (HSF) responsive elements (HSE) in the human RANKL gene promoter region. Co-expression of HSF-1 or HSF-2 with the RANKL gene promoter-luciferase reporter plasmid in human osteoblastic cells (NOBC) demonstrated a 2-fold and 4.5-fold increase in promoter activity, respectively. RT-PCR analysis for HSF-1 and 2 mRNA expression in human bone marrow-derived stromal cells (SAKA-T) and osteoblast cells detected only HSF-2 expression. As evident from EMSA analysis, in contrast to 1,25(OH)(2)D-3 SAKA-T cells treated with b-FGF demonstrated increased levels of HSF-2 binding to the HSE present in the RANKL gene promoter region. Immunocytochemical staining further confirmed nuclear localization of HSF-2 in both SAKA-T transformed stromal cells and human bone marrow derived primary stromal/preosteoblastic cells in response to b-FGF treatment. Furthermore, b-FGF treatment of SAKA-T cells transfected with the luciferase reporter plasmid containing the hRANKL HSE region (-2 kb to -1275 bp) upstream to a heterologous promoter showed increased levels of transactivation. Western blot analysis further demonstrated enhanced levels of RANKL expression and HSP-27 phosphorylation in SAKA-T cells treated with b-FGF. In addition, overexpression of HSF-2 in SAKA-T cells resulted in a 5-fold increase in the levels of RANKL expression in these cells. These data further suggest that HSF-2 is a downstream target of b-FGF to induce RANKL expression in stromal/osteoblast cells, and that HSF may play an important role in modulating RANKL gene expression in the bone microenvironment.	Univ Pittsburgh, Div Hematol, Dept Med, Pittsburgh, PA 15213 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Reddy, SV (corresponding author), Univ Pittsburgh, Div Hematol Oncol, Dept Med, Liliane S Kaufmann Bldg,Suite 301,3471 5th Ave, Pittsburgh, PA 15213 USA.	reddysv@msx.upmc.edu		Kajiya, Hiroshi/0000-0003-3275-3632; Roccisana, Jennifer/0000-0003-3631-9040; Koide, Masanori/0000-0002-6511-9999	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR049363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012603] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 049363] Funding Source: Medline; NIDCR NIH HHS [DE12603] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLINOSDOBY P, 2002, J BONE MINER RES, pM134; Darimont C, 2002, CELL GROWTH DIFFER, V13, P59; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Gronthos S, 2003, J BONE MINER RES, V18, P716, DOI 10.1359/jbmr.2003.18.4.716; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756-3282(97)00292-5; Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776; Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Kitazawa R, 2002, BIOCHEM BIOPH RES CO, V290, P650, DOI 10.1006/bbrc.2001.6251; Kozawa O, 2001, CELL SIGNAL, V13, P535, DOI 10.1016/S0898-6568(01)00180-2; Kozawa O, 2001, ARCH BIOCHEM BIOPHYS, V388, P237, DOI 10.1006/abbi.2000.2290; Lee SK, 2002, J IMMUNOL, V169, P2374, DOI 10.4049/jimmunol.169.5.2374; Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133; Mills BG, 1997, CALCIFIED TISSUE INT, V61, P16, DOI 10.1007/s002239900285; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Okada Y, 2003, J BIOL CHEM, V278, P21258, DOI 10.1074/jbc.M302113200; Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195; Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459; Reddy SV, 2000, J BONE MINER RES, V15, pS370; REDDY SV, 1995, J BONE MINER RES, V10, P601; Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756-3282(02)00950-X; Roux S, 2002, BRIT J HAEMATOL, V117, P86, DOI 10.1046/j.1365-2141.2002.03417.x; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI S, 1995, ENDOCRINOLOGY, V136, P1441, DOI 10.1210/en.136.4.1441; Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; YANG XL, 1995, J STEROID BIOCHEM, V52, P415, DOI 10.1016/0960-0760(94)00191-N	52	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10500	10507		10.1074/jbc.M303727200	http://dx.doi.org/10.1074/jbc.M303727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699143	hybrid			2022-12-27	WOS:000220050400102
J	Zahler, AM; Damgaard, CK; Kjems, J; Caputi, M				Zahler, AM; Damgaard, CK; Kjems, J; Caputi, M			SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRE-MESSENGER-RNA; HNRNP A1; SR PROTEINS; IN-VITRO; COOPERATIVE BINDING; SITE SELECTION; INTRON; 3'-SPLICE-SITE; IDENTIFICATION	Splicing of the human immunodeficiency virus, type 1, primary transcript is highly regulated. Maintaining the proper equilibrium among spliced, unspliced, and partially spliced isoforms is essential for the replication of the virus. Here we characterize a complex cis-acting element located in tat exon 2 that is required for the splicing regulation of the upstream intron. An exonic splicing enhancer (ESE) and an exonic splicing silencer (ESS) are both located within the regulatory element. Heterogeneous nuclear ribonucleoprotein ( hnRNP) A/B proteins bind the ESS to repress splicing, whereas the SR protein SC35 binds the ESE to activate it. We show that the SC35 and the hnRNP A1 binding sites overlap within the juxtaposed ESE/ESS. We propose that hnRNP A1 binding to the ESS inhibits splicing of the upstream intron by directly masking the SC35 binding site.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA; Univ Calif Santa Cruz, Dept Mol Cellular & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol RNA, Sinsheimer Labs, Santa Cruz, CA 95064 USA; Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark	State University System of Florida; Florida Atlantic University; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Aarhus University	Caputi, M (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA.	mcaputi@fau.edu	Damgaard, Christian K/G-7360-2015; Damgaard, Christian/AAP-3147-2021; Damgaard, Christian/AAR-4075-2020; Kjems, Jorgen/I-3490-2016	Damgaard, Christian/0000-0003-4940-0868; Kjems, Jorgen/0000-0003-4128-9317; Zahler, Alan/0000-0003-0027-1647	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061646] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI052820-02] Funding Source: Medline; NIGMS NIH HHS [1R01GM61646] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; GOTTLINGER HG, 1992, VIROLOGY, V189, P618, DOI 10.1016/0042-6822(92)90585-D; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Kammler S, 2001, RNA, V7, P421, DOI 10.1017/S1355838201001212; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P309; Nagel RJ, 1998, RNA, V4, P11; OREILLY MM, 1995, VIROLOGY, V213, P6365; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Rabson AB, 1997, RETROVIRUSES; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tange TO, 2001, EMBO J, V20, P5748; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wentz MP, 1997, J VIROL, V71, P8542, DOI 10.1128/JVI.71.11.8542-8551.1997; Zahler AM, 1999, METH MOL B, V118, P419; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	43	110	112	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10077	10084		10.1074/jbc.M312743200	http://dx.doi.org/10.1074/jbc.M312743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14703516	hybrid			2022-12-27	WOS:000220050400052
J	Adler, J; Bibi, E				Adler, J; Bibi, E			Determinants of substrate recognition by the Escherichia coli multidrug transporter MdfA identified on both sides of the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; RESISTANCE P-GLYCOPROTEIN; LACTOSE PERMEASE; GENOME SEQUENCE; BINDING SITE; PROTEIN; MUTATIONS; MECHANISM; RESIDUE; LEAFLET	The Escherichia coli multidrug transporter MdfA contains a membrane-embedded charged residue (Glu-26) that was shown to play an important role in substrate recognition. To identify additional determinants of multidrug recognition we isolated 58 intragenic second-site mutations that restored the function of inactive MdfA E26X mutants. In addition, two single-site mutations that enhanced the activity of wild-type MdfA were identified. Most of the mutations were found in two regions, the cytoplasmic half of transmembrane segments (TMs) 4, 5, and 6 (cluster 1) and the periplasmic half of TM 1 and 2 ( cluster 2). The identified residues were mutated to cysteines in the background of a functional cysteineless MdfA, and substrate protection against alkylation was analyzed. The results support the suggestion that the two clusters are involved in substrate recognition. Using inverted membrane vesicles we observed that a proton electrochemical gradient (Delta(mu) over tilde (H+), inside positive and acidic) enhanced the substrate-protective effect in the cytoplasmic region, whereas it largely reduced this effect in the periplasmic side of MdfA. Therefore, we propose that substrates interact with two sites in MdfA, one in the cytoplasmic leaflet of the membrane and the other in the periplasmic leaflet. Theoretically, these domains could constitute a large part of the multidrug pathway through MdfA.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Bibi, E (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	e.bibi@weizmann.ac.il		Bibi, Eitan/0000-0003-3700-2707				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Adler J, 2004, BIOCHEMISTRY-US, V43, P518, DOI 10.1021/bi035485t; Adler J, 2002, J BACTERIOL, V184, P3313, DOI 10.1128/JB.184.12.3313-3320.2002; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; Bibi E, 2001, J MOL MICROB BIOTECH, V3, P171; Bohn C, 1998, J BACTERIOL, V180, P6072, DOI 10.1128/JB.180.22.6072-6075.1998; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Edgar R, 1997, J BACTERIOL, V179, P2274, DOI 10.1128/jb.179.7.2274-2280.1997; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gruol DJ, 2002, MOL PHARMACOL, V62, P1238, DOI 10.1124/mol.62.5.1238; Gruol DJ, 2001, MOL PHARMACOL, V60, P104, DOI 10.1124/mol.60.1.104; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566; KABACK HR, 1978, BIOCHEMISTRY-US, V17, P1640, DOI 10.1021/bi00602a010; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; Levy SB, 2002, J APPL MICROBIOL, V92, p65S, DOI 10.1046/j.1365-2672.92.5s1.4.x; Lewinson O, 2003, P NATL ACAD SCI USA, V100, P1667, DOI 10.1073/pnas.0435544100; Lewinson O, 2001, BIOCHEMISTRY-US, V40, P12612, DOI 10.1021/bi011040y; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Mine T, 1998, J BIOCHEM-TOKYO, V124, P187, DOI 10.1093/oxfordjournals.jbchem.a022078; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; Nilsen IW, 1996, J BACTERIOL, V178, P3188, DOI 10.1128/jb.178.11.3188-3193.1996; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Saier MH, 2001, SEMIN CELL DEV BIOL, V12, P205, DOI 10.1006/scdb.2000.0246; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10656, DOI 10.1021/bi0004403; Vo QD, 1999, J BIOL CHEM, V274, P20318, DOI 10.1074/jbc.274.29.20318; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zgurskaya HI, 2002, INT J MED MICROBIOL, V292, P95, DOI 10.1078/1438-4221-00195	44	54	58	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8957	8965		10.1074/jbc.M313422200	http://dx.doi.org/10.1074/jbc.M313422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688269	hybrid			2022-12-27	WOS:000189265900054
J	Hinton, A; Gatti, DL; Ackerman, SH				Hinton, A; Gatti, DL; Ackerman, SH			The molecular chaperone, Atp12p, from Homo sapiens - In vitro studies with purified wild type and mutant (E240K) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL F-1-ATPASE; CITRATE SYNTHASE; YEAST; IDENTIFICATION; F1-ATPASE; SUBUNIT; STABILITY; DOMAINS	Work in Saccharomyces cerevisiae has shown that Atp12p binds to unassembled alpha subunits of F-1 and in so doing prevents the alpha subunit from associating with itself in non-productive complexes during assembly of the F-1 moiety of the mitochondrial ATP synthase. We have developed a method to prepare recombinant Atp12p after expression of its human cDNA in bacterial cells. The molecular chaperone activity of HuAtp12p was studied using citrate synthase as a model substrate. Wild type HuAtp12p suppresses the aggregation of thermally inactivated citrate synthase. In contrast, the mutant protein HuAtp12p(E240K), which harbors a lysine at the position of the highly conserved Glu-240, fails to prevent citrate synthase aggregation at 43 degreesC. No significant differences were observed between the wild type and the mutant proteins as judged by sedimentation analysis, cysteine titration, tryptophan emission spectra, or limited proteolysis, which suggests that the E240K mutation alters the activity of HuAtp12p with minimal effects on the physical integrity of the protein. An additional important finding of this work is that the equilibrium chemical denaturation curve of HuAtp12p shows two components, the first of which is associated with protein aggregation. This result is consistent with a model for Atp12p structure in which there is a hydrophobic chaperone domain that is buried within the protein interior.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, 421 E Canfield Ave, Detroit, MI 48201 USA.	sackerm@med.wayne.edu			NIGMS NIH HHS [F31 GM65068, R01 GM48157, R01 GM069840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069840, F31GM065068, R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; ILLINTON A, 2003, J BIOL CHEM, V278, P34110; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Nozaki Y, 1972, Methods Enzymol, V26, P43; PAUL MF, 1994, J BIOL CHEM, V269, P26158; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Sastry MSR, 2002, J BIOL CHEM, V277, P46026, DOI 10.1074/jbc.M205800200; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; SINGH M, 1970, J BIOL CHEM, V245, P4636; SRERE PA, 1966, J BIOL CHEM, V241, P2157; Wang ZG, 1998, J BIOL CHEM, V273, P2993, DOI 10.1074/jbc.273.5.2993; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 1996, J BIOL CHEM, V271, P4887; Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021	28	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9016	9022		10.1074/jbc.M312631200	http://dx.doi.org/10.1074/jbc.M312631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701807	hybrid			2022-12-27	WOS:000189265900061
J	Zhang, MS; Coffino, P				Zhang, MS; Coffino, P			Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLY-ALA REPEAT; KAPPA-B-ALPHA; ORNITHINE-DECARBOXYLASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DEGRADATION; INHIBITION; MECHANISM; STABILIZATION; ATPASE	The Epstein-Barr virus thwarts immune surveillance through a Gly-Ala repeat (GAr) within the viral Epstein-Barr virus-encoded nuclear antigen 1 protein. The GAr inhibits proteasome processing, an early step in antigen peptide presentation, but the mechanism of proteasome inhibition has been unclear. By embedding a GAr within ornithine decarboxylase, a natural proteasome substrate that does not require ubiquitin conjugation, we now demonstrate inhibition in a purified system, excluding involvement of ubiquitin conjugation or of proteins extraneous to substrate and proteasome. We show further that the GAr acts as a stop-transfer signal in proteasome substrate processing, resulting in vivo in partial proteolysis that halts just short of the GAr. Similarly, introducing a GAr into green fluorescent protein destabilized by the ornithine decarboxylase degradation domain also stops the progress of proteolysis, leading to the accumulation of partial degradation products. We postulate that the ATP motor of the proteasome slips when it encounters the GAr, impeding further insertion and, in this way, halting degradation.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	pcoffin@itsa.ucsf.edu		Coffino, Philip/0000-0003-0344-5083	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-45335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Ben-Shahar S, 1999, J BIOL CHEM, V274, P21963, DOI 10.1074/jbc.274.31.21963; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Dantuma NP, 2000, P NATL ACAD SCI USA, V97, P8381, DOI 10.1073/pnas.140217397; Dantuma NP, 2002, FEBS LETT, V529, P22, DOI 10.1016/S0014-5793(02)03252-0; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gaczynska M, 2003, BIOCHEMISTRY-US, V42, P8663, DOI 10.1021/bi034784f; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Heessen S, 2002, P NATL ACAD SCI USA, V99, P1532, DOI 10.1073/pnas.022306499; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hoyt MA, 2003, J BIOL CHEM, V278, P12135, DOI 10.1074/jbc.M211802200; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; LAUX G, 1988, EMBO J, V7, P769, DOI 10.1002/j.1460-2075.1988.tb02874.x; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Leight ER, 2000, REV MED VIROL, V10, P83, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;83::AID-RMV262&gt;3.0.CO;2-T; Leonchiks A, 1998, FEBS LETT, V440, P365, DOI 10.1016/S0014-5793(98)01488-4; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Oster G, 2003, TRENDS CELL BIOL, V13, P114, DOI 10.1016/S0962-8924(03)00004-7; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; Sambrook J., 2001, MOL CLONING LAB MANU; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Tellam J, 2001, J BIOL CHEM, V276, P33353, DOI 10.1074/jbc.M104535200; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Toth C, 1999, J BIOL CHEM, V274, P25921, DOI 10.1074/jbc.274.36.25921; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yin Y, 2003, SCIENCE, V301, P1371, DOI 10.1126/science.1088902; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	48	58	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8635	8641		10.1074/jbc.M310449200	http://dx.doi.org/10.1074/jbc.M310449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688254	hybrid			2022-12-27	WOS:000189265900015
J	Sancenon, V; Puig, S; Mateu-Andres, I; Dorcey, E; Thiele, DJ; Penarrubia, L				Sancenon, V; Puig, S; Mateu-Andres, I; Dorcey, E; Thiele, DJ; Penarrubia, L			The Arabidopsis copper transporter COPT1 functions in root elongation and pollen development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE RESPONSE PATHWAY; HORDEUM-VULGARE L.; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTORS; TRANSGENIC TOBACCO; DISEASE PROTEIN; MALE-STERILITY; GENE	Copper plays a dual role in aerobic organisms, as both an essential and a potentially toxic element. To ensure copper availability while avoiding its toxic effects, organisms have developed complex homeostatic networks to control copper uptake, distribution, and utilization. In eukaryotes, including yeasts and mammals, high affinity copper uptake is mediated by the Ctr family of copper transporters. This work is the first report on the physiological function of copper transport in Arabidopsis thaliana. We have studied the expression pattern of COPT1 in transgenic plants expressing a reporter gene under the control of the COPT1 promoter. The reporter gene is highly expressed in embryos, trichomes, stomata, pollen, and root tips. The involvement of COPT1 in copper acquisition was investigated in CaMV35S::COPT1 antisense transgenic plants. Consistent with a decrease in COPT1 expression and the associated copper deprivation, these plants exhibit increased mRNA levels of genes that are down-regulated by copper, decreased rates of Cu-64 uptake by seedlings and reduced steady state levels of copper as measured by atomic absorption spectroscopy in mature leaves. Interestingly, COPT1 antisense plants also display dramatically increased root length, which is completely and specifically reversed by copper addition, and an increased sensitivity to growth inhibition by the copper-specific chelator bathocuproine disulfonic acid. Furthermore, COPT1 antisense plants exhibit pollen development defects that are specifically reversed by copper. Taken together, these studies reveal striking plant growth and development roles for copper acquisition by high affinity copper transporters.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Valencia, Spain; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Univ Valencia, Dept Bot, E-46100 Burjassot, Valencia, Spain	University of Valencia; Duke University; University of Valencia	Penarrubia, L (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, Ave Dr Moliner 50, E-46100 Burjassot, Valencia, Spain.	penarrub@uv.es	Puig, Sergi/E-4788-2010; Peñarrubia, Lola/ABG-3141-2020	Puig, Sergi/0000-0002-1856-490X; Penarrubia, Lola/0000-0002-4059-2536	NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA86307] Funding Source: Medline; NIGMS NIH HHS [GM41840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acemioglu B, 2001, J COLLOID INTERF SCI, V243, P81, DOI 10.1006/jcis.2001.7873; ALBANI D, 1992, PLANT J, V2, P331; AZOUAOU Z, 1993, SEX PLANT REPROD, V6, P199; Choi YE, 2001, PLANTA, V213, P45, DOI 10.1007/s004250000487; Clemens S, 2001, PLANTA, V212, P475, DOI 10.1007/s004250000458; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DELL B, 1994, PLANT SOIL, V167, P181, DOI 10.1007/BF00007943; FOLEY RC, 1994, PLANT MOL BIOL, V26, P435, DOI 10.1007/BF00039552; Frausto da Silva J.J.R., 1991, BIOL CHEM ELEMENTS I, P388; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GRAHAM RD, 1975, NATURE, V254, P514, DOI 10.1038/254514a0; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Himelblau E, 2000, CURR OPIN PLANT BIOL, V3, P205, DOI 10.1016/S1369-5266(00)00065-0; Himelblau E, 1998, PLANT PHYSIOL, V117, P1227, DOI 10.1104/pp.117.4.1227; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; HUNT LT, 1985, J MOL EVOL, V21, P126, DOI 10.1007/BF02100086; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEWELL AW, 1988, PLANT CELL ENVIRON, V11, P273, DOI 10.1111/j.1365-3040.1988.tb01146.x; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kiegle E, 2000, PLANT J, V21, P225, DOI 10.1046/j.1365-313x.2000.00659.x; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MCCORMICK S, 1993, PLANT CELL, V5, P1265, DOI 10.1105/tpc.5.10.1265; Mira H, 2001, BIOCHEM J, V357, P545, DOI 10.1042/0264-6021:3570545; Mira H, 2001, PLANT J, V25, P521, DOI 10.1046/j.1365-313x.2001.00985.x; Mira Helena, 2002, P543; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NOBUTAKA M, 2000, PLANT MOL BIOL, V46, P185; Nuutila AM, 2000, PLANT SCI, V151, P85, DOI 10.1016/S0168-9452(99)00202-2; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Plesch G, 2001, PLANT J, V28, P455, DOI 10.1046/j.1365-313X.2001.01166.x; PRESCOTT A, 1987, PLANT MOL BIOL REP, V4, P219, DOI DOI 10.1007/BF02675414; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; SALT DE, 1995, PLANT PHYSIOL, V109, P1427, DOI 10.1104/pp.109.4.1427; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; Scheres B, 1998, CURR OPIN PLANT BIOL, V1, P32, DOI 10.1016/S1369-5266(98)80124-6; Sedbrook JC, 2002, PLANT CELL, V14, P1635, DOI 10.1105/tpc.002360; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Villanueva MTO, 2001, INT J FOOD SCI NUTR, V52, P243, DOI 10.1080/713671783; WETERINGS K, 1992, PLANT MOL BIOL, V18, P1101, DOI 10.1007/BF00047713; Woeste KE, 2000, PLANT CELL, V12, P443, DOI 10.1105/tpc.12.3.443; Wojnarowiez G, 2002, PLANT SCI, V162, P843, DOI 10.1016/S0168-9452(02)00036-5; WORRALL D, 1992, PLANT CELL, V4, P759, DOI 10.1105/tpc.4.7.759; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787	56	183	197	5	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15348	15355		10.1074/jbc.M313321200	http://dx.doi.org/10.1074/jbc.M313321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726516	hybrid			2022-12-27	WOS:000220594700104
J	Prates, MV; Sforca, ML; Regis, WCB; Leite, JRSA; Silva, LP; Pertinhez, TA; Araujo, ALT; Azevedo, RB; Spisni, A; Bloch, C				Prates, MV; Sforca, ML; Regis, WCB; Leite, JRSA; Silva, LP; Pertinhez, TA; Araujo, ALT; Azevedo, RB; Spisni, A; Bloch, C			The NMR-derived solution structure of a new cationic antimicrobial peptide from the skin secretion of the anuran Hyla punctata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-RELAXATION; FROG-SKIN; SPECTROSCOPY; CELLS; KETOCONAZOLE; ANTIBIOTICS; ELUCIDATION; INFECTIONS; PRECURSOR; PROTEINS	Amphibian skin secretions constitute an important source of molecules for antimicrobial drug research in order to combat the increasing resistance of pathogens to conventional antibiotics. Among the various types of substances secreted by the dermal granular amphibian glands, there is a wide range of peptides and proteins, often displaying potent antimicrobial activities and providing an effective defense system against parasite infection. In the present work, we report the NMR solution structure and the biological activity of a cationic 14-residue amphiphilic alpha-helical polypeptide named Hylaseptin P1 ( HSP1), isolated from the skin secretion of the hylid frog Hyla punctata. The peptide antimicrobial activity was verified against Candida albicans, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, whereas no significant lytic effect was detected toward red or white blood cells.	Embrapa Recursos Genet & Biotecnol, Lab Espectrometria Massa, Brasilia, DF, Brazil; Univ Brasilia, Inst Ciencias Biol, Dept Biol Celular, Brasilia, DF, Brazil; Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Bioquim, Campinas, SP, Brazil; Univ Brasilia, Inst Ciencias Biol, Dept Genet & Morfol, Brasilia, DF, Brazil; Lab SABIN Anal Clin, Brasilia, DF, Brazil; Univ Parma, Dept Expt Med, I-43100 Parma, Italy	Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade de Brasilia; Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Brasilia; University of Parma	Bloch, C (corresponding author), Embrapa Recursos Genet & Biotecnol, Lab Espectrometria Massa, Brasilia, DF, Brazil.	cbloch@lnls.br	Bloch, Carlos/S-8375-2019; Azevedo, Ricardo/D-6273-2012; Regis, Wiliam/AAQ-3992-2020; Silva, Luciano Paulino/G-4915-2012; Régis, Wiliam/L-8797-2014; Spisni, Alberto/AAY-7778-2020; Prates, Maura/S-8399-2019; Leite, Jose Roberto/H-9065-2013	Silva, Luciano Paulino/0000-0001-9075-7725; Régis, Wiliam/0000-0002-1462-7440; Prates, Maura/0000-0002-0206-5890; Azevedo, Ricardo/0000-0002-2137-9588; Bloch Jr, Carlos/0000-0003-2799-6883; Sforca, Mauricio/0000-0002-3395-1684; Leite, Jose Roberto/0000-0002-1096-3236				Ali MF, 2002, BBA-PROTEINS PROTEOM, V1601, P55, DOI 10.1016/S1570-9639(02)00432-6; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; [Anonymous], 2020, BIOL AMPHIBIANS, V28, P32; Arikan S, 2001, CURR PHARM DESIGN, V7, P393, DOI 10.2174/1381612013398031; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; Bok AB, 1999, DRUG SAFETY, V20, P451, DOI 10.2165/00002018-199920050-00005; Brand GD, 2002, J BIOL CHEM, V277, P49332, DOI 10.1074/jbc.M209289200; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULET P, 1991, J BIOL CHEM, V266, P24520; *BYOS TECHN, 1995, INSIGHT II US GUID V; Castano S, 1999, BBA-BIOMEMBRANES, V1416, P161, DOI 10.1016/S0005-2736(98)00219-3; Chen HM, 2001, EUR J BIOCHEM, V268, P1659, DOI 10.1046/j.1432-1033.2001.02039.x; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DORNER K, 1995, CLIN LAB HAEMATOL, V17, P23; Ellepola A N, 2000, Dent Update, V27, P165; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Giacometti A, 1999, PEPTIDES, V20, P1265, DOI 10.1016/S0196-9781(99)00131-X; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Granier F, 2000, PRESSE MED, V29, P2051; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Johansen HK, 2002, COCHRANE DB SYST REV, V2; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Kuhn-Nentwig L, 2002, J BIOL CHEM, V277, P11208, DOI 10.1074/jbc.M111099200; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kumari VK, 2001, J PEPT RES, V58, P433, DOI 10.1034/j.1399-3011.2001.00924.x; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MATSUZAKI K, 1999, BIOCHIM BIOPHYS ACTA, V1426, P1; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; National Committee for Clinical Laboratory Standards, 1995, M27A NAT COMM CLIN L; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; Ng AWK, 2003, J PHARM PHARM SCI, V6, P67; Oh JE, 1999, BIOORGAN MED CHEM, V7, P2509, DOI 10.1016/S0968-0896(99)00176-5; Park CB, 1996, BIOCHEM BIOPH RES CO, V218, P408, DOI 10.1006/bbrc.1996.0071; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pristovsek P, 2002, J COMPUT CHEM, V23, P335, DOI 10.1002/jcc.10011; Rex JH, 1997, CLIN INFECT DIS, V24, P235, DOI 10.1093/clinids/24.2.235; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STONE DJM, 1992, J CHEM SOC PERK T 1, P3173, DOI 10.1039/p19920003173; Vanhoye D, 2003, EUR J BIOCHEM, V270, P2068, DOI 10.1046/j.1432-1033.2003.03584.x; Wang YJ, 2002, J CELL BIOCHEM, V87, P147, DOI 10.1002/jcb.10282; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P40; YEAMAN MR, 2002, PHARMACOL REV, V55, P27; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	54	42	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13018	13026		10.1074/jbc.M310838200	http://dx.doi.org/10.1074/jbc.M310838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715660	hybrid			2022-12-27	WOS:000220334900122
J	Sirangelo, I; Malmo, C; Iannuzzi, C; Mezzogiorno, A; Bianco, MR; Papa, M; Irace, G				Sirangelo, I; Malmo, C; Iannuzzi, C; Mezzogiorno, A; Bianco, MR; Papa, M; Irace, G			Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROMIDE MTT REDUCTION; FIBRIL FORMATION; PRION PROTEIN; ALZHEIMERS-DISEASE; MOLTEN GLOBULE; STRUCTURAL-CHARACTERIZATION; FAMILIAL AMYLOIDOSIS; COMMON MECHANISM; ALPHA-SYNUCLEIN; AGGREGATION	The apomyoglobin mutant W7FW14F forms amyloid-like fibrils at physiological pH. We examined the kinetics of fibrillogenesis using three techniques: the time dependence of the fluorescence emission of thioflavin T and 1-anilino-8-naphthalenesulfonate, circular dichroism measurements, and electron microscopy. We found that in the early stage of fibril formation, non-native apomyoglobin molecules containing beta-structure elements aggregate to form a nucleus. Subsequently, more molecules aggregate around the nucleus, thereby resulting in fibril elongation. We evaluated by MTT assay ( 3( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) the cytotoxicity of these aggregates at the early stage of fibril elongation versus mature fibrils and the wild-type protein. Similar to other amyloid-forming proteins, cell toxicity was not due to insoluble mature fibrils but rather to early pre-fibrillar aggregates. Propidium iodide uptake showed that cell toxicity is the result of altered membrane permeability. Phalloidin staining showed that membrane damage is not associated to an altered cell shape caused by changes in the cytoskeleton.	Seconda Univ Studi Napoli, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; Seconda Univ Studi Napoli, Dipartimento Med Pubbl Anat, I-80138 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Irace, G (corresponding author), Seconda Univ Studi Napoli, Dipartimento Biochim & Biofis, Via L De Crecchio 7, I-80138 Naples, Italy.	gaetano.irace@unina2.it	Papa, Michele/A-7228-2017; Papa, Michele/AAB-1759-2021	Papa, Michele/0000-0003-4834-7970; Papa, Michele/0000-0002-6609-7453; Sirangelo, Ivana/0000-0002-6408-4990; IANNUZZI, Clara/0000-0003-0092-5997				Abe K, 1998, NEUROSCI RES, V31, P295, DOI 10.1016/S0168-0102(98)00055-8; Bismuto E, 1996, BIOCHEMISTRY-US, V35, P1173, DOI 10.1021/bi951163g; BISMUTO E, 1992, ARCH BIOCHEM BIOPHYS, V298, P624, DOI 10.1016/0003-9861(92)90458-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAIT E, 2000, J AM CHEM SOC, V122, P12707; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Jacoboni I, 2000, PROTEINS, V41, P535, DOI 10.1002/1097-0134(20001201)41:4<535::AID-PROT100>3.0.CO;2-C; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Liu YB, 1997, J NEUROCHEM, V69, P2285; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; Monji A, 2000, NEUROSCI LETT, V278, P81, DOI 10.1016/S0304-3940(99)00899-X; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1991, LAB INVEST, V65, P104; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Qahwash I, 2003, J BIOL CHEM, V278, P23187, DOI 10.1074/jbc.M213298200; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Sirangelo I, 2003, BIOCHEMISTRY-US, V42, P312, DOI 10.1021/bi020447f; Sirangelo I, 2002, J BIOL CHEM, V277, P45887, DOI 10.1074/jbc.M207659200; SIRANGELO I, 1994, FEBS LETT, V338, P11, DOI 10.1016/0014-5793(94)80107-X; Sirangelo I, 2000, EUR J BIOCHEM, V267, P3937, DOI 10.1046/j.1432-1327.2000.01401.x; Sirangelo I, 1998, BBA-PROTEIN STRUCT M, V1385, P69, DOI 10.1016/S0167-4838(98)00038-7; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	73	68	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13183	13189		10.1074/jbc.M308207200	http://dx.doi.org/10.1074/jbc.M308207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701846	hybrid			2022-12-27	WOS:000220334900140
J	Davoodi-Semiromi, A; Laloraya, M; Kumar, GP; Purohit, S; Jha, RK; She, JX				Davoodi-Semiromi, A; Laloraya, M; Kumar, GP; Purohit, S; Jha, RK; She, JX			A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; JAK-STAT; TRANSCRIPTIONAL RESPONSES; SIGNALING PATHWAYS; T-CELLS; B-CELLS; APOPTOSIS; INTERLEUKIN-2; PROLIFERATION; ERYTHROPOIETIN	A number of cytokines that finely regulate immune response have been implicated in the pathogenesis or protection of type 1 diabetes and other autoimmune diseases. It is, therefore, of pivotal importance to examine a family of proteins that serve as signal transducers and activators of transcription (STATs), which regulate the transcription of a variety of cytokines. We report here a defective gene (Stat5b) located on chromosome 11 within a previously mapped T1D susceptibility interval (Idd4) in the nonobese diabetic ( NOD) mice. Our sequencing analysis revealed a unique mutation C1462A that results in a leucine to methionine (L327M) in Stat5b of NOD mice. Leu(327), the first residue in the DNA binding domain of STAT proteins, is conserved in all identified mammalian STAT proteins. Homology modeling predicted that the mutant Stat5b has a weaker DNA binding, which was confirmed by DNA-protein binding assays. The inapt transcriptional regulation ability of the mutated Stat5b is proved by decreased levels of RNA of Stat5b-regulated genes (IL-2Rbeta and Pim1). Consequently, IL-2Rbeta and Pim1 proteins were shown by Western blotting to have lower levels in NOD compared with normal B6 mice. These proteins have been implicated in immune regulation, apoptosis, activation-induced cell death, and control of autoimmunity. Therefore, the Stat5b pathway is a key molecular defect in NOD mice.	Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA; Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; Devi Ahilya Univ, Sch Life Sci, Indore, Madhya Pradesh, India	University System of Georgia; Augusta University; State University System of Florida; University of Florida; Devi Ahilya University	She, JX (corresponding author), Med Coll Georgia, Ctr Biotechnol & Genom Med, 1120 15th St,PV6B108, Augusta, GA 30912 USA.	jshe@mail.mcg.edu	Kumar, Pradeep/GQA-7930-2022; Kumar, Pradeep/Y-4242-2019	Kumar, Pradeep/0000-0001-7603-3579; Purohit, Sharad/0000-0003-0385-3829	NIAID NIH HHS [P01 AI-42288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI042288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi T, 1997, INT IMMUNOL, V9, P1159, DOI 10.1093/intimm/9.8.1159; Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; Berns A, 1999, CANCER RES, V59, p1773S; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; Colucci F, 1996, J AUTOIMMUN, V9, P271, DOI 10.1006/jaut.1996.0034; Colucci F, 1997, P NATL ACAD SCI USA, V94, P8670, DOI 10.1073/pnas.94.16.8670; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Denny P, 1997, DIABETES, V46, P695, DOI 10.2337/diabetes.46.4.695; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Eilers M, 1999, MOL CELLS, V9, P1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; GARCHON HJ, 1994, EUR J IMMUNOL, V24, P380, DOI 10.1002/eji.1830240217; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Goudy K, 2001, P NATL ACAD SCI USA, V98, P13913, DOI 10.1073/pnas.251532298; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Klebb G, 1996, CLIN IMMUNOL IMMUNOP, V81, P282, DOI 10.1006/clin.1996.0190; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; McDuffie M, 2000, CLIN IMMUNOL, V96, P119, DOI 10.1006/clim.2000.4893; Noorchashm H, 1997, DIABETES, V46, P941, DOI 10.2337/diabetes.46.6.941; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; Podolin PL, 2000, CYTOKINE, V12, P477, DOI 10.1006/cyto.1999.0609; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.3.CO;2-M; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Saxena D, 2000, NITRIC OXIDE-BIOL CH, V4, P384, DOI 10.1006/niox.2000.0286; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; Wilson KHS, 2003, DIABETES, V52, P2151, DOI 10.2337/diabetes.52.8.2151; Yoon JW, 2001, ANN NY ACAD SCI, V928, P200; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang YC, 2003, DIABETES, V52, P708, DOI 10.2337/diabetes.52.3.708; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	48	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11553	11561		10.1074/jbc.M312110200	http://dx.doi.org/10.1074/jbc.M312110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701862	hybrid			2022-12-27	WOS:000220157600088
J	de Avalos, SV; Okamoto, Y; Hannun, YA				de Avalos, SV; Okamoto, Y; Hannun, YA			Activation and localization of inositol phosphosphingolipid phospholipase C, Isc1p, to the mitochondria during growth of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL SPHINGOMYELINASE; ENDOPLASMIC-RETICULUM; CERAMIDE; YEAST; CELL; MEMBRANE; PROTEIN; STRESS; SPHINGOLIPIDS; CLONING	Sphingomyelinases (SMases) generate ceramides, which are known to regulate cell cycle and growth. Only one enzyme that belongs to the extended family of SMases is present in S. cerevisiae, Isc1p; however, little is known about its regulation or physiologic function. Deletion of ISC1 in S. cerevisiae resulted in a growth defect, and the slow growth phenotype was rescued by plasmid-borne expression of Isc1, confirming its role in growth. The levels of phytoceramide exhibited an Isc1p-dependent increase of similar to4-fold after 24 h of growth. In addition, the specific activity of Isc1p was significantly elevated (>3-fold) between the early logarithmic and the late logarithmic/start of stationary phases of growth. The activation of the enzyme was not associated with increased levels of the protein, indicating that the mechanism is independent of transcription/translation. Interestingly, this activation was lost upon delipidation of the enzyme, raising the possibility of regulation by associated lipids. Confocal microscopy revealed that the enzyme was predominantly in the ER during early growth but became associated with mitochondria in late logarithmic growth. These results were also supported by differential centrifugation and isolation of mitochondria and further confirmed in mitochondria purified using sucrose gradients at the different stages of growth. These results reveal that the activity and localization of Isc1p are regulated in a growth-dependent manner. A novel mechanism for activation of Isc1p through localization to mitochondria is proposed. The results also suggest a role for Isc1p-generated ceramides in optimal regulation of growth.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu	OKAMOTO, Yasuo/J-8438-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Bielawska A, 2000, METHOD ENZYMOL, V311, P518; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Bligh E.G., 1959, CAN J BIOCH PHYSL, V37; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; de Avalos SV, 2002, J BIOL CHEM, V277, P639, DOI 10.1074/jbc.M109037200; DEAVALOS SV, 2004, IN PRESS BIOACTIVE L; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Egner A, 2002, P NATL ACAD SCI USA, V99, P3370, DOI 10.1073/pnas.052545099; Feoktistova A, 2001, GENETICS, V158, P1397; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOFFMANN HP, 1973, SCIENCE, V181, P749, DOI 10.1126/science.181.4101.749; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jazwinski SM, 2002, INT J BIOCHEM CELL B, V34, P1491, DOI 10.1016/S1357-2725(02)00044-4; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kaiser CA, 2002, METHOD ENZYMOL, V351, P325; Kinner A, 2003, FEBS LETT, V549, P135, DOI 10.1016/S0014-5793(03)00801-9; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Mizutani Y, 2000, BBA-MOL CELL BIOL L, V1485, P236, DOI 10.1016/S1388-1981(00)00059-7; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Okamoto Y, 2003, BIOCHEMISTRY-US, V42, P7855, DOI 10.1021/bi0341354; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Perry David K, 2003, Cancer Treat Res, V115, P345; Perry DK, 2000, METHOD ENZYMOL, V312, P22; RIEDER E, 2000, CURRENT PROTOCOLS CE; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; Schumacher MM, 2002, J BIOL CHEM, V277, P51033, DOI 10.1074/jbc.M205301200; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	45	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11537	11545		10.1074/jbc.M309586200	http://dx.doi.org/10.1074/jbc.M309586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699160	hybrid			2022-12-27	WOS:000220157600086
J	Du, LH; Lyle, CS; Obey, TB; Gaarde, WA; Muir, JA; Bennett, BL; Chambers, TC				Du, LH; Lyle, CS; Obey, TB; Gaarde, WA; Muir, JA; Bennett, BL; Chambers, TC			Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity - Evidence that mitotic Bcl-2 phosphorylation is JNK-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; C-JUN; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; MAP KINASES; PATHWAY; APOPTOSIS; GROWTH; REQUIREMENT	The c-Jun NH2-terminal kinase (JNK) subgroup of mitogen-activated protein kinases has been implicated largely in stress responses, but an increasing body of evidence has suggested that JNK also plays a role in cell proliferation and survival. We examined the effect of JNK inhibition, using either SP600125 or specific antisense oligonucleotides, on cell proliferation and cell cycle progression. SP600125 was selective for JNK in vitro and in vivo versus other kinases tested including ERK, p38, cyclin-dependent protein kinase 1 (CDK1), and CDK2. SP600125 inhibited JNK activity and KB- 3 cell proliferation with the same dose dependence, suggesting that inhibition of proliferation was a direct consequence of JNK inhibition. Inhibition of proliferation by SP600125 was associated with an increase in the G(2)-M and apoptotic fractions of cells but was not associated with p53 or p21 induction. Antisense oligonucleotides to JNK2 but not JNK1 caused highly significant inhibition of cell proliferation. Wild-type mouse fibroblasts responded similarly with proliferation inhibition and apoptosis induction, whereas c-jun(-/-) fibroblasts were refractory to the effects of SP600125, suggesting that JNK signaling to c-Jun is required for cell proliferation. Studies in synchronized KB- 3 cells indicated that SP600125 delayed transit time through S and G(2)-M phases. Correspondingly, JNK activity increased in late S phase and peaked in late G(2) phase. During synchronous mitotic progression, cyclin B levels increased concomitant with phosphorylation of c-Jun, H1 histone, and Bcl-2. In the presence of SP600125, mitotic progression was prolonged, and c-Jun phosphorylation was inhibited, but neither H1 nor Bcl-2 phosphorylation was inhibited. However, the CDK inhibitor roscovitine inhibited mitotic Bcl-2 phosphorylation. These results indicate that JNK, and more specifically the JNK2 isoform, plays a key role in cell proliferation and cell cycle progression. In addition, conclusive evidence is presented that a kinase other than JNK, most likely CDK1 or a CDK1-regulated kinase, is responsible for mitotic Bcl-2 phosphorylation.	Univ Arkansas Med Sci Hosp, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA; Celgene, Signal Res Div, San Diego, CA 92121 USA	University of Arkansas System; University of Arkansas Medical Sciences; Isis Pharmaceuticals Inc; Bristol-Myers Squibb; Celgene Corporation	Chambers, TC (corresponding author), Univ Arkansas Med Sci Hosp, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@uams.edu			NCI NIH HHS [CA 75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rieder C L, 1997, Prog Cell Cycle Res, V3, P301; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	31	128	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11957	11966		10.1074/jbc.M304935200	http://dx.doi.org/10.1074/jbc.M304935200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704147	hybrid			2022-12-27	WOS:000220157600133
J	Ido, H; Harada, K; Futaki, S; Hayashi, Y; Nishiuchi, R; Natsuka, Y; Li, SL; Wada, Y; Combs, AC; Ervasti, JM; Sekiguchi, K				Ido, H; Harada, K; Futaki, S; Hayashi, Y; Nishiuchi, R; Natsuka, Y; Li, SL; Wada, Y; Combs, AC; Ervasti, JM; Sekiguchi, K			Molecular dissection of the alpha-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-ADHESION; CHAIN-G-DOMAIN; LG MODULES; MAJOR HEPARIN; MIGRATION; IDENTIFICATION; ALPHA-3-BETA-1; ALPHA(3)BETA(1); ALPHA-6-BETA-1; PURIFICATION	The adhesive interactions of cells with laminins are mediated by integrins and non-integrin-type receptors such as alpha-dystroglycan and syndecans. Laminins bind to these receptors at the C-terminal globular domain of their alpha chains, but the regions recognized by these receptors have not been mapped precisely. In this study, we sought to locate the binding sites of laminin-10 (alpha5beta1gamma1) for alpha(3)beta(1) and alpha(6)beta(1) integrins and alpha-dystroglycan through the production of a series of recombinant laminin-10 proteins with deletions of the LG (laminin G-like) modules within the globular domain. We found that deletion of the LG4-5 modules did not compromise the binding of laminin-10 to alpha(3)beta(1) and alpha(6)beta(1) integrins but completely abrogated its binding to alpha-dystroglycan. Further deletion up to the LG3 module resulted in loss of its binding to the integrins, underlining the importance of LG3 for integrin binding by laminin-10. When expressed individually as fusion proteins with glutathione S-transferase or the N-terminal 70-kDa region of fibronectin, only LG4 was capable of binding to alpha-dystroglycan, whereas neither LG3 nor any of the other LG modules retained the ability to bind to the integrins. Site-directed mutagenesis of the LG3 and LG4 modules indicated that Asp-3198 in the LG3 module is involved in the integrin binding by laminin-10, whereas multiple basic amino acid residues in the putative loop regions are involved synergistically in the alpha-dystroglycan binding by the LG4 module.	Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan; Aichi Med Univ, Japan Sci & Technol Agcy, ERATO, Sekiguchi Biomatrix Signaling Project, Aichi 4801195, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Osaka 5941101, Japan; Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	Osaka University; Aichi Medical University; Japan Science & Technology Agency (JST); University of Wisconsin System; University of Wisconsin Madison	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp	Ervasti, James/AAZ-4786-2020; Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; AOTA S, 1994, J BIOL CHEM, V269, P24756; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Chiba A, 1997, J BIOL CHEM, V272, P2156; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hayashi Y, 2002, BIOCHEM BIOPH RES CO, V299, P498, DOI 10.1016/S0006-291X(02)02642-6; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hirosaki T, 2002, J BIOL CHEM, V277, P49287, DOI 10.1074/jbc.M111096200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kariya Y, 2003, J CELL BIOCHEM, V88, P506, DOI 10.1002/jcb.10350; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; KUNNEKEN K, 2003, J BIOL CHEM; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MATSUYAMA S, 1994, J BIOCHEM, V116, P898, DOI 10.1093/oxfordjournals.jbchem.a124613; McDearmon EL, 1998, J BIOL CHEM, V273, P24139, DOI 10.1074/jbc.273.37.24139; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Okamoto O, 2003, J BIOL CHEM, V278, P44168, DOI 10.1074/jbc.M300726200; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Pall EA, 1996, J BIOL CHEM, V271, P3817; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500	47	97	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10946	10954		10.1074/jbc.M313626200	http://dx.doi.org/10.1074/jbc.M313626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701821	hybrid, Green Published			2022-12-27	WOS:000220157600016
J	MacKenzie, F; Duriez, P; Wong, F; Noseda, M; Karsan, A				MacKenzie, F; Duriez, P; Wong, F; Noseda, M; Karsan, A			Notch4 inhibits endothelial apoptosis via RBP-J kappa-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NOTCH4; TUMOR; FAMILY; GENE; PHOSPHORYLATION; EXPRESSION; RECEPTORS; REGULATOR; REPRESSOR; SURVIVAL	Notch4, a member of the Notch family of transmembrane receptors, is expressed primarily on endothelial cells. Activation of Notch in various cell systems has been shown to regulate cell fate decisions, partly by regulating the propensity of cells to live or die. Various studies have demonstrated a role for Notch1 in modulating apoptosis, either in a positive or negative manner. In this study, we determined that constitutively active Notch4 (Notch4 intracellular domain) inhibited endothelial apoptosis triggered by lipopolysaccharide. Notch signals are transmitted by derepression and coactivation of the transcriptional repressor, RBP-Jkappa, as well as by less well defined mechanisms that are independent of RBP-Jkappa. A Notch mutant lacking the N-terminal RAM domain showed only partial antiapoptotic activity relative to Notch4 intracellular domain but stimulated equivalent RBP-Jkappa-dependent transcriptional activity. Similarly, constitutively active RBP-Jkappa activated a full transcriptional response but only demonstrated partial antiapoptotic activity. Additional studies suggest that Notch4 provides endothelial protection in two ways: inhibition of the JNK-dependent proapoptotic pathway in an RBP-Jkappa-dependent manner and induction of an antiapoptotic pathway through an RBP-Jkappa-independent upregulation of Bcl-2. Our findings demonstrate that Notch4 activation inhibits apoptosis through multiple pathways and provides one mechanism to explain the remarkable capacity of endothelial cells to withstand apoptosis.	Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1L3, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency	Karsan, A (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	akarsan@bccrc.ca	Karsan, Aly/K-2067-2015	Noseda, Michela/0000-0002-9553-5029; Duriez, Patrick/0000-0003-1814-2552				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ear T, 2001, J IMMUNOL METHODS, V257, P41, DOI 10.1016/S0022-1759(01)00445-8; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Gridley T, 2001, P NATL ACAD SCI USA, V98, P5377, DOI 10.1073/pnas.101138098; Guevara NV, 2001, PHARMACOL RES, V44, P59, DOI 10.1006/phrs.2001.0840; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jehn BM, 1999, J IMMUNOL, V162, P635; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1997, AM J PATHOL, V151, P1775; KARSAN A, 1999, HEMATOLOGY BASIC PRI, P1770; Krebs LT, 2000, GENE DEV, V14, P1343; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lee JS, 1999, J VIROL, V73, P5166, DOI 10.1128/JVI.73.6.5166-5171.1999; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; McCright B, 2001, DEVELOPMENT, V128, P491; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Ohishi K, 2000, BLOOD, V95, P2847, DOI 10.1182/blood.V95.9.2847.009k19_2847_2854; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Shutter JR, 2000, GENE DEV, V14, P1313; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	49	100	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11657	11663		10.1074/jbc.M312102200	http://dx.doi.org/10.1074/jbc.M312102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701863	hybrid			2022-12-27	WOS:000220157600100
J	Sorenson, CM				Sorenson, CM			Interaction of bcl-2 with paxillin through its BH4 domain is important during ureteric bud branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; RENAL DEVELOPMENT; CYSTIC KIDNEYS; CELL-DEATH; EXPRESSION; APOPTOSIS; PROTEINS; BINDING; MOUSE; PHOSPHORYLATION	bcl-2 protects cells from apoptosis initiated by a variety of stimuli including loss of cell adhesion. Mice deficient in bcl-2 ( bcl-2-/-) develop renal hypoplastic/cystic dysplasia, a condition that leads to significant morbidity and mortality in children. The precise mechanism of action of bcl-2 has not been elucidated. bcl-2 may merely facilitate survival of precursor cells and/or may play a more "active" role during morphogenesis by interacting with other proteins such as paxillin. Recent work in this laboratory demonstrated that bcl-2 directly associates with paxillin. The data presented here demonstrate that the bcl-2 homology 4 (BH4) domain, specifically amino acids 17-31, is necessary for the bcl-2 interaction with paxillin. Paxillin also associated with the BH4 domains of more closely related bcl-2 family members, bcl-xL and bcl-w, compared with that from the non-mammalian homologue ced9. Tyrosines 21 and 28 in the bcl-2 BH4 domain were essential for interaction with paxillin. In embryonic kidney organ culture, incubation with the bcl-2 BH4 domain resulted in inhibition of ureteric bud branching. Therefore, these data suggest that the interaction of bcl-2 with paxillin plays an important role during nephrogenesis.	Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Sorenson, CM (corresponding author), Univ Wisconsin, Dept Pediat, H4-444 CSC,600 Highland Ave, Madison, WI 53792 USA.	cmsorenson@wisc.edu						CHANDLER D, 1994, HUM PATHOL, V25, P789, DOI 10.1016/0046-8177(94)90248-8; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nor JE, 2001, CANCER RES, V61, P2183; NOVACK DV, 1994, AM J PATHOL, V145, P61; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF234, DOI 10.1152/ajprenal.1996.271.1.F234; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Sorenson CM, 2002, AM J PHYSIOL-RENAL, V282, pF442, DOI 10.1152/ajprenal.00184.2001; Sorenson CM, 2002, AM J PHYSIOL-RENAL, V283, pF1085, DOI 10.1152/ajprenal.00380.2001; SORENSON CM, 1995, AM J PHYSIOL-RENAL, V268, pF73, DOI 10.1152/ajprenal.1995.268.1.F73; Sorenson CM, 1999, AM J PHYSIOL-RENAL, V276, pF210, DOI 10.1152/ajprenal.1999.276.2.F210; Sorenson CM, 1999, DEV DYNAM, V215, P371, DOI 10.1002/(SICI)1097-0177(199908)215:4<371::AID-AJA8>3.3.CO;2-8; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; TURNER CE, 1994, J CELL SCI, V107, P1583; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WANG H, 1996, CELL, V4, P589	29	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11368	11374		10.1074/jbc.M310079200	http://dx.doi.org/10.1074/jbc.M310079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699151	hybrid			2022-12-27	WOS:000220157600066
J	Borges, N; Marugg, JD; Empadinhas, N; da Costa, MS; Santos, H				Borges, N; Marugg, JD; Empadinhas, N; da Costa, MS; Santos, H			Specialized roles of the two pathways for the synthesis of mannosylglycerate in osmoadaptation and thermoadaptation of Rhodothermus marinus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILE ARCHAEOGLOBUS-FULGIDUS; OSMOREGULATORY TREHALOSE SYNTHESIS; SYNTHASE PHOSPHATASE COMPLEX; SP STRAIN PCC-6803; GENETIC-CHARACTERIZATION; THERMUS-THERMOPHILUS; COMPATIBLE SOLUTES; ESCHERICHIA-COLI; SALINITY; PURIFICATION	Rhodothermus marinus responds to fluctuations in the growth temperature and/or salinity by accumulating mannosylglycerate (MG). Two alternative pathways for the synthesis of MG have been identified in this bacterium: a single-step pathway and a two-step pathway. In this work, the genetic and biochemical characterization of the two-step pathway was carried out with the goal of understanding the function of the two pathways and their regulatory mechanisms. Mannosyl-3-phosphoglycerate synthase (MPGS) of the two-step pathway was purified from R. marinus. Sequence information led to the isolation of two contiguous genes, mpgs (encoding MPGS) and mpgp ( encoding mannosyl-3-phosphoglycerate phosphatase). The recombinant MPGS had a low specific activity compared with other homologous MPGSs and contained similar to30 additional residues at the C terminus. Truncation of this extension produced a protein with a 10-fold higher specific activity. Moreover, the activity of the complete MPGS was enhanced upon incubation with R. marinus cell extracts, and protease inhibitors abolished activation. Therefore, the C-terminal peptide of MPGS was identified as a regulatory site for short term control of MG synthesis in R. marinus. The control of gene expression by heat and osmotic stress was also studied; the level of mannosylglycerate synthase involved in the single-step pathway was selectively enhanced by heat stress, whereas MPGS was overproduced in response to osmotic stress. The concomitant changes in the level of MG were assessed as well. We conclude that the two alternative pathways for the synthesis of MG are differently regulated at the level of expression to play specific roles in the adaptation of R. marinus to two different types of aggression. This is the only example of pathway multiplicity being rationalized in terms of the need to respond efficiently to distinct environmental stresses.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Coimbra, Dept Bioquim, P-3000 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias & Biol Mol, P-3000 Coimbra, Portugal; Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland	Universidade Nova de Lisboa; Universidade de Coimbra; Universidade de Coimbra; Nestle SA	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apartado 127, P-2780156 Oeiras, Portugal.	santos@itqb.unl.pt	Borges, Nuno/Q-3515-2019; Empadinhas, Nuno/G-3118-2011; Borges, Nuno/A-1427-2011; Santos, Helena/B-9141-2011	Borges, Nuno/0000-0002-3277-8517; Empadinhas, Nuno/0000-0001-8938-7560; Borges, Nuno/0000-0002-3277-8517; Santos, Helena/0000-0002-8050-9485; Marugg, John/0000-0003-2657-6692; da Costa, Milton/0000-0003-4027-4412				Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; BOCK K, 1974, J CHEM SOC PERK T 2, P293, DOI 10.1039/p29740000293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Curatti L, 1998, J BACTERIOL, V180, P6776, DOI 10.1128/JB.180.24.6776-6779.1998; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Empadinhas N, 2003, APPL ENVIRON MICROB, V69, P3272, DOI 10.1128/AEM.69.6.3272-3279.2003; Empadinhas N, 2001, J BIOL CHEM, V276, P43580, DOI 10.1074/jbc.M108054200; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; Goncalves LG, 2003, FEMS MICROBIOL LETT, V218, P239, DOI 10.1016/S0378-1097(02)01146-1; Hagemann M, 1997, J BACTERIOL, V179, P1727, DOI 10.1128/jb.179.5.1727-1733.1997; Hagemann M, 2001, CURR MICROBIOL, V43, P278, DOI 10.1007/s002840010301; KAASEN I, 1994, GENE, V145, P9, DOI 10.1016/0378-1119(94)90316-6; KOHLE D, 1984, BIOCHIM BIOPHYS ACTA, V799, P59, DOI 10.1016/0304-4165(84)90327-1; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; Lamosa P, 2000, APPL ENVIRON MICROB, V66, P1974, DOI 10.1128/AEM.66.5.1974-1979.2000; LONDESBOROUGH J, 1991, J GEN MICROBIOL, V137, P323, DOI 10.1099/00221287-137-2-323; Marin K, 1998, J BACTERIOL, V180, P4843, DOI 10.1128/JB.180.18.4843-4849.1998; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; Martins LO, 1999, J BIOL CHEM, V274, P35407, DOI 10.1074/jbc.274.50.35407; NUNES OC, 1992, SYST APPL MICROBIOL, V15, P92, DOI 10.1016/S0723-2020(11)80144-X; NUNES OC, 1995, APPL ENVIRON MICROB, V61, P2351, DOI 10.1128/AEM.61.6.2351-2357.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santos H, 2002, ENVIRON MICROBIOL, V4, P501, DOI 10.1046/j.1462-2920.2002.00335.x; Santos H, 2001, METHOD ENZYMOL, V334, P302; Silva Z, 1999, EXTREMOPHILES, V3, P163, DOI 10.1007/s007920050112; Silva Z, 2003, J BACTERIOL, V185, P5943, DOI 10.1128/JB.185.20.5943-5952.2003; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMSON KS, 1983, BIOCHIM BIOPHYS ACTA, V759, P154, DOI 10.1016/0304-4165(83)90307-0; VICENTESOLER J, 1991, FEMS MICROBIOL LETT, V82, P157; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x	33	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9892	9898		10.1074/jbc.M312186200	http://dx.doi.org/10.1074/jbc.M312186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701859	hybrid			2022-12-27	WOS:000220050400029
J	Lee, MR; Kim, SH; Cho, HJ; Lee, KY; Moon, AR; Jeong, HG; Lee, JS; Hyun, JW; Chung, MH; You, HJ				Lee, MR; Kim, SH; Cho, HJ; Lee, KY; Moon, AR; Jeong, HG; Lee, JS; Hyun, JW; Chung, MH; You, HJ			Transcription factors NF-YA regulate the induction of human OGG1 following DNA-alkylating agent methylmethane sulfonate (MMS) treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE MGMT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; POLYMERASE-BETA; MESSENGER-RNA; DAMAGED DNA; LUNG-CANCER; 7-METHYLGUANINE RESIDUES; SUBSTRATE-SPECIFICITY	A human 8-oxoguanine- DNA glycosylase (hOGG1) is the main enzyme that repairs 8-oxoG, which is a critical mutagenic lesion. There is a great deal of interest in the up- or down-regulation of OGG1 expression after DNA damage. In this study, we investigated the effect of a DNA-alkylating agent, methylmethane sulfonate (MMS), on hOGG1 expression level and found that MMS treatment resulted in an increase in the functional hOGG1 expression in HCT116 cells. A region between -121 and -61 of the hOGG1 promoter was found to be crucial for this induction by MMS. Site-directed mutations of the two inverted CCAAT motifs substantially abrogated the induction of the hOGG1 promoter as a result of MMS treatment. In addition, the NF-YA protein ( binding to the inverted CCAAT box) was induced after exposing cells to MMS. Moreover, gel shift and supershift analyses with the nuclear extracts prepared from HCT116 cells identified NF-YA as the transcription factor interacting with the inverted CCAAT box. Mutations of the inverted CCAAT box either prevented the binding of this factor or abolished its activation as a result of MMS treatment. Finally, this study showed that hOGG1-expressing HCT116 cells exhibited increased hOGG1 repair activity and resistance to MMS. Overall, these results demonstrate that MMS can up- regulate hOGG1 expression through the induction of the transcription factor, NFYA, and increased transcription level of the hOGG1 gene correlates with an increase in enzyme activity providing functional protection from MMS.	Chosun Univ, Res Ctr Prot Mat, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Cheju Natl Univ, Coll Med, Dept Biochem, Jeju, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Jeju National University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Res Ctr Prot Mat, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@mail.chosun.ac.kr		Jeong, Hye Gwang/0000-0002-8020-8914; You, Ho Jin/0000-0002-0530-4017				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Blons H, 1999, MOL CARCINOGEN, V26, P254; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Davis BM, 1997, CANCER RES, V57, P5093; Deutsch WA, 1997, J BIOL CHEM, V272, P32857, DOI 10.1074/jbc.272.52.32857; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; Dosch J, 1996, ONCOGENE, V13, P1927; FEIG DI, 1994, CANCER RES, V54, pS1890; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Gill RD, 1996, CANCER RES, V56, P3721; GOMBAR CT, 1980, BIOCHEM PHARMACOL, V29, P2639, DOI 10.1016/0006-2952(80)90079-9; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Hansen WK, 2000, J PHARMACOL EXP THER, V295, P1; HIBI K, 1992, ONCOGENE, V7, P445; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; Ishida T, 1999, CYTOGENET CELL GENET, V85, P232, DOI 10.1159/000015299; Ishida T, 1999, INT J CANCER, V80, P18; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; Kim HN, 2001, CARCINOGENESIS, V22, P265, DOI 10.1093/carcin/22.2.265; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kobune M, 2001, CANCER RES, V61, P5116; Koc ON, 1999, CANCER GENE THER, V6, P340, DOI 10.1038/sj.cgt.7700067; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; Maze R, 1996, P NATL ACAD SCI USA, V93, P206, DOI 10.1073/pnas.93.1.206; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MULLER N, 1985, CHEM-BIOL INTERACT, V53, P173, DOI 10.1016/S0009-2797(85)80094-6; NAKAYAMA T, 1985, NATURE, V314, P462, DOI 10.1038/314462a0; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Ochs K, 2002, CANCER RES, V62, P1524; Ochs K, 1999, CANCER RES, V59, P1544; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5879, DOI 10.1093/nar/16.13.5879; Phillips WP, 1997, CANCER RES, V57, P4817; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; Tsuruya K, 2003, DNA REPAIR, V2, P211, DOI 10.1016/S1568-7864(02)00214-8; VANDELFT JHM, 1993, ENVIRON HEALTH PERSP, V99, P25, DOI 10.2307/3431453; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Xu Y, 2001, J PHARMACOL EXP THER, V296, P825; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	78	40	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9857	9866		10.1074/jbc.M311132200	http://dx.doi.org/10.1074/jbc.M311132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688259	hybrid			2022-12-27	WOS:000220050400025
J	Wikstrom, M; Xie, J; Bogdanov, M; Mileykovskaya, E; Heacock, P; Wieslander, A; Dowhan, W				Wikstrom, M; Xie, J; Bogdanov, M; Mileykovskaya, E; Heacock, P; Wieslander, A; Dowhan, W			Monoglucosyldiacylglycerol, a foreign lipid, can substitute for phosphatidylethanolamine in essential membrane-associated functions in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; ACHOLEPLASMA-LAIDLAWII; PHOSPHOLIPID-COMPOSITION; 1,2-DIACYLGLYCEROL 3-GLUCOSYLTRANSFERASE; TRANSPORT-SYSTEM; IN-VITRO; LACKING PHOSPHATIDYLETHANOLAMINE; STRUCTURAL FEATURES; NONBILAYER LIPIDS; LACTOSE PERMEASE	The mechanisms by which lipid bilayer properties govern or influence membrane protein functions are little understood, but a liquid-crystalline state and the presence of anionic and nonbilayer (NB)-prone lipids seem important. An Escherichia coli mutant lacking the major membrane lipid phosphatidylethanolamine (NB-prone) requires divalent cations for viability and cell integrity and is impaired in several membrane functions that are corrected by introduction of the "foreign" NB-prone neutral glycolipid alpha-monoglucosyldiacylglycerol (MGlcDAG) synthesized by the MGlcDAG synthase from Acholeplasma laidlawii. Dependence on Mg2+ was reduced, and cellular yields and division malfunction were greatly improved. The increased passive membrane permeability of the mutant was not abolished, but protein-mediated osmotic stress adaptation to salts and sucrose was recovered by the presence of MGlcDAG. MGlcDAG also restored tryptophan prototrophy and active transport function of lactose permease, both critically dependent on phosphatidylethanolamine. Three mechanisms can explain the observed effects: NB-prone MGlcDAG improves the quenched lateral pressure profile across the bilayer; neutral MGlcDAG dilutes the high anionic lipid surface charge; MGlcDAG provides a neutral lipid that can hydrogen bond and/or partially ionize. The reduced dependence on Mg2+ and lack of correction by high monovalent salts strongly support the essential nature of the NB properties of MGlcDAG.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Stockholm University; University of Texas System	Wieslander, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	ake@dbb.su.se; William.Dowhan@uth.tmc.edu	Bogdanov, Mikhail/J-3695-2017	Xie, Jun/0000-0001-6943-0330; Mileykovskaya, Eugenia/0000-0002-8775-4467	NIGMS NIH HHS [GM20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arechaga I, 2000, FEBS LETT, V482, P215, DOI 10.1016/S0014-5793(00)02054-8; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Berg S, 2001, J BIOL CHEM, V276, P22056, DOI 10.1074/jbc.M102576200; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; Booth PJ, 2001, CRIT REV BIOCHEM MOL, V36, P501, DOI 10.1080/20014091074246; Botelho AV, 2002, BIOCHEMISTRY-US, V41, P6354, DOI 10.1021/bi011995g; BRABETZ W, 1993, J BACTERIOL, V175, P7488, DOI 10.1128/JB.175.22.7488-7491.1993; BRYSZEWSKA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P485, DOI 10.1016/0005-2736(88)90381-1; Cantor RS, 1999, CHEM PHYS LIPIDS, V101, P45, DOI 10.1016/S0009-3084(99)00054-7; Crooke E, 2001, BIOCHIMIE, V83, P19, DOI 10.1016/S0300-9084(00)01224-4; DAWSON RMC, 1986, DATA BIOCH RES, P456; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P10710; Dormann P, 2002, TRENDS PLANT SCI, V7, P112, DOI 10.1016/S1360-1385(01)02216-6; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; EATON LC, 1981, J BACTERIOL, V146, P1151, DOI 10.1128/JB.146.3.1151-1153.1981; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; Fishov I, 1999, MOL MICROBIOL, V32, P1166, DOI 10.1046/j.1365-2958.1999.01425.x; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; Herskovits AA, 2002, J CELL BIOL, V159, P403, DOI 10.1083/jcb.200204144; HIRAOKA S, 1993, FEBS LETT, V336, P221, DOI 10.1016/0014-5793(93)80807-7; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; KENNEDY EP, 1982, P NATL ACAD SCI-BIOL, V79, P1092, DOI 10.1073/pnas.79.4.1092; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, V1, P1064; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Laan EVDD, 2003, J BACTERIOL, V185, P3773, DOI 10.1128/JB.185.3773.3779.2003; Lewis BE, 2003, J AM CHEM SOC, V125, P7872, DOI 10.1021/ja034983m; Li L, 2003, BIOCHEMISTRY-US, V42, P9677, DOI 10.1021/bi034360l; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LUSK JE, 1969, J BIOL CHEM, V244, P1653; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Mannock DA, 2001, EUR BIOPHYS J BIOPHY, V30, P537, DOI 10.1007/s002490010185z; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; Mileykovskaya E, 1998, J BACTERIOL, V180, P4252, DOI 10.1128/JB.180.16.4252-4257.1998; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; NAGATA S, 1995, MICROBIOL-UK, V141, P729, DOI 10.1099/13500872-141-3-729; NESMEYANOVA MA, 1991, WORLD J MICROB BIOT, V7, P394, DOI 10.1007/BF00329408; Niemi AE, 1997, EUR BIOPHYS J BIOPHY, V26, P485, DOI 10.1007/s002490050103; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NOORDAM PC, 1980, CHEM PHYS LIPIDS, V27, P221, DOI 10.1016/0009-3084(80)90037-7; Pogliano J, 1999, MOL MICROBIOL, V31, P1149, DOI 10.1046/j.1365-2958.1999.01255.x; Poolman B, 2002, MOL MICROBIOL, V44, P889, DOI 10.1046/j.1365-2958.2002.02894.x; RAETZ CRH, 1977, J BIOL CHEM, V252, P5911; RICHEY B, 1987, J BIOL CHEM, V262, P7157; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; SEIMIYA T, 1978, CHEM PHYS LIPIDS, V22, P221, DOI 10.1016/0009-3084(78)90028-2; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SILVER S, 1996, ESCHERICHIA COLI SAL, V1, P1091; SPROTT GD, 1984, METHODS GEN MOL BACT, P72; Storm P, 2003, EUR J BIOCHEM, V270, P1699, DOI 10.1046/j.1432-1033.2003.03527.x; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Urban F, 1932, J BIOL CHEM, V94, P697; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Vanounou S, 2003, MOL MICROBIOL, V49, P1067, DOI 10.1046/j.1365-2958.2003.03614.x; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Weber FJ, 1996, BBA-REV BIOMEMBRANES, V1286, P225, DOI 10.1016/S0304-4157(96)00010-X; WEISSBORN AC, 1992, J BACTERIOL, V174, P4856, DOI 10.1128/JB.174.14.4856-4859.1992; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; WILKISON WO, 1988, J BIOL CHEM, V263, P14505; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yang L, 2003, BIOCHEMISTRY-US, V42, P6631, DOI 10.1021/bi0344836; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991; Yue AWB, 2003, BIOCHEMISTRY-US, V42, P1309, DOI 10.1021/bi026923j; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200; Zhukov AV, 1996, CHEM PHYS LIPIDS, V82, P1, DOI 10.1016/0009-3084(96)02538-8	80	60	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10484	10493		10.1074/jbc.M310183200	http://dx.doi.org/10.1074/jbc.M310183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688287	hybrid			2022-12-27	WOS:000220050400100
J	Bomgarden, RD; Yean, D; Yee, MC; Cimprich, KA				Bomgarden, RD; Yean, D; Yee, MC; Cimprich, KA			A novel protein activity mediates DNA binding of an ATR-ATRIP complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; CELL-CYCLE; DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; KINASE; REPLICATION; CHROMATIN; ACTIVATION; MEC1; RPA	The function of the ATR (ataxia-telangiectasia mutated and Rad3-related)-ATRIP (ATR-interacting protein) protein kinase complex is central to the cellular response to replication stress and DNA damage. In order to better understand the function of this complex, we have studied its interaction with DNA. We find that both ATR and ATRIP associate with chromatin in vivo, and they exist as a large molecular weight complex that can bind single-stranded ( ss) DNA cellulose in vitro. Although replication protein A (RPA) is sufficient for the recruitment of ATRIP to ssDNA, we show that a distinct ATR-ATRIP complex is able to bind to DNA with lower affinity in the absence of RPA. In this latter complex, we show that neither ATR nor ATRIP are able to bind DNA individually, nor do they bind DNA in a cooperative manner. However, the addition of HeLa nuclear extract is able to reconstitute the DNA binding of both ATR and ATRIP, suggesting the requirement for an additional protein activity. We also show that ATR is necessary for ATRIP to bind DNA in this low affinity mode and to form a large DNA binding complex. These observations suggest that there are at least two in vitro ATR-ATRIP DNA binding complexes, one which binds DNA with high affinity in an RPA-dependent manner and a second, which binds DNA with lower affinity in an RPA-independent manner but which requires an as of yet unidentified protein.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Cimprich, KA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA.	cimprich@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062193] Funding Source: NIH RePORTER; NCI NIH HHS [CA09151] Funding Source: Medline; NIGMS NIH HHS [GM62193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Paciotti V, 2000, GENE DEV, V14, P2046; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wolkow TD, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-6; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	35	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13346	13353		10.1074/jbc.M311098200	http://dx.doi.org/10.1074/jbc.M311098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724280	hybrid			2022-12-27	WOS:000220478500011
J	Cheng, L; Mahon, GM; Kostenko, EV; Whitehead, IP				Cheng, L; Mahon, GM; Kostenko, EV; Whitehead, IP			Pleckstrin homology domain-mediated activation of the Rho-specific guanine nucleotide exchange factor Dbs by Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ACTIN STRESS FIBERS; TRANSFORMING ACTIVITY; RAS TRANSFORMATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; FAMILY GTPASES; CELL-ADHESION; CDC42 GTPASES; PH DOMAIN	Dbs is a Rho-specific guanine nucleotide exchange factor that was identified in a screen for proteins whose expression causes deregulated growth in NIH 3T3 mouse fibroblasts. Although Rac1 has not been shown to be a substrate for Dbs in either in vitro or in vivo assays, the Rat ortholog of Dbs (Ost) has been shown to bind specifically to GTP.Rac1 in vitro. The dependence of the Rac1/Dbs interaction on GTP suggests that Dbs may in fact be an effector for Rac1. Here we show that the interaction between activated Rac1 and Dbs can be recapitulated in mammalian cells and that the Rac1 docking site resides within the pleckstrin homology domain of Dbs. This interaction is specific for Rac1 and is not observed between Rac1 and several other members of the Rho-specific guanine nucleotide exchange factor family. Co-expression of Dbs with activated Rac1 causes enhanced focus forming activity and elevated levels of GTP.RhoA in NIH 3T3 cells, indicating that Dbs is activated by the interaction. Consistent with this, activated Rac1 co-localizes with Dbs in NIH 3T3 cells, and natively expressed Rac1 relocalizes in response to Dbs expression. To summarize, we have characterized a surprisingly direct pleckstrin homology domain-mediated mechanism through which Rho GTPases can become functionally linked.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 225 Warren St, Newark, NJ 07103 USA.	whiteip@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA097066] Funding Source: NIH RePORTER; NCI NIH HHS [CA 097066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Evers EE, 2000, METHOD ENZYMOL, V325, P403; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; VAN AL, 1997, GENE DEV, V11, P2295; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	47	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12786	12793		10.1074/jbc.M313099200	http://dx.doi.org/10.1074/jbc.M313099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701795	hybrid			2022-12-27	WOS:000220334900093
J	Deguchi, H; Yegneswaran, S; Griffin, JH				Deguchi, H; Yegneswaran, S; Griffin, JH			Sphingolipids as bioactive regulators of thrombin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; SPHINGOSINE 1-PHOSPHATE; GLA DOMAIN; FACTOR-VA; VENOUS THROMBOSIS; FACTOR-X; PROTHROMBIN ACTIVATION; ANTICOAGULANT PROTEIN; FUMONISIN EXPOSURE; ENDOTHELIAL-CELLS	Sphingolipids contribute to modulation of two opposing cell processes, cell growth and apoptotic cell death; ceramide and sphingosine promote the latter and sphingosine-1-phosphate triggers the former. Thrombin, a pro-inflammatory protease that is regulated by the blood coagulation cascade, exerts similar effects depending on cell type. Here we report a new mechanism for cross-talk between sphingolipid metabolism and thrombin generation. Sphingosine and sphinganine, but not ceramide or sphingosine-1-phosphate, down-regulated thrombin generation on platelet surfaces (IC50 = 2.4 and 1.4 muM for sphingosine and sphinganine, respectively) as well as in whole plasma clotting assays. Thrombin generation was also inhibited by glucosylsphingosine, lysosphingomyelin, phytosphingosine, and primary alkylamines with > 10 carbons. Acylation of the amino group ablated anticoagulant activities. Factor Va was required for the anticoagulant property of sphingosine because prothrombin activation was inhibited by sphingosine, sphinganine, and stearylamine in the presence but not in the absence of factor Va. Sphingosine did not inhibit thrombin generation when Gla-domainless factor Xa was used in prothrombinase assays, whereas sphingosine inhibited activation of Gla-domainless prothrombin by factor Xa/factor Va in the absence of phospholipids (IC50 = 0.49 muM). Fluorescence spectroscopy studies showed that sphingosine binds to fluorescein-labeled factor Xa and that this interaction required the Gla domain. These results imply that sphingosine disrupts interactions between factor Va and the Gla domain of factor Xa in the prothrombinase complex. Thus, certain sphingolipids may be bioactive lipid mediators of thrombin generation such that certain sphingolipid metabolites may modulate proteases that affect cell growth and death, blood coagulation, and inflammation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 180,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jgriffin@scripps.edu		Griffin, John/0000-0002-4302-2547; Deguchi, Hiroshi/0000-0002-7721-1207	NHLBI NIH HHS [R01 HL 21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BRANSON HE, 1983, LANCET, V2, P1165; Castegnaro M, 1998, J CHROMATOGR B, V720, P15, DOI 10.1016/S0378-4347(98)00446-0; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cirino G, 2000, TRENDS PHARMACOL SCI, V21, P170, DOI 10.1016/S0165-6147(00)01469-3; CONKLING PR, 1989, J BIOL CHEM, V264, P18440; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Deguchi H, 2002, J BIOL CHEM, V277, P8861, DOI 10.1074/jbc.M110252200; Deguchi H, 2001, BLOOD, V97, P1907, DOI 10.1182/blood.V97.7.1907; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; Griffin J. H., 2001, WILLIAMS HEMATOLOGY, P1435; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; LECOMPTE MF, 1989, BIOCHIMIE, V71, P175, DOI 10.1016/0300-9084(89)90148-X; MANN KG, 1990, BLOOD, V76, P1; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Takeya H, 2003, BLOOD, V102, P1693, DOI 10.1182/blood-2002-11-3607; TANABE S, 1992, THROMB RES, V67, P115, DOI 10.1016/0049-3848(92)90263-A; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; van der Westhuizen L, 1999, FOOD CHEM TOXICOL, V37, P1153, DOI 10.1016/S0278-6915(99)00113-1; Yatomi Y, 2000, BLOOD, V96, P3431; Yegneswaran S, 2003, J BIOL CHEM, V278, P14614, DOI 10.1074/jbc.M206746200; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1	40	36	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12036	12042		10.1074/jbc.M302531200	http://dx.doi.org/10.1074/jbc.M302531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722105	hybrid			2022-12-27	WOS:000220334900006
J	Lindersson, E; Beedholm, R; Hojrup, P; Moos, T; Gai, WP; Hendil, KB; Jensen, PH				Lindersson, E; Beedholm, R; Hojrup, P; Moos, T; Gai, WP; Hendil, KB; Jensen, PH			Proteasomal inhibition by alpha-synuclein filaments and oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; SPORADIC PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; NEURODEGENERATIVE DISORDERS; CHAPERONE SUPPRESSION; SUBSTANTIA-NIGRA; DROSOPHILA MODEL; 20S PROTEASOME; MUTATION	A unifying feature of many neurodegenerative disorders is the accumulation of polyubiquitinated protein inclusions in dystrophic neurons, e. g. containing alpha- synuclein, which is suggestive of an insufficient proteasomal activity. We demonstrate that alpha- synuclein and 20 S proteasome components co- localize in Lewy bodies and show that subunits from 20 S proteasome particles, in contrast to subunits of the 19 S regulatory complex, bind efficiently to aggregated filamentous but not monomeric alpha- synuclein. Proteasome binding to insoluble alpha- synuclein filaments and soluble alpha- synuclein oligomers results in marked inhibition of its chymotrypsin- like hydrolytic activity through a non- competitive mechanism that is mimicked by model amyloid- Abeta peptide aggregates. Endogenous ligands of aggregated alpha- synuclein like heat shock protein 70 and glyceraldehyde- 6- phosphate dehydrogenase bind filaments and inhibit their anti- proteasomal activity. The inhibitory effect of amyloid aggregates may thus be amenable to modulation by endogenous chaperones and possibly accessible for therapeutic intervention.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ So Denmark, Inst Mol Biol, DK-5230 Odense M, Denmark; Univ Copenhagen, Dept Med Anat, DK-2200 Copenhagen, Denmark; Flinders Med Ctr, Dept Physiol, Bedford Pk, SA 5042, Australia; Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	Aarhus University; Aarhus University; University of Southern Denmark; University of Copenhagen; Flinders Medical Centre; University of Copenhagen	Jensen, PH (corresponding author), Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.	phj@biokemi.au.dk	Gai, Wei-Ping/A-3700-2008; Højrup, Peter/ABG-8477-2020	Jensen, Poul Henning/0000-0002-4439-9020; Hojrup, Peter/0000-0002-7838-6180; Moos, Torben/0000-0001-9989-0207				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Conconi M, 1999, ARCH BIOCHEM BIOPHYS, V362, P325, DOI 10.1006/abbi.1998.1037; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fonager J, 2002, EXP GERONTOL, V37, P1223, DOI 10.1016/S0531-5565(02)00128-6; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gai WP, 1999, J NEUROCHEM, V73, P2093; Gai WP, 2003, EXP NEUROL, V181, P68, DOI 10.1016/S0014-4886(03)00004-9; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; HENDIL KB, 1991, J BIOCHEM BIOPH METH, V22, P159, DOI 10.1016/0165-022X(91)90028-U; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KRISTENSEN P, 1995, BIOCHEM BIOPH RES CO, V207, P1059, DOI 10.1006/bbrc.1995.1294; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Leveugle B, 1996, ACTA NEUROPATHOL, V91, P566, DOI 10.1007/s004010050468; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Mirza B, 2000, NEUROSCIENCE, V95, P425; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rattan SIS, 1998, BIOCHEM MOL BIOL INT, V45, P753; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Tatton WG, 2000, ADV RES NEURODEGENER, V8, P77; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398	58	290	301	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12924	12934		10.1074/jbc.M306390200	http://dx.doi.org/10.1074/jbc.M306390200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711827	hybrid			2022-12-27	WOS:000220334900110
J	Nomaguchi, M; Teramoto, T; Yu, L; Markoff, L; Padmanabhan, R				Nomaguchi, M; Teramoto, T; Yu, L; Markoff, L; Padmanabhan, R			Requirements for West Nile virus (-)- and (+)-strand subgenomic RNA synthesis in vitro by the viral RNA-dependent RNA polymerase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; PUTATIVE METHYLTRANSFERASE DOMAIN; FLAVIVIRUS GENOMIC RNA; 3' UNTRANSLATED REGION; NEGATIVE-STRAND RNA; DE-NOVO SYNTHESIS; DENGUE VIRUS; SECONDARY STRUCTURE; NS3 PROTEIN; NTPASE ACTIVITY	RNA-dependent RNA polymerases (RdRPs) of the Flaviviridae family catalyze replication of positive (+)strand viral RNA through synthesis of minus (-)- and progeny (+)- strand RNAs. West Nile virus (WNV), a mosquito-borne member, is a rapidly re-emerging human pathogen in the United States since its first outbreak in 1999. To study the replication of the WNV RNA in vitro, an assay is described here that utilizes the WNV RdRP and subgenomic (-)- and (+)- strand template RNAs containing 5'- and 3'-terminal regions (TR) with the conserved sequence elements. Our results show that both 5'- and 3'-TRs of the (+)- strand RNA template including the wild type cyclization (CYC) motifs are important for RNA synthesis. However, the 3'-TR of the (-)- strand RNA template alone is sufficient for RNA synthesis. Mutational analysis of the CYC motifs revealed that the (+)- strand 5'- CYC motif is critical for (+)- strand RNA synthesis but neither the (-)- strand 5'- nor 3'-CYC motif is important for the (+)- strand RNA synthesis. Moreover, the 5'- cap inhibits the (+)- strand RNA synthesis from the 3' fold-back structure of (+)- strand RNA template without affecting the de novo synthesis of RNA. These results support a model that "cyclization" of the viral RNA play a role for (-)- strand RNA synthesis but not for (+)- strand RNA synthesis.	Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20057 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	Georgetown University; US Food & Drug Administration (FDA)	Padmanabhan, R (corresponding author), Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, SW309 Med Dent Bldg,3900 Reservoir Rd, Washington, DC 20057 USA.	rp55@georgetown.edu			NIAID NIH HHS [AI 32078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032078, R01AI032078] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Asnis DS, 2000, CLIN INFECT DIS, V30, P413, DOI 10.1086/313737; Bartelma G, 2002, VIROLOGY, V299, P122, DOI 10.1006/viro.2002.1504; Barton DJ, 2001, EMBO J, V20, P1439, DOI 10.1093/emboj/20.6.1439; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BLACKWELL JL, 1995, J VIROL, V69, P5650, DOI 10.1128/JVI.69.9.5650-5658.1995; Borowski P, 2001, J VIROL, V75, P3220, DOI 10.1128/JVI.75.7.3220-3229.2001; Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0; BRINTON MA, 1986, VIROLOGY, V153, P113, DOI 10.1016/0042-6822(86)90012-7; Brinton MA, 2001, ANN NY ACAD SCI, V951, P207; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; BRINTON MA, 1988, VIROLOGY, V162, P290, DOI 10.1016/0042-6822(88)90468-0; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Corver J, 2003, J VIROL, V77, P2265, DOI 10.1128/JVI.77.3.2265-2270.2003; Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213; De Nova-Ocampo M, 2002, VIROLOGY, V295, P337, DOI 10.1006/viro.2002.1407; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; HAHN CS, 1987, J MOL BIOL, V198, P33, DOI 10.1016/0022-2836(87)90455-4; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Khromykh AA, 2001, J VIROL, V75, P6719, DOI 10.1128/JVI.75.14.6719-6728.2001; Kim DW, 1997, VIRUS RES, V49, P17, DOI 10.1016/S0168-1702(97)01452-4; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Kuo MD, 1996, J GEN VIROL, V77, P2077, DOI 10.1099/0022-1317-77-9-2077; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Lo MK, 2003, J VIROL, V77, P10004, DOI 10.1128/JVI.77.18.10004-10014.2003; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Lyons T, 2001, J VIROL, V75, P10696, DOI 10.1128/JVI.75.22.10696-10708.2001; Meek J, 2002, CURR OPIN PEDIATR, V14, P72, DOI 10.1097/00008480-200202000-00013; MEN R, 1996, J VIROL, V70, P3390; MOHAN PM, 1991, GENE, V108, P185, DOI 10.1016/0378-1119(91)90433-C; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Nomaguchi M, 2003, J VIROL, V77, P8831, DOI 10.1128/JVI.77.16.8831-8842.2003; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Rappole JH, 2000, EMERG INFECT DIS, V6, P319, DOI 10.3201/eid0604.000401; Reigadas S, 2001, EUR J BIOCHEM, V268, P5857, DOI 10.1046/j.0014-2956.2001.02532.x; RICE CM, 1996, FIELDS VIROLOGY, P931; Roehrig JT, 2002, CURR TOP MICROBIOL, V267, P223; ROZANOV MN, 1992, J GEN VIROL, V73, P2129, DOI 10.1099/0022-1317-73-8-2129; Shi PY, 1996, BIOCHEMISTRY-US, V35, P4222, DOI 10.1021/bi952398v; Shi PY, 1996, J VIROL, V70, P6278, DOI 10.1128/JVI.70.9.6278-6287.1996; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; WESTAWAY EG, 1968, J IMMUNOL, V100, P569; Westaway EG, 2002, CURR TOP MICROBIOL, V267, P323; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yocupicio-Monroy RME, 2003, J VIROL, V77, P3067, DOI 10.1128/JVI.77.5.3067-3076.2003; You S, 1999, J BIOL CHEM, V274, P33714, DOI 10.1074/jbc.274.47.33714; You SY, 2001, J BIOL CHEM, V276, P15581, DOI 10.1074/jbc.M010923200; Zeng LL, 1998, J VIROL, V72, P7510, DOI 10.1128/JVI.72.9.7510-7522.1998	60	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12141	12151		10.1074/jbc.M310839200	http://dx.doi.org/10.1074/jbc.M310839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699096	hybrid			2022-12-27	WOS:000220334900020
J	Street, A; Macdonald, A; Crowder, K; Harris, M				Street, A; Macdonald, A; Crowder, K; Harris, M			The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN; FULL-LENGTH; CDNA-CLONE; PATHWAY; PHOSPHORYLATION; KINASE; TARGET; NEF; TRANSFORMATION; REPLICATION	Hepatitis C virus (HCV) establishes a persistent infection, with up to 80% of infected individuals proceeding to chronic hepatitis, which in many cases may result in liver cirrhosis and hepatocellular carcinoma (HCC); indeed HCV infection is increasingly associated with the development of HCC. The long time period (up to 30 years) between primary infection and the onset of HCC implies that HCV is not directly oncogenic but in some way predisposes patients to develop tumors, though the mechanism for this is unclear as yet. We report here that NS5A binds directly to the Src homology 3 domain of the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), and this interaction is mediated by a novel (non-proline-rich) motif within NS5A. Coimmunoprecipitation analysis revealed that NS5A bound native heterodimeric PI3K and enhanced the phosphotransferase activity of the catalytic ( p110) subunit both in vitro and in human cell lines harboring a subgenomic HCV replicon or expressing NS5A alone. NS5A-mediated activation of PI3K resulted in increased phosphorylation and activity of Akt/protein kinase B and concomitantly provided protection against the induction of apoptosis in both replicon-harboring cells and cells stably expressing NS5A alone. These data suggest that stimulation of PI3K by NS5A may represent an indirect mechanism for development of HCC in HCV-infected patients and further suggests potential therapeutic strategies to counteract the occurrence of HCV-related HCC.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Harris, M (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Mt Preston St, Leeds LS2 9JT, W Yorkshire, England.	mharris@bmb.leeds.ac.uk		Harris, Mark/0000-0002-9821-1003; Macdonald, Andrew/0000-0002-5978-4693				Aoubala M, 2001, J GEN VIROL, V82, P1637, DOI 10.1099/0022-1317-82-7-1637; Bartenschlager R, 1999, J VIRAL HEPATITIS, V6, P165, DOI 10.1046/j.1365-2893.1999.00152.x; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; He YP, 2003, J GEN VIROL, V84, P535, DOI 10.1099/vir.0.18658-0; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kim WR, 2002, HEPATOLOGY, V36, pS30, DOI 10.1053/jhep.2002.36791; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Linnemann T, 2002, VIROLOGY, V294, P246, DOI 10.1006/viro.2002.1365; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Macdonald A, 2003, J BIOL CHEM, V278, P17775, DOI 10.1074/jbc.M210900200; McCormick CJ, 2002, J GEN VIROL, V83, P383, DOI 10.1099/0022-1317-83-2-383; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sekulic A, 2000, CANCER RES, V60, P3504; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1999, VIROLOGY, V262, P250, DOI 10.1006/viro.1999.9889; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yeung MC, 2002, BIOTECHNIQUES, V33, P734, DOI 10.2144/02334bm03	36	171	183	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12232	12241		10.1074/jbc.M312245200	http://dx.doi.org/10.1074/jbc.M312245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709551	hybrid			2022-12-27	WOS:000220334900029
J	Tan, L; Qiu, F; Lamport, DTA; Kieliszewski, MJ				Tan, L; Qiu, F; Lamport, DTA; Kieliszewski, MJ			Structure of a hydroxyproline (Hyp)-arabinogalactan polysaccharide from repetitive Ala-Hyp expressed in transgenic Nicotiana tabacum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLYCOSYLATION CODES; ARABINOGALACTAN-PROTEINS; CELL-WALL; ACACIA-SENEGAL; EXTRACELLULAR-MATRIX; MASS-SPECTROMETRY; GUM EXUDATE; GLYCOPROTEIN; ARABINOSYLATION; CHLAMYDOMONAS	A synthetic gene encoding the fusion protein (Ala-Hyp) (51)-enhanced green fluorescent protein expressed in Nicotiana tabacum cells produced a fusion glycoprotein with all proline residues hydroxylated and substituted with an arabinogalactan polysaccharide. Alkaline hydrolysis of the fusion glycoprotein yielded a population of hydroxyproline (Hyp)-arabinogalactan polysaccharides ranging in size from 13 to 26 saccharide residues/Hyp, with a median size of 15 - 17 residues. We isolated a 15-residue Hyp-arabinogalactan for structure determination by sugar analyses and one- and two-dimensional nuclear magnetic resonance techniques that provided the assignment of proton and carbon signals of a small polysaccharide O-linked to the hydroxyl group of Hyp. The polysaccharide consisted of a 1,3-linked beta-D-Galp backbone with a single 1,6-linked beta-D-Galp "kink.'' The backbone had two side chains of Galp substituted at position 3 with an arabinose di- or trisaccharide and at position 6 with glucuronic acid or rhamnosyl glucuronic acid. Energy-minimized space-filling molecular models showed hydrogen bonding within polysaccharides attached to repetitive Ala-Hyp and also between polysaccharides and the peptide backbone. Polysaccharides distorted the peptide Ramachandran angles consistent with the circular dichroic spectra of isolated ( Ala-Hyp) 51 and its reversion to a polyproline II-like helix after deglycosylation. This first complete structure of a Hyp-arabinogalactan polysaccharide shows that computer-based molecular modeling of Hyp-rich glycoproteins is now feasible and supports the suggestion that small repetitive subunits comprise larger arabinogalactan polysaccharides.	Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA; Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA; Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England	University System of Ohio; Ohio University; Oklahoma State University System; Oklahoma State University - Stillwater; University of Sussex	Kieliszewski, MJ (corresponding author), Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA.	kielisze@helios.phy.ohiou.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [2P41 RR 05351-06] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA Y, 1980, AGR BIOL CHEM TOKYO, V44, P2487, DOI 10.1080/00021369.1980.10864347; AKIYAMA Y, 1981, PHYTOCHEMISTRY, V20, P2507, DOI 10.1016/0031-9422(81)83083-X; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BACIC A, 1988, PHYTOCHEMISTRY, V27, P679, DOI 10.1016/0031-9422(88)84074-3; BACIC A, 1987, CARBOHYD RES, V162, P85, DOI 10.1016/0008-6215(87)80203-3; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; CHURMS SC, 1983, CARBOHYD RES, V123, P267, DOI 10.1016/0008-6215(83)88483-3; CHURMS SC, 1984, CARBOHYD RES, V133, P105, DOI 10.1016/0008-6215(84)85187-3; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DEFAYE J, 1986, CARBOHYD RES, V150, P221, DOI 10.1016/0008-6215(86)80018-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du H, 1996, TRENDS CELL BIOL, V6, P411, DOI 10.1016/S0962-8924(96)20036-4; El Khadem H. S., 1988, CARBOHYDRATE CHEM, P1; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; GAMMON DW, 1986, CARBOHYD RES, V154, P289, DOI 10.1016/S0008-6215(00)90043-0; Gaspar Y, 2001, PLANT MOL BIOL, V47, P161, DOI 10.1023/A:1010683432529; Gens JS, 2000, PROTOPLASMA, V212, P115, DOI 10.1007/BF01279353; GOODENOUGH UW, 1988, J CELL SCI, V90, P717; HAYASHI T, 1984, BIOCHEM J, V217, P719; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karacsonyi S, 1998, CARBOHYD RES, V307, P271, DOI 10.1016/S0008-6215(98)00052-4; Kawaguchi K, 1996, PLANT J, V9, P777, DOI 10.1046/j.1365-313X.1996.9060777.x; KIELISZEWSKI MJ, 1995, J BIOL CHEM, V270, P2541, DOI 10.1074/jbc.270.6.2541; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; KUPCE E, 1995, J MAGN RESON SER A, V115, P273, DOI 10.1006/jmra.1995.1179; Lamport DTA, 2001, CELL MOL LIFE SCI, V58, P1363, DOI 10.1007/PL00000782; Lamport DTA, 1977, RECENT ADV PHYTOCHEM, V11, P79; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; MILLER DH, 1972, SCIENCE, V176, P918, DOI 10.1126/science.176.4037.918; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; Oxley D, 1999, P NATL ACAD SCI USA, V96, P14246, DOI 10.1073/pnas.96.25.14246; Phillips GO, 1996, FOOD HYDROCOLLOID, V10, P11, DOI 10.1016/S0268-005X(96)80048-8; POLLE AY, 2003, J BIOORG CHEM, V27, P45; POPE DG, 1977, PLANT PHYSIOL, V59, P894, DOI 10.1104/pp.59.5.894; QI W, 1991, PLANT PHYSIOL, V96, P848, DOI 10.1104/pp.96.3.848; Roy S, 1998, PLANTA, V204, P450, DOI 10.1007/s004250050279; SAULNIER L, 1995, CARBOHYD POLYM, V26, P279, DOI 10.1016/0144-8617(95)00020-8; SAULNIER L, 1992, CARBOHYD RES, V224, P219, DOI 10.1016/0008-6215(92)84108-5; SERPE MD, 1995, PLANT PHYSIOL, V109, P1007, DOI 10.1104/pp.109.3.1007; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; Sherrier DJ, 1999, ELECTROPHORESIS, V20, P2027, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2027::AID-ELPS2027>3.0.CO;2-A; Shpak E, 1999, P NATL ACAD SCI USA, V96, P14736, DOI 10.1073/pnas.96.26.14736; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; Stapley BJ, 1999, PROTEIN SCI, V8, P587; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Sumper M, 1998, INT REV CYTOL, V180, P51; Svetek J, 1999, J BIOL CHEM, V274, P14724, DOI 10.1074/jbc.274.21.14724; Tan L, 2003, PLANT PHYSIOL, V132, P1362, DOI 10.1104/pp.103.021766; TAUTVYDAS KJ, 1978, PLANTA, V140, P213, DOI 10.1007/BF00390250; TSUMURAYA Y, 1988, PLANT PHYSIOL, V86, P155, DOI 10.1104/pp.86.1.155; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; Youl JJ, 1998, P NATL ACAD SCI USA, V95, P7921, DOI 10.1073/pnas.95.14.7921; Zhao ZD, 2002, PLANT J, V31, P431, DOI 10.1046/j.1365-313X.2002.01365.x	53	117	119	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13156	13165		10.1074/jbc.M311864200	http://dx.doi.org/10.1074/jbc.M311864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724279	hybrid			2022-12-27	WOS:000220334900137
J	Fiory, F; Oriente, F; Miele, C; Romano, C; Trencia, A; Alberobello, AT; Esposito, I; Valentino, R; Beguinot, F; Formisano, P				Fiory, F; Oriente, F; Miele, C; Romano, C; Trencia, A; Alberobello, AT; Esposito, I; Valentino, R; Beguinot, F; Formisano, P			Protein kinase C-zeta and protein kinase B regulate distinct steps of insulin endocytosis and intracellular sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION; RECEPTOR; PHOSPHORYLATION; INTERNALIZATION; AUTOPHOSPHORYLATION; ACTIVATION	We have investigated the molecular mechanisms regulating insulin internalization and intracellular sorting. Insulin internalization was decreased by 50% upon incubation of the cells with the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002. PI3K inhibition also reduced insulin degradation and intact insulin release by 50 and 75%, respectively. Insulin internalization was reduced by antisense inhibition of protein kinase C-zeta(PKCzeta) expression and by overexpression of a dominant negative PKCzeta mutant (DN-PKCzeta). Conversely, overexpression of PKCzeta increased insulin internalization as a function of the PKCzeta levels achieved in the cells. Expression of wild-type protein kinase B (PKB)-alpha or of a constitutively active form (myr-PKB) did not significantly alter insulin internalization and degradation but produced a 100% increase of intact insulin release. Inhibition of PKB by a dominant negative mutant (DN-PKB) or by the pharmacological inhibitor ML-9 reduced intact insulin release by 75% with no effect on internalization and degradation. In addition, overexpression of Rab5 completely rescued the effect of PKCzeta inhibition on insulin internalization but not that of PKB inhibition on intact insulin recycling. Indeed, PKCzeta bound to and activated Rab5. Thus, PI3K controls different steps within the insulin endocytic itinerary. PKCzeta appears to mediate the PI3K effect on insulin internalization in a Rab5-dependent manner, whereas PKB directs intracellular sorting toward intact insulin release.	Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via S Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Braiman L, 2001, MOL CELL BIOL, V21, P7852, DOI 10.1128/MCB.21.22.7852-7861.2001; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; Braiman L, 2001, MOL ENDOCRINOL, V15, P565, DOI 10.1210/me.15.4.565; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Caruso M, 2000, DIABETES, V49, P1194, DOI 10.2337/diabetes.49.7.1194; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Cormont M, 1996, ENDOCRINOLOGY, V137, P3408, DOI 10.1210/en.137.8.3408; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; MARSHALL S, 1987, J BIOL CHEM, V262, P12005; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MCCLAIN DA, 1992, AM J MED SCI, V304, P192, DOI 10.1097/00000441-199209000-00009; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; THIES RS, 1990, J BIOL CHEM, V265, P10132; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301	49	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11137	11145		10.1074/jbc.M308751200	http://dx.doi.org/10.1074/jbc.M308751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711831	hybrid			2022-12-27	WOS:000220157600038
J	Katagiri, K; Shimonaka, M; Kinashi, T				Katagiri, K; Shimonaka, M; Kinashi, T			Rap1-mediated lymphocyte function-associated antigen-1 activation by the T cell antigen receptor is dependent on phospholipase C-gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ACTIVATION; RAP1-INDUCED ADHESION; SIGNAL-TRANSDUCTION; SMALL GTPASE; RAP1; MEGAKARYOCYTES; C-GAMMA-1; MIGRATION; RESPONSES; DISTINCT	The small GTPase, Rap1, is a potent activator of leukocyte integrins and enhances the adhesive activity of lymphocyte function-associated antigen-1 (LFA-1) when stimulated by the T cell receptor (TCR) or chemokines. However, the mechanism by which Rap1 is activated remains unclear. Here, we demonstrate that phospholipase C ( PLC)-gamma1 plays a critical role in the signaling pathway leading to Rap1 activation triggered by the TCR. In Jurkat T cells, TCR cross-linking triggered persistent Rap1 activation, and SDF-1 (CXCL12) activated Rap1 transiently. A phospholipase C inhibitor, U73122, abrogated Rap1 activation triggered by both the TCR and SDF-1 ( CXCL12). PLC-gamma1-deficient Jurkat T cells showed a marked reduction of TCR-triggered Rap1 activation and adhesion to intercellular adhesion molecule-1 (ICAM-1) mediated by LFA-1. In contrast, SDF-1-triggered Rap1 activation and adhesion were not affected in these cells. Transfection of these cells with an expression plasmid encoding PLC-gamma1 restored Rap1 activation by the TCR and the ability to adhere to ICAM-1, accompanied by polarized LFA-1 surface clustering colocalized with regulator of adhesion and polarization enriched in lymphoid tissues (RAPL). Furthermore, when expressed in Jurkat cells, CalDAG-GEFI, a calcium and diacylglycerol-responsive Rap1 exchange factor, associated with Rap1, and resulted in enhanced Rap1 activation and adhesion triggered by the TCR. Our results demonstrate that TCR activation of Rap1 depends on PLC-gamma1. This activity is likely to be mediated by CalDAG-GEFI, which is required to activate LFA-1.	Kyoto Univ, Grad Sch Med, Bayer Chair Dept Mol Immunol & Allergy, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Kinashi, T (corresponding author), Kyoto Univ, Grad Sch Med, Bayer Chair Dept Mol Immunol & Allergy, Sakyo Ku, Kyoto 6068501, Japan.	tkinashi@mfour.med.kyoto-u.ac.jp						Abraham RT, 2003, NAT IMMUNOL, V4, P725, DOI 10.1038/ni0803-725; Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; de Bruyn KMT, 2003, J BIOL CHEM, V278, P22412, DOI 10.1074/jbc.M212036200; Epler JA, 2000, J IMMUNOL, V165, P4941, DOI 10.4049/jimmunol.165.9.4941; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McLeod S J, 2001, Int Rev Immunol, V20, P763, DOI 10.3109/08830180109045589; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sanui T, 2003, IMMUNITY, V19, P119, DOI 10.1016/S1074-7613(03)00169-9; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Wu DQ, 2000, J CELL SCI, V113, P2935	32	85	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11875	11881		10.1074/jbc.M310717200	http://dx.doi.org/10.1074/jbc.M310717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702343	hybrid			2022-12-27	WOS:000220157600124
J	Xing, L; Huhtala, M; Pietiainen, V; Kapyla, J; Vuorinen, K; Marjomaki, V; Heino, J; Johnson, MS; Hyypia, T; Cheng, RH				Xing, L; Huhtala, M; Pietiainen, V; Kapyla, J; Vuorinen, K; Marjomaki, V; Heino, J; Johnson, MS; Hyypia, T; Cheng, RH			Structural and functional analysis of integrin alpha I-2 domain interaction with echovirus 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; DEPENDENT ADHESION SITE; INTEGRIN ALPHA-2 BETA-1; I-DOMAIN; CELLULAR RECEPTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; VITRONECTIN RECEPTOR; PICORNAVIRUS GROUP; COXSACKIEVIRUS A9	Integrins are cell surface receptors for several microbial pathogens including echovirus 1 (EV1), a picornavirus. Cryo-electron microscopy revealed that the functional domain (alpha(2)I) of human alpha(2)beta(1) integrin binds to a surface depression on the EV1 capsid. This three-dimensional structure of EV1 bound to alpha(2)I domain provides the first structural details of an integrin interacting with a picornavirus. The model indicates that alpha(2)beta(1) integrin cannot simultaneously bind both EV1 and the physiological ligand collagen. Compared with collagen binding to the alpha(2)I domain, the virus binds with a 10-fold higher affinity but in vitro uncoating of EV1 was not observed as a result of attachment of alpha(2)I. A molecular model, constructed on the basis of the EV1-integrin complex, shows that multiple alpha(2)beta(1) heterodimers can bind at adjacent sites around the virus 5-fold symmetry axes without steric hindrance. In agreement with this, virus attachment to alpha(2)beta(1) integrin on the cell surface was found to result in integrin clustering, which can give rise to signaling and facilitate the initiation of the viral entry process that takes place via caveolae-mediated endocytosis.	Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Abo Akad Univ, Dept Biochem & Pharm, SF-20500 Turku, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Jyvaskyla, Dept Cell Biol, SF-40351 Jyvaskyla, Finland; Univ Oulu, Dept Med Microbiol, Oulu 90014, Finland	Karolinska Institutet; Abo Akademi University; University of Helsinki; University of Jyvaskyla; University of Oulu	Cheng, RH (corresponding author), Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.	rhch@ucdavis.edu	Cheng, Holland/A-8973-2008	Marjomaki, Varpu/0000-0002-4592-5926; Pietiainen, Vilja/0000-0003-3125-2406; Kapyla, Jarmo/0000-0003-3036-713X; Huhtala, Mikko/0000-0001-6070-7604				Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; CHANG KH, 1989, J GEN VIROL, V70, P3269, DOI 10.1099/0022-1317-70-12-3269; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Filman DJ, 1998, ACTA CRYSTALLOGR D, V54, P1261, DOI 10.1107/S0907444998002790; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; Grist N R, 1978, Prog Med Virol, V24, P114; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; He YN, 2000, P NATL ACAD SCI USA, V97, P79, DOI 10.1073/pnas.97.1.79; Hendry E, 1999, STRUCT FOLD DES, V7, P1527, DOI 10.1016/S0969-2126(00)88343-4; Hewat EA, 2000, EMBO J, V19, P6317, DOI 10.1093/emboj/19.23.6317; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAPLAN G, 1990, J VIROL, V64, P4697, DOI 10.1128/JVI.64.10.4697-4702.1990; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nemerow GR, 1999, MICROBIOL MOL BIOL R, V63, P725, DOI 10.1128/MMBR.63.3.725-734.1999; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; Rossmann MG, 2002, TRENDS MICROBIOL, V10, P324, DOI 10.1016/S0966-842X(02)02383-1; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Xing L, 2000, EMBO J, V19, P1207, DOI 10.1093/emboj/19.6.1207; Xing L, 2003, J VIROL, V77, P6101, DOI 10.1128/JVI.77.11.6101-6107.2003; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zimmermann H, 1997, VIROLOGY, V233, P149, DOI 10.1006/viro.1997.8601	46	45	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11632	11638		10.1074/jbc.M312441200	http://dx.doi.org/10.1074/jbc.M312441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701832	hybrid			2022-12-27	WOS:000220157600097
J	Dementin, S; Burlat, B; De Lacey, AL; Pardo, A; Adryanczyk-Perrier, G; Guigliarelli, B; Fernandez, VM; Rousset, M				Dementin, S; Burlat, B; De Lacey, AL; Pardo, A; Adryanczyk-Perrier, G; Guigliarelli, B; Fernandez, VM; Rousset, M			A glutamate is the essential proton transfer gate during the catalytic cycle of the [NiFe] hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-GIGAS HYDROGENASE; SITE-DIRECTED MUTAGENESIS; DENSITY-FUNCTIONAL THEORY; NICKEL-IRON HYDROGENASE; ACTIVE-SITE; CRYSTAL-STRUCTURE; FE HYDROGENASES; KINETIC CHARACTERIZATION; ANGSTROM RESOLUTION; CARBON-MONOXIDE	Kinetic, EPR, and Fourier transform infrared spectroscopic analysis of Desulfovibrio fructosovorans [NiFe] hydrogenase mutants targeted to Glu-25 indicated that this amino acid participates in proton transfer between the active site and the protein surface during the catalytic cycle. Replacement of that glutamic residue by a glutamine did not modify the spectroscopic properties of the enzyme but cancelled the catalytic activity except the para-H-2/ortho-H-2 conversion. This mutation impaired the fast proton transfer from the active site that allows high turnover numbers for the oxidation of hydrogen. Replacement of the glutamic residue by the shorter aspartic acid slowed down this proton transfer, causing a significant decrease of H-2 oxidation and hydrogen isotope exchange activities, but did not change the para-H-2/ortho-H-2 conversion activity. The spectroscopic properties of this mutant were totally different, especially in the reduced state in which a non-photosensitive nickel EPR spectrum was obtained.	CNRS, Unite Bioenerget & Ingn Prot, Inst Biol Struct & Microbiol, F-13402 Marseille 20, France; CSIC, Inst Catalisis, Madrid 28049, Spain	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP)	Rousset, M (corresponding author), CNRS, Unite Bioenerget & Ingn Prot, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	rousset@ibsm.cnrs-mrs.fr	De Lacey, Antonio L/H-3311-2015	De Lacey, Antonio L/0000-0002-9347-0452; Dementin, Sebastien/0000-0001-6168-5371				ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Amara P, 1999, J AM CHEM SOC, V121, P4468, DOI 10.1021/ja983971b; Bertrand P, 2000, J BIOL INORG CHEM, V5, P682, DOI 10.1007/s007750000152; Bleijlevens B, 2001, J BIOL INORG CHEM, V6, P763, DOI 10.1007/s007750100252; Burgdorf T, 2002, J BACTERIOL, V184, P6280, DOI 10.1128/JB.184.22.6280-6288.2002; BUTT JN, 1993, J AM CHEM SOC, V115, P12587, DOI 10.1021/ja00079a049; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; CAMMACK R, 2001, HYDROGEN FUEL, P159; Carepo M, 2002, J AM CHEM SOC, V124, P281, DOI 10.1021/ja010204v; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; Darensbourg MY, 2000, COORDIN CHEM REV, V206, P533, DOI 10.1016/S0010-8545(00)00268-X; De Gioia L, 1999, INORG CHEM, V38, P2658, DOI 10.1021/ic9811446; De Lacey AL, 2000, BBA-PROTEIN STRUCT M, V1481, P371, DOI 10.1016/S0167-4838(00)00180-1; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; DeLacey AL, 2003, J BIOL INORG CHEM, V8, P129, DOI 10.1007/s00775-002-0397-4; DeLacey AL, 2002, J BIOL INORG CHEM, V7, P318, DOI 10.1007/s00775-001-0301-7; Dole F, 1996, BIOCHEMISTRY-US, V35, P16399, DOI 10.1021/bi961662x; Dole F, 1997, BIOCHEMISTRY-US, V36, P7847, DOI 10.1021/bi963171i; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; FERNANDEZ VM, 1985, BIOCHIM BIOPHYS ACTA, V832, P69, DOI 10.1016/0167-4838(85)90175-X; Fontecilla-Camps J. C., 2001, HYDROGEN FUEL, P93; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; Goldman CM, 1995, COMMENT INORG CHEM, V18, P1, DOI 10.1080/02603599508033861; GUIGLIARELLI B, 1995, BIOCHEMISTRY-US, V34, P4781, DOI 10.1021/bi00014a036; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; Hartmann GC, 1996, J BIOL INORG CHEM, V1, P446, DOI 10.1007/s007750050077; Higuchi Y, 1999, STRUCT FOLD DES, V7, P549, DOI 10.1016/S0969-2126(99)80071-9; Higuchi Y, 1999, BIOCHEM BIOPH RES CO, V255, P295, DOI 10.1006/bbrc.1999.0210; KRASNA AI, 1954, J AM CHEM SOC, V76, P3015, DOI 10.1021/ja01640a045; Maroney MJ, 2001, J BIOL INORG CHEM, V6, P453, DOI 10.1007/s007750100225; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; Medina M, 1996, BBA-BIOENERGETICS, V1275, P227, DOI 10.1016/0005-2728(96)00007-2; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; MOURA JJG, 1982, BIOCHEM BIOPH RES CO, V108, P1388, DOI 10.1016/S0006-291X(82)80060-0; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Ogata H, 2002, J AM CHEM SOC, V124, P11628, DOI 10.1021/ja012645k; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; Rousset M, 1998, PLASMID, V39, P114, DOI 10.1006/plas.1997.1321; ROUSSET M, 1991, MOL MICROBIOL, V5, P1735, DOI 10.1111/j.1365-2958.1991.tb01922.x; Sellmann D, 2000, ANGEW CHEM INT EDIT, V39, P561, DOI 10.1002/(SICI)1521-3773(20000204)39:3<561::AID-ANIE561>3.0.CO;2-3; Volbeda A, 2002, INT J HYDROGEN ENERG, V27, P1449, DOI 10.1016/S0360-3199(02)00072-1; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; WILLIAMS RJP, 1995, NATURE, V376, P643, DOI 10.1038/376643a0; YAGI T, 1973, J BIOCHEM-TOKYO, V73, P1069, DOI 10.1093/oxfordjournals.jbchem.a130161	47	111	114	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10508	10513		10.1074/jbc.M312716200	http://dx.doi.org/10.1074/jbc.M312716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688251				2022-12-27	WOS:000220050400103
J	Honda, S; Marumoto, T; Hirota, T; Nitta, M; Arima, Y; Ogawa, M; Saya, H				Honda, S; Marumoto, T; Hirota, T; Nitta, M; Arima, Y; Ogawa, M; Saya, H			Activation of m-calpain is required for chromosome alignment on the metaphase plate during mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CHROMOKINESIN KID; CYSTEINE PROTEASE; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; MAMMALIAN-CELLS; INHIBITOR; CALCIUM; COMPLEX; KINETOCHORES	Calpains form a superfamily of Ca2+-dependent intracellular cysteine proteases with various isoforms. Two isoforms, mu- and m-calpains, are ubiquitously expressed and known as conventional calpains. It has been previously shown that the mammalian calpains are activated during mitosis by transient increases in cytosolic Ca2+ concentration. However, it is still unknown whether the activation of calpains contributes to particular events in mitosis. With the use of RNA interference (RNAi), we investigated the roles of calpains in mitosis. Cells reduced the levels of m- calpain, but not mu-calpain, arrested at prometaphase and failed to align their chromosomes at the spindle equator. Specific peptidyl calpain inhibitors also induced aberrant mitosis with chromosome misalignment. Although both m- calpain RNAi and calpain inhibitors affected neither the separation of centrosomes nor the assembly of bipolar spindles, Mad2 was detected on the kinetochores of the misaligned chromosomes, indicating that the prometaphase arrest induced by calpain inhibition is due to activation of the spindle assembly checkpoint. Furthermore, when calpain activity was inhibited in cells having monopolar spindles, chromosomes were clustered adjacent to the centrosome, suggesting that calpain activity is involved in a polar ejection force for metaphase alignment of chromosomes. Based on these findings, we propose that activation of m- calpain during mitosis is required for cells to establish the chromosome alignment by regulating some molecules that generate polar ejection force.	Kumamoto Univ, Dept Tumor Genet & Biol, Grad Sch Med Sci, Kumamoto 8608556, Japan; Kumamoto Univ, Dept Surg Gastroenterol, Grad Sch Med Sci, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Dept Tumor Genet & Biol, Grad Sch Med Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Arima, Yoshimi/J-8057-2013	Arima, Yoshimi/0000-0002-2384-1406				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bhatt A, 2002, J CELL SCI, V115, P3415; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Kapoor TM, 2002, J CELL BIOL, V157, P551, DOI 10.1083/jcb.200202073; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Nitta M, 2002, GENES CELLS, V7, P151, DOI 10.1046/j.1356-9597.2001.00509.x; Ohsugi M, 2003, EMBO J, V22, P2091, DOI 10.1093/emboj/cdg208; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Santella L, 2000, EXP CELL RES, V259, P117, DOI 10.1006/excr.2000.4969; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; Yajima J, 2003, EMBO J, V22, P1067, DOI 10.1093/emboj/cdg102; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	30	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10615	10623		10.1074/jbc.M308841200	http://dx.doi.org/10.1074/jbc.M308841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688278	hybrid			2022-12-27	WOS:000220050400115
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Analysis of transmembrane segment 8 of the GLUT1 glucose transporter by cysteine-scanning mutagenesis and substituted cysteine accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR-TRANSPORT; EXOFACIAL LIGAND-BINDING; XENOPUS-OOCYTES; PERMEATION PATHWAY; ESCHERICHIA-COLI; SYSTEM; FAMILY; SITE; MECHANISM; KINETICS	The GLUT1 glucose transporter has been proposed to form an aqueous substrate translocation pathway via the clustering of several amphipathic transmembrane helices (Mueckler, M., Caruso, C., Baldwin, S. A., Panico, M., Blench, I., Morris, H. R., Allard, W. J., Lienhard, G. E., and Lodish, H. F. (1985) Science 229, 941-945). The possible role of transmembrane helix 8 in the formation of this permeation pathway was investigated using cysteine-scanning mutagenesis and the membrane-impermeant sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS). Twenty-one GLUT1 mutants were created from a fully functional cysteine-less parental GLUT1 molecule by successively changing each residue along transmembrane segment 8 to a cysteine. The mutant proteins were then expressed in Xenopus oocytes, and their membrane concentrations, 2-deoxyglucose uptake activities, and sensitivities to pCMBS were determined. Four positions within helix 8, alanine 309, threonine 310, serine 313, and glycine 314, were accessible to pCMBS as judged by the inhibition of transport activity. All four of these residues are clustered along one face of a putative alpha-helix. These results suggest that transmembrane segment 8 of GLUT1 forms part of the sugar permeation pathway. Updated two-dimensional models for the orientation of the 12 transmembrane helices and the conformation of the exofacial glucose binding site of GLUT1 are proposed that are consistent with existing experimental data and homology modeling based on the crystal structures of two bacterial membrane transporters.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; VIDAVER GA, 1966, J THEOR BIOL, V10, P301, DOI 10.1016/0022-5193(66)90128-7; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6	33	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10494	10499		10.1074/jbc.M310786200	http://dx.doi.org/10.1074/jbc.M310786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688257	hybrid			2022-12-27	WOS:000220050400101
J	Qiu, Y; Guo, M; Huang, SM; Stein, R				Qiu, Y; Guo, M; Huang, SM; Stein, R			Acetylation of the BETA2 transcription factor by p300-associated factor is important in insulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; HISTONE ACETYLATION; HOMEODOMAIN PROTEIN; ENHANCER ACTIVITY; FACTOR GATA-1; P300; DIFFERENTIATION; ACTIVATION; CELLS	The BETA2 transcription factor influences islet beta cell development and function. Activation of insulin gene transcription by this member of the basic helix-loop-elix gene family is mediated by p300 through the ability of this coactivator to form a functional bridge between the basal transcriptional apparatus, BETA2, and PDX-1, another key transcription factor. In this report, we examined whether BETA2-mediated stimulation was also directly influenced by the acetyltransferase activities of p300 or the p300-associated factor. BETA2 was specifically and selectively acetylated by p300-associated factor in beta cells. Sites of BETA2 acetylation were found within the loop region of the basic helix-loop-elix DNA binding/dimerization domain and a more C-erminal region involved in activation. Insulin gene transcription was decreased by blocking acetylation of BETA2 because of effects on DNA binding and activation potential. These findings suggest that acetylation of BETA2 plays a role in controlling the activation state of this islet regulatory factor.	Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37215 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37215 USA.	roland.stein@mcmail.vanderbilt.edu		, Yi/0000-0002-3282-6072	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK055091, R01DK050203] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 50203, P60 DK20593, R01 DK55091] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eckner R, 1996, BIOL CHEM, V377, P685; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kristinsson SY, 2001, DIABETOLOGIA, V44, P2098, DOI 10.1007/s001250100016; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sharma A, 1999, MOL CELL BIOL, V19, P704; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STEIN R, 2001, HDB PHYSL 7, V2, P25; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	66	30	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9796	9802		10.1074/jbc.M307577200	http://dx.doi.org/10.1074/jbc.M307577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701848	hybrid			2022-12-27	WOS:000220050400018
J	Kovtun, IV; Welch, G; Guthrie, HD; Hafner, KL; McMurray, CT				Kovtun, IV; Welch, G; Guthrie, HD; Hafner, KL; McMurray, CT			CAG repeat lengths in X- and Y-bearing sperm indicate that gender bias during transmission of Huntington's disease gene is determined in the embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOW CYTOMETRIC SEPARATION; CHROMOSOME-BEARING; MUTATION; INSTABILITY; MOUSE; PRESELECTION; PHENOTYPE; EXPANSION; ATROPHY; LOCUS	The size of the CAG tract at the Huntington's disease (HD) locus upon transmission depends on the gender of the parent. However, the basis for the parent-of-origin effect is unknown. To test whether expansion and contraction in HD are "imprinted" in the germ cells, we isolated the X- and Y-bearing sperm of HD transgenic mice. Here we show that CAG repeat distributions in the X- and Y-bearing spermatozoa of founding fathers do not differ. These data show that gender-dependent changes in CAG repeat length arise in the embryo.	Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Cytogenet, Rochester, MN 55905 USA; USDA, Germplasm & Gamete Physiol Lab, Beltsville, MD 20705 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; United States Department of Agriculture (USDA)	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.	mcmurray.cynthia@mayo.edu	Kovtun, Irina/ABA-8484-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040738] Funding Source: NIH RePORTER; NINDS NIH HHS [NS4073802S1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Giovannone B, 1997, HUM MUTAT, V10, P458, DOI 10.1002/(SICI)1098-1004(1997)10:6<458::AID-HUMU7>3.0.CO;2-9; Ikeuchi T, 1996, AM J HUM GENET, V58, P730; JOHNSON LA, 1993, HUM REPROD, V8, P1733, DOI 10.1093/oxfordjournals.humrep.a137925; Johnson LA, 1995, REPROD FERT DEVELOP, V7, P893, DOI 10.1071/RD9950893; Kennedy L, 2003, HUM MOL GENET, V12, P3359, DOI 10.1093/hmg/ddg352; Kennedy L, 2000, HUM MOL GENET, V9, P2539, DOI 10.1093/hmg/9.17.2539; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kovtun IV, 2000, HUM MOL GENET, V9, P2767, DOI 10.1093/hmg/9.18.2767; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; Leeflang EP, 1999, HUM MOL GENET, V8, P173, DOI 10.1093/hmg/8.2.173; Leeflang EP, 1996, AM J HUM GENET, V59, P896; Malter HE, 1997, NAT GENET, V15, P165, DOI 10.1038/ng0297-165; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Rens W, 1998, CYTOMETRY, V33, P476, DOI 10.1002/(SICI)1097-0320(19981201)33:4<476::AID-CYTO12>3.0.CO;2-B; REYNIERS E, 1993, NAT GENET, V4, P143, DOI 10.1038/ng0693-143; RIDLEY RM, 1988, J MED GENET, V25, P589, DOI 10.1136/jmg.25.9.589; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; Zhang Y, 2002, HUM MOL GENET, V11, P791, DOI 10.1093/hmg/11.7.791	22	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9389	9391		10.1074/jbc.M313080200	http://dx.doi.org/10.1074/jbc.M313080200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688268	hybrid			2022-12-27	WOS:000189265900103
J	Brown, SE; Cao, AT; Hines, ER; Akhurst, RJ; East, PD				Brown, SE; Cao, AT; Hines, ER; Akhurst, RJ; East, PD			A novel secreted protein toxin from the insect pathogenic bacterium Xenorhabdus nematophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORHABDUS-LUMINESCENS; SEQUENCE-ANALYSIS; BACILLUS-THURINGIENSIS; GENOME SEQUENCE; DELTA-ENDOTOXIN; IDENTIFICATION; GENES; NEMATODES; HETERORHABDITIS; PURIFICATION	The bacterium Xenorhabdus nematophila is an insect pathogen that produces several proteins that enable it to kill insects. Screening of a cosmid library constructed from X. nematophila strain A24 identified a gene that encoded a novel protein that was toxic to insects. The 42-kDa protein encoded by the toxin gene was expressed and purified from a recombinant system, and was shown to kill the larvae of insects such as Galleria mellonella and Helicoverpa armigera when injected at doses of around 30 - 40 ng/g larvae. Sequencing and bioinformatic analysis suggested that the toxin was a novel protein, and that it was likely to be part of a genomic island involved in pathogenicity. When the native bacteria were grown under laboratory conditions, a soluble form of the 42-kDa toxin was secreted only by bacteria in the phase II state. Preliminary histological analysis of larvae injected with recombinant protein suggested that the toxin primarily acted on the midgut of the insect. Finally, some of the common strategies used by the bacterial pathogens of insects, animals, and plants are discussed.	CSIRO Entomol, Acton, ACT 2601, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Brown, SE (corresponding author), CSIRO Entomol, GPO Box 1700, Acton, ACT 2601, Australia.	sue.brown@csiro.au	Brown, Susan/C-3123-2009; East, Peter/C-2352-2009					AKHURST R, 1993, NEMATODES AND THE BIOLOGICAL CONTROL OF INSECT PESTS, P127; Akhurst Raymond J., 1993, P1; AKHURST RJ, 1980, J GEN MICROBIOL, V121, P303; Akhurst RJ, 2003, J ECON ENTOMOL, V96, P1290, DOI 10.1603/0022-0493-96.4.1290; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Blackburn M, 1998, APPL ENVIRON MICROB, V64, P3036; BOEMARE NE, 1988, J GEN MICROBIOL, V134, P751; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; Bowen D, 2000, INSECT BIOCHEM MOLEC, V30, P69, DOI 10.1016/S0965-1748(99)00098-3; Bowen DJ, 1998, APPL ENVIRON MICROB, V64, P3029; BREHELIN M, 1993, J INVERTEBR PATHOL, V61, P188, DOI 10.1006/jipa.1993.1033; Brillard J, 2002, J BACTERIOL, V184, P3871, DOI 10.1128/JB.184.14.3871-3878.2002; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Burnell AM, 2000, NEMATOLOGY, V2, P31, DOI 10.1163/156854100508872; Campbell PM, 2001, INSECT BIOCHEM MOLEC, V31, P513, DOI 10.1016/S0965-1748(01)00035-2; Cao H, 2001, ANNU REV PHYTOPATHOL, V39, P259, DOI 10.1146/annurev.phyto.39.1.259; Collmer A, 2002, TRENDS MICROBIOL, V10, P462, DOI 10.1016/S0966-842X(02)02451-4; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Daborn PJ, 2002, P NATL ACAD SCI USA, V99, P10742, DOI 10.1073/pnas.102068099; Donnenberg MS, 2000, NATURE, V406, P768, DOI 10.1038/35021212; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; Ffrench-Constant R, 2003, FEMS MICROBIOL REV, V26, P433, DOI 10.1111/j.1574-6976.2003.tb00625.x; Ffrench-Constant RH, 2000, APPL ENVIRON MICROB, V66, P3310, DOI 10.1128/AEM.66.8.3310-3329.2000; Forst S, 1997, ANNU REV MICROBIOL, V51, P47, DOI 10.1146/annurev.micro.51.1.47; Forst S, 1996, MICROBIOL REV, V60, P21, DOI 10.1128/MMBR.60.1.21-43.1996; Guo LN, 1999, J BIOL CHEM, V274, P9836, DOI 10.1074/jbc.274.14.9836; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Haffani YZ, 2001, BIOTECHNOL PROGR, V17, P211, DOI 10.1021/bp000150d; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Heungens K, 2002, MOL MICROBIOL, V45, P1337, DOI 10.1046/j.1365-2958.2002.03100.x; Hilder VA, 1999, CROP PROT, V18, P177, DOI 10.1016/S0261-2194(99)00028-9; Hurst MRH, 2000, J BACTERIOL, V182, P5127, DOI 10.1128/JB.182.18.5127-5138.2000; Karim S, 2000, CURR MICROBIOL, V41, P214, DOI 10.1007/s002840010122; Keen N, 2000, P NATL ACAD SCI USA, V97, P8752, DOI 10.1073/pnas.97.16.8752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Morgan JAW, 2001, APPL ENVIRON MICROB, V67, P2062, DOI 10.1128/AEM.67.5.2062-2069.2001; Pan YH, 2002, PROG NAT SCI, V12, P310; Peel MM, 1999, J CLIN MICROBIOL, V37, P3647, DOI 10.1128/JCM.37.11.3647-3653.1999; Ryu K.G., 2000, BIOTECHNOL BIOPROC E, V5, P141, DOI [10.1007/BF02931886, DOI 10.1007/BF02931886]; Shea JE, 2000, CURR OPIN MICROBIOL, V3, P451, DOI 10.1016/S1369-5274(00)00120-X; Silverstein KAT, 2000, BIOINFORMATICS, V16, P1157, DOI 10.1093/bioinformatics/16.12.1157; SMIGIELSKI AJ, 1994, J INVERTEBR PATHOL, V64, P214, DOI 10.1016/S0022-2011(94)90225-9; Thaler JO, 1998, APPL ENVIRON MICROB, V64, P2367; Waterfield NR, 2002, TRENDS MICROBIOL, V10, P541, DOI 10.1016/S0966-842X(02)02463-0; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	48	47	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14595	14601		10.1074/jbc.M309859200	http://dx.doi.org/10.1074/jbc.M309859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14707137	hybrid, Green Published			2022-12-27	WOS:000220594700017
J	Munehira, Y; Ohnishi, T; Kawamoto, S; Furuya, A; Shitara, K; Imamura, M; Yokota, T; Takeda, S; Amachi, T; Matsuo, M; Kioka, N; Ueda, K				Munehira, Y; Ohnishi, T; Kawamoto, S; Furuya, A; Shitara, K; Imamura, M; Yokota, T; Takeda, S; Amachi, T; Matsuo, M; Kioka, N; Ueda, K			alpha 1-syntrophin modulates turnover of ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; REVERSE CHOLESTEROL TRANSPORT; STEROL REGULATORY ELEMENT; CELLULAR CHOLESTEROL; TANGIER-DISEASE; EXTRACELLULAR DOMAIN; DYSTROPHIN COMPLEX; LIPID EFFLUX; NITRIC-OXIDE; BINDING	ABCA1 (ATP-binding cassette transporter A1) mediates the release of cellular cholesterol and phospholipid to form high density lipoprotein. Functions of ABCA1 are highly regulated at the transcriptional and post-transcriptional levels, and the synthesized ABCA1 protein turns over rapidly with a half-life of 1 - 2 h. To examine whether the functions of ABCA1 are modulated by associated proteins, a yeast two-hybrid library was screened with the C-terminal 120 amino acids of ABCA1. Two PDZ (PSD95-Discs large-ZO1) proteins, alpha1-syntrophin and Lin7, were found to interact with ABCA1. Immunoprecipitation revealed that alpha1-syntrophin interacted with ABCA1 strongly and that the interaction was via the C-terminal three amino acids SYV of ABCA1. Co-expression of alpha1-syntrophin in human embryonic kidney 293 cells retarded degradation of ABCA1 and made the half-life of ABCA1 five times longer than in the cells not expressing alpha1-syntrophin. This effect is not common among PDZ-containing proteins interacting with ABCA1, because Lin7, which was also found to interact with the C terminus region of ABCA1, did not have a significant effect on the half-life of ABCA1. Co-expression of alpha1-syntrophin significantly increased the apoA-I-mediated release of cholesterol. ABCA1 was co-immunoprecipitated with alpha1-syntrophin from mouse brain. These results suggest that alpha1-syntrophin is involved in intracellular signaling, which determines the stability of ABCA1 and modulates cellular cholesterol release.	Kyoto Univ, Lab Cellular Biochem, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan	Kyoto University; Kyowa Kirin Ltd; National Center for Neurology & Psychiatry - Japan	Ueda, K (corresponding author), Kyoto Univ, Lab Cellular Biochem, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.ip		Yokota, Toshifumi/0000-0001-7316-3546; Kioka, Noriyuki/0000-0002-2708-537X; , toshifumi/0000-0001-6672-6742; Onishi, Tomohiro/0000-0003-0633-9323; Ueda, Kazumitsu/0000-0003-2980-6078				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2001, J LIPID RES, V42, P1717; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARA H, 1991, J BIOL CHEM, V266, P3080; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	32	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15091	15095		10.1074/jbc.M313436200	http://dx.doi.org/10.1074/jbc.M313436200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722086	hybrid			2022-12-27	WOS:000220594700074
J	Nagano, S; Huang, XD; Moir, RD; Payton, SM; Tanzi, RE; Bush, AI				Nagano, S; Huang, XD; Moir, RD; Payton, SM; Tanzi, RE; Bush, AI			Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (A beta) and generates A beta-COX-2 hetero-oligomers that are increased in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MOUSE MODEL; HIPPOCAMPAL-FORMATION; HYDROGEN-PEROXIDE; CLINICAL-TRIAL; METAL-BINDING; PLAQUE CORES; HUMAN BRAIN; PROTEIN; OXIDATION	Oxidative stress is associated with the neuropathology of Alzheimer's disease. We have previously shown that human Abeta has the ability to reduce Fe(III) and Cu(II) and produce hydrogen peroxide coupled with these metals, which is correlated with toxicity against primary neuronal cells. Cyclooxygenase (COX)-2 expression is linked to the progression and severity of pathology in AD. COX is a heme-containing enzyme that produces prostaglandins, and the enzyme also possesses peroxidase activity. Here we investigated the possibility of direct interaction between human Abeta and COX-2 being mediated by the peroxidase activity. Human Abeta formed dimers when it was reacted with COX-2 and hydrogen peroxide. Moreover, the peptide formed a cross-linked complex directly with COX-2. Such cross-linking was not observed with rat Abeta, and the sole tyrosine residue specific for human Abeta might therefore be the site of cross-linking. Similar complexes of Abeta and COX-2 were detected in post-mortem brain samples in greater amounts in AD tissue than in age-matched controls. COX-2-mediated cross-linking may inhibit Abeta catabolism and possibly generate toxic intracellular forms of oligomeric Abeta.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Lab Oxidat Biol, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Charlestown, MA 02129 USA; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Oxidat Disorders Lab, Parkville, Vic 3052, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Melbourne	Bush, AI (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Lab Oxidat Biol, Genet & Aging Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069	PHS HHS [R01-1912686] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Beard CM, 1998, MAYO CLIN PROC, V73, P951, DOI 10.4065/73.10.951; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brzyska M, 2001, EUR J BIOCHEM, V268, P3443, DOI 10.1046/j.1432-1327.2001.02248.x; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Forghani F, 1998, ANAL BIOCHEM, V264, P216, DOI 10.1006/abio.1998.2842; Galeazzi L, 1999, AMYLOID, V6, P7, DOI 10.3109/13506129908993282; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Head E, 2001, NEUROBIOL DIS, V8, P792, DOI 10.1006/nbdi.2001.0431; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Hensley K, 1998, J NEUROSCI, V18, P8126; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; Ho L, 1999, J NEUROSCI RES, V57, P295; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Miura T, 2001, J MOL STRUCT, V598, P79, DOI 10.1016/S0022-2860(01)00807-9; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Thomas T, 2001, NEUROREPORT, V12, P3263, DOI 10.1097/00001756-200110290-00024; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Xiang ZM, 2002, NEUROBIOL AGING, V23, P327, DOI 10.1016/S0197-4580(01)00282-2; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X	53	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14673	14678		10.1074/jbc.M313003200	http://dx.doi.org/10.1074/jbc.M313003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724276	hybrid			2022-12-27	WOS:000220594700026
J	Laux, WHG; Pande, P; Shoshani, I; Gao, JY; Boudou-Vivet, V; Gosselin, G; Johnson, RA				Laux, WHG; Pande, P; Shoshani, I; Gao, JY; Boudou-Vivet, V; Gosselin, G; Johnson, RA			Pro-nucleotide inhibitors of adenylyl cyclases in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; PHOSPHATE-PROTECTING GROUPS; HUMAN-IMMUNODEFICIENCY; CYCLIC-AMP; NUCLEOSIDE 3-POLYPHOSPHATES; PHOSPHOTRIESTER DERIVATIVES; MONONUCLEOTIDE PRODRUGS; INTRACELLULAR DELIVERY; ANTIVIRAL EVALUATION; POTENT INHIBITORS	Substituted adenine derivatives with protected phosphoryl groups were synthesized and tested as inhibitors of adenylyl cyclase in isolated enzyme and intact cell systems. Protected 3'-phosphoryl derivatives of 2', 5'-dideoxyadenosine (2',5'-dd-Ado) and beta-L-2',5'-dd-Ado, protected 5'-phosphoryl derivatives of beta-L-2', 3'-dd-Ado, and protected phosphoryl derivatives of two 9-(2-phosphonomethoxy- acyl)-adenines were synthesized. Protection was afforded by two cyclosaligenyl- or three S-acyl-2-thioethyl-substituents. These pro-nucleotides were tested for their capacity to block forskolin-induced increases in [H-3] cAMP in OB1771 and F442A preadipocytes and human macrophages prelabeled with [H-3] adenine. A striking selectivity for 2', 5'- dd-Ado- 3'-phosphoryl derivatives was observed. Cyclosaligenyl-derivatives (IC50 similar to2 muM) were much less potent than S-acyl-2-thioethyl- derivatives. Best studied of these was 2', 5'-dd-Ado- 3'-O-bis(S-pivaloyl-2-thioethyl)-phosphate, which blocked [H-3] cAMP formation in preadipocytes (IC50 similar to30 nM) and suppressed opening of cAMP-dependent Cl- channels in cardiac myocytes (IC50 similar to 800 nM). None of the pro-nucleotides inhibited adenylyl cyclase per se, whether isolated from rat brain or OB1771 cells. These compounds exhibit the hallmarks of prodrugs. Data suggest they are taken up, are deprotected, and are converted to a potent inhibitory form to inhibit adenylyl cyclase, but only by intact cells. The availability and characteristics of these prodrugs should make them useful for blocking cAMP-mediated pathways in intact cell systems, in biochemical, pharmacological, and potentially therapeutic contexts.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, Lab Chim Organ Biomol Synth, CNRS, UMR 5625, F-34095 Montpellier 5, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	roger.johnson@sunysb.edu			NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER P, 1994, COLLECT CZECH CHEM C, V59, P2127, DOI 10.1135/cccc19942127; Beltran T, 2001, BIOORG MED CHEM LETT, V11, P1775, DOI 10.1016/S0960-894X(01)00299-2; Benzaria S, 1996, J MED CHEM, V39, P4958, DOI 10.1021/jm960289o; Bolon PJ, 1996, BIOORG MED CHEM LETT, V6, P1657, DOI 10.1016/0960-894X(96)00293-4; CHENG WL, 1995, AM J PHYSIOL-ENDOC M, V269, pE642, DOI 10.1152/ajpendo.1995.269.4.E642; CLAUS TH, 1982, MOL CELL ENDOCRINOL, V26, P269, DOI 10.1016/0303-7207(82)90116-2; DECLERCQ E, 1997, CLIN MICROBIOL REV, V10, P1; DESAUBRY L, 1995, TETRAHEDRON LETT, V36, P995, DOI 10.1016/0040-4039(94)02424-A; DESAUBRY L, 1995, NUCLEOS NUCLEOT, V14, P1453, DOI 10.1080/15257779508010705; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; Doronin S, 1999, J BIOL CHEM, V274, P34745, DOI 10.1074/jbc.274.49.34745; Egron D, 2001, NUCLEOS NUCLEOT NUCL, V20, P751, DOI 10.1081/NCN-100002422; FAIN JN, 1972, J BIOL CHEM, V247, P6866; Friedman D L, 1976, Adv Cyclic Nucleotide Res, V7, P69; GAO J, 1992, J PHYSIOL-LONDON, V449, P689, DOI 10.1113/jphysiol.1992.sp019109; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GARTNER R, 1985, MOL CELL ENDOCRINOL, V42, P145, DOI 10.1016/0303-7207(85)90102-9; GREGA DS, 1987, J NEUROSCI, V7, P700; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HASLAM RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P1143, DOI 10.1016/0024-3205(72)90269-X; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; HOLY A, 1995, COLLECT CZECH CHEM C, V60, P1196, DOI 10.1135/cccc19951196; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; Ibrahimi A, 1999, AM J PHYSIOL-CELL PH, V276, pC487, DOI 10.1152/ajpcell.1999.276.2.C487; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P31; JONES RJ, 1995, ANTIVIR RES, V27, P1, DOI 10.1016/0166-3542(95)00011-A; LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCGUIGAN C, 1992, ANTIVIR RES, V17, P311, DOI 10.1016/0166-3542(92)90026-2; MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013; Meier C, 1996, ANGEW CHEM INT EDIT, V35, P70, DOI 10.1002/anie.199600701; Meier C, 1997, BIOORG MED CHEM LETT, V7, P99, DOI 10.1016/S0960-894X(96)00597-5; Meier C, 1998, J MED CHEM, V41, P1417, DOI 10.1021/jm970664s; Meier C, 1997, BIOORG MED CHEM LETT, V7, P1577, DOI 10.1016/S0960-894X(97)00265-5; Meier C, 2002, MINI-REV MED CHEM, V2, P219, DOI 10.2174/1389557023406205; NAESENS L, 1994, REV MED VIROL, V4, P147, DOI 10.1002/rmv.1980040302; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; NEYTS J, 1994, BIOCHEM PHARMACOL, V47, P39, DOI 10.1016/0006-2952(94)90435-9; PERIGAUD C, 1993, BIOORG MED CHEM LETT, V3, P2521, DOI 10.1016/S0960-894X(01)80709-5; PERIGAUD C, 1996, ADV ANTIV D, V2, P147; Peyrottes S, 2001, NUCLEOS NUCLEOT NUCL, V20, P315, DOI 10.1081/NCN-100002302; PIERRA C, 1997, THESIS U MONTPELLIER; REID IR, 1990, AM J PHYSIOL, V258, pE708, DOI 10.1152/ajpendo.1990.258.4.E708; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SASTRY JK, 1992, MOL PHARMACOL, V41, P441; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Thomas CA, 1997, BLOOD, V90, P3760, DOI 10.1182/blood.V90.9.3760; Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199	60	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13317	13332		10.1074/jbc.M309535200	http://dx.doi.org/10.1074/jbc.M309535200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699161	hybrid			2022-12-27	WOS:000220478500008
J	Sorokina, EM; Merlo, JJ; Tsygankov, AY				Sorokina, EM; Merlo, JJ; Tsygankov, AY			Molecular mechanisms of the effect of Herpesvirus saimiri protein StpC on the signaling pathway leading to NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; T-CELL-CLONES; UBIQUITIN-PROTEASOME PATHWAY; RECEPTOR-ASSOCIATED FACTORS; STAT TRANSCRIPTION FACTORS; TYPE-1 TAX PROTEIN; SUBGROUP-C STRAINS; TYROSINE PHOSPHORYLATION; IN-VITRO; LYMPHOCYTE-TRANSFORMATION	Herpesvirus saimiri (Saimiriine herpesvirus-2) causes lethal T lymphoproliferative diseases in the susceptible species and transforms T lymphocytes to continuous growth in vitro. H. saimiri-induced transformation of T cells is becoming an important experimental tool of biomedical research. Two proteins of H. saimiri subgroup C, Tip and StpC, are essential for T cell transformation by this virus. It has been shown previously that StpC transforms fibroblasts, activates NF-kappaB, and binds to tumor necrosis factor (TNF)-receptor-associated factor (TRAF) proteins, but the molecular mechanism of its action remains insufficiently understood. This study further characterized the effect of StpC on NF-kappaB. First, StpC activates NF-kappaB via the consensus pathway involving activation of I-kappaB kinase and subsequent phosphorylation and degradation of I-kappaB in both T lymphoid and epithelial cells. Second, triggering of this pathway by StpC in both T lymphoid and epithelial cells is dependent on the presence of functional NF-kappaB-inducing kinase (NIK). Third, StpC physically interacts with TRAF in epithelial cells, and the effect of StpC on NF-kappaB activity in these cells requires the presence of functional TRAF. Finally the effect of StpC is completely independent of TNF-alpha, a well described stimulus of NF-kappaB activity. Moreover it appears that StpC uncouples stimulation of NF-kappaB activity from TNF-alpha stimulation. Overall these results argue that the effect of StpC on NF-kappaB is similar to the effects of other viral proteins, "usurping" the TRAF/NIK/I-kappaB kinase pathway, and reinforce the notion that the role of StpC in cell transformation by H. saimiri may be mediated by signaling that results in NF-kappaB activation.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017					Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Broker BM, 1999, MED MICROBIOL IMMUN, V187, P127, DOI 10.1007/s004300050084; BROKER BM, 1993, J IMMUNOL, V151, P1184; Cabanillas JA, 2002, CLIN EXP IMMUNOL, V127, P366, DOI 10.1046/j.1365-2249.2002.01716.x; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Choi JK, 2000, J VIROL, V74, P8102, DOI 10.1128/JVI.74.17.8102-8110.2000; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Damania B, 2001, ADV CANCER RES, V80, P51, DOI 10.1016/S0065-230X(01)80012-9; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hartley DA, 2000, VIROLOGY, V276, P339, DOI 10.1006/viro.2000.0570; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; He ZM, 2000, CANCER RES, V60, P1845; Henderson EE, 1999, VIROLOGY, V264, P125, DOI 10.1006/viro.1999.9988; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Isakov N, 2000, EUR J BIOCHEM, V267, P3413, DOI 10.1046/j.1432-1327.2000.01412.x; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JUNG JU, 1994, VIROLOGY, V204, P751, DOI 10.1006/viro.1994.1590; JUNG JU, 1995, J VIROL, V69, P7814, DOI 10.1128/JVI.69.12.7814-7822.1995; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kjellen P, 2002, VIROLOGY, V297, P281, DOI 10.1006/viro.2002.1419; Lacey SF, 1998, AIDS RES HUM RETROV, V14, P521, DOI 10.1089/aid.1998.14.521; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; Lund T, 1997, J VIROL, V71, P378, DOI 10.1128/JVI.71.1.378-382.1997; Lund T, 1996, J VIROL, V70, P600, DOI 10.1128/JVI.70.1.600-606.1996; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Martin-Villa JM, 1998, TISSUE ANTIGENS, V52, P430, DOI 10.1111/j.1399-0039.1998.tb03069.x; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Meinl E, 2000, J NEUROIMMUNOL, V103, P1, DOI 10.1016/S0165-5728(99)00217-9; Meinl E, 2001, J BIOL CHEM, V276, P36902, DOI 10.1074/jbc.M102668200; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Nakamura H, 2001, J IMMUNOL, V167, P2657, DOI 10.4049/jimmunol.167.5.2657; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Park J, 2002, IMMUNITY, V17, P221, DOI 10.1016/S1074-7613(02)00368-0; Pecher G, 2001, BIOCHEM BIOPH RES CO, V283, P738, DOI 10.1006/bbrc.2001.4846; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Saadawi AM, 1997, TISSUE ANTIGENS, V49, P431, DOI 10.1111/j.1399-0039.1997.tb02775.x; Saha K, 1998, J VIROL, V72, P876, DOI 10.1128/JVI.72.1.876-881.1998; Saha K, 1997, VIROLOGY, V231, P1, DOI 10.1006/viro.1997.8485; Saha K, 1996, NAT MED, V2, P1272, DOI 10.1038/nm1196-1272; Saha K, 1999, J VIROL, V73, P7891, DOI 10.1128/JVI.73.9.7891-7898.1999; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Tsygankov AY, 1999, ANTICANCER RES, V19, P973; Vella C, 2002, AIDS RES HUM RETROV, V18, P933, DOI 10.1089/088922202760265605; Vella C, 1997, J GEN VIROL, V78, P1405, DOI 10.1099/0022-1317-78-6-1405; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zheng NN, 2002, J GEN VIROL, V83, P1343, DOI 10.1099/0022-1317-83-6-1343	71	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13469	13477		10.1074/jbc.M305250200	http://dx.doi.org/10.1074/jbc.M305250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724292	hybrid			2022-12-27	WOS:000220478500025
J	Avrahami, D; Shai, Y				Avrahami, D; Shai, Y			A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL ANTIMICROBIAL PEPTIDES; CIRCULAR-DICHROISM SPECTRA; FUNGAL-INFECTIONS; BACILLUS-SUBTILIS; ACYL-CHAIN; IMMUNOCOMPROMISED HOST; SELECTIVE CYTOTOXICITY; PHOSPHOLIPID-MEMBRANES; INFRARED-SPECTROSCOPY; MOLECULAR-BASIS	We report on the synthesis, biological function, and a plausible mode of action of a new group of lipopeptides with potent antifungal and antibacterial activities. These lipopeptides are derived from positively charged peptides containing D- and L-amino acids (diastereomers) that are palmitoylated (PA) at their N terminus. The peptides investigated have the sequence K4X7W, where X designates Gly, Ala, Val, or Leu (designated D-X peptides). The data revealed that PA-D-G and PA-D-A gained potent antibacterial and antifungal activity despite the fact that both parental peptides were completely devoid of any activity toward microorganisms and model phospholipid membranes. In contrast, PA-D-L lost the potent antibacterial activity of the parental peptide but gained and preserved partial antifungal activity. Interestingly, both D- V and its palmitoylated analog were inactive toward bacteria, and only the palmitoylated peptide was highly potent toward yeast. Both PA-D-L and PA-D-V lipopeptides were also endowed with hemolytic activity. Mode of action studies were performed by using tryptophan fluorescence and attenuated total reflectance Fourier transform infrared and circular dichroism spectroscopy as well as transmembrane depolarization assays with bacteria and fungi. The data suggest that the lipopeptides act by increasing the permeability of the cell membrane and that differences in their potency and target specificity are the result of differences in their oligomeric state and ability to dissociate and insert into the cytoplasmic membrane. These results provide insight regarding a new approach of modulating hydrophobicity and the self-assembly of non-membrane interacting peptides in order to endow them with both antibacterial and antifungal activities urgently needed to combat bacterial and fungal infections.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il						Alexander BD, 1997, DRUGS, V54, P657, DOI 10.2165/00003495-199754050-00002; ARIMA K, 1968, BIOCHEM BIOPH RES CO, V31, P488, DOI 10.1016/0006-291X(68)90503-2; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; BenMohamed L, 2002, LANCET INFECT DIS, V2, P425, DOI 10.1016/S1473-3099(02)00318-3; BERNHEIMER AW, 1970, J GEN MICROBIOL, V61, P361, DOI 10.1099/00221287-61-3-361; Blondelle SE, 1996, ANTIMICROB AGENTS CH, V40, P1067, DOI 10.1128/AAC.40.5.1067; BRADBURY EM, 1962, J MOL BIOL, V5, P230, DOI 10.1016/S0022-2836(62)80086-2; CAMERON DG, 1980, BIOCHIM BIOPHYS ACTA, V596, P463, DOI 10.1016/0005-2736(80)90135-2; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; de Lucca AJ, 1999, ANTIMICROB AGENTS CH, V43, P1, DOI 10.1093/jac/43.1.1; DENNING DW, 1991, J ANTIMICROB CHEMOTH, V28, P1, DOI 10.1093/jac/28.suppl_B.1; Ellis M, 2000, HOSP MED, V61, P605, DOI 10.12968/hosp.2000.61.9.1415; Frate MC, 2000, EUR J BIOCHEM, V267, P3836, DOI 10.1046/j.1432-1327.2000.01422.x; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Goldstein EJC, 2003, ANTIMICROB AGENTS CH, V47, P337, DOI 10.1128/AAC.47.1.337-341.2003; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Groll AH, 1996, J INFECTION, V33, P23, DOI 10.1016/S0163-4453(96)92700-0; Hancock REW, 2002, FEMS MICROBIOL LETT, V206, P143, DOI 10.1016/S0378-1097(01)00480-3; Harrick N.J., 1967, INTERNAL REFLECTION; Heerklotz H, 2001, BIOPHYS J, V81, P1547, DOI 10.1016/S0006-3495(01)75808-0; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Johnson MD, 2003, EXPERT OPIN PHARMACO, V4, P807, DOI 10.1517/14656566.4.5.807; Kartsonis NA, 2003, DRUG RESIST UPDATE, V6, P197, DOI 10.1016/S1368-7646(03)00064-5; Kontoyiannis DP, 2003, J HOSP INFECT, V53, P243, DOI 10.1053/jhin.2002.1278; Kustanovich I, 2002, J BIOL CHEM, V277, P16941, DOI 10.1074/jbc.M111071200; MAGETDANA R, 1994, TOXICOLOGY, V87, P151, DOI 10.1016/0300-483X(94)90159-7; Majerle A, 2003, J ANTIMICROB CHEMOTH, V51, P1159, DOI 10.1093/jac/dkg219; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Minamoto GY, 1997, MED CLIN N AM, V81, P381, DOI 10.1016/S0025-7125(05)70523-X; Mukherjee PK, 2003, INFECT IMMUN, V71, P4333, DOI 10.1128/IAI.71.8.4333-4340.2003; Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Pankuch GA, 2003, J ANTIMICROB CHEMOTH, V51, P443, DOI 10.1093/jac/dkg091; Papo N, 2002, J BIOL CHEM, V277, P33913, DOI 10.1074/jbc.M204928200; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; SHINITZKY M, 1993, J AM CHEM SOC, V115, P12545, DOI 10.1021/ja00079a038; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; Tossi A, 2000, BIOPOLYMERS, V55, P4; VOGEL H, 1981, FEBS LETT, V134, P37, DOI 10.1016/0014-5793(81)80545-5; Vollenbroich D, 1997, BIOLOGICALS, V25, P289, DOI 10.1006/biol.1997.0099; Walsh TJ, 1996, INFECT DIS CLIN N AM, V10, P365, DOI 10.1016/S0891-5520(05)70303-2; Wiederhold NP, 2003, EXPERT OPIN INV DRUG, V12, P1313, DOI 10.1517/13543784.12.8.1313; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	58	139	143	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12277	12285		10.1074/jbc.M312260200	http://dx.doi.org/10.1074/jbc.M312260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709550	hybrid			2022-12-27	WOS:000220334900034
J	Bayle, J; Letard, B; Frank, R; Dubreuil, P; De Sepulveda, P				Bayle, J; Letard, B; Frank, R; Dubreuil, P; De Sepulveda, P			Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING SUPPRESSOR; INDUCED STAT INHIBITOR; SOCS-BOX MOTIF; C-KIT; NEGATIVE REGULATION; INSULIN-RECEPTOR; PROTEIN; KINASE; BINDS; ACTIVATION	Suppressor of cytokine signaling (SOCS) proteins are a family of Src homology 2-containing adaptor proteins. Cytokine-inducible Src homology domain 2-containing protein, SOCS1, SOCS2, and SOCS3 have been implicated in the down-regulation of cytokine signaling. The function of SOCS4, 5, 6, and 7 are not known. KIT receptor signaling is regulated by protein tyrosine phosphatases and adaptor proteins. We previously reported that SOCS1 inhibited cell proliferation in response to stem cell factor (SCF). By screening the other members of SOCS family, we identified SOCS6 as a KIT-binding protein. Using KIT mutants and peptides, we demonstrated that SOCS6 bound directly to KIT tyrosine 567 in the juxtamembrane domain. To investigate the function of this interaction, we constitutively expressed SOCS6 in cell lines. Ectopic expression of SOCS6 in Ba/F3-KIT cell line decreased cell proliferation in response to SCF but not SCF-induced chemotaxis. SOCS6 reduced SCF-induced activation of ERK1/2 and p38 but not activation of AKT or STATs in Ba/F3, murine embryonic fibroblast (MEF), or COS-7 cells. SOCS6 did not impair ERK and p38 activation by other stimuli. These results indicate that SOCS6 binds to KIT juxtamembrane region, which affects upstream signaling components leading to MAPK activation. Our results indicate that KIT signaling is regulated by several SOCS proteins and suggest a putative function for SOCS6 as a negative regulator of receptor tyrosine kinases.	INSERM, U119, Lab Hematopoiese Mol & Fonct, F-13009 Marseille, France; German Res Ctr Biotechnol, Res Grp Mol Recognit, D-38124 Braunschweig, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Helmholtz Association; Helmholtz-Center for Infection Research	De Sepulveda, P (corresponding author), INSERM, U119, Lab Hematopoiese Mol & Fonct, 27 Blvd Lei Roure, F-13009 Marseille, France.		dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019; De sepulveda, paulo/K-6043-2015	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; LETARD, Sebastien/0000-0002-6508-7376				Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bourette RP, 2001, J BIOL CHEM, V276, P22133, DOI 10.1074/jbc.M101878200; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frank R, 1996, Methods Mol Biol, V66, P149; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Leung KC, 2003, P NATL ACAD SCI USA, V100, P1016, DOI 10.1073/pnas.0337600100; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Wollberg P, 2003, BIOCHEM J, V370, P1033, DOI 10.1042/BJ20020716; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	43	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12249	12259		10.1074/jbc.M313381200	http://dx.doi.org/10.1074/jbc.M313381200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707129	hybrid			2022-12-27	WOS:000220334900031
J	Fisher, N; Castleden, CK; Bourges, I; Brasseur, G; Dujardin, G; Meunier, B				Fisher, N; Castleden, CK; Bourges, I; Brasseur, G; Dujardin, G; Meunier, B			Human disease-related mutations in cytochrome b studied in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; SACCHAROMYCES-CEREVISIAE; BC(1) COMPLEX; Q(O) SITE; EXERCISE INTOLERANCE; MISSENSE MUTATION; C-OXIDASE; CENTER-N; GENE; MUTANTS	Several mutations in the mitochondrially encoded cytochrome b have been reported in patients. To characterize their effect, we introduced six " human" mutations, namely G33S, S152P, G252D, Y279C, G291D, and Delta 252 - 259 in the highly similar yeast cytochrome b. G252D showed wild type behavior in standard conditions. However, Asp- 252 may interfere with structural lipid and, in consequence, destabilize the enzyme assembly, which could explain the pathogenicity of the mutation. The mutations G33S, S152P, G291D, and Delta 252 - 259 were clearly pathogenic. They caused a severe decrease of the respiratory function and altered the assembly of the iron- sulfur protein in the bc(1) complex, as observed by immunodetection. Suppressor mutations that partially restored the respiratory function impaired by S152P or G291D were found in or close to the hinge region of the iron- sulfur protein, suggesting that this region may play a role in the stable binding of the subunit to the bc1 complex. Y279C caused a significant decrease of the bc1 function and perturbed the quinol binding. The EPR spectra showed an altered signal, indicative of a lower occupancy of the Q(o) site. The effect of human mutation of residue 279 was confirmed by another change, Y279A, which had a more severe effect on Q(o) site properties. Thus by using yeast as a model system, we identified the molecular basis of the respiratory defect caused by the disease mutations in cytochrome b.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Meunier, B (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	b.meunier@ucl.ac.uk						Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008; Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404; BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; BRASSEUR G, 1995, EUR J BIOCHEM, V230, P1118, DOI 10.1111/j.1432-1033.1995.tb20663.x; Brasseur G, 2001, BBA-BIOENERGETICS, V1506, P89, DOI 10.1016/S0005-2728(01)00186-4; BROWN S, 1993, EUR J BIOCHEM, V213, P137, DOI 10.1111/j.1432-1033.1993.tb17743.x; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COPPEE JY, 1994, FEBS LETT, V339, P1, DOI 10.1016/0014-5793(94)80373-0; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; Ding H, 1995, BIOCHEMISTRY-US, V34, P15997, DOI 10.1021/bi00049a013; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P50703, DOI 10.1074/jbc.M208556200; Hill P, 2003, ANTIMICROB AGENTS CH, V47, P2725, DOI 10.1128/AAC.47.9.2725-2731.2003; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Legros F, 2001, EUR J HUM GENET, V9, P510, DOI 10.1038/sj.ejhg.5200678; Meunier B, 2002, BBA-BIOENERGETICS, V1554, P101, DOI 10.1016/S0005-2728(02)00217-7; Meunier B, 2001, BIOCHEM J, V354, P407, DOI 10.1042/0264-6021:3540407; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Saint-Georges Y, 2002, J BIOL CHEM, V277, P49397, DOI 10.1074/jbc.M207219200; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224	26	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12951	12958		10.1074/jbc.M313866200	http://dx.doi.org/10.1074/jbc.M313866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718526	hybrid			2022-12-27	WOS:000220334900113
J	Fransen, M; Vastiau, I; Brees, C; Brys, V; Mannaerts, GP; Van Veldhoven, PP				Fransen, M; Vastiau, I; Brees, C; Brys, V; Mannaerts, GP; Van Veldhoven, PP			Potential role for Pex19p in assembly of PTS-receptor docking complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL DOCKING; TARGETING SIGNALS; MEMBRANE-PROTEINS; IMPORT; IDENTIFICATION; MULTIPLE; CELLS; LOCALIZATION; BIOGENESIS; MACHINERY	Human Pex19p binds a broad spectrum of peroxisomal membrane proteins (PMPs). It has been proposed that this peroxin may: (i) act as a cycling PMP receptor protein, (ii) facilitate the insertion of newly synthesized PMPs into the peroxisomal membrane, or (iii) function as a chaperone to associate and/or dissociate complexes comprising integral PMPs already in the peroxisomal membrane. We previously demonstrated that human Pex19p binds peroxisomal integral membrane proteins at regions distinct from their sorting sequences. Here we demonstrate that a mutant of Pex13p that fails to bind to Pex19p nevertheless targets to and integrates into the peroxisomal membrane. In addition, through in vitro biochemical analysis, we show that Pex19p competes with Pex5p and Pex13p for binding to Pex14p, supporting a role for this peroxin in regulating assembly/ disassembly of membrane-associated protein complexes. To further examine the molecular mechanism underlying this competition, six evolutionarily conserved amino acids in the Pex5p/Pex13p/Pex19p binding domain of Pex14p were subjected to site-directed mutagenesis and the corresponding mutants functionally analyzed. Our results indicate that the physically overlapping binding sites of Pex14p for Pex5p, Pex13p, and Pex19p are functionally distinct, suggesting that competition occurs through induction of structural changes, rather than through direct competition. Importantly, we also found that amino acid substitutions resulting in a strongly reduced binding affinity for Pex13p affect the peroxisomal localization of Pex14p.	Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, Afdeling Farmacol, B-3000 Louvain, Belgium	KU Leuven	Fransen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, Afdeling Farmacol, Campus Gasthuisberg O-N,Herestr 49 O-N, B-3000 Louvain, Belgium.	marc.fransen@med.kuleuven.ac.be	Fransen, Marc/C-6262-2008; Fransen, Marc/ADL-0723-2022; , Van Veldhoven Paul/U-6359-2019	Fransen, Marc/0000-0001-9284-1197; , Van Veldhoven Paul/0000-0002-4478-2564				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghys K, 2002, BIOCHEM J, V365, P41, DOI 10.1042/BJ20011432; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Hazra PP, 2002, TRAFFIC, V3, P560, DOI 10.1034/j.1600-0854.2002.30806.x; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; Vizeacoumar FJ, 2003, J CELL BIOL, V161, P321, DOI 10.1083/jcb.200210130	31	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12615	12624		10.1074/jbc.M304941200	http://dx.doi.org/10.1074/jbc.M304941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715663	hybrid			2022-12-27	WOS:000220334900075
J	Liu, XQ; De Wulf, P				Liu, XQ; De Wulf, P			Probing the ArcA-P modulon of Escherichia coli by whole genome transcriptional analysis and sequence recognition profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; SIGNAL-TRANSDUCTION SYSTEM; SUCCINATE-DEHYDROGENASE; GENE-EXPRESSION; DNA-BINDING; MEDIATING REPRESSION; AEROBIC PATHWAYS; PROMOTER; FNR; OPERON	The ArcB/ArcA two-component signal transduction system of Escherichia coli regulates gene expression in response to the redox conditions of growth. Over the years, genetic screens have lead to the identification of about 30 ArcA-P-controlled operons that are involved in redox metabolism. However, the discovery of 3 targets that are not implicated in respiratory metabolism ( the tra operon for plasmid conjugation, psi site for Xer-based recombination, and oriC site for chromosome replication) suggests that the Arc modulon may comprise additional operons that are involved in a myriad of functions. To identify these operons, we derived the ArcA-P-dependent transcription profile of E. coli using oligonucleotide-based microarray analysis. The findings indicated that 9% of all open reading frames in E. coli are affected either directly or indirectly by ArcA-P. To identify which operons are under the direct control of ArcA-P, we developed the ArcA-P recognition weight matrix from footprinting data and used it to scan the genome, yielding an ArcA-P sequence affinity map. By overlaying both methods, we identified 55 new Arc-regulated operons that are implicated in energy metabolism, transport, survival, catabolism, and transcriptional regulation. The data also suggest that the Arc response pathway, which translates into a net global downscaling of gene expression, overlaps partly with the FNR regulatory network. A conservative but reasonable assessment is that the Arc pathway recruits 100 150 operons to mediate a role in cellular adaptation that is more extensive than hitherto anticipated.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	De Wulf, P (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dewulf@mit.edu		LIU, XUEQIAO/0000-0001-7652-241X; De Wulf, Peter/0000-0001-9772-5881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chao GL, 1997, J BACTERIOL, V179, P4299, DOI 10.1128/jb.179.13.4299-4304.1997; Colloms SD, 1998, MOL MICROBIOL, V28, P521, DOI 10.1046/j.1365-2958.1998.00812.x; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; Cunningham L, 1998, FEMS MICROBIOL LETT, V169, P403, DOI 10.1111/j.1574-6968.1998.tb13347.x; De Souza-Hart JA, 2003, INFECT IMMUN, V71, P163, DOI 10.1128/IAI.71.1.163-172.2003; De Wulf P, 2002, J BIOL CHEM, V277, P26652, DOI 10.1074/jbc.M203487200; DRAPAL N, 1995, MOL MICROBIOL, V16, P597, DOI 10.1111/j.1365-2958.1995.tb02422.x; FU HA, 1991, MOL GEN GENET, V226, P209, DOI 10.1007/BF00273605; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; HASSAN HM, 1994, FEMS MICROBIOL REV, V14, P315, DOI 10.1111/j.1574-6976.1994.tb00105.x; IUCHI S, 1989, J BACTERIOL, V171, P868, DOI 10.1128/jb.171.2.868-873.1989; IUCHI S, 1994, J BACTERIOL, V176, P1695, DOI 10.1128/jb.176.6.1695-1701.1994; IUCHI S, 1993, MOL MICROBIOL, V9, P9, DOI 10.1111/j.1365-2958.1993.tb01664.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; IUCHI S, 1995, 2 COMPONENT SIGNAL T, P223; Jeon Y, 2001, J BIOL CHEM, V276, P40873, DOI 10.1074/jbc.M104855200; Kim SJ, 1999, IUBMB LIFE, V48, P215, DOI 10.1080/152165499307251; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lee YS, 2001, J BIOL CHEM, V276, P9917, DOI 10.1074/jbc.M008629200; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lynch A. Simon, 1996, P361; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; McGuire AM, 1999, MOL MICROBIOL, V32, P219, DOI 10.1046/j.1365-2958.1999.01347.x; Oshima T, 2002, MOL MICROBIOL, V46, P281, DOI 10.1046/j.1365-2958.2002.03170.x; PARK SJ, 1995, MOL MICROBIOL, V15, P473, DOI 10.1111/j.1365-2958.1995.tb02261.x; Pellicer MT, 1999, MOL GEN GENET, V261, P170, DOI 10.1007/s004380050954; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Sengupta N, 2003, INFECT IMMUN, V71, P5583, DOI 10.1128/IAI.71.10.5583-5589.2003; Shen J, 1997, MOL MICROBIOL, V26, P223, DOI 10.1046/j.1365-2958.1997.5561923.x; Strohmaier H, 1998, J MOL BIOL, V277, P309, DOI 10.1006/jmbi.1997.1598; Tani TH, 2002, P NATL ACAD SCI USA, V99, P13471, DOI 10.1073/pnas.212510999; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	42	159	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12588	12597		10.1074/jbc.M313454200	http://dx.doi.org/10.1074/jbc.M313454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711822	hybrid			2022-12-27	WOS:000220334900072
J	Takasaki, K; Shoun, H; Yamaguchi, M; Takeo, K; Nakamura, A; Hoshino, T; Takaya, N				Takasaki, K; Shoun, H; Yamaguchi, M; Takeo, K; Nakamura, A; Hoshino, T; Takaya, N			Fungal ammonia fermentation, a novel metabolic mechanism that couples the dissimilatory and assimilatory pathways of both nitrate and ethanol - Role of acetyl CoA synthetase in anaerobic ATP synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-OXYSPORUM; DENITRIFICATION; GENE; REDUCTION; PURIFICATION; INVOLVEMENT; EXPRESSION; COENZYME; CLONING; ENZYME	Fungal ammonia fermentation is a novel dissimilatory metabolic mechanism that supplies energy under anoxic conditions. The fungus Fusarium oxysporum reduces nitrate to ammonium and simultaneously oxidizes ethanol to acetate to generate ATP (Zhou, Z., Takaya, N., Nakamura, A., Yamaguchi, M., Takeo, K., and Shoun, H. (2002) J. Biol. Chem. 277, 1892-1896). We identified the Aspergillus nidulans genes involved in ammonia fermentation by analyzing fungal mutants. The results showed that assimilatory nitrate and nitrite reductases (the gene products of niaD and niiA) were essential for reducing nitrate and for anaerobic cell growth during ammonia fermentation. We also found that ethanol oxidation is coupled with nitrate reduction and catalyzed by alcohol dehydrogenase, coenzyme A (CoA)-acylating aldehyde dehydrogenase, and acetyl-CoA synthetase (Acs). This is similar to the mechanism suggested in F. oxysporum except A. nidulans uses Acs to produce ATP instead of the ADP-dependent acetate kinase of F. oxysporum. The production of Acs requires a functional facA gene that encodes Acs and that is involved in ethanol assimilation and other metabolic processes. We purified the gene product of facA (FacA) from the fungus to show that the fungus acetylates FacA on its lysine residue(s) specifically under conditions of ammonia fermentation to regulate its substrate affinity. Acetylated FacA had higher affinity for acetyl-CoA than for acetate, whereas non-acetylated FacA had more affinity for acetate. Thus, the acetylated variant of the FacA protein is responsible for ATP synthesis during fungal ammonia fermentation. These results showed that the fungus ferments ammonium via coupled dissimilatory and assimilatory mechanisms.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Chiba Univ, Pathogen Fungi & Microbial Toxicoses Res Ctr, Chiba 2608673, Japan	University of Tsukuba; University of Tokyo; Chiba University	Takaya, N (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.	ntakaya@sakura.cc.tsukuba.ac.jp		Nakamura, Akira/0000-0001-7250-7175				BARRATT RW, 1965, GENETICS, V52, P233; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; Felenbok B, 2001, PROG NUCLEIC ACID RE, V69, P149, DOI 10.1016/S0079-6603(01)69047-0; Fujinaga K, 1999, MICROBIOL-SGM, V145, P3377, DOI 10.1099/00221287-145-12-3377; HASAN SM, 1975, J GEN MICROBIOL, V87, P120, DOI 10.1099/00221287-87-1-120; JOHNSTONE LL, 1992, GENE, V111, P149; JOSE MV, 1975, J BIOL CHEM, V250, P7980; Kobayashi M, 1996, J BIOL CHEM, V271, P16263, DOI 10.1074/jbc.271.27.16263; Kurakov AV, 2000, CURR MICROBIOL, V41, P114, DOI 10.1007/s002840010104; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; Mai XH, 1996, J BACTERIOL, V178, P5897, DOI 10.1128/jb.178.20.5897-5903.1996; MARTINEZBLANCO H, 1992, J BIOL CHEM, V267, P5474; MARZLUF GA, 1993, ANNU REV MICROBIOL, V47, P31, DOI 10.1146/annurev.micro.47.1.31; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; SANDEMAN RA, 1989, MOL GEN GENET, V218, P87, DOI 10.1007/BF00330569; SCHIMPFE.L, 1968, BIOCHIM BIOPHYS ACTA, V151, P317, DOI 10.1016/0005-2744(68)90099-5; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1991, J BIOL CHEM, V266, P11078; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Takaya N, 2000, MOL GEN GENET, V263, P342, DOI 10.1007/s004380051177; Uchimura H, 2002, J BIOCHEM, V131, P579, DOI 10.1093/oxfordjournals.jbchem.a003137; Watsuji T, 2003, BIOSCI BIOTECH BIOCH, V67, P1115, DOI 10.1271/bbb.67.1115; YAMAGUCHI M, 1994, J ELECTRON MICROSC, V43, P386; Zhou ZM, 2002, J BIOL CHEM, V277, P1892, DOI 10.1074/jbc.M109096200; Zhou ZM, 2001, ARCH MICROBIOL, V175, P19, DOI 10.1007/s002030000231; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	31	78	85	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12414	12420		10.1074/jbc.M313761200	http://dx.doi.org/10.1074/jbc.M313761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722082	hybrid			2022-12-27	WOS:000220334900050
J	Thuahnai, ST; Lund-Katz, S; Dhanasekaran, P; de la Llera-Moya, M; Connelly, MA; Williams, DL; Rothblat, GH; Phillips, MC				Thuahnai, ST; Lund-Katz, S; Dhanasekaran, P; de la Llera-Moya, M; Connelly, MA; Williams, DL; Rothblat, GH; Phillips, MC			Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol - Influence of high density lipoprotein size and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SR-BI; BINDING; CELLS; CONFORMATION; PARTICLES; SURFACE; DOMAIN; LIPIDS; SITES	Scavenger receptor (SR)-BI catalyzes the selective uptake of cholesteryl ester (CE) from high density lipoprotein (HDL) by a two-step process that involves the following: 1) binding of HDL to the receptor and 2) diffusion of the CE molecules into the cell plasma membrane. We examined the effects of the size of discoidal HDL particles containing wild-type (WT) apoA-I on selective uptake of CE and efflux of cellular free (unesterified) cholesterol (FC) from COS-7 cells expressing SR-BI to determine the following: 1) the influence of apoA-I conformation on the lipid transfer process, and 2) the contribution of receptor binding-dependent processes to the overall efflux of cellular FC. Large ( 10 nm diameter) reconstituted HDL bound to SR-BI better (B-max similar to420 versus 220 ng of apoA-I/mg cell protein), delivered more CE, and promoted more FC efflux than small ( similar to 8 nm) particles. When normalized to the number of reconstituted HDL particles bound to the receptor, the efficiencies of either CE uptake or FC efflux with these particles were the same indicating that altering the conformation of WT apoA-I modulates binding to the receptor ( step 1) but does not change the efficiency of the subsequent lipid transfer ( step 2); this implies that binding induces an optimal alignment of the WT apoA-I.SR- BI complex so that the efficiency of lipid transfer is always the same. FC efflux to HDL is affected both by binding of HDL to SR-BI and by the ability of the receptor to perturb the packing of FC molecules in the cell plasma membrane.	Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Div GI Nutr,Lipid Res Grp, Philadelphia, PA 19104 USA; SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Phillips, MC (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Div GI Nutr,Lipid Res Grp, Suite 1102,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, R01HL063768] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63768, HL 22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de Beer MC, 2001, J LIPID RES, V42, P309; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; ONNELLY MA, 2003, J BIOL CHEM, V278, P25773; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rothblat GH, 1999, J LIPID RES, V40, P781; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Thuahnai ST, 2003, J LIPID RES, V44, P1132, DOI 10.1194/jlr.M200429-JLR200; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Tricerri MA, 2002, J LIPID RES, V43, P187; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	27	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12448	12455		10.1074/jbc.M311718200	http://dx.doi.org/10.1074/jbc.M311718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718538	hybrid			2022-12-27	WOS:000220334900054
J	Zhao, Q; Boschelli, F; Caplan, AJ; Arndt, KT				Zhao, Q; Boschelli, F; Caplan, AJ; Arndt, KT			Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHYSICAL INTERACTION; MOLECULAR CHAPERONE; STRUCTURAL BASIS; PROTEIN-KINASES; P50(CDC37); HSP90; RECEPTOR; CDC28; PHOSPHORYLATION	Cdc37 is a molecular chaperone that is important for the stability and activity of several protein kinases, including Cdk4 and Raf1. We first determined, using in vitro assays, that Cdc37 binds to the amino-terminal lobe of Cdk4. Subsequent mutagenesis revealed that Gly-15 (G15A) and Gly-18 (G18A) were critical for Cdc37-Cdk4 complex formation. Gly-15 and Gly-18 of Cdk4 are within the conserved Gly-X-Gly-X-X-Gly motif that is required for ATP binding to the kinase. Mutation of either glycine at the equivalent positions of Raf1 (G358A and G361A) also inhibited Cdc37 binding to Raf1. Replacing another conserved residue critical for ATP binding and kinase activity, Lys-35 (K35A), reduced Cdc37-Cdk4 complex formation but to a lesser extent. The interaction of Cdk4 with Cdc37 in vitro was not sensitive to changes in ATP levels. Cell-based assays indicated that Cdk4(G15A) and Cdk4(G18A) were present at the same level as wild type Cdk4. Equivalent amounts of p16 bound to Cdk4G15A and Cdk4(G18A) relative to wild type Cdk4, suggesting that Cdk4(G15A) and Cdk4(G18A) adopt significant tertiary structure. However, in contrast to wild type Cdk4, Cdk4(G15A), and Cdk4(G18A) had greatly reduced binding of cyclin D1, Cdc37, and Hsp90. Importantly, overexpression of Cdc37 not only stimulated cyclin D1 binding to wild type Cdk4 but also restored its binding to Cdk4(G15A). Under the same conditions, p16 binding to wild type Cdk4 was suppressed. Our findings show that the interaction of Cdc37 with its client protein kinases requires amino acid residues within a motif that is present in many protein kinases.	Wyeth Res, Dept Oncol, Pearl River, NY 10965 USA; Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Pfizer; Icahn School of Medicine at Mount Sinai	Arndt, KT (corresponding author), Wyeth Res, Dept Oncol, 401 N Middletown Rd, Pearl River, NY 10965 USA.	arndtk1@wyeth.com	Caplan, Avrom/GPT-0824-2022					Abbas-Terki T, 2000, FEBS LETT, V467, P111, DOI 10.1016/S0014-5793(00)01134-0; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; BRUGGE JS, 1982, NATURE, V295, P250, DOI 10.1038/295250a0; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; Kumar R, 2001, J BIOL CHEM, V276, P11371, DOI 10.1074/jbc.M010480200; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Lange BMH, 2002, EMBO J, V21, P5364, DOI 10.1093/emboj/cdf531; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mort-Bontemps-Soret M, 2002, MOL GENET GENOMICS, V267, P447, DOI 10.1007/s00438-002-0676-3; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Schulze-Gahmen U, 2002, NAT STRUCT BIOL, V9, P177, DOI 10.1038/nsb756; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang XT, 2002, J BIOL CHEM, V277, P24361, DOI 10.1074/jbc.M202198200	42	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12560	12564		10.1074/jbc.M308242200	http://dx.doi.org/10.1074/jbc.M308242200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701845	hybrid			2022-12-27	WOS:000220334900068
J	Nery, FC; Passos, DO; Garcia, VS; Kobarg, J				Nery, FC; Passos, DO; Garcia, VS; Kobarg, J			Ki-1/57 interacts with RACK1 and is a substrate for the phosphorylation by phorbol 12-myristate 13-acetate-activated protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING FACTOR; HISTONE DEACETYLASE; SCAFFOLD PROTEIN; HODGKINS-DISEASE; BINDING-PROTEIN; BETA-SUBUNIT; PKC-BETA; RECEPTOR; ANTIGEN; FAMILY	Ki-1/57, the 57-kDa human protein antigen recognized by the CD30 antibody Ki-1, is a cytoplasmic and nuclear protein that is phosphorylated on serine and threonine residues. When isolated from the Hodgkin's lymphoma analogous cell line L540 Ki-1/57 co-immunoprecipitated with a Thr/Ser protein kinase activity. It has been also found to interact with hyaluronic acid and has therefore been termed intracellular IHABP4 (hyaluronan-binding protein 4). Recent studies demonstrated, however, that Ki-1/57 engages in specific interaction with the chromo-helicase-DNA-binding domain protein 3, a nuclear protein involved in chromatin remodeling and transcription regulation. We used the yeast two-hybrid system to find proteins interacting with Ki-1/57 and identified the adaptor protein RACK1 (receptor of activated kinase 1). Next, we confirmed this interaction in vitro and in vivo, performed detailed mapping studies of the interaction sites of Ki-1/57 and RACK-1, and demonstrated that Ki-1/57 also co-precipitates with protein kinase C (PKC) when isolated from phorbol 12-myristate 13-acetate (PMA)-activated L540 tumor cells and is a substrate for PKC phosphorylation in vitro and in vivo. Interestingly, the interaction of Ki-1/57 with RACK1 is abolished upon activation of L540 cells with PMA, which results in the phosphorylation of Ki-1/57 and its exit from the nucleus. Taken together, our data suggest that Ki-1/57 forms a stable complex with RACK-1 in unstimulated cells and upon PMA stimulation gets phosphorylated on threonine residues located at its extreme C terminus. These events associate Ki-1/57 with the RACK1/PKC pathway and may be important for the regulation of its cellular functions.	Lab Nacl Luz Sincrotron, Ctr Biol Mol Estrutural, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Dept Genet & Evolucao, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, Dept Bioquim, BR-13083970 Campinas, SP, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas; Universidade Estadual de Campinas	Kobarg, J (corresponding author), Lab Nacl Luz Sincrotron, Ctr Biol Mol Estrutural, Rua Giuseppe Maximo Scolfaro 10-000,CP 6192, BR-13084971 Campinas, SP, Brazil.	jkobarg@lnls.br	Kobarg, Jörg/T-4736-2019	Kobarg, Jörg/0000-0002-9419-0145; Rinaldi, Vera/0000-0002-0051-1754				Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; DIEHL V, 1981, J CANCER RES CLIN, V101, P111, DOI 10.1007/BF00405072; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; FROESE P, 1987, J IMMUNOL, V139, P2081; Gallina A, 2001, VIROLOGY, V283, P7, DOI 10.1006/viro.2001.0855; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HANSEN H, 1990, RES IMMUNOL, V141, P13, DOI 10.1016/0923-2494(90)90098-J; HANSEN H, 1989, BIOL CHEM H-S, V370, P409, DOI 10.1515/bchm3.1989.370.1.409; Heaton JH, 2001, J BIOL CHEM, V276, P3341, DOI 10.1074/jbc.M006538200; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang L, 2000, J BIOL CHEM, V275, P29829, DOI 10.1074/jbc.M002737200; Kobarg J, 1997, EXP CLIN IMMUNOGENET, V14, P273; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Lemos TA, 2003, FEBS LETT, V533, P14, DOI 10.1016/S0014-5793(02)03737-7; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Machado EL, 2002, PHYTOCHEMISTRY, V61, P835, DOI 10.1016/S0031-9422(02)00429-6; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Moraes KCM, 2003, BIOL CHEM, V384, P25, DOI 10.1515/BC.2003.004; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Ogas J, 1999, P NATL ACAD SCI USA, V96, P13839, DOI 10.1073/pnas.96.24.13839; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; ROHDE D, 1992, AM J PATHOL, V140, P473; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Tcherkasowa AE, 2002, J IMMUNOL, V169, P5161, DOI 10.4049/jimmunol.169.9.5161; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; USACHEWA A, 2001, J BIOL CHEM, V27, P22948; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	53	25	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11444	11455		10.1074/jbc.M306672200	http://dx.doi.org/10.1074/jbc.M306672200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699138	hybrid			2022-12-27	WOS:000220157600075
J	Oxford, JT; DeScala, J; Morris, N; Gregory, K; Medeck, R; Irwin, K; Oxford, R; Brown, R; Mercer, L; Cusack, S				Oxford, JT; DeScala, J; Morris, N; Gregory, K; Medeck, R; Irwin, K; Oxford, R; Brown, R; Mercer, L; Cusack, S			Interaction between amino propeptides of type XI procollagen alpha 1 chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN TYPE-XI; NONCOLLAGENOUS DOMAIN; CARTILAGE; ORGANIZATION; FORMS; IX; MORPHOGENESIS; MEMBRANE; FIBRILS; GENE	Type XI collagen is a quantitatively minor yet essential constituent of the cartilage extracellular matrix. The amino propeptide of the alpha1 chain remains attached to the rest of the molecule for a longer period of time after synthesis than the other amino propeptides of type XI collagen and has been localized to the surface of thin collagen fibrils. Yeast two-hybrid system was used to demonstrate that a homodimer of alpha1(XI) amino propeptide (alpha1(XI)Npp) could form in vivo. Interaction was also confirmed using multi-angle laser light scattering, detecting an absolute weight average molar mass ranging from the size of a monomer to the size of a dimer (25,000 50,000 g/mol), respectively. Binding was shown to be saturable by ELISA. An interaction between recombinant alpha1(XI)Npp and the endogenous alpha1(XI)Npp was observed, and specificity for alpha1(XI)Npp but not alpha2(XI)Npp was demonstrated by co-precipitation. The interaction between the recombinant form of alpha1(XI)Npp and the endogenous alpha1(XI)Npp resulted in a stable association during the regeneration of cartilage extracellular matrix by fetal bovine chondrocytes maintained in pellet culture, generating a protein that migrated with an apparent molecular mass of 50-60 kDa on an SDS-polyacrylamide gel.	Boise State Univ, Dept Biol, Boise, ID 83725 USA; Shriners Hosp Children, Portland, OR 97201 USA; Robert W Franz Canc Res Ctr, Portland, OR 97213 USA	Idaho; Boise State University	Oxford, JT (corresponding author), Boise State Univ, Dept Biol, Boise, ID 83725 USA.	joxford@boiststate.edu	Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569; Keller, Kate/0000-0002-1616-972X	NCRR NIH HHS [P20RR16454, P20 RR016454-096114, P20 RR016454-086155, P20 RR016454] Funding Source: Medline; NIAMS NIH HHS [K02 AR048672-02, K02 AR048672-05, K02 AR048672-01, R01 AR047985-05, R01 AR047985-03, R01AR47985, R01 AR047985-02, R01 AR047985, K02 AR048672-04, K02 AR048672-03, K02AR48672, K02 AR048672, R01 AR047985-01, R01 AR047985-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047985, K02AR048672] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Davies GBM, 1998, DEV DYNAM, V213, P12, DOI 10.1002/(SICI)1097-0177(199809)213:1<12::AID-AJA2>3.0.CO;2-0; Douglas SP, 1998, MATRIX BIOL, V16, P497, DOI 10.1016/S0945-053X(98)90020-8; EIKENBERRY EF, 1982, ARTICULAR CARTILAGE, P133; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Gregory KE, 2000, J BIOL CHEM, V275, P11498, DOI 10.1074/jbc.275.15.11498; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Moradi-Ameli M, 1998, MATRIX BIOL, V17, P393, DOI 10.1016/S0945-053X(98)90091-9; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SMITH GN, 1987, COLLAGEN REL RES, V7, P17; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; SUSSMAN M D, 1984, Journal of Orthopaedic Research, V2, P134, DOI 10.1002/jor.1100020204; THOM JR, 1991, J BIOL CHEM, V266, P7262; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	27	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10939	10945		10.1074/jbc.M310291200	http://dx.doi.org/10.1074/jbc.M310291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699108	Green Accepted, hybrid			2022-12-27	WOS:000220157600015
J	Favari, E; Lee, M; Calabresi, L; Franceschini, G; Zimetti, F; Bernini, F; Kovanen, PT				Favari, E; Lee, M; Calabresi, L; Franceschini, G; Zimetti, F; Bernini, F; Kovanen, PT			Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1-but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CHOLESTEROL EFFLUX; APOLIPOPROTEIN-A-I; MACROPHAGE FOAM CELLS; AORTIC INTIMAL FLUID; MAST-CELLS; APOA-I; INTERSTITIAL FLUID; FATTY STREAKS; HDL; PLASMA	The ATP-binding cassette transporter A1 (ABCA1) mediates the efflux of cellular unesterified cholesterol and phospholipid to lipid-poor apolipoprotein A-I. Chymase, a protease secreted by mast cells, selectively cleaves pre-beta-migrating particles from high density lipoprotein (HDL)(3) and reduces the efflux of cholesterol from macrophages. To evaluate whether this effect is the result of reduction of ABCA1-dependent or -independent pathways of cholesterol efflux, in this study we examined the efflux of cholesterol to preparations of chymase-treated HDL3 in two types of cell: 1) in J774 murine macrophages endogenously expressing low levels of scavenger receptor class B, type I (SR-BI), and high levels of ABCA1 upon treatment with cAMP; and 2) in Fu5AH rat hepatoma cells endogenously expressing high levels of the SR-BI and low levels of ABCA1. Treatment of HDL3 with the human chymase resulted in rapid depletion of pre-beta-HDL and a concomitant decrease in the efflux of cholesterol and phospholipid (2-fold and 3-fold, respectively) from the ABCA1-expressing J774 cells. In contrast, efflux of free cholesterol from Fu5AH to chymase-treated and to untreated HDL3 was similar. Incubation of HDL3 with phospholipid transfer protein led to an increase in pre-beta-HDL contents as well as in ABCA1-mediated cholesterol efflux. A decreased cholesterol efflux to untreated HDL3 but not to chymase-treated HDL3 was observed in ABCA1-expressing J774 with probucol, an inhibitor of cholesterol efflux to lipid-poor apoA-I. Similar results were obtained using brefeldin and gliburide, two inhibitors of ABCA1-mediated efflux. These results indicate that chymase treatment of HDL3 specifically impairs the ABCA1-dependent pathway without influencing either aqueous or SR-BI-facilitated diffusion and that this effect is caused by depletion of lipid-poor pre-beta-migrating particles in HDL3. Our results are compatible with the view that HDL3 promotes ABCA1-mediated lipid efflux entirely through its lipid-poor fraction with pre-beta mobility.	Wihuri Res Inst, SF-00140 Helsinki, Finland; Univ Parma, Dept Pharmacol & Biol Sci, I-43100 Parma, Italy; Univ Havana, Dept Biochem, Havana H10400, Cuba; Univ Milan, Dept Pharmacol Sci, Ctr E Grossi Paoletti, I-30126 Milan, Italy	Wihuri Research Institute; University of Parma; Universidad de la Habana; University of Milan	Kovanen, PT (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, SF-00140 Helsinki, Finland.	petri.kovanen@wri.fi	Bernini, Franco/B-6740-2011; 应, 宁宁/G-9472-2011; Favari, Elda/B-6830-2011	Favari, Elda/0000-0002-5901-2482; FRANCESCHINI, GUIDO/0000-0003-2687-1771; Calabresi, Laura/0000-0001-5042-9532; Zimetti, Francesca/0000-0002-6665-263X				ASZATALOS BF, 1993, BIOCHIM BIOPHYS ACTA, V1169, P301; Attie AD, 2001, J LIPID RES, V42, P1717; Bernini F, 1996, BBA-LIPID LIPID MET, V1299, P103, DOI 10.1016/0005-2760(95)00200-6; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; FIELDING CJ, 1991, CURR OPIN LIPIDOL, V2, P376; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; FRANCESCHINI G, 1985, J BIOL CHEM, V260, P6321; Ghalim N, 1996, INT J CLIN LAB RES, V26, P224, DOI 10.1007/BF02602953; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Kovanen PT, 1996, CURR OPIN LIPIDOL, V7, P281, DOI 10.1097/00041433-199610000-00004; Lee M, 1999, ARTERIOSCL THROM VAS, V19, P1066, DOI 10.1161/01.ATV.19.4.1066; Lee M, 2003, J BIOL CHEM, V278, P13539, DOI 10.1074/jbc.M210847200; Lee M, 2003, J LIPID RES, V44, P539, DOI 10.1194/jlr.M200420-JLR200; Lee M, 2002, ARTERIOSCL THROM VAS, V22, P2086, DOI 10.1161/01.ATV.0000041405.07367.B5; Lee M, 2002, ARTERIOSCL THROM VAS, V22, P1475, DOI 10.1161/01.ATV.0000029782.84357.68; Lee M, 2000, J LIPID RES, V41, P975; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; Lindstedt L, 1999, J BIOL CHEM, V274, P22627, DOI 10.1074/jbc.274.32.22627; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; Lindstedt L, 2000, BIOCHEM BIOPH RES CO, V277, P552, DOI 10.1006/bbrc.2000.3704; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Porsch-Ozcurumez M, 2001, J BIOL CHEM, V276, P12427, DOI 10.1074/jbc.M100218200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothblat GH, 2002, ATHEROSCLEROSIS, V163, P1, DOI 10.1016/S0021-9150(01)00713-4; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLOOP CH, 1987, J LIPID RES, V28, P225; Sviridov D, 2002, ARTERIOSCL THROM VAS, V22, P1482, DOI 10.1161/01.ATV.0000029120.44088.FE; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	50	110	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9930	9936		10.1074/jbc.M312476200	http://dx.doi.org/10.1074/jbc.M312476200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701812	hybrid			2022-12-27	WOS:000220050400034
J	Salicioni, AM; Gaultier, A; Brownlee, C; Cheezum, MK; Gonias, SL				Salicioni, AM; Gaultier, A; Brownlee, C; Cheezum, MK; Gonias, SL			Low density lipoprotein receptor-related protein-1 promotes beta(1) integrin maturation and transport to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CYTOPLASMIC DOMAIN; CYTOSOLIC ADAPTER; LRP; MODULATION; EXPRESSION; ADHESION; BETA-1-INTEGRIN; ACTIVATION; CATABOLISM	Low density lipoprotein receptor-related protein-1 (LRP-1) mediates the endocytosis of multiple plasma membrane proteins and thereby models the composition of the cell surface. LRP-1 also functions as a catabolic receptor for fibronectin, limiting fibronectin accumulation in association with cells. The goal of the present study was to determine whether LRP-1 regulates cell surface levels of the beta(1) integrin subunit. We hypothesized that LRP-1 may down-regulate cell surface beta(1) by promoting its internalization; however, unexpectedly, LRP-1 expression was associated with a substantial increase in cell surface beta(1) integrin in two separate cell lines, murine embryonic fibroblasts (MEFs) and CHO cells. The total amount of beta(1) integrin was unchanged because LRP-1-deficient cells retained increased amounts of beta(1) in the endoplasmic reticulum (ER). Expression of human LRP-1 in LRP-1-deficient MEFs reversed the shift in subcellular beta(1) integrin distribution. Metabolic labeling experiments demonstrated that the precursor form of newly synthesized beta(1) integrin (p105) is converted into mature beta(1) (p125) more slowly in LRP-1-deficient cells. Although low levels of cell surface beta(1) integrin, in LRP-1-deficient MEFs, were associated with decreased adhesion to fibronectin, the subcellular distribution of beta(1) integrin was most profoundly dependent on LRP-1 only after the cell cultures became confluent. A mutagen-treated CHO cell line, in which LRP-1 is expressed but retained in the secretory pathway, also demonstrated nearly complete ER retention of beta(1) integrin. These studies support a model in which LRP-1 either directly or indirectly promotes maturation of beta(1) integrin precursor and thereby increases the level of beta(1) integrin at the cell surface.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu	Salicioni, Ana Maria/ABD-8384-2021	Salicioni, Ana Maria/0000-0002-8951-3587	NHLBI NIH HHS [R01 HL60551] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Alais S, 2001, J CELL SCI, V114, P1847; Arandjelovic S, 2003, BIOCHEMISTRY-US, V42, P6121, DOI 10.1021/bi0342158; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Chang DD, 2002, J BIOL CHEM, V277, P8140, DOI 10.1074/jbc.M109031200; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; DESTROOPER B, 1991, EUR J BIOCHEM, V199, P25; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HEINO J, 1989, J BIOL CHEM, V264, P380; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; LENTER M, 1994, J BIOL CHEM, V269, P12263; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Martel V, 2000, J CELL SCI, V113, P1951; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Tran H, 2002, J CELL SCI, V115, P2031; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Weaver AM, 1996, J BIOL CHEM, V271, P24894, DOI 10.1074/jbc.271.40.24894; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WILLNOW TE, 1994, J CELL SCI, V107, P719	46	66	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10005	10012		10.1074/jbc.M306625200	http://dx.doi.org/10.1074/jbc.M306625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699139	hybrid			2022-12-27	WOS:000220050400044
J	Malanga, M; Althaus, FR				Malanga, M; Althaus, FR			Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEXES; CAMPTOTHECIN; DOMAINS; LINKER; PARP-2; ASSOCIATION; COVALENT; CLEAVAGE; REPAIR; BINDS	Regulating the topological state of DNA is a vital function of the enzyme DNA topoisomerase I. However, when acting on damaged DNA, topoisomerase I may get trapped in a covalent complex with nicked DNA (stalled topoisomerase I), that, if unrepaired, may lead to genomic instability or cell death. Here we show that ADP-ribose polymers target specific domains of topoisomerase I and reprogram the enzyme to remove itself from cleaved DNA and close the resulting gap. Two members of the poly(ADP-ribose) polymerase family, PARP-1 and 2, act as poly(ADP-ribose) carriers to stalled topoisomerase I sites and induce efficient repair of enzyme-associated DNA strand breaks. Thus, by counteracting topoisomerase I-induced DNA damage, PARP-1 and PARP-2 act as positive regulators of genomic stability in eukaryotic cells.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich	Althaus, FR (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	fra@vetpharm.unizh.ch						Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Beneke S, 2000, EXP GERONTOL, V35, P989, DOI 10.1016/S0531-5565(00)00134-0; Bowman KJ, 2001, BRIT J CANCER, V84, P106, DOI 10.1054/bjoc.2000.1555; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Chatterjee S, 1989, Cancer Commun, V1, P389; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Fiorani P, 2003, J BIOL CHEM, V278, P43268, DOI 10.1074/jbc.M303899200; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MALANGA M, 1995, ANAL BIOCHEM, V228, P245, DOI 10.1006/abio.1995.1346; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Mao YH, 2000, CANCER RES, V60, P4538; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; OGATA N, 1981, J BIOL CHEM, V256, P4135; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; PANZETER PL, 1990, NUCLEIC ACIDS RES, V18, P2194, DOI 10.1093/nar/18.8.2194; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; REALINI CA, 1992, J BIOL CHEM, V267, P18858; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shuman S, 2000, METH MOL B, V95, P65; Soe K, 2001, NUCLEIC ACIDS RES, V29, P3195, DOI 10.1093/nar/29.15.3195; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; Yang Z, 2002, J BIOL CHEM, V277, P30815, DOI 10.1074/jbc.M205302200	36	108	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5244	5248		10.1074/jbc.C300437200	http://dx.doi.org/10.1074/jbc.C300437200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14699148	hybrid, Green Accepted			2022-12-27	WOS:000188776500026
J	Natale, P; Swaving, J; van der Does, C; de Keyzer, J; Driessen, AJM				Natale, P; Swaving, J; van der Does, C; de Keyzer, J; Driessen, AJM			Binding of SecA to the SecYEG complex accelerates the rate of nucleotide exchange on SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCASE SUBUNIT SECA; COLI PLASMA-MEMBRANE; DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; BACILLUS-SUBTILIS; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; CATALYTIC CYCLE	SecYEG translocase mediates the transport of preproteins across the inner membrane of Escherichia coli. SecA binds the membrane-embedded SecYEG protein-conducting channel with high affinity and then drives the stepwise translocation of preproteins across the membrane through multiple cycles of ATP binding and hydrolysis. We have investigated the kinetics of nucleotide binding to SecA while associated with the SecYEG complex. Lipid-bound SecA was separated from Se-cYEG-bound SecA by sedimentation of the proteoliposomes through a glycerol cushion, which maintains the SecA native state and effectively removes the lipid-bound SecA fraction. Nucleotide binding was assessed by means of fluorescence resonance energy transfer using fluorescent ATP analogues as acceptors of the intrinsic SecA tryptophan fluorescence in the presence of a tryptophanless variant of the SecYEG complex. Binding of SecA to the SecYEG complex elevated the rate of nucleotide exchange at SecA independently of the presence of preprotein. This defines a novel pretranslocation activated state of SecA that is primed for ATP hydrolysis upon preprotein interaction.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, NL-9750 AA Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, NL-9750 AA Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Natale, Paolo/E-9326-2012; Driessen, Arnold J.M./D-1876-2012	Natale, Paolo/0000-0002-4759-0816; Driessen, Arnold J.M./0000-0001-9258-9104				AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Bu ZM, 2003, J MOL BIOL, V332, P23, DOI 10.1016/S0022-2836(03)00840-4; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; den Blaauwen T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2003, BIOCHEMISTRY-US, V42, P8729, DOI 10.1021/bi0342057; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; PERSHT A, 1999, STRUCTURE MECH PROTE, P143; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	45	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13769	13777		10.1074/jbc.M312892200	http://dx.doi.org/10.1074/jbc.M312892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722060	hybrid, Green Published			2022-12-27	WOS:000220478500061
J	Valadez, JG; Guengerich, FP				Valadez, JG; Guengerich, FP			S-(2-chloroethyl)glutathione-generated p53 mutation spectra are influenced by differential repair rates more than sites of initial DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSE-DEPENDENT DIFFERENCES; LIGATION-MEDIATED PCR; GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; BENZO<A>PYRENE DIOL EPOXIDE; UV-INDUCED MUTAGENESIS; FUNCTIONAL ASSAY; ALKYLATING-AGENTS; SKIN-CANCER; TRANSVERSION MUTATIONS; MOLECULAR EPIDEMIOLOGY	Several steps occur between the reaction of a chemical with DNA and a mutation, and each may influence the resulting mutation spectrum, i.e. nucleotides at which the mutations occur. The half-mustard S-(2-bromoethyl) glutathione is the reactive conjugate implicated in ethylene dibromide-induced mutagenesis attributed to the glutathione-dependent pathway. A human p53-driven Ade reporter system in yeast was used to study the factors involved in producing mutations. The synthetic analog S-(2-chloroethyl) glutathione was used to produce DNA damage; the damage to the p53 exons was analyzed using a new fluorescence-based modification of ligation-mediated polymerase chain reaction and an automated sequencer. The mutation spectrum was strongly dominated by the G to A transition mutations seen in other organisms with S-(2-chloroethyl) glutathione or ethylene dibromide. The mutation spectrum clearly differed from the spontaneous spectrum or that derived from N-ethyl,N-nitrosourea. Distinct differences were seen between patterns of modification of p53 DNA exposed to the mutagen in vitro versus in vivo. In the four p53 exons in which mutants were analyzed, the major sites of mutation matched the sites with long half-lives of repair much better than the sites of initial damage. However, not all slowly repaired sites yielded mutations in part because of the lack of effect of mutations on phenotype. We conclude that the rate of DNA repair at individual nucleotides is a major factor in influencing the mutation spectra in this system. The results are consistent with a role of N-7-guanyl adducts in mutagenesis.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; IPN, Ctr Invest & Estudios Avanzados, Dept Biotecnol & Bioingn, Mexico City 07360, DF, Mexico	Vanderbilt University; Vanderbilt University; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [P30 ES00267, R01 ES10546] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010546, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBROSE BJB, 1988, ANAL BIOCHEM, V169, P151, DOI 10.1016/0003-2697(88)90266-7; AMBROSE BJB, 1985, BIOCHEMISTRY-US, V24, P6194, DOI 10.1021/bi00343a025; AMES BN, 1979, SCIENCE, V204, P587, DOI 10.1126/science.373122; Bailey EA, 1996, P NATL ACAD SCI USA, V93, P1535, DOI 10.1073/pnas.93.4.1535; BALLERING LAP, 1994, CARCINOGENESIS, V15, P869, DOI 10.1093/carcin/15.5.869; Bauer KH, 1928, MUTATIONSTHEORIE GES; BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068; BENZER S, 1961, P NATL ACAD SCI USA, V47, P403, DOI 10.1073/pnas.47.3.403; Cariello NF, 1998, NUCLEIC ACIDS RES, V26, P198, DOI 10.1093/nar/26.1.198; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Cloutier JF, 2001, J MOL BIOL, V306, P169, DOI 10.1006/jmbi.2000.4371; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; Colominas C, 1996, J AM CHEM SOC, V118, P6811, DOI 10.1021/ja954293l; Dai SM, 2000, NAT BIOTECHNOL, V18, P1108, DOI 10.1038/80323; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; Fronza G, 2000, MUTAT RES-REV MUTAT, V462, P293, DOI 10.1016/S1383-5742(00)00011-9; Graves RJ, 1996, MUTAGENESIS, V11, P229, DOI 10.1093/mutage/11.3.229; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hatahet Z, 1998, P NATL ACAD SCI USA, V95, P8556, DOI 10.1073/pnas.95.15.8556; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; Holmquist GP, 1997, MUTAT RES-REV MUTAT, V386, P69, DOI 10.1016/S1383-5742(96)00045-2; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; HURLEY LH, 1986, ACCOUNTS CHEM RES, V19, P230, DOI 10.1021/ar00128a001; INSKEEP PB, 1986, CANCER RES, V46, P2839; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; KIERDASZUK B, 1993, BIOPHYS CHEM, V46, P207, DOI 10.1016/0301-4622(93)80014-A; KIM DH, 1990, CHEM RES TOXICOL, V3, P587, DOI 10.1021/tx00018a015; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; KOGA N, 1986, BIOCHEMISTRY-US, V25, P2192, DOI 10.1021/bi00356a051; KOHN KW, 1987, NUCLEIC ACIDS RES, V15, P10531, DOI 10.1093/nar/15.24.10531; Lawley P. D., 1984, CHEM CARCINOGENS, P324; LAWLEY PD, 1961, NATURE, V192, P1081, DOI 10.1038/1921081b0; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; Liu LP, 2002, J BIOL CHEM, V277, P37920, DOI 10.1074/jbc.M205548200; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Moore DD, 1995, GLOB MOB SURV; Moshinsky DJ, 2000, ENVIRON MOL MUTAGEN, V35, P31, DOI 10.1002/(SICI)1098-2280(2000)35:1<31::AID-EM5>3.0.CO;2-S; Moshinsky DJ, 1997, P NATL ACAD SCI USA, V94, P2266, DOI 10.1073/pnas.94.6.2266; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; OLSON WA, 1973, JNCI-J NATL CANCER I, V51, P1993, DOI 10.1093/jnci/51.6.1993; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; PERSMARK M, 1994, BIOCHEMISTRY-US, V33, P8662, DOI 10.1021/bi00195a006; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P1, DOI 10.1016/S0027-5107(00)00012-9; PFEIFER GP, 1993, MUTAT RES, V288, P39, DOI 10.1016/0027-5107(93)90206-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; Pfeifer GP, 1998, ENVIRON MOL MUTAGEN, V31, P197, DOI 10.1002/(SICI)1098-2280(1998)31:3<197::AID-EM1>3.0.CO;2-I; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; RICHARDSON FC, 1990, MUTAT RES, V233, P127, DOI 10.1016/0027-5107(90)90157-Y; Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SAID B, 1991, NUCLEIC ACIDS RES, V19, P1311, DOI 10.1093/nar/19.6.1311; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Suen W, 1999, P NATL ACAD SCI USA, V96, P4500, DOI 10.1073/pnas.96.8.4500; SUN M, 1984, SCIENCE, V223, P464, DOI 10.1126/science.6362008; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Szabo Piroska E., 1996, P343; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; Vaisman A, 2003, DNA REPAIR, V2, P991, DOI 10.1016/S1568-7864(03)00094-6; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; Wei SJC, 1996, CANCER RES, V56, P3695; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; WURDEMAN RL, 1989, J AM CHEM SOC, V111, P6408, DOI 10.1021/ja00198a064; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; Yoon JH, 2003, CARCINOGENESIS, V24, P113, DOI 10.1093/carcin/24.1.113; Yoon JH, 2001, CANCER RES, V61, P7110; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	84	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13435	13446		10.1074/jbc.M312358200	http://dx.doi.org/10.1074/jbc.M312358200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715658	hybrid			2022-12-27	WOS:000220478500021
J	Sah, JF; Balasubramanian, S; Eckert, RL; Rorke, EA				Sah, JF; Balasubramanian, S; Eckert, RL; Rorke, EA			Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway - Evidence for direct inhibition of ERK1/2 and AKT kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECTOCERVICAL EPITHELIAL-CELLS; FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASES; BREAST-CANCER CELLS; CARCINOMA-CELLS; HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; MESSENGER-RNA; RETINOIC ACID; TEA	Epidermal growth factor receptor (EGFR) activation is absolutely required for cervical cell proliferation. This suggests that EGFR-inhibitory agents may be of therapeutic value. In the present study, we investigated the effects of epigallocatechin-3-gallate (EGCG), a bioactive green tea polyphenol, on EGFR signaling in cervical cells. EGCG inhibits epidermal growth factor-dependent activation of EGFR, and EGFR-dependent activation of the mitogen-activated protein kinases ERK1/2. EGCG also inhibits EGFR-dependent AKT activity. The EGCG-dependent reduction in ERK and AKT activity is associated with reduced phosphorylation of downstream substrates, including p90RSK, FKHR, and BAD. These changes are associated with increased p53, p21(WAF-1), and p27(KIP-1) levels, reduced cyclin E level, and reduced CDK2 kinase activity. Consistent with these findings, flow cytometry and TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling) staining revealed EGCG-dependent G(1) arrest. Moreover, sustained EGCG treatment caused apoptotic cell death. In addition to inhibiting EGFR, cell-free studies demonstrated that EGCG directly inhibits ERK1/2 and AKT, suggesting that EGCG acts simultaneously at multiple levels to inhibit EGF-dependent signaling. Importantly, the EGCG inhibition is selective, as EGCG does not effect the EGFR-dependent activation of JNK. These results suggest that EGCG acts to selectively inhibit multiple EGF-dependent kinases to inhibit cell proliferation.	Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rorke, EA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA.	ear4@po.cwru.edu		Sah, Jerome/0000-0001-9478-7155	NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009126] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIEHS NIH HHS [ES 009126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Akerman GS, 2001, CANCER RES, V61, P3837; Annabi B, 2002, BBA-MOL CELL RES, V1542, P209, DOI 10.1016/S0167-4889(01)00187-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; GULLICK WJ, 1986, CANCER RES, V46, P285; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hernaez JF, 1998, MUTAT RES-FUND MOL M, V402, P299, DOI 10.1016/S0027-5107(97)00309-6; Howley P M, 1991, Princess Takamatsu Symp, V22, P239; JACOBBERGER JW, 1995, EXP CELL RES, V220, P390, DOI 10.1006/excr.1995.1330; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Katiyar SK, 2001, INT J ONCOL, V18, P1307; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang YC, 1999, J CELL BIOCHEM, V75, P1; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Masuda M, 2001, CLIN CANCER RES, V7, P4220; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Murthy NS, 2000, EUR J CANCER PREV, V9, P5, DOI 10.1097/00008469-200002000-00002; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ngan HYS, 2001, TUMOR BIOL, V22, P176, DOI 10.1159/000050613; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Otsuka T, 1998, LIFE SCI, V63, P1397, DOI 10.1016/S0024-3205(98)00406-8; Page C, 2000, INT J ONCOL, V17, P23; Pianetti S, 2002, CANCER RES, V62, P652; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SIZEMORE N, 1993, CANCER RES, V53, P4511; Sizemore N, 1998, EXP CELL RES, V244, P349, DOI 10.1006/excr.1998.4179; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Ueda M, 1992, Nihon Sanka Fujinka Gakkai Zasshi, V44, P1165; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang ZQ, 2003, J BIOL CHEM, V278, P11138, DOI 10.1074/jbc.M209108200; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Zhu XF, 2001, CANCER LETT, V169, P27, DOI 10.1016/S0304-3835(01)00547-X; ZUR HH, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF55	54	206	227	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12755	12762		10.1074/jbc.M312333200	http://dx.doi.org/10.1074/jbc.M312333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701854	hybrid			2022-12-27	WOS:000220334900089
J	Sayer, NM; Cubin, M; Rhie, A; Bullock, M; Tahiri-Alaoui, A; James, W				Sayer, NM; Cubin, M; Rhie, A; Bullock, M; Tahiri-Alaoui, A; James, W			Structural determinants of conformationally selective, prion-binding aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGIFORM ENCEPHALOPATHY; RNA LIGANDS; PROTEIN; SCRAPIE; DISEASE; MICE; INFECTIVITY; POLYMERASE; CONVERSION; RESISTANT	We have recently described the isolation of 2'-fluoropyrimidine-substituted RNA aptamers that bind selectively to disease-associated beta-sheet-rich forms of the prion protein, PrP, from a number of mammalian species. These aptamers inhibit the accumulation of protease-resistant forms of PrP in a prion-seeded, in vitro conversion assay. Here we identify the minimal portions of two of these aptamers that retain binding specificity. We determine their secondary structures by a combination of modeling and solution probing. Finally, we identify an internal site for biotinylation of a minimized, synthetic aptamer and use the resultant reagent in the detection of abnormal forms of PrP in vitro.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	James, W (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	William.james@path.ox.ac.uk	james, william/H-4289-2013	james, william/0000-0002-2506-1198				AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; Hur K, 2002, MECH AGEING DEV, V123, P1637, DOI 10.1016/S0047-6374(02)00099-4; Ingrosso L, 2002, TRENDS MOL MED, V8, P273, DOI 10.1016/S1471-4914(02)02358-4; James William, 2001, Current Opinion in Pharmacology, V1, P540, DOI 10.1016/S1471-4892(01)00093-5; Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003; Kraus E, 1998, J IMMUNOL, V160, P5209; Nguyen DH, 2002, J AM CHEM SOC, V124, P15081, DOI 10.1021/ja027635d; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; Rubenstein R, 1998, BIOCHEM BIOPH RES CO, V246, P100, DOI 10.1006/bbrc.1998.8542; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Sayer N, 2002, BIOCHEM BIOPH RES CO, V293, P924, DOI 10.1016/S0006-291X(02)00308-X; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; TAHIRIALAOUI A, 2002, NUCLEIC ACIDS RES, V30, P1; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	29	88	93	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13102	13109		10.1074/jbc.M310928200	http://dx.doi.org/10.1074/jbc.M310928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711834	hybrid			2022-12-27	WOS:000220334900131
J	Shi, SL; Grothe, S; Zhang, YP; O'Connor-McCourt, MD; Poole, AR; Roughley, PJ; Mort, JS				Shi, SL; Grothe, S; Zhang, YP; O'Connor-McCourt, MD; Poole, AR; Roughley, PJ; Mort, JS			Link protein has greater affinity for versican than aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE AGGREGATING PROTEOGLYCAN; BOVINE ARTICULAR-CARTILAGE; HYALURONIC-ACID; EQUILIBRIUM-BINDING; CDNA CLONING; SULFATE; DOMAIN; BRAIN; MONOMERS; ABSENCE	The function of link protein in stabilizing the interaction between aggrecan and hyaluronan to form aggrecan aggregates, via the binding of link protein to the aggrecan G1 domain and hyaluronan, is well established. However, it is not known whether link protein can function with similar avidity with versican, another member of the large hyaluronan-binding proteoglycan family that also binds to hyaluronan via its G1 domain. To address this issue, we have compared the interaction of the versican and aggrecan G1 domains with link protein and hyaluronan using recombinant proteins expressed in insect cells and BIAcore analysis. The results showed that link protein could significantly improve the binding of both G1 domains to hyaluronan and that its interaction with VG1 is of a higher affinity than that with AG1. These observations suggest that link protein may function as a stabilizer of the interaction, not only between aggrecan and hyaluronan in cartilage, but also between versican and hyaluronan in many tissues.	Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; Natl Res Council Canada, Receptor Signalling & Prote Grp, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	McGill University; McGill University; McGill University; McGill University; National Research Council Canada	Mort, JS (corresponding author), Shriners Hosp Children, Joint Dis Lab, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.	jmort@shriners.mcgill.ca						BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKWALTER JA, 1984, J BIOL CHEM, V259, P5361; CATERSON B, 1978, BIOCHEM BIOPH RES CO, V80, P496, DOI 10.1016/0006-291X(78)91596-6; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DUDHIA J, 1990, NUCLEIC ACIDS RES, V18, P2214, DOI 10.1093/nar/18.8.2214; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; LYON M, 1983, BIOCHEM J, V213, P445, DOI 10.1042/bj2130445; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Melrose J, 1998, ANAL BIOCHEM, V256, P149, DOI 10.1006/abio.1997.2509; MORGELIN M, 1988, BIOCHEM J, V253, P175; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; Shi SL, 2003, ARTHRITIS RHEUM-US, V48, P2903, DOI 10.1002/art.11270; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	32	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12060	12066		10.1074/jbc.M310091200	http://dx.doi.org/10.1074/jbc.M310091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724283	hybrid			2022-12-27	WOS:000220334900009
J	Swiatek, W; Tsai, IC; Klimowski, L; Pepler, A; Barnette, J; Yost, HJ; Virshup, DM				Swiatek, W; Tsai, IC; Klimowski, L; Pepler, A; Barnette, J; Yost, HJ; Virshup, DM			Regulation of casein kinase I epsilon activity by Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; CATENIN DEGRADATION COMPLEX; POLYPOSIS-COLI GENE; BETA-CATENIN; PHOSPHORYLATION; AXIN; PATHWAY; SUBUNIT; FAMILY; DELTA	The Wnt/beta- catenin signaling pathway is important in both development and cancer. Casein kinase Iepsilon (CKIepsilon) is a positive regulator of the canonical Wnt pathway. CKIepsilon itself can be regulated in vitro by inhibitory autophosphorylation, and recent data suggest that in vivo kinase activity can be regulated by extracellular stimuli. We show here that the phosphorylation state and kinase activity of CKIepsilon are directly regulated by Wnt signaling. Coexpression of XWnt- 8 or addition of soluble Wnt- 3a ligand led to a significant and rapid increase in the activity of endogenous CKIepsilon. The increase in CKIepsilon activity is the result of decreased inhibitory autophosphorylation because it is abolished by preincubation of immunoprecipitated kinase with ATP. Furthermore, mutation of CKIepsilon inhibitory autophosphorylation sites creates a kinase termed CKIepsilon ( MM2) that is significantly more active than CKIepsilon and is not activated further upon Wnt stimulation. Autoinhibition of CKIepsilon is biologically relevant because CKIepsilon ( MM2) is more effective than CKIepsilon at activating transcription from a Lef1- dependent promoter. Finally, CKIepsilon ( MM2) expression in Xenopus embryos induces both axis duplication and additional developmental abnormalities. The data suggest that Wnt signaling activates CKIepsilon by causing transient dephosphorylation of critical inhibitory sites present in the carboxyl- terminal domain of the kinase. Activation of the Wnt pathway may therefore stimulate a cellular phosphatase to dephosphorylate and activate CKIepsilon.	Univ Utah, Huntsman Canc Inst, Ctr Children, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Ctr Children, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	David.Virshup@hci.utah.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [R01 CA 80809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Sillibourne JE, 2002, J MOL BIOL, V322, P785, DOI 10.1016/S0022-2836(02)00857-4; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zilian O, 1999, DEVELOPMENT, V126, P5409	43	92	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13011	13017		10.1074/jbc.M304682200	http://dx.doi.org/10.1074/jbc.M304682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722104	hybrid			2022-12-27	WOS:000220334900121
J	Uekita, T; Gotoh, I; Kinoshita, T; Itoh, Y; Sato, H; Shiomi, T; Okada, Y; Seiki, M				Uekita, T; Gotoh, I; Kinoshita, T; Itoh, Y; Sato, H; Shiomi, T; Okada, Y; Seiki, M			Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily - A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SALVAGE PATHWAY; KLEBSIELLA-PNEUMONIAE; CELL INVASION; MT1-MMP; HEMOPEXIN; CLEAVAGE; SURFACE; DOMAIN; OLIGOMERIZATION; PROTEOLYSIS	Membrane-type 1 matrix metalloproteinase (MT1MMP/MMP-14) is an enzyme that promotes tumor cell invasion in tissues. Although the proteolytic activity of MT1-MMP is indispensable for invasion, it is also regulated by functions of the cytoplasmic tail. In this study we obtained a new human gene whose product binds to the tail sequence in yeast. The product, MTCBP-1, is a 19-kDa protein that belongs to the newly proposed Cupin superfamily composed of proteins with diverse functions. MTCBP-1 expressed in cells formed a complex with MT1-MMP and co-localized at the membrane. It was also detected in both the cytoplasm and nucleus, where MT1-MMP does not exist. In human tumor cell lines MTCBP-1 expression was significantly low compared with non-transformed fibroblasts, and enforced expression of MTCBP-1 inhibited the activity of MT1-MMP in promoting cell migration and invasion. MTCBP-1 showed significant homology to the bacterial aci-reductone dioxygenase, which is an enzyme in methionine metabolism. The C-terminal part of MTCBP-1 is identical to Sip-L, which is reported to be important for human hepatitis C virus replication. Thus, MTCBP-1 may have multiple functions other than the regulation of MT1-MMP, which presumably depends on the subcellular compartment.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan	University of Tokyo; Kanazawa University; Keio University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Okada, Yasunori/B-5550-2014; Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; KINOSHITA, Takeshi/D-8436-2015; Shiomi, Takayuki/A-2228-2014	Okada, Yasunori/0000-0001-9208-4755; Shiomi, Takayuki/0000-0002-4250-1204; Itoh, Yoshifumi/0000-0002-2128-2823				Dai Y, 1999, J BIOL CHEM, V274, P1193, DOI 10.1074/jbc.274.3.1193; Dai Y, 2001, BIOCHEMISTRY-US, V40, P6379, DOI 10.1021/bi010110y; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; MYERS RW, 1993, J BIOL CHEM, V268, P24785; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pochapsky TC, 2002, NAT STRUCT BIOL, V9, P966, DOI 10.1038/nsb863; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; WRAY JW, 1993, J BIOL CHEM, V268, P21466; Yeh CT, 2001, J VIROL, V75, P11017, DOI 10.1128/JVI.75.22.11017-11024.2001	26	61	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12734	12743		10.1074/jbc.M309957200	http://dx.doi.org/10.1074/jbc.M309957200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718544	hybrid			2022-12-27	WOS:000220334900087
J	Cui, WW; Tomarev, SI; Piatigorsky, J; Chepelinsky, AB; Duncan, MK				Cui, WW; Tomarev, SI; Piatigorsky, J; Chepelinsky, AB; Duncan, MK			Mafs, Prox1, and Pax6 can regulate chicken beta B1-crystallin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CRYSTALLIN GENE; LENS DEVELOPMENT; C-MAF; TRANSCRIPTION FACTORS; HOMEOBOX GENE; TRANSGENIC MICE; MOUSE LENS; MOLECULAR-FEATURES; RESPONSIVE ELEMENT; DELTA-CRYSTALLIN	During lens fiber cell differentiation, the regulation of crystallin gene expression is coupled with dramatic morphological changes. Here we report that Mafs, Prox1, and Pax6, which are essential transcription factors for normal lens development, bind to three functionally important cis elements, PL1, PL2, and OL2, in the chicken betaB1-crystallin promoter and may cooperatively direct the transcription of this lens fiber cell preferred gene. Gel shift assays demonstrated that Mafs bind to the MARE-like sequences in the PL1 and PL2 elements, whereas Prox1, a sequence-specific DNA-binding protein like its Drosophila homolog Prospero, interacts with the OL2 element. Furthermore, Pax6, a known repressor of the chicken betaB1-crystallin promoter, binds to all three of these cis elements. In transfection assays, Mafs and Prox1 activated the chicken betaB1-crystallin promoter; however, their transactivation ability was repressed when co-transfected with Pax6. Taken together with the known spatiotemporal expression patterns of Mafs, Prox1, and Pax6 in the developing lens, we propose that Pax6 occupies and represses the chicken betaB1-crystallin promoter in lens epithelial cells, and is displaced by Prox1 and Mafs, which activate the promoter, in differentiating cortical fiber cells.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	University of Delaware; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Duncan, MK (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.	duncanm@udel.edu		Duncan, Melinda/0000-0003-1570-322X	NATIONAL EYE INSTITUTE [R01EY012221, Z01EY000126, Z01EY000311, Z01EY000253] Funding Source: NIH RePORTER; NEI NIH HHS [EY12221] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashery-Padan R, 2000, GENE DEV, V14, P2701, DOI 10.1101/gad.184000; BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293; BRAHMA SK, 1988, EXP EYE RES, V47, P507, DOI 10.1016/0014-4835(88)90060-7; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chen Q, 2002, J BIOL CHEM, V277, P24081, DOI 10.1074/jbc.M201821200; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Chow RL, 1999, DEVELOPMENT, V126, P4213; Civil A, 2002, NUCLEIC ACIDS RES, V30, P975, DOI 10.1093/nar/30.4.975; Collinson JM, 2001, P NATL ACAD SCI USA, V98, P9688, DOI 10.1073/pnas.161144098; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; DUNCAN MK, 1995, BBA-GENE STRUCT EXPR, V1261, P68, DOI 10.1016/0167-4781(94)00223-P; Duncan MK, 1996, MECH DEVELOP, V57, P79, DOI 10.1016/0925-4773(96)00533-3; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Duncan MK, 2002, MECH DEVELOP, V112, P195, DOI 10.1016/S0925-4773(01)00645-1; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; Hassan B, 1997, P NATL ACAD SCI USA, V94, P10991, DOI 10.1073/pnas.94.20.10991; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; HEJTMANCIK JF, 1985, DEV BIOL, V109, P72, DOI 10.1016/0012-1606(85)90347-1; Huang WD, 2002, J BIOL CHEM, V277, P50668, DOI 10.1074/jbc.M206544200; Ilagan JG, 1999, J BIOL CHEM, V274, P19973, DOI 10.1074/jbc.274.28.19973; Ishibashi S, 2001, MECH DEVELOP, V101, P155, DOI 10.1016/S0925-4773(00)00585-2; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Kralova J, 2002, GENE, V286, P271, DOI 10.1016/S0378-1119(02)00425-0; Krausz E, 1996, INVEST OPHTH VIS SCI, V37, P2120; Lengler J, 2001, NUCLEIC ACIDS RES, V29, P515, DOI 10.1093/nar/29.2.515; Liu YW, 2003, MOL CELL BIOL, V23, P7243, DOI 10.1128/MCB.23.20.7243-7255.2003; Muta M, 2002, GENES CELLS, V7, P791, DOI 10.1046/j.1365-2443.2002.00560.x; Ogino H, 2000, DEV GROWTH DIFFER, V42, P437; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Piatigorsky Joram, 2003, Journal of Structural and Functional Genomics, V3, P131; Planque N, 2001, J BIOL CHEM, V276, P35751, DOI 10.1074/jbc.M104523200; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Ring BZ, 2000, DEVELOPMENT, V127, P307; ROTH HJ, 1991, MOL CELL BIOL, V11, P1488, DOI 10.1128/MCB.11.3.1488; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; Taube JR, 2002, TRANSGENIC RES, V11, P397, DOI 10.1023/A:1016364001095; Tomarev SI, 1996, DEV DYNAM, V206, P354, DOI 10.1002/(SICI)1097-0177(199608)206:4<354::AID-AJA2>3.0.CO;2-H; TOMAREV SI, 1994, J MOL EVOL, V39, P134; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wistow G, 2002, MOL VIS, V8, P171; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	60	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11088	11095		10.1074/jbc.M312414200	http://dx.doi.org/10.1074/jbc.M312414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707122	hybrid			2022-12-27	WOS:000220157600032
J	Li, QX; Cheon, YP; Kannan, A; Shanker, S; Bagchi, IC; Bagchi, MK				Li, QX; Cheon, YP; Kannan, A; Shanker, S; Bagchi, IC; Bagchi, MK			A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GENE-EXPRESSION; MOUSE UTERUS; TARGETED DISRUPTION; EMBRYO IMPLANTATION; NUCLEAR RECEPTORS; FATTY-ACIDS; GROWTH; ALPHA; LIPOXYGENASES	The 12/15-lipoxygenases (12/15-LOX) catalyze the stereospecific oxygenation of arachidonic and linoleic acids into a complex series of signaling molecules, including the hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadecadienoic acids (HODEs). Our previous studies, using high density oligonucleotide microarrays, suggested a novel link between progesterone receptor ( PR) signaling and 12/15-LOX-mediated fatty acid metabolism in preimplantation mouse uterus. In this paper, using PR knockout mice, we established that the transcripts encoding leukocyte-12/15-LOX (L-12/15-LOX) and epidermal-12/15-LOX (E-12/15-LOX) are indeed downstream targets of regulation by PR in the uterine surface epithelium. Maximal induction of both L- and E-12/15-LOX on the day of implantation resulted in a marked increase in the uterine levels of the eicosanoids, 12-HETE, 15-HETE, and 13-HODE. Mice with null mutation in L-12/15-LOX had significantly reduced uterine levels of arachidonic acid metabolites and exhibited a partial impairment in implantation. Complete blockade of uterine 12/15-LOX activity by a specific inhibitor led to greater than 80% reduction in a number of implantation sites relative to untreated controls. Cell-based assays indicated that 12-HETE, 15-HETE, and 13-HODE function as activating ligands of peroxisome proliferator-activated receptor gamma (PPARgamma), suggesting that this nuclear receptor could be a downstream target of 12/15LOX-derived metabolites in the preimplantation uterus. Consistent with this hypothesis, administration of rosiglitazone, a potent PPARgamma-selective agonist, efficiently reversed inhibition of implantation by the 12/15-LOX-specific inhibitor. Rosiglitazone also induced a number of potential target genes of 12/15-LOX-derived metabolites in the pregnant uterus, indicating their regulation by PPARgamma. Collectively, our results uncovered a novel signaling pathway in which progesterone-induced synthesis of the 12/15-LOX-derived lipid mediators activates PPARgamma and its downstream gene networks, which in turn function as critical regulators of implantation in the mouse.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Biosci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bagchi, MK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 534 Burrill Hall,MC-114,407 S Goodwin Ave, Urbana, IL 61801 USA.	mbagchi@life.uiuc.edu			NICHD NIH HHS [R01 HD39291, R01 HD44611, R01 HD43381] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039291, R01HD044611, R01HD043381] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIZU E, 1986, CARCINOGENESIS, V7, P1809, DOI 10.1093/carcin/7.11.1809; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Campos MM, 2000, NEUROPEPTIDES, V34, P314, DOI 10.1054/npep.2000.0823; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheon YP, 2002, MOL ENDOCRINOL, V16, P2853, DOI 10.1210/me.2002-0270; Conrad DJ, 1999, CLIN REV ALLERG IMMU, V17, P71, DOI 10.1007/BF02737598; Dailey LA, 1999, CURR MED CHEM, V6, P389; DAS SK, 1992, ENDOCRINOLOGY, V130, P3459, DOI 10.1210/en.130.6.3459; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; DRINKWATER CC, 1987, BIOCHEMISTRY-US, V26, P6750, DOI 10.1021/bi00395a026; Espey Lawrence L., 1994, P725; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gidley-Baird A A, 1981, J Reprod Fertil Suppl, V29, P97; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McDonnell M, 2001, PROSTAG OTH LIPID M, V63, P93, DOI 10.1016/S0090-6980(00)00100-3; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mikuni M, 1998, BIOL REPROD, V58, P1211, DOI 10.1095/biolreprod58.5.1211; Mirochnitchenko O, 2000, CIRC RES, V87, P289, DOI 10.1161/01.RES.87.4.289; MIYAZAKI Y, 1989, NUCLEIC ACIDS RES, V17, P3298, DOI 10.1093/nar/17.8.3298; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAKADATE T, 1985, J PHARM PHARMACOL, V37, P71, DOI 10.1111/j.2042-7158.1985.tb04938.x; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Parr MB., 1989, BIOL UTERUS, P233; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Philibert D, 1985, ANTIPROGESTIN STEROI, P49; Pinto FM, 2001, EUR J PHARMACOL, V425, pR1, DOI 10.1016/S0014-2999(01)01186-4; PSYCHOYOS A, 1973, HDB PHYSL, P187; REICH R, 1983, PROSTAGLANDINS, V26, P1011, DOI 10.1016/0090-6980(83)90161-2; Schild RL, 2002, J CLIN ENDOCR METAB, V87, P1105, DOI 10.1210/jc.87.3.1105; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAKAHASHI T, 1994, CELL GROWTH DIFFER, V5, P919; THOMAS T, 1995, BBA-GENE STRUCT EXPR, V1261, P77, DOI 10.1016/0167-4781(94)00224-Q; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Weitlauf H. M., 1994, P391; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P3923, DOI 10.1210/en.139.9.3923	57	66	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11570	11581		10.1074/jbc.M311773200	http://dx.doi.org/10.1074/jbc.M311773200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688261	hybrid			2022-12-27	WOS:000220157600090
J	Monte, M; Benetti, R; Collavin, L; Marchionni, L; Del Sal, G; Schneider, C				Monte, M; Benetti, R; Collavin, L; Marchionni, L; Del Sal, G; Schneider, C			hGTSE-1 expression stimulates cytoplasmic localization of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; WILD-TYPE P53; DAMAGE-INDUCED PHOSPHORYLATION; RING-FINGER DOMAIN; CELL-CYCLE; DNA-DAMAGE; TERMINAL DOMAIN; ENDOGENOUS P53; PROTEIN; MDM2	hGTSE-1 (human G(2) and S phase-expressed-1) is a cell cycle-regulated protein mainly localized in the cytoplasm and apparently associated with the microtubules. hGTSE-1 is able to down-regulate levels and activity of the p53 tumor suppressor protein: it binds the C-terminal region of p53 and represses its ability to induce apoptosis after DNA damage. Here we report that, after DNA damage, hGTSE-1 becomes stabilized in a p53-independent way and accumulated in the nucleus. Further characterization of hGTSE-1 localization revealed increased nuclear staining in unstressed cells after treatment with the nuclear export inhibitor leptomycin B, or when a nuclear export signal (NES) located in its C-terminal region was mutated. Finally, we provide evidence that hGTSE-1 ectopic expression, in addition to p53 protein levels down-regulation, is able to enhance cytoplasmic localization of p53. Interestingly, NES-mutated hGTSE-1 accumulates in the nucleus, binds p53 but looses its ability to enhance cytoplasmic redistribution of p53 and to regulate p53 protein levels. Similarly, when wild type hGTSE-1 functions on p53 were analyzed in cells lacking Mdm2, it failed in regulating both p53 localization and protein levels, thus indicating that hGTSE-1 requires an intact NES and functional Mdm2 for the regulation of p53. Our results provide new insights into the mechanism of hGTSE-1 function, whereby its characterized nucleo-cytoplasmic shuttling ability is required to regulate p53.	Lab Nazl Consorzio Interuniv Biotechnol, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	schneide@sci.area.trieste.it	Marchionni, Luigi/S-6774-2017; Collavin, Licio/A-5312-2010	Marchionni, Luigi/0000-0002-7336-8071; Collavin, Licio/0000-0001-6815-5381; DEL SAL, GIANNINO/0000-0003-2185-6003; Monte, Martin/0000-0002-5068-563X; BENETTI, Roberta/0000-0001-8863-0821				Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Collavin L, 2000, FEBS LETT, V481, P57, DOI 10.1016/S0014-5793(00)01969-4; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; Mathur M, 2003, ONCOGENE, V22, P5031, DOI 10.1038/sj.onc.1206643; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Monte M, 2000, GENE, V254, P229, DOI 10.1016/S0378-1119(00)00260-2; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	45	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11744	11752		10.1074/jbc.M311123200	http://dx.doi.org/10.1074/jbc.M311123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707141	hybrid			2022-12-27	WOS:000220157600111
J	Arimura, N; Horiba, T; Imagawa, M; Shimizu, M; Sato, R				Arimura, N; Horiba, T; Imagawa, M; Shimizu, M; Sato, R			The peroxisome proliferator-activated receptor gamma regulates expression of the perilipin gene in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; A-MEDIATED LIPOLYSIS; PPAR-GAMMA; ALPHA; DIFFERENTIATION; PROMOTER; ADIPOGENESIS; ORGANIZATION; STORAGE; FAMILY	Recent studies have shown that lipid droplets are covered with a proteinaceous coat, although the functions and identities of the component proteins have not yet been well elucidated. The first identified lipid droplet-specific proteins are the perilipins, a family of proteins coating the surfaces of lipid droplets of adipocytes. The generation of perilipin-null mice has revealed that although they consume more food than control mice, they have normal body weight and are resistant to diet-induced obesity. In one study (Martinez-Botas, J., Anderson, J. B., Tessier, D., Lapillonne, A., Chang, B. H. J., Quast, M. J., Gorenstein, D., Chen, K. H., and Chan, L. ( 2000) Nat. Genet. 26, 474-479) it was reported that in an animal model obesity was reversible by breeding perilipin -/- alleles into Lepr db/db obese mice, ostensibly by increasing the metabolic rate of the mice. To understand the exact mechanisms that drive the exclusive expression of the perilipin gene in adipocytes, we analyzed the 5'-flanking region of the mouse gene. Treatment of differentiating 3T3-L1 adipocytes with an agonist of proliferator-activated receptor ( PPAR) gamma, the putative "master regulator" of adipocyte differentiation, significantly augmented perilipin gene expression. Reporter assays using the -2.0-kb promoter revealed that this region contains a functional PPARgamma-responsive element. Gel mobility shift and chromatin immunoprecipitation assays showed that endogenous PPARgamma protein binds to the perilipin promoter. PPARgamma2, an isoform exclusively expressed in adipocytes, was found to be the most potent regulator from among the PPAR family members including PPARalpha and PPARgamma1. These results make evident the fact that perilipin gene expression in differentiating adipocytes is crucially regulated by PPARgamma2, providing new insights into the adipogenic action of PPARgamma2 and adipose-specific gene expression, as well as potential anti-obesity pharmaceutical agents targeted to a reduction of the perilipin gene product.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Aichi 4678603, Japan; Basic Res Act Innovat Biosci, Tokyo 1050001, Japan	University of Tokyo; Nagoya City University	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp						BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Okuno M, 2002, FEBS LETT, V519, P108, DOI 10.1016/S0014-5793(02)02720-5; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	31	162	181	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10070	10076		10.1074/jbc.M308522200	http://dx.doi.org/10.1074/jbc.M308522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14704148	hybrid			2022-12-27	WOS:000220050400051
J	Ohhashi, Y; Hasegawa, K; Naiki, H; Goto, Y				Ohhashi, Y; Hasegawa, K; Naiki, H; Goto, Y			Optimum amyloid fibril formation of a peptide fragment suggests the amyloidogenic preference of beta(2)-microglobulin under physiological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN REVEALS; SOLID-STATE NMR; DISULFIDE BOND; NEUTRAL PH; IN-VITRO; PROTEIN AGGREGATION; PRION PROTEIN; BETA-SHEET; REDUCTION; DISEASES	beta(2)-Microglobulin (beta(2)m) is a major component of amyloid fibrils deposited in patients with dialysis-related amyloidosis. Although full-length beta(2)m readily forms amyloid fibrils in vitro by seed-dependent extension with a maximum at pH 2.5, fibril formation under physiological conditions as detected in patients has been difficult to reproduce. A 22-residue K3 peptide of beta(2)m, Ser(20)-Lys(41), obtained by digestion with Acromobacter protease I, forms amyloid fibrils without seeding. To obtain further insight into the mechanism of fibril formation, we studied the pH dependence of fibril formation of the K3 peptide and its morphology using a ThT fluorescence assay and electron microscopy, respectively. K3 peptide formed amyloid fibrils over a wide range of pH values with an optimum around pH 7 and contrasted with the pH profile of the seed-dependent extension reaction of full-length beta(2)m. This suggests that once the rigid native-fold of beta(2)m is unfolded and additional factors triggering the nucleation process are provided, full-length beta(2)m discloses an intrinsic potential to form amyloid fibrils at neutral pH. The fibril formation was strongly promoted by dimerization of K3 through Cys(25). The morphology of the fibrils varied depending on the fibril formation conditions and the presence or absence of a disulfide bond. Various fibrils had the potential to seed fibril formation of full-length beta(2)m accompanied with a characteristic lag phase, suggesting that the internal structures are similar.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci Corp, CREST, Suita, Osaka 5650871, Japan; Univ Fukui, Fac Med Sci, Fukui 9101193, Japan; Japan Sci Corp, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Gejyo F, 1990, Contrib Nephrol, V78, P47; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Gozu M, 2003, J BIOCHEM, V133, P731, DOI 10.1093/jb/mvg094; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Hasegawa K, 2003, BIOCHEM BIOPH RES CO, V304, P101, DOI 10.1016/S0006-291X(03)00543-6; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; Herrmann LM, 1998, NEUROREPORT, V9, P2457, DOI 10.1097/00001756-199808030-00006; Hirota-Nakaoka N, 2003, J BIOCHEM, V134, P159, DOI 10.1093/jb/mvg124; Hong DP, 2002, J BIOL CHEM, V277, P21554, DOI 10.1074/jbc.M200188200; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Jones S, 2003, J MOL BIOL, V325, P249, DOI 10.1016/S0022-2836(02)01227-5; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs MRH, 2000, J MOL BIOL, V300, P541, DOI 10.1006/jmbi.2000.3862; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; Monti M, 2002, PROTEIN SCI, V11, P2362, DOI 10.1110/ps.0206902; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; Ohnishi S, 2000, J MOL BIOL, V301, P477, DOI 10.1006/jmbi.2000.3980; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Takahashi Y, 2000, STRUCTURE, V8, P915, DOI 10.1016/S0969-2126(00)00183-0; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; Welker E, 2001, P NATL ACAD SCI USA, V98, P4334, DOI 10.1073/pnas.071066598; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858	55	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10814	10821		10.1074/jbc.M310334200	http://dx.doi.org/10.1074/jbc.M310334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699107	Green Published, hybrid			2022-12-27	WOS:000220050400137
J	Zhang, XC; Shan, PY; Jiang, DH; Noble, PW; Abraham, NG; Kappas, A; Lee, PJ				Zhang, XC; Shan, PY; Jiang, DH; Noble, PW; Abraham, NG; Kappas, A; Lee, PJ			Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; TRANSGENIC MICE; GENE; INJURY; DELIVERY; INHIBITION; EXPRESSION	Heme oxygenase-1 (HO-1) is emerging as an important cytoprotective enzyme system in a variety of injury models. To optimize future therapeutic applications of HO-1, it is necessary to delineate the precise functions and mechanisms as well as modes of externally regulating HO-1 expression. Investigations have been limited by difficulties with the generation of HO-1 null mice and the lack of specific HO-1 inhibitors. Lung ischemia-reperfusion (I-R) injury is the inciting event in acute lung failure following transplantation, surgery, and shock. To study the function of HO-1 in I-R-induced lung injury, we designed small interfering RNA ( siRNA) sequences that effectively suppress HO-1 expression both in vitro and in vivo in an organ-specific manner. In this study we show that there is enhanced apoptosis, via increased Fas expression and caspase 3 activity, in the presence of HO-1 siRNA in endothelial cells and mouse lung during I-R injury, whereas HO-1 overexpression attenuates apoptosis. To the best of our knowledge, we are the first to demonstrate that lung-specific siRNA delivery can be achieved by intranasal administration without the need for viral vectors or transfection agents in vivo, thereby obviating potential concerns for toxicity if siRNA technology is to have clinical application in the future.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Rockefeller Univ, New York, NY 10021 USA	Yale University; New York Medical College; Rockefeller University	Lee, PJ (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	zhang, xu/GYE-3558-2022; Jiang, Dianhua/B-1421-2009	Zhang, Xuchen/0000-0002-1484-4672; Jiang, Dianhua/0000-0002-4508-3829	NHLBI NIH HHS [HL004034, HL34300, HL55601, HL31069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL031069, R01HL031069, P01HL034300, R37HL031069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Cao GD, 2002, J NEUROSCI, V22, P5423; Chanalaris A, 2003, J MOL CELL CARDIOL, V35, P257, DOI 10.1016/S0022-2828(03)00003-8; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Hasuwa H, 2002, FEBS LETT, V532, P227, DOI 10.1016/S0014-5793(02)03680-3; Jozkowicz A, 2003, ACTA BIOCHIM POL, V50, P69, DOI 10.18388/abp.2003_3715; KAPPAS A, 2002, HEME OXYGENASE BIOL, P3; LEE PJ, 2003, LUNG BIOL HEALTH DIS, V170, P117; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Quan SO, 2001, P NATL ACAD SCI USA, V98, P12203, DOI 10.1073/pnas.211399398; Reich S, 2003, MOL VIS, V9, P210; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; Shen CX, 2003, FEBS LETT, V539, P111, DOI 10.1016/S0014-5793(03)00209-6; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5; Stammberger U, 2000, ANN THORAC SURG, V69, P1532, DOI 10.1016/S0003-4975(00)01228-5; Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhang XC, 2002, AM J PHYSIOL-LUNG C, V283, pL815, DOI 10.1152/ajplung.00485.2001	33	217	262	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10677	10684		10.1074/jbc.M312941200	http://dx.doi.org/10.1074/jbc.M312941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688267	hybrid			2022-12-27	WOS:000220050400122
J	Roberts, JA; Evans, RJ				Roberts, JA; Evans, RJ			ATP binding at human P2X(1) receptors - Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; SENSORY NEURONS; URINARY-BLADDER; HUMAN PLATELETS; ION CHANNELS; PURINOCEPTOR; ACTIVATION; RESIDUES; RAT; RECOGNITION	P2X receptors comprise a family of ATP-gated ion channels with the basic amino acids Lys-68, Arg-292, and Lys-309 (P2X(1) receptor numbering) contributing to agonist potency. In many ATP-binding proteins aromatic amino acids coordinate the binding of the adenine group. There are 20 conserved aromatic amino acids in the extracellular ligand binding loop of at least 6 of the 7 P2X receptors. We used alanine replacement mutagenesis to determine the effects of individual conserved aromatic residues on the properties of human P2X(1) receptors expressed in Xenopus oocytes. ATP evoked concentration-dependent (EC50 similar to1 muM) desensitizing currents at wild-type receptors and for the majority of mutants there was no change (10 residues) or a < 6-fold decrease in ATP potency (6 mutants). Mutants F195A and W259A failed to form detectable channels at the cell surface. F185A and F291A produced 10- and 160-fold decreases in ATP potency. The partial agonists 2', 3'-O-(4-benzoyl)- ATP (BzATP) and P-1, P-5-di(adenosine 5')-pentaphosphate (Ap(5)A) were tested on a range of mutants that decreased ATP potency to determine whether this resulted predominantly from changes in agonist binding or gating of the channel. At K68A and K309A receptors BzATP and Ap5A had essentially no agonist activity but antagonized, or for R292A potentiated, ATP responses. At F185A receptors BzATP was an antagonist but Ap5A no longer showed affinity for the receptor. These results suggest that residues Lys-68, Phe-185, Phe-291, Arg-292, and Lys-309 contribute to ligand binding at P2X(1) receptors, with Phe- 185 and Phe- 291 coordinating the binding of the adenine ring of ATP.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Univ Rd, Leicester LE1 9HN, Leics, England.	rje6@le.ac.uk	Roberts, Jon/A-6771-2012					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BEAN BP, 1990, J NEUROSCI, V10, P1; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Ennion SJ, 2001, BIOCHEM BIOPH RES CO, V289, P700, DOI 10.1006/bbrc.2001.6034; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Knofel T, 2001, J MOL BIOL, V309, P239, DOI 10.1006/jmbi.2001.4656; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lewis CJ, 2000, BRIT J PHARMACOL, V129, P124, DOI 10.1038/sj.bjp.0702993; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mahaut-Smith MP, 2000, BRIT J PHARMACOL, V131, P108, DOI 10.1038/sj.bjp.0703517; Michel AD, 1996, BRIT J PHARMACOL, V117, P1254, DOI 10.1111/j.1476-5381.1996.tb16723.x; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Nakazawa K, 2002, NEUROSCI LETT, V324, P141, DOI 10.1016/S0304-3940(02)00234-3; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Rettinger J, 2003, J GEN PHYSIOL, V121, P451, DOI 10.1085/jgp.200208730; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Vial C, 2000, BRIT J PHARMACOL, V131, P1489, DOI 10.1038/sj.bjp.0703720; Vial C, 2002, BRIT J PHARMACOL, V135, P363, DOI 10.1038/sj.bjp.0704486	34	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9043	9055		10.1074/jbc.M308964200	http://dx.doi.org/10.1074/jbc.M308964200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699168	hybrid			2022-12-27	WOS:000189265900065
J	Verges, M; Bensadoun, A; Herz, J; Belcher, JD; Havel, RJ				Verges, M; Bensadoun, A; Herz, J; Belcher, JD; Havel, RJ			Endocytosis of hepatic lipase and lipoprotein lipase into rat liver Hepatocytes in vivo is mediated by the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; 3 ENDOSOMAL FRACTIONS; CHYLOMICRON REMNANTS; BINDING-PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-B; HIGH-AFFINITY; CELLS; CATABOLISM; DEGRADATION	In isolated cell studies, the internalization and degradation of hepatic lipase (HL) has been linked to its binding to the low density lipoprotein receptor-related protein (LRP). We have utilized the receptor-associated protein ( RAP), a universal inhibitor of high affinity ligand binding to LRP, to evaluate the participation of LRP in the endocytosis of HL and lipoprotein lipase (LPL). We isolated a total endosome fraction from rat livers after a 30-min infusion of recombinant RAP, administered as a glutathione S-transferase conjugate (GST-RAP). GST-RAP infusion had no effect on the concentration of HL in liver homogenates, but its concentration in blood plasma increased progressively by 20%, and enrichment over homogenate of HL in endosomes was reduced by 50% as compared with infusion of GST alone. The concentrations of LPL in liver and plasma were 1.4 and 0.5%, respectively, those of HL, but endosomal enrichment of the two enzymes was similar (similar to10-fold). GST-RAP infusion had no effect on the concentration of LPL in liver but increased its concentration in blood plasma by 250% and reduced its endosomal enrichment by 95% or greater. GST-RAP infusion also reduced endosomal enrichment of LRP by 40%, but enrichment of several other endocytic receptors was unaffected. Endosomal enrichment of several membrane trafficking proteins associated with the endocytic pathway in hepatocytes was unaffected by GST-RAP with the exception of early endosome endosome antigen 1, which was reduced by 85%. We conclude that HL is partially and LPL almost exclusively taken up into rat hepatocytes after binding to the endocytic receptor LRP.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Anat & Biochem & Biophys, Ithaca, NY 14853 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of California System; University of California San Francisco; Cornell University; Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Havel, RJ (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.	havelr@itsa.ucsf.edu	Verges, Marcel/L-5784-2014	Verges, Marcel/0000-0002-2606-223X	NHLBI NIH HHS [R37 HL063762, HL20948, HL63762, HL14850] Funding Source: Medline; NIAID NIH HHS [AI36953, AI125144] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BELCHER JD, 1985, BIOCHEM J, V229, P343, DOI 10.1042/bj2290343; BELCHER JD, 1988, CIRCULATION, V28, P145; Bergeron N, 1998, P NATL ACAD SCI USA, V95, P15647, DOI 10.1073/pnas.95.26.15647; BRASAEMLE DL, 1993, J LIPID RES, V34, P455; Breedveld B, 1997, BIOCHEM J, V321, P425, DOI 10.1042/bj3210425; Breedveld B, 1998, BIOCHEM J, V330, P785, DOI 10.1042/bj3300785; BUCOLO G, 1973, CLIN CHEM, V19, P476; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Chappell DA, 1998, PROG LIPID RES, V37, P393, DOI 10.1016/S0163-7827(98)00017-4; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CISAR LA, 1985, J LIPID RES, V26, P380; CISAR LA, 1989, J BIOL CHEM, V264, P1767; DEMANT T, 1988, J LIPID RES, V29, P1603; Enrich C, 1996, HEPATOLOGY, V24, P226, DOI 10.1002/hep.510240136; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAMILTON RL, 1965, DISSERT ABSTR, V26, P1; HARFORD J, 1982, J BIOL CHEM, V257, P2685; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; Havel RJ, 1998, ATHEROSCLEROSIS, V141, pS1; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HORNICK CA, 1985, J CELL BIOL, V100, P1558, DOI 10.1083/jcb.100.5.1558; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACKSON RL, 1983, ENZYMES, V16, P141; JANSEN H, 1978, BIOCHEM BIOPH RES CO, V85, P148, DOI 10.1016/S0006-291X(78)80022-9; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Krapp A, 1996, J LIPID RES, V37, P926; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MARTEAU C, 1988, LIFE SCI, V42, P533, DOI 10.1016/0024-3205(88)90094-X; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; Qiu SQ, 1998, J LIPID RES, V39, P1661; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sanan DA, 1997, J LIPID RES, V38, P1002; SCHOONDERWOERD K, 1994, BIOCHEM J, V302, P717, DOI 10.1042/bj3020717; SHAFI S, 1994, J LIPID RES, V35, P709; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4	60	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9030	9036		10.1074/jbc.M312908200	http://dx.doi.org/10.1074/jbc.M312908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701798	hybrid			2022-12-27	WOS:000189265900063
J	Arakawa, R; Hayashi, M; Remaley, AT; Brewer, BH; Yamauchi, Y; Yokoyama, S				Arakawa, R; Hayashi, M; Remaley, AT; Brewer, BH; Yamauchi, Y; Yokoyama, S			Phosphorylation and stabilization of ATP binding cassette transporter a1 by synthetic Amphiphilic helical peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL; TANGIER-DISEASE; APOLIPOPROTEINS; EFFLUX; MECHANISM; RELEASE; MICE; DEGRADATION; DEFICIENCY	To investigate structural requirement of helical apolipoprotein to phosphorylate and stabilize ATP-binding cassette transporter A1 (ABCA1), synthetic peptides (Remaley, A. T., Thomas, F., Stonik, J. A., Demosky, S. J., Bark, S. E., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Patterson, A. P., Eggerman, T. L., Santamarina-Fojo, S., and Brewer, H. B. (2003) J. Lipid Res. 44, 828 836) were examined for these activities. L37pA, an L amino acid peptide that contains two class-A amphiphilic helices, and D37pA, the same peptide with all D amino acids, both removed cholesterol and phospholipid from differentiated THP-1 cells more than apolipoproteins (apos) A-I, A-II, and E. Both peptides also mediated lipid release from human fibroblasts WI-38 similar to apoA-I. L2D37pA, an L-peptide whose valine and tyrosine were replaced with D amino acids also promoted lipid release from WI-38 but less so with THP-1, whereas L3D37pA, in which alanine, lysine, and asparatic acid were replaced with D amino acids was ineffective in lipid release for both cell lines. ABCA1 protein in THP-1 and WT-38 was stabilized against proteolytic degradation by apoA-I, apoA-II, and apoE and by all the peptides tested except for L3D37pA, and ABCA1 phosphorylation closely correlated with its stabilization. The analysis of the relationship among these parameters indicated that removal of phospholipid triggers signals for phosphorylation and stabilization of AECA1. We thus concluded that an amphiphilic helical motif is the minimum structural requirement for a protein to stabilize AECA1 against proteolytic degradation.	Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Grelan Pharmaceut Co Ltd, Div Res & Dev, Tokyo 2050002, Japan; NHLBI, NIH, Mol Dis Branch, Bethesda, MD 20892 USA	Nagoya City University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan.	syokoyam@med.nagoya-cu.ac.jp	Yamauchi, Yoshio/I-7539-2014	Yamauchi, Yoshio/0000-0001-5559-4596				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; JACKSON RL, 1986, METHOD ENZYMOL, V128, P223; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; TAJIMA S, 1983, J BIOL CHEM, V258, P73; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; Yamauchi Y, 2002, BBA-MOL CELL BIOL L, V1585, P1, DOI 10.1016/S1388-1981(02)00304-9; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	20	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6217	6220		10.1074/jbc.C300553200	http://dx.doi.org/10.1074/jbc.C300553200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14701850	hybrid			2022-12-27	WOS:000188969200004
J	Moorefield, KS; Fry, SJ; Horowitz, JM				Moorefield, KS; Fry, SJ; Horowitz, JM			Sp2 DNA binding activity and trans-activation are negatively regulated in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; RETINOBLASTOMA RB PROTEIN; TRANSCRIPTION FACTOR SP1; KRUPPEL-LIKE FACTOR; GENE-EXPRESSION; AMINO-TERMINUS; GROWTH SUPPRESSION; SP-FAMILY; PROMOTER; RECEPTOR	Previous studies have indicated that Sp2 binds poorly to GC-rich sequences bound by Sp1 and Sp3, and further functional analyses of Sp2 have been limited. To study Sp2-mediated transcription, we employed a PCR-based protocol to determine the Sp2 consensus DNA-binding sequence (5'-GGGCGGGAC-3') and performed kinetic experiments to show that Sp2 binds this consensus sequence with high affinity (225 pM) in vitro. To determine the functional consequence of Sp2 interaction with this sequence in vivo, we transformed well characterized Sp-binding sites within the dihydrofolate reductase (DHFR) promoter to consensus Sp2-binding sites. Incorporation of Sp2-binding sites within the DHFR promoter increased Sp2-mediated trans-activation in transient co-transfection experiments but also revealed Sp2 to be a relatively weak trans-activator with little or no capacity for additive or synergistic trans-activation. Using chimeric molecules prepared with portions of Sp1 and Sp2 and the human prostate-specific antigen promoter, we show that Sp2 DNA binding activity and trans-activation are negatively regulated in mammalian cells. Taken together, our data indicate that Sp2 is functionally distinct relative to other Sp family members and suggest that Sp2 may play a unique role in cell physiology.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; N Carolina State Univ, Grad Program Genom Sci, Raleigh, NC 27606 USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Horowitz, JM (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	jon_horowitz@ncsu.edu			NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065405] Funding Source: NIH RePORTER; NCI NIH HHS [CA53248] Funding Source: Medline; NIGMS NIH HHS [GM065405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Bakovic M, 2000, J LIPID RES, V41, P583; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen H, 2002, CANCER RES, V62, P338; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Geng Y, 1999, BIOCHEM BIOPH RES CO, V263, P366, DOI 10.1006/bbrc.1999.1374; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; Gollner H, 2001, GENES CELLS, V6, P689, DOI 10.1046/j.1365-2443.2001.00455.x; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; Halim AB, 2001, J BIOL CHEM, V276, P9784, DOI 10.1074/jbc.M002347200; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kimura N, 2001, ENDOCRINOLOGY, V142, P1427, DOI 10.1210/en.142.4.1427; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MURATA Y, 1994, J BIOL CHEM, V269, P20674; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peters CS, 2001, J BIOL CHEM, V276, P13718, DOI 10.1074/jbc.M011562200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SHI YG, 1995, CHEM BIOL, V2, P83, DOI 10.1016/1074-5521(95)90280-5; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shimizu C, 2001, BIOCHEM BIOPH RES CO, V284, P763, DOI 10.1006/bbrc.2001.5032; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	52	32	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13911	13924		10.1074/jbc.M313589200	http://dx.doi.org/10.1074/jbc.M313589200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726517	hybrid			2022-12-27	WOS:000220478500078
J	Schneider, M; Nesheim, M				Schneider, M; Nesheim, M			A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCARBOXYPEPTIDASE-B; PROTEOLYTIC CLEAVAGE; THERMAL-STABILITY; ACTIVATION; KINETICS; BINDING; TAFI; PROTEASE; ALPHA(2)-ANTIPLASMIN; ALPHA-2-ANTIPLASMIN	Previous work using soluble fibrin surrogates or very dilute fibrin indicate that inhibition of plasmin by antiplasmin is attenuated by fibrin surrogates; however, this phenomenon has not been quantified within intact fibrin clots. Therefore, a novel system was designed to measure plasmin inhibition by antiplasmin in real time within an intact clot during fibrinolysis. This was accomplished by including the plasmin substrate S2251 and a recombinant fluorescent derivative of plasminogen (S741C-fluorescein) into clots formed from purified components. Steady state plasmin levels were estimated from the rates of S2251 hydrolysis, the rates of plasminogen activation were estimated by fluorescence decrease over time, and residual antiplasmin was deduced from residual fluorescence. From these measurements, the second order rate constant could be inferred at any time during fibrinolysis. Immediately after clot formation, the rate constant for inhibition decreased 3-fold from 9.6 x 10(6) M-1 s(-1) measured in a soluble buffer system to 3.2 x 10(6) M-1 s(-1) in an intact fibrin clot. As the clot continued to lyse, the rate constant for inhibition continued to decrease by 38-fold at maximum. To determine whether this protection was the result of plasmin exposure of carboxyl-terminal lysine residues, clots were formed in the presence of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). In the presence of TAFIa, the initial protective effect associated with clot formation occurred; however, the secondary protective effect associated with lysine residue exposure was delayed in a TAFIa concentration-dependent manner. This latter effect represents another mechanism whereby TAFIa attenuates fibrinolysis.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Rm A212,Botterell Hall, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703-6] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; Christensen U, 1996, FEBS LETT, V387, P58, DOI 10.1016/0014-5793(96)00429-2; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KOLEV K, 1994, J BIOL CHEM, V269, P17030; Lee AYY, 2001, THROMB HAEMOSTASIS, V85, P502, DOI 10.1055/s-0037-1615612; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang HY, 2003, EUR J BIOCHEM, V270, P2023, DOI 10.1046/j.1432-1033.2003.03578.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	28	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13333	13339		10.1074/jbc.M313164200	http://dx.doi.org/10.1074/jbc.M313164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715655	hybrid			2022-12-27	WOS:000220478500009
J	Brown, C; Gaspar, J; Pettit, A; Lee, R; Gu, XS; Wang, H; Manning, C; Voland, C; Goldring, SR; Goldring, MB; Libermann, TA; Gravallese, EM; Oettgen, P				Brown, C; Gaspar, J; Pettit, A; Lee, R; Gu, XS; Wang, H; Manning, C; Voland, C; Goldring, SR; Goldring, MB; Libermann, TA; Gravallese, EM; Oettgen, P			ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; FACTOR-ALPHA; SYNOVIAL FIBROBLASTS; BINDING-SITES; DNA-BINDING; ETS FAMILY; ANGIOGENESIS	Angiogenesis is a critical component of the inflammatory response associated with a number of conditions. Angiopoietin-1 (Ang-1) is an angiogenic growth factor that promotes the chemotaxis of endothelial cells and facilitates the maturation of new blood vessels. Ang-1 expression is up-regulated in response to tumor necrosis factor-alpha (TNF-alpha). To begin to elucidate the underlying molecular mechanisms by which Ang-1 gene expression is regulated during inflammation, we isolated 3.2 kb of the Ang-1 promoter that contain regulatory elements sufficient to mediate induction of the promoter in response to TNF-alpha, interleukin-1beta, and endotoxin. Surprisingly, sequence analysis of this promoter failed to reveal binding sites for transcription factors that are frequently associated with mediating inflammatory responses, such as NF-kappaB, STAT, NFAT, or C/EBP. However, putative binding sites for ETS and AP-1 transcription factor family members were identified. Interestingly, among a panel of ETS factors tested in a transient transfection assay, only the ETS factor ESE-1 was capable of transactivating the Ang-1 promoter. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are functionally important for transactivation by ESE-1. ESE-1 and Ang-1 are induced in synovial fibroblasts in response to inflammatory cytokines, with ESE-1 induction slightly preceding that of Ang-1. Mutation of a high-affinity ESE-1 binding site leads to a marked reduction in Ang-1 transactivation by ESE-1, inducibility by inflammatory cytokines, and DNA binding to the ESE-1 protein. Transcriptional profiling of cells transiently transfected with an ESE-1 expression vector demonstrates that the endogenous Ang-1 gene is directly inducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a similar and strong expression pattern in the synovium of patients with rheumatoid arthritis. Our results support a novel paradigm for the ETS factor ESE-1 as a transcriptional mediator of angiogenesis in the setting of inflammation.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital	Oettgen, P (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, 4 Blackfan Circle, Boston, MA 02115 USA.	joettgen@caregroup.harvard.edu	Wang, Hong/H-6298-2012; Pettit, Allison/O-4462-2019; Libermann, Towia/F-9866-2010; Oettgen, Peter/AAF-5026-2021	Pettit, Allison/0000-0003-4707-7892; Libermann, Towia/0000-0002-4006-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378, R01AR047952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021, R56AG022021] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67219] Funding Source: Medline; NIAID NIH HHS [AI 49527] Funding Source: Medline; NIAMS NIH HHS [AR 47952, AR 45378] Funding Source: Medline; NIA NIH HHS [AG 22021] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; ELVERT G, 2002, J BIOL CHEM; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; Escoubet-Lozach L, 2002, J ALLERGY CLIN IMMUN, V110, P553, DOI 10.1067/mai.2002.128076; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FITZGERALD O, 1991, ANN RHEUM DIS, V50, P792, DOI 10.1136/ard.50.11.792; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; Gravallese EM, 2003, ANN RHEUM DIS, V62, P100, DOI 10.1136/ard.62.2.100; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Huang XL, 1999, BIOCHEM BIOPH RES CO, V264, P133, DOI 10.1006/bbrc.1999.1472; Itaya H, 2001, THROMB HAEMOSTASIS, V85, P171, DOI 10.1055/s-0037-1612921; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; KOCH AE, 1994, J IMMUNOL, V152, P4149; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Niini T, 2002, LEUKEMIA, V16, P2213, DOI 10.1038/sj.leu.2402685; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Paleolog EM, 1998, ARTHRITIS RHEUM, V41, P1258, DOI 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Scott BB, 2002, J RHEUMATOL, V29, P230; Senger DR, 1996, AM J PATHOL, V149, P293; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shahrara S, 2002, ARTHRITIS RES, V4, P201, DOI 10.1186/ar407; STEVENS CR, 1991, ARTHRITIS RHEUM, V34, P1508; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Walsh DA, 1999, RHEUMATOLOGY, V38, P103, DOI 10.1093/rheumatology/38.2.103; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	51	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12794	12803		10.1074/jbc.M308593200	http://dx.doi.org/10.1074/jbc.M308593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715662	hybrid			2022-12-27	WOS:000220334900094
J	Fu, DX; Kobayashi, M; Lin, L				Fu, DX; Kobayashi, M; Lin, L			A p105-based inhibitor broadly represses NF-kappa B activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SKIN CARCINOGENESIS; INDUCED P105 PROTEOLYSIS; ALPHA-INDUCED APOPTOSIS; GLYCINE-RICH REGION; PRECURSOR P105; DNA-BINDING; SPLENIC MICROARCHITECTURE; NF-KAPPA-B1 P105; 65-KD SUBUNIT; HUMAN CANCER	An IkappaBalpha-based NF-kappaB super repressor (sr) has been used widely for studying genes regulated by NF-kappaB transcription factors. Repression of NF-kappaB by IkappaBalpha(sr) also facilitates tumor necrosis factor alpha-induced apoptosis in the cell. However, IkappaBalpha primarily targets RelA and c-Rel-containing complexes, leaving other NF-kappaB/Rel protein complexes, such as p50 and p52 homodimers, and RelB heterodimers uninhibited. Because these atypical NF-kappaB complexes also contribute to gene regulation and are activated in pathological conditions, broad inhibition of all NF-kappaB species is of significant pharmacological and clinical interests. We have designed, generated, and tested a p105-based NF-kappaB super repressor. We showed that p105(sr), which no longer generates p50 and undergoes signal-induced degradation, effectively inhibits all NF-kappaB activities. In addition, we also demonstrated that p105(sr) significantly enhances tumor necrosis factor alpha-mediated killing of MT1/2 skin papilloma cells where p50 homodimer activity is elevated. Our results suggest that p105(sr) is a broader range and effective NF-kappaB super repressor and can potentially be used in cells where a noncanonical NF-kappaB activity is dominant or multiple NF-kappaB activities are activated.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Lin, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	llin3@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA098252] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA 98252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; La E, 1999, MOL CARCINOGEN, V24, P276, DOI 10.1002/(SICI)1098-2744(199904)24:4<276::AID-MC5>3.0.CO;2-#; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Moorthy AK, 2003, J BIOL CHEM, V278, P556, DOI 10.1074/jbc.M207515200; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Orian A, 1999, MOL CELL BIOL, V19, P3664; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Spiegelman VS, 1997, MOL CARCINOGEN, V20, P99, DOI 10.1002/(SICI)1098-2744(199709)20:1<99::AID-MC11>3.0.CO;2-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	54	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12819	12826		10.1074/jbc.M312572200	http://dx.doi.org/10.1074/jbc.M312572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14703515	hybrid			2022-12-27	WOS:000220334900097
J	Timchenko, NA; Patel, R; Iakova, P; Cai, ZJ; Quan, L; Timchenko, LT				Timchenko, NA; Patel, R; Iakova, P; Cai, ZJ; Quan, L; Timchenko, LT			Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY REGION; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; MESSENGER-RNA; CTG REPEATS; EXPRESSION; MEF2; ACTIVATION; MUTATION	Accumulation of RNA CUG repeats in myotonic dystrophy type 1 (DM1) patients leads to the induction of a CUG-binding protein, CUGBP1, which increases translation of several proteins that are required for myogenesis. In this paper, we examine the role of overexpression of CUGBP1 in DM1 muscle pathology using transgenic mice that overexpress CUGBP1 in skeletal muscle. Our data demonstrate that the elevation of CUGBP1 in skeletal muscle causes overexpression of MEF2A and p21 to levels that are significantly higher than those in skeletal muscle of wild type animals. A similar induction of these proteins is observed in skeletal muscle of DM1 patients with increased levels of CUGBP1. Immunohistological analysis showed that the skeletal muscle from mice overexpressing CUGBP1 is characterized by a developmental delay, muscular dystrophy, and myofiber-type switch: increase of slow/oxidative fibers and the reduction of fast fibers. Examination of molecular mechanisms by which CUGBP1 up-regulates MEF2A shows that CUGBP1 increases translation of MEF2A via direct interaction with GCN repeats located within MEF2A mRNA. Our data suggest that CUGBP1-ediated overexpression of MEF2A and p21 inhibits myogenesis and contributes to the development of muscle deficiency in DM1 patients.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Timchenko, LT (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	lubovt@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA100070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049222, R01AR044387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020752] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100070] Funding Source: Medline; NIAMS NIH HHS [AR 49222, AR 44387] Funding Source: Medline; NIA NIH HHS [AG 20752] Funding Source: Medline; NIGMS NIH HHS [GM 55188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; Gunthorpe D, 1999, DEV BIOL, V215, P130, DOI 10.1006/dbio.1999.9449; Harper P., 1995, METABOLIC MOL BASES, P4227; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Monckton DG, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P181; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SAHGAL V, 1983, J NEUROL SCI, V59, P47, DOI 10.1016/0022-510X(83)90080-1; Sarkar PS, 2000, NAT GENET, V25, P110, DOI 10.1038/75500; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Wu H, 2002, J CLIN INVEST, V109, P1327, DOI 10.1172/JCI200215417; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	36	157	160	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13129	13139		10.1074/jbc.M312923200	http://dx.doi.org/10.1074/jbc.M312923200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722059	hybrid			2022-12-27	WOS:000220334900134
J	Toy-Miou-Leong, M; Cortes, CL; Beaudet, A; Rostene, W; Forgez, P				Toy-Miou-Leong, M; Cortes, CL; Beaudet, A; Rostene, W; Forgez, P			Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; LUNG-CANCER CELLS; COUPLED RECEPTOR; INTRACELLULAR TRAFFICKING; TRANSDUCTION PATHWAYS; BINDING-PROPERTIES; SMALL-INTESTINE; MESSENGER-RNA; RAT; EXPRESSION	Most G protein-coupled receptors are internalized after interaction with their respective ligand, a process that subsequently contributes to cell desensitization, receptor endocytosis, trafficking, and finally cell resensitization. Although cellular mechanisms leading to cell desensitization have been widely studied, those responsible for cell resensitization are still poorly understood. We examined here the traffic of the high affinity neurotensin receptor (NT1 receptor) following prolonged exposure to high agonist concentration. Fluorescence and confocal microscopy of Chinese hamster ovary, human neuroblastoma (CHP 212), and murine neuroblastoma (N1E-115) cells expressing green fluorescent protein-tagged NT1 receptor revealed that under prolonged treatment with saturating concentrations of neurotensin (NT) agonist, NT1 receptor and NT transiently accumulated in the perinuclear recycling compartment ( PNRC). During this cellular event, cell surface receptors remained markedly depleted as detected by both confocal microscopy and I-125-NT binding assays. In dividing cells, we observed that following prolonged NT agonist stimulation, NT1 receptors were removed from the PNRC, accumulated in dispersed vesicles inside the cytoplasm, and subsequently reappeared at the cell surface. This NT binding recovery allowed for constant cell sensitization and led to a chronic activation of mitogen-activated protein kinases p42 and p44. Under these conditions, the constant activation of NT1 receptor generates an oncogenic regulation. These observations support the potent role for neuropeptides, such as NT, in cancer progression.	Hop St Antoine, INSERM, U482, F-75012 Paris, France; Coll France, INSERM, U36, F-75005 Paris, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H2A 2B4, Canada; Hop St Antoine, INSERM, EMI 0350, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Forgez, P (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg, F-75012 Paris, France.	forgez@st-antoine.inserm.fr	Llorens-Cortes, Catherine/E-5839-2016; FORGEZ, Patricia/N-2960-2018; Rostene, William/F-2754-2017; Llorens-Cortès, catherine/AAL-3893-2021	Llorens-Cortes, Catherine/0000-0002-7667-0401; Llorens-Cortès, catherine/0000-0002-7667-0401; ROSTENE, WILLIAM/0000-0003-0409-5361				AMAR S, 1987, J NEUROCHEM, V49, P999, DOI 10.1111/j.1471-4159.1987.tb09986.x; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; BOUDIN H, 1995, BIOCHEM J, V305, P277, DOI 10.1042/bj3050277; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; DOULUT S, 1992, PEPTIDE RES, V5, P30; Elek J, 2000, ANTICANCER RES, V20, P53; EVERS BM, 1992, ANN SURG, V216, P423, DOI 10.1097/00000658-199210000-00005; FAURE MP, 1995, J NEUROSCI, V15, P4140; FAURE MP, 1995, NEUROSCIENCE, V68, P519, DOI 10.1016/0306-4522(95)00145-9; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FEURLE GE, 1981, DIGEST DIS SCI, V26, P1125, DOI 10.1007/BF01295980; Gullo L, 1998, GASTROEN CLIN BIOL, V22, P25; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; HELMSTAEDTER V, 1977, HISTOCHEMISTRY, V53, P35, DOI 10.1007/BF00511208; Hermans E, 1997, NEUROCHEM INT, V31, P291, DOI 10.1016/S0197-0186(96)00155-6; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; JENNES L, 1982, J COMP NEUROL, V210, P211, DOI 10.1002/cne.902100302; Jones SM, 2000, ONCOGENE, V19, P5558, DOI 10.1038/sj.onc.1203858; Karbowski M, 2001, J CELL SCI, V114, P281; Keezer SM, 2002, EXP CELL RES, V273, P54, DOI 10.1006/excr.2001.5421; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; Maoret JJ, 1999, INT J CANCER, V80, P448, DOI 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N; Martin S, 2002, J CELL SCI, V115, P165; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Moody TW, 2001, PEPTIDES, V22, P109, DOI 10.1016/S0196-9781(00)00362-4; Najimi M, 1998, J BIOL CHEM, V273, P21634, DOI 10.1074/jbc.273.34.21634; Navarro V, 2001, FEBS LETT, V495, P100, DOI 10.1016/S0014-5793(01)02367-5; Nouel D, 1997, J NEUROSCI, V17, P1795; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PoinotChazel G, 1996, BIOCHEM J, V320, P145, DOI 10.1042/bj3200145; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reubi JC, 1998, GUT, V42, P546, DOI 10.1136/gut.42.4.546; Reubi JC, 1999, INT J CANCER, V82, P213, DOI 10.1002/(SICI)1097-0215(19990719)82:2<213::AID-IJC11>3.3.CO;2-#; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; SETHI T, 1992, CANCER RES, V52, pS2737; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Souaze F, 1997, J BIOL CHEM, V272, P10087; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Vincent JP, 1995, CELL MOL NEUROBIOL, V15, P501, DOI 10.1007/BF02071313; Wang L, 2000, CLIN CANCER RES, V6, P566; WOOD SM, 1981, J CLIN ENDOCR METAB, V53, P1310, DOI 10.1210/jcem-53-6-1310; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	55	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12636	12646		10.1074/jbc.M303384200	http://dx.doi.org/10.1074/jbc.M303384200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699144	hybrid			2022-12-27	WOS:000220334900077
J	Chen, W; Yazicioglu, M; Cobb, MH				Chen, W; Yazicioglu, M; Cobb, MH			Characterization of OSR1, a member of the mammalian Ste20p/germinal center kinase subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; HEMATOPOIETIC PROGENITOR KINASE; RICH STE20-RELATED KINASE; STE20-LIKE PROTEIN-KINASE; P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; ACTIVATION; PATHWAY	In examining the protein kinase components of mitogen-activated protein ( MAP) kinase ( MAPK) cascades that regulate the c-Jun N-terminal kinase (JNK) in Drosophila S2 cells, we previously found that distinct upstream kinases were involved in responses to sorbitol and lipopolysaccharide. Here we have extended that analysis to the possible MAPK kinase kinase kinases (MAP4Ks) in the JNK pathway. Fray, a putative Drosophila MAP4K, provided a major contribution to JNK activation by sorbitol. To explore the possible link to JNK in mammalian cells, we isolated and characterized OSR1 ( oxidative stress-responsive 1), one of two human Fray homologs. OSR1 is a 58-kDa protein of 527 amino acids that is widely expressed in mammalian tissues and cell lines. Of potential regulators surveyed, endogenous OSR1 is activated only by osmotic stresses, notably sorbitol and to a lesser extent NaCl. However, OSR1 did not increase the activity of coexpressed JNK, nor did it activate three other MAPKs, p38, ERK2, and ERK5. A two-hybrid screen implicated another Ste20p family member, the p21-activated protein kinase PAK1, as an OSR1 target. OSR1 phosphorylated threonine 84 in the N-terminal regulatory domain of PAK1. Replacement of threonine 84 with glutamate reduced the activation of PAK1 by an active form of the small G protein Cdc42, suggesting that phosphorylation by OSR1 modulates the G protein sensitivity of PAK isoforms.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; FROST JA, 1998, J BIOL CHEM, V273, P28253; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Harden N, 1996, MOL CELL BIOL, V16, P1896; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leiserson WM, 2000, NEURON, V28, P793, DOI 10.1016/S0896-6273(00)00154-9; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ling P, 1999, MOL CELL BIOL, V19, P1359; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Nishigaki K, 2003, J BIOL CHEM, V278, P13520, DOI 10.1074/jbc.M208601200; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tamari M, 1999, J HUM GENET, V44, P116, DOI 10.1007/s100380050121; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	55	67	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11129	11136		10.1074/jbc.M313562200	http://dx.doi.org/10.1074/jbc.M313562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707132	hybrid			2022-12-27	WOS:000220157600037
J	Deterding, LJ; Ramirez, DC; Dubin, JR; Mason, RP; Tomer, KB				Deterding, LJ; Ramirez, DC; Dubin, JR; Mason, RP; Tomer, KB			Identification of free radicals on hemoglobin from its self-peroxidation using mass spectrometry and immuno-spin trapping - Observation of a histidinyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; CYTOCHROME-C; MYOGLOBIN; SITE; METMYOGLOBIN; SUPEROXIDE; PEPTIDE; DISEASE	In an effort to understand the mechanism of radical formation on heme proteins, the formation of radicals on hemoglobin was initiated by reaction with hydrogen peroxide in the presence of the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). The DMPO nitrone adducts were analyzed by mass spectrometry (MS) and immuno-spin trapping. The spin-trapped protein adducts were then subjected to tryptic digestion and MS analyses. When hemoglobin was reacted with hydrogen peroxide (H2O2) in the presence of DMPO, a DMPO nitrone adduct could be detected by immuno-spin trapping. To verify that DMPO adducts of the protein free radicals had been formed, the reaction mixtures were analyzed by flow injection electrospray ionization mass spectrometry (ESI/MS). The ESI mass spectrum of the hemoglobin/H2O2/DMPO sample shows one adduct each on both the alpha chain and the beta chain of hemoglobin which corresponds in mass to the addition of one DMPO molecule. The nature of the radicals formed on hemoglobin was explored using proteolysis techniques followed by liquid chromatography/mass spectrometry (LC/MS) and tandem mass spectrometry (MS/MS) analyses. The following sites of DMPO addition were identified on hemoglobin: Cys-93 of the beta chain, and Tyr-42, Tyr-24, and His-20 of the alpha chain. Because of the pi-pi interaction of Tyr-24 and His-20, the unpaired electron is apparently delocalized on both the tyrosine and histidine residue (pi-pi stacked pair radical).	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Deterding, LJ (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233,MD F0-03, Res Triangle Pk, NC 27709 USA.	deterdi2@niehs.nih.gov	RAMIREZ, DARIO C/K-3312-2013; Tomer, Kenneth B/E-8018-2013; Mason, Ronald P/G-5967-2019	RAMIREZ, DARIO C/0000-0001-6725-3326; Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050153, Z01ES050139, ZIAES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Borchers C, 1999, J CHROMATOGR A, V854, P119, DOI 10.1016/S0021-9673(99)00479-3; Brigellius R., 1985, OXIDATIVE STRESS, P243; BUETTNER GR, 1990, FREE RADICAL RES COM, V10, P11, DOI 10.3109/10715769009145928; Deterding LJ, 1998, J BIOL CHEM, V273, P12863, DOI 10.1074/jbc.273.21.12863; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; Dunford H. B., 1999, HEME PEROXIDASES; Everse J, 1997, FREE RADICAL BIO MED, V22, P1075, DOI 10.1016/S0891-5849(96)00499-6; FAJER J, 1975, P NATL ACAD SCI USA, V72, P4956, DOI 10.1073/pnas.72.12.4956; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; Giulivi C, 2001, J BIOL CHEM, V276, P24129, DOI 10.1074/jbc.M010697200; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; Harris MN, 2002, CHEM RES TOXICOL, V15, P1589, DOI 10.1021/tx025594t; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; He YY, 2003, PHOTOCHEM PHOTOBIOL, V77, P585, DOI 10.1562/0031-8655(2003)077<0585:UHRDBI>2.0.CO;2; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KIM YM, 1995, FREE RADICAL RES, V22, P11, DOI 10.3109/10715769509147524; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; Nagababu E, 2002, BIOCHEMISTRY-US, V41, P7407, DOI 10.1021/bi0121048; Navaratnam S, 1998, J CHEM SOC FARADAY T, V94, P2577, DOI 10.1039/a803477j; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Romero N, 2003, J BIOL CHEM, V278, P44049, DOI 10.1074/jbc.M305895200; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; TEW D, 1988, J BIOL CHEM, V263, P17880; Thillet J, 1985, Free Radic Res Commun, V1, P89, DOI 10.3109/10715768509056541; Webber AN, 2001, BBA-BIOENERGETICS, V1507, P61, DOI 10.1016/S0005-2728(01)00198-0; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; Wright PJ, 2003, J AM CHEM SOC, V125, P8655, DOI 10.1021/ja0291888; Zhang HM, 2002, BIOCHEMISTRY-US, V41, P13507, DOI 10.1021/bi026122g	37	104	106	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11600	11607		10.1074/jbc.M310704200	http://dx.doi.org/10.1074/jbc.M310704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699100	hybrid			2022-12-27	WOS:000220157600093
J	Hesselager, M; Timmermann, DB; Ahring, PK				Hesselager, M; Timmermann, DB; Ahring, PK			pH dependency and desensitization kinetics of heterologously expressed combinations of acid-sensing ion channel subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL TISSUE ACIDOSIS; SENSORY NEURONS; MOLECULAR-CLONING; GATED CHANNELS; HUMAN SKIN; PROTON; CELLS; PAIN; CURRENTS; MEMBRANE	The exact subunit combinations of functional native acid-sensing ion channels (ASICs) have not been established yet, but both homomeric and heteromeric channels are likely to exist. To determine the ability of different subunits to assemble into heteromeric channels, a number of ASIC1a-, ASIC1b-, ASIC2a-, ASIC2b-, and ASIC3-containing homo- and heteromeric channels were studied by whole-cell patch clamp recordings with respect to pH sensitivity, desensitization kinetics, and level of sustained current normalized to peak current. Analyzing and comparing data for these three features demonstrated unique heteromeric channels in a number of co-expression experiments. Formation of heteromeric ASIC1a + 2a and ASIC1b + 2a channels was foremost supported by the desensitization characteristics that were independent of proton concentration, a feature none of the respective homomeric channels has. Several lines of evidence supported formation of ASIC1a + 3, ASIC1b + 3, and ASIC2a + 3 heteromeric channels. The most compelling was the desensitization characteristics, which, besides being proton-independent, were faster than those of any of the respective homomeric channels. ASIC2b, which homomerically expressed is not activated by protons per se, did not appear to form unique heteromeric combinations with other subunits and in fact appeared to suppress the function of ASIC1b. Co-expression of three subunits such as ASIC1a + 2a + 3 and ASIC1b + 2a + 3 resulted in data that could best be explained by coexistence of multiple channel populations within the same cell. This observation seems to be in good agreement with the fact that ASIC-expressing sensory neurons display a variety of acid-evoked currents.	NeuroSearch AS, DK-2750 Ballerup, Denmark		Ahring, PK (corresponding author), NeuroSearch AS, Pederstrupvej 93, DK-2750 Ballerup, Denmark.	pka@neurosearch.dk	Harms, Hauke/I-4406-2012	Harms, Hauke/0000-0002-7316-7341; Ahring, Joergen Philip Kiaer/0000-0003-1807-3331				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Grunder S, 2000, NEUROREPORT, V11, P1607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Petruska JC, 2000, J NEUROPHYSIOL, V84, P2365, DOI 10.1152/jn.2000.84.5.2365; STEEN KH, 1993, NEUROSCI LETT, V154, P113, DOI 10.1016/0304-3940(93)90184-M; Steen KH, 1996, PAIN, V66, P163, DOI 10.1016/0304-3959(96)03034-5; STEEN KH, 1995, NEUROSCI LETT, V199, P29, DOI 10.1016/0304-3940(95)12002-L; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835	24	250	256	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11006	11015		10.1074/jbc.M313507200	http://dx.doi.org/10.1074/jbc.M313507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701823	hybrid			2022-12-27	WOS:000220157600023
J	Levinthal, DJ; DeFranco, DB				Levinthal, DJ; DeFranco, DB			Transient phosphatidylinositol 3-kinase inhibition protects immature primary cortical neurons from oxidative toxicity via suppression of extracellular signal-regulated kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; INDEPENDENT CA2+ CHANNELS; CELL-DEATH; PHOSPHOINOSITIDE 3-KINASE; GROWTH-FACTOR; NEURODEGENERATIVE DISORDERS; HIPPOCAMPAL-NEURONS; IN-VITRO; PATHWAY; PHOSPHORYLATION	Oxidative stress has been shown to underlie a diverse range of neuropathological conditions. Glutamate-induced oxidative toxicity is a well described model of oxidative stress-induced neurodegeneration that relies upon the ability of extracellular glutamate to inhibit a glutamate/ cystine antiporter, which results in a depletion of intracellular cysteine and the blockade of continued glutathione synthesis. Glutathione depletion leads to a gradual toxic accumulation of reactive oxygen species. We have previously determined that glutamate-induced oxidative toxicity is accompanied by a robust increase in activation of the mitogen-activated protein kinase (MAPK) member extracellular-signal regulated kinase (ERK) and that this activation is essential for neuronal cell death. This study demonstrates that delayed ERK activation is dependent upon the activity of phosphoinositol-3 kinase (PI3K) and that transient but not sustained PI3K inhibition leads to significant protection of neurons from oxidative stress-induced neurodegeneration. Furthermore, we show that transient PI3K inhibition prevents the delayed activation of MEK-1, a direct activator of ERK, during oxidative stress. Thus, this study is the first to demonstrate a novel level of cross-talk between the PI3K and ERK pathways in cultured immature cortical neuronal cultures that contributes to the unfolding of a cell death program. The PI3K pathway, therefore, may serve opposing roles during the progression of oxidative stress in neurons, acting at distinct kinetic phases to either promote or limit a slowly developing program of cell death.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DeFranco, DB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E1352 BST, Pittsburgh, PA 15261 USA.	dod1@pitt.edu	Levinthal, David/AAJ-6606-2021	Levinthal, David/0000-0001-8453-8382	NINDS NIH HHS [R01 NS38319, T32 NS07433, F30 NS43824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS043824, T32NS007433, R01NS038319] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Blair LAC, 1999, J NEUROSCI, V19, P1940; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Du S, 2002, J NEUROSCI, V22, P7408; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Henshall DC, 2002, J NEUROSCI, V22, P8458; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Kansra V, 2001, J BIOL CHEM, V276, P31831, DOI 10.1074/jbc.M009374200; Kawanabe Y, 2003, MOL PHARMACOL, V63, P808, DOI 10.1124/mol.63.4.808; Kawanabe Y, 2002, MOL PHARMACOL, V62, P756, DOI 10.1124/mol.62.3.756; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; Mizuta I, 1998, CELL MOL LIFE SCI, V54, P721, DOI 10.1007/s000180050199; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, J NEUROSCI, V22, P7923; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; RATAN RR, 1994, J NEUROCHEM, V62, P376; Sanna PP, 2002, J NEUROSCI, V22, P3359; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11206	11213		10.1074/jbc.M314261200	http://dx.doi.org/10.1074/jbc.M314261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715649	hybrid			2022-12-27	WOS:000220157600046
J	Logan, IR; Sapountzi, V; Gaughan, L; Neal, DE; Robson, CN				Logan, IR; Sapountzi, V; Gaughan, L; Neal, DE; Robson, CN			Control of human PIRH2 protein stability - Involvement of TIP60 and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEX; UBIQUITIN LIGASE ACTIVITY; RING-FINGER DOMAIN; EARLY EMBRYONIC LETHALITY; TUMOR-SUPPRESSOR P53; ANDROGEN RECEPTOR; PROSTATE-CANCER; MDM2-DEFICIENT MICE; MDM2 DEGRADATION; GENE-EXPRESSION	Murine PIRH2 (mPIRH2) was recently identified as a RING finger-containing ubiquitin-protein isopeptide ligase that interacts with both p53 and the human androgen receptor. mpirh2 is a p53-responsive gene that is up-regulated by UV, and mPIRH2 protein has the capacity to polyubiquitylate p53, perhaps leading to p53 destruction. mpirh2 therefore has properties similar to those of the oncogene mdm2. Here, we have identified human PIRH2 (hPIRH2) as a TIP60-interacting protein. To investigate its regulation, we characterized hPIRH2 in parallel with hPIRH2 variants possessing mutations of conserved RING finger residues. We observed that wild-type hPIRH2 is an unstable protein with a short half-life and is a target for RING domain-dependent proteasomal degradation. Accordingly, we found that hPIRH2 was ubiquitylated in cells. The TIP60-hPIRH2 association appeared to regulate hPIRH2 stability; co-expression of TIP60 enhanced hPIRH2 protein stability and altered hPIRH2 subcellular localization. These results suggest that hPIRH2 activities can be controlled, at the post-translational level, in multiple ways.	Univ Newcastle, Sch Med, No Inst Canc Res, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 2QQ, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robson, CN (corresponding author), Univ Newcastle, Sch Med, No Inst Canc Res, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	C.N.Robson@ncl.ac.uk		Neal, David/0000-0002-6033-5086				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; LEACH FS, 1993, CANCER RES, V53, P2231; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nordentoft I, 2003, BIOCHEM J, V374, P165, DOI 10.1042/BJ20030087; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; QUELLE DE, 1995, CELL, V83, P993; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	65	54	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11696	11704		10.1074/jbc.M312712200	http://dx.doi.org/10.1074/jbc.M312712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701804	hybrid			2022-12-27	WOS:000220157600105
J	Mooney, LM; Whitmarsh, AJ				Mooney, LM; Whitmarsh, AJ			Docking interactions in the c-Jun N-terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; SCAFFOLD PROTEIN; MAP KINASES; JNK; IDENTIFICATION; STRESS; PHOSPHORYLATION; ACTIVATION	The c-JunN-terminal kinase (JNK) signaling pathway is a major mediator of stress responses in cells. Similar to other mitogen-activated protein kinases (MAPKs), JNK activity is controlled by a cascade of protein kinases and by protein phosphatases, including dual-specificity MAPK phosphatases. Components of the JNK pathway associate with scaffold proteins that modulate their activities and cellular localization. The JNK-interacting protein-1 (JIP-1) scaffold protein specifically binds JNK, MAPK kinase 7 (MKK7), and members of the mixed lineage kinase (MLK) family, and regulates JNK activation in neurons. In this study we demonstrate that distinct regions within the N termini of MKK7 and the MLK family member dual leucine zipper kinase (DLK) mediate their binding to JIP-1. We have also identified amino acids in JNK required for: (a) binding to JIP-1 and for JIP-1-mediated JNK activation, (b) docking to MAPK kinase 4 (MKK4) and efficient phosphorylation by MKK4, and (c) docking to its substrate c-Jun and efficient c-Jun phosphorylation. None of the amino acids identified were essential for JNK docking to MKK7 or the dual-specificity phosphatase MAPK phosphatase 7 (MKP7). These findings uncover molecular determinants of JIP-1 scaffold complex assembly and demonstrate that there are overlapping, but also distinct, binding determinants within JNK that mediate interactions with scaffold proteins, activators, phosphatases, and substrates.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Whitmarsh, AJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	alan.j.whitmarsh@man.ac.uk		Whitmarsh, Alan/0000-0003-1184-6610				Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; DAI TN, 1995, ONCOGENE, V10, P849; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Im JY, 2003, J NEUROSCI RES, V74, P326, DOI 10.1002/jnr.10761; Ito M, 1999, MOL CELL BIOL, V19, P7539; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Thompson NA, 2001, J BIOL CHEM, V276, P27745, DOI 10.1074/jbc.C100222200; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tu Z, 2003, CELL SIGNAL, V15, P65, DOI 10.1016/S0898-6568(02)00056-6; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200	54	60	66	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11843	11852		10.1074/jbc.M311841200	http://dx.doi.org/10.1074/jbc.M311841200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699111	hybrid			2022-12-27	WOS:000220157600121
J	Ohkawa, K; Ishida, H; Nakanishi, F; Hosui, A; Ueda, K; Takehara, T; Hori, M; Hayashi, N				Ohkawa, K; Ishida, H; Nakanishi, F; Hosui, A; Ueda, K; Takehara, T; Hori, M; Hayashi, N			Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PROTEIN INTERACTS; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; TRANSGENIC MICE; CDK INHIBITORS; PHOSPHORYLATION; APOPTOSIS; RECEPTOR	We investigated how the hepatitis C virus (HCV) core protein affects the cell cycle profile and cell cycle-related molecules by using the HCV core-expressing stable transfectant. Analysis of the cell cycle profile showed that HCV core impaired G(1) to S transition. The E2F-mediated transcription, phosphorylation of the retinoblastoma protein, and cyclin-dependent kinase (CDK) 4 and CDK2 activities were suppressed in HCV core-expressing cells. The expression levels of G(1) phase-related CDKs/cyclins and various CDK inhibitors were not substantially affected by expression of HCV core. When influences of HCV core on CDK-activating kinase (CAK) were examined, the expression levels of the CAK components, CDK7, cyclin H, and MAT1, were not affected. However, formation of the ternary CAK complex, CAK activity, and the CDK2 level with activating phosphorylation were inhibited by expression of the HCV core. The direct effect of HCV core on CAK was further assessed in the cell-free system by adding the in vitro translated HCV core protein to the anti-CDK7 immunoprecipitate from the cell. The results showed that HCV core led to dissociation of MAT1 from the CAK complex and suppressed the CAK activity. Furthermore, the binding assay revealed that the HCV core was directed against CDK7. Their interaction occurred mainly in the nucleus by the immunostaining. In conclusion, the HCV core protein interacts with CAK and functions as an extrinsic suppressor of CAK. This may be the molecular basis of HCV core-mediated suppression of cell cycle progression. Our findings suggest a novel mechanism concerning HCV core-mediated alteration in the cell cycle machinery.	Osaka Univ, Grad Sch Med, Dept Mol Therapeut, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Microbiol, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Hayashi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Therapeut, 2-2 Yamadaoka, Osaka 5650871, Japan.	hayashin@moltx.med.osaka-u.ac.jp	Hosui, Atsushi/AAC-1771-2020	Hosui, Atsushi/0000-0003-0777-8045				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HIRAMATSU N, 1992, HEPATOLOGY, V16, P306, DOI 10.1002/hep.1840160205; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Hosui A, 2003, J BIOL CHEM, V278, P28562, DOI 10.1074/jbc.M210485200; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Ohkawa K, 2003, HEPATOL RES, V25, P396, DOI 10.1016/S1386-6346(03)00017-2; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tokushige K, 1997, J VIROL METHODS, V64, P73, DOI 10.1016/S0166-0934(96)02143-X; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; YI S, 1993, INT J CANCER, V55, P952, DOI 10.1002/ijc.2910550613; Yoshida H, 2001, J BIOL CHEM, V276, P16399, DOI 10.1074/jbc.M006671200; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	54	27	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11719	11726		10.1074/jbc.M308560200	http://dx.doi.org/10.1074/jbc.M308560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711830	hybrid			2022-12-27	WOS:000220157600108
J	Rizhsky, L; Davletova, S; Liang, HJ; Mittler, R				Rizhsky, L; Davletova, S; Liang, HJ; Mittler, R			The zinc finger protein Zat12 is required for cytosolic ascorbate peroxidase 1 expression during oxidative stress in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; ABIOTIC STRESS; DROUGHT STRESS; CELL-DEATH; PATHWAYS; TOLERANCE; THALIANA; PATHOGEN; TOBACCO	Cytosolic ascorbate peroxidase 1 (Apx1) is a key H2O2 removal enzyme in plants. Microarray analysis of Apx1-deficient Arabidopsis plants revealed that the expression of two zinc finger proteins (Zat12 and Zat7) and a WRKY transcription factor (WRKY25) is elevated in knock-out Apx1 plants grown under controlled conditions. Because mutants lacking Apx1 accumulate H2O2, we examined the correlation between H2O2 and the expression of Zat12, Zat7, WRKY25, and Apx1. The expression of Zat12, Zat7, and WRKY25 was simultaneously elevated in cells in response to oxidative stress (i.e. H2O2 or paraquat application), heat shock, or wounding. In contrast, light or osmotic stress did not enhance the expression of these putative transcription factors. All stresses tested enhanced the expression of Apx1. Transgenic plants expressing Zat12 or Zat7 could tolerate oxidative stress. In contrast, transgenic plants expressing WRKY25 could not. Although the expression of Zat12, Zat7, or WRKY25 in transgenic plants did not enhance the expression of Apx1 under controlled conditions, Zat12-deficient plants were unable to enhance the expression of Apx1, Zat7, or WRKY25 in response to H2O2 or paraquat application. Zat12-deficient plants were also more sensitive than wild type plants to H2O2 application as revealed by a higher level of H2O2-induced protein oxidation detected in these plants by protein blots. Our results suggest that Zat12 is an important component of the oxidative stress response signal transduction network of Arabidopsis required for Zat7, WRKY25, and Apx1 expression during oxidative stress.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA; Iowa State Univ Sci & Technol, Dept Bot, Inst Plant Sci, Ames, IA 50011 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Iowa State University	Mittler, R (corresponding author), Univ Nevada, Dept Biochem, Mail Stop 330, Reno, NV 89557 USA.	ronm@unr.edu	Rizshsky, Ludmila/D-3133-2011; Mittler, Ron/ABE-6496-2020; Davletova, Sholpan/K-5764-2015	Davletova, Sholpan/0000-0003-4759-3256; Rizhsky, Ludmila/0000-0003-2323-8225				BENT AF, 2000, PLANT MOL BIOL MANUA; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Cheong YH, 2002, PLANT PHYSIOL, V129, P661, DOI 10.1104/pp.002857; Desikan R, 2001, PLANT PHYSIOL, V127, P159, DOI 10.1104/pp.127.1.159; Epple P, 2003, P NATL ACAD SCI USA, V100, P6831, DOI 10.1073/pnas.1130421100; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Fowler S, 2002, PLANT CELL, V14, P1675, DOI 10.1105/tpc.003483; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kazuoka T, 2000, PLANT J, V24, P191, DOI 10.1046/j.1365-313x.2000.00864.x; Klok EJ, 2002, PLANT CELL, V14, P2481, DOI 10.1105/tpc.004747; Knight H, 2001, TRENDS PLANT SCI, V6, P262, DOI 10.1016/S1360-1385(01)01946-X; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; Mittler R, 1998, PLANT CELL, V10, P461, DOI 10.1105/tpc.10.3.461; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Neill S, 2002, CURR OPIN PLANT BIOL, V5, P388, DOI 10.1016/S1369-5266(02)00282-0; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; Panchuk II, 2002, PLANT PHYSIOL, V129, P838, DOI 10.1104/pp.001362; Pastori GM, 2002, PLANT PHYSIOL, V129, P460, DOI 10.1104/pp.011021; Pnueli L, 2003, PLANT J, V34, P187, DOI 10.1046/j.1365-313X.2003.01715.x; Rizhsky L, 2003, J BIOL CHEM, V278, P38921, DOI 10.1074/jbc.M304987200; Rizhsky L, 2001, PLANT MOL BIOL, V46, P313, DOI 10.1023/A:1010617220067; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; Vranova E, 2002, J EXP BOT, V53, P1227, DOI 10.1093/jexbot/53.372.1227; Vranova E, 2002, P NATL ACAD SCI USA, V99, P10870, DOI 10.1073/pnas.152337999; Zhang JZ, 2003, CURR OPIN PLANT BIOL, V6, P430, DOI 10.1016/S1369-5266(03)00081-5; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329	31	326	385	3	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11736	11743		10.1074/jbc.M313350200	http://dx.doi.org/10.1074/jbc.M313350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722088	hybrid			2022-12-27	WOS:000220157600110
J	Mori, M; Yoneyama, M; Ito, T; Takahashi, K; Inagaki, F; Fujita, T				Mori, M; Yoneyama, M; Ito, T; Takahashi, K; Inagaki, F; Fujita, T			Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CREB-BINDING PROTEIN/P300; NF-KAPPA-B; VIRUS-INFECTION; TRANSCRIPTION FACTORS; POSITIVE FEEDBACK; IN-VIVO; IRF-3; INDUCTION; INVOLVEMENT	Interferon regulatory factor (IRF)-3 is a critical transcription factor regulating innate immune responses against viral and bacterial infections. Signals activated by various pathogens are integrated by IRF-3 kinase, resulting in the specific phosphorylation of IRF-3 in the cytoplasm. This phosphorylation induces dimerization and association with the coactivators CREB-binding protein/p300, and the resultant complex activates the target genes in the nucleus. However, the phosphorylation sites that determine the active/inactive status of IRF-3 have been a source of controversy. In this study, we generated an antibody that specifically detects the phosphorylation of Ser-386 and used it as a probe. We found: 1) viral infection specifically induces phosphorylation of the Ser-386; 2) recently identified IRF-3 kinases (IKK-i/epsilon and TBK-1) phosphorylate Ser-386 and induce its dimerization; 3) phosphorylation of Ser-386 is exclusively observed with the dimer; 4) mutation at Ser-386 abolishes the dimerization potential; 5) a constitutively active 5D mutant designed to mimic phosphorylation of Ser/Thr residues other than Ser-385 and - 386 is secondarily phosphorylated at Ser-386, presumably by an irrelevant kinase. These results strongly suggest that Ser-386 is the target of the IRF-3 kinase and critical determinant for the activation of IRF-3.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Nagasaki Univ, Sch Med, Dept Biochem, Nagasaki 8528523, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan	Tokyo Metropolitan Institute of Medical Science; Nagasaki University; Hokkaido University	Fujita, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	fujita@rinshoken.or.jp	Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408				De Maeyer E, 1998, Int Rev Immunol, V17, P53, DOI 10.3109/08830189809084487; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Nomura F, 2000, GENES CELLS, V5, P191; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; SEN GC, 1992, J BIOL CHEM, V267, P5017; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	25	162	168	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9698	9702		10.1074/jbc.M310616200	http://dx.doi.org/10.1074/jbc.M310616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14703513	hybrid			2022-12-27	WOS:000220050400007
J	Zhang, XY; Zhang, XD; Borrow, JM; Nguyen, T; Hersey, P				Zhang, XY; Zhang, XD; Borrow, JM; Nguyen, T; Hersey, P			Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; DECOY RECEPTORS; TRANSCRIPTION INITIATION; PROTEIN EXPRESSION; KILLER/DR5 GENE; RICH ELEMENTS; SEQUENCE; REGION; MEMBER	In the present study, it was found that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2 protein expression did not correlate with mRNA expression in melanoma cell lines. In particular, early passage primary cultures from patients had low TRAIL-R2 protein expression compared with later passage cultures although TRAIL-R2 mRNA expression was similar in early and late passages. Similarly, cell lines made resistant to TRAIL by cultures in TRAIL had low TRAIL-R2 protein expression but normal levels of mRNA for TRAIL-R2. Expression from a luciferase reporter gene construct with the 3'-untranslated region (UTR) ( but not the 5'-UTR) of TRAIL-R2 was suppressed when transfected into the TRAIL-selected ( resistant) melanoma lines compared with that seen in the parental ( sensitive) lines. Similar results were seen in early passage ( resistant) cultures compared with late passage ( sensitive) primary melanoma cultures. RNA gel shift assays demonstrated protein(s) binding to the 3'-UTR of TRAIL-R2 mRNA that were more evident in TRAIL-resistant cultures with low TRAIL-R2 protein expression. A 23-base fragment of the 3'-UTR inhibited binding of the proteins to the 3'-UTR, and a probe using this fragment bound to proteins in TRAIL-selected melanoma lines and early passage isolates of melanoma. Binding of the 3'-UTR probe to the cytosolic protein( s) was induced by exposure to TRAIL and was lost from the TRAIL selected lines 2 - 3 days after withdrawal of TRAIL from the cultures. These results are consistent with post-transcriptional regulation of TRAIL-R2 expression by cytosolic proteins induced by TRAIL that bind to the 3'-UTR region of TRAIL-R2 mRNA.	Immunol & Oncol Unit, Newcastle, NSW 2300, Australia		Hersey, P (corresponding author), Immunol & Oncol Unit, David Maddison Bldg,Corner King & Watt St, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au	zhang, xian/GYA-0290-2022; zhang, xu/GYE-3558-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022	Zhang, Xu Dong/0000-0001-9457-8003				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Iyer S, 2000, J BIOL CHEM, V275, P17051, DOI 10.1074/jbc.M909219199; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Phillips TA, 1999, J IMMUNOL, V162, P6053; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; SHARROW CO, 1996, CURRENT PROTOCOLS IM; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thomas WD, 1998, J IMMUNOL, V161, P2195; WALKER J, 1998, METHODS MOL BIOL; Wang EH, 1997, CANCER RES, V57, P5426; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747	34	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10606	10614		10.1074/jbc.M308211200	http://dx.doi.org/10.1074/jbc.M308211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688276	hybrid			2022-12-27	WOS:000220050400114
J	Ohnishi, H; Miyata, T; Yasuda, H; Satoh, Y; Hanatsuka, K; Kita, H; Ohashi, A; Tamada, K; Makita, N; Iiri, T; Ueda, N; Mashima, H; Sugano, K				Ohnishi, H; Miyata, T; Yasuda, H; Satoh, Y; Hanatsuka, K; Kita, H; Ohashi, A; Tamada, K; Makita, N; Iiri, T; Ueda, N; Mashima, H; Sugano, K			Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta(1) regulation of pancreatic stellate cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; TARGETED DISRUPTION; ACTIVIN-A; CELLS; RAT; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Pancreatic stellate cells (PSCs) play a major role in promoting pancreatic fibrosis. Transforming growth factor-beta(1) (TGF-beta(1)) regulates PSC activation and proliferation in an autocrine manner. The intracellular signaling pathways of the regulation were examined in this study. Immunoprecipitation and immunocytochemistry revealed that Smad2, Smad3, and Smad4 were functionally expressed in PSCs. Adenovirus-mediated expression of Smad2, Smad3, or dominant-negative Smad2/3 did not alter TGF-beta(1) mRNA expression level or the amount of autocrine TGF-beta(1) peptide. However, expression of dominant-negative Smad2/3 inhibited PSC activation and enhanced their proliferation. Co-expression of Smad2 with dominant-negative Smad2/3 restored PSC activation inhibited by dominant-negative Smad2/3 expression without changing their proliferation. By contrast, co-expression of Smad3 with dominant- negative Smad2/3 attenuated PSC proliferation enhanced by dominant- negative Smad2/3 expression without altering their activation. Exogenous TGF-beta(1) increased TGFbeta(1) mRNA expression in PSCs. However, PD98059, a specific inhibitor of mitogen-activated protein kinase kinase (MEK1), inhibited ERK activation by TGF-beta(1), and consequently attenuated TGF-beta(1) enhancement of its own mRNA expression in PSCs. We propose that TGF-beta(1) differentially regulates PSC activation, proliferation, and TGF-beta(1) mRNA expression through Smad2-, Smad3-, and ERK-dependent pathways, respectively.	Jichi Med Sch, Dept Gastroenterol, Minami Kawachi, Tochigi 3290498, Japan; Showa Univ, Fujigaoka Hosp, Div Gastroenterol, Kanagawa 2278501, Japan; Univ Tokyo, Sch Med, Dept Endocrinol & Nephrol, Tokyo 1138655, Japan; Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan	Jichi Medical University; Showa University; University of Tokyo; University of Tokyo	Ohnishi, H (corresponding author), Jichi Med Sch, Dept Gastroenterol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	hohnishi@jichi.ac.jp	Mashima, Hirosato/ABE-6412-2020					Apte MV, 1999, GUT, V44, P534, DOI 10.1136/gut.44.4.534; Apte MV, 1998, GUT, V43, P128, DOI 10.1136/gut.43.1.128; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Haber PS, 1999, AM J PATHOL, V155, P1087, DOI 10.1016/S0002-9440(10)65211-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kanamaru C, 2001, J BIOL CHEM, V276, P45636, DOI 10.1074/jbc.M105302200; KIM SJ, 1989, J BIOL CHEM, V264, P7041; Kruse ML, 2000, REGUL PEPTIDES, V90, P47, DOI 10.1016/S0167-0115(00)00104-X; LEE MS, 1995, AM J PATHOL, V147, P42; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OHNISHI H, 1995, J CLIN INVEST, V95, P2304, DOI 10.1172/JCI117922; Ohnishi H, 1997, J BIOL CHEM, V272, P16056, DOI 10.1074/jbc.272.25.16056; Ohnishi H, 1999, GASTROENTEROLOGY, V116, P943, DOI 10.1016/S0016-5085(99)70078-8; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	27	82	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8873	8878		10.1074/jbc.M309698200	http://dx.doi.org/10.1074/jbc.M309698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688282	hybrid			2022-12-27	WOS:000189265900044
